<SEC-DOCUMENT>0001171843-21-001411.txt : 20210301
<SEC-HEADER>0001171843-21-001411.hdr.sgml : 20210301
<ACCEPTANCE-DATETIME>20210301091927
ACCESSION NUMBER:		0001171843-21-001411
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		97
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210301
DATE AS OF CHANGE:		20210301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOCRYST PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000882796
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				621413174
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-23186
		FILM NUMBER:		21694363

	BUSINESS ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-859-1302

	MAIL ADDRESS:	
		STREET 1:		4505 EMPEROR BOULEVARD
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>bcrx20201231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:bcrx="http://www.biocryst.com/20201231" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31">
 <head>
  <title>bcrx20201231_10k.htm</title>
  <!-- Generated by ThunderDome Portal - 2/28/2021 4:48:50 PM -->
  <meta http-equiv="Content-Type" content="text/html" /></head>
 <body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0000882796</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">BIOCRYST PHARMACEUTICALS INC</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="dei:AmendmentFlag" format="ixt:booleanfalse">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="dei:DocumentFiscalYearFocus">2020</ix:nonNumeric>
<ix:nonFraction id="c69831007" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c69831008" contextRef="i_2019-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c69831009" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-6">5,000</ix:nonFraction>
<ix:nonFraction id="c69831010" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-6">5,000</ix:nonFraction>
<ix:nonFraction id="c69831011" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c69831012" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c69828094" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction>
<ix:nonFraction id="c69828095" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction>
<ix:nonFraction id="c69828104" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c69828105" contextRef="i_2019-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c69828106" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-7">450,000</ix:nonFraction>
<ix:nonFraction id="c69828107" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-7">450,000</ix:nonFraction>
<ix:nonFraction id="c69828108" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="3" format="ixt:numdotdecimal" decimals="-3">176,883</ix:nonFraction>
<ix:nonFraction id="c69828110" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">176,883</ix:nonFraction>
<ix:nonFraction id="c69828109" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="3" format="ixt:numdotdecimal" decimals="-3">154,082</ix:nonFraction>
<ix:nonFraction id="c69828111" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">154,082</ix:nonFraction>
<ix:nonFraction id="c69828254" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:RepaymentsOfLinesOfCredit" scale="3" format="ixt:numdotdecimal" decimals="-4">52,420</ix:nonFraction>
<ix:nonFraction id="c69828332" contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:numdotdecimal" decimals="-3">92</ix:nonFraction>
<ix:nonFraction id="c69828342" contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">10,455</ix:nonFraction>
<ix:nonFraction id="c69828377" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">283</ix:nonFraction>
<ix:nonFraction id="c69828387" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:numdotdecimal" decimals="-3">115</ix:nonFraction>
<ix:nonFraction id="c69828397" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">43,621</ix:nonFraction>
<ix:nonFraction id="c69828407" contextRef="d_2019-01-01_2019-12-31" unitRef="Share" name="bcrx:ClassOfWarrantOrRightIssuedDuringPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">11,765</ix:nonFraction>
<ix:nonFraction id="c69828437" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-4">510</ix:nonFraction>
<ix:nonFraction id="c69828448" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:numdotdecimal" decimals="-3">246</ix:nonFraction>
<ix:nonFraction id="c69828462" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">22,044</ix:nonFraction>
<ix:nonFraction id="c69828473" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="bcrx:ClassOfWarrantOrRightIssuedDuringPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">3,511</ix:nonFraction>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember" name="bcrx:MaturityPeriodOfHighQualityMarketablesecurities" id="c69828560" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonFraction id="c69831136" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember" unitRef="USD" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c69828591" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c69828592" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c69828593" format="ixt-sec:duryear">7</ix:nonNumeric>
<ix:nonFraction id="c69828614" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:AdvertisingExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c69828615" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:AdvertisingExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c69829093" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c69829118" format="ixt-sec:duryear">4</ix:nonNumeric>
<ix:nonFraction id="c69831164" contextRef="d_2020-01-01_2020-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:numdotdecimal" decimals="2">21</ix:nonFraction>
<ix:nonFraction id="c69831165" contextRef="d_2019-01-01_2019-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:numdotdecimal" decimals="2">21</ix:nonFraction>
<ix:nonFraction id="c69831166" contextRef="d_2018-01-01_2018-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:numdotdecimal" decimals="2">21</ix:nonFraction>
<ix:nonFraction id="c69830313" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" format="ixt:numdotdecimal" decimals="-4">4,080</ix:nonFraction>
<ix:nonFraction id="c69830314" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" format="ixt:numdotdecimal" decimals="-3">4,938</ix:nonFraction>
<ix:nonFraction id="c69830315" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" format="ixt:numdotdecimal" decimals="-3">4,905</ix:nonFraction>
<ix:nonFraction id="c69830319" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" format="ixt:numdotdecimal" decimals="-3">1,456</ix:nonFraction>
<ix:nonFraction id="c69830320" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" format="ixt:numdotdecimal" decimals="-3">281</ix:nonFraction>
<ix:nonFraction id="c69830321" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" format="ixt:numdotdecimal" decimals="-3">18</ix:nonFraction>
<ix:nonFraction id="c69830325" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction>
<ix:nonFraction id="c69830326" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction>
<ix:nonFraction id="c69830327" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:OpenTaxYear" id="c69829408">2017 2018 2019</ix:nonNumeric>
<ix:nonFraction id="c69829412" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c69829413" contextRef="i_2018-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" name="bcrx:ContractTerm" id="c69829532" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember" name="bcrx:RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" id="c69829552" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" name="bcrx:RenewablePeriodOfAgreement" id="c69829592" format="ixt-sec:duryear">5</ix:nonNumeric></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="bcrx-20201231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>
<xbrli:context id="d_2020-01-01_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2020-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-01-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-RoyaltyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_ProductOrServiceAxis-RoyaltyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-12-31_ProductOrServiceAxis-RoyaltyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201409Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201409Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2020-01-01_2020-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">bcrx:CollaborationReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">bcrx:CollaborationReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-RAPIVABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-ORLADEYOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-12-31_CounterpartyNameAxis-SeqirusUKLimitedMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-03-09</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-03-01</xbrli:startDate><xbrli:endDate>2011-03-09</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2011-03-01_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-03-01</xbrli:startDate><xbrli:endDate>2011-03-09</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-03-09</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-01_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_LegalEntityAxis-JPRRoyaltySubLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="JPYPerUSD"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="i_2020-11-30_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver550000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-BCX9930Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder150000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween150000And230000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver230000Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver230000Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermALoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermBLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermBLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermCLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermCLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PikInterestPaymentIsMadeMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:PikInterestPaymentIsMadeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PriorToTheSecondAnniversaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:PriorToTheSecondAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-BetweenTheSecondAndThirdAnniversariesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:BetweenTheSecondAndThirdAnniversariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-BetweenTheThirdAndFourthAnniversariesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:BetweenTheThirdAndFourthAnniversariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-AfterFourthAnniversaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AfterFourthAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-07</xbrli:startDate><xbrli:endDate>2020-12-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoanADrawnMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:TermLoanADrawnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoanAAndBDrawnMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:TermLoanAAndBDrawnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoansABAndCDrawnMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:TermLoansABAndCDrawnMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoansABAndCDrawnAndCureRightExercisedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:TermLoansABAndCDrawnAndCureRightExercisedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermALoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityFirstTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:SecuredCreditFacilityFirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityFirstTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:SecuredCreditFacilityFirstTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-05</xbrli:startDate><xbrli:endDate>2019-02-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilitySecondTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:SecuredCreditFacilitySecondTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityThirdTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:SecuredCreditFacilityThirdTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-05</xbrli:startDate><xbrli:endDate>2019-02-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-05</xbrli:startDate><xbrli:endDate>2019-02-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-01-01_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-01-01_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-01-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bcrx:AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bcrx:AccruedLiabilitiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bcrx:AccruedLiabilitiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-11-08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-11-08</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-08-06_2018-08-06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-06</xbrli:startDate><xbrli:endDate>2018-08-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-08-06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-08-06</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-11-18_2019-11-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-18</xbrli:startDate><xbrli:endDate>2019-11-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-11-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-18</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-11-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-21</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-11-21_2019-11-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-21</xbrli:startDate><xbrli:endDate>2019-11-21</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-04-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-06-01_2020-06-01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bcrx:WarrantsIssuedInPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-06-01_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bcrx:WarrantsIssuedInPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-08-01</xbrli:startDate><xbrli:endDate>2013-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-12-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-12-01_2019-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:August2013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardDateAxis-December2019Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:August2013Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardDateAxis-December2019Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2019Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2017-12-31_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-12-31_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PlanNameAxis-IncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange01Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange01Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange02Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange02Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange03Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange03Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange04Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange04Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange05Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange05Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange06Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange06Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_TaxCreditCarryforwardAxis-ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-08-01_2020-08-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:BaseContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AdditionalDevelopmentOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-03-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-04-01_2020-12-31_TypeOfArrangementAxis-ASPRBARDAContractMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-04-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-06</xbrli:startDate><xbrli:endDate>2018-09-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-03_2020-09-03_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-03</xbrli:startDate><xbrli:endDate>2020-09-03</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-05</xbrli:startDate><xbrli:endDate>2019-11-05</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-05</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-LicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-ServiceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-16</xbrli:startDate><xbrli:endDate>2015-06-16</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-06-16_2020-12-31_CounterpartyNameAxis-CSLLimitedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-16</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-03-04_2020-03-04_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bcrx:ArbitrationProceedingsOfSulAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-04</xbrli:startDate><xbrli:endDate>2020-03-04</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-OtherIncomeMember_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bcrx:ArbitrationProceedingsOfSulAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bcrx:ArbitrationProceedingsOfSulAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2006-06-01</xbrli:startDate><xbrli:endDate>2006-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2011-11-11_TypeOfArrangementAxis-MundipharmaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:MundipharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-11-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2000-06-01</xbrli:startDate><xbrli:endDate>2000-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2000-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:UABMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-01_2020-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-01_2020-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-10-01_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-03-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-04-01_2019-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-07-01_2019-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-10-01_2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_DebtInstrumentAxis-CreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000882796</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
  <div>
    &#xa0;
  </div>
  <div><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>UNITED STATES</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>SECURITIES AND EXCHANGE COMMISSION</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>Washington, D.C. 20549</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>Form <ix:nonNumeric name="dei:DocumentType" contextRef="d_2020-01-01_2020-12-31">10-K</ix:nonNumeric></b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="color:#000000;"><ix:nonNumeric name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" contextRef="d_2020-01-01_2020-12-31">&#x2612;</ix:nonNumeric>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="color:#000000;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" contextRef="d_2020-01-01_2020-12-31">December 31, 2020</ix:nonNumeric></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="color:#000000;"><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2020-01-01_2020-12-31">&#x2610;</ix:nonNumeric>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><span style="color:#000000;">For the transition period from _____ to _____</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>Commission File Number <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2020-01-01_2020-12-31">000-23186</ix:nonNumeric></b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">(Exact name of registrant as specified in its charter)</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr><td style="vertical-align:top;width:41.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2020-01-01_2020-12-31">Delaware</ix:nonNumeric></b></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">(State or other jurisdiction</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">of incorporation or organization)</span></p> </td><td style="vertical-align:top;width:20.4%;">&#xa0;</td><td style="vertical-align:top;width:37.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2020-01-01_2020-12-31">62-1413174</ix:nonNumeric></b></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">(I.R.S. Employer</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Identification No.)</span></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2020-01-01_2020-12-31">4505 Emperor Blvd., Suite 200</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2020-01-01_2020-12-31">Durham</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" contextRef="d_2020-01-01_2020-12-31">North Carolina</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2020-01-01_2020-12-31">27703</ix:nonNumeric></b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">(Address of principal executive offices)</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>(<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2020-01-01_2020-12-31">919</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2020-01-01_2020-12-31">859-1302</ix:nonNumeric></b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">(Registrant&#x2019;s telephone number, including area code)</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Securities registered pursuant to Section 12(b) of the Act</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr><td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 33%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Title of each class</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 32%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Trading Symbol(s)</span></p> </td><td style="vertical-align: bottom; width: 1%;">&#xa0;</td><td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 33%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Name of each exchange on which registered</span></p> </td></tr>
<tr><td style="vertical-align: top; border-bottom: 1px rgb(0, 0, 0); width: 33%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2020-01-01_2020-12-31">Common Stock, $0.01 par value</ix:nonNumeric></b></span></p> </td><td style="vertical-align: top; width: 1%;">&#xa0;</td><td style="vertical-align: top; border-bottom: 1px rgb(0, 0, 0); width: 32%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2020-01-01_2020-12-31">BCRX</ix:nonNumeric></b></span></p> </td><td style="vertical-align: top; width: 1%;">&#xa0;</td><td style="vertical-align: top; border-bottom: 1px rgb(0, 0, 0); width: 33%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2020-01-01_2020-12-31">Nasdaq Global Select Market</ix:nonNumeric></b></span></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Securities registered pursuant to Section 12(g) of the Act: None.</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="d_2020-01-01_2020-12-31">Yes</ix:nonNumeric> &#x2612;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;No &#x2610;</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &#x2610;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="d_2020-01-01_2020-12-31">No</ix:nonNumeric> &#x2612;</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2020-01-01_2020-12-31">Yes</ix:nonNumeric> &#x2612;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;No &#x2610;</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xa7; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2020-01-01_2020-12-31">Yes</ix:nonNumeric> &#x2612;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;No &#x2610;</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><tbody><tr><td style="vertical-align: top; width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2020-01-01_2020-12-31">Large accelerated filer</ix:nonNumeric></span></p> </td><td style="vertical-align: top; width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">&#x2612;</span></p> </td><td style="vertical-align: top; width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Accelerated filer</span></p> </td><td style="vertical-align: top; width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">&#x2610;</span></p> </td></tr>
<tr><td style="vertical-align: top; width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Non-accelerated filer</span></p> </td><td style="vertical-align: top; width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">&#x2610;</span></p> </td><td style="vertical-align: top; width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Smaller reporting company</span></p> </td><td style="vertical-align: top; width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2020-01-01_2020-12-31">&#x2610;</ix:nonNumeric></span></p> </td></tr>
<tr><td style="vertical-align: top; width: 25%;">&#xa0;</td><td style="vertical-align: top; width: 25%;">&#xa0;</td><td style="vertical-align: top; width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Emerging growth company</span></p> </td><td style="vertical-align: top; width: 25%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2020-01-01_2020-12-31">&#x2610;</ix:nonNumeric></span></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x2610;</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#x2612;</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2020-01-01_2020-12-31">&#x2610;</ix:nonNumeric>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;No &#x2612;</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">The registrant estimates that the aggregate market value of the Common Stock on June 30, 2020 (based upon the closing price shown on the Nasdaq Global Select Market on June 30, 2020) held by non-affiliates was $<ix:nonFraction name="dei:EntityPublicFloat" scale="0" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2020-06-30">832,869,919</ix:nonFraction>.</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">The number of shares of Common Stock, par value $0.01, of the registrant outstanding as of January 31, 2021 was <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2021-01-31">177,182,751</ix:nonFraction> shares.</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Portions of the registrant&#x2019;s definitive proxy statement to be filed in connection with the solicitation of proxies for its 2021 annual meeting of stockholders are incorporated by reference into Items 10, 11, 12, 13, and 14 under Part III hereof.</span></p>
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#xa0;
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink">
    &#xa0;
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></div>
  <div>
    &#xa0;
  </div>
  <div>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><span style="text-decoration: underline; "><b>TABLE OF CONTENTS</b></span></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
   <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
    <tbody>
     <tr>
      <td style="vertical-align:top;width:91.3%;">&#xa0;</td>
      <td style="vertical-align:top;width:8.7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><span style="text-decoration: underline; "><b>Page No.</b></span></span></p> </td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;">&#xa0;</td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#cautionary" style="-sec-extract:exhibit;"><span style="color:#000000;">Cautionary Note Regarding Forward-Looking Statements</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#cautionary" style="-sec-extract:exhibit;"><span style="color:#000000;">i</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="#riskfactor" style="-sec-extract:exhibit;"><span style="color:#000000;">Risk Factor Summary</span></a></td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#riskfactor" style="-sec-extract:exhibit;"><span style="color:#000000;">ii</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;">&#xa0;</td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><a href="#p1" style="-sec-extract:exhibit;"><span style="color:#000000;"><span style="text-decoration: underline; "><b>PART I</b></span></span></a></p> </td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;">&#xa0;</td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><a href="#p1i1" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 1. Business</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#p1i1" style="-sec-extract:exhibit;"><span style="color:#000000;">1</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><a href="#i1a" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 1A. Risk Factors</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i1a" style="-sec-extract:exhibit;"><span style="color:#000000;">14</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><a href="#i1b" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 1B. Unresolved Staff Comments</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i1b" style="-sec-extract:exhibit;"><span style="color:#000000;">36</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><a href="#i2" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 2. Properties</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i2" style="-sec-extract:exhibit;"><span style="color:#000000;">36</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><a href="#i3" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 3. Legal Proceedings</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i3" style="-sec-extract:exhibit;"><span style="color:#000000;">36</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><a href="#i4" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 4. Mine Safety Disclosures</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i4" style="-sec-extract:exhibit;"><span style="color:#000000;">36</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;">&#xa0;</td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><a href="#p2" style="-sec-extract:exhibit;"><span style="color:#000000;"><span style="text-decoration: underline; "><b>PART </b></span><span style="text-decoration: underline; "><b>II</b></span></span></a></p> </td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;">&#xa0;</td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:48.35pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-48.35pt;text-transform:uppercase;"><a href="#i5" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i5" style="-sec-extract:exhibit;"><span style="color:#000000;">36</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><a href="#i6" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 6. Selected Financial Data</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i6" style="-sec-extract:exhibit;"><span style="color:#000000;">38</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:48.35pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-48.35pt;text-transform:uppercase;"><a href="#i7" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i7" style="-sec-extract:exhibit;"><span style="color:#000000;">38</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><a href="#i7a" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i7a" style="-sec-extract:exhibit;"><span style="color:#000000;">49</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><a href="#i8" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 8. Financial Statements and Supplementary Data</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i8" style="-sec-extract:exhibit;"><span style="color:#000000;">51</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:48.35pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-48.35pt;text-transform:uppercase;"><a href="#i9" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i9" style="-sec-extract:exhibit;"><span style="color:#000000;">78</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><a href="#i9a" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 9A. Controls and Procedures</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i9a" style="-sec-extract:exhibit;"><span style="color:#000000;">78</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><a href="#i9b" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 9B. Other Information</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i9b" style="-sec-extract:exhibit;"><span style="color:#000000;">78</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;">&#xa0;</td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><a href="#p3" style="-sec-extract:exhibit;"><span style="color:#000000;"><span style="text-decoration: underline; "><b>PART III</b></span></span></a></p> </td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;">&#xa0;</td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><a href="#i10" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 10. Directors, Executive Officers, and Corporate Governance</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i10" style="-sec-extract:exhibit;"><span style="color:#000000;">79</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-transform:uppercase;"><a href="#i11" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 11. Executive Compensation</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i11" style="-sec-extract:exhibit;"><span style="color:#000000;">79</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.85pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-52.85pt;text-transform:uppercase;"><a href="#i12" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i12" style="-sec-extract:exhibit;"><span style="color:#000000;">79</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.85pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-52.85pt;text-transform:uppercase;"><a href="#i13" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i13" style="-sec-extract:exhibit;"><span style="color:#000000;">79</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.85pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-52.85pt;text-transform:uppercase;"><a href="#i14" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 14. Principal Accountant Fees and Services</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i14" style="-sec-extract:exhibit;"><span style="color:#000000;">79</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;">&#xa0;</td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.85pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-52.85pt;text-transform:uppercase;"><a href="#p4" style="-sec-extract:exhibit;"><span style="color:#000000;"><span style="text-decoration: underline; "><b>PART IV</b></span></span></a></p> </td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;">&#xa0;</td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.85pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-52.85pt;text-transform:uppercase;"><a href="#i15" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 15. Exhibit and Financial Statement Schedules</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i15" style="-sec-extract:exhibit;"><span style="color:#000000;">79</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.85pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-52.85pt;text-transform:uppercase;"><a href="#i16" style="-sec-extract:exhibit;"><span style="color:#000000;">Item 16. Form 10-K Summary</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#i16" style="-sec-extract:exhibit;"><span style="color:#000000;">86</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;">&#xa0;</td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:52.85pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-52.85pt;text-transform:uppercase;"><a href="#sig" style="-sec-extract:exhibit;"><span style="color:#000000;">Signatures</span></a></p> </td>
      <td style="vertical-align: top; width: 8.7%; text-align: center;"><a href="#sig" style="-sec-extract:exhibit;"><span style="color:#000000;">87</span></a></td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;">&#xa0;</td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_230468.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-4.1</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_230469.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-10.16</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_230470.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-10.26</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_230471.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-10.28&#xa0;</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_230463.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-10.29&#xa0;</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_230489.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-10.32&#xa0;</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_230490.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-10.33&#xa0;</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_230492.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-10.35&#xa0;</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_230493.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-10.36&#xa0;</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_230494.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-10.82&#xa0;</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_230497.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-10.87&#xa0;</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_230714.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-10.91&#xa0;</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_230719.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-10.92</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_230510.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-21</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_227978.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-23</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_227979.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-31.1</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_227980.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-31.2</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_227981.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-32.1</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align:top;width:91.3%;"><a href="ex_227982.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">EX-32.2</span></a></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 91.3%;"><span style="color:#000000;">EX-101</span></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

     <tr>
      <td style="vertical-align: top; width: 91.3%;"><span style="color:#000000;">EX-104<b>&#xa0;</b></span></td>
      <td style="vertical-align:top;width:8.7%;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM">
        &#xa0;
      </div>
     </div>
    </div>
    <hr />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:27pt;"><span style="color:#000000;"><i>When used in this report, unless otherwise indicated, &#x201c;we,&#x201d; &#x201c;our,&#x201d; &#x201c;us,&#x201d; the &#x201c;Company,&#x201d; and &#x201c;BioCryst&#x201d; refer to BioCryst Pharmaceuticals, Inc.</i></span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><span style="color:#000000;"><b><a id="cautionary" title="cautionary" href="#"></a>Cautionary Note Regarding Forward-Looking Statements</b></span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.2pt;margin-right:10.2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">This Annual Report on Form 10-K (this &#x201c;report&#x201d;) includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the &#x201c;safe harbor&#x201d; created in Section 21E. In particular, statements about our expectations, beliefs, plans, objectives or assumptions of future events or performance are contained or incorporated by reference in this report. All statements other than statements of historical facts contained herein are forward-looking statements. These forward-looking statements can generally be identified by the use of words such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;intends,&#x201d; &#x201c;plans,&#x201d; &#x201c;believes,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;expects,&#x201d; &#x201c;estimates,&#x201d; &#x201c;predicts,&#x201d; &#x201c;potential,&#x201d; the negative of these words or similar expressions. Statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements. Discussions containing these forward-looking statements are principally contained in the &#x201c;Business,&#x201d; &#x201c;Risk Factors,&#x201d; and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; sections of this report, as well as any amendments we make to those sections in filings with the Securities and Exchange Commission (&#x201c;SEC&#x201d;). These forward-looking statements include, but are not limited to, statements about:</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the&#xa0;</span><span style="font-size: 10pt; color: rgb(0, 0, 0);">preclinical develo</span><span style="font-size: 10pt; color: rgb(0, 0, 0);">pment, clinical deve</span><span style="font-size: 10pt; color: rgb(0, 0, 0);">lopment, commercialization, or post-marketing studies of our products and product candidates, including ORLADEYO&#x2122; (berotralstat), BCX9930, BCX9250, peramivir, galidesivir, and early stage discovery programs;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the timing and success of our commercialization of ORLADEYO in the U.S. and elsewhere;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.95pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.95pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the potential for government stockpiling orders of our products and product candidates, including the timing or likelihood of entering into any U.S. government stockpile order and our ability to execute any such order;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the potential funding from our contracts with the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services (&#x201c;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases within the HHS (&#x201c;NIAID/HHS&#x201d;) for the development of galidesivir;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.95pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.95pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">additional regulatory approvals, or milestones, royalties or profit from sales of our products by us or our partners;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the implementation of our business model, strategic plans for our business, products, product candidates and technology;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">our ability to establish and maintain collaborations or out-license rights to our products and product candidates;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">plans, programs, progress and potential success of our collaborations, including Torii for ORLADEYO in Japan, Shionogi and Green Cross for peramivir in their territories, and Mundipharma for mundesine;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">our and our subsidiary guarantors&#x2019; ability to satisfy obligations under our Credit Agreement and to comply with the covenants as set forth in the agreements governing our debt obligations;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the ability of our subsidiary, JPR Royalty Sub LLC, to satisfy its obligations in respect of the PhaRMA Notes (as defined in &#x201c;Business&#x2e3b;Collaborations and In-License Relationships&#x2e3b;Shionogi Royalty Monetization and Non-Recourse Notes Payable&#x201d; in Part I, Item 1 of this report);</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the scope of protection we are able to establish and maintain for intellectual property rights covering our products, product candidates, and technology;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">our ability to operate our business without infringing the intellectual property rights of others;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">estimates of our expenses, revenues, capital requirements, annual cash utilization, and our needs for additional financing;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the timing or likelihood of regulatory filings or regulatory agreements, deferrals, and approvals;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">our ability to manage our liquidity needs, including our ability to raise additional capital, to fund our operations or repay our recourse debt obligations;&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">our financial performance; and</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">competitive companies, technologies, and our industry.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       i
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.2pt;margin-right:10.2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We have based any forward-looking statements on our current expectations about future events or performance. While we believe these expectations are reasonable, forward-looking statements are inherently subject to known and unknown risks and uncertainties, many of which are beyond our control. Actual results may differ materially from those suggested or implied by these forward-looking statements for various reasons, including those discussed in this report under the heading &#x201c;Risk Factors&#x201d; in Part I, Item 1A, some of which are summarized in the &#x201c;Risk Factor Summary&#x201d; below. Any forward-looking statement is subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, industry, and future growth. Given these risks and uncertainties, you are cautioned not to place undue reliance on our forward-looking statements. The forward-looking statements included in this report are made only as of the date hereof. We do not undertake, and specifically decline, any obligation to update any of these statements or to publicly announce the results of any revisions to any forward-looking statements to reflect future events or developments, except as may be required by U.S. federal securities laws.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><span style="color:#000000;"><b><a id="riskfactor" title="riskfactor" href="#"></a>Risk Factor Summary</b></span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:31.5pt;"><span style="color:#000000;">An investment in the Company involves risks.&#xa0; You should carefully read this entire report and consider the uncertainties and risks discussed in the &#x201c;Risk Factors&#x201d; section in Part I, Item 1A of this report, which may adversely affect our business, financial condition, or results of operations, along with the other information included in our other filings with the Securities and Exchange Commission, before deciding to invest in the Company.&#xa0; A summary of the principal factors that make an investment in the Company speculative or risky is set forth below.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">The ongoing novel coronavirus (&#x201c;COVID-19&#x201d;) pandemic could create challenges in all aspects of our business, including, without limitation, delays, stoppages, difficulties, and increased expenses with respect to our and our partners&#x2019; development, regulatory processes, and supply chains, negatively impact our ability to access the capital or credit markets to finance our operations, or have the effect of heightening many of the risks described below or in the &#x201c;Risk Factors&#x201d; section in Part I, Item 1A of this report.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">We have incurred losses since our inception, expect to continue to incur losses, and may never be profitable.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">We may need to raise additional capital in the future.&#xa0; If we are unable to raise capital when needed, we may need to adjust our operations.&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Our success depends upon our ability to advance our product candidates through the various stages of development, especially through the clinical trial process, to receive and maintain regulatory approval for the commercial sale of our product candidates, and to successfully commercialize any approved products. The development process and related regulatory processes are complex and uncertain, may be lengthy and expensive, and require, among other things, an indication that our products and product candidates are safe and effective. For example, applicable regulatory agencies could refuse to approve, or impose restrictions or warnings on, our product candidates, require us to conduct additional studies or adopt study designs that differ from our planned development strategies, suspend or terminate our clinical trials, or take other actions that could materially impact the cost, timing, and success of our planned development strategies.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">We rely heavily upon third parties, including development partners, contractors, contract research organizations, and third-party suppliers, manufacturers, and distributors, for many important stages of our product candidate development and in the commercialization of certain of our products and product candidates.&#xa0; Our failure to maintain these relationships, the failure of any such third party to perform its obligations under agreements with us, or the failure of such a relationship to meet our expectations could have a material adverse impact on our business, financial condition, and results of operations.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">If we fail to obtain additional financing or acceptable partnership arrangements, we may be unable to complete the development and commercialization of our products and product candidates or continue operations.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">The commercial viability of any approved product could be compromised if the product is less effective than expected, causes undesirable side effects that were not previously identified, or fails to achieve market acceptance by physicians, patients, third-party payors, health authorities, and others.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">There can be no assurance that our or our partners&#x2019; commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">We expect to continue expanding our development and regulatory capabilities and implementing sales, marketing, and distribution capabilities, and as a result, we may encounter difficulties managing our growth, which could disrupt our operations.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.&#xa0; In addition, developments by others may render our products, product candidates, or technologies obsolete or noncompetitive.&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">We are subject to various laws and regulations related to our products and product candidates, and if we or our employees, consultants, or partners do not comply with these laws and regulations, we could face substantial penalties and our reputation could be harmed.&#xa0; In addition, we and our partners may be subject to new legislation, regulatory proposals, and healthcare payor initiatives that may increase our costs of compliance and adversely affect our or our partners&#x2019; ability to market our products, obtain collaborators, and raise capital.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       ii
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of those rights would diminish.&#xa0; Legal proceedings to protect or enforce our patents, the patents of our partners, or our other intellectual property rights could be expensive, time consuming, and unsuccessful.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">We face an inherent risk of liability in the event that the use or misuse of our products or product candidates results in personal injury or death and our product liability insurance coverage may be insufficient.&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">We face risks related to our government-funded programs.&#xa0; If the BARDA/HHS or the NIAID/HHS were to eliminate, reduce, or delay funding from our contracts, this would have a significant negative impact on the programs associated with such funding and could have a significant impact on our revenues and cash flows.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">If we fail to reach milestones or to make annual minimum payments or otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional remedies.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Our Credit Agreement contains conditions and restrictions that limit our flexibility in drawing on the additional funds thereunder and in operating our business.&#xa0; We may be required to make a prepayment or repay our outstanding indebtedness under the Credit Agreement earlier than we expect if a prepayment event or an event of default occurs, including a material adverse change with respect to us, which could have a material adverse effect on our business.&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">International expansion of our business exposes us to business, regulatory, political, operational, financial, and economic risks.&#xa0; For example, our actual or perceived failure to comply with European governmental regulations and other obligations related to privacy, data protection, and information security could harm our business.&#xa0; In addition, the United Kingdom&#x2019;s withdrawal from the European Union could result in increased regulatory and legal complexity, which may make it more difficult for us to do business in Europe and impose additional challenges in securing regulatory approval of our product candidates in Europe.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">If our facilities incur damage or power is lost for a significant length of time, our business will suffer.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">A significant disruption in our information technology systems or a cybersecurity breach could adversely affect our business.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">Our existing principal stockholders hold a substantial amount of our common stock and may be able to influence significant corporate decisions, which may conflict with the interest of other stockholders.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">Our stock price has been, and is likely to continue to be, highly volatile, which could cause the value of an investment in our common stock to decline significantly.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">Natural disasters, epidemic or pandemic disease outbreaks, trade wars, political unrest, or other events could disrupt our business or operations or those of our development partners, manufacturers, regulators, or third parties with whom we conduct business now or in the future.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">We are subject to legal proceedings, which could result in losses or unexpected expenditure of time and resources.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">If we fail to retain our existing key personnel or fail to attract and retain additional key personnel, the development of our product candidates and commercialization of our products and the related expansion of our business will be delayed or stopped.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       iii
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><a id="p1" title="p1" href="#"></a>PART I</b></span></p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><a id="p1i1" title="p1i1" href="#"></a>ITEM 1.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<i><b>BUSINESS</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Our Business</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We are a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. We focus on oral treatments for rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. We integrate the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. Structure-guided drug design is a drug discovery approach by which we design synthetic compounds from detailed structural knowledge of the active sites of enzyme targets associated with particular diseases. We use X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. Enzymes are proteins that act as catalysts for many vital biological reactions. Our goal generally is to design a compound that will fit in the active site of an enzyme and thereby prevent its catalytic activity. Molecules from our discovery efforts which are commercially available or that are in active development are summarized in the table below:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:center;"><span style="color:#000000;"><b>Drug/Drug Candidate</b></span></p> </td>
     <td style="vertical-align:bottom;width:2%;">&#xa0;</td>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:20.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:center;"><span style="color:#000000;"><b>Drug Class</b></span></p> </td>
     <td style="vertical-align:bottom;width:2%;">&#xa0;</td>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:22.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:center;"><span style="color:#000000;"><b>Therapeutic Area(s)</b></span></p> </td>
     <td style="vertical-align:bottom;width:2%;">&#xa0;</td>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:14%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:center;"><span style="color:#000000;"><b>Phase</b></span></p> </td>
     <td style="vertical-align:bottom;width:2%;">&#xa0;</td>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:20.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:center;"><span style="color:#000000;"><b>Rights</b><b>*</b></span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:15%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:20.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:22.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:14%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:20.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">ORLADEYO&#x2122;</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">(berotralstat)</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Oral Serine Protease Inhibitor Targeting Kallikrein (once-daily treatment)</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Hereditary Angioedema (&#x201c;HAE&#x201d;)</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:14%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Approved</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">(U.S. &amp; Japan);&#xa0;MAA accepted for review and CHMP positive opinion received (European Union)</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">BioCryst (worldwide, except Japan); Torii Pharmaceutical Co., Ltd. (Japan)</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:15%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:14%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">BCX9930</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Oral Factor D Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Complement-mediated diseases</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:14%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Phase 1</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">BioCryst (worldwide)</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:15%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:14%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">BCX9250</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Oral Activin Receptor-like Kinase-2 Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Fibrodysplasia ossificans progressiva (&#x201c;FOP&#x201d;)</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:14%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Phase 1</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">BioCryst (worldwide)</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:15%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:14%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">RAPIVAB&#xae;</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">(peramivir injection)</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Intravenous Neuraminidase Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Acute uncomplicated Influenza</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:14%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Approved</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">(U.S., Australia &amp; Canada)</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">BioCryst (worldwide, except Japan, Taiwan, Korea and Israel)</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:15%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:14%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">RAPIACTA&#xae;</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">(peramivir injection)</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Intravenous Neuraminidase Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Uncomplicated seasonal Influenza</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:14%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Approved</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">(Japan &amp; Taiwan)</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Shionogi &amp; Co., Ltd.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">(Japan &amp; Taiwan)</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:15%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:14%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">PERAMIFLU&#xae;</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">(peramivir injection)</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Intravenous Neuraminidase Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Uncomplicated seasonal Influenza</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:14%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Approved</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">(Korea)</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Green Cross Corporation</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">(Korea)</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:15%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:14%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Galidesivir</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">(BCX4430)</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">RNA dependent-RNA Polymerase Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Broad spectrum antiviral for 20 RNA viruses, including Marburg, Yellow Fever, and Ebola</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:14%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Phase 1</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">BioCryst</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">(worldwide)</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:15%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:14%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.6%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Mundesine&#xae;</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">(forodesine)</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Oral Purine Nucleoside Phosphorylase Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Oncology &#x2013; PTCL</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:14%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Approved</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">(Japan)</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:20.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Mundipharma International Corporation Limited</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">(worldwide)</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:27pt;">&#xa0;</td>
     <td style="width:9pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:4pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">*</span></p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:4pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;"><i>See &#x201c;Business-</i><i>Collaborations and In-License Relationships&#x201d; for a </i><i>description of our relationships with </i><i>the third parties identified in this column.</i></span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:-9pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Business Strategy</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:7.2pt;margin-right:18.45pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Our business strategy is to create stockholder value both by focusing our discovery and development efforts on oral drugs for rare diseases for which a significant unmet medical need exists and by efficiently commercializing these drugs in the United States and certain other regions upon regulatory approval. By focusing on rare disease markets, we believe that we can more effectively control the costs of, and our strategic allocation of financial resources toward, post-approval commercialization.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">1</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We select disease targets and product candidates in which a small molecule would offer a significant benefit over existing products or would be the first to market. We strive to advance our product candidate portfolio from discovery to commercial markets efficiently by utilizing a small group of talented and highly-skilled employees working in conjunction with strategic outsource partners. BioCryst is unique in its approach to treat orphan diseases with orally-administered, small molecules, identified by utilizing crystallography and structure-guided drug design. The principal elements of our strategy are:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:8pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;"><i>&#x25cf;</i></span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:8pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;"><i>Focusing on High Value-Added Structure-Guided Drug Design Technologies. </i>We utilize structure-guided drug design in order to most<i> </i>efficiently develop new therapeutic candidates. Structure-guided drug design is a process by which we design a product candidate through detailed analysis of the enzyme target, which the product candidate must inhibit in order to stop the progression of the disease or disorder. We believe that structure-guided drug design is a powerful tool for the efficient development of small-molecule product candidates that have the potential to be safe and effective. Our structure-guided drug design technologies typically allow us to design and synthesize multiple product candidates that inhibit the same enzyme target, with the goal of establishing broad intellectual property protection and formulating compounds with competitive advantages.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;"><i>&#x25cf;</i></span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;"><i>Selecting Inhibitors that are Promising Product Candidates. </i>We start by selecting disease targets with well-understood biology and<i> </i>characteristics that fit with our ability to utilize structure-guided drug design capabilities to build potent and specific enzyme inhibitors. Next, we narrow our selection of these product candidates based on product characteristics, such as initial indications of safety and biologic activity on the target.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:5pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;"><i>&#x25cf;</i></span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:5pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;"><i>Developing our Product Candidates Efficiently.&#xa0;</i>An important element of our business strategy is to efficiently progress our product<i> </i>candidates through the development process. In order to accomplish this, we typically strive for disease targets with a defined clinical and regulatory pathway for approval or diseases where high unmet needs allow for frequent interactions with regulators. In addition, as we determine such relationships to be appropriate or desirable, we control certain fixed costs and overhead by outsourcing with strategic partners and contractors or entering into license agreements with third parties, including the U.S. Government. For example, our galidesivir research program is currently being developed under U.S. Government contracts. By contracting with the U.S. Government and outsourcing certain aspects of our operations, we are able to control overhead costs and focus financial resources directly where they provide the most benefit and reduce our business risk.&#xa0;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;"><i>&#x25cf;</i></span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;"><i>Commercializing our Product Candidates Globally. </i>A core part of our strategy is to commercialize our rare disease products globally. We<i> </i>have established commercial teams in the United States and Europe for the commercialization of ORLADEYO, and we are continuing to build the structure and expertise to commercialize our products in markets where we believe we can do this efficiently and effectively. We have also established relationships with licensing and distribution partners in certain markets, including Japan, and will continue to seek such relationships where we determine this to be an effective approach.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Products and Product Candidates</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>ORLADEYO (Berotralstat/BCX7353)</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Hereditary Angioedema (&#x201c;HAE&#x201d;) is a rare, severely debilitating and potentially fatal genetic condition with a prevalence of between 1 in 33,000 to 1 in 67,000 people. HAE symptoms include recurrent episodes of edema in various locations, including the hands, feet, face, genitalia and airway. Airway swelling is particularly dangerous and can lead to death by asphyxiation. In addition, patients often have bouts of severe abdominal pain, nausea and vomiting caused by swelling in the intestinal wall. By inhibiting plasma kallikrein, ORLADEYO, our HAE drug, suppresses bradykinin production. Bradykinin is the mediator of acute swelling attacks in HAE patients. </span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">ORLADEYO is an oral, once-daily therapy discovered and developed by BioCryst for the prevention of HAE attacks.&#xa0; ORLADEYO, in the 110 mg and 150 mg capsule dosage forms, was approved by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) in December 2020 for prophylaxis to prevent attacks of HAE in adults and pediatric patients 12 years and older.&#xa0; On December 16, 2020, we announced that ORLADEYO is now available for shipment to patients with a prescription in the U.S. and that our exclusive specialty pharmacy provider for ORLADEYO in the U.S. began shipping to patients.&#xa0; Through EMPOWER Patient Services, administered by our specialty pharmacy provider, we aim to streamline access to therapy by providing each HAE patient and their healthcare provider with a single point of contact for access to ORLADEYO.&#xa0; A dedicated care coordinator will support access for each patient with comprehensive financial support tools and reimbursement support. </span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">ORLADEYO, in the 150 mg capsule dosage form, also received marketing and manufacturing approval from the Ministry of Health, Labor and Welfare (&#x201c;MHLW&#x201d;) in Japan in January 2021 for prophylactic treatment of HAE in adults and pediatric patients 12 years and older.&#xa0; ORLADEYO is the first and only prophylactic HAE medication approved in Japan and will be commercialized in Japan by our partner, Torii Pharmaceutical Co., Ltd. (&#x201c;Torii&#x201d;).&#xa0; See &#x201c;Collaborations and In-License Relationships&#x201d; below for a description of this relationship.&#xa0; Torii will launch ORLADEYO in Japan following the successful completion of our pricing negotiations with the Japanese National Health Insurance System.&#xa0; OrphanPacific, Inc. is our representative partner in Japan and holds the marketing authorization for ORLADEYO in Japan.&#xa0;</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">2</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">On March 30, 2020, we announced that the European Medicines Agency (&#x201c;EMA&#x201d;) had validated our marketing authorization application (&#x201c;MAA&#x201d;) submission for approval of ORLADEYO for the prevention of HAE attacks.&#xa0; With this validation, the EMA began its formal review of the MAA under the centralized procedure for all member states of the European Union (the &#x201c;EU&#x201d;), Norway, Iceland, and Liechtenstein.&#xa0; On February 25, 2021, we announced that the Committee for Medicinal Products for Human Use (&#x201c;CHMP&#x201d;) of the EMA has adopted a positive opinion recommending the approval of ORLADEYO for routine prevention of recurrent attacks of HAE in adult and adolescent patients aged 12 years and older.&#xa0; The European Commission (&#x201c;EC) will review the CHMP recommendation, and a final approval decision from the EC on the MAA for ORLADEYO is expected in the second quarter of 2021. </span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">The United Kingdom&#x2019;s (&#x201c;U.K.&#x201d;) Medicines and Healthcare products Regulatory Agency (&#x201c;MHRA&#x201d;) has granted a Promising Innovative Medicine designation to ORLADEYO. On October 30, 2020, we announced that the MHRA has granted ORLADEYO a positive scientific opinion through the Early Access to Medicines Scheme (&#x201c;EAMS&#x201d;).&#xa0; Under the EAMS, HAE patients in the U.K. aged 12 years and older can gain access to ORLADEYO for the routine prevention of recurrent attacks of HAE before the drug is granted marketing authorization by the EC. We plan to file for a U.K. marketing authorization with the MHRA following our receipt of a positive opinion from the CHMP.&#xa0; This is expected to result in a U.K. marketing authorization shortly after a final decision by the EC. </span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">On December 7, 2020, we entered into a Purchase and Sale Agreement (the &#x201c;Royalty Purchase Agreement&#x201d;) with RPI 2019 Intermediate Finance Trust (&#x201c;RPI&#x201d;), pursuant to which we sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $125 million in cash.&#xa0; Under the Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the U.S., certain key European markets, and other markets where we sell ORLADEYO directly or through distributors (collectively, the &#x201c;Key Territories&#x201d;).&#xa0; In addition, RPI is entitled to receive a tiered revenue share on amounts generally received by us on account of ORLADEYO sublicense revenue or net sales by licensees outside of the Key Territories.&#xa0; No payment will be due to RPI for any achievement milestone which may be payable under the existing out-license for ORLADEYO.&#xa0; See &#x201c;Note 3-Royalty Monetizations-ORLADEYO Royalty Monetization&#x201d; in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report for additional information about our obligations under the Royalty Purchase Agreement.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">We completed the build-out of our U.S. commercial infrastructure in 2020 to support the launch of ORLADEYO in the U.S. and are currently building our commercial infrastructure to support European launches.&#xa0; Based on proprietary analyses of HAE prevalence and market research studies with HAE patients, physicians, and payors in the U.S. and Europe, we anticipate the commercial market for ORLADEYO has the potential to reach a global peak of more than $500 million in annual sales.&#xa0; These expectations are subject to numerous risks and uncertainties that may cause our actual results, performance, or achievements to be materially different.&#xa0; There can be no assurance that our commercialization methods and strategies will succeed, or that the market for ORLADEYO will develop in line with our current expectations.&#xa0; See &#x201c;Risk Factors</span>&#x2014;<span style="color:#000000;">Risks Relating to Our Business</span>&#x2014;<span style="color:#000000;">Risks Relating to Drug Development and Commercialization</span>&#x2014;There can be no assurance that our commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain<span style="color:#000000;">&#x201d; in Part I, Item 1A of this report for further discussion of these risks.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Complement-Mediated Diseases</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The complement system is part of the body&#x2019;s natural immune system and is responsible for helping the body eliminate microbes (including viral and bacterial infections) and damaged cells. It is comprised of proteins that are primarily produced in the liver and circulate in the blood. Once activated, the complement system stimulates inflammation, phagocytosis and cell lysis. Excessive or uncontrolled activation of the complement system can cause severe, and potentially fatal, immune and inflammatory disorders. The complement system comprises biological cascades of amplifying enzyme cleavages involving more than 30 proteins and protein fragments, and may be activated through three pathways: the classical pathway (initiated by antibody-antigen complexes), the lectin pathway (initiated by lectin binding) and the alternative pathway (initiated by microbial surfaces). The alternative pathway also provides a critical amplification loop for all three pathways, regardless of the initiating mechanism. Factor D is an essential enzyme in the alternative pathway, thus making Factor D an attractive target to address complement-mediated diseases. Several rare diseases are known to be mediated by dysregulation of the complement system.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Discovered by BioCryst, BCX9930 is a novel, oral, potent, and selective small molecule inhibitor of Factor D currently in early clinical development for the treatment of complement-mediated diseases. Based on the safety and proof-of-concept (&#x201c;PoC&#x201d;) data generated to date in paroxysmal nocturnal hemoglobinuria (&#x201c;PNH&#x201d;) patients, we are working closely with regulators and key opinion leaders in hematology and nephrology to map the advanced development strategy across a broad set of indications. Our goal is to develop oral BCX9930 as a monotherapy for complement-mediated diseases.</span>&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On February 25, 2021, we announced that we have completed enrollment of our ongoing dose ranging trial in treatment-na&#xef;ve (no prior treatment with C5 inhibitors) PNH patients and PNH patients with an inadequate response to C5 inhibitors.&#xa0; &#xa0;The objectives of the trial are to evaluate the safety and tolerability and characterize the pharmacokinetic (&#x201c;PK&#x201d;) and pharmacodynamic (&#x201c;PD&#x201d;) profiles of BCX9930 after single ascending doses (&#x201c;SAD&#x201d;) and multiple ascending doses (&#x201c;MAD&#x201d;) in healthy subjects (parts 1 and 2). In part 3 of the trial, there is an additional objective to demonstrate PoC in treatment-na&#xef;ve PNH patients and PNH patients who are inadequate responders to C5 therapy (eculizumab or ravulizumab) by evaluating key biomarkers of effectiveness and assessing the dose range in PNH patients taking BCX9930. Based on the safety, tolerability, PK and PD dose-response results from parts 1 and 2 of the phase 1 trial, we completed additional MAD dosing cohorts in healthy subjects and advanced to part 3 of the trial.&#xa0; We plan to present data from the 16 enrolled PNH patients (10 treatment na&#xef;ve and 6 inadequate C5 responders) at our upcoming R&amp;D day on March 22, 2021.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">3</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On September 30, 2020, we announced new data from treatment-na&#xef;ve PNH patients receiving doses through 400 mg twice-daily of oral BCX9930 as monotherapy in the ongoing part 3 PoC dose-ranging trial. Oral BCX9930 was shown to drive rapid and dose-dependent reductions in key biomarkers, including lactate dehydrogenase (&#x201c;LDH&#x201d;), and increasing hemoglobin levels in all PNH patients in the trial. Increases in hemoglobin levels were maintained without transfusions. BCX9930 was safe and well tolerated at all doses in the trial. No drug-related serious adverse events had been reported. One subject was discontinued due to an unrelated serious adverse event.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On August 31, 2020, we announced that the FDA has granted orphan drug designation for BCX9930 for the treatment of PNH. Orphan drug designation qualifies BCX9930 for various development incentives, including tax credits for certain clinical costs, a waiver of the new drug application fee, and a designated period of market exclusivity following approval. On August 3, 2020, we announced that the FDA granted fast track designation for BCX9930 in PNH. According to the FDA, the purpose of the fast track designation is to get important new drugs to patients earlier by facilitating the development, and expediting the review, of drugs to treat serious conditions and meet an unmet medical need.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Under the Royalty Purchase Agreement, RPI will be entitled to receive 1.0% of global net sales, if any, of BCX9930. See &#x201c;Note 3-Royalty Monetizations-ORLADEYO Royalty Monetization&#x201d; in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report for additional information about our obligations under the Royalty Purchase Agreement.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Fibrodysplasia Ossificans Progressiva (&#x201c;FOP&#x201d;)</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">FOP is an ultra-rare disease that affects approximately 1 in 2 million people worldwide. It is a severely disabling condition characterized by the irregular formation of bone outside the normal skeleton, also known as heterotopic ossification (&#x201c;HO&#x201d;). HO can occur in muscles, tendons and soft tissue. FOP patients progressively become bound by this irregular ossification, with restricted movement and fused joints, resulting in deformities and premature mortality. In patients with FOP, minor trauma can result in rapid development of painful inflammatory masses. These progress over several weeks resulting in the replacement of the affected soft tissue by permanent bone masses. There is no cure for this condition, and there are no approved treatments for FOP.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In 2018, we announced the advancement of a program exploring activin receptor-like kinase-2 (&#x201c;ALK2&#x201d;) inhibitors for treatment of FOP. ALK2 enzyme is a part of the normal signaling pathway for bone formation and responds to binding its specific ligands (bone morphogenic proteins, or BMPs), by stimulating normal bone growth and renewal in healthy children and adults. Specific activating mutations of the ALK2 gene are seen in all cases of FOP. An activating mutation in ALK2 is necessary for the disease to occur, making the ALK2 kinase an ideal drug target for treatment of FOP with an ALK2 kinase inhibitor</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The goal of our ALK2 inhibitor program is to discover and develop orally administered kinase inhibitor drug candidates that are able to slow or prevent HO. Our lead compound, BCX9250, reduced HO in an experimental model of ALK2-driven HO in laboratory rats, with up to 89 percent reduction in volume of HO compared to controls.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On December 21, 2020, we announced that in a phase 1 clinical trial, BCX9250 was safe and well tolerated at all doses studied, with linear and dose-proportional exposure supporting once-daily dosing. The randomized, double-blind, placebo-controlled dose-ranging trial evaluated safety, tolerability, and PK of SAD and MAD of BCX9250 in healthy subjects. The SAD study was designed to randomize four cohorts of eight subjects each to receive oral BCX9250 (n=6) or placebo (n=2) at dose levels of 5 mg, 10 mg, 15 mg, and 25 mg. Subjects in the 15 mg cohort also received a second single dose to evaluate food effect on absorption of BCX9250. The MAD study was designed to randomize 4 cohorts of 12 subjects each to receive oral BCX9250 (n=10) or placebo (n=2) at dose levels of 5 mg, 10 mg, 15 mg, and 20 mg once-daily for 7 days. Drug exposure increased with dose in an approximately linear and dose-proportional manner. Drug levels after a high fat meal were similar to those after dosing on an empty stomach. Drug exposure at 20 mg once-daily in the MAD was similar to that achieved with doses that suppressed HO in a nonclinical model of activity of orally dosed BCX9250. In both the SAD and the MAD studies, oral BCX9250 was safe and well tolerated, with no serious adverse events, no study discontinuations due to adverse events, no grade 3 or 4 adverse events, and no clinically significant changes in vital signs, electrocardiograms, or safety laboratory parameters. No safety signals were seen.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Peramivir Injection (RAPIVAB</b></i><i><b>, ALPIVAB, RAPICACTA, PERAMIFLU)</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">RAPIVAB (peramivir injection) was developed under a $234.8 million contract from the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services (&#x201c;BARDA/HHS&#x201d;). In January 2010, our partner, Shionogi &amp; Co., Ltd. (&#x201c;Shionogi&#x201d;), received the first approval for peramivir injection and launched it in Japan under the commercial name RAPIACTA. It is approved in Japan for the treatment of adults, children, and infants with uncomplicated seasonal influenza and those patients at high-risk for complications associated with influenza. In August 2010, our partner, Green Cross Corporation (&#x201c;Green Cross&#x201d;), received marketing and manufacturing approval from the Korean Food &amp; Drug Administration under the commercial name PERAMIFLU to treat patients with influenza A &amp; B viruses, including pandemic H1N1 and avian influenza. See &#x201c;Collaborations and In-License Relationships&#x201d; below for a discussion of these licensing arrangements.</span>&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Peramivir was also approved in the United States in 2014, Taiwan in 2016, Canada in 2017, and the EU and Australia in 2018. A Supplemental New Drug Application (&#x201c;sNDA&#x201d;) was approved in the United States in February 2021, extending RAPIVAB&#x2019;s availability for the treatment of acute uncomplicated influenza to pediatric patients six months and older. Prior to this approval, peramivir had been indicated in the United States for pediatric patients two years and older.&#xa0; In the United States, peramivir is indicated for the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than two days. In May 2018, peramivir, with the brand name of ALPIVAB, received approval from the EMA, although we withdrew the ALPIVAB registration in November 2020.&#xa0; ALPIVAB was not commercially available in the EU at the time of the withdrawal.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">4</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">In September 2018, the U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;) awarded us a $34.7 million contract for the procurement of up to 50,000 doses of RAPIVAB over a five-year period to supply the Strategic National Stockpile for use in a public health emergency. We delivered 20,000 doses of RAPIVAB under this contract in 2019 for a total price of approximately $13.9 million.&#xa0; On September 3, 2020, we announced that HHS exercised its option to purchase an additional 10,000 doses of RAPIVAB under this contract for $6.9 million.&#xa0; As a result, we expect to deliver at least one shipment of 10,000 doses within the contract in 2021.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Galidesivir (BCX4430)</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Galidesivir is a broad-spectrum antiviral (&#x201c;BSAV&#x201d;) that has been shown to be active against more than 20 RNA viruses in nine different families, including filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses. In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Marburg, Yellow Fever, Ebola, and Zika viruses and from exposures to aerosolized Marburg virus, an experimental condition designed to mimic an exposure scenario that could result during a bioterrorist attack. Our galidesivir research program is currently being developed under contracts with the National Institute of Allergy and Infectious Diseases within the HHS (&#x201c;NIAID/HHS&#x201d;) and BARDA/HHS.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The objective of our BSAV program is to develop galidesivir as a broad-spectrum therapeutic for viruses that pose a threat to national health and security. The primary focus of the program is treatment of hemorrhagic fever viruses. NIAID/HHS funding has supported galidesivir&#x2019;s development as a treatment for Marburg virus, Yellow Fever and Ebola virus. Since September 2013, NIAID/HHS has supported the development of galidesivir as a therapeutic for Ebola and Marburg viruses. As of the date hereof, all options under our initial contract with NIAID/HHS have been awarded. The total amount under the initial contract, as amended, is $45.9 million, inclusive of the $2.9 million added to the contract in August 2020 to support the development of galidesivir. Since March 2015, BARDA/HHS has supported the development of galidesivir as a potential treatment for filoviruses. The total BARDA/HHS contract value to advance the program through toxicology studies and manufacturing work to support a new drug application is $39.1 million if all contract options are exercised. As of the date hereof, a total of $20.6 million has been awarded under exercised options within this contract.</span>&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In April 2020, we agreed with NIAID/HHS to add a group of COVID-19 patients to an ongoing clinical trial in Yellow Fever.&#xa0; On April 9, 2020, we announced that we had opened a randomized, double-blind, placebo-controlled clinical trial in Brazil to assess the safety, clinical impact, and antiviral effects of galidesivir in patients with COVID-19.&#xa0; </span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On August 31, 2020, we announced that NIAID/HHS awarded us a new $43.9 million contract for the manufacture and evaluation of the safety, efficacy, and tolerability of galidesivir and that it also added $2.9 million to its existing contract with us to support the development of galidesivir.&#xa0; NIAID/HHS made an initial award of $6.3 million under the new contract.</span>&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On December 22, 2020, we announced that data from part 1 of the clinical trial in Brazil showed that galidesivir was safe and generally well tolerated in patients infected with SARS-Cov-2, the virus that causes COVID-19.&#xa0; The trial was not designed or sized to demonstrate clinical efficacy, and no clinical efficacy benefit with galidesivir treatment compared to placebo treatment was observed in the trial.&#xa0; Based on our ongoing discussions with NIAID/HHS, we expect NIAID/HHS to continue its support for the development of galidesivir with a focus on biodefense threats, such as Marburg virus disease, and to discontinue the pursuit of a COVID-19 indication for galidesivir.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Mundesine (forodesine)</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">Mundesine is a Purine Nucleoside Phosphorylase (&#x201c;PNP&#x201d;) inhibitor developed by Mundipharma International Corporation Limited (&#x201c;Mundipharma&#x201d;) as a treatment for cancer under a world-wide license agreement. PNP is a purine salvage pathway enzyme. High doses of PNP inhibitors could be useful in the treatment of hematological malignancies. Mundipharma has received orphan drug status for Mundesine, and following its successful completion of a phase 2 pivotal study in recurrent/refractory peripheral T-cell lymphoma (&#x201c;PTCL&#x201d;) patients in Japan, Mundesine was approved in April 2017 by the MHLW in Japan. We are currently entitled to receive royalties on Mundesine.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Collaborations and In-License Relationships</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Torii Pharmaceutical Co., Ltd. (&#x201c;Torii&#x201d;)</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On November 5, 2019, we entered into a Commercialization and License Agreement with Torii (the &#x201c;Torii Agreement&#x201d;), granting Torii the exclusive right to commercialize ORLADEYO for the prevention of HAE attacks in Japan.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">5</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Under the Torii Agreement, we received an upfront, non-refundable payment of $22.0 million and are eligible to receive an additional milestone payment of $15.0 million upon receipt from Japan&#x2019;s National Health Insurance system of a reimbursement price approval for ORLADEYO in excess of the threshold specified in the Torii Agreement.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In addition, under the Torii Agreement, we are entitled to receive tiered royalty payments, ranging from 20% to 40% of annual net sales of ORLADEYO in Japan during each calendar year. Torii&#x2019;s royalty payment obligations are subject to customary reductions in certain circumstances, but may not be reduced by more than 50% of the amount that otherwise would have been payable to us in the applicable calendar quarter. Torii&#x2019;s royalty payment obligations commence upon the first commercial sale of ORLADEYO in Japan and expire upon the later of (i) the tenth anniversary of the date of first commercial sale of ORLADEYO in Japan, (ii) the expiration of our patents covering ORLADEYO, and (iii) the expiration of regulatory exclusivity for ORLADEYO in Japan. We will be responsible for supplying Torii with its required amounts of ORLADEYO. The activities of the parties pursuant to the Torii Agreement will be overseen by a joint steering committee, to be composed of an equal number of representatives from each party to coordinate the development and commercialization of ORLADEYO in Japan.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Under the Torii Agreement, we granted Torii a right of first negotiation (&#x201c;ROFN&#x201d;) to commercialize ORLADEYO in Japan for the acute treatment of HAE attacks if we develop ORLADEYO for such indication and to commercialize any additional kallikrein inhibitor that we may develop in the future for use in HAE in Japan. Under both ROFNs, if the parties do not agree to terms with respect to a definitive amendment to the Torii Agreement or new agreement, as applicable, the terms of the amendment or agreement would be set by a third-party arbitrator.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Seqirus UK Limited</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">In June 2015, we entered into a license agreement (the &#x201c;SUL Agreement&#x201d;) with CSL Limited (&#x201c;CSL&#x201d;), a company organized under the laws of Australia, granting Seqirus UK Limited (&#x201c;SUL&#x201d;), a limited company organized under the laws of the United Kingdom and a subsidiary of CSL, and its affiliates worldwide rights to develop, manufacture, and commercialize peramivir for the treatment of influenza, except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan. On March 4, 2020, the International Court of Arbitration of the International Chamber of Commerce (&#x201c;ICC Tribunal&#x201d;) delivered a Partial Arbitration Award (the &#x201c;Partial Arbitration Award&#x201d;) in an arbitration matter between us and SUL with respect to the SUL Agreement. In the Partial Arbitration Award, the ICC Tribunal found that, during the term, SUL materially breached and abandoned its core duties to us under the Diligent Efforts (as defined in the SUL Agreement) requirements of the SUL Agreement as applicable in the U.S. The ICC Tribunal granted a declaratory judgment in favor of us terminating the SUL Agreement and restoring all rights to peramivir to us. We agreed with SUL on a transition process for the product, with a full transition of commercialization of the product in the U.S. and Australia returned to us as of August 1, 2020 and November 1, 2020, respectively.&#xa0; The ICC Tribunal also awarded us attorneys&#x2019; fees and expenses incurred in securing the declaratory judgment as well as the costs incurred by us in the arbitration. Finally, the ICC Tribunal found that SUL breached the SUL Agreement by failing to pay a milestone payment due to us within 30 days of the approval of peramivir for adult use in the EU and awarded us $5.0 million (plus interest) for this claim. The ICC Tribunal retained jurisdiction for further proceedings relating to the award of attorneys&#x2019; fees and for any dispute relating to the return to us of all rights to peramivir in the Territory.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Shionogi &amp; Co., Ltd. (&#x201c;Shionogi&#x201d;)</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>&#xa0;</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In February 2007, we entered into a License, Development and Commercialization Agreement (as<i> </i>amended, supplemented or otherwise modified, the &#x201c;Shionogi Agreement&#x201d;), an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially life-threatening human influenza. In October 2008, we and Shionogi amended the Shionogi Agreement to expand the territory covered by the agreement to include Taiwan. Under the terms of the Shionogi Agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan in exchange for a $14.0 million upfront payment. The license provided for development milestone payments (up to $21.0 million), which have all been paid, and for commercial milestone payments (up to $95.0 million) in addition to double-digit (between 10% and 20%) royalty payments on product sales of peramivir.</span>&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In December 2017, we, on behalf of JPR Royalty Sub LLC, a wholly-owned subsidiary of BioCryst (&#x201c;Royalty Sub&#x201d;), instituted arbitration proceedings against Shionogi in order to resolve a dispute with Shionogi under the Shionogi Agreement regarding the achievement of sales milestones and escalating royalties. The arbitration proceedings concluded with the decision that no sales milestones had been achieved and that royalties would remain the same. The costs associated with the arbitration proceedings are recoverable from the assets of Royalty Sub in accordance with the terms of the indenture and servicing agreement relating to the PhaRMA Notes (as defined below under &#x201c;Shionogi Royalty Monetization and Non-Recourse Notes Payable&#x201d;).</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;"><span style="color:#000000;">Generally, all payments under the Shionogi Agreement are non-refundable and non-creditable, but they are subject to audit. Shionogi is responsible for all development, regulatory, and marketing costs in Japan. The term of the Shionogi Agreement is from February 28, 2007 until terminated. Either party may terminate the Shionogi Agreement in the event of an uncured breach. Shionogi has the right of termination without cause. In the event of termination, all license and rights granted to Shionogi shall terminate and shall revert back to us. We developed peramivir under a license from the University of Alabama Birmingham (&#x201c;UAB&#x201d;) and have paid sublicense payments to UAB on the upfront payments and will owe sublicense payments on any future event payments and/or royalties received by us from Shionogi.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:29pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;"><i>&#xa0;</i></span></p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">6</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:29pt;margin-top:0pt;text-align:justify;"><span style="color:#000000;"><i>Shionogi Royalty Monetization and Non-Recourse Notes Payable</i>.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:29pt;margin-top:0pt;text-align:justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">On March 9, 2011, we completed a $30.0 million financing transaction to<i> </i>monetize certain future royalty and milestone payments under the Shionogi Agreement.&#xa0; Pursuant to the transaction, Royalty Sub issued $30.0 million in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due 2020 (the &#x201c;PhaRMA Notes&#x201d;) in a private placement to institutional investors. The PhaRMA Notes were issued under an indenture, dated as of March 9, 2011 (the &#x201c;Indenture&#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee.&#xa0; We received net proceeds of $22.7 million from this transaction.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">As part of the transaction, we entered into a purchase and sale agreement, dated as of March 9, 2011, with Royalty Sub, whereby we transferred to Royalty Sub, among other things, (i) our rights to receive commercial royalty and milestone payments from Shionogi under the Shionogi Agreement and (ii) the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below under &#x201c;Foreign Currency Hedge,&#x201d; the &#x201c;Currency Hedge Agreement&#x201d;) put into place by us in connection with the transaction. Royalty payments are paid by Shionogi in Japanese yen, and milestone payments are paid in U.S. dollars. Our collaboration with Shionogi was not impacted by this transaction.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Principal and interest on the PhaRMA Notes are payable from, and are secured by, (i) the rights to royalty and milestone payments under the Shionogi Agreement, which were transferred by us to Royalty Sub, and (ii) payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14.0% per annum, payable annually in arrears on September 1st of each year (the &#x201c;Payment Date&#x201d;). We remain entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment by Royalty Sub of the PhaRMA Notes.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Royalty Sub&#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of our pledge of our equity interests in Royalty Sub in support of the PhaRMA Notes. We may, but are not obligated to, make capital contributions to a capital account that may be used to redeem, or on up to one occasion pay any interest shortfall on, the PhaRMA Notes.</span>&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In September 2014, Royalty Sub was unable to pay the full amount of interest payable in September 2013 by the next succeeding payment date for the PhaRMA Notes, which was September 1, 2014. This inability constituted an event of default under the terms of the Indenture. Accordingly, we have classified the PhaRMA Notes and related accrued interest as current liabilities on our balance sheet since that time. The PhaRMA Notes matured on December 1, 2020, at which time the outstanding principal amount of the PhaRMA Notes of $30.0 million, together with all accrued and unpaid interest of $20.6 million, was due in full.&#xa0; As of December 31, 2020, the PhaRMA Notes remained in default, and we will continue to record the liability and accrued interest owed until it is determined that we are no longer the financial obligor.</span>&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The failure by Royalty Sub to repay in full the outstanding principal amount of the PhaRMA Notes, together with any accrued and unpaid interest, at the December 1, 2020 final maturity date, constituted an additional event of default under the PhaRMA Notes.&#xa0; As a result of the continuing events of default under the PhaRMA Notes, the holders of the PhaRMA Notes may foreclose on the collateral securing the PhaRMA Notes and our equity interests in Royalty Sub, and they may exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes and we might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential foreclosure, we believe the primary impact to us would be the loss of future royalty payments from Shionogi and the legal costs associated with retiring the PhaRMA Notes. As a result, we do not currently expect the continuing events of default on the PhaRMA Notes to have a significant impact on our future results of operations or cash flows. However, there can be no assurance that this will be the case or that we will not otherwise be adversely affected as a result of the continuing events of default under the PhaRMA Notes.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Indenture does not contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, events of default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:5pt;margin-top:0pt;text-align:justify;"><span style="color:#000000;"><i>Foreign Currency Hedge </i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;"><i>&#xa0;</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">In connection with the issuance by Royalty Sub of the PhaRMA Notes, we entered into the Currency Hedge Agreement to<i> </i>hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, we had the right to purchase dollars and sell yen at a rate of 100 yen per dollar. The final tranche of the options under the Currency Hedge Agreement expired in November 2020.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Currency Hedge Agreement did not qualify for hedge accounting treatment; therefore, mark-to-market adjustments are recognized in our Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments resulted in losses of $0.6 million, $0.4 million, and $1.0 million for the twelve months ended December 30, 2020, 2019, and 2018, respectively. In addition, realized currency exchange gains of $0.7 million, $0.9 million, and $1.0 million were recognized in 2020, 2019, and 2018, respectively, related to the exercise of the U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">7</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Green Cross Corporation (&#x201c;Green Cross&#x201d;)</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">In June 2006, we entered into an agreement with Green Cross to develop and commercialize peramivir<i> </i>in Korea. Under the terms of the agreement, Green Cross is responsible for all development, regulatory, and commercialization costs in Korea. Under the agreement, we received a one-time license fee of $250,000. The license provides that we will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay us a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea. Both parties have the right to terminate the agreement in the event of an uncured material breach. In the event of termination, all rights, data, materials, products, and other information would be transferred to us.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">In August 2010, we announced that Green Cross had received marketing and manufacturing approval from the Korean Food &amp; Drug Administration for i.v. peramivir, under the commercial name PERAMIFLU. PERAMIFLU is intended to treat patients with influenza A &amp; B viruses, including pandemic H1N1 and avian influenza. Green Cross received the indication of single dose administration of 300 mg i.v. peramivir.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Mundipharma</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>&#xa0;</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We are party to an exclusive, royalty bearing right and license agreement with Mundipharma for the development and<i> </i>commercialization of Mundesine for use in oncology. The agreement, as amended and restated, provides for the possibility of future event payments totaling $15.0 million for achieving specified regulatory events for certain indications and provides that we will receive tiered royalties ranging from mid-to high-single digit percentages of net product sales in each country where Mundesine is sold by Mundipharma. We licensed forodesine and other PNP inhibitors from AECOM/IRL (as defined below) and will owe sublicense payments to AECOM/IRL on all milestone payments and royalties received by us from Mundipharma.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd.</b></i><i><b> (&#x201c;AECOM&#x201d; and &#x201c;IRL,&#x201d; respectively)</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;"><i>&#xa0;</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">In June 2000, we licensed a series of potent inhibitors of PNP from AECOM and IRL (together, the &#x201c;Licensors&#x201d;). The lead product candidate from this collaboration is forodesine. We have obtained worldwide exclusive rights to develop and ultimately distribute it, or any other, product candidates that might arise from research on these inhibitors. We have the option to expand our license agreement with the Licensors to include other inventions in the field made by the investigators or employees of the Licensors. Under this agreement, as amended and restated, we have agreed to use commercially reasonable efforts to develop these drugs and to pay certain milestone payments for each licensed product (which range in the aggregate from $1.4 million to almost $4.0 million per indication) for future development, single digit royalties on net sales of any resulting product made by us, and to share a portion of future payments received from other third-party partners, if any. In addition, we have agreed to pay annual license fees, which can range from $150,000 to $500,000, that are creditable against actual royalties and other payments due to the Licensors. The Licensors have also granted us an exclusive worldwide license of galidesivir for any antiviral use.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>The University of Alabama at Birmingham (&#x201c;UAB&#x201d;) </b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>&#xa0;</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We currently have agreements with UAB for influenza neuraminidase and complement<i> </i>inhibitors. Under the terms of these agreements, UAB performed specific research for us in return for research payments and license fees. UAB has granted us certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed with us. We have agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other third-party partners. We have completed the research under the UAB agreements. These two agreements have initial 25-year terms, are automatically renewable for five-year terms throughout the life of the last patent, and are terminable by us upon three months&#x2019; notice and by UAB under certain circumstances. Upon termination, both parties shall cease using the other parties&#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions, and UAB shall resume full ownership of all UAB licensed products. There is currently no activity between us and UAB on these agreements, but when we license this technology, such as in the case of the Shionogi and Green Cross agreements, or commercialize products related to these programs, we will owe sublicense fees or royalties on amounts received.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Government Contracts</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;"><i>RAPIVAB (Peramivir Injection)</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;"><i>&#xa0;</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">In September 2018, HHS awarded us a $34.7 million contract for the procurement of up to 50,000 doses of RAPIVAB over a five-year period, including an initial base order of 10,000 doses. In each of September 2019 and 2020, HHS exercised its options to purchase an additional 10,000 doses of RAPIVAB. We delivered a total of 20,000 doses of RAPIVAB and recorded approximately $13.9 million of product sales in 2019. We expect to deliver at least one shipment of 10,000 doses within the contract in 2021, totaling approximately $6.9 million in product sales. The RAPIVAB purchases by HHS will supply the Strategic National Stockpile, the nation&#x2019;s largest supply of life-saving pharmaceuticals and medical supplies for use in a public health emergency.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">8</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;"><i>Galidesivir</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;"><i>&#xa0;</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In March 2015, BARDA/HHS awarded us a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This BARDA/HHS contract has a potential value of $39.1 million if all contract options are exercised. As of the date of this report, a total of $20.6 million has been awarded under exercised options within this contract.</span>&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In September 2013, NIAID/HHS contracted with us for the development of galidesivir as a treatment for Marburg, and subsequently, Yellow Fever and Ebola virus disease. All options under this contract have been awarded, and the total value of the contract, as amended, is $45.9 million, inclusive of the $2.9 million added to the contract in August 2020 to support the development of galidesivir. In August 2020, NIAID/HHS awarded us a new $43.9 million contract for the manufacture and evaluation of the safety, efficacy, and tolerability of galidesivir.&#xa0; NIAID/HHS made an initial award of $6.3 million under this new contract.&#xa0; See &#x201c;Products and Product Candidates -- Galidesivir&#x201d; above.&#xa0; Based on our ongoing discussions with NIAID/HHS, we expect NIAID to continue its support for the development of galidesivir with a focus on biodefense threats, such as Marburg virus disease, and to discontinue the pursuit of a COVID-19 indication for galidesivir.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The contracts with BARDA/HHS and NIAID/HHS are cost-plus-fixed-fee contracts. That is, we are entitled to receive reimbursement for all costs incurred in accordance with the contracts provisions that are related to the development of peramivir and galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress and the continuation of the contract is based on our performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are also terminable by the government at any time for breach or without cause.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>&#xa0;</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Patents and Proprietary Information</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Our success will depend in part on our ability to obtain and enforce patent protection for our products, methods, processes, and other proprietary technologies, preserve our trade secrets, and operate without infringing on the proprietary rights of other parties, both in the United States and in other countries. We own or have rights to certain proprietary information, proprietary technology, issued and allowed patents and patent applications which relate to compounds we are developing. We actively seek, when appropriate, protection for our products, proprietary technology, and proprietary information by means of U.S. and foreign patents, trademarks, and contractual arrangements. In addition, we rely upon trade secrets and contractual arrangements to protect certain of our proprietary information, proprietary technology, and products and product candidates.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. Our ability to maintain and solidify our proprietary position for our technology will depend on our success in obtaining effective patent claims and enforcing those claims once granted. We do not know whether any of our patent applications or those patent applications that we license will result in the issuance of any patents. Our issued patents and those that may issue in the future, or those licensed to us, may be challenged, invalidated, rendered unenforceable or circumvented, which could limit our ability to stop competitors from marketing related products or the length of term of patent protection that we may have for our products. In addition, the rights granted under any issued patents may not provide us with competitive advantages against competitors with similar compounds or technology. Furthermore, our competitors may independently develop similar technologies or duplicate any technology developed by us in a manner that does not infringe our patents or other intellectual property. Because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any of our product candidates or those developed by our partners can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the patent.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">As of December 31, 2020, we have been issued approximately 21 U.S. patents that expire between 2021 and 2039 and that relate to our kallikrein inhibitor compounds, neuraminidase inhibitor compounds, BSAV compounds and PNP inhibitor compounds. We have licensed a number of compounds protected by certain composition of matter patents from AECOM and IRL, totaling three additional U.S. patents that expire between 2023 and 2029. Additionally, we have approximately 24 Patent Cooperation Treaty or U.S. patent applications pending related to kallikrein inhibitor compounds, neuraminidase inhibitor compounds, BSAV compounds, PNP inhibitor compounds, FOP program compounds, and complement-mediated disease program compounds. Our pending applications may not result in issued patents, our patents may not cover the products of interest or may not be enforceable in all, or any jurisdictions and our patents may not provide us with sufficient protection against competitive products or otherwise be commercially viable. After expiration of composition of matter patents for our products and product candidates, we may rely on data exclusivity, or in some cases, method of use patents. The enforceability of these patents varies from jurisdiction to jurisdiction and may not be allowed or enforceable in some territories where we may seek approval. We may not have the funds to continue patent prosecution or to defend all of our existing patents in our current patent estate and may selectively abandon patents or patent families worldwide or in certain territories.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Our success is also dependent upon the skills, knowledge and experience of our scientific and technical personnel, none of which is patentable. To help protect our rights, we require all employees, consultants, advisors and partners to enter into confidentiality agreements, which prohibit the disclosure of confidential information to anyone outside of BioCryst and, where possible, require disclosure and assignment to us of their ideas, developments, discoveries, and inventions. These agreements may not provide adequate protection for our trade secrets, know-how, or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">9</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Competition</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The pharmaceutical and biotechnology industries are intensely competitive. Many companies, including biotechnology, chemical and pharmaceutical companies, are actively engaged in activities similar to ours, including research, development, and commercialization of drugs for the treatment of rare medical conditions. Many of these companies have substantially greater financial and other resources, larger research and development staffs, and more extensive commercial and manufacturing organizations than we do. In addition, many have considerable experience in preclinical testing, clinical trials, and other regulatory approval procedures. In addition, there are also academic institutions, governmental agencies and other research organizations who conduct research in areas in which we are working. We expect to encounter significant competition for any of the pharmaceutical products we plan to develop. Companies that successfully complete clinical trials, obtain required regulatory approvals, and commence commercial marketing and sales of their products may achieve a significant competitive advantage.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>HAE</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>&#xa0;</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">HAE is an autosomal dominant disease characterized by painful, unpredictable, recurrent attacks of inflammation affecting the hands, feet,<i> </i>face, abdomen, urogenital tract, and the larynx. The inflammation can be disfiguring, debilitating, or in the case of laryngeal attacks, life-threatening. Prevalence for HAE is uncertain but is estimated to be approximately 1 case per 33,000 to 67,000 persons without known differences among ethnic groups and is caused by deficient (Type I) or dysfunctional (Type II) levels of C1-Inhibitor (&#x201c;C1-INH&#x201d;), a naturally occurring molecule that is known to inhibit kallikrein, bradykinin, and other serine proteases in the blood. If left untreated, HAE can result in a mortality rate as high as 40% primarily due to upper airway obstruction. There are several licensed therapies for HAE, including the following:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:3pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:3pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">C1-INH replacement therapy is available as an acute therapy (Berinert&#xae;) and as a prophylactic therapy (Haegarda&#xae; and Cinryze&#xae;). These therapies are dosed subcutaneously and intravenously. Recombinant C1-INH (Ruconest&#xae;) is also available as an acute therapy.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:3pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:3pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">Kallikrein Inhibitors -&#xa0;Kalbitor&#xae; (ecallantide) is a specific recombinant plasma kallikrein inhibitor that is dosed subcutaneously by healthcare providers to treat acute HAE attacks. Takhzyro&#x2122; (lanadelumab-flyo) is a monoclonal antibody approved for prophylaxis of HAE attacks and can be self-administered as a subcutaneous injection.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:3pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:3pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">Bradykinin receptor antagonist -&#xa0;Firazyr&#xae; (icatibant) is the treatment of acute attacks and is administered by subcutaneous administration. To date, there have been seven generic forms of icatibant approved by the FDA.</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;">&#xa0;</td>
     <td> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&#xa0;</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:3pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:3pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">Other medications -&#xa0;Prophylactic administration of synthetic attenuated androgens (generically available as danazol or stanozolol) has been utilized to reduce the frequency or severity of attacks. However, long-term use of danazol or stanozolol may result in liver damage, virilization and arterial hypertension. Six-month liver function tests, annual lipid profiles, and biennial hepatic ultrasound are recommended for patients on chronic androgen therapy.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:3pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">We are aware of a number of HAE therapies in clinical development that, if approved, may compete with ORLADEYO. These include:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:25pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:9.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><span style="color:#000000;"><b>Company</b></span></span></p> </td>
     <td style="vertical-align:bottom;width:2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:18%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><span style="color:#000000;"><b>Asset</b></span></span></p> </td>
     <td style="vertical-align:bottom;width:2.1%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:27%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><span style="color:#000000;"><b>Mechanism of Action</b></span></span></p> </td>
     <td style="vertical-align:bottom;width:2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:15.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><span style="color:#000000;"><b>Route of Administration</b></span></span></p> </td>
     <td style="vertical-align:bottom;width:2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:7.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><span style="color:#000000;"><b>Trial Phase</b></span></span></p> </td>
     <td style="vertical-align:bottom;width:2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:12.4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="text-decoration: underline; "><span style="color:#000000;"><b>Role in Therapy</b></span></span></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:9.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">KalVista</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:18%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">KVD-900</span></p> </td>
     <td style="vertical-align:top;width:2.1%;">&#xa0;</td>
     <td style="vertical-align:top;width:27%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Kallikrein inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Oral</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:7.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">II</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:12.4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Acute treatment</span></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:9.3%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:18%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">KVD-824</span></p> </td>
     <td style="vertical-align:top;width:2.1%;">&#xa0;</td>
     <td style="vertical-align:top;width:27%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Kallikrein inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Oral</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:7.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">I</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:12.4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Prophylaxis</span></p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:9.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Pharvaris</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:18%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">PHA121 (PHVS416/PHVS719)</span></p> </td>
     <td style="vertical-align:top;width:2.1%;">&#xa0;</td>
     <td style="vertical-align:top;width:27%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">B2 bradykinin antagonist</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Oral</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:7.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">II</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:12.4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Acute and Prophylaxis</span></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:9.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Attune</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:18%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">ATN-249</span></p> </td>
     <td style="vertical-align:top;width:2.1%;">&#xa0;</td>
     <td style="vertical-align:top;width:27%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Kallikrein inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Oral</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:7.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">I</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:12.4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Prophylaxis</span></p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:9.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">CSL</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:18%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">CSL312</span></p> </td>
     <td style="vertical-align:top;width:2.1%;">&#xa0;</td>
     <td style="vertical-align:top;width:27%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Anti-factor XII mAb</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">IV/Subcutaneous</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:7.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">III</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:12.4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Prophylaxis</span></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:9.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Ionis</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:18%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">IONIS-PKK-LRx</span></p> </td>
     <td style="vertical-align:top;width:2.1%;">&#xa0;</td>
     <td style="vertical-align:top;width:27%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Antisense inhibitor of prekallikrein</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Subcutaneous</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:7.5%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">II</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:12.4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Prophylaxis</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:24pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Complement-Mediated Diseases</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:24pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>&#xa0;</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:24pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Several rare diseases are known to be mediated by defects of the complement system, including PNH, atypical hemolytic uremic syndrome (&#x201c;aHUS&#x201d;), complement 3 glomerulopathy (&#x201c;C3G&#x201d;), and myasthenia gravis. Alexion Pharmaceuticals, Inc.&#x2019;s Soliris<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup> (eculizumab) is a C5 inhibitor approved for PNH, aHUS, myasthenia gravis, and neuromyelitis optica spectrum disorder. Soliris had global sales of over $3.9 billion in 2019. Alexion also recently received FDA approval for Ultomiris&#x2122; (ravulizumab), a longer-acting C5 inhibitor, as a treatment for PNH in late 2018 and aHUS in late 2019. Global sales for Ultomiris were $339 million in 2019. In addition, Alexion acquired Achillion, a developer of oral Factor D inhibitors, in early 2020. In December 2020, Alexion agreed to be acquired by AstraZeneca, with the deal expected to close in the third quarter of 2021.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:25pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">10</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: left;"><span style="color:#000000">In addition to BCX9930, we are aware of a number of complement pathway-based products in development, which include:</span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:97.6%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:14.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>Company</b></span></p> </td>
     <td style="vertical-align:bottom;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:22.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>Asset</b></span></p> </td>
     <td style="vertical-align:bottom;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:19.9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><b>Mechanism of Action</b></span></p> </td>
     <td style="vertical-align:bottom;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:22.6%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><b>Route of Administration</b></span></p> </td>
     <td style="vertical-align:bottom;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:11.7%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><b>Trial Phase</b></span></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:14.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Apellis</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:22.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Pegcetacoplan&#xa0;(APL-2)</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:19.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">C3 Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:22.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Subcutaneous</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">NDA</span></p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:14.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Akari</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Nomacopan</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:19.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">C5 Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Subcutaneous</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">III</span></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:14.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Roche</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Crovalimab (RG6107)</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:19.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">C5 Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">IV / Subcutaneous</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">III</span></p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:14.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Regeneron</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Pozelimab</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:19.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">C5 Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">IV / Subcutaneous</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">III</span></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:14.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Omeros</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Narsoplimab</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:19.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">MASP-2</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">IV / Subcutaneous</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">BLA</span></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:14.1%;">&#xa0;</td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">OMS906</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:19.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">MASP-3</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Subcutaneous</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">I</span></p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:14.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Alexion</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Danicopan&#xa0;(ALXN2040)</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:19.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Factor D Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Oral</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">III</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:14.1%;">&#xa0;</td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Vermicopan&#xa0;(ALXN2050)</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:19.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Factor D Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Oral</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">II</span></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:14.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Novartis</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Iptacopan (LNP023)</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:19.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Factor B Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Oral</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">III</span></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:14.1%;">&#xa0;</td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Tesidolumab</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:19.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">C5 Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">IV</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">II</span></p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:14.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">ChemoCentryx</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Avacopan</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:19.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">C5aR Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Oral</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">NDA</span></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:14.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Ra / UCB</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Zilucoplan</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:19.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">C5 Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Subcutaneous</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">II</span></p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:14.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Alnylam</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Cemdisiran</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:19.9%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">C5 Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:22.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Subcutaneous</span></p> </td>
     <td style="vertical-align:top;width:2.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">II</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Amgen (Phase 3), Samsung, and Isu Abxis are also in clinical trials developing biosimilars of eculizumab.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>FOP</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>&#xa0;</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">FOP is a rare, severely disabling condition characterized by HO. HO can occur in muscles, tendons, and soft tissue. FOP patients progressively become bound by this irregular ossification, with restricted movement and fused joints, resulting in deformities and premature mortality. There are currently no approved treatments for FOP.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:25pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">In addition to BCX9250, we are aware of a number of FOP therapies in clinical development, which include:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:10%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>Company</b></span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>Asset</b></span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:37.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>Mechanism of Action</b></span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:21.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>Route of Administration</b></span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:11.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>Trial Phase</b></span></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:10%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Ipsen</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Palovarotene</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:37.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Retinoic Acid Receptor (RAR) Gamma Agonist</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:21.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Oral</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:11.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">III</span></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10%;">&#xa0;</td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">BLU-782</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:37.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">ALK-2 Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:21.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Oral</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">I</span></p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Regeneron</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Garetosmab</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:37.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Anti-activin A</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:21.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">IV</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">II</span></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:10%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Incyte</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">INCB00928</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:37.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">ALK-2 Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:21.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Oral</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">I</span></p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:10%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Keros</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.7%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">KER-047</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:37.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">ALK-2 Inhibitor</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:21.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Oral</span></p> </td>
     <td style="vertical-align:top;width:2%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">I</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:26pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Antivirals</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:26pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>&#xa0;</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The pharmaceutical market for products that prevent or treat influenza is very competitive. Key competitive factors for RAPIVAB<i> </i>(peramivir injection) include, among others, efficacy, ease of use, safety, price and cost-effectiveness, storage and handling requirements, and reimbursement. A number of products are currently available in the U.S. and/or other counties, including Japan, for the prevention or treatment of influenza, including seasonal flu vaccines, F. Hoffmann-La Roche Ltd.&#x2019;s (&#x201c;Roche&#x201d;) TAMIFLU<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup> (oseltamivir), generic oseltamivir, GlaxoSmithKline plc&#x2019;s (&#x201c;GSK&#x201d;) RELENZA<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>, Genentech and Shiongi&#x2019;s XOFLUZA&#x2122; and Daiichi Sankyo Co., Ltd.&#x2019;s INAVIR<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>. In addition, FUJIFILM Corporation&#x2019;s favipiravir, a polymerase inhibitor, is approved in Japan.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Various government entities throughout the world are offering incentives, grants, and contracts to encourage additional investment into preventative and therapeutic agents against influenza, which may have the effect of further increasing the number of our competitors and/or providing advantages to certain competitors.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Galidesivir is a product candidate in our BSAV research program and is currently being developed under contracts with NIAID/HHS and BARDA/HHS. The objective of our BSAV program is to develop galidesivir as a broad-spectrum therapeutic for viruses that pose a threat to national health and security. The U.S. Government is investing in a number of programs intended to address gaps in its medical countermeasure plan. Currently, there are five investigational therapeutics under a compassionate use/expanded access framework that can be available in an outbreak setting to treat Ebola virus disease.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In order to compete successfully in these and other therapeutic areas, we must develop proprietary positions in patented drugs for therapeutic markets that have not been satisfactorily addressed by conventional research strategies and, in the process, expand our expertise in structure-based drug design. Our product candidates, even if successfully tested and developed, may not be adopted by physicians over other products and may not offer economically feasible alternatives to other therapies.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Research and Development</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We initiated our research and development activities in 1986. We have assembled a scientific research staff with expertise in a broad base of advanced research technologies, including protein biochemistry, X-ray crystallography, chemistry, and pharmacology. Our research facilities, located in Birmingham, Alabama, include protein biochemistry and organic synthesis laboratories, testing facilities, X-ray crystallography, computer and graphics equipment and facilities to make product candidates on a small scale for early-stage clinical trials.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">11</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Compliance</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We conduct our business in an ethical, fair, honest, and lawful manner. We act responsibly, respectfully, and with integrity in our relationships with patients, health care professionals, collaborators, governments, regulatory entities, stockholders, suppliers, and vendors.&#xa0;</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In order to ensure compliance with applicable laws and regulations, our Chief Financial Officer, Chief Legal Officer, and Senior Vice President of Human Resources oversee compliance training, education, auditing, and monitoring; enforce disciplinary guidelines for any infractions of our corporate polices; implement new policies and procedures; respond to any detected issues; and undertake corrective action procedures. Our controls address compliance with laws and regulations that govern public pharmaceutical companies, including, but not limited to, the following: federal and state law, such as the Sarbanes-Oxley Act of 2002 and the U.S. Foreign Corrupt Practices Act of 1977; Nasdaq listing requirements; the regulations of the Financial Industry Regulatory Authority, the SEC, the FDA, and HHS; and applicable laws and regulations administered by foreign regulatory authorities, including those of the EU, the U.K., and Japan. Our standard operating procedures are designed to provide a framework for corporate governance in accordance with ethical standards and best legal practices.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Government Regulation</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">The FDA regulates the pharmaceutical and biotechnology industries in the U.S., and our product candidates are subject to extensive and rigorous domestic government regulations prior to commercialization. The FDA regulates, among other things, the development, testing, manufacture, safety, efficacy, record-keeping, labeling, storage, approval, advertising, promotion, sale and distribution of pharmaceutical products. In foreign countries, our products are also subject to extensive regulation by foreign governments. These government regulations are a significant factor in the production and marketing of any pharmaceutical products that we develop. Failure to comply with applicable FDA and other regulatory requirements at any stage during the regulatory process may subject us to sanctions, including:</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">delays;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">warning letters;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">fines;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">product recalls or seizures;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">injunctions;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">penalties;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">refusal of the FDA to review pending market approval applications or supplements to approval applications;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">total or partial suspension of production;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">civil penalties;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">withdrawals of previously approved marketing applications; and</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">criminal prosecutions.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">The regulatory review and approval process is lengthy, expensive, and uncertain. Before obtaining regulatory approvals for the commercial sale of any products, we or our partners must demonstrate that our product candidates are safe and effective for use in humans. The approval process takes many years, substantial expenses may be incurred, and significant time may be devoted to clinical development.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">The policies of the FDA and foreign regulatory authorities may change, and additional government regulations may be enacted which could prevent or delay regulatory approval of our product candidates or approval of new indications for our existing products. We cannot predict the likelihood, nature, or extent of adverse governmental regulation that might arise from future legislative or administrative action, either in the United States or abroad.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>FDA Regulation</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Before testing potential product candidates in humans, we carry out laboratory and animal studies to determine safety and biological activity. After completing preclinical trials, we must file an investigation new drug application (&#x201c;IND&#x201d;), including a proposal to begin clinical trials, with the FDA. Thirty days after filing an IND, a phase 1 human clinical trial can start, unless the FDA places a hold on the trial.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">Clinical trials to support a new drug application (&#x201c;NDA&#x201d;) are typically conducted in three sequential phases, but the phases may overlap.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Phase 1 &#x2014; During phase 1, which involves the initial introduction of the drug into healthy volunteers, the drug is tested to assess metabolism, PK, and pharmacological actions and safety, including side effects associated with increasing doses.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">12</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:26pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Phase 2 &#x2014; Phase 2 usually involves trials in a limited patient population to: (1) assess the efficacy of the drug in specific, targeted indications; (2) assess dosage tolerance and optimal dosage; and (3) identify possible adverse effects and safety risks.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Phase 3 (pivotal) &#x2014; If a compound is found to be potentially effective and to have an acceptable safety profile in phase 2 evaluations, phase 3 clinical trials, also called pivotal studies, major studies, or advanced clinical trials, are undertaken to further demonstrate clinical efficacy and to further test for safety within an expanded patient population at geographically dispersed clinical trial sites. In general, the FDA requires that at least two adequate and well-controlled phase 3 clinical trials be conducted.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">Initiation and completion of the clinical trial phases are dependent on several factors, including things that are beyond our control. For example, the clinical trials cannot begin at a particular site until that site receives approval from its Institutional Review Board (&#x201c;IRB&#x201d;), which reviews the protocol and related documents. This process can take several weeks to several months. In addition, clinical trials are dependent on patient enrollment, but the rate at which patients enroll in the study depends on:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">willingness of investigators to participate in a study;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">ability of clinical sites to obtain approval from their IRB;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the availability of the required number of eligible subjects to be enrolled in a given trial;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the availability of existing or other experimental drugs for the disease we intend to treat;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the willingness of patients to participate; and</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the patients meeting the eligibility criteria.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">Delays in planned patient enrollment may result in increased expense and longer development timelines.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">After successful completion of the required clinical testing, generally an NDA is submitted. Upon receipt of the NDA, the FDA will review the application for completeness. Within 60 days, the FDA will determine if the application is sufficiently complete to warrant full review and will consider the application &#x201c;filed&#x201d; at that time. Also upon receipt of the application, the FDA will assign a review priority to the application. Priority review applications are usually reviewed within 6 months; standard review applications are usually reviewed within 10 months. The FDA may refer NDAs for new molecular entities to an appropriate advisory committee for review and evaluation in regard to providing a recommendation as to whether the application should be approved. The FDA is not bound to follow the recommendation of an advisory committee.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Following the review of the application, which may include requests for additional information from the sponsor and results from inspections of manufacturing and clinical sites, the FDA will issue an &#x201c;action letter&#x201d; on the application. The action letter will either be an &#x201c;approval letter,&#x201d; in which case the product may be lawfully marketed in the United States, or a &#x201c;complete response letter.&#x201d; A complete response letter will state that the FDA cannot approve the NDA in its present form and, usually, will describe all of the specific deficiencies that the FDA has identified in the application. The complete response letter, when possible, will include the FDA&#x2019;s recommended actions to place the application in a condition for approval. Deficiencies can be minor (e.g., labeling changes) or major (e.g., requiring additional clinical trials). A complete response letter may also be issued before the FDA conducts the required facility inspection and/or reviews labeling, leaving the possibility that additional deficiencies in the original NDA could be subsequently cited. An applicant receiving a complete response letter is permitted to resubmit the NDA addressing the identified deficiencies (in which case a new two- or six-month review cycle will begin), or withdraw the NDA. The FDA may consider a failure to take action within one year of a complete response letter to be a request to withdraw, unless the applicant has requested an extension of time in which to resubmit the NDA. If the FDA approves an NDA, the marketing of the product will be limited to the particular disease states and conditions of use that are described in the product label.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We and all of our contract manufacturers are also required to comply with the applicable FDA current Good Manufacturing Practice, or cGMP, regulations during clinical development and to ensure that the product can be consistently manufactured to meet the specifications submitted in an NDA. The cGMP regulations include requirements relating to product quality, as well as the corresponding maintenance of records and documentation. Manufacturing facilities must be approved by the FDA before they can be used to manufacture our products. Based on an inspection, the FDA determines whether manufacturing facilities are in compliance with applicable regulations. Manufacturing facilities in non-United States countries that are utilized to manufacture drugs for distribution into the United States are also subject to inspection by the FDA. Additionally, failure to comply with local regulatory requirements could affect production and availability of product in relevant markets.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Foreign Regulation</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In addition to regulations in the United States, we are subject to a variety of foreign regulatory requirements governing human clinical trials and marketing approval for drugs. The foreign regulatory approval process includes all of the risks associated with FDA approval set forth above, as well as additional country-specific regulations. Whether or not we obtain FDA approval for a product, we must obtain approval of a product by the comparable regulatory authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary greatly from country to country.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">13</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">For example, under EU regulatory systems, we may submit marketing authorizations either under a centralized or decentralized procedure. The centralized procedure provides for the grant of a single marketing authorization that is valid for all EU member states. The decentralized procedure provides for mutual recognition of national approval decisions, and the holder of a national marketing authorization may submit an application to the remaining member states. The U.K.&#x2019;s exit from the EU, or Brexit, has caused political and economic uncertainty, including in the regulatory framework applicable to our operations and product candidates, and this uncertainty may persist for years.</span>&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Under the Japanese regulatory system administered by the Japanese Pharmaceuticals and Medical Devices Agency (&#x201c;PMDA&#x201d;), pre-marketing approval and clinical studies are required for all pharmaceutical products. To obtain manufacturing/marketing approval, we must submit an application for approval to the MHLW with results of nonclinical and clinical studies to show the quality, efficacy, and safety of a new drug. A data compliance review, good Clinical Practices, or GCP, on-site inspection, cGMP audit, and detailed data review are undertaken by the PMDA. The application is then discussed by the committees of the Pharmaceutical Affairs and Food Sanitation Council (&#x201c;PAFSC&#x201d;). Based on the results of these reviews, the final decision on approval is made by MHLW. In Japan, the National Health Insurance system maintains a Drug Price List specifying which pharmaceutical products are eligible for reimbursement, and the MHLW sets the prices of the products on this list. Following the January 2021 approval of ORLADEYO in Japan, negotiations regarding the reimbursement price with MHLW have begun. The price will be determined within 60 to 90 days following approval unless the applicant disagrees, which may result in extended pricing negotiations. The government generally introduces price cut rounds every other year and also mandates price decreases for specific products. New products judged innovative or useful, that are indicated for pediatric use, or that target orphan or small population diseases, however, may be eligible for a pricing premium. The Japanese government has also promoted the use of generics, where available.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Human </b><b>Capital </b><b>Resources</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">As of January 31, 2021, we had approximately 246 employees, of whom approximately 119 employees were engaged in the research and development function of our operations. Our research and development staff, approximately 48 of whom hold Ph.D. or M.D. degrees, have diversified experience in biochemistry, pharmacology, X-ray crystallography, synthetic organic chemistry, computational chemistry, medicinal chemistry, clinical development and regulatory affairs. </span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">We believe that our ability to successfully execute on our strategic initiatives is highly dependent upon our ability to recruit, retain, and reward our employees.&#xa0; We engage in targeted recruitment strategies to fill highly skilled positions.&#xa0; Our employees enjoy competitive salaries and benefits, as well as equity participation.&#xa0; Our compensation philosophy is designed to provide an appealing, competitive, and rewarding compensation program that encourages high personal and company performance, strong cultural and ethical behavior, and incentives aligned with stockholder interests.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">We are committed to providing a workplace that protects the health and wellbeing of our employees.&#xa0; All employees are required to abide by our Code of Conduct and Compliance Plan and health and safety parameters and to contribute to a positive, inclusive, and friendly company culture. Where we believe such arrangements can be effective, we have implemented flexible working arrangements, including work from home arrangements, for our employees, in part, to encourage employee health and wellness during the global COVID-19 pandemic. We consider our relations with our employees to be satisfactory.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Corporate Information</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We are a Delaware corporation originally founded in 1986. Our corporate headquarters is located at 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703, and our corporate telephone number is (919) 859-1302. For more information about us, please visit our website at www.biocryst.com. The information on our website is not incorporated into this Form 10-K.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Financial Information</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: justify; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">For information related to our revenues, profits, net loss and total assets, in addition to other financial information, please refer to the Consolidated Financial Statements and Notes to Consolidated Financial Statements contained in Part II, Item 8 of this report. Financial information about revenues derived from foreign countries is included in Note 1 to Consolidated Financial Statements contained in this report.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Available Information</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Our website address is www.biocryst.com. We make available, free of charge, at our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. We also make available at our website copies of our audit committee charter, compensation committee charter, corporate governance and nominating committee charter and our code of business conduct, which applies to all our employees as well as the members of our Board of Directors. Any amendment to, or waiver from, our code of business conduct will be posted on our website.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><a id="i1a" title="i1a" href="#"></a>ITEM 1A.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<i><b>RISK FACTORS</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:28.7pt;"><span style="color:#000000;"><i>An investment in our stock involves risks. You should carefully read this entire report and consider the following uncertainties and risks, which may adversely affect our business, financial condition or results of operations, along with all of the other information included in our other filings with the </i><i>SEC</i><i>, before deciding to buy our common stock.</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">14</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Risks Relating to Our Business</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:justify;"><span style="color:#000000;"><span style="text-decoration: underline; ">Risks Relating to COVID-19</span></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:justify;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:9pt;margin-top:0pt;text-align:justify;text-indent:-0.4pt;"><span style="color:#000000;"><i><b>Our business, operations, clinical development or commercialization plans and timelines, and access to capital could be adversely affected by the effects of the recent COVID-19 pandemic on us or on third parties with whom we conduct business, including without limitation our development partners, manufacturers, </b></i><i><b>clinical</b></i><i><b> research organizations (&#x201c;</b></i><i><b>CROs</b></i><i><b>&#x201d;)</b></i><i><b>, and others, as well as on the regulatory and government agencies with whom we work.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 24.3pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">The COVID-19 pandemic has spread to multiple countries around the world, is affecting the United States and global economies, and may cause significant disruptions to our business, operations, and clinical development or commercialization plans and timelines, as well as the business and operations of third parties with whom we conduct business. For example, quarantines, shelter-in-place, similar government orders and evolving business policies and procedures have impacted and may continue to impact, among other things: (1) our personnel and those of third parties on whom we rely, including our development partners (such as Torii), manufacturers, CROs, and others; (2) the conduct of our current and future clinical trials and commercial interactions; and (3) the operations of the FDA, EMA, PMDA and other health and governmental authorities, which could result in delays of reviews and approvals.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:24.3pt;"><span style="color:#000000;">If our operations or those of third parties with whom we conduct business are impaired or curtailed as a result of these events, the development and commercialization of our products and product candidates could be stopped or delayed, or the costs of such development and commercialization activities could increase, any of which could have a material adverse impact on our business. For example, if interruptions related to COVID-19 were to impair our or Torii&#x2019;s ability to perform under the Torii Agreement to complete our regulatory interactions in Japan, including with respect to the pending approval of a reimbursement price for ORLADEYO for the treatment of HAE, then the timing and success of our development and commercialization of ORLADEYO in Japan could be severely impacted.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.3pt;"><span style="color:#000000;">Our suppliers or other vendors may be unable to meet their obligations to us or perform their services as expected as a result of the COVID-19 pandemic or other health epidemics. In such circumstances, we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner. Such delays could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. Although we carefully manage our relationships with our suppliers and vendors, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.3pt;"><span style="color:#000000;">In addition, our clinical trials have been and may continue to be affected by the COVID-19 pandemic. For example, the acceleration of COVID-19 slowed startup of the inadequate C5 responder cohorts in our complement oral Factor D inhibitor program and, as a result, delayed the reporting of related data. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic or concerns among patients about participating in clinical trials during a pandemic. Some patients may have difficulty following certain aspects of clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our inability to successfully recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 or experience additional restrictions by their institutions, city, or state could adversely impact our clinical trial operations.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:17pt;margin-top:0pt;text-align:left;text-indent:24.3pt;"><span style="color:#000000;">If global health concerns prevent the FDA, EMA, PMDA or other regulatory authorities from conducting their inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA, EMA, PMDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business and clinical development plans and timelines.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:24.3pt;"><span style="color:#000000;">We have implemented work-from-home policies for our employees, which may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.3pt;"><span style="color:#000000;">The spread of COVID-19, which has caused a broad impact globally, may also materially affect our access to capital. While the future economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, the pandemic could result in significant disruption of global financial markets, reducing our ability to access the equity or debt capital markets or obtain other sources of capital, which could negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:left;text-indent:24.3pt;"><span style="color:#000000;">The global pandemic of COVID-19 continues to evolve rapidly. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. These effects could be material, and we will continue to monitor the COVID-19 situation closely. We do not yet know the full extent and magnitude of the impacts that COVID-19 has had or will have on our business, on the healthcare system, or on the global economy. In addition, the COVID-19 pandemic could have the effect of heightening many of the other risks described below.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:left;text-indent:24.3pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">15</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="text-decoration: underline; ">Financial and Liquidity Risks</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>We have incurred losses since our inception, expect to continue to incur such losses, and may never be profitable.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">Since our inception, we have not achieved sustained profitability. We expect to incur additional losses for the foreseeable future, and our losses could increase as our research and development efforts and commercial activities progress. We expect that such losses will fluctuate from quarter to quarter and that losses and fluctuations may be substantial. To become profitable, we, or our collaborative partners, must successfully manufacture and develop product candidates, receive regulatory approval, and successfully commercialize our products and/or enter into profitable commercialization arrangements with other parties. It could take longer than expected before we receive, or we may never receive, significant revenue from any current or future license agreements or significant revenues directly from product sales.&#xa0; Even if we are able to successfully commercialize our existing products, or to develop new commercially viable products, certain obligations we have to third parties, including, without limitation, our obligation to pay RPI royalties on certain ORLADEYO and BCX9930 revenues under the Royalty Purchase Agreement, may reduce the profitability of such products.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Because of the numerous risks and uncertainties associated with developing our product candidates, launching new products, and their potential for commercialization, we are unable to predict the extent of any future losses. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. If we are unable to achieve and sustain profitability, the market value of our common stock will likely decline.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13pt; text-align: left;"><i><b>We may need to raise additional capital in the future.&#xa0; If we are unable to raise capital when needed, we may need to adjust our operations.</b></i></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">We have sustained operating losses for the majority of our corporate history and expect that our 2021 expenses will exceed our 2021 revenues. We expect to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations.</span>&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">Our liquidity needs will be largely determined by the success of operations in regard to the commercialization of our products and the progression of our product candidates in the future. Our plans for managing our liquidity needs primarily include controlling the timing and spending on our research and development programs, raising additional funds through equity financings, and commercializing our approved products. We also may consider other plans to fund operations including: (1) securing or increasing U.S. Government funding of our programs, including obtaining additional and delivering on procurement contracts; (2) out-licensing rights to certain of our products or product candidates, pursuant to which we would receive cash milestone payments and/or royalties; (3) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (4) obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (5) reducing spending on research and development programs, including by discontinuing and suspending development; and/or (6) restructuring operations to change our overhead structure.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">There can be no assurance that any of our plans will be successful or that additional capital will be available to us on reasonable terms, or at all, when needed. If we are unable to obtain sufficient additional capital, we may be forced to adjust or curtail our operations; delay, reduce, or stop ongoing clinical trials or commercialization efforts; cease operations altogether; or file for bankruptcy.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><span style="text-decoration: underline; ">Risks Relating to Drug Development and Commercialization</span></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;"><i><b>Our success depends upon our ability to advance our product candidates through the various stages of development, especially through the clinical trial process, and to receive regulatory approval for the commercial sale of our product candidates.</b></i></span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">To receive the regulatory approvals necessary for the commercial sale of our product candidates, we or our partners must demonstrate through preclinical studies and clinical trials that each product candidate is safe and effective. The development process and related regulatory process are complex and uncertain. The preclinical and clinical development of our product candidates is susceptible to the risk of failure inherent at any stage of drug development, including failure to demonstrate efficacy and safety, the occurrence of adverse events that are severe or medically or commercially unacceptable, our or our partners&#x2019; failure to comply with trial protocols, applicable regulatory requirements, and industry standards, or a determination by the FDA or any comparable foreign regulatory authority that a product candidate may not continue development or be approved in accordance with our development plans or at all. We cannot guarantee that any preclinical studies and clinical trials will be conducted as planned or completed on schedule, if at all, or that the results of such trials will be sufficient to support regulatory approval for our product candidates.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Progression of our product candidates through the clinical development process is dependent upon our trials indicating that our product candidates have adequate safety and efficacy in the patients being treated by achieving pre-determined safety and efficacy endpoints according to the clinical trial protocols. Failure to achieve any of these endpoints in any of our programs, including BCX9930, BCX9250, galidesivir, and our other rare disease product candidates, could result in delays in or modifications to our trials or require the performance of additional unplanned trials. If any of our product candidates is associated with adverse events or undesirable side effects or has properties that are unexpected, we may need to abandon development or limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Product candidates that initially show promise in clinical or preclinical testing could later be found to cause undesirable or unexpected side effects that could result in delays in the development of our product candidates, significant unexpected costs, or the termination of programs. The development plans for our product candidates, including our clinical trials, may not be adequately designed or executed, which could negatively affect the outcome and analysis of study results. Because of the cost and duration of clinical trials, we may decide to discontinue development of product candidates that are unlikely to show favorable results in clinical trials, unlikely to help advance a product to the point of a meaningful collaboration, or unlikely to have reasonable commercial potential.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">16</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Undesirable or inconclusive data in our pre-clinical studies and clinical trials or side effects in humans could result in the FDA or foreign regulatory authorities (including, e.g., the EMA, the MHLW or the MHRA) refusing to approve a product candidate for any targeted indications or imposing restrictions or warnings that could impact development or the ultimate commercial viability of a product candidate. In addition, the FDA or foreign regulatory authorities may determine that study data from our product candidates necessitates additional studies or study designs which differ from our planned development strategy, and such regulatory authorities may also require patient monitoring and testing or may implement restrictions or other conditions on our development activities, any of which could materially impact the cost and timing of our planned development strategy. We, our partners, the FDA, or foreign regulatory authorities may suspend or terminate clinical trials at any time if we or they believe the trial participants face unacceptable health risks.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 25pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Our ability to successfully complete the clinical development process is dependent upon many factors, including but not limited to:</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 26pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">our or our partners&#x2019; ability to secure suitable clinical sites and investigators and to enroll and maintain an adequate number of patients on a timely basis or at all;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 15pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">patients that enroll in a clinical trial may not comply with the clinical trial protocol or maintain contact with investigators to provide complete data during and after treatment;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">our product candidates may not prove to be either safe or effective or may produce unfavorable or inconclusive results;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 6pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">we or our partners may decide, or be required by regulatory authorities, to suspend or terminate clinical research for various reasons, including a finding that the participants are being exposed to unacceptable health risks, undesirable side effects or other unexpected characteristics of the product candidate, noncompliance with regulatory requirements or their standards of conduct, or findings of undesirable effects caused by a chemically or mechanistically similar product or product candidate;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 9pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">regulatory authorities may disagree with our or our partners&#x2019; clinical trial protocols or our or their interpretation of data from preclinical studies and clinical trials;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">clinical protocols or study procedures may not be adequately designed or followed by the investigators;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">formulation improvements may not work as expected, which could negatively impact commercial demand for our product candidates;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 15pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">regulatory authorities may fail to approve or subsequently find fault with the manufacturing processes or facilities of third-party manufacturers with which we or our partners enter into agreements for clinical and commercial supplies;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 11pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">the supply or quantity of raw materials or manufactured product candidates or other materials necessary to conduct development activities may be insufficient, inadequate, or unavailable at an acceptable cost, and we or our partners may experience interruptions in supply;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 5pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">our or our partners&#x2019; development plans may be delayed or changed as a result of changes in development strategy, the impact of new or different regulations, requirements, and guidelines, or other unexpected events or conditions;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">the cost of pre-clinical studies and clinical trials may be greater than we anticipate;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 8pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">we or our third-party contractors, including those manufacturing our product candidates or components or ingredients thereof, or conducting clinical trials or laboratory testing on our or our partners&#x2019; behalf, may fail to comply with regulatory requirements and industry standards or meet contractual obligations in a timely manner or at all; and</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">the impact of the COVID-19 pandemic on one or more of the foregoing factors.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 3pt 0pt 0pt; text-align: left; text-indent: 24.05pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Clinical trials are lengthy and expensive. Many of the factors listed above could result in increased clinical development costs or longer clinical development times for any of our programs. We or our partners incur substantial expense for, and devote significant time to, preclinical testing and clinical trials, yet we cannot be certain that the tests and trials will ever result in the commercial sale of a product. Even if we or our partners successfully complete clinical trials for our product candidates, we or our partners might not file the required regulatory submissions in a timely manner, may not receive regulatory approval for the product candidates, in which case we would be unable to generate any revenues from product sales or licensing arrangements, or any product candidate, if approved, may be subject to restrictions on labeling, marketing, distribution, prescribing, and use, which could adversely impact the sales of such product.</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 12pt 0pt 13pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>If our development collaborations with third parties, such as our development partners, contractors and contract research organizations, fail, the development of our product candidates will be delayed or stopped.</b></i></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 25pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">We rely heavily upon third parties for many important stages of our product candidate development, including but not limited to:</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 20pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">discovery of natural proteins that cause or enable biological reactions necessary for the progression of the disease or disorder, called enzyme targets;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">execution of certain pharmacology preclinical studies and late-stage development for our compounds and product candidates;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">management&#xa0;of our phase 1, 2 and 3 clinical trials, including medical monitoring, laboratory testing, and data management;&#xa0;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">execution of toxicology studies that may be required to obtain approval for our product candidates;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">formulation improvement strategies and methods;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 9pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">manufacturing the starting materials and drug substance required to formulate our products and the product candidates to be used in our clinical trials, toxicology studies and any potential commercial product; and</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">management of certain regulatory interactions outside of the United States.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">17</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Our failure to engage in successful collaborations at any one of these stages would greatly impact our business. If we do not license enzyme targets or inhibitors from academic institutions or from other biotechnology companies on acceptable terms, our drug development efforts would suffer. Similarly, if the contract research organizations or third-party contractors that conduct our initial or late-stage clinical trials, conduct our toxicology or other studies, manufacture our starting materials, drug substance and product candidates, provide laboratory testing or other services in connection with our clinical trials, or assist with our regulatory function breach their obligations to us, perform their services inconsistent with industry standards, or fail to comply with regulatory requirements, this would delay or prevent both the development of our product candidates and the availability of any potential commercial product.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">If we lose our relationship with any one or more of these parties, we could experience a significant delay in both identifying another comparable provider and then contracting for its services. We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it is likely that this provider may need additional time to respond to our needs and may not provide the same type or level of service as the original provider. In addition, any provider that we retain will be subject to applicable FDA current Good Laboratory Practices, current Good Manufacturing Practices (&#x201c;cGMP&#x201d;) and current Good Clinical Practices, and comparable foreign standards. We do not have control over compliance with these regulations by these providers. Consequently, if these practices and standards are not adhered to by these providers, the development and commercialization of our product candidates could be delayed. If any of the foregoing risks are realized, our business, financial condition and results of operations could be materially adversely affected.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;"><i><b>If we fail to obtain additional financing or acceptable partnership arrangements, we may be unable to complete the development and commercialization of our products and product candidates or continue operations.</b></i></span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">As our programs advance, our costs are likely to increase. Our current and planned discovery, development, approval, and commercialization efforts will require significant capital. Our expenses, revenues and cash utilization rate could vary significantly depending on many factors, including: our ability to obtain regulatory approval for our product candidates, including BCX9930, BCX9250, and galidesivir; our ability to maintain regulatory approval for, successfully commercialize, and achieve market acceptance of our products, including ORLADEYO; our ability to raise additional capital; the amount of funding we receive from partnerships with third parties for the development and commercialization of our products and product candidates (including our collaborations with Torii, BARDA/HHS, and NIAID/HHS); the commercial success of our products achieved by our partners; the amount or profitability of any orders for peramivir or galidesivir by any government agency or other party; the progress and results of our current and proposed clinical trials for our product candidates; and the progress made in the manufacture of our lead products and the progression of our other programs.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">In order to continue future operations, progress our drug development programs, and commercialize our current products and product candidates, we will be required to raise additional capital. In addition to seeking strategic partnerships, transactions and government funding, we may access the equity or debt markets, incur additional borrowings, or seek other sources of funding to meet liquidity needs at any time. Additional funding, whether through additional sales of securities, additional borrowings, royalty or other monetization transactions, collaborative arrangements with partners, including corporate partners such as Torii and governmental agencies such as BARDA/HHS or NIAID/HHS, or from other sources, may not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable than those of our currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or rights of our existing stockholders. Additional borrowings may subject us to more restrictive covenants than are currently applicable to us under our Credit Agreement (as defined under &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations -- Overview -- Recent Corporate Highlights -- Financing Transactions&#x201d; in Part II, Item 7 of this report). In addition, collaborative arrangements may require us to transfer certain material rights to such corporate partners. Insufficient funds or lack of an acceptable partnership may require us to delay, scale-back or eliminate certain of our research and development programs.&#xa0;</span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">Our ability to raise additional capital when needed or at all may be limited and may greatly depend upon our success in commercializing and achieving market acceptance of ORLADEYO and the success of our current drug development programs, including the progress, timeline and ultimate outcome of the development programs (including but not limited to formulation progress, long-term human safety studies, and carcinogenicity, drug-drug interaction, toxicity, or other required studies) for BCX9250 for the treatment of FOP, BCX9930 for diseases of the complement system, our broad-spectrum antiviral program, including galidesivir, and other rare disease product candidates, as well as any post-approval studies for our products. In addition, constriction and volatility in the equity and debt markets, including as a result of the impacts of COVID-19, may restrict our future flexibility to raise capital when such needs arise. Furthermore, we have exposure to many different industries, financing partners and counterparties, including commercial banks, investment banks and partners (which include investors, licensing partners, and the U.S. Government) which may be unstable or may become unstable in the current economic and political environment, including as a result of the impacts of COVID-19. Any such instability may impact these parties&#x2019; ability to fulfill contractual obligations to us or they might limit or place burdensome conditions upon future transactions with us. Also, it is possible that suppliers may be negatively impacted. Any such unfavorable outcomes in our current programs or unfavorable economic conditions could place severe downward pressure on the price of our common stock and may decrease opportunities to raise capital in the capital or credit markets, and further could reduce the return available on invested corporate cash, which, if severe and sustained, could have a material and adverse impact on our results of operations and cash flows and limit our ability to continue development and commercialization of our products and product candidates.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">18</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:36pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>If we or our partners do not obtain governmental approval for our product candidates</b></i><i><b> or maintain governmental approval for our products</b></i><i><b>, we or our partners will not be able to commercialize and sell these </b></i><i><b>products and </b></i><i><b>potential products, which would significantly harm our business because we will receive no revenue.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">We or our partners must obtain regulatory approval before marketing or selling our products. If the FDA or a comparable foreign regulatory authority delays or denies regulatory approval of one of our product candidates, or revokes approval of a previously approved product, we would be unable to market or sell the product in the applicable jurisdiction and would not receive revenue from sales or licensing arrangements related thereto, which could have a material and adverse impact on our business.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">The process of preparing for and obtaining regulatory approval in any jurisdiction may be lengthy and expensive, and approval is never certain. Because of the risks and uncertainties inherent to the development process, including risks and uncertainties related to the impact of COVID-19, our product candidates could take a significantly longer time to gain regulatory approval than we expect or may never gain approval. As discussed under &#x201c;Risk Factors&#x2014;Risks Relating to Our Business&#x2014;Risks Relating to Drug Development and Commercialization&#x2014;Our success depends upon our ability to advance our products through the various stages of development, especially through the clinical trial process, and to receive regulatory approval for the commercial sale of our products,&#x201d; we or our partners may<i> </i>experience any number of unfavorable outcomes during or as a result of pre-clinical studies and clinical trials that could delay or prevent regulatory approval of our product candidates, or negatively impact our management&#x2019;s credibility, our value and our operating results.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Even if the FDA or foreign regulatory authorities approve a product candidate, the approval may limit the indicated uses for a product candidate, impose other restrictions on the product candidate, and/or may require post-approval studies that could impair the commercial viability of a product candidate. If we receive approval to market our potential products, whether in the United States or internationally, we will continue to be subject to extensive regulatory requirements. These requirements are wide ranging and govern, among other things:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">adverse drug experience reporting regulations;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">product promotion;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">product manufacturing, including good manufacturing practice requirements; and</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">product changes or modifications.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Our failure to comply with existing or future regulatory requirements for regulatory approval, or our loss of, or changes to, previously obtained approvals, could impair our ability to generate any revenues from product sales or licensing arrangements, which could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>We focus on rare diseases, which may create additional risks and challenges.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Because we focus on developing drugs as treatments for rare diseases, we may seek orphan drug, breakthrough therapy or fast track designations for our product candidates in the United States or the equivalent designations elsewhere in the world. Often, regulatory authorities have broad discretion in determining whether or not to grant such designations. We cannot guarantee that our product candidates will receive orphan drug status from the FDA or equivalent designations from other regulatory authorities. We also cannot guarantee that we will receive breakthrough therapy, fast track, or equivalent designations, which provide certain potential benefits such as more frequent meetings with the applicable regulatory authorities to discuss development plans, intensive guidance on efficient drug development programs, and potential eligibility for rolling review or priority review. Even if we are successful in obtaining any such designations for our product candidates, such designations may not lead to faster development or regulatory review or approval and do not increase the likelihood that our product candidates will receive marketing approval. For instance, although BCX9930 for PNH has received Fast Track and Orphan Drug designations from the FDA, and ORLADEYO has a Promising Innovative Medicine designation from the MHRA, as well as orphan drug status from the EMA, we may not experience a faster development, review or approval process compared to the conventional process in the relevant jurisdictions. We may not be able to obtain or maintain these designations for ORLADEYO, BCX9930 or other product candidates that receive them, and our competitors may obtain these designations for their product candidates, which could impact our ability to develop and commercialize our product candidates or compete with such competitors, which may adversely impact our business, financial condition or results of operations.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:24pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>The commercial viability of any approved product could be compromised if the product is less effective than expected, causes undesirable side effects that were not previously identified, or fails to achieve market acceptance within the medical community.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 10pt 0pt 0pt; text-align: left; text-indent: 24.05pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">If, after obtaining regulatory approval of a product, we or others discover that it is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following adverse events could occur:</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 20pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">regulatory authorities may withdraw their approval of, or impose marketing or manufacturing restrictions on, the product, or require us or our partners to create a medication guide outlining the risks of unidentified side effects for distribution to patients;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">19</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 20pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">we or our partners may be required to recall the product, change the way the product is administered, conduct additional clinical trials, or be subject to civil or criminal penalties; and</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">the product may become less competitive and our reputation may suffer.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 24.05pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Even after receiving regulatory approval, any product could fail to gain sufficient, or even any, market acceptance by physicians, patients, third party payors, health authorities and others in the medical community. For example, physicians are often reluctant to switch their patients from existing therapies even when new and potentially more effective or convenient treatments enter the market. Further, patients often acclimate to the therapy that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch therapies due to lack of reimbursement for existing therapies. If an approved product does not achieve an adequate level of market acceptance, it may not generate significant revenues. The occurrence of any of the foregoing could have a material and adverse impact on our business.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13pt; text-align: justify; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;"><i><b>If we fail to successfully commercialize or establish collaborative relationships to commercialize certain of our products and product candidates, or if any partner terminates or fails to perform its obligations under agreements with us, potential revenues from commercialization of our products and product candidates could be reduced, delayed or eliminated.</b></i></span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: justify; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">Our business strategy is to increase the asset value of our product candidate portfolio. We believe this is best achieved by retaining full product rights or through collaborative arrangements with third parties as appropriate. As needed, potential third-party relationships could include preclinical development, clinical development, regulatory approval, marketing, sales, and distribution of our products and product candidates.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 24.05pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Currently, we have established collaborative relationships with Torii for the commercialization of ORLADEYO in Japan, with each of Shionogi and Green Cross for the development and commercialization of peramivir, and with Mundipharma for the development and commercialization of Mundesine (forodesine). The process of establishing and implementing collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 28pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory commercial, regulatory or clinical results, including post approval clinical commitments, a change in business strategy, a change of control or other reasons;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">our contracts for collaborative arrangements may expire;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">our partners may choose to pursue alternative technologies, including those of our competitors;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 20pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">we may have disputes with a partner that could lead to litigation or arbitration, such as the recent arbitration proceeding between us and SUL, which could result in substantial costs and divert the attention of our management;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">we do not have day-to-day control over the activities of our partners and have limited control over their decisions;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 17pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">our ability to generate future event payments and royalties from our partners depends upon their abilities to establish the safety and efficacy of our product candidates, obtain regulatory approvals and achieve market acceptance of products developed from our product candidates;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 13pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may utilize our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">we or our partners may not devote sufficient capital or resources towards our products and product candidates; and</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">we or our partners may not comply with applicable government regulatory requirements.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 4pt 0pt 54pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">If we or our partners fail to fulfill our responsibilities in a timely manner, or at all, our commercialization efforts related to that collaboration could be reduced, delayed or terminated, or it may be necessary for us to assume responsibility for activities that would otherwise have been the responsibility of our partner. If we are unable to establish and maintain collaborative relationships on acceptable terms, we may have to delay or discontinue further development or commercialization of one or more of our products or product candidates, undertake commercialization activities at our own expense or find alternative sources of funding. Any delay in the development or commercialization of our products and product candidates would severely affect our business, because if our product candidates do not progress through the development process or reach the market in a timely manner, or at all, we may not receive any revenues from product sales or licensing arrangements.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>The results of our partnership with Torii may not meet our current expectations.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">We have an agreement with Torii for the development and commercialization of ORLADEYO in Japan. We do not have a history of working with Torii and cannot predict the success of this collaboration. Our ability to realize the expected benefits of this collaboration, including with respect to the receipt or amounts of potential milestone or royalty payments, is subject to a number of risks, including that applicable regulatory agencies may not provide reimbursement approvals on a timely basis or at all, the commercial potential of ORLADEYO may not meet our current expectations, we or Torii may fail to comply with our respective obligations under the Torii Agreement, and third parties may fail to perform their obligations to us on a timely basis or at all.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">20</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">The Torii Agreement provides for a potential milestone payment upon receipt of a reimbursement price approval from Japan&#x2019;s National Health Insurance system in excess of the threshold specified in the Torii Agreement, which we may not receive on a timely basis or at all. The Torii Agreement also provides that we will be entitled to receive tiered royalty payments, the amounts of which will depend upon the amount of annual net sales of ORLADEYO in Japan during each calendar year and other factors. We remain responsible for regulatory activities with respect to ORLADEYO in Japan for one year after the first commercial sale. We expect to use third parties to satisfy many of our obligations under the Torii Agreement, including but not limited to our regulatory and other responsibilities in Japan. If our interactions, or those of our third party agents, are unsuccessful, we could fail to meet our obligations under the Torii Agreement, fail to receive reimbursement authorization in excess of the specified threshold, which could negatively impact the commercial success and the partnership, impact the economic benefit expected or require additional development of ORLADEYO.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Torii may terminate the Torii Agreement under certain limited circumstances, including upon one year&#x2019;s written notice after the sixth anniversary of the first commercial sale of ORLADEYO in Japan. If the Torii Agreement is terminated in connection with these provisions, we will no longer be entitled to receive any milestone or royalty payments thereunder, which could have a material adverse impact on our business and results of operations.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Torii will have sole control over and decision-making authority with respect to commercialization activities for ORLADEYO for the prevention of HAE attacks in Japan, subject to oversight from a joint steering committee. Therefore, our receipt of, and the amounts of, any royalty payments under the Torii Agreement are dependent upon Torii&#x2019;s successful performance of such commercialization activities. In addition, competitive products and variations in patient demand, prescription levels, reimbursement determinations or other factors may limit the commercial potential of ORLADEYO in Japan, which could materially reduce the amount of any royalties we would be entitled to receive under the Torii Agreement.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Under the Torii Agreement, we will be responsible for supplying Torii with its required amounts of ORLADEYO for commercial sale. If, due to the failure of our third-party contract manufacturers to produce sufficient drug product, we fail to supply to Torii the required amounts of ORLADEYO, then Torii&#x2019;s ability to successfully commercialize ORLADEYO in Japan could be materially impaired, and we may receive less royalty income under the Torii Agreement, or none at all.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:34pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;"><span style="color:#000000;">Any of the foregoing risks could materially adversely impact our ability to obtain reimbursement price approval for ORLADEYO in Japan and to perform our obligations under the Torii Agreement, which could materially reduce the economic benefits of the Torii Agreement to us and impair or result in the termination of our collaboration with Torii.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>&#xa0;</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>There can be no assurance that our commercialization efforts, methods, and strategies for</b></i><i><b> our products or technologies</b></i><i><b> will succeed</b></i><i><b>, and our future revenue generation is uncertain.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 13pt 0pt 0pt; text-align: left; text-indent: 24.05pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">There can be no assurance that our commercialization efforts, methods and strategies will succeed. Although we have expanded and added experienced professionals to our internal commercial team, as a company we do not have a great deal of experience in commercializing our product candidates or technologies. In addition, we may be unable to establish or sufficiently increase our sales, marketing and distribution capabilities for products we currently, or plan to, commercialize. Our ability to receive revenue from products we or our partners commercialize is subject to several risks, including:</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 13pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 35pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">we or our partners may fail to successfully complete clinical trials, or satisfy post-marketing commitments, sufficient to obtain and keep regulatory agency marketing approval;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 15pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">many&#xa0;competitors are more experienced and have significantly more resources, and their products could reach the market faster, be more cost effective or have a better efficacy or tolerability profile than our products and product candidates;&#xa0;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 18pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">we&#xa0;may fail to employ a comprehensive and effective intellectual property strategy, which could result in decreased commercial value of our Company and our products and product candidates;&#xa0;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 16pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">we may fail to employ a comprehensive and effective regulatory strategy, which could result in a delay or failure in commercialization of our products;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">our ability to successfully commercialize our products is affected by the competitive landscape, which cannot be fully known at this time;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">revenue from product sales would depend on our ability to obtain and maintain favorable pricing;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">reimbursement is constantly changing, which could greatly affect usage of our products;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 32pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">future revenue from product sales would depend on our ability to successfully complete clinical studies, obtain regulatory approvals, and manufacture, market, distribute and commercialize our approved drugs; and</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 32pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">the impact of the COVID-19 pandemic on us or our partners.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 32pt 0pt 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 32pt 0pt 0pt; text-align: left; text-indent: 27pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Even if we are able to successfully commercialize our existing products, or to develop new commercially viable products, certain obligations we have to third parties, including, without limitation, our obligations to pay royalties on certain ORLADEYO and BCX9930 revenues under the Royalty Purchase Agreement may reduce the profitability of such products.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">21</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:7pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>We expect to </b></i><i><b>continue </b></i><i><b>expand</b></i><i><b>ing</b></i><i><b> our development and regulatory capabilities and implement</b></i><i><b>ing</b></i><i><b> sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">We expect to continue experiencing significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, regulatory affairs, sales, marketing, and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. For example, we expanded our internal commercial team in 2020 in preparation for the commercial launch of ORLADEYO. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. In addition, if a commercial launch for any product or product candidate for which we recruit a commercial team and establish marketing capabilities in any region is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:1pt;margin-top:0pt;text-align:left;"><i><b><span style="color:#000000;">We depend on third-party vendors&#xa0;</span>in the manufacture and distribution of </b></i><span style="color:#000000;"><i><b>our products, product candidates and the materials for our product candidates. If we cannot rely on existing third-party </b></i><i><b>vendors</b></i><i><b>, we will be required to incur significant costs and potential delays in finding new third-party </b></i><i><b>vendors, which could adversely impact the development and commercialization timeframes for our products and product candidates</b></i><i><b>.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">We depend on third-party vendors, including third-party manufacturers, distributors, and specialty pharmacies, in the manufacture and distribution of our products, product candidates, and the materials for our product candidates. Often, especially in the early development and commercialization process, we have only one or limited sources for a particular product or service, such as manufacturing and/or distribution. <span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">We depend on these third-party vendors to perform their obligations in a timely manner and in accordance with applicable governmental regulations. Our third-party vendors, particularly our third-party manufacturers and distributors, which may be the only vendor we have engaged for a particular product or service, may encounter difficulties with meeting our requirements, including but not limited to problems involving, as applicable:</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">insufficient resources being devoted in the manner necessary to satisfy our requirements within expected timeframes;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">inconsistent production yields;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">product liability claims or recalls of commercial product;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">difficulties in scaling production to commercial and validation sizes;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">interruption of the delivery of materials required for the manufacturing process;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">failure to distribute commercial supplies of our products to commercial vendors or end users in a timely manner;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">scheduling of plant time with other vendors or unexpected equipment failure;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">potential catastrophes that could strike their facilities or have an effect on infrastructure;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">potential impurities in our drug substance or products that could affect availability of product for our clinical trials or future commercialization;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">poor quality control and assurance or inadequate process controls;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">failure to provide us with accurate or timely information regarding inventories, the number of patients who are using our products, or serious adverse events and/or product complaints regarding our products;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">inability of third parties to satisfy their financial obligations to us or to others;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">potential breach of the manufacturing or distribution agreement by the third party;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">possible termination or nonrenewal of a critical agreement by the third party at a time that is costly or inconvenient to us; and</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 16pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">lack of compliance or cooperation with regulations and specifications or requests set forth by the FDA or other foreign regulatory agencies or local customs, particularly associated with ORLADEYO, BCX9930, BCX9250, galidesivir, peramivir and our early stage compounds.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24.05pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Many additional factors could cause production or distribution interruptions with the manufacture and distribution of any of our products and product candidates, including human error, natural disasters, pandemics, labor disputes, acts of terrorism or war, equipment malfunctions, or raw material shortages.&#xa0;</span>If our commercial distribution partners are not able to satisfy our requirements within the expected timeframe, or are unable to provide us with accurate or timely information and data, including inventories and sales, serious adverse events, and/or product complaints, our business, including our commercial launch and sales of ORLADEYO may be at risk. In addition, if specialty pharmacy services, including our third-party call center services, which provide patient support and financial services, prescription intake and distribution, reimbursement adjudication, and ongoing compliance support is not effectively managed, the continuance of our commercial launch and sales of ORLADEYO may be delayed or compromised.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 24.05pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">In addition, our contract manufacturers may not be able to manufacture the materials required for our product candidates at a cost or in quantities necessary to make them commercially viable. Our raw materials, drug substances, and product candidates are manufactured by a limited group of suppliers, including some at a single facility. If any of these suppliers were unable to produce these items, this could significantly impact our supply of product candidate material for further preclinical testing and clinical trials. To date, our third-party manufacturers have met our manufacturing requirements, but they may not continue to do so. Furthermore, changes in the manufacturing process or procedure, including a change in the location where the drug is manufactured or a change of a third-party manufacturer, may require prior review and approval in accordance with the FDA&#x2019;s cGMP and comparable foreign requirements. This review may be costly and time-consuming and could delay or prevent the launch of a product. The FDA or foreign regulatory authorities may at any time implement new standards, or change their interpretation and enforcement of existing standards, for manufacture, packaging or testing of products. If we or our contract manufacturers are unable to comply, we or they may be subject to regulatory action, civil actions or penalties any of which could be costly to us and could result in a delay or shortage of product.</span>&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">If we are unable to maintain current third-party relationships, or enter into new agreements with additional third parties on commercially reasonable terms, or if there is poor manufacturing or distribution performance or failure to comply with any regulatory agency on the part of any of our third-party vendors, we may not be able to complete development of, obtain timely approval of, or commercialize, our products and product candidates.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">22</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1pt 0pt 13pt; text-align: left;"><i><b><span style="color:#000000;">Commercialization of our products by </span>us and&#xa0;<span style="color:#000000;">our partners is subject to the potential commercialization risks described herein and numerous additional risks. Any potential revenue benefits to us, including in the form of milestone payments, royalties or other consideration are highly speculative.</span></b></i></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 24.05pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Commercialization success of our products is uncertain and is subject to all the risks and uncertainties disclosed in our other risk factors relating to drug development and commercialization. In addition, commercialization of our products is subject to further risks and may be negatively impacted by a number of factors, including, but not limited to, the following:</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 35pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">our products may not prove to be adequately safe and effective for market approval in markets other than the markets in which they are currently approved;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 21pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">necessary funding for post-marketing commitments and further development of our products may not be available timely, at all, or in sufficient amounts;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">advances in competing products could substantially replace potential demand for our products;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 31pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">government and third-party payors may not provide sufficient coverage or reimbursement which would negatively impact the demand for our products;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 31pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">we may not be able to supply commercial material to our partners and our partners may not be able to maintain or establish sufficient and acceptable commercial manufacturing, either directly or through third-party manufacturers;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 29pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">the commercial demand and acceptance for our products by healthcare providers and by patients may not be sufficient to result in substantial product revenues to our partners and may result in little to no milestones or royalties to us;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">effectiveness of marketing and commercialization efforts for our products by our partners;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">market satisfaction with existing alternative therapies;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">perceived efficacy relative to other available therapies;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">disease prevalence;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">cost of treatment;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">pricing and availability of alternative products;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">marketing and sales activities of competitors;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">shifts in the medical community to new treatment paradigms or standards of care; and</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">relative convenience and ease of administration.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="text-decoration: underline; ">Risks Relating to Competing in Our Industry</span></span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>&#xa0;</b></i></span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13pt; text-align: left;"><i><b>We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.</b></i></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">The biotechnology and pharmaceutical industries are highly competitive and subject to rapid and substantial technological change. There are many companies seeking to develop products for the same indications that we currently target. Our competitors in the United States and elsewhere are numerous and include, among others, major multinational pharmaceutical and chemical companies and specialized biotechnology firms. Most of these competitors have greater resources than we do, including greater financial resources, larger research and development staffs and more experienced manufacturing, marketing, and sales organizations. In addition, most of our competitors have greater experience than we do in conducting clinical trials and obtaining FDA and other regulatory approvals. Accordingly, our competitors may succeed in obtaining FDA or other regulatory approvals of product candidates more rapidly than we do or for products that compete with our products. Companies that complete clinical trials, obtain required regulatory approvals, and commence commercial sale of their drugs before we do may achieve a significant competitive advantage, including patent and FDA exclusivity rights that would delay our ability to market products. We face, and will continue to face, competition in the commercialization of our products, licensing of potential product candidates for desirable disease targets, licensing of desirable product candidates, and development and marketing of our product candidates from academic institutions, government agencies, research institutions and biotechnology and pharmaceutical companies. Competition may also arise from, among other things:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">other drug development technologies;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">methods of preventing or reducing the incidence of disease, including vaccines; and</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">new small molecule or other classes of therapeutic agents.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Developments by others may render our </b></i><i><b>products, </b></i><i><b>product candidates</b></i><i><b>,</b></i><i><b> or technologies obsolete or noncompetitive.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">We received FDA approval of ORLADEYO, an oral, once-daily therapy for the prevention of HAE, in December 2020. In addition, we are performing research on or developing products for the treatment of several other rare diseases, including diseases of the complement system and FOP, as well as developing broad spectrum antivirals for use as medical countermeasures. We expect to encounter significant competition for our pharmaceutical products and product candidates. Companies that complete clinical trials, obtain required funding or government support, obtain required regulatory approvals and commence commercial sales or stockpiling orders of their products before their competitors may achieve a significant competitive advantage. There are licensed therapies for HAE (including Berinert<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>, Haegarda<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>, Cinryze<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>, Kalbitor<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>, Takhzyro<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>, Firazyr<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup> (icatibant), generic icatibant, and Ruconest<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>), therapies for certain complement-mediated diseases such as PNH, aHUS, myasthenia gravis, and neuromyelitis optica spectrum disorder (Soliris<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup> and Ultomiris<sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup>), products for the prevention or treatment of influenza (seasonal flu vaccines, Tamiflu<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup> (oseltamivir), generic oseltamivir, Relenza<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>, and Inavir<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>, favipiravir, and Xofluza&#x2122;), and a number of additional products in clinical development in these therapeutic areas and for the treatment of FOP. In addition, various government entities throughout the world may offer incentives, grants and contracts to encourage additional investment into preventative and therapeutic agents against viruses such as influenza, coronavirus, Ebola, and others, which may have the effect of further increasing the number of our competitors and/or providing advantages to certain competitors. See &#x201c;Business&#x2014;Competition&#x201d; in Part I, Item 1 of this report for further discussion of our competitors, competitive products or programs, and the competitive conditions in these and other therapeutic areas.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">23</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">If one or more of our competitors&#x2019; products or programs, including potential competitors not currently identified, are successful, the market for our products may be reduced or eliminated.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:25pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Compared to us, many of our competitors and potential competitors have substantially greater:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">capital resources;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">research and development resources, including personnel and technology;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">regulatory experience;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">preclinical study and clinical testing experience;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">manufacturing, marketing, and sales experience; and</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">production facilities.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:12.45pt;"><span style="color:#000000;">Any of these competitive factors could impede our funding efforts, render our products, product candidates, or technologies noncompetitive or eliminate or reduce demand for our products and product candidates.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><span style="text-decoration: underline; ">Legal and Regulatory Risks</span></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:11pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>We are subject to various laws and regulations related to our products and product candidates and, if we or our partners do not comply with these laws and regulations, we could face substantial penalties.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Our or our partners&#x2019; activities related to approved products or, following their regulatory approval, any of our product candidates under development, such as BCX9930, BCX9250, and galidesivir, are subject to regulatory and law enforcement authorities in the United States (including the FDA, the Federal Trade Commission, the Department of Justice, and state and local governments) and their foreign equivalents (including the EMA, MHLW, MHRA, and others).</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">We are responsible for reporting adverse drug experiences, have responsibility for certain post-approval studies, and may have responsibilities and costs related to a recall or withdrawal of our products from sale in the jurisdictions in which they are approved. We may also incur liability associated with product manufacturing contracted by us or in support of any of our partners. We are required to maintain records and provide data and reports to regulatory agencies related to our products (e.g. risk evaluation and mitigation strategies, track and trace requirements, adverse events), and we may incur certain promotional regulatory and government pricing risks, all of which could have a material adverse impact on our operations and financial condition. Similar responsibilities would apply upon regulatory approval of any of our other product candidates currently under development.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">In addition, we are subject to the federal physician sunshine act and certain similar physician payment and drug pricing transparency legislation in various states. We are also subject to various federal and state laws pertaining to health care &#x201c;fraud and abuse,&#x201d; including both federal and state anti-kickback and false claims laws. Outside of the United States, we may be subject to analogous foreign laws and regulations in the various jurisdictions in which we operate. These laws and regulations apply to our or our partners&#x2019; operations, sales and marketing practices, price reporting, and relationships with physicians and other customers and third-party payors. Anti-kickback laws generally prohibit a manufacturer from soliciting, offering, receiving, or paying any remuneration to generate business, including the purchase or prescription of a particular drug. Although the specific provisions of these laws vary, their scope is generally broad and there may be no regulations, guidance or court decisions that clarify how the laws apply to particular industry practices. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented for payment to third party payors (including Medicare and Medicaid) claims for reimbursement or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. The sunshine provisions apply to manufacturers with products reimbursed under certain government programs and require those manufacturers to disclose annually to the federal government certain payments made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as, ownership and investment interests held by physicians (as defined above) and their immediate family members. State laws may also require disclosure of pharmaceutical pricing information and marketing expenditures. Although we seek to comply with these statutes, it is possible that our practices, or those of our partners, might be challenged under health care fraud and abuse, anti-kickback, false claims or similar laws. Violations of the physician sunshine act and similar legislation or the fraud and abuse laws may be punishable by civil or criminal sanctions, including fines and civil monetary penalties, and future exclusion from participation in government healthcare programs.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">24</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">The principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to certain regulatory authorities, including the FDA and comparable foreign regulatory authorities. Consequently, the FDA or other regulatory authority may conclude that a financial relationship between us and a principal investigator creates a conflict of interest or otherwise affects interpretation of the study. In the event of a conflict of interest with respect to a study, the integrity of the data generated at the applicable clinical trial site may be questioned or the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or other regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span>&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">We have a number of outstanding post-approval commitments to the FDA and EMA that we retain, which we may not complete successfully or on time for any number of reasons, including but not limited to lack of funds to complete the studies and insufficient interest by appropriate sites, investigators or study subjects. For example, as a condition of the approval of RAPIVAB, we were required to complete pediatric patient trials and to submit the final results of these clinical trials to the FDA and EMA. We may be subject to penalties if we fail to comply with post-approval legal and regulatory requirements, and our products could be subject to continual recordkeeping and reporting requirements, review and periodic inspections by the FDA and other regulatory bodies. Regulatory approval of a product may be subject to limitations on the indicated uses for which the product may be marketed or to the other restrictive conditions of approval that limit our ability to promote, sell or distribute a product. Furthermore, the approval of our products and any other future product candidates may be subject to requirements for costly post-approval testing and surveillance to monitor its safety or efficacy.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Advertising and promotion are subject to stringent FDA rules and oversight, and as an NDA-holder, we may be held responsible for any advertising and promotion that is not in compliance with the rules and regulations. In particular, the claims in all promotional materials and activities must be consistent with the FDA approvals for approved products and must be appropriately substantiated and fairly balanced with information on the safety risks and limitations of the products. We are also required to engage in appropriate truthful, non-misleading, and non-promotional scientific exchange concerning our products, and applicable regulatory authorities, competitors, and other third parties may take the position that we are not in compliance with such regulations. In addition to medical education efforts, we may offer patient support services to assist patients receiving treatment with our commercially approved products which have increasingly become the focus of government investigation.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Adverse event information concerning approved products must be reviewed, and as an NDA-holder, we are required to make expedited and periodic adverse event reports to the FDA and other regulatory authorities. In addition, the research, manufacturing, distribution, sale and promotion of products are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, state and local governments, and foreign equivalents of the foregoing. All of these activities are also potentially subject to healthcare false claims and fraud and abuse laws, as well as consumer protection and unfair competition laws.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">If our operations with respect to our products that are subject to healthcare laws and regulations are found to be in violation of any of the healthcare fraud and abuse laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. Moreover, achieving and sustaining compliance with all applicable fraud and abuse laws may be costly.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:10pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Our employees and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">We are subject to the risk of fraud or other misconduct by our employees and consultants, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee and consultant misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee and consultant misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">25</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:33pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>We and our partners may be subject to new legislation, regulatory proposals and healthcare payor initiatives that may increase our costs of compliance and adversely affect our or our partners&#x2019; ability to market our products, obtain collaborators and raise capital.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">The Patient Protection and Affordable Care Act, or PPACA, made extensive changes to the delivery of health care in the U.S. The PPACA included numerous provisions that affect pharmaceutical companies, some of which became effective immediately and others of which have taken effect over the past several years. For example, the PPACA expanded health care coverage to the uninsured through private health insurance reforms and an expansion of Medicaid. The PPACA also imposed substantial costs on pharmaceutical manufacturers, such as an increase in liability for rebates paid to Medicaid, new drug discounts that must be offered to certain enrollees in the Medicare prescription drug benefit, an annual fee imposed on all manufacturers of brand prescription drugs in the U.S., and an expansion of an existing program requiring pharmaceutical discounts to certain types of hospitals and federally subsidized clinics. The PPACA also contains cost containment measures that could reduce reimbursement levels for health care items and services generally, including pharmaceuticals. It also required reporting and public disclosure of payments and other transfers of value provided by pharmaceutical companies to physicians and teaching hospitals.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">The continuing efforts of the government, insurance companies, managed care organizations and other payors of health care services to contain or reduce costs of health care could result in decreased net revenues from our pharmaceutical products and decrease potential returns from our development efforts. In addition, pharmaceutical and device manufacturers are also required to report and disclose certain payments and transfers of value to, and investment interests held by, physicians and their immediate family members during the preceding calendar year. Failure to submit required information may result in civil monetary penalties for payments, transfers of value or ownership or investment interests not reported in an annual submission. Compliance with the PPACA and state laws with similar provisions is difficult and time consuming, and companies that do not comply with these state laws face civil penalties. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">In addition, there have been a number of other legislative and regulatory proposals aimed at changing the pharmaceutical industry. For example, legislation has been enacted in certain states and at a federal level that requires development of an electronic pedigree to track and trace each prescription drug at the saleable unit level through the distribution system. Compliance with these electronic pedigree requirements may increase our operational expenses and impose significant administrative burdens. In addition, our compliance may be deemed insufficient and we could face a material adverse effect on our business, financial condition, results of operations and growth prospects. As a result of these and other new proposals, we may determine to change our current manner of operation, provide additional benefits or change our contract arrangements, any of which could have a material adverse effect on our business, financial condition and results of operations.</span>&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Adequate coverage and reimbursement in the U.S. and other markets is critical to the commercial success of our approved products. Recently in the U.S. there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, reform government program reimbursement methodologies. Individual states in the United States have been increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. Third-party payors are increasingly challenging the prices charged for medical products and services and, in some cases, imposing restrictions on the coverage of particular drugs. Many third-party payors negotiate the price of medical services and products and develop formularies which establish pricing and reimbursement levels. Exclusion of a product from a formulary can lead to its sharply reduced usage in the third-party payor&#x2019;s patient population. The process for obtaining coverage can be lengthy and costly, and we expect that it could take several months before a particular payor initially reviews our product and makes a decision with respect to coverage. For example, third-party payors may require cost-benefit analysis data from us in order to demonstrate the cost-effectiveness of our products or any other product we might bring to market. For any individual third-party payor, we may not be able to provide data sufficient to gain reimbursement on a similar or preferred basis to competitive products, or at all which may have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:24pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>We are subject to data security and privacy risks, and o</b></i><i><b>ur actual or perceived failure to comply with regulations and other legal obligations related to privacy</b></i><i><b> and</b></i><i><b> data protection could harm our business.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:24pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>&#xa0;</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">We are subject to legal obligations related to privacy and data protection. Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use, and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. For example, we are subject to the California Consumer Privacy Act, which gives California residents expanded rights to access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. We are also subject to the General Data Protection Regulation in the EU. See &#x201c;Risks Relating to Our Business&#x2014;Risks Relating to International Operations&#x2014;Our actual or perceived failure to comply with European governmental regulations and other legal obligations related to privacy, data protection and information security could harm our business&#x201d; in this section for additional discussion of international privacy laws and regulations. Failure to comply with these laws and regulations could result in government enforcement actions, private litigation, or harm to our reputation and our business.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:24pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>&#xa0;</b></i></span></p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">26</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:24pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>If because of our use of hazardous materials, we violate any environmental controls or regulations that apply to such materials, we may incur substantial costs and expenses in our remediation efforts.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:22.5pt;"><span style="color:#000000;">Our research and development involves the controlled use of hazardous materials, chemicals and various radioactive compounds. We are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and some waste products. Accidental contamination or injury from these materials could occur. In the event of an accident, we could be liable for any damages that result, and any liabilities could exceed our resources. Compliance with environmental laws and regulations or a violation of such environmental laws and regulations could require us to incur substantial unexpected costs, which would materially and adversely affect our results of operations.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><span style="text-decoration: underline; ">Intellectual Property Risks</span></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:28pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of those rights would diminish.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Our success will depend in part on our ability and the abilities of our partners to obtain, protect and enforce viable intellectual property rights including but not limited to trade name, trademark and patent protection for our Company and its products, methods, processes and other technologies we may license or develop, to preserve our trade secrets, and to operate without infringing the proprietary rights of third parties both domestically and abroad. The patent position of biotechnology and pharmaceutical companies is generally highly uncertain, involves complex legal and factual questions and has recently been the subject of much litigation. Neither the United States Patent and Trademark Office (&#x201c;USPTO&#x201d;), the Patent Cooperation Treaty offices, nor the courts of the United States and other jurisdictions have consistent policies nor predictable rulings regarding the breadth of claims allowed or the degree of protection afforded under many biotechnology and pharmaceutical patents. Further, we may not have worldwide patent protection for all of our product candidates and our intellectual property rights may not be legally protected or enforceable in all countries throughout the world. In some jurisdictions, some of our product candidates in certain programs, including our HAE program, may have short or no composition of matter patent life and we may therefore rely on orphan drug exclusivity or data exclusivity. There can be no assurance that we will obtain orphan drug exclusivity or data exclusivity in every jurisdiction. Further, in some jurisdictions, we may rely on formulation patents or method of use patents. Both the ability to achieve issuance and the enforcement of formulation and method of use patents can be highly uncertain and can vary from jurisdiction to jurisdiction, and such patents may therefore not adequately prevent competitors and potential infringers in some jurisdictions. The validity, scope, enforceability and commercial value of the rights protected by such patents, therefore, is highly uncertain.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:25pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;"><span style="color:#000000;">We also rely on trade secrets to protect technology in cases when we believe patent protection is not appropriate or obtainable. However, trade secrets are difficult to protect. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborators and advisors, our ability to receive patent protection or protect our proprietary information may be imperiled.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:25pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>We may be involved in legal proceedings to protect or enforce our patents, the patents of our partners or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming and unsuccessful. An adverse result in any legal proceeding could put one or more of our patents at risk. Our success depends in part on avoiding the infringement of other parties&#x2019; patents and other intellectual property rights as well as avoiding the breach of any licenses relating to our technologies and products. In the United States, patent applications filed in recent years are confidential for 18 months, while older applications are not published until the patent issues. As a result, avoiding patent infringement may be difficult and we may inadvertently infringe third-party patents or proprietary rights. These third parties could bring claims against us, our partners or our licensors that even if resolved in our favor, could cause us to incur substantial expenses and, if resolved against us, could additionally cause us to pay substantial damages. Further, if a patent infringement suit were brought against us, our partners or our licensors, we or they could be forced to stop or delay research, development, manufacturing or sales of any infringing product in the country or countries covered by the patent we infringe, unless we can obtain a license from the patent holder. Such a license may not be available on acceptable terms, or at all, particularly if the third party is developing or marketing a product competitive with the infringing product. Even if we, our partners or our licensors were able to obtain a license, the rights may be nonexclusive, which would give our competitors access to the same intellectual property.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">If we or our partners are unable or fail to adequately initiate, protect, defend or enforce our intellectual property rights in any area of commercial interest or in any part of the world where we wish to seek regulatory approval for our products, methods, processes and other technologies, the value of the product candidates to produce revenue would diminish. Additionally, if our products, methods, processes, and other technologies or our commercial use of such products, processes, and other technologies, including but not limited to any trade name, trademark or commercial strategy infringe the proprietary rights of other parties, we could incur substantial costs. The USPTO and the patent offices of other jurisdictions have issued to us a number of patents for our various inventions and we have in-licensed several patents from various institutions. We have filed additional patent applications and provisional patent applications with the USPTO. We have filed a number of corresponding foreign patent applications and intend to file additional foreign and U.S. patent applications, as appropriate. We have also filed certain trademark and trade name applications worldwide. We cannot assure you as to:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">27</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">the degree and range of protection any patents will afford against competitors with similar products;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">if and when patents will issue;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 21pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">if patents do issue, we cannot be sure that we will be able to adequately defend such patents and whether or not we will be able to adequately enforce such patents; or</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">whether or not others will obtain patents claiming aspects similar to those covered by our patent applications.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 15pt 0pt 0pt; text-align: left; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">If the USPTO or other foreign patent office upholds patents issued to others or if the USPTO grants patent applications filed by others, we may have to:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">obtain licenses or redesign our products or processes to avoid infringement;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">stop using the subject matter claimed in those patents; or</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">pay damages.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">We may initiate, or others may bring against us, litigation or administrative proceedings related to intellectual property rights, including proceedings before the USPTO or other foreign patent office. Any judgment adverse to us in any litigation or other proceeding arising in connection with a patent or patent application could materially and adversely affect our business, financial condition and results of operations. In addition, the costs of any such proceeding may be substantial whether or not we are successful.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Our success is also dependent upon the skills, knowledge and experience, none of which is patentable, of our scientific and technical personnel. To help protect our rights, we require all employees, consultants, advisors and partners to enter into confidentiality agreements that prohibit the disclosure of confidential information to anyone outside of our company and require disclosure and assignment to us of their ideas, developments, discoveries and inventions. These agreements may not provide adequate protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use or disclosure or the lawful development by others of such information, and if any of our proprietary information is disclosed, our business will suffer because our revenues depend upon our ability to license or commercialize our product candidates and any such events would significantly impair the value of such product candidates.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><span style="text-decoration: underline; ">Product Liability Risks</span></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:7pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>&#xa0;</b></i></span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><i><b>We face an inherent risk of liability in the event that the use or misuse of our products or product candidates results in personal injury or death and our product liability insurance coverage may be insufficient.</b></i></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">If the use or misuse of any products we sell, or a partner sells, harms people, we may be subject to costly and damaging product liability claims brought against us by consumers, healthcare providers, pharmaceutical companies, third-party payors or others. The use of our product candidates in clinical trials, including post marketing clinical studies, could also expose us to product liability claims. We cannot predict all of the possible harms or side effects that may result from the use of our products or the testing of product candidates, and therefore, the amount of insurance coverage we currently have may not be adequate to cover all liabilities or defense costs we might incur. A product liability claim or series of claims brought against us could give rise to a substantial liability that could exceed our resources. Even if claims are not successful, the costs of defending such claims and potential adverse publicity could be harmful to our business.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face even greater risks upon any commercialization by us of our product candidates. We have product liability insurance covering our clinical trials. Clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance or increase our existing coverage at a reasonable cost to protect us against losses that could have a material adverse effect on our business. An individual may bring a product liability claim against us if one of our products or product candidates causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought against us, with or without merit, could result in:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">liabilities that substantially exceed our product liability insurance, which we would then be required to pay from other sources, if available;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:80pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">an increase of our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, or at all;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">withdrawal of clinical trial volunteers or patients;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">damage to our reputation and the reputation of our products, resulting in lower sales;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">regulatory investigations that could require costly recalls or product modifications;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">litigation costs; and</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the diversion of management&#x2019;s attention from managing our business.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">28</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;"><span style="text-decoration: underline; ">Risks Relating to Contractual Arrangements</span></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:2pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>We face risks related to our government-funded programs; if BARDA/HHS or NIAID/HHS were to eliminate, reduce or delay funding from our contracts, this would have a significant negative impact on the programs associated with such funding and could have a significant negative impact on our revenues and cash flows.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">We have completed work under a contract with BARDA/HHS for the development of RAPIVAB and have entered into contracts with BARDA/HHS and NIAID/HHS for the development of galidesivir as a treatment for diseases caused by RNA pathogens, including Marburg virus disease, Yellow Fever and Ebola virus disease. In contracting with these government agencies, we are subject to various U.S. Government contract requirements, including general clauses for a cost-reimbursement research and development contract, which may limit our reimbursement or, if we are found to be in violation, could result in contract termination. If the U.S. Government terminates any of its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract schedule and terms, significant negative impact on our cash flows and operations could result.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">U.S. Government contracts typically contain a number of extraordinary provisions that would not typically be found in commercial contracts and which may create a disadvantage and additional risks to us as compared to competitors that do not rely on U.S. Government contracts. These risks include the ability of the U.S. Government to unilaterally:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">terminate or reduce the scope of our contract with or without cause;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">interpret relevant regulations (federal acquisition regulation clauses);</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">require performance under circumstances which may not be favorable to us;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">require an in-process review where the U.S. Government will review the project and its options under the contract;</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">control the timing and amount of funding, which impacts the development progress of our programs; and</span></p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">audit and object to our contract-related costs and fees, including allocated indirect costs.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">The U.S. Government may terminate its contracts with us either for its convenience or if we default by failing to perform in accordance with the contract schedule and terms. Termination for convenience provisions generally enable us to recover only our costs incurred or committed, and settlement expenses and profit on the work completed prior to termination. Termination does not permit these recoveries under default provisions. In the event of termination or upon expiration of a contract, the U.S. Government may dispute wind-down and termination costs and may question prior expenses under the contract and deny payment of those expenses. Should we choose to challenge the U.S. Government for denying certain payments under a contract, such a challenge could subject us to substantial additional expenses which we may or may not recover. Further, if the U.S. Government terminates its contracts with us for its convenience, or if we default by failing to perform in accordance with the contract schedule and terms, significant negative impact on our cash flows and operations could result.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">As a U.S. Government contractor, we are required to comply with applicable laws, regulations and standards relating to our accounting practices and are subject to periodic audits and reviews. As part of any such audit or review, the U.S. Government may review the adequacy of, and our compliance with, our internal control systems and policies, including those relating to our purchasing, property, estimating, compensation and management information systems. Audits under the active BARDA/HHS and NIAID/HHS galidesivir contracts may occur at the election of the U.S. Government and have been concluded through fiscal 2015; all subsequent fiscal years are still open and auditable. Based on the results of its audits, the U.S. Government may adjust our contract-related costs and fees, including allocated indirect costs. This adjustment could impact the amount of revenues reported on a historic basis and could impact our cash flows under the contracts prospectively. In addition, in the event BARDA/HHS or NIAID/HHS determines that certain costs and fees were unallowable or determines that the allocated indirect cost rate was higher than the actual indirect cost rate, BARDA/HHS or NIAID/HHS would be entitled to recoup any overpayment from us as a result. In addition, if an audit or review uncovers any improper or illegal activity, we may be subject to civil and criminal penalties and administrative sanctions, including termination of our contracts, forfeiture of profits, suspension of payments, fines and suspension or prohibition from doing business with the U.S. Government. We could also suffer serious harm to our reputation if allegations of impropriety were made against us. In addition, under U.S. Government purchasing regulations, some of our costs may not be reimbursable or allowed under our contracts. Further, as a U.S. Government contractor, we are subject to an increased risk of investigations, criminal prosecution, civil fraud, whistleblower lawsuits and other legal actions and liabilities as compared to private sector commercial companies.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>There are risks related to the potential government use or sale of our antivirals.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Government use or sale, in emergency situations or otherwise, of our antivirals&#x2014;including peramivir for the treatment of influenza&#x2014;may result in risks to us or our collaborative partners. There can be no assurance that government use of our antivirals (whether as indicated or outside of their current indications) will prove to be generally safe, well-tolerated and effective. Any government sale or use (on an emergency basis or otherwise) of our antivirals in any country may create liabilities for us or our partners.</span>&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">In September 2018, we entered into a contract with the U.S. Government for the procurement of up to 50,000 doses of RAPIVAB (peramivir injection) over a five-year period. In addition, we are working with NIAID/HHS to further develop galidesivir. There can be no assurance that we or our manufacturers will be able to fully meet the demand for such antivirals with respect to these or future arrangements. Further, we may not receive a favorable purchase price for future orders, if any, of our antivirals by governmental entities. Our competitors may develop products that could compete with or replace any antivirals selected for government sale or use. We may face competition in markets where we have no existing intellectual property protection or are unable to successfully enforce our intellectual property rights.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">29</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">There can be no assurance that the non-U.S. partnerships that we have entered into for peramivir will result in any order for peramivir in those countries or that peramivir will be approved for any use or will achieve market approval in additional countries. There can be no assurance that galidesivir will be approved for use in any countries. In the event that any emergency use or market approval is granted in any country, there can be no assurance that any government order or commercialization of the applicable product or product candidate in such countries will be substantial or will be profitable to us.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:32pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>&#xa0;</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:32pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>If we fail to reach milestones or to make annual minimum payments or otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional remedies.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">If we are unable or fail to meet payment obligations, performance milestones relating to the timing of regulatory filings, product supply obligations, post approval commitments, or development and commercial diligence obligations; are unable or fail to make milestone payments or material data use payments in accordance with applicable provisions; or fail to pay the minimum annual payments under any of our in-licenses relating to our products or product candidates, our licensors may terminate the applicable license or seek other available remedies. As a result, our development of the respective product candidate or commercialization of the product would cease.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;"><i><b>Royalties and milestone payments from Shionogi under the Shionogi Agreement are required to be used by Royalty Sub to satisfy its obligations under its PhaRMA Notes, and generally will not be available to us for other purposes unless and until Royalty Sub has repaid in full its obligations under the PhaRMA Notes.</b></i></span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">In March 2011, our wholly-owned subsidiary, Royalty Sub, issued $30.0 million in aggregate principal amount of PhaRMA Notes. The PhaRMA Notes are secured principally by (i) certain royalty and milestone payments under the Shionogi Agreement, pursuant to which Shionogi licensed from us the rights to market peramivir in Japan and Taiwan and (ii) the pledge by us of our equity interest in Royalty Sub. Payments from Shionogi to us on non-governmental sales under the Shionogi Agreement will generally not be available to us for other purposes unless and until Royalty Sub has repaid in full its obligations under the PhaRMA Notes. Accordingly, these funds have been and will continue to be required to be dedicated to Royalty Sub&#x2019;s debt service and not available to us for product development or other purposes. Since September 1, 2014, payments from Shionogi have been insufficient for Royalty Sub to service its obligations under the PhaRMA Notes, resulting in a continuing event of default with respect to the PhaRMA Notes since that time. As a result of the continuing event of default, the holders of the PhaRMA Notes may be able to foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may exercise other remedies available to them under the indenture or other documents related to the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs and we might otherwise be adversely affected.</span>&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">The PhaRMA Notes had a final legal maturity date of December 1, 2020, at which time the outstanding principal amount of the PhaRMA Notes of $30.0 million, together with accrued and unpaid interest of $20.6 million, was due in full. The failure by Royalty Sub to repay in full the outstanding principal amount of the PhaRMA Notes, together with any accrued and unpaid interest, at the December 1, 2020 final maturity date constituted an additional event of default under the PhaRMA Notes. We cannot predict whether holders of PhaRMA Notes will seek to pursue any remedies as a result of the continuing events of default with respect to the PhaRMA Notes. The PhaRMA Notes are the obligation of Royalty Sub. As a result, we do not currently expect the continuing events of default on the PhaRMA Notes to have a significant impact on our future results of operations or cash flows. However, we cannot assure you that this will be the case or that we will not otherwise be adversely affected as a result the continuing events of default under the PhaRMA Notes or the failure by Royalty Sub to repay the PhaRMA Notes at maturity.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:3pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Because continuing </b></i><i><b>event</b></i><i><b>s</b></i><i><b> of default exist under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to pursue acceleration of the PhaRMA Notes and foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub. As a result, we may not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be adversely affected.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">As Royalty Sub has been unable to service its obligations under the PhaRMA Notes and continuing events of default exist under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub and may exercise other remedies available to them under the indenture or other documents related to the PhaRMA Notes. In such event, we may not realize the benefit of future royalty payments that might otherwise accrue to us following repayment of the PhaRMA Notes, we may incur legal costs and we might otherwise be adversely affected. In addition, the PhaRMA Notes have a final legal maturity date of December 1, 2020, at which time the outstanding principal amount of the PhaRMA Notes, together with accrued and unpaid interest, was due in full. The failure by Royalty Sub to repay in full the outstanding principal amount of the PhaRMA Notes, together with any accrued and unpaid interest, at the December 1, 2020 final maturity date constituted an additional event of default under the PhaRMA Notes. We cannot predict whether holders of PhaRMA Notes will seek to pursue any remedies as a result of the continuing events of default with respect to the PhaRMA Notes. The PhaRMA Notes are the obligation of Royalty Sub. As a result, we do not currently expect the continuing events of default on the PhaRMA Notes to have a significant impact on our future results of operations or cash flows. However, we cannot assure you that this will be the case or that we will not otherwise be adversely affected as a result the continuing events of default under the PhaRMA Notes or the failure by Royalty Sub to repay the PhaRMA Notes at maturity.</span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">30</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:14pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>We have incurred significant indebtedness, which could adverse</b></i><i><b>ly</b></i><i><b> affect our business. Additionally, </b></i><i><b>o</b></i><i><b>ur </b></i><i><b>Credit Agreement</b></i><i><b> contains&#xa0;</b></i></span><i><b>conditions and</b></i>&#xa0;<span style="color:#000000;"><i><b>restrictions that limit our flexibility in </b></i></span><i><b>drawing on the additional funds thereunder and in </b></i><span style="color:#000000;"><i><b>operating our business. We may be required to make a prepayment or repay </b></i><i><b>our</b></i><i><b> </b></i><i><b>outstanding indebtedness earlier than we expect if a prepayment event or an event of default occurs, including a material adverse change with respect to us, which could have a material adverse effect on our business.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 43pt 0pt 0pt; text-align: left; text-indent: 24.05pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">As of December 31, 2020, we had an outstanding principal balance under our Credit Agreement of $125.0 million.&#xa0;</span>We may also draw up to another $75.0 million in aggregate principal amount under the Term B Loan and the Term C Loan (each as defined in the Credit Agreement) under the Credit Agreement if, among other conditions, the Company reaches defined revenue milestones and, with respect to a draw on the Term C Loan, the Term B Loan has been funded prior to or contemporaneously with the Term C Loan.&#xa0;<span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Our indebtedness could have important consequences to our stockholders. For example, it:</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 43pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 43pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">increases our vulnerability to adverse general economic or industry conditions;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 43pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">limits our flexibility in planning for, or reacting to, changes in our business or the industry in which we operate;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 43pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">makes us more vulnerable to increases in interest rates, as borrowings under our Credit Agreement are at variable rates;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 43pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">requires us to dedicate a portion of our cash flow from operations to interest payments, limiting the availability of cash for other purposes;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 43pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">limits our ability to obtain additional financing or refinancing in the future for working capital or other purposes; and</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 43pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">places us at a competitive disadvantage compared to our competitors that have less indebtedness.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 43pt 0pt 45pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 43pt 0pt 0pt; text-align: left; text-indent: 24.05pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Furthermore, our Credit Agreement contains various covenants that limit our ability to engage in specified types of transactions. Subject to certain exceptions, these covenants limit our ability to, among other things, grant certain types of liens on our assets; make certain investments; incur or assume certain debt, including accessing additional tranches of debt under the Credit Agreement; engage in certain mergers, acquisitions, and similar transactions; dispose of assets; license certain property; distribute dividends; make certain restricted payments; change the nature of our business; engage in transactions with affiliates and insiders; prepay other indebtedness; or engage in sale and leaseback transactions.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">The Credit Agreement also contains certain financial covenants, including a minimum liquidity covenant that requires us to maintain at all times, as applicable, at least $15.0 million of unrestricted cash and cash equivalents if only the Term A Loan (as defined in the Credit Agreement) has been drawn; at least $20.0 million of unrestricted cash and cash equivalents if the Term B Loan&#xa0;has been drawn but the Term C Loan&#xa0;has not been drawn; and at least $15.0 million (or, in certain circumstances, $20.0 million) of unrestricted cash and cash equivalents if the Term C Loan has been drawn, subject to certain exceptions. In addition, if we draw upon the Term C Loan, we will be required to achieve certain minimum targets for consolidated net revenues from ORLADEYO sales in the U.S.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">The covenants contained in the Credit Agreement could cause us to be unable to pursue business opportunities that we or our stockholders may consider beneficial without the lenders&#x2019; permission or without repaying all outstanding obligations under the Credit Agreement.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">A breach of any of these covenants could result in an event of default under the Credit Agreement. An event of default will also occur if, among other things, we fail to pay amounts due under the Credit Agreement, we fail to repay certain other indebtedness having an aggregate principal amount in excess of one percent of our borrowings under the Credit Agreement, a material adverse change in our business, assets, properties, liabilities, or condition occurs, or a material impairment of our ability to perform our obligations under the Credit Agreement occurs, we experience a change of control, certain negative regulatory events occur, including without limitation the loss of a required permit or a recall of a product, or we fail to make required payments under our Royalty Purchase Agreement with RPI. In the case of a continuing event of default under the Credit Agreement, the lenders under the Credit Agreement could elect to declare all amounts outstanding to be immediately due and payable, proceed against the collateral in which we granted to the lenders a security interest, or otherwise exercise the rights of a secured creditor. Amounts outstanding under the Credit Agreement are secured by a security interest in, subject to certain exceptions, substantially all of our assets. Because substantially all of our assets are pledged to secure the Credit Agreement obligations, our ability to incur additional secured indebtedness or to sell or dispose of assets to raise capital may be impaired, which could have an adverse effect on our financial flexibility.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><span style="text-decoration: underline; ">Risks Relating to International Operations</span></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>International expansion of our business exposes us to business, regulatory, political, operational, financial, and economic risks.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;"><span style="color:#000000;">Our business strategy includes international expansion, including the commercialization of products outside of the United States. We currently conduct clinical studies and regulatory activities and have hired, and expect to continue hiring, employees outside of the United States. Doing business internationally involves a number of risks, including but not limited to:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">31</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:21pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">multiple, conflicting, and changing laws and regulations such as privacy and data regulations, transparency regulations, tax laws, export and import restrictions, employment laws, regulatory requirements, and other governmental approvals, permits, and licenses;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">introduction of new health authority requirements and/or changes in health authority expectations;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">failure by us or our partners to obtain and maintain regulatory approvals for the use of our products in various countries;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">complexities and difficulties in obtaining protection for, and enforcing, our intellectual property;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">difficulties in staffing and managing foreign operations;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">complexities associated with managing multiple payor reimbursement regimes, government payors, or patient self-pay systems;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">limits on our ability to penetrate international markets;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:26pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products, and exposure to foreign currency exchange rate fluctuations;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:6pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:6pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">natural disasters and political and economic instability, including wars, terrorism, political unrest, results of certain elections and votes, actual or threatened public health emergencies and outbreak of disease (including for example, the recent coronavirus outbreak), boycotts, adoption or expansion of government trade restrictions, and other business restrictions;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">certain expenses including, among others, expenses for travel, translation, and insurance;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:9pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:9pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">regulatory and compliance risks that relate to maintaining accurate information and control over commercial operations and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, or FCPA, including its books and records provisions or anti-bribery provisions, or the U.K. Bribery Act and similar foreign laws and regulations; and</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:21pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">regulatory and compliance risks relating to doing business with any entity that is subject to sanctions administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:31pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Any of these factors could significantly harm our future international expansion of operations and, consequently, our business and results of operations.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Additionally, in some countries, such as Japan and the countries of the EU, the pricing of prescription pharmaceuticals is subject to governmental control and access. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we or our partners may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be materially harmed.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:12pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Our actual or perceived failure to comply with European governmental regulations and other legal obligations related to privacy, data protection and information security could harm our business.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">EU member states, Switzerland and other countries have adopted data protection laws and regulations, which impose significant compliance obligations. For example, the General Data Protection Regulation (&#x201c;GDPR&#x201d;) imposes strict requirements on controllers and processors of personal data, including special protections for &#x201c;special category data,&#x201d; which includes health, biometric and genetic information of data subjects located in the EU. Further, GDPR provides a broad right for EU member states to create supplemental national laws, for example relating to the processing of health, genetic and biometric data, which could further limit our ability to use and share such data or could cause our costs to increase and harm our business and financial condition. GDPR grants individuals the opportunity to object to the processing of their personal information, allows them to request deletion of personal information in certain circumstances, and provides the individual with an express right to seek legal remedies in the event the individual believes his or her rights have been violated. Further, the GDPR imposes strict rules on the transfer of personal data out of the EU to the United States or other regions that have not been deemed to offer &#x201c;adequate&#x201d; privacy protections.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU member states, which may deviate slightly from the GDPR, may result in significant fines of up to 4% of global revenues, or &#x20ac;20.0 million, whichever is greater, and in addition to such fines, our failure to comply with the requirements of GDPR may subject us to litigation and/or adverse publicity, which could have material adverse effects on our reputation and business. As a result of the implementation of the GDPR, we are required to put in place additional mechanisms to ensure compliance with the new data protection rules. For example, the GDPR requires us to make more detailed disclosures to data subjects, requires disclosure of the legal basis on which we can process personal data, makes it harder for us to obtain valid consent for processing, will require the appointment of a data protection officer where sensitive personal data (i.e., health data) is processed on a large scale, introduces mandatory data breach notification throughout the EU, imposes additional obligations on us when we are contracting with service providers and requires us to adopt appropriate privacy governance including policies, procedures, training and data audit.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">We are subject to the supervision of local data protection authorities in those jurisdictions where we undertake clinical trials. We depend on a number of third parties in relation to the provision of our services, a number of which process personal data of EU individuals on our behalf. With each such provider we are required to enter into contractual arrangements under which they are contractually obligated to only process personal data according to our instructions, and conduct diligence to ensure that they have sufficient technical and organizational security measures in place.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">32</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">We are also subject to evolving European privacy laws on electronic marketing and cookies. The EU is in the process of replacing the e-Privacy Directive (2002/58/EC) with a new set of rules taking the form of a regulation that will be directly implemented in the laws of each European member state. While this e-Privacy Regulation was originally intended to be adopted on May 25, 2018, it is still going through the European legislative process and the timing of its adoption remains unclear.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:15pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>&#xa0;</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:15pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>The United Kingdom&#x2019;s decision to withdraw from the EU could result in increased regulatory and legal complexity, which may make it more difficult for us to do business in Europe and impose additional challenges in securing regulatory approval of our product candidates in Europe.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">The United Kingdom&#x2019;s exit from the EU, or Brexit, has caused political and economic uncertainty, including in the regulatory framework applicable to our operations and product candidates, and this uncertainty may persist for years. Brexit could, among other outcomes, disrupt the free movement of goods, services and people between the United Kingdom and the EU, and result in increased legal and regulatory complexities, as well as potential higher costs of conducting business in Europe. The long-term effects of Brexit will depend in part on how the current and future trade agreements between the United Kingdom and the EU take effect in practice. Changes in United Kingdom or EU regulations may cause disruption or delays in granting clinical trial authorization or opinions for marketing authorization, disruption of importation and export of active substance and other components of new drug formulations, and disruption of the supply chain for clinical trial product and final authorized formulations.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">The cumulative effects of the disruption to the regulatory framework may add considerably to the development lead time to marketing authorization and commercialization of products in the EU and/or the United Kingdom. It is possible that there will be increased regulatory complexities, which can disrupt the timing of our clinical trials and regulatory approvals. In addition, changes in, and legal uncertainty with regard to, national and international laws and regulations may present difficulties for our clinical and regulatory strategy. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in the United Kingdom and/or the EU and restrict our ability to generate revenues and achieve and sustain profitability.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">In addition, as a result of Brexit, other European countries may seek to conduct referenda with respect to their continuing membership with the EU. Given these possibilities and others we may not anticipate, as well as the absence of comparable precedent, it is unclear what financial, regulatory and legal implications the withdrawal of the United Kingdom from the EU will&#xa0;have and how such withdrawal will&#xa0;affect us, and the full extent to which our business could be adversely affected.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><span style="text-decoration: underline; ">Risks Relating to Technology</span></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 13pt; text-align: left;"><i><b>If our facilities, or the facilities of our third-party vendors, incur damage or power is lost for a significant length of time, our business will suffer.</b></i></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1pt 0pt 0pt; text-align: left; text-indent: 24.05pt;">We and our third-party vendors store commercial product, clinical and stability samples at our facilities that could be damaged if the facilities incur physical damage or in the event of an extended power failure. We have backup power systems in addition to backup generators to maintain power to all critical functions, but any loss of these samples could result in significant delays in our drug development process.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:24.05pt;"><span style="color:#000000;">In addition, we store most of our preclinical and clinical data at our facilities. Duplicate copies of most critical data are secured off-site. Any significant degradation or failure of our computer systems could cause us to inaccurately calculate or lose our data. Loss of data could result in significant delays in our drug development process and any system failure could harm our business and operations.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>A significant disruption in our information technology systems or a cybersecurity breach could adversely affect our business.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">We are increasingly dependent on information technology systems to operate our business. In addition, the FDA and comparable foreign regulatory authorities regulate, among other things, the record keeping and storage of data pertaining to potential pharmaceutical products. We currently store most of our preclinical research data, our clinical data and our manufacturing data at our facility. While we do store duplicate copies of most of our clinical data offsite and a significant portion of our data is included in regular backups of our systems, we could lose important data if our facility incurs damage, or if our vendor data systems fail, suffer damage or are destroyed.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Like other companies in our industry, our networks and infrastructure may be vulnerable to cyber-attacks or intrusions, including by computer hackers, foreign governments, foreign companies, or competitors, or may be breached by employee error, malfeasance or other disruption. A breakdown, invasion, corruption, destruction, or interruption of critical information technology systems could negatively impact operations. If our systems are damaged, fail to function properly or otherwise become unavailable, we may incur substantial costs to repair or replace them, and we may experience loss of critical data and interruptions or delays in our ability to perform critical functions, which could adversely affect our business, financial condition or results of operations. Any compromise of our data security could also result in a violation of applicable privacy and other laws, significant legal and financial exposure, damage to our reputation, loss or misuse of the information and a loss of confidence in our data security measures, which could harm our business. There can be no assurance that our efforts to protect our data and information technology systems will prevent breakdowns or breaches in our systems, or those of third parties with which we do business, and any such events could adversely affect our business.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">33</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Risks </b><b>R</b><b>elating to </b><b>I</b><b>nvesting in </b><b>O</b><b>ur </b><b>C</b><b>ommon </b><b>S</b><b>tock</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:11pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Our existing principal stockholders hold a substantial amount of our common stock and may be able to influence significant corporate decisions, which may conflict with the interest of other stockholders.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">S</span>everal of our stockholders own greater than 5% of our outstanding common stock. Our top ten stockholders own close to 50% of BioCryst and can individually, and as a group, influence our operations based upon their concentrated ownership and may also be able to influence the outcome of matters requiring approval of the stockholders, including the election of our directors and other corporate actions<span style="color:#000000;">.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:24pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Our stock price has been, and is likely to continue to be, highly volatile, which could cause the value of an investment in our common stock to decline significantly.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">The market prices for securities of biotechnology companies in general have been highly volatile and may continue to be highly volatile in the future. Moreover, our stock price has fluctuated frequently, and these fluctuations are often not related to our financial results. For the twelve months ended December 31, 2020, the 52-week range of the market price of our stock was from $1.58 to $8.99 per share. The following factors, in addition to other risk factors described in this section, may have a significant impact on the market price of our common stock:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">announcements of technological innovations or new products by us or our competitors;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">developments or disputes concerning patents or proprietary rights;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">additional dilution through sales of our common stock or other derivative securities;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">status of new or existing licensing or collaborative agreements and government contracts;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">announcements relating to the status of our programs;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">developments and announcements regarding new and virulent strains of influenza;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">we or our partners achieving or failing to achieve development milestones;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">publicity regarding actual or potential medical results relating to products under development by us or our competitors;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">publicity regarding certain public health concerns for which we are or may be developing treatments;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">regulatory developments in both the United States and foreign countries;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">public concern as to the safety of pharmaceutical products;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">actual or anticipated fluctuations in our operating results;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">changes in financial estimates or recommendations by securities analysts;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">changes in the structure of healthcare payment systems, including developments in price control legislation;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">additions or departures of key personnel or members of our board of directors;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">purchases or sales of substantial amounts of our stock by existing stockholders, including officers or directors;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">economic and other external factors or other disasters or crises; and</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">period-to-period fluctuations in our financial results.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Future sales and issuances of securities may dilute the ownership interests of our current stockholders and cause our stock price to decline.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">Future sales of our common stock by us or our current stockholders into the public market could cause the market price of our stock to fall. As of January 31, 2021, there were 177,182,751 shares of our common stock outstanding. We may from time to time issue securities in relation to a license arrangement, collaboration, merger or acquisition. We may also sell, for our own account, shares of common stock or other equity securities, from time to time at prices and on terms to be determined at the time of sale.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">As of January 31, 2021, there were 24,780,638 stock options outstanding and 4,587,872 shares available for issuance under our Amended and Restated Stock Incentive Plan, 4,307,668 stock options outstanding and 92,332 shares available for issuance under our&#xa0;</span>Amended and Restated&#xa0;<span style="color:#000000;">Inducement Equity Incentive Plan and 2,679,554 shares available for issuance under our Amended and Restated Employee Stock Purchase Plan. In addition, we could also make equity grants outside of our Amended and Restated Stock Incentive Plan or Amended and Restated Inducement Equity Incentive Plan. The shares underlying existing stock options, restricted stock units and possible future stock options, stock appreciation rights and stock awards have been registered pursuant to registration statements on Form S-8.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">If some or all of such shares are sold or otherwise issued into the public market over a short period of time, our current stockholders&#x2019; ownership interests may be diluted and the value of all publicly traded shares is likely to decline, as the market may not be able to absorb those shares at then-current market prices. Additionally, such sales and issuances may make it more difficult for us to sell equity securities or equity-related securities in the future at a time and price that our management deems acceptable, or at all.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">34</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">In March 2017, we entered into a Registration Rights Agreement with entities affiliated with Baker Bros. Advisors LP (the &#x201c;Baker Entities&#x201d;) to provide that, if requested, we will register the shares of our common stock beneficially owned by the Baker Entities for resale under the Securities Act. Our registration obligations pursuant to the Registration Rights Agreement cover all shares then held or thereafter acquired by the Baker Entities, for up to ten years, and include our obligation to facilitate certain underwritten public offerings of our common stock by the Baker Entities in the future. On May 10, 2017, we filed a registration statement on Form S-3 with respect to 11,710,951 shares of common stock held by the Baker Entities. Subsequently, on November 21, 2019, certain of the Baker Entities acquired pre-funded warrants to purchase 11,764,706 shares of our common stock at a price of $1.69 per warrant. In addition, on June 1, 2020, we issued pre-funded warrants to purchase 3,511,111 shares of our common stock at a price of $4.49 per warrant, including pre-funded warrants acquired by certain of the Baker Entities to purchase 3,252,375 shares of our common stock. Each warrant has an exercise price of $0.01 per share. If the Baker Entities, by exercising their underwriting rights or otherwise, sell a large number of our shares, or the market perceives that the Baker Entities intend to sell a large number of our shares, this could adversely affect the market price of our common stock.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>We have anti-takeover provisions in our corporate charter documents that may result in outcomes with which you do not agree.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:justify;text-indent:24.05pt;"><span style="color:#000000;">Our board of directors has the authority to issue up to 5,000,000 shares of undesignated preferred stock and to determine the rights, preferences, privileges and restrictions of those shares without further vote or action by our stockholders. The rights of the holders of any preferred stock that may be issued in the future may adversely affect the rights of the holders of common stock. The issuance of preferred stock could make it more difficult for third parties to acquire a majority of our outstanding voting stock.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:24.05pt;"><span style="color:#000000;">I</span>n addition, our Certificate of Incorporation provides for staggered terms for the members of the board of directors and supermajority approval of the removal of any member of the board of directors and prevents our stockholders from acting by written consent. Our Certificate of Incorporation also requires supermajority approval of any amendment of these provisions. These provisions and other provisions of our bylaws and of Delaware law applicable to us could delay or make more difficult a merger, tender offer or proxy contest involving us<span style="color:#000000;">.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>We have never paid dividends on our common stock and do not anticipate doing so in the foreseeable future.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:25pt;"><span style="color:#000000;">We have never paid cash dividends on our stock. We currently intend to retain all future earnings, if any, for use in the operation of our business. Accordingly, we do not anticipate paying cash dividends on our common stock in the foreseeable future.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:12pt;margin-top:0pt;text-align:justify;"><span style="color:#000000;"><i><b>Our Amended and Restated Bylaws provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for certain litigation that may be initiated by our stockholders, which may limit a stockholder&#x2019;s ability to obtain a favorable judicial forum for such disputes with us or our directors, officers or employees.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:24.3pt;"><span style="color:#000000;">Our Amended and Restated Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, stockholders, employees or agents to us or our stockholders, (iii) any action asserting a claim against us or any of our directors, officers, stockholders, employees or agents arising out of or relating to any provision of the General Corporation Law of Delaware or our Certificate of Incorporation or Amended and Restated Bylaws or (iv) any action against us or any of our directors, officers, stockholders, employees or agents governed by the internal affairs doctrine of the State of Delaware. This exclusive forum provision does not apply to establish the Delaware Court of Chancery as the forum for actions or proceedings brought to enforce a duty or liability created by the Securities Act&#xa0;</span>of 1933, as amended, or the Securities Exchange Act of 1934, as amended, or any other claim for which the federal courts have exclusive jurisdiction<span style="color:#000000;">.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:24.3pt;"><span style="color:#000000;">This exclusive forum provision may limit a stockholder&#x2019;s ability to choose its preferred judicial forum for disputes with us or our directors, officers, employees or agents, which may discourage the filing of lawsuits with respect to such claims. If a court were to find this exclusive forum provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in another jurisdiction, which could adversely affect our business and financial condition.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><span style="text-decoration: underline; ">General Risk Factors</span></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:10pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Natural disasters, epidemic or pandemic disease outbreaks, trade wars, political unrest or other events could disrupt our business or operations or those of our development partners, manufacturers, regulators or other third parties with whom we conduct business now or in the future.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:29.15pt;"><span style="color:#000000;">A wide variety of events beyond our control, including natural disasters, epidemic or pandemic disease outbreaks (such as the ongoing COVID-19 pandemic), trade wars, political unrest or other events could disrupt our business or operations or those of our development partners (such as Torii), manufacturers, regulatory authorities, or other third parties with whom we conduct business. These events may cause businesses and government agencies to be shut down, supply chains to be interrupted, slowed, or rendered inoperable, and individuals to become ill, quarantined, or otherwise unable to work and/or travel due to health reasons or governmental restrictions. If our operations or those of third parties with whom we have business are impaired or curtailed as a result of these events, the development and commercialization of our products and product candidates could be impaired or halted, which could have a material adverse impact on our business. See &#x201c;Risk Factors&#x2014;Risks Relating to Our Business&#x2014;</span>Risks Relating to COVID-19<span style="color:#000000;">&#x2014;Our business, operations, clinical development or commercialization plans and timelines, and access to capital could be adversely affected by the effects of the recent COVID-19 pandemic on us or on third parties with whom we conduct business, including without limitation our development partners, manufacturers, CROs, and others, as well as on the regulatory and government agencies with whom we work.&#x201d;</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">35</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>We are subject to legal proceedings, which could result in losses or unexpected expenditure of time and resources.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">From time to time, we may be involved in disputes, called upon to initiate legal proceedings or to defend ourselves in such legal proceedings relating to our business. Due to the inherent uncertainties in legal proceedings, we cannot accurately predict the ultimate outcome of any such proceedings. An unfavorable outcome in any such proceedings could have an adverse impact on our business, financial condition and results of operations. If our stock price is volatile, we may become involved in securities class action lawsuits in the future. Any current or future dispute resolution or legal proceeding, regardless of the merits of any such proceeding, could result in substantial costs and a diversion of management&#x2019;s attention and resources that are needed to successfully run our business.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Insurance coverage is increasingly more costly and difficult to obtain or maintain.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:24.05pt;"><span style="color:#000000;">While we currently have insurance for our business, property, directors and officers, and our products, insurance is increasingly more costly and narrower in scope, and we may be required to assume more risk in the future. If we are subject to claims or suffer a loss or damage in excess of our insurance coverage, we will be required to bear any loss in excess of our insurance limits. If we are subject to claims or suffer a loss or damage that is outside of our insurance coverage, we may incur significant uninsured costs associated with loss or damage that could have an adverse effect on our operations and financial position. Furthermore, any claims made on our insurance policies may impact our ability to obtain or maintain insurance coverage at reasonable costs or at all.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:8pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>If we fail to retain our existing key personnel or fail to attract and retain additional key personnel, the development of our product candidates and commercialization of our products and the related expansion of our business will be delayed or stopped.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">We are highly dependent upon our senior management and scientific team, the unexpected loss of whose services might impede the achievement of our development and commercial objectives. This risk has been heightened in the current environment as a result of the ongoing COVID-19 pandemic. Competition for key personnel with the experience that we require is intense and is expected to continue to increase. Our inability to attract and retain the required number of skilled and experienced management, commercial, operational and scientific personnel will harm our business because we rely upon these personnel for many critical functions of our business.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><a id="i1b" title="i1b" href="#"></a>ITEM 1B.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<i><b>UNRESOLVED STAFF COMMENTS</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:23pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">None.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><a id="i2" title="i2" href="#"></a>ITEM 2.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<i><b>PROPERTIES</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We lease property in both Durham, North Carolina and Birmingham, Alabama. Our headquarters, including our clinical and regulatory operations, are based in Durham, while our principal research facility is located in Birmingham. We currently lease approximately 33,000 square feet in Durham through June 30, 2021 and approximately 34,000 square feet in Birmingham through October 31, 2026. We also lease smaller office spaces in Ireland, Germany, and France. We believe that our facilities are adequate for our current and planned future operations.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><a id="i3" title="i3" href="#"></a>ITEM 3.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<i><b>LEGAL PROCEEDINGS</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">None.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><a id="i4" title="i4" href="#"></a>ITEM 4.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<i><b>MINE SAFETY DISCLOSURES</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Not applicable.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><a id="p2" title="p2" href="#"></a>PART II</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><a id="i5" title="i5" href="#"></a>ITEM 5.&#xa0; &#xa0; &#xa0;</b><i><b>MARKET FOR REGISTRANT&#x2019;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><br /> <span style="color:#000000;"><b style="font-size: 10pt;">Market Information</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Our common stock trades on the Nasdaq Global Select Market under the symbol BCRX.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">36</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Holders</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">As of January 31, 2021, there were approximately 167 holders of record of our common stock.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Dividends</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">We have never paid cash dividends and do not anticipate paying cash dividends in the foreseeable future.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Stock Performance Graph</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">This performance graph is not &#x201c;soliciting material,&#x201d; is not deemed filed with the SEC and is not to be incorporated by reference in any filing by us under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. The stock price performance shown on the graph is not necessarily indicative of future price performance.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><span style="color:#000000;"><b>PERFORMANCE GRAPH FOR BIOCRYST</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><span style="color:#000000;"><b>Indexed Comparison Since 201</b><b>5</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><b>Beginning Investment at 12/31/15</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><b>Investment at 12/31/16</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><b>Investment at 12/31/17</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><b>Investment at 12/31/18</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><b>Investment at 12/31/19</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><b>Investment at 12/31/20</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">BioCryst Pharmaceuticals, Inc.</span></p> </td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">100.00</span></td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">61.34</span></td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">47.58</span></td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">78.20</span></td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">33.43</span></td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">72.19</span></td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Nasdaq Stock Market (U.S.)</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">100.00</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">113.01</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">137.17</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">129.71</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">170.14</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">206.32</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Nasdaq Pharmaceutical Stocks</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">100.00</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">98.91</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">117.83</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">127.20</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">145.65</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">160.97</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The above graph measures the change in a $100 investment in our common stock based on its closing price of $10.32 on December 31, 2015 and its year-end closing price thereafter. Our relative performance is then compared with the CRSP Total Return Indexes for the Nasdaq Stock Market (U.S.) and Nasdaq Pharmaceutical Stocks.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Recent Sales of Unregistered Securities</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">None.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Issuer Purchases of Equity Securities</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">There were no repurchases of our common stock or shares surrendered to satisfy tax obligations during the fourth quarter of 2020.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">37</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><a id="i6" title="i6" href="#"></a>ITEM 6.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<i><b>SELECTED FINANCIAL DATA</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The selected Statement of Operations Data and Balance Sheet data with respect to the years ended December 31, 2020, 2019, 2018, 2017, and 2016 set forth below are derived from our consolidated financial statements. The selected financial data set forth below should be read in conjunction with &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; contained in Part II, Item 7 of this report and our consolidated financial statements and the notes thereto appended to this report.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="18" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><span style="color:#000000;"><b style="background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; text-align: center; text-indent: 0pt;">Years Ended December 31,</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><b>&#xa0;</b></span></td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:22.5pt;margin-top:0pt;text-align:right;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:21.5pt;margin-top:0pt;text-align:right;"><span style="color:#000000;"><b><b>2019</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:21.5pt;margin-top:0pt;text-align:right;"><span style="color:#000000;"><b><b>201</b><b>8</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:21.5pt;margin-top:0pt;text-align:right;"><span style="color:#000000;"><b><b>2017</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19.5pt;margin-top:0pt;text-align:right;"><span style="color:#000000;"><b><b>201</b><b>6</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="19" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><span style="color:#000000;"><b style="font-size: 10pt; text-align: right;">(In thousands, except per share amounts)</b></span></td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;"><b>Statement of Operations Data:</b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Total revenues</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">17,812</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">48,835</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">20,653</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">25,186</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">26,353</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Cost of product sold</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,550</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,726</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,142</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,297</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Research and development expenses</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">122,964</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">107,068</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">84,888</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">66,962</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">61,008</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Selling, general and administrative expenses</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">67,929</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">37,121</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">29,514</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">13,933</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">11,253</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Royalty expense</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">126</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">375</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">471</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">560</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">402</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Loss from operations</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(174,757</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(99,455</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(94,220</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(57,411</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(48,607</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Net loss</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(182,814</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(108,897</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(101,252</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(65,782</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(55,144</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Basic and diluted net loss per share</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(1.09</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.94</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.98</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.78</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.75</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Weighted average shares outstanding</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">167,267</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">115,600</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">103,185</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">84,451</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">73,699</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><b><b><b>As of December 31,</b></b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:22.5pt;margin-top:0pt;text-align:right;"><span style="color:#000000;"><b><b><b>2020</b></b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:18.5pt;margin-top:0pt;text-align:right;"><span style="color:#000000;"><b><b><b>2019</b></b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:23.5pt;margin-top:0pt;text-align:right;"><span style="color:#000000;"><b><b><b>201</b><b>8</b></b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:21.5pt;margin-top:0pt;text-align:right;"><span style="color:#000000;"><b><b><b>2017</b></b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19.5pt;margin-top:0pt;text-align:right;"><span style="color:#000000;"><b><b><b>201</b><b>6</b></b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="19" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;"><span style="color:#000000;"><b style="font-size: 10pt; text-align: right;">(In thousands)</b></span></td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;"><b>Balance Sheet Data:</b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Cash, cash equivalents, restricted cash and investments</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">302,587</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">137,777</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">128,387</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">158,978</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">65,122</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Receivables</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">8,646</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">22,146</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,293</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,117</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">8,768</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Inventory</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">7,039</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,649</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">500</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Total assets</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">334,715</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">175,282</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">146,841</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">178,259</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">89,847</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Long-term deferred revenue</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">8,184</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Non-recourse notes payable</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">30,000</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">29,561</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">29,121</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">28,682</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">28,243</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Royalty financing obligation</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">124,717</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Senior credit facility</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">50,309</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">29,952</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">23,214</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">22,777</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Secured term loan</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">119,735</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000">-</span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000">-</span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000">-</span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Accumulated deficit</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(1,023,442</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(840,628</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(731,969</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(631,843</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(566,061</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Total stockholders&#x2019; (deficit) equity</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(19,262</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">38,252</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">49,235</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">83,767</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,578</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><a id="i7" title="i7" href="#"></a>ITEM 7.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<i><b>MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;"><i>The following Management&#x2019;s Discussion and Analysis (&#x201c;MD&amp;A&#x201d;) is intended to help the reader understand our results of operations and financial condition. MD&amp;A is provided as a supplement to, and should be read in conjunction with, our audited financial statements and the accompanying notes to the financial statements and other disclosures included in this </i><i>report</i><i> (including </i><i>the </i><i>&#x201c;Cautionary Note Regarding Forward-Looking Statements&#x201d; at the beginning of this report and </i><i>the </i><i>&#x201c;Risk Factors&#x201d; section in Part I, </i><i>Item 1A</i><i> of this report</i><i>).</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Overview</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We are a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. We focus on oral treatments for rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. We integrate the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. In addition to these discovery and development efforts, our business strategy includes the efficient commercialization of these drugs in the U.S. and certain other regions upon regulatory approval. By focusing on rare disease markets, we believe that we can more effectively control the costs of, and our strategic allocation of financial resources toward, post-approval commercialization.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Our revenues are difficult to predict and depend on several factors, including those discussed in the &#x201c;Risk Factors&#x201d; section in Part I, Item 1A of this report. For example, our revenues depend, in part, on regulatory approval decisions for our products and product candidates, the effectiveness of our and our collaborative partners&#x2019; commercialization efforts, market acceptance of our products, particularly ORLADEYO, the resources dedicated to our products by us and our collaborative partners, and ongoing discussions with government agencies regarding contract awards for development and procurement, as well as entering into, or modifying, licensing agreements for our product candidates. Furthermore, revenues related to our collaborative development activities are dependent upon the progress toward and the achievement of developmental milestones by us or our collaborative partners.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">38</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Our operating expenses are also difficult to predict and depend on several factors, including research and development expenses (and whether these expenses are reimbursable under government contracts), drug manufacturing, and clinical research activities, the ongoing requirements of our development programs, the availability of capital and direction from regulatory agencies, which are difficult to predict, and the factors discussed in the &#x201c;Risk Factors&#x201d; section in Part I, Item 1A of this report. Management may be able to control the timing and level of research and development and selling, general and administrative expenses, but many of these expenditures will occur irrespective of our actions due to contractually committed activities and/or payments.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">As a result of these factors, we believe that period-to-period comparisons are not necessarily meaningful and you should not rely on them as an indication of future performance. Due to all of the foregoing factors, it is possible that our operating results will be below the expectations of market analysts and investors. In such event, the prevailing market price of our common stock could be materially adversely affected.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Critical Accounting Policies and Estimates</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The accompanying discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements and the related disclosures, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. We evaluate our estimates, judgments and the policies underlying these estimates on a periodic basis, as situations change, and regularly discuss financial events, policies, and issues with members of our audit committee and our independent registered public accounting firm. In particular, we routinely evaluate our estimates and policies regarding revenue recognition, administration, inventory and manufacturing, taxes, stock-based compensation, research and development, consulting and other expenses and any associated liabilities. Our estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. The results of our estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. See &#x201c;Critical Accounting Policies&#x201d; at the end of this &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; for a description of accounting policies that we believe are the most critical to aid you in fully understanding and evaluating our reported financial results and that affect the more significant judgments and estimates that we use in the preparation of our financial statements.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Recent Corporate Highlights</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;"><i>COVID-19</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The outbreak of COVID-19 has severely impacted global economic activity and caused significant volatility in financial markets. To date, our financial condition, results of operations, and liquidity have not been materially impacted by the direct effects of the COVID-19 pandemic. However, as discussed under &#x201c;Risk Factors-Risks Related to Our Business-Risks Related to COVID-19&#x201d; in Part I, Item 1A of this report, the acceleration of COVID-19 slowed startup of the inadequate responder cohorts in our complement oral Factor D inhibitor program. The COVID-19 pandemic is constantly evolving, and its full impact to our business is uncertain.&#xa0;</span>We are continuing to monitor developments with respect to the COVID-19 pandemic and to make adjustments as needed to assist in protecting the safety of our employees and communities while continuing our business activities. Our remote working arrangements are ongoing where possible, and we continue to restrict business-related travel. To date, implementation of these measures has not required material expenditures or significantly impacted our ability to operate our business or our internal control over financial reporting and disclosure controls and procedures. We are continuing to monitor the potential impacts of COVID-19 on our operations and those of our partners, suppliers, customers, and regulators<span style="color:#000000;">.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>ORLADEYO (b</i><i>erotralstat)</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">ORLADEYO is an oral, once-daily therapy discovered and developed by BioCryst for the prevention of HAE attacks.&#xa0; ORLADEYO, in both 110 mg and 150 mg capsule dosage forms, was approved by the FDA in December 2020 for prophylaxis to prevent attacks of HAE in adults and pediatric patients 12 years and older.&#xa0; On December 16, 2020, we announced that ORLADEYO is now available for shipment to patients with a prescription in the U.S. and that our exclusive specialty pharmacy provider for ORLADEYO in the U.S. began shipping to patients.&#xa0; We completed the build-out of our U.S. commercial infrastructure in 2020 to support the launch of ORLADEYO in the U.S. and are currently building our commercial infrastructure to support European launches.&#xa0;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">ORLADEYO, in the 150 mg capsule dosage form, also received marketing and manufacturing approval from the MHLW in Japan in January 2021 for prophylactic treatment of HAE in adults and pediatric patients 12 years and older.&#xa0; Torii, our collaborative partner, will launch ORLADEYO in Japan following the successful completion of our pricing negotiations with the Japanese National Health Insurance System.&#xa0;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">On March 30, 2020, we announced that the EMA had validated our MAA submission for approval of ORLADEYO for the prevention of HAE attacks.&#xa0; With this validation, the EMA began its formal review of the MAA under the centralized procedure for all member states of the EU, Norway, Iceland, and Liechtenstein.&#xa0; On February 25, 2021, we announced that the CHMP has adopted a positive opinion recommending the approval of ORLADEYO for routine prevention of recurrent attacks of HAE in adult and adolescent patients aged 12 years and older.&#xa0; The EC will review the CHMP recommendation, and a final approval decision from the EC on the MAA for ORLADEYO is expected in the second quarter of 2021.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">39</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;">On October 30, 2020, we announced that the MHRA has granted ORLADEYO a positive scientific opinion through the EAMS.&#xa0; Under the EAMS, HAE patients in the U.K. aged 12 years and older can gain access to ORLADEYO for the routine prevention of recurrent attacks of HAE before the drug is granted marketing authorization.&#xa0; We plan to file for a U.K. marketing authorization with the MHRA following our receipt of a positive opinion from the CHMP.&#xa0; This is expected to result in a U.K. marketing authorization shortly after a final decision by the EC.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;">We completed the build-out of our U.S. commercial infrastructure in 2020 to support the launch of ORLADEYO in the U.S. and are currently building our commercial infrastructure to support European launches.&#xa0; Based on proprietary analyses of HAE prevalence and market research studies with HAE patients, physicians, and payors in the U.S. and Europe, we anticipate the commercial market for ORLADEYO has the potential to reach a global peak of more than $500 million in annual sales.&#xa0; These expectations are subject to numerous risks and uncertainties that may cause our actual results, performance, or achievements to be materially different.&#xa0; There can be no assurance that our commercialization methods and strategies will succeed, or that the market for ORLADEYO will develop in line with our current expectations.&#xa0; See &#x201c;Risk Factors-Risks Relating to Our Business-Risks Relating to Drug Development and Commercialization-There can be no assurance that our commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain&#x201d; in Part I, Item 1A of this report for further discussion of these risks.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Complement-Mediated Diseases</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Discovered by BioCryst, BCX9930 is a novel, oral, potent, and selective small molecule inhibitor of Factor D currently in early clinical development for the treatment of complement-mediated diseases. Based on the safety and PoC data generated to date in PNH patients, we are working closely with key opinion leaders in hematology and nephrology to map the development strategy across a broad set of indications. Our goal is to develop BCX9930 as a monotherapy for complement-mediated diseases.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On</span>&#xa0;February 25, 2021, we announced that we have completed enrollment of our ongoing dose ranging trial in treatment-na&#xef;ve (no prior treatment with C5 inhibitors) PNH patients and PNH patients with an inadequate response to C5 inhibitors.&#xa0; We plan to present data from the 16 enrolled PNH patients (10 treatment na&#xef;ve and 6 inadequate C5 responders) at our upcoming R&amp;D day on March 22, 2021<span style="color:#000000;">.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On September 30, 2020, we announced new data from treatment-na&#xef;ve PNH patients receiving doses through 400 mg twice-daily of oral BCX9930 as monotherapy in the ongoing part 3 PoC dose-ranging trial. Oral BCX9930 was shown to drive rapid and dose-dependent reductions in key biomarkers, including LDH, and increasing hemoglobin levels in all PNH patients in the trial. Increases in hemoglobin levels were maintained without transfusions. BCX9930 was safe and well tolerated at all doses in the trial. No drug-related serious adverse events had been reported. One subject was discontinued due to an unrelated serious adverse event.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On</span>&#xa0;August 31, 2020, we announced that the FDA granted orphan drug designation for BCX9930 for the treatment of PNH.&#xa0; Orphan drug designation qualifies BCX9930 for various development incentives, including tax credits for certain clinical costs, a waiver of the new drug application fee, and a designated period of market exclusivity following approval.&#xa0; On August 3, 2020, we announced that the FDA granted fast track designation for BCX9930 in PNH<span style="color:#000000;">.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>FOP</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The goal of our ALK2 inhibitor is to discover and develop orally administered kinase inhibitor drug candidates that are able to slow or prevent HO. On December 21, 2020, we announced that in a phase 1 clinical trial, BCX9250, our lead compound, was safe and well tolerated at all doses studied, with linear and dose-proportional exposure supporting once-daily dosing. The randomized, double-blind, placebo-controlled dose-ranging trial evaluated safety, tolerability, and PK of SAD and MAD of BCX9250 in healthy subjects. The SAD study was designed to randomize four cohorts of eight subjects each to receive oral BCX9250 (n=6) or placebo (n=2) at dose levels of 5 mg, 10 mg, 15 mg, and 25 mg. Subjects in the 15 mg cohort also received a second single dose to evaluate food effect on absorption of BCX9250. The MAD study was designed to randomize 4 cohorts of 12 subjects each to receive oral BCX9250 (n=10) or placebo (n=2) at dose levels of 5 mg, 10 mg, 15 mg, and 20 mg once-daily for 7 days. Drug exposure increased with dose in an approximately linear and dose-proportional manner. Drug levels after a high fat meal were similar to those after dosing on an empty stomach. Drug exposure at 20 mg once-daily in the MAD was similar to that achieved with doses that suppressed HO in a nonclinical model of activity of orally dosed BCX9250. In both the SAD and the MAD studies, oral BCX9250 was safe and well tolerated, with no serious adverse events, no study discontinuations due to adverse events, no grade 3 or 4 adverse events, and no clinically significant changes in vital signs, electrocardiograms, or safety laboratory parameters. No safety signals were seen.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Peramivir Injection (RAPIVAB, ALPIVAB, RAPICACTA, PERAMIFLU)</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On March 4, 2020, the ICC Tribunal delivered a Partial Arbitration Award in the arbitration matter between the Company and SUL with respect to the SUL Agreement. In the Partial Arbitration Award, the ICC Tribunal found that, during the term, SUL materially breached and abandoned its core duties to us under the Diligent Efforts (as defined in the SUL Agreement) requirements of the SUL Agreement as applicable in the U.S. The ICC Tribunal granted a declaratory judgment in favor of us terminating the SUL Agreement and restoring all rights to peramivir to us. We agreed with SUL on a transition process for the product, with a full transition of commercialization of the product in the U.S. and Australia returned to us as of August 1, 2020 and November 1, 2020, respectively. The ICC Tribunal also awarded us attorneys&#x2019; fees and expenses incurred in securing the declaratory judgment as well as the costs incurred by us in the arbitration. Finally, the ICC Tribunal found that SUL breached the SUL Agreement by failing to pay a milestone payment due to us within 30 days of the approval of peramivir for adult use in the EU&#xa0;and awarded us $5.0 million (plus interest) for this claim. The ICC Tribunal retained jurisdiction for further proceedings relating to the award of attorneys&#x2019; fees and for any dispute relating to the return to us of all rights to peramivir in the Territory.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">40</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;"><span style="color:#000000;">On September 3, 2020, we announced that HHS has exercised its option to purchase an additional 10,000 doses of our antiviral influenza therapy, RAPIVAB (peramivir injection), for $6.9 million.&#xa0;</span>As a result, we expect to deliver at least one shipment of 10,000 doses in 2021.&#xa0;<span style="color:#000000;">The order is part of a $34.7 million contract awarded to us in 2018 for the procurement of up to 50,000 doses of RAPIVAB over a five-year period for the Strategic National Stockpile.</span></p>
  <p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:28.7pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Galidesivir (formerly BCX4430)</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:21pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">In April 2020, we agreed with NIAID/HHS to add a group of COVID-19 patients to an ongoing clinical trial in Yellow Fever. On April 9, 2020, we announced that we had opened a randomized, double-blind, placebo-controlled clinical trial in Brazil to assess the safety, clinical impact, and antiviral effects of galidesivir in patients with COVID-19. NIAID/HHS awarded us a new $43.9 million contract for the manufacture and evaluation of the safety, efficacy, and tolerability of galidesivir in August 2020, and it also added $2.9 million to its existing contract with us to support the development of galidesivir.&#xa0;</span>NIAID/HHS made an initial award of $6.3 million under the new contract.</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:21pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">On December 22, 2020, we announced that data from part 1 of the clinical trial in Brazil showed that galidesivir was safe and generally well tolerated in patients infected with SARS-Cov-2, the virus that causes COVID-19. The trial was not designed or sized to demonstrate clinical efficacy, and no clinical efficacy benefit with galidesivir treatment compared to placebo treatment was observed in the trial. Based on our ongoing discussions with NIAID/HHS, we expect NIAID</span>/HHS <span style="color:#000000;"> to continue its support for the development of galidesivir with a focus on biodefense threats, such as Marburg virus disease, and to discontinue the pursuit of a COVID-19 indication for galidesivir.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Financing Transactions</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>&#xa0;</i></span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;"><span style="text-decoration: underline; "><i>Royalty Monetization</i></span><i>.</i>&#xa0; On December 7, 2020, we entered into the Royalty Purchase Agreement with RPI, pursuant to which we sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $125 million in cash (the &#x201c;Royalty Sale&#x201d;).&#xa0; Under the Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the Key Territories.&#xa0; In addition, RPI is entitled to receive a tiered revenue share on amounts generally received by us on account of ORLADEYO sublicense revenue or net sales by licensees outside of the Key Territories. No payment will be due to RPI for any achievement milestone which may be payable under the existing out-license for ORLADEYO.&#xa0; Under the Royalty Purchase Agreement, RPI will also be entitled to receive 1.0% of global net sales, if any, of BCX9930.&#xa0; See &#x201c;Note 3-Royalty Monetizations-ORLADEYO Royalty Monetization&#x201d; in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report for additional information about our obligations under the Royalty Purchase Agreement.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;"><span style="text-decoration: underline; "><i>Credit Agreement</i></span>.&#xa0; On December 7, 2020, we entered into a $200.0 million Credit Agreement with Athyrium Opportunities III Co-Invest 1 LP (&#x201c;Athyrium&#x201d; and such agreement, the &#x201c;Credit Agreement&#x201d;), as lender and as administrative agent for the lenders.&#xa0;BioCryst Ireland Limited, BioCryst US Sales Co., LLC, and BioCryst UK Limited, each of which is a wholly-owned subsidiary of ours, are guarantors to the Credit Agreement. The Credit Agreement provides for an initial term loan in the principal amount of $125.0 million (the &#x201c;Term A Loan&#x201d;), which was received by us on December 7, 2020 and is classified as &#x201c;Secured term loan&#x201d; on our balance sheet as of December 31, 2020.&#xa0; We used a portion of the proceeds from the Term A Loan to repay the approximate $43.3 million of outstanding indebtedness, including accrued interest, under our secured credit facility with MidCap Financial Trust (&#x201c;MidCap&#x201d;), which terminated in December 2020 upon such repayment.&#xa0; We intend to use the remaining proceeds to support the launch of ORLADEYO in the United States and Europe and to advance the development of BCX9930 into clinical trials in multiple complement-mediated diseases, and for other general corporate purposes.&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Credit Agreement also provides for two additional term loans, at our option, in the respective principal amounts of $25.0 million (the &#x201c;Term B Loan&#x201d;) and $50.0 million (the &#x201c;Term C Loan&#x201d;).&#xa0; The Term B Loan and the Term C Loan may be drawn upon if, among other conditions, we reach defined revenue milestones and, with respect to a draw on the Term C Loan, the Term B Loan has been funded prior to or contemporaneously with the Term C Loan.&#xa0; The maturity date of the Credit Agreement is December 7, 2025. See &#x201c;Note 4-Credit Agreement&#x201d; in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report for additional information about our obligations under the Credit Agreement.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Results of Operations</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The discussion below presents a summary of our results of operations for fiscal years 2020 and 2019. See Part II, Item 7, &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations-Results of Operations&#x201d; of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the Securities and Exchange Commission on March 13, 2020, for a summary of our results of operations for the fiscal year ended December 31, 2018.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">41</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Year Ended December 31, 20</b></i><i><b>20</b></i><i><b> Compared to 201</b></i><i><b>9</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Total revenues in 2020 were $17.8 million, compared to $48.8 million in 2019. The decrease in revenue was primarily due to the recognition of $20.1 million of revenue related to a one-time $22.0 million upfront milestone payment we received in 2019 upon execution of the Torii Agreement, with the remaining amount of $1.9 million recognized in 2020. Additionally, we recognized $13.9 million of RAPIVAB product sales under our HHS contract in 2019. We did not have any RAPIVAB product sales under our HHS contract in 2020.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Revenues in 2020 included $3.3 million of product revenue,&#xa0;</span>the majority of which was&#xa0;<span style="color:#000000;">from peramivir inventory sales to our commercial partners, $3.2 million of royalty revenue from Shionogi, Green Cross and SUL associated with sales of peramivir in Japan, Taiwan, Korea and the United States, $1.9 million of deferred revenue amortization related to the Torii Agreement and $9.2 million of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS related to the development of galidesivir. Revenues in 2019 included $6.1 million of royalty revenue from SUL, Shionogi and Green Cross associated with sales of peramivir in the United States, Japan and Korea, $4.9 million of reimbursement of collaborative expenses from NIAID/HHS and BARDA/HHS under U.S. Government development contracts, $3.7 million of peramivir product revenue from inventory sales to our commercial partners, $13.9 million of RAPIVAB product revenue from inventory sales to BARDA/HHS under our Government procurement contract and $20.1 million related to the Torii Agreement upfront milestone payment.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Research and development expenses (&#x201c;R&amp;D expenses&#x201d;) increased to $123.0 million in 2020 from $107.1 million in 2019. The increase in 2020 R&amp;D expenses, as compared to 2019, was primarily due to increased spending on our complement-mediated diseases and galidesivir programs, as well as an increase in other research, preclinical and development activities, partially offset by a reduction in spend on the ORLADEYO program, which launched commercially in the U.S. during December 2020.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The following table summarizes our R&amp;D expenses for the periods indicated (amounts are in thousands):</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><span style="color:#000000;"><b><b>2020</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>2019</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>2018</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">R&amp;D expenses by program:</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"><span style="color:#000000;">BCX7353</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">44,329</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">57,059</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">53,993</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"><span style="color:#000000;">BCX9930</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">35,265</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">26,640</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">10,189</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"><span style="color:#000000;">FOP</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,583</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,167</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">8,871</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"><span style="color:#000000;">Galidesivir</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">9,705</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,680</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,428</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"><span style="color:#000000;">Peramivir</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,613</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,143</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,936</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"><span style="color:#000000;">Other 2nd generation HAE compounds</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">&#x2212;</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">357</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"><span style="color:#000000;">Other research, preclinical and development costs</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">29,469</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">10,373</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">7,114</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-top: 0pt; margin-left: 9pt;"><span style="color:#000000;">Total R&amp;D expenses</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">122,964</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">107,068</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">84,888</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">R&amp;D expenses include all direct and indirect expenses and are allocated to specific programs at the point of development of a lead product candidate. Direct expenses are charged directly to the program to which they relate, and indirect expenses are allocated based upon internal direct labor hours dedicated to each respective program. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties to conduct laboratory studies, develop manufacturing processes, manufacture the product candidates, conduct and manage clinical trials, as well as other costs related to our clinical and preclinical studies. Indirect R&amp;D expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our research and development efforts. R&amp;D expenses vary according to the number of programs in clinical development and the stage of development of our clinical programs. Later stage clinical programs tend to cost more than earlier stage programs due to the longer length of time of the clinical trials and the higher number of patients enrolled in these clinical trials.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Selling, general and administrative (&#x201c;SG&amp;A&#x201d;) expenses increased to $67.9 million in 2020 compared to $37.1 million in 2019. The increase of $30.8 million was primarily due to increased spending on commercial activities, including building a sales organization, as well as increases in medical affairs activities to support the U.S. commercial launch of ORLADEYO in 2020.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">Interest and other income was $9.4 million in 2020, compared to $1.9 million in 2019. The increase was primarily due to recognition of other income related to our arbitration proceedings.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Interest expense is related to the non-recourse PhaRMA Notes issued in March 2011, borrowings under our secured credit facility with MidCap, the Royalty Sale, and the $125.0 million Term A Loan under our new Credit Agreement with Athyrium. The Royalty Purchase Agreement requires us to recognize a liability (the &#x201c;Royalty Financing Obligation&#x201d;) for the future sale of royalties under the agreement. This liability is amortized using the effective interest rate method, resulting in the recognition of non-cash interest expense over the estimated term of the Royalty Purchase Agreement. Interest expense increased to $14.5 million in 2020, compared to $11.9 million in 2019, primarily due to the amortization of interest associated with the royalty financing obligation, which resulted in $2.1 million of non-cash interest expense, and interest expense of $0.9 million associated with the Term A Loan borrowing under the Credit Agreement. In December 2020, we repaid the outstanding indebtedness under our secured credit facility with MidCap.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Loss on debt extinguishment is comprised of the write-off of unamortized deferred financing costs and original issue discount of $1.2 million and a prepayment fee of $0.8 million associated with the repayment of the outstanding indebtedness under our secured credit facility with MidCap.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">42</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;">We realized a currency exchange gain of $0.7 million in 2020, compared to a $0.9 million currency exchange gain in 2019 related to the exercise of a U.S. dollar/Japanese yen currency option under the Currency Hedge Agreement. A mark-to-market loss of $0.6 million was recognized in 2020, compared to a mark-to-market loss of $0.4 million recognized in 2019, related to the Currency Hedge Agreement, resulting from changes in the U.S. dollar/Japanese yen exchange rate during the year. The final tranche of the options under the Currency Hedge Agreement expired in November 2020.&#xa0; Additionally, we realized currency exchange losses in 2020 of $1.0 million as a result of expanded international operating activities.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Liquidity and Capital Resources</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Our </span>operations have principally been funded through public offerings and private placements of equity securities; cash from collaborative and other research and development agreements, including U.S. Government contracts for RAPIVAB and galidesivir; to a lesser extent, the PhaRMA Notes financing and our secured credit facility with MidCap, which terminated in December 2020 when we repaid the outstanding indebtedness under the facility with a portion of the net proceeds from the Term A Loan under the Credit Agreement; and more recently, the Credit Agreement and the Royalty Sale.&#xa0; To date, we have been awarded a BARDA/HHS RAPIVAB development contract totaling $234.8 million, which expired on June 30, 2014, a NIAID/HHS galidesivir development contract totaling $45.9 million, which is ongoing, a second NIAID/HHS galidesivir development contract totaling $43.9 million, which is ongoing, and a BARDA/HHS galidesivir development contract totaling $39.1 million, which is also ongoing. The total amount of NIAID/HHS and BARDA/HHS galidesivir funding obligated under awarded options is $52.2 million and $20.6 million, respectively. In addition to the above, we have previously received funding from other sources, including other collaborative and other research and development agreements, government grants, equipment lease financing, facility leases, research grants, and interest income on our investments<span style="color:#000000;">.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On&#xa0;</span>June 1, 2020, we issued 22,044,447 shares of common stock to the public at a purchase price of $4.50 per share and pre-funded warrants to purchase 3,511,111 shares of common stock at a purchase of $4.49 per pre-funded warrant, for total net proceeds to us of $108.1 million after deducting underwriting discounts and commissions and other offering expenses payable by us. The pre-funded warrants are exercisable in accordance with the terms in the warrant agreement and have an exercise price of $0.01 per share, which is subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications, or similar events affecting our common stock and also upon any distributions of assets to our stockholders<span style="color:#000000;">.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On December 7, 2020, we entered into the Royalty Purchase Agreement with RPI, pursuant to which we sold to RPI the right to receive certain royalty payments from us on account of ORLADEYO and BCX9930 for a purchase price of $125.0 million in cash. We also entered into the Credit Agreement with Athyrium on December 7, 2020, pursuant to which we received a $125.0 million Term A Loan. We used a portion of the net proceeds from the Term A Loan to repay the approximate $43.3 million of outstanding indebtedness, including accrued interest, under our secured credit facility with MidCap. We intend to use the remaining proceeds to support the launch of ORLADEYO in the U.S. and Europe and to advance the development of BCX9930 into clinical trials in multiple complement-mediated diseases, and for other general corporate purposes. The Credit Agreement also provides for two additional term loans, at our option, in the respective principal amounts of $25.0 million for the Term B Loan and $50.0 million for the Term C Loan. The Term B Loan and the Term C Loan may be drawn upon if, among other conditions, we reach defined revenue milestones and, with respect to a draw on the Term C Loan, the Term B Loan has been funded prior to or contemporaneously with the Term C Loan. The maturity date of the Credit Agreement is December 7, 2025. See &#x201c;Note 3-Royalty Monetizations-ORLADEYO Royalty Monetization&#x201d; and &#x201c;Note 4-Credit Agreement&#x201d; in the Notes to Consolidated Financial Statements in Part II, Item 8 of this report for additional information about the Royalty Sale and the Credit Agreement, respectively.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:17.15pt;"><span style="color:#000000;">As of December 31, 2020, we had net working capital of $218.1 million, an increase of approximately $146.1 million from $72.0 million at December 31, 2019. The increase in working capital was primarily due to cash provided from the Royalty Sale and the Credit Agreement in December 2020, as well as the June 2020 public offering of our common stock and pre-funded warrants to purchase our common stock, partially offset by our normal operating expenses associated with the development of our product candidates and expenses incurred in anticipation of our launch and commercialization of ORLADEYO. Our principal sources of liquidity at December 31, 2020 were approximately $272.1 million in cash and cash equivalents and approximately $28.2 million in investments considered available-for-sale.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">We intend to contain costs and cash flow requirements by closely managing our third-party costs and headcount, leasing scientific equipment and facilities, contracting with other parties to conduct certain research and development projects, and using consultants. We expect to incur additional expenses, potentially resulting in significant losses, as we continue to pursue our research and development activities and commercialize ORLADEYO. We may incur additional expenses related to the filing, prosecution, maintenance, defense, and enforcement of patent and other intellectual property claims and additional regulatory costs as our clinical programs advance through later stages of development. The objective of our investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. We place our excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of our credit exposure. We have not realized any significant losses on our investments.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">43</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">We plan to finance our needs principally from the following:</span></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">lease, royalty, or loan financing and future public or private equity or debt financing;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">our existing capital resources and interest earned on that capital;</span></p> </td>
    </tr>

    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;">revenues from product sales;&#xa0;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">payments under existing, and executing new, contracts with the U.S. Government; and</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
   <tbody>
    <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">
     <td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">payments under current or future collaborative and licensing agreements with corporate partners.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 9pt 0pt 0pt; text-align: left; text-indent: 27pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">As our commercialization activities and research and development programs continue to advance, our costs will increase. Our current and planned clinical trials, plus the related development, manufacturing, regulatory approval process requirements, and additional personnel resources and testing required for the continuing development of our product candidates and the commercialization of our products will consume significant capital resources and will increase our expenses. Our expenses, revenues and cash utilization rate could vary significantly depending on many factors, including our ability to raise additional capital, the development progress of our collaborative agreements for our product candidates, the amount and timing of funding we receive from existing U.S. Government contracts for galidesivir, the amount of funding or assistance, if any, we receive from new U.S. Government contracts or other new partnerships with third parties for the development and/or commercialization of our products and product candidates, the progress and results of our current and proposed clinical trials for our most advanced product candidates, the progress made in the manufacturing of our lead product candidates, commercialization and market acceptance of our products, and the overall progression of our other programs. The impact of the ongoing COVID-19 pandemic on one or more of the foregoing factors could negatively affect our expenses, revenues, and cash utilization rate.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Based&#xa0;</span>on our expectations for revenue, operating expenses and our option to access an additional $75 million under the Credit Agreement, we believe our financial resources will be sufficient to fund our operations into 2023. However, we have sustained operating losses for the majority of our corporate history and expect that our 2021 expenses will exceed our 2021 revenues. We expect to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. Our liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of our products and the future progression of our product candidates. We also may consider other plans to fund future operations, including: (1) securing or increasing U.S. Government funding of our programs, including obtaining procurement contracts; (2) out-licensing rights to certain of our products or product candidates, pursuant to which the we would receive cash milestones; (3) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (4) obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (5) reducing spending on one or more research and development programs, including by discontinuing development; and/or (6) restructuring operations to change our overhead structure. We may issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities, and units, through private placement transactions or registered public offerings. Our future liquidity needs, and ability to address those needs, will largely be determined by the success of our products and product candidates; the timing, scope, and magnitude of our commercial expenses; and key development and regulatory events and our decisions in the future<span style="color:#000000;">.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">Our long-term capital requirements and the adequacy of our available funds will depend upon many factors, including:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">market acceptance of approved products and successful commercialization by either us or our partners;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">our ability to perform under our government contracts and to receive reimbursement and stockpiling procurement contracts;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the magnitude of work under our government contracts;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the progress and magnitude of our research, drug discovery and development programs;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">changes in existing collaborative relationships or government contracts;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:6pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:6pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">our ability to establish additional collaborative relationships with academic institutions, biotechnology or pharmaceutical companies and governmental agencies or other third parties;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:4.05pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:4.05pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the extent to which our partners, including governmental agencies, will share in the costs associated with the development of our programs or run the development programs themselves;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:13pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:13pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">our ability to negotiate favorable development and marketing strategic alliances for certain products and product candidates;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:13pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:13pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">any decision to build or expand internal development and commercial capabilities;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the scope and results of preclinical studies and clinical trials to identify and develop product candidates;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">our ability to engage sites and enroll subjects in our clinical trials;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the scope of manufacturing of our products to support our commercial operations and of our product candidates to support our preclinical research and clinical trials;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">increases in personnel and related costs to support the development and commercialization of our </span>products and <span style="color:#000000;">product candidates;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the scope of manufacturing of our drug substance and product candidates required for future NDA filings;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">competitive and technological advances;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the time and costs involved in obtaining regulatory approvals;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">post-approval commitments for ORLADEYO, RAPIVAB, and other products that receive regulatory approval; and</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: left; font-size: 10pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:39pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">the costs involved in all aspects of intellectual property strategy and protection, including the costs involved in preparing, filing, prosecuting, maintaining, defending, and enforcing patent claims.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">44</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We expect that we will be required to raise additional capital to complete the development and commercialization of our current&#xa0;</span>products and&#xa0;<span style="color:#000000;">product candidates, and we may seek to raise capital in the future. Additional funding, whether through additional sales of equity or debt securities, collaborative or other arrangements with corporate partners or from other sources, including governmental agencies in general and existing government contracts specifically, may not be available when needed or on terms acceptable to us. The issuance of preferred or common stock or convertible securities, with terms and prices significantly more favorable than those of the currently outstanding common stock, could have the effect of diluting or adversely affecting the holdings or rights of our existing stockholders. In addition, collaborative arrangements may require us to transfer certain material rights to such corporate partners. Insufficient funds may require us to delay, scale back or eliminate certain of our research and development programs. Our future working capital requirements, including the need for additional working capital, will be largely determined by the advancement of our portfolio of product candidates and commercialization of ORLADEYO, as well as rate of reimbursement by U.S. Government agencies of our galidesivir expenses and any future decisions regarding the future of the RAPIVAB and galidesivir programs, including those relating to stockpiling procurement. More specifically, our working capital requirements will be dependent on the number, magnitude, scope and timing of our development programs; regulatory approval of our product candidates; obtaining funding from collaborative partners; the cost, timing and outcome of regulatory reviews, regulatory investigations, and changes in regulatory requirements; the costs of obtaining patent protection for our product candidates; the timing and terms of business development activities; the rate of technological advances relevant to our operations; the efficiency of manufacturing processes developed on our behalf by third parties; the timing, scope and magnitude of commercial spending, and the level of required administrative support for our daily operations.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The restrictive covenants contained in the Credit Agreement with Athyrium could cause us to be unable to pursue business opportunities that we or our stockholders may consider beneficial without the lender&#x2019;s permission or without repaying all obligations outstanding under the Credit Agreement. These covenants limit our ability to, among other things, grant certain types of liens on our assets; make certain investments; incur or assume certain debt, including accessing additional tranches of debt under the Credit Agreement; engage in certain mergers, acquisitions, and similar transactions; dispose of assets; license certain property; distribute dividends; make certain restricted payments; change the nature of our business; engage in transactions with affiliates and insiders; prepay other indebtedness; or engage in sale and leaseback transactions. A breach of any of these covenants could result in an event of default under the Credit Agreement. As of December 31, 2020, we were in compliance with the covenants under the Credit Agreement.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Financial Outlook for 202</b></i><i><b>1</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In the launch period for ORLADEYO, the Company is not providing specific revenue or operating guidance. Based on our expectations for revenue, operating expenses, and our option to access an additional $75 million from our existing credit facility, we believe our current cash runway takes us into 2023.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Off-Balance Sheet Arrangements</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">As of December 31, 2020, we are not involved in any unconsolidated entities or off&#x2013;balance sheet arrangements.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Contractual Obligations</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In the table below, we set forth our enforceable and legally binding obligations and future commitments and obligations related to all contracts that we are likely to continue regardless of the fact that they are cancelable as of December 31, 2020. Some of the amounts we include in this table are based on management&#x2019;s estimates and assumptions about these obligations, including their duration, the possibility of renewal, anticipated actions by third parties, and other factors. Because these estimates and assumptions are necessarily subjective, the obligations we will actually pay in future periods may vary from those reflected in the table.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Payments Due by Period</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>(In thousands)</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Less Than</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>More Than</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 40%; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;"><b>Contractual Obligations</b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Total</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;"><b><b>1 Year</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>1-3 Years</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>3-5 Years</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>5 Years</b></b></span></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Operating lease obligations</span></p> </td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">11,165</span></td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,302</span></td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,378</span></td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,158</span></td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">7,327</span></td>
     <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Purchase obligations(1)</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">99,741</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">99,741</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Contingent license obligations</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,050</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">150</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">300</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">300</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">300</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Non-recourse notes payable(2)</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">53,331</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">53,331</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Secured term loan</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">209,339</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">16,080</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">193,259</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">-</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Total</span></p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">374,626</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">154,524</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">17,758</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">194,717</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">7,627</span></td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">(1)</span></p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">Purchase obligations include commitments related to clinical development, manufacturing and research operations and other purchase commitments.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="width:18pt;vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt; text-align: justify; font-size: 10pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;">(2)</span></p> </td>
     <td style="vertical-align:top;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:34pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;"><span style="color: #000000; ">The&#xa0;</span>PhaRMA Notes had a final legal maturity date of December 1, 2020, at which time the outstanding principal, together with accrued and unpaid interest, was due in full. As of December 31, 2020, the PhaRMA Notes remain outstanding and in default and the Company will continue to record the liability and accrued interest owed until the Company is determined to no longer be the financial obligor<span style="color:#000000;">.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">45</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The above amounts exclude future potential payments under our Royalty Purchase Agreement with RPI, pursuant to which we are required to make certain royalty payments to RPI based on net product sales of ORLADEYO and BCX9930, as well as on certain ORLADEYO sublicense revenue. Due to the nature of this arrangement, the future potential payments related to the attainment of additional regulatory approvals and sales-based milestones over a period of several years are inherently uncertain, and accordingly, no amounts have been presented for these future potential payments.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In addition to the above, we have committed to make potential future &#x201c;sublicense&#x201d; payments to third parties as part of in-licensing and development programs. Payments under these agreements generally become due and payable only upon achievement of certain developmental, regulatory and/or commercial milestones. Because the achievement of these milestones is neither probable nor reasonably estimable, such contingencies have not been recorded on our balance sheet.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Critical Accounting Policies</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We have established various accounting policies that govern the application of U.S. GAAP, which were utilized in the preparation of our consolidated financial statements. Certain accounting policies involve significant judgments and assumptions by management that have a material impact on the carrying value of certain assets and liabilities. Management considers such accounting policies to be critical accounting policies. The judgments and assumptions used by management are based on historical experience and other factors, which are believed to be reasonable under the circumstances. Because of the nature of the judgments and assumptions made by management, actual results could differ from these judgments and estimates, which could have a material impact on the carrying values of assets and liabilities and the results of operations.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">While our significant accounting policies are more fully described in &#x201c;Note 1-Significant Accounting Policies and Concentrations of Risk&#x201d; to the Consolidated Financial Statements in Part II, Item 8 of this report, we believe that the following accounting policies are the most critical to aid you in fully understanding and evaluating our reported financial results and affect the more significant judgments and estimates that we use in the preparation of our financial statements.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Inventory</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Our inventories consist of peramivir finished goods and work in process, which are valued at the lower of cost or net realizable value using the first-in, first-out (i.e., FIFO) method. Cost includes materials, labor, overhead, shipping and handling costs. Our inventories are subject to expiration dating. We regularly evaluate the carrying value of our inventories and provide valuation reserves for any estimated obsolete, short-dated or unmarketable inventories. In addition, we may experience spoilage of our raw materials and supplies. Our determination that a valuation reserve might be required, in addition to the quantification of such reserve, requires us to utilize significant judgment. In connection with the FDA approval of RAPIVAB and other regulatory approvals, we began capitalizing costs associated with the production of peramivir inventories.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>&#xa0;</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Accrued Expenses</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We enter into contractual agreements with third-party vendors who provide research and development, manufacturing, and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. We record liabilities under these contractual commitments when an obligation has been incurred. This accrual process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed and estimating the level of service performed and the associated cost when we have not yet been invoiced or otherwise notified of actual cost. The majority of our service providers invoice us monthly in arrears for services performed. We make estimates of our accrued expenses as of each balance sheet date based on the facts and circumstances known to us. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued expenses include:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">fees paid to CROs in connection with preclinical and toxicology studies and clinical trials;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">fees paid to investigative sites in connection with clinical trials;</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">fees paid to contract manufacturers in connection with the production of our raw materials, drug substance, drug products, and product candidates; and</span></p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">&#x25cf;</span></p> </td>
     <td> <p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><span style="color:#000000;">professional fees.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We base our expenses related to clinical trials on our estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we will adjust the accrual accordingly. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of these costs, our actual expenses could differ from our estimates.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">46</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Revenue Recognition</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:21pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We adopted the provisions of ASC 606 as of January 1, 2018 using the modified retrospective method as applied to contracts that were not completed as of that date. As a result, financial information for reporting periods beginning after January 1, 2018 are presented under ASC 606, while comparative financial information has not been adjusted and continues to be reported in accordance with our historical accounting policy for revenue recognition prior to the adoption of ASC 606.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We recognize revenue when we satisfy a performance obligation by transferring promised goods or services to a customer. Revenue is measured at the transaction price that is based on the amount of consideration that we expect to receive in exchange for transferring the promised goods or services to the customer. The transaction price includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will not occur.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We have collaboration and license agreements with a number of third parties as well as research and development agreements with certain government entities. Our primary sources of revenue are license, service, royalty and product sale revenues from these collaborative and other research and development arrangements.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and we have no further continuing performance obligations or we have completed the performance obligations under the terms of the agreement.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Arrangements that involve the delivery of more than one performance obligation are initially evaluated as to whether the intellectual property licenses granted by us represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. Variable consideration is assessed at each reporting period as to whether it is not subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which we separately sell the products or services. If a standalone selling price is not directly observable, then we estimate the standalone selling price considering market conditions and entity-specific factors. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each may be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was not probable at the inception of the agreement; and (ii) we have a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under our contracts with BARDA/HHS and NIAID/HHS, revenue is recognized as reimbursable direct and indirect costs are incurred.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Under certain of our license agreements, we receive royalty payments based upon our licensees&#x2019; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Product Sales</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">Our principal sources of product sales are sales of peramivir to our licensing partners and sales of RAPIVAB to HHS under our procurement contract. In December 2020, we launched ORLADEYO and began recording product revenue. We recognize revenue for sales when the customer obtains control of the product, which generally occurs upon delivery.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Contract Balances</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue and billings in excess of revenue recognized (contract liabilities) on the Consolidated Balance Sheets.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">47</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><span style="text-decoration: underline; "><i>Contract assets</i></span>. Our long-term contracts are billed as work progresses in accordance with the contract terms and conditions, either at periodic<i> </i>intervals or upon achievement of certain milestones. Often this results in billing occurring subsequent to revenue recognition, resulting in contract assets. Contract assets are generally classified as current assets in the Consolidated Balance Sheets.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><span style="text-decoration: underline; "><i>Contract liabilities</i></span>. We often receive cash payments from customers in advance of our performance, resulting in contract liabilities. These contract<i> </i>liabilities are classified as either current or long-term in the Consolidated Balance Sheets based on the timing of when we expect to recognize the revenue.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Contract Costs</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We may incur direct and indirect costs associated with obtaining a contract. Incremental contract costs that we expect to recover are capitalized and amortized over the expected term of the contract. Non-incremental contract costs and costs that we expect to recover are expensed as incurred.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Research and Development Expenses</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Our research and development costs are charged to expense when incurred. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of our manufacturing and clinical and preclinical studies are performed by third-party CROs. Costs for studies performed by CROs are accrued by us over the service periods specified in the contracts and estimates are adjusted, if required, based upon our on-going review of the level of services actually performed.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:23pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Additionally, we have license agreements with third parties, such as AECOM, IRL, and UAB, which require fees related to sublicense agreements or maintenance fees. We expense sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. We expense maintenance payments as incurred.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Deferred collaboration expenses represent sub-license payments paid to our academic partners upon receipt of consideration from various commercial partners, and other consideration to our academic partners for modification to existing license agreements. These deferred expenses would not have been incurred without receipt of such payments or modifications from our commercial partners and are being expensed in proportion to the related revenue being recognized. We believe that this accounting treatment appropriately matches expenses with the associated revenue.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We group our R&amp;D expenses into two major categories: direct external expenses and indirect expenses. Direct expenses consist of compensation for R&amp;D personnel and costs of outside parties to conduct laboratory studies, develop manufacturing processes and manufacture the product candidate, conduct and manage clinical trials, as well as other costs related to our clinical and preclinical studies. These costs are accumulated and tracked by active program. Indirect expenses consist of lab supplies and services, facility expenses, depreciation of development equipment and other overhead of our research and development efforts. These costs apply to work on non-active product candidates and our discovery research efforts.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Stock-Based Compensation</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in our Consolidated Statements of Comprehensive Loss based on their fair values. Stock-based compensation cost is estimated at the grant date based on the fair value of the award and is recognized as expense on a straight-line basis over the requisite service period of the award. Determining the appropriate fair value model and the related assumptions for the model requires judgment, including estimating the life of an award, the stock price volatility, and the expected term. We utilize the Black-Scholes option-pricing model to value our awards and recognize compensation expense on a straight-line basis over the vesting periods. The estimation of share-based payment awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from our current estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. In addition, we have outstanding performance-based stock options for which no compensation expense is recognized until &#x201c;performance&#x201d; has occurred. Significant management judgment is also required in determining estimates of future stock price volatility and forfeitures to be used in the valuation of the options. Actual results, and future changes in estimates, may differ substantially from our current estimates.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Interest Expense and Royalty Financing Obligation</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>&#xa0;</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;"><span style="color:#000000;">The royalty financing obligation is eligible to be repaid based on royalties from net sales of ORLADEYO. Interest expense is accrued using the effective interest rate method over the estimated period the related liability will be paid. This requires us to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. We impute interest on the carrying value of the royalty financing obligation and record interest expense using an imputed effective interest rate. We will reassess the expected royalty payments each reporting period and account for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that we make estimates that could impact the carrying value of the liability, as well as the period over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact the liability balance, interest expense and the time period for repayment.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>&#xa0;</b></i></span></p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">48</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Foreign Currency Hedge</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In connection with our issuance of the PhaRMA Notes, we entered into a foreign Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, we have the right to purchase dollars and sell yen at a rate of 100 yen per dollar. The final tranche of the options under the Currency Hedge Agreement expired in November of 2020.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;">The Currency Hedge Agreement did not qualify for hedge accounting treatment and therefore mark-to-market adjustments were recognized in our Consolidated Statements of Comprehensive Loss. Mark-to-market adjustments were determined by quoted prices in markets that are not actively traded and for which significant inputs are observable directly or indirectly, representing Level 2 in the fair value hierarchy as defined by generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;).</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Tax</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We account for uncertain tax positions in accordance with U.S. GAAP. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. We have recorded a valuation allowance against all potential tax assets, due to uncertainties in our ability to utilize deferred tax assets, primarily consisting of certain net operating losses carried forward, before they expire. The valuation allowance is based on estimates of taxable income in each of the jurisdictions in which we operate and the period over which our deferred tax assets will be recoverable.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>&#xa0;</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>Impact of Inflation</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">We do not believe that our operating results have been materially impacted by inflation during the past three years. However, we cannot be assured that our operating results will not be adversely affected by inflation in the future. We will continually seek to mitigate the adverse effects of inflation on the services that we use through improved operating efficiencies and cost containment initiatives.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Recent Accounting Pronouncements</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">&#x201c;Note 1-Significant Accounting Policies and Concentrations of Risk&#x201d; to the Consolidated Financial Statements included in Part II, Item 8 of this report discusses accounting pronouncements recently issued or proposed but not yet required to be adopted.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><a id="i7a" title="i7a" href="#"></a>ITEM 7A.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<i><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</b></i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Interest Rate Risk</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We are subject to interest rate risk on our investment portfolio and borrowings under our Credit Agreement. The Term A Loan under the Credit Agreement bears interest each quarter at a rate equal to the three-month LIBOR rate, which is capped to be no less than 1.75% and no more than 3.50% (&#x201c;LIBOR&#x201d;), plus 8.25% or, for each quarterly interest period in which a PIK Interest Payment is made, the LIBOR plus 10.25%. Accordingly, increases in interest rates could increase the associated interest payments that we are required to make on the term loans. As of December 31, 2020, interest was accrued at 12.2% on the $125.0 million Term A Loan under the Credit Agreement.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We invest in marketable securities in accordance with our investment policy. The primary objectives of our investment policy are to preserve capital, maintain proper liquidity to meet operating needs and maximize yields. Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment. We place our excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of credit exposure. Some of the securities we invest in may have market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Our investment exposure to market risk for changes in interest rates relates to the increase or decrease in the amount of interest income we can earn on our portfolio, changes in the market value due to changes in interest rates and other market factors as well as the increase or decrease in any realized gains and losses. Our investment portfolio includes only marketable securities and instruments with active secondary or resale markets to help ensure portfolio liquidity. A hypothetical 100 basis point increase or decrease in interest rates along the entire interest rate yield curve would not significantly affect the fair value of our interest sensitive financial instruments, including our borrowings, but may affect our future earnings and cash flows. We generally have the ability to hold our fixed-income investments to maturity and therefore do not expect that our operating results, financial position or cash flows will be materially impacted due to a sudden change in interest rates. However, our future investment income may fall short of expectations due to changes in interest rates, or we may suffer losses in principal if forced to sell securities which have declined in market value due to changes in interest rates or other factors, such as changes in credit risk related to the securities&#x2019; issuers. To minimize this risk, we schedule our investments to have maturities that coincide with our expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, we do not believe that we have material exposure to interest rate risk arising from our investments. Generally, our investments are not collateralized. We have not realized any significant losses from our investments.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">49</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We do not use interest rate derivative instruments to manage exposure to interest rate changes. We ensure the safety and preservation of invested principal funds by limiting default risk, market risk and reinvestment risk. We reduce default risk by investing in investment grade securities.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Foreign Currency Risk</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The majority of our transactions and the greatest magnitude of these transactions occur in U.S. dollars and we do not have significant operating subsidiaries or significant investments in foreign countries as of December 31, 2020. Therefore, we are not subject to significant foreign currency exchange risk in our normal operations.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In connection with the issuance by Royalty Sub of the PhaRMA Notes, we had entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The final tranche of the options under the Currency Hedge Agreement expired in November 2020.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">50</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><span style="color:#000000;"><b><a id="i8" title="i8" href="#"></a>ITEM 8.&#xa0; &#xa0; &#xa0;</b><i><b>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></i></span></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-size: 10pt; margin: 0 0 0 102.5pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif"><span style="color:#000000;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></span></p>
  <p style="font-size: 10pt; margin: 0 0 0 102.5pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif">&#xa0;</p>
  <p style="font-size: 10pt; margin: 0 0 0 101.5pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif"><span style="color:#000000;"><b><a id="bs" title="bs" href="#"></a>CONSOLIDATED BALANCE SHEETS</b></span></p>
  <p style="font-size: 10pt; margin: 0 0 0 101.5pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif"><span style="color:#000000;"><b>(In thousands, except per share amounts)</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); padding-bottom: 1px;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;"><b><b><b><em style="font: inherit;"><em style="font: inherit;">December 31,</em></em></b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgba(0, 0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0pt;"><span style="color:#000000;"><b><b><b>20</b><b>20</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-size: 10pt; margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0pt;"><span style="color:#000000;"><b><b><b><em style="font: inherit;">2019</em></b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: center;"><span style="color:#000000;"><b>ASSETS</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Cash and cash equivalents</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828048" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">272,127</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828049" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">114,172</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Restricted cash</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828050" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">2,221</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828051" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,551</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Investments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828052" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">28,239</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828053" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">22,054</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Receivables</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828054" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">8,646</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828055" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">22,146</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Inventory</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828056" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:numdotdecimal" decimals="-3">7,039</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828057" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Prepaid expenses and other current assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828058" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5,528</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828059" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">4,422</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; margin-left: 9pt;"><span style="color:#000000;">Total current assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828060" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-5">323,800</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828061" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">164,345</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Property and equipment, net</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828062" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">7,113</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828063" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">7,347</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Other assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828064" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,802</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828065" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">3,590</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; margin-left: 9pt;"><span style="color:#000000;">Total assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828066" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:numdotdecimal" decimals="-3">334,715</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828067" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:numdotdecimal" decimals="-3">175,282</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; text-align: center;"><span style="color:#000000;"><b>LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Accounts payable</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828069" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">18,713</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828070" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">13,988</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Accrued expenses</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828071" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">33,942</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828072" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">21,365</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Interest payable</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828073" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:InterestPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">21,670</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828074" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:InterestPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">14,904</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Deferred collaboration revenue</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828075" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredRevenueCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">150</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828076" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredRevenueCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">2,120</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Lease financing obligation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828077" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,179</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828078" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,377</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Senior credit facility</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828079" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LinesOfCreditCurrent" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828080" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:LinesOfCreditCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">9,020</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Non-recourse notes payable</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828081" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:NotesPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828082" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:NotesPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">29,561</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; margin-left: 9pt;"><span style="color:#000000;">Total current liabilities</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828083" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">105,654</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828084" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">92,335</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Royalty financing obligation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828085" contextRef="i_2020-12-31" unitRef="USD" name="bcrx:FutureRoyaltiesPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">124,717</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828086" contextRef="i_2019-12-31" unitRef="USD" name="bcrx:FutureRoyaltiesPayable" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Lease financing obligation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828087" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,871</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828088" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,406</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Senior credit facility</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828089" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LineOfCredit" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828090" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:LineOfCredit" scale="3" format="ixt:numdotdecimal" decimals="-3">41,289</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Secured term loan</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828091" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LongTermDebtNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">119,735</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828092" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:LongTermDebtNoncurrent" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Stockholders&#x2019; equity:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; margin-left: 9pt;"><span style="color:#000000;">Preferred stock, <span style="-sec-ix-hidden:c69831007"><span style="-sec-ix-hidden:c69831008">$0.01</span></span> par value; shares authorized &#x2014; <span style="-sec-ix-hidden:c69831009"><span style="-sec-ix-hidden:c69831010">5,000</span></span>; <span style="-sec-ix-hidden:c69831011"><span style="-sec-ix-hidden:c69831012">no</span></span> shares outstanding</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69828094">-</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69828095">-</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; margin-left: 18pt; text-indent: -9pt;"><span style="color:#000000;">Common stock, <span style="-sec-ix-hidden:c69828104"><span style="-sec-ix-hidden:c69828105">$0.01</span></span> par value; shares authorized &#x2014; <span style="-sec-ix-hidden:c69828106"><span style="-sec-ix-hidden:c69828107">450,000</span></span>; shares issued and outstanding &#x2014; <span style="-sec-ix-hidden:c69828108"><span style="-sec-ix-hidden:c69828110">176,883</span></span> at December 31, 2020 and <span style="-sec-ix-hidden:c69828109"><span style="-sec-ix-hidden:c69828111">154,082</span></span> at December 31, 2019</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828102" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,769</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828103" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,541</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Additional paid-in capital</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828112" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:numdotdecimal" decimals="-3">1,002,408</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828113" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:numdotdecimal" decimals="-5">877,300</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Accumulated other comprehensive income (loss)</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828114" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px;"><span style="color:#000000;"><ix:nonFraction id="c69828115" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">39</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif;"><span style="color:#000000;">Accumulated deficit</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69828116" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,023,442</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69828117" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">840,628</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; margin-left: 18pt; text-indent: -9pt;"><span style="color:#000000;">Total stockholders&#x2019; (deficit) equity</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69828118" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">19,262</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828119" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">38,252</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; margin-left: 18pt; text-indent: -9pt;"><span style="color:#000000;">Total liabilities and stockholders&#x2019; equity</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828120" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">334,715</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0px; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828121" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">175,282</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0">&#xa0;</p>
  <p style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0"><span style="color:#000000;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">51</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><a id="cl" title="cl" href="#"></a>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>(In thousands, except per share amounts)</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="10" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Year Ended December 31,</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><span style="color:#000000;"><b><b>2019</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>2018</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Revenues</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Product sales, net</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828123" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">3,301</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828124" contextRef="d_2019-01-01_2019-12-31_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">17,533</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Royalty revenue</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828126" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">3,381</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828127" contextRef="d_2019-01-01_2019-12-31_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">6,303</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828128" contextRef="d_2018-01-01_2018-12-31_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">6,101</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Collaborative and other research and development</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828129" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-4">11,130</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828130" contextRef="d_2019-01-01_2019-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">24,999</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828131" contextRef="d_2018-01-01_2018-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">14,552</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 20pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:20pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Total revenues</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828132" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">17,812</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828133" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">48,835</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828134" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">20,653</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Expenses</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Cost of products sold</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828136" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" format="ixt:numdotdecimal" decimals="-4">1,550</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828137" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" format="ixt:numdotdecimal" decimals="-3">3,726</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Research and development</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828139" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">122,964</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828140" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">107,068</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828141" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">84,888</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Selling, general and administrative</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828142" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">67,929</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828143" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">37,121</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828144" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">29,514</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Royalty</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828145" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:RoyaltyExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">126</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828146" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:RoyaltyExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">375</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828147" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:RoyaltyExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">471</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 20pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:20pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Total operating expenses</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828148" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="3" format="ixt:numdotdecimal" decimals="-3">192,569</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828149" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="3" format="ixt:numdotdecimal" decimals="-4">148,290</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828150" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="3" format="ixt:numdotdecimal" decimals="-3">114,873</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Loss from operations</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828151" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">174,757</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828152" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">99,455</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828153" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">94,220</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Interest and other income</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828154" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="bcrx:InterestAndOtherIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-4">9,420</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828155" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="bcrx:InterestAndOtherIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3">1,933</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828156" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="bcrx:InterestAndOtherIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3">2,252</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Interest expense</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828157" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">14,501</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828158" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">11,892</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828159" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">9,176</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Loss on extinguishment of debt</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828160" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">2,011</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">-</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">-</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Gain (loss) on foreign currency</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69828163" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">965</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828164" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" format="ixt:numdotdecimal" decimals="-3">517</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69828165" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">108</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Net loss</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828166" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">182,814</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828167" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">108,897</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828168" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">101,252</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Unrealized gain (loss) on available for sale investments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69828169" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">36</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828170" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">336</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69828171" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Net comprehensive loss</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69828172" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">182,850</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69828173" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">108,561</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69828174" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">101,306</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Basic and diluted net loss per common share</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>(<ix:nonFraction id="c69828175" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1.09</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>)</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>(<ix:nonFraction id="c69828176" contextRef="d_2019-01-01_2019-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.94</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>)</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>(<ix:nonFraction id="c69828177" contextRef="d_2018-01-01_2018-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.98</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>)</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Weighted average shares outstanding</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b><ix:nonFraction id="c69828178" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">167,267</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b><ix:nonFraction id="c69828179" contextRef="d_2019-01-01_2019-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-5">115,600</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b><ix:nonFraction id="c69828180" contextRef="d_2018-01-01_2018-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" format="ixt:numdotdecimal" decimals="-3">103,185</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><span style="color:#000000;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">52</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><span style="color:#000000;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-left: 0pt; margin-top: 0pt; text-align: center;"><span style="color:#000000;"><b><a id="cf" title="cf" href="#"></a>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-bottom: 0pt; margin-left: 0pt; margin-top: 0pt; text-align: center;"><span style="color:#000000;"><b>(In thousands, except per share amounts)</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="10" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><span style="color:#000000;"><b><b>Year Ended December 31,</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>2019</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>2018</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Operating activities:</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Net loss</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828181" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">182,814</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828182" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">108,897</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828183" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">101,252</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Depreciation and amortization</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828185" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">748</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828186" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">724</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828187" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:numdotdecimal" decimals="-4">770</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Loss (gain) on disposal of property and equipment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828190" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">7</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock-based compensation expense</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828191" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">14,794</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828192" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">17,719</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828193" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">9,396</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Amortization of debt issuance costs</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828194" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AmortizationOfFinancingCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">2,428</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828195" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:AmortizationOfFinancingCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">1,278</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828196" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:AmortizationOfFinancingCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">885</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Amortization of premium/discount on investments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828197" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="bcrx:AmortizationOfDiscountAndPremiumOnInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">121</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828198" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="bcrx:AmortizationOfDiscountAndPremiumOnInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">117</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828199" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="bcrx:AmortizationOfDiscountAndPremiumOnInvestments" scale="3" format="ixt:numdotdecimal" decimals="-4">110</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Change in fair value of foreign currency derivative</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828200" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInDerivativeAssets" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">632</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828201" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInDerivativeAssets" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">347</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828202" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInDerivativeAssets" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,049</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Changes in operating assets and liabilities:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Receivables</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828204" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInReceivables" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">13,903</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828205" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInReceivables" scale="3" format="ixt:numdotdecimal" decimals="-3">17,853</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828206" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInReceivables" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,824</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Inventory</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828207" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInInventories" scale="3" format="ixt:numdotdecimal" decimals="-3">7,039</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828208" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInInventories" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,649</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828209" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInInventories" scale="3" format="ixt:numdotdecimal" decimals="-3">1,649</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Prepaid expenses and other assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828210" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-4">2,140</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828211" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">1,364</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828212" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">866</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Accounts payable and accrued expenses</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828213" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">17,355</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828214" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">11,741</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828215" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">4,487</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Interest payable</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828216" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" format="ixt:numdotdecimal" decimals="-3">6,766</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828217" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" format="ixt:numdotdecimal" decimals="-3">3,056</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828218" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">247</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Deferred revenue</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69828219" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">1,970</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828220" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">1,899</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69828221" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">7,079</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><b>Net cash used in operating activities:</b></span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>(<ix:nonFraction id="c69828222" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">137,216</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>)</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>(<ix:nonFraction id="c69828223" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">89,584</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>)</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>(<ix:nonFraction id="c69828224" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">92,565</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>)</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Investing activities:</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Acquisition of property and equipment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828226" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">514</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828227" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">343</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828228" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">366</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Purchases of investments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828229" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">49,818</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828230" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">3,018</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828231" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">62,614</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Sales and maturities of investments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828232" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">43,475</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828233" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">81,295</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828234" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">67,748</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Realized gain on investments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828235" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="bcrx:ProceedsFromRealizedGainOnInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828236" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="bcrx:ProceedsFromRealizedGainOnInvestments" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828237" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="bcrx:ProceedsFromRealizedGainOnInvestments" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><b>Net cash provided by (used in) investing activities:</b></span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>(<ix:nonFraction id="c69828238" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">6,856</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>)</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b><ix:nonFraction id="c69828239" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">77,934</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b><ix:nonFraction id="c69828240" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">4,768</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Financing activities:</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Sale of common stock, net</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828242" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:numdotdecimal" decimals="-3">93,279</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828243" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:numdotdecimal" decimals="-5">58,500</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828244" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:numdotdecimal" decimals="-5">53,400</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Sale of pre-funded warrants</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828245" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" format="ixt:numdotdecimal" decimals="-3">14,817</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828246" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" format="ixt:numdotdecimal" decimals="-3">19,882</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Net proceeds from common stock issued under stock-based compensation plans</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828248" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">2,446</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828249" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">1,239</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828250" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">2,852</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Proceeds from senior credit facility</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828251" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828252" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" format="ixt:numdotdecimal" decimals="-3">19,477</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828253" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:ProceedsFromLinesOfCredit" scale="3" format="ixt:numdotdecimal" decimals="-3">10,353</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Payment of senior credit facility</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69828254">(52,420</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828256" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:RepaymentsOfLinesOfCredit" scale="3" format="ixt:numdotdecimal" decimals="-3">4,025</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Net proceeds from secured term loan</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828257" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">119,867</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Net proceeds from royalty financing obligation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828260" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="bcrx:ProceedsFromRoyaltyFinancingObligation" scale="3" format="ixt:numdotdecimal" decimals="-3">124,708</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">(Decrease) increase in lease financing obligation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69828265" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="bcrx:IncreaseDecreaseInFinancingLeaseObligations" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">76</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><b>Net cash provided by financing activities:</b></span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b><ix:nonFraction id="c69828266" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">302,697</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b><ix:nonFraction id="c69828267" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">99,098</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b><ix:nonFraction id="c69828268" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">62,504</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Increase (decrease) in cash, cash equivalents and restricted cash</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828269" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-3">158,625</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828270" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-3">87,448</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828271" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">25,293</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Cash, cash equivalents and restricted cash at beginning of year</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828272" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">115,723</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828273" contextRef="i_2018-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">28,275</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828274" contextRef="i_2017-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">53,568</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Cash, cash equivalents and restricted cash at end of year</b></span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b><ix:nonFraction id="c69828275" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">274,348</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b><ix:nonFraction id="c69828276" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">115,723</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b><ix:nonFraction id="c69828277" contextRef="i_2018-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">28,275</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><span style="color:#000000;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">53</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><a id="se" title="se" href="#"></a>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#x2019; EQUITY</b><b> (DEFICIT)</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>(In thousands, except per share amounts)</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;"><b><b>Accumulated</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b><em style="font: inherit;">&#xa0;</em></b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Additional</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Other</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b><em style="font: inherit;">&#xa0;</em></b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Total</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Common</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Paid-In</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Comprehensive</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Accumulated</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Stockholders&#x2019;</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Stock</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Capital</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">(Loss) Income</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Deficit</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Equity</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 40%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Balance at December 31, 201</b><b>7</b></span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>$</b></span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b><ix:nonFraction id="c69828293" contextRef="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">984</ix:nonFraction></b></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>$</b></span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b><ix:nonFraction id="c69828294" contextRef="i_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">714,869</ix:nonFraction></b></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>$</b></span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>(<ix:nonFraction id="c69828295" contextRef="i_2017-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">243</ix:nonFraction></b></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>)</b></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>$</b></span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>(<ix:nonFraction id="c69828296" contextRef="i_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">631,843</ix:nonFraction></b></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>)</b></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>$</b></span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b><ix:nonFraction id="c69828297" contextRef="i_2017-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">83,767</ix:nonFraction></b></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Impact to retained earnings from adoption of ASC 606</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828301" contextRef="i_2017-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201409Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,126</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828302" contextRef="i_2017-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201409Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,126</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Net loss</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828306" contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">101,252</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828307" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">101,252</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Other comprehensive (loss)</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828310" contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828312" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">54</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Exercise of stock options, 1,106 shares, net</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828313" contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">11</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828314" contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-4">2,490</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828317" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">2,501</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Employee stock purchase plan sales, <span style="-sec-ix-hidden:c69828332">92</span> shares, net</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828323" contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828324" contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-4">350</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828327" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">351</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Issuance of common stock, <span style="-sec-ix-hidden:c69828342">10,455</span> shares, net</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828333" contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">105</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828334" contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">53,295</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828337" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-5">53,400</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Stock-based compensation expense</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">-</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828344" contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">9,396</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828347" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">9,396</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Balance at December 31, 201</b><b>8</b></span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b><ix:nonFraction id="c69828348" contextRef="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,101</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000"><b>$</b></span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b><ix:nonFraction id="c69828349" contextRef="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-5">780,400</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000"><b>$</b></span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>(<ix:nonFraction id="c69828350" contextRef="i_2018-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">297</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>)</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000"><b>$</b></span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>(<ix:nonFraction id="c69828351" contextRef="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">731,969</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>)</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000"><b>$</b></span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b><ix:nonFraction id="c69828352" contextRef="i_2018-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">49,235</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Impact to retained earnings from adoption of ASC 842</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828356" contextRef="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">238</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828357" contextRef="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">238</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Net loss</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828361" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">108,897</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828362" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">108,897</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Other comprehensive income</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828365" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">336</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828367" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3">336</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Exercise of stock options, <span style="-sec-ix-hidden:c69828377">283</span> shares, net</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828368" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828369" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">832</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828372" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">835</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Employee stock purchase plan sales, <span style="-sec-ix-hidden:c69828387">115</span> shares, net</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828378" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828379" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">403</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828382" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">404</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Issuance of common stock, <span style="-sec-ix-hidden:c69828397">43,621</span> shares, net</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828388" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">436</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828389" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">58,064</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828392" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-5">58,500</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Issuance of pre-funded warrants, <span style="-sec-ix-hidden:c69828407">11,765</span> warrants</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828399" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:numdotdecimal" decimals="-3">19,882</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828402" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:numdotdecimal" decimals="-3">19,882</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Stock-based compensation expense</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828409" contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">17,719</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828412" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">17,719</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Balance at December 31, 20</b><b>19</b></span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b><ix:nonFraction id="c69828413" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,541</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b><ix:nonFraction id="c69828414" contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-5">877,300</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b><ix:nonFraction id="c69828415" contextRef="i_2019-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">39</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>(<ix:nonFraction id="c69828416" contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">840,628</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>)</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b><ix:nonFraction id="c69828417" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">38,252</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Net loss</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828421" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">182,814</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828422" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">182,814</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Other comprehensive (loss)</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828425" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">36</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69828427" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">36</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Exercise of stock options, <span style="-sec-ix-hidden:c69828437">510</span> shares, net</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828428" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">5</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828429" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">1,809</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828432" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">1,814</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Employee stock purchase plan sales, <span style="-sec-ix-hidden:c69828448">246</span> shares, net</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828438" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828439" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">629</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828442" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">632</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Issuance of common stock, <span style="-sec-ix-hidden:c69828462">22,044</span> shares, net</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828449" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-4">220</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828451" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">93,059</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828457" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">93,279</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Issuance of pre-funded warrants, <span style="-sec-ix-hidden:c69828473">3,511</span> warrants</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828464" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:numdotdecimal" decimals="-3">14,817</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828467" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:numdotdecimal" decimals="-3">14,817</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Stock-based compensation expense</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828476" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">14,794</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828482" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">14,794</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Balance at December 31, 2020</b></span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b><ix:nonFraction id="c69828483" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,769</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b><ix:nonFraction id="c69828484" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">1,002,408</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b><ix:nonFraction id="c69828485" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>(<ix:nonFraction id="c69828486" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,023,442</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>)</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>$</b></span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>(<ix:nonFraction id="c69828487" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">19,262</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><b>)</b></span></td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">See accompanying notes to consolidated financial statements.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">54</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><span style="color:#000000;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><span style="color:#000000;"><b><a id="notes" title="notes" href="#"></a>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><span style="color:#000000;"><b>(In thousands, except per share amounts)</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c1757829" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Note <em style="font: inherit;">1</em> &#x2014; Significant Accounting Policies and Concentrations of Risk</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="bcrx:DescriptionOfCompanyPolicyTextBlock" id="c69831137" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>The Company</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 27pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was founded in <em style="font: inherit;">1986</em> and incorporated in Delaware in <em style="font: inherit;">1991,</em> and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. The Company has incurred losses and negative cash flows from operations since inception.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">Based on the Company&#x2019;s expectations for revenue, operating expenses, and its option to access an additional $<ix:nonFraction id="c69828502" contextRef="i_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" format="ixt:numdotdecimal" decimals="-6">75</ix:nonFraction> million from its existing credit facility, the Company believes its financial resources available at <em style="font: inherit;"> December 31, 2020 </em>will be sufficient to fund its operations into <em style="font: inherit;">2023.</em> The Company has sustained operating losses for the majority of its corporate history and expects that its <em style="font: inherit;">2021</em> expenses will exceed its <em style="font: inherit;">2021</em> revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of its products and the progression of its product candidates in the future. The Company also <em style="font: inherit;"> may </em>consider other plans to fund future operations, including: (<em style="font: inherit;">1</em>) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (<em style="font: inherit;">2</em>) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (<em style="font: inherit;">3</em>) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (<em style="font: inherit;">4</em>) obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (<em style="font: inherit;">5</em>) reducing spending on <em style="font: inherit;">one</em> or more research and development programs, including by discontinuing development; and/or (<em style="font: inherit;">6</em>) restructuring operations to change its overhead structure. The Company <em style="font: inherit;"> may </em>issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates, timing, scope and magnitude of its commercial expenses and key development and regulatory events and its decisions in the future.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c69831138" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Basis of Presentation</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 9pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). Such consolidated financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were <em style="font: inherit;">no</em> adjustments other than normal recurring adjustments.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c69831139" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Cash and Cash Equivalents</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 1pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of <em style="font: inherit;">three</em> months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="c69831140" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Restricted Cash</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Restricted cash as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> reflects $<ix:nonFraction id="c69828548" contextRef="i_2020-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">796</ix:nonFraction> and $<ix:nonFraction id="c69828551" contextRef="i_2019-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">134</ix:nonFraction>, respectively, in royalty revenue paid by Shionogi &amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note <em style="font: inherit;">3</em>) and $<ix:nonFraction id="c69828557" contextRef="i_2020-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,425</ix:nonFraction> and $<ix:nonFraction id="c69828559" contextRef="i_2019-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember" unitRef="USD" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,417</ix:nonFraction>, respectively, the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:InvestmentPolicyTextBlock" id="c69831141" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Investments</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that <em style="font: inherit;"> may </em>consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of <span style="-sec-ix-hidden:c69828560">three</span> years and requires an average portfolio maturity of <em style="font: inherit;">no</em> more than <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember" name="bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities" id="c69828562" format="ixt-sec:durmonth">18</ix:nonNumeric> months. Some of the securities the Company invests in <em style="font: inherit;"> may </em>have market risk. This means that a change in prevailing interest rates <em style="font: inherit;"> may </em>cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does <em style="font: inherit;">not</em> believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are <em style="font: inherit;">not</em> collateralized. The Company has <em style="font: inherit;">not</em> realized any significant losses from its investments.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
        <span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">55</em></span>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 7pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond <em style="font: inherit;">three</em> months and which mature at or less than <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember" name="bcrx:MaturityperiodOfShortTermInvestment" id="c69828569" format="ixt-sec:durmonth">12</ix:nonNumeric> months from the balance sheet date are classified as current. Investments with a maturity beyond <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_RangeAxis-MinimumMember" name="bcrx:LongtermInvestmentMaturityMinimum" id="c69828570" format="ixt-sec:durmonth">12</ix:nonNumeric> months from the balance sheet date are classified as long-term. At <em style="font: inherit;"> December 31, 2020, </em>the Company believes that the cost of its investments is recoverable in all material respects.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 14pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair values of the Company&#x2019;s fixed income investments are classified as Level <em style="font: inherit;">2</em> in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but <em style="font: inherit;">not</em> identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are <em style="font: inherit;">not</em> active. These fair values are obtained from independent pricing services which utilize Level <em style="font: inherit;">2</em> inputs.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 14pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">&#xa0;</p>
    <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="c87A4B6EB-0B75-4729-A4CE-C0791CB26B26" escape="true" continuedAt="c3338224B-10C7-4EE3-AEF8-ECC29AE80DAF">
     <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>December 31, 2020</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Amortized Cost</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Accrued Interest</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Gross Unrealized Gains</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Gross Unrealized Losses</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Estimated Fair Value</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Obligations of U.S. Government and its agencies</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828715" contextRef="i_2020-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">24,986</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828716" contextRef="i_2020-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">14</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">3</em></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">(3</em></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828719" contextRef="i_2020-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-6">25,000</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Certificates of deposit</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828720" contextRef="i_2020-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">3,225</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828721" contextRef="i_2020-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">11</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828722" contextRef="i_2020-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828724" contextRef="i_2020-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">3,239</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Total Investments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828725" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">28,211</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828726" contextRef="i_2020-12-31" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">25</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c69828727" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">6</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">(3</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828729" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">28,239</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
    </ix:nonNumeric> <p style="margin: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
    <ix:continuation id="c3338224B-10C7-4EE3-AEF8-ECC29AE80DAF">
     <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>December 31, 2019</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Amortized Cost</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Accrued Interest</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Gross Unrealized Gains</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Gross Unrealized Losses</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Estimated Fair Value</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Obligations of U.S. Government and its agencies</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828730" contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">10,488</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828731" contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-4">50</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828732" contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">23</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828734" contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">10,561</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Corporate debt securities</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828735" contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">9,742</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828736" contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">59</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828737" contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-4">10</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(<ix:nonFraction id="c69828738" contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828739" contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-4">9,810</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Certificates of deposit</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828740" contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">1,669</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828741" contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">7</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828742" contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">7</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828744" contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">1,683</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Total Investments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828745" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">21,899</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828746" contextRef="i_2019-12-31" unitRef="USD" name="bcrx:AvailableForSaleDebtSecuritiesAccruedInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">116</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828747" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-4">40</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(<ix:nonFraction id="c69828748" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828749" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">22,054</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
    </ix:continuation> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company&#x2019;s investments at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> have maturities of <em style="font: inherit;">one</em> year or less.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ReceivablesPolicyTextBlock" id="c69831142" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Receivables from Collaborations</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 1pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&#x201c;Green Cross&#x201d;), Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;) and Seqirus UK Limited (&#x201c;SUL&#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date&#xa0;</span>based on historical collection experience or specific circumstances and <ix:nonFraction id="c69830429" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember" unitRef="USD" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> amounts were recorded at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
        <span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">56</em></span>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">At <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em>the Company had the following receivables:</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
    <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock" id="c7C399358-8B24-47B2-9750-A736790F2714" escape="true" continuedAt="F0BDFFB5-0C98-4C92-8958-E6766C468A07">
     <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b style="font-size: 10pt;">December 31, 20</b><b style="font-size: 10pt;">20</b><b style="font-size: 10pt;"> </b><b style="font-size: 10pt;"> </b><b style="font-size: 10pt;"> </b></b></span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Billed</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Unbilled</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Total</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">U.S. Department of Health and Human Services</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828751" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5,402</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828752" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5,402</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Shionogi &amp; Co. Ltd.</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828753" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,037</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828754" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">4</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828755" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,041</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Green Cross Corporation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828756" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">740</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828757" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">21</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828758" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">761</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Mundipharma International Holdings Limited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828759" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">39</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828761" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">39</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Total receivables</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828762" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,816</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828763" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5,427</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828764" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">8,243</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
    </ix:nonNumeric> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
    <ix:continuation id="F0BDFFB5-0C98-4C92-8958-E6766C468A07">
     <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="11" rowspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b style="font-size: 10pt;">December 31, 2019</b></span></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Billed</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Unbilled</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Total</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">U.S. Department of Health and Human Services</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828765" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,353</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828766" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">15,023</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828767" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">16,376</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Shionogi &amp; Co. Ltd.</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828768" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,336</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828769" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">4</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828770" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">1,340</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Green Cross Corporation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828771" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,924</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828772" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">8</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828773" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,932</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Mundipharma International Holdings Limited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828774" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">56</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">-</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828776" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">56</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Seqirus UK Limited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828777" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,091</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828778" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">351</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828779" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,442</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Total receivables</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828780" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">6,760</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828781" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">15,386</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><ix:nonFraction id="c69828782" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:ReceivablesNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">22,146</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
    </ix:continuation> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: justify; text-indent: 26.75pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: justify; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Receivables from Product Sales</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 3.05pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Receivables&#xa0;</span>from product sales are recorded for amounts due to the Company related to sales of RAPIVAB and ORLADEYO.&#xa0; At <em style="font: inherit;"> December 31, 2020, </em>receivables related to sales of RAPIVAB and ORLADEYO were $<ix:nonFraction id="c69828578" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-RAPIVABMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="3" format="ixt:numdotdecimal" decimals="-3">254</ix:nonFraction> and $<ix:nonFraction id="c69828579" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-ORLADEYOMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="3" format="ixt:numdotdecimal" decimals="-3">149</ix:nonFraction>, respectively.&#xa0; There were <ix:nonFraction id="c69828580" contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember" unitRef="USD" name="us-gaap:AccountsReceivableNet" scale="3" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> receivables from product sales as of <em style="font: inherit;"> December 31, 2019. </em>Receivables from product sales are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions and the Company&#x2019;s own historical collection experience. &#xa0;<ix:nonFraction id="c69830435" contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember" unitRef="USD" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> reserve or allowance amounts were recorded at <em style="font: inherit;"> December 31, 2020</em><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:InventoryPolicyTextBlock" id="c69831143" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Inventory</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">At <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> the Company&#x2019;s inventory related to peramivir which is being manufactured for the Company&#x2019;s partners and the U.S. Government.&#xa0; Inventory as of <em style="font: inherit;"> December 31, 2020, </em>consisted of raw materials of $<ix:nonFraction id="c69828582" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:InventoryRawMaterials" scale="3" format="ixt:numdotdecimal" decimals="-3">206</ix:nonFraction>, work-in-process of $<ix:nonFraction id="c69828583" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:InventoryWorkInProcess" scale="3" format="ixt:numdotdecimal" decimals="-3">2,555</ix:nonFraction> and finished goods of $<ix:nonFraction id="c69828584" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:InventoryFinishedGoods" scale="3" format="ixt:numdotdecimal" decimals="-3">4,548</ix:nonFraction>. As of <em style="font: inherit;"> December 31, 2019, </em>the Company inventory consisted of peramivir finished goods of $<ix:nonFraction id="c69828585" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:InventoryFinishedGoods" scale="3" format="ixt:numdotdecimal" decimals="-3">276</ix:nonFraction>.&#xa0; Inventory is stated at the lower of cost and net realizable value, determined under the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out (&#x201c;FIFO&#x201d;) method, or market. As of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> the Company had inventory reserves of $<ix:nonFraction id="c69828589" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:InventoryValuationReserves" scale="3" format="ixt:numdotdecimal" decimals="-4">270</ix:nonFraction> and $<ix:nonFraction id="c69830445" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:InventoryValuationReserves" scale="3" format="ixt:numdotdecimal" decimals="-3">276</ix:nonFraction>, respectively, for estimated unrecoverable capitalized inventory costs.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company capitalizes subsequent costs related to the production of inventories.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>&#xa0;</b></i></span></p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c69831144" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Property and Equipment</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of <span style="-sec-ix-hidden:c69828591">three</span> years. Laboratory equipment, office equipment, and software are depreciated over a life of <span style="-sec-ix-hidden:c69828592">five</span> years. Furniture and fixtures are depreciated over a life of <span style="-sec-ix-hidden:c69828593">seven</span> years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are <em style="font: inherit;">not</em> expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="c69831145" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Patents and Licenses</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 12pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">57</em></span>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="bcrx:AccruedExpensesPolicyTextBlock" id="c69831146" escape="true"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Accrued Expenses</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 5pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company generally enters into contractual agreements with <em style="font: inherit;">third</em>-party vendors who provide research and development, manufacturing,&#xa0;</span>distribution,&#xa0;<span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has <em style="font: inherit;">not</em> yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#xa0;</p>
    <table style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;</span></p> </td></tr>
</tbody></table>
    <table style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">fees paid to investigative sites in connection with clinical trials;</span></p> </td></tr>
<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance, drug products, and product candidates; and</span></p> </td></tr>
</tbody></table>
    <table style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">professional fees.</span></p> </td></tr>
</tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-17.15pt;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and <em style="font: inherit;"> may </em>result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em>the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Accrued expenses were comprised of the following:</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
    <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="c1757834" escape="true">
     <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><b><b>December 31,</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Compensation and benefits</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c69828783" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">11,030</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828784" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">6,190</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Development costs</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828785" contextRef="i_2020-12-31" unitRef="USD" name="bcrx:AccruedDevelopmentCosts" scale="3" format="ixt:numdotdecimal" decimals="-4">15,150</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828786" contextRef="i_2019-12-31" unitRef="USD" name="bcrx:AccruedDevelopmentCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">11,302</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Inventory</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828787" contextRef="i_2020-12-31" unitRef="USD" name="bcrx:AccruedInventoryExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,453</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828788" contextRef="i_2019-12-31" unitRef="USD" name="bcrx:AccruedInventoryExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">29</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Professional fees</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828789" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">333</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828790" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">326</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Duties and taxes</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828791" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:TaxesPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">80</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828792" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:TaxesPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">67</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Other</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828793" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">4,896</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828794" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,451</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Total accrued expenses</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828795" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">33,942</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828796" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">21,365</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
    </ix:nonNumeric> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c69831147" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Income Taxes</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="c69831148" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Accumulated Other Comprehensive Loss</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. For the year ended <em style="font: inherit;"> December 31, 2020, </em>realized gains of $<ix:nonFraction id="c69828600" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction> were reclassified out of accumulated other comprehensive loss. <ix:nonFraction id="c69828601" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" scale="3" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> reclassifications out of accumulated other comprehensive loss were recorded in <em style="font: inherit;">2019.</em></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="c69831149" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Revenue Recognition</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:14pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company recognizes revenue when it satisfies a performance obligation by transferring promised goods or services to a customer. Revenue is measured at the transaction price that is based on the amount of consideration that the Company expects to receive in exchange for transferring the promised goods or services to the customer. The transaction price includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will <em style="font: inherit;">not</em> occur.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
        <span style="color:#000000;"><em style="font: inherit;">58</em></span>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">The Company has collaboration and license agreements with a number of <em style="font: inherit;">third</em> parties as well as research and development agreements with certain government entities. The Company&#x2019;s primary sources of revenue are license, service, royalty and product sale revenues from these collaborative and other research and development arrangements.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has <em style="font: inherit;">no</em> further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Arrangements that involve the delivery of more than <em style="font: inherit;">one</em> performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort we expend or costs we incur toward the satisfaction of performance obligation in relation to the total estimated effort of costs. Variable consideration is assessed at each reporting period as to whether it is <em style="font: inherit;">not</em> subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is <em style="font: inherit;">not</em> directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each <em style="font: inherit;"> may </em>be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was <em style="font: inherit;">not</em> probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:14pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Product Sales</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">The Company&#x2019;s principal sources of product sales are sales of peramivir to our licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services under the Company&#x2019;s procurement contract. In <em style="font: inherit;"> December 2020, </em>the Company launched ORLADEYO and began recording product revenue. The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">The Company recorded the following revenues for the years ended <em style="font: inherit;"> December 31:</em></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
    <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="c1757835" escape="true">
     <table class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><span style="color:#000000;">2020</span></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><span style="color:#000000;">2019</span></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><span style="color:#000000;">2018</span></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Product sales, net</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828797" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">3,301</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828798" contextRef="d_2019-01-01_2019-12-31_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">17,533</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Royalty revenue</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828800" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">3,381</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828801" contextRef="d_2019-01-01_2019-12-31_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">6,303</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828802" contextRef="d_2018-01-01_2018-12-31_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">6,101</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Collaborative and other research and development revenues:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"><span style="color:#000000;">U.S. Department of Health and Human Services</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828804" contextRef="d_2020-01-01_2020-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">9,231</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828805" contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">4,898</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828806" contextRef="d_2018-01-01_2018-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,552</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"><span style="color:#000000;">Torii Pharmaceutical Co., Ltd.</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828807" contextRef="d_2020-01-01_2020-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,899</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828808" contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">20,101</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"><span style="color:#000000;">Seqirus UK Limited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828812" contextRef="d_2018-01-01_2018-12-31_CounterpartyNameAxis-SeqirusUKLimitedMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">12,000</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Total collaborative and other research and development revenues</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828813" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-4">11,130</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828814" contextRef="d_2019-01-01_2019-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">24,999</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828815" contextRef="d_2018-01-01_2018-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">14,552</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Total revenues</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828816" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">17,812</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828817" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">48,835</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828818" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">20,653</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
    </ix:nonNumeric> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
        <span style="color:#000000;"><em style="font: inherit;">59</em></span>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Advertising</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed in &#x201c;Selling, general and administrative&#x201d; as the costs are incurred. Advertising expenses related to the launch of ORLADEYO were $<ix:nonFraction id="c69828612" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AdvertisingExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">6,567</ix:nonFraction> for year ended <em style="font: inherit;"> December 31, 2020. </em>The Company did <span style="-sec-ix-hidden:c69828614"><span style="-sec-ix-hidden:c69828615">not</span></span> incur advertising and product promotion expenses in <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018.</em></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c69831150" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Research and Development Expenses</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by <em style="font: inherit;">third</em>-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Additionally, the Company has license agreements with <em style="font: inherit;">third</em> parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#x2019;s academic partners for modification to existing license agreements. These deferred expenses would <em style="font: inherit;">not</em> have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c69831151" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Stock-Based Compensation</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which <em style="font: inherit;">no</em> compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="bcrx:InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" id="c69831153" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Interest Expense and Royalty </b></i><i><b>Financing Obligation</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The royalty financing obligation is eligible to be repaid based on royalties from net sales of ORLADEYO. Interest expense is accrued using the effective interest rate method over the estimated period the related liability will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of the royalty financing obligation and records interest expense using an imputed effective interest rate. The Company will reassess the expected royalty payments each reporting period and account for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that the Company make estimates that could impact the carrying value of the liability, as well as the period over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact the liability balance, interest expense and the time period for repayment.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" id="c69831154" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Interest Expense and Deferred Financing Costs</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Interest expense for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> was $<ix:nonFraction id="c69828624" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">14,501</ix:nonFraction> $<ix:nonFraction id="c69828625" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">11,892</ix:nonFraction> and $<ix:nonFraction id="c69828626" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">9,176</ix:nonFraction>, respectively, and primarily relates to the issuance of the PhaRMA Notes (defined in Note <em style="font: inherit;">3</em>) and the Prior Credit Facility and Amended and Restated Senior Credit Facility (each defined in Note <em style="font: inherit;">4</em>). Costs directly associated with the issuance of the PhaRMA Notes, the Prior Credit Facility and the Amended and Restated Senior Credit Facility have been capitalized and are netted against the non-recourse notes payable and senior credit facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Amended and Restated Senior Credit Facility (as subsequently amended and restated) using the effective interest rate method. In <em style="font: inherit;"> December 2020, </em>the Company incurred costs directly associated with its royalty monetization (defined in Note <em style="font: inherit;">3</em>) and borrowings under the Credit Agreement (defined in Note <em style="font: inherit;">4</em>). These costs have been deferred and are being amortized to interest expense over the terms of the respective arrangements. Amortization of deferred financing costs and original issue discount included in interest expense was $<ix:nonFraction id="c69828631" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" scale="3" format="ixt:numdotdecimal" decimals="-3">1,217</ix:nonFraction>, $<ix:nonFraction id="c69828632" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" scale="3" format="ixt:numdotdecimal" decimals="-3">1,278</ix:nonFraction> and $<ix:nonFraction id="c69828633" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" scale="3" format="ixt:numdotdecimal" decimals="-3">885</ix:nonFraction> for each of the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively. In <em style="font: inherit;"> December 2020, </em>the outstanding principal balance of the Senior Credit Facility was repaid and related unamortized deferred financing costs and original issue discount of $<ix:nonFraction id="c69828636" contextRef="d_2020-01-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" scale="3" format="ixt:numdotdecimal" decimals="-3">1,211</ix:nonFraction> were fully expensed as part of loss on debt extinguishment.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <span style="color:#000000;"><em style="font: inherit;">60</em></span>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="bcrx:CurrencyHedgeAgreementPolicyTextBlock" id="c69831155" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Currency Hedge Agreement</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The final tranche of the options under the Currency Hedge Agreement expired in <em style="font: inherit;"> November </em>of <em style="font: inherit;">2020.</em>&#xa0; The Currency Hedge Agreement did <em style="font: inherit;">not</em> qualify for hedge accounting treatment; therefore mark-to-market adjustments were recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> resulted in losses of $<ix:nonFraction id="c69828642" contextRef="d_2020-01-01_2020-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeLossOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-3">632</ix:nonFraction>, $<ix:nonFraction id="c69828643" contextRef="d_2019-01-01_2019-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeLossOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-3">347</ix:nonFraction> and $<ix:nonFraction id="c69828644" contextRef="d_2018-01-01_2018-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeLossOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-3">1,049</ix:nonFraction>, respectively. Mark-to-market adjustments were determined by a <em style="font: inherit;">third</em>-party pricing model which uses quoted prices in markets that are <em style="font: inherit;">not</em> actively traded and for which significant inputs are observable directly or indirectly, representing Level <em style="font: inherit;">2</em> in the fair value hierarchy as defined by U.S. GAAP. In addition, realized currency exchange gains of $<ix:nonFraction id="c69828648" contextRef="d_2020-01-01_2020-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeGainOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-3">662</ix:nonFraction>, $<ix:nonFraction id="c69828649" contextRef="d_2019-01-01_2019-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeGainOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-3">863</ix:nonFraction> and $<ix:nonFraction id="c69828650" contextRef="d_2018-01-01_2018-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeGainOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-3">941</ix:nonFraction> were recognized in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under the Company&#x2019;s foreign currency hedge.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c69831156" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Net Loss Per Share</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018</em> does <em style="font: inherit;">not</em> include <ix:nonFraction id="c69828657" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">14,957</ix:nonFraction>, <ix:nonFraction id="c69828658" contextRef="d_2019-01-01_2019-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">2,805</ix:nonFraction>, and <ix:nonFraction id="c69828659" contextRef="d_2018-01-01_2018-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">2,274</ix:nonFraction>, respectively, of potential common shares as their impact would be anti-dilutive.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:UseOfEstimates" id="c69831157" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Use of Estimates</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to the valuation of stock options,&#xa0;</span>the royalty financing&#xa0;<span style="color:#000000;">and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="bcrx:ConcentrationOfMarketRiskPolicyTextBlock" id="c69831158" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Significant Customers and Other Risks</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:23pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Significant Customers</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Other than royalty revenues, the Company&#x2019;s primary sources of revenue that have an underlying cash flow stream are the reimbursement of galidesivir (formerly <em style="font: inherit;">BCX4430</em>) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS and sales of RAPIVAB (peramivir injection) under our procurement contract with the Assistant Secretary for Preparedness and Response within the United States Department of Health and Human Services. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of <em style="font: inherit;">third</em>-party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:23pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Risks from Third Party Manufacturing and Distribution Concentration</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on single source distributors for distribution of approved drug products. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#x2019;s product candidates in development.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
        <span style="color:#000000;"><em style="font: inherit;">61</em></span>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:23pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Credit Risk</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances <em style="font: inherit;"> may </em>exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember" name="bcrx:AverageMaturityForPortfolioInvestments" id="c69828664" format="ixt-sec:durmonth">18</ix:nonNumeric> months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is <em style="font: inherit;">no</em> assumed credit risk.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"></p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c69831159" escape="true"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Recent Accounting Pronouncements</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In <em style="font: inherit;"> June 2016, </em>the FASB issued Accounting Standards Update <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of</i> <i>Credit Losses on Financial Instruments </i>(&#x201c;ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13&#x201d;</em>)<i>.</i><i> </i>ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires a financial asset (or a group of financial assets) measured at amortized<i> </i>cost basis to be presented at the net amount expected to be collected. In addition, ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires credit losses relating to available-for-sale debt securities to be recorded through an allowance for credit losses. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is effective for public companies for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2019. </em>The Company adopted ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em> as of <em style="font: inherit;"> January 1, 2020. </em>Given the nature of the Company&#x2019;s receivables from collaborators, investment portfolio and other financial assets, adoption of this standard did <em style="font: inherit;">not</em> have a material effect on the Company's financial position, results of operations or cash flows.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In <em style="font: inherit;"> August 2018, </em>the FASB issued Accounting Standards Update <em style="font: inherit;">No.</em> <em style="font: inherit;">2018</em>-<em style="font: inherit;">15,</em> <i>Intangibles - Goodwill and Other - Internal-Use Software (Subtopic</i> <i><em style="font: inherit;">350</em>-<em style="font: inherit;">40</em>) </i>(&#x201c;ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15&#x201d;</em>). ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15</em> aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service<i> </i>contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance requires entities to capitalize costs for certain implementation activities in the application development stage and expense the capitalized implementation costs over the expected term of the hosting arrangement. ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2019, </em>with early adoption permitted. The Company elected to adopt this standard early, beginning <em style="font: inherit;"> October 1, 2019 </em>on a prospective basis. Adoption did <em style="font: inherit;">not</em> have a material effect on the Company's financial position, results of operations or cash flows.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;">The Company has reviewed other new accounting pronouncements that were issued as of <em style="font: inherit;"> December 31, 2020 </em>and does <em style="font: inherit;">not</em> believe that these pronouncements are either applicable to the Company, or that they will have a material impact on its financial position or results of operations.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p></ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c1757836" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note <em style="font: inherit;">2</em> &#x2014; Property and Equipment</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;"><span style="color:#000000;">Property and equipment consisted of the following at <em style="font: inherit;"> December 31:</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c1757837" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Furniture and fixtures</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828825" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">722</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828826" contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">602</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Office equipment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828827" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">211</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828828" contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">184</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Software</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828829" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">1,159</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828830" contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">1,159</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Laboratory equipment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828831" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">3,774</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828832" contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">3,462</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Leasehold improvements</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="color:#000000;"><ix:nonFraction id="c69828835" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">8,583</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="color:#000000;"><ix:nonFraction id="c69828836" contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">8,528</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828839" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">14,449</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69828840" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">13,935</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Less accumulated depreciation and amortization</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69828841" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">7,336</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69828842" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">6,588</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Property and equipment, net</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828843" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">7,113</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69828844" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">7,347</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">Depreciation and amortization expense for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018</em> was $<ix:nonFraction id="c69828822" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">748</ix:nonFraction>, $<ix:nonFraction id="c69828823" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">724</ix:nonFraction>, and $<ix:nonFraction id="c69828824" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:numdotdecimal" decimals="-4">770</ix:nonFraction>, respectively.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="bcrx:RoyaltyMonetizationTextBlock" id="c1757838" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note <em style="font: inherit;">3&#x2014;Royalty</em> Monetizations</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>RAPIACTA Royalty Monetization</b></i><i><b>s</b></i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13.5pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Overview</i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On&#xa0;</span><em style="font: inherit;"> March 9, 2011, </em>the Company completed a $<ix:nonFraction id="c69828846" contextRef="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction> financing transaction to monetize certain future royalty and milestone payments under the Company&#x2019;s agreement with Shionogi (the &#x201c;Shionogi Agreement&#x201d;), pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and Taiwan. The Company received net proceeds of $<ix:nonFraction id="c69828847" contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">22,691</ix:nonFraction> from the transaction after transaction costs of $<ix:nonFraction id="c69828848" contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" unitRef="USD" name="bcrx:TransactionCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">4,309</ix:nonFraction> and the establishment of a $<ix:nonFraction id="c69828849" contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember" unitRef="USD" name="bcrx:InterestReserve" scale="3" format="ixt:numdotdecimal" decimals="-6">3,000</ix:nonFraction> interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the <em style="font: inherit;"> September 2012 </em>interest payment<span style="color:#000000;">.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">As&#xa0;</span>part of the transaction, the Company entered into a purchase and sale agreement dated as of <em style="font: inherit;"> March 9, 2011 </em>with JPR Royalty Sub, LLC, a wholly-owned subsidiary of the Company (&#x201c;Royalty Sub&#x201d;), whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii) the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#x201c;Currency Hedge Agreement&#x201d;) put into place by the Company in connection with the transaction. Royalty payments are paid by Shionogi in Japanese yen, and any milestone payments will be paid in U.S. dollars. The Company&#x2019;s collaboration with Shionogi was <em style="font: inherit;">not</em> impacted as a result of this transaction<span style="color:#000000;">.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <span style="color:#000000;"><em style="font: inherit;">62</em></span>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13.5pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Non-Recourse Notes Payable</i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> March 9, 2011, </em>Royalty Sub completed a private placement to institutional investors of $<ix:nonFraction id="c69828852" contextRef="d_2011-03-01_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="USD" name="bcrx:PrivatePlacementOfSeniorSecuredNotes" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction> in aggregate principal amount of its PhaRMA Senior Secured <ix:nonFraction id="c69828853" contextRef="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">14.0</ix:nonFraction>% Notes due on <em style="font: inherit;"> December 1, 2020 (</em>the &#x201c;PhaRMA Notes&#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of <em style="font: inherit;"> March 9, 2011 (</em>the &#x201c;Indenture&#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at <ix:nonFraction id="c69828854" contextRef="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">14</ix:nonFraction>% per annum, payable annually in arrears on <em style="font: inherit;"> September </em><em style="font: inherit;">1st</em> of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Royalty Sub&#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company <em style="font: inherit;"> may, </em>but is <em style="font: inherit;">not</em> obligated to, make capital contributions to a capital account that <em style="font: inherit;"> may </em>be used to redeem, or on up to <em style="font: inherit;">one</em> occasion pay any interest shortfall on, the PhaRMA Notes.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">In <em style="font: inherit;"> September 2014, </em>Royalty Sub was unable to pay the accrued interest obligation due <em style="font: inherit;"> September 3, 2013. </em>Under the terms of the Indenture, Royalty Sub&#x2019;s inability to pay the full amount of interest payable in <em style="font: inherit;"> September 2013 </em>by the next succeeding payment date for the PhaRMA Notes, which was <em style="font: inherit;"> September 1, 2014, </em>constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the <em style="font: inherit;"> December 31, 2014 </em>balance sheet, and thereafter. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes <em style="font: inherit;"> may </em>foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is <em style="font: inherit;">not</em> expected to have a significant impact on the Company&#x2019;s future results of operations or cash flows. The PhaRMA Notes had a final legal maturity date of <em style="font: inherit;"> December 1, 2020, </em>at which time the outstanding principal amount of the PhaRMA Notes of $<ix:nonFraction id="c69828861" contextRef="i_2020-12-01_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="USD" name="us-gaap:SecuredDebt" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction>, together with accrued and unpaid interest of $<ix:nonFraction id="c69828862" contextRef="i_2020-12-01_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="USD" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">20,614</ix:nonFraction>, was due in full. As of <em style="font: inherit;"> December 31, 2020, </em>the PhaRMA Notes remain outstanding and in default and the Company will continue to record the liability and accrued interest owed until the Company is determined to <em style="font: inherit;">no</em> longer be the financial obligor.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:38pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Indenture does <em style="font: inherit;">not</em> contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">As of <em style="font: inherit;"> December 31, 2020, </em>the aggregate fair value of the PhaRMA Notes was estimated to be approximately <ix:nonFraction id="c69828865" contextRef="i_2019-12-31_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="Pure" name="bcrx:PercentageOfCarryingAmountInExcessOfFairValue1" scale="-2" format="ixt:numdotdecimal" decimals="2">3</ix:nonFraction>% of its carrying value of $<ix:nonFraction id="c69828866" contextRef="i_2019-12-31_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_LegalEntityAxis-JPRRoyaltySubLLCMember" unitRef="USD" name="us-gaap:NotesPayableFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction>. The estimated fair value of the PhaRMA Notes is classified as Level <em style="font: inherit;">3</em> in the fair value hierarchy as defined in U.S. GAAP.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Foreign Currency Hedge</i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company had&#xa0;the right to purchase dollars and sell yen at a rate of <ix:nonFraction id="c69828868" contextRef="i_2020-11-30_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember" unitRef="JPYPerUSD" name="us-gaap:DerivativeForwardExchangeRate1" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction> yen per dollar. The final tranche of the options under the Currency Hedge Agreement expired in <em style="font: inherit;"> November </em>of <em style="font: inherit;">2020.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Currency Hedge Agreement did <em style="font: inherit;">not</em> qualify for hedge accounting treatment; therefore mark-to-market adjustments were recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> resulted in losses of $<ix:nonFraction id="c69828874" contextRef="d_2020-01-01_2020-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeLossOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-3">632</ix:nonFraction>, $<ix:nonFraction id="c69828875" contextRef="d_2019-01-01_2019-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeLossOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-3">347</ix:nonFraction> and $<ix:nonFraction id="c69828876" contextRef="d_2018-01-01_2018-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeLossOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-3">1,049</ix:nonFraction>, respectively. In addition, realized currency exchange gains of $<ix:nonFraction id="c69828877" contextRef="d_2020-01-01_2020-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeGainOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-3">662</ix:nonFraction>, $<ix:nonFraction id="c69828878" contextRef="d_2019-01-01_2019-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeGainOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-3">863</ix:nonFraction> and $<ix:nonFraction id="c69828879" contextRef="d_2018-01-01_2018-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember" unitRef="USD" name="us-gaap:DerivativeGainOnDerivative" scale="3" format="ixt:numdotdecimal" decimals="-3">941</ix:nonFraction> were recognized in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under the Company&#x2019;s foreign currency hedge.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <span style="color:#000000;"><em style="font: inherit;">63</em></span>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>ORLADEYO Royalty Monetization</b></i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">On <em style="font: inherit;"> December 7, 2020, </em>the Company and RPI <em style="font: inherit;">2019</em> Intermediate Finance Trust (&#x201c;RPI&#x201d;) entered into a Purchase and Sale Agreement (the &#x201c;Royalty Purchase Agreement&#x201d;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $<ix:nonFraction id="c69828885" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" format="ixt:numdotdecimal" decimals="-6">125,000</ix:nonFraction> in cash (the &#x201c;Royalty Sale&#x201d;).&#xa0; Under the Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the United States, certain key European markets, and other markets where the Company sells ORLADEYO directly or through distributors (collectively, the &#x201c;Key Territories&#x201d;) in an amount equal to:&#xa0;(i) <ix:nonFraction id="c69828886" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" format="ixt:numdotdecimal" decimals="4">8.75</ix:nonFraction>% of aggregate annual net sales of ORLADEYO in the Key Territories for annual net sales up to <em style="font: inherit;">$350,000</em> and (ii) <ix:nonFraction id="c69828888" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" format="ixt:numdotdecimal" decimals="4">2.75</ix:nonFraction>% of annual net sales in the Key Territories for annual net sales between <em style="font: inherit;">$350,000</em> and <em style="font: inherit;">$550,000.</em>&#xa0; <ix:nonFraction id="c69828891" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver550000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" scale="-2" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> royalty payments are payable on annual net sales in the Key Territories over <em style="font: inherit;">$550,000.</em>&#xa0; In addition, RPI will be entitled to receive <ix:nonFraction id="c69828893" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-BCX9930Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" scale="-2" format="ixt:numdotdecimal" decimals="2">1.0</ix:nonFraction>% of global net sales, if any, of <em style="font: inherit;">BCX9930.</em></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">Under the Royalty Purchase Agreement, RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees outside of the Key Territories (the &#x201c;Other Markets&#x201d;) equal to: (i) <ix:nonFraction id="c69828895" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets; (ii) <ix:nonFraction id="c69828896" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder150000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>% of proceeds received on annual net sales of up to <em style="font: inherit;">$150,000</em> in the Other Markets; and (iii) <ix:nonFraction id="c69828898" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween150000And230000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" scale="-2" format="ixt:numdotdecimal" decimals="1">10</ix:nonFraction>% of proceeds received by the Company on annual net sales between <em style="font: inherit;">$150,000</em> and <em style="font: inherit;">$230,000</em> in the Other Markets. <ix:nonFraction id="c69828902" contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver230000Member" unitRef="Pure" name="bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" scale="-2" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> royalty payments are payable on annual net sales above <em style="font: inherit;">$230,000</em> in the Other Markets. <em style="font: inherit;">No</em> payment will be due to RPI for any achievement milestone which <em style="font: inherit;"> may </em>be payable under the existing out-license for ORLADEYO.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company will be required to make royalty payments of amounts owed to RPI each calendar quarter following the <em style="font: inherit;">first</em> commercial sale of ORLADEYO in any country.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Under the Royalty Purchase Agreement, the Company has agreed to specified affirmative and negative covenants, including covenants regarding periodic reporting of information by the Company to RPI, <em style="font: inherit;">third</em>-party audits of royalties paid under the Royalty Purchase Agreement, and restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness other than certain royalty sales and as is permitted to be incurred under the terms of the Company&#x2019;s Credit Agreement with Athyrium Opportunities III Co-Invest <em style="font: inherit;">1</em> LP. Refer to Note <em style="font: inherit;">4</em> for further details on the Credit Agreement. The restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness are eliminated after the achievement of certain specified milestones in the Royalty Purchase Agreement.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The cash consideration of $<ix:nonFraction id="c69828909" contextRef="i_2020-12-31_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember" unitRef="USD" name="bcrx:FutureRoyaltiesPayable" scale="3" format="ixt:numdotdecimal" decimals="-6">125,000</ix:nonFraction> obtained pursuant to the Royalty Purchase Agreement is recorded in &#x201c;Royalty financing obligation&#x201d; on the Company&#x2019;s consolidated balance sheet as of <em style="font: inherit;"> December 31, 2020. </em>The fair value for the royalty financing obligation at the time of the transaction was based on the Company&#x2019;s estimates of future royalties expected to be paid to RPI over the life of the arrangement. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration and sales price and are determined using forecasts from market data sources, which are considered Level <em style="font: inherit;">3</em> inputs. Deferred issuance costs, which consist primarily of advisory and legal fees, totaled $<ix:nonFraction id="c69828911" contextRef="i_2020-12-31_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember" unitRef="USD" name="us-gaap:DeferredFinanceCostsNet" scale="3" format="ixt:numdotdecimal" decimals="-4">2,370</ix:nonFraction> as of <em style="font: inherit;"> December 31, 2020. </em>The liability and the deferred issuance costs are amortized using the effective interest method over the term of the arrangement, in accordance with the respective guidance. The effective interest rate as of <em style="font: inherit;"> December 31, 2020 </em>was approximately <ix:nonFraction id="c69828912" contextRef="i_2020-12-31_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">24</ix:nonFraction>%. For <em style="font: inherit;">2020,</em> accrued interest expense in the amount of $<ix:nonFraction id="c69828914" contextRef="i_2020-12-31_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember" unitRef="USD" name="us-gaap:InterestPayableCurrentAndNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,108</ix:nonFraction> was added to the initial balance of the liability. The Company will utilize the prospective method to account for subsequent changes in the estimated future payments to be made to RPI.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_DebtInstrumentAxis-CreditAgreementMember" name="us-gaap:DebtDisclosureTextBlock" id="c1757839" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note </b><b><em style="font: inherit;">4</em></b><b> &#x2014; </b><b>Credit Agreement</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">On <em style="font: inherit;"> December 7, 2020, </em>the Company entered into a $<ix:nonFraction id="c69828919" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-8">200,000</ix:nonFraction> Credit Agreement with Athyrium Opportunities III Co-Invest <em style="font: inherit;">1</em> LP (&#x201c;Athyrium&#x201d;), as lender and as administrative agent for the lenders.&#xa0;BioCryst Ireland Limited, BioCryst US Sales Co., LLC, and BioCryst UK Limited, each of which is a wholly-owned subsidiary of the Company, are guarantors to the Credit Agreement. The Credit Agreement provides for an initial term loan in the principal amount of $<ix:nonFraction id="c69828921" contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-6">125,000</ix:nonFraction> (the &#x201c;Term A Loan&#x201d;), which was received by the Company on <em style="font: inherit;"> December 7, 2020 </em>and is recorded in &#x201c;Secured term loan&#x201d; on the Company&#x2019;s balance sheet as of <em style="font: inherit;"> December 31, 2020.&#xa0; </em>The Company used a portion of the proceeds from the Term A Loan to repay $<ix:nonFraction id="c69828922" contextRef="d_2020-12-07_2020-12-07_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:RepaymentsOfLinesOfCredit" scale="3" format="ixt:numdotdecimal" decimals="-3">43,298</ix:nonFraction> of outstanding indebtedness, including accrued interest, under its existing credit facility with MidCap Financial Trust.&#xa0; The Company intends to use the remaining proceeds to support the launch of ORLADEYO in the United States and Europe and to advance the development of <em style="font: inherit;">BCX9930</em> into clinical trials in multiple complement-mediated diseases, and for other general corporate purposes.&#xa0;</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Credit Agreement also provides for <em style="font: inherit;">two</em> additional term loans, at the Company's option, in the respective principal amounts of $<ix:nonFraction id="c69828925" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermBLoanMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-6">25,000</ix:nonFraction> (the &#x201c;Term B Loan&#x201d;) and $<ix:nonFraction id="c69828926" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermCLoanMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-7">50,000</ix:nonFraction> (the &#x201c;Term C Loan&#x201d;).&#xa0; The Term B Loan and the Term C Loan <em style="font: inherit;"> may </em>be drawn upon if, among other conditions, the Company reaches defined revenue milestones and, with respect to a draw on the Term C Loan, the Term B Loan has been funded prior to or contemporaneously with the Term C Loan.&#xa0; The maturity date of the Credit Agreement is <em style="font: inherit;"> December 7, 2025.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Credit Agreement provides for quarterly interest-only payments until the maturity date, with the unpaid principal amount of the outstanding Term Loans due and payable on the maturity date.&#xa0; For each of the <em style="font: inherit;">first</em> <em style="font: inherit;">eight</em> full fiscal quarters following <em style="font: inherit;"> December 7, 2020, </em>the Company has the option to make the applicable interest payment-in-kind (a &#x201c;PIK Interest Payment&#x201d;) by capitalizing the entire amount of interest accrued during the applicable interest period with the unpaid original principal amount outstanding on the last day of such period. The Term Loans will bear interest at a rate equal to the <em style="font: inherit;">three</em>-month LIBOR rate, which shall be <em style="font: inherit;">no</em> less than <ix:nonFraction id="c69828931" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="Pure" name="bcrx:DebtInstrumentLiborFloor" scale="-2" format="ixt:numdotdecimal" decimals="4">1.75</ix:nonFraction>% and <em style="font: inherit;">no</em> more than <ix:nonFraction id="c69828933" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="Pure" name="bcrx:DebtInstrumentLiborCap" scale="-2" format="ixt:numdotdecimal" decimals="3">3.50</ix:nonFraction>% (&#x201c;LIBOR&#x201d;), plus <ix:nonFraction id="c69828934" contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember" unitRef="Pure" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" format="ixt:numdotdecimal" decimals="4">8.25</ix:nonFraction>%, or for each interest period in which a PIK Interest Payment is made, the LIBOR plus <ix:nonFraction id="c69828935" contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PikInterestPaymentIsMadeMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember" unitRef="Pure" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" format="ixt:numdotdecimal" decimals="4">10.25</ix:nonFraction>%.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <span style="color:#000000;"><em style="font: inherit;">64</em></span>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Subject to certain exceptions, the Company is required to make mandatory prepayments of the Term Loans with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sale), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events, subject to certain exceptions. The Company <em style="font: inherit;"> may </em>make voluntary prepayments in whole or in part. Prepayments are subject to a premium equal to, (i) with respect to any voluntary prepayment and certain mandatory prepayments paid on or prior to the <em style="font: inherit;">second</em> anniversary of the applicable Term Loan borrowing date, the amount, if any, by which (a) the sum of (<em style="font: inherit;">1</em>) <ix:nonFraction id="c69828939" contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PriorToTheSecondAnniversaryMember" unitRef="Pure" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" scale="-2" format="ixt:numdotdecimal" decimals="2">102.00</ix:nonFraction>% of the principal amount of the Term Loan being prepaid plus (<em style="font: inherit;">2</em>) the present value of all interest that would have accrued on the principal amount of the Term Loan being prepaid through and including the <em style="font: inherit;">second</em> anniversary of the date of the borrowing of such Term Loan, plus <ix:nonFraction id="c69828942" contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PriorToTheSecondAnniversaryMember" unitRef="Pure" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" scale="-2" format="ixt:numdotdecimal" decimals="3">0.50</ix:nonFraction>%, exceeds (b) the principal amount of the Term Loan being prepaid; (ii) with respect to any prepayment made between the <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> anniversaries of the applicable Term Loan borrowing date, <ix:nonFraction id="c69828945" contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-BetweenTheSecondAndThirdAnniversariesMember" unitRef="Pure" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" scale="-2" format="ixt:numdotdecimal" decimals="2">2.00</ix:nonFraction>% of the principal amount of the Term Loan being prepaid; (iii) with respect to any prepayment made between the <em style="font: inherit;">third</em> and <em style="font: inherit;">fourth</em> anniversaries of the applicable Term Loan&#xa0;</span>borrowing date<span style="color:#000000;">, <ix:nonFraction id="c69828948" contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-BetweenTheThirdAndFourthAnniversariesMember" unitRef="Pure" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" scale="-2" format="ixt:numdotdecimal" decimals="2">1.00</ix:nonFraction>% of the principal amount of the Term Loan being prepaid; and (iv) with respect to any prepayment made after the <em style="font: inherit;">fourth</em> anniversary of the applicable Term Loan borrowing date, <ix:nonFraction id="c69828950" contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-AfterFourthAnniversaryMember" unitRef="Pure" name="bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" scale="-2" format="ixt:numdotdecimal" decimals="-3">0.00</ix:nonFraction>% of the principal amount of the Term Loan being prepaid. Upon the prepayment or repayment, including at maturity, of all or any of the Term Loans, the Company is obligated to pay an exit fee in an amount equal to <ix:nonFraction id="c69828951" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="Pure" name="bcrx:DebtInstrumentExitFeePercentageOfPrincipal" scale="-2" format="ixt:numdotdecimal" decimals="2">2.00</ix:nonFraction>% of the principal amount of the Term Loans prepaid or repaid. In addition, each Term Loan is subject to a <ix:nonFraction id="c69828952" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="Pure" name="bcrx:DebtInstrumentCommitmentFeePercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">1.00</ix:nonFraction>% commitment fee at its respective borrowing date.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Credit Agreement also contains representations and warranties and affirmative and negative covenants customary for financings of this type, as well as customary events of default. &#xa0;Certain of the customary negative covenants limit the ability of the Company and certain of its subsidiaries to, among other things, grant liens, make investments, incur additional indebtedness, engage in mergers, acquisitions, and similar transactions, dispose of assets, license certain property, distribute dividends, make certain restricted payments, change the nature of the Company's business, engage in transactions with affiliates and insiders, prepay other indebtedness, or engage in sale and leaseback transactions, subject to certain exceptions. &#xa0;Additionally, as of the last day of each fiscal quarter (a &#x201c;Test Date&#x201d;), beginning with the <em style="font: inherit;">first</em> Test Date occurring immediately after the Term C Loan is drawn, if applicable, the Company <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> permit consolidated net revenues from ORLADEYO sales in the United States for the <em style="font: inherit;">four</em>-fiscal quarter period ending on such Test Date to be less than the specified amounts set forth in the Credit Agreement (collectively, the &#x201c;Revenue Tests&#x201d;).&#xa0; If the Company fails to satisfy the Revenue Tests as of any Test Date, it will have a <em style="font: inherit;">one</em>-time right (the &#x201c;Cure Right&#x201d;) to repay in full the entire amount of the Term C Loans outstanding at such time together with all accrued and unpaid interest thereon plus the prepayment premium, exit fee, and any other fees or amounts payable under the Credit Agreement at such time.&#xa0; In addition, the Credit Agreement contains a minimum liquidity covenant requiring the Company to maintain at all times, as applicable, at least $<ix:nonFraction id="c69828957" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoanADrawnMember" unitRef="USD" name="bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" scale="3" format="ixt:numdotdecimal" decimals="-6">15,000</ix:nonFraction> of unrestricted cash and cash equivalents if only the Term A Loan has been drawn; at least $<ix:nonFraction id="c69828958" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoanAAndBDrawnMember" unitRef="USD" name="bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" scale="3" format="ixt:numdotdecimal" decimals="-7">20,000</ix:nonFraction> of unrestricted cash and cash equivalents if the Term B Loan has been drawn but the Term C Loan has <em style="font: inherit;">not</em> been drawn; and at least $<ix:nonFraction id="c69828960" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoansABAndCDrawnMember" unitRef="USD" name="bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" scale="3" format="ixt:numdotdecimal" decimals="-6">15,000</ix:nonFraction> (or, if the Cure Right has been exercised, $<ix:nonFraction id="c69828961" contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoansABAndCDrawnAndCureRightExercisedMember" unitRef="USD" name="bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" scale="3" format="ixt:numdotdecimal" decimals="-7">20,000</ix:nonFraction>) of unrestricted cash and cash equivalents if the Term C Loan has been drawn, subject to certain exceptions.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">A failure to comply with the covenants in the Credit Agreement could permit the Lenders under the Credit Agreement to declare the outstanding principal as well as accrued interest and fees, to be immediately due and payable.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The Company's obligations under the Credit Agreement are secured by a security interest in, subject to certain exceptions, substantially all of the Company's assets.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">As of <em style="font: inherit;"> December 31, 2020, </em>the Company had borrowings of $<ix:nonFraction id="c69828962" contextRef="i_2020-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="USD" name="us-gaap:LongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-6">125,000</ix:nonFraction> under the Credit Agreement. The carrying amount of the debt approximates its fair value based on prevailing interest rates as of the balance sheet date.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The Credit Agreement provides for quarterly interest-only payments until the maturity date, with the unpaid principal amount of the outstanding Term Loans due and payable on the maturity date of <em style="font: inherit;"> December 7, 2025. </em>The Company has elected the <em style="font: inherit;">first</em> quarterly interest payment to be a PIK Interest Payment and began accruing interest at a rate of <ix:nonFraction id="c69828964" contextRef="i_2020-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" format="ixt:numdotdecimal" decimals="4">12.17</ix:nonFraction>%. As of <em style="font: inherit;"> December 31, 2020, </em>debt fees and issuance costs totaled $<ix:nonFraction id="c69828965" contextRef="i_2020-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" format="ixt:numdotdecimal" decimals="-3">7,764</ix:nonFraction> and are being amortized as interest expense on an effective interest rate method over the term of the Term A Loan. Interest expense of $<ix:nonFraction id="c69828966" contextRef="d_2020-01-01_2020-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">925</ix:nonFraction>, net of deferred financing amortization of $<ix:nonFraction id="c69828967" contextRef="d_2020-01-01_2020-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember" unitRef="USD" name="us-gaap:AmortizationOfFinancingCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">131</ix:nonFraction>, related to the Credit Agreement was recognized in <em style="font: inherit;">2020</em> related to the Term A Loan.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The Credit Agreement contains <em style="font: inherit;">two</em> provisions that, if deemed probable, would create the recognition of an embedded feature; however, at this time, the Company does <em style="font: inherit;">not</em> believe either provision is probable.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember" name="us-gaap:DebtDisclosureTextBlock" id="c1757840" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note </b><b><em style="font: inherit;">5</em></b><b> &#x2014; Senior Credit Facility</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> February 5, 2019, </em>the Company entered into a $<ix:nonFraction id="c69828972" contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-8">100,000</ix:nonFraction> Senior Credit Facility with an affiliate of MidCap Financial Services, LLC, as administrative agent (the &#x201c;Second Amended and Restated Senior Credit Facility&#x201d;). Borrowings under the Second Amended and Restated Senior Credit Facility were available in <em style="font: inherit;">three</em> tranches, with (i) the <em style="font: inherit;">first</em> tranche comprised of $<ix:nonFraction id="c69828975" contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityFirstTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-7">50,000</ix:nonFraction> funded at closing, which included $<ix:nonFraction id="c69828976" contextRef="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityFirstTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction> of proceeds that were deemed rolled over from the outstanding principal amount under the Company&#x2019;s prior credit agreement, (ii) the <em style="font: inherit;">second</em> tranche comprised of $<ix:nonFraction id="c69828978" contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilitySecondTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-7">30,000</ix:nonFraction>, and (iii) the <em style="font: inherit;">third</em> tranche comprised of $<ix:nonFraction id="c69828980" contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityThirdTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="3" format="ixt:numdotdecimal" decimals="-7">20,000</ix:nonFraction>, with the <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> tranches to have been funded upon the completion of certain contingencies related to the Company&#x2019;s development activities of its product candidates and the establishment of certain financial covenants. On <em style="font: inherit;"> September 10, 2019 </em>the Company executed the <em style="font: inherit;">first</em> amendment to the Second Amended and Restated Credit Facility which extended the commitment termination date for the <em style="font: inherit;">second</em> tranche to <em style="font: inherit;"> November 30, 2019. </em>On <em style="font: inherit;"> November 30, 2019, </em>the Company&#x2019;s access to the <em style="font: inherit;">second</em> tranche expired.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <span style="color:#000000;"><em style="font: inherit;">65</em></span>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Second Amended and Restated Senior Credit Facility refinanced and replaced the Amended and Restated Senior Credit Facility dated as of <em style="font: inherit;"> July 20, 2018 (</em>the &#x201c;Amended and Restated Senior Credit Facility&#x201d;). The Second Amended and Restated Senior Credit Facility had a variable interest rate of LIBOR (which was <em style="font: inherit;">not</em> to be less than <ix:nonFraction id="c69828988" contextRef="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="Pure" name="bcrx:DebtInstrumentMinimumLibor" scale="-2" format="ixt:numdotdecimal" decimals="3">0.5</ix:nonFraction>%) plus <ix:nonFraction id="c69828989" contextRef="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember" unitRef="Pure" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" format="ixt:numdotdecimal" decimals="2">8</ix:nonFraction>%. The Second Amended and Restated Senior Credit Facility included an interest-only payment period through <em style="font: inherit;"> June 2020 </em>and scheduled monthly principal and interest payments for the subsequent <ix:nonNumeric contextRef="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" name="us-gaap:DebtInstrumentTerm" id="c69828990" format="ixt-sec:durmonth">30</ix:nonNumeric> months. The Company used a portion of the proceeds of the Second Amended and Restated Senior Credit Facility to pay off outstanding amounts under the Amended and Restated Senior Credit Facility and the remainder was used for general corporate purposes.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In <em style="font: inherit;"> December 2020, </em>the Company repaid the outstanding principal of the Second Amended and Restated Senior Credit Facility of $<ix:nonFraction id="c69828991" contextRef="d_2020-12-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:ExtinguishmentOfDebtAmount" scale="3" format="ixt:numdotdecimal" decimals="-7">40,000</ix:nonFraction> along with exit fees and accrued interest through the payoff date that totaled $<ix:nonFraction id="c69828992" contextRef="d_2020-12-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:PaymentsOfDebtExtinguishmentCosts" scale="3" format="ixt:numdotdecimal" decimals="-3">3,298</ix:nonFraction>. The unamortized deferred financing cost and original issue discount of $<ix:nonFraction id="c69828993" contextRef="d_2020-12-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember" unitRef="USD" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" scale="3" format="ixt:numdotdecimal" decimals="-3">1,211</ix:nonFraction> was expensed as a loss on debt extinguishment.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:LeasesOfLessorDisclosureTextBlock" id="c1757841" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note <em style="font: inherit;">6</em></b><b> &#x2014; Lease Obligations and Other Contingencies</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In <em style="font: inherit;"> February 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02:</em> <i>Leases (Topic <em style="font: inherit;">842</em>)</i>. This ASU requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most operating leases. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em> is effective for annual and interim periods beginning after <em style="font: inherit;"> December 15, 2018, </em>including interim periods within those fiscal years. In <em style="font: inherit;"> July 2018, </em>the FASB issued ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">11,</em> <i>Leases (Topic <em style="font: inherit;">842</em>): Targeted Improvements</i>, which provides companies with an additional optional transition method to apply the new standard to leases in effect at the adoption date through a cumulative effect adjustment. The Company adopted the new lease standard as of <em style="font: inherit;"> January 1, 2019 </em>using this optional transition method.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company elected the package of practical expedients referenced in ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02,</em> which permits companies to retain original lease identification and classification without reassessing initial direct costs for existing leases. The Company also elected the practical expedient that exempts leases with an initial lease term of <em style="font: inherit;">twelve</em> months or less, as well as the practical expedient that allows companies to select, by class of underlying asset, <em style="font: inherit;">not</em> to separate lease and non-lease components. Adoption of this standard resulted in the recognition of a right-of-use asset and a lease liability on the Company&#x2019;s <em style="font: inherit;"> January 1, 2019 </em>Consolidated Balance Sheet of $<ix:nonFraction id="c69829007" contextRef="i_2019-01-01_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-3">3,621</ix:nonFraction> and $<ix:nonFraction id="c69829008" contextRef="i_2019-01-01_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">4,822</ix:nonFraction>, respectively. There was <em style="font: inherit;">no</em> material impact on the Company&#x2019;s Consolidated Statement of Comprehensive Loss, and the cumulative transition adjustment recorded to retained earnings upon adoption was $<ix:nonFraction id="c69829010" contextRef="i_2019-01-01_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3">238</ix:nonFraction>.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of <em style="font: inherit;"> December 31, 2020. </em>Certain operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#x2019;s Consolidated Balance Sheet represent payments over the lease term, which includes renewal options for certain real estate leases that we are likely to exercise. As part of the Company&#x2019;s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Renewal options for our leases range from <ix:nonNumeric contextRef="i_2019-12-31_RangeAxis-MinimumMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="c69829011" format="ixt-sec:duryear">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i_2019-12-31_RangeAxis-MaximumMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="c69829012" format="ixt-sec:duryear">5</ix:nonNumeric> years in length and begin from <em style="font: inherit;">2023</em> through <em style="font: inherit;">2026.</em> The weighted average lease term for the Company&#x2019;s operating leases was <ix:nonNumeric contextRef="i_2020-12-31" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="c69829015" format="ixt-sec:duryear">13.1</ix:nonNumeric> years. The discount rate used in the calculation of the Company&#x2019;s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company&#x2019;s collateralized borrowing rate from lending institutions. The weighted average discount rate for the Company&#x2019;s operating leases was <ix:nonFraction id="c69829016" contextRef="i_2020-12-31" unitRef="Pure" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:numdotdecimal" decimals="3">12.7</ix:nonFraction>%.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company has <em style="font: inherit;">not</em> made any residual value guarantees related to its operating leases; therefore, the Company has <em style="font: inherit;">no</em> corresponding liability recorded on its Consolidated Balance Sheets.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">Aggregate lease expense under operating leases was $<ix:nonFraction id="c69829019" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,754</ix:nonFraction> and $<ix:nonFraction id="c69829020" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,464</ix:nonFraction> for the <em style="font: inherit;">twelve</em>-month periods ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of <em style="font: inherit;">twelve</em> months or less was <em style="font: inherit;">not</em> material.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Future lease payments for assets under operating leases as of <em style="font: inherit;"> December 31, 2020, </em>are as follows:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="bcrx:LesseeLeaseLiabilityMaturityTableTextBlock" id="c1757842" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Remaining Maturities of Lease Liabilities</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td></tr>
<tr style="vertical-align: bottom;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Year Ending December 31,</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0.5pt 0pt 0pt; text-align: center;"><span style="color:#000000;"><b><b>Operating Leases</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">2021</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829041" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" format="ixt:numdotdecimal" decimals="-3">1,302</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">2022</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829042" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" format="ixt:numdotdecimal" decimals="-3">758</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">2023</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829043" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" format="ixt:numdotdecimal" decimals="-3">619</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">2024</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829044" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" format="ixt:numdotdecimal" decimals="-3">577</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">2025</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829045" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" format="ixt:numdotdecimal" decimals="-3">582</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Thereafter</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829046" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" format="ixt:numdotdecimal" decimals="-3">7,327</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 12pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Total lease payments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829047" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" format="ixt:numdotdecimal" decimals="-3">11,165</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Less imputed interest</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829048" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">6,115</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 12pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Total</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829049" contextRef="i_2020-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-4">5,050</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The&#xa0;</span>Company&#x2019;s current lease liability at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> was $<ix:nonFraction id="c69829026" contextRef="i_2020-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentMember" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,179</ix:nonFraction> and $<ix:nonFraction id="c69829027" contextRef="i_2019-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentMember" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,377</ix:nonFraction>, respectively. The Company&#x2019;s long-term lease liability as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> was $<ix:nonFraction id="c69829029" contextRef="i_2020-12-31_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,871</ix:nonFraction> and $<ix:nonFraction id="c69829030" contextRef="i_2019-12-31_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,406</ix:nonFraction>, respectively. The current and long-term portions of the Company&#x2019;s lease liability are presented within &#x201c;Lease financing obligations&#x201d; on the Consolidated Balance Sheets. Cash paid for amounts included in the measurement of lease liabilities was $<ix:nonFraction id="c69829031" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="3" format="ixt:numdotdecimal" decimals="-3">1,696</ix:nonFraction> and $<ix:nonFraction id="c69829032" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="3" format="ixt:numdotdecimal" decimals="-3">1,457</ix:nonFraction> for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively. The Company&#x2019;s right-of use asset balance associated with operating leases totaled $<ix:nonFraction id="c69829034" contextRef="i_2020-12-31_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-3">3,802</ix:nonFraction> and $<ix:nonFraction id="c69829035" contextRef="i_2019-12-31_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-4">3,590</ix:nonFraction> at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively. These amounts are presented within &#x201c;Other assets&#x201d; on the Consolidated Balance Sheets. Operating right-of-use assets are recorded net of accumulated amortization of $<ix:nonFraction id="c69829037" contextRef="i_2020-12-31" unitRef="USD" name="bcrx:OperatingLeaseRightofuseAssetAccumulatedAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">2,641</ix:nonFraction> and $<ix:nonFraction id="c69829038" contextRef="i_2019-12-31" unitRef="USD" name="bcrx:OperatingLeaseRightofuseAssetAccumulatedAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">1,386</ix:nonFraction> as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively<span style="color:#000000;">.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <span style="color:#000000;"><em style="font: inherit;">66</em></span>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c1757843" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note </b><b><em style="font: inherit;">7</em></b><b> &#x2014; Stockholders&#x2019; Equity</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Sales of Common Stock</b></i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:22pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> November 8, 2017, </em>the Company filed a $<ix:nonFraction id="c69829051" contextRef="i_2017-11-08" unitRef="USD" name="bcrx:MaximumAggregateOfferingPrice" scale="3" format="ixt:numdotdecimal" decimals="-8">200,000</ix:nonFraction> shelf registration statement on Form S-<em style="font: inherit;">3</em> with the SEC. This shelf registration statement became effective on <em style="font: inherit;"> December 12, 2017 </em>and allowed the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> August 6, 2018, </em>the Company completed an underwritten public offering of <ix:nonFraction id="c69829053" contextRef="d_2018-08-06_2018-08-06" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">10,455</ix:nonFraction> shares of its common stock, offered at a price to the public of $<ix:nonFraction id="c69829054" contextRef="i_2018-08-06" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">5.50</ix:nonFraction> per share, including shares issued pursuant to the underwriters&#x2019; <em style="font: inherit;">30</em>-day option to purchase additional shares, which was exercised in full. The net proceeds from this offering were approximately $<ix:nonFraction id="c69829056" contextRef="d_2018-08-06_2018-08-06" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:numdotdecimal" decimals="-5">53,400</ix:nonFraction> after deducting underwriting discounts and commissions and estimated offering expenses.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> November 18, 2019, </em>the Company completed an underwritten public offering of <ix:nonFraction id="c69829057" contextRef="d_2019-11-18_2019-11-18" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">43,621</ix:nonFraction> shares of its common stock, offered at a price to the public of $<ix:nonFraction id="c69829058" contextRef="i_2019-11-18" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1.45</ix:nonFraction> per share, including shares issued pursuant to the underwriters&#x2019; <em style="font: inherit;">30</em>-day option to purchase additional shares, which was exercised in full. The net proceeds from this offering were approximately $<ix:nonFraction id="c69829060" contextRef="d_2019-11-18_2019-11-18" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:numdotdecimal" decimals="-5">58,500</ix:nonFraction> after deducting underwriting discounts and commissions and estimated offering expenses.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> November 21, 2019, </em>the Company completed an offering of pre-funded warrants to purchase up to <ix:nonFraction id="c69829061" contextRef="i_2019-11-21" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="3" format="ixt:numdotdecimal" decimals="-3">11,765</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction id="c69829062" contextRef="i_2019-11-21" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1.69</ix:nonFraction> per warrant. Each pre-funded warrant is exercisable subject to conditions in the warrant agreement into <em style="font: inherit;">1</em> share of common stock at an exercise price of $<ix:nonFraction id="c69829064" contextRef="i_2019-11-21" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction> per share. The net proceeds from this offering were $<ix:nonFraction id="c69829065" contextRef="d_2019-11-21_2019-11-21" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" format="ixt:numdotdecimal" decimals="-3">19,882</ix:nonFraction>, excluding any proceeds the Company <em style="font: inherit;"> may </em>receive upon the subsequent exercise of the pre-funded warrants. All warrants issued in this offering remain outstanding at <em style="font: inherit;"> December 31, 2020.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> April 24, 2020, </em>the Company filed a $<ix:nonFraction id="c69829066" contextRef="i_2020-04-24" unitRef="USD" name="bcrx:MaximumAggregateOfferingPrice" scale="3" format="ixt:numdotdecimal" decimals="-8">500,000</ix:nonFraction> shelf registration statement on Form S-<em style="font: inherit;">3</em> with the SEC. This shelf registration statement became effective on <em style="font: inherit;"> May 14, 2020 </em>and allows the Company to sell securities, including common stock, preferred stock, depository shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> June 1, 2020, </em>the Company issued <ix:nonFraction id="c69829068" contextRef="d_2020-06-01_2020-06-01" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">22,044</ix:nonFraction> shares of common stock to the public at a purchase price of $<ix:nonFraction id="c69829069" contextRef="i_2020-06-01" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">4.50</ix:nonFraction> per share and pre-funded warrants to purchase <ix:nonFraction id="c69829070" contextRef="i_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">3,511</ix:nonFraction> shares of common stock at a purchase of $<ix:nonFraction id="c69829071" contextRef="d_2020-06-01_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember" unitRef="USDPerShare" name="bcrx:ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" scale="0" format="ixt:numdotdecimal" decimals="INF">4.49</ix:nonFraction> per pre-funded warrant, for total net proceeds to the Company of $<ix:nonFraction id="c69829072" contextRef="d_2020-06-01_2020-06-01" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:numdotdecimal" decimals="-6">108,096</ix:nonFraction> million after deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant is exercisable subject to conditions in the warrant agreement into <em style="font: inherit;">1</em> share of common stock at an exercise price of $<ix:nonFraction id="c69829074" contextRef="i_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction> per share. All warrants issued in this offering remain outstanding at <em style="font: inherit;"> December 31, 2020.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c1757844" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note <em style="font: inherit;">8</em></b><b> &#x2014; Stock-Based Compensation</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">As of <em style="font: inherit;"> December 31, 2020, </em>the Company had <em style="font: inherit;">three</em> stock-based employee compensation plans, the Amended and Restated Stock Incentive Plan (&#x201c;Incentive Plan&#x201d;), the&#xa0;</span>Amended and Restated&#xa0;<span style="color:#000000;">Inducement Equity Incentive Plan (&#x201c;Inducement Plan&#x201d;) and the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The Incentive Plan was amended and restated on <em style="font: inherit;"> March 19, 2020 </em>and approved by the Company&#x2019;s stockholders on <em style="font: inherit;"> May 12, 2020. </em>The Inducement Plan was adopted by the Board of Directors on <em style="font: inherit;"> April 24, 2019 </em>and amended and restated by the Board of Directors in <em style="font: inherit;"> February 2020 </em>and in <em style="font: inherit;"> July 2020. </em>The ESPP was amended and restated in <em style="font: inherit;"> March 2020 </em>and approved by the Company&#x2019;s stockholders on <em style="font: inherit;"> May 12, 2020. </em>Stock-based compensation expense of $<ix:nonFraction id="c69829077" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">14,794</ix:nonFraction> ($<ix:nonFraction id="c69829078" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">12,938</ix:nonFraction> of expense related to the Incentive Plan, $<ix:nonFraction id="c69829079" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,494</ix:nonFraction> of expense related to the Inducement Plan, $<ix:nonFraction id="c69829080" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">362</ix:nonFraction> of expense related to the ESPP) was recognized during <em style="font: inherit;">2020,</em> while $<ix:nonFraction id="c69829082" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">17,719</ix:nonFraction> ($<ix:nonFraction id="c69829083" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">17,164</ix:nonFraction> of expense related to the Incentive Plan, $<ix:nonFraction id="c69829084" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-InducementPlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">323</ix:nonFraction> of expense related to the Inducement Plan, $<ix:nonFraction id="c69829085" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">232</ix:nonFraction> of expense related to the ESPP) was recognized during <em style="font: inherit;">2019</em> and $<ix:nonFraction id="c69829087" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">9,396</ix:nonFraction> ($<ix:nonFraction id="c69829088" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">9,223</ix:nonFraction> of expense related to the Incentive Plan, $<ix:nonFraction id="c69829089" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">173</ix:nonFraction> of expense related to the ESPP) was recognized during <em style="font: inherit;">2018.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:23pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company accounts for stock-based compensation in accordance with FASB authoritative guidance regarding share-based payments. Total stock-based compensation was allocated as follows:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c1757845" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="10" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><span style="color:#000000;"><b><b>Year Ended December 31,</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>8</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Research and development</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829208" contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">10,222</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829209" contextRef="d_2019-01-01_2019-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">13,977</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829210" contextRef="d_2018-01-01_2018-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">6,867</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Selling, general and administrative</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829211" contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">4,572</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829212" contextRef="d_2019-01-01_2019-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">3,742</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829213" contextRef="d_2018-01-01_2018-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,529</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Total stock-based compensation expense</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829214" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">14,794</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829215" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">17,719</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829216" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">9,396</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <span style="color:#000000;"><em style="font: inherit;">67</em></span>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Stock Incentive Plan</b></i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#x2019;s stock at the date of grant. Commencing <em style="font: inherit;"> March 1, 2011, </em>stock option awards and restricted stock units granted to employees generally vest <ix:nonFraction id="c69829092" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">25</ix:nonFraction>% each year until fully vested after <span style="-sec-ix-hidden:c69829093">four</span> years. In <em style="font: inherit;"> August 2013, </em><em style="font: inherit;"> December 2014 </em>and <em style="font: inherit;"> December 2019, </em>the Company issued <ix:nonFraction id="c69829094" contextRef="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" format="ixt:numdotdecimal" decimals="-3">1,032</ix:nonFraction>, <ix:nonFraction id="c69829095" contextRef="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" format="ixt:numdotdecimal" decimals="-4">1,250</ix:nonFraction> and <ix:nonFraction id="c69829096" contextRef="d_2019-12-01_2019-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" format="ixt:numdotdecimal" decimals="-3">315</ix:nonFraction> performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of <em style="font: inherit;"> December 31, 2020, </em><ix:nonFraction id="c69829097" contextRef="d_2020-01-01_2020-12-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="0">100</ix:nonFraction>%, <ix:nonFraction id="c69829098" contextRef="d_2020-01-01_2020-12-31_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">85</ix:nonFraction>% and <ix:nonFraction id="c69829099" contextRef="d_2020-01-01_2020-12-31_AwardDateAxis-December2019Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="0">100</ix:nonFraction>% of the <em style="font: inherit;"> August 2013, </em><em style="font: inherit;"> December 2014 </em>and <em style="font: inherit;"> December 2019 </em>grants, respectively, have vested. During <em style="font: inherit;">2020,</em> the Company recognized $<ix:nonFraction id="c69829102" contextRef="d_2020-01-01_2020-12-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,768</ix:nonFraction> and $<ix:nonFraction id="c69829103" contextRef="d_2020-01-01_2020-12-31_AwardDateAxis-December2019Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">684</ix:nonFraction> of stock compensation expense related to milestones within the <em style="font: inherit;"> August 2013 </em>and <em style="font: inherit;"> December 2019 </em>grants for which achievement became probable. Stock option awards granted to non-employee directors of the Company generally vest over <em style="font: inherit;">one</em> year. All stock option awards have contractual terms of <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c69829105" format="ixt-sec:duryear">10</ix:nonNumeric> years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Related activity under the Incentive Plan is as follows:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="c8E0CFA93-2E69-4763-A357-3334C9545AA8" escape="true" continuedAt="c3144EB31-AFA8-4B70-A487-AD30CFB137C1">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Weighted</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Average</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Awards</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Options</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Exercise</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Available</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Outstanding</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Price</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2017</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829223" contextRef="i_2017-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-3">468</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829224" contextRef="i_2017-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">14,452</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829225" contextRef="i_2017-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">6.06</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Plan amendment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829226" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-5">4,400</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Restricted stock awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829229" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">13</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829232" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" scale="3" format="ixt:numdotdecimal" decimals="-3">4,272</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829233" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">4,272</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829234" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">7.15</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards exercised</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829236" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">1,011</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829237" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.92</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards cancelled</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829238" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" scale="3" format="ixt:numdotdecimal" decimals="-3">222</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69829239" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">222</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829240" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">7.44</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2018</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829241" contextRef="i_2018-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-3">805</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829242" contextRef="i_2018-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">17,491</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829243" contextRef="i_2018-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">6.49</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Plan amendment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829244" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-6">4,000</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Restricted stock awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829247" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">27</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829250" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" scale="3" format="ixt:numdotdecimal" decimals="-3">4,511</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829251" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">4,511</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829252" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.91</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards exercised</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829254" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">251</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829255" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.75</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards cancelled</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829256" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" scale="3" format="ixt:numdotdecimal" decimals="-3">701</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69829257" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">701</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829258" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">6.82</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2019</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829259" contextRef="i_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-3">968</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829260" contextRef="i_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-4">21,050</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829261" contextRef="i_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.96</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Plan amendment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829262" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-6">8,000</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Restricted stock awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829265" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">31</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829268" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" scale="3" format="ixt:numdotdecimal" decimals="-3">7,469</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829269" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">7,469</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829270" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">8.06</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards exercised</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829272" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-4">510</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c69829273" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.56</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards cancelled</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829274" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" scale="3" format="ixt:numdotdecimal" decimals="-3">3,124</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69829275" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">3,124</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829276" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">6.93</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2020</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829277" contextRef="i_2020-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-3">4,592</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829278" contextRef="i_2020-12-31_PlanNameAxis-IncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">24,885</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829279" contextRef="i_2020-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">6.52</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">For stock option awards granted under the Incentive Plan during <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018</em> was $<ix:nonFraction id="c69829112" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">5.48</ix:nonFraction>, $<ix:nonFraction id="c69829113" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">2.63</ix:nonFraction>, and $<ix:nonFraction id="c69829114" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">4.92</ix:nonFraction>, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Inducement Equity Incentive Plan</b></i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The&#xa0;</span>Company has the ability to grant stock option awards to newly-hired employees as inducements material to each employee entering employment with the Company. Stock option awards granted to newly hired employees generally vest <ix:nonFraction id="c69829116" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">25</ix:nonFraction>% each year until fully vested after <span style="-sec-ix-hidden:c69829118">four</span> years. Each stock option has a term of <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c69829120" format="ixt-sec:duryear">10</ix:nonNumeric> years and is subject to the terms and conditions of the Inducement Plan. The vesting and exercise provisions of all awards granted under the Inducement Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Inducement Plan<span style="color:#000000;">.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Related activity under the Inducement Plan is as follows:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <ix:continuation id="c3144EB31-AFA8-4B70-A487-AD30CFB137C1">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Weighted</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Average</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Awards</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Options</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Exercise</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Available</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Outstanding</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Price</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2019</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829286" contextRef="i_2019-12-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-3">171</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829287" contextRef="i_2019-12-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">1,329</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829288" contextRef="i_2019-12-31_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.60</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Plan amendment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829289" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-5">2,900</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829292" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" scale="3" format="ixt:numdotdecimal" decimals="-3">3,002</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829293" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">3,002</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829294" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">4.02</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards cancelled</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829295" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" scale="3" format="ixt:numdotdecimal" decimals="-4">160</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69829296" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-4">160</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829297" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">4.15</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2020</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829298" contextRef="i_2020-12-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-3">229</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829299" contextRef="i_2020-12-31_PlanNameAxis-InducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">4,171</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829300" contextRef="i_2020-12-31_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.88</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <span style="color:#000000;"><em style="font: inherit;">68</em></span>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">For stock option awards granted under the Inducement Plan during <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> was $<ix:nonFraction id="c69829130" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">2.73</ix:nonFraction> and $<ix:nonFraction id="c69829131" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-InducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">2.41</ix:nonFraction>, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The following table summarizes the key assumptions used by the Company to value the stock option awards granted under all plans during <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> respectively. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if <em style="font: inherit;">not</em> yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#x2019;s publicly traded common stock. The Company has assumed <ix:nonFraction id="c69829137" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> expected dividend yield, as dividends have never been paid to stock or option holders and will <em style="font: inherit;">not</em> be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on <em style="font: inherit;">zero</em>-coupon government issues with a remaining term equal to the expected term.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Plans</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c1757848" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td>&#xa0;</td><td style="padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; padding-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>8</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Expected Life</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c69829304" format="ixt-sec:duryear">5.5</ix:nonNumeric></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonNumeric contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c69829305" format="ixt-sec:duryear">5.5</ix:nonNumeric></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonNumeric contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c69829306" format="ixt-sec:duryear">5.5</ix:nonNumeric></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Expected Volatility</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829307" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="2">84</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829308" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="2">81</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829309" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="2">82</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Expected Dividend Yield</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829310" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0.0</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829311" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0.0</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829312" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0.0</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Risk-Free Interest Rate</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829313" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="3">0.4</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829314" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="3">1.8</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829315" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="3">2.7</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The total intrinsic value of stock option awards exercised under the Incentive Plan was $<ix:nonFraction id="c69829140" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,562</ix:nonFraction> during <em style="font: inherit;">2020,</em> $<ix:nonFraction id="c69829142" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" format="ixt:numdotdecimal" decimals="-3">1,127</ix:nonFraction> during <em style="font: inherit;">2019,</em> and $<ix:nonFraction id="c69829144" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" format="ixt:numdotdecimal" decimals="-3">4,504</ix:nonFraction> during <em style="font: inherit;">2018.</em> The intrinsic value represents the total proceeds (fair market value at the date of exercise, less the exercise price, times the number of stock option awards exercised) received by all individuals who exercised stock option awards during the period. <ix:nonFraction id="c69829146" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> stock option awards were exercised under the Inducement Plan in <em style="font: inherit;">2020.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:25pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">The following table summarizes, at <em style="font: inherit;"> December 31, 2020, </em>by price range: (<em style="font: inherit;">1</em>) for stock option awards outstanding under the Incentive Plan, the number of stock option awards outstanding, their weighted average remaining life and their weighted average exercise price; and (<em style="font: inherit;">2</em>) for stock option awards exercisable under the Plan, the number of stock option awards exercisable and their weighted average exercise price:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="c1757849" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td colspan="9" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"><span style="color:#000000;"><b style="font-size: 10pt;">Outstanding</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Exercisable</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Weighted</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Weighted</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Weighted</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Average</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Average</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Average</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Remaining</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Exercise</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Exercise</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Range</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Number</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;"><b><b>Life</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Price</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Number</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Price</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>$</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>0</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b><ix:nonFraction id="c69829318" contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">3</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829319" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:numdotdecimal" decimals="INF">2,514</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c69829320" format="ixt-sec:duryear">6.1</ix:nonNumeric></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829321" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:numdotdecimal" decimals="INF">2.19</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829322" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:numdotdecimal" decimals="INF">1,414</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829323" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">1.25</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>3</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><span style="color:#000000;"><b><ix:nonFraction id="c69829326" contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">6</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829327" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:numdotdecimal" decimals="INF">12,689</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c69829328" format="ixt-sec:duryear">7.0</ix:nonNumeric></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829329" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:numdotdecimal" decimals="INF">4.22</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829330" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:numdotdecimal" decimals="INF">6,854</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829331" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">2.48</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>6</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b><ix:nonFraction id="c69829334" contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">9</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829335" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:numdotdecimal" decimals="INF">10,852</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c69829336" format="ixt-sec:duryear">9.2</ix:nonNumeric></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829337" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:numdotdecimal" decimals="INF">7.88</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829338" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:numdotdecimal" decimals="INF">2,005</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829339" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">4.89</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>9</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b><ix:nonFraction id="c69829342" contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">12</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829343" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:numdotdecimal" decimals="INF">2,347</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c69829344" format="ixt-sec:duryear">4.5</ix:nonNumeric></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829345" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:numdotdecimal" decimals="INF">10.85</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829346" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:numdotdecimal" decimals="INF">2,129</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829347" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">4.51</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>12</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b><ix:nonFraction id="c69829350" contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">15</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829351" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:numdotdecimal" decimals="INF">559</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c69829352" format="ixt-sec:duryear">4.1</ix:nonNumeric></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829353" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:numdotdecimal" decimals="INF">12.30</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829354" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:numdotdecimal" decimals="INF">539</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829355" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">6.43</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>15</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b><ix:nonFraction id="c69829358" contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">18</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829359" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:numdotdecimal" decimals="INF">95</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c69829360" format="ixt-sec:duryear">4.5</ix:nonNumeric></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829361" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:numdotdecimal" decimals="INF">15.39</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829362" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:numdotdecimal" decimals="INF">95</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829363" contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">10.57</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>$</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>0</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b><ix:nonFraction id="c69829366" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">18</ix:nonFraction></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829367" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" format="ixt:numdotdecimal" decimals="INF">29,056</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" id="c69829368" format="ixt-sec:duryear">7.5</ix:nonNumeric></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829369" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" format="ixt:numdotdecimal" decimals="INF">6.14</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829370" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" format="ixt:numdotdecimal" decimals="INF">13,036</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829371" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" format="ixt:numdotdecimal" decimals="INF">3.27</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The weighted average remaining contractual life of stock option awards exercisable under the plans at <em style="font: inherit;"> December 31, 2020 </em>was <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c69829150" format="ixt-sec:duryear">5.3</ix:nonNumeric> years.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">The aggregate intrinsic value of stock option awards outstanding and exercisable under the plans at <em style="font: inherit;"> December 31, 2020 </em>was $<ix:nonFraction id="c69829151" contextRef="i_2020-12-31_PlanNameAxis-InducementPlanMember" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" format="ixt:numdotdecimal" decimals="-3">29,716</ix:nonFraction>. The aggregate intrinsic value represents the value (the period&#x2019;s closing market price, less the exercise price, times the number of in-the-money stock option awards) that would have been received by all stock option award holders under the plans had they exercised their stock option awards at the end of the year.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <span style="color:#000000;"><em style="font: inherit;">69</em></span>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The total fair value of the stock option awards vested under the plans was $<ix:nonFraction id="c69829153" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" format="ixt:numdotdecimal" decimals="INF">18,739</ix:nonFraction>&#xa0;during <em style="font: inherit;">2020,</em> $<ix:nonFraction id="c69829155" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" format="ixt:numdotdecimal" decimals="-3">12,499</ix:nonFraction> during <em style="font: inherit;">2019,</em> and $<ix:nonFraction id="c69829157" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="3" format="ixt:numdotdecimal" decimals="-3">8,952</ix:nonFraction> during <em style="font: inherit;">2018.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">As&#xa0;</span>of <em style="font: inherit;"> December 31, 2020, </em>the number of stock option awards vested and expected to vest under the plans is <ix:nonFraction id="c69829159" contextRef="i_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="3" format="ixt:numdotdecimal" decimals="-3">26,487</ix:nonFraction>. The weighted average exercise price of these stock option awards is $<ix:nonFraction id="c69829160" contextRef="i_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">6.13</ix:nonFraction> and their weighted average remaining contractual life is <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="c69829161" format="ixt-sec:duryear">7.4</ix:nonNumeric> years<span style="color:#000000;">.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The following table summarizes the changes in the number and weighted-average grant-date fair value of non-vested stock option awards during <em style="font: inherit;">2020:</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c1757850" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;"><b><b>Non-Vested Stock Option Awards</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><b>Weighted Average Grant-Date Fair Value</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Balance December 31, 2019</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829372" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="3" format="ixt:numdotdecimal" decimals="-3">11,688</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829373" contextRef="i_2019-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">3.77</ix:nonFraction></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Stock option awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829374" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" format="ixt:numdotdecimal" decimals="-3">10,471</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829375" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">4.69</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Stock option awards vested</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829376" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="3" format="ixt:numdotdecimal" decimals="-3">4,543</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829377" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">4.12</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Stock option awards forfeited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69829378" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">1,596</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829379" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">3.96</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Balance December 31, 2020</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829380" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="3" format="ixt:numdotdecimal" decimals="-4">16,020</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69829381" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">4.25</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">As of <em style="font: inherit;"> December 31, 2020, </em>there was approximately $<ix:nonFraction id="c69829163" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" format="ixt:numdotdecimal" decimals="-3">56,094</ix:nonFraction> of total unrecognized compensation cost related to non-vested employee stock option awards granted by the Company. That cost is expected to be recognized as follows: $<ix:nonFraction id="c69829164" contextRef="i_2020-12-31" unitRef="USD" name="bcrx:EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" scale="3" format="ixt:numdotdecimal" decimals="-3">17,758</ix:nonFraction> in <em style="font: inherit;">2021,</em> $<ix:nonFraction id="c69829166" contextRef="i_2020-12-31" unitRef="USD" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" scale="3" format="ixt:numdotdecimal" decimals="-3">16,281</ix:nonFraction> in <em style="font: inherit;">2022,</em> $<ix:nonFraction id="c69829168" contextRef="i_2020-12-31" unitRef="USD" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" scale="3" format="ixt:numdotdecimal" decimals="-3">12,484</ix:nonFraction> in <em style="font: inherit;">2023,</em> and $<ix:nonFraction id="c69829170" contextRef="i_2020-12-31" unitRef="USD" name="bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" scale="3" format="ixt:numdotdecimal" decimals="-3">9,571</ix:nonFraction> in <em style="font: inherit;">2024.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><b><i>Employee Stock Purchase Plan</i></b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company has reserved a total of <ix:nonFraction id="c69829172" contextRef="i_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="3" format="ixt:numdotdecimal" decimals="-3">4,475</ix:nonFraction> shares of common stock to be purchased under the ESPP, of which <ix:nonFraction id="c69829173" contextRef="i_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" format="ixt:numdotdecimal" decimals="-3">2,873</ix:nonFraction> shares remain available for purchase at <em style="font: inherit;"> December 31, 2020. </em>Eligible employees <em style="font: inherit;"> may </em>authorize up to <ix:nonFraction id="c69829174" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Pure" name="bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum" scale="-2" format="ixt:numdotdecimal" decimals="2">15</ix:nonFraction>% of their salary to purchase common stock at the lower of <ix:nonFraction id="c69829175" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Pure" name="bcrx:PercentageOfCommonStockSharesBeginning" scale="-2" format="ixt:numdotdecimal" decimals="2">85</ix:nonFraction>% of the beginning or <ix:nonFraction id="c69829176" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Pure" name="bcrx:PercentageOfCommonStockSharesEnding" scale="-2" format="ixt:numdotdecimal" decimals="2">85</ix:nonFraction>% of the ending price during <em style="font: inherit;">six</em>-month purchase intervals. <em style="font: inherit;">No</em> more than <ix:nonFraction id="c69829179" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" scale="3" format="ixt:numdotdecimal" decimals="-3">3</ix:nonFraction> shares <em style="font: inherit;"> may </em>be purchased by any <em style="font: inherit;">one</em> employee at the <em style="font: inherit;">six</em>-month purchase dates and <em style="font: inherit;">no</em> employee <em style="font: inherit;"> may </em>purchase stock having a fair market value at the commencement date of $<ix:nonFraction id="c69829183" contextRef="i_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USD" name="bcrx:ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">25</ix:nonFraction> or more in any <em style="font: inherit;">one</em> calendar year.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">There were <ix:nonFraction id="c69829185" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:numdotdecimal" decimals="-3">246</ix:nonFraction>, <ix:nonFraction id="c69829186" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:numdotdecimal" decimals="-3">115</ix:nonFraction>, and <ix:nonFraction id="c69829187" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="3" format="ixt:numdotdecimal" decimals="-3">92</ix:nonFraction> shares of common stock purchased under the ESPP in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> respectively, at a weighted average price per share of $<ix:nonFraction id="c69829191" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USDPerShare" name="us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" scale="0" format="ixt:numdotdecimal" decimals="INF">2.56</ix:nonFraction>, $<ix:nonFraction id="c69829192" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USDPerShare" name="us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" scale="0" format="ixt:numdotdecimal" decimals="INF">3.51</ix:nonFraction>, and $<ix:nonFraction id="c69829193" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USDPerShare" name="us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" scale="0" format="ixt:numdotdecimal" decimals="INF">3.83</ix:nonFraction>, respectively. Expense of $<ix:nonFraction id="c69829194" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">362</ix:nonFraction>, $<ix:nonFraction id="c69829195" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">232</ix:nonFraction>, and $<ix:nonFraction id="c69829196" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">173</ix:nonFraction> related to the ESPP was recognized during <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#x201c;look-back&#x201d; option were determined using a Black-Scholes option pricing model. The weighted average grant date fair values of shares granted under the ESPP during <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> were $<ix:nonFraction id="c69829203" contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.47</ix:nonFraction>, $<ix:nonFraction id="c69829204" contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">2.01</ix:nonFraction>, and $<ix:nonFraction id="c69829205" contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.89</ix:nonFraction>, respectively.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c1757851" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note </b><b><em style="font: inherit;">9</em></b><b> &#x2014; Income Taxes</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The Company has incurred net losses since inception and, consequently, has <em style="font: inherit;">not</em> recorded any U.S. Federal and state income tax expense or benefit.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The components of loss before provision for income taxes were as followings:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="c1757852" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>2020</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Domestic</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829418" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">176,613</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Foreign</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69829419" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">6,201</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Loss before provision for income taxes</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69829420" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">182,814</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The differences between the Company&#x2019;s effective tax rate and the statutory tax rate in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> are as follows:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c1757889" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>8</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Income tax benefit at federal statutory rate (<span style="-sec-ix-hidden:c69831164"><span style="-sec-ix-hidden:c69831165"><span style="-sec-ix-hidden:c69831166">21%</span></span></span> for 2020, 2019 and 2018)</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69830298" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">38,391</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69830299" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">22,868</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69830300" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">21,263</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">State and local income taxes net of federal tax benefit</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69830301" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">2,544</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69830302" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">1,591</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69830303" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">2,547</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Permanent items</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69830304" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">774</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69830305" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">691</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69830306" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">503</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Rate change</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69830307" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">82</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69830308" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" format="ixt:numdotdecimal" decimals="-3">625</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69830309" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">29</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Expiration of attribute carryforwards</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69830310" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" scale="3" format="ixt:numdotdecimal" decimals="-3">3,774</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69830311" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" scale="3" format="ixt:numdotdecimal" decimals="-3">3,976</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69830312" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" scale="3" format="ixt:numdotdecimal" decimals="-3">2,183</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Research and development tax credits</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830313">(4,080</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830314">(4,938</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830315">(4,905</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Foreign rate differential</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69830316" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" format="ixt:numdotdecimal" decimals="-3">542</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">-</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">-</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Other</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830319">1,456</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830320">281</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830321">18</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Change in valuation allowance</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69830322" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" format="ixt:numdotdecimal" decimals="-3">38,551</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69830323" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" format="ixt:numdotdecimal" decimals="-3">23,824</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69830324" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" format="ixt:numdotdecimal" decimals="-4">26,040</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Income tax expense</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: #000000; "><span style="-sec-ix-hidden:c69830325">-</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830326">-</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830327">-</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <span style="color:#000000;"><em style="font: inherit;">70</em></span>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company recognizes the impact of a tax position in its financial statements if it is more likely than <em style="font: inherit;">not</em> that the position will be sustained on audit based on the technical merits of the position. The Company has concluded that it has an uncertain tax position pertaining to its research and development and orphan drug credit carryforwards. The Company has established these credits based on information and calculations it believes are appropriate and the best estimate of the underlying credit. Any changes to the Company&#x2019;s unrecognized tax benefits are offset by an adjustment to the valuation allowance and there would be <em style="font: inherit;">no</em> impact on the Company&#x2019;s financial statements. The Company does <em style="font: inherit;">not</em> expect its unrecognized tax benefits to change significantly over the next <em style="font: inherit;">12</em> months.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="c1757890" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Balance at January 1,</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69830328" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:numdotdecimal" decimals="-4">7,210</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69830329" contextRef="i_2018-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:numdotdecimal" decimals="-3">5,976</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Additions to current period tax positions</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69830330" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" format="ixt:numdotdecimal" decimals="-4">1,020</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69830331" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" format="ixt:numdotdecimal" decimals="-3">1,234</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Additions to prior period tax positions</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Reductions to prior period tax provisions</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Balance at December 31,</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69830336" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:numdotdecimal" decimals="-4">8,230</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69830337" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:numdotdecimal" decimals="-4">7,210</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company&#x2019;s ability to utilize the net operating loss and tax credit carryforwards in the future <em style="font: inherit;"> may </em>be subject to substantial restrictions in the event of past or future ownership changes as defined in Section <em style="font: inherit;">382</em> of the Internal Revenue Code of <em style="font: inherit;">1986,</em> as amended and similar state tax law.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c1757855" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Deferred tax assets:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Net federal and state operating losses</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829468" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" format="ixt:numdotdecimal" decimals="-3">159,939</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829469" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="3" format="ixt:numdotdecimal" decimals="-4">155,190</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Research and development credits</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829470" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" format="ixt:numdotdecimal" decimals="-3">66,331</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829471" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" format="ixt:numdotdecimal" decimals="-3">63,275</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Royalty income</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829472" contextRef="i_2020-12-31" unitRef="USD" name="bcrx:DeferredTaxAssetsRoyaltyIncome" scale="3" format="ixt:numdotdecimal" decimals="-3">28,034</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829473" contextRef="i_2019-12-31" unitRef="USD" name="bcrx:DeferredTaxAssetsRoyaltyIncome" scale="3" format="ixt:zerodash" decimals="-3">-</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock-based compensation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829474" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" format="ixt:numdotdecimal" decimals="-3">10,732</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829475" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" format="ixt:numdotdecimal" decimals="-3">9,786</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Leasing obligations</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69830346" contextRef="i_2020-12-31" unitRef="USD" name="bcrx:DeferredTaxAssetsLeasingObligations" scale="3" format="ixt:numdotdecimal" decimals="-3">1,135</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69830347" contextRef="i_2019-12-31" unitRef="USD" name="bcrx:DeferredTaxAssetsLeasingObligations" scale="3" format="ixt:numdotdecimal" decimals="-4">1,070</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Other</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69830348" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="3" format="ixt:numdotdecimal" decimals="-3">5,563</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><ix:nonFraction id="c69830349" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOther" scale="3" format="ixt:numdotdecimal" decimals="-3">3,801</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Total deferred tax assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69830350" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="3" format="ixt:numdotdecimal" decimals="-3">271,734</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69830351" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="3" format="ixt:numdotdecimal" decimals="-3">233,122</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Deferred tax liabilities:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Fixed assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69830352" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">124</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69830353" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">114</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Right of use asset</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69830354" contextRef="i_2020-12-31" unitRef="USD" name="bcrx:DeferredTaxLiabilitiesRightOfUseAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">854</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69830355" contextRef="i_2019-12-31" unitRef="USD" name="bcrx:DeferredTaxLiabilitiesRightOfUseAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">803</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Total deferred tax liabilities</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69830356" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">978</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69830357" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">917</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Valuation allowance</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69830358" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:numdotdecimal" decimals="-3">270,756</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(<ix:nonFraction id="c69830359" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:numdotdecimal" decimals="-3">232,205</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Net deferred tax assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#x2212;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The majority of the Company&#x2019;s deferred tax assets relate to net operating loss and research and development carryforwards that can only be realized if the Company is profitable in future periods. It is uncertain whether the Company will realize any tax benefit related to these carryforwards. Accordingly, the Company has provided a full valuation allowance against the net deferred tax assets due to uncertainties as to their ultimate realization. The valuation allowance will remain at the full amount of the deferred tax assets until it is more likely than <em style="font: inherit;">not</em> that the related tax benefits will be realized. The Company&#x2019;s valuation allowance increased by $<ix:nonFraction id="c69829395" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" format="ixt:numdotdecimal" decimals="-3">38,551</ix:nonFraction>, $<ix:nonFraction id="c69829396" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" format="ixt:numdotdecimal" decimals="-3">23,824</ix:nonFraction>, and $<ix:nonFraction id="c69829397" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" format="ixt:numdotdecimal" decimals="-4">26,040</ix:nonFraction> in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> respectively.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">As of <em style="font: inherit;"> December 31, 2020, </em>the Company had U.S. federal operating loss carryforwards of $<ix:nonFraction id="c69829401" contextRef="i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="3" format="ixt:numdotdecimal" decimals="-3">677,109</ix:nonFraction>, state operating loss carryforwards of $<ix:nonFraction id="c69829402" contextRef="i_2020-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="3" format="ixt:numdotdecimal" decimals="-3">494,608</ix:nonFraction>, foreign net operating losses of $<ix:nonFraction id="c69829403" contextRef="i_2020-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="3" format="ixt:numdotdecimal" decimals="-3">6,427</ix:nonFraction>, and U.S. research and development and orphan drug credit carryforwards of $<ix:nonFraction id="c69829404" contextRef="i_2020-12-31_TaxCreditCarryforwardAxis-ResearchMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">74,561</ix:nonFraction>, which will expire at various dates from <em style="font: inherit;">2021</em> through <em style="font: inherit;">2040.</em> Federal losses, state losses, research and development credit carryforwards began expiring in <em style="font: inherit;">2020.</em> The foreign net operating losses have an indefinite carryforward period.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Tax years <span style="-sec-ix-hidden:c69829408">2017</span>-<em style="font: inherit;">2020</em> remain open to examination by the major taxing jurisdictions to which the Company is subject. Additionally, years prior to <em style="font: inherit;">2017</em> are also open to examination to the extent of loss and credit carryforwards from those years. The Company recognizes interest and penalties accrued related to unrecognized tax benefits as components of its income tax provision. However, there were <ix:nonFraction id="c69829411" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="3" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> provisions or accruals for interest and penalties in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <span style="color:#000000;"><em style="font: inherit;">71</em></span>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="c1757857" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note </b><b><em style="font: inherit;">10</em></b><b> &#x2014; Employee <em style="font: inherit;">401</em>(k) Plan</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In <em style="font: inherit;"> January 1991, </em>the Company adopted an employee retirement plan (<em style="font: inherit;">&#x201c;401</em>(k) Plan&#x201d;) under Section <em style="font: inherit;">401</em>(k) of the Internal Revenue Code covering all employees. Employee contributions <em style="font: inherit;"> may </em>be made to the <em style="font: inherit;">401</em>(k) Plan up to limits established by the Internal Revenue Service. Company matching contributions <em style="font: inherit;"> may </em>be made at the discretion of the Board of Directors. The Company made matching contributions of $<ix:nonFraction id="c69829509" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">1,569</ix:nonFraction>, $<ix:nonFraction id="c69829510" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">926</ix:nonFraction>, and $<ix:nonFraction id="c69829511" contextRef="d_2018-01-01_2018-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">724</ix:nonFraction> in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> respectively.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="c1757858" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note <em style="font: inherit;">11</em></b><b> &#x2014; Collaborative and Other Research and Development Contracts</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;)</i>. In&#xa0;</span><em style="font: inherit;"> September 2013, </em>NIAID/HHS contracted with the Company for the development of galidesivir as a treatment for Marburg virus disease and subsequently, Yellow Fever and Ebola virus disease. As of <em style="font: inherit;"> December 31, 2020, </em>all options under this contract have been awarded, and the total value of the contract, as amended, is $<ix:nonFraction id="c69829519" contextRef="d_2020-01-01_2020-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" unitRef="USD" name="bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" scale="3" format="ixt:numdotdecimal" decimals="-3">45,931</ix:nonFraction>, inclusive of the <em style="font: inherit;">$2,897</em> added to the contract in <em style="font: inherit;"> August 2020 </em>to support the development of galidesivir. In <em style="font: inherit;"> August 2020, </em>NIAID/HHS awarded the Company a new contract, with potential aggregate funding up of to $<ix:nonFraction id="c69829521" contextRef="d_2020-08-01_2020-08-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" unitRef="USD" name="bcrx:CollaborativeAgreementContractCovenantMaximumAmountOfFunding" scale="3" format="ixt:numdotdecimal" decimals="-3">43,908</ix:nonFraction> if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir. NIAID/HHS made an initial award of $<ix:nonFraction id="c69829523" contextRef="d_2020-08-01_2020-08-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember" unitRef="USD" name="bcrx:CollaborativeAgreementContractValue" scale="3" format="ixt:numdotdecimal" decimals="-3">6,326</ix:nonFraction> to the Company under this new contract<span style="color:#000000;">.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>Biomedical Advanced Research</i><i> and </i><i>Development Authority</i><i> (&#x201c;BARDA/HHS&#x201d;)</i>. In <em style="font: inherit;"> March 2015, </em>BARDA/HHS awarded the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This BARDA/HHS contract includes a base contract of $<ix:nonFraction id="c69829525" contextRef="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember" unitRef="USD" name="us-gaap:GovernmentContractReceivable" scale="3" format="ixt:numdotdecimal" decimals="-3">16,265</ix:nonFraction> to support galidesivir drug manufacturing, as well as $<ix:nonFraction id="c69829527" contextRef="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember" unitRef="USD" name="us-gaap:GovernmentContractReceivable" scale="3" format="ixt:numdotdecimal" decimals="-3">22,855</ix:nonFraction> in additional development options that can be exercised by the government, bringing the potential value of the contract to $<ix:nonFraction id="c69829528" contextRef="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember" unitRef="USD" name="us-gaap:GovernmentContractReceivable" scale="3" format="ixt:numdotdecimal" decimals="-4">39,120</ix:nonFraction>. As of <em style="font: inherit;"> December 31, 2020, </em>a total of $<ix:nonFraction id="c69829529" contextRef="d_2015-04-01_2020-12-31_TypeOfArrangementAxis-ASPRBARDAContractMember" unitRef="USD" name="bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts" scale="3" format="ixt:numdotdecimal" decimals="-3">20,574</ix:nonFraction> has been awarded under exercised options within this contract.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The contracts with NIAID/HHS and BARDA/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress, and the continuation of the contract is based on the Company&#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;)</i>. In&#xa0;</span><em style="font: inherit;"> September 2018, </em>HHS awarded the Company a $<ix:nonFraction id="c69829530" contextRef="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="bcrx:CollaborativeAgreementContractValue" scale="3" format="ixt:numdotdecimal" decimals="-4">34,660</ix:nonFraction> contract for the procurement of up to <em style="font: inherit;">50,000</em> doses of RAPIVAB (peramivir injection) over a <span style="-sec-ix-hidden:c69829532">five</span>-year period, including an initial base order of <em style="font: inherit;">10,000</em> doses. In <em style="font: inherit;"> September 2019, </em>HHS exercised its option to purchase an additional <em style="font: inherit;">10,000</em> doses of RAPIVAB. The Company delivered a total of <em style="font: inherit;">20,000</em> doses of RAPIVAB and approximately $<ix:nonFraction id="c69829537" contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ProceedsFromCollaborators" scale="3" format="ixt:numdotdecimal" decimals="-3">13,864</ix:nonFraction> of product sales in <em style="font: inherit;">2019.</em> On <em style="font: inherit;"> September 3, 2020, </em>the Company announced that HHS had exercised an option under this contract to purchase an additional <em style="font: inherit;">10,000</em> doses of RAPIVAB for $<ix:nonFraction id="c69829540" contextRef="d_2020-09-03_2020-09-03_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember" unitRef="USD" name="us-gaap:ProceedsFromCollaborators" scale="3" format="ixt:numdotdecimal" decimals="-3">6,932</ix:nonFraction>, which the Company expects to deliver in <em style="font: inherit;">2021.</em>&#xa0; <em style="font: inherit;">No</em> shipments were delivered in <em style="font: inherit;">2020</em> under this additional <em style="font: inherit;">10,000</em> dose option<span style="color:#000000;">.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>Torii Pharmaceutical Co., Ltd. (&#x201c;Torii&#x201d;)</i>. On <em style="font: inherit;"> November 5, 2019, </em>the Company entered into a Commercialization and License Agreement with Torii (the &#x201c;Torii Agreement&#x201d;), granting Torii the exclusive right to commercialize ORLADEYO&#x2122; for the prevention of hereditary angioedema (&#x201c;HAE&#x201d;) attacks in Japan.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>&#xa0;</i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Under the Torii Agreement, the Company received an upfront, non-refundable payment of $<ix:nonFraction id="c69829545" contextRef="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember" unitRef="USD" name="bcrx:UpfrontPaymentsReceivableAmount" scale="3" format="ixt:numdotdecimal" decimals="-6">22,000</ix:nonFraction> and is eligible to receive an additional milestone payment of $<ix:nonFraction id="c69829546" contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember" unitRef="USD" name="bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" scale="3" format="ixt:numdotdecimal" decimals="-6">15,000</ix:nonFraction> upon receipt from Japan&#x2019;s National Health Insurance System of a reimbursement price approval for ORLADEYO in excess of the threshold specified in the Torii Agreement.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In addition, under the Torii Agreement, the Company is entitled to receive tiered royalty payments, ranging from <ix:nonFraction id="c69829547" contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MinimumMember" unitRef="Pure" name="bcrx:RoyaltyRateIfMaintainsSakigakeDesignation" scale="-2" format="ixt:numdotdecimal" decimals="1">20</ix:nonFraction>% to <ix:nonFraction id="c69829548" contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MaximumMember" unitRef="Pure" name="bcrx:RoyaltyRateIfMaintainsSakigakeDesignation" scale="-2" format="ixt:numdotdecimal" decimals="1">40</ix:nonFraction>% of annual net sales of ORLADEYO in Japan during each calendar year. Torii&#x2019;s royalty payment obligations are subject to customary reductions in certain circumstances, but <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be reduced by more than <ix:nonFraction id="c69829550" contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember" unitRef="Pure" name="bcrx:MaximumCustomaryReductionOnRoyaltyRate" scale="-2" format="ixt:numdotdecimal" decimals="1">50</ix:nonFraction>% of the amount that otherwise would have been payable to the Company in the applicable calendar quarter. Torii&#x2019;s royalty payment obligations commence upon the <em style="font: inherit;">first</em> commercial sale of ORLADEYO in Japan and expire upon the later of (i) the <span style="-sec-ix-hidden:c69829552">tenth</span> anniversary of the date of <em style="font: inherit;">first</em> commercial sale of ORLADEYO in Japan, (ii) the expiration of the Company&#x2019;s patents covering ORLADEYO, and (iii) the expiration of regulatory exclusivity for ORLADEYO in Japan. The Company will be responsible for supplying Torii with its required amounts of ORLADEYO. The activities of the parties pursuant to the Torii Agreement will be overseen by a joint steering committee, to be composed of an equal number of representatives from each party to coordinate the development and commercialization of ORLADEYO in Japan.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Under the Torii Agreement, the Company has granted Torii a right of <em style="font: inherit;">first</em> negotiation (&#x201c;ROFN&#x201d;) to commercialize ORLADEYO in Japan for the acute treatment of HAE attacks if the Company develops ORLADEYO for such indication and to commercialize any additional kallikrein inhibitor that the Company <em style="font: inherit;"> may </em>develop in the future for use in HAE in Japan. Under both ROFNs, if the parties do <em style="font: inherit;">not</em> agree to terms with respect to a definitive amendment to the Torii Agreement or new agreement, as applicable, the terms of the amendment or agreement would be set by a <em style="font: inherit;">third</em>-party arbitrator.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <span style="color:#000000;"><em style="font: inherit;">72</em></span>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company identified performance obligations related to (i) the license to develop and commercialize ORLADEYO, (ii) regulatory approval support and (iii) reimbursement pricing approval support. These were each determined to be distinct from the other performance obligations. The Company allocated the <em style="font: inherit;">$22,000</em> upfront consideration to the identified performance obligations using estimation approaches to determine the standalone selling prices under ASC <em style="font: inherit;">606.</em> Specifically, in determining the value related to the license, a valuation approach utilizing risk adjusted discounted cash flow projections was used and an expected cost plus margin approach was utilized for the other performance obligations. The Company recognized $<ix:nonFraction id="c69829560" contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">20,101</ix:nonFraction> in revenue in <em style="font: inherit;">2019</em> including $<ix:nonFraction id="c69829562" contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-LicenseMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">19,344</ix:nonFraction> associated with the license which was transferred to Torii at the execution of the Agreement and $<ix:nonFraction id="c69829563" contextRef="d_2020-01-01_2020-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-ServiceMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">757</ix:nonFraction> related to the <em style="font: inherit;">2020</em> services provided in the performance of the <em style="font: inherit;">two</em> approvals. The remaining $<ix:nonFraction id="c69829566" contextRef="d_2020-01-01_2020-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" format="ixt:numdotdecimal" decimals="-3">1,899</ix:nonFraction> of the <em style="font: inherit;">$22,000</em> upfront payment was recognized as revenue in <em style="font: inherit;">2020</em> as the services were delivered.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>Seqirus UK Limited (&#x201c;SUL&#x201d;). </i>On <em style="font: inherit;"> June 16, 2015, </em>the Company and SUL, a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia,<i> </i>entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &#x201c;Territory&#x201d;). Under the terms of the SUL Agreement, the Company received an upfront payment of $<ix:nonFraction id="c69829569" contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember" unitRef="USD" name="us-gaap:ProceedsFromLicenseFeesReceived" scale="3" format="ixt:numdotdecimal" decimals="-4">33,740</ix:nonFraction> and has achieved all development milestones under the contract totaling $<ix:nonFraction id="c69829570" contextRef="d_2015-06-16_2020-12-31_CounterpartyNameAxis-CSLLimitedMember" unitRef="USD" name="bcrx:MilestonePaymentReceived" scale="3" format="ixt:numdotdecimal" decimals="-6">12,000</ix:nonFraction>.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> March 4, 2020, </em>the International Court of Arbitration of the International Chamber of Commerce (&#x201c;ICC Tribunal&#x201d;) delivered a Partial Arbitration Award (the &#x201c;Partial Arbitration Award&#x201d;) in an arbitration matter between the Company and SUL with respect to the SUL Agreement. In the Partial Arbitration Award, the ICC Tribunal found that, during the term, SUL materially breached and abandoned its core duties to the Company under the Diligent Efforts (as defined in the SUL Agreement) requirements of the SUL Agreement as applicable in the U.S. The ICC Tribunal granted a declaratory judgment in favor of the Company terminating the SUL Agreement and restoring all rights to peramivir to the Company. The parties agreed on a transition process for the product, with a full transition of commercialization of the product in the U.S. and Australia returned to the Company as of <em style="font: inherit;"> August 1, 2020 </em>and <em style="font: inherit;"> November 1, 2020, </em>respectively. The ICC Tribunal also awarded the Company its attorneys&#x2019; fees and expenses incurred in securing the declaratory judgment as well as the costs incurred by the Company in the arbitration. Finally, the ICC Tribunal found that SUL breached the SUL Agreement by failing to pay the milestone payment due to the Company within <em style="font: inherit;">30</em> days of the approval of peramivir for adult use in the European Union and awarded the Company $<ix:nonFraction id="c69829573" contextRef="d_2020-03-04_2020-03-04_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember" unitRef="USD" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" scale="3" format="ixt:numdotdecimal" decimals="-6">5,000</ix:nonFraction> (plus interest) for this claim. The ICC Tribunal retained jurisdiction for further proceedings relating to the award of attorneys&#x2019; fees and for any dispute relating to the return to the Company of all rights to peramivir in the Territory. The Company recorded the settlement gain of $<ix:nonFraction id="c69829574" contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-OtherIncomeMember_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember" unitRef="USD" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="3" format="ixt:numdotdecimal" decimals="-3">8,893</ix:nonFraction> in other income and legal fees and other expenses of $<ix:nonFraction id="c69829575" contextRef="d_2020-01-01_2020-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember" unitRef="USD" name="us-gaap:LegalFees" scale="3" format="ixt:numdotdecimal" decimals="-3">5,026</ix:nonFraction> in selling, general and administrative expenses for the year ended <em style="font: inherit;"> December 31, 2020.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>Shionogi &amp; Co., Ltd. (&#x201c;Shionogi&#x201d;). </i>In <em style="font: inherit;"> February 2007, </em>the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially<i> </i>life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to UAB on any future milestone payments and/or royalties received by the Company from Shionogi. In <em style="font: inherit;"> October 2008, </em>the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In <em style="font: inherit;"> December 2017, </em>the Company, on behalf of Royalty Sub, instituted arbitration proceedings against Shionogi in order to resolve a dispute with Shionogi under the Shionogi Agreement regarding the achievement of sales milestones and escalating royalties. The arbitration proceedings have concluded, with the decision that <em style="font: inherit;">no</em> sale milestones had been achieved and that royalties would remain the same. The costs associated with the arbitration proceedings are recoverable from the assets of Royalty Sub in accordance with the terms of the indenture and servicing agreement relating to the PhaRMA Notes.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>Green Cross Corporation (&#x201c;Green Cross&#x201d;). </i>In <em style="font: inherit;"> June 2006, </em>the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be<i> </i>responsible for all development, regulatory, and commercialization costs in Korea. The Company received a <em style="font: inherit;">one</em>-time license fee of $<ix:nonFraction id="c69829578" contextRef="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember" unitRef="USD" name="us-gaap:ProceedsFromLicenseFeesReceived" scale="3" format="ixt:numdotdecimal" decimals="-4">250</ix:nonFraction>. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;). </i>In <em style="font: inherit;"> February 2006, </em>the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and<i> </i>commercialization of Mundesine, a Purine Nucleoside Phosphorylase (&#x201c;PNP&#x201d;) inhibitor, for use in oncology. The agreement, as amended and restated, provides for the possibility of future event payments totaling $<ix:nonFraction id="c69829579" contextRef="i_2011-11-11_TypeOfArrangementAxis-MundipharmaMember" unitRef="USD" name="bcrx:PotentialMilestonePaymentsReceivable" scale="3" format="ixt:numdotdecimal" decimals="-6">15,000</ix:nonFraction> for achieving specified regulatory events for certain indications and tiered royalties ranging from mid to high single-digit percentages of net product sales in each country where Mundesine is sold by Mundipharma. The Company licensed forodesine and other PNP inhibitors from AECOM/IRL (as defined below) and will owe sublicense payments to AECOM/IRL on all milestone payments and royalties received from Mundipharma.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
       <span style="color:#000000;"><em style="font: inherit;">73</em></span>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;"><i>Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&#x201c;AECOM&#x201d; and &#x201c;IRL&#x201d; respectively). </i>In <em style="font: inherit;"> June 2000, </em>the Company licensed a series of potent inhibitors of PNP from AECOM and IRL,<i> </i>(together, the &#x201c;Licensors&#x201d;). The lead product candidates from this collaboration is forodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the agreement to include other inventions in the field made by the investigators or employees of the Licensors. Under this agreement, as amended and restated, the Company has agreed to use commercially reasonable efforts to develop these drugs and to pay certain milestone payments for each licensed product (which range in the aggregate from $<ix:nonFraction id="c69829582" contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" unitRef="USD" name="bcrx:MilestonePaymentMinimum" scale="3" format="ixt:numdotdecimal" decimals="-5">1,400</ix:nonFraction> to almost $<ix:nonFraction id="c69829583" contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" unitRef="USD" name="bcrx:MilestonePaymentMaximum" scale="3" format="ixt:numdotdecimal" decimals="-6">4,000</ix:nonFraction> per indication) for future development, single digit royalties on net sales of any resulting product made by the Company, and to share a portion of future payments received from other <em style="font: inherit;">third</em>-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $<ix:nonFraction id="c69829585" contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" unitRef="USD" name="bcrx:AnnualLicenseFeeMinimum" scale="3" format="ixt:numdotdecimal" decimals="-4">150</ix:nonFraction> to $<ix:nonFraction id="c69829587" contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember" unitRef="USD" name="bcrx:AnnualLicenseFeeMaximum" scale="3" format="ixt:numdotdecimal" decimals="-5">500</ix:nonFraction>, that are creditable against actual royalties and other payments due to the Licensors. The Licensors have also granted the Company an exclusive worldwide license of galidesivir for any antiviral use.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>The University of Alabama at Birmingham (&#x201c;UAB&#x201d;). </i>The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific<i> </i>research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed by UAB with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other <em style="font: inherit;">third</em>-party partners. The Company has completed the research under the UAB agreements. These <em style="font: inherit;">two</em> agreements each have an initial <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember" name="bcrx:PeriodOfAgreement" id="c69829590" format="ixt-sec:duryear">25</ix:nonNumeric>-year term, are automatically renewable for <span style="-sec-ix-hidden:c69829592">five</span>-year terms throughout the life of the last patent and are terminable by the Company upon <em style="font: inherit;">three</em> months&#x2019; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently <em style="font: inherit;">no</em> activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts received.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="c1757859" escape="true">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note <em style="font: inherit;">12</em></b><b>&#xa0;&#x2014; Quarterly Financial Information (Unaudited)</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="c1757860" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>First</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Second</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Third</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Fourth</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>20</b><b>20</b><b> Quarters</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Revenues</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829603" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">4,823</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829604" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,871</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829605" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">6,102</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829606" contextRef="d_2020-10-01_2020-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">4,016</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Net Loss</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829607" contextRef="d_2020-01-01_2020-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">37,599</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829608" contextRef="d_2020-04-01_2020-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">38,607</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829609" contextRef="d_2020-07-01_2020-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">46,115</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829610" contextRef="d_2020-10-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">60,493</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Basic and diluted net loss per share</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829611" contextRef="d_2020-01-01_2020-03-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.24</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829612" contextRef="d_2020-04-01_2020-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.24</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829613" contextRef="d_2020-07-01_2020-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.26</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829614" contextRef="d_2020-10-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.34</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>2019 Quarters</b></span></p> </td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#xa0;</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Revenues</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829616" contextRef="d_2019-01-01_2019-03-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">5,887</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829617" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,448</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829618" contextRef="d_2019-07-01_2019-09-30" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,775</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><ix:nonFraction id="c69829619" contextRef="d_2019-10-01_2019-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">39,725</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Net Loss</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829620" contextRef="d_2019-01-01_2019-03-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">31,054</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829621" contextRef="d_2019-04-01_2019-06-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">37,629</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829622" contextRef="d_2019-07-01_2019-09-30" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">37,592</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829623" contextRef="d_2019-10-01_2019-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">2,622</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Basic and diluted net loss per share</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829624" contextRef="d_2019-01-01_2019-03-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.28</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829625" contextRef="d_2019-04-01_2019-06-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.34</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829626" contextRef="d_2019-07-01_2019-09-30" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.34</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(<ix:nonFraction id="c69829627" contextRef="d_2019-10-01_2019-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.02</ix:nonFraction></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><ix:exclude>&#xa0;</ix:exclude></b></span></p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">74</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><a id="report" title="report" href="#"></a>Report of Independent Registered Public Accounting Firm</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">To the Stockholders and Board of Directors of BioCryst Pharmaceuticals, Inc.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Opinion on the Financial Statements</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">We have audited the accompanying consolidated balance sheets of BioCryst Pharmaceuticals, Inc. (the Company) as of December 31, 2020 and 2019, the related consolidated statements of comprehensive loss, stockholders&#x2019; equity (deficit) and cash flows for each of the three years in the period ended December 31, 2020, and the related notes<sup style="vertical-align:top;line-height:120%;font-size:pt"><b> </b></sup>(collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework),<b> </b>and our report dated March 1, 2021 expressed an unqualified opinion thereon.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Basis for Opinion</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Critical Audit Matters</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:171pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><b><i>&#xa0;</i></b></span></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:29.8%;">&#xa0;</td>
     <td style="vertical-align:top;width:70.2%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b><i>Accrued Clinical Trial and Manufacturing Activities</i></b></span></p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:29.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i>Description of the </i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i>Matter</i></span></p> </td>
     <td style="vertical-align:top;width:70.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">As discussed in Note 1 to the consolidated financial statements, the Company has recorded $33.9 million of accrued expenses, which includes costs for clinical trial and manufacturing activities (together, clinical related activities) based upon estimates of expenses incurred through the balance sheet date that have yet to be invoiced by the contract research organizations (CROs), clinical study sites, contract manufacturing organizations, or other vendors (together, clinical vendors). This accrual process involves identifying services that have been performed and estimating the level of service performed and the associated cost when the Company has not yet been invoiced or otherwise notified of actual cost.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Auditing the Company&#x2019;s accruals for costs associated with in-process clinical related activities may include judgment because the timing and pattern of vendor invoicing may not correspond to the level of services provided and the estimate can incorporate significant assumptions such as expected patient enrollment, site activation, and estimated project duration.</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:29.8%;">&#xa0;</td>
     <td style="vertical-align:top;width:70.2%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:29.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i>How We Addressed </i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i>the Matter in Our</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i>Audit</i></span></p> </td>
     <td style="vertical-align:top;width:70.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">We obtained an understanding, evaluated the design and tested the operating effectiveness of internal controls that addressed the information used in and the identified risks related to the Company&#x2019;s process for recording accrued costs for clinical related activities.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">To evaluate the accrual for clinical related expenses, our audit procedures included, among others, inspecting the Company&#x2019;s contracts with clinical vendors (including pending change orders), testing the completeness and accuracy of the underlying data used in the estimate of the level of service provided including evaluating the significant assumptions as discussed above for the applicable in process contracts with clinical vendors. To assess the significant assumptions, we corroborated the progress of clinical related activities through inquiry with the Company&#x2019;s clinical team and with information obtained directly from third party clinical vendors, as well as tested invoices received from clinical vendors subsequent to the balance sheet date.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><i>&#xa0;</i></b></span></p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">75</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><span style="color:#000000;"><b><i>&#xa0;</i></b></span></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:29.8%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:70.2%;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b><i>Valuation of Royalty Financing Obligation</i></b></span></p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:29.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i>Description of the </i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i>Matter</i></span></p> </td>
     <td style="vertical-align:top;width:70.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">As described in Note 3 to the consolidated financial statements, the Company entered into a Royalty Purchase Agreement (&#x201c;RPA&#x201d;) in December 2020 with a third party. Pursuant to the RPA, the Company received proceeds of $125.0 million in exchange for the right to receive royalty payments based on future net revenues of the Company&#x2019;s drug, Orladeyo.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">The Company recorded the financing as a non-current liability instrument (royalty financing obligation) on the balance sheet at its carrying value of $124.7 million as of December 31, 2020 and imputed interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the liability to be repaid in full over the anticipated life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level and timing of forecasted net revenues which affects the repayment timing and ultimate amount of repayment. The Company evaluates the interest rate quarterly based on its current revenue forecasts utilizing the prospective method.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Auditing the royalty financing obligation was complex and highly judgmental due to the estimation uncertainty in determining the effective interest rate. The Company&#x2019;s effective interest rate model includes revenue projections for which royalties will be paid, which are sensitive to significant assumptions (including population, penetration and sales price) that are affected by expectations about future market conditions.</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:29.8%;">&#xa0;</td>
     <td style="vertical-align:top;width:70.2%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:29.8%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i>How We Addressed </i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i>the Matter in Our</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i>Audit</i></span></p> </td>
     <td style="vertical-align:top;width:70.2%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company&#x2019;s processes to account for the royalty financing obligation, including controls over management&#x2019;s review of the revenue projections within the model.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">To evaluate the royalty financing obligation, our audit procedures included, among others, assessing the underlying data and assumptions used by the Company in its effective interest rate model. We compared the significant assumptions in the revenue projections to current industry, market and economic trends. We recalculated the current year interest expense based on the amortization schedule and estimate of royalties using the effective interest method, and performed sensitivity analyses to evaluate the changes in the effective interest rate, and associated interest expense, that would result from changes in the assumptions.</span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">/s/ Ernst &amp; Young LLP</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">We have served as the Company&#x2019;s auditor since 1993.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Raleigh, North Carolina</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">March 1, 2021</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">76</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><a id="report2" title="report2" href="#"></a>Report of Independent Registered Public Accounting Firm</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">To the Stockholders and Board of Directors of BioCryst Pharmaceuticals, Inc.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Opinion on Internal Control Over Financial Reporting</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">We have audited BioCryst Pharmaceuticals Inc.&#x2019;s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control&#x2014;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework)<b> </b>(the COSO criteria). In our opinion, BioCryst Pharmaceuticals Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of BioCryst Pharmaceuticals, Inc. as of December 31, 2020 and 2019, the related consolidated statements of comprehensive loss, stockholders&#x2019; equity (deficit) and cash flows for each of the three years in the period ended December 31, 2020, and the related notes<b> </b>and our report dated March 1, 2021 expressed an unqualified opinion thereon.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Basis for Opinion</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">The Company&#x2019;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#x2019;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#x2019;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Definition and Limitations of Internal Control Over Financial Reporting</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">A company&#x2019;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#x2019;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">/s/ Ernst &amp; Young LLP</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Raleigh, North Carolina</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">March 1, 2021</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">77</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><span style="color:#000000;"><b><a id="i9" title="i9" href="#"></a>ITEM 9.&#xa0; &#xa0; &#xa0;&#xa0;<i>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</i></b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;"><br /> <span style="color:#000000;">None.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><a id="i9a" title="i9a" href="#"></a>ITEM 9A.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b><i>CONTROLS AND PROCEDURES</i></b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Evaluation of Disclosure Controls and Procedures</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">We maintain a set of disclosure controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), is recorded, processed, summarized and reported, within the time periods specified in the SEC&#x2019;s rules and forms. Our disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to management, including our principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. We carried out an evaluation as required by paragraph (b) of Rule 13a-15 or Rule 15d-15 under the Exchange Act, under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) or Rule 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2020, our disclosure controls and procedures are effective.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Management&#x2019;s Report on Internal Control Over Financial Reporting</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting and for the assessment of the effectiveness of internal control over financial reporting. As defined in Rule 13a-15(f) or Rule 15d-15(f) under the Exchange Act, internal control over financial reporting is a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements in accordance with U.S. GAAP. Internal control over financial reporting includes policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and the dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In connection with the preparation of our annual financial statements, management has undertaken an assessment of the effectiveness of our internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control &#x2014; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework) (the COSO Framework). Management&#x2019;s assessment included an evaluation of the design of our internal control over financial reporting and testing of the operational effectiveness of those controls.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Based on this assessment, management has concluded that, as of December 31, 2020, our internal control over financial reporting was effective. Management believes our internal control over financial reporting will provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Ernst &amp; Young LLP, the independent registered public accounting firm that audited our financial statements included in this report, has issued an attestation report on the Company&#x2019;s internal control over financial reporting, a copy of which appears on page 77&#xa0;of this annual report.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Changes in Internal Control over Financial Reporting</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">There have been no changes in our internal control over financial reporting that occurred during the quarter ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><a id="i9b" title="i9b" href="#"></a>ITEM 9B.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b><i>OTHER INFORMATION</i></b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:29pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">None.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">78</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><span style="color:#000000;"><b><a id="p3" title="p3" href="#"></a>PART III</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><a id="i10" title="i10" href="#"></a>ITEM 10.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b><i>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</i></b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The information required by this item is set forth under the captions <i>&#x201c;Items to be Voted upon &#x2014; 1. Election of Directors,&#x201d; &#x201c;Executive Officers,&#x201d;</i> and <i>&#x201c;Corporate Governance&#x201d; </i>in our definitive Proxy Statement for the 2021 Annual Meeting of Stockholders and incorporated herein by reference.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><a id="i11" title="i11" href="#"></a>ITEM 11.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b><i>EXECUTIVE COMPENSATION</i></b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;"><span style="color:#000000;">The information required by this item is set forth under the captions <i>&#x201c;Compensation Discussion and Analysis,&#x201d; &#x201c;Summary Compensation Table,&#x201d;</i> <i>&#x201c;Grants of Plan-Based Awards in 20</i><i>20</i><i>,&#x201d; &#x201c;Outstanding Equity Awards at December 31, 20</i><i>20</i><i>,&#x201d; &#x201c;20</i><i>20</i><i> Option Exercises and Stock Vested,&#x201d; &#x201c;Potential Payments Upon Termination or Change in Control,&#x201d; &#x201c;20</i><i>20</i><i> Director Compensation,&#x201d; &#x201c;Compensation Committee Interlocks and Insider Participation</i><i>,</i><i>&#x201d; &#x201c;Compensation Committee Report</i><i>,</i><i>&#x201d;</i> and <i>&#x201c;Delinquent Section 16(a) Reports&#x201d;</i> in our definitive Proxy Statement for the 2021 Annual Meeting of Stockholders and incorporated herein by reference.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color:#000000;"><b><a id="i12" title="i12" href="#"></a>ITEM 12.&#xa0; &#xa0; &#xa0;<i>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</i></b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;"><span style="color:#000000;">The information required by this item is set forth under the captions <i>&#x201c;Equity Compensation Plan Information&#x201d;</i> and <i>&#x201c;Security Ownership of Certain</i> <i>Beneficial Owners and Management&#x201d; </i>in our definitive Proxy Statement for the 2021 Annual Meeting of Stockholders and incorporated herein by<i> </i>reference.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><a id="i13" title="i13" href="#"></a>ITEM 13.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b><i>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</i></b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:45pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The information required by this item is set forth under the captions <i>&#x201c;Certain Relationships and Related Transactions&#x201d;</i> and <i>&#x201c;Corporate</i> <i>Governance&#x201d; </i>in our definitive Proxy Statement for the 2021 Annual Meeting of Stockholders and incorporated herein by reference.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b><a id="i14" title="i14" href="#"></a>ITEM 14.</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b><i>PRINCIPAL ACCOUNTING FEES AND SERVICES</i></b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The information required by this item is set forth under the caption <i>&#x201c;Items to be Voted upon &#x2014; 2. Ratification of Appointment of Independent</i> <i>Registered Public Accountants&#x201d; </i>in our definitive Proxy Statement for the 2021 Annual Meeting of Stockholders and incorporated herein by reference.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:center;"><span style="color:#000000;"><b><a id="p4" title="p4" href="#"></a>PART IV</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:center;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><b><a id="i15" title="i15" href="#"></a>ITEM 15.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</b><b><i>EXHIBITS, FINANCIAL STATEMENT SCHEDULES</i></b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;text-indent:9pt;"><span style="color:#000000;"><i>(a) Financial Statements</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The following financial statements appear in Item 8 of this Form 10-K:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:88.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:11.4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>Page in</b></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>Form 10-K</b></span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:88.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;"><a href="#bs" style="-sec-extract:exhibit;"><span style="color:#000000;">Consolidated Balance Sheets at December 31, 2020 and 2019</span></a></p> </td>
     <td style="vertical-align:top;width:11.4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><a href="#bs" style="-sec-extract:exhibit;"><span style="color:#000000;">51</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:88.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;"><a href="#cl" style="-sec-extract:exhibit;"><span style="color:#000000;">Consolidated Statements of Comprehensive Loss for the years ended December 31, 2020, 2019, and 2018</span></a></p> </td>
     <td style="vertical-align:top;width:11.4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><a href="#cl" style="-sec-extract:exhibit;"><span style="color:#000000;">52</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:88.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;"><a href="#cf" style="-sec-extract:exhibit;"><span style="color:#000000;">Consolidated Statements of Cash Flows for the years ended December 31, 2020, 2019, and 2018</span></a></p> </td>
     <td style="vertical-align:top;width:11.4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><a href="#cf" style="-sec-extract:exhibit;"><span style="color:#000000;">53</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:88.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;"><a href="#se" style="-sec-extract:exhibit;"><span style="color:#000000;">Consolidated Statements of Stockholders&#x2019; Equity for the years ended December 31, 2020, 2019, and 2018</span></a></p> </td>
     <td style="vertical-align:top;width:11.4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><a href="#se" style="-sec-extract:exhibit;"><span style="color:#000000;">54</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:88.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;"><a href="#notes" style="-sec-extract:exhibit;"><span style="color:#000000;">Notes to Consolidated Financial Statements</span></a></p> </td>
     <td style="vertical-align:top;width:11.4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><a href="#notes" style="-sec-extract:exhibit;"><span style="color:#000000;">55</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:88.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;"><a href="#report" style="-sec-extract:exhibit;"><span style="color:#000000;">Report of Independent Registered Public Accounting Firm on Consolidated Financial Statements</span></a></p> </td>
     <td style="vertical-align:top;width:11.4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><a href="#report" style="-sec-extract:exhibit;"><span style="color:#000000;">75</span></a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:88.6%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;"><a href="#report2" style="-sec-extract:exhibit;"><span style="color:#000000;">Report of Independent Registered Public Accounting Firm on Internal Control</span></a></p> </td>
     <td style="vertical-align:top;width:11.4%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><a href="#report2" style="-sec-extract:exhibit;"><span style="color:#000000;">77</span></a></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:20pt;margin-top:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:justify;text-indent:22.75pt;"><span style="color:#000000;">No financial statement schedules are included because the information is either provided in the consolidated financial statements or is not required under the related instructions or is inapplicable and such schedules therefore have been omitted.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:justify;text-indent:22.75pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">79</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:justify;text-indent:13.5pt;"><span style="color:#000000;"><i>(b) Exhibits</i></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:justify;text-indent:13.5pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
   <tbody>
    <tr style="vertical-align: top">
     <td style="width: 9%"><span style="color:#000000;"><span style="text-decoration: underline; "><b>Number</b></span></span></td>
     <td style="width: 1%">&#xa0;</td>
     <td style="width: 90%"><span style="color:#000000;"><span style="text-decoration: underline; "><b>Description</b></span></span></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000103570406000836/d42297exv3w1.htm"><span style="color:#000000;">3.1</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000103570406000836/d42297exv3w1.htm"><span style="color:#000000;">Third Restated Certificate of Incorporation of BioCryst Pharmaceuticals, Inc. Incorporated by reference to Exhibit 3.1 to the Company&#x2019;s Form 8-K filed December 22, 2006.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231007001386/c70813exv3w1.htm"><span style="color:#000000;">3.2</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231007001386/c70813exv3w1.htm"><span style="color:#000000;">Certificate of Amendment to the Third Restated Certificate of Incorporation of BioCryst Pharmaceuticals, Inc. Incorporated by reference to Exhibit 3.1 to the Company&#x2019;s Form 8-K filed July 24, 2007.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex31.htm"><span style="color:#000000;">3.3</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex31.htm"><span style="color:#000000;">Certificate of Amendment to the Third Restated Certificate of Incorporation of BioCryst Pharmaceuticals, Inc. Incorporated by reference to Exhibit 3.1 to the Company&#x2019;s Form 8-K filed May 7, 2014.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231008006580/c76716exv3w1.htm"><span style="color:#000000;">3.4</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231008006580/c76716exv3w1.htm"><span style="color:#000000;">Certificate of Increase of Authorized Number of Shares of Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit 3.1 to the Company&#x2019;s Form 8-K filed November 4, 2008.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex32.htm"><span style="color:#000000;">3.5</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514186707/d722313dex32.htm"><span style="color:#000000;">Certificate of Increase of Authorized Number of Shares of Series B Junior Participating Preferred Stock. Incorporated by reference to Exhibit 3.2 to the Company&#x2019;s Form 8-K filed May 7, 2014.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_31.htm"><span style="color:#000000;">3.6</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_31.htm"><span style="color:#000000;">Certificate of Elimination of the Series B Junior Participating Preferred Stock.&#xa0;&#xa0;Incorporated by reference to Exhibit 3.1 to the Company&#x2019;s Form 8-K filed May 13, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_32.htm"><span style="color:#000000;">3.7</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_32.htm"><span style="color:#000000;">Certificate of Amendment to the Third Restated Certificate of Incorporation of BioCryst Pharmaceuticals, Inc.&#xa0;&#xa0;Incorporated by reference to Exhibit 3.2 to the Company&#x2019;s Form 8-K filed May 13, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231008006580/c76716exv3w2.htm"><span style="color:#000000;">3.8</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231008006580/c76716exv3w2.htm"><span style="color:#000000;">Amended and Restated Bylaws of BioCryst Pharmaceuticals, Inc., effective October 29, 2008. Incorporated by reference to Exhibit 3.2 to the Company&#x2019;s Form 8-K filed November 4, 2008.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000110465918003194/a18-3548_1ex3d1.htm#Exhibit3_1_084143"><span style="color:#000000;">3.9</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000110465918003194/a18-3548_1ex3d1.htm#Exhibit3_1_084143"><span style="color:#000000;">Amendment to Amended and Restated By-Laws of BioCryst Pharmaceuticals, Inc., effective January 21, 2018. Incorporated by reference to Exhibit 3.1 to the Company&#x2019;s Form 8-K filed January 22, 2018.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_230468.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(4.1)</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_230468.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">Description of Securities</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095012311046591/g27110exv4w3.htm"><span style="color:#000000;">4.2</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095012311046591/g27110exv4w3.htm"><span style="color:#000000;">Indenture, dated as of March 9, 2011 by and between JPR Royalty Sub LLC and U.S. Bank National Association, as trustee. Incorporated by reference to Exhibit 4.3 to the Company&#x2019;s Form 10-Q filed May&#xa0;6, 2011.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000114036119021088/ex4_1.htm"><span style="color:#000000;">4.3</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000114036119021088/ex4_1.htm"><span style="color:#000000;">Form of Pre-Funded Warrant to Purchase Common Stock, dated November 21, 2019. Incorporated by reference to Exhibit 4.1 to the Company&#x2019;s Form 8-K filed November 21, 2019.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000114036120012787/nt10011234x7_ex4-1.htm"><span style="color:#000000;">4.4</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000114036120012787/nt10011234x7_ex4-1.htm"><span style="color:#000000;">Form of Pre-Funded Warrant to Purchase Common Stock, dated June 1, 2020.&#xa0;&#xa0;Incorporated by reference to Exhibit 4.1 to the Company&#x2019;s Form 8-K filed June 1, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312512248790/d358788dex101.htm"><span style="color:#000000;">10.1&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312512248790/d358788dex101.htm"><span style="color:#000000;">BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated March 29, 2012). Incorporated by reference to Exhibit 10.1 of the Company&#x2019;s Form 8-K filed May 25, 2012.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514181823/d721175dex101.htm"><span style="color:#000000;">10.2&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514181823/d721175dex101.htm"><span style="color:#000000;">BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated March 8, 2014). Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 8-K filed May 5, 2014.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316010246/exh_101.htm"><span style="color:#000000;">10.3&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316010246/exh_101.htm"><span style="color:#000000;">BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated May 23, 2016).&#xa0;&#xa0;Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Registration Statement on Form S-8, filed May 23, 2016.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317003361/exh_101.htm"><span style="color:#000000;">10.4&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317003361/exh_101.htm"><span style="color:#000000;">BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated April 3, 2017). Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 8-K filed May 30, 2017.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184318007398/exh_101.htm"><span style="color:#000000;">10.5&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184318007398/exh_101.htm"><span style="color:#000000;">BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated September 17, 2018). Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 8-K filed October 31, 2018.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319003812/exh_101.htm"><span style="color:#000000;">10.6&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319003812/exh_101.htm"><span style="color:#000000;">BioCryst Pharmaceuticals, Inc. Stock Incentive Plan (as amended and restated as of April 12, 2019). Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 8-K filed June 4, 2019.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_101.htm"><span style="color:#000000;">10.7&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_101.htm"><span style="color:#000000;">BioCryst Pharmaceuticals, Inc. Amended and Restated Stock Incentive Plan (as amended and restated as of March 19, 2020).&#xa0;&#xa0;Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 8-K filed May 13, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095014408001624/g12086exv10w4.htm"><span style="color:#000000;">10.8&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095014408001624/g12086exv10w4.htm"><span style="color:#000000;">Form of Notice of Grant of Non-Employee Director Automatic Stock Option and Stock Option Agreement under the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Incorporated by reference to Exhibit 10.4 to the Company&#x2019;s Form 10-K filed March 4, 2008.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">80</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
   <tbody>
    <tr style="vertical-align: top">
     <td style="width: 9%"><a href="http://www.sec.gov/Archives/edgar/data/882796/000095014408001624/g12086exv10w5.htm"><span style="color:#000000;">10.9&amp;</span></a></td>
     <td style="width: 1%">&#xa0;</td>
     <td style="width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/882796/000095014408001624/g12086exv10w5.htm"><span style="color:#000000;">Form of Notice of Grant of Stock Option and Stock Option Agreement under the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. Incorporated by reference to Exhibit 10.5 to the Company&#x2019;s Form 10-K filed March 4, 2008.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315001186/exh_107.htm"><span style="color:#000000;">10.10&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315001186/exh_107.htm"><span style="color:#000000;">Standard Stock Option Agreement under the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.&#xa0;&#xa0;Incorporated by reference to Exhibit 10.7 to the Company&#x2019;s Form 10-K filed March 2, 2015.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315001186/exh_108.htm"><span style="color:#000000;">10.11&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315001186/exh_108.htm"><span style="color:#000000;">Form of Notice of Grant of Restricted Stock Unit Award and Restricted Stock Unit Agreement under the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.&#xa0;&#xa0;Incorporated by reference to Exhibit 10.8 of the Company&#x2019;s Form 10-K filed March 2, 2015.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_102.htm"><span style="color:#000000;">10.12&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003680/exh_102.htm"><span style="color:#000000;">BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan (as amended and restated as of March 19, 2020).&#xa0;&#xa0;Incorporated by reference to Exhibit 10.2 to the Company&#x2019;s Form 8-K filed May 13, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319002720/exh_991.htm"><span style="color:#000000;">10.13&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319002720/exh_991.htm"><span style="color:#000000;">BioCryst Pharmaceuticals, Inc. Inducement Equity Incentive Plan (effective as of April 24, 2019). Incorporated by reference to Exhibit 99.1 to the Company&#x2019;s Form S-8 (File No. 333-231108) filed April 29, 2019.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003557/exh_102.htm"><span style="color:#000000;">10.14&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003557/exh_102.htm"><span style="color:#000000;">BioCryst Pharmaceuticals, Inc. Inducement Equity Incentive Plan (as amended and restated February 7, 2020).&#xa0;&#xa0;Incorporated by reference to Exhibit 10.2 of the Company&#x2019;s Form 10-Q filed May 11, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320005862/exh_991.htm"><span style="color:#000000;">10.15&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320005862/exh_991.htm"><span style="color:#000000;">BioCryst Pharmaceuticals, Inc. Inducement Equity Incentive Plan (as amended and restated July 17, 2020).&#xa0;&#xa0;Incorporated by reference to Exhibit 99.1 to the Company&#x2019;s Form S-8 (File No. 333-245024) filed August 12, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_230469.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(10.16)&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_230469.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">Form of Notice of Grant of Stock Option and Standard Stock Option Agreement under the BioCryst Pharmaceuticals, Inc. Inducement Equity Incentive Plan.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320008616/exh_101.htm"><span style="color:#000000;">10.17&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320008616/exh_101.htm"><span style="color:#000000;">BioCryst Pharmaceuticals, Inc. Annual Incentive Plan (effective as of December 16, 2020).&#xa0;&#xa0;Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 8-K filed December 17, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095014408001624/g12086exv10w2.htm"><span style="color:#000000;">10.18&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095014408001624/g12086exv10w2.htm"><span style="color:#000000;">Executive Relocation Policy. Incorporated by reference to Exhibit 10.2 to the Company&#x2019;s Form&#xa0;10-K filed March 4, 2008.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095014407002193/g06036exv10w12.htm"><span style="color:#000000;">10.19&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095014407002193/g06036exv10w12.htm"><span style="color:#000000;">Amended and Restated Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Jon P. Stonehouse, dated February 14, 2007. Incorporated by reference to Exhibit 10.12 to the Company&#x2019;s Form 10-K filed March 14, 2007.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095012311053914/g27379exv10w1.htm"><span style="color:#000000;">10.20&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095012311053914/g27379exv10w1.htm"><span style="color:#000000;">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Thomas R. Staab II, dated May 23, 2011. Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 8-K filed May 25, 2011.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320001710/exh_1018.htm"><span style="color:#000000;">10.21&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320001710/exh_1018.htm"><span style="color:#000000;">Separation Agreement between BioCryst Pharmaceuticals, Inc. and Thomas R. Staab II, dated November 7, 2019.&#xa0;&#xa0;Incorporated by reference to Exhibit 10.18 to the Company's Form 10-K filed March 13, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231008004374/c74405exv10w27.htm"><span style="color:#000000;">10.22&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231008004374/c74405exv10w27.htm"><span style="color:#000000;">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and William P. Sheridan, dated June 12, 2008. Incorporated by reference to Exhibit 10.27 to the Company&#x2019;s Form 10-Q filed August 8, 2008.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514091609/d668682dex1010.htm"><span style="color:#000000;">10.23&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514091609/d668682dex1010.htm"><span style="color:#000000;">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Yarlagadda S. Babu, dated April 27, 2012. Incorporated by reference to Exhibit 10.10 to the Company&#x2019;s Form 10-K filed March 10, 2014.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514091609/d668682dex1011.htm"><span style="color:#000000;">10.24&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514091609/d668682dex1011.htm"><span style="color:#000000;">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Alane P. Barnes, dated August 8, 2013. Incorporated by reference to Exhibit 10.11 to the Company&#x2019;s Form 10-K filed March 10, 2014.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319005326/exh_101.htm"><span style="color:#000000;">10.25&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319005326/exh_101.htm"><span style="color:#000000;">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Megan Sniecinski, dated May 31, 2019.&#xa0;&#xa0;Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 10-Q filed August 8, 2019.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_230470.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(10.26)&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_230470.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Charles Gayer, dated January 14, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003557/exh_101.htm"><span style="color:#000000;">10.27&amp;</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320003557/exh_101.htm"><span style="color:#000000;">Employment Letter Agreement between BioCryst Pharmaceuticals, Inc. and Anthony Doyle, dated March 29, 2020.&#xa0;&#xa0;Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 10-Q filed May 11, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_230471.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(10.28)&#x2020;*</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_230471.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">License, Development and Commercialization Agreement dated as of February 28, 2007, by and between the Company and Shionogi &amp; Co., Ltd. Incorporated by reference to Exhibit 10.4 to the Company&#x2019;s Form 10-Q filed May 10, 2007.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">81</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
   <tbody>
    <tr style="vertical-align: top">
     <td style="width: 9%"><a href="ex_230463.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(10.29)&#x2020;*</span></a></td>
     <td style="width: 1%">&#xa0;</td>
     <td style="width: 90%"><a href="ex_230463.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">First Amendment to License, Development and Commercialization Agreement, effective as of September 30, 2008, between the Company and Shionogi &amp; Co., Ltd. Incorporated by reference to Exhibit 10.19 to the Company&#x2019;s Form 10-K filed March 6, 2009.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231007001618/c70922exv4w1.htm"><span style="color:#000000;">10.30</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000136231007001618/c70922exv4w1.htm"><span style="color:#000000;">Stock and Warrant Purchase Agreement dated as of August 6, 2007, by and among BioCryst Pharmaceuticals, Inc. and each of the Investors identified on the signature pages thereto. Incorporated by reference to Exhibit 4.1 of the Company&#x2019;s Form 8-K filed August 7, 2007.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095013405003342/d22636exv4w1.htm"><span style="color:#000000;">10.31</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095013405003342/d22636exv4w1.htm"><span style="color:#000000;">Stock Purchase Agreement, dated as of February&#xa0;17, 2005, by and among BioCryst Pharmaceuticals, Inc., Baker Bros. Investments, L.P., Baker Biotech Fund II, L.P., Baker Bros. Investments II, L.P., Baker Biotech Fund&#xa0;II (Z), L.P., Baker/Tisch Investments, L.P., Baker Biotech Fund III, L.P., Baker Biotech Fund&#xa0;I, L.P., Baker Biotech Fund&#xa0;III (Z), L.P. and 14159, L.P. Incorporated by reference to Exhibit 4.1 to the Company&#x2019;s Form 8-K filed February&#xa0;17, 2005.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_230489.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(10.32)&#x2020;*</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_230489.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">License Agreement dated as of June 27, 2000, by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., as amended by the First Amendment Agreement dated as of July 26, 2002 and the Second Amendment Agreement dated as of April 15, 2005.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_230490.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(10.33)&#x2020;*</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_230490.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">Third Amendment Agreement by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of December&#xa0;11, 2009.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095012310074183/g24253exv10w1.htm"><span style="color:#000000;">10.34#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095012310074183/g24253exv10w1.htm"><span style="color:#000000;">Fourth Amendment Agreement by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of May 5, 2010. Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 10-Q filed August 6, 2010. (Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_230492.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(10.35)&#x2020;*</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_230492.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">Fifth Amendment Agreement by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of November 17, 2011.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_230493.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(10.36)&#x2020;*</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_230493.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">Sixth Amendment Agreement by and among Albert Einstein College of Medicine, Industrial Research, Ltd. and BioCryst Pharmaceuticals, Inc., dated as of June 19, 2012.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315004473/exh_106.htm"><span style="color:#000000;">10.37</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315004473/exh_106.htm"><span style="color:#000000;">Novation Agreement among Albert Einstein College of Medicine of Yeshiva University, BioCryst Pharmaceuticals, Inc., Mundipharma International Corporation Limited, Callaghan Innovation Research Limited, and Victoria Link Limited, dated May 18, 2015.&#xa0;Incorporated by reference to Exhibit 10.6 to the Company&#x2019;s Form 10-Q filed August 7, 2015.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315004473/exh_107.htm"><span style="color:#000000;">10.38</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315004473/exh_107.htm"><span style="color:#000000;">Novation Agreement among Albert Einstein College of Medicine of Yeshiva University, BioCryst Pharmaceuticals, Inc., Callaghan Innovation Research Limited, and Victoria Link Limited, dated June 24, 2015.&#xa0;&#xa0;Incorporated by reference to Exhibit 10.7 to the Company&#x2019;s Form 10-Q filed August 7, 2015.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095012311046591/g27110exv10w1.htm"><span style="color:#000000;">10.39</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095012311046591/g27110exv10w1.htm"><span style="color:#000000;">Purchase and Sale Agreement, dated as of March 9, 2011 between BioCryst Pharmaceuticals, Inc. and JPR Royalty Sub LLC. Incorporated by reference to Exhibit 10.1 of the Company&#x2019;s Form 10-Q filed May 6, 2011.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095012311046591/g27110exv10w2.htm"><span style="color:#000000;">10.40</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095012311046591/g27110exv10w2.htm"><span style="color:#000000;">Pledge and Security Agreement, dated as of March 9, 2011 between BioCryst Pharmaceuticals, Inc. and U.S. Bank National Association, as trustee. Incorporated by reference to Exhibit 10.2 of the Company&#x2019;s Form 10-Q filed May 6, 2011.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095012311046591/g27110exv10w3.htm"><span style="color:#000000;">10.41</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000095012311046591/g27110exv10w3.htm"><span style="color:#000000;">Confirmation of terms and conditions of ISDA Master Agreement, dated as of March 7, 2011, between Morgan Stanley Capital Services Inc. and BioCryst Pharmaceuticals, Inc. dated as of March 9, 2011. Incorporated by reference to Exhibit 10.3 of the Company&#x2019;s Form 10-Q filed May 6, 2011.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312513434942/d605961dex102.htm"><span style="color:#000000;">10.42#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312513434942/d605961dex102.htm"><span style="color:#000000;">Agreement, dated as of September&#xa0;12, 2013, between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases. Incorporated by reference to Exhibit 10.2 of the Company&#x2019;s Form 10-Q filed November&#xa0;8, 2013. (Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514091609/d668682dex1051.htm"><span style="color:#000000;">10.43#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514091609/d668682dex1051.htm"><span style="color:#000000;">Amendment #1 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated December 26, 2013.&#xa0;Incorporated by reference to Exhibit 10.51 to the Company&#x2019;s Form 10-K filed on March 10, 2014.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">82</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
   <tbody>
    <tr style="vertical-align: top">
     <td style="width: 9%"><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514091609/d668682dex1052.htm"><span style="color:#000000;">10.44#</span></a></td>
     <td style="width: 1%">&#xa0;</td>
     <td style="width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/882796/000119312514091609/d668682dex1052.htm"><span style="color:#000000;">Amendment #2 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated January 24, 2014.&#xa0;Incorporated by reference to Exhibit 10.52 to the Company&#x2019;s Form 10-K filed on March 10, 2014.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184314003839/exh_105.htm"><span style="color:#000000;">10.45#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184314003839/exh_105.htm"><span style="color:#000000;">Amendment #3 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 17, 2014. Incorporated by reference to Exhibit 10.5 to the Company&#x2019;s Form 10-Q filed on August 8, 2014.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184314003839/exh_106.htm"><span style="color:#000000;">10.46#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184314003839/exh_106.htm"><span style="color:#000000;">Amendment #4 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 17, 2014. Incorporated by reference to Exhibit 10.6 to the Company&#x2019;s Form 10-Q filed on August 8, 2014.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184314005367/exh_101.htm"><span style="color:#000000;">10.47#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184314005367/exh_101.htm"><span style="color:#000000;">Amendment #5 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated August 11, 2014. Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 10-Q filed on November 7, 2014.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184314005367/exh_102.htm"><span style="color:#000000;">10.48#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184314005367/exh_102.htm"><span style="color:#000000;">Amendment #6 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated August 27, 2014.&#xa0;Incorporated by reference to Exhibit 10.2 to the Company&#x2019;s Form 10-Q filed on November 7, 2014.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184314005367/exh_103.htm"><span style="color:#000000;">10.49#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184314005367/exh_103.htm"><span style="color:#000000;">Amendment #8 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated September 17, 2014.&#xa0;Incorporated by reference to Exhibit 10.3 to the Company&#x2019;s Form 10-Q filed on November 7, 2014.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184314005367/exh_104.htm"><span style="color:#000000;">10.50#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184314005367/exh_104.htm"><span style="color:#000000;">Amendment #9 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated October 29, 2014.&#xa0;Incorporated by reference to Exhibit 10.4 to the Company&#x2019;s Form 10-Q filed on November 7, 2014.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315004473/exh_102.htm"><span style="color:#000000;">10.51#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315004473/exh_102.htm"><span style="color:#000000;">Amendment #10 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated February 13, 2015.&#xa0;Incorporated by reference to Exhibit 10.2 to the Company&#x2019;s Form 10-Q filed on August 7, 2015.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315004473/exh_103.htm"><span style="color:#000000;">10.52#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315004473/exh_103.htm"><span style="color:#000000;">Amendment #11 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated March 19, 2015.&#xa0;Incorporated by reference to Exhibit 10.3 to the Company&#x2019;s Form 10-Q filed on August 7, 2015.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315004473/exh_104.htm"><span style="color:#000000;">10.53#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315004473/exh_104.htm"><span style="color:#000000;">Amendment #12 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 12, 2015.&#xa0;Incorporated by reference to Exhibit 10.4 to the Company&#x2019;s Form 10-Q filed on August 7, 2015.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315004473/exh_105.htm"><span style="color:#000000;">10.54#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315004473/exh_105.htm"><span style="color:#000000;">Amendment #13 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 17, 2015.&#xa0;Incorporated by reference to Exhibit 10.5 to the Company&#x2019;s Form 10-Q filed on August 7, 2015.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315006102/exh_103.htm"><span style="color:#000000;">10.55#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315006102/exh_103.htm"><span style="color:#000000;">Amendment #14 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated September 16, 2015.&#xa0;Incorporated by reference to Exhibit 10.3 to the Company&#x2019;s Form 10-Q filed on November 6, 2015.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316008207/exh_1070.htm"><span style="color:#000000;">10.56</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316008207/exh_1070.htm"><span style="color:#000000;">Amendment #15 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated November 16, 2015. Incorporated by reference to Exhibit 10.70 to the Company&#x2019;s Form 10-K filed on February 26, 2016.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316008207/exh_1071.htm"><span style="color:#000000;">10.57#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316008207/exh_1071.htm"><span style="color:#000000;">Amendment #16 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated December 18, 2015. Incorporated by reference to Exhibit 10.71 to the Company&#x2019;s Form 10-K filed on February 26, 2016. (Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317001159/exh_1074.htm"><span style="color:#000000;">10.58</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317001159/exh_1074.htm"><span style="color:#000000;">Amendment #17 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated April 18, 2016. Incorporated by reference to Exhibit 10.74 to the Company&#x2019;s Form 10-K filed on February 27, 2017.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">83</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
   <tbody>
    <tr style="vertical-align: top">
     <td style="width: 9%"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316011576/exh_103.htm"><span style="color:#000000;">10.59#</span></a></td>
     <td style="width: 1%">&#xa0;</td>
     <td style="width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316011576/exh_103.htm"><span style="color:#000000;">Amendment #18 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated June 30, 2016. Incorporated by reference to Exhibit 10.3 to the Company&#x2019;s Form 10-Q filed on August 8, 2016. (Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316013033/exh_101.htm"><span style="color:#000000;">10.60#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316013033/exh_101.htm"><span style="color:#000000;">Amendment #19 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated August 10, 2016. Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 10-Q filed on November 8, 2016. (Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317001159/exh_1077.htm"><span style="color:#000000;">10.61#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317001159/exh_1077.htm"><span style="color:#000000;">Amendment #20 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated January 9, 2017. Incorporated by reference to Exhibit 10.77 to the Company&#x2019;s Form 10-K filed on February 27, 2017.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184318003719/exh_101.htm"><span style="color:#000000;">10.62#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184318003719/exh_101.htm"><span style="color:#000000;">Amendment #21 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated March 21, 2018. Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 10-Q filed on May 9, 2018. (Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184318007788/exh_103.htm"><span style="color:#000000;">10.63</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184318007788/exh_103.htm"><span style="color:#000000;">Amendment #22 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated September 10, 2018. Incorporated by reference to Exhibit 10.3 to the Company&#x2019;s Form 10-Q filed November 8, 2018.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320007740/ex_211509.htm"><span style="color:#000000;">10.64</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320007740/ex_211509.htm"><span style="color:#000000;">Amendment #23 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated August 21, 2020.&#xa0;&#xa0;Incorporated by reference to Exhibit 10.2 to the Company&#x2019;s Form 10-Q filed November 6, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320007740/ex_211510.htm"><span style="color:#000000;">10.65</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320007740/ex_211510.htm"><span style="color:#000000;">Amendment #23 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated September 14, 2020.&#xa0;&#xa0;Incorporated by reference to Exhibit 10.3 to the Company&#x2019;s Form 10-Q filed November 6, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320007740/ex_211511.htm"><span style="color:#000000;">10.66&#x2020;*</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320007740/ex_211511.htm"><span style="color:#000000;">Agreement, dated September 1, 2020, between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases.&#xa0;&#xa0;Incorporated by reference to Exhibit 10.4 to the Company&#x2019;s Form 10-Q filed November 6, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320007740/ex_211512.htm"><span style="color:#000000;">10.67&#x2020;*</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320007740/ex_211512.htm"><span style="color:#000000;">Amendment #1 to the Agreement between BioCryst Pharmaceuticals, Inc. and the National Institute of Allergy and Infectious Diseases, dated October 14, 2020.&#xa0;&#xa0;Incorporated by reference to the Company&#x2019;s Form 10-Q filed November 6, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315002688/exh_102.htm"><span style="color:#000000;">10.68#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315002688/exh_102.htm"><span style="color:#000000;">Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, dated March 27, 2015. Incorporated by reference to Exhibit 10.2 to the Company&#x2019;s Form 10-Q filed on May 8, 2015.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315004473/exh_101.htm"><span style="color:#000000;">10.69#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315004473/exh_101.htm"><span style="color:#000000;">Amendment #1 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness and Response, dated June 2, 2015.&#xa0;Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 10-Q filed on August 7, 2015.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315006102/exh_101.htm"><span style="color:#000000;">10.70#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315006102/exh_101.htm"><span style="color:#000000;">Amendment #2 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness and Response, dated July 8, 2015. Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 10-Q filed on November 6, 2015.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315006102/exh_102.htm"><span style="color:#000000;">10.71#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184315006102/exh_102.htm"><span style="color:#000000;">Amendment #3 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness and Response, dated August 25, 2015. Incorporated by reference to Exhibit 10.2 to the Company&#x2019;s Form 10-Q filed on November 6, 2015.&#xa0;(Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316009811/exh_101.htm"><span style="color:#000000;">10.72#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316009811/exh_101.htm"><span style="color:#000000;">Amendment #4 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness and Response, dated February 25, 2016. Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 10-Q filed on May 9, 2016. (Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">84</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
   <tbody>
    <tr style="vertical-align: top">
     <td style="width: 9%"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316011576/exh_101.htm"><span style="color:#000000;">10.73#</span></a></td>
     <td style="width: 1%">&#xa0;</td>
     <td style="width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316011576/exh_101.htm"><span style="color:#000000;">Amendment #5 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness and Response, dated April 11, 2016. Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 10-Q filed on August 8, 2016. (Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316011576/exh_102.htm"><span style="color:#000000;">10.74#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316011576/exh_102.htm"><span style="color:#000000;">Amendment #6 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness and Response, dated May 20, 2016. Incorporated by reference to Exhibit 10.2 to the Company&#x2019;s Form 10-Q filed on August 8, 2016. (Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316013033/exh_102.htm"><span style="color:#000000;">10.75#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184316013033/exh_102.htm"><span style="color:#000000;">Amendment #7 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness and Response, dated September 26, 2016. Incorporated by reference to Exhibit 10.2 to the Company&#x2019;s Form 10-Q filed on November 8, 2016. (Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317006746/exh_101.htm"><span style="color:#000000;">10.76</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317006746/exh_101.htm"><span style="color:#000000;">Amendment #8 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness and Response, dated September 20, 2017. Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 10-Q filed on November 8, 2017.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184318001855/exh_1088.htm"><span style="color:#000000;">10.77#</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184318001855/exh_1088.htm"><span style="color:#000000;">Amendment #9 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness and Response, dated December 1, 2017. Incorporated by reference to Exhibit 10.88 to the Company&#x2019;s Form 10-K filed on March 12, 2018.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184318007788/exh_101.htm"><span style="color:#000000;">10.78</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184318007788/exh_101.htm"><span style="color:#000000;">Amendment #10 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness and Response, dated March 19, 2018. Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 10-Q filed on November 8, 2018.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184318007788/exh_102.htm"><span style="color:#000000;">10.79</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184318007788/exh_102.htm"><span style="color:#000000;">Amendment #11 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness and Response, dated September 20, 2018. Incorporated by reference to Exhibit 10.2 to the Company&#x2019;s Form 10-Q filed on November 8, 2018. (Portions omitted pursuant to request for confidential treatment.)</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320005753/ex_196806.htm"><span style="color:#000000;">10.80&#x2020;*</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320005753/ex_196806.htm"><span style="color:#000000;">Amendment #12 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness Response, dated April 17, 2020.&#xa0;&#xa0;Incorporated by reference to Exhibit 10.3 to the Company&#x2019;s Form 10-Q filed August 7, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320007740/ex_211515.htm"><span style="color:#000000;">10.81</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320007740/ex_211515.htm"><span style="color:#000000;">Amendment #13 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness Response, dated September 29, 2020.&#xa0;&#xa0;Incorporated by reference to Exhibit 10.8 to the Company&#x2019;s Form 10-Q filed November 6, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_230494.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(10.82)</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_230494.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">Amendment #14 to the Agreement between BioCryst Pharmaceuticals, Inc. and the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services&#x2019; Office of the Assistant Secretary for Preparedness Response, dated November 24, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317001617/exh_101.htm"><span style="color:#000000;">10.83</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184317001617/exh_101.htm"><span style="color:#000000;">Registration Rights Agreement, dated March 15, 2017, by and between BioCryst Pharmaceuticals, Inc. 667, L.P., and Baker Brothers Life Sciences, L.P. Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 8-K filed March 17, 2017.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000110465918003194/a18-3548_1ex10d1.htm"><span style="color:#000000;">10.84</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000110465918003194/a18-3548_1ex10d1.htm"><span style="color:#000000;">Amendment to the Registration Rights Agreement, dated January 21, 2018, by and among BioCryst Pharmaceuticals, Inc., 667, L.P. and Baker Brothers Life Sciences, L.P. Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 8-K filed January 22, 2018.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000114036119020989/ex10_1.htm"><span style="color:#000000;">10.85</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000114036119020989/ex10_1.htm"><span style="color:#000000;">Securities Purchase Agreement, dated November 19, 2019, among BioCryst Pharmaceuticals, Inc., Baker Brothers Life Sciences, L.P. and 667, L.P. Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 8-K filed on November 20, 2019.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">85</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; border-collapse: collapse; font-size: 10pt">
   <tbody>
    <tr style="vertical-align: top">
     <td style="width: 9%"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184318006425/exh_101.htm"><span style="color:#000000;">10.86</span></a></td>
     <td style="width: 1%">&#xa0;</td>
     <td style="width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184318006425/exh_101.htm"><span style="color:#000000;">Agreement dated as of September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the Centers for Disease Control and Prevention. Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 8-K filed on September 6, 2018.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_230497.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(10.87)</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_230497.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">Amendment #1 to Agreement between BioCryst Pharmaceuticals, Inc. and the Centers for Disease Control and Prevention, dated October 1, 2018, assigning contract administration to ASPR-BARDA within the U.S. Department of Health and Human Services.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319006137/exh_101.htm"><span style="color:#000000;">10.88</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184319006137/exh_101.htm"><span style="color:#000000;">Amendment #2 to Agreement between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services, dated September 23, 2019. Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 8-K filed on September 26, 2019.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320006249/exh_101.htm"><span style="color:#000000;">10.89</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320006249/exh_101.htm"><span style="color:#000000;">Amendment #3, dated August 31, 2020, to the Contract dated September 1, 2018 between BioCryst Pharmaceuticals, Inc. and the U.S. Department of Health and Human Services.&#xa0;&#xa0;Incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Form 8-K filed September 3, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320001710/exh_1083.htm"><span style="color:#000000;">10.90&#x2020;*</span></a></td>
     <td>&#xa0;</td>
     <td><a href="http://www.sec.gov/Archives/edgar/data/882796/000117184320001710/exh_1083.htm"><span style="color:#000000;">Commercialization and License Agreement dated as of November 5, 2019 between BioCryst Pharmaceuticals, Inc. and Torii Pharmaceutical Co., Ltd.&#xa0;&#xa0;Incorporated by reference to Exhibit 10.83 to the Company's Form 10-K filed March 13, 2020.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_230714.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(10.91)&#x2020;*</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_230714.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">Purchase and Sale Agreement, dated as of December 7, 2020, between BioCryst Pharmaceuticals, Inc. and RPI 2019 Intermediate Finance Trust.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_230719.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(10.92)&#x2020;*</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_230719.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">Credit Agreement, dated as of December 7, 2020, among BioCryst Pharmaceuticals, Inc., as borrower, BioCryst Ireland Limited, as a guarantor, the other guarantors from time to time party thereto, the lenders from time to time party thereto, and Athyrium Opportunities III Co-Invest 1 LP, as lender and as administrative agent for the lenders.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_230510.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(21)</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_230510.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">Subsidiaries of the Registrant.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_227978.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(23)</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_227978.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_227979.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(31.1)</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_227979.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_227980.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(31.2)</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_227980.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_227981.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(32.1)</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_227981.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><a href="ex_227982.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">(32.2)</span></a></td>
     <td>&#xa0;</td>
     <td><a href="ex_227982.htm" style="-sec-extract:exhibit;"><span style="color:#000000;">Certification of the Chief Financial Officer pursuant to 18.U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.</span></a></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><span style="color:#000000;">(101)</span></td>
     <td>&#xa0;</td>
     <td><span style="color:#000000;">Financial statements from the Annual Report on Form 10-K of BioCryst Pharmaceuticals, Inc. for the fiscal year ended December 31, 2020, formatted in Inline XBRL:&#xa0;&#xa0;(i) Consolidated Balance Sheets, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Cash Flows, (iv) Consolidated Statements of Stockholders&#x2019; Equity and (v) Notes to Consolidated Financial Statements.</span></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><span style="color:#000000;">(104)</span></td>
     <td>&#xa0;</td>
     <td><span style="color:#000000;">Cover Page Interactive Data File &#x2013; The cover page from this annual report on Form 10-K for the fiscal year ended December 31, 2020 is formatted in Inline XBRL (contained in Exhibit 101).</span></td>
    </tr>

    <tr style="vertical-align: top">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: top">
     <td><span style="color:#000000;">#</span></td>
     <td>&#xa0;</td>
     <td><span style="color:#000000;">Confidential treatment granted.</span></td>
    </tr>

    <tr style="vertical-align: top">
     <td><span style="color:#000000;">&#x2020;</span></td>
     <td>&#xa0;</td>
     <td><span style="color:#000000;">Portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K.&#xa0;&#xa0;The Company agrees to furnish to the Securities and Exchange Commission a copy of any omitted portions of the exhibit upon request.</span></td>
    </tr>

    <tr style="vertical-align: top">
     <td><span style="color:#000000;">*</span></td>
     <td>&#xa0;</td>
     <td><span style="color:#000000;">Certain identified information has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the Company if publicly disclosed.</span></td>
    </tr>

    <tr style="vertical-align: top">
     <td><span style="color:#000000;">&amp;</span></td>
     <td>&#xa0;</td>
     <td><span style="color:#000000;">Management contracts.</span></td>
    </tr>

    <tr style="vertical-align: top">
     <td><span style="color:#000000;">( )</span></td>
     <td>&#xa0;</td>
     <td><span style="color:#000000;">Filed herewith.</span></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:justify;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:justify;"><span style="color:#000000;"><b><a id="i16" title="i16" href="#"></a>ITEM 16.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</b><b><i>FORM 10-K SUMMARY.</i></b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:justify;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:justify;"><span style="color:#000000;">None.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">86</span>
     </div>
    </div>
   </div>
   <hr />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><a id="sig" title="sig" href="#"></a>SIGNATURES</b></span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March 1, 2021.</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;">BIOCRYST PHARMACEUTICALS, INC.</span></p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">By:</span></p> </td>
     <td style="vertical-align: bottom; border-bottom: 1px solid rgb(0, 0, 0); width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">/s/ Jon P. Stonehouse</span></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Jon P. Stonehouse</span></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i>Chief Executive Officer</i></span></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on March 1, 2021:</span></p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:98.5%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><span style="text-decoration: underline; ">Signature</span></b></span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><span style="text-decoration: underline; ">Title(s)</span></b></span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">/s/ Jon P. Stonehouse</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">President, Chief Executive Officer and Director</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Jon P. Stonehouse</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">(Principal Executive Officer)</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">/s/ Anthony Doyle</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Senior Vice President and Chief Financial Officer</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Anthony Doyle</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">(Principal Financial Officer)</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">/s/ Michael L. Jones</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Executive Director, Finance and Principal Accounting Officer</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Michael L. Jones</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">(Principal Accounting Officer)</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">/s/ George B. Abercrombie</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Director</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">George B. Abercrombie</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">/s/ Stephen Aselage</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Director</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Stephen Aselage</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">/s/ Theresa Heggie</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Director</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Theresa Heggie</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">/s/ Nancy Hutson</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Director</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Nancy Hutson, Ph.D.</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">/s/ Robert A. Ingram</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Director</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Robert A. Ingram</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">/s/ Kenneth B. Lee, Jr.</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Director</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Kenneth B. Lee, Jr.</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">/s/ Alan G. Levin</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Director</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Alan G. Levin</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom:solid 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#xa0;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">/s/ Helen Thackray</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;">Director</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;border-bottom: 1px #000000;;width:39.3%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Helen Thackray, M.D.</span></p> </td>
     <td style="vertical-align:top;width:9.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:51.1%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b>&#xa0;</b></span></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;">&#xa0;</p>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">
      <span style="color:#000000;">87</span>
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex_230468.htm
<DESCRIPTION>EXHIBIT 4.1
<TEXT>
<html><head>
	<title>ex_230468.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:right;"><b>Exhibit 4.1</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>DESCRIPTION OF SECURITIES</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;text-indent:36pt;"><i>BioCryst Pharmaceuticals, Inc. (&#8220;BioCryst&#8221; or the &#8220;Company&#8221;) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).&nbsp; BioCryst&#8217;s common stock is registered under Section 12(b) of the Exchange Act and is listed on The Nasdaq Stock Market LLC (Nasdaq Global Select Market) under the symbol &#8220;BCRX&#8221;.</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;text-indent:36pt;"><i>The following is a summary of the material terms of BioCryst&#8217;s capital stock.&nbsp; This summary is not complete and is qualified in its entirety by reference to the Company&#8217;s Third Restated Certificate of Incorporation, as amended (the &#8220;Certificate of Incorporation&#8221;), and the Company&#8217;s Amended and Restated Bylaws, as amended (the &#8220;Bylaws&#8221;), each of which is filed as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.1 is a part.</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;"><b>Authorized Capital Stock</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;text-indent:36pt;">Under the Certificate of Incorporation, BioCryst is currently authorized to issue up to 450,000,000 shares of common stock, par value $0.01 per share (&#8220;Common Stock&#8221;), and 5,000,000 shares of preferred stock, par value $0.01 per share (&#8220;Preferred Stock&#8221;). The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the capital stock of the Company entitled to vote.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;"><b>Common Stock</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;text-indent:36pt;">Holders of Common Stock are entitled to one vote per share on all matters submitted to a vote of stockholders. There are no cumulative voting rights. Directors are elected by a plurality of the votes cast by the stockholders entitled to vote. Except as provided otherwise in the Certificate of Incorporation, the Bylaws, or the General Corporation Law of the State of Delaware (the &#8220;DGCL&#8221;), the holders of a majority of the Common Stock present in person or represented by proxy and voting on a matter shall decide any matter to be voted upon by the stockholders at a meeting.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;text-indent:36pt;">Holders of Common Stock have the right to receive dividends as and when declared by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) from funds legally available therefor, subject to any preferential dividend rights of any Preferred Stock then outstanding. BioCryst has never paid cash dividends on its Common Stock.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;text-indent:36pt;">&nbsp;Upon the Company&#8217;s dissolution or liquidation, whether voluntary or involuntary, holders of Common Stock are entitled to receive all assets legally available for distribution to stockholders, subject to any preferential rights of any Preferred Stock then outstanding. Holders of Common Stock have no preemptive rights and have no rights to convert their Common Stock into any other securities. There are no redemption or sinking fund provisions applicable to the Common Stock. All outstanding shares of Common Stock are validly issued, fully paid and nonassessable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;"><b>Anti-Takeover Provisions</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;text-indent:36pt;">Some provisions of the Certificate of Incorporation, the Bylaws, and DGCL may have the effect of delaying, discouraging, or preventing a change in control of the Company or changes in its management. Pursuant to the Certificate of Incorporation and the Bylaws:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:39pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">the Board is authorized to issue &#8220;blank check&#8221; preferred stock without further stockholder approval;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:39pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">the Board is classified, with members thereof serving staggered three-year terms;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:39pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">stockholders may not cumulate votes in the election of directors;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:39pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">vacancies on the Board may be filled only by the Board;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:39pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">stockholders may remove directors only for cause and only by the affirmative vote of the holders of at least 75 percent of the total number of votes entitled to be cast by the holders of all of the shares of the Company&#8217;s capital stock then entitled to vote generally in the election of directors (a &#8220;supermajority vote&#8221;);</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:39pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">stockholders may take action only at a duly called meeting of the stockholders, and stockholders are not permitted to act by written consent;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:39pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">special meetings of stockholders may be called only by the Board; and</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:39pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">stockholders must satisfy advance notice procedures to submit proposals or nominate directors for consideration at a stockholders meeting.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;text-indent:36pt;">A supermajority vote is required to amend Article NINTH and Article TENTH of the Certificate of Incorporation, which pertain to the number, classification, and removal of the Company&#8217;s directors, the creation and filling of vacancies on the Board, the requirement that actions of stockholders be taken at a duly called meeting and not by written consent, and the requirement that special meetings only be called by the Board.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In addition, BioCryst is subject to the provisions of Section 203 of the DGCL. In general, the statute prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date that the person became an interested stockholder unless, with some exceptions, the business combination or the transaction in which the person became an interested stockholder is approved in a prescribed manner. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the stockholder, and an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns (or within three years prior, did own) 15% or more of the corporation&#8217;s outstanding voting stock. This provision may have the effect of delaying, deferring, or preventing a change in control without further action by the stockholders.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;"><b>Exclusive Forum for Certain Actions</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;text-indent:36pt;">The Bylaws also provide that unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: &nbsp;(i) any derivative action or proceeding brought on the Company&#8217;s behalf; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of the Company&#8217;s directors, officers, stockholders, employees, or agents to the Company or to the Company&#8217;s stockholders; (iii) any action asserting a claim against the Company or any of its directors, officers, stockholders, employees, or agents arising out of or relating to any provision of the DGCL, the Certificate of Incorporation, or the Bylaws; or (iv) any action against the Company or any of its directors, officers, stockholders, employees, or agents governed by the internal affairs doctrine of the State of Delaware. The Bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of Common Stock will be deemed to have notice of, and to have consented to, this choice of forum provision.&nbsp; This exclusive forum provision may limit a stockholder&#8217;s ability to choose its preferred judicial forum for disputes with the Company or the Company&#8217;s directors, officers, employees, or agents.&nbsp; This exclusive forum provision does not apply to establish the Delaware Court of Chancery as the forum for actions or proceedings brought to enforce a duty or liability created by the Securities Act of 1933, as amended, or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>3
<FILENAME>ex_230469.htm
<DESCRIPTION>EXHIBIT 10.16
<TEXT>
<html><head>
	<title>ex_230469.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 10.16</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>INDUCEMENT EQUITY INCENTIVE PLAN</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>NOTICE OF GRANT OF STOCK OPTION</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">Notice is hereby given of the following stock option grant (the &#8220;Option&#8221;) to purchase shares of the Common Stock of BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) pursuant to the Company&#8217;s Inducement Equity Incentive Plan (the &#8220;Plan&#8221;):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="margin-left:1.4%;width:86.7%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:11.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:30.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:8.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:49%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:11.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:30.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Optionee:</u></p>
			</td>
			<td style="vertical-align:bottom;width:8.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:49%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:11.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:30.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:8.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:49%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:11.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:30.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Grant Date:</u></p>
			</td>
			<td style="vertical-align:bottom;width:8.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:49%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:11.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:30.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:8.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:49%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:11.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:30.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Option Price:</u></p>
			</td>
			<td style="vertical-align:bottom;width:8.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:49%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:11.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:30.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:8.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:49%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:11.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:30.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Number of Optioned Shares:</u></p>
			</td>
			<td style="vertical-align:bottom;width:8.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:49%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:11.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:30.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:8.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:49%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:11.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:30.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Option Expiration Date:</u></p>
			</td>
			<td style="vertical-align:bottom;width:8.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:49%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:11.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:30.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:8.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:49%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:11.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:30.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Type of Option:</u></p>
			</td>
			<td style="vertical-align:bottom;width:8.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:top;width:49%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Non-Statutory Stock Option (NSO)</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"><u>Exercise Schedule / Vesting Terms</u>:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">Optionee understands that the Option is granted subject to and in accordance with the express terms and conditions of the Plan and agrees to be bound by and conform to the terms and conditions of the Plan, the Plan Prospectus, this Notice of Grant of Stock Option and its accompanying Stock Option Agreement. Optionee acknowledges that copies of the Plan, the Plan Prospectus, and the Stock Option Agreement are available to Optionee on the Company&#8217;s intranet and have been made available to Optionee.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"><u>No Employment or Service Contract</u>. Nothing in the Option Agreement or the Plan shall confer upon the Optionee the right to continue in the Service of the Company for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company or the Optionee, which rights are hereby expressly reserved by each, to terminate Optionee&#8217;s Service at any time for any reason whatsoever, with or without cause.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">By my signature below, I hereby acknowledge receipt of this Option granted on the Grant Date specified above and issued to me under the terms and conditions of the Plan.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="1" style="vertical-align: bottom; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align: bottom; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Optionee:</p>
			</td>
			<td style="vertical-align: bottom; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
			<td colspan="3" rowspan="1" style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Address:</p>
			</td>
			<td style="vertical-align: bottom; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></td>
			<td colspan="1" style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></td>
			<td colspan="1" style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name:</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: bottom; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="1" style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Dated:</p>
			</td>
			<td style="vertical-align: bottom; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></td>
			<td colspan="1" style="vertical-align: top; width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title:</p>
			</td>
			<td colspan="2" style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></td>
		</tr>

</table>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>BIOCRYST PHARMACEUTICALS, INC.</b><br>
<u><b>STANDARD STOCK OPTION AGREEMENT<br>
INDUCEMENT EQUITY INCENTIVE PLAN<br>
WITNESSETH:</b></u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:justify;"><u><b>RECITALS</b></u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Board of Directors of BioCryst Pharmaceuticals, Inc. (the &#8220;<u>Company</u>&#8221;) has adopted the Company&#8217;s Inducement Equity Incentive Plan (the &#8220;<u>Plan</u>&#8221;) for the purpose of attracting and retaining the services of selected prospective employees who are expected to contribute to the financial success of the Company or its parent or subsidiary corporations.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Optionee is an individual who is expected to render valuable services to the Company or its parent or subsidiary corporations, and this Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Company&#8217;s grant of a stock option to Optionee.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: justify; text-indent: 18pt;">NOW, THEREFORE, it is hereby agreed as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u><b>Grant of Option</b></u><b>. </b>Subject to and upon the terms and conditions set forth in this Agreement, the Company hereby grants to Optionee, as of the grant date (the &#8220;<u>Grant Date</u>&#8221;) specified in the accompanying Notice of Grant of Stock Option (the &#8220;<u>Grant Notice</u>&#8221;), a stock option to purchase up to that number of shares of the Company&#8217;s Common Stock (the &#8220;<u>Optioned Shares</u>&#8221;) specified in the Grant Notice. The Optioned Shares shall be purchasable from time to time during the option term at the option price per share (the &#8220;<u>Option Price</u>&#8221;) specified in the Grant Notice.&nbsp; The option is a nonqualified stock option.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u><b>Option Term</b></u><b>. </b>This option shall expire at the close of business on the Expiration Date specified in the Grant Notice, unless sooner terminated in accordance with Paragraph 5 or 6 of this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u><b>Limited Transferability</b></u><b>. </b>During the lifetime of the Optionee, this option shall be exercisable only by the Optionee and shall not be assignable or transferable by the Optionee except for a transfer by will or by the laws of descent and distribution following the Optionee&#8217;s death. Notwithstanding the foregoing, this option may, in connection with the Optionee&#8217;s estate plan, be assigned in whole or in part during the Optionee&#8217;s lifetime either as (i) as a gift to one or more members of Optionee&#8217;s immediate family, to a trust in which Optionee and/or one or more such family members hold more than fifty percent (50%) of the beneficial interest or an entity in which more than fifty percent (50%) of the voting interests are owned by Optionee and/or one or more such family members, or (ii) pursuant to a domestic relations order. The assigned portion shall be exercisable only by the person or persons who acquire a proprietary interest in the option pursuant to such assignment. The terms applicable to the assigned portion shall be the same as those in effect for this option immediately prior to such assignment and shall be set forth in such documents issued to the assignee as the Plan Administrator may deem appropriate.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u><b>Exercisability</b></u><b>. </b>This option shall become exercisable for the Optioned Shares in installments as is specified in the Grant Notice. As the option becomes exercisable for one or more installments, the installments shall accumulate and the option shall remain exercisable for the accumulated installments until the Expiration Date or the sooner termination of the option term under this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u><b>Acceleration; Termination</b></u><b>. </b>The option term specified in Paragraph 2 shall terminate (and this option shall cease to be exercisable) prior to the Expiration Date should one of the following provisions become applicable:</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 27pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Except to the extent otherwise provided in subparagraphs (ii) through (v) below, should optionee cease to remain in Service at any time during the option term, then the period for exercising this option shall be reduced to a three (3)-month period commencing with the date of such cessation of Service, but in no event shall this option be exercisable at any time after the Expiration Date. Upon the expiration of such three (3)-month period or (if earlier) upon the Expiration Date, this option shall terminate and cease to be outstanding. However, should Optionee die during the three (3)-month period following his or her cessation of Service, the personal representative of the Optionee&#8217;s estate or the person or persons to whom this option is transferred pursuant to the Optionee&#8217;s will or in accordance with the laws of descent or distribution shall have a twelve (12)-month period following the date of the Optionee&#8217;s death during which to exercise this Option.</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 27pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should Optionee, after completing five (5) full years of Service, die while in Service, then the exercisability of each of his or her outstanding options shall automatically accelerate so that each such option shall become fully exercisable with respect to the total number of Optioned Shares at the time subject to such option and may be exercised for all or any portion of such shares.&nbsp; The personal representative of the Optionee&#8217;s estate or the person or persons to whom this option is transferred pursuant to the Optionee&#8217;s will or in accordance with the laws of descent and distribution shall have a twelve (12)-month period following the date of the Optionee&#8217;s death during which to exercise this option, but in no event shall this option be exercisable at any time after the Expiration Date.</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 27pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should Optionee die while in Service prior to completing five (5) full years of Service, then the period for which each outstanding vested option held by the Optionee at the time of death shall be exercisable by the Optionee&#8217;s estate or the person or persons to whom the option is transferred pursuant to the Optionee&#8217;s will shall be limited to the twelve (12)-month period following the date of the Optionee&#8217;s death, but in no event shall this option be exercisable at any time after the Expiration Date.</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 27pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: 27pt; text-align: justify;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should Optionee become permanently disabled (as defined in Section 22(e)(3) of the Internal Revenue Code) and cease by reason thereof to remain in Service at any time during the option term, then the period for exercising this option shall be reduced to a twelve (12)-month period commencing with the date of such cessation of Service, but in no event shall this option be exercisable at any time after the Expiration Date. Upon the expiration of such twelve (12)-month period or (if earlier) upon the Expiration Date, this option shall terminate and cease to be outstanding.</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-indent: 27pt; text-align: justify;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Should (A) the Optionee&#8217;s Service be terminated for misconduct (including, but not limited to, any act of dishonesty, willful misconduct, fraud or embezzlement) or (B) the Optionee make any unauthorized use or disclosure of confidential information or trade secrets of the Company or its parent or subsidiary corporations, then in any such event this option (vested and unvested) shall terminate immediately and cease to be exercisable.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-indent: 27pt; text-align: justify;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the limited period of exercisability applicable in accordance with subparagraphs (i) through (iv) above, this option may not be exercised for more than the number of the Optioned Shares (if any) for which this option is, at the time of the Optionee&#8217;s cessation of Service, exercisable in accordance with the exercise provisions specified in this Agreement and the Grant Notice.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-indent: 27pt; text-align: justify;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For purposes of this Paragraph 5 and for all other purposes under this Agreement, the following definitional provisions shall be in effect:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 108pt; text-align: justify;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Optionee shall be deemed to remain in Service for so long as the Optionee continues to render periodic services to the Company or any parent or subsidiary corporation, whether as an Employee, a non-employee member of the Company&#8217;s Board of Directors or an independent consultant or advisor.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 108pt; text-align: justify;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Optionee shall be deemed to be an Employee and to continue in the Company&#8217;s employ for so long as the Optionee remains in the employ of the Company or one or more of its parent or subsidiary corporations, subject to the control and direction of the employer entity as to both the work to be performed and the manner and method of performance.&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 108pt; text-align: justify;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A corporation shall be considered to be a subsidiary corporation of the Company if it is a member of an unbroken chain of corporations beginning with the Company, provided each such corporation in the chain (other than the last corporation) owns, at the time of determination, stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 108pt; text-align: justify;">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A corporation shall be considered to be a parent corporation of the Company if it is a member of an unbroken chain ending with the Company, provided each such corporation in the chain (other than the Company) owns, at the time of determination, stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u><b>Corporate Transaction</b></u><b>.</b>&nbsp; In the event of a Corporate Transaction or a Change in Control, the option shall be treated as specified in the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u><b>Adjustment in Optioned Shares.</b></u></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: 45pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the event any change is made to the Common Stock issuable under the Plan by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares, or other change affecting the outstanding Common Stock as a class without receipt of consideration, then appropriate adjustments shall be made to (i) the total number and/or class of Optioned Shares subject to this option and (ii) the Option Price payable per share in order to reflect such change and thereby preclude a dilution or enlargement of benefits hereunder.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-indent: 45pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If this option is to be assumed or is otherwise to remain outstanding after a Corporate Transaction, then this option shall be appropriately adjusted to apply and pertain to the number and class of securities which would have been issuable to the Optionee in the consummation of such Corporate Transaction had the option been exercised immediately prior to such Corporate Transaction, and appropriate adjustments shall also be made to the Option Price payable per share, <u>provided</u> the aggregate Option Price payable hereunder shall remain the same.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u><b>Privilege of Stock Ownership</b></u>. The holder of this option shall not have any shareholder rights with respect to the Optioned Shares until such individual shall have exercised the option and paid the Option Price.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u><b>Manner of Exercising Option</b></u><b>. </b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In order to exercise this option with respect to all or any part of the Optioned Shares for which this option is at the time exercisable, Optionee (or in the case of exercise after Optionee&#8217;s death, the Optionee&#8217;s executor, administrator, heir or legatee, as the case may be) must take the following actions:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 72pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Provide the Plan Administrator (or its designee) with written notice of the option exercise (the &#8220;Exercise Notice&#8221;) specifying the number of Optioned Shares for which the option is being exercised.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 72pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pay the aggregate Option Price for the purchased shares in one of the following alternative forms:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 108pt; text-align: justify;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; full payment in cash or check payable to the Company&#8217;s order; or</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 108pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 108pt; text-align: justify;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; full payment in shares of Common Stock held by Optionee for the requisite period necessary to avoid a charge to the Company&#8217;s reported earnings and valued at Fair Market Value on the Exercise Date; or</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 108pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 108pt; text-align: justify;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; full payment in a combination of shares of Common Stock held for the requisite period necessary to avoid a charge to the Company&#8217;s earnings and valued at Fair Market Value on the Exercise Date and cash or check drawn to the Company&#8217;s order;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 108pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 108pt; text-align: justify;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; full payment through a &#8220;net settlement&#8221; procedure pursuant to which the Company shall withhold shares of Common Stock issuable in connection with the exercise of the option with a Fair Market Value equal to the Option Price plus all applicable Federal and state income and employment taxes required to be withheld by the Company by reason of such purchase; or</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 108pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 108pt; text-align: justify;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the Company&#8217;s outstanding Common Stock is registered under Section 12(g) of the Securities Exchange Act of 1934, as amended, at the time this option is exercised, then payment of the Option Price may also be effected through a broker-dealer sale and remittance procedure pursuant to which Optionee (i) shall provide irrevocable written instructions to a designated brokerage firm to effect the immediate sale of the purchased shares and remit to the Company, out of the sale proceeds available on the settlement date, sufficient funds to cover the aggregate Option Price payable for the purchased shares plus all applicable Federal and state income and employment taxes required to be withheld by the Company by reason of such purchase and (ii) shall provide written directives to the Company to deliver the certificates for the purchased shares directly to such brokerage firm in order to complete the sale.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:108pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 72pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Furnish to the Company appropriate documentation that the person or persons exercising the option (if other than Optionee) have the right to exercise this option.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For purposes of subparagraph (a) above and for all other valuation purposes under this Agreement, the Fair Market Value per share of Common Stock on any relevant date shall be determined in accordance with the following provisions:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 72pt; text-align: justify;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the Common Stock is not at the time listed or admitted to trading on any national securities exchange but is traded in the over-the-counter market, the Fair Market Value shall be the mean between the highest bid and lowest asked prices (or, if such information is available, the closing selling price) per share of Common Stock on the date in question in the over-the-counter market, as such prices are reported by the Financial Industry Regulatory Authority through the Nasdaq system or any successor system. If there are no reported bid and asked prices (or closing selling price) for the Common Stock on the date in question, then the mean between the highest bid price and lowest asked price (or the closing selling price) on the last preceding date for which such quotations exist shall be determinative of Fair Market Value.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 72pt; text-align: justify;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the Common Stock is at the time listed or admitted to trading on any national securities exchange, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question on the securities exchange determined by the Plan Administrator to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such exchange. If there is no reported sale of Common Stock on such exchange on the date in question, then the Fair Market Value shall be the closing selling price on the exchange on the last preceding date for which such quotation exists.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 72pt; text-align: justify;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the Common Stock is on the date in question neither listed or admitted to trading on any stock exchange nor traded in the over-the-counter market, then the fair market value shall be determined by the Plan Administrator after taking into account such factors as the Plan Administrator shall deem appropriate.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Exercise Date shall be the date on which the Exercise Notice is delivered to the Plan Administrator. Except to the extent the sale and remittance procedure specified above is utilized for the exercise of the option, payment of the Option Price for the purchased shares must accompany such notice.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-align: left; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As soon as practical after the Exercise Date, the Company shall issue to or on behalf of Optionee (or other person or persons exercising this option) the purchased Optioned Shares via electronic means or through delivery of a certificate or certificates representing the purchased Optioned Shares.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 36pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In no event may this option be exercised for any fractional share.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><b>Compliance with Laws and Regulations</b></u><b>.</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The exercise of this option (or of its tandem stock appreciation right) and the issuance of Common Stock hereunder shall be subject to compliance by the Company and the Optionee with all applicable requirements of law relating thereto and with all applicable regulations of any stock exchange or over-the-counter market on which shares of the Company&#8217;s Common Stock may be listed or traded at the time of such exercise and issuance.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In connection with the exercise of this option (or its tandem stock appreciation right), Optionee shall execute and deliver to the Company such representations in writing as may be requested by the Company in order for it to comply with the applicable requirements of federal and state securities laws.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><b>Successors and Assigns</b></u><b>. </b>Except to the extent otherwise provided in Paragraph 3 or 6, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns of Optionee and the successors and assigns of the Company.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><b>Liability of Company</b></u><b>.</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the Optioned Shares covered by this Agreement exceed, as of the Grant Date, the number of shares of Common Stock which may without shareholder approval be issued under the Plan, then this option shall be void with respect to such excess shares unless shareholder approval of an amendment sufficiently increasing the number of shares of Common Stock issuable under the Plan is obtained in accordance with the provisions of the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 43.2pt; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the lawful issuance and sale of any Common Stock pursuant to this Agreement shall relieve the Company of any liability with respect to the non-issuance or sale of the Common Stock as to which such approval shall not have been obtained. The Company, however, shall use its best efforts to obtain all such approvals.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><b>No Employment or Service Contract</b></u><b>.</b> Nothing in this Agreement or in the Plan shall confer upon the Optionee any right to continue in the Service of the Company (or any parent or subsidiary corporation of the Company employing or retaining Optionee) for any period of time or interfere with or otherwise restrict in any way the rights of the Company (or any parent or subsidiary corporation of the Company employing or retaining Optionee) or the Optionee, which rights are hereby expressly reserved by each, to terminate the Optionee&#8217;s Service at any time for any reason whatsoever, with or without cause.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><b>Notices</b></u><b>.</b> Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and addressed to the Company in care of the Corporate Secretary at its principal corporate offices. Any notice required to be given or delivered to Optionee shall be in writing and addressed to Optionee at the address indicated below Optionee&#8217;s signature line on the Grant Notice. All notices shall be deemed to have been given or delivered upon personal delivery or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified<b>.</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><b>Construction</b></u><b>.</b>&nbsp; This Agreement and the option evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the express terms and provisions of the Plan. All decisions of the Plan Administrator with respect to any question or issue arising under the Plan or this Agreement shall be conclusive and binding on all persons having an interest in this option.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><b>Governing Law</b></u><b>. </b>The interpretation, performance, and enforcement of this Agreement shall be governed by the laws of the State of Delaware without resort to that State&#8217;s conflict-of-laws rules.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><b>Taxes</b></u><b>.</b> In the event this option is designated as a non-statutory stock option in the Grant Notice, Optionee hereby agrees to make appropriate arrangements with the Company or parent or subsidiary corporation employing Optionee for the satisfaction of any federal, state or local income tax withholding requirements and federal social security employee tax requirements applicable to the exercise of this option.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><b>Restrictions on Optioned Shares</b></u><b>.</b>&nbsp; The Company may impose such restrictions, conditions or limitations as it determines appropriate as to the timing and manner of any resales by Optionee or other subsequent transfers by Optionee of any Optioned Shares, including without limitation (a) restrictions under an insider trading policy, (b) restrictions designed to delay and/or coordinate the timing and manner of sales by Optionee and other optionees and (c) restrictions as to the use of a specified brokerage firm for such resales or other transfers.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><b>Conflict with Plan</b></u><b>.</b>&nbsp; In the event of a conflict between the terms and conditions of this Agreement and the Plan, the Plan controls.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><b>Electronic Delivery</b></u><b>.</b>&nbsp; Optionee hereby consents to the delivery of information (including, without limitation, information required to be delivered to Recipient pursuant to applicable securities laws) regarding the Company and its subsidiaries and affiliates, the Plan, and the option via Company web site or other electronic delivery.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-indent: 18pt; text-align: justify;">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u><b>Headings</b></u><b>.</b>&nbsp; The headings preceding the text of the sections hereof are inserted solely for convenience of reference, and shall not constitute a part of this Agreement, nor shall they affect its meaning, construction or effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row" style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center;">7</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>4
<FILENAME>ex_230470.htm
<DESCRIPTION>EXHIBIT 10.26
<TEXT>
<html><head>
	<title>ex_230470.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:right;"><b><div id="cke_bm_140C" style="display: none;">&nbsp;</div>Exhibit 10.26</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: center;"><img alt="header1026.jpg" src="header1026.jpg"></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:right;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">January 14, 2020</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Charles Gayer</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">711 Watts Street</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Durham, NC 27701</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Dear Charlie:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-indent: 36pt;">On behalf of BioCryst Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;), we are pleased to offer you the position of Chief Commercial Officer. We, along with the other members of the Company&#8217;s Board of Directors (the &#8220;Board&#8221;), and the Company&#8217;s management team, are all very impressed with what you will bring to the Company in this role.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">This letter agreement (the &#8220;Agreement&#8221;) will serve to confirm our agreement with respect to the terms and conditions of your employment.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:45pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>1.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Term of Employment.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:18.45pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(a)</p>
			</td>
			<td style="vertical-align: top; width: 89%;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:18.45pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Subject to the terms and conditions of this Agreement, the Company hereby employs Charles Gayer (&#8220;Employee&#8221;) as Chief Commercial Officer. Employee shall commence employment at the Company&#8217;s offices in Durham, North Carolina. Employee shall devote substantially full-time attention to the business and affairs of the Company and its affiliates. Employee may (i) serve on corporate, civic, charitable or non-profit boards or committees, subject in all cases to the prior approval of the Board and other applicable written policies of the Company and its affiliates as in effect from time to time, and (ii) manage personal and family investments, participate in industry organizations and deliver lectures at educational institutions or events, so long as no such service or activity interferes, individually or in the aggregate, with the performance of Employee&#8217;s responsibilities hereunder.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:25.95pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(b)</p>
			</td>
			<td style="vertical-align: top; width: 89%;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:25.95pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The term of employment of Employee under this Agreement shall commence no later than January 15, 2020 (the &#8220;Effective Date&#8221;) and terminate on the second anniversary of the Effective Date unless earlier terminated in accordance with the provisions of Section&nbsp;4. In the event Employee is retained by the Company as Chief Commercial Officer past the second anniversary of the Effective Date, the terms of Employee&#8217;s employment shall continue to be governed by this Agreement unless otherwise provided by the Board.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<div style="text-align: center;"><img alt="footer1026.jpg" src="footer1026.jpg"></div>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="2" data-suffix="" data-textalign="center">&nbsp;</div>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:45pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>2.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Basic Full-Time Compensation and Benefits.</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">(a)</td>
			<td style="vertical-align: top; width: 89%;">Commencing as of the Effective Date, as basic compensation for services rendered under this Agreement, Employee shall be entitled to receive from the Company a salary of&nbsp;$31,250 per month ($375,000 per annum) (the &#8220;Base Salary&#8221;), payable in accordance with the Company&#8217;s standard payroll practices as in effect from time to time during the term of this Agreement. The Base Salary will be reviewed annually by the Board or a committee thereof and may be raised at the discretion of the Board or such committee.</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">(b)</td>
			<td style="vertical-align: top; width: 89%;">Employee shall be eligible to earn a cash bonus, payable as soon as reasonably practicable in the calendar year following each calendar year during the term of this Agreement, based on the Company&#8217;s and/or Employee&#8217;s achievement of performance related goals proposed by management and approved by the Board or a committee thereof for the Company&#8217;s applicable fiscal year (the &#8220;Incentive Compensation&#8221;). The Incentive Compensation actually earned, if any, shall be determined in the sole discretion of the Board or a committee thereof and shall be based on a target amount equal to forty percent (40%) of the Base Salary earned by Employee during such fiscal year (the &#8220;Target Amount&#8221;). The Board or a committee thereof may, in its discretion, approve an Incentive Compensation payment in excess of the Target Amount if the performance goals have been exceeded. Employee must be currently employed at the Company in order to receive the Incentive Compensation payment for each fiscal year.</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:29.7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(c)</p>
			</td>
			<td style="vertical-align: top; width: 89%;">Employee shall be entitled to receive such other benefits and perquisites provided to similarly situated executive officers of the Company, subject to modification or termination at any time, which benefits may include, without limitation, reasonable vacation (currently four (4) weeks), sick leave, medical benefits, life insurance, and participation in profit sharing or retirement plans.</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:45pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>3.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Performance Based Equity Awards.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:29.7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(d)</p>
			</td>
			<td style="vertical-align: top; width: 89%;">During the term of this Agreement, Employee shall be eligible to receive equity-based compensation as determined in the sole discretion of the Board or a committee thereof, which may be subject to the achievement of certain performance targets set by the Board or such committee. All such equity-based awards shall be subject to the terms and conditions set forth in the Company&#8217;s Stock Incentive Plan as in effect from time to time and award agreements issued thereunder.</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:45pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>4.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Termination.</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:29.7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(a)</p>
			</td>
			<td style="vertical-align: top; width: 89%;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:29.7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">If Employee&#8217;s employment is terminated by the Company for Cause or by Employee other than pursuant to a Constructive Termination, or due to the expiration of the stated term of this Agreement or Employee&#8217;s death or Disability, the Company shall pay Employee (i) any accrued and unpaid Base Salary, payable on the next payroll date; (ii)</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:29.7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 89%;">reimbursement for any and all monies advanced or expenses incurred in connection with Employee&#8217;s employment for reasonable and necessary expenses incurred by Employee on behalf of the Company for the period ending on the termination date, which amount shall be reimbursed within thirty (30) days of the Company&#8217;s receipt of proper documentation from Employee; (iii) any compensation that Employee had previously deferred (including any interest earned or credited thereon), in accordance with the terms and conditions of the applicable deferred compensation plans or arrangements then in effect, to the extent vested as of Employee&#8217;s termination date, paid pursuant to the terms of such plans or arrangements; and (iv) any vested amount or benefit payable under any benefit plan or program in accordance with the terms thereof (the foregoing items in this Section 4(a), the &#8220;Accrued Obligations&#8221;).</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">For all purposes under this Agreement, a termination for &#8220;Cause&#8221; shall mean a determination by the Board that Employee&#8217;s employment be terminated for any of the following reasons: (i) failure or refusal to comply in any material respect with lawful policies, standards or regulations of Company; (ii) a violation of a federal or state law or regulation applicable to the business of the Company; (iii) conviction or plea of no contest to a felony under the laws of the United States or any State; (iv) fraud or misappropriation of property belonging to the Company or its affiliates; (v) a breach in any material respect of the terms of any confidentiality, invention assignment or proprietary information agreement with the Company or with a former employer, (vi) failure to satisfactorily perform Employee&#8217;s duties after having received written notice of such failure and at least thirty (30) days to cure such failure, or (vii) misconduct or gross negligence in connection with the performance of Employee&#8217;s duties.</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">&nbsp;</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">For all purposes under this Agreement, &#8220;Disability&#8221; shall mean the inability of Employee to perform Employee&#8217;s duties hereunder by reason of physical or mental incapacity for ninety (90) days, whether consecutive or not, during any consecutive twelve (12) month period.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">(b)</td>
			<td style="vertical-align: top; width: 89%;">If Employee&#8217;s employment is terminated by the Company without Cause, or by Employee pursuant to a Constructive Termination, then Employee will receive any Accrued Obligations and, subject to Section 4(c), Employee will receive the following:&nbsp;(i)continuation of Base Salary for one (1) year following the effective termination date, payable in accordance with the regular payroll practices of the Company; (ii) payment of one times Employee&#8217;s annual target Incentive Compensation in effect for the fiscal year in which Employee&#8217;s termination date occurs, payable in equal installments over the regularly scheduled payroll periods of the Company for the one year following the effective date of termination; and (iii) if Employee elects to continue health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;COBRA&#8221;) following termination of employment, the Company shall pay the monthly premium under COBRA on the same basis as active employees until the earlier of (x) 12 months following the effective termination date, or (y) the date upon which Employee commences employment with an entity other than the Company. Employee will notify the Company in writing within five (5) days of Employee&#8217;s receipt of an offer of employment with any entity other than the Company and will accordingly identify the&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp; &nbsp;</td>
			<td style="vertical-align: top; width: 89%;">date upon which Employee will commence employment in such writing (clauses (i) through (iii), &#8220;Severance&#8221;).</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">For all purposes under this Agreement, &#8220;Change of Control&#8221; shall mean: (i) the sale, transfer, or other disposition of all or substantially all of the assets of the Company in liquidation or dissolution of the Company; (ii) the consummation of a merger or consolidation of the Company with any other corporation or other entity, other than (I) a merger or consolidation (A) which results in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent fifty percent (50%) or more of the combined voting power of the surviving entity or the ultimate parent thereof outstanding immediately after such merger or consolidation and (B) immediately following which the individuals who comprise the Board immediately prior thereto constitute fifty percent (50%) or more of the board of directors of the entity surviving such merger or consolidation or, if the Company or the entity surviving such merger or consolidation is then a subsidiary, the ultimate parent thereof, or (II) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no Person is or becomes the beneficial owner (within the meaning of Rule 13d-3 of the Securities Exchange Act of 1934, as amended (the &#8220;1934 Act&#8221;)), directly or indirectly, of securities of the Company (not including in the securities beneficially owned by such Person any securities acquired directly from the Company or its affiliates) representing more than fifty percent (50%) of the combined voting power of the Company&#8217;s then outstanding securities; (iii) any person or related group of persons (other than the Company or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company) directly or indirectly acquires beneficial ownership (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing more than fifty percent (50%) of the total combined voting of the Company&#8217;s outstanding securities pursuant to a tender or exchange offer made directly to the Company&#8217;s stockholders; or (iv) a change in the composition of the Board over a period of twelve (12) consecutive months such that a majority of the Board members (rounded up to the next whole number) ceases to be comprised of individuals who either (A) have been Board members continuously since the beginning of such period or (B) have been elected or nominated for election as Board members during such period by at least two-thirds of the Board members described in clause (A) who were still in office at the time such election or nomination was approved by the Board.</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">For all purposes under this Agreement, &#8220;Constructive Termination&#8221; shall mean a resignation of employment within 30 days of the occurrence of any of the following events which occurs within 6 months following a Change of Control: (i) a material reduction in Employee&#8217;s responsibilities; (ii) a material reduction in Employee&#8217;s Base Salary, unless such reduction is comparable in percentage to, and is part of, a reduction in the base salary of all executive officers of the Company; or (iii) a relocation of Employee&#8217;s principal office to a location more than 50 miles from the location of Employee&#8217;s principal office immediately preceding a Change of Control.</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:20.7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(c)</p>
			</td>
			<td style="vertical-align: top; width: 89%;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:20.7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The Company&#8217;s obligation to provide Severance is conditioned upon Employee returning to the Company all of its property and confidential information that is in Employee&#8217;s</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:20.7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 89%;">possession and Employee&#8217;s execution and non-revocation of an enforceable release of claims (the &#8220;Release&#8221;). If Employee chooses not to execute the Release, revokes Employee&#8217;s execution of the Release, or fails to comply with the terms of the Release, then the Company shall have no obligation to provide Severance and such Severance amount is subject to recoupment by the Company. The Release shall be provided to Employee no later than seven (7) days following Employee&#8217;s separation from service and Employee must execute it within the time period specified in the Release (which shall not be longer than forty-five (45) days from the date of receipt). The Release shall not be effective until any applicable revocation period has expired.</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="width: 7%;"><b>5.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Non-Competition; Proprietary Information and Inventions.</b></td>
		</tr>
		<tr>
			<td colspan="3" style="width: 7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:22.95pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(a)</p>
			</td>
			<td style="vertical-align: top; width: 89%;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:22.95pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><u>Proprietary Information and Inventions Agreement; Non-Competition and Non- Solicitation Agreement</u>. As a condition precedent to the employment of Employee by the Company as Chief Commercial Officer pursuant to the terms of this Agreement, Employee shall execute (i) the Company&#8217;s Proprietary Information and Inventions Agreement, attached hereto as Exhibit A, and (ii) the Company&#8217;s Non-Competition and Non-Solicitation Agreement, attached hereto as Exhibit B.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:23.7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(b)</p>
			</td>
			<td style="vertical-align: top; width: 89%;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:23.7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><u>Equitable Remedies</u>. Employee acknowledges and recognizes that a violation of the Proprietary Information and Inventions Agreement or the Non-Competition and Non- Solicitation Agreement by Employee may cause irreparable and substantial damage and harm to the Company or its affiliates, could constitute a failure of consideration, and that money damages will not provide a full remedy for the Company for such violations. Employee agrees that in the event of Employee&#8217;s breach of the Proprietary Information and Inventions Agreement or the Non-Competition and Non-Solicitation Agreement, the Company will be entitled, if it so elects, to institute and prosecute proceedings at law or in equity to obtain damages with respect to such breach, to enforce the specific performance of such agreement(s) by Employee, and to enjoin Employee from engaging in any activity in violation hereof.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:45pt;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>6.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Miscellaneous</b>.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:67pt;">&nbsp;</td>
			<td style="width: 44px; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:25.95pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(a)</p>
			</td>
			<td style="vertical-align: top; width: 1228px;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:25.95pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><u>Entire Agreement</u>. This Agreement, including the exhibits hereto, constitutes the entire agreement between the parties relating to the employment of Employee by the Company and there are no terms relating to such employment other than those contained in this Agreement. No modification or variation hereof shall be deemed valid unless in writing and signed by the parties hereto. No waiver by either party of any provision or condition of this Agreement shall be deemed a waiver of similar or dissimilar provisions or conditions at any time.</p>
			</td>
		</tr>
		<tr>
			<td style="width:67pt;">&nbsp;</td>
			<td style="width: 44px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1228px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:67pt;">&nbsp;</td>
			<td style="width: 44px; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:27.45pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(b)</p>
			</td>
			<td style="vertical-align: top; width: 1228px;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:27.45pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><u>Assignability</u>. This Agreement may not be assigned without prior written consent of the parties hereto. To the extent allowable pursuant to this Agreement, this Agreement shall be binding upon and shall inure to the benefit of each of the parties hereto and their respective executors, administrators, personal representatives, heirs, successors and assigns.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:25.95pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(c)</p>
			</td>
			<td style="vertical-align: top; width: 89%;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:25.95pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><u>Notices</u>. Any notice or other communication given or rendered hereunder by any party hereto shall be in writing and delivered personally or sent by registered or certified mail, postage prepaid, at the respective addresses of the parties hereto as set forth below.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">(d)</td>
			<td style="vertical-align: top; width: 89%;"><u>Captions</u>. The section headings contained herein are inserted only as a matter of convenience and reference and in no way define, limit or describe the scope of this Agreement or the intent of any provision hereof.</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">(e)</td>
			<td style="vertical-align: top; width: 89%;"><u>Taxes</u>. All amounts to be paid to Employee hereunder are in the nature of compensation for Employee&#8217;s employment by the Company, and shall be subject to withholding, income, occupation and payroll taxes and other charges applicable to such compensation.</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 89%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">(f)</td>
			<td style="vertical-align: top; width: 89%;"><u>Section 409A</u>. The parties intend for the payments and benefits under this Agreement to be exempt from Section 409A of the Code or, if not so exempt, to be paid or provided in a manner which complies with the requirements of such section and intend that this Agreement shall be construed and administered in accordance with such intention. In the event the Company determines that a payment or benefit under this Agreement may not be in compliance with Section 409A of the Code, the Company shall reasonably confer with Employee in order to modify or amend this Agreement to comply with Section 409A of the Code and to do so in a manner to best preserve the economic benefit of this Agreement. Notwithstanding anything contained herein to the contrary, (i) in the event&nbsp;(i) any payments described in Section 4 would be &#8220;deferred compensation&#8221; subject to Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;); and&nbsp;(ii) Employee is a &#8220;specified employee&#8221; (as defined in Code Section 409A(2)(B)(i)), such payments shall, to the extent required by Code Section 409A, be delayed for the minimum period and in the minimum manner necessary to avoid the imposition of the tax required by Section 409A of the Code; (ii) each amount to be paid or benefit to be provided under this Agreement shall be construed as a separately identified payment for purposes of Section 409A of the Code; (iii) any payments that are due within the &#8220;short term deferral period&#8221; as defined in Section 409A of the Code shall not be treated as deferred compensation unless applicable law requires otherwise; and (iv) amounts reimbursable to Employee under this Agreement shall be paid to Employee on or before the last day of the year following the year in which the expense was incurred and the amount of expenses eligible for reimbursement (and in-kind benefits provided to Employee) during any one (1) year may not affect amounts reimbursable or provided in any subsequent year. Notwithstanding anything in this Agreement to the contrary, in the event any payments hereunder could occur in one of two calendar years as a result of being dependent upon the Release becoming nonrevocable, then, to the extent required to avoid the imposition of taxes or penalties under Section 409A of the Code, such payments shall commence on the first regularly scheduled payroll date of the Company, following the date the Release becomes nonrevocable, that occurs in the second of such two calendar years.</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:18.45pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(g)</p>
			</td>
			<td style="vertical-align: top; width: 89%;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:18.45pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><u>Golden Parachute Provisions</u>. If it is determined that any payment or benefit provided by the Company to or for the benefit of Employee, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, including, by example and not by way of limitation, acceleration by the Company or otherwise of the date of vesting or payment under any plan, program, arrangement or agreement of the Company would be subject to the excise tax imposed by Internal Revenue Code section 4999 or any interest or penalties with respect to such excise tax (such excise tax together with any such interest and penalties, shall be referred to as the &#8220;Excise Tax&#8221;), then the Company shall first make a calculation under which such payments or benefits provided to Employee are reduced to the extent necessary so that no portion thereof shall be subject to the Excise Tax (the &#8220;4999 Limit&#8221;). The Company shall then compare (i) Employee&#8217;s Net After-Tax Benefit (as defined below) assuming application of the 4999 Limit with&nbsp;(ii) Employee&#8217;s Net After-Tax Benefit without application of the 4999 Limit. Employee shall be entitled to the greater of (i) or (ii). &#8220;Net After-Tax Benefit&#8221; shall mean the sum of&nbsp;(x) all payments that Employee receives or is entitled to receive that are contingent on a change in the ownership or effective control of the Company or in the ownership of a substantial portion of the assets of the Company within the meaning of Internal Revenue Code section 280G(b)(2), less (y) the amount of federal, state, local, employment, and Excise Tax (if any) imposed with respect to such payments. Any reduction pursuant to this Section 6(g) shall be implemented by determining the Parachute Payment Ratio (as defined below) for each &#8220;parachute payment&#8221; and then reducing the &#8220;parachute payments&#8221; in order beginning with the &#8220;parachute payment&#8221; with the highest Parachute Payment Ratio. For &#8220;parachute payments&#8221; with the same Parachute Payment Ratio, such &#8220;parachute payments&#8221; shall be reduced based on the time of payment of such &#8220;parachute payments,&#8221; with amounts having later payment dates being reduced first. For &#8220;parachute payments&#8221; with the same Parachute Payment Ratio and the same time of payment, such &#8220;parachute payments&#8221; shall be reduced on a pro rata basis (but not below zero) prior to reducing &#8220;parachute payments&#8221; with a lower Parachute Payment Ratio. &#8220;Parachute Payment Ratio&#8221; shall mean a fraction the numerator of which is the value of the applicable &#8220;parachute payment&#8221; for purposes of Internal Revenue Code Section 280G and the denominator of which is the actual present value of such payment.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 7%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:22.95pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(h)</p>
			</td>
			<td style="vertical-align: top; width: 89%;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:22.95pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><u>Governing Law</u>. This Agreement is made and shall be governed by and construed in accordance with the laws of the State of North Carolina without respect to its conflicts of law principles.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">[Signature Page Follows]</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">If the foregoing correctly sets forth our understanding, please signify your acceptance of such terms by executing this Agreement, thereby signifying your assent, as indicated below.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td colspan="2" style="width: 50%;">Yours very truly,</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td colspan="2">BIOCRYST PHARMACEUTICALS, INC.</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td colspan="2">&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>By:</td>
			<td><u>/s/ Jon Stonehouse&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
			<td>Jon Stonehouse</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
			<td>Chief Executive Officer</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>Cc:</td>
			<td>Stephanie Angelini</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
			<td>Senior Vice President, Human Resources</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">AGREED AND ACCEPTED</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Sign:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>/s/ Charles Gayer&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;Charles Gayer</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72.45pt;margin-right:75.45pt;margin-top:0pt;text-align:center;"><b>Exhibit A</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>(Proprietary Information and Inventions Agreement)</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">EMPLOYEE&#8217;S PROPRIETARY INFORMATION AND INVENTIONS AGREEMENT</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">I, Charles Gayer, recognize that BioCryst Pharmaceuticals, Inc., a Delaware corporation (hereinafter the &#8220;Company&#8221;), is engaged in a continuous program of research, development, and production respecting its business, present and future, including fields generally related to its business.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt 0pt 34pt; text-align: left;">I understand that:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:21.45pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">A.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:21.45pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">As part of my employment by the Company I will faithfully and diligently serve and endeavor to further and safeguard the interests of the Company, and I recognize that I am expected to make new contributions and inventions of value to the Company;</p>
			</td>
		</tr>
		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="width:15pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:42pt;">&nbsp;</td>
			<td style="width:15pt;vertical-align:top;">B.</td>
			<td style="vertical-align:top;">My employment creates a relationship of confidence and trust between me and the Company with respect to any information:</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:69pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">i.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">applicable to the business of the Company; or</p>
			</td>
		</tr>
		<tr>
			<td style="width:69pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:69pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">ii.</td>
			<td style="vertical-align:top;">applicable to the business of any client or customer of the Company,</td>
		</tr>
		<tr>
			<td style="width:69pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:69pt;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="width:10pt;vertical-align:top;">in each case which may be made known to me by the Company or by any client or customer of Company or learned by me during the period of my employment.</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:43pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:19.95pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">C.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:19.95pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The Company possesses and will continue to possess information that has been created, discovered or developed by, or assigned, disclosed or otherwise become known to, the Company (including without limitation information created, discovered, developed, disclosed or made known by me during the period of or arising out of my employment by the Company) , which information is not generally known to the public. All of the aforementioned information is hereinafter called &#8220;Proprietary Information.&#8221; By way of illustration, but not limitation, Proprietary Information includes trade secrets, processes, formulas, data and know-how, improvements, inventions, techniques, marketing plans, financial information, strategies, forecasts, and customer lists.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:31pt;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="width: 34px; vertical-align: top;">In consideration of my employment by the Company, employment as Chief Commercial Officer under the terms of the Agreement executed contemporaneously herewith and the compensation received by me from the Company from time to time, I hereby agree as follows:</td>
		</tr>
		<tr>
			<td style="width:31pt;">&nbsp;</td>
			<td style="width: 34px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1286px;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:31pt;">&nbsp;</td>
			<td style="width: 34px; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:22.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">1.</p>
			</td>
			<td style="vertical-align: top; width: 1286px;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:22.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">All Proprietary Information shall be the sole property of the Company, and the Company shall be the sole owner of all rights, title and interest in connection therewith. I hereby assign to the Company any and all rights I may have or acquire in such Proprietary Information. At all times, both during my employment by the Company and after its termination, I will keep in confidence and trust all Proprietary Information, and I will not use or disclose any Proprietary Information or anything relating to it without the prior written consent of the</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 94%;">Company, except as may be necessary in the ordinary course of performing my duties as an employee of the Company. In the event I am required to disclose Proprietary Information pursuant to applicable law or court order, I shall, whenever legally permissible, promptly disclose such request to the Company, and cooperate with the Company to seek a protective order and to otherwise limit such disclosure from becoming public.</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:19.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">2.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:19.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Notwithstanding anything set forth in this Agreement, or any other agreement that I have with the Company or its affiliates to the contrary, I shall not be prohibited from reporting possible violations of federal or state law or regulation to any governmental agency or entity, legislative body, or any self-regulatory organization, or making other disclosures that are protected under the whistleblower provisions of federal or state law or regulation, nor am I required to notify the Company regarding any such reporting, disclosure or cooperation with the government. Pursuant to 18 U.S.C. &#167; 1833(b), I understand that I will not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret of the Company or its affiliates that (i) is made (A) in confidence to a federal, state, or local government official, either directly or indirectly, or to my attorney and (B) solely for the purpose of reporting or investigating a suspected violation of law; or (ii) is made in a complaint or other document that is filed under seal in a lawsuit or other proceeding. I understand that if I file a lawsuit for retaliation by the Company for reporting a suspected violation of law, I may disclose the trade secret to my attorney and use the trade secret information in the court proceeding if I (x) file any document containing the trade secret under seal, and (y) do not disclose the trade secret, except pursuant to court&nbsp;order.&nbsp; Nothing in this Agreement, or any other agreement that I have with the Company or its affiliates, is intended to conflict with 18 U.S.C. &#167; 1833(b) or create liability for disclosures of trade secrets that are expressly allowed by such section.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">3.</td>
			<td style="vertical-align: top; width: 94%;">I agree that, during the period of my employment by the Company, I will not, without the Company&#8217;s express prior written consent, engage in any employment or consulting other than for the Company. In the event of the termination of my employment by me or by the Company for any reason or at any time upon the Company&#8217;s request, I will promptly deliver to the Company all documents and data of any nature pertaining to my work with the Company and I will not take with me any documents or data containing or pertaining to any Proprietary Information.</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">4.</td>
			<td style="vertical-align: top; width: 94%;">I will promptly and fully disclose to the Company, or any persons designated by it, all improvements, inventions, formulas, processes, techniques, know-how, and data, whether or not patentable, copyrightable, or otherwise protectible as intellectual property, made or conceived or reduced to practice by me, either alone or jointly with others, during the period of my employment by the Company which are related to or useful in the business of the Company, or result from the performance of my duties as an employee of the Company or result from use of assets or premises owned, leased, or contracted for by the Company (all said improvements, inventions, formulas, processes, techniques, know-how, and data shall be collectively hereinafter called &#8220;Inventions&#8221;). I agree to keep complete, accurate, and authentic accounts, notes, data, and records of all Inventions in the manner and form requested by the Company, which accounts, notes, data, and records shall be and remain the sole property of the Company. I agree to surrender the same promptly to the Company upon</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 94%;">its request or, in the absence of such a request, upon the termination of my employment by the Company.</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">5.</td>
			<td style="vertical-align: top; width: 94%;">I agree that all Inventions are and shall be the sole property of the Company, and that the Company shall be the sole owner of all intellectual property and other rights in connection therewith, and by reason of my being employed by Company, to the extent permitted by law, all of the Inventions consisting of copyrightable subject matter is &#8220;work made for hire&#8221; as defined in the Copyright Act of 1976 (17 U.S.C. &#167; 101). To the extent that any Invention is not a &#8220;work made for hire,&#8221; I hereby assign to the Company for no additional consideration any and all rights I may have or acquire in or to such Inventions, including the right to sue, counterclaim, and recover for all past, present, and future infringement, misappropriation, or dilution thereof, and all rights corresponding thereto throughout the world. I further agree as to all such Inventions to assist the Company in every proper way (but at the Company&#8217;s expense) to apply for, obtain, maintain and from time to time enforce such intellectual property rights, including patents and extensions and continuations of said patents, on said Inventions in any and all countries, and to that end I will execute all documents for use in applying for, obtaining and maintaining such intellectual property enforcing same, as the Company may desire, together with any further assignments thereof to the Company or persons designated by it. The foregoing obligation to assist the Company shall continue beyond the termination of my employment, but the Company shall compensate me at a reasonable rate after such termination for time actually spent by me at the Company&#8217;s request on such assistance.</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:20.7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">6.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:20.7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">As a matter of record I attach hereto a complete list of all inventions or improvements relevant to the subject matter of my employment by the Company which have been conceived, made, or reduced to practice by me, alone or jointly with others, prior to my engagement by the Company which I desire to remove from the operation of this Agreement. I covenant that such list is complete. If no such list is attached to this Agreement, I represent that I have no such inventions and improvements at the time of signing this Agreement.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">7.</td>
			<td style="vertical-align: top; width: 94%;">I represent that my performance of all of the terms of this Agreement and as an employee of the Company does not and will not breach any agreement to keep in confidence proprietary information of any third party acquired by me in confidence or in trust prior to my employment by the Company. I have not entered into, and I agree that I will not enter into, any agreement either written or oral, in conflict herewith.</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">8.</td>
			<td style="vertical-align: top; width: 94%;">I understand that, as part of the consideration of the offer of employment extended to me by the Company or of my continued employment by the Company, as the case may be, I will not bring, have not brought, with me to the Company and I will not use, have not used, in the performance of my responsibilities at the Company, materials or documents of a former employer, unless I have obtained written authorization from the former employer for their possession and use. Accordingly, this is to advise the Company that the only materials that I will bring to the Company or use in my employment are identified on the attached sheet and, as to each such item, I represent that I have obtained, prior to the effective date of my employment with the Company, written authorization for their possession and use in my employment with the Company. I also understand that, in my employment with the</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 94%;">Company. I am not to breach any obligation of confidentiality that I have to former employers, and I agree that I shall fulfill all such obligations during my employment with the Company.</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">9.</td>
			<td style="vertical-align: top; width: 94%;">This Agreement shall be effective as of the first day of my employment by the Company. I understand and agree that this Agreement is not a contract of employment.</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 94%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 3%;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:20.7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">10.</p>
			</td>
			<td style="vertical-align: top; width: 94%;">This Agreement shall be binding upon me, my heirs, executors, assigns, administrators, and other legal representatives and shall inure to the benefit of the Company, its successors and assigns.</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">[Signature Page Follows]</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">IN WITNESS WHEREOF, the Company has caused this Proprietary Information and Inventions Agreement to be executed by its duly authorized officer and Employee has executed the same as of the dates set forth below.</p>

<p style="font-size: 0.5pt; margin: 0 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-size: 0.5pt; margin: 0 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-size: 0.5pt; margin: 0 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="margin-left:2.5%;width:84.2%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.4%;">BIOCRYST<br>
			PHARMACEUTICALS, INC.</td>
			<td style="vertical-align:top;width:48.8%;">EMPLOYEE</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:48.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:48.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:48.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align:top;width:45.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ Stephanie Angelini &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
			<td style="vertical-align:top;width:48.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ Charles Gayer &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Stephanie Angelini</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">SVP, Human Resources</p>
			</td>
			<td style="vertical-align:top;width:48.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Charles Gayer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:48.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.4%;">Date: <u>January 14, 2020&nbsp; &nbsp; &nbsp;</u></td>
			<td style="vertical-align:top;width:48.8%;">Date: <u>January 14, 2020&nbsp; &nbsp; &nbsp;</u></td>
		</tr>

</table>

<p style="font-size: 0.5pt; margin: 0 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Exhibit B</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>(Non-Competition and Non-Solicitation Agreement)</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">This Non-Competition and Non-Solicitation Agreement (the &#8220;Agreement&#8221;) is made and entered into this 14th day of January, 2020 (the &#8220;Effective Date&#8221;) by and between BioCryst Pharmaceuticals, Inc., (the &#8220;Company&#8221;) and Charles Gayer (the &#8220;Employee&#8221;). The Company and Employee are sometimes referred to in this Agreement individually as a &#8220;Party&#8221; and collectively as &#8220;Parties.&#8221;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>WHEREAS, </b>Employee is commencing employment as Chief Commercial Officer with the Company pursuant to an Employment Agreement entered into between Employee and the Company (the &#8220;Employment Agreement&#8221;) and is simultaneously entering into an Employee&#8217;s Proprietary Information and Inventions Agreement (the &#8220;PIIA&#8221;) with the Company; and</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>WHEREAS, </b>in consideration for Employee&#8217;s promises and obligations set forth herein, the Company is offering Employee employment as Chief Commercial Officer under the terms set forth in the Employment Agreement entered into contemporaneous herewith to which Employee was not previously entitled.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><b>NOW THEREFORE, </b>in consideration of the mutual promises and obligations set forth below and other good and valuable consideration, the receipt and sufficiency of which the Parties acknowledge, the Company and Employee agree as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:67pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt 7.2pt; text-align: left; font-size: 10pt; text-indent: 36pt;"><b>1.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b><u><b>COMPANY BUSINESS AND PROTECTABLE INTERESTS.</b></u><b> </b>Employee acknowledges that: (i) by virtue of Employee&#8217;s position with the Company, Employee will have access to Proprietary Information, as that term is defined in the PIIA, which information has not become publicly available (&#8220;Confidential Information&#8221;); (ii) the Company together with its subsidiaries (the &#8220;Company Group&#8221;) is currently engaged primarily, but not exclusively, in the business of the discovery, development and commercialization of medicines and programs for rare diseases (the &#8220;Business&#8221;); (iii) during the course of Employee&#8217;s employment, the Company Group&#8217;s Business may expand or change, in which case, such expansions or changes shall correspondingly expand or (if abandoned) contract the definition of &#8220;Business&#8221; and Employee&#8217;s obligations under this Agreement; (iv) due to the nature of the Business, Confidential Information developed by the Company Group in furtherance of the treatment for a particular rare disease would have commercial value to any other entity pursuing the development of medicines for the same disease regardless of the location of that entity, and the use of that information by such an entity would have a negative commercial impact on the Company Group;&nbsp;(v) the Company Group has clients, customers and collaborative partners throughout the United States and the world and the specific location of a competing business is not necessarily relevant to the capacity of that business to compete with the Company Group; and (vi) the provisions of this Agreement are reasonably necessary to protect the Company Group&#8217;s legitimate business interests, are reasonable as to time, territory and scope of activities which are restricted, do not interfere with public policy or public interest and are described with sufficient accuracy and definiteness to enable Employee to understand the scope of the restrictions imposed upon Employee.</p>
			</td>
		</tr>

</table>

<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="B-" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">B-1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:67pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt 7.2pt; text-align: left; font-size: 10pt; text-indent: 36pt;"><b>2.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b><u><b>COMPETITIVE BUSINESS ACTIVITIES.</b></u><b>&nbsp;&nbsp; </b>Employee agrees that during the period of Employee&#8217;s employment with the Company Group and for a period of time ending on the date occurring one year after the date Employee&#8217;s employment terminates (irrespective of the circumstances of such termination), Employee will not:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:103pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt 0pt 0pt 45pt; text-align: left; font-size: 10pt; text-indent: 36pt;">(a)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; on Employee&#8217;s own or another&#8217;s behalf, whether as an officer, director, manager, stockholder, partner, member, associate, owner, employee, consultant, or otherwise do any of the following or provide material assistance to any other party or entity to do so:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td colspan="3" style="width: 141pt; padding: 0pt 34.95pt 0pt 81pt; text-align: left; text-indent: 54pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">(i)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; engage in the Business with respect to medicines or programs with which Employee was materially involved on behalf of the Company Group during Employee&#8217;s employment or with respect to which Employee obtained Confidential Information during Employee&#8217;s employment;</p>
			</td>
		</tr>
		<tr>
			<td style="width:141pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="width: 141pt; padding: 0pt 34.95pt 0pt 81pt; text-indent: 54pt; text-align: left;">(ii)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;solicit or do business which is the same, similar to or otherwise in competition with the Business, from or with persons or entities: (a) who are clients, customers or collaborative partners of the Company Group; (b) with whom or which Employee or someone for whom Employee was responsible solicited, negotiated, contracted, serviced or had material contact with on the Company Group&#8217;s behalf; (c) with respect to whom or which Employee obtained Confidential Information during and as a consequence of Employee&#8217;s employment by the Company Group; or (d) who were clients, customers or collaborative partners of the Company at any time during the last year of Employee&#8217;s employment with the Company Group; nor shall Employee request, induce, or solicit such persons or entities to curtail or cancel their business with the Company Group;</td>
		</tr>
		<tr>
			<td style="width:141pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="width: 141pt; padding: 0pt 34.95pt 0pt 81pt; text-indent: 54pt; text-align: left;">(iii)&nbsp; &nbsp; &nbsp; &nbsp; offer employment to, hire or otherwise solicit for employment any employee or other person who had been employed or retained by the Company Group during the last year of Employee&#8217;s employment with the Company Group and with whom Employee had material contacts during the course of Employee&#8217;s employment; nor shall Employee request, induce, or solicit any employee or independent contractor of the Company Group who had been employed or retained by the Company Group during the last year of Employee&#8217;s employment with the Company Group and with whom Employee had material contacts during the course of Employee&#8217;s employment to terminate his or her employment or independent contractor relationship with the Company Group; or</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 45pt; text-align: left; text-indent: 36pt;">(b)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; take any action, which is materially detrimental, or otherwise intended to be adverse to the Company Group&#8217;s goodwill, name, business relations, prospects and operations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td colspan="3" style="width: 103pt; padding: 0pt 0pt 0pt 45pt; text-indent: 36pt; text-align: left;">(c)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; The restrictions set forth in Section 2(a)(i) apply to the following separate and distinct geographical areas: (i) the world; (ii) North America (iii) Europe; (iv) the</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">B-2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td colspan="3" style="width: 8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt 0pt 0pt 45pt; text-align: left; font-size: 10pt;">United States; (v) the United Kingdom; (vi) the State of North Carolina; (vii) the State of Alabama; (viii) within a 60-mile radius of any location of the Company Group in which Employee had an office or performed material services during Employee&#8217;s employment with the Company Group; (ix) any city, metropolitan area, county, state or country in which Employee&#8217;s substantial services were provided, or for which Employee had substantial responsibility, or in which Employee worked on Company Group projects, while employed by the Company Group; (x) any city, metropolitan area, county, state or country in which the Company Group is located or does or, during Employee&#8217;s employment with the Company Group, did business.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 8%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 88%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="width: 8%; padding: 0pt 0pt 0pt 45pt; text-indent: 36pt; text-align: left;">(d)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; The restrictions set forth in Section 2(a)(i) apply only to prohibit Employee from engaging in activities that are materially similar to the activities in which Employee engaged on behalf of the Company Group or with respect to which Employee would reasonably be expected to use Confidential Information.</td>
		</tr>
		<tr>
			<td style="width: 8%;">&nbsp;</td>
			<td style="width: 4%; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 88%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="width: 8%; padding: 0pt 0pt 0pt 45pt; text-indent: 36pt; text-align: left;">(e)&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Notwithstanding the foregoing, Employee&#8217;s ownership, directly or indirectly, of not more than one percent of the issued and outstanding stock of a corporation the shares of which are regularly traded on a national securities exchange or in the over-the-counter market shall not violate Sections 2(a)-(b).</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td colspan="3" style="width:67pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin: 0pt 7.2pt; text-align: left; font-size: 10pt; text-indent: 36pt;"><b>3.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b><u><b>REMEDIES.</b></u><b> </b>Employee acknowledges that Employee&#8217;s failure to abide by this Agreement would cause irreparable harm to the Company Group for which legal remedies would be inadequate. Therefore, in addition to any legal or other relief to which the Company Group may be entitled by virtue of Employee&#8217;s failure to abide by these provisions; the Company Group may seek equitable relief, including, but not limited to, preliminary and permanent injunctive relief, for Employee&#8217;s actual or threatened failure to abide by these provisions, and Employee will indemnify the Company Group for all expenses including attorneys&#8217; fees in seeking to enforce these provisions.</p>
			</td>
		</tr>
		<tr>
			<td style="width:67pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="width: 67pt; padding: 0pt 7.2pt; text-indent: 36pt; text-align: left;"><b>4.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b><u><b>TOLLING.</b></u><b> </b>The period during which Employee must refrain from the activities set forth in Sections 2(a)-(b) shall be tolled during any period in which Employee fails to abide by these provisions.</td>
		</tr>
		<tr>
			<td style="width:67pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="width: 67pt; padding: 0pt 7.2pt; text-indent: 36pt; text-align: left;"><b>5.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b><u><b>VIOLATION BY COMPANY.</b></u><b>&nbsp;</b>In the event that Employee alleges and proves a violation by the Company Group of any obligation of the Company Group to Employee by agreement or operation of law, such violation shall not excuse Employee from Employee&#8217;s obligations pursuant to this Agreement, but rather Employee shall be entitled to remedies available for the specific violation alleged and proven.</td>
		</tr>
		<tr>
			<td style="width:67pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="width: 67pt; padding: 0pt 7.2pt; text-indent: 36pt; text-align: left;"><b>6.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b><u><b>OTHER AGREEMENTS.</b></u><b> </b>Nothing in this Agreement shall terminate, revoke, or diminish Employee&#8217;s obligations or the Company Group&#8217;s rights and remedies under law or pursuant to the PIIA, relating to trade secrets or proprietary information.</td>
		</tr>
		<tr>
			<td style="width:67pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="width: 67pt; padding: 0pt 7.2pt; text-indent: 36pt; text-align: left;"><b>7.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b><u><b>ENTIRE AGREEMENT.</b></u><b> </b>This Agreement and the PIIA, together constitute the exclusive and complete agreement between the Parties with respect to this subject matter and supersedes any other right of the Employee to severance under any plan, arrangement or</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">B-3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td colspan="3" style="width: 67pt; padding-left: 9pt;">agreement of the Company. No change or modification of this Agreement shall be valid or binding upon the Parties unless such change or modification is in writing and is signed by the Parties.</td>
		</tr>
		<tr>
			<td style="width:67pt;">&nbsp;</td>
			<td style="width: 34px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1238px;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="width: 67pt; padding: 0pt 7.2pt; text-indent: 36pt; text-align: left;"><b>8.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b><u><b>WAIVER OF BREACH.</b></u><b> </b>The Company&#8217;s or Employee&#8217;s waiver of any breach of a provision of this Agreement shall not waive any subsequent breach by the other Party.</td>
		</tr>
		<tr>
			<td style="width:67pt;">&nbsp;</td>
			<td style="width: 34px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1238px;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="width: 67pt; padding: 0pt 7.2pt; text-indent: 36pt; text-align: left;"><b>9.&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b><u><b>SEVERABILITY.</b></u><b> </b>If a court of competent jurisdiction holds that any provision or sub-part thereof contained in this Agreement is invalid, illegal, or unenforceable, that invalidity, illegality, or unenforceability shall not affect any other provision in this Agreement. Additionally, if any of the provisions of this Agreement are held unenforceable by a court of competent jurisdiction, then the Parties desire that such provision, clause, or phrase be &#8220;blue- penciled&#8221; or rewritten by the court to the extent necessary to render it enforceable.</td>
		</tr>
		<tr>
			<td style="width:67pt;">&nbsp;</td>
			<td style="width: 34px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1238px;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="width: 67pt; padding: 0pt 7.2pt; text-indent: 36pt; text-align: left;"><b>10.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b><u><b>PARTIES BOUND.</b></u><b> </b>The terms, provisions, covenants and agreements contained in this Agreement shall apply to, be binding upon and inure to the benefit of the Company&#8217;s successors and assigns, and Employee&#8217;s heirs, executors, administrators, and other legal representatives. Employee may not assign this Agreement.</td>
		</tr>
		<tr>
			<td style="width:67pt;">&nbsp;</td>
			<td style="width: 34px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1238px;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="width: 67pt; padding: 0pt 7.2pt; text-indent: 36pt; text-align: left;"><b>11.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b><u><b>REMEDIES.</b></u><b> </b>Employee acknowledges that Employee&#8217;s breach of this Agreement would cause the Company irreparable harm for which damages would be difficult, if not impossible, to ascertain and legal remedies would be inadequate. Therefore, in addition to any legal or other relief to which the Company may be entitled by virtue of Employee&#8217;s breach or threatened breach of this Agreement, the Company may seek equitable relief, including but not limited to preliminary and permanent injunctive relief and all other available remedies.</td>
		</tr>
		<tr>
			<td style="width:67pt;">&nbsp;</td>
			<td style="width: 34px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1238px;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="width: 67pt; padding: 0pt 7.2pt; text-indent: 36pt; text-align: left;"><b>12.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b><u><b>GOVERNING LAW.</b></u><b> </b>This Agreement and the employment relationship created by it shall be interpreted and construed in accordance with the laws of the State of North Carolina, including its statutes of limitations, without giving effect to any conflict-of-laws rule that would result in the application of the laws of a different jurisdiction. The Parties consent to exclusive jurisdiction in North Carolina for the purpose of any litigation relating to this Agreement and agree that any litigation by or involving them relating to this Agreement shall be conducted in the state courts of North Carolina or the appropriate federal district court located in North Carolina. Employee consents to the exercise of personal jurisdiction in any state or federal court located in North Carolina and waives any objection based upon personal jurisdiction or <i>forum non conveniens </i>with respect to any action commenced in such courts.</td>
		</tr>
		<tr>
			<td style="width:67pt;">&nbsp;</td>
			<td style="width: 34px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1238px;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="width: 67pt; padding: 0pt 7.2pt; text-indent: 36pt; text-align: left;"><b>13.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b><u><b>COUNTERPARTS.</b></u><b> </b>This Agreement may be executed in counterparts, each of which shall be an original, with the same effect as if the signatures affixed thereto were upon the same instrument.</td>
		</tr>
		<tr>
			<td style="width:67pt;">&nbsp;</td>
			<td style="width: 34px; vertical-align: top;">&nbsp;</td>
			<td style="vertical-align: top; width: 1238px;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="width: 67pt; padding: 0pt 7.2pt; text-indent: 36pt; text-align: left;"><b>14.&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</b><u><b>EMPLOYEE ACKNOWLEDGMENT.</b></u><b> </b>Employee understands and agrees that (i) this Agreement is not a contract of employment for any particular term and (ii) the consideration for this Agreement includes but is not limited to his promotion to Chief Commercial Officer and the compensation, benefits and other terms set forth in the Agreement executed simultaneously with this Agreement, to which he otherwise would not have been entitled.</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">B-4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 7.2pt; text-align: left; text-indent: 36pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">IN WITNESS WHEREOF, the Company has caused this Non-Competition and Non- Solicitation Agreement to be executed by its duly authorized officer and Employee has executed the same as of the dates set forth below.</p>

<p style="font-size: 0.5pt; margin: 0 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-size: 0.5pt; margin: 0 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="margin-left:2.5%;width:84.2%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.4%;">BIOCRYST<br>
			PHARMACEUTICALS, INC.</td>
			<td style="vertical-align:top;width:48.8%;">EMPLOYEE</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:48.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:48.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:48.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align:top;width:45.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ Stephanie Angelini &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
			<td style="vertical-align:top;width:48.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ Charles Gayer &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Stephanie Angelini</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">SVP, Human Resources</p>
			</td>
			<td style="vertical-align:top;width:48.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Charles Gayer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:48.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:45.4%;">Date: <u>January 14, 2020&nbsp; &nbsp; &nbsp;</u></td>
			<td style="vertical-align:top;width:48.8%;">Date: <u>January 14, 2020&nbsp; &nbsp; &nbsp;</u></td>
		</tr>

</table>

<p style="font-size: 0.5pt; margin: 0 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-size: 0.5pt; margin: 0 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">B-5</div>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>5
<FILENAME>ex_230471.htm
<DESCRIPTION>EXHIBIT 10.28
<TEXT>
<html><head>
	<title>ex_230471.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 10.28</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT IN PLACES MARKED &#8220;[***]&#8221; BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>by and between</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>and</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>SHIONOGI &amp; CO., LTD.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>Dated as of February 28, 2007</b></p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">This <b>LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT </b>(this &#8220;<i><b>Agreement</b></i>&#8221;) is entered into as of February 28, 2007 by and between BIOCRYST PHARMACEUTICALS, INC., a corporation organized and existing under the laws of the State of Delaware having offices at 2190 Parkway Lake Drive, Birmingham, Alabama 35244 (&#8220;<i><b>BioCryst</b></i>&#8221;), and SHIONOGI &amp; CO., LTD., a corporation organized and existing under the laws of the Japan having offices at 1-8, Doshomachi 3-chome, Chuo-ku, Osaka 541-0045, Japan (&#8220;<i><b>Shionogi</b></i>&#8221;). BioCryst and Shionogi are each referred to herein by name or individually as a &#8220;<i><b>Party</b></i>&#8221; or collectively as the &#8220;<i><b>Parties</b></i>.&#8221;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>BACKGROUND</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"><b>WHEREAS, </b>BioCryst owns or controls patents, know-how and other intellectual property related to a compound known as Peramivir.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"><b>WHEREAS, </b>Shionogi has expertise in the discovery, development, manufacture and sale of pharmaceutical products in the Territory (as defined below).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"><b>WHEREAS, </b>Shionogi wishes to obtain, and BioCryst wishes to grant, in the Territory only, rights and licenses under certain of BioCryst&#8217;s patents, know-how and trademarks to Shionogi so that Shionogi can obtain the necessary regulatory approvals to sell Licensed Products (as defined below) in the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"><b>NOW, THEREFORE, </b>in consideration of the premises and mutual covenants herein below, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 1<br>
DEFINITIONS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">1.1 Defined Terms. As used in this Agreement, the following terms shall have the meanings indicated:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(a) "<i><b>Affiliate</b></i>&#8221; means any corporation or other entity which is directly or indirectly controlling, controlled by or under common control of a Party, for so long as such control exists. For the purposes of this Section 1.1(a), &#8220;control&#8221; means direct or indirect ownership of fifty percent (50%) or more (or, if less than fifty percent (50%), the maximum ownership interest permitted by applicable Law) of the voting rights, shares or other equity or income interest of a Party.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(b) "<i><b>BioCryst Know-How</b></i>&#8221; means Know-How owned, developed or controlled by, or licensed to, BioCryst.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(c) "<i><b>BioCryst Intellectual Property Rights</b></i>&#8221; means all Intellectual Property Rights owned or controlled by BioCryst, including but not limited to BioCryst Know-How, the BioCryst Marks, and BioCryst Patents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(d) "<i><b>BioCryst Logo</b></i>&#8221; means the company logo of BioCryst in a form provided, and approved in writing, by BioCryst from time to time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(e) "<i><b>BioCryst Marks</b></i>&#8221; means the BioCryst Logo and any trademark, trade name or logo approved by BioCryst for use in connection with the Commercialization of the Licensed Product (whether or not owned by BioCryst).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(f) "<i><b>BioCryst Patents</b></i>&#8221; means those Patents owned, licensed or controlled by BioCryst which are filed in the Territory and which relate to the manufacture, use or sale of Licensed Products and/or Compound, which are set forth on Schedule 1.1(f).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(g) "<i><b>Budget</b></i>&#8221; means, individually, the applicable budget set forth in the Development Plan or Commercialization plan.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(h) "<i><b>cGMPs</b></i>&#8221; means the United States then-current good manufacturing practices and the equivalent standards of the Japanese government.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(i) "<i><b>Change of Control</b></i>&#8221; means, with respect to a Party, any of the following events: (i) any corporation or other entity is or becomes the &#8220;beneficial owner&#8221; (as such term is used in sections 12(d) and 13(d) of the Securities Exchange Act of 1934, as amended, except that a corporation or other entity shall be deemed to have &#8220;beneficial ownership&#8221; of all shares that any such corporation or other entity has the right to acquire, whether such right may be exercised immediately or only after the passage of time), of a majority of the total voting power represented by all classes of capital stock then outstanding of such Party normally entitled to vote in elections of directors of the Party; (ii) such Party consolidates with or merges into another corporation or entity, or any corporation or entity consolidates with or merges into such Party, other than (A) a merger or consolidation which would result in the voting securities of such Party outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof) a majority of the combined voting power of the voting securities of such Party or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation, or (B) a merger or consolidation effected to implement a recapitalization of such Party (or similar transaction) in which no corporation or other entity becomes the beneficial owner, directly or indirectly, of voting securities of such Party representing a majority of the combined voting power of such Party&#8217;s then outstanding securities; or (iii) such Party conveys, transfers or leases all or substantially all of its assets to any corporation or other entity other than a wholly-owned subsidiary of such Party in one or more related transactions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(j) &#8220;<i><b>COGS</b></i>&#8221; or &#8220;<i><b>Cost of Goods Sold</b></i>&#8221; means, [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(k) &#8220;<i><b>Combination Product</b></i>&#8221; means [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(l) "<i><b>Commercialization</b></i>&#8221; means, with respect to Licensed Product, any and all processes and activities conducted to establish and maintain sales for such Licensed Product, including offering for sale, detailing, selling (including launch), marketing (including education and advertising activities), promoting, manufacturing Licensed Product from Compound, but not manufacturing Compound itself), storing, transporting, supporting, distributing, and importing such product, but shall exclude development and manufacturing of Compound. &#8220;Commercialize&#8221; and &#8220;Commercializing&#8221; shall have their correlative meanings.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(m) "<i><b>Compound</b></i>&#8221; means the chemical compound known as &#8220;<i><b>Peramivir</b></i>&#8221; having the following chemical structure:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">(1S,2S,3R,4R)-3-[(1S)-1-(acetylamino)-2-ethylbutyl] -4-[(aminoiminomethyl)amino]-2-hydroxy-cyclopentanecarboxylic acid, trihydrate</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div style="text-align: center;"><img alt="compound1028.jpg" src="compound1028.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">including the salts, esters, prodrugs, metabolites, tautomers, isomers, labeled compounds, conjugates, complexes, and other related compounds thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(n) "<i><b>Data</b></i>&#8221; means any and all research, pharmacology, medicinal chemistry, chemistry, manufacturing and controls, nonclinical, clinical and other data (including investigator reports and clinical study reports (both preliminary and final), statistical analyses, expert opinions and reports, safety and other electronic databases), in each case specifically directed to, or used in the Development and Commercialization of, a Licensed Product and/or Compound.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(o) "<i><b>Development</b></i>&#8221; means, with respect to a Licensed Product, any and all processes and activities conducted to obtain Marketing Approvals for such product, including IND Enabling Studies and all other activities conducted thereafter, which may involve nonclinical studies, studies of chemistry, manufacturing and controls, clinical trials, quality of life assessments, pharmacoeconomics, post-marketing studies, label expansion studies, and further activities related to development of such product to a stage ready for Commercialization thereof. &#8220;Develop&#8221; and &#8220;Developing&#8221; shall have their correlative meanings.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(p) "<i><b>Development Costs</b></i>&#8221; means all costs and expenses to be incurred by a Party in the course of the Development of Licensed Product, including, but not limited, to the costs of conducting clinical trials, regulatory filing and maintenance fees, pricing and reimbursement filing and maintenance fees and costs relating to approval by the Regulatory Authority of the Licensed Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(q) "<i><b>Development Plan</b></i>&#8221; means the development plan pursuant to which Shionogi shall Develop the Licensed Product, which shall be prepared by the JSC within forty-five (45) days after the Effective Date, attached to this Agreement as Schedule 1.1(q) and made a part of this Agreement, and which may be modified at anytime, and from time to time by the JSC.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(r) &#8220;<i><b>Diligent Efforts</b></i>&#8221; means, [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(s) &#8220;<i><b>Effective Date</b></i>&#8221; means the date hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(t) "<i><b>FDA</b></i>&#8221; means the United States Food and Drug Administration, or any successor entity thereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(u) "<i><b>Field</b></i>&#8221; means the prevention and/or treatment of all forms of influenza, in humans (including avian influenza) .</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(v) "<i><b>GAAP</b></i>&#8221; means then-current generally accepted accounting principles in the United States as established by the Financial Accounting Standards Board or any successor entity or other entity generally recognized as having the right to establish such principles, in each case consistently applied.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(w) <i><b>&#8220;Generic Product&#8221; </b></i>means [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(x) "<i><b>GLP</b></i>&#8221; means the then-current good laboratory practice (or similar standards) for the performance of laboratory activities for pharmaceutical products as are required by any Regulatory Authority in the applicable jurisdiction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(y) &#8220;<i><b>Governmental Entity</b></i>&#8221; means [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(z) <b>"</b><i><b>Guiding Principle</b></i><b>&#8221; </b>means in the timely Development of Licensed Products.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(aa) "<i><b>IND</b></i>&#8221; means an Investigation of New Drug filing (or the Japanese equivalent) with a Regulatory Authority in the Territory for purposes of obtaining permission to initiate human clinical testing in such jurisdiction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(bb) "<i><b>IND Enabling Studies</b></i>&#8221; means studies which in each case are reasonably necessary to obtain approval of an IND, including GLP, ADME (absorption, distribution, metabolism and excretion), toxicology, pharmacology and safety pharmacology studies, or studies of chemistry, manufacturing and controls.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(cc) "<i><b>Initiation</b></i>&#8221; means, with respect to a particular clinical trial, the date of enrollment of the first subject or patient in such trial.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(dd) "<i><b>Insolvency Event</b></i>&#8221; means, with respect to any Party, the occurrence of any of the following: (i) such Party shall commence a voluntary case concerning itself under any bankruptcy, liquidation or insolvency code; (ii) an involuntary case is commenced against such Party under any bankruptcy, liquidation or insolvency code and the petition is not controverted within ten (10) business days, or is not dismissed within sixty (60) days, after commencement of the case; (iii) a custodian is appointed for, or takes charge of, all or substantially all of the property of such Party or such Party commences any other proceedings under any reorganization, arrangement, adjustment of debt, relief of debtors, dissolution, insolvency or liquidation or similar law of any jurisdiction whether now or hereafter in effect relating to such Party or there is commenced against such Party any such proceeding which remains undismissed for a period of sixty (60) days; (iv) any order of relief or other order approving any such case or proceeding is entered; (v) such Party is adjudicated insolvent or bankrupt; (vi) such Party suffers any appointment of any custodian, receiver or the like for it or any substantial part of its property to continue undischarged or unstayed for a period of sixty (60) days; (vii) such Party makes a general assignment for the benefit of creditors; (viii) such Party shall be unable to pay, its debts generally as they become due; (ix) such party shall call a meeting of its creditors with a view to arranging a compromise or adjustment of its debts; (x) such Party shall by any act or failure to act consent to, approve of or acquiesce in any of the foregoing; or (xi) any corporate, limited liability company, partnership or individual action, as applicable, is taken by such Party for the purpose of effecting any of the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(ee) "<i><b>Intellectual Property Rights</b></i>&#8221; shall mean all Patent, copyright, trade secret, trademark and other proprietary and intellectual property rights, anywhere in the world.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(ff) &#8220;<i><b>Japan</b></i>&#8221; means the country of Japan.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(gg) &#8220;<i><b>JSC</b></i>&#8221; or &#8220;<i><b>Joint Steering Committee</b></i>&#8221; shall have the meaning set forth in Section 4.1.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(hh) "<i><b>Know-How</b></i>&#8221; means all scientific and technical information and know-how, trade secrets, Data and technology now or hereafter during the term of this Agreement (whether patented, patentable or not) owned, developed or acquired by a Party or any of its Affiliates or as to which such Party or any of its Affiliates has the right to license (without a payment obligation to any third party), which relates to the Licensed Product and/or Compound, including but not limited to (a) medical, clinical, toxicological or other scientific Data; and (b) processes and analytical methodology useful in the development, testing, formulation, analysis or packaging (but not manufacturing of Compound) of the Licensed Product and/or Compound.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(ii) "<i><b>Law</b></i>&#8221; means, individually and collectively, any and all laws, ordinances, rules, directives and regulations of any kind whatsoever of any governmental or regulatory authority within the applicable jurisdiction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(jj) &#8220;<i><b>Licensed Product</b></i>&#8221; means [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(kk) "<i><b>Marketing Approval</b></i>&#8221; means, with respect to a particular product in a particular jurisdiction, all approvals, licenses, registrations or authorizations necessary for the Commercialization of such product in such jurisdiction. Marketing Approval shall be deemed to have been received upon first receipt by a Party or its designee of notice from the applicable Regulatory Authority that Commercialization of such product has been approved in such jurisdiction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(ll) &#8220;Marketing Approval Application&#8221; or &#8220;MAA&#8221; means a filing with the applicable Regulatory Authority for purposes of obtaining Marketing Approval in a particular jurisdiction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(mm) &#8220;Material Use&#8221; means [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(nn) "<i><b>MHLW</b></i>&#8221; means the Ministry of Health, Labour and Welfare of Japan or any successor entity thereto<i>.</i></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(oo) "<i><b>NDA</b></i>&#8221; means a New Drug Application (or the Japanese equivalent), including all supplements and amendments thereto, for the approval of the Licensed Product as a new drug by the MHLW or applicable Regulatory Authority in the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(pp) &#8220;<i><b>Net Sales</b></i>&#8221; means, [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(qq) "<i><b>Patent</b></i>&#8221; means any of the following, whether existing now or in the future anywhere in the world: (a) patents and patent applications; (b) continuations, continuations-in-part, divisionals and substitute applications with respect to any such patent application; (c) any patents issued based on or claiming priority to any such patent applications; (d) any reissue, reexamination, renewal or extension (including any supplemental patent certificate) of any such patents; and (e) any confirmation patent or registration patent or patent of addition based on any such patents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(rr) "<i><b>Phase I Clinical Trial</b></i>&#8221; means a clinical trial of Licensed Product including small scale clinical trial in human subjects to obtain information on such Licensed Product&#8217;s safety, tolerability, pharmacological activity, pharmacokinetics and/or pharmacodynamics, and supporting Marketing Approval of such Licensed Product in the Field, as more fully defined in 21 CFR 312.21(a) or the equivalent statute or regulation in the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(ss) "<i><b>Phase II Clinical Trial</b></i>&#8221; means a well-controlled clinical trial of Licensed Product in patients, a principal purpose of which is to make a preliminary determination that such Licensed Product is safe for its intended use and to obtain sufficient information about such Licensed Product&#8217;s safety, as well as to obtain an indication of the dosage regimen required, to permit the design of further clinical studies, and supporting Marketing Approval of such Licensed Product in the Field, as more fully defined in 21 CFR 312.21(b) or the equivalent statute or regulation in the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(tt) "<i><b>Phase III Clinical Trial</b></i>&#8221; means a large scale clinical trial conducted in a sufficient number of patients that is designed to establish that the Licensed Product is safe and efficacious for its intended use, and to obtain warnings, precautions and adverse reactions that are associated with such Licensed Product in the dosage range to be prescribed, and supporting Marketing Approval of such Licensed Product in the Field, as more fully defined in 21 CFR 312.21(c) or the equivalent statute or regulation in the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(uu) &#8220;<i><b>Plans</b></i>&#8221; means, collectively, the Development Plan and the Commercialization Plan.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(vv) "<i><b>Pre-Existing Third Party License</b></i>&#8221; means the agreement dated as of November 23, 1994 by and between, on the one hand The UAB Research Foundation (<i><b>&#8220;UAB</b></i>&#8221;), and on the other hand BioCryst, as amended and may be amended from time to time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(ww) "<i><b>Promotional Material</b></i>&#8221; means all Licensed Product packaging and labeling, and all written, printed, graphic, electronic, audio or video matter, including journal advertisements, sales visual aids, leave behind items, formulary binders, reprints, direct mail, direct-to consumer advertising, Internet postings, broadcast advertisements and sales reminder aids (for example, scratch pads, pens and other like items), in each case created by a Party or on its behalf and used or intended for use in connection with any promotion of a Licensed Product in the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(xx) "<i><b>Regulatory Authority</b></i>&#8221; means any federal, national, multinational, state, provincial or local regulatory agency, department, bureau or other governmental entity with authority over the Development, Commercialization or other use (including the granting of Marketing Approvals) of any Licensed Product in any jurisdiction, including the FDA, the MHLW and the Pharmaceuticals and Medical Devices Agency.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(yy) "<i><b>Regulatory Filings</b></i>&#8221; means all submissions, applications, filings and approvals by, with or from any Regulatory Authority.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(zz) "<i><b>Sale</b></i>&#8221;, &#8220;<i><b>Sold</b></i>&#8221; or &#8220;<i><b>Sell</b></i>&#8221; shall mean the sale, transfer or disposition of a Licensed Product for commercial or clinical purposes as provided in this Agreement, for value to a Third Party (whether an end user, wholesaler or otherwise) by Shionogi or any of its Affiliates.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(aaa) &#8220;<i><b>Shionogi Know-How</b></i>&#8221; means all Know-How owned, developed or acquired by or on behalf of Shionogi and its Affiliates.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(bbb) &#8220;<i><b>Territory</b></i>&#8221; means Japan.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(ccc) "<i><b>Third Party&#8221; </b></i>means any entity other than Shionogi or BioCryst, or their respective Affiliates.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(ddd) &#8220;<i><b>U.S. Government</b></i>&#8221; shall mean the federal government of the United States of America and any of its branches and instrumentalities, including its departments, agencies, bureaus, commissions, boards, courts, corporations, offices, and other entities, and any divisions or units thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(eee) &#8220;<i><b>Valid Claim</b></i>&#8221; means a claim in any unexpired and issued BioCryst Patent that has not been revoked or held invalid by a final unappealable decision of a court or governmental agency of competent jurisdiction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 2<br>
LICENSE GRANT, RETAINED RIGHTS AND PROVISION OF DATA</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">2.1 <u>License Grant; Reservation of Rights</u>. Solely to the extent necessary for Shionogi to perform its obligations hereunder in accordance with the terms of this Agreement, and subject to all of the rights retained hereunder, BioCryst hereby grants Shionogi a personal, non-sublicensable, non-transferable, non-assignable right and license under the BioCryst Patents and BioCryst Know-How, to (i) exclusively Develop Licensed Products solely in the Field and in the Territory, and (ii) exclusively Commercialize Licensed Products solely in the Field and in the Territory. Other than as explicitly set forth in this Section 2.1, no other licenses to the BioCryst Intellectual Property Rights or otherwise (including but not limited to all rights in BioCryst Intellectual Property Rights outside the Field and outside the Territory) are granted in this Agreement. [***]</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">2.2 <u>Manufacturing</u>. [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">2.3 <u>Retained Rights; Government Rights</u>. All rights granted to Shionogi hereunder are subject to rights reserved by and/or granted to UAB or the U. S. Government. Shionogi specifically understands and agrees that BioCryst shall have the unrestricted and fully unfettered right under the BioCryst Intellectual Property Rights outside of the Field in the Territory and outside of the Territory in the Field, including in connection with the testing, Development, manufacture and Commercialization of products covered by the BioCryst Patents and BioCryst Know-How.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">2.4 <u>BioCryst Logo</u>. BioCryst hereby grants to Shionogi a personal, non-sublicensable, non-transferable, non-assignable right and license to use the BioCryst Logo on Licensed Products in the Field in the Territory in accordance with the terms of this Agreement. Shionogi agrees to mark (i) all packaging, labeling and package inserts for Licensed Product and (ii) such Promotional Material as shall be agreed upon by the Parties in writing, with the BioCryst Logo. All use of the BioCryst Logos shall be as directed by BioCryst and shall be in a form, style and prominence as directed by BioCryst, and all goodwill associated with the use of the BioCryst Logos shall inure to BioCryst.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">2.5 <u>Transfer of Data</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(a) <u>BioCryst Existing Data</u>. BioCryst shall transfer to Shionogi, [***] after the Effective Date, all Data (to the extent contractually permissible) possessed or controlled by BioCryst as of the Effective Date, including, but not limited to [***]. Certain Data (including the Future Data described below) specified by Shionogi shall be accompanied by a statement or certificate by an employee or agent of BioCryst in such form as mutually agreed upon by the Parties. Shionogi acknowledges and agrees that delivery of Data in electronic form shall be acceptable. BioCryst represents and warrants that<b>, </b>to its best knowledge, all studies, testings and clinical trials from which the Data were derived were conducted in accordance with then-applicable United States Laws.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(b) <u>Shionogi Nonclinical Data and Phase I Data</u>. Shionogi will promptly, [***] disclose to BioCryst all nonclinical Data and Data from Phase I Clinical Trials (whether or not such Data meets the criteria of &#8220;Future Data&#8221;, set forth below in Section 2.5(c)(i)) developed by or on behalf of Shionogi or which otherwise comes into Shionogi&#8217;s possession or control after the Effective Date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(c) <u>Future Data</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:36pt;">(i) <u>Data Exchange</u>. From time to time (including upon request by either Party) during the Term of this Agreement, each Party shall, [***], disclose to the other Party all previously undisclosed Data relating to the Licensed Product and/or Compound that (i) comes into such Party&#8217;s possession or control after the Effective Date and (ii) is necessary to obtain or maintain a Marketing Approval for a Licensed Product (&#8220;<i><b>Future Data</b></i>&#8221;). [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:36pt;">(ii) <u>Material Use</u>. [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(d) <u>Raw Data</u>. A Party generating the Data subject to exchange under Section 2.5(a) and (c)(ii) shall keep all of raw data from which the Data were derived in commercially usable condition in accordance with applicable Laws and shall allow the other Party access to such raw data upon the reasonable request by the other Party.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 3<br>
COMMERCIAL MATTERS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">3.1 <u>General</u>. Shionogi shall use Diligent Efforts to Develop Licensed Products in the Field in the Territory, including any IND, MAA, Marketing Approval and any approval for any product labeling or Promotional Materials and to maintain all such Regulatory Filings; and unless otherwise agreed or required by applicable Laws, all such approvals shall be owned by and be held in the name of Shionogi or its Affiliates. BioCryst shall cooperate with Shionogi in preparing all Regulatory Filings and correspondence with Regulatory Authorities in the Territory. Shionogi shall use Diligent Efforts to Commercialize the Licensed Products in the Territory. Notwithstanding the foregoing covenant to cooperate, the Parties acknowledge and agree that all responsibility for Regulatory Filings and exercising Diligent Efforts in the Territory shall be Shionogi&#8217;s.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">3.2 <u>BioCryst&#8217;s Participation</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(a) <u>Protocols</u>. Shionogi shall pay due consideration to the protocols and desired endpoints in the trials sponsored by BioCryst in preparing the protocols for the clinical trials to be conducted by or on behalf of Shionogi in the Territory. Shionogi shall provide BioCryst with the outline of the draft of protocols (in the English language) for clinical trials. Consistent with applicable Laws, Shionogi shall afford BioCryst an opportunity to comment on such protocols within fifteen (15) business days after receipt and shall consider in good faith such BioCryst&#8217;s comments with respect thereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(b) <u>Filings and Correspondence</u>. Shionogi shall promptly provide BioCryst with (i) copies of all Regulatory Filings relating to the Territory submitted by Shionogi (in the original language) and (ii) copies of material correspondence with Regulatory Authorities in the Territory (including minutes of meetings, telephone conferences and/or discussions with such Regulatory Authority) (in the original language). Shionogi agrees to assist BioCryst the English translation of such documents at BioCryst&#8217;s cost.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(c) <u>Regulatory Meetings</u>. Shionogi shall promptly provide BioCryst with reasonable advanced notice (to the extent practicable) of meetings, scheduled or unscheduled, with any Regulatory Authority that pertain to a Licensed Product, and, to the extent not prohibited by applicable Law, shall afford BioCryst&#8217;s representatives an opportunity to attend and participate in all such meetings with relevant Regulatory Authorities as observers, to the extent reasonably practicable under the circumstances. Likewise, BioCryst shall promptly provide Shionogi with reasonable advanced notice (to the extent practicable) of meetings, scheduled or unscheduled, with any Regulatory Authority that pertain to a Licensed Product developed by BioCryst (for clarity, BioCryst itself, and not licensees of BioCryst) outside the Territory, and, to the extent not prohibited by applicable Law, shall afford Shionogi&#8217;s representatives an opportunity to attend and participate in all such meetings with relevant Regulatory Authorities as observers, to the extent reasonably practicable under the circumstances.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(d) <u>JSC Oversight</u>. In addition to Section 3.2(a), (b) and (c) above with respect to Regulatory Filings and meetings with Regulatory Authorities, Shionogi&#8217;s Development and Commercialization activities, including the content and subject matter of, and strategy for, any MAA, all correspondence submitted to Regulatory Authorities related to clinical trial design, all proposed labeling and labeling discussions and decisions with Regulatory Authorities, and all post-Marketing Approval labeling discussions and decisions with Regulatory Authorities (including the final approved labeling), and post-Marketing Approval labeling changes or expansions, in each case relating in any way to Licensed Product, shall be subject to reasonable oversight by the JSC.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">3.3 <u>Cooperation</u>. Each Party agrees to make its personnel reasonably available, upon reasonable notice by the other Party, at their respective places of employment to consult with the other Party on issues arising related to the activities conducted in accordance with this Article 3 or otherwise relating to regulatory matters involving the Licensed Product, including any request from any Regulatory Authority, including regulatory, scientific, technical and clinical testing issues, or otherwise. Each Party (the &#8220;<i><b>Enabling Party</b></i>&#8221;) agrees to cooperate with the other (the "<i><b>Filing Party</b></i>&#8221;), at its request, to comply with specific requests of a Regulatory Authority (such as requests to inspect clinical trial sites), with respect to Data supplied or to be supplied by the Enabling Party to the Filing Party for filing with such Regulatory Authority, or with respect to Licensed Product supplied by the Enabling Party. The Enabling Party shall ensure that its contractors likewise comply with this Section 3.3.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">3.4 <u>Use of Contractors</u>. Subject to the terms of this Agreement, Shionogi shall have the right to use the services of Third Party contractors, including contract research organizations, contract sales forces and the like, to assist Shionogi in fulfilling its obligations and exercising its rights under this Agreement, provided that each such Third Party is bound by a written agreement, that is consistent with terms of this Agreement, including confidentiality and intellectual property ownership provisions consistent with those set forth therein<b>. </b>Shionogi shall provide BioCryst with quarter annual updates of the identity of all contractors who assist Shionogi in exercising its rights or fulfilling its obligations hereunder. For the purposes of clarity, Shionogi shall remain responsible for the performance by all such contractors.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">3.5 <u>Development Supply</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(a) From the Effective Date through [***], BioCryst will supply to Shionogi, at Shionogi<b>&#8216;</b>s expense, and Shionogi agrees to purchase exclusively from BioCryst, (i) the Licensed Product (including its placebos if needed) for use in clinical studies to be conducted in the Territory by or on behalf of (subject to the terms of Section 3.4, above) Shionogi, and (ii) the Compound necessary for the Development of the Licensed Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(b) On [***], BioCryst will supply Shionogi with Compound (at Shionogi&#8217;s expense) and Shionogi will have established the necessary resources to formulate Licensed Product from Compound for clinical use. The Parties agree to evaluate in good faith the above arrangement on an ongoing basis to ensure the timely progression and development of the Licensed Product in the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(c) During the term of this Agreement, BioCryst shall supply to Shionogi, [***] of Compound (in such individual amounts and at such times as reasonably agreed upon by the Parties) for Shionogi to use Diligent Efforts to develop an optimized intramuscular formulation of the Compound for use by Shionogi in the Territory and for use by BioCryst outside the Territory pursuant to Section 10.2<b>.</b> In addition, if the Parties agree in writing that Shionogi may explore the possibility to Develop New Formulations under mutually agreed conditions, BioCryst shall also supply to Shionogi, [***] (but upon such additional terms and conditions as the Parties may agree), the Compound for Development of such New Formulation. Both Parties understand and agree that there are no assurances that Shionogi&#8217;s efforts will generate an optimized intramuscular formulation of the Compound or lead to the successful Development of New Formulations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(d) All Licensed Product and Compound delivered by BioCryst to Shionogi shall be manufactured in accordance and in compliance with the specifications to be determined by BioCryst; provided, however that BioCryst shall give due consideration to revised specifications (if any) requested by Shionogi. BioCryst shall carry out its responsibilities hereunder in conformance with cGMPs and all other applicable Laws (all of the foregoing, in the United States). All supply of Licensed Product and Compound shall be subject to the terms and conditions set forth in this Section 3.5 and shall be subject to the terms and on prices as attached in Schedule 3.5 hereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(e) BioCryst shall transfer to Shionogi the formulation and manufacturing processes that (i) are maintained or subsequently developed or optimized by BioCryst and (ii) are designed to ensure the quality of Licensed Product. All transfer of such Know-How shall take place in Birmingham, Alabama unless otherwise agreed upon by the Parties. If the transfer is to occur wholly or partially outside of Birmingham, Alabama, then Shionogi shall promptly [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">3.6 <u>Commercial Supply</u>. BioCryst will supply to Shionogi, at Shionogi&#8217;s expense, and Shionogi agrees to purchase exclusively from BioCryst, Compound in bulk powder form for purposes of Commercialization in the Territory. Such supply shall be subject to the terms and on prices as attached in Schedule 3.5 hereto<b>. </b>Shionogi shall be responsible for manufacturing Licensed Product from Compound provided by BioCryst to Shionogi.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">3.7 <u>Covenant and Manufacturing Option</u>. For the avoidance of doubt, the Parties hereby agree that they intend that BioCryst supply, and Shionogi exclusively purchase from BioCryst, Compound for all uses contemplated in this Agreement. Shionogi hereby acknowledges and agrees that it has no rights to, and shall not (and it and its Affiliates shall not otherwise) manufacture or have manufactured or purchase from a Third Party Compound unless otherwise agreed in writing between BioCryst and Shionogi. However, Shionogi shall have the option to manufacture or have manufactured Compound for the Territory; [***]. In the event that Shionogi exercises such option to manufacture Compound, BioCryst shall transfer to Shionogi all BioCryst Know-How or other technologies relating to manufacture of the Compound. All transfer of such Know-How shall take place in Birmingham, Alabama unless otherwise agreed upon by the Parties. If the transfer is to occur wholly or partially outside of Birmingham, Alabama, then Shionogi shall [***]. In such event, all products Commercialized in the Field which derive from such Compound shall be deemed for all purposes hereunder to be a Licensed Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 4<br>
GOVERNANCE</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">4.1 <u>Joint Steering Committee</u>. Promptly following the Effective Date, but no later than forty-five (45) days after the Effective Date, the Parties shall establish a joint steering committee (the <b>"</b><i><b>Joint Steering Committee</b></i><b>&#8221; </b>or <b>"</b><i><b>JSC</b></i><b>"</b>) to oversee, review and coordinate the conduct and progress of the Development of Licensed Product in the Territory. The JSC shall be responsible for, among other things: annually reviewing and updating the Development Plan; monitoring the competitive landscape for the Licensed Product in the Territory; and undertaking such other matters as are specifically provided for the JSC under this Agreement. Shionogi shall keep the JSC fully informed of progress and results of its activities under the Development Plan through its members on the JSC and as otherwise provided herein.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">4.2 <u>Committee Membership</u>. The JSC shall be comprised of an equal number of representatives from each of BioCryst and Shionogi. The exact number of such representatives shall initially be three (3) for each of BioCryst and Shionogi, or such other number as the Parties may agree. The initial members of the JSC shall be as set forth on Exhibit A. Either Party may replace its respective committee representatives at any time with prior written notice to the other Party. Unless otherwise agreed, the JSC shall have at least one representative with relevant decision-making authority from each Party such that the JSC is able to effectuate all of its decisions within the scope of its responsibilities. In the event a JSC member from either Party is unable to attend or participate in a JSC meeting, the Party who designated such representative may designate a substitute representative for the meeting in its sole discretion.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">4.3 <u>Subcommittees</u>. From time to time, the JSC may establish subcommittees to oversee particular projects or activities, and such subcommittees will be constituted as the JSC approves (each, a &#8220;<i><b>Subcommittee</b></i>&#8221;). If any Subcommittee is unable to reach a decision on any matter after endeavoring in good faith for [***] to do so, such matter shall be referred to the JSC for resolution as provided in Section 4.6.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">4.4 <u>Committee Co-Chairs</u>. Each Party shall appoint one of its members to the JSC to co-chair the JSC&#8217;s meetings (each, a &#8220;<i><b>Co-Chair</b></i>&#8221;). The Co-Chairs shall (i) ensure the orderly conduct of the JSC&#8217;s meetings, (ii) attend each JSC meeting (either in-person, videoconference or telephonically), and (iii) prepare and issue written minutes of each meeting within thirty (30) days thereafter accurately reflecting the discussions and decisions of such Committee. In the event the Co-Chair from either Party is unable to attend or participate in a JSC meeting, the Party who designated such Co-Chair may designate a substitute Co-Chair for the meeting in its sole direction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">4.5 <u>Committee Meetings</u>. The JSC shall meet quarterly, or as more or less often as otherwise agreed by the Parties, and such meeting may be conducted by telephone, videoconference or in person as determined by the Co-Chairs. As appropriate, other employee representatives of the Parties may attend JSC meetings as nonvoting observers if mutually agreed by the Parties. Each Party may also call for special meetings of the JSC to resolve particular matters requested by such Party and within the areas of responsibility of the JSC. Each Co-Chair shall ensure that its JSC members receive adequate notice of such meetings.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">4.6 <u>Decision Making</u>. Decisions of the JSC shall be made by consensus of the members present in person or by other means (e.g., teleconference) at any meeting, with each Party having one vote. In order to make any decision, the JSC must have present (in person, videoconference or telephonically) at least one representative of each Party. All decisions of the JSC shall be consistent with the Guiding Principle. Notwithstanding anything herein to the contrary, the JSC shall have no authority to amend, modify or waive compliance with this Agreement. In the event that the JSC cannot reach agreement with respect to any matter that is subject to its decision-making authority, then the matter shall be resolved pursuant to the provisions set forth in Article 15 (&#8220;<i><b>Dispute Resolution</b></i>&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">4.7 <u>Performance of Representatives</u>. BioCryst and Shionogi shall cause each of their representatives on the JSC and any other committee (including Subcommittees) or team established under this Agreement to vote, and shall otherwise perform their respective activities under this Agreement, in a good faith manner consistent with the Guiding Principle.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">4.8 <u>Day-to-Day Decision-Making Authority</u>. Shionogi shall have decision making authority with respect to the day-to-day operations of the Development and Commercialization of Licensed Product in the Territory, provided that such decisions are not inconsistent with the Plans or the Guiding Principle, other decisions of the JSC and any other committee (including Subcommittees) or team established under this Agreement within the scope of their authority specified therein, or the express terms and conditions thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 5<br>
DEVELOPMENT</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">5.1 <u>General</u>. Shionogi shall use Diligent Efforts to Develop in the Territory Licensed Product for use in the Field, all in accordance with the Development Plan. Shionogi shall be responsible for conducting, and shall use Diligent Efforts to conduct, the activities set forth in the Development Plan to progress and complete such activities within the timeframes set forth in the Development Plan. Shionogi agrees not to perform, directly or indirectly (or through any Third Party on behalf of Shionogi), any Development activities outside the Territory with respect to any Licensed Product, and not to perform any Development activities in or for use in the Territory with respect to any Licensed Product except in accordance with the Development Plan or, in each case, as otherwise provided herein. Shionogi shall pay due consideration to the protocols and desired endpoints in the trials sponsored by BioCryst in preparing the protocols for the clinical trials to be conducted by or on behalf of Shionogi in the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">5.2 <u>Product Development outside the Territory</u>. BioCryst shall have sole decision-making authority with regard to the Development and Commercialization of Licensed Products outside the Territory (and no rights under this Agreement are granted to Shionogi outside the Territory).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">5.3 <u>Development Reports</u>. Within thirty (30) days after the end of each calendar quarter, Shionogi shall prepare and provide to BioCryst a written report that (i) summarizes the progress of the Development activities performed by Shionogi hereunder during the preceding calendar quarter, (ii) identifies any issues or circumstances of which it is aware that may prevent or adversely affect in a material manner the activities under the Development Plan in the then-current calendar quarter, and, to the extent reasonably practicable, (iii) identifies steps that may be taken, or changes that may be made, to resolve such issues. Shionogi shall maintain records in sufficient detail as will properly reflect all work done in the performance of activities arising out of, in conducting, or otherwise in connection with its Licensed Product Development activities. Likewise, BioCryst shall prepare and provide to Shionogi a quarterly written report summarizing the Development performed by BioCryst outside the Territory in reasonable detail. To the extent known by BioCryst and permitted by its licensees (and not otherwise prohibited by Law), BioCryst shall provide the foregoing information to Shionogi relating to BioCryst&#8217;s licensees outside of the Territory, provided that Shionogi shall keep such information strictly confidential pursuant to Section 11.2. BioCryst shall also provide Shionogi with its development plan and any amendment thereto in a timely manner.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">5.4 <u>Interactions Between Committees and Internal Teams</u>. The Parties recognize that while they will establish the various committees and teams for the purposes hereof, each Party maintains internal structures (including its own committees, teams and review boards) that will be involved in administering such Party&#8217;s activities under this Agreement. The Parties shall establish procedures (including the appointment of alliance managers) to facilitate communications between the various committees and teams hereunder and the relevant internal committee, team or board within the Party in order to maximize the efficiency of the Parties&#8217; activities pursuant to this Agreement. In addition, each of the Joint Steering Committee and any subcommittee shall coordinate with each other as appropriate.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">5.5 <u>Development Costs</u>. Development Costs relating to the Licensed Product in the Territory shall be borne 100% by Shionogi, subject to Section 2.5(c).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">5.6 <u>Clinical Milestone Events</u>. Shionogi shall use Diligent Efforts to achieve the events set forth in the table below (each a &#8220;<i><b>Milestone Event</b></i>&#8221;) by the date set forth in the table below (each a &#8220;<i><b>Milestone Date</b></i>&#8221;) in furtherance of the Development of the Licensed Products. The Parties agree that the JSC shall have forty-five (45) days from the Effective Date to review, and comment on the Milestone Events contained herein and shall use such Milestone Events contained herein as a framework to create other more detailed steps it feels necessary to Develop the Licensed Products. Any changes or additions to the Milestone Events or Milestone Dates made by the JSC shall be made in good faith and shall be consistent with the Guiding Principles and shall be included in the Development Plan.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:88.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:10.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:88.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Milestone Event</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:11%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Milestone Date</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:88.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:10.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:88.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11.25pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-11.25pt;">Submission of the first Phase II Clinical Trial protocol to MHLW or the applicable Regulatory Authority in the Territory</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:10.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">[***]</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:88.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11.25pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-11.25pt;">Submission of the first Phase III Clinical Trial protocol to MHLW or the applicable Regulatory Authority in the Territory</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:10.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">[***]</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:88.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11.25pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-11.25pt;">Submission of NDA to MHLW or the applicable Regulatory Authority in the Territory</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:10.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">[***]</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 6</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>COMMERCIALIZATION</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">6.1 <u>General</u>. Shionogi undertakes that it will Commercialize the Licensed Products in the Territory and carry out its obligations hereunder in compliance with all applicable Laws.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">6.2 <u>Commercialization Plan</u>. Shionogi shall, beginning [***] prior to the anticipated date of Marketing Approval for a Licensed Product in the Territory and continuing until the expiration of the term of this Agreement, prepare and submit to BioCryst for its review and comment (which comments Shionogi shall consider reasonably and in good faith), a Territory-wide plan for the Commercialization of such Licensed Product in the Field following receipt of the requisite Marketing Approval (a &#8220;<i><b>Commercialization Plan</b></i>&#8221;) covering in detail (to the extent available) the [***] period prior to the first anticipated date on which such Licensed Product would be first shipped in commercial quantities for commercial sale to Third Parties in the Territory, and providing general plans (with an estimated Budget) for the [***] period following such anticipated shipping date. On or before December 15 of each calendar year, Shionogi shall update each Commercialization Plan to include detailed plans for the following calendar year (with an estimated Budget), and shall submit such updated Commercialization Plan to BioCryst for its review and comment (which comments Shionogi shall reasonably consider in good faith). Each Commercialization Plan shall include a detailed description of each Commercialization activity to be conducted in the Territory thereunder, including the following, as applicable:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(a) [***];</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(b) [***];</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(c) [***];</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(d) [***]<b>;</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(e) [***];</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(f) [***];</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(g) [***];</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(h) [***];</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(i) [***]</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(j) [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">6.3 <u>Amendments</u>. Shionogi shall review the Commercialization Plans on a regular basis during each calendar year and shall promptly submit any significant modifications of such plans to BioCryst for review and comment (which comments Shionogi shall reasonably consider in good faith).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">6.4 <u>Promotional Material</u>. No later than [***] prior to the expected date of National Health Insurance (NHI) price listing for the first Licensed Product in the Territory, Shionogi shall provide BioCryst with a representative example of its proposed major Promotional Material, and BioCryst shall have the right to make comments or observations thereon within [***] of its receipt thereof. Thereafter, Shionogi shall provide BioCryst with a representative example of its Promotional Material as soon as practicable after BioCryst&#8217;s written request, such a request shall not be made more than once each calendar year, and BioCryst shall have the right to make comments or observations thereon within [***] of its receipt thereof. Notwithstanding BioCryst&#8217;s right to make comments or observations, and other than with respect to the BioCryst Logos (with respect to which BioCryst shall have sole decision-making power, even with respect to Shionogi&#8217;s Promotional Literature) all other decisions with respect to Shionogi&#8217;s Promotional Material shall be made by Shionogi in its sole discretion after in good faith taking into consideration BioCryst&#8217;s comments and observations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">6.5 <u>Costs of Commercialization</u>. Shionogi shall be responsible for all costs associated with the Commercialization of Licensed Products within the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">6.6 <u>Trademark</u>. Shionogi shall have the right to select the trademark, from among the stocks of trademarks of Shionogi or BioCryst to be used in connection with the Commercialization of the Licensed Product in the Territory after paying due consideration of the opinions of the JSC. If Shionogi selects a registered trademark owned by BioCryst in the Territory, BioCryst shall grant to Shionogi a royalty-free license to use such trademark for the Licensed Product in the Field and in the Territory for the term of this Agreement upon such additional terms as BioCryst may request<b>. </b>If Shionogi selects its own registered trademark for use on Licensed Products in the Territory (the &#8220;<i><b>Licensed Product Mark</b></i>&#8221;), the ownership of such Licensed Product Mark shall remain in Shionogi and such Licensed Product Mark shall not be included in the BioCryst Marks.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">6.7 <u>Outside of Territory</u>. Shionogi shall ensure that no Licensed Products are Commercialized outside of the Territory. Shionogi shall ensure that no Licensed Products are manufactured outside of the Territory, except as specifically provided herein.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 7<br>
ADVERSE EVENT AND PRODUCT COMPLAINT REPORTING</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">7.1 <u>By Shionogi</u>. Shionogi will promptly (a) provide BioCryst with all Licensed Product complaints, adverse event information and safety data from clinical studies and Commercialization in its control; and (b) report all such adverse events in the Territory in accordance with Laws, and provide such information to BioCryst in such a manner and time so as to enable BioCryst to comply with all applicable Laws outside the Territory. Shionogi shall maintain a Territory-wide adverse event database for the Licensed Products and shall generate adverse event reports for BioCryst&#8217;s use. BioCryst shall have free and unfettered access to all data in such database. Shionogi shall be responsible for submitting adverse events reports to the applicable Regulatory Authorities in the Territory. Shionogi shall bear 100% of the costs of adverse events reporting and of maintaining the Territory-wide adverse events database.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">7.2 <u>By BioCryst</u>. BioCryst will promptly (a) provide Shionogi with all Licensed Product complaints, adverse event information and safety data from clinical studies and Commercialization in its control; and (b) report all such adverse events outside the Territory in accordance with Laws, and provide such information to Shionogi in such a manner and time so as to enable Shionogi to comply with all applicable Laws in the Territory. BioCryst shall, at its own cost, maintain a global adverse event database for the Licensed Products and shall generate adverse event reports outside the Territory for Shionogi&#8217;s use. Shionogi shall have free and unfettered access to all data in such database. BioCryst shall be responsible for submitting adverse events reports to the applicable Regulatory Authorities outside the Territory, with respect to which BioCryst shall bear 100% of the costs.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">7.3 <u>Adverse Events and Reporting</u>. As soon as reasonably practicable, but in no event later than three (3) months after the Effective Date, the Parties shall jointly establish, and mutually agree upon adverse event and complaint reporting procedures which each Party must adhere to and shall execute a separate agreement relating thereto. Such procedures shall at all times include any measures necessary for each Party to fully comply with applicable Laws and such procedures may be amended with the Parties&#8217; mutual consent from time to time. Such operating procedures and any material revisions to them shall be provided to the JSC for review and comment before execution of the aforesaid agreement. In addition, each Party shall promptly notify the other if such Party becomes aware of any information or circumstance that is likely to have a material adverse effect on the Development or Commercialization of the Licensed Products.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 8<br>
INSURANCE</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">8.1 Shionogi shall obtain and maintain, during the term of this Agreement, comprehensive general liability insurance, including products liability insurance and coverage for clinical trials, with reputable and financially secure insurance carriers in a form and at levels, respectively, that are reasonable and customary in the pharmaceutical industry for companies of comparable size and activities, but in any event shall be a minimum of [***] per occurrence with an annual aggregate limit of not less than [***]. The premium of any insurance will be borne by Shionogi. Such liability insurance shall be maintained on an occurrence basis to provide such protection for [***] after expiration or termination of this Agreement. Shionogi shall furnish to BioCryst on request certificates issued by the insurance company setting forth the amount of the liability insurance (or evidence of self insurance). BioCryst shall receive thirty (30) days written notice prior to termination or material reduction to the level of Shionogi&#8217;s insurance policy as required by this Article 8.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 9<br>
PAYMENTS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">9.1 <u>Signing Fee</u>. Within [***] of the Effective Date, in partial consideration for the licenses and rights granted to Shionogi under this Agreement, Shionogi shall pay or cause to be paid, a non-refundable, non-creditable payment of Fourteen Million U.S. Dollars ($14,000,000) to BioCryst as a signing fee (the &#8220;<i><b>Signing Fee</b></i>&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">9.2 <u>Milestone Payments.</u> As additional partial consideration for the licenses and rights granted by BioCryst to Shionogi herein, Shionogi shall pay to BioCryst the following one-time, non-refundable, non-creditable payments:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(a) [***]. Notwithstanding the foregoing, in the event of bona fide extraordinary circumstances relating to the profile of the Licensed Product which first arose during the Phase [***] Trial [***], the Parties will discuss in good faith extending the period for payment under Section 9.2(a)(i), above, which in no event shall exceed the [***] of receipt of the final case report form from the Phase [***] Trial for a Licensed Product in the Territory. If such bona fide safety concern is related to a formulation and Shionogi notifies BioCryst of its good faith decision to re-conduct a Phase [***] Trial with a newly developed formulation, then the payment set forth in this Subsection 9.2 (a) shall be made no later than the earlier of [***]. If such newly developed formulation again demonstrates in Phase [***] Trial a bona fide safety concern after re-conducting Phase [***] Trial and Shionogi has again made the good faith decision to repeat Phase [***] Trial(s) with another newly developed formulation, [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(b) [***] in the Territory for a Licensed Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(c) [***] in the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">9.3 <u>Royalty Payments</u>. In partial consideration for the licenses and rights granted to Shionogi under this Agreement, Shionogi shall pay to BioCryst the following royalty payments, which shall be paid within [***] after the end of each calendar quarter:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(a) for sales of Licensed Products to any Governmental Entity ( &#8220;<i><b>Non-Commercial Sales</b></i><b>"</b>), the greater of [***]. For the purposes of this Agreement, &#8220;<i><b>Adjusted Net Sales</b></i>&#8221; shall mean [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(b) for sales of Licensed Products to non-Governmental Entity parties (&#8220;<i><b>Commercial Sales</b></i>&#8221;), royalty payments on incremental Net Sales according to the following rates for the following ranges of Net Sales:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:36pt;">(i) [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:36pt;">(ii) [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:36pt;">By way of example [***]:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:34.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:19.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:26.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:34.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Amount of Net Sales</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:21.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Royalty Rate</p>
			</td>
			<td style="vertical-align:bottom;width:9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:28.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Royalty Payment</p>
			</td>
			<td style="vertical-align:bottom;width:5.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:34.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:19.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:26.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:5.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:34.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11.25pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-11.25pt;">[***]</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:19.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">[*</p>
			</td>
			<td style="vertical-align:bottom;width:9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">**]%</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:26.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">[*</p>
			</td>
			<td style="vertical-align:bottom;width:5.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">**]</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:bottom;width:34.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11.25pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-11.25pt;">[***]</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:19.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">[*</p>
			</td>
			<td style="vertical-align:bottom;width:9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">**]%</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:26.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">[*</p>
			</td>
			<td style="vertical-align:bottom;width:5.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">**]</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:34.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11.25pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-11.25pt;">[***]</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:19.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:26.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">[*</p>
			</td>
			<td style="vertical-align:bottom;width:5.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">**]</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(c) <u>Term</u>. The term for the obligations to pay royalties under this Section 9.3 shall expire on the date that is the later of (i) [***]. If the royalty obligations in this Section 9.3(c) are prohibited by applicable Law, then the royalty obligations shall continue until such time as the obligation is prohibited by applicable Law.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(d) <u>Patent Coverage Adjustment</u><b>. </b>If there is no Valid Claim that, but for this Agreement would be infringed by the manufacture, use or sale of Licensed Product in the Territory, then the royalty obligations from Shionogi to BioCryst shall be reduced by [***]. If there is a Valid Claim, and if</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:36pt;">(i)</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:36pt;">[***] , <i>then </i>[***]</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:36pt;">(ii)</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:36pt;">[***]</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">Where:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 79px;">&nbsp;</td>
			<td style="vertical-align: top; width: 15px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8226;</b></p>
			</td>
			<td style="vertical-align: top; width: 9px;">&nbsp;</td>
			<td style="vertical-align: top; width: 1257px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">GPS = the number of units of Generic Products sold in the Territory for a given period; and</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 79px;">&nbsp;</td>
			<td style="vertical-align: top; width: 15px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8226;</b></p>
			</td>
			<td style="vertical-align: top; width: 9px;">&nbsp;</td>
			<td style="vertical-align: top; width: 1257px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">LPS = the number of units of Licensed Products sold in the Territory for a given period.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">For purposes of this Section 9.3(d) the number of &#8220;<i><b>units</b></i>&#8221; sold shall be appropriately adjusted to account for units of varying volumes.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(e) <u>Third Party Rights. </u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:36pt;">(i) <u>New Formulations</u>. In the event Third Party Intellectual Property Rights are necessary (or desired by Shionogi) in order to Develop or Commercialize New Formulations of Licensed Products in the Territory and BioCryst desires to obtain a license to such Third Party Intellectual Property Rights for outside the Territory, Shionogi shall procure a worldwide license to such Intellectual Property Rights from such Third Party (each, a &#8220;<i><b>Third Party New Formulations License</b></i>&#8221;). Shionogi agrees (a) to keep BioCryst apprised of and involved in the negotiations of such license, (b) to take into consideration BioCryst&#8217;s requests regarding the same, and (c) not to execute any agreement for a Third Party New Formulations License with such Third Party without obtaining BioCryst&#8217;s prior consent on the terms and conditions of such agreement which relate to the license outside the Territory. If BioCryst obtains rights under the Third Party New Formulations License outside the Territory, BioCryst shall bear royalties and other payments owed to the licensing Third Party of such Third Party Intellectual Property Rights outside the Territory. The Parties agree that no royalty offset (described in Section 9.3(e)(ii), below) shall be available to Shionogi for payments made under Third Party New Formulations Licenses.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:36pt;">(ii) <u>Royalty Offset</u>. In the event that, Shionogi, in order to exploit the licenses and rights granted to it under Section 2.1 hereof, actually makes royalty or other payments to one or more Third Parties (&#8220;<i><b>Third Party Payments</b></i>&#8221;) as consideration for a license to Intellectual Property Rights of such Third Parties, in the absence of which the importation or use of Compound or manufacture, use or sale of Licensed Product could not legally be made in the Territory due to the infringement of valid claims in such Intellectual Property Rights of such Third Parties, then Shionogi shall have the right to reduce the royalties otherwise due to BioCryst pursuant to this Section 9.3 for such Licensed Product by [***] of such Third Party Payments. Notwithstanding the foregoing, the offset set forth in this Section 9.3(e) (ii) shall in no event reduce the royalty for Licensed Product in the Territory by [***] of the royalty rate otherwise due to BioCryst pursuant to this Section 9.3.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(f) <u>Royalty Reports</u>. All royalty payments shall be accompanied by a written report from Shionogi to BioCryst, showing for the calendar quarter for which such payment applies, in U.S. Dollars, all information required by BioCryst to verify the royalty payments payable hereunder, including but not limited to the information set forth on Schedule 9.3(f) and any other information customary with industry standards of the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">9.4 <u>One-time Net Sales Milestone Payments for Sales of Licensed Products</u>. In partial consideration for the licenses and rights granted to Shionogi under this Agreement, Shionogi shall pay or cause to be paid, to BioCryst within [***] of the first achievement of the following milestones, the following one-time, non-refundable, non-creditable payments in the amounts set forth next to such milestone:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:63.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:35.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:63.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Cumulative Calendar Year Net Sales</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:35.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:63.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>including both Non-Commercial Sales</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:35.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:63.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>and Commercial Sales</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;border-bottom:solid 1px #000000;;width:35.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Payment (in U.S. Dollars)</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:63.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:35.9%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:63.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8226;</b> [***]</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:35.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8226;</b> [***]</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:63.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8226;</b> [***]</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:35.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8226;</b> [***]</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:63.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8226;</b> [***]</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:35.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8226;</b> [***]</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:63.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8226;</b> [***]</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:35.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8226;</b> [***]</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:63.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Total Commercial Sales Milestone Payments:</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:35.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>$95 million</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">9.5 <u>Payments for Clinical and Commercial Supply</u>. In consideration for the supply of Licensed Product and Compound for Development and commercial use, Shionogi shall pay to BioCryst an amount equal to [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">9.6 <u>Payments; Foreign Exchange</u>. All amounts referenced herein are in United States Dollars. Unless otherwise specified, all payments under this Agreement shall be made within thirty (30) days of the date of invoice, in U.S. Dollars, by wire transfer to a bank and to an account designated by BioCryst. Any payment amount, or any component used to calculate a payment amount, computed in a currency other than the U.S. Dollar shall be converted into U.S. Dollars at the exchange rate for transfers from such currency to U.S. Dollars as quoted by [***] on the business day immediately prior to the payment day. Any payments or portions thereof due hereunder which are not paid when due shall bear interest equal to the lesser [***]. This Section 9.6 shall in no way limit any other remedies available to either Party. Other than as set forth herein or except in the case of overpayment, all payments hereunder shall be non-refundable and non-creditable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">9.7 Taxes. The Parties agree that all amounts due by Shionogi to BioCryst under this Agreement shall be treated as &#8220;<i><b>royalties</b></i>&#8221; for purposes of the U.S. Japan Income Tax Treaty. Accordingly, all payments hereunder shall be made free and clear, and without deduction or withholding, of any present or future taxes, duties, levies and other similar charges, including related interest, additions to tax and penalties (&#8220;<i><b>Taxes</b></i>&#8221;). [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">9.8 <u>Audit Rights</u>. Each Party shall have the right, at its own expense, to inspect the other Party&#8217;s relevant financial books and records through an independent certified public accountant designated by the auditing Party and reasonably acceptable to the Party being audited upon at least fifteen (15) days advance written notice for the purpose of confirming the audited Party&#8217;s compliance with the terms herein. Each Party and its Affiliates shall keep full, true and accurate books of account containing all particulars that may be necessary for the purpose of calculating all royalties and other payments payable under this Agreement and shall retain such books of account for a minimum of [***] after the applicable reporting period. Audit results and findings shall be shared by the auditing Party with the audited Party. If the audit reveals an underpayment, the audited Party shall make up such underpayment within thirty (30) days, plus interest at the rate of [***]. If the audit reveals an overpayment, the auditing Party shall return such overpayment within thirty (30) days. If the audit reveals an underpayment or overpayment in the amount of [***] for any calendar quarter, then the audited Party shall reimburse the auditing Party for the costs of the audit. Notwithstanding the foregoing, any audit of BioCryst shall be limited to the books and records necessary in order to verify the calculation of COGS.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 10<br>
INTELLECTUAL PROPERTY</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">10.1 <u>Prosecution and Maintenance of BioCryst Patents</u>. BioCryst shall prosecute and maintain the BioCryst Patents as BioCryst reasonably determines. As between BioCryst and Shionogi, BioCryst shall determine whether, where and when to maintain any of the BioCryst Patents and to file any patent applications included in the BioCryst Patents and, if it determines to take any action, it shall do so at its own cost and expense. However, with respect to the BioCryst Patent Japanese [***] (&#8220;<i><b>Core Patent</b></i>&#8221;), BioCryst undertakes to prosecute and maintain such Core Patent in the Territory and shall provide Shionogi with copies of all material communications received from or filed in patent office(s) in the Territory. In the event that BioCryst determines not to continue to prosecute or maintain any of the BioCryst Patents, BioCryst shall notify Shionogi not less than [***] before any relevant deadlines. Thereafter, Shionogi shall have the right to pursue at its sole cost and discretion the prosecution or maintenance of such patent application or patent. The Parties shall reasonably cooperate with each other in gaining patent term extension(s) or the like applicable to the BioCryst Patents in the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">10.2 <u>Inventions</u>. The ownership of any improvements to the BioCryst Intellectual Property Rights (including any Patents and any other BioCryst Intellectual Property Rights, whether patentable or not) that include, are based on, or are derived from, Compound or Licensed Product (or the Development or Commercialization thereof)<b>, </b>BioCryst Patents or the BioCryst Know-How, including but not limited to the Shionogi Know-How (&#8220;<i><b>Agreement Improvements</b></i>&#8221;, which for the avoidance of doubt shall include Intellectual Property Rights underlying New Formulations and shall include the Licensed Product Mark) shall be determined in accordance with the laws of inventorship of the United States. Shionogi hereby grants to BioCryst an irrevocable, exclusive, worldwide, perpetual, royalty-free, fully paid up, transferable and sublicensable right under Shionogi&#8217;s interest in Agreement Improvements (including without limitation to Shionogi&#8217;s interest in joint inventions made with BioCryst) to make, have made, use, sell, import, have imported, and otherwise fully commercially exploit such inventions outside of the Territory in all fields and inside the Territory outside of the Field (it being understood that the Licensed Product Mark shall not be used by BioCryst inside the Territory). Notwithstanding the foregoing, in the case that Agreement Improvements are relevant to Compound or Licensed Products (including New Formulations) and also other products, technology or applications, then the foregoing license grant shall be deemed to be non-exclusive.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">10.3 <u>Infringement by Third Party</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(a) Each Party shall notify the other Party promptly of any conduct on the part of Third Parties that it deems to be a potential infringement, misappropriation, act of unfair competition, dilution or other violation of the BioCryst Intellectual Property Rights.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(b) BioCryst will have the first right, in its sole discretion and expense, to take any and all action it deems necessary to stop such violation, including the bringing of an action based on the BioCryst Intellectual Property Rights or for unfair competition with respect thereto. BioCryst will exclusively control the prosecution or settlement of any such action and will bring such action in the name of BioCryst only or in the name of both BioCryst and Shionogi. Shionogi shall have the right (but not obligation) to participate in such action through its own counsel at Shionogi&#8217;s cost. If BioCryst does not take any action to stop such violation within sixty (60) days from the date when either of BioCryst or Shionogi notifies the other Party of such violation, Shionogi shall have the right (but not obligation) to take any and all action it deems necessary to stop such violation. In either case, the Parties shall provide all reasonable assistance to each other and reasonably cooperate to prosecute or settle such action. Each of BioCryst and Shionogi shall recover their respective actual out-of-pocket expenses or equitable proportions thereof associated with any such action or settlement thereof from any monetary proceeds, damages and other relief obtained by BioCryst and/or Shionogi. Any excess amount shall be retained by the Party in charge of the enforcement action; provided, however, that if such party is Shionogi, all such proceeds shall be deemed to be &#8220;<i><b>Net Sales</b></i>&#8221; under the terms of this Agreement, for which a royalty shall be paid to BioCryst.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(c) In the event that any action is brought against BioCryst or Shionogi or any Affiliate of either Party alleging the violation of the Intellectual Property Rights of a Third Party by reason of the Development, manufacture or Commercialization of Compound and/or Licensed Product in the Field and in the Territory, Shionogi shall have the first right, but not the obligation, to defend itself and BioCryst in such action at its sole expense. BioCryst shall have the right to participate in such action through its own counsel at BioCryst&#8217;s cost. The Parties shall provide all reasonable assistance to each other and reasonably cooperate to defend or settle such action. Neither Party shall assert counterclaims based on the BioCryst Intellectual Property Rights, or compromise, settle or otherwise dispose of any such action without the other Party&#8217;s advice and prior consent, provided that the Party not defending the action shall not unreasonably withhold its consent to any settlement which does not have a material adverse effect on its business.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 11<br>
PUBLICITY; CONFIDENTIALITY</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">11.1 <u>Publicity</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(a) <u>Oversight by Communications Subcommittee</u>. The JSC shall constitute a Communications Subcommittee. Prior to communicating or disclosing any publications, abstracts, scientific presentations, websites, press releases or other disclosures relating to the relationship of the Parties, each Party shall submit to the Communications Subcommittee a copy of such communication or disclosure for review in accordance with this Agreement and guidelines established by the Communications Subcommittee. Such guidelines shall include among other things a process for ensuring submission of all such communications and disclosures by the Parties to the Communications Subcommittee reasonably in advance of disclosure to allow sufficient time for review, including the preparation of a communications calendar that anticipates disclosures expected to be made during the following calendar quarter. If the Communications Subcommittee is unable to agree upon the acceptability of a public disclosure after endeavoring to do so in good faith, BioCryst&#8217;s Co-Chair shall have the right to cast the deciding vote.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(b) <u>Prior Review</u>. Each Party may disclose results and significant developments regarding Licensed Product and other activities in connection with this Agreement from time to time only with the approval of the other Party, which approval shall not be unreasonably withheld, conditioned or delayed. Such disclosures may include achievement of significant events in the research, Development (including regulatory process), manufacture or Commercialization of Licensed Product under this Agreement or the receipt of material payments. When a Party (the &#8220;<i><b>Requesting Party</b></i>&#8221;) elects to make any such public disclosure under this Section 11.1(b), it will give the other Party (the &#8220;<i><b>Cooperating Party</b></i>&#8221;) through its Communications Subcommittee representatives, a copy of any such statement and at least five (5) business days to review and comment on such statement, it being understood that if the Cooperating Party does not notify the Requesting Party in writing within such five (5) business day period of any objections, such disclosure shall be deemed approved, and in any event the Cooperating Party shall work diligently and reasonably to agree on the text of any proposed disclosure in an expeditious manner. The principles to be observed in such disclosures shall be accuracy, compliance with applicable Law and regulatory guidance documents, and reasonable sensitivity to potential negative reactions of the FDA and/or the MHLW or the applicable Regulatory Authority in the Territory (and their foreign counterparts).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(c) <u>Publications</u>. Except as required by applicable Law or court order, any publication or presentation of Confidential Information (as defined below), including studies or clinical trials carried out by a Party or the Parties under this Agreement shall be subject to the oversight and guidelines of the Communications Subcommittee. The Communications Subcommittee shall establish, promptly after the Effective Date, guidelines that (i) allow for each Party&#8217;s timely review of all such publications or presentations, (ii) provide for protection of Confidential Information and ensure coordination with other applicable joint-committees prior to any disclosure of protectable subject matter, and (iii) ensure that all such publications and presentations are consistent with good scientific practice and accurately reflect work done and the contributions of the Parties. Unless otherwise mutually agreed upon by the Parties, (A) the Party desiring to publish or present any (the &#8220;<i><b>Publishing Party</b></i>&#8221;) shall transmit to the other Party (the &#8220;<i><b>Reviewing Party</b></i>&#8221;) for review and comment a copy of the proposed publication or presentation, at least [***] prior to the submission of the proposed publication or presentation to any Third Party; (B) the Publishing Party shall postpone the publication or presentation for up to an additional [***] upon request by the Reviewing Party in order to allow the Reviewing Party to consider appropriate patent applications or other protection to be filed on information contained in the publication or presentation; (C) upon request of the Reviewing Party, the Publishing Party shall remove all Confidential Information of the Reviewing Party from the information intended to be published or presented; and (D) the Publishing Party shall consider all reasonable comments made by the Reviewing Party to the proposed publication or presentation. For the avoidance of doubt, no restriction set forth in this Section 11.1 shall apply to BioCryst&#8217;s actions outside the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">11.2 <u>Confidential Information; Exceptions</u>. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that the receiving Party shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any confidential and proprietary information or materials of the other Party furnished to it by the other Party or learned by it from or through its exercise of its rights pursuant to this Agreement (collectively, &#8220;<i><b>Confidential Information</b></i>&#8221;) during the term hereof and for a period of five (5) years following the termination of this Agreement; provided, however, that the obligation to keep a Party&#8217;s trade secrets confidential shall survive for such time as such information remains a protected trade secret. For the avoidance of doubt, Agreement Improvements shall be deemed to be the Confidential Information of both Parties. Notwithstanding the foregoing, Confidential Information shall not include any information to the extent that it can be established by written documentation of the receiving Party that such information:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(a) was already known to the receiving Party, other than under an obligation of confidentiality (except to the extent such obligation has expired or an exception is applicable under the relevant agreement pursuant to which such obligation established), at the time of disclosure;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(b) was generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(c) became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the receiving Party in breach of this Agreement; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(d) was disclosed to the receiving Party, other than under an obligation of confidentiality (except to the extent such obligation has expired or an exception is applicable under the relevant agreement pursuant to which such obligation established), by a Third Party who had no obligation to the disclosing Party not to disclose such information to others.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">11.3 <u>This Agreement</u>. Each of the Parties agrees not to disclose to any Third Party the terms and conditions of this Agreement without the prior approval of the other Party, except (i) to advisors (including attorneys and accountants) on a need to know basis, in each case under circumstances that reasonably ensure the confidentiality thereof, or (ii) under circumstances that reasonably ensure the confidentiality of the information, to the extent necessary to comply with the terms of agreements with Third Parties existing as of the Effective Date; provided, however, that if a Party is required by Law to make any such disclosure of the terms or conditions of this Agreement, it will give reasonable advance notice to the other Party of such disclosure requirement and will use its reasonable efforts to secure confidential treatment of the terms and conditions which the Parties agree should be maintained as confidential. In addition to the foregoing, with respect to complying with the disclosure requirements of the U.S. Securities and Exchange Commission, the Financial Services Agency of Japan (collectively the &#8220;<i><b>Securities Authorities</b></i>&#8221;) in connection with any required filing with any of the Securities Authorities of this Agreement, the filing Party shall provide to the other Party a copy of the proposed filing and the Parties shall work cooperatively in good faith, taking into consideration the other Party&#8217;s suggestions, regarding the text of the disclosure as well as information for which the filing Party will seek to obtain confidential treatment. Notwithstanding the foregoing, the Parties shall agree upon and release a mutual press release to announce the effectiveness of this Agreement together with a corresponding Question &amp; Answer outline for use in responding to inquiries about the Agreement; thereafter, the Parties may each disclose to Third Parties the information contained in such press release and Question &amp; Answer outline without the need for further approval by the other.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">11.4 <u>Authorized Disclosure</u>. Except as expressly provided otherwise in this Agreement, each Party may use and disclose Confidential Information of the other Party as follows: (i) under appropriate confidentiality provisions substantially equivalent to those in this Agreement, in connection with the performance of its obligations or as reasonably necessary or useful in the exercise of its rights under this Agreement in complying with the terms of agreements with Third Parties existing as of the Effective Date; (ii) to the extent such disclosure is reasonably necessary in filing or prosecuting patent, copyright and trademark applications in accordance with this Agreement, prosecuting or defending litigation, complying with applicable governmental regulations, obtaining regulatory approval or fulfilling post-approval regulatory obligations, or otherwise required by Law, provided, however, that if a Party is required by Law to make any such disclosure of the other Party&#8217;s Confidential Information it will, except where impracticable for necessary disclosures (for example, in the event of medical emergency), give reasonable advance notice to the other Party of such disclosure requirement and, except to the extent inappropriate in the case of patent applications, will use its reasonable efforts to secure confidential treatment of such Confidential Information required to be disclosed; (iii) in communication with advisors (including lawyers and accountants) on a need to know basis, in each case under appropriate confidentiality provisions substantially equivalent to those of this Agreement; or (iv) to the extent mutually agreed to by the Parties. Notwithstanding the foregoing and for the avoidance of doubt, Shionogi acknowledges and agrees that BioCryst may disclose to the U.S. Government or other Regulatory Authority all Data received from Shionogi<u>;</u> provided, however, that in the event BioCryst intends to disclose the Data or information (including databases) under a different process than the process applied by Shionogi in its protocol, CSR and/or analytical report, then BioCryst shall obtain Shionogi&#8217;s consent prior to such disclosure.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 12<br>
SHIONOGI OPTION TO LICENSE OTHER PRODUCTS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">12.1 <u>Right of First Negotiation</u>. BioCryst hereby grants [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">12.2 [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 13<br>
REPRESENTATIONS, WARRANTIES AND COVENANTS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">13.1 <u>By BioCryst</u>. BioCryst hereby represents and warrants to, and covenants with, Shionogi as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(a) BioCryst is duly organized and validly existing under the Laws of its jurisdiction of incorporation and has full corporate power and authority, and has taken all corporate action necessary, to enter into and perform its obligations under this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(b) This Agreement is a legal, valid and binding obligation of BioCryst, enforceable against BioCryst in accordance with its terms. Neither the execution and delivery of this Agreement by BioCryst, nor the performance by BioCryst of its obligations hereunder, conflicts with any agreement, instrument or understanding, oral or written, by which BioCryst is bound.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(c) To BioCryst&#8217;s knowledge, no authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable Law currently in effect, is required in connection with the execution and delivery of this Agreement by BioCryst, or the performance by BioCryst of its obligations hereunder.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(d) BioCryst has sufficient right in and to BioCryst Patents and BioCryst Know-How to enable it to carry out its obligations under this Agreement. To its best knowledge, BioCryst has not committed and shall not commit any breach of the Pre-Existing Third Party License which will lead to a forfeiture of the rights granted under this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(e) BioCryst has not been debarred or the subject of debarment proceedings by any Regulatory Authority. BioCryst shall not knowingly use in connection with the Development of Licensed Product any employee, consultant or investigator that has been debarred or the subject or debarment proceedings by any Regulatory Authority.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(f) BioCryst shall use diligent efforts in carrying out its obligations pursuant to this Agreement, consistent with all applicable United States Laws and highest industry standards.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">13.2 <u>By Shionogi</u>. Shionogi hereby represents and warrants to, and covenants with, BioCryst as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(a) Shionogi is duly organized and validly existing under the Laws of its jurisdiction of incorporation and has full corporate power and authority, and has taken all corporate action necessary, to enter into and perform its obligations under this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(b) This Agreement is a legal, valid and binding obligation of Shionogi, enforceable against Shionogi in accordance with its terms. Neither the execution and delivery of this Agreement by Shionogi, nor the performance by Shionogi of its obligations hereunder, conflicts with any agreement, instrument or understanding, oral or written, by which Shionogi is bound.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(c) To Shionogi&#8217;s knowledge, no authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable Law currently in effect, is required in connection with the execution and delivery of this Agreement by Shionogi, or the performance by Shionogi of its obligations hereunder.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(d) Neither Shionogi nor any of its Affiliates have been debarred or the subject of debarment proceedings by any Regulatory Authority. Neither Shionogi nor any of its Affiliates shall use in connection with the Development of Licensed Product any employee, consultant or investigator that has been debarred or the subject or debarment proceedings by any Regulatory Authority.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(e) Shionogi shall use Diligent Efforts in carrying out its obligations pursuant to this Agreement, consistent with all applicable Laws and highest industry standards.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">13.3 <u>Disclaimer</u>. ALL PATENTS, KNOW-HOW, DATA AND OTHER INTELLECTUAL PROPERTY RIGHTS, AND ALL LICENSED PRODUCT AND COMPOUND PROVIDED HEREUNDER IS PROVIDED AS-IS. NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY WITH REGARD TO ANY PATENT, KNOW-HOW, DATA, LICENSED PRODUCT, COMPOUND OR OTHERWISE IN CONNECTION WITH THIS AGREEMENT EXCEPT AS SPECIFICALLY SET FORTH IN THIS AGREEMENT. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, EACH PARTY DISCLAIMS, AND WAIVES ALL WARRANTIES OF AND TO, THE OTHER, EXPRESS OR IMPLIED, ARISING BY LAW OR OTHERWISE, WITH RESPECT TO ANY LICENSED PRODUCT, BIOCRYST INTELLECTUAL PROPERTY RIGHTS OR OTHERWISE IN CONNECTION WITH THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, IMPLIED WARRANTY ARISING FROM COURSE OF PERFORMANCE, COURSE OR DEALING OR USAGE OF TRADE, AND ANY IMPLIED WARRANTY OF NONINFRINGEMENT.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">OTHER THAN IN CONNECTION WITH A PARTY&#8217;S INDEMNITY OBLIGATIONS, A BREACH OF THE LICENSE GRANTS TO SHIONOGI OR IN CONNECTION WITH AN INDEMNIFYING PARTY&#8217;S INDEMNITY OBLIGATIONS UNDER THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, EXEMPLARY, SPECIAL OR PUNITIVE DAMAGES WHATSOEVER RESULTING OR ARISING FROM ANY CAUSE OR CLAIM WHATSOEVER, WHETHER BY TORT, OR CONTRACT OR OTHERWISE, INCLUDING BUT NOT LIMITED TO LOSS OF PROFITS AND LOSS OF SAVINGS, BUSINESS DATA, OR GOODWILL. SHIONOGI&#8217;S SOLE AND EXCLUSIVE REMEDY FOR DAMAGES RELATING TO LICENSED PRODUCT OR COMPOUND SUPPLIED BY BIOCRYST SHALL BE REPLACEMENT BY BIOCRYST OF ANY NON-CONFORMING MATERIAL<b>.</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">13.4 <u>Compliance with Laws</u>. Shionogi understands and acknowledges that BioCryst is subject to regulation by agencies of the U.S. Government, including, but not limited to, the U.S. Department of Commerce and the U.S. Treasury Department&#8217;s Office of Foreign Assets Control, both of which regulate the import, export and diversion of certain products and technology from and to certain countries. Any and all obligations of BioCryst to provide the Compound or Licensed Product, as well as any other technical information or assistance, and all rights on the part of Shionogi to perform its obligations hereunder, shall be subject in all respects to such United States laws and regulations as shall from time to time govern the license and delivery of technology and products abroad by persons subject to the jurisdiction of the United States, including but not limited to regulations promulgated under Executive Order No. 12924 of August 19, 1994 issued pursuant to the President&#8217;s authority under the International Emergency Economic Powers Act, Title 50 U.S. C., Chapter 35, Section 1701 et seq. and those contained in Title 31, Part 500 of the U.S. Code of Federal Regulations. Shionogi agrees to cooperate with BioCryst including, without limitation, providing required documentation, in order to comply with any and all applicable United States Laws and regulations. Shionogi warrants that it shall comply with all United States Laws and regulations governing exports in effect from time to time that are applicable to BioCryst as if such laws and regulations were applicable to Shionogi. In the event any rights or obligations hereunder are or become illegal or the subject of sanctions or restrictions, then BioCryst shall have the right, in its sole discretion, to terminate, without penalty and immediately upon written notice, the provisions of this Agreement which in BioCryst&#8217;s sole discretion relate to such restrictions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 14<br>
TERM AND TERMINATION</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">14.1 <u>Term</u>. The term of this Agreement shall commence on the Effective Date and shall continue unless terminated pursuant to this Article 14.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">14.2 <u>Termination By BioCryst</u>. Without limiting any other rights or remedies either Party may have under this Agreement or otherwise, BioCryst shall have the right to terminate this Agreement upon notice to Shionogi at any time in the event that the Pre-Existing Third Party License is terminated (or modified to an extent that BioCryst cannot perform its obligations hereunder), or if any of the following shall occur:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(a) if Shionogi breaches, in any material respect, any of its representations, warranties or obligations under this Agreement, and, if curable, such breach is not cured within thirty (30) days after Shionogi&#8217;s receipt of written notice of such breach; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(b) if Shionogi suffers an Insolvency Event.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">14.3 <u>Termination By Shionogi</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(a) <u>Termination for Breach</u>. Without limiting any other rights or remedies either Party may have under this Agreement or otherwise, Shionogi shall have the right to terminate this Agreement upon written notice to BioCryst, if BioCryst breaches, in any material respect, any of its representations, warranties or obligations under this Agreement, and, if curable, such breach is not cured within thirty (30) days after BioCryst&#8217;s receipt of written notice of such breach.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(b) <u>Termination without Cause</u>. Shionogi shall have the right to terminate this Agreement at any time at its discretion by providing BioCryst with [***] prior written notice. Shionogi agrees to terminate this Agreement pursuant to this Section 14.3(b) in the event that, at any time, Shionogi does not plan to exercise, or has not exercised, or will not exercise, Diligent Efforts to Develop or Commercialize Licensed Products.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">14.4 <u>Effect of Termination</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(a) The termination or expiration of this Agreement shall not affect any payment of any debts or obligations accruing prior to such date of termination or expiration. Sections [***] shall survive the termination or expiration of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(b) Furthermore, upon termination of this Agreement all licenses and rights granted to Shionogi shall terminate, and Shionogi shall terminate all activities related to the Development and Commercialization of Licensed Products, cease all use of the BioCryst Intellectual Property Rights, and shall return to BioCryst all documents (including copies) of any kind concerning the Compound, BioCryst Intellectual Property Rights or the Licensed Products and other Confidential Information received from BioCryst or otherwise created in the course of performing this Agreement. Shionogi shall promptly destroy all Compound and Licensed Product which it holds in stock at the time of such termination or expiration of this Agreement. Shionogi shall promptly and diligently provide to BioCryst all assistance reasonably necessary in order to assist BioCryst in transitioning and assigning to BioCryst all aspects of the Parties&#8217; relationship hereunder, including but not limited to all work in progress, regulatory submissions, Agreement Improvements and Shionogi Know-How to BioCryst. For the avoidance of doubt, and in consideration for BioCryst&#8217;s granting the New NI Compound option to Shionogi, Shionogi hereby assigns to BioCryst all Intellectual Property Rights in the Agreement Improvements (to the extent that such Agreement Improvements are solely related to the Compound and/or Licensed Product; and to the extent such Agreement Improvements are not solely related to the Compound and/or Licensed Product, Shionogi will and hereby does grant to BioCryst an irrevocable, non-exclusive, worldwide, perpetual, royalty-free, fully paid up, transferable and sublicensable right under Shionogi&#8217;s interest in such Agreement Improvements), and agrees to take all further actions reasonably requested by BioCryst to perfect such assignment and vest the rights assigned to BioCryst in BioCryst or its designee(s). Shionogi shall pay to BioCryst any and all amounts already due under this Agreement and transfer and assign to BioCryst any Regulatory Filings relating to the Licensed Product that are in Shionogi&#8217;s possession (including and but not limited to any IND, MAA, Marketing Approval or any approval for any product labeling or Promotional Materials owned by or held in the name of Shionogi or its Affiliates), including the ownership thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">(c) In the event of termination of this Agreement by a Party for the other Party&#8217;s uncured material breach, such termination shall not affect the terminating Party&#8217;s right to claim damages against the breaching Party for such breach. In the event the non-breaching Party waives its right under Section 14.3 to terminate, such non-breaching Party shall not be prevented from seeking damages for a material breach by the breaching Party during the Term of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 15<br>
DISPUTE RESOLUTION</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">15.1 <u>General</u>. Any dispute or disagreement between the Parties arising out of, under or in connection with this Agreement shall be settled in accordance with this Article 15.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">15.2 <u>Informal Mediation</u>. In the event any dispute or disagreement between the Parties arises out of, under or in connection with this Agreement, either Party shall submit the dispute to the following executives for resolution: for BioCryst, Senior Executive Officer responsible for corporate development (or such successor as may be named by BioCryst); for Shionogi: General Manager of License Department responsible for alliance management (or such successor as may be named by Shionogi). Such executives shall work together in good faith for a period of [***] to resolve the dispute.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">15.3 <u>Escalation</u>. In the event that a dispute is not resolved pursuant to the provisions of Section 15.2, above, the dispute or disagreement shall be submitted to the Senior Officers (defined below) for resolution. In such event, either Party, by written notice to the other Party, may formally request that the dispute be resolved by the Senior Officers, specifying the nature of the dispute with sufficient specificity to permit adequate consideration by the Senior Officers. The Parties shall cause their respective Senior Officers to use commercially reasonable efforts to resolve the referred dispute in good faith within [***] of receiving such written notification, including, without limitation, by means of a face-to-face meeting if requested by either Party. &#8220;<i><b>Senior Officers</b></i>&#8221; means, for Shionogi, the Senior Executive Officer or similar ranking officer, and for BioCryst, the CEO or similar ranking officer.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">15.4 <u>Arbitration</u>. Any disputes, controversies between the Parties arising under or in connection with this Agreement not resolved through the procedures set out in the preceding clauses of this ARTICLE 15 shall be finally settled by arbitration without the right to appeal, in New York City, if requested by Shionogi, or in Osaka, if requested by BioCryst, before a panel of three (3) arbitrators under the Rules of the International Chamber of Commerce (&#8220;<i><b>ICC Rules</b></i>&#8221;), which Rules are deemed to be incorporated by reference to this clause. Each Party shall nominate an arbitrator, and the Party-nominated arbitrators shall agree upon the third arbitrator who will be the chair of the arbitrate tribunal. If the two Party-nominated arbitrators are unable to agree upon the chair, the chair shall be selected as provided in the ICC Rules. The arbitration award shall be binding upon the Parties and enforceable by any court of competent jurisdiction. The arbitration award shall include an award as to costs including attorney fees. These provisions shall not prevent a Party from making application to any court of competent jurisdiction seeking equitable relief in case of urgency.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">15.5 <u>No Arbitration of Intellectual Property Issues</u>. Notwithstanding anything to the contrary contained herein, unless otherwise agreed by the Parties, disputes relating to Intellectual Property Rights shall not be subject to arbitration, and shall be submitted to a court of competent jurisdiction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 16<br>
INDEMNIFICATION</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">16.1 <u>Indemnification by Shionogi</u>. Shionogi shall indemnify, defend, and hold harmless BioCryst, the Affiliates of BioCryst, and their respective officers, directors, managers, members, partners, owners, employees, licensees, successors, and assigns (collectively, the "<i><b>BioCryst Indemnitees</b></i>&#8221;) from and against all actions, causes of action, suits, debts, obligations, losses, damages, amounts paid in settlement, liabilities, costs, and expenses whatsoever, including reasonable attorneys&#8217; fees (collectively, &#8220;<i><b>Losses</b></i>&#8221;), whether arising out of a claim involving a Third Party or between the Parties, resulting to, imposed upon, asserted against, or incurred by any of BioCryst Indemnitees in connection with, or arising out of or relating to this Agreement, including without limitation, the Licensed Products and the Development or Commercialization thereof (including but not limited to product liability claims and recalls in the Territory), and/or any breach by Shionogi of a representation, warranty or covenant under this Agreement<b>.</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">23</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">16.2 <u>Indemnification by BioCryst</u>. BioCryst shall indemnify, defend, and hold harmless Shionogi, the Affiliates of Shionogi, and their respective officers, directors, managers, members, partners, owners, employees, licensees, successors, and assigns (collectively, the &#8220;<i><b>Shionogi Indemnitees</b></i>&#8221;) from and against all Losses, whether arising out of a claim involving a Third Party or between the Parties, resulting to, imposed upon, asserted against, or incurred by any of Shionogi Indemnitees in connection with, or arising out of or relating to (a) any material breach of this Agreement by BioCryst or (b)the gross negligence or willful misconduct on the part of BioCryst.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">16.3 <u>Indemnification Procedures</u>. If any claim, demand, action or proceeding is made or commenced by any Third Party (a &#8220;<i><b>Third-Party Claim</b></i>&#8221;) against any BioCryst Indemnitee or Shionogi Indemnitee that is entitled to be indemnified with respect thereto under this ARTICLE 16 (the "<i><b>Indemnified Party</b></i>&#8221;), the Indemnified Party shall give the other Party (the &#8220;<i><b>Indemnifying Party</b></i>&#8221;) prompt written notice thereof; the failure to give such written notice shall not affect the liability of the Indemnifying Party under this Agreement except to the extent such failure materially and adversely affects the ability of the Indemnifying Party to defend the Third-Party Claim. The Indemnifying Party shall have the right to assume the defense and resolution of the Third-Party Claim, provided that (i) the Indemnified Party shall have the right to participate in the defense of the Third-Party Claim at its own expense through counsel of its choice (control of the defense will remain with the Indemnifying Party), (ii) the Indemnifying Party shall not consent to the entry of any judgment or enter into any settlement that would require any act or forbearance on the part of the Indemnified Party or which does not unconditionally release the Indemnified Party from all liability in respect of the Third-Party Claim without the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld, conditioned or delayed, and (iii) the Indemnified Party may undertake the defense of the Third-Party Claim, at the Indemnifying Party&#8217;s expense, if the Indemnifying Party fails promptly to assume and diligently to prosecute the defense.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>ARTICLE 17<br>
MISCELLANEOUS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">17.1 <u>Assignment</u>. This Agreement and any rights granted hereunder are personal to each Party and shall not be sold, assigned, sublicensed, encumbered or otherwise transferred (each a "<i><b>Transfer</b></i>&#8221;), directly or indirectly, by operation of law or otherwise, by either Party without the prior written consent of the other Party, which consent may be granted or withheld in such other Party&#8217;s sole discretion; provided, however, that BioCryst, without notice and at any time for any reason, may Transfer this Agreement in whole or in part to (i) any of its Affiliates who agree to be bound by the terms and conditions of this Agreement or (ii) to any successor of BioCryst by merger, sale of all or substantially all of its business assets to which this Agreement relates or otherwise. Any attempted Transfer of this Agreement or any of the rights granted hereunder in violation of this Section 17.1 shall be void <i>ab initio</i>. The consent by any Party to any Transfer shall not constitute a waiver of the necessity for such consent in any subsequent Transfer. Notwithstanding anything to the contrary contained in this Section 17.1, either Party shall have the right to assign its rights under this Agreement in connection with a Change of Control of such Party to the successor in interest to such Party; provided, however, that the Party effecting a Change of Control shall give written notice of such Change of Control to the other Party within ten (10) days of such Change of Control, and such Transfer shall not relieve such assigning Party of its obligations under this Agreement except to the extent any permitted assignee assumes in writing the obligations of the assigning Party under this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">17.2 <u>Section 365(n)</u>. All licenses granted under this Agreement are deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of right to &#8220;intellectual property&#8221; as defined in Section 101 of such Code. In addition, if Shionogi desires to register license granted hereunder with the Japanese Patent Office, BioCryst shall provide reasonable cooperation to this end.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">24</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">17.3 <u>Governing Law; Venue</u>. This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of New York without regard to choice-of-law principles of the State of New York. All actions arising under this Agreement which are not arbitrable shall be brought in the State and Federal Courts located in New York County, New York. The Parties hereby irrevocably submit to the jurisdiction of such courts.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">17.4 <u>Severability</u>. If any one or more of the provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality or enforceability of the remaining provisions hereof shall not in any way be affected or impaired thereby. In the event any provisions shall be held invalid, illegal or unenforceable, the Parties shall use best efforts to substitute a valid, legal and enforceable provision, which, insofar as practical, implements the purposes hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">17.5 <u>Notices</u>. All notices, requests, demands and other communications hereunder shall be given in writing and shall be: (a) personally delivered; (b) sent by telecopier, facsimile transmission or other electronic means of transmitting written documents; or (c) sent to the Parties at their respective addresses indicated herein by registered or certified U.S. mail, return receipt requested and postage prepaid, or by private overnight mail courier service. The respective addresses to be used for all such notices, demands or requests are as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">If to BioCryst, to:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:79.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">BIOCRYST PHARMACEUTICALS, INC.<br>
2190 Parkway Lake Drive<br>
Birmingham, Alabama 35244<br>
USA<br>
Attention: CEO<br>
Facsimile No.: +1-205-4640</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">with a copy to:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:79.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">Proskauer Rose LLP<br>
1585 Broadway<br>
New York, New York 10036-8299<br>
USA<br>
Attention: Daryn Grossman, Esq.<br>
Telephone: +1-212-969-3000<br>
Facsimile: +1-212-969-2900</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">or to such other person or address as BioCryst shall furnish to Shionogi in writing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">If to Shionogi, to:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:79.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">SHIONOGI &amp; CO., LTD.<br>
12-4, Sagisu 5 chome<br>
Fukushima-ku, Osaka 553-0002<br>
Japan<br>
Attention: General Manager, License Department<br>
Telephone: +81-6-6455-2393<br>
Facsimile: +81-6-6455-2053</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">or to such other person or address as Shionogi shall furnish to BioCryst in writing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">If personally delivered, such communication shall be deemed delivered upon actual receipt; if electronically transmitted pursuant to this paragraph, such communication shall be deemed delivered on the day transmitted unless it is received after 5:00 p.m., local time, or on a day which is not a business day, in which case it shall be deemed delivered on the next business day after transmission (and sender shall bear the burden of proof of delivery); if sent by overnight courier pursuant to this paragraph, such communication shall be deemed delivered upon receipt; and if sent by mail pursuant to this paragraph, such communication shall be deemed delivered as of the date of delivery indicated on the receipt issued by the relevant postal service; or, if the addressee fails or refuses to accept delivery, as of the date of such failure or refusal. Either Party may change its address for the purposes of this Agreement by giving notice thereof in accordance with this Section 17.4.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">25</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">17.6 <u>No Waiver</u>. None of the provisions of this Agreement can be waived except in a writing signed by the Party granting the waiver. No failure by a Party to exercise any right under this Agreement shall operate as a waiver of such right, nor shall any single or partial exercise of any right preclude any other or further exercise of that right or the exercise of any other rights. The waiver by any Party of any breach of this Agreement shall not be deemed a waiver of any prior or subsequent breach. All remedies of either Party shall be cumulative and the pursuit of one remedy shall not be deemed a waiver of any other remedy.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">17.7 <u>Further Assurances</u>. Each Party shall execute, acknowledge and deliver, without additional consideration, such further assurances, instruments and documents, and shall take such further actions, as the other Party shall reasonably request in order to fulfill the intent of this Agreement and the transactions contemplated hereby.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">17.8 <u>No Third-Party Beneficiaries</u>. Nothing in this Agreement is intended or shall be construed to give any other person or entity any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein, other than BioCryst Indemnitees, Shionogi Indemnitees and any assignee permitted under Section 17.1 above.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">17.9 <u>Relationship of the Parties</u>. The relationship of the Parties under this Agreement shall be solely that of independent contractors and nothing herein shall be construed to create or imply any relationship of employment, agency, joint venture, partnership or any relationship other than that of independent contractors. BioCryst and Shionogi acknowledge and agree that each of them is engaged in a separate and independent business and neither shall state, represent or imply any interest in or control over the business of the other.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">17.10 <u>Government Funding</u>. BioCryst&#8217;s obligations under this Agreement have been funded in whole or in part with Federal funds from the Office of Public Health Emergency Preparedness, Office of Public Health Emergency Medical Countermeasures, under Contract No, HHSO100200700032C.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">17.11 <u>Cost</u>. Unless otherwise specified, each Party shall bear the full Cost of its compliance with the terms of this Agreement and its respective obligations hereunder. For purposes of this Agreement, the term &#8220;<b>Costs</b>&#8221; when used herein means the fully allocated costs including but not limited to the fully allocated cost of goods and services and manufacturing overhead directly related to Licensed Product, and allocation of all administrative and general expenses directly related to Licensed Product. Costs shall be determined by generally accepted accounting principles, applied on a consistent basis.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">17.12 <u>Interpretation</u>. The captions and headings to this Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement. Unless specified to the contrary, references to Articles, Sections, Schedules or Exhibits mean the particular Articles, Sections, Schedules or Exhibits to this Agreement and references to this Agreement include all Exhibits and Schedules attached hereto. Each accounting term used herein that is not specifically defined herein shall have the meaning given to it under GAAP, but only to the extent consistent with its usage and the other definitions in this Agreement. Unless context otherwise clearly requires, whenever used in this Agreement: (i) the words "<b>include</b>&#8221; or &#8220;<b>including</b>&#8221; shall be construed as incorporating, also, &#8220;<b>but not limited to</b>&#8221; or "<b>without limitation</b>;&#8221; (ii) the word &#8220;<b>day</b>&#8221;, &#8220;<b>month</b>&#8221; or &#8220;<b>year</b>&#8221; means a calendar day, month or year unless otherwise specified; (iii) the word &#8220;<b>notice</b>&#8221; means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this Agreement; (iv) the words &#8220;<b>hereof</b>,&#8221; &#8220;<b>herein</b>,&#8221; &#8220;<b>hereby</b>&#8221; and derivative or similar words refer to this Agreement (including any Exhibits and Schedules); (v) provisions that require that a Party, the Parties or any committee or team hereunder &#8220;<b>agree,</b>&#8221; "<b>consent</b>&#8221; or &#8220;<b>approve</b>&#8221; or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise; (vi) words of any gender include the other gender; and (vii) references to any specific Law or article, section or other division thereof shall be deemed to include the then-current amendments thereto or any replacement Law thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">26</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">17.13 <u>No Modifications</u>. Unless otherwise specified herein and the Exhibits attached hereto, nothing contained in this Agreement shall affect the rights and obligations of the Parties under the other License Documents, and the terms and conditions of all such agreements shall remain in full force and effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">17.14 <u>Entire Agreement</u>. This Agreement and the Exhibits and Schedules attached hereto constitute the entire understanding between the Parties relating to the subject matter hereof, and no amendment or modification to this Agreement shall be valid or binding upon the Parties unless designated as such, made in writing and signed by the representatives of such Parties</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">17.15 <u>Counterparts</u>. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, and all of which together, shall constitute one and the same instrument.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><i>[The remainder of this page intentionally left blank]</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">27</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><b>IN WITNESS WHEREOF</b>, the Parties have executed and delivered this Agreement in duplicate originals by their duly authorized representatives as of the date and year first above written.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:61.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:61.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:37.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>SHIONOGI &amp; CO., LTD.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:61.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:37.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:61.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By: /s/JON P. STONEHOUSE</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:37.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By: /s/MOTOZO SHIONO</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:61.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name: JON P. STONEHOUSE</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:37.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name: MOTOZO SHIONO</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:61.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title: Chief Executive Officer</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:37.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title: President</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">28</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>6
<FILENAME>ex_230463.htm
<DESCRIPTION>EXHIBIT 10.29
<TEXT>
<html><head>
	<title>ex_230463.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 10.29</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT IN PLACES MARKED &#8220;[***]&#8221; BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>FIRST AMENDMENT<br>
TO<br>
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:18pt;">This First Amendment (this &#8220;<b>Amendment</b>&#8221;) to the License, Development and Commercialization Agreement between BioCryst Pharmaceuticals, Inc. (&#8220;<b>BioCryst</b>&#8221;) and Shionogi &amp; Co., Ltd. (&#8220;<b>Shionogi</b>&#8221;), dated as of February 28, 2007 (the &#8220;<b>Agreement</b>&#8221;), shall be effective as of September 30, 2008 (the &#8220;<b>First Amendment Date</b>&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>WITNESSETH</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:18pt;">WHEREAS, pursuant to Section 17.14 of the Agreement, the Agreement may be amended in writing by BioCryst and Shionogi; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:18pt;">WHEREAS, BioCryst and Shionogi desire to amend the Agreement to expand the Territory to Taiwan (defined below) and to provide rights for Shionogi to perform a Phase III Clinical Trial in Hong Kong (defined below), which is outside the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:18pt;">NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein and in the Agreement, BioCryst and Shionogi, intending to be legally bound hereby, amend, update and supplement the Agreement as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">1. <u>Amendment of the Agreement</u>. The parties hereby agree to amend the Agreement, effective as of the First Amendment Date as follows:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">a.</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:97.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Definitions</u>. The following definitions shall be added to Section 1.1 of the Agreement, as follows:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">(fff) <i>&#8220;</i><i><b>Hong Kong</b></i><i>&#8221; </i>means the Hong Kong Special Administrative Region of the People&#8217;s Republic of China.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">(ggg) <i>&#8220;</i><i><b>2008 Trial</b></i><i>&#8221; </i>means the Phase III Clinical Trial described in Section 5.1(a), below.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">(hhh) &#8220;<i><b>Taiwan</b></i><i>&#8221; </i>means the territories of Taiwan, Republic of China.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">b.</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:97.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Territory</u>. Section 1.1(bbb) of the Agreement is hereby amended and restated in its entirety as: &#8220;&#8220;<b>Territory</b>&#8221; means Japan and Taiwan&#8221;.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.7%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:97.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">c.</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:97.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>References to Japan</u>. The following references to &#8220;Japan&#8221; or &#8220;Japanese&#8221; are hereby amended and restated in their entirety as follows:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">1(h) <i>&#8220;</i><i><b>cGMPs</b></i><i>&#8221; </i>means the United States then-current good manufacturing practices and the equivalent standards of the Governmental Entities in the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">1(aa) <i>&#8220;</i><i><b>IND</b></i><i>&#8221; </i>means an Investigation of a New Drug Filing (or the Japanese or Taiwanese equivalent) with a Regulatory Authority in the Territory for purposes of obtaining permission to initiate human clinical testing in such jurisdiction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">1(oo) &#8220;<i><b>NDA</b></i><i>&#8221; </i>means a New Drug Application (or the Japanese or Taiwanese equivalent), including all supplements and amendments thereto, for the approval of the Licensed Product as a new drug by the MHLW or applicable Regulatory Authority in the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">d.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:96.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Section 2.1</u>. Section 2.1 is hereby amended and restated in its entirety as:</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><u>License Grant; Reservation of Rights; Right to Conduct 2008 Trial in Hong Kong</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:25.95pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:18pt;">(a) Solely to the extent necessary for Shionogi to perform its obligations hereunder in accordance with the terms of this Agreement, and subject to all of the rights retained hereunder, BioCryst hereby grants Shionogi a personal, non-sublicensable, non-transferable, non-assignable right and license under the BioCryst Patents and BioCryst Know-How, to (i) exclusively Develop Licensed Products solely in the Field and in the Territory, and (ii) exclusively Commercialize Licensed Products solely in the Field and in the Territory. The foregoing license grant shall be deemed to extend to Shionogi&#8217;s Affiliate, Taiwan Shionogi &amp; CO., Ltd. (&#8220;Shionogi Taiwan&#8221;) solely with respect to activities in Taiwan. Other than as explicitly set forth in this Section 2.1, no other licenses to the BioCryst Intellectual Property Rights or otherwise (including but not limited to all rights in BioCryst Intellectual Property Rights outside the Field and outside the Territory) are granted in this Agreement. <b>[***]</b>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:25.95pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:18pt;">(b) In connection with the 2008 Trial, and only for such purpose, BioCryst hereby grants Shionogi the limited, nonexclusive right to conduct the 2008 Trial in Hong Kong. For the purposes of clarity, it is understood and agreed that the foregoing right set forth in this Section 2.1(b) is granted in furtherance of Shionogi&#8217;s rights in the Territory, is subject in all respects to all of the terms and conditions set forth in this Agreement including the license grant and retained rights, including in Sections 2.1(a) and 2.3, and does not include any further rights to Develop or Commercialize in Hong Kong. All rights granted under this Section 2.1(b) shall terminate upon the completion of the 2008 Trial.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">e.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:96.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Section 2.2</u>. Section 2.2 is hereby amended and restated in its entirety as:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"><u>Manufacturing</u>. <b>[***]</b>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">f.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:96.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Section 3.5(f)</u>. The following is hereby added as a new Section 3.5(f):</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">(f) BioCryst will be obligated to supply Licensed Product and Compound to Shionogi pursuant to this Section 3.5 (and otherwise under this Agreement) only in Japan, and not in any other location, including Taiwan, unless otherwise agreed to in writing by the Parties.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">g.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:96.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Section 3.6</u>. The following is hereby added to the end of Section 3.6:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">BioCryst will be obligated to supply Compound to Shionogi pursuant to this Section 3.6 (and otherwise under this Agreement) only in Japan, and not in any other location, including Taiwan, unless otherwise agreed to in writing by the Parties.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">h.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:96.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Section 5.1</u>. The following is hereby added at the end of the existing Section 5.1:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">Shionogi hereby acknowledges and agrees that, notwithstanding the fact that the Territory includes the jurisdictions of Japan and Taiwan, Shionogi shall give priority to its Development activities and achievement of the Milestone Events set forth in Section 5.6 in Japan over Taiwan.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">i.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:97.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Section 5.1(a)</u>. The following is hereby added as a new Section 5.1(a) of the Agreement:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">5.1(a) <u>2008 Trial Diligence</u>. Shionogi hereby agrees to use Diligent Efforts to undertake and complete the 2008 Trial in accordance with the criteria and time frames set forth on Schedule 5.1(a), solely at Shionogi&#8217;s cost and expense.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">j.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:97.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Section 5.2</u>. Section 5.2 is hereby amended and restated in its entirety as:</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><u>Product Development outside the Territory</u>. Other than as expressly set forth in Section 2.1(b) and solely with respect to Hong Kong, BioCryst shall have sole decision-making authority with regard to the Development and Commercialization of Licensed Products outside the Territory (and no rights under this Agreement are granted to Shionogi outside the Territory).</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">k.</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:97%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Section 6.6</u>. The following is herby added to the end of the existing Section 6.6 of the Agreement:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">In no event may Shionogi or any Affiliate of Shionogi directly or indirectly register, or attempt to register, or assert any rights to any party in respect of any translation of a trademark, domain name or trade name owned by BioCryst.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">l.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:97.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Section 9.3</u>. The preamble of Section 9.3 is herby amended and restated in its entirety as:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"><u>Royalty Payments</u>. In partial consideration for the licenses and rights granted to Shionogi under this Agreement, Shionogi shall pay to BioCryst the following royalty payments, on a country-by-country basis within the Territory (pursuant to the currency and exchange provisions set forth in Section 9.6 herein and the taxes provision in Section 9.7 herein), as calculated based on Net Sales in Japanese Yen, regardless of the country of sale (as converted, where applicable), which shall be paid within <b>[***] </b>the end of each calendar quarter:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">m.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:97.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.3(c). Section 9.3(c) is hereby amended and restated in its entirety as:</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"><u>Term</u>. The term for the obligations to pay royalties under this Section 9.3 shall expire on a country-by-country basis within the Territory on the date that is the later of (i) <b>[***] </b>and (ii) <b>[***]</b>. If the royalty obligations in this Section 9.3(c) are prohibited by applicable Law, then the royalty obligations shall continue until such time as the obligation is prohibited by applicable Law.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">n.</p>
			</td>
			<td style="vertical-align:top;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:97.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.3(d). Section 9.3(d) is hereby amended and restated in its entirety as:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"><u>Patent Coverage Adjustment</u>. If there is no Valid Claim that, but for this Agreement would be infringed by the manufacture, use or sale of Licensed Product in either Japan or Taiwan, then the royalty obligations from Shionogi to BioCryst shall be reduced by <b>[***]</b>. If there is a Valid Claim in Japan, and if</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">(i)</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 25%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">[***]</p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 73%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">, <i>then </i><b>[***]</b>; OR</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">(ii)</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 25%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">[***]</p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 73%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">, <i>then </i><b>[***]</b></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">Where:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8226;</b></p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:98.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">GPS = the number of units of Generic Products sold in Japan for a given period, and</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:98.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8226;</b></p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:98.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">LPS = the number of units of Licensed Products sold in Japan for a given period.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">For purposes of this Section 9.3(d) the number of &#8220;<i><b>units</b></i><i>&#8221; </i>sold shall be appropriately adjusted to account for units of varying volumes.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">o.</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:97.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Section 9.3(f). Section 9.3(f) is hereby amended and restated in its entirety as:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:16.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;"><u>Royalty Reports</u>. All royalty payments shall be accompanied by written reports from Shionogi to BioCryst, showing for the calendar quarter for which such payment applies, in U.S. Dollars, all information required by BioCryst to verify the royalty payments payable hereunder, including but not limited to the information set forth on Schedule 9.3(f) for each country within the Territory, and any other information customary with industry standards of the Territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">p.</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:97.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Section 10.1</u>. The references to &#8220;the Territory&#8221; in Section 10.1 are hereby changed to &#8220;Japan&#8221;.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">2. <u>Shionogi Taiwan</u>. Shionogi hereby guarantees the obligations of Shionogi Taiwan and agrees to ensure that Shionogi Taiwan complies with each and every one of Shionogi&#8217;s obligations under the Agreement.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">3. <u>No Other Changes</u>. Except as expressly modified by this Amendment, all terms and conditions of the Agreement shall remain in full force and effect.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">4. <u>Interpretation of Certain Terms</u>. All terms which are capitalized but not defined in this Amendment shall have the meanings ascribed in the Agreement. The words &#8220;this Agreement,&#8221; &#8220;hereunder,&#8221; &#8220;hereof&#8221; and other similar words in the Agreement from and after the First Amendment Date shall mean and include the Agreement as amended hereby.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">5. <u>Governing Law; Venue</u>. This Amendment shall be governed by and construed and enforced in accordance with the laws of the State of New York without regard to choice-of-law principles of the State of New York. All actions arising under this Amendment which are not arbitrable shall be brought in the State and Federal Courts located in New York County, New York. The Parties hereby irrevocably submit to the jurisdiction of such courts.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">6. <u>Counterparts</u>. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">IN WITNESS WHEREOF, the undersigned have duly executed this Amendment as a sealed instrument by and through their duly authorized representatives.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:4.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:8.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:34.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:39%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="5" style="vertical-align:top;width:48.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>BIOCRYST PHARMACEUTICALS, INC.</b><br>
			2190 Parkway Lake Drive<br>
			Birmingham, Alabama 35244<br>
			United States</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td colspan="6" style="vertical-align:top;width:50.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Shionogi &amp; Co., Ltd.</b><br>
			1-8, Doshomachi 3-chome<br>
			Chuo-ku, Osaka 541-0045<br>
			Japan</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:34.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:4.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:39%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:43%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ David McCullough</u></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:4.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:45.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ Takuko Yamada Sawada</u></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.9%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;border-bottom: 1px #000000;;width:43%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:4.9%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;border-bottom: 1px #000000;;width:45.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name:<br>
			Title:</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:34.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">David McCullough<br>
			VP Corp. Dev., Strategy, Commercial</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:4.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name:<br>
			Title:</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:39%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Takuko Yamada Sawada<br>
			Corporate Officer, Executive General<br>
			Manager, Pharmaceutical Development Div.</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:4.9%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:8.4%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:34.4%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:4.9%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:39%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date:</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:43%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">October 15, 2008</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:4.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date:</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:45.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">October 3, 2008</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><br>
&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">SCHEDULE 5.1(a)<br>
PHASE III CLINICAL TRIAL DESCRIPTION</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">The Phase III trial which Shionogi plans to conduct in the 2008/2009 flu season and use for registration in the Territory for the purpose of receiving Marketing Approval from the Regulatory Authorities in the Territory for the treatment of seasonal flu. The formulation in this Phase III study will be administered intravenously.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>7
<FILENAME>ex_230489.htm
<DESCRIPTION>EXHIBIT 10.32
<TEXT>
<html><head>
	<title>ex_230489.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 10.32</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:12pt;margin:0pt 7.2pt;text-align:left;"><b>CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT IN PLACES MARKED &#8220;[***]&#8221; BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>LICENSE AGREEMENT<br>
BETWEEN<br>
ALBERT EINSTEIN COLLEGE OF MEDICINE, INDUSTRIAL RESEARCH, LTD<br>
AND<br>
BIOCRYST PHARMACEUTICALS, INC.</b></p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:95.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Statement</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">1</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">1.</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Definitions</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">2</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">1.01<b> &#8220;Field&#8221;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">2</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">1.02<b> &#8220;Agreement Patents&#8221;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">2</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">1.03<b> &#8220;Licensed Product&#8221;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">2</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">1.04<b> &#8220;Net Sales&#8221;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">2</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">1.05<b> &#8220;Net Proceeds&#8221;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">3</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">1.06<b> &#8220;Affiliate&#8221;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">3</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">1.07<b> &#8220;Sublicensee&#8221;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">3</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">1.08<b> &#8220;Contract Research&#8221;</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">4</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2.</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Licensors&#8217; Agreements With U.S. And New Zealand Governments</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">4</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">3.</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Agreement Patents</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">5</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">4.</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">License Grant</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">8</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">5.</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Confidentiality</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">9</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">6.</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Royalties and Payments</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">11</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">7.</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Payment Reports and Records</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">15</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">8.</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Infringement</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">16</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">9.</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Prohibition on Use of Names; No Publicity</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">17</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">10.</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Term and Termination</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">18</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">11.</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Amendment and Assignment</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">20</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">12.</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Miscellaneous Provisions</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">20</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:4.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">13.</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:90.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Notices</p>
			</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;">23</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
		</tr>

</table>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><u><b>LICENSE AGREEMENT</b></u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">This Agreement is entered into as of June ___, 2000 (&#8220;Effective Date&#8221;), by and among Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, a corporation organized and existing under the laws of the State of New York having an office and place of business at 1300 Morris Park Avenue, Bronx, New York 10461 (&#8220;AECOM&#8221;), Industrial Research Ltd., a company organized and existing under the laws of New Zealand, having an office and place of business at Gracefield Research Centre, Gracefield Road, P.O. Box 31-310, Lower Hutt, New Zealand (&#8220;Industrial&#8221;) (AECOM and Industrial are collectively referred to herein as &#8220;Licensors&#8221;), and BioCryst Pharmaceuticals Inc., a corporation organized and existing under the laws of the State of Delaware having an office and place of business at 2190 Parkway Lake Drive, Birmingham, Alabama 35244 (&#8220;Licensee&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><u><b>Statement</b></u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">AECOM and Industrial have established laboratories directed by Drs. Vern Schramm, Peter C. Tyler and Richard H. Furneaux (&#8220;the Investigators&#8221;) to conduct research relating to the identification and characterization of novel inhibitors of human purine nucleoside phosphorylase (&#8220;PNP&#8221;). Licensee wishes to acquire an exclusive license in the Field (defined below) from Licensors with respect to certain patent rights and related know-how owned by Licensors.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">NOW, THEREFORE, in consideration of the promises and mutual covenants, conditions and limitations herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Licensors and Licensee agree as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:12pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><b>1.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;"><u><b>Definitions</b></u></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>1.01</b></p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8220;Field&#8221;</b> means any use of inhibitors for human PNP that have an IC50 value less than [***], as determined by the method described in Bantia, <i>et al.</i>, <u>Immunopharmacology</u> 35, page 54, paragraph 2.1 (1997).</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>1.02</b></p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8220;Agreement Patents&#8221; </b>means the U.S., New Zealand and PCT patent applications listed on Appendix A, together with any and all patents which issue from or are based on such applications and from any and all divisionals and continuations of such applications, any and all reissues of such patents and any and all patents which are based on such applications. Appendix A shall be updated from time to time by the parties, which as of the Effective Date includes all patents, patent applications and inventions which (1) are in the Field (2) include, as an inventor, the Investigators or employees of Licensors working under the supervision of the Investigators and (3) are owned by one or more of the Licensors. Agreement Patents shall not include any patents which have expired or been found finally to be invalid by a court or administrative agency of competent jurisdiction from which no appeal can be or is taken.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>1.03</b></p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8220;Licensed Product&#8221; </b>means any product or service in the Field the development, manufacture, use or sale of which is covered by a claim in an Agreement Patent, on a country-by-country basis.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>1.04</b></p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8220;Net Sales&#8221; </b>means the total consideration, in any form, received by Licensee and its Affiliates in connection with the sale or other disposition of Licensed Products by Licensee and/or any of its Affiliates to an independent third party, less:</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">(a)&nbsp; trade discounts allowed, refunds, returns and recalls; and,</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">(b)&nbsp; when included in gross sales, freight, shipping, duties, and sales, V.A.T. and/or use taxes based on sales prices, but not including taxes when assessed on incomes derived from such sales.</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:25.95pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">For any non-cash consideration received as Net Sales, the parties will appoint an independent third party to determine the present day value of such consideration and that value shall be added to Net Sales in place of the non-cash consideration.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>1.05</b></p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8220;Net Proceeds&#8221; </b>shall mean the total consideration, in any form (including, but not limited to, royalties, license signing fees, maintenance fees, milestones and minimum payments, whether or not such fees and payments are creditable against future royalties to be paid to Licensee, research and development funds other than Contract Research, and just that portion of the funds received for equity purchases of Licensee which exceeds the fair market value of the equity), received by Licensee from a Sublicensee in connection with the grant to said Sublicensee of the right to make and sell (or otherwise dispose of) Licensed Products. For any non-cash consideration received as Net Proceeds, the parties will appoint an independent third party to determine the present day value of such consideration and that value shall be added to Net Proceeds in place of the non-cash consideration. Net Proceeds does not include Contract Research.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>1.06</b></p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8220;Affiliate&#8221; </b>means any entity, that, directly or indirectly, through one or more intermediates, controls, is controlled by, or is under common control with Licensee. For the purposes of this definition, control shall mean the direct or indirect ownership of at least fifty percent (50%) of (i) the stock shares entitled to vote for the election of directors or (ii) ownership interest.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>1.07</b></p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8220;Sublicensee&#8221;</b> shall mean any non-Affiliate third party to whom Licensee has granted the right to make and sell (or otherwise dispose of) Licensed Products.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">1.08</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&#8220;Contract Research&#8221; </b>shall mean those funds received by Licensee from a Sublicensee in connection with the grant to said Sublicensee of a sublicense to make and sell (or otherwise dispose of) Licensed Products, which funds are specifically earmarked and actually used to pay for synthesis, manufacturing, toxicology studies, clinical studies, and/or other research and/or development by Licensee relating directly to Licensed Products, which work is to be performed by or for Licensee after the date of the sublicense agreement and is to be performed at cost, without any profit to Licensee.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2.</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u><b>Licensors&#8217; Agreements With U.S. And New Zealand Governments</b></u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2.01</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">AECOM, through its Investigator, has and will perform research sponsored in part by the United States Government and related to the Field. As a result of this government sponsorship of the aforementioned research, the United States Government retains certain rights in such research as set forth in 35 U.S.C. &#167;200 <u>et.</u>&nbsp;<u>seq.</u> and applicable regulations. AECOM will take all necessary action to reserve for Licensee exclusive rights to the technology developed by Investigator in the Field under the sponsorship of the government (and licensed to Licensee hereunder), with the proviso that such reservation shall be to the extent permitted under 35 U.S.C. Section 200 <u>et.</u>&nbsp;<u>seq.</u> and applicable regulations.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2.02</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The continuance of such government sponsored research by AECOM and its Investigator during the term of this Agreement will not constitute a breach of this Agreement. All rights reserved to the U.S. Government under 35 U.S.C. &#167;200 <u>et.</u>&nbsp;<u>seq</u>. and applicable regulations shall remain so reserved and shall in no way be affected by this Agreement. AECOM and its Investigator are not obligated under this Agreement to take any action which would conflict in any respect with their past, current or future obligations to the U.S. Government as to work already performed and to be performed in the future.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2.03</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Industrial has and may continue to perform research sponsored in part by the New Zealand Foundation for Research, Science and Technology and related to the Field. Industrial retains ownership of all intellectual property generated in the course of the aforementioned research.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2.04</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">AECOM, through its Investigator, will conduct research in collaboration with the National Cancer Institute (&#8220;NCI&#8221;) and with contractors hired by NCI (including, for example, Industrial) relating to Licensed Products pursuant to grants issued by NCI and/or the National Institutes of Health. Such research may include synthesis of Licensed Product, animal trials for determining toxicity and metabolism, IND filings, and clinical trials in humans. AECOM agrees to keep Licensee fully informed regarding this research program and to consult with Licensee concerning all phases of this research program. The participation of AECOM (and Industrial) in this government sponsored collaborative research program and the conduct of this research program by AECOM, NCI and contractors of NCI during the term of this Agreement will not constitute a breach of this Agreement.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">3.</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u><b>Agreement Patents</b></u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">3.01</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">As of the Effective Date, Licensee will pay the cost of prosecuting, maintaining and resisting challenges to the validity of the Agreement Patents listed on Appendix A (as well as the cost of filing, prosecuting, maintaining and resisting challenges to the validity of corresponding applications in at least the United States, Europe (an EPO filing designating all member countries, (Canada, China, Japan, Korea and Australia) using patent counsel selected by Licensors and approved by Licensee, which approval shall not be unreasonably withheld. In this regard, Licensee will pay the cost of defending and/or prosecuting any interference, reexamination, reissue, opposition, cancellation and nullity proceedings involving Agreement Patents. Licensors will keep Licensee fully informed concerning such applications and will consult with Licensee concerning the prosecution of such applications. In the event that Licensee elects not to maintain or prosecute any patent or patent application within the Agreement Patents, Licensee shall give Licensor thirty (30) days prior written notice of such election. Any patents or patent applications so elected shall at the end of the notice period cease to be considered Agreement Patents, and Licensor shall then be free, at its election, to abandon or maintain the prosecution of such patent application or issued patent or grant rights to such patent application or issued patent to third parties. Licensee will also pay the costs of filing and prosecuting the foreign patent applications listed as Nos. 6, 7, 8, 9, 10 and 11 on Appendix A incurred by Licensors between [***] and the Effective Date, up to a maximum of [***] Dollars ($[***]).</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">3.02</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Subject to paragraph 3.01, should Licensors wish to seek, obtain and maintain protection for foreign counterparts of the Agreement Patents in jurisdictions (other than the United States, Europe, Japan, Canada, China, Korea and Australia) in which Licensees do not agree to pay the cost, Licensors shall have the option of proceeding to do so at Licensors&#8217; own cost. All such applications filed and patents granted shall form part of the Agreement Patents.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">3.03</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During the term of this Agreement, Licensors grant to Licensee the option to expand Agreement Patents to include inventions which are (1) in the Field, (2) made by the Investigators, or by employees of Licensors working under the supervision of the Investigators, subsequent to the Effective Date, and (3) owned by one or more of Licensors (&#8220;Option Inventions&#8221;). Licensors will disclose all Option Inventions to Licensee in writing promptly after such Invention is made and before any publication thereof and will provide Licensee with a suitable description and other information reasonably requested by Licensee for the purpose of evaluating the Option Invention. Within thirty (30) business days of Licensee&#8217;s receipt of an Option Invention disclosure, Licensee will provide written notification to Licensors that either:</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">(a)&nbsp; &nbsp;Licensee is not interested in expanding Agreement Patents to include the Option Invention, in which event Licensee&#8217;s option with respect to the subject Option Invention shall immediately expire; or</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">(b)&nbsp; &nbsp;Licensee is interested in expanding Agreement Patents to include the subject Option Invention, in which event Licensee shall pay to Licensors [***] Dollars ($[***]), which payment is not refundable and not creditable against any other&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; payment due to Licensors hereunder, and Licensee&#8217;s option with respect to the subject Option Invention shall be extended for another sixty (60) days or until the filing of a patent application on the Option Invention by Licensors, whichever&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; is longer;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">(c)&nbsp; &nbsp;If Licensors are unable to obtain a U.S. patent on an Option Invention selected by Licensee pursuant to subparagraph (b) because of prior disclosures or publications of the Option Invention by the Investigators or by employees of Licensors&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;working under the supervision of the Investigators, then Licensors shall promptly refund to Licensee all amounts paid by Licensee in respect of such Option Invention pursuant to any and all of Sections 3.01, 3.03(b) and 3.04.</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">3.04</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Within thirty (30) days of the expiration of the extended option period set forth in subparagraph 3.03(b) above, Licensee shall pay to Licensors [***] Dollars ($[***]), which payment is not refundable and not creditable against any other payment due to Licensors hereunder. Upon Licensors&#8217; receipt of such payment the definition of Agreement Patents shall be deemed amended to include the patent application filed on the subject Option Invention. If Licensee fails to make the [***] Dollar ($[***]) payment, then Licensee&#8217;s option with respect to the subject Option Invention shall immediately expire and the definitions of Agreement Patents will not be amended to include the patent application filed on the subject Option Invention.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">3.05</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In the event that Licensee elects for any reason to not include an Option Invention as an Agreement Patent, or Licensee&#8217;s option expires, Licensors shall be free to publish such invention in the scientific literature and/or seek patent protection, in its own discretion, and exploit such invention outside of the Field, however, Licensors shall not otherwise license, disclose or otherwise provide such inventions to any third party for use within the Field.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">4.</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u><b>License Grant</b></u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">4.01</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Subject to Article 2, Licensors hereby grant to Licensee and Affiliates a worldwide, exclusive license to the Agreement Patents, along with the right by Licensee only to grant sublicenses, to make, have made, use, have used, import and sell Licensed Products. Licensee will not grant any sublicense under Agreement Patents unless it first receives the prior written consent of Licensors as to the identity of the proposed sublicensee, which consent will not be unreasonably withheld. For purposes of the foregoing, each of the top [***] ([***]) pharmaceutical companies as reported by Scripps World Pharmaceutical News (at the time of the proposed sublicense) shall hereby be deemed approved by Licensors. Licensee shall provide Licensors with a full and complete copy of any such sublicense within thirty (30) days of execution thereof by Licensee.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">4.02</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Notwithstanding the exclusive rights granted to Licensee pursuant to paragraph 4.01, Licensors shall retain the right to make, use and practice Agreement Patents in their own laboratories solely for non-commercial scientific purposes and for continued non-commercial research. Further, Licensors shall have the right to make available to not-for-profit scientific institutions and non-commercial researchers small quantities of biological materials covered under Agreement Patents, solely for non-commercial scientific and research purposes, provided this is done under a material transfer agreement, substantially in the form of Appendix B.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">4.03</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Nothing contained in this Agreement shall be construed or interpreted as a grant, by implication or otherwise, of any license except as expressly specified in Paragraph 4.01 hereof. The license specified in Paragraph 4.01 is limited to the Field. Licensors are free to grant licenses to third parties under Agreement Patents for all uses outside of the Field.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">5.</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u><b>Confidentiality</b></u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">5.01</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Nothing herein contained shall preclude Licensors from making required reports or disclosures to the NIH or to any other philanthropic or governmental funding organization, provided, however, that no Licensee Confidential Information is disclosed in the process.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">5.02</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:96%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Licensee will retain in confidence confidential information of Licensors and Licensee will not disclose any such confidential information to any third party without the consent of Licensors, except that Licensee shall have the right to disclose such information to any third party for commercial or research and development purposes under written terms of confidentiality and non-disclosure which are commercially reasonable. Licensee will keep confidential all confidential information of Licensors for a period of five (5) years after termination or expiration of this Agreement, provided, however, that the obligation of confidentiality will not apply to any such information which:</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:5.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(a)</p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:87.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">was known to Licensee or generally known to the public prior to its disclosure hereunder; or</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:middle;width:5.4%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:87.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:5.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(b)</p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:87.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">subsequently becomes known to the public by some means other than a breach of this Agreement, including but not limited to publication and/or laying open to inspection of any patent applications or patents; or</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:middle;width:5.4%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:87.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:5.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(c)</p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:87.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">is subsequently disclosed to Licensee by a third party having a lawful right to make such disclosure; or</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:middle;width:5.4%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:87.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:5.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(d)</p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:87.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">is required to be disclosed by regulation, law or court order to the most limited extent necessary to comply therewith, provided Licensor is given a fair opportunity to defend against such disclosure; or</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:middle;width:5.4%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:87.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:5.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(e)</p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:87.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">is independently developed by Licensee without the benefit of Agreement Know-how as evidenced by Licensee&#8217;s written records.</p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td colspan="2" style="vertical-align:top;width:6.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">5.03</p>
			</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:92.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">During the term of this Agreement, it is contemplated that Licensors may become aware of written, oral, visual or other proprietary and confidential business information, scientific information, technology, inventions, technical information, biological materials, processes and the like which are owned or controlled by Licensee (&#8220;Licensee Confidential Information&#8221;). Licensors agree to retain such Licensee Confidential Information in confidence and not to disclose any such Licensee Confidential Information to a third party without prior written consent of Licensee for a period ending five (5) years after termination of this Agreement, except that such obligations shall not apply to any information which:</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:5.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:3.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:87.5%;">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:5.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(a)</p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:87.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">was known to Licensors or generally known to the public prior to its disclosure hereunder; or</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:middle;width:5.4%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:87.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:5.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(b)</p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:87.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">subsequently becomes known to the public by some means other than a breach of this Agreement; or</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:middle;width:5.4%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:87.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:5.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(c)</p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:87.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">is subsequently disclosed to Licensors by a third party having a lawful right to make such disclosure; or</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:middle;width:5.4%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:87.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:5.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(d)</p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:87.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">is required to be disclosed by regulation, law or court order to the most limited extent necessary to comply therewith, provided Licensee is given a fair opportunity to defend against such disclosure; or</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:middle;width:5.4%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:87.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:5.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(e)</p>
			</td>
			<td style="vertical-align:top;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:top;width:87.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">is independently developed by Licensors without the benefit of Licensee Confidential Information as evidenced by Licensors&#8217; written records.</p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td colspan="2" style="vertical-align:top;width:6.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">6.</p>
			</td>
			<td style="vertical-align:top;width:2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:91.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u><b>Royalties and Payments</b></u></p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:6.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:middle;width:91.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:6.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">6.01</p>
			</td>
			<td style="vertical-align:top;width:2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:91.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Licensee will pay to Licensors a royalty of [***] percent ([***]%) on Net Sales. Licensee shall make such payments beginning with the first sale of such Licensed Products and ending with the longer of [***] ([***]) years from First Commercial Sale of a Licensed Product or until the expiration of the last Agreement Patent which covers a Licensed Product made, used or sold by Licensee or its Affiliates. For the purpose of this paragraph, &#8220;First Commercial Sale&#8221; shall occur when Licensee or an Affiliate makes an unrestricted release of a Licensed Product to its sales and marketing organizations in national markets throughout (i) the United States or (ii) in a major western European country or (iii) Japan, intended to reach the general market for the Licensed Product.</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:6.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:middle;width:91.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:6.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">6.02</p>
			</td>
			<td style="vertical-align:top;width:2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:91.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Licensee shall pay to Licensors [***] percent ([***]%) of Net Proceeds.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:5.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:2.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:87.5%;">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:2.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:93.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">6.03</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(a)</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Only one royalty will be payable on Net Sales by Licensee and Affiliates and Sublicensees on a Licensed Product under paragraph 6.01, regardless of the number of patent claims in an Agreement Patent which cover such Licensed Product.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:2.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:93.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(b)</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">If a Licensed Product is not covered by a claim of an issued patent of Agreement Patents in the country of manufacture, use or sale, then the royalty payable on that Licensed Product pursuant to paragraph 6.01 shall be reduced by [***] percent ([***]%).</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">6.04</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">(a)</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">Within [***] ([***]) days of execution of this Agreement, Licensee shall pay to Licensors [***] Dollars (US$[***]) as a license signing fee, which payment is non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">(b)</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">On the [***] anniversary of the Effective Date of this Agreement, Licensee will pay to Licensors [***] Dollars (US$[***]) as a license maintenance fee, which fee is non-refundable but is creditable against actual royalties and actual payments due to Licensors pursuant to paragraphs 6.01 and 6.02 during the twelve month period following the anniversary.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">(c)</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">On the [***] anniversary of the Effective Date of this Agreement, Licensee will pay to Licensors [***] Dollars (US$[***]) as a license maintenance fee, which fee is non-refundable but is creditable against actual royalties and actual payments due to Licensors pursuant to paragraphs 6.01 and 6.02 during the twelve month period following the anniversary.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">(d)</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">If the first clinical trials (Phase I) for a Licensed Product are initiated by Licensee (or an Affiliate or a Sublicensee) before the [***] anniversary of the Effective Date, then on each of the [***], [***], [***], [***] and [***] anniversaries of the Effective Date of this Agreement, Licensee will pay to Licensors [***] Dollars (US$[***]) as a license maintenance fee, which fees are non-refundable but are creditable against actual royalties and actual payments due to Licensors pursuant to paragraphs 6.01 and 6.02 during the twelve month period following each anniversary.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">(e)</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">If the first clinical trials (Phase I) for a Licensed Product are not initiated by Licensee (or an Affiliate or a Sublicensee) before the [***] anniversary of the Effective Date, then on each of the [***], [***], [***], [***] and [***] anniversaries of the Effective Date of this Agreement, Licensee will pay to Licensors [***] Dollars (US$[***]) as a license maintenance fee, which fees are non-refundable but are creditable against actual royalties and actual payments due to Licensors pursuant to paragraphs 6.01 and 6.02 during the twelve month period following each anniversary. However, if such clinical trials are initiated by Licensee (or an Affiliate or a Sublicensee) after the [***] anniversary and before the [***] anniversary, then any license maintenance fees due thereafter pursuant to this paragraph shall be reduced from [***] Dollars (US$[***]) to [***] Dollars (US$[***]).</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">(f)</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">If the first Phase III trials for a Licensed Product are initiated by Licensee (or an Affiliate or a Sublicensee) before the [***] anniversary of the Effective Date, then on the [***] anniversary of the Effective Date of this Agreement, and within [***] ([***]) days of each anniversary thereafter until expiration of this Agreement, Licensee will pay to Licensors [***] Dollars (US$[***]) as a license maintenance fee, which fees are non-refundable but are creditable against actual royalties and actual payments due to Licensors pursuant to paragraphs 6.01 and 6.02 during the twelve month period following each anniversary.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">(g)</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">If the first Phase III trials for a Licensed Product are not initiated by Licensee (or an Affiliate or a Sublicensee) before the [***] anniversary of the Effective Date, then on the [***] anniversary of the Effective Date of this Agreement, and within [***] ([***]) days of each anniversary thereafter until expiration of this Agreement, Licensee will pay to Licensors [***] Dollars (US$[***]) as a license maintenance fee, which fees are non-refundable but are creditable against actual royalties and actual payments due to Licensors pursuant to paragraphs 6.01 and 6.02 during the twelve month period following each anniversary. However, if such clinical trials are initiated by Licensee (or an Affiliate or a Sublicensee) after the [***] anniversary, then any license maintenance fees due thereafter pursuant to this paragraph shall be reduced from [***] Dollars (US$[***]) to [***] Dollars (US$[***]).</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">6.05</p>
			</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Licensee shall make the following milestone payments to Licensors:</p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">(a)</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">Except as specified below, upon the filing by Licensee (or an Affiliate) of each IND for a Licensed Product (or each indication for a Licensed Product), Licensee shall pay to Licensors [***] Dollars ($[***]), which payment is non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. Upon the filing by Licensee (or an Affiliate) of each IND for a Licensed Product for an [***] (i.e., [***]) indication, Licensee shall pay to Licensors only [***] Dollars ($[***]) pursuant to this subparagraph for such filing, which payment is non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. Upon the filing by Licensee (or an Affiliate) of an IND for a Licensed Product that is not, on its face, directly associated with any indication (i.e. a generic IND), Licensee shall owe [***] payment to Licensors pursuant to this subparagraph for such filing.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">(b)</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">Except as specified below, upon the initiation by Licensee (or an Affiliate) of Phase II clinical trials (i.e. the first administration of a Licensed Product to a patient, including combined Phase I and Phase II trials) for each Licensed Product (or each indication for a Licensed Product), Licensee shall pay to Licensors [***] Dollars (US$[***]), which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. Upon the initiation by Licensee (or an Affiliate) of Phase II clinical trials for each Licensed Product for an [***] indication, Licensee shall pay to Licensors only [***] Dollars ($[***]), pursuant to this subparagraph for the initiation of such trials, which payment is non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">(c)</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">Except as specified below, upon the initiation by Licensee (or an Affiliate) of Phase III clinical trials for each Licensed Product (or each indication for a Licensed Product), Licensee shall pay to Licensors [***] Dollars (US$[***]), which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. Upon the initiation by Licensee (or an Affiliate) of Phase III clinical trials for each Licensed Product for an [***] indication, Licensee shall owe [***] payment to Licensors pursuant to this subparagraph for the initiation of such trials.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:3.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.5%;">(d)</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:93.3%;">Except as specified below, upon Licensee&#8217;s (or an Affiliate&#8217;s) first receipt of governmental approval (FDA or equivalent approval in a European country or Japan) to market each Licensed Product (or each indication for a Licensed Product), Licensee shall pay to Licensors [***] Dollars (US$[***]), which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. Upon Licensee&#8217;s (or an Affiliate&#8217;s) first receipt of governmental approval (FDA or equivalent approval in a European country or Japan) to market each Licensed Product for an [***] indication, Licensee shall pay to Licensors only [***] Dollars ($[***]) pursuant to this subparagraph for such FDA approval, which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement.</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td colspan="3" style="vertical-align:top;width:6.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">6.06</p>
			</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:91.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Licensee&#8217;s failure to pay full royalties under paragraphs 6.01 or 6.02 or to make the payments required by paragraph 6.05, after written notice of such failure and an opportunity to cure (thirty days), shall be a breach of a material condition of this Agreement. Licensee&#8217;s failure to make any of the payments required by paragraph 6.04, after written notice of such failure and an opportunity to cure (thirty days), shall be the equivalent of an immediate termination of this Agreement by Licensee pursuant to paragraph 10.02.</p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:middle;width:6.7%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:91.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:6.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">7.</p>
			</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:91.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u><b>Payment Reports and Records</b></u></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:middle;width:6.7%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:91.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:6.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">7.01</p>
			</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:91.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">[***] of all payments required to be made by Licensee to Licensors pursuant to this Agreement shall be made to Industrial in U.S. Dollars by wire transfer or by check payable to Industrial and sent to the address set out in paragraph 13.01 for Industrial and [***] shall be made to AECOM in U.S. Dollars by wire transfer or by check payable to AECOM and sent to the address set out in paragraph 13.01 for AECOM.</p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:middle;width:6.7%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:91.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:6.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">7.02</p>
			</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:91.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Payment due from Licensee to Licensors pursuant to paragraphs 6.01 and 6.02 will be paid within thirty (30) days after the end of each calendar year quarter during which the payment accrued. Payment shall be accompanied by a statement of the amount of Net Sales and Net Proceeds realized by Licensee and Affiliates and Sublicensees, the amount of any deduction, and the total payment due from Licensee to Licensors.</p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:6.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:91.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:6.7%;">7.03</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:91.9%;">Licensee and its Affiliates shall maintain complete and accurate books of account and records showing Net Sales, Net Proceeds and Contract Research. Such books and records of Licensee and its Affiliates shall be open to inspection, in confidence, during usual business hours, by an independent certified public accountant appointed by AECOM on behalf of Licensors to whom Licensee has no reasonable objection, for two (2) years after the calendar year to which they pertain, for the purpose of verifying the accuracy of the payments made to Licensors by Licensee pursuant to this Agreement. Licensee shall use commercially reasonable efforts to require any Sublicensees hereunder to maintain such books and allow such inspection by Licensee and shall, on request, disclose such information to Licensors as part of such inspection. Inspection shall be at Licensors&#8217; sole expense and reasonably limited to those matters related to Licensee&#8217;s payment obligations under this Agreement and shall take place not more than once per calendar year. However, if the inspection reveals an underpayment to Licensors of ten percent 10% or greater, then the cost of the inspection shall be borne by Licensee. All information provided and/or inspected during such audits shall be subject to the confidentiality obligations of this Agreement.</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:6.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:91.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:6.7%;">8.</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:91.9%;"><u><b>Infringement</b></u></td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:6.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:91.9%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:6.7%;">8.01</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:91.9%;">Licensee shall have the right, in its sole discretion and its expense, to initiate legal proceedings on its behalf or in Licensors&#8217; names, if necessary, against any infringer, or potential infringer, of an Agreement Patent who makes, uses or sells products in the Field. Licensee shall notify Licensors of its intention to initiate such proceedings at least twenty (20) days prior to commencement thereof. Any settlement or recovery received from any such proceeding shall be divided [***] percent ([***]%) to Licensee and [***] percent ([***]%) to Licensors after Licensee deducts from any such settlement or recovery its actual counsel fees and out-of-pocket expenses relative to any such legal proceeding. If Licensee decides not to initiate legal proceedings against any such infringer, then Licensors shall have the right to initiate such legal proceedings. Any settlement or recovery received from any such proceeding initiated by Licensors shall be divided [***] percent ([***]%) to Licensee and [***] percent ([***]%) to Licensors after Licensors deducts from any such settlement or recovery its actual counsel fees and out-of-pocket expenses relative to any such legal proceeding.</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:4.1%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.8%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:91.9%;">&nbsp;</td>
		</tr>

</table>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:5.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">8.02</p>
			</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">In the event that either party initiates or carries on legal proceedings to enforce any Agreement Patent against an alleged infringer, the other party shall fully cooperate with and supply all assistance reasonably requested at the expense of the party requesting such assistance. Further, the other party, at its expense, shall have the right to be represented by counsel of its choice in any such proceeding. The party who initiates or carries on the legal proceedings shall have the sole right to conduct such proceedings provided, however, that such party shall consult with the other party to this Agreement prior to entering into any settlement thereof.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:middle;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">9.</p>
			</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u><b>Prohibition on Use of Names; No Publicity</b></u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:middle;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">9.01</p>
			</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Licensors and Licensee each shall not use the name of the other without prior written consent, except if the use of such name is required by law, regulation, federal securities law, or judicial order, in which event the party intending to use such name will promptly inform the other prior to any such required use. Neither party will make any public announcement regarding the existence of this Agreement and/or the collaboration hereunder without obtaining the prior written consent of the other party, except if such announcement is required by law, regulation, federal securities law or judicial order, in which event the party intending to make such announcement will promptly inform the other party prior to such announcement.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">10.</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;"><u><b>Term and Termination</b></u></td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">10.01</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">Unless terminated earlier under other provisions hereof, this Agreement will expire upon the termination of Licensee&#8217;s last obligation to make payments to Licensors hereunder with respect to all of the Agreement Patents existing as of the Effective Date. Upon termination or expiration of this Agreement for any reason, Sections 5, 9, 10.05, 12 and 13 shall survive.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">10.02</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">Licensee may terminate this Agreement and the licenses granted hereunder any time after payment of the amounts specified in paragraph 6.04(a) by giving notice to Licensors sixty (60) days prior to such termination. Upon such expiration, Licensee shall not use Agreement Patents for any purpose and all of Licensee&#8217;s rights in Agreement Patents shall be terminated.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">10.03</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">If either Licensors or Licensee defaults on or breaches any material condition of this Agreement, the aggrieved party may serve notice upon the other party of the alleged default or breach. If such default or breach is not remedied within sixty (60) days from the date of such notice, the aggrieved party may at its election terminate this Agreement. Any failure to terminate hereunder shall not be construed as a waiver by the aggrieved party of its right to terminate for future defaults or breaches. Licensee&#8217;s damages for any breach of the Agreement by Licensors will be limited to a reduction or suspension of the payment obligations of Licensee hereunder. Upon termination of this Agreement by Licensors pursuant to this paragraph, the licenses granted by Licensors to Licensee shall terminate and Licensee shall not use Agreement Patents for any purpose and all of Licensee&#8217;s rights in Agreement Patents shall be terminated.</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">10.04</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">If Licensee becomes insolvent or makes an assignment for the benefit of creditors or if proceedings for a voluntary bankruptcy are instituted on behalf of Licensee or if Licensee is declared bankrupt or insolvent, Licensors may at their election terminate this Agreement by notice to Licensee. Upon termination of this Agreement by Licensors pursuant to this paragraph, the licenses granted by Licensors to Licensee shall terminate and Licensee shall not use Agreement Patents for any purpose and all of Licensee&#8217;s rights in Agreement Patents shall be terminated.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">10.05</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">Termination of this Agreement by Licensee or Licensors shall not prejudice the rights of either party accruing herein.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">10.06</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">If Licensee terminates this Agreement pursuant to paragraph 10.02 or if Licensors terminate this Agreement pursuant to paragraphs 10.03 or 10.04, then Licensee hereby grants to Licensors, or shall use commercially reasonable efforts to procure for Licensors, a worldwide, royalty-bearing, non-exclusive license, with the right to grant sublicenses, under any Improvement Patents or Improvement Know-How (as defined below) developed by or for Licensee or its Affiliates during the term of this Agreement. As used in this paragraph, the term &#8220;Improvement Patents&#8221; means any U.S. or foreign patent application or patent which claims an invention the practice of which would be covered by a claim of patent or patent application of Agreement Patents, or practice of which results in a product covered by a claim of a patent or patent application of Agreement Patents. &#8220;Improvement Know How&#8221; means confidential information, including clinical trial information, the practical application of which would be covered by a claim of a patent or patent application of Agreement Patents, or which results in a product covered by a claim of a patent or patent application of Agreement Patents. The royalty-rate for such license shall be determined by good faith negotiations between the parties and which shall not exceed Licensee&#8217;s obligations under this agreement including license fees, milestone payments and royalty obligations. Further, Licensors shall bear the cost of any license procured from a third party by Licensee for the benefit of Licensors, so long as such license is accepted by Licensors.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">11.</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;"><u><b>Amendment and Assignment</b></u></td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">11.01</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">This Agreement sets forth the entire understanding between the parties pertaining to the subject matter hereof.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">11.02</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">Except as otherwise provided herein, this Agreement may not be amended, supplemented or otherwise modified, except by an instrument in writing signed by both parties.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">11.03</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">Without the prior written approval of the other party, which approval shall not be unreasonably withheld, no party may assign this Agreement except to an entity acquiring substantially all of the such party&#8217;s business to which this Agreement relates.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">12.</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;"><u><b>Miscellaneous Provisions</b></u></td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">12.01</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">This Agreement shall be construed and the rights of the parties governed in accordance with the laws of the State of New York, excluding its law of conflict of laws. Any dispute or issue arising hereunder, including any alleged breach by any party, shall be heard, determined and resolved by an action commenced in the state or federal courts in New York, New York, which the parties hereby agree shall have proper jurisdiction and venue over the issues and the parties. Licensors and Licensee hereby agree to submit to the jurisdiction of the state or federal courts in New York and waive the right to make any objection based on jurisdiction or venue. The New York courts shall have the right to grant all relief to which Licensors and Licensee are or shall be entitled hereunder, including all equitable relief as the Court may deem appropriate.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">12.02</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">This Agreement has been prepared jointly.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">12.03</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">If any term or provision of this Agreement or the application thereof to any person or circumstance shall to any extent be invalid or unenforceable, the remainder of this Agreement or the application of such term or provision to persons or circumstances other than those as to which it is held invalid or unenforceable shall not be affected thereby and each term and provision of this Agreement shall be valid and enforced to the fullest extent permitted by law.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td colspan="2" style="vertical-align:top;width:5.6%;">12.04</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">Licensee agrees to indemnify AECOM and Industrial, their trustees, employees and agents for the cost of defense and for damages awarded, if any, as a result of any third party claims, liabilities, suits or judgments arising out of the research, development, marketing, manufacture and sale of Licensed Products by Licensee, its Affiliates and its sublicensees, and/or the licenses granted under this Agreement, so long as such claims, liabilities, suits, or judgments are not attributable to grossly negligent or intentionally wrongful acts or omissions by Licensors, their trustees, employees and agents or a breach by Licensors of this Agreement. This indemnity is conditioned upon Licensors&#8217; obligation to: (i) advise Licensee of any claim or lawsuit, in writing promptly after Licensors has received notice of said claim or lawsuit (ii) assist Licensee and its representatives in the investigation and defense of any lawsuit and/or claim for which indemnification is provided (iii) permit Licensee to control the defense of such claim or lawsuit for which indemnification is provided. For purposes of clarity, Licensee will not indemnify Licensors, their trustees, employees or agents for any liabilities incurred or arising out of Licensor&#8217;s activities under Section 2 of this Agreement.</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:5.6%;">12.05</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">Nothing in this Agreement is or shall be construed as:</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 2.8%;">&nbsp;</td>
			<td colspan="6" rowspan="1" style="vertical-align: top; width: 2.8%;">(a)&nbsp; &nbsp; A warranty or representation by Licensors that anything made or used by Licensee under any license granted in this Agreement is or will be free from infringement of patents, copyrights, and other rights of third parties; or</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 2.8%;">&nbsp;</td>
			<td colspan="6" style="vertical-align: top; width: 2.8%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 2.8%;">&nbsp;</td>
			<td colspan="6" style="vertical-align: top; width: 2.8%;">(b)&nbsp; &nbsp; Granting by implication, estoppel, or otherwise any license, right or interest other than as expressly set forth herein.</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:5.6%;">12.06</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">Except as expressly set forth in this Agreement, the parties MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, STATUTE OR OTHERWISE, AND THE PARTIES SPECIFICALLY DISCLAIM ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR WARRANTY OF NON-INFRINGEMENT.</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:5.6%;">12.07</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">Licensee will utilize commercially reasonable efforts to develop and commercially exploit Licensed Products. Between the Effective Date and the [***] anniversary thereof, Licensee shall spend at least [***] Dollars (US$[***]) on the development of Licensed Products with at least [***] Dollars (US$[***]) to be spent to fund development other than at BioCryst and its Affiliates. Licensee will spend this amount whether or not one or more sublicenses are granted by Licensee during this time period; except that if Licensee does not spend this amount, [***] percent ([***]%) of the difference between the required amount and the amount that Licensee has actually spent, shall be paid to Licensor in a single cash payment. At least one month before the first anniversary of the Effective Date and each anniversary thereafter until the commercialization of the first Licensed Product, Licensee shall provide Licensors in writing with a development plan, budget and report which sets forth (1) the work to be undertaken by Licensee on the development and commercialization of Licensed Products during the next twelve-month period, (2) the funds to be expended by Licensee in this regard, and (3) the funds actually expended by Licensee and the progress made thus far on the development and commercialization of Licensed Products during the previous twelve month period including, where requested by Licensors, a summary of the results of development and clinical trials undertaken (once these results are allowed to be released), which summary shall include all triggers of Licensee&#8217;s financial obligations to Licensors.</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:top;width:5.6%;">12.08</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">Licensors and Licensee represent and warrant that, to the best of their knowledge, as of the Effective Date:</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:1.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:88.6%;">&nbsp;</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(i)</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:96.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">they have the legal right and authority to enter into this Agreement and to perform all of their obligations hereunder;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:3.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(ii)</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:96.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">the execution, delivery and performance of this Agreement does not and will not conflict with, or constitute a breach or default under, or require the consent of any third party under any other agreement or violate any provision of law, statute, rule or regulation or any ruling, writ, injunction, order, judgment or decree of any court, administrative agency or other governmental body;</p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(iii)</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:96.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">when executed by all parties, this Agreement will constitute the valid and legally binding obligation and shall be enforceable in accordance with its terms;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:3.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:middle;width:96.4%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(iv)</p>
			</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:96.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">there are no existing or threatened actions, suits or claims pending or threatened against it that may affect the performance of its obligations under the Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:top;width:5.6%;">12.09</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">Licensors further represent and warrant that as of the Effective Date and to the best of their knowledge, they are not aware of any intellectual property rights of third parties (other than the prior patents cited by the patent offices in connection with the prosecution of Agreement Patents) that would be infringed by the practice of the Agreement Patents.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">12.10</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">Licensee represents and warrants that before Licensee, or its Affiliates or Sublicensees makes any sales of Licensed Products, Licensee or its Affiliates or Sublicensees will have adequate insurance and financial resources to cover all liability for any failure of such Licensed Product including, without limitation, failure in design, manufacture, production and/or operation.</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">13.</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;"><u><b>Notices</b></u></td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.6%;">13.01</td>
			<td style="vertical-align:top;width:1.3%;">&nbsp;</td>
			<td colspan="4" style="vertical-align:top;width:93.1%;">Any notice or report required or permitted hereunder shall be given in writing, and shall be deemed to have been properly given and effective upon delivery; by registered or certified mail, return receipt request, or by facsimile with proof of receipt and a confirmation copy sent by overnight courier, or overnight courier, to the following addresses:</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><u><b>To Licensee</b></u><b>:</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">BioCryst Pharmaceuticals, Inc.<br>
2190 Parkway Lake Drive<br>
Birmingham, Alabama 35244</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Attn: John R. Uhrin</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><u><b>With Copy to</b></u><b>:</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Brobeck, Phleger &amp; Harrison LLP<br>
1633 Broadway, 47th Floor<br>
NewYork, NY 10019<br>
Attention: Nigel L. Howard, Esq.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><u><b>To AECOM</b></u><b>:</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Albert Einstein College of Medicine<br>
of Yeshiva University<br>
1300 Morris Park Avenue<br>
Bronx, NY 10461</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Attention: Office of Industrial Liaison</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><u><b>With Copy to</b></u><b>:</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Kenneth P. George, Esq.<br>
Amster, Rothstein &amp; Ebenstein<br>
90 Park Avenue &#8211; 21st Floor<br>
New York, NY 10016</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><u><b>To Industrial</b></u><b>:</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Dr. Richard H. Furneaux<br>
Industrial Research Ltd.<br>
Gracefield Research Centre<br>
Gracefield Road<br>
P.O. Box 31-310<br>
Lower Hutt, New Zealand</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;"><u><b>With Copy to:</b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">West Walker Bennett<br>
Mobil on the Park<br>
157 Lambton Quay<br>
P.O. Box 1344<br>
Wellington, New Zealand</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Attn: Mr. Mike Bennett</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;"><b>IN WITNESS WHEREOF</b>, the parties have entered into this Agreement effective as of the day and year first above written.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:17.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:10%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:71.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:81.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, A DIVISION OF YESHIVA UNIVERSITY</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>WITNESS:</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ Emanuel Genn&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Emanuel Genn</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ [illegible]</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Associate Dean for Business Affairs</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">June 23, 2000</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">June 23, 2000</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:81.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>INDUSTRIAL RESEARCH LTD.</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>WITNESS:</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ [illegible]&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ [illegible]</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Executive Officer</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">23 June 2000</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:81.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>BIOCRYST PHARMACEUTICALS, INC.</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>WITNESS:</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ J. Claude Bennett&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">J. Claude Bennett, M.D.</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ [illegible]</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">President and Chief Operating Officer</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">V.P. Corporate Development</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">June 21, 2000</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">June 21, 2000</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:17.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:10%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:71.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>

</table>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-size: 0.5pt; margin: 0 7.2pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><u><b>FIRST AMENDMENT AGREEMENT</b></u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">This Amendment Agreement is made effective July 26, 2002 by and between Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, a corporation organized and existing under the laws of the State of New York, having an office and place of business at 1300 Morris Park Avenue, Bronx, New York 10461 (&#8220;AECOM&#8221;), Industrial Research Ltd., a company organized and existing under the laws of New Zealand, having an office and place of business at Gracefield Research Centre, Gracefield Road, P.O. Box 31-310, Lower Hutt, New Zealand (&#8220;Industrial&#8221;) (AECOM and Industrial are collectively referred to herein as &#8220;Licensors&#8221;), and BioCryst Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware having an office and place of business at 2190 Parkway Lake Drive, Birmingham, Alabama 35244 (&#8220;Licensee&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><u><b>Statement</b></u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">Licensors and Licensee are parties to a License Agreement dated June 27, 2000 (&#8220;the License Agreement&#8221;) and wish to make changes to the License Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">NOW, THEREFORE, in consideration of the mutual covenants contained in the License Agreement and in this First Amendment Agreement and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">1. Paragraph 6.05 of the License Agreement is hereby amended to read as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">6.05 Licensee shall make the following milestone payments to Licensors:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td colspan="2" style="vertical-align: top; width: 42.4972px;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 61.1335px;">(a)</td>
			<td style="vertical-align: top; width: 5.86648px;">&nbsp;</td>
			<td style="vertical-align: top; width: 1247px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Except as specified below, upon the filing by Licensee (or an Affiliate) of each IND for a Licensed Product (or each indication for a Licensed Product), Licensee shall pay to Licensors [***] Dollars ($[***]), which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. Upon the filing by Licensee (or an Affiliate) of each IND for a Licensed Product for a [***] (&#8220;[***]&#8221;) indication, Licensee shall pay to Licensors only [***] Dollars ($[***]) pursuant to this subparagraph for such filing, which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. Upon the filing by Licensee (or an Affiliate) of an IND for a Licensed Product that is not, on its face, directly associated with any indication (i.e. a generic IND), Licensee shall owe [***] payment to Licensors pursuant to this subparagraph for such filing.</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 42.4972px;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 61.1335px;">&nbsp;</td>
			<td style="vertical-align: top; width: 5.86648px;">&nbsp;</td>
			<td style="vertical-align: top; width: 1247px;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 42.4972px;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 61.1335px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(b)</p>
			</td>
			<td style="vertical-align: top; width: 5.86648px;">&nbsp;</td>
			<td style="vertical-align: top; width: 1247px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Except as specified below, upon the initiation by Licensee (or an Affiliate) of Phase II clinical trials (i.e. the administration of a Licensed Product to a patient for the primary purpose of assessing clinical efficacy; and not Phase I clinical trials for the primary purpose of assessing safety or pharmacokinetics) for each Licensed Product (or each indication for a Licensed Product), Licensee shall pay to Licensors [***] Dollars (US$[***]), which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. Upon the initiation by Licensee (or an Affiliate) of Phase II clinical trials for each Licensed Product for a [***] indication, Licensee shall pay to Licensors only [***] Dollars ($[***]), pursuant to this subparagraph for the initiation of such trials, which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement.</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: middle; width: 42.4972px;">&nbsp;</td>
			<td colspan="2" style="vertical-align: middle; width: 61.1335px;">&nbsp;</td>
			<td style="vertical-align: middle; width: 5.86648px;">&nbsp;</td>
			<td style="vertical-align: middle; width: 1247px;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 42.4972px;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 61.1335px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(c)</p>
			</td>
			<td style="vertical-align: top; width: 5.86648px;">&nbsp;</td>
			<td style="vertical-align: top; width: 1247px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Except as specified below, upon the initiation by Licensee (or an Affiliate) of Phase III clinical trials for each Licensed Product (or each indication for a Licensed Product), Licensee shall pay to Licensors [***] Dollars (US$[***]), which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. Upon the initiation by Licensee (or an Affiliate) of Phase III clinical trials for each Licensed Product for a [***] indication, Licensee shall pay to Licensors only [***] Dollars ($[***]), pursuant to this subparagraph for the initiation of such trials, which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement.</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 42.4972px;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 61.1335px;">&nbsp;</td>
			<td style="vertical-align: top; width: 5.86648px;">&nbsp;</td>
			<td style="vertical-align: top; width: 1247px;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: top; width: 42.4972px;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 61.1335px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(d)</p>
			</td>
			<td style="vertical-align: top; width: 5.86648px;">&nbsp;</td>
			<td style="vertical-align: top; width: 1247px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Except as specified below, upon Licensee&#8217;s (or an Affiliate&#8217;s) first receipt of governmental approval (FDA or equivalent approval in a European country or Japan) to market each Licensed Product (or each indication for a Licensed Product), Licensee shall pay to Licensors [***] Dollars (US$[***]), which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. Upon Licensee&#8217;s (or an Affiliate&#8217;s) first receipt of governmental approval (FDA or equivalent approval in a European country or Japan) to market each Licensed Product for a [***] indication, Licensee shall pay to Licensors only [***] Dollars ($[***]) pursuant to this subparagraph for such FDA approval, which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:3%;">&nbsp;</td>
			<td style="vertical-align: middle; width: 1px;">&nbsp;</td>
			<td style="vertical-align: middle; width: 59.5028px;">&nbsp;</td>
			<td style="vertical-align: middle; width: 1px;">&nbsp;</td>
			<td style="vertical-align: middle; width: 5.86648px;">&nbsp;</td>
			<td style="vertical-align: middle; width: 1247px;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">2. Upon execution of this First Amendment Agreement, Licensee shall pay to Licensors [***] Dollars ($[***]), which payment is non-refundable and not creditable against any other payment due to Licensors. Licensors waive any claim for any payments due to Licensors under paragraph 6.05 for events occurring prior to July 26, 2002.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">3. The applicable provisions of this First Amendment Agreement shall be deemed to be incorporated into the License Agreement in full and to be an integral part thereof as though fully set forth therein. With the exception of the above amendments, all other provisions of the License Agreement shall remain in full force and effect.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">IN WITNESS WHEREOF, the parties hereto have entered into and executed this Amendment Agreement on the date first above written.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:51.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:8.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:29.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:60.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>ALBERT EINSTEIN COLLEGE</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:38.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>BIOCRYST</b></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:60.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>OF MEDICINE OF YESHIVA UNIVERSITY</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:38.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>PHARMACEUTICALS, INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:51.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:29.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:51.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:29.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>By:</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:51.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ Emanuel Genn&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>By:</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:29.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ W. Randall Pittman&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Name:</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:51.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Emanuel Genn</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Name:</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:29.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">W. Randall Pittman</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Title:</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:51.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Associate Dean for Business Affairs</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Title:</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:29.3%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Financial Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:51.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:29.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:60.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>INDUSTRIAL RESEARCH LTD.</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:29.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:51.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:29.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:51.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ David Michael Bibby&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:29.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name:</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:51.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">David Michael Bibby</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:29.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title:</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:51.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">General Manager &#8212; Science Development</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8.9%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:29.3%;">&nbsp;</td>
		</tr>

</table>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><u><b>SECOND AMENDMENT AGREEMENT</b></u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">This Second Amendment Agreement is made effective April 15, 2005 by and between Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, a corporation organized and existing under the laws of the State of New York, having an office and place of business at 1300 Morris Park Avenue, Bronx, New York 10461 (&#8220;AECOM&#8221;), Industrial Research Ltd., a company organized and existing under the laws of New Zealand, having an office and place of business at Gracefield Research Centre, Gracefield Road, P.O. Box 31-310, Lower Hutt, New Zealand (&#8220;Industrial&#8221;) (AECOM and Industrial are collectively referred to herein as &#8220;Licensors&#8221;), and BioCryst Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware having an office and place of business at 2190 Parkway Lake Drive, Birmingham, Alabama 35244 (&#8220;Licensee&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><u><b>Statement</b></u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">Licensors and Licensee are parties to a License Agreement dated June 27, 2000, as amended by a First Amendment Agreement effective July 26, 2002 (collectively &#8220;the License Agreement&#8221;), and now wish to make changes to the License Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">NOW, THEREFORE, in consideration of the mutual covenants contained in the License Agreement and in this Second Amendment Agreement and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">1. Subparagraph 6.05(b) of the License Agreement is hereby amended to read as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 5%;">&nbsp;</td>
			<td style="vertical-align: top; width: 1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:left;">(b)</p>
			</td>
			<td style="vertical-align: top; width: 1%;">&nbsp;</td>
			<td style="vertical-align: top; width: 93%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Except as specified below, upon the initiation by Licensee (or an Affiliate) of Phase II clinical trials (i.e. the administration of a Licensed Product to a patient for the primary purpose of assessing clinical efficacy; and not Phase I clinical trials for the primary purpose of assessing safety or pharmacokinetics) for each Licensed Product (or each indication for a Licensed Product), Licensee shall pay to Licensors [***] Dollars (US$[***]), which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. Upon the initiation by Licensee (or an Affiliate) of Phase II clinical trials for each Licensed Product for a [***] indication, Licensee shall pay to Licensors only [***] Dollars ($[***]), pursuant to this subparagraph for the initiation of such trials, which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. No payment shall be due under this paragraph for any Phase II clinical trial initiated by a third party Investigator, even if the trial is supported by Licensee (an &#8220;Investigator Initiated Trial&#8221;). However, If the Investigator Initiated Trial enables Licensee (or an Affiliate) to initiate a Phase III clinical trial or if Licensee (or an Affiliate) proceeds to initiate a similar Phase II clinical trial, then the payment required by this paragraph shall become due and payable.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">2. The applicable provisions of this Second Amendment Agreement shall be deemed to be incorporated into the License Agreement in full and to be an integral part thereof as though fully set forth therein. With the exception of the above amendments, all other provisions of the License Agreement shall remain in full force and effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">IN WITNESS WHEREOF, the parties hereto have entered into and executed this Second Amendment Agreement on the date first above written.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td colspan="3" style="vertical-align:top;width:48.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>ALBERT EINSTEIN COLLEGE</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:50.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>BIOCRYST</b></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:48.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>OF MEDICINE OF YESHIVA</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:50.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>PHARMACEUTICALS, INC.</b></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:48.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>UNIVERSITY</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:42.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:48.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:42.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:40.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:42.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:40.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ Emanuel Genn&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:42.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ Randall B. Riggs&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name:</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:40.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Emanuel Genn</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name:</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:42.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Randall B. Riggs</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title:</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:40.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Associate Dean for Business Affairs</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title:</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:42.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Vice President, Business Development</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:40.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:42.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" rowspan="1" style="vertical-align:top;width:8%;"><b>INDUSTRIAL RESEARCH LTD.</b></td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:42.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8%;">By:</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:40.5%;"><u>/s/ G.A. Todd&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:42.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8%;">Name:</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:40.5%;">G.A. Todd</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:42.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:8%;">Title:</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:40.5%;">General Manager New Ventures</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:42.5%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>8
<FILENAME>ex_230490.htm
<DESCRIPTION>EXHIBIT 10.33
<TEXT>
<html><head>
	<title>ex_230490.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 10.33</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT IN PLACES MARKED &#8220;[***]&#8221; BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><u><b>THIRD AMENDMENT AGREEMENT </b></u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:18pt;">This Amendment Agreement is made effective December 11, 2009 by and between Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, a corporation organized and existing under the laws of the State of New York, having an office and place of business at 1300 Morris Park Avenue, Bronx, New York 10461 (&#8220;AECOM&#8221;), Industrial Research Ltd., a company organized and existing under the laws of New Zealand, having an office and place of business at Gracefield Research Centre, Gracefield Road, P.O. Box 31-310, Lower Hutt, New Zealand (&#8220;Industrial&#8221;) (AECOM and Industrial are collectively referred to herein as &#8220;Licensors&#8221;), and BioCryst Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware having an office and place of business at 2190 Parkway Lake Drive, Birmingham, Alabama 35244 (&#8220;Licensee&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><u><b>Statement </b></u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:18pt;">Licensors and Licensee are parties to a License Agreement dated June 27, 2000, as amended by a First Amendment Agreement effective July 26, 2002 and a Second Amendment Agreement effective April 15, 2005 (collectively &#8220;the License Agreement&#8221;), and now wish to make changes to the License Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:18pt;">NOW, THEREFORE, in consideration of the mutual covenants contained in the Licensee Agreement and in this Third Amendment Agreement and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:18pt;">1. Paragraph 6.01 of the License Agreement is hereby amended to include the following additional sentence:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:18pt;">Notwithstanding the [***] royalty on Net Sales set forth above, if Licensee later requests a different royalty rate for a Licensed Product for a [***] indication, Licensors agree to consider such request.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:18pt;">2. Paragraph 6.05 of the License Agreement is hereby amended to read as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:18pt;">6.05 Licensee shall make the following milestone payments to Licensors:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Except as specified below, upon the filing by Licensee (or an Affiliate) of each IND for a Licensed Product (or each indication for a Licensed Product), Licensee shall pay to Licensors [***], which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. Upon the filing by Licensee (or an Affiliate) of each IND for a Licensed Product for a [***] indication, Licensee shall pay to Licensors only [***] pursuant to this Subparagraph for such filing, which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. Upon the filing by Licensee (or an Affiliate) of an IND for a Licensed Product that is not, on its face, directly associated with any indication (i.e. a generic IND), Licensee shall owe [***] to Licensors pursuant to this Subparagraph for such filing.</p>
			</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">[***] shall be due under this Subparagraph for a Licensed Product solely for a [***] indication.</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Except as specified below, upon the initiation by Licensee (or an Affiliate) of Phase II clinical trials (i.e. the administration of a Licensed Product to a patient for the primary purpose of assessing clinical efficacy; and not Phase I clinical trials for the primary purpose of assessing safety or pharmacokinetics) for each Licensed Product (or each indication for a Licensed Product), Licensee shall pay to Licensors [***], which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. Upon the initiation by Licensee (or an Affiliate) of Phase II clinical trials for each Licensed Product for a [***] indication, Licensee shall pay to Licensors only [***], pursuant to this Subparagraph for the initiation of such trials, which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. No payment shall be due under this paragraph for any Phase II clinical trial initiated by a third party Investigator, even if the trial is supported by Licensee (an &#8220;Investigator Initiated Trial&#8221;). However, if the Investigator Initiated Trial enables Licensee (or an Affiliate) to initiate a Phase III clinical trial or if Licensee (or an Affiliate) proceeds to initiate a similar Phase II clinical trial, then the payment required by this paragraph shall become due and payable.</p>
			</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">[***] shall be due under this Subparagraph for a Licensed Product solely for a [***] indication.</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">c.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Except as specified below, upon the initiation by Licensee (or an Affiliate) of Phase III clinical trials for each Licensed Product (or each indication for a Licensed Product), Licensee shall pay to Licensors [***], which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. Upon the initiation by Licensee (or an Affiliate) of Phase III clinical trials for each Licensed Product for a [***] Indication, Licensee shall pay to Licensors only [***], pursuant to this Subparagraph for the initiation of such trials, which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement.</p>
			</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">[***] shall be due under this Subparagraph for a Licensed Product solely for a [***] indication.</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">d.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Except as specified below, upon Licensee&#8217;s (or an Affiliate&#8217;s) first receipt of governmental approval (FDA or equivalent approval in a European country or Japan) to market each Licensed Product (or each Indication for a Licensed Product), Licensee shall pay to Licensors [***], which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement. Upon Licensee&#8217;s (or an Affiliate&#8217;s) first receipt of governmental approval (FDA or equivalent approval in a European country or Japan) to market each Licensed Product for a [***] indication, Licensee shall pay to Licensors only [***] pursuant to this Subparagraph for such FDA approval, which payments are non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement.</p>
			</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">[***] shall be due under this Subparagraph for a Licensed Product solely for a [***] indication.</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">e.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The first time the aggregate Net Sales of Licensed Products for a [***] indication in a consecutive twelve month period total [***], Licensee shall pay to Licensors [***], which payment is non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement.</p>
			</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:56pt;">&nbsp;</td>
			<td style="width:11pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">f.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The first time the aggregate Net Sales of Licensed Products in a consecutive (12) twelve month period total [***], Licensee shall pay to Licensors [***], which payment is non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement.</p>
			</td>
		</tr>
		<tr>
			<td style="width:56pt;">&nbsp;</td>
			<td style="width:11pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">g.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The first time the aggregate Net Sales of Licensed Products in a consecutive twelve (12) month period total [***], Licensee shall pay to Licensors [***], which payment is non-refundable and not creditable against any other payment due to Licensors pursuant to this Agreement.</p>
			</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">&nbsp;</td>
			<td style="vertical-align:top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">h.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The calculation of Net Sales pursuant to Subparagraphs (f) and (g) above shall exclude: (i) Net Sales of Licensed Products for a [***] indication; and (ii) Net Sales of Licensed Products solely for a [***] indication.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:18pt;">3. The applicable provisions of this Third Amendment Agreement shall be deemed to be incorporated into the License Agreement in full and to be an integral part thereof as though fully set forth therein. With the exception of the above amendments, all other provisions of the License Agreement shall remain in full force and effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:18pt;">IN WITNESS WHEREOF, the parties hereto have entered into and executed this Third Amendment Agreement on the date first above written.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:bottom;width:5.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:54.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:32.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:60%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>ALBERT EINSTEIN COLLEGE</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:38.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>BIOCRYST</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:60%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>OF MEDICINE OF YESHIVA</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:38.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>PHARMACEUTICALS, INC.</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:60%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>UNIVERSITY</b></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:32.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:54.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ John L. Harb&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:32.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ Alane Barnes&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:54.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name: John L. Harb</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:32.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name: Alane Barnes</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:54.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title: Assistant Dean<br>
			Scientific Operations</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:32.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title: General Counsel</p>
			</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:54.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:32.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" rowspan="1" style="vertical-align:top;width:5.1%;"><b>INDUSTRIAL RESEARCH LTD.</b></td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:32.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:54.6%;">By: <u>/s/ Jeff Lycett&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:32.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:54.6%;">Name: Jeff Lycett</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:32.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:5.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:54.6%;">Title:&nbsp;Board Secretary</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:32.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.2%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.35
<SEQUENCE>9
<FILENAME>ex_230492.htm
<DESCRIPTION>EXHIBIT 10.35
<TEXT>
<html><head>
	<title>ex_230492.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 10.35</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT IN PLACES MARKED &#8220;[***]&#8221; BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><u><b>FIFTH AMENDMENT AGREEMENT </b></u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">This Amendment Agreement is made effective November 17, 2011 by and among Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, a corporation organized and existing under the laws of the State of New York, having an office and place of business at 1300 Morris Park Avenue, Bronx, New York 10461 (&#8220;AECOM&#8221;), Industrial Research Ltd., a company organized and existing under the laws of New Zealand, having an office and place of business at Gracefield Research Centre, Gracefield Road, P.O. Box 31-310, Lower Hutt, New Zealand (&#8220;Industrial&#8221;) (AECOM and Industrial are collectively referred to herein as &#8220;Licensors&#8221;), and BioCryst Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware having an office and place of business at 2190 Parkway Lake Drive, Birmingham, Alabama 35244 (&#8220;Licensee&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><u><b>Statement </b></u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">Licensors and Licensee are parties to a License Agreement dated June 27, 2000, as amended by a First Amendment Agreement effective July 26, 2002, a Second Amendment Agreement effective April 15, 2005, a Third Amendment Agreement effective December 11, 2009 and a Fourth Amendment Agreement effective May 5, 2010 (collectively &#8220;the License Agreement&#8221;), and now wish to further amend the License Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">NOW, THEREFORE, in consideration of the mutual covenants contained in the License Agreement and in this Fifth Amendment Agreement and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Paragraph 6.02 of the License Agreement is hereby amended to read in its entirety as follows:</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:43.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">6.02&nbsp; (a) Licensee shall pay to Licensors [***] percent ([***]%) of Net Proceeds.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:65.7pt;margin-right:7.2pt;margin-top:0pt;text-align:left;">(b) Licensee shall pay to Licensors [***] percent ([***] %) of Sublicensee Royalties.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:79.2pt;margin-right:7.2pt;margin-top:0pt;text-align:left;text-indent:-13.5pt;">(c)&nbsp;Any payments due to be paid by Licensee to Licensors under paragraph 6.02(a) may be made either in cash or, at the sole option of Licensee, in Qualified Licensee Shares or a combination of cash and Qualified Licensee Shares. Any such Qualified Licensee Shares shall be subject to the terms of Sections 6 and 8 hereof. Any Qualified Licensee Shares issued under paragraph 6.02(a) shall be valued based on the Volume Weighted Average Price of such shares determined as of the date payment is due under paragraph 7.02 of the License Agreement. Notwithstanding the foregoing, unless otherwise agreed to by the parties, Licensee shall not be permitted to issue Qualified Licensee Shares (i) to the extent that the number of Qualified Licensee Shares to be issued would exceed six (6) times the average daily trading volume of Licensee&#8217;s common stock for the twenty (20) consecutive trading days ending on the trading day immediately before the date such Qualified Licensee Shares are to be issued or (ii) if Licensee does not meet the eligibility requirements for continued listing on the applicable Trading Market (as defined below).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:55pt;">&nbsp;</td>
			<td style="width:12pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The applicable provisions of this Fifth Amendment Agreement shall be deemed to be incorporated into the License Agreement in full and to be an integral part thereof as though fully set forth therein. With the exception of the above amendments, all other provisions of the License Agreement shall remain in full force and effect.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">IN WITNESS WHEREOF, the parties hereto have entered into and executed this Fifth Amendment Agreement as of the date first above written.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:12.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:42.1%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:10.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:33%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:bottom;width:54.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ALBERT EINSTEIN COLLEGE OF MEDICINE OF<br>
			YESHIVA UNIVERSITY</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:44.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">BIOCRYST PHARMACEUTICALS, INC.</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:12.1%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:42.7%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:0.6%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:11%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:33.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:12.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align:bottom;width:0.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:42.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ John L. Harb&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:10.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ Alane Barnes&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:12.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name:</p>
			</td>
			<td style="vertical-align:bottom;width:0.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:42.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">John L. Harb</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:10.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name:</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Alane Barnes</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:12.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title:</p>
			</td>
			<td style="vertical-align:bottom;width:0.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:42.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Assistant Dean Scientific Operations</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:10.7%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title:</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">VP, General Counsel</p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:middle;width:54.8%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:0.6%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:11%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:33.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align:top;width:54.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">INDUSTRIAL RESEARCH, LTD.</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:10.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:33%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:12.1%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:42.7%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:0.6%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:11%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:33.5%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:12.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align:bottom;width:0.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:42.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ Shaun Coffey&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:10.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:33%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:12.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name:</p>
			</td>
			<td style="vertical-align:bottom;width:0.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:42.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Shaun Coffey</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:10.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:33%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:12.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title:</p>
			</td>
			<td style="vertical-align:bottom;width:0.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:42.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Executive</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:10.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:33%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">-2-</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.36
<SEQUENCE>10
<FILENAME>ex_230493.htm
<DESCRIPTION>EXHIBIT 10.36
<TEXT>
<html><head>
	<title>ex_230493.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 10.36</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT IN PLACES MARKED &#8220;[***]&#8221; BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. </b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><u><b>SIXTH AMENDMENT AGREEMENT </b></u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">This Sixth Amendment Agreement is made effective June 19, 2012 by and among Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, a corporation organized and existing under the laws of the State of New York, having an office and place of business at 1300 Morris Park Avenue, Bronx, New York 10461 (&#8220;AECOM&#8221;), Industrial Research Ltd., a company organized and existing under the laws of New Zealand, having an office and place of business at Gracefield Research Centre, Gracefleld Road, P.O. Box 31-310, Lower Hutt, New Zealand (&#8220;Industrial&#8221;) (AECOM and Industrial are collectively referred to herein as &#8220;Licensors&#8221;), and BioCryst Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware having an office and place of business at 2190 Parkway Lake Drive, Birmingham, Alabama 35244 (&#8220;Licensee&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>Statement </b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">Licensors and Licensee are parties to a License Agreement dated June 27, 2000, as amended by a First Amendment Agreement effective July 26, 2002, a Second Amendment Agreement effective April 15, 2005, a Third Amendment Agreement effective December 11, 2009, a Fourth Amendment Agreement effective May 5, 2010 and a Fifth Amendment Agreement effective November 17, 2011 (collectively &#8220;the License Agreement&#8221;), and now wish to further amend the License Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">NOW, THEREFORE, in consideration of the mutual covenants contained in the License Agreement and in this Sixth Amendment Agreement and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">1.</p>
			</td>
			<td style="vertical-align:top;width:97.5%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Paragraph 1.01 of the License Agreement is hereby amended to read in its entirety as follows:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">1.01 &#8220;<b>Field&#8221;</b> means (i) any use of inhibitors for human PNP that have an IC50 value less than ***, as determined by the method described in Bantia, <i>et al.</i>, Immunopharmacology, 35, page 54, paragraph 2.1 (1997) and (ii) any antiviral use of BCX-4430, including but not limited to prophylactic antiviral and therapeutic antiviral uses. Except for those compounds which are also inhibitors for human PNP as described above, specifically excluded from the &#8220;Field&#8221; are inhibitors for MTAP and/or MTAN and processes for producing and using such inhibitors to inhibit MTAP and/or MTAN. An inhibitor for the human MTAP enzyme is defined as having a Ki or Ki* value of [***] or less using the assays with human MTAP published in<i> Biochemistry </i><b>2004, </b><i>43, </i>9-18, page 10. An inhibitor for the bacterial MTAN enzyme is defined as having a Ki or Ki* value of [***] or less using the assays with <i>E. coli</i> MTAN published in the <i>Journal of Biological Chemistry</i> <b>2005</b>, 280:18265-18273, page 18268. Non-limiting examples of excluded inhibitors are the compounds listed below:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">[***]</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:0.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:2.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">2.</p>
			</td>
			<td style="vertical-align:top;width:97%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The following new Paragraph 1.09 is hereby added to the License Agreement:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">1.09 &#8220;<b>BCX-4430</b>&#8221; means the compound known as BCX-4430 having the following chemical structure [***] together with its isomers, positional isomers, radioisomers, salt forms, anhydrides, hydrates, polymorphs, metabolites, prodrugs and ester forms.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:0.2%;">&nbsp;</td>
			<td style="vertical-align:top;width:1.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">3.</p>
			</td>
			<td style="vertical-align:top;width:98.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The applicable provisions of this Sixth Amendment Agreement shall be deemed to be incorporated into the License Agreement in full and to be an integral part thereof as though fully set forth therein. With the exception of the above amendments, all other provisions of the License Agreement shall remain in full force and effect.</p>
			</td>
		</tr>

</table>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;text-indent:36pt;">IN WITNESS WHEREOF, the parties hereto have entered into and executed this Sixth Amendment Agreement as of the date first above written.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align:middle;width:12.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.6%;">&nbsp;</td>
			<td style="vertical-align:middle;width:37.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:11.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:34.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:0.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="5" style="vertical-align:top;width:52.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ALBERT EINSTEIN COLLEGE OF</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">MEDICINE OF YESHIVA UNIVERSITY</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:top;width:46.4%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">BIOCRYST PHARMACEUTICALS, INC.</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:12.8%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:38.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:1.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:11.5%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:35.2%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:0.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:12.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align:bottom;width:0.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:37.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ John L. Harb&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
			<td style="vertical-align:bottom;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:11.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:34.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ Alane Barnes&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:12.8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Name:</p>
			</td>
			<td style="vertical-align:bottom;width:0.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:37.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">John L. Harb</p>
			</td>
			<td style="vertical-align:bottom;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:11.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name:</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:34.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Alane Barnes</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:12.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title:</p>
			</td>
			<td style="vertical-align:bottom;width:0.6%;">&nbsp;</td>
			<td colspan="3" style="vertical-align:bottom;width:39.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Assistant Dean Scientific Operations</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:11.2%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title:</p>
			</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:34.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">VP, General Counsel</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="5" style="vertical-align:middle;width:52.6%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:11.5%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:35.2%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:0.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="5" style="vertical-align:top;width:52.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">INDUSTRIAL RESEARCH, LTD.</p>
			</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:11.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:34.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:12.8%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:38.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:1.4%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:11.5%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:35.2%;">&nbsp;</td>
			<td colspan="2" style="vertical-align:middle;width:0.7%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:12.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align:bottom;width:0.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:37.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>/s/ Shaun Coffey&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</u></p>
			</td>
			<td style="vertical-align:bottom;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:11.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:34.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:12.8%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">Name:</p>
			</td>
			<td style="vertical-align:bottom;width:0.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:37.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Shaun Coffey</p>
			</td>
			<td style="vertical-align:bottom;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:11.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:34.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:12.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title:</p>
			</td>
			<td style="vertical-align:bottom;width:0.6%;">&nbsp;</td>
			<td style="vertical-align:top;width:37.8%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Executive</p>
			</td>
			<td style="vertical-align:bottom;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:11.2%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:34.6%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:0.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:0.3%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.82
<SEQUENCE>11
<FILENAME>ex_230494.htm
<DESCRIPTION>EXHIBIT 10.82
<TEXT>
<html><head>
	<title>ex_230494.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;"><b>Exhibit 10.82</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><img alt="exh1082_01.jpg" src="exh1082_01.jpg"></div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><img alt="exh1082_02.jpg" src="exh1082_02.jpg"></div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div><img alt="exh1082_03.jpg" src="exh1082_03.jpg"></div>
</div>
</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.87
<SEQUENCE>12
<FILENAME>ex_230497.htm
<DESCRIPTION>EXHIBIT 10.87
<TEXT>
<html><head>
	<title>ex_230497.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; padding:0in .1in;">
<p style="margin: 0pt 0pt 0pt 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-indent: -9pt; text-align: right;"><b>Exhibit 10.87</b></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><img alt="exh1087_01.jpg" src="exh1087_01.jpg"></div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><img alt="exh1087_02.jpg" src="exh1087_02.jpg"></div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>
</div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><img alt="exh1087_03.jpg" src="exh1087_03.jpg"></div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><img alt="exh1087_04.jpg" src="exh1087_04.jpg"></div>

<div style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div><img alt="exh1087_05.jpg" src="exh1087_05.jpg"></div>
</div>
</div>
</div>
</div>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.91
<SEQUENCE>13
<FILENAME>ex_230714.htm
<DESCRIPTION>EXHIBIT 10.91
<TEXT>
<html><head>
	<title>ex_230714.htm</title>
	<!-- Generated by ThunderDome Portal - 2/27/2021 1:51:35 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;"><b>Exhibit 10.91</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>Certain information has been omitted from this exhibit in places marked &#8220;[***]&#8221; because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed or because it contains personally identifiable information omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;font-variant:small-caps;margin:0pt;text-align:center;text-transform:uppercase;"><b>&nbsp;</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;font-variant:small-caps;margin:0pt;text-align:center;">Purchase and Sale Agreement</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;font-variant:small-caps;margin:0pt;text-align:center;">By and Between</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;font-variant:small-caps;margin:0pt;text-align:center;">BioCryst Pharmaceuticals, Inc.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;font-variant:small-caps;margin:0pt;text-align:center;">and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;font-variant:small-caps;margin:0pt;text-align:center;">RPI 2019 Intermediate Finance Trust</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;font-variant:small-caps;margin:0pt;text-align:center;">Dated as of December 7, 2020</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>TABLE OF CONTENTS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><u>Page</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td colspan="2" style="vertical-align: middle; width: 10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ARTICLE 1 DEFINITIONS</p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">1</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 1.1&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Definitions</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">1</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 1.2&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Certain Interpretations</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">23</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: middle; width: 10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ARTICLE 2 PURCHASE, SALE AND ASSIGNMENT OF THE REVENUE PARTICIPATION RIGHT</p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">24</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 2.1&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Purchase, Sale and Assignment</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">24</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 2.2&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Purchase Price</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">25</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 2.3&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>No Assumed Obligations, Etc.</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">25</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: middle; width: 10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ARTICLE 3 CLOSING</p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">25</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 3.1&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Closing</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">25</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 3.2&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Payment of Purchase Price</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">25</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 3.3&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Bill of Sale</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">25</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: middle; width: 10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ARTICLE 4 REPRESENTATIONS AND WARRANTIES</p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">25</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 4.1&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Seller&#8217;s Representations and Warranties</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">25</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 4.2&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Buyer&#8217;s Representations and Warranties</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">30</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 4.3&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>No Implied Representations and Warranties</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">31</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: middle; width: 10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ARTICLE 5 CONDITIONS TO CLOSING</p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">32</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 5.1&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Conditions to the Buyer&#8217;s Obligations</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">32</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 5.2&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Conditions to the Seller&#8217;s Obligations</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">34</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: middle; width: 10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ARTICLE 6 COVENANTS</p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">35</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 6.1&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Reporting</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">35</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 6.2&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Royalty Payments; Revenue Participation and Royalty Payment Details</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">36</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 6.3&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Disclosures</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">37</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 6.4&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Inspections and Audits of the Seller</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">37</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 6.5&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Intellectual Property Matters</u>.</p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">37</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 6.6&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>In-Licenses</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">38</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 6.7&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Out-Licenses and Permitted Sales</u>.</p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">39</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 6.8&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Restricted Indebtedness</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">39</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 6.9&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Diligence</u>.</p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">40</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 6.10&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Efforts to Consummate Transactions</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">40</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 6.11&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Further Assurances</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">40</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 6.12&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Back-Up Security Interest</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">40</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 6.13&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Certain Tax Matters</u>.</p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">41</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: middle; width: 10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ARTICLE 7 INDEMNIFICATION</p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">41</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 7.1&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>General Indemnity</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">41</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 7.2&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Notice of Claims</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">42</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 7.3&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Limitations on Liability</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">42</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 7.4&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Exclusive Remedy</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">42</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 7.5&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Tax Treatment of Indemnification Payments</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">43</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: middle; width: 10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ARTICLE 8 CONFIDENTIALITY</p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">43</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 8.1&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Confidentiality</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">43</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 8.2&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Authorized Disclosure</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">43</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align: middle; width: 10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ARTICLE 9 TERMINATION</p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">44</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 9.1&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Mutual Termination</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">44</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 9.2&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Automatic Termination</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">45</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 9.3&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Survival</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">45</p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">(i)</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td colspan="2" style="vertical-align: middle; width: 10%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ARTICLE 10 MISCELLANEOUS</p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">45</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 10.1&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Headings</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">45</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 10.2&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Notices</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">45</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 10.3&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Expenses</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">46</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 10.4&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Assignment</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">46</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 10.5&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Amendment and Waiver</u>.</p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">47</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 10.6&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Entire Agreement</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">47</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 10.7&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>No Third Party Beneficiaries</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">47</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 10.8&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Governing Law</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">47</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 10.9&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Jurisdiction; Venue</u>.</p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">47</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 10.10&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Severability</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">48</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 10.11&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Specific Performance</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">48</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 10.12&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Counterparts</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">49</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 10.13&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Relationship of the Parties</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">49</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 10.14&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Intercreditor Agreement</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">49</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Section 10.15&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 80%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><u>Trustee Capacity of Wilmington Trust, National Association</u></p>
			</td>
			<td style="vertical-align: middle; width: 10%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">49</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">(ii)</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><u><b>Index of Exhibits, Schedules and Annexes</b></u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="vertical-align: middle; width: 97px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit A:</p>
			</td>
			<td style="vertical-align: middle; width: 19px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 1219px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">BCX9930</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 97px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit B:</p>
			</td>
			<td style="vertical-align: middle; width: 19px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 1219px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Intercreditor Agreement</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 97px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit C:</p>
			</td>
			<td style="vertical-align: middle; width: 19px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 1219px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Bill of Sale</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 97px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit D:</p>
			</td>
			<td style="vertical-align: middle; width: 19px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 1219px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Draft Label</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 97px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit E:</p>
			</td>
			<td style="vertical-align: middle; width: 19px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 1219px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Forms of Seller Opinion</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: middle; width: 97px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exhibit F:</p>
			</td>
			<td style="vertical-align: middle; width: 19px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
			</td>
			<td style="vertical-align: middle; width: 1219px;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Form of Royalty Report</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">(iii)</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;">PURCHASE AND SALE AGREEMENT</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">This PURCHASE AND SALE AGREEMENT, dated as of December 7, 2020 (this &#8220;<u>Agreement</u>&#8221;), is made and entered into by and between RPI 2019 Intermediate Finance Trust, a Delaware statutory trust (the &#8220;<u>Buyer</u>&#8221;), and BioCryst Pharmaceuticals, Inc., a Delaware corporation (the &#8220;<u>Seller</u>&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><u>W I T N E S S E T H</u>:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">WHEREAS, the Seller is in the business of, among other things, developing and commercializing the Products; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">WHEREAS, the Buyer desires to purchase the Revenue Participation Right from the Seller in exchange for payment of the Purchase Price, and the Seller desires to sell the Revenue Participation Right to the Buyer in exchange for the Buyer&#8217;s payment of the Purchase Price, in each case on the terms and conditions set forth in this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">NOW THEREFORE, in consideration of the representations, warranties, covenants and agreements set forth herein and for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Seller and the Buyer hereby agree as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE 1</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><br>
DEFINITIONS</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Definitions</u>. The following terms, as used herein, shall have the following meanings:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Affiliate</u>&#8221; means, with respect to any particular Person, any other Person directly or indirectly controlling, controlled by or under common control with such particular Person. For purposes of the foregoing sentence, the term &#8220;control&#8221; means direct or indirect ownership of (x) fifty percent (50%) or more, including ownership by trusts with substantially the same beneficial interests, of the voting and equity rights of such Person, firm, trust, corporation, partnership or other entity or combination thereof, or (y) the power to direct the management of such person, firm, trust, corporation, partnership or other entity or combination thereof, by contract or otherwise.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Agreement</u>&#8221; is defined in the preamble.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Athyrium</u>&#8221; means Athyrium Opportunities III Co-Invest 1 LP, together with its successors in such capacity.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Athyrium Credit Agreement</u>&#8221; means that certain Credit Agreement dated as of the date hereof among the Seller, each Person identified as a &#8220;Guarantor&#8221; on the signature pages thereto and each other Person that joins as a Guarantor (together with their successors and permitted assigns) (each, a &#8220;<u>Guarantor</u>&#8221;), each of the Persons identified as a &#8220;Lender&#8221; on the signature pages thereto and their successors and assigns, and Athyrium, as administrative agent, and its successors and assigns, as amended, restated, amended and restated, supplemented, waived, replaced (whether or not upon termination, and whether with the original lenders or otherwise), increased, restructured, repaid, refunded, refinanced or otherwise modified from time to time, including any indentures, credit facilities, term loan facility or other agreement extending the maturity thereof, refinancing, replacing or otherwise restructuring all or a portion of the Indebtedness under such indentures, credit facilities, term loan facility or other agreement or any successor or replacement indentures, credit facilities, term loan facility or other agreement and whether with the original obligors, agent, lenders, institutional investors or otherwise, and whether provided under the original Athyrium Credit Agreement or one or more other credit or other agreements or indentures, and any agreement (and related document) governing Indebtedness incurred to refinance, in whole or in part, the borrowings, other extensions of credit and commitments then outstanding or permitted to be outstanding under such debt facilities or successor debt facilities, whether by the same or any other obligor, issuer, agent, lender or group of lenders (or institutional investors).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Athyrium</u><u> Indebtedness</u>&#8221; means all of the Seller&#8217;s and its Subsidiaries&#8217; Indebtedness and other Obligations and commitments to provide credit extensions to the Seller or any of its Subsidiaries, in each case, under the Athyrium Loan Documents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Athyrium Loan Documents</u>&#8221; means (a) the Athyrium Credit Agreement, and (b) each other &#8220;Loan Document&#8221; or such similar term as defined in the Athyrium Credit Agreement, in each case as amended, restated, amended and restated, modified or otherwise supplemented from time to time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Attributable Indebtedness</u>&#8221; means &#8220;Attributable Indebtedness&#8221; or such similar term as defined in the Athyrium Credit Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Back-Up Security Interest</u>&#8221; is defined in Section 2.1(b).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Bankruptcy Laws</u>&#8221; means, collectively, bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, fraudulent transfer or other similar laws affecting the enforcement of creditors&#8217; rights generally.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>BCX9930</u>&#8221; means (a) the oral Factor D inhibitor known as BCX9930 described on Exhibit A hereto, [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>BCX9930 </u><u>Royalty Payment</u><u>s</u>&#8221; means, for each calendar quarter, an amount payable to the Buyer equal to (a) the amount of worldwide aggregate BCX9930 Net Sales (other than Product Partnering Revenue attributable to BCX9930) during such calendar quarter, multiplied by one percent (1%), and (b) the amount of Product Partnering Revenue attributable to BCX9930 multiplied by one percent (1%).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Business Day</u>&#8221; means any day other than (a)&nbsp;a Saturday or Sunday or (b)&nbsp;a day on which banking institutions located in New York are permitted or required by applicable law or regulation to remain closed.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Buyer</u>&#8221; is defined in the preamble.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Buyer Indemnified Parties</u>&#8221; is defined in Section 7.1(a).</p>

<div contenteditable="false" data-applyto="p" data-auto-pgnum="start" data-displaynum="2" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-pgnumtype="auto" data-prefix="" data-startnum="2" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Capital Lease</u>&#8221; means, as applied to any Person, any lease of any property by that Person as lessee which, in accordance with GAAP, is required to be accounted for as a capital lease on the balance sheet of that Person.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Clinical and Commercial </u><u>Quarterly Report</u>&#8221; is defined in Section 6.1(a).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Clinical and Commercial </u><u>Semi</u><u>-Annual</u><u> Report</u>&#8221; is defined in Section 6.1(a).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Clinical Trial</u>&#8221; means a clinical trial intended to support the Marketing Approval or Commercialization of a Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Clinical Updates</u>&#8221; means (a) a summary of any material updates with respect to the Clinical Trials, including the number of patients currently enrolled in each such Clinical Trial, the number of sites conducting each such Clinical Trial, the material progress of each such Clinical Trial, any material modifications to each such Clinical Trial, any adverse events in the Clinical Trials, (b) written plans to start new Clinical Trials, and (c) investigator brochures for the Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Closing</u>&#8221; means the closing of the sale, transfer, assignment and conveyance of the Revenue Participation Right hereunder.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Closing Date</u>&#8221; means the date on which the Closing occurs pursuant to Section 3.1.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>CMC</u>&#8221; means chemistry, manufacturing and controls with respect to a Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&#8220;<u>Combination Product</u>&#8221; means:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a single pharmaceutical formulation (whether co-formulated or administered together via the same administration route) containing as its active ingredients both a Product and one or more other therapeutically or prophylactically active pharmaceutical or biologic ingredients (each an &#8220;<u>Other Component</u>&#8221;), or</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a combination therapy comprised of a Product and one or more Other Component(s), whether priced and sold in a single package containing such multiple products, packaged separately but sold together for a single price, or sold under separate price points but labeled for use together,</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">in each case, including all dosage forms, formulations, presentations, and package configurations. Drug delivery vehicles, adjuvants and excipients will not be deemed to be &#8220;active ingredients&#8221;, except in the case where such delivery vehicle, adjuvant or excipient is recognized by the FDA as an active ingredient in accordance with 21 C.F.R. 210.3(b)(7). All references to Products in this Agreement shall be deemed to include Combination Products.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Commercial Updates</u>&#8221; means a summary of material updates with respect to the Seller&#8217;s and its Affiliates&#8217; and any Licensee&#8217;s sales and marketing activities and, if material, commercial manufacturing matters with respect to a Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Commercialization</u>&#8221; means any and all activities directed to the distribution, marketing, detailing, promotion, selling and securing of reimbursement of a Product (including the using, importing, selling and offering for sale of such Product), and shall include post-Marketing Approval studies to the extent required by a Regulatory Authority, post-launch marketing, promoting, detailing, distributing, selling such Product, importing, exporting or transporting such Product for sale, and regulatory compliance with respect to the foregoing. When used as a verb, &#8220;Commercialize&#8221; shall mean to engage in Commercialization. Except with respect to post-Marketing Approval studies required by a Regulatory Authority, Commercialization shall not include any activities directed to the research or development (including pre-clinical and clinical development) or manufacture of a Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Commercially Reasonable Efforts</u>&#8221; means the level of efforts and resources (measured as of the time that such efforts and resources are required to be used under this Agreement) that are commonly used by a commercial-stage public biotechnology company of similar size and resources to Seller (provided that such size and resources shall not decrease below the size and resources of the Seller as of the Closing Date), to develop, manufacture or commercialize, as the case may be, a comparable product for a comparable clinical indication (with respect to market size and commercial opportunity) at a similar stage in its development or product life and of a similar market and potential to the Product, but without regard to the Seller&#8217;s financial obligations under this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Confidential Information</u>&#8221; is defined in Section 8.1.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Con</u><u>trolling Agreement</u>&#8221; is defined in Section 10.14.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Convertible </u><u>Bond </u><u>Indebtedness</u>&#8221; means any Indebtedness having a feature which entitles the holder thereof to convert or exchange all or a portion of such Indebtedness into shares of common capital stock of the Seller; provided, that, (a) the principal amount (or accreted value, if applicable) of such Convertible Bond Indebtedness does not exceed $[***], (b) such Convertible Bond Indebtedness shall be unsecured, (c) no Subsidiary shall Guarantee such Convertible Bond Indebtedness, (d) such Convertible Bond Indebtedness shall not mature, and no scheduled or mandatory principal payments, repayments, prepayments, cash settlements, repurchases, redemptions or sinking fund or like payments (but excluding, for the avoidance of doubt, regularly scheduled cash interest payments and conversion of such Convertible Bond Indebtedness into shares of common capital stock of the Seller in accordance with the terms thereof) of such Convertible Bond Indebtedness shall be required at any time on or prior to the date that is one (1) year after the &#8220;Maturity Date&#8221; or such similar term under the Athyrium Loan Documents (which in the case of the maturity of such Convertible Bond Indebtedness shall be tested at the time of incurrence thereof), other than upon a &#8220;Change of Control&#8221;, &#8220;fundamental change&#8221;, &#8220;make-whole fundamental change&#8221; or similar event, (e) such Convertible Bond Indebtedness shall (i) not include (A) any financial maintenance covenants or (B) other covenants and defaults that are, taken as a whole, more restrictive on the Seller and its Subsidiaries than the covenants and defaults set forth in the Athyrium Loan Documents and (ii) have a cash interest rate of less than the greater of (x) [***] percent ([***]%) per annum and (y) such cash interest rate as the administrative agent under the Athyrium Credit Agreement, in its sole discretion, shall approve in writing after the Closing Date, upon the request of the Seller in light of changes to market interest rates for similar convertible notes, (f) such Convertible Bond Indebtedness shall include conversion, redemption and fundamental change provisions that are customary for public market convertible indebtedness (pursuant to a public offering or an offering under Rule 144A or Regulation S of the Securities Act), (g) such Convertible Bond Indebtedness shall be subordinated in right of payment to the Royalty Payments that are owed or may be owed in the future to the Buyer pursuant to the terms of a subordination, intercreditor, or other similar agreement (or terms of subordination incorporated into the indenture under which such Convertible Bond Indebtedness is issued), in each case in form and substance, and on terms, approved by the Buyer, the Seller, and the applicable Third Party in writing, (h) no Default or Event of Default or such similar terms (in each case as defined in the Athyrium Credit Agreement) shall have occurred and be continuing at the time of incurrence of such Convertible Bond Indebtedness or could result therefrom, and (i) the Seller shall have delivered to the administrative agent under the Athyrium Credit Agreement a certificate of an officer of the Seller certifying as to the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Direct Sales Territories</u>&#8221; means the United States, the United Kingdom, Germany, France, [***] and [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Disclosing Party</u>&#8221; is defined in Section 8.1.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Disclosure Schedule</u>&#8221; means the Disclosure Schedule, dated as of the date hereof, delivered to the Buyer by the Seller concurrently with the execution of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Distributor</u>&#8221; means a Third Party that (a) purchases or has the option to purchase any Product in finished form from or at the direction of the Seller or any of its Affiliates, (b) has the right, option or obligation to distribute, market and sell such Product (with or without packaging rights) in one or more regions, and (c) does not otherwise make any royalty, milestone, profit share or other similar payment to the Seller or its Affiliate based on such Third Party&#8217;s sale of the Product. The term &#8220;packaging rights&#8221; in this definition will mean the right for the Distributor to package or have packaged Product supplied in unpackaged bulk form into individual ready-for-sale packs.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>EMA</u>&#8221; means the European Medicines Agency, or any successor agency thereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Equity Interests</u>&#8221; means, with respect to any Person, all of the shares of capital stock of (or other ownership or profit interests in) such Person, all of the warrants, options or other rights for the purchase or acquisition from such Person of shares of capital stock of (or other ownership or profit interests in) such Person, all of the securities convertible into or exchangeable for shares of capital stock of (or other ownership or profit interests in) such Person or warrants, rights or options for the purchase or acquisition from such Person of such shares (or such other interests), and all of the other ownership or profit interests in such Person (including partnership, member, membership or trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or other interests are outstanding on any date of determination, but excluding, for the avoidance of doubt, any Convertible Bond Indebtedness to the extent that the same have not yet been converted into shares of common capital stock of the Seller.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>ERISA</u>&#8221; means the Employee Retirement Income Security Act of 1974.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Existing </u><u>Out</u><u>-License</u>&#8221; is defined in Section 4.1(h)(ii).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Existing Patent Rights</u>&#8221; is defined in Section 4.1(k)(i).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>FD&amp;C Act</u>&#8221; means the United States Federal Food, Drug, and Cosmetic Act.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>FDA</u>&#8221; means the U.S. Food and Drug Administration, or any successor agency thereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>First Commercial Sale</u>&#8221; means, with respect to a Product, the first sale for use or consumption by an end-user of such Product in any country of the world after Marketing Approval of such Product has been granted in such country, or such marketing and sale is otherwise permitted, by the Regulatory Authority of such country.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>GAAP</u>&#8221; means generally accepted accounting principles in the United States in effect from time to time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Guarantee</u>&#8221; means, as to any Person, (a) any obligation, contingent or otherwise, of such Person guaranteeing or having the economic effect of guaranteeing any indebtedness or other obligation payable or performable by another Person (the &#8220;primary obligor&#8221;) in any manner, whether directly or indirectly, and including any obligation of such Person, direct or indirect, (i) to purchase or pay (or advance or supply funds for the purchase or payment of) such indebtedness or other obligation, (ii) to purchase or lease property, securities or services for the purpose of assuring the obligee in respect of such indebtedness or other obligation of the payment or performance of such indebtedness or other obligation, (iii) to maintain working capital, equity capital or any other financial statement condition or liquidity or level of income or cash flow of the primary obligor so as to enable the primary obligor to pay such indebtedness or other obligation, or (iv) entered into for the purpose of assuring in any other manner the obligee in respect of such indebtedness or other obligation of the payment or performance thereof or to protect such obligee against loss in respect thereof (in whole or in part), (b) any lien on any assets of such Person securing any indebtedness or other obligation of any other Person, whether or not such indebtedness or other obligation is assumed by such Person (or any right, contingent or otherwise, of any holder of such indebtedness to obtain any such lien) or (c) any direct or indirect liability, contingent or not, of that Person for (i) any obligations for undrawn letters of credit for the account of that Person or (ii) all obligations from any interest rate, currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices. The amount of any Guarantee shall be deemed to be an amount equal to the stated or determinable amount of the related primary obligation, or portion thereof, in respect of which such Guarantee is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by the guaranteeing Person in good faith. The term &#8220;Guarantee&#8221; as a verb has a corresponding meaning.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Guarantor</u>&#8221; is defined in the definition of the Athyrium Credit Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Governmental Entity</u>&#8221; means any: (a)&nbsp;nation, principality, republic, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (b)&nbsp;federal, state, local, municipal, foreign or other government; (c)&nbsp;governmental or quasi-governmental authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or other entity and any court, arbitrator or other tribunal); (d)&nbsp;multi-national organization or body; or (e)&nbsp;individual, body or other entity exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Gross Sales</u>&#8221; is defined in the definition of &#8220;Net Sales&#8221;.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>HAE</u>&#8221; is defined in Section 5.1(a).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>HSBC Cash Collateral Accounts</u>&#8221; means, collectively, Deposit Account #[***] and Deposit Account #[***] of the Seller established and maintained at HSBC Bank for the sole purpose of securing the Seller&#8217;s obligations under the HSBC Letter of Credit; provided that (a) no such Deposit Account shall hold an aggregate of cash and cash equivalents in excess of [***] percent ([***]%) of the aggregate face amount of the letters of credit it is securing and (b) with respect to all such Deposit Accounts, the aggregate amount deposited there in at any time does not exceed [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>HSBC Letter of Credit</u>&#8221; means the letter of credit issued by HSBC Bank in favor of the landlord with respect to the Seller&#8217;s leased real property located at 2100 Riverchase Center, Ste. 200 / Building 200, Birmingham, AL 35244, in an aggregate face amount equal to One Million Four Hundred Thousand Dollars ($1,400,000).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>HSBC Liens</u>&#8221; means Liens in favor of HSBC Bank on the HSBC Cash Collateral Accounts to the extent securing obligations of the Seller permitted pursuant to clause (g) of the definition of Permitted Contingent Obligations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Improvements</u>&#8221; means any improvement, invention or discovery relating to a Product (other than with respect to a new composition of matter), including the formulation, or the method of manufacture of a Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>In-License</u>&#8221; means any license, settlement agreement or other agreement or arrangement between the Seller or any of its Affiliates and any Third Party pursuant to which the Seller or any of its Affiliates obtains a license or a covenant not to sue or similar grant of rights to any Patents or other intellectual property rights of such Third Party that is necessary for the research, development, manufacture, use or Commercialization of a Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Indebtedness</u>&#8221; of any Person means any indebtedness for borrowed money, any obligation evidenced by a note, bond, debenture or similar instrument, or any guarantee of any of the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Indemnified Party</u>&#8221; is defined in Section 7.2.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Indemnifying Party</u>&#8221; is defined in Section 7.2.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Indirect Sales Territories</u>&#8221; means all countries except for the Direct Sales Territories.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Intellectual Property </u><u>Product Rights</u>&#8221; means any and all of the following as they exist throughout the world at any time: (a) the Patent Rights; (b) rights in registered and unregistered trademarks, service marks, trade names, trade dress, logos, packaging design, slogans and Internet domain names, and registrations and applications for registration of any of the foregoing, in each case, with respect to any Product; (c) rights in all Know-How necessary for the development, manufacture or Commercialization of any Product; and (d) any and all other intellectual property rights and/or proprietary rights, whether or not patentable, specifically relating to any of the foregoing, as necessary for the development, manufacture or Commercialization of a Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Intellectual Property Rights</u>&#8221; means any and all of the following as they exist throughout the world at any time: (a) the Patent Rights and (b) the Know-How Rights.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Intellectual Property Updates</u>&#8221; means an updated list of the Patent Rights, including any new Patents issued or filed, amended or supplemented, relating to a Product in any country or any abandonments or other termination of prosecution with respect to any of the Patent Rights, and any other material information or developments with respect to the Intellectual Property Rights.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Intercreditor Agreement</u>&#8221; means that certain Intercreditor Agreement by and among Athyrium, the Seller and the Buyer, and acknowledged and agreed to by the Seller, BioCryst Ireland Limited, and any future Guarantor, in substantially the form attached hereto as Exhibit B, as amended, amended and restated, supplement and otherwise modified from time to time in accordance with the terms thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Judgment</u>&#8221; means any judgment, order, writ, injunction, citation, award or decree of any nature.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>JPR Royalty Sub</u>&#8221; means JPR Royalty Sub LLC, a Delaware limited liability company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>JPR Indenture</u>&#8221; means that certain Indenture, dated as of March 9, 2011, by and between JPR Royalty Sub and U.S. Bank, National Association, as in effect on the date hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Know-How</u>&#8221; means any and all proprietary or confidential information, know-how and trade secrets, including processes, formulae, models and techniques (but excluding rights in research in progress, algorithms, data, databases, data collections, chemical and biological materials and the results of experimentation and testing).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Know-How</u><u> Rights</u>&#8221; means any and all Know-How owned or in-licensed by the Seller or any of its Affiliates or under which the Seller or any of its Affiliates is or may become empowered to grant licenses necessary for the development, manufacture, or Commercialization of a Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Knowledge of the Seller</u>&#8221; means the actual knowledge of the individuals listed on <u>Schedule 1.1</u> of the Disclosure Schedule, after reasonable due inquiry.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>L</u><u>icense Revenue</u>&#8221; means any payments or other consideration in any form received by Seller or any of its Affiliates from a Licensee or any of its Affiliates or sublicensees under or pursuant to an Out-License of any rights relating to Orladeyo or any sublicense under or other agreement ancillary to such Out-License, or payments received by Seller or any of its Affiliates from a Third Party in lieu of any of the foregoing payments, in each case, except for:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a) payments or grants received from a commercial or non-commercial Third Party, specifically to cover future reasonable, documented fully-burdened costs incurred by or on behalf of Seller or any Affiliate after the execution of such Out-License directly attributable to the performance of research and development of Orladeyo, which costs are expressly covered by the Licensee under such Out-License;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b) equity investments in Seller or any Affiliate to the extent priced at or below fair market value, provided that in the case of common stock or its equivalent, fair market value shall be the greater of: (i) the last reported closing price of Seller&#8217;s common stock on Nasdaq, or (ii) the 30-day volume-weighted average price of Seller&#8217;s common stock;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c) loans received as part of a debt financing for so long as an obligation of repayment exists, provided that if at the time any such debt becomes due, the amount of such debt that is forgiven, and, for accounting or Tax purposes (in accordance with GAAP), is booked as income to Seller or its Affiliates, then such amount shall be deemed License Revenue hereunder;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d) loans received where Orladeyo forms part of the security package provided for the loan for so long as an obligation of repayment exists; provided that at the time any such debt becomes due, the amount of such debt that is forgiven, and, for accounting or Tax purposes (in accordance with GAAP), is booked as income to Seller or its Affiliates, shall be deemed License Revenue hereunder;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(e) Tax credits or Tax receipts; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(f) sales or supply of Orladeyo inventory at or below Seller&#8217;s actual cost of goods sold, provided, however that any mark-up from, or other amounts in excess of, the Seller&#8217;s cost of goods sold for such inventory shall be License Revenue.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Notwithstanding anything to the contrary in this Agreement, &#8220;License Revenue&#8221; shall include, without limitation, any and all royalties, upfront payment, license signing fee, license maintenance fee, minimum royalty payment in excess of earned royalties, option fee, lump sum payment, distribution fee, joint marketing fee, profit share, milestone payment, and other payments. In the event Seller or its Affiliate(s) receives non-monetary consideration, License Revenue shall be calculated based on the fair market value of such consideration at the time of the transaction (where fair market value shall be determined by agreement of the Parties or by an independent appraiser mutually agreeable to the Parties), assuming an arm&#8217;s length transaction made in the ordinary course of business. To the extent that Seller makes any offsetting payments to a Licensee (such as a true-up payment) that are specifically permitted pursuant to the Out-License (not entered into in violation of this Agreement) with such Licensee, then the License Revenue under such Out-License shall be calculated net of such payments. Without limiting clauses (a) through (f) above, to the extent that Seller permits any Licensee to set off any payments payable pursuant to the Out-License with such Licensee against any amounts payable by Seller to such Licensee, then the License Revenue under such Out-License shall include all such payments payable to Seller under such Out-License without giving effect to any such setoff.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Licensee</u>&#8221; means, with respect to any Product, a Third Party to whom the Seller or any Affiliate of the Seller has granted a license or sublicense to Commercialize such Product. For clarity, a Distributor shall not be deemed to be a &#8220;Licensee.&#8221;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Lien</u>&#8221; means any mortgage, lien, pledge, participation interest, charge, adverse claim, security interest, encumbrance or restriction of any kind, including any restriction on use, transfer or exercise of any other attribute of ownership of any kind.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Loss</u>&#8221; means any and all Judgments, damages, losses, claims, costs, liabilities and expenses, including reasonable fees and out-of-pocket expenses of counsel.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Loss of Market Exclusivity</u>&#8221; shall mean, on a Product-by-Product and country-by-country basis, the later to occur of: (a) the expiration of the last-to-expire Valid Claim of a Patent Right covering such Product in such country; and (b) the expiry of all Regulatory Exclusivity Periods for such Product in such country.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Marketing Approval</u>&#8221; means, an NDA approved by the FDA, a Marketing Authorization Application approved by the EMA under the centralized European procedure, or any corresponding non-U.S. or non-EMA application, registration or certification in a Direct Sales Territory, necessary or reasonably useful to market a Product approved by the corresponding Regulatory Authority, including pricing and reimbursement approvals where required. For clarity, notwithstanding the foregoing, solely with respect to Section 5.1(a) and Section 6.2, &#8220;Marketing Approval&#8221; shall not include pricing and reimbursement approvals.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Material Adverse Effect</u>&#8221; means (a) an adverse effect in any material respect on the timing, duration or amount of the Royalty Payments, (b) a material adverse effect on (i) a Product, (ii) any of the Intellectual Property Rights, including the Seller&#8217;s rights in or to any Intellectual Property Rights, (iii) any Marketing Approval of a Product or the timing thereof, (iv) the legality, validity or enforceability of any provision of this Agreement, (v) the ability of the Seller to perform any of its obligations under this Agreement, (vi) the rights or remedies of the Buyer under this Agreement, or (vii) the business of the Seller or its Affiliates or (c) an adverse effect in any material respect on the Revenue Participation Rights, the Product Collateral, or the Back-Up Security Interest.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>MidCap</u><u> Credit Agreement</u>&#8221; means that certain Second Amended and Restated Credit and Security Agreement, dated as of February 5, 2019, by and among the Seller, the Subsidiaries of the Seller from time to time, MidCap Financial Trust, as administrative agent, and the lenders party thereto from time to time, .</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>MidCap Indebtedness</u>&#8221; means all Indebtedness or other obligations of the Seller and its Subsidiaries outstanding under the Midcap Loan Documents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Mid</u><u>C</u><u>ap Loan Documents</u>&#8221; &#8221; means the MidCap Credit Agreement, the &#8220;Security Documents&#8221; (as defined therein) and all other agreements and documents entered into in connection therewith.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Minimum Return </u><u>Date</u>&#8221; means the earlier of the following dates: (a) the date on which the trailing [***] months of net revenue of the Company, in accordance with GAAP, equals at least $[***] million and all Royalty Payments for any Net Sales of Products that make up such revenue have been paid to Buyer; (b) the date on which Seller&#8217;s market capitalization is at least $[***] billion for [***] consecutive trading days; (c) the date that is on or after [***] years after the Closing Date and on which Seller&#8217;s market capitalization is at least $[***] billion for [***] consecutive trading days; and (d) the date of expiration of the last-to-expire Valid Claim of the Patent Rights covering Orladeyo in the United States.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>NDA</u>&#8221; means a New Drug Application submitted to the FDA in the United States in accordance with the FD&amp;C Act with respect to a pharmaceutical product or any analogous application or submission with any Regulatory Authority outside of the United States.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Net Sales</u>&#8221; means, with respect to each Product, the gross amount invoiced, billed or otherwise recorded for sales of such Product anywhere in the world by or on behalf of the Seller, its Affiliates, any Distributor, or any Licensee of the Seller or any of the Seller&#8217;s Affiliates (each of the foregoing Persons, for purposes of this definition, shall be considered a &#8220;<u>Related Party</u>&#8221;) to a Third Party in an arms-length transaction (&#8220;<u>Gross Sales</u>&#8221;) less the following amounts, to the extent actually incurred or accrued in accordance with generally accepted accounting principles consistently applied, and not reimbursed by such Third Party, provided, that any given amount may be taken as a permitted deduction only once:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reasonable and customary rebates, chargebacks, quantity, trade and similar discounts, credits and allowances and other price reductions reasonably granted, allowed, incurred or paid in so far as they are applied to sales of a Product;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;discounts (including cash, quantity, trade, governmental, and similar discounts), coupons, retroactive price reductions, charge back payments and rebates granted to managed care organizations or to federal, state and local governments, or to their agencies (including payments made under the new &#8220;Medicare Part D Coverage Gap Discount Program&#8221; and the &#8220;Annual Fee for Branded Pharmaceutical Manufacturers&#8221; specific to the Product), in each case, as applied to sales of the Product and actually given to customers;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reasonable and customary credits, adjustments, and allowances, including those granted on account of price adjustments, billing errors, and damage, Product otherwise not in saleable condition, and rejection, return or recall of a Product;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reasonable and customary freight and insurance costs incurred with respect to the shipment of a Product to customers, in each case if charged separately and invoiced to the customer;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;customs duties, surcharges and other similar governmental charges incurred in connection with the exportation or importation of a Product to the extent included in the gross amount invoiced;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;sales, use, value-added, excise, turnover, inventory and other similar Taxes (excluding income Taxes), and that portion of annual fees due under Section 9008 of the United States Patient Protection and Affordable Care Act of 2010 (Pub. L. No. 111-48) and any other fee imposed by any equivalent applicable law, in each of the foregoing cases, that Seller allocates to sales of a Product in accordance with Seller&#8217;s standard policies and procedures consistently applied across its products, as adjusted for rebates and refunds, imposed in connection with the sales of the Product to any Third Party, to the extent such Taxes are not paid by the Third Party;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;actual copayment waiver amounts uncollected or uncollectible debt amounts with respect to sales of a Product, provided that if the debt is thereafter paid, the corresponding amount shall be added to the Net Sales of the period during which it is paid;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reasonable, customary and documented out of pocket amounts directly relating to co-pay programs, bridging programs or other similar patient assistance programs which may be implemented from time to time by the Seller; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other similar or customary deductions taken in the ordinary course of business as permitted in calculating net sales or net revenue (as applicable) under generally accepted accounting principles consistently applied.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">For clarity, &#8220;Net Sales&#8221; will not include (i) sales or dispositions for charitable, promotional, pre-clinical, clinical, regulatory, compassionate use, named patient use or indigent or other similar programs, reasonable quantities of Products used as samples, and Products used in the development of Products, (ii) sales or dispositions between any of the Related Parties (unless a Related Party is the final end-user of such Product), but will include subsequent sales or dispositions of Products to a non-Related Party, (iii) License Revenue, or (iv) solely with respect to BCX9930, any amounts or other consideration received by a Related Party from a Licensee, Distributor, or a non-Related Party in consideration of the grant of a (sub)license or co-promotion or distribution right to such non-Related Party.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">With respect to sales of a Product invoiced in U.S. dollars, Net Sales shall be determined in U.S. dollars. With respect to sales of a Product invoiced in a currency other than U.S. dollars, Net Sales shall be determined by converting the currencies at which the sales are made into U.S. dollars, at rates of exchange determined in a manner consistent with the Seller&#8217;s or a Licensee&#8217;s, as applicable, method for calculating rates of exchange in the preparation of the Seller&#8217;s or such Licensee&#8217;s annual financial statements in accordance with generally accepted accounting principles consistently applied.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Net Sales for any Combination Product shall be calculated on a country-by-country basis by multiplying actual Net Sales of such Combination Product by the fraction A/(A+B) where &#8220;A&#8221; is the weighted average invoice price of the Product contained in such Combination Product when sold separately in such country during the applicable accounting period in which the sales of the Combination Product were made, and &#8220;B&#8221; is the combined weighted average invoice prices of all of the Other Components contained in such Combination Product sold separately in such country during such same accounting period. If a Product contained in such Combination Product is not sold separately in finished form in such country, the Seller and the Buyer shall determine Net Sales for such Product by mutual agreement based on the relative contribution of such Product and each such other active ingredient in such Combination Product in accordance with the above formula, and shall take into account in good faith any applicable allocations and calculations that may have been made for the same period in other countries.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Obligations</u>&#8221; means &#8220;Obligations&#8221; or such similar term as defined in the Athyrium Credit Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Orladeyo</u>&#8221; means (a) the product known as ORLADEYO&#8482; (berotralstat) that is the subject of NDA No. 214094, [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Orladeyo Direct Sales</u>&#8221; means (a) Net Sales of Orladeyo by or on behalf of the Seller, any of the Seller&#8217;s Affiliates or its or their respective Distributors anywhere in the world, in each case other than (i) Net Sales of Orladeyo by or on behalf of any Licensee, and (ii) Product Partnering Revenue attributable to Orladeyo; and (b) Net Sales of Orladeyo by or on behalf of any Licensee in or for the Direct Sales Territories.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Orladeyo Direct Sales Royalty Rate</u>&#8221; means the percentage based on the applicable level of Orladeyo Direct Sales in a calendar year as set forth in the chart below:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 50%; border-top: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Payment Tiers based on Annual </b><b>Orladeyo Direct Sales</b></p>
			</td>
			<td style="vertical-align: top; border: thin solid rgb(0, 0, 0); width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Orladeyo</b><b> Direct Sales</b><b> Royalty Rate</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 50%; border-left: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A. Annual Orladeyo Direct Sales&nbsp;of up to $350,000,000</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 50%; border-left: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">8.75%</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 50%; border-left: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">B. Annual Orladeyo Direct Sales&nbsp;exceeding $350,000,000 and less than or equal to $550,000,000</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 50%; border-left: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">2.75%</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 50%; border-left: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">C. Annual Orladeyo Direct Sales&nbsp;in excess of $550,000,000</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 50%; border-left: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">0%</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Orladeyo Indirect </u><u>Revenue</u>&#8221; means all License Revenue received by the Seller or any of the Seller&#8217;s Affiliates from any Licensee of Orladeyo, other than (a) the regulatory approval milestone payable under Section 8.2.1 of the Torii License, (b) in respect of Orladeyo Direct Sales, and (c) Product Partnering Revenue attributable to Orladeyo.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Orladeyo Indirect </u><u>Revenue </u><u>Sharing </u><u>Rate</u>&#8221; means the percentage based on the applicable level of Orladeyo Indirect Revenue in a calendar year as set forth in the chart below:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="vertical-align: top; border: thin solid rgb(0, 0, 0); width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Applicable</b><b>&nbsp;</b><b>Orladeyo Indirect Revenue</b></p>
			</td>
			<td style="vertical-align: top; border-bottom: thin solid rgb(0, 0, 0); width: 34%; border-top: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0); border-image: initial;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Orladeyo </b><b>Indirect Revenue Sharing </b><b>Rate</b></p>
			</td>
			<td style="vertical-align: top; border-bottom: thin solid rgb(0, 0, 0); width: 33%; border-top: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0); border-image: initial;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Orladeyo Indirect Revenue Threshold</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-right: thin solid rgb(0, 0, 0); border-bottom: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0); border-image: initial; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">A. Orladeyo Indirect Revenue that does not constitute (a) Orladeyo Indirect Royalties, or (b) a milestone payment attributable to a threshold of commercial sales achieved or similar sales-based measurement (collectively, such Orladeyo Indirect Revenue set forth in this Row A, the &#8220;<u>Orladeyo Flat Rate Indirect Revenue</u>&#8221;).</p>
			</td>
			<td style="vertical-align: top; border-right: thin solid rgb(0, 0, 0); border-bottom: thin solid rgb(0, 0, 0); border-image: initial; width: 34%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">20%</p>
			</td>
			<td style="vertical-align: top; border-right: thin solid rgb(0, 0, 0); border-bottom: thin solid rgb(0, 0, 0); border-image: initial; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">N/A</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-right: thin solid rgb(0, 0, 0); border-bottom: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0); border-image: initial; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">B. All Orladeyo Indirect Revenue including (without duplication) Orladeyo Indirect Royalties but excluding Orladeyo Flat Rate Indirect Revenue</p>
			</td>
			<td style="vertical-align: top; border-right: thin solid rgb(0, 0, 0); border-bottom: thin solid rgb(0, 0, 0); border-image: initial; width: 34%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">20%</p>
			</td>
			<td style="vertical-align: top; border-right: thin solid rgb(0, 0, 0); border-bottom: thin solid rgb(0, 0, 0); border-image: initial; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Annual Orladeyo Indirect Sales up to $150,000,000 in such calendar year</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-right: thin solid rgb(0, 0, 0); border-bottom: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0); border-image: initial; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">C. All Orladeyo Indirect Revenue including (without duplication) Orladeyo Indirect Royalties but excluding Orladeyo Flat Rate Indirect Revenue</p>
			</td>
			<td style="vertical-align: top; border-right: thin solid rgb(0, 0, 0); border-bottom: thin solid rgb(0, 0, 0); border-image: initial; width: 34%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">10%</p>
			</td>
			<td style="vertical-align: top; border-right: thin solid rgb(0, 0, 0); border-bottom: thin solid rgb(0, 0, 0); border-image: initial; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Annual Orladeyo Indirect Sales exceeding $150,000,000 and less than or equal to $230,000,000 in such calendar year</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border-right: thin solid rgb(0, 0, 0); border-bottom: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0); border-image: initial; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">D. All Orladeyo Indirect Revenue including (without duplication) Orladeyo Indirect Royalties but excluding Orladeyo Flat Rate Indirect Revenue</p>
			</td>
			<td style="vertical-align: top; border-right: thin solid rgb(0, 0, 0); border-bottom: thin solid rgb(0, 0, 0); border-image: initial; width: 34%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">0%</p>
			</td>
			<td style="vertical-align: top; border-right: thin solid rgb(0, 0, 0); border-bottom: thin solid rgb(0, 0, 0); border-image: initial; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Annual Orladeyo Indirect Sales exceeding $230,000,000 in such calendar year</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Orladeyo Indirect </u><u>Sales</u>&#8221; means Net Sales of Orladeyo by or on behalf of any Licensee in or for the Indirect Sales Territories.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Orladeyo Indirect </u><u>Royalt</u><u>ies</u>&#8221; means Orladeyo Indirect Revenue that constitutes (a) royalties payable on Orladeyo Indirect Sales, (b) any payments made in lieu of the foregoing, (c) recovery of monetary damages from a Third Party in an action brought for such Third Party&#8217;s infringement of any Patent Rights, where such damages, whether in the form of judgment or settlement, are awarded for such infringement of such Patent Rights, and (d) any interest on all of the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Orladeyo Royalty Payment</u><u>s</u>&#8221; means, for each calendar quarter, an amount payable to the Buyer equal to (a) the amount of all aggregate Orladeyo Direct Sales during such calendar quarter multiplied by the Orladeyo Direct Sales Royalty Rate, (b) the amount of all aggregate Orladeyo Indirect Revenue during such calendar quarter multiplied by the applicable Orladeyo Indirect Revenue Sharing Rate, and (c) and the amount of Product Partnering Revenue attributable to Orladeyo multiplied by 8.75%.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Other Component</u>&#8221; is defined in the definition of &#8220;Combination Products&#8221;.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Other Intercreditor Agreement</u>&#8221; means an intercreditor agreement, among, the Buyer, the Seller and the administrative agent, trustee or representative under the Athyrium Credit Agreement and/or the holders of any Indebtedness incurred pursuant to clause (b)(ii) of the definition of Restricted Indebtedness or any agent, representative or trustee acting on behalf of such holders, on substantially the same terms as the Intercreditor Agreement, as amended, amended and restated, supplement and otherwise modified from time to time in accordance with the terms thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Out-License</u>&#8221; means each license or other agreement between the Seller or any of its Affiliates and any Third Party (other than Distributors) pursuant to which the Seller or any of its Affiliates grants a license or sublicense of any Intellectual Property Right to market, detail, promote, sell or secure reimbursement of a Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Patents</u>&#8221; means any and all patents and patent applications existing as of the date of this Agreement and all patent applications filed hereafter, including any continuation, continuation-in-part, division, provisional or any substitute applications, any patent issued with respect to any of the foregoing patent applications, any certificate, reissue, reexamination, renewal or patent term extension or adjustment (including any supplementary protection certificate) of any such patent or other governmental actions which extend any of the subject matter of a patent, and any substitution patent, confirmation patent or registration patent or patent of addition based on any such patent, and all foreign counterparts of any of the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Patent Rights</u>&#8221; means any and all Patents owned or in-licensed by the Seller or any of its Affiliates or under which the Seller or any of its Affiliates is or may become empowered to grant licenses necessary or reasonably useful in the development, manufacture, use, marketing, promotion, sale or distribution of a Product, as well as existing or future Patents covering any Improvements.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Permitted Contingent Obligations</u>&#8221; means (a) Guarantees resulting from endorsements for collection or deposit in the ordinary course of business; (b) Guarantees incurred in the ordinary course of business with respect to surety and appeal bonds, performance bonds and other similar obligations not to exceed [***] in the aggregate at any time outstanding; (c) Guarantees arising under indemnity agreements with title insurers; (d) Guarantees arising with respect to customary indemnification obligations in favor of purchasers in connection with sales, transfers, licenses, leases or other dispositions of personal property assets permitted under the Athyrium Loan Documents; (e) Guarantees arising under the Athyrium Loan Documents; (f) Guarantees existing or arising in connection with any security deposit or letter of credit obtained for the sole purpose of securing a lease of real property, or in connection with ancillary bank services such as a corporate credit card facility, provided that the aggregate face amount of all such security deposits, letters of credit and ancillary bank services does not at any time exceed [***] in the aggregate at any time outstanding; and (g) the HSBC Letter of Credit secured solely by HSBC Liens.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Permitted Indebtedness</u>&#8221; is defined in the definition of &#8220;Restricted Indebtedness&#8221;.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Permitted License</u>&#8221; is defined in Section 6.7(a).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Permitted Liens</u>&#8221; means the following:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens for Taxes, assessments or governmental charges or levies not yet due or which are being contested in good faith and by appropriate proceedings diligently conducted, if adequate reserves with respect thereto are maintained on the books of the applicable Person in accordance with GAAP;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;statutory Liens of landlords and Liens of carriers, warehousemen, mechanics, materialmen and suppliers and other Liens imposed by law or pursuant to customary reservations or retentions of title arising in the ordinary course of business, <u>provided</u>, <u>that</u>, such Liens secure only amounts not yet due and payable or, if due and payable, are unfiled and no other action has been taken to enforce the same or are being contested in good faith by appropriate proceedings for which adequate reserves determined in accordance with GAAP have been established;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liens on property existing at the time of acquisition of such property provided that such liens were in existence prior to such acquisition and not incurred in contemplation thereof;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permitted Licenses, including any interest or title of a licensee under a Permitted License;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens under the Athyrium Loan Documents;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pledges or deposits in the ordinary course of business in connection with workers&#8217; compensation, unemployment insurance and other social security legislation, other than any Lien imposed by ERISA;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;deposits to secure the performance of bids, trade contracts and leases (other than Indebtedness), statutory obligations, surety and appeal bonds, indemnity and performance bonds and other obligations of a like nature incurred in the ordinary course of business;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;easements, rights-of-way, restrictions and other similar encumbrances affecting real property which, in the aggregate, are not substantial in amount, and which do not materially interfere with the ordinary conduct of the business of the applicable Person;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;licenses, sublicenses, leases or subleases granted to others in the ordinary course of business or otherwise and not interfering in any material respect with the Revenue Participation Right, the Product Rights, the Product Collateral, or the Back-Up Security Interest;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any interest of title of a lessor under, and Liens arising from UCC financing statements (or equivalent filings, registrations or agreements in foreign jurisdictions) relating to, leases permitted by this Agreement</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;normal and customary banker&#8217;s liens and rights of setoff upon deposits of cash in favor of banks or other depository institutions;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens of a collection bank arising under Section 4-210 of the UCC on items in the course of collection;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens of sellers of goods to the Seller and any of its Subsidiaries arising under Article 2 of the UCC or similar provisions of applicable law in the ordinary course of business, covering only the goods sold and securing only the unpaid purchase price for such goods and related expenses;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HSBC Liens; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;cash collateral securing letters of credit permitted under clause (f) of the definition of Permitted Contingent Obligations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Permitted Purchaser</u>&#8221; means any Third Party who acquires rights to Orladeyo and/or BXC9930, as applicable, in a Permitted Sale.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Permitted Sale</u>&#8221; means any sale, transfer, assignment or other disposition, not constituting an Out-License, of any rights relating to Orladeyo and/or BXC9930, as applicable, solely to the extent such rights pertain to the [***] (collectively, the &#8220;<u>Permitted Sale Territory</u>&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Permitted Sale</u><u> Territory</u>&#8221; is defined in the definition of &#8220;Permitted Sale&#8221;.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Person</u>&#8221; means any individual, firm, corporation, company, partnership, limited liability company, trust, joint venture, association, estate, trust, Governmental Entity or other entity, enterprise, association or organization.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Prime Rate</u>&#8221; means the prime rate published by The Wall Street Journal, from time to time, as the prime&nbsp;rate.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Product</u>&#8221; and &#8220;<u>Products</u>&#8221; means, individually and collectively, Orladeyo and BCX9930.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Product Collateral</u>&#8221; means the Seller&#8217;s rights, title and interests in (a) the Products (including all inventory of the Products), (b) the Product Rights owned, licensed or otherwise held by the Seller, and (c) any proceeds from either (a) or (b) above, including all accounts receivable and general intangibles resulting from the sale, license or other disposition of Products by the Seller or its Licensees.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Product</u><u> Partnering Revenue</u>&#8221; means the pre-tax profit realized by Seller or its Affiliates arising from any Permitted Sale, with the profit being calculated as: (i) aggregate payments or other consideration in any form received by Seller or any of its Affiliates from a Permitted Sale, or payments received by Seller or any of its Affiliates from a Third Party in lieu of any of the foregoing payments arising from a Permitted Sale, in each case, except for the Excluded Payments (defined below), minus (ii) aggregate out-of-pocket expenses incurred by Seller or its Affiliates after the Closing Date solely for the development or commercialization of Orladeyo and/or BXC9930, as applicable, in the Permitted Sale Territory. For purposes of Product Partnering Revenue, &#8220;Excluded Payments&#8221; means:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(a) payments or grants received from a commercial or non-commercial Third Party, specifically to cover future reasonable, documented fully-burdened costs incurred by or on behalf of Seller or any Affiliate after the execution of such Permitted Sale directly attributable to the performance of research and development of Orladeyo and/or BXC9930, as applicable, within the Permitted Sale Territory, which costs are expressly covered by the purchaser under such Permitted Sale;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(b) equity investments in Seller or any Affiliate to the extent priced at or below fair market value, provided that in the case of common stock or its equivalent, fair market value shall be the greater of: (i) the last reported closing price of Seller&#8217;s common stock on Nasdaq, or (ii) the 30-day volume-weighted average price of Seller&#8217;s common stock;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(c) loans received as part of a debt financing for so long as an obligation of repayment exists, provided that if at the time any such debt becomes due, the amount of such debt that is forgiven, and, for accounting or Tax purposes (in accordance with GAAP), is booked as income to Seller or its Affiliates, then such amount shall be deemed Product Partnering Revenue hereunder;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(d) loans received where Orladeyo and/or BXC9930, as applicable, forms part of the security package provided for the loan for so long as an obligation of repayment exists, provided that if at the time any such debt becomes due, the amount of such debt that is forgiven, and, for accounting or Tax purposes (in accordance with GAAP), is booked as income to Seller or its Affiliates, then such amount shall be deemed Product Partnering Revenue hereunder;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(e) Tax credits or Tax receipts; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">(f) sales or supply of Orladeyo and/or BXC9930, as applicable, inventory at or below Seller&#8217;s actual cost of goods sold, provided, however that any mark-up from, or other amounts in excess of, the Seller&#8217;s cost of goods sold for such inventory shall be Product Partnering Revenue.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">Notwithstanding anything to the contrary in this Agreement, &#8220;Product Partnering Revenue&#8221; shall include, without limitation, any and all contingent payments, upfront payments, option fees, lump-sum payments, distribution fees, joint-marketing fees, profit share, milestone payments, and other payments. In the event Seller or its Affiliate(s) receives non-monetary consideration pursuant to a Permitted Sale, Product Partnering Revenue shall be calculated based on the fair market value of such consideration at the time of the transaction (where fair market value shall be determined by agreement of the Parties or by an independent appraiser mutually agreeable to the Parties), assuming an arm&#8217;s length transaction made in the ordinary course of business. To the extent that Seller makes any offsetting payments to a Permitted Purchaser (such as a true-up payment) that are specifically permitted pursuant to the Permitted Sale (not entered into in violation of this Agreement) with such Permitted Purchaser, then the Product Partnering Revenue under such Permitted Sale shall be calculated net of such payments. To the extent that Seller permits any Permitted Purchaser to set off any payments payable pursuant to the Permitted Sale with such Permitted Purchaser against any amounts payable by Seller to such Permitted Purchaser, then the Product Partnering Revenue under such Permitted Sale shall include all such payments payable to Seller under such Permitted Sale without giving effect to any such setoff.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Product Rights</u>&#8221; means any and all of the following, as they exist throughout the world: (a) Intellectual Property Product Rights, (b) regulatory filings, submissions and approvals, including Marketing Approvals, with or from any Regulatory Authorities with respect to any of the Products, (c) In-Licenses and (d) Out-Licenses.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Purchase Price</u>&#8221; is defined in Section 2.2.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Receiving Party</u>&#8221; is defined in Section 8.1.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Regulatory and IP </u><u>S</u><u>emi-Annual Report</u>&#8221; is defined in Section 6.1.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Regulatory Authority</u>&#8221; means any national or supranational governmental authority, including the FDA, the EMA or such equivalent regulatory authority, or any successor agency thereto, that has responsibility in granting a Marketing Approval.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Regulatory Exclusivity Period</u>&#8221; shall mean, with respect to each Product in any country, any period of data, market or other regulatory exclusivity (other than Patent exclusivity) granted or afforded by law or by a Regulatory Authority in such country that confers exclusive marketing rights with respect to such Product in such country or prevents another party from using or otherwise relying on any data supporting the Marketing Approval for such Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Regulatory Updates</u>&#8221; means a summary of any and all material information and developments that materially impact a Product with respect to any regulatory filings or submissions made to any Regulatory Authority.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Related Party</u>&#8221; is defined in the definition of &#8220;Net Sales&#8221;.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Report</u>&#8221; is defined in Section 6.1.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Representative</u>&#8221; means, with respect to any Person, (a)&nbsp;any direct or indirect member or partner of such Person and (b)&nbsp;any manager, director, trustee, officer, employee, agent, advisor or other representative (including attorneys, accountants, consultants, contractors, actual and potential lenders, investors, co-investors and assignees, bankers and financial advisers) of such Person.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Restricted Indebtedness</u>&#8221; mean any financing, sale, or loan of royalties on the Products, or any Indebtedness, in each case other than the following (collectively, &#8220;<u>Permitted Indebtedness</u>&#8221;):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;true sales of royalties that contain no financial covenants or other provisions typically found in loan agreements, and in connection with such true sale Seller or its Affiliates do not grant any Lien on any assets of Seller or its Affiliates, other than a back-up security interest to perfect the true sale;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) additional Indebtedness incurred pursuant to the Athyrium Loan Documents, (ii) other secured Indebtedness, so long as in the case of any Indebtedness incurred pursuant to this clause (ii), the holders of such Indebtedness or any agent, representative or trustee acting on behalf of such holders have become party to the Intercreditor Agreement or entered into an Other Intercreditor Agreement, and (iii) unsecured Indebtedness, so long as (x) the principal amount of any Indebtedness incurred pursuant to this clause (b) (together with the aggregate outstanding principal amount of all Indebtedness previously incurred pursuant to this clause (b)) does not at the time of incurring such additional Indebtedness exceed [***]% of the aggregate principal amount of Indebtedness and commitments to extend credit under the Athyrium Loan Documents outstanding at such time and (y) except as otherwise agreed by the parties, such unsecured Indebtedness contemplated by clause (iii) shall be subordinated in right of payment to the Royalty Payments that are owed or may be owed in the future to the Buyer pursuant to the terms of a subordination, intercreditor, or other similar agreement (or terms of subordination incorporated into the indenture under which such unsecured indebtedness is issued), in each case in form and substance, and on terms, approved by the Buyer, the Seller, and the applicable Third Party lender of such unsecured indebtedness in writing;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;certain customary de minimis exceptions incurred in the ordinary course of business;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness under the Athyrium Loan Documents, and renewals, refinancings and extensions thereof;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;intercompany Indebtedness permitted under the Athyrium Loan Documents (and at any time when the Athyrium Loan Documents are not outstanding, any bona fide intercompany Indebtedness entered into in the good faith business judgment of the Seller);</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;obligations (contingent or otherwise) of the Seller or any Subsidiary existing or arising under any Swap Contract, provided, that, such obligations are (or were) entered into by such Person in the ordinary course of business for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated by such Person, or changes in the value of securities issued by such Person, and not for purposes of speculation or taking a &#8220;market view&#8221;;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;purchase money Indebtedness (including obligations in respect of capital leases or synthetic leases) hereafter incurred by the Seller or any of its Subsidiaries to finance the purchase of fixed assets, and renewals, refinancings, and extensions thereof, provided, that, (i) no default or &#8220;Event of Default&#8221; has occurred under the Athyrium Loan Documents and is continuing both immediately prior to and after giving effect thereto, (ii) the total of all such Indebtedness for all such Persons taken together shall not exceed an aggregate principal amount of $[***] at any one time outstanding, (iii) such Indebtedness when incurred shall not exceed the purchase price of the asset(s) financed, and (iv) no such Indebtedness shall be refinanced for a principal amount in excess of the principal balance outstanding thereon at the time of such refinancing except by an amount equal to unpaid accrued interest and premium thereon plus other amounts owing or paid related to such Indebtedness, and fees, commissions and expenses (including upfront fees and original issue discount) reasonably incurred, in connection with such refinancing</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other unsecured Indebtedness hereafter incurred by the Seller or any of its Subsidiaries in an aggregate amount not to exceed $[***] at any one time outstanding;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permitted Contingent Obligations;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness incurred in the ordinary course of business not to exceed $[***] in the aggregate at any time outstanding owed to any Person providing property, casualty, liability, or other insurance to the loan parties, including to finance insurance premiums, so long as the amount of such Indebtedness is not in excess of the amount of the unpaid cost of, and shall be incurred only to defer the cost of, such insurance for the policy year in which such Indebtedness is incurred and such Indebtedness is outstanding only during such policy year;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convertible Bond Indebtedness;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attributable Indebtedness in respect of Capital Leases incurred pursuant to automobile leases entered into in the ordinary course of business as part of employee compensation for employees based in Europe; provided that the aggregate amount of such Attributable Indebtedness incurred pursuant to this clause (l) shall not exceed $[***] at any one time outstanding; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other Indebtedness permitted by the Athyrium Credit Agreement after the Closing Date requested by the Seller in its good faith business judgment, not with the purpose or effect of adversely impacting the Buyer, the Revenue Participation Right, the Product Rights, the Product Collateral, or the Back-up Security Interest and permitted by the holders of the Indebtedness under the Athyrium Credit Agreement and the Intercreditor Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Revenue Participation Right</u>&#8221; means the right to receive the Royalty Payments.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Royalty Payment</u><u>s</u>&#8221; means the Orladeyo Royalty Payments and BCX9930 Royalty Payments.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Safety Notices</u>&#8221; means any recalls, field notifications, market withdrawals, warnings, &#8220;dear doctor&#8221; letters, investigator notices, safety alerts or other notices of action issued or instigated by the Seller, any of its Affiliates or any Regulatory Authority relating to an alleged lack of safety or regulatory compliance of any Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>SEC</u>&#8221; means the Securities and Exchange Commission.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Seller</u>&#8221; is defined in the preamble. References to the Seller herein (i) shall be deemed to include any assignee of the Seller pursuant to Section 10.4, but (ii) shall not include any Permitted Purchaser.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Seller Certificate</u>&#8221; is defined in Section 5.1(l).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Seller Indemnified Parties</u>&#8221; is defined in Section 7.1(b).<b> </b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Subsidiary</u>&#8221; means any and all corporations, partnerships, limited liability companies, joint ventures, associations and other entities controlled (by contract or otherwise) by the Seller directly or indirectly through one or more intermediaries. For purposes hereof, the Seller shall be deemed to control a partnership, limited liability company, association or other business entity if the Seller, directly or indirectly through one or more intermediaries, shall be allocated a majority of partnership, limited liability company, association or other business entity gains or losses or shall be or control the managing director or general partner of such partnership, limited liability company, association or other business entity. Notwithstanding the foregoing, until discharge of the JPR Indenture pursuant to and in accordance with Section 11.1 thereof, unless expressly provided herein, Subsidiaries of the Seller shall not include JPR Royalty Sub.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Swap Contract</u>&#8221; means (a) any and all rate swap transactions, basis swaps, credit derivative transactions, forward rate transactions, commodity swaps, commodity options, forward commodity contracts, equity or equity index swaps or options, bond or bond price or bond index swaps or options or forward bond or forward bond price or forward bond index transactions, interest rate options, forward foreign exchange transactions, cap transactions, floor transactions, collar transactions, currency swap transactions, cross-currency rate swap transactions, currency options, spot contracts, or any other similar transactions or any combination of any of the foregoing (including any options to enter into any of the foregoing), whether or not any such transaction is governed by or subject to any master agreement, and (b) any and all transactions of any kind, and the related confirmations, which are subject to the terms and conditions of, or governed by, any form of master agreement published by the International Swaps and Derivatives Association, Inc., any International Foreign Exchange Master Agreement, or any other master agreement (any such master agreement, together with any related schedules, a &#8220;<u>Master Agreement</u>&#8221;), including any such obligations or liabilities under any Master Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">&#8220;<u>Tax</u>&#8221; or &#8220;<u>Taxes</u>&#8221; means any federal, state, local or foreign income, gross receipts, license, payroll, employment, excise, severance, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security, unemployment, disability, real property, personal property, abandoned property, value added, alternative or add-on minimum, estimated or other tax of any kind whatsoever, including any interest, penalty or addition thereto, whether disputed or not.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Third Party</u>&#8221; means any Person that is not the Seller or the Seller&#8217;s Affiliates.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Torii License</u>&#8221; means that certain Commercialization and License Agreement between Torii Pharmaceutical Co., Ltd. and Biocryst Pharmaceuticals, Inc. dated November 5, 2019.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>UCC</u>&#8221; means the Uniform Commercial Code as in effect from time to time in the State of New York; provided, that, if, with respect to any financing statement or by reason of any provisions of applicable law, the perfection or the effect of perfection or non-perfection of the back-up security interest or any portion thereof granted pursuant to Section 2.1(b) is governed by the Uniform Commercial Code as in effect in a jurisdiction of the United States other than the State of New York, then &#8220;UCC&#8221; means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions of this Agreement and any financing statement relating to such perfection or effect of perfection or non-perfection.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Valid Claim</u>&#8221; shall mean: (a) any claim of an issued and unexpired Patent included within the Patent Rights, that shall not have been withdrawn, lapsed, abandoned, revoked, canceled or disclaimed, or held invalid or unenforceable by a court, Governmental Entity, national or regional patent office or other appropriate body that has competent jurisdiction in a decision being final and unappealable or unappealed within the time allowed for appeal; and (b) a claim of a pending Patent application included within the Patent Rights that is filed and being prosecuted in good faith and that has not been finally abandoned or finally rejected and which has been pending for no more than [***] years from the date of filing of the earliest Patent application to which such pending Patent application claims priority.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Interpretations</u>. Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;either&#8221; and &#8220;or&#8221; are not exclusive and &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; are not limiting and shall be deemed to be followed by the words &#8220;without limitation&#8221;;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;extent&#8221; in the phrase &#8220;to the extent&#8221; means the degree to which a subject or other thing extends, and such phrase does not mean simply &#8220;if&#8221;;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8220;hereof,&#8221; &#8220;hereto,&#8221; &#8220;herein&#8221; and &#8220;hereunder&#8221; and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;references to a Person are also to its permitted successors and assigns;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;definitions are applicable to the singular as well as the plural forms of such terms;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;references to an &#8220;Article&#8221;, &#8220;Section&#8221; or &#8220;Exhibit&#8221; refer to an Article&nbsp;or Section of, or an Exhibit to, this Agreement, and references to a &#8220;Schedule&#8221; refer to the corresponding part of the Disclosure Schedule;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;references to &#8220;$&#8221; or otherwise to dollar amounts refer to the lawful currency of the United States; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;references to a law include any amendment or modification to such law and any rules and regulations issued thereunder, whether such amendment or modification is made, or issuance of such rules and regulations occurs, before or after the date of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE 2</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><br>
PURCHASE, SALE AND ASSIGNMENT OF THE REVENUE PARTICIPATION RIGHT</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Purchase, Sale and Assignment</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">23</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the Closing and upon the terms and subject to the conditions of this Agreement, the Seller shall sell, transfer, assign and convey to the Buyer, without recourse (except as expressly provided herein), and the Buyer shall purchase, acquire and accept from the Seller, the Revenue Participation Right, free and clear of all Liens, except for any Lien contemplated under subparts (a), (b), (f), (g), and (k) of the definition of &#8220;Permitted Liens&#8221;. Immediately upon the sale to the Buyer by the Seller of the Revenue Participation Right pursuant to this <u>Section 2.1</u>, all of the Seller&#8217;s right, title and interest in and to the Revenue Participation Right shall terminate, and all such right, title and interest shall vest in the Buyer.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is the intention of the parties hereto that the sale, transfer, assignment and conveyance contemplated by this Agreement be, and is, a true, complete, absolute and irrevocable sale, transfer, assignment and conveyance by the Seller to the Buyer of all of the Seller&#8217;s right, title and interest in and to the Revenue Participation Right. Neither the Seller nor the Buyer intends the transactions contemplated by this Agreement to be, or for any purpose characterized as, a loan from the Buyer to the Seller or a pledge, a security interest, a financing transaction or a borrowing. It is the intention of the parties hereto that the beneficial interest in and title to the Revenue Participation Right and any &#8220;proceeds&#8221; (as such term is defined in the UCC) thereof shall not be part of the Seller&#8217;s estate in the event of the filing of a petition by or against the Seller under any Bankruptcy Laws. Each of the Seller and the Buyer hereby waives, to the maximum extent permitted by applicable law, any right to contest or otherwise assert that this Agreement does not constitute a true, complete, absolute and irrevocable sale, transfer, assignment and conveyance by the Seller to the Buyer of all of the Seller&#8217;s right, title and interest in and to the Revenue Participation Right under applicable Law, which waiver shall, to the maximum extent permitted by applicable Law, be enforceable against the Seller in any bankruptcy or insolvency proceeding relating to the Seller. Accordingly, the Seller shall treat the sale, transfer, assignment and conveyance of the Revenue Participation Right as a sale of an &#8220;account&#8221; or a &#8220;payment intangible&#8221; (as appropriate) in accordance with the UCC, and the Seller hereby authorizes the Buyer to file financing statements (and continuation statements with respect to such financing statements when applicable) naming the Seller as the debtor and the Buyer as the secured party in respect to the Revenue Participation Right. Not in derogation of the foregoing statement of the intent of the parties hereto in this regard, and for the purposes of providing additional assurance to the Buyer in the event that, despite the intent of the parties hereto, the sale, transfer, assignment and conveyance contemplated hereby is hereafter held not to be a sale, the Seller does hereby grant to the Buyer, as security for the payment of amounts to the Buyer equal to the Purchase Price (including a market rate of return thereon) less all Royalty Payments received by the Buyer pursuant to this Agreement, a security interest in and to all right, title and interest in, to and under the Revenue Participation Right, the Royalty Payments (excluding, for the avoidance of doubt, accounts and payment intangibles (each as defined in the UCC) of the Seller) and the Product Collateral, and the Seller does hereby authorize the Buyer, from and after the Closing, to file such financing statements (and continuation statements with respect to such financing statements when applicable) in such manner and such jurisdictions as are necessary or appropriate to perfect such security interest (the &#8220;<u>Back-Up Security Interest</u>&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Purchase Price</u>. At the Closing and upon the terms and subject to the conditions of this Agreement, the purchase price to be paid as consideration to the Seller for the sale, transfer, assignment and conveyance of the Revenue Participation Right to the Buyer is One Hundred Twenty-Five Million Dollars ($125,000,000) in cash (the &#8220;<u>Purchase Price</u>&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">24</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Assumed Obligations, Etc.</u> Notwithstanding any provision in this Agreement to the contrary, the Buyer is only agreeing, on the terms and conditions set forth in this Agreement, to purchase, acquire and accept the Revenue Participation Right and is not assuming any liability or obligation of the Seller of whatever nature, whether presently in existence or arising or asserted hereafter.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE 3</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><br>
CLOSING</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing</u>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Subject to the satisfaction of the conditions set forth in ARTICLE 5, the<b> </b>Closing shall take place remotely via the exchange of documents and signatures on the date hereof, subject to the satisfaction or waiver of the conditions set forth in ARTICLE 5 (other than those conditions that by their nature are to be satisfied at the Closing).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Payment of Purchase Price</u>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. At the Closing, the Buyer shall deliver (or cause to be delivered) payment of the Purchase Price to the Seller by electronic funds transfer or wire transfer of immediately available funds to one or more accounts specified by the Seller.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Bill of Sale</u>. At the Closing, upon confirmation of the receipt of the Purchase Price, the Seller shall deliver to the Buyer a duly executed bill of sale evidencing the sale, transfer, assignment and conveyance of the Revenue Participation Right in form attached hereto as Exhibit C.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE 4</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><br>
REPRESENTATIONS AND WARRANTIES</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Seller&#8217;s Representations and Warranties</u>. Except as set forth on the Disclosure Schedules attached hereto, the Seller represents and warrants to the Buyer that as of the date hereof:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Existence; Good Standing</u>. The Seller is a corporation duly incorporated, validly existing and in good standing under the laws of the State of Delaware. The Seller is duly licensed or qualified to do business and is in corporate good standing in each jurisdiction in which the nature of the business conducted by it or the character or location of the properties and assets owned, leased or operated by it makes such licensing or qualification necessary, except where the failure to be so licensed or qualified and in corporate good standing has not and would not reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorization</u>. The Seller has all requisite corporate power and authority to execute, deliver and perform its obligations under this Agreement. The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary corporate action on the part of the Seller.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Enforceability</u>. This Agreement has been duly executed and delivered by an authorized officer of the Seller and constitutes the valid and binding obligation of the Seller, enforceable against the Seller in accordance with its terms, except as may be limited by applicable Bankruptcy Laws or by general principles of equity (whether considered in a proceeding in equity or at law).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">25</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Conflicts</u>. The execution, delivery and performance by the Seller of this Agreement and the consummation of the transactions contemplated hereby and thereby do not and will not (i)&nbsp;contravene or conflict with the certificate of incorporation or bylaws of the Seller, (ii)&nbsp;contravene or conflict with or constitute a material default under any law binding upon or applicable to the Seller or the Revenue Participation Right or (iii)&nbsp;contravene or conflict with or constitute a material default under any material agreement or Judgment binding upon or applicable to the Seller or the Revenue Participation Right.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Consents</u>. Except for the consents that have been obtained on or prior to the Closing, the UCC financing statements contemplated by Section 2.1(b), or any filings required by the federal securities laws or stock exchange rules, no consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by the Seller in connection with (i)&nbsp;the execution and delivery by the Seller of this Agreement, (ii)&nbsp;the performance by the Seller of its obligations under this Agreement or (iii)&nbsp;the consummation by the Seller of any of the transactions contemplated by this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Litigation</u>. Neither the Seller nor any of its Subsidiaries is a party to, and has not received any written notice of, any action, suit, investigation or proceeding pending before any Governmental Entity and, to the Knowledge of the Seller, no such action, suit, investigation or proceeding has been threatened against the Seller, that, individually or in the aggregate, has had or would, if determined adversely, reasonably be expected to have a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All applications, submissions, information and data related to a Product submitted or utilized as the basis for any request to any Regulatory Authority by or on behalf of the Seller were true and correct in all material respects as of the date of such submission or request, and, to the Knowledge of the Seller any material updates, changes, corrections or modification to such applications, submissions, information or data required under applicable laws or regulations have been submitted to the necessary Regulatory Authorities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Seller nor any of its Subsidiaries has committed any act, made any statement or failed to make any statement that would reasonably be expected to provide a basis for the FDA or EMA to invoke its policy with respect to &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities&#8221;, or similar policies, set forth in any applicable laws or regulations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">26</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:72pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller has provided to the Buyer prior to the date hereof in a data room available to the Buyer true and correct copies or summaries of all material written communications sent or received by the Seller and any of its Affiliates to or from any Regulatory Authorities that relate to each Product since [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:72pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of the Seller, any of its Subsidiaries and, to the Seller&#8217;s Knowledge, any Third Party manufacturer of any Product, has received from the FDA a &#8220;Warning Letter&#8221;, Form FDA-483, &#8220;Untitled Letter,&#8221; or similar material written correspondence or notice alleging violations of applicable laws and regulations enforced by the FDA, or any comparable material written correspondence from any other Regulatory Authority with regard to either Product or the manufacture, processing, packaging or holding thereof, the subject of which communication is unresolved and if determined adversely to the Seller or such Subsidiary would, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:72pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since [***], (A) there have been no Safety Notices, (B) to the Seller&#8217;s Knowledge, there are no unresolved material product complaints with respect to any Product, which would result in a Material Adverse Effect, and (C) to the Seller&#8217;s knowledge, there are no facts currently in existence that would, individually or in the aggregate, reasonably be expected to result in (1) a material Safety Notice with respect to any Product, or (2) a material change in the labeling of any Product. Since [***], neither the Seller nor any of its Subsidiaries has experienced any significant failures in the manufacturing of any Product for clinical use or commercial sale that, individually or in the aggregate, have had or would reasonably be expected to result in, if such failure occurred again, a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Licenses</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>In-Licenses</u>. There are no In-Licenses. <b> </b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:72pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Out-Licenses</u>. Except as set forth on <u>Schedule&nbsp;</u><u>4.1(h)(ii)</u> of the Disclosure Schedule, there are no Out-Licenses (any Out-License set forth on <u>Schedule&nbsp;</u><u>4.1(h)(ii)</u> of the Disclosure Schedule, an &#8220;<u>Existing </u><u>Out</u><u>-License</u>&#8221;). A true, correct and complete copy of each Existing Out-License has been provided to the Buyer by the Seller in a data room available to the Buyer. Neither the Seller nor the respective counterparty thereto has made or entered into any amendment, supplement or modification to, or granted any waiver under any provision of any Existing Out-License.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:72pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Validity and Enforceability of </u><u>Out-Licenses</u>. Each Existing Out-License is a valid and binding obligation of the Seller and the counterparty thereto. To the Knowledge of the Seller, each Existing Out-License is enforceable against each counterparty thereto in accordance with its terms except as may be limited by applicable Bankruptcy Laws or by general principles of equity (whether considered in a proceeding in equity or at law). The Seller has not received any written notice in connection with any Existing Out-License challenging the validity, enforceability or interpretation of any provision of such agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">27</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:72pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Termination</u>. The Seller has not (A)&nbsp;given notice to a counterparty of the termination of any Existing Out-License (whether in whole or in part) or any notice to a counterparty expressing any intention or desire to terminate any Existing Out-License or (B)&nbsp;received from a counterparty thereto any written notice of termination of any Existing Out-License (whether in whole or in part) or any written notice from a counterparty expressing any intention or desire to terminate any Existing Out-License.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:72pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Breaches or Defaults</u>. There is and has been no material breach or default under any provision of any Existing Out-License either by the Seller or, to the Knowledge of the Seller, by the respective counterparty (or any predecessor thereof) thereto, and there is no event that upon notice or the passage of time, or both, would reasonably be expected to give rise to any breach or default either by the Seller or, to the Knowledge of the Seller, by the respective counterparty to such agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:72pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Payments Made</u>. The respective counterparty of each Existing Out-License has made all payments to the Seller required under each Existing Out-License as of the date hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:72pt;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Assignments</u>. The Seller has not consented to any assignment by the counterparty to any Existing Out-License of any of its rights or obligations under any such Existing Out-License and, to the Knowledge of the Seller, the counterparty has not assigned any of its rights or obligations under any such Existing Out-License to any Person.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:72pt;">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Indemnification Claims</u>. The Seller has not notified any Person of any claims for indemnification under any Existing Out-License nor has the Seller received any claims for indemnification under any Existing Out-License.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:72pt;">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Infringement</u>. Neither the Seller nor any of its Subsidiaries has received any written notice from, or given any written notice to, any counterparty to any Existing Out-License regarding any infringement of any of the Existing Patent Rights licensed thereunder.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Liens; Title to Revenue Participation Right</u>. None of the property or assets, in each case, that specifically relate to the Products, including Intellectual Property Rights, of the Seller or any of its Subsidiaries is subject to any Lien, except for a Permitted Lien. Upon the Closing, the Buyer will have acquired, subject to the terms and conditions set forth in this Agreement, good and marketable title to the Revenue Participation Right, free and clear of all Liens, except for a Lien contemplated by subparts (a), (b), (f), (g), and (k) of the definition of &#8220;Permitted Liens&#8221;.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">28</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Manufacturing</u><u>; Supply</u>. All Products have, since [***], been manufactured, transported, stored and handled in all material respects in accordance with applicable law and with good manufacturing practices. Since [***], neither the Seller nor any Affiliate of the Seller has experienced any significant failures in the manufacturing or supply of any Product that, individually or in the aggregate, have had or would reasonably be expected to result in, if such failure occurred again, a Material Adverse Effect. The Seller has on hand or has made adequate provisions to secure sufficient clinical quantities of Products to complete all clinical trials and all activities required for Marketing Approvals, in each case, that are ongoing or planned as of the date hereof. The Seller has on hand or has made adequate provisions to secure sufficient quantities of Orladeyo to support the commercial launch of Orladeyo in the Direct Sales Territories.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Intellectual Property</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Schedule 4.1(</u><u>k</u><u>)(i)</u><u>(A)</u> of the Disclosure Schedule lists all of the currently existing Patents included within the Patent Rights (the &#8220;<u>Existing</u><u> Patent Rights</u>&#8221;). The Seller is the sole and exclusive owner of all of the Existing Patent Rights. <u>Schedule 4.1(</u><u>k</u><u>)(i)(A)</u> of the Disclosure Schedule specifies as to each listed patent or patent application the jurisdictions by or in which each such patent has issued as a patent or such patent application has been filed, including the respective patent or application numbers.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither Seller nor any of its Subsidiaries is a party to any pending and, to the Knowledge of the Seller, there is no threatened, litigation, interference, reexamination, opposition or like procedure involving any of the Existing Patent Rights.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of the issued patents within the Existing Patent Rights are (A) to the Knowledge of the Seller, valid and enforceable, and (B) in full force and effect. None of the issued patents within the Existing Patent Rights have lapsed, expired or otherwise terminated. Neither Seller nor any of its Subsidiaries has received any written notice relating to the lapse, expiration or other termination of any of the issued patents within the Existing Patent Rights, and neither Seller nor its Subsidiaries has received any written legal opinion that alleges that, an issued patent within any of the Existing Patent Rights is invalid or unenforceable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither Seller nor any of its Subsidiaries has received any written notice that there is any, and, to the Knowledge of the Seller, there is no, Person who is or claims to be an inventor under any of the Existing Patent Rights who is not a named inventor thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither Seller not its Affiliates has received any written notice of any claim by any Person challenging the inventorship or ownership of, the rights of the Seller in and to, or the patentability, validity or enforceability of, any of the Existing Patent Rights, or asserting that the development, manufacture, importation, sale, offer for sale or use of the Product infringes, misappropriates or otherwise violates or will infringe, misappropriate or otherwise violate such Person&#8217;s Patents or other intellectual property rights.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">29</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the Knowledge of the Seller, the discovery, development manufacture, importation, sale, offer for sale or use of each Product, in each case in the form such Product exists as of the date hereof and as such activity is currently contemplated by the Seller, has not and will not, infringe, misappropriate or otherwise violate any Patents or other intellectual property rights owned by any Third Party.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the Knowledge of the Seller, no Person has infringed, misappropriated or otherwise violated, or is infringing, misappropriating or otherwise violating, any of the Intellectual Property Rights.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller has paid all maintenance fees, annuities and like payments required as of the date hereof with respect to each of the Existing Patent Rights.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Indebtedness</u>. <u>Schedule 4.1(l)</u> sets forth a complete list of the outstanding Indebtedness of the Seller and its Subsidiaries in excess of $[***] in the aggregate.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Lien Related Representation and Warranties</u>. The Seller&#8217;s exact legal name is, and for the immediately preceding five (5) years has been, &#8220;BioCryst Pharmaceuticals, Inc.&#8221; The Seller is, and for the prior five (5) years has been, incorporated in the State of Delaware.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Brokers&#8217; Fees</u>. Except for Cowen and Company, there is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized to act on behalf of the Seller who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Buyer&#8217;s Representations and Warranties</u>. The Buyer hereby represents and warrants to the Seller that:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Existence; Good Standing</u>. The Buyer is a statutory trust duly organized, validly existing and in good standing under the laws of the State of Delaware.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorization</u>. The Buyer has the requisite trust right, power and authority to execute, deliver and perform its obligations under this Agreement. The execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary action on the part of the Buyer.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Enforceability</u>. This Agreement has been duly executed and delivered by an authorized person of the owner trustee of the Buyer and constitutes the valid and binding obligation of the Buyer, enforceable against the Buyer in accordance with its terms, except as may be limited by applicable Bankruptcy Laws or by general principles of equity (whether considered in a proceeding in equity or at law).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">30</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Conflicts</u>. The execution, delivery and performance by the Buyer of this Agreement do not and will not (i)&nbsp;contravene or conflict with the organizational documents of the Buyer, (ii)&nbsp;contravene or conflict with or constitute a default under any material provision of any law binding upon or applicable to the Buyer or (iii)&nbsp;contravene or conflict with or constitute a default under any material contract or other material agreement or Judgment binding upon or applicable to the Buyer.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Consents</u>. Except for any filings required by the federal securities laws or stock exchange rules, no consent, approval, license, order, authorization, registration, declaration or filing with or of any Governmental Entity or other Person is required to be done or obtained by the Buyer in connection with (i)&nbsp;the execution and delivery by the Buyer of this Agreement, (ii)&nbsp;the performance by the Buyer of its obligations under this Agreement or (iii)&nbsp;the consummation by the Buyer of any of the transactions contemplated by this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Litigation</u>. There is no action, suit, investigation or proceeding pending or, to the knowledge of the Buyer, threatened before any Governmental Entity to which the Buyer is a party that would, if determined adversely, reasonably be expected to prevent or materially and adversely affect the ability of the Buyer to perform its obligations under this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Financing</u>. The Buyer has sufficient cash to pay the Purchase Price at the Closing. The Buyer acknowledges that its obligations under this Agreement are not contingent on obtaining financing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Tax Status</u>. Under current law, the Buyer is exempt from U.S. federal withholding tax on all payments with respect to the Revenue Participation Right by reason of the Buyer&#8217;s status as eligible for zero percent treaty rates with respect to such payments.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Brokers&#8217; Fees</u>. There is no investment banker, broker, finder, financial advisor or other intermediary who has been retained by or is authorized to act on behalf of the Buyer who might be entitled to any fee or commission in connection with the transactions contemplated by this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Implied Representations and Warranties</u>. The Buyer acknowledges and agrees that, other than the express representations and warranties of the Seller specifically contained in ARTICLE 4, (a) there are no representations or warranties of the Seller either expressed or implied with respect to the Patent Rights or Royalty Payment and that the Buyer does not rely on, and shall have no remedies in respect of, any representation or warranty not specifically set forth in ARTICLE 4, and all other representations and warranties are hereby expressly disclaimed, and (b) nothing contained herein guarantees that sales of the Products or the aggregate Royalty Payments due to the Buyer will achieve any specific amounts (it being understood and agreed that nothing in this Section 4.3 shall limit in any way the Seller&#8217;s obligations under ARTICLE 8). Notwithstanding the foregoing, claims for fraud, gross negligence, or willful misconduct shall not be waived or limited in any way by this Section 4.3. Except for the Revenue Participation Right, Back-up Security Interest and the Buyer&#8217;s rights under Section 6.5(d), the Buyer further acknowledges and agrees that no licenses or assignments under any assets (including the Patent Rights or any other intellectual property) of the Seller and its Affiliates are granted pursuant to this Agreement, including by implication, estoppel, exhaustion or otherwise.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">31</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE 5</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><br>
CONDITIONS TO CLOSING</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conditions to the Buyer&#8217;s Obligations</u>. The obligations of the Buyer to consummate the transactions contemplated hereunder on the Closing Date are subject to the satisfaction or waiver, at or prior to the Closing Date, of each of the following conditions precedent:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall have received Marketing Approval from the FDA for Orladeyo to prevent attacks of hereditary angioedema (&#8220;<u>HAE</u>&#8221;) in adults and adolescent patients twelve (12) years and older with a final product label in the form of the draft label attached hereto as Exhibit D.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall have performed and complied in all material respects with all agreements, covenants, obligations and conditions required to be performed and complied with by it under this Agreement at or prior to the Closing Date, and the Buyer shall have received a certificate executed by a duly authorized officer of the Seller on the Closing Date certifying on behalf of the Seller to the effect of the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The representations and warranties of the Seller contained in Section 4.1 shall have been true and correct in all material respects as of the date hereof and shall be true and correct in all material respects as of the Closing Date as though made at and as of the date hereof and as of the Closing Date, respectively, except to the extent any such representation or warranty expressly speaks as of a particular date, in which case it shall be true and correct in all material respects as of such date; <u>provided</u>, that to the extent that any such representation or warranty is qualified by the term &#8220;material&#8221; or &#8220;Material Adverse Effect&#8221; such representation or warranty (as so written, including the term &#8220;material&#8221; or &#8220;Material Adverse Effect&#8221;) shall have been true and correct in all respects as of the date hereof and shall be true and correct in all respects as of the Closing Date or such other date, as applicable. The Buyer shall have received a certificate executed by an authorized officer of the Seller on the Closing Date certifying on behalf of the Seller to the effect of the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No event or events shall have occurred, or be reasonably likely to occur, that, individually or in the aggregate, have had or would reasonably be expected to result in (or, with the giving of notice, the passage of time or otherwise, would result in) a Material Adverse Effect. The Buyer shall have received a certificate executed by a duly authorized officer of the Seller on the Closing Date certifying on behalf of the Seller to the effect of the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">32</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There shall not have been issued and be in effect any Judgment of any Governmental Entity enjoining, preventing or restricting the consummation of the transactions contemplated by this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There shall not have been instituted or be pending any action or proceeding by any Governmental Entity or any other Person (i)&nbsp;challenging or seeking to make illegal, to delay materially or otherwise directly or indirectly to restrain or prohibit the consummation of the transactions contemplated hereby, (ii)&nbsp;seeking to obtain material damages in connection with the transactions contemplated hereby or (iii)&nbsp;seeking to restrain or prohibit the Buyer&#8217;s purchase of the Revenue Participation Right.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Buyer shall have received a fully executed copy of the Athyrium Credit Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all Midcap Indebtedness and related Liens shall have been paid off and released, as applicable, on or prior to the Closing Date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Buyer shall have received the Intercreditor Agreement, duly executed and delivered by the Seller and Athyrium.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Buyer shall have received a valid, properly executed Internal Revenue Service Form W-9 certifying that the Seller is exempt from U.S. federal &#8220;backup&#8221; withholding Tax.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall have delivered to the Buyer the legal opinions of Gibson, Dunn &amp; Crutcher, LLP, as counsel to the Seller, in substantially the forms attached hereto as Exhibit E.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Buyer shall have received a certificate of the Secretary or an Assistant Secretary of the Seller, dated the Closing Date, certifying as to (i)&nbsp;the incumbency of each officer of the Seller executing this Agreement and (ii)&nbsp;the attached thereto copies of (A) the Seller&#8217;s certificate of incorporation, (B) bylaws, and (C) resolutions adopted by the Seller&#8217;s Board of Directors authorizing the execution and delivery by the Seller of this Agreement and the consummation by the Seller of the transactions contemplated hereby (the &#8220;<u>Seller Certificate</u>&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall have confirmed it has scheduled delivery to Buyer of a CD or USB containing copies of all documents uploaded to the [***] data room and the [***] Virtual Data Site, in each case, related to the transactions contemplated by this Agreement, as of the date hereof, maintained by the Seller and made available to the Buyer, including all documents referred to in Section 4.1(g)(iii) and Section 4.1(h)(i).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conditions to the Seller&#8217;s Obligations</u>. The obligations of the Seller to consummate the transactions contemplated hereunder on the Closing Date are subject to the satisfaction or waiver, at or prior to the Closing Date, of each of the following conditions precedent:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Buyer shall have performed and complied in all material respects with all agreements, covenants, obligations and conditions required to be performed and complied with by it under this Agreement at or prior to the Closing Date, and the Seller shall have received a certificate executed by a duly authorized person of RP Management, LLC, as Administrator of the Buyer, on the Closing Date certifying on behalf of the Buyer to the effect of the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">33</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The representations and warranties of the Buyer contained in Section 4.2 shall have been true and correct in all material respects as of the date hereof and shall be true and correct in all material respects as of the Closing Date as though made at and as of the date hereof and Closing Date, respectively, except to the extent any such representation or warranty expressly speaks as of a particular date, in which case it shall be true and correct in all material respects as of such date; <u>provided</u>, that to the extent that any such representation or warranty is qualified by the term &#8220;material,&#8221; or &#8220;Material Adverse Effect&#8221; such representation or warranty (as so written, including the term &#8220;material&#8221; or &#8220;Material Adverse Effect&#8221;) shall have been true and correct in all respects as of the date hereof and shall be true and correct in all respects as of the Closing Date or such other date, as applicable. The Seller shall have received a certificate executed by a duly authorized person of RP Management, LLC, as Administrator of the Buyer, on the Closing Date certifying on behalf of the Buyer to the effect of the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There shall not have been issued and be in effect any Judgment of any Governmental Entity enjoining, preventing or restricting the consummation of the transactions contemplated by this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There shall not have been instituted or be pending any action or proceeding by any Governmental Entity or any other Person (i)&nbsp;challenging or seeking to make illegal, to delay materially or otherwise directly or indirectly to restrain or prohibit the consummation of the transactions contemplated hereby, (ii)&nbsp;seeking to obtain material damages in connection with the transactions contemplated hereby or (iii)&nbsp;seeking to restrain or prohibit the Buyer&#8217;s purchase of the Revenue Participation Right.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall have received a valid, properly executed Internal Revenue Service Form W-8BEN-E certifying that the Buyer is exempt from U.S. federal withholding Tax in respect of all payments with respect to the Revenue Participation Rights under an applicable United States income Tax treaty.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Buyer shall have delivered to the Seller standard existence and authority opinions in respect of the Buyer, enforceability opinions on this Agreement, and an opinion that this Agreement does not conflict with the organizational documents of the Buyer or applicable law, each such opinion in a form previously agreed upon by the Seller and the Buyer.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall have received a certificate of an authorized person of the owner trustee of the Buyer, dated the Closing Date, certifying as to the incumbency of the officers executing this Agreement on behalf of the Buyer.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">34</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE 6</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><br>
COVENANTS</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reporting</u>. From and after the date hereof, the Seller shall provide the Buyer:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;promptly following the end of each calendar quarter, but in any event, in each case, no later than [***] calendar days after the end of such calendar quarter, as applicable, a reasonably detailed quarterly report setting forth, with respect to such same period, (i) the Clinical Updates and (ii) the Commercial Updates (the &#8220;<u>Clinical and Commercial </u><u>Quarterly Report</u>&#8221;); provided that beginning with (A) the [***] calendar quarter following Regulatory Approval (in the case of Clinical Updates) or (B) the [***] calendar quarter following the First Commercial Sale in the United States (in the case of Commercial Updates) of a given Product (on a Product-by-Product basis), the Seller shall no longer be required to deliver Clinical and Commercial Quarterly Reports for such Product and shall thereafter promptly following the end of each [***]-month period in a calendar year ([***]), but in any event, in each case, no later than [***] calendar days after the end of such [***]-month period, as applicable, a reasonably detailed semi-annual report setting forth, with respect to such same period, (1) any Clinical Updates and (2) the Commercial Updates (the &#8220;<u>Clinical and Commercial </u><u>Semi-Annual </u><u>Report</u>&#8221;);</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;promptly following the end of each [***]-month period in a calendar year ([***]), but in any event, in each case, no later than [***] calendar days after the end of such [***]-month period, as applicable, a reasonably detailed semi-annual report setting forth, with respect to such same period, (i) the Regulatory Updates, and (ii) the Intellectual Property Updates (the &#8220;<u>Regulatory and IP </u><u>Semi-Annual Report</u>&#8221;, and, collectively with the Quarterly Reports, the Clinical and Commercial Quarterly Report and the Semi-Annual Clinical and Commercial Reports, the &#8220;<u>Reports</u>&#8221;); and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall include in each Report any (i) material CMC updates and (ii) details as to the achievement of any development, sales, regulatory or other milestone event set forth in each Out-License.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall also provide the Buyer with such additional information regarding the updates included in each Report as the Buyer may reasonably request from time to time. The Seller shall prepare and maintain and shall cause its Affiliates and Licensees to prepare and maintain reasonably complete and accurate records of the information to be disclosed in each Report. All Reports, and the Confidential Information contained therein, shall be the Confidential Information of Seller and subject to the obligations of confidentiality set forth in ARTICLE 8.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Royalty</u><u> </u><u>Payments; Revenue </u><u>Participation and Royalty Payment Details</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From and after the First Commercial Sale of a Product in any country, the Seller shall pay to the Buyer, without any setoff or offset (subject, in each case, to Section 6.13), the Royalty Payment for each calendar quarter promptly, but in any event no later than [***] calendar days after the end of each of the first three calendar quarters and [***] calendar days after the end of the last calendar quarter in each calendar year (or [***] Business Days after the filing of the Company&#8217;s annual report on Form 10-K, if earlier), provided that for any payments received by the Seller after the date that is [***] calendar days after the end of each calendar quarter, such payment will be paid with the following calendar quarter&#8217;s Royalty Payment. A late fee of [***]% over the Prime Rate (calculated on a per annum basis) will accrue on all unpaid amounts with respect to any Royalty Payment from the date such obligation was due. The imposition and payment of a late fee shall not constitute a waiver of the Buyer&#8217;s rights with respect to such payment default.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">35</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From and after the First Commercial Sale of a Product in any country, for each calendar quarter promptly, but in any event no later than [***] calendar days after the end of each of the first three calendar quarters and [***] calendar days after the end of the last calendar quarter in each calendar year (or [***] Business Days after the filing of the Company&#8217;s annual report on Form 10-K, if earlier), the Seller shall provide to Buyer a report, in substantially the form attached to this Agreement as Exhibit F, setting forth in reasonable detail (i) with respect to BCX9930, Gross Sales and Net Sales for the applicable calendar quarter and calendar year to date, on a country-by-country basis (including a detailed break-down of all permitted deductions from Gross Sales used to determine Net Sales and any Net Sales described in Section 6.5(d)), (ii) with respect to Orladeyo, (A) the calculation of Orladeyo Direct Sales, including Gross Sales and Net Sales for the applicable calendar quarter and calendar year to date, on a country-by-country basis (including a detailed break-down of all permitted deductions from Gross Sales used to determine Net Sales and any Net Sales described in Section 6.5(d)), (B) the calculation of Orladeyo Indirect Revenues on a country-by-country and Licensee-by-Licensee basis (including a detailed breakdown of Orladeyo Indirect Revenue consisting of royalties, upfront payments, milestones and other fixed payments), and (iii) with respect to each Product, (A) the calculation of the Royalty Payment payable to the Buyer for the applicable calendar quarter, identifying, on a country-by-country basis, the number of units of each Product sold by the Seller, its Affiliates and each Licensee and (B) foreign currency exchange rates used (which shall be rates of exchange determined in a manner consistent with the Seller&#8217;s method for calculating rates of exchange in the preparation of the Seller&#8217;s annual financial statements in accordance with accounting principles generally accepted in the United States); provided that for any reports received by the Seller after the date that is [***] calendar days after the end of each calendar quarter, the Seller shall provide to the Buyer the relevant information from such reports in the following calendar quarter&#8217;s report.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any payments required to be made by either party under this Agreement shall be made in United States Dollars via electronic funds transfer or wire transfer of immediately available funds to such bank account as the other party shall designate in writing prior to the date of such payment.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Disclosures</u>. Except for a press release previously approved in form and substance by the Seller and the Buyer or any other public announcement using substantially the same text as such press release, neither the Buyer nor the Seller shall, and each party hereto shall cause its respective Representatives, Affiliates and Affiliates&#8217; Representatives not to issue a press release or other public announcement or otherwise make any public disclosure with respect to this Agreement or the subject matter hereof without the prior written consent of the other party hereto (which consent shall not be unreasonably withheld or delayed), except as may be required by applicable law or stock exchange rule (in which case the party hereto required to make the press release or other public announcement or disclosure shall allow the other party hereto reasonable time to comment on, and, if applicable, reasonably direct the disclosing party to seek confidential treatment in respect of portions of, such press release or other public announcement or disclosure in advance of such issuance).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">36</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Inspections and Audits of the Seller</u>. Following the Closing, upon at least fourteen (14) Business Days written notice and during normal business hours, no more frequently than once per calendar year, the Buyer may cause an inspection and/or audit by an independent public accounting firm reasonably acceptable to the Seller to be made of the Seller&#8217;s books of account for the three (3) calendar years prior to the audit for the purpose of determining the correctness of Royalty Payments made under this Agreement. Upon the Buyer&#8217;s reasonable request, no more frequently than once per calendar year while any Out-License remains in effect, the Seller shall use Commercially Reasonable Efforts to exercise any rights it may have under any Out-License relating to a Product to cause an inspection and/or audit by an independent public accounting firm to be made of the books of account of any counterparty thereto for the purpose of determining the correctness of Royalty Payments made under this Agreement. All of the out-of-pocket expenses of any inspection or audit requested by the Buyer hereunder (including the fees and expenses of such independent public accounting firm designated for such purpose) shall be borne solely by the Buyer, unless the independent public accounting firm determines that Royalty Payments previously paid during the period of the audit were underpaid by an amount greater than [***] of the Royalty Payments actually paid during such period, in which case such expenses shall be borne by the Seller. Any such accounting firm shall not disclose the confidential information of the Seller or any such Licensee relating to a Product to the Buyer, except to the extent such disclosure is necessary to determine the correctness of Royalty Payments or otherwise would be included in a Report. All information obtained by the Buyer as a result of any such inspection or audit shall be Confidential Information subject to ARTICLE 8. If any audit discloses any underpayments by the Seller to the Buyer, then such underpayment, shall be paid by the Seller to the Buyer within thirty (30) calendar days of it being so disclosed. If any audit discloses any overpayments by the Seller to the Buyer, then the Seller shall have the right to credit the amount of the overpayment against each subsequent quarterly Royalty Payment due to the Buyer until the overpayment has been fully applied. If the overpayment is not fully applied prior to the final quarterly Royalty Payment due hereunder, the Buyer shall promptly refund an amount equal to any such remaining overpayment.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Intellectual Property Matters</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall provide to the Buyer a copy of any written notice received by the Seller from a Third Party alleging or claiming that the making, having made, using, importing, offering for sale or selling of a Product infringes or misappropriates any Patents or other intellectual property rights of such Third Party, together with copies of material correspondence sent or received by the Seller related thereto, as soon as practicable and in any event not more than [***] following such delivery or receipt.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall promptly inform the Buyer of any infringement by a Third Party of any Patent Right of which any of the individuals named in the definition of &#8220;Knowledge of the Seller&#8221; (or the successors of such Person at the Seller) becomes aware. Without limiting the foregoing, the Seller shall provide to the Buyer a copy of any written notice of any suspected infringement of any Patent Rights delivered or received by the Seller, as well as copies of material correspondence related thereto, as soon as practicable and in any event not more than [***] following such delivery or receipt.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">37</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Within [***] of initiating, or permitting a Licensee to initiate, an enforcement action regarding any suspected infringement by a Third Party of any Patent Right, the Seller shall provide the Buyer with written notice of such enforcement action.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the Seller recovers monetary damages from a Third Party in an action brought for such Third Party&#8217;s infringement of any Patent Rights relating to a Product, where such damages, whether in the form of judgment or settlement, are awarded for such infringement of such Patent Rights, (i) such recovery will be allocated first to the reimbursement of any expenses incurred by the Seller (or any party to an In-License or Permitted Licensees of such Patent Rights entitled to such reimbursement under any such In-License or Out-License ) in bringing such action (including all reasonable attorney&#8217;s fees), (ii) any remaining amounts will be reduced, if applicable, to comply with allocation of recovered damages with licensors of such Patent Rights required under any In-Licenses or Permitted Licensees of such Patent Rights under any Out-Licenses, if any, and (iii) any residual amount of such damages after application of (i) and (ii) will be treated as Orladeyo Direct Sales with respect to the Direct Sales Territories, Orladeyo Indirect Sales with respect to the Indirect Sales Territories, Product Partnering Revenue with respect to the Permitted Sale Territory, or BCX9930 Net Sales, as applicable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>In-Licenses</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall promptly (and in any event within [***]) provide the Buyer with (i) executed copies of any In-License entered into by the Seller or its Affiliates, and (ii) executed copies of each amendment, supplement, modification or written waiver of any provision of any In-License.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall use Commercially Reasonable Efforts to comply in all material respects with its obligations under any In-Licenses it enters into and shall not take any action or forego any action that would reasonably be expected to result in a material breach thereof. Promptly, and in any event within [***], after receipt of any (written or oral) notice from a counterparty to any In-License or its Affiliates of an alleged material breach under any In-License, the Seller shall provide the Buyer a copy thereof. The Seller shall use its Commercially Reasonable Efforts to cure any material breaches by it under any In-License and shall give written notice to the Buyer upon curing any such breach. The Seller shall provide the Buyer with written notice following becoming aware of a counterparty&#8217;s material breach of its obligations under any In-License. The Seller shall not terminate any In-License without providing the Buyer prior written notice. Promptly, and in any event within [***] following the Seller&#8217;s notice to a counterparty to any In-License of an alleged breach by such counterparty under any such In-License, the Seller shall provide the Buyer a copy thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 6.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Out-Licenses</u><u> and Permitted Sales</u>.</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">38</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to compliance with this Section 6.7, the Seller may enter into either (i) an Out-License with a Third Party or enter into an agreement to research, develop or manufacture any Product in all or any portion of the world without the Buyer&#8217;s prior written consent; <u>provided</u>, that such license shall not assign or otherwise convey title to or impose any Lien, other than the grant of the license or sublicense, in favor of any Third Party (any such license, a &#8220;<u>Permitted License</u>&#8221;), or (ii) a Permitted Sale.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall promptly (and in any event within [***]) provide the Buyer with (i) executed copies of each Out-License and Permitted Sale, and (ii) executed copies of each amendment, supplement, modification or written waiver of any material provision of an Out-License or Permitted Sale.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall include in all Out-Licenses (other than Existing Out-Licenses) and all definitive agreement(s) for Permitted Sales provisions permitting the Seller to audit such Licensee or Permitted Purchaser (as applicable) and shall use commercially reasonable efforts to include terms and conditions consistent in all material respects with the Buyer&#8217;s rights to audit the Seller set forth in Section 6.4.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall provide the Buyer prompt (and in any event within [***]) written notice of a Licensee&#8217;s material breach of its obligations under any Out-License or a Permitted Purchaser&#8217;s material breach of its obligations under any Permitted Sale of which any of the individuals named in the definition of &#8220;Knowledge of the Seller&#8221; (or the successors of such Person at the Seller) becomes aware.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall provide the Buyer with written notice promptly (and in any event within [***]) following the termination of any Out-License or Permitted Sale.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 6.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Restricted Indebtedness</u>. Prior to the Minimum Return Date, the Seller shall not, and shall not permit any of its Subsidiaries to, create, incur, assume or suffer to exist any Restricted Indebtedness. As a condition to the incurrence of any secured Permitted Indebtedness for borrowed money with one or more lenders other than the holders of Indebtedness under the Athyrium Credit Agreement, either (i) the Seller shall cause such lender or lenders or any agent, representative or trustee acting on behalf of such lender or lenders to become a party to the Intercreditor Agreement in accordance with the terms thereof or (ii) the Buyer shall enter, and the Seller shall enter and cause such lender or lenders or any agent, representative or trustee acting on behalf of such lender or lenders to enter into an Other Intercreditor Agreement. Notwithstanding the foregoing and except as otherwise agreed by the parties, following the Minimum Return Date, the Seller shall not, and shall not permit any of its Subsidiaries to incur any Convertible Bond Indebtedness unless such Convertible Bond Indebtedness shall be subordinated in right of payment to the Royalty Payment that are owed or may be owed in the future to the Buyer pursuant to the terms of a subordination, intercreditor, or other similar agreement (or terms of subordination incorporated into the indenture under which such Convertible Bond Indebtedness is issued), in each case in form and substance, and on terms, approved by the Buyer, the Seller, and the applicable Third Party in writing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 6.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Diligence</u>.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">39</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller shall use Commercially Reasonable Efforts to complete clinical development and Commercialize (either directly or through Licensees) (a) Orladeyo in the Direct Sales Territories for HAE, and (b) BCX9930 in the Direct Sales Territories for paroxysmal nocturnal hemoglobinuria. In furtherance of the foregoing, the Seller shall use Commercially Reasonable Efforts to prepare, execute, deliver and file any and all agreements, documents or instruments that are necessary or desirable to secure and maintain all Marketing Approvals required to Commercialize Orladeyo and BCX9930 in the Direct Sales Territories and the Seller shall use Commercially Reasonable Efforts to not withdraw or abandon, or fail to take any action necessary to prevent the withdrawal or abandonment of, any such Marketing Approvals.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On a country-by-country and Product-by-Product basis, if a Loss of Market Exclusivity has occurred in such country for such Product, the Seller&#8217;s obligations under Section 6.9(a) shall no longer apply in such country for such Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 6.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Efforts to Consummate Transactions</u>. Subject to the terms and conditions of this Agreement, each of the Seller and the Buyer will use its commercially reasonable efforts prior to the Closing to take, or cause to be taken, all actions and to do, or cause to be done, all things reasonably necessary under applicable law to consummate the transactions contemplated by this Agreement. Each of the Buyer and the Seller agrees to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary in order to consummate or implement expeditiously the transactions contemplated by this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 6.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Further Assurances</u>. After the Closing, the Seller and the Buyer agree to execute and deliver such other documents, certificates, agreements and other writings and to take such other actions as may be reasonably necessary in order to give effect to the transactions contemplated by this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 6.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Back-Up Security Interest</u>. Notwithstanding anything herein to the contrary, the Seller shall not enter into any contracts or arrangement or otherwise knowingly take any action or knowingly fail to act in a manner that would, individually or in the aggregate, reasonably be expected to materially and adversely affect the Buyer&#8217;s interest in the Revenue Participation Right or the Back-Up Security Interest. The parties agree that the entry into the Athyrium Loan Documents and any agreement evidencing any secured Indebtedness permitted by clause (b)(ii) of the definition of Restricted Indebtedness, which shall be subject to and in compliance with the Intercreditor Agreement or any Other Intercreditor Agreement, shall be deemed to not materially and adversely affect the Buyer&#8217;s interest in the Revenue Participation Right or the Back-Up Security Interest.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 6.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Tax Matters</u>.</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Seller and the Buyer agree that for Tax purposes, (a) the Seller and the Buyer shall treat the transactions contemplated by this Agreement as a sale of the Revenue Participation Right and (b) any and all amounts remitted by the Seller to the Buyer after the Closing Date pursuant to this Agreement shall be treated as received by the Seller as agent for the Buyer. The parties hereto agree not to take any position that is inconsistent with the provisions of this Section 6.13(a) on any tax return or in any audit or other tax-related administrative or judicial proceeding unless the other party hereto has consented in writing (such consent not to be unreasonably withheld, conditioned or delayed) to such actions. If there is an inquiry by any Governmental Entity of the Buyer or the Seller related to the treatment described in this Section 6.13(a), the parties hereto shall cooperate with each other in responding to such inquiry in a reasonable manner which is consistent with this Section 6.13(a).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">40</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything to the contrary in this Agreement, each of the Buyer and the Seller shall be entitled to withhold and deduct (or cause to be withheld and deducted) from any amount payable under this Agreement to the other party any Tax that the Buyer or the Seller, as applicable, determines that it is required to withhold and deduct under applicable law, and any such amount withheld and deducted shall be treated for all purposes of this Agreement as being paid to the other party; provided that each of the Buyer and the Seller shall give the other party prior notice and the opportunity, in good faith, to contest and prevent such withholding and deduction. The parties hereto shall use commercially reasonable efforts to give or cause to be given to the other party hereto such assistance and such information concerning the reasons for withholding or deduction (including, in reasonable detail, the method of calculation for the deduction or withholding thereof) as may be reasonably necessary to enable the Buyer or the Seller, as applicable, to claim exemption therefrom, or credit therefor, or relief (whether at source or by reclaim) therefrom, and, in each case, shall furnish the Buyer or the Seller, as applicable, with proper evidence of the taxes withheld and deducted and remitted to the relevant taxing authority. The Buyer agrees (i) to notify the Seller in writing if (A) Buyer becomes ineligible to use or deliver the Form W-8BEN-E delivered to the Seller under Section 5.2(e), or (B) the Form W-8BEN-E delivered to the Seller under Section 5.2(e) ceases to be accurate or complete, and (ii) to provide (to the extent it is legally eligible to do so) any additional Tax forms that the Seller may reasonably request.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE 7</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><br>
INDEMNIFICATION</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>General Indemnity</u>. From and after the Closing:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Seller hereby agrees to indemnify, defend and hold harmless the Buyer and its Affiliates and its and their directors, managers, trustees, officers, agents and employees (the &#8220;<u>Buyer Indemnified Parties</u>&#8221;) from, against and in respect of all Losses suffered or incurred by the Buyer Indemnified Parties to the extent arising out of or resulting from (i)&nbsp;any breach of any of the representations or warranties of the Seller in this Agreement, and (ii)&nbsp;any breach of any of the covenants or agreements of the Seller in this Agreement; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Buyer hereby agrees to indemnify, defend and hold harmless the Seller and its Affiliates and its and their directors, officers, agents and employees (the &#8220;<u>Seller Indemnified Parties</u>&#8221;) from, against and in respect of all Losses suffered or incurred by the Seller Indemnified Parties to the extent arising out of or resulting from (i)&nbsp;any breach of any of the representations or warranties of the Buyer in this Agreement, and (ii)&nbsp;any breach of any of the covenants or agreements of the Buyer in this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice of Claims</u>. If either a Buyer Indemnified Party, on the one hand, or a Seller Indemnified Party, on the other hand (such Buyer Indemnified Party on the one hand and such Seller Indemnified Party on the other hand being hereinafter referred to as an &#8220;<u>Indemnified Party</u>&#8221;), has suffered or incurred any Losses for which indemnification may be sought under this ARTICLE 7, the Indemnified Party shall so notify the other party from whom indemnification is sought under this ARTICLE 7 (the &#8220;<u>Indemnifying Party</u>&#8221;) promptly in writing describing such Loss, the amount or estimated amount thereof, if known or reasonably capable of estimation, and the method of computation of such Loss, all with reasonable particularity and containing a reference to the provisions of this Agreement in respect of which such Loss shall have occurred. If any claim, action, suit or proceeding is asserted or instituted by or against a Third Party with respect to which an Indemnified Party intends to claim any Loss under this ARTICLE 7, such Indemnified Party shall promptly notify the Indemnifying Party of such claim, action, suit or proceeding and tender to the Indemnifying Party the defense of such claim, action, suit or proceeding. A failure by an Indemnified Party to give notice and to tender the defense of such claim, action, suit or proceeding in a timely manner pursuant to this Section 7.2 shall not limit the obligation of the Indemnifying Party under this ARTICLE 7, except to the extent such Indemnifying Party is actually prejudiced thereby.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">41</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitations on Liability</u>(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Except for claims arising from a breach of confidentiality obligations under ARTICLE 8 or in cases of fraud, gross negligence, or willful misconduct, no party hereto shall be liable for any consequential, punitive, special or incidental damages under this ARTICLE 7 (and no claim for indemnification hereunder shall be asserted) as a result of any breach or violation of any covenant or agreement of such party (including under this ARTICLE 7) in or pursuant to this Agreement. In connection with the foregoing, the parties hereto acknowledge and agree that (i) the Buyer&#8217;s damages, if any, for any such action or claim will typically include Losses for Royalty Payments that the Buyer was entitled to receive in respect of its ownership of the Royalty Payments but did not receive timely or at all due to such indemnifiable event and (ii) the Buyer shall be entitled to make claims for all such missing or delayed Royalty Payments as Losses hereunder, and such missing or Royalty Payments shall not be deemed consequential, punitive, special, indirect or incidental damages</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exclusive Remedy</u>. Except as set forth in Section 10.11, from and after Closing, the rights of the parties hereto pursuant to (and subject to the conditions of) this ARTICLE 7 shall be the sole and exclusive remedy of the parties hereto and their respective Affiliates with respect to any Losses (whether based in contract, tort or otherwise) resulting from or relating to any breach of the representations, warranties covenants and agreements made under this Agreement or any certificate, document or instrument delivered hereunder, and each party hereto hereby waives, to the fullest extent permitted under applicable law, and agrees not to assert after Closing, any other claim or action in respect of any such breach. Notwithstanding the foregoing, claims for fraud, gross negligence, or willful misconduct shall not be waived or limited in any way by this ARTICLE 7.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Tax Treatment of Indemnification Payments</u>. For all purposes hereunder, any indemnification payments made pursuant to this ARTICLE 7 will be treated as an adjustment to the Purchase Price for U.S. federal income tax to the fullest extent permitted by applicable law.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">42</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE 8</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><br>
CONFIDENTIALITY</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Confidentiality</u>. Except as provided in this ARTICLE 8, Section 10.4 or otherwise agreed in writing by the parties, the parties hereto agree that, during the term of this Agreement and for [***] years thereafter, each party (the &#8220;<u>Receiving Party</u>&#8221;) shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of any rights or the performance of any obligations hereunder) any information furnished to it by or on behalf of the other party (the &#8220;<u>Disclosing Party</u>&#8221;) pursuant to this Agreement (such information, &#8220;<u>Confidential Information</u>&#8221; of the Disclosing Party), except for that portion of such information that:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;was already known to the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the Disclosing Party;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;became generally available to the public or otherwise part of the public domain after its disclosure and other than through any act or omission of the Receiving Party in breach of this Agreement or any other agreement;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is independently developed by the Receiving Party or any of its Affiliates, as evidenced by written records, without the use of or reference of the Confidential Information; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;is subsequently disclosed to the Receiving Party on a non-confidential basis by a Third Party without obligations of confidentiality with respect thereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 8.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorized Disclosure</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Either party may disclose Confidential Information to the extent such disclosure is reasonably necessary in the following situations:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;prosecuting or defending litigation;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;complying with applicable laws and regulations, including regulations promulgated by securities exchanges;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;complying with a valid order of a court of competent jurisdiction or other Governmental Entity;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for regulatory, Tax or customs purposes;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;for audit purposes, provided that each recipient of Confidential Information must be bound by customary and reasonable obligations of confidentiality and non-use prior to any such disclosure;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">43</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosure to its Affiliates and Representatives on a need-to-know basis, provided that each such recipient of Confidential Information must be bound by contractual or professional obligations of confidentiality and non-use at least as stringent as those imposed upon the parties hereunder prior to any such disclosure;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;upon the prior written consent of the Disclosing Party;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;disclosure to its potential investors, and other sources of funding, including debt financing, or potential partners, collaborators or acquirers, and their respective accountants, financial advisors and other professional representatives, provided, that such disclosure shall be made only to the extent customarily required to consummate such investment, financing transaction partnership, collaboration or acquisition and that each recipient of Confidential Information must be bound by customary obligations of confidentiality and non-use prior to any such disclosure;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:36pt;">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as is necessary in connection with a permitted assignment pursuant to Section 10.4.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding the foregoing, in the event the Receiving Party is required to make a disclosure of the Disclosing Party&#8217;s Confidential Information pursuant to Section 8.2(a)(i), (ii), (iii) or (iv), it will, except where impracticable, give reasonable advance notice to the Disclosing Party of such disclosure and use reasonable efforts to secure confidential treatment of such information. In any event, the Buyer shall not file any patent application based upon or using the Confidential Information of Seller provided hereunder.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything set forth in this Agreement, materials and documentation relating to the Seller&#8217;s Intellectual Property Rights may be only disclosed to or accessed by the Buyer and its attorneys and auditors, without further disclosure to any other Representative of the Buyer.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE 9</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><br>
TERMINATION</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Mutual </u><u>Termination</u>. This Agreement may be terminated by mutual written agreement of the Buyer and the Seller.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Automatic Termination</u>. Unless earlier terminated as provided in Section 9.1, following the Closing, this Agreement shall continue in full force and effect until sixty (60) days after such time as the Seller is no longer obligated to make any Royalty Payments under this Agreement, at which point this Agreement shall automatically terminate, except with respect to any rights that shall have accrued prior to such termination.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Survival</u>. Notwithstanding anything to the contrary in this ARTICLE 9, the following provisions shall survive termination of this Agreement: Section 6.3 (Disclosures), ARTICLE 7 (Indemnification), ARTICLE 8 (Confidentiality), this Section 9.3 (Survival) and ARTICLE 10 (Miscellaneous). Termination of the Agreement shall not relieve any party of liability in respect of breaches under this Agreement by any party on or prior to termination.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">44</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">ARTICLE 10</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><br>
MISCELLANEOUS</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Headings</u>. The table of contents and the descriptive headings of the several Articles and Sections of this Agreement and the Exhibits and Schedules are for convenience only, do not constitute a part of this Agreement and shall not control or affect, in any way, the meaning or interpretation of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. All notices and other communications under this Agreement shall be in writing and shall be by email with PDF attachment, facsimile, courier service or personal delivery to the following addresses, or to such other addresses as shall be designated from time to time by a party hereto in accordance with this Section 10.2:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;">If to the Seller, to it at:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">BioCryst Pharmaceuticals, Inc.</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">4505 Emperor Blvd., Suite 200</p>

<p style="background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">Durham, North Carolina 27703</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">Attention: Alane Barnes</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">E-mail: [***]</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;">with a copy to:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">Gibson, Dunn &amp; Crutcher LLP</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">555 Mission Street</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">San Francisco, CA 94105</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">Attention: Ryan Murr</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">E-mail: rmurr@gibsondunn.com</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;">If to the Buyer, to it at:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:36pt;margin-top:0pt;text-align:left;">RPI 2019 Intermediate Finance Trust</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:36pt;margin-top:0pt;text-align:left;">110 E. 59th Street, Suite 3300</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">New York, New York 0022</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">Attention: George Lloyd<i> </i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">Email: [***]</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;">with a copy to:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">Goodwin Procter LLP<br>
100 Northern Avenue<br>
Boston, Massachusetts 02210</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">Attention: Arthur R. McGivern &amp; Jacqueline Mercier</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:90pt;margin-right:0pt;margin-top:0pt;text-align:left;">Email: amcgivern@goodwinlaw.com &amp; jmercier@goodwinlaw.com</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">45</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">All notices and communications under this Agreement shall be deemed to have been duly given (i)&nbsp;when delivered by hand, if personally delivered, (ii)&nbsp;when sent, if sent by facsimile, with an acknowledgement of sending being produced by the sending facsimile machine, (iii) when sent, if by email with PDF attachment, with an acknowledgement of receipt being produced by the recipient&#8217;s email account, or (iv)&nbsp;one Business Day following sending within the United States by overnight delivery via commercial one-day overnight courier service.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Expenses</u>. Except as otherwise provided herein, all fees, costs and expenses (including any legal, accounting and banking fees) incurred in connection with the preparation, negotiation, execution and delivery of this Agreement and to consummate the transactions contemplated hereby shall be paid by the party hereto incurring such fees, costs and expenses.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 10.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Assignment</u>. The Seller may not assign in whole or in part this Agreement, any of its rights or obligations hereunder, or any of its rights in a Product, including any Product Rights, without the Buyer&#8217;s prior written consent, except (a) for a Permitted Sale; or (b) to a Third Party in connection with the sale or transfer of all or substantially all of the Seller&#8217;s business or assets related to a Product, whether by merger, sale of assets, reorganization, or other conveyance of title and only if upon closing any such transaction, the Seller causes such Affiliate or Third Party, as applicable, to deliver a writing to the Buyer in which it assumes all of the obligations of the Seller to the Buyer under this Agreement, and such Affiliate or Third Party shall be deemed an assignee of Seller under this Agreement; provided that, for the avoidance of doubt, nothing in this Section 10.4 shall restrict the Sellers from engaging in a Permitted Sale, from licensing any Product Rights pursuant to a Permitted License, from transferring the Marketing Approvals for any jurisdiction to a Licensee or a Permitted Purchaser in connection with a Permitted License or Permitted Sale covering such jurisdiction, or incurring any Permitted Indebtedness.&nbsp; Following the Closing, the Buyer may assign this Agreement in whole or in part to any Person, including to any Third Party or to one or more of its Affiliates; provided that the Buyer shall cause such Person to become a party to the Intercreditor Agreement in accordance with the terms thereof or enter into an intercreditor agreement with the administrative agent, trustee or representative under the Athyrium Credit Agreement in form and substance substantially the same as the Intercreditor Agreement. This Agreement shall be binding upon, inure to the benefit of and be enforceable by, the parties hereto and their respective permitted successors and assigns.&nbsp; Any purported assignment in violation of this Section 10.4 shall be null and void. Notwithstanding the foregoing, nothing in this Agreement shall prohibit Athyrium or the administrative agent, trustee or representative under the Athyrium Credit Agreement at such time from taking any action permitted by the Intercreditor Agreement or an Other Intercreditor Agreement, including but not limited to commencing or maintaining any Enforcement Action (as defined in the Intercreditor Agreement) or such similar term (as defined in an Other Intercreditor Agreement) or exercising any rights with respect to its collateral under the Bankruptcy Laws.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">46</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 10.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendment and Waiver</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Agreement may be amended, modified or supplemented only in a writing signed by each of the parties hereto. Any provision of this Agreement may be waived only in a writing signed by the party hereto granting such waiver.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No failure or delay on the part of any party hereto in exercising any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right, power or remedy. No course of dealing between the parties hereto shall be effective to amend, modify, supplement or waive any provision of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 10.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Entire Agreement</u>. This Agreement, the Exhibits annexed hereto and the Disclosure Schedule constitute the entire understanding between the parties hereto with respect to the subject matter hereof and supersede all other understandings and negotiations with respect thereto. As of the date hereof, the Non-Disclosure Agreement between RP Management, LLC and the Seller, dated as of [***] is hereby terminated without further force and effect, superseded by ARTICLE 8 of this Agreement and all obligations between the parties relating to confidentiality shall be governed by ARTICLE 8 of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 10.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Third Party Beneficiaries</u>. This Agreement is for the sole benefit of the Seller and the Buyer and their permitted successors and assigns and nothing herein expressed or implied shall give or be construed to give to any Person, other than the parties hereto and such successors and assigns, any legal or equitable rights hereunder, except that the Indemnified Parties shall be third party beneficiaries of the benefits provided for in Section 7.1.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 10.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law</u>. This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any other jurisdiction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 10.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Jurisdiction; Venue</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS RESPECTIVE PROPERTY AND ASSETS, TO THE EXCLUSIVE JURISDICTION OF ANY NEW YORK STATE COURT OR FEDERAL COURT OF THE UNITED STATES OF AMERICA SITTING IN NEW YORK COUNTY, NEW YORK, AND ANY APPELLATE COURT THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, OR FOR RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT IN RESPECT THEREOF, AND THE BUYER AND THE SELLER HEREBY IRREVOCABLY AND UNCONDITIONALLY AGREE THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN ANY SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. THE BUYER AND THE SELLER HEREBY AGREE THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY APPLICABLE LAW. EACH OF THE BUYER AND THE SELLER HEREBY SUBMITS TO THE EXCLUSIVE PERSONAL JURISDICTION AND VENUE OF SUCH NEW YORK STATE AND FEDERAL COURTS. THE BUYER AND THE SELLER AGREE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THAT PROCESS MAY BE SERVED ON THE BUYER OR THE SELLER IN THE SAME MANNER THAT NOTICES MAY BE GIVEN PURSUANT TO SECTION&nbsp;10.2 HEREOF.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">47</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT MAY LEGALLY AND EFFECTIVELY DO SO, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT IN ANY NEW YORK STATE OR FEDERAL COURT. EACH OF THE BUYER AND THE SELLER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;text-transform:uppercase;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Party hereby jointly and severally waives any and all right to trial by jury in any action or proceeding relating to this Agreement or any other document delivered hereunder or in connection herewith, or any transaction arising from or connected to any of the foregoing. Each of the Parties represents that this waiver is knowingly, willingly, and voluntarily given.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 10.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. If any term or provision of this Agreement shall for any reason be held to be invalid, illegal or unenforceable in any situation in any jurisdiction, then, to the extent that the economic and legal substance of the transactions contemplated hereby is not affected in a manner that is materially adverse to either party hereto, all other terms and provisions of this Agreement shall nevertheless remain in full force and effect and the enforceability and validity of the offending term or provision shall not be affected in any other situation or jurisdiction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 10.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Specific Performance</u>. Each of the parties acknowledges and agrees that the other party would be damaged irreparably in the event any of the provisions of this Agreement are not performed in accordance with their specific terms or otherwise are breached or violated. Accordingly, each of the parties agrees that, without posting bond or other undertaking, the other party will be entitled to seek an injunction or injunctions to prevent breaches or violations of the provisions of this Agreement and to seek to enforce specifically this Agreement and the terms and provisions hereof in any action, suit or other proceeding instituted in any court of the United States or any state thereof having jurisdiction over the parties and the matter in addition to any other remedy to which it may be entitled, at law or in equity. Each of the parties further agrees that, in the event of any action for specific performance in respect of such breach of violation, it will not assert the defense that a remedy at law would be adequate.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 10.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Counterparts</u>. This Agreement may be executed in any number of counterparts and by the parties hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Copies of executed counterparts transmitted by telecopy, facsimile or other similar means of electronic transmission, including &#8220;PDF,&#8221; shall be considered original executed counterparts, provided receipt of such counterparts is confirmed.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">48</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 10.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Relationship of the Parties</u>. The relationship between the Buyer and the Seller is solely that of purchaser and seller, and neither the Buyer nor the Seller has any fiduciary or other special relationship with the other party or any of its Affiliates. This Agreement is not a partnership or similar agreement, and nothing contained herein shall be deemed to constitute the Buyer and the Seller as a partnership, an association, a joint venture or any other kind of entity or legal form for any purposes, including any Tax purposes. The Buyer and the Seller agree that they shall not take any inconsistent position with respect to such treatment in a filing with any Governmental Entity.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 10.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Intercreditor Agreement</u>. Notwithstanding anything to the contrary herein, the Liens and Back-Up Security Interest granted to the Buyer and its successors and assigns pursuant to this Agreement and the exercise of any right or remedy by the Buyer and its successors and assigns hereunder are subject to the provisions of the Intercreditor Agreement and the provisions of any Other Intercreditor Agreement.&nbsp; If there is conflict between the terms of the Intercreditor Agreement or an Other Intercreditor Agreement (each a &#8220;<u>Controlling Agreement</u>&#8221;), on the one hand, and the terms of this Agreement, on the other hand, with respect to the Liens, security interests or the exercise of any right or remedy of the Buyer or any holder of any Indebtedness that is a party to a Controlling Agreement, then the terms of such Controlling Agreement will control.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:72pt;">Section 10.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Trustee Capacity of Wilmington Trust</u><u>, National Association</u>. Notwithstanding anything contained herein to the contrary, it is expressly understood and agreed by the parties hereto that (i) this Agreement is executed and delivered by Wilmington Trust, National Association, not individually or personally but solely in its trustee capacity, in the exercise of the powers and authority conferred and vested in it under the trust agreement of the Buyer, (ii) each of the representations, undertakings and agreements herein made on the part of the Buyer is made and intended not as a personal representation, undertaking and agreement by Wilmington Trust, National Association, but is made and intended for the purpose of binding only the Buyer and, (iii) nothing herein contained shall be construed as creating any liability on Wilmington Trust, National Association, individually or personally, to perform any covenant either expressed or implied contained herein, all such liability, if any, being expressly waived by the parties hereto and by any Person claiming by, through or under the parties hereto, (iv) Wilmington Trust, National Association has made no investigation as to the accuracy or completeness of any representations and warranties made by the Buyer in this Agreement, and (v) under no circumstances shall Wilmington Trust, National Association be personally liable for the payment of any indebtedness or expenses of the Buyer or be liable for the breach or failure of any obligation, representation, warranty or covenant made or undertaken by the Buyer under this Agreement or any related documents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><i>[Signature Page Follows]</i></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">49</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed and delivered by their respective representatives thereunto duly authorized as of the date first above written.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.55pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-6.55pt;">SELLER</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">BIOCRYST PHARMACEUTICALS, INC.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Anthony Doyle</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name: Anthony Doyle</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title: Chief Financial Officer</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:6.55pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-6.55pt;">BUYER</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">RPI 2019 INTERMEDIATE FINANCE TRUST</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Wilmington Trust, National Association, not in its individual capacity but solely in its capacity as owner trustee</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">By:</p>
			</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Cynthia L. Major</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name: Cynthia L. Major</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Title: Banking Officer</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 35%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">[Signature Page to Purchase and Sale Agreement]</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">50</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.92
<SEQUENCE>14
<FILENAME>ex_230719.htm
<DESCRIPTION>EXHIBIT 10.92
<TEXT>
<html><head>
	<title>ex_230719.htm</title>
	<!-- Generated by ThunderDome Portal - 2/28/2021 1:22:56 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;"><b>Exhibit 10.92</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>Certain information has been omitted from this exhibit in places marked &#8220;[***]&#8221; because it is both not material and would likely cause competitive harm to the registrant if publicly disclosed or because it contains personally identifiable information omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K.</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">CREDIT AGREEMENT</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Dated as of December 7, 2020</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">among</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">BIOCRYST PHARMACEUTICALS, INC.,<br>
as the Borrower,</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">BIOCRYST IRELAND LIMITED</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">as a Guarantor</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">The other Guarantors from time to time party hereto,</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">The Lenders from time to time party hereto<br>
<br>
and<br>
<br>
ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP,<br>
as Administrative Agent</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;text-transform:uppercase;"><b>&nbsp;</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>TABLE OF CONTENTS</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><u><b>Page</b></u></p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td colspan="2" style="vertical-align:middle;width:96.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="text-transform:uppercase;">Article </font>I DEFINITIONS AND ACCOUNTING TERMS</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">1</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">1.01&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Defined Terms</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">1</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">1.02&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Other Interpretive Provisions</p>
			</td>
			<td style="vertical-align: middle; width: 3.4%; text-align: right;">39</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">1.03&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Accounting Terms</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">40</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">1.04&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Times of Day</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">41</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">1.05&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">LIBOR Determinations</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">41</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:96.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="text-transform:uppercase;">Article </font>II THE COMMITMENTS</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">41</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">2.01&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Commitments.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">41</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">2.02&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Borrowings.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">42</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">2.03&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Prepayments</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">42</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">2.04&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Termination of Commitments</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">46</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">2.05&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Repayment of Loans</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">46</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">2.06&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Interest; Other Amounts</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">46</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">2.07&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Fees</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">47</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">2.08&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Evidence of Debt</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">47</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">2.09&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Computation of Interest</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">48</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">2.10&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Payments Generally</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">48</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">2.11&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Sharing of Payments by Lenders</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">48</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">2.12&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Defaulting Lenders.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">49</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:96.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="text-transform:uppercase;">Article III TAXES</font></p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">50</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">3.01&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Taxes</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">50</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">3.02&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Survival</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">52</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:96.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="text-transform:uppercase;">Article IV GUARANTY</font></p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">52</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">4.01&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Guaranty</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">52</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">4.02&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Obligations Unconditional</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">53</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">4.03&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Reinstatement</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">53</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">4.04&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Certain Additional Waivers</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">54</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">4.05&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Remedies</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">54</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">4.06&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Rights of Contribution</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">54</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">4.07&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Guarantee of Payment; Continuing Guarantee</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">54</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">4.08&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Limitations.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">54</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">4.09&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Guarantor Intent</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">54</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:96.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="text-transform:uppercase;">Article V CONDITIONS PRECEDENT TO BORROWINGS</font></p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">55</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">5.01&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Conditions to Initial Borrowing</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">55</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">5.02&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Conditions to all Borrowings</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">58</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:96.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="text-transform:uppercase;">Article VI REPRESENTATIONS AND WARRANTIES</font></p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">59</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.01&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Existence, Qualification and Power</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">59</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.02&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Authorization; No Contravention</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">59</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.03&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Governmental Authorization; Other Consents</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">59</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.04&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Binding Effect</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">60</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.05&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial Statements; No Material Adverse Effect</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">60</p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">i</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.06&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Litigation</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">61</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.07&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">No Default</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">61</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.08&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Ownership of Property; Liens</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">61</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.09&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Environmental Compliance</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">61</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.10&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Insurance</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">62</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.11&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Taxes</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">62</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.12&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ERISA Compliance</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">63</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.13&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Subsidiaries and Capitalization; Management Fees</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">63</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.14&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Margin Regulations; Investment Company Act</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">64</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.15&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Disclosure</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">64</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.16&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Compliance with Laws</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">65</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.17&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Intellectual Property; Licenses, Etc.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">65</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.18&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Solvency</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">67</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.19&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Perfection of Security Interests in the Collateral</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">67</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.20&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Business Locations</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">67</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.21&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Sanctions Concerns; Anti-Corruption Laws; PATRIOT Act</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">67</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.22&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Material Contracts</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">68</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.23&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Regulatory Compliance.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">68</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.24&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Labor Matters</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">73</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.25&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Affected Financial Institution</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">73</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.26&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Ranking of Loans</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">73</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.27&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Consummation of the Royalty Financing</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">73</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.28&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Regulation H</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">73</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.29&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Data Privacy.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">73</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.30&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Centre of Main Interests and Establishments.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">74</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.31&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">JPR Royalty Sub.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">74</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.32&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Royalty and Other Payments.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">74</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">6.33&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Non-Competes.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">74</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:96.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="text-transform:uppercase;">Article VII AFFIRMATIVE COVENANTS</font></p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">75</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.01&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Financial Statements; Lender Calls</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">75</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.02&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Certificates; Other Information</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">75</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.03&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Notices</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">78</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.04&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Payment of Obligations</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">80</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.05&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Preservation of Existence, Etc.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">80</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.06&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Maintenance of Properties</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">80</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.07&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Maintenance of Insurance</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">80</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.08&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Compliance with Laws</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">81</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.09&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Books and Records</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">81</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.10&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Inspection Rights</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">81</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.11&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Use of Proceeds</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">82</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.12&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Additional Subsidiaries</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">82</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.13&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">ERISA Compliance</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">82</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.14&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Pledged Assets</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">82</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.15&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Compliance with Material Contracts</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">83</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.16&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Deposit Accounts</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">83</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.17&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Regulatory Compliance</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">84</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.18&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Intellectual Property; Consent of Licensors</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">86</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.19&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Anti-Corruption Laws</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">86</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.20&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Post-Closing Obligations</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">86</p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">ii</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.21&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">JPR Royalty Sub - Indenture.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">86</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.22&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Restrictions on Cash</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">87</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">7.23&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">People with Significant Control Regime</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">88</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:96.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="text-transform:uppercase;">Article VIII NEGATIVE COVENANTS</font></p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">88</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.01&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Liens</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">88</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.02&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Investments</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">90</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.03&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Indebtedness</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">90</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.04&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Fundamental Changes</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">91</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.05&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Dispositions</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">92</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.06&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Restricted Payments</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">92</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.07&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Change in Nature of Business</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">93</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.08&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Transactions with Affiliates and Insiders</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">93</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.09&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Burdensome Agreements</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">93</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.10&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Use of Proceeds</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">94</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.11&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Prepayment of Other Indebtedness</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">94</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.12&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Organization Documents; Fiscal Year; Legal Name, Jurisdiction of Formation and Form of Entity; Certain Amendments</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">94</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.13&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Ownership of Subsidiaries</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">95</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.14&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Sale Leasebacks</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">95</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.15&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Sanctions; Anti-Corruption Laws</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">95</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.16&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Minimum Liquidity.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">95</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.17&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Minimum Orladeyo Consolidated U.S. Net Product Sales</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">96</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">8.18&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">MDCP.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">96</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:96.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="text-transform:uppercase;">Article IX EVENTS OF DEFAULT AND REMEDIES</font></p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">96</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">9.01&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Events of Default</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">96</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">9.02&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Remedies Upon Event of Default</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">100</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">9.03&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Application of Funds</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">101</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">9.04&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Cure Right</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">101</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:96.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="text-transform:uppercase;">Article X INCREASED COSTS AND INABILITY TO DETERMINE RATES</font></p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">102</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">10.01&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Increased Costs, Etc.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">102</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">10.02&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Mitigation Obligations; Replacement of Lenders.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">103</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">10.03&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Inability to Determine Rates</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">103</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">10.04&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Illegality</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">107</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">10.05&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Survival</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">107</p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="vertical-align:middle;width:96.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="text-transform:uppercase;">Article XI ADMINISTRATIVE AGENT</font></p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">107</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">11.01&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Appointment and Authority</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">107</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">11.02&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Rights as a Lender</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">108</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">11.03&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Exculpatory Provisions</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">108</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">11.04&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Reliance by Administrative Agent</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">109</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">11.05&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Delegation of Duties</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">109</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">11.06&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Resignation of Administrative Agent</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">109</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">11.07&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Non-Reliance on Administrative Agent and Other Lenders</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">110</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">11.08&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Administrative Agent May File Proofs of Claim</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">110</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">11.09&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Collateral and Guaranty Matters</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">111</p>
			</td>
		</tr>

</table>

<p style="margin: 0; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">iii</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td colspan="2" style="vertical-align:middle;width:96.6%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><font style="text-transform:uppercase;">Article XII MISCELLANEOUS</font></p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">112</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.01&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Amendments, Etc.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">112</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.02&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Notices and Other Communications; Facsimile Copies</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">113</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.03&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">No Waiver; Cumulative Remedies; Enforcement</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">115</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.04&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Expenses; Indemnity; and Damage Waiver</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">115</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.05&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Marshalling; Payments Set Aside</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">117</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.06&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Successors and Assigns; Transfers</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">117</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.07&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Treatment of Certain Information; Confidentiality</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">120</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.08&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Set-off</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">121</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.09&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Interest Rate Limitation</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">122</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.10&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Counterparts; Integration; Effectiveness</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">122</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.11&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Survival of Representations and Warranties</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">122</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.12&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Severability</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">122</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.13&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Replacement of Lenders.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">123</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.14&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Governing Law; Jurisdiction; Etc.</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">123</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.15&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Waiver of Right to Trial by Jury</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">124</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.16&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Judgment Currency</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">125</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.17&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Electronic Execution of Assignments and Certain Other Documents</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">125</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.18&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">USA PATRIOT Act</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">126</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.19&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">No Advisory or Fiduciary Relationship</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">126</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.20&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Acknowledgement and Consent to Bail-In of EEA Financial Institutions</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">126</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.21&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Publicity</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">127</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:6.7%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">12.22&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td style="vertical-align:middle;width:89.9%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Conflicts</p>
			</td>
			<td style="vertical-align:middle;width:3.4%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">127</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">SCHEDULES</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">1.01</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Products, Services and Facilities</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">2.01</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Commitments and Applicable Percentages</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">6.10</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Insurance</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">6.13(a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Subsidiaries</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">6.13(b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Capitalization</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">6.17</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">IP Rights</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">6.20(a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Locations of Real Property</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">6.20(b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Taxpayer and Organizational Identification Numbers</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">6.20(c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Changes in Legal Name, State of Organization and Structure</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">6.22</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Material Contracts</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">6.23</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Regulatory Compliance</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">6.32</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Royalty and Other Payments</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">7.20</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Post-Closing Obligations</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">8.01</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Liens Existing on the Closing Date</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">8.02</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Investments Existing on the Closing Date</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">8.03</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Indebtedness Existing on the Closing Date</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">12.02</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Certain Addresses for Notices</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">iv</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">EXHIBITS</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">A</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Form of Loan Notice</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">B-1</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Form of Term A Note</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">B-2</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Form of Term B Note</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">B-3</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Form of Term C Note</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">C</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Form of Assignment and Assumption</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">D</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Form of Compliance Certificate</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">E</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Form of Joinder Agreement</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:72pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">F</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Form of Orladeyo Label</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-72pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-72pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-72pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-72pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-72pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-72pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-72pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-72pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:108pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-72pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">v</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>CREDIT AGREEMENT</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">This CREDIT AGREEMENT is entered into as of December 7, 2020 among BIOCRYST PHARMACEUTICALS, INC., a Delaware corporation (the &#8220;<u>Borrower</u>&#8221;), the Guarantors (defined herein) listed on the signature pages hereto and from time to time party hereto, the Lenders (defined herein) from time to time party hereto and ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP, a Delaware limited partnership, as Administrative Agent for the Lenders (each as defined below).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Borrower has requested that the Lenders make an investment in the Borrower in the form of term loan facilities and the Lenders are willing to do so on the terms and conditions set forth herein.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">In consideration of the mutual covenants and agreements herein contained, the parties hereto covenant and agree as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="text-transform:uppercase;">Article </font>I&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<br>
<br>
DEFINITIONS AND ACCOUNTING TERMS</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">1.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Defined Terms</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">As used in this Agreement, the following terms shall have the meanings set forth below:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Accrediting Organization</u>&#8221; means any Person from which any Loan Party or Subsidiary has received an accreditation as of the Closing Date or thereafter.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Acquisition</u>&#8221; means, with respect to any Person, (a) the acquisition by such Person, in a single transaction or in a series of related transactions, of (i) assets of another person which constitute all or substantially all of the assets of such Person, or of any division, line of business or other business unit of such Person or (ii) at least a majority of the Voting Stock of another Person or (b) a Product Acquisition, in each case whether or not involving a merger, amalgamation or consolidation with such other Person and whether for cash, property, services, assumption of Indebtedness, securities or otherwise.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Administrative Agent</u>&#8221; means Athyrium Opportunities III Co-Invest 1 LP, a Delaware limited partnership, in its capacity as administrative agent under any of the Loan Documents, or any successor administrative agent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Administrative Agent&#8217;s Office</u>&#8221; means the Administrative Agent&#8217;s address and, as appropriate, account as set forth on <u>Schedule 12.02</u> or such other address or account as the Administrative Agent may from time to time notify the Borrower and the Lenders.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Affected Financial Institution</u>&#8221; means (a) any EEA Financial Institution or (b) UK Financial Institution.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Affiliate</u>&#8221; means, with respect to a specified Person, (a) another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified and (b) other than with respect to any Lender and the Administrative Agent,&nbsp;any manager, officer or director of such Person.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Agreement</u>&#8221; means this Credit Agreement.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Applicable Percentage</u>&#8221; means with respect to any Lender at any time, (a) in respect of the Term A Facility, with respect to any Term A Lender at any time, the percentage (carried out to the ninth decimal place) of the Term A Facility represented by (i) at any time during the Term A Availability Period, such Term A Lender&#8217;s Term A Commitment at such time and (ii) thereafter, the outstanding principal amount of such Term A Lender&#8217;s Term A Loans at such time, (b) in respect of the Term B Facility, with respect to any Term B Lender at such time, the percentage (carried out to the ninth decimal place) of the Term B Facility represented by (i) at any time during the Term B Availability Period, such Term B Lender&#8217;s Term B Commitment at such time and (ii) at any time thereafter, the outstanding principal amount of such Term B Lender&#8217;s Term B Loans at such time and (c) in respect of the Term C Facility, with respect to any Term C Lender at such time, the percentage (carried out to the ninth decimal place) of the Term C Facility represented by (i) at any time during the Term C Availability Period, such Term C Lender&#8217;s Term C Commitment at such time and (ii) at any time thereafter, the outstanding principal amount of such Term C Lender&#8217;s Term C Loans at such time. The initial Applicable Percentage of each Lender in respect of each Facility is set forth opposite the name of such Lender on <u>Schedule 2.01</u> or in the Assignment and Assumption pursuant to which such Lender becomes a party hereto, as applicable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Appropriate Lender</u>&#8221; means, at any time, with respect to any Facility, a Lender that has a Commitment with respect to such Facility or holds a Loan under such Facility at such time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Approved Fund</u>&#8221; means any Fund that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Assignment and Assumption</u>&#8221; means an assignment and assumption agreement entered into by a Lender and an Eligible Assignee (with the consent of any party whose consent is required by <u>Section 12.06(b)</u>, and accepted by the Administrative Agent), in substantially the form of <u>Exhibit C</u> hereto or any other form (including electronic documentation generated by MarkitClear or other electronic platform) approved by the Administrative Agent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Athyrium</u>&#8221; means Athyrium Capital Management, LP and its successors and assigns.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Attributable Indebtedness</u>&#8221; means, on any date, (a) in respect of any Capital Lease of any Person, the capitalized amount thereof that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP, (b) in respect of any Synthetic Lease of any Person, the capitalized amount of the remaining lease payments under the relevant lease that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP if such lease were accounted for as a Capital Lease and (c) in respect of any Securitization Transaction of any Person, the outstanding principal amount of such financing, after taking into account reserve accounts and making appropriate adjustments, determined by the Administrative Agent in its reasonable judgment.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Audited Financial Statements</u>&#8221; means the audited consolidated balance sheet of the Borrower and its Subsidiaries for the fiscal year of the Borrower ended December 31, 2019, and the related consolidated statements of income or operations, shareholders&#8217; equity and cash flows of the Borrower and its Subsidiaries for such fiscal year, including the notes thereto, audited by independent public accountants of recognized national standing and prepared in conformity with GAAP.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Back-Up Security Interest</u>&#8221; means the &#8220;Back-Up Security Interest&#8221; as such term is defined in the Royalty Financing Agreement as in effect on the date hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Bail-In Action</u>&#8221; means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Bail-In Legislation</u>&#8221; means, with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law, rule, regulation or requirement for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, Part I of the United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or insolvency proceedings).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>BCX9930</u>&#8221; means the molecule described in investigational new drug application (IND) 142,217 filed with the FDA and in analogous filings in jurisdictions outside the United States and referenced by the Borrower as &#8220;BCX9930&#8221;.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>BCX9930 Product Family</u>&#8221; means (a) BCX9930, [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>BCX9930 Net Product Sales</u>&#8221; means, for any period, consolidated net revenues of the Borrower and its Subsidiaries from sales of the BCX9930 Product Family in any jurisdiction for such period, all as determined and reported in accordance with GAAP.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Board of Directors</u>&#8221; means (a) with respect to a corporation, the board of directors of the corporation or any committee thereof duly authorized to act on behalf of such board, (b) with respect to a partnership, the Board of Directors of the general partner of the partnership, (c) with respect to a limited liability company, the managing member or members or any controlling committee of managing members thereof, and (d) with respect to any other Person, the board or committee of such Person serving a similar function.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Borrower</u>&#8221; has the meaning set forth in the introductory paragraph hereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Borrowing</u>&#8221; means a Term A Borrowing, a Term B Borrowing or a Term C Borrowing, as the context may require.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Business Day</u>&#8221; means any day other than a Saturday, Sunday or other day on which commercial banks are authorized to close under the Laws of, or are in fact closed in, New York, New York.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Businesses</u>&#8221; means, at any time, a collective reference to the businesses operated by the Borrower and its Subsidiaries at such time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Buyer</u>&#8221; means the &#8220;Buyer&#8221; as such term is defined in the Royalty Financing Agreement as in effect on the date hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Capital Lease</u>&#8221; means, as applied to any Person, any lease of any property by that Person as lessee which, in accordance with GAAP, is required to be accounted for as a capital lease on the balance sheet of that Person.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Cash Equivalents</u>&#8221; means, as at any date, (a) securities issued or directly and fully guaranteed or insured by the United States or any agency or instrumentality thereof (<u>provided</u>, <u>that</u>, the full faith and credit of the United States is pledged in support thereof) having maturities of not more than twelve months from the date of acquisition, (b) Dollar denominated time deposits and certificates of deposit of (i)&nbsp;any United States commercial bank of recognized standing having capital and surplus in excess of $[***] or (ii) any bank whose short-term commercial paper rating from S&amp;P is at least A-1 or the equivalent thereof or from Moody&#8217;s is at least P-1 or the equivalent thereof (any such bank being an &#8220;<u>Approved Bank</u>&#8221;), in each case with maturities of not more than 270 days from the date of acquisition, (c) commercial paper and variable or fixed rate notes issued by any Approved Bank (or by the parent company thereof) or any variable or fixed rate notes issued by, or guaranteed by, any domestic corporation rated A-1 (or the equivalent thereof) or better by S&amp;P or P-1 (or the equivalent thereof) or better by Moody&#8217;s and maturing within six months of the date of acquisition, (d) repurchase agreements entered into by any Person with a bank or trust company (including any of the Lenders) or recognized securities dealer having capital and surplus in excess of $[***] for direct obligations issued by or fully guaranteed by the United States in which such Person shall have a perfected first priority security interest (subject to no other Liens) and having, on the date of purchase thereof, a fair market value of at least 100% of the amount of the repurchase obligations, and (e) Investments, classified in accordance with GAAP as current assets, in money market investment programs registered under the Investment Company Act of 1940, which are administered by reputable financial institutions having capital of at least $[***] and the portfolios of which are limited to Investments of the character described in the foregoing subdivisions (a)&nbsp;through (d).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#8220;<u>Cash Pay Election</u>&#8221; shall have the meaning set forth in <u>Section 2.</u><u>06</u><u>(d)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>cGCP</u>&#8221; means the then current Good Clinical Practices that establish the international ethical and scientific quality standards for designing, conducting, recording and reporting clinical trials that are promulgated or endorsed for the United States by the FDA (including through ICH E6 and 21 CFR Parts&nbsp;50, 54, 56 and 312) and for outside the United States by comparable Governmental Authorities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>cGLP</u>&#8221; means the then current Good Laboratory Practices that establish the international ethical and scientific quality standards for designing, conducting, recording and reporting non-clinical and laboratory testing that are promulgated or endorsed for the United States by the FDA and for outside the United States by comparable Governmental Authorities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>cGMP</u>&#8221; means the then current Good Manufacturing Practice for drugs and biologics (including the regulations for drugs and finished pharmaceutical products contained in 21 C.F.R. Parts 210 and 211 and related Guidance documents issued by the United States Food and Drug Administration), or medical devices (including the Quality System Regulations contained in 21 C.F.R. Part 820, as applicable, and related Guidance documents issued by the United States Food and Drug Administration), and for outside the United States by comparable Governmental Authorities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>CHAMPVA</u>&#8221; means, collectively, the Civilian Health and Medical Program of the Department of Veterans Affairs, and all laws and implementing rules and regulations and requirements pertaining to such program, in each case as the same may be amended, supplemented or otherwise modified from time to time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Change in Law</u>&#8221; means the occurrence, after the date of this Agreement, of any of the following: (i) the adoption or taking effect of any law, rule, regulation or treaty, (ii) any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any Governmental Authority or (iii) the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Governmental Authority; <u>provided</u> that, notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a &#8220;Change in Law&#8221;, regardless of the date enacted, adopted or issued.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Change of Control</u>&#8221; means the occurrence of any of the following events:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any &#8220;person&#8221; or &#8220;group&#8221; (as such terms are used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, but excluding any employee benefit plan of such person or its subsidiaries, and any person or entity acting in its capacity as trustee, agent or other fiduciary or administrator of any such plan), becomes the &#8220;beneficial owner&#8221; (as defined in Rules 13d-3 and 13d-5 under the Securities Exchange Act of 1934, except that a person or group shall be deemed to have &#8220;beneficial ownership&#8221; of all securities that such person or group has the right to acquire, whether such right is exercisable immediately or only after the passage of time (such right, an &#8220;option right&#8221;)), directly or indirectly, of Equity Interests representing 35% or more of the aggregate ordinary voting power in the election of the Board of Directors of the Borrower represented by the issued and outstanding Equity Interests of the Borrower on a fully-diluted basis (and taking into account all such securities that such person or group has the right to acquire pursuant to any option right); or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;during any period of twelve (12) consecutive months, a majority of the members of the Board of Directors of the Borrower cease to be composed of individuals (i) who were members of that Board of Directors on the first day of such period, (ii) whose election, appointment or nomination to that Board of Directors was approved by individuals referred to in <u>clause (i)</u> above constituting at the time of such election, appointment or nomination at least a majority of that Board of Directors, or (iii) whose election, appointment or nomination to that Board of Directors was approved by individuals referred to in <u>clauses</u> <u>(i)</u> and <u>(ii)</u> above constituting at the time of such election or nomination at least a majority of that Board of Directors; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any &#8220;Change of Control&#8221; (or any comparable term) shall occur under any document, instrument or other agreement evidencing any Indebtedness with an aggregate principal amount in excess of the Threshold Amount; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;except to the extent expressly permitted by this Agreement, the Borrower shall cease to directly or indirectly own, beneficially and of record (other than director&#8217;s qualifying shares of investments by foreign nationals to the extent mandated by applicable Laws), 100% of the issued and outstanding Equity Interests of each Subsidiary of the Borrower.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#8220;<u>CLIA</u>&#8221; means the Clinical Laboratory Improvement Amendments (42 U.S.C. &#167; 263a) and the implementing regulations at 42 C.F.R. pt. 493.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#8220;<u>Clinical Trial Material</u>&#8221; means any raw materials, parts, or supplies used in the ordinary course of development of a Product for which regulatory approval has not yet been obtained and that are used exclusively for purposes of supporting clinical and preclinical research.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Closing Date</u>&#8221; means the date hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>CMS</u>&#8221; means the U.S. Centers for Medicare and Medicaid Services.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Collateral</u>&#8221; means a collective reference to all real and personal property with respect to which Liens in favor of the Administrative Agent, for the benefit of the Secured Parties, are purported to be granted pursuant to and in accordance with the terms of the Collateral Documents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Collateral Access Agreement</u>&#8221; means an agreement in form and substance reasonably satisfactory to the Administrative Agent pursuant to which a lessor of real property on which Collateral is stored or otherwise located, or a warehouseman, processor or other bailee of inventory or other property owned by any Loan Party, acknowledges the Liens of the Administrative Agent and waives (or, if approved by the Administrative Agent, subordinates) any Liens held by such Person on such property, and permits the Administrative Agent reasonable access to any Collateral stored or otherwise located thereon.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">5</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Collateral Documents</u>&#8221; means a collective reference to the Security Agreement, the Pledge Agreement, the Deposit Account Control Agreements, the Perfection and Due Diligence Certificate, the Collateral Access Agreements, the Real Property Security Documents, the IP Security Agreements, the Irish Security Documents and other security documents as may be executed and delivered by the Loan Parties pursuant to the terms of <u>Section 7.12</u>, <u>Section 7.14</u>, <u>Section 7.20</u> or pursuant to the terms of any Collateral Document.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Commitment</u>&#8221; means a Term A Commitment, a Term B Commitment or a Term C Commitment, as the context may require.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Companies Act</u>&#8221; means the Companies Act 2014, of Ireland.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Compliance Certificate</u>&#8221; means a certificate substantially in the form of <u>Exhibit D</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Confidential Information</u>&#8221; means all non-public information, whether written, oral or in any electronic, visual or other medium, that is the subject of reasonable efforts to keep it confidential and that is owned by the Borrower or any Subsidiary or that the Borrower or any Subsidiary is licensed, authorized or otherwise granted rights under or to, and that is used by the Borrower or any other Person to manufacture, develop, import, market, promote, advertise, offer for sale, sell, use and/or otherwise distribute or provide a Product or Service.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Consolidated Revenues</u>&#8221; means, for any period, for the Borrower and its Subsidiaries on a consolidated basis, revenues for such period as determined and reported in accordance with GAAP; <u>provided</u>, <u>that</u>, &#8220;Consolidated Revenues&#8221; shall exclude the revenues generated by any Subsidiary to the extent that the declaration or payment of dividends or similar distributions by that Subsidiary of the income resulting from such revenues is not at the time permitted by operation of the terms of its Organization Documents or any agreement, instrument, judgment, decree, order, statute, rule or governmental regulation applicable to that Subsidiary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Contractual Obligation</u>&#8221; means, as to any Person, any provision of any security issued by such Person or of any agreement, instrument or other undertaking to which such Person is a party or by which it or any of its property is bound.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Control</u>&#8221; means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise. &#8220;<u>Controlling</u>&#8221; and &#8220;<u>Controlled</u>&#8221; have meanings correlative thereto. Without limiting the generality of the foregoing, a Person shall be deemed to be Controlled by another Person if such other Person possesses, directly or indirectly, power to vote [***]% or more of the securities having ordinary voting power for the election of directors, managing general partners or the equivalent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Convertible Bond Indebtedness</u>&#8221; means Indebtedness having a feature which entitles the holder thereof to convert or exchange all or a portion of such Indebtedness into shares of common capital stock of the Borrower; <u>provided, that,</u> (a) the principal amount (or accreted value, if applicable) of such Convertible Bond Indebtedness does not exceed $[***], (b) such Convertible Bond Indebtedness shall be unsecured, (c) no Subsidiary shall Guarantee such Convertible Bond Indebtedness, (d) such Convertible Bond Indebtedness shall not mature, and no scheduled or mandatory principal payments, repayments, prepayments, cash settlements, repurchases, redemptions or sinking fund or like payments (but excluding, for the avoidance of doubt, regularly scheduled cash interest payments and conversion of such Convertible Bond Indebtedness into shares of common capital stock of the Borrower in accordance with the terms thereof) of such Convertible Bond Indebtedness shall be required at any time on or prior to the date that is one (1) year after the Maturity Date, other than upon a &#8220;Change of Control&#8221;, &#8220;fundamental change&#8221;, &#8220;make-whole fundamental change&#8221; or similar event, (e) such Convertible Bond Indebtedness shall (i) not include (A) any financial maintenance covenants or (B) other covenants and defaults that are, taken as a whole, more restrictive on the Borrower and its Subsidiaries than the covenants and defaults set forth in the Loan Documents and (ii) have a cash interest rate of less than the greater of (x) [***] percent ([***]%) per annum and (y) such cash interest rate as the Administrative Agent, in its sole discretion, shall approve in writing after the Closing Date, upon the request of the Borrower in light of changes to market interest rates for similar convertible notes, (f) such Convertible Bond Indebtedness shall include conversion, redemption and fundamental change provisions that are customary for public market convertible indebtedness (pursuant to a public offering or an offering under Rule 144A or Regulation S of the Securities Act), (g) such Convertible Bond Indebtedness shall be subordinated in right of payment to the Obligations pursuant to the terms of a subordination, intercreditor, or other similar agreement (or terms of subordination incorporated into the indenture under which such Convertible Bond Indebtedness is issued), in each case, in form and substance, and on terms, approved by the Administrative Agent in writing in its sole discretion, (h) no Default or Event of Default shall have occurred and be continuing at the time of incurrence of such Convertible Bond Indebtedness or could result therefrom and (i) the Borrower shall have delivered to the Administrative Agent a certificate of a Responsible Financial Officer of the Borrower certifying as to the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">6</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Copyright License</u>&#8221; means any agreement, whether written or oral, providing for the grant of any right to use any Work under any Copyright.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Copyrights</u>&#8221; means (a) all proprietary rights afforded Works pursuant to Title 17 of the United States Code, including, without limitation, all rights in mask works, copyrights and original designs, and all proprietary rights afforded such Works by other countries for the full term thereof (and including all rights accruing by virtue of bilateral or international treaties and conventions thereto), whether registered or unregistered, including, but not limited to, all applications for registration, renewals, extensions, reversions or restorations thereof now or hereafter provided for by law and all rights to make applications for registrations and recordations, regardless of the medium of fixation or means of expression, which are owned by the Borrower or any Subsidiary or which the Borrower or any Subsidiary is licensed, authorized or otherwise granted rights under or to the Borrower or the Borrower; and (b) all copyright rights under the copyright laws of the United States and all other countries for the full term thereof (and including all rights accruing by virtue of bilateral or international copyright treaties and conventions), whether registered or unregistered, including, but not limited to, all applications for registration, renewals, extensions, reversions or restorations of copyrights now or hereafter provided for by law and all rights to make applications for copyright registrations and recordations, regardless of the medium of fixation or means of expression, which are owned by the Borrower or any Subsidiary or which the Borrower or any Subsidiary is licensed, authorized or otherwise granted rights under or to, and which are used by the Borrower or any other Person to manufacture, develop, import, market, promote, advertise, offer for sale, sell, use, provide and/or otherwise distribute a Product or Service.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Covered Party</u>&#8221; has the meaning specified in <u>Section 12.21</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Cure Right</u>&#8221; has the meaning specified in <u>Section 9.04</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Debt Issuance</u>&#8221; means the issuance by any Loan Party or any Subsidiary of any Indebtedness other than Indebtedness permitted under <u>Section 8.03</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Debtor Relief Laws</u>&#8221; means the Bankruptcy Code of the United States, and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of the United States or other applicable jurisdictions from time to time in effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">7</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Default</u>&#8221; means any event or condition that constitutes an Event of Default or that, with the giving of any notice, the passage of time, or both, would be an Event of Default.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Default Rate</u>&#8221; means an interest rate equal to the sum of (a) Three-Month LIBOR for the applicable Interest Period <u>plus</u> (b) [***]% per annum, to the fullest extent permitted by applicable Laws.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Defaulting Lender</u>&#8221; means, subject to <u>Section 2.12(b)</u>, any Lender, as determined by the Administrative Agent, that (a) has failed to perform any of its funding obligations hereunder, including with respect to any Term A Commitments, any Term B Commitments or any Term C Commitments, within three (3) Business Days of the date required to be funded by it hereunder, (b) has notified the Borrower or the Administrative Agent that it does not intend to comply with its funding obligations hereunder or (c) has, or has a direct or indirect parent company that has, (i) become the subject of a proceeding under any Debtor Relief Law, (ii) had a receiver, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or a custodian appointed for it, (iii) taken any action in furtherance of, or indicated its consent to, approval of or acquiescence in any such proceeding or appointment or (iv) become the subject of a Bail-In Action; provided, that, a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any Equity Interests in that Lender or any direct or indirect parent company thereof by a Governmental Authority.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Delaware Divided LLC</u>&#8221; means any Delaware LLC which has been formed upon the consummation of a Delaware LLC Division.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Delaware LLC</u>&#8221; means any limited liability company organized or formed under the laws of the State of Delaware.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Delaware LLC Division</u>&#8221; means the statutory division of any Delaware LLC into two or more Delaware LLCs pursuant to Section 18-217 of the Delaware Limited Liability Company Act.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Deposit Account</u>&#8221; means a &#8220;deposit account&#8221; (as defined in Article 9 of the Uniform Commercial Code), investment account, securities account or other account in which funds are held or invested to or for the credit or account of any Loan Party.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Deposit Account Control Agreement</u>&#8221; means any account control agreement by and among a Loan Party, the applicable depository bank or securities intermediary (as the case may be) and the Administrative Agent, in each case in form and substance reasonably satisfactory to the Administrative Agent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Designated Jurisdiction</u>&#8221; means any country or territory to the extent that such country or territory is the subject of any Sanction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Disposition</u>&#8221; or &#8220;<u>Dispose</u>&#8221; means the sale, transfer, license, lease or other disposition (including any Sale and Leaseback Transaction or any issuance by any Subsidiary of its Equity Interests) of any property by any Loan Party or any Subsidiary, including any sale, assignment, transfer or other disposal, with or without recourse, of any notes or accounts receivable or any rights and claims associated therewith (including any disposition, allocation, transfer or conveyance of property to a Delaware Divided LLC pursuant to a Delaware LLC Division), but excluding the following: (a) the sale, lease, license, transfer or other disposition of inventory in the ordinary course of business (including Stockpile Sales), (b) the sale, lease, license, transfer or other disposition in the ordinary course of business of surplus, obsolete or worn out equipment no longer used or useful in the conduct of business of any Loan Party or any Subsidiary, (c) any sale, lease, license, transfer or other disposition of property to any Loan Party or any Subsidiary; <u>provided</u>, <u>that</u>, if the transferor of such property is a Loan Party, (i) the transferee thereof must be a Loan Party or (ii) to the extent such transaction constitutes an Investment, such transaction is permitted under <u>Section 8.02</u>, (d) the abandonment or other disposition of IP Rights that are not material and are no longer used or useful in any material respect in the business of the Borrower and its Subsidiaries taken as a whole, (e) licenses, sublicenses, leases or subleases (other than relating to intellectual property) granted to third parties in the ordinary course of business and not interfering with the Businesses, (f) any Involuntary Disposition, (g) dispositions of cash and Cash Equivalents in the ordinary course of business pursuant to transactions permitted hereunder, (h) dispositions consisting of the sale, transfer, assignment or other disposition of unpaid and overdue accounts receivable in connection with the collection, compromise or settlement thereof in the ordinary course of business and not as part of a financing transaction, (i) the sale of the &#8220;Revenue Participation Right&#8221; (or other comparable term) in accordance with the terms of the Royalty Financing Documents or the terms of the Other Royalty Financing Documents, (j) any disposition of the equity interests of JPR Royalty Sub pursuant to an exercise of remedies under the Pledge and Security Agreement (as defined in the JPR Indenture) or in connection with the compromise or settlement of claims with holders of Indebtedness issued under the JPR Indenture, (k) dispositions of Clinical Trial Material that, in the good faith determination of Borrower, is no longer used or useful in the conduct of the business of Borrower and its Subsidiaries, (l) the sale, transfer or other disposition of a de minimis number of shares of the Equity Interests of a Non-U.S. Subsidiary in order to qualify members of the governing body of such Subsidiary if required by applicable Law, (m) to the extent constituting a Disposition, Liens permitted by <u>Section 8.01</u> and Investments permitted by <u>Section 8.02</u> and (n) the unwinding of Swap Contracts permitted by <u>Section 8.03(d)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">8</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Disqualified Capital Stock</u>&#8221; means any Equity Interest which, by its terms (or by the terms of any security into which it is convertible or for which it is exchangeable), or upon the happening of any event, (a) matures (excluding any maturity as the result of an optional redemption by the issuer thereof) or is mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, or is redeemable at the option of the holder thereof, in whole or in part, prior to the one hundred and eighty-first (181<sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup>) day after the Maturity Date, (b) requires the payment of any cash dividends at any time prior to the one hundred and eighty-first (181<sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup>) day after the Maturity Date, (c) contains any repurchase obligation which may come into effect prior to payment in full of all Obligations, or (d) is convertible into or exchangeable (unless at the sole option of the issuer thereof) for (i) debt securities or (ii) any Equity Interests referred to in <u>clause (a)</u>, <u>(b)</u> or <u>(c)</u> above, in each case at any time prior to the one hundred and eighty-first (181<sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup>) day after the Maturity Date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Dollar</u>&#8221; and &#8220;<u>$</u>&#8221; mean lawful money of the United States.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Domain Names</u>&#8221; means all domain names and URLs that are registered and/or owned by the Borrower or any Subsidiary or which the Borrower or any Subsidiary is licensed, authorized or otherwise granted rights under or to.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Earn Out Obligations</u>&#8221; means, with respect to an Acquisition, all obligations of the Borrower or any Subsidiary to make earn out or other contingency payments (including purchase price adjustments, non-competition and consulting agreements, other indemnity obligations, royalty payments and sale, or development and other milestone payments) pursuant to the documentation relating to such Acquisition. For purposes of determining the aggregate consideration paid for an Acquisition at the time of such Acquisition, the amount of any Earn Out Obligations shall be deemed to be the maximum amount of the earn-out payments in respect thereof as specified in the documents relating to such Acquisition.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>EEA Financial Institution</u>&#8221; means (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in <u>clause (a)</u> of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in <u>clauses (a)</u> or <u>(b)</u> of this definition and is subject to consolidated supervision with its parent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">9</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>EEA Member Country</u>&#8221; means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>EEA Resolution Authority</u>&#8221; means any public administrative authority or any person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Eligible Assets</u>&#8221; means long-term assets that are used or useful in the same or a similar line of business as the Borrower and its Subsidiaries were engaged in on the Closing Date (or any reasonable extension or expansions thereof).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Eligible Assignee</u>&#8221; means any Person that meets the requirements to be an assignee under <u>Section 12.06</u> (subject to such consents, if any, as may be required under <u>Section 12.06(b)(iii)</u>).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>English Subsidiary</u>&#8221; means (a) BioCryst UK Limited and (b) any other Subsidiary that is organized under the laws of England from time to time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Environmental Laws</u>&#8221; means any and all federal, state, local, foreign and other applicable statutes, laws, regulations, ordinances, rules, judgments, orders, decrees, permits, concessions, grants, franchises, licenses, agreements or governmental restrictions relating to pollution and the protection of the environment or the release of any materials into the environment, including those related to hazardous substances or wastes, air emissions and discharges to waste or public systems.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Environmental Liability</u>&#8221; means any liability, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines, penalties or indemnities), of the Borrower, any other Loan Party or any of their respective Subsidiaries directly or indirectly resulting from or based upon (a)&nbsp;violation of any Environmental Law, (b) the generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (c) exposure to any Hazardous Materials, (d) the release or threatened release of any Hazardous Materials into the environment or (e) any contract, agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Equity Interests</u>&#8221; means, with respect to any Person, all of the shares of capital stock of (or other ownership or profit interests in) such Person, all of the warrants, options or other rights for the purchase or acquisition from such Person of shares of capital stock of (or other ownership or profit interests in) such Person, all of the securities convertible into or exchangeable for shares of capital stock of (or other ownership or profit interests in) such Person or warrants, rights or options for the purchase or acquisition from such Person of such shares (or such other interests), and all of the other ownership or profit interests in such Person (including partnership, member, membership or trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or other interests are outstanding on any date of determination, but excluding, for the avoidance of doubt, any Convertible Bond Indebtedness to the extent that the same have not yet been converted into shares of common capital stock of the Borrower.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>ERISA</u>&#8221; means the Employee Retirement Income Security Act of 1974.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">10</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>ERISA Affiliate</u>&#8221; means any trade or business (whether or not incorporated) under common control with the Borrower within the meaning of Section 414(b) or (c) of the Internal Revenue Code (and Sections 414(m) and (o) of the Internal Revenue Code for purposes of provisions relating to Section 412 of the Internal Revenue Code).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>ERISA Event</u>&#8221; means (a) a Reportable Event with respect to a Pension Plan, (b) the withdrawal of the Borrower or any ERISA Affiliate from a Pension Plan subject to Section 4063 of ERISA during a plan year in which such entity was a &#8220;substantial employer&#8221; as defined in Section 4001(a)(2) of ERISA or a cessation of operations that is treated as such a withdrawal under Section 4062(e) of ERISA, (c) a complete or partial withdrawal by the Borrower or any ERISA Affiliate from a Multiemployer Plan, (d) the filing of a notice of intent to terminate, the treatment of a Pension Plan amendment as a termination under Sections 4041 or 4041A of ERISA, (e) the institution by the PBGC of proceedings to terminate a Pension Plan, (f) any event or condition which constitutes grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Pension Plan, (g) the determination that any Pension Plan is considered an at-risk plan or a plan in endangered or critical status within the meaning of Sections 430, 431 and 432 of the Internal Revenue Code or Sections 303, 304 and 305 of ERISA, or (h) the imposition of any liability under Title IV of ERISA, other than for PBGC premiums due but not delinquent under Section 4007 of ERISA, upon the Borrower or any ERISA Affiliate.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>EU Bail-In Legislation Schedule</u>&#8221; means the EU Bail-In Legislation Schedule published by the Loan Market Association (or any successor person), as in effect from time to time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Event of Default</u>&#8221; has the meaning set forth in <u>Section 9.01</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Examiner</u>&#8221; means an examiner appointed under Section 509 of the Companies Act.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Excluded Business Interruption Proceeds</u>&#8221; means (a) cash proceeds of business interruption insurance not in excess of $[***] in any fiscal year (the &#8220;<u>Annual Business Interruption Cap</u>&#8221;) and (b) any cash proceeds of business interruption insurance in excess of the Annual Business Interruption Cap in any fiscal year which are actually applied to operating expenses or to rebuild or replace the property or remedy the event or occurrence giving rise to the business interruption event in respect of which such business interruption insurance proceeds are being paid.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Excluded Prepayment Amount</u>&#8221; has the meaning provided in <u>Section 2.03(b)(vi)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Excluded Property</u>&#8221; means, with respect to any Loan Party, including any Person that becomes a Loan Party after the Closing Date as contemplated by <u>Section 7.12</u>, (a) any property which, subject to the terms of <u>Section 8.09</u>, is subject to a Lien of the type described in Section 8.01(i) pursuant to documents which prohibit such Loan Party from granting any other Liens in such property, (b) any United States intent-to-use trademark applications to the extent that, and solely during the period in which, the grant of a security interest therein would impair the validity or enforceability of such intent-to-use trademark applications under applicable federal law; provided, that, upon submission and acceptance by the United States Patent and Trademark Office of a statement of use or an amendment to allege use pursuant to 15 U.S.C. Section 1060(a) (or any successor provision), such intent-to-use trademark application shall no longer constitute &#8220;Excluded Property&#8221; and shall be considered Collateral, (c) any permit, lease, license, contract or other agreement of a Loan Party if the grant of a security interest in such permit, lease, license, contract or other agreement in the manner contemplated by the Collateral Documents, under the terms thereof or under applicable Law, is prohibited and would result in the termination thereof or give the other parties thereto the right to terminate, accelerate or otherwise alter such Loan Party&#8217;s rights, titles and interests thereunder (including upon the giving of notice or the lapse of time or both); provided, that, (x) any such limitation described in this clause (c) on the security interests granted under the Collateral Documents shall only apply to the extent that any such prohibition would not be rendered ineffective pursuant to the Uniform Commercial Code or any other applicable Law or principles of equity and (y) in the event of the termination or elimination of any such prohibition or the requirement for any consent contained in any applicable Law, permit, lease, license, contract or other agreement, to the extent sufficient to permit any such item to become Collateral, a security interest in such permit, lease, license, contract or other agreement shall be automatically and simultaneously granted under the applicable Collateral Document and such permit, lease, license, contract or other agreement shall no longer constitute &#8220;Excluded Property&#8221; and shall be considered Collateral, (d) the equity interests in JPR Royalty Sub to the extent that Borrower is prohibited from pledging such interests pursuant to the terms of the Pledge and Security Agreement (as defined in the JPR Indenture), provided that, upon the termination or expiration of such prohibition or termination of, or payment in full of the &#8220;Secured Obligations&#8221; under the JPR Indenture, the equity interests in JPR Royalty Sub shall automatically be subject to the security interest granted in favor of Agent hereunder and shall become part of the &#8220;Collateral&#8221;, (e) the HSBC Cash Collateral Accounts and (f) the Equity Interests of any Non-U.S. Subsidiary (other than any Irish Subsidiary and any English Subsidiary) to the extent not required to be pledged to secure the Obligations pursuant to <u>Section 7.14(a)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">11</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Excluded Subsidiary</u>&#8221; means (a) subject to <u>Section 7.21(c)</u>, JPR Royalty Sub, <sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>(b) any Immaterial Non-U.S. Subsidiary, (c) MDCP, (d) any Non-U.S. Regulatory Approval Subsidiaries, (e) any Non-U.S. Subsidiary (other than any English Subsidiary and any Irish Subsidiary), the grant or perfection of a security interest in the assets of such Non-U.S. Subsidiary in support of, or the guaranteeing of, the Obligations would result in material adverse tax consequences to the Borrower and its Subsidiaries (as reasonably determined by the Borrower with the consent of the Administrative Agent) and (f) any Non-U.S. Subsidiary (other than any English Subsidiary and any Irish Subsidiary) with respect to which it is reasonably agreed by the Borrower and the Administrative Agent that the cost or other consequences of providing a guarantee of the Obligations shall outweigh the benefits to be obtained by the Lenders therefrom as a result of capital maintenance rules, corporate benefit requirements or similar Laws of the jurisdiction of organization of such Non-U.S. Subsidiary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Exempt </u><u>Immaterial </u><u>Subsidiary</u>&#8221; means at any time, an Exempt Subsidiary that (a) as of the last day of the fiscal quarter of the Borrower most recently ended for which the Borrower was required to deliver financial statements pursuant to <u>Section 7.01(a)</u> or <u>(b)</u>, did not have (together with its Subsidiaries, on a consolidated basis) assets in excess of (i) [***]% of the consolidated total assets of the Borrower and its Subsidiaries at the end of such fiscal quarter for any one Exempt Immaterial Subsidiary and (ii) [***]% of the consolidated total assets of the Borrower and its Subsidiaries at the end of such fiscal quarter for all Exempt Immaterial Subsidiaries in the aggregate and (b)&nbsp;for the period of four fiscal quarters most recently ended for which the Borrower was required to deliver financial statements pursuant to <u>Section 7.01(a)</u> or <u>(b)</u>, did not have (together with its Subsidiaries, on a consolidated basis) Consolidated Revenues (without giving effect to proviso in the definition thereof) attributable to such Exempt Subsidiary for such period in excess of (i) [***]% of Consolidated Revenues for such period for any one Exempt Immaterial Subsidiary and (ii) [***]% of Consolidated Revenues for such period for all Exempt Immaterial Subsidiaries in the aggregate.<b>.</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Exempt Subsidiary</u>&#8221; means any of the following: (a) BioCryst UK, Ltd., BioCryst Deutschland GmbH and BioCryst France SAS and (b) any other Non U.S. Subsidiary that is formed after the Closing Date (but, for the avoidance of doubt, excluding any Non-U.S. Subsidiary that is acquired after the Closing Date) and organized under the laws of France, Germany, Ireland, [***], Japan, [***] or United Kingdom.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Existing Indebtedness</u>&#8221; means all Indebtedness for borrowed money of the Borrower and its Subsidiaries in existence immediately prior to the Term A Borrowing Date, including the MidCap Indebtedness.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">12</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Extraordinary Receipts</u>&#8221; means any cash received by or paid to or for the account of any Person not in the ordinary course of business, including (1) tax refunds, (2) pension plan reversions, (3) indemnity payments (other than to the extent such indemnity payments are (i) immediately payable to a Person that is not an Affiliate of the Borrower or any of its Subsidiaries or (ii) received by the Borrower or any of its Subsidiaries as reimbursement for (A) actual losses or costs incurred by the Borrower or any of its Subsidiaries or (B) any payment previously made, in each case by the Company and its Subsidiaries in connection with any such indemnity payments), and (4) proceeds of judgments, settlements or other consideration of any kind in connection with any cause of action (other than to the extent (i) an amount equal to such proceeds of judgments, settlements or causes of action or such proceeds of judgments, settlements or causes of action have already been paid or are immediately payable to a Person that is not the Borrower or any of its Subsidiaries or Affiliates in accordance with requirements of law, settlements of the underlying events related thereto or with contractual obligations entered into in the ordinary course of business in effect prior to such judgment, settlement or cause or action or (ii) such proceeds of judgments, settlements or causes of action are received by the Borrower or any of its Subsidiaries as reimbursement for (A) actual losses or (B) any out-of-pocket costs, in each case incurred or made by the Borrower and its Subsidiaries prior to the receipt thereof directly related to the event resulting from the subject judgment, settlement or cause of action); provided, that Extraordinary Receipts shall in any event not include (x) proceeds described in <u>Section 2.</u><u>0</u><u>3(b)(i)</u> hereof, (y) proceeds of purchase price adjustments in connection with any Permitted Acquisition and (z) proceeds of issuances of common equity or other Equity Interests (other than Disqualified Capital Stock).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Facility</u>&#8221; means the Term A Facility, the Term B Facility or the Term C Facility, as the context may require.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Facility Termination Date</u>&#8221; means the date as of which all of the following shall have occurred: (a) all of the Commitments have terminated and (b) all Obligations have been paid in full in cash (other than contingent indemnification obligations for which no claim has been asserted).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Facilities</u>&#8221; means, at any time, a collective reference to the facilities (including any laboratory) and real properties owned, leased or operated by any Loan Party or any Subsidiary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>FATCA</u>&#8221; means Sections 1471 through 1474 of the Internal Revenue Code as of the Closing Date (or any amended or successor version that is substantively comparable and not materially more onerous to comply with) and any current or future regulations thereunder, official interpretations thereof, any agreement entered into pursuant to Section 1471(b)(1) of the Internal Revenue Code and any treaty, law, regulation or intergovernmental agreements entered into (which facilitates the implementation of any law or regulation) thereunder.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>FDA</u>&#8221; means the United States Food and Drug Administration or any successor entity thereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>FDCA</u>&#8221; means the Federal Food, Drug, and Cosmetic Act, as amended, 21 U.S.C. Section 301 et seq. and all regulations promulgated thereunder.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Federal Funds Rate</u>&#8221; means, for any day, the rate per annum equal to the weighted average of the rates on overnight federal funds transactions with members of the Federal Reserve System arranged by federal funds brokers on such day, as published by the Federal Reserve Bank of New York on the Business Day next succeeding such day; <u>provided</u>, <u>that</u>, if such day is not a Business Day, the Federal Funds Rate for such day shall be such rate on such transactions on the next preceding Business Day as so published on the next succeeding Business Day.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">13</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Flood Hazard Property</u>&#8221; means any real property subject to a Mortgage that is in an area designated by the Federal Emergency Management Agency as having special flood or mudslide hazards.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>FRB</u>&#8221; means the Board of Governors of the Federal Reserve System of the United States.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Fund</u>&#8221; means any Person (other than a natural Person) that is (or will be) engaged in making, purchasing, holding or otherwise investing in notes, loans and/or similar extensions of credit in the ordinary course of its activities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>GAAP</u>&#8221; means generally accepted accounting principles in the United States set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board, consistently applied and as in effect from time to time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Government Account Debtor</u>&#8221; means the United States government or a political subdivision thereof, or any state, county or municipality or department, agency or instrumentality thereof, that is responsible for payment of an Account under any Government Reimbursement Program, or any agent, administrator, intermediary or carrier for the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Government Account Debtor Account</u>&#8221; means a Deposit Account in the name of a Loan Party that receives all incoming payments from Government Account Debtors and other account debtors of the Loan Parties, which Deposit Account shall be subject to the requirements of <u>Section 7.16(b)(ii)</u> hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Governmental Authority</u>&#8221; means the government of the United States or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies such as the European Union or the European Central Bank).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Government Reimbursement Program</u>&#8221; means (a) Medicare, (b) Medicaid, (c) the Federal Employees Health Benefit Program under 5 U.S.C. &#167;&#167; 8902 et seq., (d) TRICARE, (e) CHAMPVA, or (f) if applicable within the context of this Agreement, any agent, administrator, administrative contractor, intermediary or carrier for any of the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Guarantee</u>&#8221; means, as to any Person, (a) any obligation, contingent or otherwise, of such Person guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation payable or performable by another Person (the &#8220;primary obligor&#8221;) in any manner, whether directly or indirectly, and including any obligation of such Person, direct or indirect, (i) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation, (ii) to purchase or lease property, securities or services for the purpose of assuring the obligee in respect of such Indebtedness or other obligation of the payment or performance of such Indebtedness or other obligation, (iii) to maintain working capital, equity capital or any other financial statement condition or liquidity or level of income or cash flow of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation, or (iv) entered into for the purpose of assuring in any other manner the obligee in respect of such Indebtedness or other obligation of the payment or performance thereof or to protect such obligee against loss in respect thereof (in whole or in part), (b) any Lien on any assets of such Person securing any Indebtedness or other obligation of any other Person, whether or not such Indebtedness or other obligation is assumed by such Person (or any right, contingent or otherwise, of any holder of such Indebtedness to obtain any such Lien) or (c) any direct or indirect liability, contingent or not, of that Person for (i) any obligations for undrawn letters of credit for the account of that Person or (ii) all obligations from any interest rate, currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices. The amount of any Guarantee shall be deemed to be an amount equal to the stated or determinable amount of the related primary obligation, or portion thereof, in respect of which such Guarantee is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by the guaranteeing Person in good faith. The term &#8220;Guarantee&#8221; as a verb has a corresponding meaning.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">14</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Guarantors</u>&#8221; means (a) each Subsidiary of the Borrower identified as a &#8220;Guarantor&#8221; on the signature pages hereto and (b) each other Person that joins as a Guarantor (i) pursuant to <u>Section 7.12</u> (and &#8220;Guarantor&#8221; shall mean, as the context may require, each of them individually) or (ii) subject to the Administrative Agent&#8217;s prior written consent, at the written election of the Borrower, in each case of the foregoing clauses (a) and (b), together with their successors and permitted assigns.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Guaranty</u>&#8221; means the Guaranty made by the Guarantors in favor of the Secured Parties pursuant to <u>Article IV</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Hazardous Materials</u>&#8221; means all explosive or radioactive substances or wastes and all hazardous or toxic substances, wastes or other pollutants, including petroleum or petroleum distillates, asbestos or asbestos-containing materials, polychlorinated biphenyls, radon gas, infectious or medical wastes and all other substances or wastes of any nature regulated pursuant to any Environmental Law.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Healthcare Laws</u>&#8221; means all applicable Laws relating to the procurement, testing, development, clinical and non-clinical evaluation or investigation, product approval, manufacture, production, distribution, dispensing, importation, exportation, use, handling, quality, reimbursement, sale, labeling, advertising, promotion, or postmarket requirements of any drug product or any ingredient or component thereof, including as applicable the FDCA and similar state or foreign laws, controlled substances laws, consumer product safety laws, Medicare, Medicaid, TRICARE, HIPAA, CLIA, the Patient Protection and Affordable Care Act (P.L. 111-1468), all federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute (42 U.S.C. &#167;1320a-7b), the civil False Claims Act (31 U.S.C. &#167;3729 et seq.) and all laws, policies, procedures, requirements and regulations pursuant to which Permits are issued, in each case, as the same may be amended from time to time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>HHS</u>&#8221; means the United States Department of Health and Human Services and any successor agency thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>HIPAA</u>&#8221; means (a) the Health Insurance Portability and Accountability Act of 1996; (b) the Health Information Technology for Economic and Clinical Health Act (Title XIII of the American Recovery and Reinvestment Act of 2009); and (c) any state or local laws regulating the privacy and/or security of individually identifiable information imposing a more restrictive standard, in each case as the same may be amended, modified or supplemented from time to time, any successor statutes thereto, and any and all rules or regulations promulgated from time to time thereunder.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>HSBC Cash Collateral Accounts</u>&#8221; means, collectively, Deposit Account #[***] and Deposit Account #[***] of the Borrower established and maintained at HSBC Bank for the sole purpose of securing the Borrower&#8217;s obligations under the HSBC Letter of Credit; provided that (a) no such Deposit Account shall hold an aggregate of cash and cash equivalents in excess of [***] percent ([***]%) of the aggregate face amount of the letters of credit it is securing and (b) with respect to all such Deposit Accounts, the aggregate amount deposited there in at any time does not exceed [***] Dollars ($[***]).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>HSBC Letter of Credit</u>&#8221; means the letter of credit issued by HSBC Bank in favor of the landlord with respect to the Borrower&#8217;s leased real property located at 2100 Riverchase Center, Ste. 200 / Building 200, Birmingham, AL 35244, in an aggregate face amount equal to One Million Four Hundred Thousand Dollars ($1,400,000).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">15</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Immaterial Non-U.S. Subsidiary</u>&#8221; means at any time a Non-U.S. Subsidiary that (a) as of the last day of the fiscal quarter of the Borrower most recently ended for which the Borrower was required to deliver financial statements pursuant to <u>Section 7.01(a)</u> or <u>(b)</u>, did not have (together with its Subsidiaries, on a consolidated basis) assets in excess of (i) [***]% of the consolidated total assets of the Borrower and its Subsidiaries at the end of such fiscal quarter for any one Immaterial Non-U.S. Subsidiary and (ii)&nbsp;[***]% of the consolidated total assets of the Borrower and its Subsidiaries at the end of such fiscal quarter for all Immaterial Non-U.S. Subsidiaries in the aggregate and (b)&nbsp;for the period of four fiscal quarters most recently ended for which the Borrower was required to deliver financial statements pursuant to <u>Section 7.01(a)</u> or <u>(b)</u>, did not have (together with its Subsidiaries, on a consolidated basis) Consolidated Revenues (without giving effect to proviso in the definition thereof) attributable to such Non-U.S. Subsidiary for such period in excess of (i) [***]% of Consolidated Revenues for such period for any one Immaterial Non-U.S. Subsidiary and (ii) [***]% of Consolidated Revenues for such period for all Immaterial Non-U.S. Subsidiaries in the aggregate; <u>provided</u>, <u>however</u>, that in no event will any Non U.S. Subsidiary (x) that is organized under the laws of France, Germany, Ireland, [***], Japan, [***] or United Kingdom or (y) which is acquired pursuant to a Permitted Acquisition, in each case, constitute an Immaterial Non-U.S. Subsidiary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Indebtedness</u>&#8221; means, as to any Person at a particular time, without duplication, all of the following, whether or not included as indebtedness or liabilities in accordance with GAAP:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 45pt; text-align: justify; text-indent: 36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all obligations, whether current or long-term, for borrowed money (including the Obligations) and all obligations of such Person evidenced by bonds, debentures, notes, loan agreements or other similar instruments;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all purchase money Indebtedness;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the principal portion of all obligations under conditional sale or other title retention agreements relating to property purchased by such Person or any Subsidiary thereof (other than customary reservations or retentions of title under agreements with suppliers entered into in the ordinary course of business);</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all obligations arising under letters of credit (including standby and commercial), bankers&#8217; acceptances, bank guaranties, surety bonds and similar instruments;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all obligations in respect of the deferred purchase price of property or services (other than trade accounts payable in the ordinary course of business and, in each case, not due more than 90 days after the date on which such trade account payable was created), including, without limitation, any Earn Out Obligations that have become a liability on the balance sheet in accordance with GAAP;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Attributable Indebtedness of Capital Leases, Securitization Transactions and Synthetic Leases;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all obligations of such Person to purchase, redeem, retire, defease or otherwise make any payment in respect of any Disqualified Capital Stock in such Person or any other Person, valued, in the case of a redeemable preferred interest, at the greater of its voluntary or involuntary liquidation preference <u>plus</u> accrued and unpaid dividends;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">16</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or otherwise, to be secured by) any Lien on, or payable out of the proceeds of production from, property owned or acquired by such Person, whether or not the obligations secured thereby have been assumed;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Swap Termination Value of any Swap Contract;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all Guarantees with respect to outstanding Indebtedness of the types specified in <u>clauses (a)</u> through <u>(i)</u> above of any other Person; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;all Indebtedness of the types referred to in <u>clauses (a)</u> through <u>(j)</u> above of any partnership or joint venture (other than a joint venture that is itself a corporation or limited liability company) in which such Person or a Subsidiary thereof is a general partner or joint venturer, unless such Indebtedness is expressly made non-recourse to such Person or such Subsidiary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">For purposes hereof, the amount of any direct obligation arising under letters of credit (including standby and commercial), bankers&#8217; acceptances, bank guaranties, surety bonds and similar instruments shall be the maximum amount available to be drawn thereunder.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Indemnitee</u>&#8221; has the meaning set forth in <u>Section 12.04(b)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Indirect Lender</u>&#8221; means any Person that is not a U.S. Person and either (1) directly holds equity interests in a Lender that is treated as a partnership or disregarded entity for United States federal income tax purposes or (2) directly holds equity interests in a U.S. Person that is treated as a partnership or disregarded entity for U.S. federal income tax purposes that, directly, or indirectly through entities each of which is treated a partnership or a disregarded entity for U.S. federal income tax purposes, holds equity interests in a Lender.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Information</u>&#8221; has the meaning set forth in <u>Section 12.07</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Intercreditor Agreement</u>&#8221; means the Intercreditor Agreement dated as of the Closing Date by and among the Administrative Agent and the Buyer, and acknowledged and agreed to by the Borrower and the Guarantors as amended, amended and restated, supplemented and otherwise modified from time to time in accordance with the terms thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Interest Period</u>&#8221; means, with respect to any Borrowing (a) initially, the period beginning on (and including) the date of such Borrowing and ending on (and including) the next following Interest Payment Date, and (b) thereafter, the period beginning on (and including) the first day immediately following such Interest Payment Date and ending on the earlier of (and including) (i) the next following Interest Payment Date and (ii) the Maturity Date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Interest Payment Date</u>&#8221; means (a) the last Business Day of each March, June, September and December, and (b) the Maturity Date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Interim Financial Statements</u>&#8221; means the unaudited consolidated financial statements of the Borrower and its Subsidiaries for each of the fiscal quarters ended March 31, 2020, June 30, 2020 and September 30, 2020, including balance sheets and statements of income or operations, shareholders&#8217; equity and cash flows.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Internal Revenue Code</u>&#8221; means the United States Internal Revenue Code of 1986, as amended.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">17</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Internal Revenue Service</u>&#8221; means the United States Internal Revenue Service, as amended.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Investment</u>&#8221; means, as to any Person, any direct or indirect acquisition or investment by such Person, whether by means of (a) the purchase or other acquisition of Equity Interests of another Person, (b) a loan, advance or capital contribution to, Guarantee or assumption of debt of, or purchase or other acquisition of any other debt or equity participation or interest in, another Person, including any partnership or joint venture interest in such other Person and any arrangement pursuant to which the investor Guarantees Indebtedness of such other Person, or (c) an Acquisition. For purposes of covenant compliance, the amount of any Investment shall be the amount actually invested, without adjustment for subsequent increases or decreases in the value of such Investment, but giving effect to any repayments of principal in the case of Investments in the form of loans and any return of capital or return on Investment in the case of equity Investments, but in each case not in excess of the amount of the initial Investment.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Involuntary Disposition</u>&#8221; means any loss of, damage to or destruction of, or any condemnation or other taking for public use of, any property of any Loan Party or any of its Subsidiaries.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>IP Rights</u>&#8221; means, collectively, all Confidential Information, all Copyrights, all Copyright Licenses, all Domain Names, all Permits, all Other Intellectual Property, all Other IP Agreements, all Patents, all Patent Licenses, all Proprietary Databases, all Proprietary Software, all Trademarks, all Trademark Licenses, all Trade Secrets, all Websites and all Website Agreements.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>IP Security Agreement</u>&#8221; means notices of grant of security interest in the form required by the Security Agreement executed and delivered by a Loan Party.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#8220;<u>Irish All Asset Debenture</u>&#8221; means that certain Irish law governed all asset debenture (other than Excluded Property) dated as of the Closing Date executed in favor of the Administrative Agent, for the benefit of the Secured Parties, by each of the Loan Parties that is an Irish Subsidiary, in form and substance reasonably acceptable to the Administrative Agent, as amended or modified from time to time in accordance with the terms hereof, to include such other agreements, third-party assessments, certificates, notices, acknowledgments of such notices and documents that the Administrative Agent may reasonable request in connection therewith as is customary or appropriate.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Irish Security Documents</u>&#8221; means, collectively, the Irish All Asset Debenture and the Irish Share Charge.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#8220;<u>Irish Share Charge</u>&#8221; means that certain Irish law governed share charge dated as of the Closing Date executed in favor of the Administrative Agent, for the benefit of the Secured Parties, by each of the Loan Parties holding any Equity Interests in an Irish Subsidiary, in form and substance reasonably acceptable to the Administrative Agent, as amended or modified from time to time in accordance with the terms hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Irish Subsidiary</u>&#8221; means any Subsidiary that is incorporated under the laws of Ireland.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Joinder Agreement</u>&#8221; means a joinder agreement substantially in the form of <u>Exhibit E</u> executed and delivered by a Subsidiary in accordance with the provisions of <u>Section 7.12</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>JPR </u><u>Indenture</u>&#8221; means that certain Indenture, dated as of March 9, 2011, by and between JPR Royalty Sub and U.S. Bank, National Association, as in effect on the date hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>JPR Royalty Sub</u>&#8221; means JPR Royalty Sub LLC, a Delaware limited liability company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">18</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Key Products</u>&#8221; means, collectively, the Orladeyo Product Family and the BCX9930 Product Family.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Key Territories</u>&#8221; means the United States, France, Germany, [***], [***] and the United Kingdom.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Laws</u>&#8221; means, collectively, all international, foreign, federal, state and local statutes, treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of law.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Legal Reservations</u>&#8221; means:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the principle that equitable remedies may be granted or refused at the discretion of a court and the limitation of enforcement by laws relating to insolvency, reorganisation and other laws generally affecting the rights of creditors;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the time barring of claims under the Statute of Limitation 1957 and defences of set-off or counterclaim;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the principle that security expressed to be fixed security may take effect as floating security; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any other matters which are set out as qualifications or reservations as to matters of law of general application in any legal opinions delivered pursuant to this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Lenders</u>&#8221; means each of the Persons identified as a &#8220;Lender&#8221; on the signature pages hereto and their successors and assigns.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Lending Office</u>&#8221; means, as to any Lender, the office address of such Lender and, as appropriate, account of such Lender set forth on <u>Schedule 12.02</u> or such other address or account as such Lender may from time to time notify the Borrower and the Administrative Agent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Lien</u>&#8221; means any mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or other), charge, or preference, priority or other security interest or preferential arrangement in the nature of a security interest of any kind or nature whatsoever (including any conditional sale or other title retention agreement, any easement, right of way or other encumbrance on title to real property, and any financing lease having substantially the same economic effect as any of the foregoing).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Loan</u>&#8221; means an extension of credit by a Lender to the Borrower under <u>Article II</u> in the form of a Term A Loan, a Term B Loan or a Term C Loan.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Loan Documents</u>&#8221; means this Agreement, each Note, each Joinder Agreement, each Collateral Document, the Intercreditor Agreement and any other agreement, instrument or document designated by its terms as a &#8220;Loan Document&#8221;.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Loan Notice</u>&#8221; means a notice of a Borrowing of Loans pursuant to <u>Section 2.02(a),</u> which shall be substantially in the form of <u>Exhibit A.</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">19</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Loan Parties</u>&#8221; means, collectively, the Borrower and each Guarantor.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#8220;<u>Make-Whole Amount</u>&#8221; means, on any date of determination, with respect to any amount of any Loan that is repaid or required to be repaid prior to the date as set forth in clause (a) of the definition of &#8220;Maturity Date&#8221;, an amount equal to the amount, if any, by which (a) the sum of (i) one hundred two percent (102%) of the principal amount of the Loan repaid or required to be repaid <u>plus</u> (ii) the present value as of such date of determination (as determined by the Administrative Agent in accordance with customary practice) of all interest that would have accrued on the principal amount of the Loans repaid or required to be repaid through and including the second anniversary of the date of the Borrowing of such Loan, computed using a discount rate equal to the Three-Month Treasury Rate (<u>provided</u> that if a PIK Election was made for the most recently completed Interest Period, this present value computation shall be calculated assuming that the Borrower would have made the PIK Election for all of the remaining periods eligible for such PIK Election) <u>plus</u> one half of one percent (0.50%), exceeds (b) the principal amount of the Loan repaid or required to be repaid.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Market Withdrawal</u>&#8221; means a Person&#8217;s removal or correction of a distributed product which involves a minor violation that would not be subject to legal action by the FDA, CMS or any other Governmental Authority or which involves no violation, e.g., normal stock rotation practices, routine equipment adjustments and repairs, etc., as that term is defined in 21 C.F.R. 7.3(j).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Material Adverse Effect</u>&#8221; means (a) a material adverse change in, or a material adverse effect upon, the business, assets, properties, liabilities (actual or contingent), or condition (financial or otherwise) of the Borrower and its Subsidiaries taken as a whole, (b) a material impairment of the rights and remedies of the Administrative Agent or any Lender under any Loan Document to which it is a party or a material impairment in the perfection, value or priority of the Administrative Agent&#8217;s security interests in the Collateral, (c) a material impairment of the ability of any Loan Party to perform its obligations under any Loan Document to which it is a party, or (d) a material adverse effect upon the legality, validity, binding effect or enforceability against any Loan Party of any Loan Document to which it is a party.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Material Contracts</u>&#8221; means (i) the Organization Documents of the Loan Parties, (ii) those agreements listed on <u>Schedule 6.22</u>, (iii) the Royalty Financing Documents and any Other Royalty Financing Documents and (iv) after the Closing Date, any agreement of the type described in any of clauses (a) through (g) of <u>Section 6.22</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Material IP Rights</u>&#8221; means IP Rights (i) with respect to each of the Key Products and (ii) any other Product material to the Loan Parties, their respective properties or the conduct or operation of their respective businesses taken as a whole.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Material Product</u>&#8221; means (a) each of the Key Products and (b) each other Product the loss of which could reasonably be expected, either individually or, together with its related (as determined based on the applicable drug substance) Products in the aggregate, to have a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Material</u><u> Required</u><u> </u><u>Permit</u>&#8221; means (a) any Required Permit with respect to any Material Product in any Key Territory or Ireland and (b) any other Required Permit where, in the case of this clause (b), the loss of which, the failure to possess or maintain, or any restriction placed thereon, in each case, could reasonably be expected, either individually or in the aggregate, to result in (i) a material adverse effect on any Product Development and Commercialization Activities or (ii) a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Maturity Date</u>&#8221; means (a) December 7, 2025, or (b) if earlier, such earlier date on which the Loans are accelerated in whole pursuant to <u>Section 9.02</u> hereof; <u>provided</u>, <u>that</u>, if such date is not a Business Day, the Maturity Date shall be the first Business Day immediately preceding such date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">20</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Maximum Rate</u>&#8221; has the meaning set forth in <u>Section 12.09</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>MDCP</u>&#8221; means MDCP, LLC, a Delaware limited liability company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Medicaid</u>&#8221; shall mean a medical assistance program administered by a state agency and approved by the CMS pursuant to Title XIX of the Social Security Act, (42 U.S.C. &#167;&#167; 1396 et seq.) and the regulations promulgated thereunder, or any successor program.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Medicare</u>&#8221; means that certain federal program providing health insurance for eligible elderly and other individuals, under which physicians, hospitals, skilled nursing homes, home health care and other providers are paid for certain covered services they provide to the beneficiaries of such program, which program is more fully described in Title XVIII of the Social Security Act (42 U.S.C. &#167;&#167; 1395 et seq.) and the regulations promulgated thereunder, or any successor program.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>MidCap Indebtedness</u>&#8221; means the all Indebtedness or other obligations of the Borrower and its Subsidiaries outstanding under that certain Second Amended and Restated Credit and Security Agreement, dated as of February 5, 2019, by and among the Borrower, the Subsidiaries of the Borrower party thereto from time to time, MidCap Financial Trust, as administrative agent, and the lenders party thereto from time to time, the &#8220;Security Documents&#8221; (as defined therein) and all other agreements and documents entered into in connection therewith, in each case, as amended, modified or otherwise supplemented from time to time prior to the Term A Borrowing Date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Moody&#8217;s</u>&#8221; means Moody&#8217;s Investors Service, Inc. and any successor thereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Mortgages</u>&#8221; means, individually or collectively, as the context requires, each of the mortgages, deeds of trust or deeds to secure debt that purport to grant to the Administrative Agent, for the benefit of the Secured Parties, a security interest in the fee interest and/or leasehold interests of any Loan Party in real property (other than Excluded Property).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Multiemployer Plan</u>&#8221; means any employee benefit plan of the type described in Section 4001(a)(3) of ERISA, to which the Borrower or any ERISA Affiliate makes or is obligated to make contributions, or during the preceding five plan years, has made or been obligated to make contributions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Multiple Employer Plan</u>&#8221; means a Plan which has two or more contributing sponsors (including the Borrower or any ERISA Affiliate) at least two of whom are not under common control, as such a plan is described in Section 4064 of ERISA.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>NDA</u>&#8221; means a new drug application filed with the FDA pursuant to Section 505(b) of the FDCA, along with all supplements and amendments thereto, and any similar application for marketing authorization required by any country, jurisdiction or Governmental Authority other than the United States.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Net Cash Proceeds</u>&#8221; means the aggregate cash or Cash Equivalents proceeds received by any Loan Party or any Subsidiary in respect of any Disposition, Debt Issuance, Involuntary Disposition or Extraordinary Receipt (other than Excluded Business Interruption Proceeds), net of (a) reasonable direct costs incurred in connection therewith (including, without limitation, legal, accounting and investment banking fees, and sales commissions), (b) Taxes paid or payable as a result thereof, (c) in the case of any Disposition, the amount necessary to retire any Indebtedness secured by a Permitted Lien (ranking senior to any Lien of the Administrative Agent) on the related property and (d) in the case of any Extraordinary Receipt, reasonable direct costs incurred in connection with the collection of such proceeds, awards or other payments; it being understood that &#8220;Net Cash Proceeds&#8221; shall include, without limitation, any cash or Cash Equivalents received upon the sale or other disposition of any non-cash consideration received by any Loan Party or any Subsidiary in any Disposition, Involuntary Disposition or Extraordinary Receipt.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">21</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Net Cash Proceeds - Licensing</u>&#8221; means Net Cash Proceeds received by the Borrower or any Subsidiary in respect of any Non-Permitted License or Permitted License, including, without limitation, all upfront payments, royalties, milestone payments, sublicense revenues or other proceeds received in connection therewith.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Net Cash Proceeds &#8211; </u><u>Non-Permitted </u><u>Royalty Financing</u>&#8221; means Net Cash Proceeds received by the Borrower or any Subsidiary in respect of any Non-Permitted Royalty Financing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Non-Consenting Lender</u>&#8221; means any Lender that does not approve any consent, waiver or amendment that (a) requires the approval of all Lenders or all affected Lenders in accordance with the terms of <u>Section 12.01(a)</u> and (b) has been approved by the Required Lenders.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Non-FDA Governmental Action</u>&#8221; has the meaning set forth in <u>Section 9.01(s)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Non-Key Products</u>&#8221; means Products of the Borrower and its Subsidiaries other than the Key Products.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Non-Key Territories</u>&#8221; means any jurisdiction other than the Key Territories.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Non-Permitted License</u>&#8221; means any exclusive or non-exclusive license or sublicense of a Key Product (or any IP Rights related to a Key Product) in any Key Territory. For the avoidance of doubt, but subject to the definition of Permitted License, Non-Permitted Licenses shall not include (i) any exclusive or non-exclusive license or sublicense of a Key Product (or any IP Rights related to a Key Product) in a Non-Key Territory and (ii) any exclusive or non-exclusive license or sublicense of a Product that is not a Key Product (or any IP Rights related to such Product that is not a Key Product) in any territory.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Non-Permitted Royalty Financing</u>&#8221; means the sale, transfer or financing of a right to receive any sales or revenue or other consideration with respect to a Product (or any IP Rights related a Product) other than the Royalty Financing and any Other Royalty Financing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Non-U.S. Regulatory Approval Subsidiary</u>&#8221; means any Non-U.S. Subsidiary organized under the laws of any of any jurisdiction (other than France, Germany, Ireland, [***], Japan, [***] and the United Kingdom), all of the assets of which consist of a local law regulatory approval; <u>provided</u>, <u>however</u>, that in no event will any Non U.S. Subsidiary which is acquired pursuant to a Permitted Acquisition constitute a Non-U.S. Regulatory Approval Subsidiary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Non-U.S. Subsidiary</u>&#8221; means any Subsidiary that is not a U.S. Subsidiary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Note</u>&#8221; or &#8220;<u>Notes</u>&#8221; means the Term A Notes, the Term B Notes, and the Term C Notes, individually or collectively, as appropriate.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Obligations</u>&#8221; means (a) all advances to, and debts, liabilities, obligations, covenants and duties of, any Loan Party arising under any Loan Document or otherwise with respect to any Loan (including any PIK Interest Payments) and (b) all costs and expenses incurred in connection with enforcement and collection of the foregoing, including the fees, charges and disbursements of counsel, in each case, whether direct or indirect (including those acquired by assumption), absolute or contingent, due or to become due, now existing or hereafter arising and including interest and fees that accrue after the commencement by or against any Loan Party or any Affiliate thereof of any proceeding under any Debtor Relief Laws naming such Person as the debtor in such proceeding, regardless of whether such interest and fees are allowed claims in such proceeding.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">22</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>OFAC</u>&#8221; means the Office of Foreign Assets Control of the United States Department of the Treasury.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Operating Lease</u>&#8221; means any lease of any Facility separate and distinct from the owner of the applicable Facility, and all amendments thereto and extensions thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Organization Documents</u>&#8221; means, (a) with respect to any corporation, the certificate or articles of incorporation and the bylaws, (b) with respect to any limited liability company, the certificate or articles of formation, incorporation or organization and operating agreement or constitutional documents, and (c) with respect to any partnership, joint venture, trust or other form of business entity, the partnership, joint venture or other applicable agreement of formation or organization, including in each case of the foregoing <u>clauses (a)</u> through <u>(c)</u> the equivalent or comparable constitutive documents with respect to any non-U.S. jurisdiction, and any agreement, instrument, filing or notice with respect thereto filed in connection with its formation or organization with the applicable Governmental Authority in the jurisdiction of its formation or organization and, if applicable, any certificate or articles of formation or organization of such entity.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Orladeyo</u>&#8221; means the Product described in the NDA No. 214094 filed with the FDA and analogous applications in jurisdictions outside the United States and referenced by the Borrower as ORLADEYO&#8482; (berotralstat).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Orladeyo Product Family</u>&#8221; means (a) Orladeyo, [***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Orladeyo Consolidated U.S. Net Product Sales</u>&#8221; means, for any period, consolidated net revenues of the Loan Parties from sales of Orladeyo in the United States for the usage by patients in the United States for such period, excluding (i) the revenues of any Subsidiary to the extent that the declaration or payment of dividends or similar distributions by that Subsidiary of the income resulting from such revenues is not at the time permitted by operation of the terms of its Organization Documents or any agreement, instrument, judgment, decree, order, statute, rule or governmental regulation applicable to that Subsidiary, (ii) for the avoidance of doubt, distribution income, service payments, royalty payments, license income, and all other forms of non-product sales during such period and (iii) the aggregate amount of all payments paid or required to be paid in respect of such period under the Royalty Financing Documents and, for the avoidance of doubt and without limiting the restrictions set forth in the definitions of Other Royalty Financings and Royalty Financing Restrictions, the Other Royalty Financing Documents, all as determined and reported in accordance with GAAP.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Orladeyo Net Product Sales</u>&#8221; means, for any period, consolidated net revenues of the Borrower and its Subsidiaries from sales of the Orladeyo Product Family in any jurisdiction for such period, all as determined and reported in accordance with GAAP.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Other Intellectual Property</u>&#8221; means all worldwide intellectual property rights, industrial property rights, proprietary rights and common-law rights, whether registered or unregistered, which are not otherwise included in Confidential Information, Copyrights, Copyright Licenses, Domain Names, Permits, Other IP Agreements, Patents, Patent Licenses, Trademarks and Trademark Licenses, Proprietary Databases, Proprietary Software, Websites, Website Agreements and Trade Secrets, including, without limitation, all rights to and under all new and useful algorithms, concepts, data (including all clinical data relating to a Product or Service), databases, designs, discoveries, inventions, know-how, methods, processes, protocols, show-how, software (other than commercially available, off-the-shelf software), specifications for Products and processes for Services, techniques, technology, trade dress and all improvements thereof and thereto, which is owned by the Borrower or any Subsidiary or which the Borrower or any Subsidiary is licensed, authorized or otherwise granted rights under or to, and which is used by the Borrower or any other Person to advertise, develop, manufacture, import, market, promote, offer for sale, sell, use, provide and/or otherwise distribute a Product or Service.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">23</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Other IP Agreements</u>&#8221; means any agreement, whether written or oral, providing for the grant of any right under any Confidential Information, Permits, Proprietary Database, Proprietary Software, Trade Secret and/or any other IP Rights, to the extent that the grant of any such right is not otherwise the subject of a Copyright License, Trademark License, Patent License or Website Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Other Royalty Financings</u>&#8221; means one or more future royalty financings through true sales by the Borrower of a synthetic royalty tied to annual net sales of (i) BCX9930 within the Key Territories, (ii) BCX9930 within the Non-Key Territories and/or (iii) the Non-Key Products, pursuant to the terms of the Other Royalty Financing Documents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Other Royalty Financing Documents</u>&#8221; means the documents governing or evidencing any Other Royalty Financing, which shall, in each case, be subject to the Royalty Financing Restrictions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Outstanding Amount</u>&#8221; means with respect to any Loans on any date, the aggregate outstanding principal amount thereof after giving effect to any borrowings and prepayments or repayments of any Loans occurring on such date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Participant</u>&#8221; has the meaning set forth in <u>Section 12.06(h)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Participant Register</u>&#8221; has the meaning specified in <u>Section 12.06(d)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Patent License</u>&#8221; means any agreement, whether written or oral, providing for the grant of any right under any Patent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Patents</u>&#8221; means all letters patent and patent applications in the United States and all other countries (and all letters patent that issue therefrom) and all reissues, extensions, renewals, divisions and continuations (including continuations-in-part and continuing prosecution applications) thereof, for the full term thereof, together with the right to claim the priority thereto, which are owned by the Borrower or any Subsidiary or which the Borrower or any Subsidiary is licensed, authorized or otherwise granted rights under or to.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>PATRIOT Act</u>&#8221; means the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>PBGC</u>&#8221; means the Pension Benefit Guaranty Corporation or any successor thereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Pension Act</u>&#8221; means the Pension Protection Act of 2006.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Pension Funding Rules</u>&#8221; means the rules of the Internal Revenue Code and ERISA regarding minimum required contributions (including any installment payment thereof) to Pension Plans and set forth in Section 412, 430, 431, 432 and 436 of the Internal Revenue Code and Sections 302, 303, 304 and 305 of ERISA.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Pension Plan</u>&#8221; means any employee pension benefit plan (including a Multiple Employer Plan or a Multiemployer Plan) that is maintained or is contributed to by the Borrower or any ERISA Affiliate and that is either covered by Title IV of ERISA or is subject to minimum funding standards under Section 412 of the Internal Revenue Code.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">24</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Perfection and Due Diligence Certificate</u>&#8221; means that certain Perfection and Due Diligence Certificate dated as of the Closing Date executed by the Loan Parties and certified to the Lenders and the Administrative Agent, as amended or modified from time to time in accordance with the terms hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Permits</u>&#8221; means licenses, certificates, accreditations, product clearances or approvals, provider numbers or provider authorizations, marketing authorizations, other authorizations, registrations, permits, consents and approvals issued in connection with the conduct of the Borrower&#8217;s or any Subsidiary&#8217;s business or to comply with any applicable Laws, including those issued by any Governmental Authority or any other Person, including, without limitation, those relating to Environmental Laws.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Permitted Acquisition</u>&#8221; means an Investment consisting of an Acquisition by a Loan Party; <u>provided</u>, <u>that</u>: (x) the Required Lenders have consented thereto in writing or (y) (a) no Default or Event of Default shall have occurred and be continuing or would result from such Acquisition, (b) the property acquired (or the property of the Person acquired) in such Acquisition is used or useful in the same or a reasonably related line of business as the Borrower and its Subsidiaries were engaged in on the Closing Date (or any reasonable extensions or expansions thereof), (c) the Administrative Agent shall have received all items in respect of the Equity Interests or property acquired in such Acquisition required to be delivered by the terms of <u>Section 7.12</u> and/or <u>Section 7.14</u>, (d) such Acquisition shall not be a &#8220;hostile&#8221; acquisition and shall have been approved by the Board of Directors and/or the shareholders (or equivalent) of the applicable Loan Party and the target of such Acquisition, (e) the Borrower shall have delivered to the Administrative Agent pro forma financial statements for the Borrower and its Subsidiaries after giving effect to such Acquisition for the twelve month period ending as of the most recent fiscal quarter end in a form satisfactory to the Administrative Agent, (f) the representations and warranties made by the Loan Parties in each Loan Document shall be true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) both (i) at and as if made as of the date of execution of the definitive documentation for such Acquisition (assuming for such purposes that such Acquisition has been consummated) and (ii) at and as if made as of the date of such Acquisition (assuming for such purposes that such Acquisition has been consummated) except to the extent any such representation and warranty expressly relates to an earlier date, in which case it shall be true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) as of such earlier date, (g) Borrower shall have demonstrated to the reasonable satisfaction of the Administrative Agent that, after giving effect to such Acquisition on a pro forma basis, the Loan Parties are in compliance with the financial covenants set forth in <u>Section 8.16</u> and, if the Term C Borrowing Date has occurred and for so long as the Borrower has not exercised the Cure Right in accordance with <u>Section 9.04</u>, <u>Section 8.17,</u> (h) the aggregate consideration (including cash and non-cash consideration, deferred purchase price and any Earn Out Obligations) paid by the Borrower and its Subsidiaries for all such Acquisitions during the term of this Agreement shall not exceed $[***] in the aggregate, and (i) Borrower shall have delivered to the Administrative Agent a certificate of a Responsible Financial Officer of Borrower certifying that the foregoing conditions have been satisfied.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Permitted Contingent Obligations</u>&#8221; means (a) Guarantees resulting from endorsements for collection or deposit in the ordinary course of business; (b) Guarantees incurred in the ordinary course of business with respect to surety and appeal bonds, performance bonds and other similar obligations not to exceed [***] in the aggregate at any time outstanding; (c) Guarantees arising under indemnity agreements with title insurers; (d) Guarantees arising with respect to customary indemnification obligations in favor of purchasers in connection with Dispositions of personal property assets permitted hereunder; (e) Guarantees arising under the Loan Documents; (f) [reserved]; (g) Guarantees existing or arising in connection with any security deposit or letter of credit obtained for the sole purpose of securing a lease of real property, or in connection with ancillary bank services such as a corporate credit card facility, provided that the aggregate face amount of all such security deposits, letters of credit and ancillary bank services does not at any time exceed [***]; and (h) the HSBC Letter of Credit secured solely by Liens permitted under <u>Section 8.01(s)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">25</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Permitted Licenses</u>&#8221; means, collectively, (a) the licenses set forth in <u>Schedule 1.01</u>, and (b)&nbsp;exclusive and non-exclusive licenses and sublicenses (other than any Non-Permitted License) entered into after the Closing Date for the use of IP Rights of the Borrower or any of its Subsidiaries entered into in the ordinary course of business and not interfering in any material respect with the business of any Loan Party or any of its Subsidiaries; <u>provided</u>, <u>that</u>, solely with respect to clause (b) above, with respect to each such license and sublicense, (i)&nbsp;no Event of Default has occurred or is continuing at the time of such license or sublicense, (ii) after giving effect thereto, the Borrower and its Subsidiaries retain sufficient rights to use or benefit from the subject IP Rights as to enable them to conduct their business in the ordinary course, (iii) such license or sublicense constitutes an arm&#8217;s-length transaction, the terms of which, on their face, (x) do not provide for a sale or assignment of any IP Rights and (y) do not restrict the ability of the Borrower or any of its Subsidiaries, as applicable, to pledge, grant a Lien on, or assign or otherwise transfer any IP Rights of the Borrower or any Subsidiary (except, in the case of this clause (y) with respect to such license or sublicense, customary non-assignment provisions that restrict the assignability of such license or sublicense but do not otherwise restrict the ability of the Borrower or any Subsidiary (as applicable) to pledge, grant a Lien on or assign or otherwise transfer any other IP Rights), (iv) all upfront payments, royalties, milestone payments, sublicense revenues or other proceeds (other than upfront payments, royalties, milestone payments, sublicense revenues or other proceeds of less than $[***] in the aggregate per Permitted License) arising from the licensing agreement that are payable to a Loan Party are paid to a Deposit Account that is governed by a Deposit Account Control Agreement or solely in the case of a Deposit Account of Loan Party that is a Non-U.S Subsidiary, in which the Administrative Agent otherwise has a first-priority, perfected security interest for the benefit of the Secured Parties, (v) in the case of any exclusive license or sublicense, (A) the Borrower delivers ten (10) days&#8217; prior written notice and a brief summary of the terms of the proposed license or sublicense to the Administrative Agent and delivers to the Administrative Agent copies of the final executed licensing documents in connection with such exclusive license or sublicense promptly upon consummation thereof and (B) any such license or sublicense could not result in a legal transfer of title of the licensed or sublicensed property and (vi) such license has been approved by the Borrower&#8217;s Board of Directors.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Permitted Liens</u>&#8221; means, at any time, Liens in respect of property of any Loan Party or any of its Subsidiaries permitted to exist at such time pursuant to the terms of <u>Section 8.01</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Person</u>&#8221; means any natural person, corporation, limited liability company, trust, unincorporated organization, joint venture, association, company, partnership, Governmental Authority or any other legal entity, whether acting in an individual, fiduciary or other capacity.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>PHSA</u>&#8221; means the Public Health Service Act, 42 U.S.C. Section 201 et seq., as amended, and all regulations promulgated thereunder.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#8220;<u>PIK Election</u>&#8221; shall have the meaning set forth in <u>Section 2.</u><u>06</u><u>(d)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#8220;<u>PIK Interest</u>&#8221; shall have the meaning set forth <u>Section 2.</u><u>06</u><u>(d)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#8220;<u>PIK Interest Payment</u>&#8221; shall have the meaning set forth in <u>Section 2.</u><u>06</u><u>(d)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Plan</u>&#8221; means any employee benefit plan within the meaning of Section 3(3) of ERISA (including a Pension Plan), maintained for employees of the Borrower or any ERISA Affiliate or any such Plan to which the Borrower or any ERISA Affiliate is required to contribute on behalf of any of its employees or otherwise has any liability.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">26</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Pledge Agreement</u>&#8221; means the pledge agreement dated as of the Closing Date executed in favor of the Administrative Agent, for the benefit of the Secured Parties, by each of the Loan Parties, as amended or modified from time to time in accordance with the terms hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Product</u>&#8221; means any current or future service or product researched, designed, developed, imported, exported, manufactured, licensed, marketed, advertised, sold, offered for sale, performed, distributed, promoted, tested, provided or commercialized by or on behalf of the Borrower or any Subsidiary, including any such product in development or which may be developed in connection with or that embody, in whole or in part, the IP Rights, including those products set forth on <u>Schedule 1.01</u> (as updated from time to time in accordance with the terms of this Agreement), <u>provided</u>, <u>that</u>, if the Borrower shall fail to comply with its obligations under this Agreement to give notice to the Administrative Agent and update <u>Schedule 1.01</u> prior to manufacturing, selling, developing, testing or marketing any new Product, any such improperly undisclosed Product shall be deemed to be included in this definition.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Product Acquisition</u>&#8221; means any transaction or series of related transactions for the purpose of or resulting, directly or indirectly, in the acquisition of a product license or a product line, and/or related IP Rights acquired or licensed by a Loan Party or any of its Subsidiaries from a Person (other than a Loan Party, any Subsidiary thereof or any Affiliate thereof) to facilitate the advertisement, development, importing, manufacturing, marketing, offering for sale, promotion, sale, testing, use or distribution of such product or product line by a Loan Party or a Subsidiary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Product Collateral</u>&#8221; means the &#8220;Product Collateral&#8221; as such term is defined in the Royalty Financing Agreement as in effect on the date hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Product Development and Commercialization Activities</u>&#8221; means, with respect to any Material Product, any combination of research, development, manufacture, import, use, sale, importation, storage, labeling, marketing, promotion, supply, distribution, testing, packaging, purchasing or other commercialization activities, receipt of payment in respect of any of the foregoing, or like activities the purpose of which is to develop or commercially exploit such Material Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Proprietary Databases</u>&#8221; means any material non-public proprietary database that is owned by the Borrower or any Subsidiary or that the Borrower or any Subsidiary is licensed, authorized or otherwise granted rights under or to, and that is used by the Borrower or any other Person to manufacture, develop, import, market, promote, advertise, offer for sale, sell, use and/or otherwise distribute or provide a Product or Service.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:37.4pt;">&#8220;<u>Proprietary Software</u>&#8221; means any proprietary software owned, licensed or otherwise used, other than any software that is generally commercially available, off-the-shelf and/or open source including, without limitation, the object code and source code forms of such software and all associated documentation, which is owned by the Borrower or any Subsidiary or which the Borrower or any Subsidiary is licensed, authorized or otherwise granted rights under or to, and that is used by the Borrower or any other Person to manufacture, develop, import, market, promote, advertise, offer for sale, sell, use and/or otherwise distribute or provide a Product or Service.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Qualified Capital Stock</u>&#8221; of any Person means any Equity Interests of such Person that are not Disqualified Capital Stock.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">27</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Real Property Security Documents</u>&#8221; means with respect to the fee interest and/or leasehold interest of any Loan Party in any real property:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a fully executed and notarized Mortgage encumbering the fee interest of such Loan Party in such real property;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if requested by the Administrative Agent in its sole discretion, maps or plats of an as-built survey of the sites of such real property certified to the Administrative Agent and the title insurance company issuing the policies referred to in <u>clause (c)</u> of this definition in a manner satisfactory to each of the Administrative Agent and such title insurance company, dated a date satisfactory to each of the Administrative Agent and such title insurance company by an independent professional licensed land surveyor, which maps or plats and the surveys on which they are based shall be sufficient to delete any standard printed survey exception contained in the applicable title policy and be made in accordance with the Minimum Standard Detail Requirements for Land Title Surveys jointly established and adopted by the American Land Title Association and the National Society of Professional Surveyors, Inc. in 2016 with items 2, 3, 4, 6(b), 7(a), 7(b)(1), 7(c), 8, 9, 10, 11(a), 13, 14, 16,17, 18 and 19 on Table A thereof completed;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ALTA mortgagee title insurance policies issued by a title insurance company acceptable to the Administrative Agent with respect to such real property, assuring the Administrative Agent that the Mortgage covering such real property creates a valid and enforceable first priority mortgage lien on such real property, free and clear of all defects and encumbrances except Permitted Liens, which title insurance policies shall otherwise be in form and substance satisfactory to the Administrative Agent and shall include such endorsements as are requested by the Administrative Agent;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;evidence as to (i) whether such real property is a Flood Hazard Property and (ii) if such real property is a Flood Hazard Property, (A) whether the community in which such real property is located is participating in the National Flood Insurance Program, (B) the applicable Loan Party&#8217;s written acknowledgment of receipt of written notification from the Administrative Agent (1) as to the fact that such real property is a Flood Hazard Property and (2) as to whether the community in which each such Flood Hazard Property is located is participating in the National Flood Insurance Program and (C) copies of insurance policies or certificates of insurance of the Borrower and its Subsidiaries evidencing flood insurance satisfactory to the Administrative Agent and naming the Administrative Agent and its successors and/or assigns as sole loss payee on behalf of the Secured Parties;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if requested by the Administrative Agent in its sole discretion, an environmental assessment report, as to such real property, in form and substance and from professional firms acceptable to the Administrative Agent;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if requested by the Administrative Agent in its sole discretion, evidence reasonably satisfactory to the Administrative Agent that such real property, and the uses of such real property, are in compliance in all material respects with all applicable zoning laws (the evidence submitted as to which should include the zoning designation made for such real property, the permitted uses of such real property under such zoning designation and, if available, zoning requirements as to parking, lot size, ingress, egress and building setbacks);</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in the case of a leasehold interest of any Loan Party in such real property, (i) such Collateral Access Agreements as may be required by the Administrative Agent, and (ii) evidence that the applicable lease, a memorandum of lease with respect thereto, or other evidence of such lease in form and substance satisfactory to the Administrative Agent, has been or will be recorded in all places to the extent necessary or desirable, in the judgment of the Administrative Agent, so as to enable the Mortgage encumbering such leasehold interest to effectively create a valid and enforceable first priority lien (subject to Permitted Liens) on such leasehold interest in favor of the Administrative Agent (or such other Person as may be required or desired under local law); and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">28</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:45pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if requested by the Administrative Agent in its sole discretion, an opinion of legal counsel to the Loan Party granting the Mortgage on such real property, addressed to the Administrative Agent and each Lender, in form and substance reasonably acceptable to the Administrative Agent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Recipient</u>&#8221; means the Administrative Agent and any Lender.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Register</u>&#8221; has the meaning provided in <u>Section 12.06</u><u>(c)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Related Parties</u>&#8221; means, with respect to any Person, such Person&#8217;s Affiliates and the partners, directors, officers, employees, agents, trustees, administrators, managers, consultants, advisors, sub-advisors and representatives of such Person and of such Person&#8217;s Affiliates.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Repatriation</u>&#8221; and &#8220;<u>Repatriated</u>&#8221; has the meaning provided in <u>Section 2.03(b)(vi)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Reportable Event</u>&#8221; means any of the events set forth in Section 4043(c) of ERISA, other than events for which the thirty-day notice period has been waived.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Required Lenders</u>&#8221; means, at any time, Lenders having Total Credit Exposures representing more than fifty percent (50%) of the Total Credit Exposures of all Lenders. The Total Credit Exposure of any Defaulting Lender shall be disregarded in determining Required Lenders at any time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Required Permit</u>&#8221; means a Permit (a) issued or required under Laws applicable to the business or Facilities of the Borrower or any Subsidiary or necessary to be eligible to receive payment and compensation from and to participate in any material Third Party Payor Arrangements or any Government Reimbursement Program, or in the manufacturing, testing, developing, importing, exporting, possession, ownership, warehousing, marketing, promoting, sale, labeling, furnishing, distribution or delivery of goods or services under Laws applicable to the business or Facilities of the Borrower or any Subsidiary (including without limitation, at any point in time, all licenses, approvals and permits issued by the FDA, CMS or any other Governmental Authority necessary for the testing, development, manufacture, marketing, sale or provision of any Product or Service by the Borrower or any Subsidiary as such activities are being conducted by the Borrower or such Subsidiary with respect to such Product or Service at such time), or (b) issued by any Person from which the Borrower or any Subsidiary has, as of the Closing Date, received an accreditation.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Resolution Authority</u>&#8221; means an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK Resolution Authority.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Responsible Financial Officer</u>&#8221; means the chief financial officer, treasurer or assistant treasurer of the Borrower. Any document delivered hereunder that is signed by a Responsible Financial Officer of the Borrower shall be conclusively presumed to have been authorized by all necessary corporate, partnership and/or other action on the part of the Borrower and such Responsible Financial Officer shall be conclusively presumed to have acted on behalf of the Borrower.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">29</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Responsible Officer</u>&#8221; means the chief executive officer, president, chief financial officer, chief operating officer, chief legal officer, general counsel, treasurer, assistant treasurer or any senior vice president of a Loan Party or in the case of a Non-U.S. Subsidiary that is a Loan Party, any of its directors, and, solely for purposes of the delivery of certificates pursuant to <u>Sections 5.01</u> or <u>7.12(b)</u>, the secretary or any assistant secretary of a Loan Party. Any document delivered hereunder that is signed by a Responsible Officer of a Loan Party shall be conclusively presumed to have been authorized by all necessary corporate, partnership and/or other action on the part of such Loan Party and such Responsible Officer shall be conclusively presumed to have acted on behalf of such Loan Party.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#8220;<u>Restricted Payment</u>&#8221; means (a) any dividend or other distribution, direct or indirect, on account of any shares (or equivalent) of any class of Equity Interests of any Loan Party or any of its Subsidiaries, now or hereafter outstanding, (b) any redemption, retirement, sinking fund or similar payment, purchase or other acquisition for value, direct or indirect, of any shares (or equivalent) of any class of Equity Interests of any Loan Party or any of its Subsidiaries, now or hereafter outstanding, (c) any payment made to retire, or to obtain the surrender of, any outstanding warrants, options or other rights to acquire shares of any class of Equity Interests of any Loan Party or any of its Subsidiaries, now or hereafter outstanding, (d) any payment made in respect of management, consulting, transaction or similar advisory fees (other than normal and reasonable compensation (including in the form of Equity Interests) and reimbursement of expenses of officers and directors in the ordinary course of business) to or for the account of any officer, director or holder (or any Affiliate of any holder) of at least 5% of the Equity Interests of any Loan Party or any of its Subsidiaries, (e) any payment made to the holders of Convertible Bond Indebtedness and (f) any payment made to any &#8220;Buyer&#8221; (or other comparable term) pursuant to the Royalty Financing Documents or the Other Royalty Financing Documents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#8220;<u>Revenue Participation Right</u>&#8221; means the &#8220;Revenue Participation Right&#8221; as such term is defined in the Royalty Financing Agreement as in effect on the date hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 36pt;">&#8220;<u>Royalty Financed BCX9930 Net Sales</u>&#8221; means, for any fiscal year, consolidated net revenues of the Borrower and its Subsidiaries from sales of BCX9930 in any Key Territory for such period, <u>including</u> distribution income, service payments, royalty payments and license income during such fiscal year, all as determined and reported in accordance with GAAP, but <u>excluding</u> the revenues of any Subsidiary to the extent that the declaration or payment of dividends or similar distributions by that Subsidiary of the income resulting from such revenues is not at the time permitted by operation of the terms of its Organization Documents or any agreement, instrument, judgment, decree, order, statute, rule or governmental regulation applicable to that Subsidiary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Royalty Financing</u>&#8221; means, subject to the Royalty Financing Restrictions, that certain true sale of the Revenue Participation Right to RPI 2019 Intermediate Finance Trust, a Delaware statutory trust, on the Term A Borrowing Date pursuant to the terms of the Royalty Financing Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Royalty Financing Agreement</u>&#8221; means the Purchase and Sale Agreement, dated as of December 7, 2020, between the Borrower and RPI 2019 Intermediate Finance Trust, a Delaware statutory trust, as amended, supplemented or otherwise modified from time to time in accordance with the terms of the Loan Documents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Royalty Financing Documents</u>&#8221; means the Royalty Financing Agreement, the Royalty Financing Side Letter, the Intercreditor Agreement and any other agreement, instrument or document entered into from time to time in connection therewith, in each case, as amended, supplemented or otherwise modified from time to time in accordance with the terms of the Loan Documents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">30</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Royalty Financing Restrictions</u>&#8221; means with respect to the Royalty Financing or any Other Royalty Financing, that (i) neither the Royalty Financing nor any such Other Royalty Financing shall have or provide for any (a)&nbsp;payment or return minimums, (b) redemption or buy-back obligations or any financial or other covenants (except for (x) customary exceptions such as royalty payments, reporting, audits, tax treatment and withholding, diligence, confidentiality, licensing and prosecution, maintenance and defense of IP Rights and (y) in the case of the Royalty Financing Documents, restrictions on Indebtedness pursuant to Section 6.8 of the Royalty Financing Agreement as in effect on the date hereof (but, in any event, shall permit the Indebtedness and other Obligations pursuant to the Loan Documents), (c) Lien on any asset of the Borrower or any of its Subsidiaries (including on the Borrower&#8217;s or such Subsidiary&#8217;s IP Rights, regulatory permits, receivables or other agreements), except (i) in the case of the Royalty Financing Documents, but subject to the Intercreditor Agreement, the Back-Up Security Interest in respect of the Revenue Participation Right and the Product Collateral and (ii) in the case of any Other Royalty Financing Documents, but subject to the execution and delivery of an intercreditor agreement in form and substance acceptable to the Administrative Agent, the grant by the Borrower of a backup security interest in the synthetic royalty purchased pursuant to such Other Royalty Financing Documents upon the recharacterization of the applicable Other Royalty Financing as a secured loan, not in any other asset of the Borrower or any Subsidiary, or (d) negative pledge restricting incurrence of any Lien on any asset of the Borrower or any of its Subsidiaries or other burdensome restrictions consisting of restrictions on making Restricted Payments to any Loan Party, paying Indebtedness or other obligations owed to any Loan Party, making loans or advances to any Loan Party, transferring any of its property to any Loan Party, or either pledging its property pursuant to or acting as a Loan Party pursuant to the Loan Documents or any renewals, refinancings, exchanges, refundings or extension thereof, (ii) neither the Royalty Financing nor any such Other Royalty Financing shall be structured in a manner that adversely affects the Borrower&#8217;s or any Subsidiary&#8217;s receipt of proceeds of Orladeyo Net Product Sales or BCX9930 Net Product Sales, expect (x) in the case of the Royalty Financing, the sale of the Revenue Participation Right and (y) in the case of any Other Royalty Financing, the sale of the right to receive a portion of the proceeds of BCX9930 Net Product Sales, (iii) in the case of the Royalty Financing, for any fiscal quarter, the terms of the Royalty Financing Documents shall provide for a royalty participation rate not to exceed (a) the Orladeyo Direct Sales Royalty Rate (as such term is defined in the Royalty Financing Agreement as in effect on the date hereof) multiplied by aggregate Orladeyo Direct Sales (as such term is defined in the Royalty Financing Agreement as in effect on the date hereof) during such fiscal quarter, (b) the Orladeyo Indirect Revenue Sharing Rate (as such term is defined in the Royalty Financing Agreement as in effect on the date hereof) multiplied by aggregate Orladeyo Indirect Revenue (as such term is defined in the Royalty Financing Agreement as in effect on the date hereof) during such fiscal quarter, (c) eight and three-quarters percent (8.75%) of Product Partnering Revenue (as such term is defined in the Royalty Financing Agreement as in effect on the date hereof) attributable to Orladeyo (as such term is defined in the Royalty Financing Agreement as in effect on the date hereof) for such fiscal quarter, (d) one percent (1.0%) of BCX9930 Net Sales (as each such term is defined in the Royalty Financing Agreement as in effect on the date hereof) (other than Product Partnering Revenue (as each such term is defined in the Royalty Financing Agreement as in effect on the date hereof) attributable to BCX9930 (as each such term is defined in the Royalty Financing Agreement as in effect on the date hereof)) for such fiscal quarter and (e) one percent (1.0%) of BCX9930 Product Partnering Revenue (as such term is defined in the Royalty Financing Agreement as in effect on the date hereof) attributable to BCX9930 (as such term is defined in the Royalty Financing Agreement as in effect on the date hereof) for such fiscal quarter, (iv) in the case of all Other Royalty Financings of BCX9930 within the Key Territories, the royalty participation rate with respect thereto shall not exceed [***] of Royalty Financed BCX9930 Net Sales in the aggregate for all Other Royalty Financings, (v) in the case of all Other Royalty Financings, shall not have covenants and defaults that are more restrictive on the Borrower and its Subsidiaries than the covenants and defaults set forth in the Royalty Financing Documents (but, in any event, the Other Royalty Financing Documents shall not include a restriction on the incurrence or maintenance of Indebtedness) or that conflict with, or prevent Borrower and its Subsidiaries from complying with, the covenants and defaults set forth in the Royalty Financing Documents, (vi) the Borrower shall cause any successor or permitted assignee of the Buyer under the Royalty Financing Documents to become a party to the Intercreditor Agreement in accordance with the terms thereof concurrently with such succession or assignment and (vii) the Borrower shall cause any successor or permitted assignee of the purchaser or buyer under the Other Royalty Financing Documents to become a party to the intercreditor agreement contemplated by clause (c)(ii) above to which such purchaser or buyer is a party in accordance with the terms thereof concurrently with such succession or assignment.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">31</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Royalty Financing Side Letter</u>&#8221; means the letter agreement dated as of December 7, 2020 between the Borrower and RPI 2019 Intermediate Finance Trust, a Delaware statutory trust, as amended, supplemented or otherwise modified from time to time in accordance with the terms of the Loan Documents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Royalty Payment</u>&#8221; means the &#8220;Royalty Payment&#8221; as such term is defined in the Royalty Financing Agreement as in effect on the date hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>S&amp;P</u>&#8221; means Standard &amp; Poor&#8217;s Financial Services LLC, a subsidiary of McGraw-Hill Financial, Inc., and any successor thereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Safety Notices</u>&#8221; has the meaning set forth in <u>Section 6.23(i)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Sale and Leaseback Transaction</u>&#8221; means, with respect to any Loan Party or any Subsidiary, any arrangement, directly or indirectly, with any Person whereby the Loan Party or such Subsidiary shall sell or transfer any property used or useful in its business, whether now owned or hereafter acquired, and thereafter rent or lease such property or other property that it intends to use for substantially the same purpose or purposes as the property being sold or transferred.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Sanction(s)</u>&#8221; means any sanction administered or enforced by the United States government (including, without limitation, OFAC), the United Nations Security Council, the European Union, Her Majesty&#8217;s Treasury (&#8220;<u>HMT</u>&#8221;) or other relevant sanctions authority.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Scheduled Unavailability Date</u>&#8221; has the meaning specified in <u>Section 10.03(c)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>SEC</u>&#8221; means the Securities and Exchange Commission, or any Governmental Authority succeeding to any of its principal functions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Secured Parties</u>&#8221; means, collectively, the Administrative Agent, the Lenders, the Indemnitees, each co-agent or subagent appointed by the Administrative Agent from time to time pursuant to <u>Section 11.05</u> and each of the foregoing Persons successors and assigns.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Securities Act</u>&#8221; means the Securities Act of 1933.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Securitization Transaction</u>&#8221; means, with respect to any Person, any financing transaction or series of financing transactions (including factoring arrangements) pursuant to which such Person or any Subsidiary of such Person may sell, convey or otherwise transfer, or grant a security interest in, accounts, payments, receivables, rights to future lease payments or residuals or similar rights to payment to a special purpose subsidiary or affiliate of such Person.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Security Agreement</u>&#8221; means the security agreement dated as of the Closing Date executed in favor of the Administrative Agent, for the benefit of the Secured Parties, by each of the Loan Parties, as amended or modified from time to time in accordance with the terms thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">32</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Services</u>&#8221; means services provided by the Borrower or any Affiliate thereof to un-Affiliated Persons, including without limitation any sales, laboratory analysis, testing, consulting, marketing, commercialization and any other healthcare-related services.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Small Business Act</u>&#8221; means the Small Business Act (15 U.S. Code Chapter 14A &#8211; Aid to Small Business).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Small Business Administration</u>&#8221; means the U.S. Small Business Administration.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Solvent</u>&#8221; or &#8220;<u>Solvency</u>&#8221; means, with respect to any Person as of a particular date, that on such date (a) such Person is able to pay its debts and other liabilities, contingent obligations and other commitments as they mature in the ordinary course of business, (b) such Person does not intend to, and does not believe that it will, incur debts or liabilities beyond such Person&#8217;s ability to pay as such debts and liabilities mature in their ordinary course, (c) such Person is not engaged in a business or a transaction, and is not about to engage in a business or a transaction, for which such Person&#8217;s property would constitute unreasonably small capital after giving due consideration to the prevailing practice in the industry in which such Person is engaged or is to engage, (d) the fair value of the property of such Person is greater than the total amount of liabilities, including, without limitation, contingent liabilities, of such Person and (e) the present fair salable value of the assets of such Person is not less than the amount that will be required to pay the probable liability of such Person on its debts as they become absolute and matured. In computing the amount of contingent liabilities at any time, it is intended that such liabilities will be computed at the amount which, in light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected to become an actual or matured liability.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Specified Products</u>&#8221; means (a) means the molecule described in investigational new drug applications (IND) [***], [***], [***] and [***] filed with the FDA and referenced by the Borrower as &#8220;BCX4430 (galidesivir)&#8221; and (b) means the Product described in the NDA No. 206426 filed with the FDA and referenced by the Borrower as RAPIVAB&#8482;(peramivir injection), in each case, as in existence as of the Closing Date; <u>provided</u> that, for the avoidance of doubt, no Specified Product shall include any Key Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Stockpile Sales</u>&#8221; means (a) &#8220;Non-Commercial Sales&#8221; as defined in the Purchase and Sale Agreement dated as of March 9, 2011 between the Borrower and JPR Royalty Sub, LLC as in effect on the date hereof and entered into in connection with the JPR Indenture, but excluding, for the avoidance of doubt, any sales, transfers, leases, licenses or other dispositions of any Key Product and (b) any sales (but excluding, for the avoidance of doubt, any license, lease or other disposition) of a Product for a profit in the ordinary course of business to Governmental Authorities to supply stockpiles for use in a public health emergency.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Subsidiary</u>&#8221; of a Person means a corporation, partnership, joint venture, limited liability company or other business entity of which a majority of the shares of Voting Stock is at the time beneficially owned, or the management of which is otherwise controlled, directly, or indirectly through one or more intermediaries, or both, by such Person. Unless otherwise specified, all references herein to a &#8220;Subsidiary&#8221; or to &#8220;Subsidiaries&#8221; shall refer to a Subsidiary or Subsidiaries of the Borrower. Notwithstanding the foregoing, until discharge of the JPR Indenture pursuant to and in accordance with Section 11.1 thereof, unless expressly provided herein, Subsidiaries of the Borrower shall not include JPR Royalty Sub.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Swap Contract</u>&#8221; means (a) any and all rate swap transactions, basis swaps, credit derivative transactions, forward rate transactions, commodity swaps, commodity options, forward commodity contracts, equity or equity index swaps or options, bond or bond price or bond index swaps or options or forward bond or forward bond price or forward bond index transactions, interest rate options, forward foreign exchange transactions, cap transactions, floor transactions, collar transactions, currency swap transactions, cross-currency rate swap transactions, currency options, spot contracts, or any other similar transactions or any combination of any of the foregoing (including any options to enter into any of the foregoing), whether or not any such transaction is governed by or subject to any master agreement, and (b) any and all transactions of any kind, and the related confirmations, which are subject to the terms and conditions of, or governed by, any form of master agreement published by the International Swaps and Derivatives Association, Inc., any International Foreign Exchange Master Agreement, or any other master agreement (any such master agreement, together with any related schedules, a &#8220;<u>Master Agreement</u>&#8221;), including any such obligations or liabilities under any Master Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">33</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Swap Termination Value</u>&#8221; means, in respect of any one or more Swap Contracts, after taking into account the effect of any legally enforceable netting agreement relating to such Swap Contracts, (a) for any date on or after the date such Swap Contracts have been closed out and termination value(s) determined in accordance therewith, such termination value(s) and (b) for any date prior to the date referenced in <u>clause (a)</u>, the amount(s) determined as the mark-to-market value(s) for such Swap Contracts, as determined based upon one or more mid-market or other readily available quotations provided by any recognized dealer in such Swap Contracts (which may include a Lender or any Affiliate of a Lender).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Synthetic Lease</u>&#8221; means any synthetic lease, tax retention operating lease, off-balance sheet loan or similar off-balance sheet financing arrangement whereby the arrangement is considered borrowed money indebtedness for tax purposes but is classified as an operating lease or does not otherwise appear on a balance sheet under GAAP.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Taxes</u>&#8221; has the meaning set forth in <u>Section 3.01(a)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term A Availability Period</u>&#8221; means the period commencing on and including the Closing Date and ending on the earliest of (a) June 1, 2021, (b) the date of termination of the Term A Commitments pursuant to <u>Section 2.04</u> and (c) the date of termination of the Term A Commitments pursuant to <u>Section 9.02.</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term A Borrowing</u>&#8221; means a borrowing consisting of simultaneous Term A Loans made by each of the Term A Lenders pursuant to <u>Section 2.01(a).</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term A Borrowing Date</u>&#8221; means the date that the Term A Borrowing shall be made pursuant to <u>Section 2.01(a).</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term A Commitment</u>&#8221; means, as to each Term A Lender, its obligation to make a Term A Loan to the Borrower pursuant to <u>Section 2.01(a),</u> in the principal amount set forth opposite such Lender&#8217;s name on <u>Schedule 2.01.</u> The aggregate principal amount of the Term A Commitments of all of the Term A Lenders as in effect on the Closing Date is ONE HUNDRED TWENTY-FIVE MILLION DOLLARS ($125,000,000).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term A Draw Condition</u><u>s</u>&#8221; means the condition that the Borrower shall have delivered (on or before the date that the Term A Borrowing is requested in accordance with <u>Section 2.02(a)</u>) to the Administrative Agent (i) a certificate of a Responsible Financial Officer of the Borrower (in form and substance reasonably satisfactory to the Administrative Agent) certifying, and such other evidence as the Administrative Agent may request demonstrating, that the FDA has approved Borrower&#8217;s NDA for the testing, manufacturing, marketing and commercial sale in the United States of Orladeyo for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and adolescent patients 12 years and older with either (a) a final product label consistent with the draft Orladeyo label in the form attached hereto as <u>Exhibit F</u> or (b) such other a final product label approved by the Required Lenders in writing, in their sole discretion and (ii) evidence satisfactory to the Administrative Agent that the Loan Parties are in compliance with the requirements set forth in <u>Section 8.16(i)</u> immediately prior to the Term A Borrowing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">34</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term A Facility</u>&#8221; means, at any time, (a) on or prior to the Term A Borrowing Date, the aggregate amount of the Term A Commitments at such time and (b) thereafter, the aggregate principal amount of the Term A Loans of all Term A Lenders outstanding at such time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term A Lender</u>&#8221; means (a) at any time on or prior to the Term A Borrowing Date, any Lender that has a Term A Commitment at such time and (b) at any time thereafter, any Lender that holds one or more Term A Loans at such time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term A Loan</u>&#8221; means an advance made by any Term A Lender under the Term A Facility.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term A Note</u>&#8221; has the meaning set forth in <u>Section 2.08.</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term B Availability Period</u>&#8221; means the period commencing on and including the Term A Borrowing Date and ending on the earliest of (a) [***], (b) the date of termination of the Term B Commitments pursuant to <u>Section 2.04</u> and (c) the date of termination of the Term B Commitments pursuant to <u>Section 9.02.</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term B Borrowing</u>&#8221; means a borrowing consisting of simultaneous Term B Loans made by each of the Term B Lenders pursuant to <u>Section 2.01(b).</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term B Borrowing Date</u>&#8221; means the date that the Term B Borrowing shall be made pursuant to <u>Section 2.01(b).</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term B Commitment</u>&#8221; means, as to each Lender, its obligation to make a Term B Loan to the Borrower pursuant to <u>Section 2.01(b),</u> in the principal amount set forth opposite such Lender&#8217;s name on <u>Schedule 2.01.</u> The aggregate principal amount of the Term B Commitments of all of the Lenders as in effect on the Closing Date is TWENTY-FIVE MILLION DOLLARS ($25,000,000).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term B Draw Conditions</u>&#8221; means the conditions that (i) the Borrower shall have delivered (on or before the date that the Term B Borrowing is requested in accordance with <u>Section 2.02(a)</u>) to the Administrative Agent (a) a certificate of a Responsible Financial Officer of the Borrower (in form and substance reasonably satisfactory to the Administrative Agent) certifying, and such other evidence as the Administrative Agent may request demonstrating, that Orladeyo Consolidated U.S. Net Product Sales for any [***] period ending on or before [***] were at least $[***] and (b) evidence satisfactory to the Administrative Agent that the Loan Parties are in compliance with the requirements set forth in <u>Section 8.16(ii)</u> immediately prior to the Term B Borrowing, and (ii) if the date on which the Term B Borrowing is requested in accordance with <u>Section 2.02(a)</u> is on or prior to the Term A Borrowing Date, the Term A Borrowing shall have occurred prior to (or contemporaneously with) the Term B Borrowing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term B Facility</u>&#8221; means, at any time, (a) on or prior to the Term B Borrowing Date, the aggregate amount of the Term B Commitments at such time and (b) thereafter, the aggregate principal amount of the Term B Loans of all Term B Lenders outstanding at such time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term B Lender</u>&#8221; means (a) at any time on or prior to the Term B Borrowing Date, any Lender that has a Term B Commitment at such time and (b) at any time thereafter, any Lender that holds one or more Term B Loans at such time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term B Loan</u>&#8221; means an advance made by any Term B Lender under the Term B Facility.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">35</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term B Note</u>&#8221; has the meaning set forth in <u>Section 2.08</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term C Availability Period</u>&#8221; means the period commencing on and including the Term B Borrowing Date and ending on the earliest of (a) [***], (b) the date of termination of the Term C Commitments pursuant to <u>Section 2.04</u>, (c) the date of termination of the Term C Commitments pursuant to <u>Section 9.02</u> and (d) the repayment in full of the Term A Loans and/or the Term B Loans.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term C Borrowing</u>&#8221; means a borrowing consisting of simultaneous Term C Loans made by each of the Term C Lenders pursuant to <u>Section 2.01(c)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term C Borrowing Date</u>&#8221; means the date that the Term C Borrowing shall be made pursuant to <u>Section 2.01(c).</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term C Commitment</u>&#8221; means, as to each Lender, its obligation to make a Term C Loan to the Borrower pursuant to <u>Section 2.01(c)</u>, in the principal amount set forth opposite such Lender&#8217;s name on <u>Schedule 2.01</u>. The aggregate principal amount of the Term C Commitments of all of the Lenders as in effect on the Closing Date is FIFTY MILLION DOLLARS ($50,000,000).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term C Draw Conditions</u>&#8221; means the conditions that (i) the Borrower shall have delivered (on or before the date that the Term C Borrowing is requested in accordance with <u>Section 2.02(a)</u>) to the Administrative Agent (a) a certificate of a Responsible Financial Officer of the Borrower (in form and substance reasonably satisfactory to the Administrative Agent) certifying, and such other evidence as the Administrative Agent may request demonstrating, that Orladeyo Consolidated U.S. Net Product Sales for any [***] period ending on or before [***] were at least $[***] and (b) evidence satisfactory to the Administrative Agent that the Loan Parties are in compliance with the requirements set forth in <u>Section 8.16(iii)</u> immediately prior to the Term C Borrowing, and (ii) if the date on which the Term C Borrowing is requested in accordance with <u>Section 2.02(a)</u> is on or prior to the Term A Borrowing Date and/or the Term B Borrowing Date, the Term A Borrowing and the Term B Borrowing shall have occurred prior to (or contemporaneously with) the Term C Borrowing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term C Facility</u>&#8221; means, at any time, (a) on or prior to the Term C Borrowing Date, the aggregate amount of the Term C Commitments at such time and (b) thereafter, the aggregate principal amount of the Term C Loans of all Term C Lenders outstanding at such time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term C Lender</u>&#8221; means (a) at any time on or prior to the Term C Borrowing Date, any Lender that has a Term C Commitment at such time and (b) at any time thereafter, any Lender that holds one or more Term C Loans at such time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term C Loan</u>&#8221; means an advance made by any Term C Lender under the Term C Facility.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term C Note</u>&#8221; has the meaning set forth in <u>Section 2.08</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Test Date</u>&#8221; has the meaning set forth in <u>Section 8.17</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Third Party</u>&#8221; means any Person other than the Borrower, any Subsidiary thereof or any Affiliate thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Third Party Payor</u>&#8221; means (i) a commercial medical insurance company, health maintenance organization, professional provider organization or other third party payor that reimburses providers for diagnostic laboratory services provided to individual patients, (ii) a nonprofit medical insurance company (such as the Blue Cross, Blue Shield entities), and (iii) a Government Account Debtor making payments under a Government Reimbursement Program.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">36</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Third Party Payor Arrangement</u>&#8221; shall mean a written agreement or arrangement with a Third Party Payor pursuant to which the Third Party Payor pays all or a portion of the charges of any Loan Party or its Subsidiaries for providing diagnostic laboratory services.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Three-Month LIBOR</u>&#8221; means, with respect to any Interest Period, a rate per annum equal to the lesser of (i) the greater of (x) 1.75% per annum and (y) the three-month London Interbank Offered Rate (or a comparable or successor rate which rate is approved by the Administrative Agent) for deposits in Dollars at approximately 11:00 a.m. (London, England time), as determined by the Administrative Agent from the appropriate Bloomberg screen page selected by the Administrative Agent (or any successor thereto or similar source reasonably determined by the Administrative Agent from time to time), two (2) Business Days prior to the first day of such Interest Period, adjusted for any reserve requirement and any subsequent costs arising from a change in governmental regulation, if applicable, such rate to be rounded up to the nearest 1/16 of 1% and (ii) 3.50% per annum. The Administrative Agent&#8217;s determination of Three-Month LIBOR and internal records of applicable interest rates shall be determinative in the absence of manifest error. For all purposes hereunder, in no event shall Three-Month LIBOR be less than 1.75% or greater than 3.50%.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Three-Month Treasury Rate</u>&#8221; means, as of any date of determination, the weekly average yield as of such date of determination of actually traded United States Treasury securities adjusted to a constant maturity of three (3) months (as compiled and published in the most recent Federal Reserve Statistical Release H.15(519) that has become publicly available at least two (2) Business Days prior to such date of determination (or, if such Federal Reserve Statistical Release H.15(519) is no longer published, any publicly available source of similar market data)). For the avoidance of doubt, this calculation is based on yields on actively traded non-inflation-indexed issues adjusted to constant maturities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Threshold Amount</u>&#8221; means an amount equal to [***]% of the aggregate outstanding principal amount of the Loans on any date after giving effect to any borrowings made on or before such date but without giving effect to any prepayments or repayments of Loans occurring on or before such date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Total Credit Exposure</u>&#8221; means, as to any Lender at any time, the unused Commitments of such Lender and the Outstanding Amount of all Loans of such Lender at such time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Trademark License</u>&#8221; means any agreement, written or oral, providing for the grant of any right to use any Trademark.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Trademarks</u>&#8221; means all statutory and common-law trademarks, trade names, corporate names, company names, business names, fictitious business names, trade styles, service marks, logos and other source or business identifiers, and the goodwill associated therewith, now existing or hereafter adopted or acquired, all registrations and recordings thereof, and all applications to register in connection therewith, under the laws of the United States, any state thereof, the Netherlands, any political subdivision thereof or any other country or any political subdivision thereof, or otherwise, for the full term and all renewals thereof, which are owned by the Borrower or any Subsidiary or which the Borrower or any Subsidiary is licensed, authorized or otherwise granted rights under or to, and which are used by the Borrower or any other Person to manufacture, develop, import, market, promote, advertise, offer for sale, sell, use, provide and/or otherwise distribute a Product or Service.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Trade Secrets</u>&#8221; means any data or information that is not commonly known by or available to the public, and which (a) derives economic value, actual or potential, from not being generally known to and not being readily ascertainable by proper means by other Persons who can obtain economic value from its disclosure or use, (b) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy, and (c) which are owned by the Borrower or any Subsidiary or which the Borrower or any Subsidiary is licensed, authorized or otherwise granted rights under or to.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">37</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Transaction</u>&#8221; means, individually or collectively as the context may indicate, (a) the payoff of all Existing Indebtedness on the Term A Borrowing Date, (b) the entering by the Borrower and the other Loan Parties of the Loan Documents to which they are a party and incurrence of the Term A Borrowing and (c) the payment of fees, costs and expenses in connection with the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Treasury Regulations</u>&#8221; means the regulations, including temporary regulations, promulgated by the United States Treasury Department under the Internal Revenue Code, as such regulations may be amended from time to time (including the corresponding provisions of any future regulations).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>TRICARE</u>&#8221; means the program administered pursuant to 10 U.S.C. Section 1071 (et. seq), Sections 1320a-7 and 1320a-7a of Title 42 of the United States Code and the regulations promulgated pursuant to such statutes.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>UK Financial Institution</u>&#8221; means any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended form time to time) promulgated by the United Kingdom Prudential Regulation Authority) or any person subject to IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>UK Resolution Authority</u>&#8221; means the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial Institution.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Uniform Commercial Code</u>&#8221; or &#8220;<u>UCC</u>&#8221; means the Uniform Commercial Code as in effect in the State of New York; provided, that, if perfection or the effect of perfection or non-perfection or the priority of any security interest in any Collateral is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of New York, &#8220;Uniform Commercial Code&#8221; means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions hereof or of the other Loan Documents relating to such perfection, effect of perfection or non-perfection or priority.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>United States</u>&#8221; and &#8220;<u>U.S.</u>&#8221; mean the United States of America.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Unrestricted Cash</u>&#8221; means cash or Cash Equivalents of the Loan Parties (without duplication), that (a) do not appear (or would not be required to appear) as &#8220;restricted&#8221; on a consolidated balance sheet of the Borrower as determined in accordance with GAAP, and (b) are not subject to any Lien in favor of any Person (other than rights of setoff permitted under <u>Section 8.01(l)</u>, Liens permitted by <u>Section 8.01(c)</u> and Liens in favor of the Administrative Agent).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>U.S. Person</u>&#8221; means a &#8220;United States Person&#8221; within the meaning of Section 7701(a)(30) of the Internal Revenue Code.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>U.S. Special Resolution Regimes</u>&#8221; has the meaning specified in Section 12.21.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>U.S. Subsidiary</u>&#8221; means any Subsidiary that is organized under the laws of any state of the United States or the District of Columbia.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">38</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Voting Stock</u>&#8221; means, with respect to any Person, Equity Interests issued by such Person the holders of which are ordinarily, in the absence of contingencies, entitled to vote for the election of directors (or persons performing similar functions) of such Person, even though the right so to vote has been suspended by the happening of such a contingency.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Websites</u>&#8221; means all websites that the Borrower or any Subsidiary shall operate, manage or control through a Domain Name, whether on an exclusive basis or a nonexclusive basis, including, without limitations, all content, elements, data, information, materials, hypertext markup language (HTML), software and code, works of authorship, textual works, visual works, aural works, audiovisual works and functionality embodied in, published or available through each such website and all IP Rights in each of the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Website Agreements</u>&#8221; means all agreements between the Borrower and/or any Subsidiary and any other Person pursuant to which such Person provides any services relating to the hosting, design, operation, management or maintenance of any Website, including without limitation, all agreements with any Person providing website hosting, database management or maintenance or disaster recovery services to the Borrower and/or any Subsidiary and all agreements with any domain name registrar, as all such agreements may be amended, supplemented or otherwise modified from time to time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Wholly Owned Subsidiary</u>&#8221; means any Person 100% of whose Equity Interests are at the time owned by the Borrower directly or indirectly through other Persons 100% of whose Equity Interests are at the time owned, directly or indirectly, by the Borrower.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Withholding Agent</u>&#8221; means any Loan Party, the Administrative Agent and any other Person required by applicable Law to withhold or deduct amounts from a payment made by or on account of any obligation of any Loan Party under any Loan Document.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Work</u>&#8221; means any work or subject matter that is subject to protection pursuant to Title 17 of the United States Code.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Write-Down and Conversion Powers</u>&#8221; means, with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">1.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Other Interpretive Provisions</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">With reference to this Agreement and each other Loan Document, unless otherwise specified herein or in such other Loan Document:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The definitions of terms herein shall apply equally to the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words &#8220;include,&#8221; &#8220;includes&#8221; and &#8220;including&#8221; shall be deemed to be followed by the phrase &#8220;without limitation.&#8221; The word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall.&#8221; Unless the context requires otherwise, (i) any definition of or reference to any agreement, instrument or other document (including the Loan Documents and any Organization Document) shall be construed as referring to such agreement, instrument or other document as from time to time amended, modified, extended, restated, replaced or supplemented from time to time (subject to any restrictions set forth herein or in any other Loan Document), (ii) any reference herein to any Person shall be construed to include such Person&#8217;s successors and assigns, (iii) the words &#8220;hereto&#8221;, &#8220;herein,&#8221; &#8220;hereof&#8221; and &#8220;hereunder,&#8221; and words of similar import when used in any Loan Document, shall be construed to refer to such Loan Document in its entirety and not to any particular provision thereof, (iv) all references in a Loan Document to Articles, Sections, Preliminary Statements, Exhibits and Schedules shall be construed to refer to Articles and Sections of, and Preliminary Statements, Exhibits and Schedules to, the Loan Document in which such references appear, (v) any reference to any law shall include all statutory and regulatory provisions consolidating, amending, replacing or interpreting such law and any reference to any law or regulation shall, unless otherwise specified, refer to such law or regulation as amended, modified, extended, restated, replaced or supplemented from time to time, and (vi) the words &#8220;asset&#8221; and &#8220;property&#8221; shall be construed to have the same meaning and effect and to refer to any and all real and personal property and tangible and intangible assets and properties, including cash, securities, accounts, contract rights and IP Rights.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">39</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the computation of periods of time from a specified date to a later specified date, the word &#8220;<u>from</u>&#8221; means &#8220;from and including;&#8221; the words &#8220;<u>to</u>&#8221; and &#8220;<u>until</u>&#8221; each mean &#8220;to but excluding;&#8221; and the word &#8220;<u>through</u>&#8221; means &#8220;to and including.&#8221;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section headings herein and in the other Loan Documents are included for convenience of reference only and shall not affect the interpretation of this Agreement or any other Loan Document.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any reference herein to a merger, transfer, amalgamation, consolidation, assignment, sale, disposition or transfer, or similar term, shall be deemed to apply to a division of or by a limited liability company, or an allocation of assets to a series of a limited liability company (or the unwinding of such a division or allocation), as if it were a merger, transfer, amalgamation, consolidation, assignment, sale, disposition or transfer, or similar term, as applicable, to, of or with a separate Person. Any division of a limited liability company shall constitute a separate Person hereunder (and each division of any limited liability company that is a Subsidiary, joint venture or any other like term shall also constitute such a Person or entity).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">1.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Accounting Terms</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Generally</u>. Except as otherwise specifically prescribed herein, all accounting terms not specifically or completely defined herein shall be construed in conformity with, and all financial data (including financial ratios and other financial calculations) required to be submitted pursuant to this Agreement shall be prepared in conformity with, GAAP applied on a consistent basis, as in effect from time to time, applied in a manner consistent with that used in preparing the Audited Financial Statements, except as otherwise specifically prescribed herein; <u>provided</u>, <u>however</u>, <u>that</u>, calculations of Attributable Indebtedness under any Synthetic Lease or the implied interest component of any Synthetic Lease shall be made by the Borrower in accordance with accepted financial practice and consistent with the terms of such Synthetic Lease. Notwithstanding the foregoing, for purposes of determining compliance with any covenant contained herein, Indebtedness of the Borrower and its Subsidiaries shall be deemed to be carried at 100% of the outstanding principal amount thereof, and the effects of FASB ASC 825 and FASB ASC 470-20, on financial liabilities shall be disregarded.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Changes in GAAP</u>. Borrower will provide a written summary of material changes in GAAP and in the consistent application thereof with each annual and quarterly financial statement delivered in accordance with <u>Section 7.01</u>. If at any time any change in GAAP would affect the computation of any financial requirement set forth in any Loan Document, and either the Borrower or the Required Lenders shall so request, the Administrative Agent, the Lenders and the Borrower shall negotiate in good faith to amend such requirement to preserve the original intent thereof in light of such change in GAAP (subject to the approval of the Required Lenders); <u>provided</u>, <u>that</u>, until so amended, (i) such requirement shall continue to be computed in accordance with GAAP prior to such change therein and (ii) the Borrower shall provide to the Administrative and the Lenders financial statements and other documents required under this Agreement or as requested hereunder setting forth a reconciliation between calculations of such requirement made before and after giving effect to such change in GAAP. Notwithstanding any other provision contained in this Agreement, all terms of an accounting or financial nature used herein shall be construed, and all computations of amounts and ratios referred to herein shall be made, without giving effect to any change to GAAP occurring before or after the Closing Date as a result of ASU 2016-02, Leases (Topic 842) issued by the Financial Accounting Standards Board or any other proposals issued by the Financial Accounting Standards Board in connection therewith, in each case if such change would require treating any lease (or similar arrangement conveying the right to use) as a capital lease where such lease (or similar arrangement) was not required to be so treated under GAAP as in effect prior to such change.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">40</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Calculations.</u> For purposes of all calculations hereunder, the principal amount of Convertible Bond Indebtedness shall be the outstanding principal (or notional) amount thereof, valued at par.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Consolidation of Variable Interest Rate Entities</u>. All references herein to consolidated financial statements of the Borrower and its Subsidiaries or to the determination of any amount for the Borrower and its Subsidiaries on a consolidated basis or any similar reference shall, in each case, be deemed to include each variable interest entity that the Borrower is required to consolidate pursuant to FASB ASC 810 as if such variable interest entity was a Subsidiary as defined herein.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">1.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Times of Day</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Unless otherwise specified, all references herein to times of day shall be references to United States Eastern time (daylight or standard, as applicable).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">1.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>LIBOR Determinations</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Administrative Agent does not warrant, nor accept responsibility, nor shall the Administrative Agent have any liability with respect to the administration, submission or any other matter related to the rates in the definition of &#8220;Three-Month LIBOR&#8221; or with respect to any comparable or successor rate thereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="text-transform:uppercase">Article&nbsp;</font>II<br>
<br>
THE COMMITMENTS</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">2.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Commitments.</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Term A Borrowing.</u> Subject to the terms and conditions set forth herein, each Term A Lender severally agrees to make a single term loan to the Borrower, in Dollars, on any Business Day during the Term A Availability Period, in an aggregate amount not to exceed such Term A Lender&#8217;s Term A Commitment; <u>provided, that,</u> on or prior to such Business Day, the Term A Draw Conditions shall have been satisfied; <u>provided</u>, <u>further</u>, <u>that</u>, for the avoidance of doubt, it is understood and agreed that there shall be no more than one (1) Term A Borrowing during the term of this Agreement. The Term A Borrowing shall consist of Term A Loans made simultaneously by the Term A Lenders in accordance with their respective Term A Commitments. Term A Borrowings repaid or prepaid may not be reborrowed.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Term B Borrowing.</u> Subject to the terms and conditions set forth herein, each Term B Lender severally agrees to make a single term loan to the Borrower, in Dollars, on any Business Day during the Term B Availability Period, in an aggregate amount not to exceed such Term B Lender&#8217;s Term B Commitment; <u>provided, that,</u> on or prior to such Business Day, the Term B Draw Conditions shall have been satisfied; <u>provided</u>, <u>further</u>, <u>that</u>, for the avoidance of doubt, it is understood and agreed that there shall be no more than one (1) Term B Borrowing during the term of this Agreement. The Term B Borrowing shall consist of Term B Loans made simultaneously by the Term B Lenders in accordance with their respective Term B Commitments. Term B Borrowings repaid or prepaid may not be reborrowed.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">41</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Term C Borrowing.</u> Subject to the terms and conditions set forth herein, each Term C Lender severally agrees to make a single term loan to the Borrower, in Dollars, on any Business Day during the Term C Availability Period, in an aggregate amount not to exceed such Term C Lender&#8217;s Term C Commitment; <u>provided, that,</u> on or prior to such Business Day, the Term C Draw Conditions shall have been satisfied; <u>provided</u>, <u>further</u>, <u>that</u>, for the avoidance of doubt, it is understood and agreed that there shall be no more than one (1) Term C Borrowing during the term of this Agreement. The Term C Borrowing shall consist of Term C Loans made simultaneously by the Term C Lenders in accordance with their respective Term C Commitments. Term C Borrowings repaid or prepaid may not be reborrowed.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">2.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Borrowings</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Borrowing shall be made upon the Borrower&#8217;s irrevocable notice (in the form of a written Loan Notice, appropriately completed and signed by a Responsible Financial Officer of the Borrower) to the Administrative Agent, which must be given not later than 9:00 a.m. on the date at least twenty (20) Business Days (or such shorter period as the Administrative Agent may agree in its sole discretion) in advance of the requested date of the Term A Borrowing, the Term B Borrowing or the Term C Borrowing, as the case may be. Each Loan Notice shall specify (i) the requested date of the Borrowing (which shall be a Business Day) and (ii) the principal amount of Loans to be borrowed. For the avoidance of doubt, the Term A Borrowing shall be in a principal amount of $125,000,000, the Term B Borrowing shall be in a principal amount of $25,000,000 and the Term C Borrowing shall be in a principal amount of $50,000,000.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following receipt of a Loan Notice for a Facility, the Administrative Agent shall promptly notify each Appropriate Lender of the amount of its Applicable Percentage under such Facility of the applicable Loans. Each Appropriate Lender shall make the amount of its Loan available to the Administrative Agent in immediately available funds at the Administrative Agent&#8217;s Office not later than 1:00 p.m. on the Business Day specified in the applicable Loan Notice. Upon satisfaction of the applicable conditions set forth in <u>Section 5.02</u> (and, if such Borrowing is the initial Borrowing, <u>Section 5.01)</u> and subject to the Term A Draw Conditions, the Term B Draw Conditions and the Term C Draw Conditions, as applicable, the Administrative Agent shall make all funds so received available to the Borrower in like funds as received by the Administrative Agent by wire transfer of such funds in accordance with instructions provided to (and acceptable to) the Administrative Agent by the Borrower.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">2.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Prepayments</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Voluntary Prepayments</u>. Subject to the payment of any prepayment or repayment premium as required under <u>Section 2.03(d)</u>, the exit fee required under <u>Section 2.07(b)</u> and any other fees or amounts payable hereunder at such time, the Borrower may, upon written notice from the Borrower to the Administrative Agent, voluntarily prepay the Loans, in whole or in part; <u>provided</u>, <u>that</u>, (i) such notice must be received not later than 11:00 a.m. five (5) Business Days prior to the date of prepayment and (ii) any such prepayment shall be in a principal amount of $5,000,000 or a whole multiple of $1,000,000 in excess thereof (or, if less, the entire principal amount thereof then outstanding). Each such notice shall specify the date and amount of such prepayment. If such notice is given by the Borrower, the Borrower shall make such prepayment and the payment amount specified in such notice shall be due and payable on the date specified therein. Any prepayment pursuant to this <u>Section 2.03(a)</u> shall be accompanied by (x) all accrued interest on the principal amount of the Loans prepaid, (y) the prepayment or repayment premium required under <u>Section 2.03(d)</u> and the exit fee required under <u>Section 2.07(b)</u> and (z) all fees, costs, expenses, indemnities and other amounts due and payable hereunder at the time of prepayment. Each such prepayment shall be applied <u>first,</u> to outstanding Term C Loans (if any), <u>second,</u> to outstanding Term B Loans (if any) and <u>third,</u> to outstanding Term A Loans. Each such prepayment shall be applied to the Loans of the Lenders in accordance with their respective Applicable Percentages in respect of each of the relevant Facilities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">42</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Mandatory Prepayments of Loans</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Dispositions; Involuntary Dispositions; Etc</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(A) The Borrower shall promptly (and, in any event, within three (3) Business Days, unless the Borrower delivers written notice to the Administrative Agent of its intent to exercise the reinvestment rights pursuant to this <u>clause </u><u>(i)</u><u>(A)</u> within such three (3) Business Day period) prepay the Loans in an aggregate amount equal to 100% of the Net Cash Proceeds (other than any Net Cash Proceeds &#8211; Licensing, any Net Cash Proceeds &#8211; Non-Permitted Royalty Financing and any Net Cash Proceeds received by any Loan Party or any Subsidiary from the Royalty Financing or any Other Royalty Financing) of all Dispositions (other than any Disposition pursuant to <u>Section 8.05(c)</u> hereof) and Involuntary Dispositions, to the extent such Net Cash Proceeds are not (1) in the case of either Dispositions or Involuntary Dispositions, reinvested in Eligible Assets or (2) solely in the case of Involuntary Dispositions, used for the repair or restoration of the property which was the subject of the Involuntary Disposition, in each case within 270 days of the date of such Disposition or Involuntary Disposition.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(B) The Borrower shall promptly (1) (and, in any event, within one (1) Business Day) prepay the Loans in an aggregate amount equal to 100% of any Net Cash Proceeds &#8211; Licensing received by any Loan Party or any Subsidiary pursuant to a Non-Permitted License (it being understood and agreed that the payment pursuant to this clause (B)(1) shall be in addition to any other right and remedy that the Administrative Agent or any other Secured Party has as a result of an Event of Default arising from the entering into such Non-Permitted License) and (2) (and, in any event, within three (3) Business Days) prepay the Loans, in an amount equal, on a dollar-for-dollar basis, to any Net Cash Proceeds - Licensing received by any Loan Party or Subsidiary pursuant to a Permitted License which are paid to the Buyer in connection with the Royalty Financing or any buyer or purchaser under the Other Royalty Financing Documents in connection with an Other Royalty Financing, as applicable, solely to the extent such payment exceeds the amount then required to be paid pursuant to the express terms of the Royalty Financing Documents or the Other Royalty Financing Documents, as applicable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(C) The Borrower shall promptly (and, in any event, within one (1) Business Day) prepay the Loans in an aggregate amount equal to 100% of any Net Cash Proceeds &#8211; Non-Permitted Royalty Financing received by any Loan Party or any Subsidiary (it being understood and agreed that the payment pursuant to this clause (C) shall be in addition to any other right and remedy that the Administrative Agent or any other Secured Party has as a result of an Event of Default arising from the entering into such Non-Permitted Royalty Financing).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">Any prepayment pursuant to this <u>clause (i)</u> shall be applied as set forth in <u>clause (iv)</u> below.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">43</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Extraordinary Receipts</u>. The Borrower shall promptly (and, in any event, within three (3) Business Days, unless the Borrower delivers written notice to the Administrative Agent of its intent to exercise the reinvestment rights pursuant to this <u>clause (ii)</u> within such three (3) Business Day period) upon the receipt by any Loan Party or any Subsidiary of the Net Cash Proceeds of any Extraordinary Receipts, prepay the Loans in an aggregate amount equal to 100% of such Net Cash Proceeds to the extent such Net Cash Proceeds are not reinvested in Eligible Assets within 270 days of the date of receipt of the Net Cash Proceeds of such Extraordinary Receipts. Any prepayment pursuant to this <u>clause (ii)</u> shall be applied as set forth in <u>clause (iv)</u> below.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Debt Issuance</u>. The Borrower shall promptly (and, in any event, within one (1) Business Day) upon the receipt by any Loan Party or any Subsidiary of the Net Cash Proceeds of any Debt Issuance, prepay the Loans in an aggregate amount equal to 100% of such Net Cash Proceeds (it being understood and agreed that the payment pursuant to this clause (iii) shall be in addition to any other right and remedy that the Administrative Agent or any other Secured Party has as a result of an Event of Default arising from such Debt Issuance). Any prepayment pursuant to this <u>clause (iii)</u> shall be applied as set forth in <u>clause (iv)</u> below.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Application of Mandatory Prepayments</u>. The Borrower shall provide the Administrative Agent with written notice of any payment to be made under this Section 2.03(b) at least five (5) Business Days prior to the date such payment is required to be under this <u>Section 2.03(b)</u>. All payments under this <u>Section 2.03(b)</u><i> </i>shall be applied (i) first to all fees, costs, expenses, indemnities and other amounts due and payable hereunder (other than as contemplated by the immediately following clause (ii)), and (ii) then proportionately (based on the relation of such amounts to the total amount of the relevant payment under this <u>Section 2.03(b)</u>) to the payment or prepayment (as applicable) of the following amounts of the Obligations: default interest, if any, prepayment or repayment premium required by <u>Section 2.03(d)</u>, the exit fee required under <u>Section 2.07(b)</u> and accrued and unpaid interest and principal. Each such prepayment pursuant to the immediately foregoing clause (ii) shall be applied <u>first,</u> to outstanding Term C Loans (if any), <u>second,</u> to outstanding Term B Loans (if any) and <u>third,</u> to outstanding Term A Loans. Each such prepayment shall be applied to the Loans of the Lenders in accordance with their respective Applicable Percentages in respect of each of the relevant Facilities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Declined Proceeds</u>. Each Lender may reject all or a portion of its share of any mandatory prepayment of Loans required to be made pursuant to this <u>Section 2.03(b)</u> (such declined amounts, the &#8220;<u>Declined Proceeds</u>&#8221;) by providing written notice (each, a &#8220;<u>Rejection Notice</u>&#8221;) to the Administrative Agent no later than 3:00 p.m. two (2) Business Days prior to the date of such prepayment. Each Rejection Notice from a given Lender shall specify the principal amount of the mandatory repayment of Loans to be rejected by such Lender. If a Lender fails to deliver a Rejection Notice to the Administrative Agent within the time frame specified above or such Rejection Notice fails to specify the principal amount of the Loans to be rejected, any such failure will be deemed an acceptance of the total amount of such mandatory prepayment of Loans. Any Declined Proceeds shall be offered to the Lenders not so declining such prepayment on a pro rata basis in accordance with the amounts of the Loans of such Lender (with such non-declining Lenders having the right to decline any prepayment with Declined Proceeds by providing written notice to the Administrative Agent no later than 3:00 p.m. one (1) Business Day prior to the date of such prepayment). If a non-declining Lender fails to deliver notice to the Administrative Agent within the time frame specified, any such non-declining Lender shall be deemed to have declined the additional proceeds. To the extent such non-declining Lenders elect to decline their share of such Declined Proceeds, any Declined Proceeds remaining thereafter shall be retained by the Borrower.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">44</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Repatriation</u>. Notwithstanding the foregoing terms of this <u>Section 2.03(b)</u>, to the extent any or all of the Net Cash Proceeds of any Disposition by, or receipt of the Net Cash Proceeds of any Involuntary Disposition or Extraordinary Receipts by, a Subsidiary that is a Non-U.S. Subsidiary otherwise giving rise to a prepayment pursuant to this <u>Section 2.03(b)</u>, is prohibited by any applicable local requirements of Law from being repatriated to the Borrower or any Subsidiary that is a U.S. Subsidiary including through the repayment of intercompany Indebtedness (each, a &#8220;<u>Repatriation</u>&#8221;; with &#8220;<u>Repatriated</u>&#8221; having a correlative meaning), <u>provided</u> that the Borrower and its Subsidiaries shall take all commercially reasonable actions available under local Law to permit such Repatriation, or if the Repatriation of any such amount would reasonably be expected to result in material adverse tax consequences with respect to the Borrower and its Subsidiaries, taken as a whole, an amount equal to the portion of such Net Cash Proceeds so affected (such amount, the &#8220;<u>Excluded Prepayment Amount</u>&#8221;), will not be required to be applied to prepay Loans at the times provided in this <u>Section 2.03(b)</u>; <i>provided</i>, that if and to the extent any such Repatriation ceases to be prohibited, restricted or delayed by applicable local requirements of Law or such Repatriation ceases, to result in material adverse tax consequences with respect to the Borrower and its Subsidiaries, taken as a whole (taking into account any foreign tax credit or benefit actually received in connection with such Repatriation), at any time following the date on which the applicable mandatory prepayment pursuant to this <u>Section 2.03(b)</u> was otherwise required to be made, the Borrower shall promptly pay an amount equal to such portion of the Excluded Prepayment Amount to the Lenders, which payment shall be applied in accordance with <u>Section 2.03(b)(iv)</u>. Notwithstanding anything to the contrary contained herein or in any other Loan Document, for the avoidance of doubt, nothing in this <u>Section 2.03(b)</u> shall require the Borrower to cause any amounts to be repatriated to the United States.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Change of Control</u>. Upon the occurrence of a Change of Control, the Borrower shall, unless otherwise directed by the Required Lenders, prepay the Outstanding Amount of the Loans together with all accrued and unpaid interest thereon <u>plus</u> the prepayment or repayment premium, if any, required by <u>Section 2.03(d)</u> and the exit fee required under <u>Section 2.07(b)</u> <u>plus</u> all other Obligations (it being understood and agreed that the payment pursuant to this clause (c) shall be in addition to any other right and remedy that the Administrative Agent or any other Secured Party has as a result of an Event of Default arising from the occurrence of such Change of Control).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Prepayment and </u><u>Repayment Premiums</u>. Notwithstanding anything to the contrary in this Agreement or any other Loan Document, if all or any portion of the Loans are repaid, prepaid, or required to be repaid or prepaid (including by acceleration), pursuant to this <u>Section 2.03</u>, <u>Article IX</u> or otherwise, then, in all cases, the Borrower shall pay to the Lenders, for their respective ratable accounts, on the date on which such repayment or prepayment is paid or required to be paid, in addition to the other Obligations so repaid, prepaid or required to be repaid or prepaid, a prepayment or repayment premium equal to: (i) with respect to any prepayment or repayment paid or required to be paid on or prior to the second anniversary of the date of the Borrowing of such Loan, an amount equal to the Make-Whole Amount with respect to such prepayment or repayment, (ii) with respect to any prepayment or repayment paid or required to be paid after the second anniversary of the date of the Borrowing of such Loan, but on or prior to the third anniversary of the date of the Borrowing of such Loan, two percent (2.00%) of the principal amount of such Loan that is prepaid or required to be prepaid, (iii) with respect to any prepayment or repayment paid or required to be paid after the third anniversary of the date of the Borrowing of such Loan, but on or prior to the fourth anniversary of the date of the Borrowing of such Loan, one percent (1.00%) of the principal amount of such Loan that is prepaid or required to be prepaid and (iv) with respect to any prepayment or repayment paid or required to be paid after the fourth anniversary of the date of the Borrowing of such Loan, zero percent (0.00%) of the principal amount of such Loan that is prepaid or required to be prepaid.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">45</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">2.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination of Commitments</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Voluntary.</u> The Borrower may, upon written notice to the Administrative Agent during (i) the Term B Availability Period, terminate in full the Term B Commitments or (ii) the Term C Availability Period, terminate in full the Term C Commitments; <u>provided, that:</u> any such notice shall be received by the Administrative Agent not later than 9:00 a.m. five (5) Business Days prior to the date of termination. Each notice delivered by the Borrower pursuant to this Section shall be irrevocable. Upon any termination of the Term B Commitments or the Term C Commitments, the Commitments of each Appropriate Lender shall be reduced by such Lender&#8217;s Applicable Percentage of such reduction amount. The Borrower may not terminate the Term A Commitments.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Mandatory.</u> The Term A Commitments will be automatically and permanently reduced to zero upon the Term A Borrowing pursuant to <u>Section 2.01.</u> The Term B Commitments will be automatically and permanently reduced to zero upon the Term B Borrowing pursuant to <u>Section 2.01</u>. The Term C Commitments will be automatically and permanently reduced to zero upon the Term C Borrowing pursuant to <u>Section 2.01</u>. The Term A Commitments shall be automatically and permanently reduced to zero on the date that the Term A Availability Period shall end. The Term B Commitments shall be automatically and permanently reduced to zero on the date that the Term B Availability Period shall end. The Term C Commitments shall be automatically and permanently reduced to zero on the date that the Term C Availability Period shall end.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">2.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Repayment of Loans</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Borrower shall repay the outstanding principal amount of the Loans, together with all accrued and unpaid interest thereon, the prepayment and repayment premiums required by <u>Section 2.03(d)</u><u> </u>(provided, for clarity, that such premiums under <u>Section 2.03(d)</u> shall not be due and payable as a result of a repayment made pursuant to this <u>Section 2.05</u> due to the occurrence of the date set forth in <u>clause (a)</u> of the definition of &#8220;Maturity Date&#8221;), the exit fee required under <u>Section 2.07(b)</u> and all other outstanding Obligations, on the Maturity Date. Loans repaid or prepaid may not be reborrowed.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">2.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Interest; Other Amounts</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Pre-Default Rate</u>. Subject to the provisions of <u>subsection (b)</u> below, during any Interest Period each Loan shall bear interest during such Interest Period on the outstanding principal amount thereof <u>either</u>, (i) if such Interest Period (A) ends on or before the last day of the eighth (8<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup>) full fiscal quarter ending after the Term A Borrowing Date and a Cash Pay Election is made pursuant to <u>Section 2.06(d)</u> for such Interest Period or (B) begins after the last day of the eighth (8<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup>) full fiscal quarter ending after the Term A Borrowing Date, at a rate equal to the sum of (x) Three-Month LIBOR for such Interest Period <u>plus</u> (y) 8.25% per annum, or (ii) if such Interest Period ends on or before the last day of the eighth (8<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup>) full fiscal quarter ending after the Term A Borrowing Date and a PIK Election is made pursuant to <u>Section 2.06(d)</u> for such Interest Period, at a rate equal to the sum of (x)&nbsp;Three-Month LIBOR for such Interest Period <u>plus</u> (y) 10.25%, per annum.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Default Rate</u>. Notwithstanding anything the contrary set forth in <u>Section 2.06(a</u><u>)</u>, (i) upon the occurrence of and during the continuance of any Event of Default during any Interest Period all outstanding Obligations shall bear interest during the continuance of such Event of Default at an interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable Laws and (ii) accrued and unpaid interest (including interest on past due interest) shall be due and payable in cash on demand. The interest rate shall be recalculated and, if necessary, adjusted for each Interest Period, in each case pursuant to the terms hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">46</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Interest Generally</u>. Subject to <u>Section 2.06(b)</u>, interest on each Loan shall be due and payable in cash in arrears on each Interest Payment Date unless a PIK Election is made pursuant to <u>Section 2.06(d)</u> and at such other times as may be specified herein. Interest hereunder shall be due and payable in accordance with the terms hereof before and after judgment, and before and after the commencement of any proceeding under any Debtor Relief Law.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>PIK Interest Election</u>. For each Interest Period ending on or before the last day of the eighth (8<sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup>) full fiscal quarter ending after the Term A Borrowing Date, the Borrower hereby elects (such election, a &#8220;<u>PIK Election</u>&#8221;) that, so long as (x) no Default or Event of Default has occurred and is continuing and (y) the Borrower has not, at least five (5) Business Days prior to the beginning of such Interest Period, provided the Administrative Agent a written election indicating that it will decline the PIK Election for such Interest Period and interest on any Loan accrued during such Interest Period shall be due and payable in cash in arrears on the applicable Interest Payment Date (a &#8220;<u>Cash Pay Election</u>&#8221;), interest on any Loan accrued during such Interest Period may be paid in kind (&#8220;<u>PIK Interest</u>&#8221;) by capitalizing the entire amount of such PIK Interest with the unpaid principal amount of such Loan outstanding on the last day of such Interest Period (each, a &#8220;<u>PIK Interest Payment</u>&#8221;). Following each such increase in the principal amount of such Loan as a result of any PIK Interest Payment, such Loans will bear interest on such increased principal amount from and after the date of each such PIK Interest Payment and each reference to such Loan shall include such PIK Interest for all purposes of the Loan Documents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">2.07&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Fees</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Commitment Fee</u>. The Borrower shall pay to the Lenders, for their respective ratable accounts, on the date of each Borrowing, a commitment fee in an amount equal to one percent (1.00%) of the principal amount of the Loans borrowed on such date. Such fee shall be fully earned when paid and shall be non-refundable for any reason whatsoever. It is understood and agreed that Athyrium, the Administrative Agent and the Lenders reserve the right to allocate, in whole or in part, to their respective Affiliates, the fees payable to such Persons hereunder in such manner as Athyrium, the Administrative Agent, the Lenders and such Affiliates shall agree in their sole discretion.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exit Fee</u>. If all or any portion of the Loans are repaid, prepaid, or required to be repaid or prepaid (including by acceleration), pursuant to <u>Section 2.03</u>, <u>Section 2.05</u>, <u>Article IX</u> or otherwise, then, in all cases, the Borrower shall pay to the Lenders, for their respective ratable accounts, on the date on which such repayment or prepayment is repaid, paid or required to be repaid or prepaid, as the case may be, in addition to the other Obligations so prepaid, repaid or required to be prepaid or repaid, an exit fee in an amount equal to two percent (2.00%) of the principal amount of such Loan prepaid, repaid or required to be prepaid or repaid, as the case may be, on such date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">2.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Evidence of Debt</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Loans made by each Lender shall be evidenced by one or more accounts or records maintained by such Lender in the ordinary course of business. The accounts or records maintained by each Lender shall be conclusive absent manifest error of the amount of Loans made by the Lenders to the Borrower and the interest and payments thereon. Any failure to so record or any error in doing so shall not, however, limit or otherwise affect the obligation of the Borrower hereunder to pay any amount owing with respect to the Obligations. Upon the request of any Lender made through the Administrative Agent, the Borrower shall execute and deliver to such Lender a promissory note, which shall evidence such Lender&#8217;s Loans in addition to such accounts or records. Each such promissory note shall (a) in the case of the Term A Loans, be in the form of <u>Exhibit B-1</u> (a &#8220;<u>Term A Note</u>&#8221;), (b) in the case of the Term B Loans, be in the form of <u>Exhibit B-2</u> (a &#8220;<u>Term B Note</u>&#8221;) and (c) in the case of the Term C Loans, be in the form of <u>Exhibit B-3</u> (the &#8220;<u>Term C Note</u>&#8221;). Each Lender may attach schedules to its Note and endorse thereon the date, amount and maturity of its Loans and payments with respect thereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">47</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">2.09&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Computation of Interest</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">All computations of interest shall be made on the basis of a 360-day year and actual days elapsed. Interest shall accrue on each Loan for the day on which such Loan is made, and shall not accrue on a Loan, or any portion thereof, for the day on which such Loan or such portion is paid.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">2.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Payments Generally</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>General</u>. All payments to be made by the Borrower shall be made free and clear of and without condition or deduction (subject to Section 3.01) for any counterclaim, defense, recoupment or setoff. Subject to <u>Section 9.03</u>, all payments of principal, interest, prepayment and repayment premiums and fees on the Loans and all other Obligations payable by any Loan Party under the Loan Documents shall be due, without any presentment thereof, directly to the Lenders, at the respective Lending Offices of the Lenders; <u>provided, that,</u> if at the time of any such payment a Lender is a Defaulting Lender, such Defaulting Lender&#8217;s <i>pro rata </i>share of such payment shall be made directly to the Administrative Agent. The Loan Parties will make such payments in Dollars, in immediately available funds not later than 2:00 p.m. on the date due, marked for attention as indicated, or in such other manner or to such other account in any United States bank as the Lenders may from time to time direct in writing. All payments received by the Lenders after 2:00 p.m. shall be deemed received on the next succeeding Business Day and any applicable interest or fee shall continue to accrue in respect of such succeeding Business Day. If any payment to be made by the Borrower shall come due on a day other than a Business Day, payment shall be made on the next following Business Day, and such extension of time shall be reflected in computing interest.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Obligations of Lenders are Several</u>. The obligations of the Lenders hereunder to make Loans and to make payments pursuant to <u>Section 12.04(d)</u> are several and not joint. The failure of any Lender to make any Loan or to make any payment under <u>Section 12.04(d)</u> on any date required hereunder shall not relieve any other Lender of its corresponding obligation to do so on such date, and no Lender shall be responsible for the failure of any other Lender to so make its Loan or to make its payment under <u>Section 12.04(d)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Funding Source</u>. Nothing herein shall be deemed to obligate any Lender to obtain the funds to make any Loan in any particular place or manner or to constitute a representation by any Lender that it has obtained or will obtain the funds to make any Loan in any particular place or manner.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">2.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Sharing of Payments by Lenders</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">If any Lender shall, by exercising any right of setoff or otherwise, obtain payment in respect of any principal of or interest on its portion of any of the Loans or prepayment or repayment premium or exit fees in connection therewith resulting in such Lender&#8217;s receiving payment of a proportion of the aggregate amount of the Loans and accrued interest thereon and prepayment or repayment premium or exit fees in connection therewith greater than its <i>pro rata share</i> thereof as provided herein, then such Lender shall (a) notify the Administrative Agent of such fact and (b) purchase for cash at face value participations in the portions of the Loans of the Other Lenders, or make such other adjustments as shall be equitable, so that the benefit of all such payments shall be shared by the Lenders ratably in accordance with the aggregate amount of principal of, accrued interest on and prepayment and repayment premiums or exit fees in connection with their respective portions of the Loans and other amounts owing them; <u>provided</u>, <u>that</u>:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">48</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:37.4pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:37.4pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if any such participations are purchased and all or any portion of the payment giving rise thereto is recovered, such participations shall be rescinded and the purchase price shall be restored to the extent of such recovery, without interest; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:37.4pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:37.4pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the provisions of this <u>Section 2.11</u> shall not be construed to apply to (x) any payment made by or on behalf of the Borrower pursuant to and in accordance with the express terms of this Agreement (including the application of funds arising from the existence of a Defaulting Lender) or (y) any payment obtained by a Lender as consideration for the assignment of or sale of any participation in any of its portion of the Loans to any assignee or participant, other than an assignment to the Borrower or any Subsidiary (as to which the provisions of this Section shall apply).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Each Loan Party consents to the foregoing and agrees, to the extent it may effectively do so under applicable Law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise against such Loan Party rights of setoff and counterclaim with respect to such participation as fully as if such Lender were a direct creditor of such Loan Party in the amount of such participation.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">2.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Defaulting Lenders</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustments.</u> Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender, then, until such time as that Lender is no longer a Defaulting Lender, to the extent permitted by applicable Law:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Waivers and Amendment.</u> The Defaulting Lender&#8217;s right to approve or disapprove any amendment, waiver or consent with respect to this Agreement shall be restricted as set forth in <u>Section 12.01.</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 36pt; text-align: justify; text-indent: 36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reallocation of Payments.</u> Any payment of principal, interest, fees or other amounts received by the Administrative Agent for the account of that Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to <u>Article IX</u> or otherwise, and including any amounts made available to the Administrative Agent by that Defaulting Lender pursuant to <u>Section 12.08),</u> shall be applied at such time or times as may be determined by the Administrative Agent as follows: <u>first,</u> to the payment of any amounts owing by that Defaulting Lender to the Administrative Agent hereunder; <u>second,</u> as the Borrower may request (so long as no Default or Event of Default exists), to the funding of any Loan in respect of which that Defaulting Lender has failed to fund its portion thereof as required by this Agreement, as determined by the Administrative Agent; <u>third,</u> if so determined by the Administrative Agent and the Borrower, to be held in a non-interest bearing deposit account and released in order to satisfy obligations of that Defaulting Lender to fund Loans under this Agreement; <u>fourth,</u> to the payment of any amounts owing to the Lenders as a result of any judgment of a court of competent jurisdiction obtained by any Lender against that Defaulting Lender as a result of that Defaulting Lender&#8217;s breach of its obligations under this Agreement; <u>fifth,</u> so long as no Default or Event of Default exists, to the payment of any amounts owing to the Borrower as a result of any judgment of a court of competent jurisdiction obtained by the Borrower against that Defaulting Lender as a result of that Defaulting Lender&#8217;s breach of its obligations under this Agreement; and <u>sixth,</u> to that Defaulting Lender or as otherwise directed by a court of competent jurisdiction; <u>provided, that,</u> if (x) such payment is a payment of the principal amount of any Loans in respect of which that Defaulting Lender has not fully funded its appropriate share and (y) such Loans were made at a time when the conditions set forth in <u>Section 5.02</u> were satisfied or waived, such payment shall be applied solely to pay the Loans of all non-Defaulting Lenders on a <u>pro rata</u> basis prior to being applied to the payment of any Loans of that Defaulting Lender. Any payments, prepayments, repayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender pursuant to this <u>Section 2.12 (a)(ii)</u> shall be deemed paid to and redirected by that Defaulting Lender, and each Lender irrevocably consents hereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">49</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Defaulting Lender Cure.</u> If the Borrower and the Administrative Agent agree in writing in their sole discretion that a Defaulting Lender should no longer be deemed to be a Defaulting Lender, the Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein, that Lender will cease to be a Defaulting Lender; <u>provided, that,</u> no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrower while that Lender was a Defaulting Lender; <u>provided, further, that,</u> except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lender having been a Defaulting Lender.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="text-transform:uppercase">Article&nbsp;</font>III<br>
<br>
TAXES</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">3.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Taxes</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All payments of principal and interest on the Loans and all other amounts payable hereunder by a Loan Party to any Recipient shall be made free and clear of and without deduction or withholding for or on account of any present or future income, excise, stamp, documentary, property or franchise taxes and other taxes, fees, duties, levies, assessments, withholding taxes or other charges of any nature whatsoever (including interest and penalties thereon), in each case, imposed by any taxing authority (&#8220;<u>Taxes</u>&#8221;), unless required by applicable Law. If any withholding or deduction of any Taxes from any payment by or on account of any obligation of any Loan Party hereunder is required by applicable Law (any such Taxes, excluding (w) Taxes imposed on or measured by net income, branch profits taxes and franchise taxes, in each case imposed by the jurisdiction (or any political subdivision thereof) under or in which a Recipient is organized, has its principal office or applicable lending office or otherwise conducts business or with which a Recipient has a present or former connection (other than solely as the result of entering into any of the Loan Documents or taking any action thereunder), (x) U.S. back-up withholding and other withholding Taxes imposed on amounts payable to or for the account of a Recipient with respect to an applicable interest in any Loan or Commitment pursuant to a Law in effect on the date on which such Recipient acquires such interest in the Loans or Commitment, except in each case to the extent that, pursuant to this <u>Section 3.01</u>, amounts with respect to such taxes were payable by such Recipient&#8217;s assignor immediately before such Recipient became a party hereto, (y) Taxes that would not have been imposed but for the failure of a Recipient to provide the Borrower with any certification, form or other documentation (including without limitation an IRS Form W-9 or IRS Form W-8) establishing an exemption from such Taxes and (z) any withholding tax imposed under FATCA (all non-excluded items shall hereinafter be referred to as &#8220;<u>Indemnified </u><u>Taxes</u>&#8221;, and Taxes described in <u>clauses (w)-(z)</u> shall hereinafter be referred to as &#8220;<u>Excluded Taxes</u>&#8221;), then (i) the applicable Withholding Agent shall be entitled to make such withholding or deduction and shall pay directly to the relevant Governmental Authority the full amount required to be so withheld or deducted within the time allowed and in the minimum amount required by applicable law, (ii) the applicable Withholding Agent shall promptly forward to the Administrative Agent an official receipt or other documentation satisfactory to the Administrative Agent evidencing such payment to such Governmental Authority and (iii) the sum payable by the applicable Loan Party shall be increased by such additional amount or amounts as is necessary to ensure that the net amount actually received by the applicable Recipient will equal the full amount such Recipient would have received had no such withholding or deduction for Indemnified Taxes been required.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">50</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Borrower shall indemnify each Recipient, within ten (10) days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed on or attributable to amounts payable under this Section) payable or paid by such Recipient or required to be withheld or deducted from a payment by such Recipient and any reasonable expenses arising therefrom or with respect thereto, whether or not such taxes were correctly or legally imposed or asserted by the relevant Governmental Authority.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Lender shall execute and deliver to the Borrower on or prior to the date that such Lender becomes a party hereto (and from time to time thereafter upon the reasonable request of the Borrower), one or more (as the Borrower may reasonably request) duly completed and executed copies of any forms, certificates or documents reasonably requested by the Borrower certifying as to such Lender&#8217;s entitlement to any available exemption from or reduction of withholding or deduction of taxes. In addition, any Lender, if reasonably requested by the Borrower, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Borrower as will enable the Borrower or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. No Loan Party shall be required to pay additional amounts to any Lender pursuant to this <u>Section 3.01</u> with respect to taxes attributable to the failure of such Lender to comply with this paragraph.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Lender agrees that if any form or certification it previously delivered pursuant to this <u>Section 3.01</u> expires or becomes obsolete or inaccurate in any respect, it shall promptly update such form or certification or promptly notify the Administrative Agent and the Borrower of its inability to do so.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the parties to the Agreement shall, within ten (10) days of a reasonable request by another party to the Agreement, supply to that other party</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such forms, documentation and other information relating to its status under FATCA as that other party reasonably requests for the purposes of that other Party&#8217;s compliance with FATCA, and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such forms, documentation and other information relating to its status as that other Party reasonably requests for the purposes of that other Party&#8217;s compliance with any other law, regulation, or exchange of information regime, such as the Common Reporting Standard.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any party determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section (including by the payment of additional amounts pursuant to this Section), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent of indemnity payments made under this Section with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such indemnified party the amount paid over pursuant to this <u>clause (f)</u> (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this <u>clause (f)</u>, in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this <u>clause (f)</u> the payment of which would place the indemnified party in a less favorable net after-Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This <u>clause (f)</u> shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential) to the indemnifying party or any other Person.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">51</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, due to a change in Sections 871(h) or 881(c) of the Internal Revenue Code (or any successor provisions) after the date a Person becomes an Indirect Lender under this Agreement, any withholding is required to be made by a Lender or any Affiliate thereof to such Indirect Lender attributable to payments made by any Loan Party hereunder, such Loan Party shall pay to such Lender such additional amount or amounts as is necessary to ensure that the net amount actually received by any Indirect Lender will equal the full amount such Indirect Lender would have received had no such withholding or deduction been required;<i> provided</i> that in the event additional amounts are due in respect of an Indirect Lender, immediately before such Indirect Lender transfers a direct or indirect interest in a Lender to a transferee and withholding is required to be made by a Lender or any Affiliate to such transferee Indirect Lender attributable to payments made by any Loan Party hereunder, a Loan Party shall be required to pay additional amounts pursuant to this Section in an amount not exceeding the additional amounts payable prior to the transfer by the transferor Indirect Lender; <i>provided</i>, <i>further</i> that no such additional amounts shall be payable by a Loan Party to the extent such withholding could have been avoided by any Indirect Lender and each entity in the chain of ownership between such Indirect Lender and the Lender providing Internal Revenue Service Forms W-9, W-8ECI, W-8BEN, W-8BEN-E or W-8IMY (as applicable) or any successor forms thereto, to the Lender or other entity in the chain of ownership between such Indirect Lender and the Lender, as applicable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">3.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Survival</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">All of the Loan Parties&#8217; obligations under this <u>Article III</u> shall survive termination of the Commitments, prepayment or repayment of all Obligations hereunder and the resignation or replacement of the Administrative Agent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="text-transform:uppercase">Article&nbsp;</font>IV<br>
<br>
GUARANTY</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">4.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>The Guaranty</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Each of the Guarantors hereby jointly and severally guarantees to each Secured Party and the Administrative Agent as hereinafter provided, as primary obligor and not as surety, the prompt payment of the Obligations of the Borrower and any other Guarantors in full when due (whether at stated maturity, as a mandatory prepayment, by acceleration or otherwise) strictly in accordance with the terms thereof. The Guarantors hereby further agree that if any of the Obligations are not paid in full when due (whether at stated maturity, as a mandatory prepayment, by acceleration or otherwise), the Guarantors will, jointly and severally, promptly pay the same, without any demand or notice whatsoever, and that in the case of any extension of time of payment or renewal of any of the Obligations, the same will be promptly paid in full when due (whether at extended maturity, as a mandatory prepayment, by acceleration or otherwise) in accordance with the terms of such extension or renewal.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Notwithstanding any provision to the contrary contained herein or in any other of the Loan Documents, the obligations of each Guarantor under this Agreement and the other Loan Documents shall be limited to an aggregate amount equal to the largest amount that would not render such obligations subject to avoidance under the Debtor Relief Laws or any comparable provisions of any applicable state or federal law.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">52</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">4.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Obligations Unconditional</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The obligations of the Guarantors under <u>Section 4.01</u> are joint and several, absolute and unconditional, irrespective of the value, genuineness, validity, regularity or enforceability of any of the Loan Documents, or any other agreement or instrument referred to therein, or any substitution, release, impairment or exchange of any other guarantee of or security for any of the Obligations, and, to the fullest extent permitted by applicable law, irrespective of any law or regulation or other circumstance whatsoever which might otherwise constitute a legal or equitable discharge or defense of a surety or guarantor, it being the intent of this <u>Section 4.02</u> that the obligations of the Guarantors hereunder shall be absolute and unconditional under any and all circumstances. Each Guarantor agrees that such Guarantor shall have no right of subrogation, indemnity, reimbursement or contribution against the Borrower or any other Guarantor for amounts paid under this <u>Article IV</u> until such time as the Obligations (other than contingent indemnification obligations for which no claim has been asserted) have been paid in full and the Commitments have expired or terminated. Without limiting the generality of the foregoing, it is agreed that, to the fullest extent permitted by law, the occurrence of any one or more of the following shall not alter or impair the liability of any Guarantor hereunder, which shall remain absolute and unconditional as described above:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;at any time or from time to time, without notice to any Guarantor, the time for any performance of or compliance with any of the Obligations shall be extended, or such performance or compliance shall be waived;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any of the acts mentioned in any of the provisions of any of the Loan Documents, or any other agreement or instrument referred to in the Loan Documents shall be done or omitted;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the maturity of any of the Obligations shall be accelerated, or any of the Obligations shall be modified, supplemented or amended in any respect, or any right under any of the Loan Documents including any change in the purpose of, an extension of or increase in any facility or the addition of any new facility under the Loan Documents or other document, or any other agreement or instrument referred to in the Loan Documents shall be waived or any other guarantee of any of the Obligations or any security therefor shall be released, impaired or exchanged in whole or in part or otherwise dealt with;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any Lien granted to, or in favor of, any Secured Party as security for any of the Obligations shall fail to attach or be perfected;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any of the Obligations shall be determined to be void or voidable (including, without limitation, for the benefit of any creditor of any Guarantor) or shall be subordinated to the claims of any Person (including, without limitation, any creditor of any Guarantor); or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any insolvency or similar proceedings.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">With respect to its obligations hereunder, each Guarantor hereby expressly waives diligence, presentment, demand of payment, protest and all notices whatsoever, and any requirement that the Secured Parties exhaust any right, power or remedy or proceed against any Person under any of the Loan Documents, or any other agreement or instrument referred to in the Loan Documents, or against any other Person under any other guarantee of, or security for, any of the Obligations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">4.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reinstatement</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The obligations of the Guarantors under this <u>Article IV</u> shall be automatically reinstated if and to the extent that for any reason any payment by or on behalf of any Person in respect of the Obligations is rescinded or must be otherwise restored by any holder of any of the Obligations, whether as a result of any proceedings in bankruptcy or reorganization or otherwise, and each Guarantor agrees that it will indemnify the Secured Parties on demand for all reasonable costs and expenses (including, without limitation, the fees, charges and disbursements of counsel) incurred by the Secured Parties in connection with such rescission or restoration, including any such costs and expenses incurred in defending against any claim alleging that such payment constituted a preference, fraudulent transfer or similar payment under any bankruptcy, insolvency or similar law.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">53</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">4.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Additional Waivers</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Each Guarantor agrees that such Guarantor shall have no right of recourse to security for the Obligations, except through the exercise of rights of subrogation pursuant to <u>Section 4.02</u> and through the exercise of rights of contribution pursuant to <u>Section 4.06</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">4.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Guarantors agree that, to the fullest extent permitted by law, as between the Guarantors, on the one hand, and the Secured Parties, on the other hand, the Obligations may be declared to be forthwith due and payable as provided in <u>Section 9.02</u> (and shall be deemed to have become automatically due and payable in the circumstances provided in said <u>Section 9.02</u>) for purposes of <u>Section 4.01</u> notwithstanding any stay, injunction or other prohibition preventing such declaration (or preventing the Obligations from becoming automatically due and payable) as against any other Person and that, in the event of such declaration (or the Obligations being deemed to have become automatically due and payable), the Obligations (whether or not due and payable by any other Person) shall forthwith become due and payable by the Guarantors for purposes of <u>Section 4.01</u>. The Guarantors acknowledge and agree that their obligations hereunder are secured in accordance with the terms of the Collateral Documents and that the Secured Parties may exercise their remedies thereunder in accordance with the terms thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">4.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Rights of Contribution</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Guarantors agree among themselves that, in connection with payments made hereunder, each Guarantor shall have contribution rights against the other Guarantors as permitted under applicable law. Such contribution rights shall be subordinate and subject in right of payment to the obligations of such Guarantors under the Loan Documents and no Guarantor shall exercise such rights of contribution until all Obligations (other than contingent indemnification obligations for which no claim has been asserted) have been paid in full and the Commitments have been terminated.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">4.07&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Guarantee of Payment; Continuing Guarantee</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The guarantee in this <u>Article IV</u> is a guaranty of payment and not of collection, is a continuing guarantee, and shall apply to all Obligations whenever arising.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">4.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitations</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The guarantee in this <u>Article IV</u> insofar as it is from BioCryst Ireland Limited does not apply to any liability to the extent that it would result in such guarantee constituting unlawful financial assistance within the meaning of Section 82 of the Companies Act.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">4.09&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Guarantor Intent</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">54</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Without prejudice to generality of <u>Section 4.02</u>, each Guarantor expressly confirms that it intends that this Guaranty shall extend from time to time to any (however fundamental) variation, increase, extension or addition of or to any of the Loan Documents, Collateral and/or any facility or amount made available under any of the Loan Documents for the purposes of or in connection with any of the following: business acquisitions of any nature; increasing working capital; enabling investor distributions to be made; carrying out restructurings; refinancing existing facilities; refinancing any other indebtedness; making facilities available to new borrowers; any other variation or extension of the purposes for which any such facility or amount might be made available from time to time; and any fees, costs and/or expenses associated with any of the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="text-transform:uppercase">Article&nbsp;</font>V<br>
<br>
CONDITIONS PRECEDENT TO BORROWINGS</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">5.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conditions to Initial Borrowing</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">This Agreement shall become effective upon, and the obligation of each Lender to make its portion of the Loans to be advanced on the Closing Date is subject to, satisfaction of the following conditions precedent:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Loan Doc</u><u>uments</u>. Receipt by the Administrative Agent of executed counterparts of this Agreement and the other Loan Documents, each properly executed by a Responsible Officer of the signing Loan Party (or, in the case of a Loan Party incorporated in Ireland, properly in the manner specified in the resolutions of the board of directors thereof) and each other party to such Loan Documents, in each case in form and substance satisfactory to the Administrative Agent and the Lenders.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Opinions of Counsel</u>. Receipt by the Administrative Agent of favorable opinions of legal counsel to the Loan Parties or in the case of BioCryst Ireland Limited, legal counsel to the Administrative Agent, addressed to the Administrative Agent and each Lender, dated as of the Closing Date, and in form and substance satisfactory to the Administrative Agent and its counsel.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Financial Statements; Due Diligence</u>. The Administrative Agent shall have received the Audited Financial Statements, the Interim Financial Statements and such other reports, statements and due diligence items as the Administrative Agent or any Lender shall request.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Material Adverse Effect</u>. Since the date of the Audited Financial Statements, there shall not have occurred any event or condition that has had or could reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Litigation</u>. There shall not exist any action, suit, investigation or proceeding pending or threatened in any court or before an arbitrator or Governmental Authority that could reasonably be expected, either individually or in the aggregate, to have a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Organization Documents, Resolutions, Etc</u>. Receipt by the Administrative Agent of the following, each of which shall be pdf scans, in form and substance satisfactory to the Administrative Agent and its legal counsel:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;copies of the Organization Documents of each Loan Party certified to be true and complete as of a recent date by the appropriate Governmental Authority of the state or other jurisdiction of its incorporation or organization, where applicable, and certified by a secretary or assistant secretary of such Loan Party to be true and correct as of the Closing Date;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">55</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such certificates of resolutions, shareholder resolutions or other action, incumbency certificates and/or other certificates of Responsible Officers of each Loan Party as the Administrative Agent may require evidencing the identity, authority and capacity of each Responsible Officer thereof and each Responsible Financial Officer thereof authorized to act as a Responsible Officer or a Responsible Financial Officer in connection with this Agreement and the other Loan Documents to which such Loan Party is a party; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such documents and certifications as the Administrative Agent may require to evidence that each Loan Party is duly organized, incorporated or formed, and is validly existing, in good standing and qualified to engage in business in its state of organization or formation, including certificates of good standing or status in all applicable jurisdictions (which shall exclude, for the avoidance of doubt, Ireland).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Perfection and Priority of Liens</u>. Receipt by the Administrative Agent of the following, each of which shall be in form and substance satisfactory to the Administrative Agent:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;searches of Uniform Commercial Code filings in the jurisdiction of formation of each Loan Party or where a filing would need to be made in order to perfect the Administrative Agent&#8217;s security interest in the Collateral, copies of the financing statements on file in such jurisdictions, evidence that no Liens exist other than Permitted Liens;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;UCC financing statements for each appropriate jurisdiction as is necessary, in the Administrative Agent&#8217;s sole discretion, to perfect the Administrative Agent&#8217;s security interest in the Collateral;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;searches of ownership of, and Liens on, the IP Rights of each Loan Party in the appropriate governmental offices;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;duly executed IP Security Agreements as are necessary, in the Administrative Agent&#8217;s sole discretion, to perfect the Administrative Agent&#8217;s security interest in the IP Rights of the Loan Parties;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[reserved];</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[reserved];</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[reserved];</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;perfection actions, including, without limitation, searches, certifications, notices and any other items required pursuant to or reasonably requested in connection with the Collateral Documents to be executed on the Closing Date; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;agreement between Irish legal counsel to the Administrative Agent and Irish legal counsel to BioCryst Ireland Limited on the wording of the short and further particulars for each security filing to be made in the Irish Companies Registration Office.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Reserved</u>].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Closing Certificate</u>. Receipt by the Administrative Agent of a certificate signed by a Responsible Officer of the Borrower certifying, as of the Closing Date, (i) that the conditions specified in <u>Sect</u><u>ions 5.0</u><u>1(d)</u>, <u>(e)</u> and <u>(k)</u> and <u>5.02(a)</u> and <u>(b)</u> have been satisfied, (ii) that the Borrower and its Subsidiaries (after giving effect to the Transactions and the incurrence of Indebtedness related thereto) are Solvent on a consolidated basis, (iii) that the Borrower and its Subsidiaries have no Indebtedness for borrowed money, other than Indebtedness permitted by <u>Section 8.03</u>, (iv) that neither the Borrower nor any Subsidiary has outstanding any Disqualified Capital Stock and (v) as true and complete an attached description of all intercompany Indebtedness of the Borrower and its Subsidiaries.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">56</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Existing Indebtedness</u>. All of the Existing Indebtedness shall be repaid in full and all security interests related thereto shall be terminated on or prior to the Closing Date, in each case, evidenced by payoff letters and lien releases reasonably satisfactory to the Administrative Agent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Governmental and Third Party Approvals</u>. The Borrower and its Subsidiaries shall have received all material governmental, shareholder and third-party consents and approvals necessary in connection with the transactions contemplated by this Agreement, the other Loan Documents, the Royalty Financing Documents and the other transactions contemplated hereby and all applicable waiting periods shall have expired without any action being taken by any Person that could reasonably be expected to restrain, prevent or impose any material adverse conditions on the Borrower or any of its Subsidiaries or such other transactions or that could seek to threaten any of the foregoing, and no law or regulation shall be applicable which could reasonably be expected to have such effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Corporate Structure and Capitalization</u>. The capital and ownership structure of the Borrower on the Closing Date, on a pro forma basis after giving effect to the transactions contemplated by the Loan Documents and the Royalty Financing Documents, shall be reasonably satisfactory to the Administrative Agent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Letter of Direction</u>. Receipt by the Administrative Agent of a satisfactory letter of direction containing funds flow information with respect to the proceeds of the Loan to be made on the Closing Date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Fees</u>. Receipt by Athyrium and its Affiliates, the Administrative Agent and the Lenders of any fees required to be paid hereunder or under the other Loan Documents on or before the Closing Date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Costs; Expenses</u>. The Borrower shall have paid all reasonable and documented expenses, fees and charges of the Lenders and Administrative Agent incurred in connection with the Loan Documents, including all documented expenses, fees, charges and disbursements of counsel to the Lenders and Administrative Agent and all due diligence expenses of Athyrium and its Affiliates and the Lenders, in each case, incurred on or prior to the Closing Date, plus such additional amounts of such fees, charges and disbursements as shall constitute their reasonable estimate of such fees, charges and disbursements incurred or to be incurred by it through the closing proceedings (<u>provided</u>, <u>that</u>, such estimate shall not thereafter preclude a final settling of accounts between the Borrower, the Lenders and the Administrative Agent), in each case, to the extent an invoice therefor is sent at least one (1) Business Day prior to the Closing Date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Royalty Financing Documents</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Royalty Financing Documents shall have been executed and delivered and the transactions thereunder fully consummated substantially concurrently with the execution and delivery of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receipt by the Administrative Agent of the Royalty Financing Documents, each in form and substance satisfactory to Administrative Agent and the Lenders in their sole discretion.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">57</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Borrower shall deliver a certificate of a Responsible Officer to Administrative Agent certifying that (A) Administrative Agent has received a true, correct and complete executed copy of each Royalty Financing Document, (B) the Borrower and its Subsidiaries are in compliance in all material respects with the Royalty Financing Documents to which it is a party, and such Person has not received any notice of default or termination thereunder and (C) no Royalty Financing Document has been amended or waived or modified in any manner, without the written consent of the Administrative Agent and the Lenders.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[</u><u>Reserved</u>].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination of MDCP Licenses</u>. Receipt by the Administrative Agent of satisfactory evidence that all agreements, licenses, permits and assignments in favor of MDCP or providing MDCP any right or interest in any IP Rights of the Borrower or any Subsidiary, including without limitation that certain License and Services Agreement between the Borrower and MDCP, dated as of September 23, 2016, as amended restated or otherwise modified from time to time, have been terminated and released.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Other</u>. Receipt by the Administrative Agent and the Lenders of such other documents, instruments, agreements and information as requested by the Administrative Agent or any Lender, including, but not limited to, information regarding litigation, tax, accounting, labor, insurance, pension liabilities (actual or contingent), real estate leases, material contracts, debt agreements, property ownership, environmental matters, contingent liabilities and management of the Borrower and its Subsidiaries; such information may include, if requested by the Administrative Agent or any Lender, asset appraisal reports and written audits of accounts receivable, inventory, payables, controls and systems.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Without limiting the generality of the provisions of the last paragraph of <u>Section 11.03,</u> for purposes of determining compliance with the conditions specified in this <u>Section 5.01,</u> each Lender that has signed this Agreement shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be consented to or approved by or acceptable or satisfactory to a Lender unless the Administrative Agent shall have received notice from such Lender prior to the proposed Closing Date specifying its objection thereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">5.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conditions to all Borrowings</u>. The obligation of each Lender to honor any Loan Notice is subject to the following conditions precedent:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Representations and Warranties</u>. The representations and warranties of the Borrower and each other Loan Party contained in <u>Article VI</u> or any other Loan Document, or which are contained in any document furnished at any time under or in connection herewith or therewith, shall be true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) on and as of the date of such Borrowing, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct in all material respects (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) as of such earlier date, and except that for purposes of this <u>Section 5.02</u>, the representations and warranties contained in <u>subsections (a)</u> and <u>(b)</u> of <u>Section 6.05</u> shall be deemed to refer to the most recent statements furnished pursuant to <u>clauses (a)</u> and <u>(b)</u>, respectively, of <u>Section 7.01</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Default</u>. No Default or Event of Default shall exist, or would result from such proposed Borrowing or from the application of the proceeds thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Material Adverse Effect</u>. Since the date of the Audited Financial Statements, there shall not have occurred any event or condition that has had or could reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">58</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Loan Notice</u>. The Administrative Agent shall have received a Loan Notice in accordance with the requirements hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Term A Draw Conditions</u>. With respect to the Term A Borrowing, the Term A Draw Conditions shall have been satisfied.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Term B Draw Conditions</u>. With respect to the Term B Borrowing, the Term B Draw Conditions shall have been satisfied.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Term C Draw Conditions</u>. With respect to the Term C Borrowing, the Term C Draw Conditions shall have been satisfied.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Each Loan Notice submitted by the Borrower shall be deemed to be a representation and warranty that the conditions specified in <u>Section 5.02</u> have been satisfied as of the date of the applicable Borrowing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="text-transform:uppercase">Article&nbsp;</font>VI<br>
<br>
REPRESENTATIONS AND WARRANTIES</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Each Loan Party represents and warrants to the Administrative Agent and the Lenders, on the Closing Date, the date of each Borrowing and each other date required by a Loan Document, that:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Existence, Qualification and Power</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Each Loan Party and each of its Subsidiaries (a) is duly organized, incorporated or formed, validly existing and (where such concept exists in the case of Non-U.S. Subsidiaries) in good standing under the Laws of the jurisdiction of its incorporation or organization, (b) has all requisite power and authority and all requisite Permits, governmental licenses, authorizations, consents and approvals to (i) own or lease its assets and carry on its business and (ii) execute, deliver and perform its obligations under the Loan Documents to which it is a party and to consummate the Transactions to which it is a party, and (c) is duly qualified and is licensed and in good standing under the Laws of each jurisdiction where its ownership, lease or operation of properties or the conduct of its business requires such qualification or license; except in each case referred to in <u>clause (b)(i)</u> or <u>(c)</u>, to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Authorization; No Contravention</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The execution, delivery and performance by each Loan Party of each Loan Document, and Royalty Financing Document to which such Person is party have been duly authorized by all necessary corporate or other organizational action, and do not (a) contravene the terms of any of such Person&#8217;s Organization Documents, (b) conflict with or result in any breach or contravention of, or the creation of any Lien under, or require any payment to be made under (i) the JPR Indenture or the other Deal Documents (as defined in the JPR Indenture) or any indenture, credit agreement, or promissory note evidencing Indebtedness or any other material Contractual Obligation to which such Person is a party or affecting such Person or the properties of such Person or any of its Subsidiaries or (ii) any order, judgment, injunction, writ or decree of any Governmental Authority or any arbitral award to which such Person or its property is subject, or (c) violate any applicable Law (including, without limitation, Regulation U or Regulation X issued by the FRB).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Governmental Authorization; Other Consents</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">59</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">No approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with the execution, delivery or performance by, or enforcement against, any Loan Party of this Agreement or any other Loan Document other than (a) those that have already been obtained and are in full force and effect, (b) filings to perfect the Liens created by the Collateral Documents and (c) the filing of any applicable reports under securities laws.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Binding Effect</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Each Loan Document has been duly executed and delivered by each Loan Party that is party thereto. Each Loan Document constitutes a legal, valid and binding obligation of each Loan Party that is party thereto, enforceable against each such Loan Party in accordance with its terms, subject to applicable Debtor Relief Laws or other Laws affecting creditors&#8217; rights generally and subject to general principles of equity and subject in the case of each Irish Subsidiary, to the Legal Reservations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Financial Statements; No Material Adverse Effect</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audited Financial Statements (i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein, (ii) fairly present in all material respects the financial condition of the Borrower and its Subsidiaries as of the date thereof and their results of operations for the period covered thereby in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein, and (iii) show all material indebtedness and other material liabilities, direct or contingent, of the Borrower and its Subsidiaries as of the date thereof, including material liabilities for taxes, commitments and Indebtedness.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Interim Financial Statements (i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein, (ii) fairly present in all material respects the financial condition of the Borrower and its Subsidiaries as of the date thereof and their results of operations for the period covered thereby, subject, in the case of <u>clauses (i)</u> and <u>(ii)</u>, to the absence of footnotes and to normal year-end audit adjustments, and (iii) show all material indebtedness and other material liabilities, direct or contingent, of the Borrower and its Subsidiaries as of the date thereof, including material liabilities for taxes, material commitments and Indebtedness.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From the date of the Audited Financial Statements to and including the Closing Date, there has been no Disposition by any Loan Party or any Subsidiary, or any Involuntary Disposition, of any material part of the business or property of any Loan Party or any Subsidiary, and no purchase or other acquisition by any of them of any business or property (including any Equity Interests of any other Person) material to any Loan Party or any Subsidiary, in each case, which is not reflected in the foregoing financial statements or in the notes thereto and has not otherwise been disclosed in writing to the Lenders on or prior to the Closing Date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements delivered pursuant to <u>Section 7.01(a)</u> and <u>(b)</u> have been prepared in accordance with GAAP (except as may otherwise be permitted under <u>Section 7.01(a)</u> or <u>(b)</u>, as applicable) and present fairly in all material respects (on the basis disclosed in the footnotes to such financial statements) the consolidated financial condition, results of operations and cash flows of the Borrower and its Subsidiaries as of the dates thereof and for the periods covered thereby.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">60</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since the date of the Audited Financial Statements, there has been no event or circumstance, either individually or in the aggregate, that has had or could reasonably be expected to have a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Litigation</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">There are no actions, suits, proceedings, claims or disputes pending, threatened or contemplated, at law, in equity, in arbitration or before any Governmental Authority, by or against any Loan Party or any of its Subsidiaries or against any of their properties or revenues that (a) purport to affect or pertain to this Agreement or any other Loan Document, or any of the transactions contemplated hereby or (b) either individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.07&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Default</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither any Loan Party nor any Subsidiary is (i) in default under or with respect to any Material Contract (A) as of the Closing Date and (B) after the Closing Date in a manner that could reasonably be expected to result in a material adverse effect on any Product Development and Commercialization Activities, or (ii) in default under or with respect to any other Contractual Obligation that, in the case of this clause (ii), could reasonably be expected to have a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Default has occurred and is continuing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Ownership of Property; Liens</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Each Loan Party and its Subsidiaries has good record and marketable title in fee simple to, or valid leasehold interests in, all real property necessary or used in the ordinary conduct of its business. The property of each Loan Party and its Subsidiaries is subject to no Liens, other than Permitted Liens.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.09&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Environmental Compliance</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Facilities and all operations at the Facilities are in compliance in all material respects with all applicable Environmental Laws, and there is no violation in any material respect of any Environmental Law with respect to the Facilities or the Businesses, and there are no conditions relating to the Facilities or the Businesses, that could give rise to liability that, individually or in the aggregate, could reasonably be expected to exceed the Threshold Amount under any applicable Environmental Laws.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of the Facilities contains, or has previously contained, any Hazardous Materials at, on or under the Facilities in amounts or concentrations that constitute or constituted a violation in any material respect of Environmental Laws, or could reasonably be expected to give rise to liability under Environmental Laws that, individually or in the aggregate, could exceed the Threshold Amount.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither any Loan Party nor any Subsidiary has received any written or verbal notice of, or inquiry from any Governmental Authority regarding, any violation, alleged violation, non-compliance, liability or potential liability regarding environmental matters or compliance with Environmental Laws with regard to any of the Facilities or the Businesses that could reasonably be expected to give rise to liability that, individually or in the aggregate, could exceed the Threshold Amount, nor does any Responsible Officer of any Loan Party have knowledge or reason to believe that any such notice will be received or is being threatened.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">61</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hazardous Materials have not been transported or disposed of from the Facilities, or generated, treated, stored or disposed of at, on or under any of the Facilities or any other location, in each case by or on behalf of any Loan Party or any Subsidiary in violation in any material respect of any applicable Environmental Law, or in a manner that could reasonably be expected to give rise to liability under any applicable Environmental Law that, individually or in the aggregate, could exceed the Threshold Amount.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No judicial proceeding or governmental or administrative action is pending or, to the knowledge of the Loan Parties, threatened, under any Environmental Law to which any Loan Party or any Subsidiary is or will be named as a party, nor are there any consent decrees or other decrees, consent orders, administrative orders or other orders, or other administrative or judicial requirements outstanding under any Environmental Law with respect to any Loan Party, any Subsidiary, the Facilities or the Businesses.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There has been no release or threat of release of Hazardous Materials at or from the Facilities, or arising from or related to the operations (including, without limitation, disposal) of any Loan Party or any Subsidiary in connection with the Facilities or otherwise in connection with the Businesses, in violation in any material respect of Environmental Laws, or in amounts or in a manner that could give rise to liability under Environmental Laws that could reasonably be expected to, individually or in the aggregate, exceed the Threshold Amount.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Insurance</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The properties of the Borrower and its Subsidiaries are insured with financially sound and reputable insurance companies that are not Affiliates of such Persons, in such amounts, with such deductibles and covering such risks as are customarily carried by companies engaged in similar businesses and owning similar properties in localities where the Borrower or its applicable Subsidiary operates. The insurance coverage of the Borrower and its Subsidiaries as in effect on the Closing Date is outlined as to carrier, policy number, expiration date, type, coverage amounts and deductibles on <u>Schedule 6.10</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Borrower and its Subsidiaries maintain, if available, fully paid flood hazard insurance on all real property that is located in a special flood hazard area in the United States and that constitutes Collateral on such terms and in such amounts as required by The National Flood Insurance Reform Act of 1994 or as otherwise required by the Administrative Agent or the Required Lenders.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Taxes</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Loan Parties and their Subsidiaries have filed all federal, state and other material tax returns and reports required to be filed by it, and have paid all federal, state and other material taxes, assessments, governmental fees and other governmental charges levied or imposed upon them or their properties, income or assets otherwise due and payable, except those which are being contested in good faith by appropriate proceedings diligently conducted and for which adequate reserves have been provided in accordance with GAAP and the failure to make such payment pending such contest could not reasonably be expected to result in a Material Adverse Effect. There is no proposed tax assessment against any Loan Party or any Subsidiary that would, if made, exceed the Threshold Amount.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither any Loan Party nor any Subsidiary thereof is party to any tax sharing agreement with any Person that is not a Loan Party (other than any agreement the primary purpose of which is not the sharing of taxes).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">62</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the Closing Date, no claims or investigations are pending, or to the knowledge of any Loan Party, threatened with respect to any Taxes that could reasonably be expected to result in liabilities of a Loan Party or Subsidiary in an amount in excess of the Threshold Amount.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>ERISA Compliance</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Plan is in compliance, in both form and operation, in all material respects with the applicable provisions of ERISA, the Internal Revenue Code and other federal or state laws. Each Pension Plan that is intended to be a qualified plan under Section 401(a) of the Internal Revenue Code has received a current favorable determination letter (or is entitled to rely on a current advisory or opinion letter issued to a volume submitter or prototype plan provider) from the Internal Revenue Service to the effect that the form of such Plan is qualified under Section 401(a) of the Internal Revenue Code and the trust related thereto has been determined by the Internal Revenue Service to be exempt from federal income tax under Section 501(a) of the Internal Revenue Code or an application for such a letter is currently pending with the Internal Revenue Service. To the knowledge of the Loan Parties, nothing has occurred that would prevent, or cause the loss of, such tax-qualified status.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no pending or, to the knowledge of the Loan Parties, threatened claims, actions or lawsuits, or action by any Governmental Authority, with respect to any Plan that could reasonably be expected to have a Material Adverse Effect. There has been no prohibited transaction or violation of the fiduciary responsibility rules with respect to any Plan that has resulted or could reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) No ERISA Event has occurred and none of the Borrower and any ERISA Affiliate is aware of any fact, event or circumstance that could reasonably be expected to constitute or result in an ERISA Event with respect to any Pension Plan, (ii) the Borrower and each ERISA Affiliate has met all material and applicable requirements under the Pension Funding Rules in respect of each Pension Plan, and no waiver of the minimum funding standards under the Pension Funding Rules has been applied for or obtained, (iii) as of the most recent valuation date for any Pension Plan, the funding target attainment percentage (as defined in Section 430(d)(2) of the Internal Revenue Code) is sixty percent (60%) or higher and none of the Borrower and any ERISA Affiliate knows of any facts or circumstances that could reasonably be expected to cause the funding target attainment percentage for any such plan to drop below sixty percent (60%) as of the next valuation date, (iv) none of the Borrower and any ERISA Affiliate has incurred any liability to the PBGC other than for the payment of premiums, and there are no premium payments which have become due that are unpaid, (v) none of the Borrower and any ERISA Affiliate has engaged in a transaction that could be subject to Section 4069 or Section 4212(c) of ERISA, and (vi) no Pension Plan has been terminated by the plan administrator thereof nor by the PBGC, and no event or circumstance has occurred or exists that could reasonably be expected to cause the PBGC to institute proceedings under Title IV of ERISA to terminate any Pension Plan.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of the Borrower and any ERISA Affiliate has established or otherwise has any liability with respect to a &#8220;welfare plan&#8221;, as such term is defined in Section 3(1) of ERISA, that either provides post-employment welfare benefits other than as required by Section 4980B of the Internal Revenue Code (or similar state law) or is a health or life insurance plan that is not fully insured by a third party insurance company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Subsidiaries and Capitalization; Management Fees</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Set forth on <u>Schedule 6.13(a)</u> is a complete and accurate list as of the Closing Date of each Subsidiary of any Loan Party and JPR Royalty Sub, together with (i) jurisdiction of organization, (ii) number of shares of each class of Equity Interests outstanding, (iii) number and percentage of outstanding shares of each class owned (directly or indirectly) by any Loan Party or any Subsidiary, (iv) number and effect, if exercised, of all outstanding options, warrants, rights of conversion or purchase and all other similar rights with respect thereto and (v) identification of each Subsidiary that is an Excluded Subsidiary, a Non-U.S. Regulatory Approval Subsidiary and/or an Immaterial Non-U.S. Subsidiary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">63</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Set forth on <u>Schedule 6.13(b)</u> is a true and complete table showing the authorized and issued capitalization of each of the Borrower, its Subsidiaries and JPR Royalty Sub as of the Closing Date on a fully diluted basis. All issued and outstanding Equity Interests of the Borrower and each of its Subsidiaries are duly authorized and validly issued, fully paid, non-assessable, free and clear of all Liens and such Equity Interests were issued in compliance with all applicable Laws. As of the Closing Date, except as described on <u>Schedule 6.13(b)</u> or the Borrower&#8217;s Organizational Documents, there are no outstanding commitments or other obligations of the Borrower or any Subsidiary to issue, and no rights of any Person to acquire, any shares of any Equity Interests of the Borrower or any of its Subsidiaries. There are no agreements (voting or otherwise) among the Borrower&#8217;s equity holders with respect to any other aspect of the Borrower&#8217;s or any Subsidiary&#8217;s affairs, except as set forth on <u>Schedule 6.13(b)</u> or as contained in the Borrower&#8217;s Organizational Documents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the Closing Date, no Loan Party, nor any of their respective Subsidiaries, directly or indirectly, are obligated to pay any management, consulting, transaction or similar advisory fees (other than normal and reasonable compensation (including in the form of Equity Interests) and reimbursement of expenses of officers and directors in the ordinary course of business) to or for the account of any officer, director or holder (or any Affiliate of any holder) of at least 5% of the Equity Interests of such Person.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Margin Regulations; Investment Company Act</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Loan Party is engaged and no Loan Party will engage, principally or as one of its important activities, in the business of purchasing or carrying margin stock (within the meaning of Regulation U issued by the FRB), or extending credit for the purpose of purchasing or carrying margin stock. Following the application of the proceeds of each Borrowing, not more than 25% of the value of the assets (either of the Borrower only or of the Borrower and its Subsidiaries on a consolidated basis) will be margin stock.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Loan Party, any Person Controlling any Loan Party, or any Subsidiary is or is required to be registered as an &#8220;investment company&#8221; under the Investment Company Act of 1940.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Disclosure</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Each Loan Party has disclosed to the Administrative Agent and the Lenders all agreements, instruments and corporate or other restrictions to which it or any of its Subsidiaries is subject, and all other matters known to it, that, either individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect. No report, financial statement, certificate or other information furnished (whether written or oral) (other than forward-looking information and projections and information of a general economic nature and general information about the Loan Parties&#8217; industry) by or on behalf of any Loan Party to the Administrative Agent or any Lender in connection with the transactions contemplated hereby and the negotiation of this Agreement or delivered hereunder or under any other Loan Document (in each case, as modified or supplemented by other information so furnished) contains any material misstatement of fact or omits to state any fact necessary to make the statements therein, in the light of the circumstances under which they were made and taken as a whole, not misleading. Each Loan Party represents, with respect to projections, estimates, budgets and other forward-looking information, only that such information was prepared in good faith based on assumptions believed to be reasonable at the time such projections were prepared.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">64</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Laws</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Each Loan Party and each Subsidiary is in compliance with the requirements of all Laws and all judgments, orders, writs, injunctions and decrees applicable to it or to its properties, except in such instances in which (a) such requirement of Law or judgment, order, writ, injunction or decree is being contested in good faith by appropriate proceedings diligently conducted or (b) the failure to comply therewith could not reasonably be expected to have a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Intellectual Property; Licenses, Etc.</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Schedule 6.17 Part (a)</u> sets forth a complete and accurate list of the following as of the Closing Date: (i) all Copyrights and all Trademarks of any Loan Party or any Subsidiary, that are registered, or in respect of which an application for registration has been filed or recorded, with the United States Patent and Trademark Office or the United States Copyright Office or with any other Governmental Authority (or comparable organization or office established in any country or pursuant to an international treaty or similar international agreement for the filing, recordation or registration of interests in intellectual property), together with relevant identifying information with respect to such Copyrights and Trademarks, (ii) all Patents of any Loan Party or any Subsidiary that are issued, or in respect of which an application has been filed or recorded, with the United States Patent and Trademark Office or with any other Governmental Authority (or comparable organization or office established in any country or pursuant to an international treaty or similar international agreement for the filing, recordation or registration of interests in intellectual property), together with relevant identifying information with respect to such Patents, (iii) all Domain Names owned by any Loan Party or any Subsidiary or which any Loan Party or any Subsidiary is licensed, authorized or otherwise granted rights under or to, or owned by a Person on behalf of any Loan Party or any Subsidiary, together with relevant identifying information with respect to such Domain Names, (iv) each Copyright License, each Patent License and each Trademark License of any Loan Party or any Subsidiary and (v) each other Material IP Right of any Loan Party or any Subsidiary, in each case with respect to this clause (v), other than Trade Secrets.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All Material IP Rights (other than Material IP Rights that are not material or are no longer used or useful in any material respect in the business of the Borrower or any of its Subsidiaries) are in full force and effect, and have not expired, lapsed or been forfeited, cancelled or abandoned. Each of the Borrower and the Subsidiaries, have, since taking title to the Material IP Rights, performed all acts and have paid all required annuities, fees, costs, expenses and taxes to maintain the Material IP Rights in full force and effect in each of the Key Territories, as applicable, or have caused others to do the same. All documents filed or recorded with a patent office or other relevant intellectual property registry for registration, recordation or issuance of Material IP Rights in each of the Key Territories have been duly and properly filed and recorded. None of the Material IP Rights have been or are subject to any pending or outstanding injunction, directive, order, judgment, or other disposition of dispute that adversely restricts, or when any such pending dispute is concluded may adversely restrict, the use, transfer, registration, licensing or other exploitation of any such Material IP Rights in any of the Key Territories, or otherwise adversely affects, or may adversely affect, the scope, validity, use, right to use, registrability, or enforceability of such Material IP Rights in any of the Key Territories. No action or proceeding is pending that could reasonably be expected to result in any of the foregoing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Borrower or a Subsidiary owns or has a valid license or other valid right to use all Material IP Rights, free and clear of any and all Liens other than Permitted Liens. To the extent any of the Material IP Rights were authored, developed, conceived or created, in whole or in part, for or on behalf of the Borrower or a Subsidiary by any Person, then the Borrower or the Subsidiary or their predecessors in interest, as applicable, has entered into a written agreement with such Person in which such Person has assigned all right, title and interest in and to such Material IP Rights to the Borrower or such Subsidiary, or their predecessors in interest, including the right to sue for and collect past damages, as applicable. Except as otherwise indicated on <u>Schedule 6.17 Part (b)</u>, each of the Borrower and each Subsidiary is the sole and exclusive owner of all right, title and interest in and to all such Material IP Rights that are owned by it.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">65</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Borrower nor any Subsidiary has made any assignment or agreement in conflict with the security interest in any of the Material IP Rights of the Borrower or any Subsidiary hereunder and no license agreement with respect to any of the Material IP Rights conflicts with the security interest granted to the Administrative Agent, on behalf of the Lenders, pursuant to the terms of the Collateral Documents. Except as described in <u>Schedule 6.17 Part (c)</u>, and except for software that is commercially available to the public, no Loan Party is a party to, nor is bound by, any inbound license or other similar agreement, the failure, breach or termination of which could reasonably be expected to cause a Material Adverse Effect, or that prohibits or otherwise restricts the Loan Parties from granting a security interest in the applicable Loan Party&#8217;s interest in such license or agreement or any other property.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To the Loan Parties&#8217; knowledge, no Person is infringing, misappropriating, violating, or diluting any Material IP Rights (i) as of the Closing Date and (ii) after the Closing Date in a manner that could reasonably be expected to result in a material adverse effect on any Product Development and Commercialization Activities, and as of the Closing Date, no Loan Party has given notice to any third party alleging that such third party is infringing, misappropriating, violating, or diluting, any Material IP Rights.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With respect to each Copyright License, Trademark License and Patent License listed on Schedule 6.17 Part (a)(iv) that comprise Material IP Rights, such agreement (i) is in full force and effect and is binding upon and enforceable against the Borrower and the Subsidiaries party thereto and all other parties thereto in accordance with its terms, (ii) has not been amended or otherwise modified and (iii) has not suffered a default or breach thereunder, in each case of the foregoing clauses (i), (ii) and (iii), (A) as of the Closing Date, and (B) after the Closing Date, except as could not reasonably be expected to result in a material adverse effect on any Product Development and Commercialization Activities. To the Loan Parties&#8217; knowledge, neither the Borrower nor any of the Subsidiaries has taken any action that would permit any other Person party to any such license agreement to have, and no such Person otherwise has, any defenses, counterclaims or rights of setoff thereunder (1) as of the Closing Date and (2) after the Closing Date, that could reasonably be expected to result in a material adverse effect on any Product Development and Commercialization Activities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth on <u>Schedule 6.17 Part (d)</u>, (i) no written claim, and no other claim known to the Borrower or any Subsidiary has been made that alleges that the Material IP Rights, or the conduct or operation of its business of the Borrower or the Subsidiaries, including the development, manufacture, use, sale, provision or other commercialization of any Product or Service, infringes, misappropriates, violates, or dilutes any intellectual property or proprietary or other rights of that third party, in each case, (A) as of the Closing Date and (B) after the Closing Date that could be reasonably expected to result in a material adverse effect on any Product Development and Commercialization Activities and (ii) there is no basis for such a claim known to the Borrower or any Subsidiary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Borrower and the Subsidiaries have used commercially reasonable efforts and precautions to protect their interests in, and the value and confidentiality of their respective Confidential Information and Trade Secrets, including any source code for Proprietary Software.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">66</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth on <u>Schedule 6.17 Part (f)</u>:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as of the Closing Date the consummation of the transactions contemplated hereby and, except as otherwise permitted by <u>Section 7.18(b)</u>, the exercise by the Administrative Agent or the Lenders of any right or remedy set forth in the Loan Documents will not constitute a breach or violation of, or otherwise affect the enforceability or approval of, (i) any licenses associated with Material IP Rights or (ii) any Material Required Permits; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;at any time after the Closing Date, except with respect to Excluded Property, the consummation of the transactions contemplated hereby and, except as otherwise permitted by <u>Section 7.18(b)</u>, the exercise by the Administrative Agent or the Lenders of any right or remedy set forth in the Loan Documents will not constitute a breach or violation of, or otherwise affect the enforceability or approval of, (i) any licenses associated with IP Rights or (ii) any Required Permits.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Solvency</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Borrower is Solvent on an individual basis, and the Borrower and its Subsidiaries are Solvent on a consolidated basis.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Perfection of Security Interests in the Collateral</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Collateral Documents create valid security interests in, and Liens on, the Collateral purported to be covered thereby, which security interests and Liens will be, upon the timely and proper filings, deliveries, notations and other actions contemplated in the Collateral Documents, perfected security interests and Liens (to the extent that such security interests and Liens can be perfected by such filings, deliveries, notations and other actions contemplated in the Collateral Documents), prior to all other Liens other than Permitted Liens.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Business Locations</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Set forth on <u>Schedule 6.20(a)</u> is a list of all real property that is owned or leased by the Loan Parties as of the Closing Date (with (x) a description of each real property that is Excluded Property, (y) a designation of whether such real property is owned or leases and (z) if any Loan Party maintains books and records at such real property). Set forth on <u>Schedule 6.20(b)</u> is the tax payer identification number and organizational identification number of each Loan Party as of the Closing Date. The exact legal name and jurisdiction of organization of (a) the Borrower is as set forth on <u>Schedule 6.20(b)</u> and (b) each Guarantor is (i) as set forth on <u>Schedule 6.20(b)</u> or (ii) as set forth on Schedule 1 to the Joinder Agreement pursuant to which such Guarantor became a party hereto. Except as set forth on <u>Schedule 6.20(c)</u>, no Loan Party has during the five years preceding the Closing Date (i) changed its legal name, (ii) changed its jurisdiction of organization, or (iii) been party to a merger, amalgamation, consolidation or such other structural change.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Sanctions Concerns; Anti-Corruption Laws; PATRIOT Act</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Sanctions Concerns</u>. No Loan Party, nor any Subsidiary, nor JPR Royalty Sub, nor, to the knowledge of the Loan Parties and their Subsidiaries, any director, officer, employee, agent, Affiliate or representative thereof, is an individual or entity that is, or is owned or controlled by, any individual or entity that is (i) currently the subject or target of any Sanctions, (ii) included on OFAC&#8217;s List of Specially Designated Nationals, HMT&#8217;s Consolidated List of Financial Sanctions Targets and the Investment Ban List, or any similar list enforced by any other relevant sanctions authority or (iii) located, organized or resident in a Designated Jurisdiction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">67</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Anti-Corruption Laws</u>. The Loan Parties, their Subsidiaries and JPR Royalty Sub have conducted their business in compliance with the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010 and other similar anti-corruption legislation in other applicable jurisdictions, and have instituted and maintained policies and procedures designed to promote and achieve compliance with such Laws.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>PATRIOT Act</u>. To the extent applicable, each of the Loan Parties, their Subsidiaries and JPR Royalty Sub is in compliance, in all material respects, with (i) the Trading with the Enemy Act, as amended, and each of the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle B, Chapter V, as amended) and any other enabling legislation or executive order relating thereto and (ii) the PATRIOT Act.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">6.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Material Contracts</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Except for the Organization Documents of the Loan Parties and the other agreements set forth on <u>Schedule 6.22</u> as of the Closing Date there are no (a) employment agreements covering the management of the Borrower or any Subsidiary, (b) collective bargaining agreements or other labor agreements covering any employees of the Borrower or any Subsidiary, (c) agreements for managerial, consulting or similar services to which the Borrower or any Subsidiary is a party or by which it is bound, (d) agreements regarding the Borrower or any Subsidiary, its assets or operations or any investment therein to which any of its equity holders is a party or by which it is bound, (e) real estate leases, licenses of IP Rights or other lease or license agreements to which the Borrower or any Subsidiary is a party, either as lessor or lessee, or as licensor or licensee (other than licenses arising from the purchase of &#8220;off the shelf&#8221; products), (f) customer or supply agreements to which the Borrower or any Subsidiary is a party, in each case with respect to the preceding <u>clauses (a)</u>, <u>(c)</u>, <u>(d)</u>, <u>(e)</u> and <u>(f</u>) solely to the extent the breach, default or the termination of such agreement, lease or license could reasonably be expected to result in a material adverse effect on Product Development and Commercialization Activities or (g) any other agreements or instruments to which the Borrower or any Subsidiary is a party, and the breach, nonperformance or cancellation of which, or the failure of which to renew, could reasonably be expected to have a Material Adverse Effect. <u>Schedule 6.22</u> sets forth, with respect to each real estate lease agreement to which the Borrower or any Subsidiary is a party as of the Closing Date, the address of the subject property and the annual rental (or, where applicable, a general description of the method of computing the annual rental). The consummation of the transactions contemplated by the Loan Documents will not give rise to a right of termination in favor of any party to any Material Contract. Each Material Contract (a) is in full force and effect and is binding upon and enforceable against the Borrower and its Subsidiaries party thereto and, to the knowledge of any Loan Party, all other parties thereto in accordance with its terms, and (b) is not currently subject to any material breach or default by the Borrower or any Subsidiary or, to the knowledge of any Loan Party, any other party thereto. None of the Borrower nor any of its Subsidiaries has taken or failed to take any action that would permit any other Person party to any Material Contract to have, and, to the knowledge of any Loan Party, no such Person otherwise has, any defenses, counterclaims or rights of setoff thereunder (1) as of the Closing Date and (2) after the Closing Date that could reasonably be expected to result in a material adverse effect on any Product Development and Commercialization Activities. As of the Closing Date, none of the Material Contracts are non-assignable by their terms (other than those certain agreements separately noted in <u>Schedule 6.22</u> as being non-assignable) or as a matter of law, or prevent the granting of a security interest therein.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Regulatory Compliance.</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">68</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">Except for the matters disclosed on <u>Schedule&nbsp;6.23</u>:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Borrower and its Subsidiaries have obtained all Material Required Permits, or have contracted with third parties holding Material Required Permits to obtain any and all rights, in each case necessary for the conduct of the Businesses or for compliance with all applicable Laws and all such Material Required Permits or rights thereto are in full force and effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Borrower and its Subsidiaries have not received any written communication from any Governmental Authority regarding, and there are no facts or circumstances that are likely to give rise to, (A) any material adverse change in any Material Required Permit, or any failure to materially comply with any Laws or any term or requirement of any Material Required Permit, (B) any revocation, withdrawal, suspension, hold, cancellation, material limitation, termination or material modification of any Material Required Permit or (C) any pending or threatened enforcement action seeking to seize any Product, enjoin manufacture or distribution, or halt the receipt, processing, or production of products, components, or raw materials due to alleged nonconformance with cGMPs or the requirements associated with any Material Required Permit.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of the officers, directors, employees, shareholders, agents, or Affiliates of the Borrower or any Subsidiary or, to the Loan Parties&#8217; knowledge, any other Person involved in the development of (including seeking regulatory approval for) any Product or Service, has been convicted of any crime or engaged in any conduct for which debarment is authorized by 21 U.S.C. Section 335a or disqualification as a clinical investigator under 21 C.F.R. &#167; 312.70 or any similar applicable Laws, and neither the Borrower nor any Subsidiary nor any of its officers, employees or, to knowledge of any Loan Party, agents or contractors has engaged in any conduct that would reasonably be expected to result in debarment or disqualification as a clinical investigator.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of the officers, directors, employees, shareholders, agents, or Affiliates of the Borrower or any Subsidiary or, to the Loan Parties&#8217; knowledge, any consultant or independent contractor engaged by the Loan Parties, has made an untrue statement of material fact or fraudulent statement to the FDA, CMS or any other Governmental Authority or failed to disclose a material fact required to be disclosed to the FDA, CMS or any other Governmental Authority, committed an act, made a statement, or failed to make a statement, in each case that could reasonably be expected to provide a basis for the FDA to invoke its policy respecting &#8220;Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities,&#8221; set forth in 56 Fed. Reg. 46191 (September 10, 1991) or for any other Government Authority to invoke a similar policy or Law.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All applications, notifications, submissions, information, claims, reports and statistics and other data and conclusions derived therefrom, utilized as the basis for or submitted in connection with any and all requests for a Material Required Permit from the FDA, CMS or any other Governmental Authority relating to the Borrower or any Subsidiary, their business operations, Products and Services, when submitted to the FDA, CMS or any other Governmental Authority, were true, complete and correct in all material respects as of the date of submission, and any necessary or required updates, changes, corrections or modifications to such applications, submissions, information and data have been properly and timely submitted to the FDA, CMS or any other Governmental Authority. The Material Required Permits issued by the FDA, CMS or any other Governmental Authority for the Products and Services are valid and supported by proper research, design, testing, analysis and disclosure.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All preclinical and clinical trials that have been conducted and/or are being conducted by or on behalf of the Borrower and its Subsidiaries, including those trials whose results and data have been submitted to any Governmental Authority, including the FDA and its counterparts worldwide, are being or have been conducted in compliance in all material respects with the required experimental protocols, procedures and controls and otherwise in compliance with applicable Laws, including cGLP and cGCP, the Animal Welfare Act, all applicable similar Laws in other jurisdictions, and all Laws relating to the protection of human subjects. Neither the Borrower nor any Subsidiary has received any written notice that the FDA, any other Governmental Authority, or any institutional review board has recommended, initiated, or threatened to initiate any action to suspend or terminate any clinical trial sponsored by the Borrower or its Subsidiaries, including a full or partial clinical hold, or to otherwise restrict the preclinical research on or clinical study of any Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">69</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Borrower nor any Subsidiary nor any of its officers and employees has received any written notice that any Governmental Authority, including without limitation the FDA, the Office of the Inspector General of HHS or the United States Department of Justice has commenced recommended or threatened to initiate any action against the Borrower or a Subsidiary or their respective officers, directors, employees, shareholders or agents and Affiliates, or to the knowledge of the Loan Parties, their licensees, manufacturers and contractors, seeking to enjoin from conducting business at any facility owned or used by any of them (including the Facilities) or for any material civil penalty, injunction, seizure or criminal action.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All manufacturing operations relating to the Products conducted by or on behalf of the Borrower and its Subsidiaries have been and are being conducted in compliance with applicable provisions of cGMP as required by 21 U.S.C. &#167; 351(a)(2)(B) and as set forth in 21 C.F.R. Parts 210 and 211 and applicable guidance documents, as amended from time to time. Neither the Borrower nor any Subsidiary nor to the Loan Parties&#8217; knowledge, any third party conducting services on behalf of the Borrower or its Subsidiaries, has received from the FDA a Warning Letter, Form FDA-483, Untitled Letter, other written correspondence or written notice setting forth allegedly objectionable observations or alleged violations of Laws enforced by the FDA, or any comparable correspondence from any state or local authority with regard to any Product, Service or Facilities, or the manufacture, testing, processing, packaging, supply, promotion, labeling, commercialization, import, export, sale, distribution, or holding of any Product or Service, or any comparable correspondence from any foreign counterpart of the FDA, or any comparable correspondence from any foreign counterpart of any state or local authority.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither the Borrower nor any Subsidiary (A) has initiated in any recalls, field notifications, Market Withdrawals, warnings, &#8220;Dear Doctor&#8221; letters, investigator notices, safety alerts, &#8220;serious adverse event&#8221; reports or other notice of action, including as a result of any Risk Evaluation and Mitigation Strategy proposed by the FDA, relating to an alleged material safety issue or regulatory compliance issue relating to the Products or Services issued by the Borrower or any Subsidiary, any clinical investigator, and/or other third party (&#8220;<u>Safety Notices</u>&#8221;), (B) has knowledge of any complaints with respect to the Products, Services or Facilities which, if true, could reasonably be expected to result in a liability in excess of the Threshold Amount, and (C) has knowledge of any facts that would be reasonably likely to result in (1) a material Safety Notice with respect to the Products or Services, or (2) a termination or suspension of developing and testing of any of the Products or Services.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All Products, Services, Facilities and Material Required Permits in relation thereto in existence as of the Closing Date are listed on <u>Schedule 1.01</u> and the Borrower has delivered to the Lenders on or prior to the Closing Date copies of all Material Required Permits relating to such Products, Services or Facilities issued or outstanding as of the Closing Date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Product is not adulterated or misbranded in any material respect within the meaning of the FDCA.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Product is not an article prohibited from introduction into interstate commerce under any provisions of the FDCA.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">70</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With respect to each Product and Service, (a) each such Product and Service has been and shall be tested, developed, manufactured, handled, packaged, stored, supplied, imported, owned, warehoused, marketed, commercialized, promoted, sold, labeled, furnished, distributed, marketed and provided in accordance in all material respects with all applicable Permits and Laws, (b) all material reports, notices, or other submissions required to be submitted to Governmental Authority under applicable Law have been timely submitted, and (c) all records required to be maintained under applicable Law have been and are being lawfully maintained in all material respects.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without limiting the generality of <u>Section 6.23(a)</u> and <u>(b)</u> above, with respect to any Product or Service being researched, developed, tested, manufactured, handled, labeled, packaged, stored, supplied, promoted, distributed, marketed, commercialized, imported, exported, sold, or provided by or on behalf of the Borrower and its Subsidiaries, the Borrower and its Subsidiaries, and the applicable third parties, have received, and such Product or Service shall be the subject of, all Material Required Permits necessary in connection with the research, development, testing, manufacture, handling, labeling, packaging, storage, supply, promotion, distribution, marketing, commercialization, import, export, sale, or provision of such Product or Service as such activities are being conducted by or on behalf of the Borrower or such Subsidiary, and, neither the Borrower nor any Subsidiary nor to the Loan Parties&#8217; knowledge, any third party, has received any notice from any applicable Government Authority, specifically including the FDA, that such Government Authority is conducting an investigation or review of (A) the Borrower and its Subsidiaries&#8217; or any applicable third party&#8217;s manufacturing, operations, facilities and processes for such Product or Service which have disclosed any material deficiencies or violations of Laws or the Material Required Permits related to the manufacture or processes related to such Product or Service, or (B) that any such Material Required Permit has been revoked or withdrawn, nor has any such Governmental Authority issued any order or recommendation to restrict or enjoin the development, testing or manufacturing of such Product or Service by the Borrower and its Subsidiaries.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without limiting the generality of <u>Section 6.23(a)</u> and <u>(b)</u> above, with respect to any Product or Service marketed, sold, commercialized or provided by or on behalf of the Borrower or any of its Subsidiaries, the Borrower and its Subsidiaries, and the applicable third parties, shall have received, and such Product or Service shall be the subject of, all Material Required Permits necessary in connection with the marketing, sale, commercialization or provision of such Product or Service as currently being marketed, sold or commercialized by or on behalf of the Borrower and its Subsidiaries, and, neither the Borrower nor any Subsidiary nor to the Loan Parties&#8217; knowledge, any third party, has received any notice from any applicable Governmental Authority, specifically including the FDA, that such Governmental Authority is conducting an investigation or review of any such Material Required Permit or that any such Material Required Permit has been revoked or withdrawn, nor has any such Governmental Authority issued any order or recommendation to restrict or enjoin the marketing, sale, commercialization or provision of such Product or Service or that such Product or Service be withdrawn from the marketplace.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Facilities is duly registered or licensed under the applicable Laws of the jurisdiction where the Facility is located. The Facilities and the services provided at such Facilities are qualified for participation in the Government Reimbursement Programs, and each Loan Party and each of their Subsidiaries is entitled to reimbursement under the Government Reimbursement Programs for services rendered at such Facilities to qualified beneficiaries. To the knowledge of any Loan Party, all Persons providing professional health care services for or on behalf of any Loan Party (either as an employee or independent contractor) are appropriately licensed in every jurisdiction in which they hold themselves out as professional health care providers.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Loan Party and each of their respective Subsidiaries has received and maintain accreditation in good standing and without impairment by all applicable Accrediting Organizations, to the extent required by Law (including any equivalent regulation) or the terms of any Operating Lease pertaining to any Facility. No Loan Party nor any of its respective Subsidiaries has received any notice or communication from any Accrediting Organization that a Facility is (i) subject to or is required to file a plan of correction with respect to any accreditation survey, or (ii) in danger of losing its accreditation due to a failure to comply with a plan of correction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">71</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any Operating Lease has been approved by all necessary Governmental Authorities. Under applicable Laws in the jurisdiction in which each Facility is located, the reimbursement rate of the applicable Loan Party under any applicable Governmental Reimbursement Program is not affected by the rental rates under the Operating Lease. The rentals provided for under the Operating Lease comply with all applicable Laws and do not exceed the sums permitted to be paid under applicable Laws.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Loan Party, nor any of its respective Subsidiaries, nor any of their respective officers, nor, to the knowledge of any Loan Party, any of their respective employees, agents or contractors, have engaged in any activity which is not in compliance in all material respects with any applicable Healthcare Laws. To the knowledge of each Loan Party and its respective Subsidiary, there are no pending and there have been no threatened investigations, subpoenas, civil investigative demands, actions, suits or proceedings by any Governmental Authority with respect to any alleged violation by Loan Party or Subsidiary of any Healthcare Laws, except to the extent that any such investigations, subpoenas, civil investigative demands, actions, suits or proceedings could not reasonably be expected, either individually or in the aggregate, to have a material adverse effect on any Product Development and Commercialization Activities and could not reasonably be expected, either individually or in the aggregate, to have a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Loan Party and each of their respective Subsidiaries has timely filed or caused to be timely filed all material cost reports required by any Government Reimbursement Program to have been filed or made with respect to the operations of the Loan Parties. No Loan Party nor any of their Subsidiaries (i) has retained a material overpayment received from, or failed to refund any material amount due to any Government Reimbursement Program in violation of any applicable Laws, or (ii) has received, except to the extent the same has been promptly reported to the Lenders, written notice of, or has knowledge of, any material overpayment or refund due to any Third Party Payor.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Loan Party nor any of its Subsidiaries nor any of their respective officers, directors, or employees nor, to the knowledge of any Loan Party, any owner, partner, agent, or other Person with a &#8220;direct or indirect ownership interest&#8221; (as that phrase is defined in 42 C.F.R. &#167; 420.201) in any Loan Party or any Subsidiary of any Loan Party, has (i) been has been excluded, debarred, suspended or been otherwise determined to be, or identified as, ineligible to participate in any healthcare or contracting program of any Governmental Authority, including without limitation, under 42 U.S.C. &#167;&#167; 1320a-7 or 1320a-7a; (ii) (ii) is the subject of any investigation or review regarding their participation in any such program, (iii) has been convicted of any crime relating to any such program but not yet excluded, debarred, suspended or otherwise declared ineligible, or (iv) engaged in any activities which are prohibited, or are cause for civil penalties, or grounds for mandatory or permissive exclusion, debarment or suspension pursuant to any of these authorities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Loan Party and each of their respective Subsidiaries is in compliance in all material respects with HIPAA to the extent applicable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Reserved].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Loan Party nor any of their Subsidiaries, nor any officer, director, partner, agent or managing employee of any Loan Party or any Subsidiary of any Loan Party, is a party to or bound by any individual integrity agreement, corporate integrity agreement, corporate compliance agreement, deferred prosecution agreement, or other formal or informal agreement with any Governmental Authority concerning compliance with Healthcare Laws or the requirements of any Material Required Permit.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">72</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Labor Matters</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">There are no existing or, to the knowledge of the Loan Parties, threatened strikes, lockouts or other labor disputes involving the Borrower or any Subsidiary that singly or in the aggregate could reasonably be expected to have a Material Adverse Effect. Hours worked by and payment made to employees of the Borrower and its Subsidiaries are not in violation in any material respect of the Fair Labor Standards Act or any other applicable law, rule or regulation dealing with such matters.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Affected Financial Institution</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">No Loan Party or any of their Subsidiaries is an Affected Financial Institution.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Ranking of Loans</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Indebtedness represented by the Loans and the other Obligations under the applicable Loan Documents of each Loan Party is intended to constitute senior secured Indebtedness, and accordingly is, and shall be, at all times while the Loans and the other Obligations remain outstanding or the Lenders have any outstanding Commitments hereunder, <i>pari passu </i>or senior in right of payment with all Indebtedness (if any) of such Loan Party.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Consummation of the Royalty Financing</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The transactions contemplated by the Royalty Financing Documents have been or concurrently with the Term A Borrowing will be consummated in all material respects pursuant to the provisions of the Royalty Financing Documents, true and complete copies of which have been delivered to Administrative Agent, and in all material respects in compliance with all applicable Law.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Regulation H</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">No real property subject to a Mortgage is a Flood Hazard Property unless the Administrative Agent shall have received the following: (a) the applicable Loan Party&#8217;s written acknowledgment of receipt of written notification from the Administrative Agent (i) as to the fact that such Mortgaged Property is a Flood Hazard Property and (ii) as to whether the community in which each such Flood Hazard Property is located is participating in the National Flood Insurance Program, (b) copies of insurance policies or certificates of insurance of the applicable Loan Party evidencing flood insurance reasonably satisfactory to the Administrative Agent and naming the Administrative Agent as loss payee on behalf of the Lenders and (c) such other flood hazard determination forms, notices and confirmations thereof as requested by the Administrative Agent. All flood hazard insurance policies required hereunder have been obtained and remain in full force and effect, and the premiums thereon have been paid in full.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Data Privacy</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">In connection with its collection, storage, transfer (including without limitation, any transfer across national borders) and/or use of any personally identifiable information from any individuals, including, any customers, prospective customers, employees and/or other third parties, each Loan Party is and has been in compliance with all applicable laws in all relevant jurisdictions, the Loan Parties&#8217; privacy policies, and the requirements of any contract or codes of conduct to which the each Loan Party is a party, except as could not reasonably be expected to result in liability, individually or in the aggregate, in excess of the Threshold Amount. Each Loan Party is and has been in compliance with all laws relating to data loss, theft and breach of security notification obligations, except as could not reasonably be expected to result in liability, individually or in the aggregate, in excess of the Threshold Amount.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">73</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Centre of Main Interests and Establishments</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">For the purposes of Regulation (EU) 2015/848 of 20 May 2015 on insolvency proceedings (recast) (the &#8220;<u>Regulation</u>&#8221;), BioCryst Ireland Limited&#8217;s centre of main interest (as that term is used in Article 3(1) of the Regulation) is situated in its jurisdiction of incorporation and it has no &#8220;establishment&#8221; (as that term is used in Article 2(10) of the Regulations) in any other jurisdiction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>JPR Royalty Sub</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) JPR Royalty Sub does not have any Indebtedness (other than the Indebtedness under the JPR Indenture), (ii) none of the property, assets and revenues of JPR Royalty Sub is subject to a Lien (other than Liens of the Trustee (as defined in the JPR Indenture as in effect on the date hereof) on the Collateral (as defined in the JPR Indenture as in effect on the date hereof) pursuant to the JPR Indenture) and (iii) none of the Borrower and its Subsidiaries Guarantees or is otherwise liable for any of the Indebtedness or other obligations of JPR Royalty Sub.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) None of the Indebtedness and other liabilities of JPR Royalty Sub under the JPR Indenture and other Deal Documents (as defined in the JPR Indenture) are recourse to the Borrower and its Subsidiaries (other than the pledge by the Borrower of its membership interests in JPR Royalty Sub pursuant to the &#8220;Pledge and Security Agreement&#8221; (as defined in the JPR Indenture as in effect on the date hereof), it being understood that the only recourse to the Borrower is (x) such membership interests and no other assets of the Borrower or any of its Subsidiaries and (y) pursuant to the expense reimbursement obligations set forth in Section 12.1 of such &#8220;Pledge and Security Agreement&#8221; and the indemnification obligations set forth in Section 19.1 of such &#8220;Pledge and Security Agreement&#8221;) and (ii) as of the Closing Date, none of the holders of such Indebtedness and any trustee or agent acting on behalf of such holders has taken any action to accelerate such Indebtedness or otherwise enforce its rights or exercise its remedies under any of the JPR Indenture and other Deal Documents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Royalty and Other Payments. </u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">As of the Closing Date, except as set forth on <u>Schedule 6.32</u>, neither the Borrower, nor any of its Subsidiaries, is obligated to pay any royalty, milestone payment, deferred payment or any other contingent payment in respect of any Key Product (except pursuant to the Royalty Financing).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">6.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Competes. </u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">As of the Closing Date, neither the Borrower, nor any of its Subsidiaries, nor, to the Borrower&#8217;s knowledge, any of their respective directors, officers or employees, is subject to a non-compete agreement that will, or could reasonably be expected to, materially interfere with any of the Product Commercialization and Development Activities, including the development, commercialization or marketing of any Key Product.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">74</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="text-transform:uppercase">Article&nbsp;</font>VII<br>
<br>
AFFIRMATIVE COVENANTS</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">So long as any Lender shall have any Commitments hereunder, or any Loan or other Obligation hereunder shall remain unpaid or unsatisfied (other than contingent indemnification obligations for which no claim has been asserted), each Loan Party shall and shall cause each Subsidiary to:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Financial Statements; Lender Calls</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deliver to the Administrative Agent and each Lender, as soon as available, and in any event within one hundred twenty (120) days after the end of each fiscal year of the Borrower (or, if earlier, when required to be filed with a Governmental Authority), a consolidated balance sheet of the Borrower and its Subsidiaries as at the end of such fiscal year, and the related consolidated statements of income or operations, changes in shareholders&#8217; equity and cash flows for such fiscal year, setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail and prepared in accordance with GAAP, audited and accompanied by an unqualified report and opinion of an independent certified public accountant of nationally recognized standing acceptable to the Required Lenders, which report and opinion shall be prepared in accordance with generally accepted auditing standards and shall not be subject to any &#8220;going concern&#8221; or like qualification or exception or any qualification or exception as to the scope of such audit (except as may be required as a result of (I) any breach or anticipated breach of any of the financial covenants in <u>Section 8.16</u> or <u>Section 8.17</u> or (II) the impending maturity of the Loans or the impending expiration of the Commitments solely in the case of the audit delivered with respect to the fiscal year immediately prior to the fiscal year during which such maturity or expiration is scheduled hereunder to occur); and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deliver to the Administrative Agent and each Lender, as soon as available, and in any event within forty-five (45) days after the end of each fiscal quarter of each fiscal year of the Borrower, including the final fiscal quarter of each fiscal year (or, if earlier, when required to be filed with a Governmental Authority), a consolidated<b> </b>balance sheet of the Borrower and its Subsidiaries as at the end of such fiscal quarter, and the related consolidated<b> </b>statements of income or operations, changes in shareholders&#8217; equity and cash flows for such fiscal quarter and for the portion of the Borrower&#8217;s fiscal year then ended, setting forth in each case in comparative form the figures for the corresponding fiscal quarter of the previous fiscal year and the corresponding portion of the previous fiscal year, all in reasonable detail and certified by a Responsible Financial Officer of the Borrower as fairly presenting in all material respects the financial condition, results of operations, shareholders&#8217; equity and cash flows of the Borrower and its Subsidiaries in accordance with GAAP, subject only to normal year-end audit adjustments and the absence of footnotes.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the request of the Administrative Agent, Borrower shall conduct quarterly conference calls that the Lenders may attend to discuss the financial condition and results of operations of Borrower and its subsidiaries for the most recently ended measurement period for which financial statements have been delivered pursuant to <u>Section 7.01(a)</u> and<u> Section 7.01(b)</u>, at a date and time to be determined by Administrative Agent, in consultation with the Borrower, and with reasonable advance notice to the Borrower and Lenders.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certificates; Other Information</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Deliver to the Administrative Agent and each Lender, in form and detail satisfactory to the Administrative Agent and the Required Lenders:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;concurrently with the delivery of the financial statements referred to in <u>Sections 7.01(a)</u> and <u>(b)</u> (i) a duly completed Compliance Certificate signed by a Responsible Financial Officer of the Borrower, certifying compliance with the covenant set forth in <u>Section 8.16</u> and, if the Term C Borrowing Date shall have occurred and for so long as the Borrower has not exercised the Cure Right in accordance with <u>Section 9.04</u>, <u>Section 8.17</u>, and (ii) a written summary, such as the summary included within the financial statements delivered pursuant to <u>Section 7.01(a)</u>, describing how any changes in GAAP during such period directly and materially impacted such financial statements;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">75</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as soon as practicable, and in any event not later than sixty (60) days after the commencement of each fiscal year of the Borrower, an annual business plan and budget of the Borrower and its Subsidiaries for the then current fiscal year containing, among other things, projections for each quarter of such fiscal year, in form and substance reasonably satisfactory to the Administrative Agent;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;promptly after the same are available, copies of each annual report, proxy or financial statement or other report or communication sent to the equity holders of any Loan Party, and copies of any annual, regular, periodic and special reports and registration statements which a Loan Party may file or be required to file with the SEC under Section 13 or 15(d) of the Securities Exchange Act of 1934, and not otherwise required to be delivered to the Administrative Agent pursuant hereto;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;concurrently with the delivery of the financial statements referred to in <u>Sections 7.01(a)</u> and <u>(b)</u>, solely to the extent written notice to the Administrative Agent of such event was not previously provided, including in connection with any mandatory prepayment of the Loans pursuant to <u>Section 2.03(b)</u>, a certificate of a Responsible Financial Officer of the Borrower containing information regarding (w) the acquisition or establishment of any Deposit Account by any Loan Party or any Government Account Debtor Account by any Loan Party, (x) all Dispositions, Involuntary Dispositions, Acquisitions and Extraordinary Receipts that occurred during the period covered by such financial statements in an amount greater than $[***], (y) the amount of all Debt Issuances that occurred during the period covered by such financial statements and (z) any Material Contracts entered into (together with copies of such Material Contracts) during the period covered by such financial statements;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;promptly after any request by the Administrative Agent or any Lender, copies of any detailed audit reports, management letters or recommendations submitted to the Board of Directors (or the audit committee of the Board of Directors) of the Borrower by independent accountants in connection with the accounts or books of the Borrower or any Subsidiary, or any audit of any of them;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;promptly after the furnishing thereof, copies of any notice of default or any material statement or report furnished to any holder of debt securities of any Loan Party or any Subsidiary pursuant to the terms of any indenture, loan or credit or similar agreement and not otherwise required to be furnished to the Lenders pursuant to <u>Section 7.01</u> or any other clause of this <u>Section 7.02</u>;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;promptly, and in any event within five (5) Business Days after receipt thereof by any Loan Party or any Subsidiary thereof, (i) copies of each notice or other correspondence received from the SEC (or comparable agency in any applicable non-U.S. jurisdiction) concerning any investigation or possible investigation or other inquiry by such agency regarding financial or other operational results of any Loan Party or any Subsidiary thereof and (ii) copies of any material written correspondence or any other material written communication from the FDA, CMS or any other similar regulatory body;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;within [***] following the occurrence of any facts, events or circumstances known to any Loan Party or any Subsidiary, whether threatened, existing or pending, that would make any of the representations and warranties contained in <u>Section 6.23</u> untrue, incomplete or incorrect in any material respect (together with such supporting data and information as shall be necessary to fully explain to the Lenders the scope and nature of the fact, event or circumstance), and shall provide to the Lenders within five (5) Business Days of any Lender&#8217;s request, such additional information as any Lender shall reasonably request regarding such disclosure;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">76</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;promptly, such additional information regarding the business, financial or corporate affairs of any Loan Party or any Subsidiary, or compliance with the terms of the Loan Documents, as the Administrative Agent or any Lender may from time to time reasonably request;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;concurrently with the delivery of the financial statements referred to in <u>Sections 7.01(a)</u> and <u>(b)</u>, a certificate of a Responsible Officer of the Borrower (i) listing (A) all applications by any Loan Party, if any, for Copyrights, Patents or Trademarks made since the date of the prior certificate (or, in the case of the first such certificate, the Closing Date), (B) all issuances of registrations or letters on existing applications by any Loan Party for Copyrights, Patents and Trademarks received since the date of the prior certificate (or, in the case of the first such certificate, the Closing Date), (C) all Trademark Licenses, Copyright Licenses and Patent Licenses entered into by any Loan Party since the date of the prior certificate (or, in the case of the first such certificate, the Closing Date), (D) such supplements to <u>Schedule 6.17</u> as are necessary to cause such schedule to be true and complete as of the date of such certificate and (ii) with respect to any insurance coverage of any Loan Party or any Subsidiary that was renewed, replaced or modified during the period covered by such financial statements, such updated information with respect to such insurance coverage as is required to be included on <u>Schedule 6.10</u><u>;</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) concurrently with the delivery of the financial statements referred to in <u>Sections 7.01(a)</u> and <u>(b)</u>, the Borrower shall give written notice to the Lenders of the manufacturing, sale, development, testing or marketing of any new Product for which an investigational new drug application or similar application has been filed with the FDA or other Government Authority, as applicable. or new Service, or the opening of any new Facility, in each case by the Borrower or any Subsidiary during such period to which such financial statements relate (which notice shall include a brief description of such Product, Service or Facility) along with a copy of an updated <u>Schedule 1.01</u> and, (ii) at the request of the Administrative Agent, the Borrower shall provide to the Administrative Agent and the Lenders copies of all Material Required Permits relating to such new Product, Service or Facility and/or the Borrower&#8217;s or the applicable Subsidiary&#8217;s manufacture, sale, development, testing or marketing thereof (if applicable) issued or outstanding as of such date;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;concurrently with the delivery thereof to the Buyer pursuant to the Royalty Financing Documents or any buyer or purchaser pursuant to the Other Royalty Financing Documents, as applicable, and solely to the extent such information is not otherwise required to be furnished to the Administrative Agent or Lenders pursuant to <u>Section 7.01</u> or any other clause of this <u>Section 7.02</u>, a copy of (i) any report, notice or other information delivered to the Buyer pursuant to Section 6.1 or 6.2(b) of the Royalty Financing Agreement and (ii) any other report, notice or other information delivered pursuant to any Royalty Financing Document or Other Royalty Financing Document, as applicable; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;promptly, and in any event within [***] after (i) receipt or delivery thereof by any Loan Party or any Subsidiary, copy of any notice of default or termination delivered under the Royalty Financing Documents or Other Royalty Financing Documents and (ii) any Loan Party becomes aware thereof, notice of the occurrence of any default under the Royalty Financing Documents or Other Royalty Financing Documents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Documents required to be delivered pursuant to <u>Section 7.01(a)</u> or <u>(b)</u> or <u>Section 7.02</u> may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date (i) on which the Borrower posts such documents, or provides a link thereto on the Borrower&#8217;s website on the Internet at the website address listed on <u>Schedule 12.02</u>, or (ii) on which such documents are posted on the Borrower&#8217;s behalf on an Internet or intranet website, if any, to which each Lender and the Administrative Agent have access (whether a commercial, third-party website or whether sponsored by the Administrative Agent, including if filed with the SEC through EDGAR); <u>provided</u>, <u>that</u>: (x) the Borrower shall deliver paper copies of such documents to the Administrative Agent or any Lender upon its request to the Borrower, and shall continue to deliver such paper copies until a written request to cease delivering paper copies is given by the Administrative Agent or such Lender and (y) other than with respect the financial statements required to be delivered pursuant to <u>Section 7.01(a)</u> or <u>(b)</u>, the Borrower shall notify the Administrative Agent and each Lender (by facsimile or electronic mail) of the posting of any such documents and provide to the Administrative Agent by electronic mail electronic versions (i.e., soft copies) of such documents. The Administrative Agent shall have no obligation to request the delivery of or to maintain paper copies of the documents referred to above, and in any event shall have no responsibility to monitor compliance by the Borrower with any such request for delivery by a Lender, and each Lender shall be solely responsible for requesting delivery to it or maintaining its copies of such documents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">77</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The Borrower hereby acknowledges that certain of the Lenders may have personnel who do not wish to receive material non-public information with respect to the Borrower or its Affiliates, or the respective securities of any of the foregoing, and who may be engaged in investment and other market-related activities with respect to such Persons&#8217; securities. The Borrower hereby agrees that if requested by the Administrative Agent it will, following the receipt of such request, (x) in good faith, identify that portion of the materials and/or information provided by, or to be provided by, or on behalf of the Borrower hereunder that does not constitute material non-public information with respect to the Borrower or its Affiliates or their respective securities (the &#8220;<u>Public Borrower Materials</u>&#8221;) and (y) clearly and conspicuously mark all Public Borrower Materials &#8220;PUBLIC&#8221; which, at a minimum, shall mean that the word &#8220;PUBLIC&#8221; shall appear prominently on the first page thereof (it being understood that by marking Public Borrower Materials &#8220;PUBLIC,&#8221; the Borrower shall be deemed to have authorized the Administrative Agent, any Affiliate thereof and the Lenders to treat such Public Borrower Materials as not containing any material non-public information (although it may be sensitive and proprietary) with respect to the Borrower or its securities for purposes of United States federal and state securities laws (<u>provided</u>, <u>however</u>, that to the extent such Public Borrower Materials constitute Information, they shall be treated as set forth in <u>Section 12.07</u>)).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly (and in any event, within [***]) notify the Administrative Agent and each Lender of the occurrence of any Default.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly (and in any event, within [***]) notify the Administrative Agent and each Lender of any matter that has resulted or could reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly (and in any event, within [***]) notify the Administrative Agent and each Lender of the occurrence of any ERISA Event.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As soon as reasonably practicable, but in any event no later than the day on which the delivery of the financial statements referred to in <u>Sections 7.01(a)</u> and <u>(b)</u> are delivered or required to be delivered, notify the Administrative Agent and each Lender of any material change in accounting policies or financial reporting practices by the Borrower or any Subsidiary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly (and in any event, within [***]) notify the Administrative Agent and each Lender of any litigation, arbitration or governmental investigation or proceeding not previously disclosed by a Loan Party which has been instituted or, to the knowledge of the Loan Parties, is threatened against the Borrower or any Subsidiary or to which any of the properties of any thereof is subject which could reasonably be expected to result in losses and/or expenses in excess of the Threshold Amount.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Promptly (and in any event, within [***] following receipt by, or delivery by, a Loan Party, Subsidiary or JPR Royalty Sub, as the case may be), copies of (A) any notice alleging any breach of any Material Contract, in each case, by any party thereto and (B) any termination of (or notice of such termination with respect to) any Material Contract and (ii) concurrently with the delivery of the next financial statements referred to in <u>Sections 7.01(a)</u> and <u>(b)</u> which are delivered following receipt by, or delivery by, a Loan Party, as the case may be, copies of (A) any material written notice or material written correspondence relating to, or involving, the Material Contracts, (B) any new Material Contract entered into and (C) any amendment of any Material Contract, the JPR Indenture or any other Deal Document (as defined in the JPR Indenture).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">78</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly (and in any event within [***]) notify the Administrative Agent and each Lender of any return, recovery, dispute or claim related to any Product, Service or inventory that involves more than $[***].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly (and in any event, within [***] of the occurrence of or any Loan Party learning of, as applicable) notify the Administrative Agent and each Lender of (i) any Governmental Authority, including but not limited to the FDA or CMS, is conducting or has conducted (A) an investigation of any of the Facilities of any Loan Party or any Subsidiary thereof, processes for any Product and/or in the development or provision of Services, which investigation has disclosed any material deficiencies or violations of Laws and/or the Material Required Permits (including cGMP compliance) related to such Facilities, Products or Services or (B) an investigation or review of any Material Required Permit (other than routine reviews in the ordinary course of business associated with the renewal of a Required Permit, routine pre-approval inspections and similar FDA visits and which could not reasonably be expected to result in a Material Adverse Effect), (ii) development, testing, manufacturing, marketing, sale and/or provision of any Product or Services that is material to the businesses operated by the Borrower and its Subsidiaries should cease, be suspended, or be interrupted, or the FDA or any institutional review board (or ethics committee) should provide written notice recommending or requiring any such cessation, suspension, or interruption, (iii) if a Product or Service that is material to the businesses operated by the Borrower and its Subsidiaries has been approved for marketing and sale, any marketing or sales of such Product or Service should cease or be interrupted or such Product or Service should be withdrawn from the marketplace, or the FDA, CMS or any other Governmental Authority should provide written notice threatening, recommending or initiating any such cessation, interruption, or withdrawal, (iv) any Material Required Permit has been revoked or withdrawn, (v) adverse clinical test results with respect to any Product or Service have occurred, (vi) any Market Withdrawals or other forms of retrieval from the marketplace of any Product or Service from any market (other than discrete batches or lots that are not material in quantity or amount and are not made in conjunction with a larger recall) have been conducted (or requested by the FDA, CMS or any other Governmental Authority), (vii) the occurrence of any violation of any applicable Laws by the Borrower or any of the other Subsidiaries in the development or provision of Products or Services, and record keeping and reporting to the FDA, CMS or any other Governmental Authority that could reasonably be expected to require or lead to an investigation, corrective action or enforcement, regulatory or administrative action, (viii) all fines or penalties imposed by any Governmental Authority under any Healthcare Law against any Loan Party or any of its Subsidiaries, or (ix) any significant failures in the manufacturing of any Product such that the amount of such Product successfully manufactured in accordance with all specifications thereof and the required payments to be made by or to the applicable Loan Party or Subsidiary therefor in any month shall decrease significantly with respect to the quantities of such Product and payments produced in the prior month (each event described in the foregoing clauses (i) through (viii), a &#8220;<u>Regulatory Reporting Event</u>&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly (and in any event, within [***] of the occurrence of or any Loan Party learning of, as applicable) notify the Administrative Agent and each Lender of (x) any holder of the Indebtedness under the JPR Indenture and the other Deal Documents or any trustee or agent acting on behalf of such holders taking any action to accelerate such Indebtedness or otherwise enforce its rights or exercise its remedies under any of the JPR Indenture and other Deal Documents and (y) any proceeding under any Debtor Relief Law relating to JPR Royalty Sub or to all or any material part of its property that is instituted.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">79</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Each notice pursuant to this <u>Section 7.03</u> shall be accompanied by a statement of a Responsible Officer of the Borrower setting forth details of the occurrence referred to therein and stating what action the applicable Loan Party has taken and proposes to take with respect thereto. Each notice pursuant to <u>Section 7.03(a)</u> shall describe with particularity any and all provisions of this Agreement and any other Loan Document that have been breached. With respect to any Regulatory Reporting Event, the Loan Parties shall provide to the Administrative Agent and the Lenders such further information (including copies of such documentation) as the Administrative Agent or any Lender shall reasonably request with respect to such Regulatory Reporting Event.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Payment of Obligations</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Pay and discharge, prior to delinquency, all of its obligations and liabilities, including: (a) all federal, state and other material tax liabilities, assessments and governmental charges or levies upon it or its properties or assets, unless the same are being contested in good faith by appropriate proceedings diligently conducted and adequate reserves in accordance with GAAP are being maintained by the applicable Loan Party or Subsidiary and the failure to make such payment pending such contest could not reasonably be expected to result in a Material Adverse Effect and (b) all lawful claims which, if unpaid, would by law become a Lien upon its property (other than a Permitted Lien).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Preservation of Existence, Etc.</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preserve, renew and maintain in full force and effect its legal existence under the Laws of the jurisdiction of its organization except in a transaction permitted by <u>Section 8.04</u> or <u>Section 8.05</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preserve, renew and maintain in full force and effect its good standing under (i) the Laws of the jurisdiction of its organization, and (ii) except to the extent the failure to do so could not reasonably be expected to have a Material Adverse Effect, each other jurisdiction where it conducts its Business (in each case where such concept exists in such jurisdiction in the case of Non-U.S. Subsidiaries).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Take all reasonable action to maintain all rights, privileges, permits, licenses and franchises the failure of which to maintain could reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Maintenance of Properties</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maintain, preserve and protect all of its material properties and equipment necessary in the operation of its business in good working order and condition, ordinary wear and tear and impact of casualty event excepted.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Make all necessary repairs thereto and renewals and replacements thereof, except where the failure to do so could not reasonably be expected, either individually or in the aggregate, to have a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Use the standard of care typical in the industry in the operation and maintenance of its Facilities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.07&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Maintenance of Insurance</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">80</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maintain with financially sound and reputable insurance companies not Affiliates of the Borrower, insurance with respect to its properties and business against loss or damage of the kinds customarily insured against by Persons engaged in the same or similar business, of such types and in such amounts as are customarily carried under similar circumstances by such other Persons.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without limiting the foregoing, (i) maintain, if available, fully paid flood hazard insurance on all real property that is located in a special flood hazard area and that constitutes Collateral, on such terms and in such amounts as required by The National Flood Insurance Reform Act of 1994 or as otherwise required by the Administrative Agent, (ii) furnish to the Administrative Agent evidence of the renewal (and payment of renewal premiums therefor) of all such policies prior to the expiration or lapse thereof, and (iii) furnish to the Administrative Agent prompt written notice of any redesignation of any such improved real property into or out of a special flood hazard area.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cause the Administrative Agent and its successors and/or assigns to be named as lender&#8217;s loss payee or mortgagee as its interest may appear, and/or additional insured with respect to any such insurance providing liability coverage or coverage in respect of any Collateral, and cause each provider of any such insurance to agree, by endorsement upon the policy or policies issued by it or by independent instruments furnished to the Administrative Agent, that it will give the Administrative Agent thirty (30) days (or such lesser amount as the Administrative Agent may agree to in its sole discretion) prior written notice before any such policy or policies shall be altered or canceled.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly notify the Administrative Agent of any real property subject to a Mortgage that is, or becomes, a Flood Hazard Property.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Laws</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Comply with the requirements of all Laws and all orders, writs, injunctions and decrees applicable to it or to its business or property, except in such instances in which (a) such requirement of Law or order, writ, injunction or decree is being contested in good faith by appropriate proceedings diligently conducted, or (b) the failure to comply therewith could not reasonably be expected to have a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.09&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Books and Records</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maintain proper books of record and account, in which full, true and correct entries in conformity with GAAP consistently applied shall be made of all financial transactions and matters involving the assets and business of such Loan Party or such Subsidiary, as the case may be.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Maintain such books of record and account in material conformity with all applicable requirements of any Governmental Authority having regulatory jurisdiction over such Loan Party or such Subsidiary, as the case may be.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Inspection Rights</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Permit representatives and independent contractors of the Administrative Agent and each Lender to visit and inspect any of its properties, to examine its corporate, financial and operating records, and make copies thereof or abstracts therefrom, and to discuss its affairs, finances and accounts with its directors, officers, and independent public accountants, all at the expense of the Borrower and at such reasonable times during normal business hours and as often as may be desired, upon reasonable advance notice to the Borrower; <u>provided</u>, <u>however</u>, so long as no Event of Default exists, the Borrower shall only be required to reimburse the Administrative Agent (but not any Lender) for one such visit and inspection in any fiscal year; <u>provided</u>, <u>further</u>, <u>however</u>, when an Event of Default exists, the Administrative Agent or any Lender (or any of their respective representatives or independent contractors) may do any of the foregoing at the expense of the Borrower at any time during normal business hours, as often as desired and without advance notice.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">81</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Use of Proceeds</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Use the proceeds of the Loans (i) refinance the existing Indebtedness of the Borrower, (ii) to support the launch activities and commercialization efforts for Orladeyo, (iii) to fund research and development and (iv) for other general corporate purposes, <u>provided</u>, <u>that</u>, in no event shall the proceeds of the Loans be used in contravention of any Law or of any Loan Document.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Additional Subsidiaries</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Within thirty (30) days after the acquisition or formation of any Subsidiary (including, without limitation, upon the formation of any Subsidiary that is a Delaware Divided LLC) (it being understood that any Excluded Subsidiary ceasing to be an Excluded Subsidiary but remaining a Subsidiary shall be deemed to be the acquisition of a Subsidiary for purposes of this Section):</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;notify the Administrative Agent thereof in writing, together with the (i) jurisdiction of organization, (ii) number of shares of each class of Equity Interests outstanding, (iii) number and percentage of outstanding shares of each class owned (directly or indirectly) by the Borrower or any Subsidiary and (iv) number and effect, if exercised, of all outstanding options, warrants, rights of conversion or purchase and all other similar rights with respect thereto; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;cause such Person (other than any Excluded Subsidiary) to (i) to become a Guarantor by executing and delivering to the Administrative Agent a Joinder Agreement or such other documents as the Administrative Agent shall reasonably request for such purpose, and (ii) deliver to the Administrative Agent documents of the types referred to in <u>Sections 5.01(f)</u>-<u>(h)</u> (or, in the case of any Non-U.S. Subsidiary, comparable security documents, including local law equity pledge or similar agreements) in order to grant Liens to the Administrative Agent for the benefit of the Secured Parties in all assets of, and the Equity Interests in, such Subsidiary constituting Collateral and favorable opinions of counsel to such Persons (which shall cover, among other things, the legality, validity, binding effect and enforceability of the documentation referred to in <u>clause (i)</u> or <u>(ii)</u>, as applicable), all in form, content and scope reasonably satisfactory to the Administrative Agent; <u>provided</u> that an Exempt Immaterial Subsidiary shall not be required to deliver any Collateral Documents (other than an equity pledge or similar agreement granting Liens to the Administrative Agent for the benefit of the Secured Parties in the Equity Interests in such Exempt Immaterial Subsidiary) governed by the laws of the jurisdiction in which such Exempt Immaterial Subsidiary is organized until such Exempt Immaterial Subsidiary ceases to constitute an Exempt Immaterial Subsidiary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>ERISA Compliance</u>. Do, and cause each of its ERISA Affiliates to do, each of the following: (a) maintain each Plan, both in form and operation, in compliance in all material respects with the applicable provisions of ERISA, the Internal Revenue Code and other federal or state law, (b) cause each Plan that is qualified under Section 401(a) of the Internal Revenue Code to maintain such qualification, and (c) make all required contributions to any Plan subject to Section 412, Section 430 or Section 431 of the Internal Revenue Code.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Pledged Assets</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Equity Interests</u>. To secure the Obligations, cause (i) 100% of the issued and outstanding Equity Interests of each U.S. Subsidiary (including, without limitation, each U.S. Subsidiary that is a Delaware Divided LLC) directly owned by any Loan Party and (ii) 65% (or such greater percentage that, (A) could not reasonably be expected to cause the undistributed earnings of such Non-U.S. Subsidiary as determined for United States federal income tax purposes to be treated as a deemed dividend to such Non-U.S. Subsidiary&#8217;s United States parent and (B) could not reasonably be expected to cause any material adverse tax consequences) of the issued and outstanding Equity Interests entitled to vote (within the meaning of Treas. Reg. Section 1.956-2(c)(2)) and 100% of the issued and outstanding Equity Interests not entitled to vote (within the meaning of Treas. Reg. Section 1.956-2(c)(2)) in each Non-U.S. Subsidiary directly owned by any Loan Party, in each case, to be subject at all times to a first priority, perfected Lien in favor of the Administrative Agent, for the benefit of the Secured Parties, pursuant to the terms and conditions of the Collateral Documents. In connection with the foregoing, the Borrower shall cause to be delivered to Administrative Agent opinions of counsel requested by the Administrative Agent and any filings and deliveries necessary to perfect the security interests in such Equity Interests, all in form and substance satisfactory to the Administrative Agent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">82</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Other Property</u>. Cause all property (other than Excluded Property) of each Loan Party (including each Loan Party that is a Delaware Divided LLC) to be subject at all times to first priority, perfected and, in the case of real property (whether leased or owned), title insured Liens in favor of the Administrative Agent to secure the Obligations pursuant to the Collateral Documents or, with respect to any such property acquired subsequent to the Closing Date, such other additional security documents, including Real Property Security Documents, as the Administrative Agent shall request (subject to Permitted Liens), and in connection with the foregoing, deliver to the Administrative Agent such other documentation as the Administrative Agent may request, including filings and deliveries necessary to perfect such Liens, Organization Documents, resolutions, Real Property Security Documents and favorable opinions of counsel to such Persons and the Lenders, all in form, content and scope reasonably satisfactory to the Administrative Agent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Material Contracts</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Comply with each Material Contract of such Person, except where the failure to so comply could not reasonably be expected, either individually or in the aggregate, to have a material adverse effect on any Product Development and Commercialization Activities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Deposit Accounts</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Reserved].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Cause all Deposit Accounts of the Loan Parties (other than (A) deposit accounts established solely as payroll purposes, (B) the Government Account Debtor Account, (C) the HSBC Cash Collateral Accounts and (D) other Deposit Accounts holding less than $[***] in the aggregate at any time for all such Deposit Accounts under this clause (D)) at all times to be subject to Deposit Account Control Agreements in form and substance satisfactory to the Administrative Agent or solely in the case of a Loan Party that is a Non-U.S. Subsidiary, to be subject to a first priority, perfected security interest in favor of the Administrative Agent for the benefit of the Secured Parties, and (ii) cause all payments owing by a Government Account Debtor to a Loan Party to be deposited into the Government Account Debtor Account, which account shall (x) be subject to irrevocable standing instructions causing all funds therein to be transferred via an automatic immediate intrabank transfer by the close of each Business Day to a Deposit Account subject to a Deposit Account Control Agreement or solely in the case of a Loan Party that is a Non-U.S. Subsidiary, to a Deposit Account subject to a first priority, perfected security interest in favor of the Administrative Agent for the benefit of the Secured Parties, and (y) not be used for any purpose other than receiving funds from Government Account Debtors and other account debtors of the Loan Parties.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">83</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Regulatory Compliance</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without limiting the generality of <u>Section 7.08</u>, in connection with the research, development, testing, manufacture, handling, labeling, packaging, storage, supply, promotion, distribution, marketing, commercialization, marketing, commercialization, import, export, sale or provision of each and any Product or Service by the Borrower or any Subsidiary, or the operation of any Facility, the Borrower or such Subsidiary shall comply with all Required Permits at all times issued by any Government Authority, specifically including the FDA and CMS, with respect to such research, development, testing, manufacture, handling, labeling, packaging, storage, supply, promotion, distribution, marketing, commercialization, import, export, sales or provision of such Product or Service by the Borrower or such Subsidiary, in each case, except where the failure to do any of the foregoing (x) could not reasonably be expected, either individually or in the aggregate, to have a Material Adverse Effect and (y) could not reasonably be expected, either individually or in the aggregate, to have a material adverse effect on any Product Development and Commercialization Activities.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Borrower and each Subsidiary shall (i) take all necessary action to timely renew and maintain all Material Required Permits, accreditations and qualifications which are necessary or material to the conduct of its business, or to receive payment for all applicable Services, (ii) be and remain in compliance with all Third Party Arrangements and Healthcare Laws and all requirements for participation in, and for licensure required to provide the goods or services that are reimbursable under, all Third Party Payor Arrangements and Government Reimbursement Programs; and (iii) use commercially reasonable efforts to cause all Persons providing professional health care services for or on behalf of any Loan Party or Subsidiary (either as an employee or independent contractor) to comply with all applicable material Healthcare Laws in the performance of their duties, and to maintain in full force and effect all professional licenses required to perform such duties.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All preclinical and clinical trials that have been conducted and/or are being conducted by or on behalf of the Borrower and its Subsidiaries, including those trials whose results and data have been submitted to any Governmental Authority, including the FDA and its counterparts worldwide, are being or have been conducted in compliance in all material respects with the required experimental protocols, procedures and controls and otherwise in compliance with applicable Laws, including cGLP and cGCP, the Animal Welfare Act, and all applicable similar Laws in other jurisdictions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Loan Party and each of their respective Subsidiaries shall maintain a corporate and health care regulatory compliance program (&#8220;RCP&#8221;) which addresses the requirements of all applicable Healthcare Laws and includes the following components: (i) standards of conduct and policies and procedures for compliance with Healthcare Laws; (ii) a specific officer within high-level personnel identified as having overall responsibility for compliance with such standards of conduct and policies and procedures; (iii) training and education programs which effectively communicate the compliance standards and procedures to employees and agents, including Healthcare Laws; (iv) auditing and monitoring systems and reasonable steps for achieving compliance with such standards of conduct and policies and procedures including publicizing a reporting system to allow employees and other agents to anonymously report criminal or suspect conduct and potential compliance problems; (v) disciplinary guidelines and consistent enforcement of compliance policies including discipline of individuals responsible for the failure to detect violations of the RCP; and (vi) mechanisms to promptly respond to detected violations of the RCP. Each Loan Party and each of their respective Subsidiaries shall modify such RCPs from time to time, as may be necessary to ensure continuing compliance with all material applicable Healthcare Laws. Upon request, the Lenders (and/or their consultants) shall be permitted to review such RCPs.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">84</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrower shall provide to Lenders upon request, an accurate, complete and current list of all Third Party Payor Arrangements and participation agreements with Government Account Debtors with respect to the business of the Loan Parties.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrower shall promptly furnish or cause to be furnished to the Lenders copies of (i) all reports of investigational/inspectional observations issued to and received by the Loan Parties or any of their Subsidiaries, and issued by any Governmental Authority relating to such Person&#8217;s business, (ii) copies of all establishment investigation/inspection reports issued to and received by Loan Parties or any of their Subsidiaries and issued by any Governmental Authority, (iii) copies of all warning and untitled letters, subpoenas, civil investigative demands, as well as other material documents received by Loan Parties or any of their Subsidiaries from the FDA, CMS, HHS, the United States Department of Justice, or any other Governmental Authority relating to or arising out of the conduct applicable to the business of the Loan Parties or any of their Subsidiaries that asserts past or ongoing lack of compliance with any applicable Laws and Healthcare Laws, (iv) copies of any written recommendation from any Governmental Authority in any Key Territory, Ireland, Japan or the European Union (or any agency thereof) or the competent authority of a European Union member state, that any Loan Party or any of its respective Subsidiaries, or any obligor to which any Loan Party or any of its respective Subsidiaries provides Products or Services, should have its licensure, provider or supplier number, or accreditation suspended, revoked, or limited in any way, or any penalties or sanctions imposed and (v) notice of any material investigation or material audit or similar proceeding by the FDA, CMS, any other Governmental Authority in any Key Territory, Ireland, Japan or the European Union (or any agency thereof) or the competent authority of a European Union member state.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each Loan Party and each of their respective Subsidiaries will at all times be in compliance in all material respects with HIPAA to the extent applicable.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[Reserved].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cause all Facilities to operate in material compliance with applicable Laws except to the extent that any non-compliance could not reasonably be expected, either individually or in the aggregate, to result in (x) a material adverse effect on any Product Development and Commercialization Activities and (y) a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any Facility is currently accredited by an Accrediting Organization, each Loan Party and each of their respective Subsidiaries will (i) maintain such accreditation in good standing and without limitation or impairment, (ii) promptly submit to the Accrediting Organization a plan of correction for any deficiencies listed on any accreditation survey report, and (iii) cure all such deficiencies within such time frame as is necessary to preserve and maintain in good standing and without limitation or impairment such accreditation, in each case, except to the extent that the failure to do so could not reasonably be expected, either individually or in the aggregate, to result in (x) a material adverse effect on any Product Development and Commercialization Activities and (y) a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Borrower shall provide the Administrative Agent (i) prior written notice of any material change to the terms of its normal billing payment and reimbursement policies and procedures with respect thereto (including, without limitation, the amount and timing of finance charges, fees and write-offs) and (ii) within a reasonable time written notice of any change in a Government Reimbursement Program that materially impacts the Borrower&#8217;s normal billing payment policies and procedures or expected reimbursement amounts, together with a description of the expected impacts.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Loan Parties shall maintain in full force and effect, and free from restrictions, probations, conditions or known conflicts which would materially impair the use or operation of any Facility for its current use, except to the extent that the failure to do so could not reasonably be expected, either individually or in the aggregate, to result in (x) a material adverse effect on any Product Development and Commercialization Activities and (y) a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">85</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Intellectual Property; Consent of Licensors</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Maintain in full force and effect or pursue the prosecution of, as the case may be, and pay all costs and expenses relating to, all Material IP Rights owned or controlled by such Loan Party or its respective Subsidiaries, except for any such Material IP Rights that are no longer used or useful in any material respect in the business of the Borrower and its Subsidiaries, taken as a whole; (ii) notify the Administrative Agent, promptly after learning thereof, of any material infringement, misappropriation or other violation by any Person of its Material IP Rights; (iii) use commercially reasonable efforts to pursue, enforce, and maintain in full force and effect legal protection for all Material IP Rights, including Patents, developed or controlled by such Loan Party or any of its respective Subsidiaries, except for any such Material IP Rights that are no longer used or useful in any material respect in the business of the Borrower and its Subsidiaries, taken as a whole; and (iv) notify the Administrative Agent, promptly after learning thereof, of any claim by any Person that the conduct of the Businesses infringes any Material IP Rights of that Person and, if requested by the Administrative Agent, use commercially reasonable efforts to resolve such claim, in each case of this clause (iv), other than with respect to Material IP Rights that are obsolete or no longer used or useful in the conduct of the business of Borrower and its Subsidiaries, taken as a whole, or the cost of maintaining any such Material IP Rights that are immaterial would outweigh the benefit to Borrower and its Subsidiaries of so maintaining.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly after entering into or becoming bound by any material license or similar material agreement (other than (i) over-the-counter software that is commercially available to the public and (ii) any license agreement relating to IP Rights that are not Material IP Rights) after the Closing Date, the Loan Parties shall (i) provide written notice to the Administrative Agent of the material terms of such license or similar agreement and (ii) in good faith take such commercially reasonable actions (which commercially reasonable actions, for the avoidance of doubt, shall not include payment of any fees or other amounts or making any material concessions with respect to the terms of such license or agreement by such Loan Party) as the Administrative Agent or Required Lenders may reasonably request to obtain the consent of, or waiver by, any Person whose consent or waiver is necessary for the Administrative Agent to be granted and perfect a valid security interest in such license or agreement and to fully exercise its rights under any of the Loan Documents in the event of a disposition or liquidation of the rights, assets or property that is the subject of such license or agreement; <u>provided</u>, <u>that</u>, the failure to obtain any such consent or waiver shall not by itself constitute a Default.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Anti-Corruption Laws</u>. Conduct its business in compliance with the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010 and other similar anti-corruption legislation in other jurisdictions and maintain policies and procedures designed to promote and achieve compliance with such Laws.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Post-Closing Obligations</u>. Within the time periods set forth therefor on <u>Schedule 7.20</u> (or such longer periods of time as may be agreed to by the Administrative Agent in its sole discretion), deliver to the Administrative Agent such documents, instruments, certificates or agreements as are listed on <u>Schedule 7.20</u> or take such actions as are described on <u>Schedule 7.20</u>, in each case in form and substance reasonably satisfactory to the Administrative Agent.<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>JPR Royalty Sub - Indenture</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">86</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until discharge of the JPR Indenture pursuant to and in accordance with Section 11.1 thereof, the Borrower hereby agrees that it shall, to the extent required by the JPR Indenture and other Deal Documents (as defined in the JPR Indenture), and all agreements and documents entered into from time to time in connection therewith (including, without limitation, any amendments or modifications thereof) and not otherwise prohibited pursuant to the terms of the Loan Documents, perform (i) [reserved], (ii) such administrative activities necessary to maintain the continuing existence of JPR Royalty Sub, such as completing required annual registration or report filings with state filing offices, and (iii) such activities in the ordinary course of business incidental to its ownership of the equity interests of JPR Royalty Sub, to the extent that failure perform any of the foregoing activities described in <u>clauses (a)(i)</u>, <u>(ii)</u> and <u>(iii)</u> could reasonably be expected to result in a Material Adverse Effect.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until discharge of the JPR Indenture pursuant to and in accordance with Section 11.1 thereof, it shall constitute a breach of this <u>Section 7.21</u> by the Borrower if (i) JPR Royalty Sub shall (A)&nbsp;transact or engage in any activities, business or operations or consummate any transactions other than the performance of its obligations and activities reasonably incidental thereto under the JPR Indenture and the other Deal Documents, and all agreements and documents entered into from time to time in connection therewith (including, without limitation, any amendments or modifications thereof), (B) amend the terms of the JPR Indenture or the other Deal Documents in a manner that is materially adverse to the Administrative Agent or any Lender or that could reasonably be expected to result in a Material Adverse Effect, (C)&nbsp;allow its Organization Documents to be modified in a manner (1) that is adverse to the Administrative Agent or any Lender in any material respect, (2) that could reasonably be expected to result in a Material Adverse Effect or (3) that would have the effect of eliminating or modifying any of the &#8220;special purpose entity&#8221; restrictions set forth in such Organization Documents, (D) violate the &#8220;special purpose entity&#8221; restrictions set forth in such Organization documents in any material respect, (E)&nbsp;merge or consolidate with any other Person, (F) own any assets other than the Purchased Assets (as defined in the JPR Indenture), (G) create, incur, assume or suffer to exist any Indebtedness (other than the Indebtedness under the JPR Indenture) and (H) create, incur, assume or suffer to exist any Lien upon any of its property, assets or revenues, whether now owned or hereafter acquired (other than Liens of the Trustee (as defined in the JPR Indenture as in effect on the date hereof) on the Collateral (as defined in the JPR Indenture as in effect on the date hereof) pursuant to the JPR Indenture) or (ii) any Loan Party or any Subsidiary shall, directly or indirectly, (A) make any Investment in JPR Royalty Sub, (B) sell, transfer, license, lease or dispose of any asset or property of such Loan Party or Subsidiary to JPR Royalty Sub or (C) Guarantee or otherwise become liable for any Indebtedness or other liability of JPR Royalty Sub (other than the pledge by the Borrower of its membership interests in JPR Royalty Sub pursuant to the &#8220;Pledge and Security Agreement&#8221; (as defined in the JPR Indenture as in effect on the date hereof), it being understood that the only recourse to the Borrower is (I) such membership interests and no other assets of the Borrower or any of its Subsidiaries and (II) pursuant to the expense reimbursement obligations set forth in Section 12.1 of such &#8220;Pledge and Security Agreement&#8221; and the indemnification obligations set forth in Section 19.1 of such &#8220;Pledge and Security Agreement&#8221;).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following discharge of the JPR Indenture pursuant to and in accordance with Section 11.1 thereof, the Borrower shall, within [***] or, if not then permitted pursuant to the JPR Indenture or other Deal Documents, within [***] of such first date thereafter as may be permitted under the JPR Indenture and such other Deal Documents, and at its election, either (a) dissolve JPR Royalty Sub and liquidate its assets into the Borrower or (b) take such actions required by Administrative Agent to cause JPR Royalty Sub to become a Guarantor under the Loan Documents pursuant to <u>Section 7.12</u> with respect to newly formed or acquired Subsidiaries.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictions on Cash</u>. Without limiting the restrictions set forth in Sections 7.21 or 8.18, respectively, the Loan Parties shall ensure that the total amount of cash and Cash Equivalents held by all Subsidiaries of the Borrower that are not Loan Parties does not, as of the end of each fiscal quarter, exceed $[***] in the aggregate.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">87</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">7.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>People with Significant Control Regime</u>. Each of the Loan Parties shall within the relevant timeframe, comply with any notice it receives pursuant to Part 21A of the Companies Act 2006 from any company incorporated in the United Kingdom whose shares are the subject of Collateral Documents and promptly provide the Administrative Agent with a copy of that notice.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="text-transform:uppercase">Article&nbsp;</font>VIII<br>
<br>
NEGATIVE COVENANTS</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">So long as any Lender shall have any Commitments hereunder, any Loan or other Obligation hereunder shall remain unpaid or unsatisfied (other than contingent indemnification obligations for which no claim has been asserted), no Loan Party shall, nor shall it permit any Subsidiary to, directly or indirectly:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Liens</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Create, incur, assume or suffer to exist any Lien upon any of its property, assets or revenues, whether now owned or hereafter acquired, other than the following:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens pursuant to any Loan Document;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens existing on the date hereof and listed on <u>Schedule 8.01</u>;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens (other than Liens imposed under ERISA) for taxes, assessments or governmental charges or levies not yet delinquent or which are being contested in good faith and by appropriate proceedings diligently conducted, if adequate reserves with respect thereto are maintained on the books of the applicable Person in accordance with GAAP;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;statutory Liens of landlords and Liens of carriers, warehousemen, mechanics, materialmen and suppliers and other Liens imposed by law or pursuant to customary reservations or retentions of title arising in the ordinary course of business, <u>provided</u>, <u>that</u>, such Liens secure only amounts not yet due and payable or, if due and payable, are unfiled and no other action has been taken to enforce the same or are being contested in good faith by appropriate proceedings for which adequate reserves determined in accordance with GAAP have been established; <u>provided further</u>, <u>that</u>, such Liens do not have priority over any of the Administrative Agent&#8217;s Liens on the Collateral and the aggregate amount secured by all such Liens does not at any time exceed the Threshold Amount;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;pledges or deposits in the ordinary course of business in connection with workers&#8217; compensation, unemployment insurance and other social security legislation, other than any Lien imposed by ERISA;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;deposits to secure the performance of bids, trade contracts and leases (other than Indebtedness), statutory obligations, surety and appeal bonds, indemnity and performance bonds and other obligations of a like nature incurred in the ordinary course of business;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;easements, rights-of-way, restrictions and other similar encumbrances affecting real property which, in the aggregate, are not substantial in amount, and which do not materially interfere with the ordinary conduct of the business of the applicable Person;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">88</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens securing judgments, decrees or attachments (or appeal or other surety bonds relating to such judgments) not constituting an Event of Default under <u>Section 9.01(h)</u>;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens securing Indebtedness permitted under <u>Section 8.03(e)</u>; <u>provided</u>, <u>that</u>: (i) such Liens do not at any time encumber any property other than the property financed by such Indebtedness, (ii) the Indebtedness secured thereby does not exceed the cost (negotiated on an arm&#8217;s length basis) of the property being acquired on the date of acquisition and (iii) such Liens attach to such property concurrently with or within ninety (90) days after the acquisition thereof;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;licenses, sublicenses, leases or subleases (other than relating to intellectual property) granted to others in the ordinary course of business not interfering in any material respect with the business of any Loan Party or any of its Subsidiaries;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any interest of title of a lessor under, and Liens arising from UCC financing statements (or equivalent filings, registrations or agreements in foreign jurisdictions) relating to, leases permitted by this Agreement;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;normal and customary banker&#8217;s liens and rights of setoff upon deposits of cash in favor of banks or other depository institutions;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens of a collection bank arising under Section 4-210 of the Uniform Commercial Code on items in the course of collection;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens of sellers of goods to the Borrower and any of its Subsidiaries arising under Article 2 of the Uniform Commercial Code or similar provisions of applicable law in the ordinary course of business, covering only the goods sold and securing only the unpaid purchase price for such goods and related expenses;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permitted Licenses;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;solely with respect to the Borrower, the pledge of its membership interests in JPR Royalty Sub pursuant to the &#8220;Pledge and Security Agreement&#8221; (as defined in the JPR Indenture as in effect on the date hereof);</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[reserved];</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens granted in the ordinary course of business on the unearned portion of insurance premiums securing the financing of insurance premiums permitted by <u>Section 8.03(h)</u>;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liens in favor of HSBC Bank on the HSBC Cash Collateral Accounts to the extent securing obligations of Borrower permitted pursuant to <u>clause (h)</u> of the definition of Permitted Contingent Obligations;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;cash collateral securing letters of credit permitted under clause (g) of the definition of &#8220;Permitted Contingent Obligations&#8221;; <u>provided</u> that the aggregate amount of such cash collateral shall not exceed [***] percent ([***]%) of the face amount of the letter of credit it is securing; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other Liens securing obligations (other than obligations constituting Capital Leases, letters of credit or debt for borrowed money) in an aggregate principal amount outstanding at any time not to exceed the Threshold Amount.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">89</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Investments</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Make any Investments, except:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments held by a Loan Party or a Subsidiary in the form of cash or Cash Equivalents;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments existing on date hereof and set forth in <u>Schedule 8.02</u>;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments in any Person that is a Loan Party prior to giving effect to such Investment;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments by any Subsidiary of the Borrower that is not a Loan Party in any other Subsidiary of the Borrower that is not a Loan Party;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) Investments consisting of extensions of credit in the nature of accounts receivable or notes receivable arising from the grant of trade credit in the ordinary course of business, (y)&nbsp;Investments received in satisfaction or partial satisfaction thereof from financially troubled account debtors to the extent reasonably necessary in order to prevent or limit loss and (z) Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permitted Acquisitions;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other Investments not exceeding the Threshold Amount in the aggregate at any one time outstanding; <u>provided</u>, <u>that</u>, no Investment otherwise permitted by this <u>clause (g)</u> shall be permitted to be made if any Default has occurred and is continuing or would result therefrom; provided, further, that any Investment by a Loan Party in a Non-U.S. Subsidiary that is not a Loan Party in reliance on this clause (g) shall be limited to cash and Cash Equivalents;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments of cash and Cash Equivalents by Loan Parties in Non-U.S. Subsidiaries that are not Loan Parties, but solely to the extent that the aggregate amount of such Investments does not exceed $[***] at any time outstanding;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[reserved];</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of any Loan Party; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investments consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the ordinary course of business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of the Borrower pursuant to employee stock purchase plans or agreements approved by the Borrower&#8217;s board of directors, in an aggregate amount for all such Investments made in reliance of this <u>clause (k)</u> not to exceed $[***] at any one time outstanding; <u>provided</u>, <u>that</u>, no Investment otherwise permitted by this <u>clause (</u><u>k</u><u>)</u> shall be permitted to be made if any Default has occurred and is continuing or would result therefrom.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Indebtedness</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Create, incur, assume or suffer to exist any Indebtedness, except:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">90</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness under the Loan Documents;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness of the Borrower and its Subsidiaries existing on the date hereof and described on <u>Schedule 8.03</u> and renewals, refinancings and extensions thereof; provided that no such Indebtedness shall be refinanced for a principal amount in excess of the principal balance outstanding thereon at the time of such refinancing except by an amount equal to unpaid accrued interest and premium thereon and fees, commissions and expenses (including upfront fees and original issue discount) reasonably incurred, in connection with such refinancing;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;intercompany Indebtedness permitted under <u>Section 8.02</u> (other than by reference to this <u>Section 8.03</u> (or any sub-clause hereof));</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;obligations (contingent or otherwise) of the Borrower or any Subsidiary existing or arising under any Swap Contract, <u>provided</u>, <u>that</u>, such obligations are (or were) entered into by such Person in the ordinary course of business for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated by such Person, or changes in the value of securities issued by such Person, and not for purposes of speculation or taking a &#8220;market view&#8221;;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;purchase money Indebtedness (including obligations in respect of Capital Leases or Synthetic Leases) hereafter incurred by the Borrower or any of its Subsidiaries to finance the purchase of fixed assets, and renewals, refinancings and extensions thereof, <u>provided</u>, <u>that</u>, (i) no Default or Event of Default has occurred and is continuing both immediately prior to and after giving effect thereto, (ii) the total of all such Indebtedness for all such Persons taken together shall not exceed an aggregate principal amount of $[***] at any one time outstanding, (iii) such Indebtedness when incurred shall not exceed the purchase price of the asset(s) financed, and (iv) no such Indebtedness shall be refinanced for a principal amount in excess of the principal balance outstanding thereon at the time of such refinancing except by an amount equal to unpaid accrued interest and premium thereon plus other amounts owing or paid related to such Indebtedness, and fees, commissions and expenses (including upfront fees and original issue discount) reasonably incurred, in connection with such refinancing;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;other unsecured Indebtedness hereafter incurred by the Borrower or any of its Subsidiaries in an aggregate amount not to exceed $[***] at any one time outstanding;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permitted Contingent Obligations;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indebtedness incurred in the ordinary course of business not to exceed $[***] in the aggregate at any time outstanding owed to any Person providing property, casualty, liability, or other insurance to the Loan Parties, including to finance insurance premiums, so long as the amount of such Indebtedness is not in excess of the amount of the unpaid cost of, and shall be incurred only to defer the cost of, such insurance for the policy year in which such Indebtedness is incurred and such Indebtedness is outstanding only during such policy year;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convertible Bond Indebtedness; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attributable Indebtedness in respect of Capital Leases incurred pursuant to automobile leases entered into in the ordinary course of business as part of employee compensation for employees based in Europe; provided that the aggregate amount of such Attributable Indebtedness incurred pursuant to this <u>clause (j)</u> shall not exceed $[***] at any one time outstanding.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Fundamental Changes</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">91</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Merge, dissolve, liquidate, consolidate, with or into another Person, or Dispose of (whether in one transaction or in a series of transactions) all or substantially all of its assets (whether now owned or hereafter acquired) to or in favor of any Person (including, in each case, pursuant to a Delaware LLC Division); <u>provided</u>, <u>that</u>, notwithstanding the foregoing provisions of this <u>Section 8.04</u> but subject to the terms of <u>Sections 7.12</u> and <u>7.14</u>, (a) the Borrower may merge or consolidate with any of its direct Subsidiaries, provided that the Borrower shall be the continuing or surviving entity, (b) any Loan Party (other than the Borrower) may merge or consolidate with any other Loan Party, (c) any Subsidiary that is not a Loan Party may be merged or consolidated with or into any Loan Party, provided that such Loan Party shall be the continuing or surviving entity, (d) any Subsidiary that is not a Loan Party may be merged or consolidated with or into any other direct Subsidiary of it that is not a Loan Party and (e) any Subsidiary that is not a Loan Party may dissolve, liquidate or wind up its affairs at any time provided that such dissolution, liquidation or winding up could not reasonably be expected to have a Material Adverse Effect and all of its assets and business are transferred to a Loan Party prior to or concurrently with such dissolution, liquidation or winding up; <u>provided</u>, <u>that</u>, in the case of (a) through (d) above, the merging parties are organized in the same jurisdiction (it being understood that for this purpose, States of the United States shall be deemed to be the same jurisdiction as each other).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Dispositions</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Make any Disposition, except, so long as no Default or Event of Default shall have occurred and be continuing both immediately prior to and after giving effect to such Disposition, (a) Permitted Licenses and dispositions of Inventory and Clinical Trial Material to licensees in connection with, and pursuant to reasonable and customary terms of, a Permitted License (provided that such dispositions shall be limited to Inventory and Clinical Trial Material related to the Product that is the subject of such Permitted License), (b) other Dispositions to the extent, in the case of this <u>clause (</u><u>b</u><u>)</u>, (i) the consideration paid in connection therewith shall be cash or Cash Equivalents paid contemporaneous with consummation of the transaction and shall be in an amount not less than the fair market value of the property disposed of, (ii) such Disposition does not involve the sale, lease, license, transfer or other disposition of the Equity Interests in any Subsidiary, any Products and/or any IP Rights, and (iii) the aggregate fair market value of all of the assets sold or otherwise disposed of in such Disposition together with the aggregate fair market value of all assets sold or otherwise disposed of by the Borrower and its Subsidiaries in all such transactions does not exceed $[***] per fiscal year of the Borrower, and (c) asset sales of the Specified Products to any Person that is not an Affiliate of any Loan Party, Subsidiary or Affiliate of a Loan Party or Subsidiary (excluding, for the avoidance of doubt, the Disposition of any Equity Interests of a Subsidiary), to the extent, in the case of this <u>clause (</u><u>c</u><u>)</u>, that, the consideration paid in connection therewith shall be cash paid contemporaneously with the consummation of the transaction and shall be in an amount not less than the fair market value of the property disposed; <u>provided</u>, <u>however</u>, that this <u>clause (</u><u>c</u><u>)</u> shall not include any Disposition in the form of a separate license, sale, transfer or financing of a right to receive any sales or revenue with respect to a Specified Product (or any IP Rights related to a Specified Product); <u>provided further that</u>, for the avoidance of doubt, the foregoing proviso shall not restrict any Permitted License or Other Royalty Financing otherwise separately permitted pursuant to the terms of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Restricted Payments</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Declare or make, directly or indirectly, any Restricted Payment, or incur any obligation (contingent or otherwise) to do so, except that:<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) each Subsidiary may make Restricted Payments to any Loan Party and (ii) each Subsidiary that is not a Loan Party may make Restricted Payments to another Subsidiary that is not a Loan Party;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">92</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Borrower and each Subsidiary may declare and make dividend payments or other distributions payable solely in the Qualified Capital Stock of such Person;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Borrower may make (i) any payment of cash in lieu of a fractional share in accordance with the terms of any indenture governing Convertible Bond Indebtedness and (ii) subject to any subordination provisions applicable thereto, regularly scheduled interest payments as and when due in accordance with the terms of any indenture governing Convertible Bond Indebtedness;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the Borrower may make cashless repurchases of its Equity Interests deemed to occur upon exercise of stock options or warrants of such Equity Interests to represent a portion of the exercise price of such options or warrants and (ii) to the extent constituting a Restricted Payment, the Borrower may acquire (or withhold) its Equity Interests pursuant to any employee stock option or similar plan in satisfaction of withholding or similar taxes payable by any present or former officer, employee, director or member of management and the Borrower may make deemed repurchases in connection with the exercise of stock options; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (i) the Borrower may (x) make the Royalty Payment on a quarterly basis to the Buyer pursuant to Section 6.2(a) of the Royalty Financing Agreement and (y) make any other payments to the Buyer required to be made under the Royalty Financing Documents as in effect on the date hereof and (ii) subject to the Royalty Financing Restrictions, the Borrower may pay any revenue participation payment owing to the purchaser or buyer under any Other Royalty Financing Document pursuant to any comparable section in such Other Royalty Financing Document.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.07&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Change in Nature of Business</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Engage in any material line of business substantially different from those lines of business conducted by the Borrower and its Subsidiaries on the Closing Date or any business substantially related or incidental thereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Transactions with Affiliates and Insiders</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Enter into or permit to exist any transaction or series of transactions, with any officer, director or Affiliate of a Loan Party or a Subsidiary other than (a) advances of working capital to any Loan Party, (b) [reserved], (c) intercompany transactions expressly permitted by <u>Section 8.02</u>, <u>Section 8.03</u>, <u>Section 8.04</u>, <u>Section 8.05</u> or <u>Section 8.06</u> (in each case, other than by reference to this <u>Section 8.08</u> (or any sub-clause hereof)), (d) normal and reasonable compensation and reimbursement of expenses of officers and directors in the ordinary course of business (e) except as otherwise specifically limited in this Agreement, other transactions which are entered into in the ordinary course of such Person&#8217;s business on terms and conditions substantially as favorable to such Person as would be obtainable by it in a comparable arm&#8217;s-length transaction with a Person other than an officer, director or Affiliate and (f) transactions solely between or among Loan Parties.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.09&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Burdensome Agreements</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Enter into, or permit to exist, any Contractual Obligation that (a) encumbers or restricts the ability of any such Person to (i) make Restricted Payments to any Loan Party, (ii) pay any Indebtedness or other obligations owed to any Loan Party, (iii) make loans or advances to any Loan Party, (iv) transfer any of its property to any Loan Party, (v) pledge its property pursuant to the Loan Documents or any renewals, refinancings, exchanges, refundings or extension thereof or (vi) act as a Loan Party pursuant to the Loan Documents or any renewals, refinancings, exchanges, refundings or extension thereof, except (in respect of any of the matters referred to in <u>clauses (i)</u> through <u>(v)</u> above) for (1) this Agreement and the other Loan Documents, (2) any document or instrument governing Indebtedness incurred pursuant to <u>Section 8.03(e)</u>, <u>provided</u>, <u>that</u>, any such restriction contained therein relates only to the asset or assets constructed or acquired in connection therewith, (3) customary provisions restricting assignment of any agreement entered into by the Borrower or any Subsidiary in the ordinary course of business, or (4) customary restrictions and conditions contained in any agreement relating to the sale of any property permitted under <u>Section 8.05</u> pending the consummation of such sale s or (b) requires the grant of any security for any obligation if such property is given as security for the Obligations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">93</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Use of Proceeds</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Use the proceeds of any Loan, whether directly or indirectly, and whether immediately, incidentally or ultimately, to purchase or carry margin stock (within the meaning of Regulation U of the FRB) or to extend credit to others for the purpose of purchasing or carrying margin stock or to refund indebtedness originally incurred for such purpose.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Prepayment of Other Indebtedness</u>,</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Make (or give any notice with respect thereto) any voluntary or optional payment or prepayment or voluntary or optional redemption or acquisition for value of (including without limitation, by way of depositing money or securities with the trustee with respect thereto before due for the purpose of paying when due), refund, refinance or exchange of any Indebtedness of any Loan Party or any Subsidiary that is (or is required to be) (a) subordinated in right of payment to the Obligations, (b) unsecured Indebtedness or (c) Indebtedness secured by Liens which are junior to the Liens securing the Obligations, in the case of each of the foregoing <u>clauses (a)</u> through <u>(c)</u> except for (i) any settlement or conversion of Convertible Bond Indebtedness solely with or into common stock of the Borrower<u> and (ii)</u> any payment of cash in lieu of a fractional share in accordance with the terms of any indenture governing Convertible Bond Indebtedness in connection with the settlement or conversion of Convertible Bond Indebtedness permitted by clause (i) above of this <u>Section 8.11</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Organization Documents; Fiscal Year; Legal Name, Jurisdiction of Formation and Form of Entity; Certain Amendments</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amend, modify or change its Organization Documents in a manner materially adverse to the Lenders.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change its fiscal year.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Without providing five (5) days prior written notice to the Administrative Agent and otherwise taking any steps that in the Administrative Agent&#8217;s reasonable discretion would be necessary, appropriate or convenient in order to perfect and maintain perfection of the security interests granted under the Security Documents, change its name, jurisdiction of organization or form of organization.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amend, supplement, waive or otherwise modify (or permit the amendment, supplement, waiver or modification), or enter into any forbearance from exercising any rights with respect to, (i) any Material Contract (other than any Royalty Financing Document or Other Royalty Financing Document) if such amendment, supplement, waiver, other modification or forbearance could reasonably be expected to result in a material adverse effect on any Product Development and Commercialization Activities, (ii) any document or other agreement evidencing Indebtedness in excess of the Threshold Amount in a manner materially adverse to the Administrative Agent or any Lender or (iii) any Royalty Financing Document or Other Royalty Financing Document, in each case, in a manner adverse to the Administrative Agent or any Lender.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">94</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Each Loan Party shall, prior to entering into any amendment, supplement, waiver or other modification of, or forbearance with respect to, any Royalty Financing Document, Other Royalty Financing Document, other Material Contract or any document or other agreement evidencing Indebtedness in excess of the Threshold Amount to the extent such amendment, supplement, waiver, modification or forbearance is not permitted by this <u>Section 8.12</u>, deliver to Administrative Agent reasonably in advance of the execution thereof, any final or execution form copy of amendments, supplements, waivers or other modifications to such documents, and, if approval of Administrative Agent is required by the terms of this <u>Section 8.12</u> prior to the taking of any such action, the Loan Parties agree not to take, nor permit any of its Subsidiaries to take, any such action with respect to any such documents without obtaining such approval from Administrative Agent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Ownership of Subsidiaries</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Notwithstanding any other provisions of this Agreement to the contrary, (a) permit any Person (other than any Loan Party or any Wholly-Owned Subsidiary of the Borrower) to own any Equity Interests of any Subsidiary of any Loan Party, except to qualify directors where required by applicable law or to satisfy other requirements of applicable law with respect to the ownership of Equity Interests of Non-U.S. Subsidiaries, (b) permit any Loan Party or any Subsidiary to issue or have outstanding any shares of Disqualified Capital Stock or (c) create, incur, assume or suffer to exist any Lien (other than Liens permitted under <u>Section 8.01(a)</u>) on any Equity Interests of any Subsidiary of any Loan Party.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Sale Leasebacks</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Enter into any Sale and Leaseback Transaction.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Sanctions; Anti-Corruption Laws</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directly or indirectly, use the proceeds of any Loan, or lend, contribute or otherwise make available such proceeds of any Loan to any Person, to fund any activities of or business with any Person, or in any Designated Jurisdiction, that, at the time of such funding, is the subject of Sanctions, or in any other manner that will result in a violation by any Person (including any Person participating in the transactions hereunder, whether as a Lender, Administrative Agent or otherwise) of Sanctions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directly or indirectly, use the proceeds of any Loan for any purpose which would breach the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010 and other similar anti-corruption legislation in other jurisdictions.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Minimum Liquidity</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Permit the amount of Unrestricted Cash of the Loan Parties held in Deposit Accounts for which the Administrative Agent shall have received a Deposit Account Control Agreement at any time to be less than:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if only the Term A Borrowing has occurred: $15,000,000;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if the Term B Borrowing has occurred but the Term C Loan Borrowing has not occurred: $20,000,000;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if the Term C Borrowing has occurred (and the Cure Right has not been exercised pursuant to <u>Section 9.04</u>): $15,000,000; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">95</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if the Cure Right has been exercised pursuant to <u>Section 9.04</u>: $20,000,000.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Minimum Orladeyo Consolidated U.S. Net Product Sales</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">As of the last day of each fiscal quarter of the Borrower (a &#8220;<u>Test Date</u>&#8221;) beginning with the first Test Date occurring immediately after the Term C Borrowing Date, permit Orladeyo Consolidated U.S. Net Product Sales for the four-fiscal quarter period ending on such Test Date to be less than the amount set forth in the table below:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="vertical-align: middle; width: 48.1%; border-top: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0); border-image: initial;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Test Date ending after Term C Loan Borrowing Date:</b></p>
			</td>
			<td style="vertical-align: middle; width: 51.9%; border-top: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0); border-image: initial;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Minimum Orladeyo Consolidated U.S. Net Product Sales</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48.1%; border-top: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0); border-image: initial;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">First Test Date</p>
			</td>
			<td style="vertical-align: top; width: 51.9%; border-top: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0); border-image: initial;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">$[***]</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48.1%; border-top: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0); border-image: initial;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Second Test Date:</p>
			</td>
			<td style="vertical-align: top; width: 51.9%; border-top: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0); border-image: initial;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">$[***]</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 48.1%; border-top: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0); border-image: initial;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Third Test Date:</p>
			</td>
			<td style="vertical-align: top; width: 51.9%; border-top: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0); border-image: initial;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">$[***]</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; border: thin solid rgb(0, 0, 0); width: 48.1%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Fourth Test Date and each Test Date thereafter:</p>
			</td>
			<td style="vertical-align: top; border-bottom: thin solid rgb(0, 0, 0); width: 51.9%; border-top: thin solid rgb(0, 0, 0); border-right: thin solid rgb(0, 0, 0); border-image: initial;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">$[***]</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">8.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>MDCP</u>.<u> </u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Permit MDCP to (a) conduct any business operations, (b) have any cash or other assets (including any licenses or permits) or any liabilities (other than de minimis assets or liabilities as required by applicable Law), (c) own any Equity Interests of any Loan Party or any other Subsidiary of any Loan Party or (d)&nbsp;operate any part of the business of any Loan Party or any other Subsidiary.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Directly or indirectly, (A) make any Investment in MDCP or (B) sell, transfer, license, lease or dispose of any asset or property of such Loan Party or Subsidiary to MDCP.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="text-transform:uppercase">Article&nbsp;</font>IX<br>
<br>
EVENTS OF DEFAULT AND REMEDIES</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Events of Default</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Any of the following shall constitute an Event of Default:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Payment</u>. The Borrower or any other Loan Party fails to pay (i) when and as required to be paid herein, any amount of principal of any Loan (including any prepayment or repayment premium or exit fee due in connection with such principal amount), or (ii) within three Business Days after the same becomes due, any interest on any Loan, any fee due hereunder or any other amount payable hereunder or under any other Loan Document; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Specific Covenants</u>. Any Loan Party fails to perform or observe any term, covenant or agreement contained in any of <u>Section 7.01</u>, <u>7.02</u>, <u>7.03</u>, <u>7.05</u> (solely as to any Loan Party), <u>7.10</u>, <u>7.11</u>, <u>7.12</u>, <u>7.14</u>, <u>7.16</u>, <u>7.17</u>, <u>7.18</u><u>(b)</u>, <u>7.19</u>, <u>7.20</u>, <u>7.21</u> or <u>7.</u><u>22</u> or <u>Article VIII</u>; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">96</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Other Defaults</u>. Any Loan Party fails to perform or observe any other covenant or agreement (not specified in <u>subsection (a)</u> or <u>(b)</u> above) contained in any Loan Document on its part to be performed or observed and such failure continues for thirty (30) days after the earlier to occur of the date on which (i) a Responsible Officer of any Loan Party becomes aware of such failure or (ii) written notice thereof shall have been given to any Loan Party by the Administrative Agent or any Lender; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Representations and Warranties</u>. Any representation, warranty, certification or statement of fact made or deemed made by or on behalf of the Borrower or any other Loan Party herein, in any other Loan Document, or in any document delivered in connection herewith or therewith shall be incorrect or misleading in any material respect (and in all respects if any such representation or warranty is already qualified by materiality or reference to Material Adverse Effect) when made or deemed made; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Cross-Default</u>. (i) Any Loan Party or any Subsidiary (A) fails to make any payment beyond any applicable grace period (whether by scheduled maturity, required repayment or prepayment, acceleration, demand, or otherwise) in respect of any Indebtedness or Guarantee (other than Indebtedness hereunder, Indebtedness under Swap Contracts and Indebtedness under the JPR Indenture) having an aggregate principal amount (including undrawn committed or available amounts and including amounts owing to all creditors under any combined or syndicated credit arrangement) of more than the Threshold Amount, or (B) fails to observe or perform any other agreement or condition relating to any such Indebtedness or Guarantee or contained in any instrument or agreement evidencing, securing or relating thereto, or any other event occurs, the effect of which default or other event is to cause, or to permit the holder or holders of such Indebtedness or the beneficiary or beneficiaries of such Guarantee (or a trustee or agent on behalf of such holder or holders or beneficiary or beneficiaries) to cause, with the giving of notice if required, such Indebtedness to be demanded or to become due or to be repurchased, prepaid, defeased or redeemed (automatically or otherwise), or an offer to repurchase, repay, prepay, defease or redeem such Indebtedness to be made, prior to its stated maturity, or such Guarantee to become payable or cash collateral in respect thereof to be demanded; or (ii) there occurs under any Swap Contract an Early Termination Date (as defined in such Swap Contract) resulting from (A) any event of default under such Swap Contract as to which the Borrower or any Subsidiary is the Defaulting Party (as defined in such Swap Contract) or (B) any Termination Event (as so defined) under such Swap Contract as to which the Borrower or any Subsidiary is an Affected Party (as so defined) and, in either event, the Swap Termination Value owed by the Borrower or such Subsidiary as a result thereof is greater than the Threshold Amount; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Insolvency Proceedings, Etc.</u> Any Loan Party or any of its Subsidiaries institutes or consents to the institution of any proceeding under any Debtor Relief Law, or makes an assignment for the benefit of creditors; or applies for or consents to the appointment of any receiver, trustee, custodian, conservator, liquidator, rehabilitator, Examiner or similar officer for it or for all or any material part of its property; or any receiver, trustee, custodian, conservator, liquidator, rehabilitator, Examiner or similar officer is appointed without the application or consent of such Person and the appointment continues undischarged or unstayed for sixty (60) calendar days; or any proceeding under any Debtor Relief Law relating to any such Person or to all or any material part of its property is instituted without the consent of such Person and continues undismissed or unstayed for sixty (60) calendar days, or an order for relief is entered in any such proceeding; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Inability to Pay Debts; Attachment</u>. (i) Any Loan Party or any of its Subsidiaries becomes unable or admits in writing its inability or fails generally to pay its debts as they become due, or is declared to be unable to pay its debts under applicable Law, or (ii) any writ or warrant of attachment or execution or similar process is issued or levied against all or any material part of the property of any such Person and is not released, vacated or fully bonded within thirty (30) days after its issue or levy; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">97</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Judgments</u>. There is entered against any Loan Party or any Subsidiary (i) one or more final judgments or orders for the payment of money in an aggregate amount exceeding $[***] (to the extent not covered by independent third-party insurance as to which the insurer does not dispute coverage) or (ii) any one or more non-monetary final judgments that have, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect and, in either case, (A) enforcement proceedings are commenced by any creditor upon such judgment or order or (B) such judgment or order shall not have been vacated or discharged or stayed or bonded pending appeal within thirty (30) calendar days from entry thereof; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>ERISA</u>. (i) An ERISA Event occurs with respect to a Pension Plan or Multiemployer Plan which has resulted or could reasonably be expected to result in liability of any Loan Party under Title IV of ERISA to the Pension Plan, Multiemployer Plan or the PBGC in an aggregate amount in excess of the Threshold Amount, or (ii) the Borrower or any ERISA Affiliate fails to pay when due, after the expiration of any applicable grace period, any installment payment with respect to its withdrawal liability under Section 4201 of ERISA under a Multiemployer Plan in an aggregate amount in excess of the Threshold Amount; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Invalidity of Loan Documents</u>. Any Loan Document, at any time after its execution and delivery and for any reason other than as expressly permitted hereunder or thereunder, ceases to be in full force and effect; or any Loan Party or any other Person contests in any manner the validity or enforceability of any Loan Document; or any Loan Party denies that it has any or further liability or obligation under any Loan Document, or purports to revoke, terminate or rescind any Loan Document; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Material Adverse Effect</u>. There occurs any circumstance or circumstances that has had, either individually or in the aggregate, or could reasonably be expected, either individually or in the aggregate, to have a Material Adverse Effect; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Change of Control</u>. There occurs any Change of Control; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Invalidity of Subordination Provisions</u>. Any subordination provision in any document or instrument governing Indebtedness that is purported to be subordinated to the Obligations or any subordination provision in any subordination agreement that relates to any Indebtedness that is to be subordinated to the Obligations, or any subordination provision in any guaranty by any Loan Party of any such Indebtedness, shall cease to be in full force and effect, or any Person (including any holder of any such Indebtedness) shall contest in any manner the validity, binding nature or enforceability of any such provision; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Injunction</u>. Any court order enjoins, restrains, or prevents any Loan Party from conducting any material part of its business for a period of thirty (30) consecutive days during which a stay of enforcement of such court order, by reason of a pending appeal or otherwise, is not in effect; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Regulatory Matters</u>. If any of the following occurs: (i) the FDA, CMS, EMA, DEA, or any other Governmental Authority issues a letter or other written communication asserting that any approved Product lacks a Material Required Permit or does not comply with applicable Law, in each such case described in this <u>clause (</u><u>o</u><u>)</u>, that causes such Loan Party or its applicable Subsidiary to discontinue, materially adversely alter or suspend manufacturing, or cease distribution of any of its Material Products, or causes a delay in the manufacture or offering of any of its Material Products, that could reasonably be expected, either individually or in the aggregate, to result in a material adverse effect on any Product Development and Commercialization Activities; (ii) any involuntary or voluntary recall of any Material Product that could reasonably be expected, either individually or in the aggregate, to have a Material Adverse Effect; or (iii) any Loan Party or any Subsidiary enters into a settlement agreement with the FDA, CMS, EMA, DEA, or any other Governmental Authority that could reasonably be expected, either individually or in the aggregate, to have a Material Adverse Effect.; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">98</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Reserved]</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Third Party Payor Arrangements</u>. If any of the following occurs: a Loan Party or any officer, director, chief operating officer, chief financial officer, treasurer, secretary or senior vice president of a Loan Party (A) shall have been found guilty of an act of fraud or been convicted of a felony crime that relates to any services provided by any Loan Party to a Third Party Payor or in connection with a Third Party Payor Arrangement or (B) shall have been indicted for a felony crime relating to any services provided by any Loan Party to a Third Party Payor or in connection with a Third Party Payor Arrangement; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Overpayment</u>. If any Loan Party is found to have been overpaid by a Government Account Debtor by more than the Threshold Amount during any period covered by an audit conducted by such Government Account Debtor, and such Loan Party has not within thirty (30) days after its receipt of knowledge of such overpayment either (i) repaid or reserved for such overpayment in a manner reasonably acceptable to the Required Lenders or (ii) notified the applicable Government Account Debtor or Governmental Authority and requested a repayment schedule for such overpayment; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Material Products</u>. If any of the following occurs: (i) the FDA shall revoke, withdraw, suspend, cancel, materially adversely limit, terminate or materially adversely modify any approved Required Permit related to any Material Product; (ii) any Governmental Authority (other than the FDA) shall revoke, withdraw, suspend, cancel, materially limit, terminate or materially modify any approved Required Permit related to any Material Product (in each case, a &#8220;<u>Non-FDA Governmental Action</u>&#8221;) and, in any such case, Consolidated Revenues shall decrease by greater than [***], as assessed as at the end of each of the four fiscal quarters immediately following such Non-FDA Governmental Action by comparing Consolidated Revenues for the four fiscal quarter period most recently ended prior to such Non-FDA Governmental Action for which the Borrower was required to deliver financial statements pursuant to <u>Section 7.01(a)</u> or <u>(b)</u> as against Consolidated Revenues for the four fiscal quarter period ending on the applicable date of assessment; or (iii) any Safety Notice is issued or initiated in connection with any Material Product after approval by the FDA or any other Governmental Authority and Consolidated Revenues shall decrease by greater than [***], as assessed as at the end of each of the four fiscal quarters immediately following the issuance or initiation of such Safety Notice by comparing Consolidated Revenues for the four fiscal quarter period most recently ended prior to the issuance or initiation of such Safety Notice for which the Borrower was required to deliver financial statements pursuant to <u>Section 7.01(a)</u> or <u>(b)</u> as against Consolidated Revenues for the four fiscal quarter period ending on the applicable date of assessment;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Royalty Financing and Other Royalty Financings</u>. (i) The Borrower or any Subsidiary fails to pay within [***] after the same becomes due any amount owing under any Royalty Financing Document or any Other Royalty Financing Document, unless the amount of such payment is otherwise being disputed in good faith by the Borrower or such Subsidiary, in accordance with the terms of such Royalty Financing Document or Other Royalty Financing Documents, as applicable or (ii) any other material breach or default under any Royalty Financing Document or any Other Royalty Financing Document occurs and continues unremedied for more than thirty (30) days; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Public Securities Exchange</u>. The Borrower&#8217;s equity fails to remain registered with the SEC in good standing; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">99</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Delisting</u>. The Borrower fails to maintain at least one class of common shares of the Borrower which is subject to price quotations on a national stock exchange in the United States (such as NASDAQ, NYSE, AMEX or any successor thereto); or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Permitted License</u><u> and Non-Permitted Royalty Financing</u>. The Borrower or any Subsidiary enters into a Non-Permitted License or a Non-Permitted Royalty Financing.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">9.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Remedies Upon Event of Default</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">If any Event of Default occurs and is continuing, the Administrative Agent shall, at the request of, or may, with the consent of, the Required Lenders may take any or all of the following actions:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;declare the commitment of each Lender to make Loans to be terminated, whereupon such commitments and obligations shall be terminated;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;declare the unpaid principal amount of all outstanding Loans, all interest accrued and unpaid thereon, prepayment and repayment premiums thereto (if any) and exit fees and all other amounts owing or payable hereunder or under any other Loan Document to be immediately due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived by the Loan Parties; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;exercise on behalf of itself and the Lenders all rights and remedies available to the Administrative Agent and/or the Lenders under the Loan Documents;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"><u>provided</u>, <u>however</u>, that upon the occurrence of an Event of Default under <u>Section 9.01(f)</u> or <u>(g)</u>, the obligation of each Lender to make any Loans shall automatically terminate, the unpaid principal amount of all outstanding Loans and all interest, prepayment and repayment premiums, exit fees and other amounts as aforesaid shall automatically become due and payable, in each case without further act of the Administrative Agent or any Lender.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Upon the acceleration (including automatic acceleration triggered by any insolvency proceeding pursuant to <u>Section 9.01(f)</u>), all outstanding Notes, accrued and unpaid interest, the prepayment and repayment premiums required by <u>Section 2.03(d)</u>, the exit fee required by <u>Section 2.07(b)</u> and the other Obligations become immediately due and payable. If the Obligations are accelerated for any reason, the prepayment and repayment premiums required by <u>Section 2.03(d)</u> and the exit fee required by <u>Section 2.07(b)</u> will also be due and payable as though such Obligations were voluntarily prepaid and any discount on the Loans shall be deemed earned in full and, in each case, shall constitute part of the Obligations, in view of the impracticability and extreme difficulty of ascertaining actual damages and by mutual agreement of the parties as to a reasonable calculation of each Lender&#8217;s lost profits as a result thereof. Any prepayment or repayment premium required by <u>Section 2.03(d)</u> or the exit fee required by <u>Section 2.07(b)</u> payable pursuant to the preceding sentence shall be presumed to be the liquidated damages sustained by each Lender as the result of the early termination and the Loan Parties agree that it is reasonable under the circumstances currently existing. The prepayment and repayment premiums required by <u>Section 2.03(d)</u> and the exit fee required by <u>Section 2.07(b)</u> shall also be payable, and any discount on the Loans shall be deemed earned in full, in each case, in the event that the Obligations (and/or this Agreement) are satisfied or released by foreclosure (whether by power of judicial proceeding), deed in lieu of foreclosure or by any other means. TO THE EXTENT PERMITTED BY APPLICABLE LAW, THE BORROWER AND THE OTHER LOAN PARTIES EXPRESSLY WAIVE THE PROVISIONS OF ANY PRESENT OR FUTURE STATUTE OR LAW THAT PROHIBITS OR MAY PROHIBIT THE COLLECTION OF THE FOREGOING PREPAYMENT OR REPAYMENT PREMIUM, EXIT FEE AND ANY DISCOUNT ON THE LOANS IN CONNECTION WITH ANY SUCH ACCELERATION. The Borrower and the other Loan Parties expressly agree that (i) the prepayment and repayment premiums required by <u>Section 2.03(d)</u>, the exit fee required by <u>Section 2.07(b)</u> and discount on the Loans provided for herein, are reasonable and are the product of an arm&#8217;s length transaction between sophisticated business people, ably represented by counsel, (ii) the prepayment and repayment premiums required by <u>Section 2.03(d)</u>, the exit fee required by <u>Section 2.07(b)</u> and discount on the Loans, shall be payable notwithstanding the then prevailing market rates at the time payment is made, (iii) there has been a course of conduct between the Lenders and the Borrower and the other Loan Parties giving specific consideration in this transaction for such agreement to pay the prepayment and repayment premiums required by <u>Section 2.03(d)</u>, the exit fee required by <u>Section 2.07(b)</u> and discount on the Loans, (iv) the Borrower and the other Loan Parties shall be estopped hereafter from claiming differently than as agreed to in this paragraph and (v) the prepayment premium required by <u>Section 2.03(</u><u>d</u><u>)</u>, the exit fee required by <u>Section 2.07(b)</u> and any discount on the Loans represent a good faith, reasonable estimate and calculation of the lost profits or damages of the Lenders and that it would be impractical and extremely difficult to ascertain the actual amount of damages to the Lenders or profits lost by the Lenders as a result of any early termination. The Borrower and the other Loan Parties expressly acknowledge that their agreement to pay the prepayment and repayment premiums required by <u>Section 2.03(d)</u> and the exit fee required by <u>Section 2.0</u><u>7</u><u>(</u><u>b</u><u>)</u>, as herein described and discount on the Loans to the Lenders as herein described, is a material inducement to the Lenders to make the Loans hereunder.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">100</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">9.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Application of Funds</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">After the exercise of remedies provided for in <u>Section 9.02</u> (or after the Loans have automatically become immediately due and payable as set forth in the proviso to <u>Section 9.02</u>), any amounts received by any Lender or the Administrative Agent on account of the Obligations shall be applied by the Administrative Agent in the following order:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><u>First</u>, to payment of that portion of the Obligations constituting fees, indemnities, expenses and other amounts (including fees, charges and disbursements of counsel to the Administrative Agent and amounts payable under <u>Articles III</u> and <u>X</u>) payable to the Administrative Agent in its capacity as such;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><u>Second</u>, to payment of that portion of the Obligations constituting fees, indemnities and other amounts (other than principal, interest, prepayment and repayment premiums and exit fees) payable to the Secured Parties (other than the Administrative Agent) (including fees, charges and disbursements of counsel to the respective Secured Parties (other than the Administrative Agent)) arising under the Loan Documents and amounts payable under <u>Articles III and X</u>, ratably among them in proportion to the respective amounts described in this clause <u>Second</u> payable to them;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><u>Third</u>, to payment of that portion of the Obligations constituting accrued and unpaid interest on and prepayment and repayment premiums and the exit fee with respect to the Loans, ratably among the Lenders in proportion to the respective amounts described in this clause <u>Third</u> held by them;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><u>Fourth</u>, to payment of that portion of the Obligations constituting accrued and unpaid principal of the Loans, ratably among the Lenders in proportion to the respective amounts described in this clause <u>Fourth</u> held by them; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><u>Last</u>, the balance, if any, after all of the Obligations have been indefeasibly paid in full, to the Borrower or as otherwise required by Law.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">9.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Cure Right</u>. Notwithstanding anything to the contrary contained herein, in the event the Loan Parties fail to comply with the minimum Orladeyo Consolidated U.S. Net Product Sales requirement set forth in <u>Section 8.17</u> as of any Test Date, the Borrower shall have a one-time right (the &#8220;<u>Cure Right</u>&#8221;), to repay in full the entire amount of the Term C Loans outstanding at such time together with all accrued and unpaid interest thereon plus the prepayment or repayment premium required by <u>Section 2.03(d)</u> and the exit fee required under <u>Section 2.07(b)</u> plus any other fees or amounts payable hereunder at such time. The exercise of the Cure Right shall be subject to the following conditions: (a) the Borrower shall have delivered to the Administrative Agent irrevocable written notice of the Borrower&#8217;s intent to exercise the Cure Right with respect to such Test Date not later than 9:00 a.m. on the date at least five (5) Business Days in advance the Borrower making the Cure Right payment and (b) such Cure Right payment shall be made by the Borrower no later than thirty (30) days after such Test Date. Following the exercise of the Cure Right and the repayment in full pursuant to this <u>Section 9.04</u>, no Default or Event of Default under <u>Section 9.01(b)</u> for the failure to perform the covenant contained in <u>Section 8.17</u> shall be deemed to have existed for so long as, on a pro forma basis, the Loan Parties are in compliance with the financial covenant set forth in <u>Section 8.16(</u><u>iv</u><u>)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">101</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="text-transform:uppercase">Article&nbsp;</font>X<br>
<br>
INCREASED COSTS AND INABILITY TO DETERMINE RATES</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">10.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Increased Costs, Etc.</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Increased Costs Generally.</u> If any Change in Law shall:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;impose, modify or deem applicable any reserve, special deposit, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account of, or credit extended or participated in by, any Lender;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;subject any Recipient to any Taxes (other than (A) Indemnified Taxes and (B) Excluded Taxes) on its loans, loan principal, commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;impose on any Lender any other condition, cost or expense (other than Taxes) affecting this Agreement; and the result of any of the foregoing shall be to increase the cost to such Lender of making or maintaining any Loan (or of maintaining its obligation to make any such Loan), then, upon written demand of such Lender, the Borrower will pay to such Lender, as the case may be, such additional amount or amounts as will compensate such Lender, as the case may be, for such additional costs incurred or reduction suffered.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Capital Requirements</u>. If any Lender determines that any Change in Law affecting such Lender or any Lending Office of such Lender or such Lender&#8217;s holding company, if any, regarding capital or liquidity requirements has or would have the effect of reducing the rate of return on such Lender&#8217;s capital or on the capital of such Lender&#8217;s holding company, if any, as a consequence of this Agreement, the Commitments of such Lender or the Loans made by such Lender to a level below that which such Lender or such Lender&#8217;s holding company could have achieved but for such Change in Law (taking into consideration such Lender&#8217;s policies and the policies of such Lender&#8217;s holding company with respect to capital adequacy), then from time to time the Borrower will pay to such Lender, as the case may be, such additional amount or amounts as will compensate such Lender or such Lender&#8217;s holding company for any such reduction suffered.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certificates for Reimbursement.</u> A certificate of a Lender setting forth the amount or amounts necessary to compensate such Lender or its holding company, as the case may be, as specified in <u>clause (a)</u> or <u>(b)</u> of this Section and delivered to the Borrower shall be conclusive absent manifest error. The Borrower shall pay such Lender the amount shown as due on any such certificate within ten (10) days after receipt thereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">102</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Delay in Requests.</u> Failure or delay on the part of any Lender to demand compensation pursuant to the foregoing provisions of this Section shall not constitute a waiver of such Lender&#8217;s right to demand such compensation, <u>provided</u>, <u>that</u>, the Borrower shall not be required to compensate a Lender pursuant to the foregoing provisions of this Section for any increased costs incurred or reductions suffered more than nine (9) months prior to the date that such Lender notifies the Borrower of the Change in Law giving rise to such increased costs or reductions and of such Lender&#8217;s intention to claim compensation therefor (except that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the nine-month period referred to above shall be extended to include the period of retroactive effect thereof).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">10.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Mitigation Obligations; Replacement of Lenders</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Designation of a Different Lending Office</u>. If any Lender requests compensation under <u>Section 10.0</u><u>1</u> or requires the Borrower to pay any Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to <u>Section 3.01</u> or if any Lender gives a notice pursuant to <u>Section 10.0</u><u>4</u>, then at the request of the Borrower such Lender shall, as applicable, use reasonable efforts to designate a different Lending Office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or affiliates, if, in the judgment of such Lender, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to <u>Section 3.01</u> or <u>10.01</u>, as the case may be, in the future, or eliminate the need for the notice pursuant to <u>Section </u><u>10</u><u>.04</u>, as applicable, and (ii) in each case, would not subject such Lender, as the case may be, to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender. The Borrower hereby agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Replacement of Lenders.</u> If any Lender requests compensation under <u>Section 10.01</u>, or if the Borrower is required to pay any Taxes or additional amounts to any Lender or any Governmental Authority for the account of any Lender pursuant to <u>Section 3.01</u> and, in each case, such Lender has declined or is unable to designate a different Lending Office in accordance with <u>Section 10.02(a)</u>, the Borrower may replace such Lender in accordance with <u>Section 12.13.</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">10.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Inability to Determine Rates</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If prior to the commencement of any Interest Period:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:67.5pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Administrative Agent determines (which determination shall be conclusive absent manifest error) that (1) adequate and reasonable means do not exist for ascertaining Three-Month LIBOR for such Interest Period; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:67.5pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the Administrative Agent is advised by the Required Lenders that Three-Month LIBOR for such Interest Period will not adequately and fairly reflect the cost to such Lenders of making or maintaining their Loans for such Interest Period;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">then the Administrative Agent shall give notice thereof to the Borrower and the Lenders by as promptly as practicable thereafter. In the event of any such determination, until the Administrative Agent has advised the Borrower that the circumstances giving rise to such notice no longer exist, Three-Month LIBOR shall be determined by the Administrative Agent solely by reference to clause&nbsp;(ii) of the definition of Three-Month LIBOR.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">103</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Benchmark Replacement</u>. Notwithstanding anything to the contrary herein or in any other Loan Document, but without limiting <u>Section </u><u>10</u><u>.03(a)</u> above, upon the occurrence of a Benchmark Transition Event or an Early Opt-in Election, as applicable, the Administrative Agent and the Borrower may amend this Agreement to replace Three-Month LIBOR with a Benchmark Replacement. Any such amendment with respect to a Benchmark Transition Event will become effective at 5:00 p.m. on the fifth (5th) Business Day after the Administrative Agent has posted such proposed amendment to all Lenders and the Borrower so long as the Administrative Agent has not received, by such time, written notice of objection to such amendment from Lenders comprising the Required Lenders. Any such amendment with respect to an Early Opt-in Election will become effective on the date that Lenders comprising the Required Lenders have delivered to the Administrative Agent written notice that such Required Lenders accept such amendment. No replacement of Three-Month LIBOR with a Benchmark Replacement pursuant to this <u>Section </u><u>10.03</u> will occur prior to the applicable Benchmark Transition Start Date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Benchmark Replacement Conforming Changes</u>. In connection with the implementation of a Benchmark Replacement, the Administrative Agent will have the right to make Benchmark Replacement Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Benchmark Replacement Conforming Changes will become effective without any further action or consent of any other party to this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices: Standards for Decisions and Determinations</u>. The Administrative Agent will promptly notify the Borrower and the Lenders of (i) any occurrence of a Benchmark Transition Event or an Early Opt-in Election, as applicable, and its related Benchmark Replacement Date and Benchmark Transition Start Date, (ii) the implementation of any Benchmark Replacement, (iii) the effectiveness of any Benchmark Replacement Conforming Changes and (iv) the commencement or conclusion of any Benchmark Unavailability Period. Any determination, decision or election that may be made by the Administrative Agent or Lenders pursuant to this <u>Section</u><u> 10.03</u>, including any determination with respect to a tenor, rate or adjustment or of the occurrence or non-occurrence of an event, circumstance or date and any decision to take or refrain from taking any action, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from any other party hereto, except, in each case, as expressly required pursuant to this <u>Section 10.03</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Benchmark Unavailability Period</u>. Upon the Borrower&#8217;s receipt of notice of the commencement of a Benchmark Unavailability Period, Three-Month LIBOR shall be determined by the Administrative Agent solely by reference to clause&nbsp;(ii) of the definition of Three-Month LIBOR during such Benchmark Unavailability Period.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Defined Terms</u>. As used in this <u>Section</u><u> 10.03</u>:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Benchmark Replacement</u>&#8221; means the sum of: (a) the alternate benchmark rate (which may include Term SOFR) that has been selected by the Administrative Agent and the Borrower giving due consideration to (i) any selection or recommendation of a replacement rate or the mechanism for determining such a rate by the Relevant Governmental Body or (ii) any evolving or then-prevailing market convention for determining a rate of interest as a replacement to Three-Month LIBOR for U.S. dollar-denominated syndicated credit facilities and (b) the Benchmark Replacement Adjustment; provided that, if the Benchmark Replacement as so determined would be less than 1.75% per annum, the Benchmark Replacement will be deemed to be 1.75% per annum for the purposes of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">104</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Benchmark Replacement Adjustment</u>&#8221; means, with respect to any replacement of Three-Month LIBOR with an Unadjusted Benchmark Replacement for each applicable Interest Period, the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected by the Administrative Agent and the Borrower giving due consideration to (i) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of Three-Month LIBOR with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental Body or (ii) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of Three-Month LIBOR with the applicable Unadjusted Benchmark Replacement for U.S. dollar-denominated syndicated credit facilities at such time.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:39.6pt;">&#8220;<u>Benchmark Replacement Conforming Changes</u>&#8221; means, with respect to any Benchmark Replacement, any technical, administrative or operational changes (including changes to the definition of &#8220;Interest Period,&#8221; timing and frequency of determining rates and making payments of interest and other administrative matters) that the Administrative Agent decides may be appropriate to reflect the adoption and implementation of such Benchmark Replacement and to permit the administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the Administrative Agent decides that adoption of any portion of such market practice is not administratively feasible or if the Administrative Agent determines that no market practice for the administration of the Benchmark Replacement exists, in such other manner of administration as the Administrative Agent decides is reasonably necessary in connection with the administration of this Agreement).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:39.6pt;">&#8220;<u>Benchmark Replacement Date</u>&#8221; means the earlier to occur of the following events with respect to Three-Month LIBOR:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:22.5pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in the case of clause (1) or (2) of the definition of &#8220;Benchmark Transition Event,&#8221; the later of (a) the date of the public statement or publication of information referenced therein and (b) the date on which the administrator of Three-Month LIBOR permanently or indefinitely ceases to provide Three-Month LIBOR; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:22.5pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in the case of clause (3) of the definition of &#8220;Benchmark Transition Event,&#8221; the date of the public statement or publication of information referenced therein.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:39.6pt;">&#8220;<u>Benchmark Transition Event</u>&#8221; means the occurrence of one or more of the following events with respect to Three-Month LIBOR:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:22.5pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a public statement or publication of information by or on behalf of the administrator of Three-Month LIBOR announcing that such administrator has ceased or will cease to provide Three-Month LIBOR, permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide Three-Month LIBOR;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:22.5pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a public statement or publication of information by the regulatory supervisor for the administrator of Three-Month LIBOR, the U.S. Federal Reserve System, an insolvency official with jurisdiction over the administrator for Three-Month LIBOR, a resolution authority with jurisdiction over the administrator for Three-Month LIBOR or a court or an entity with similar insolvency or resolution authority over the administrator for Three-Month LIBOR, which states that the administrator of Three-Month LIBOR has ceased or will cease to provide Three-Month LIBOR permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide Three-Month LIBOR; or</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">105</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:22.5pt;">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a public statement or publication of information by the regulatory supervisor for the administrator of Three-Month LIBOR announcing that Three-Month LIBOR is no longer representative.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:39.6pt;">&#8220;<u>Benchmark Transition Start Date</u>&#8221; means (a) in the case of a Benchmark Transition Event, the earlier of (i) the applicable Benchmark Replacement Date and (ii) if such Benchmark Transition Event is a public statement or publication of information of a prospective event, the 90th day prior to the expected date of such event as of such public statement or publication of information (or if the expected date of such prospective event is fewer than 90 days after such statement or publication, the date of such statement or publication) and (b) in the case of an Early Opt-in Election, the date specified by the Administrative Agent or the Required Lenders, as applicable, by notice to the Borrower, the Administrative Agent (in the case of such notice by the Required Lenders) and the Lenders.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Benchmark Unavailability Period</u>&#8221; means, if a Benchmark Transition Event and its related Benchmark Replacement Date have occurred with respect to Three-Month LIBOR and solely to the extent that Three-Month LIBOR has not been replaced with a Benchmark Replacement, the period (x) beginning at the time that such Benchmark Replacement Date has occurred if, at such time, no Benchmark Replacement has replaced Three-Month LIBOR for all purposes hereunder in accordance with this <u>Section</u><u> 10.03</u> and (y) ending at the time that a Benchmark Replacement has replaced Three-Month LIBOR for all purposes hereunder pursuant to this <u>Section</u><u> 10.03</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Early Opt-in Election</u>&#8221; means the occurrence of:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) a determination by the Administrative Agent or (ii) a notification by the Required Lenders to the Administrative Agent (with a copy to the Borrower) that the Required Lenders have determined that U.S. dollar-denominated syndicated credit facilities being executed at such time, or that include language similar to that contained in this <u>Section</u><u> 10.03</u> are being executed or amended, as applicable, to incorporate or adopt a new benchmark interest rate to replace Three-Month LIBOR, and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:18pt;">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the election by the Administrative Agent or (ii) the election by the Required Lenders to declare that an Early Opt-in Election has occurred and the provision, as applicable, by the Administrative Agent of written notice of such election to the Borrower and the Lenders or by the Required Lenders of written notice of such election to the Administrative Agent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Federal Reserve Bank of New </u><u>York</u><u>&#8217;</u><u>s </u><u>Website</u>&#8221; means the website of the Federal Reserve Bank of New York at http://www.newyorkfed.org, or any successor source.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Relevant Governmental Body</u>&#8221; means the Federal Reserve Board and/or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the Federal Reserve Board and/or the Federal Reserve Bank of New York or any successor thereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>SOFR</u>&#8221; with respect to any day means the secured overnight financing rate published for such day by the Federal Reserve Bank of New York, as the administrator of the benchmark, (or a successor administrator) on the Federal Reserve Bank of New York&#8217;s Website.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Term SOFR</u>&#8221; means the forward-looking term rate based on SOFR that has been selected or recommended by the Relevant Governmental Body.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">106</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:28.8pt;margin-top:0pt;text-align:justify;text-indent:36pt;">&#8220;<u>Unadjusted Benchmark Replacement</u>&#8221; means the Benchmark Replacement excluding the Benchmark Replacement Adjustment.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">10.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Illegality</u>. If any Lender determines that any Law has made it unlawful, or that any Governmental Authority has asserted that it is unlawful, for any Lender to make or maintain any Loan whose interest is determined by reference to Three-Month LIBOR, or to determine or charge interest rates based upon Three-Month LIBOR, or any Governmental Authority has imposed material restrictions on the authority of such Lender to purchase or sell, or to take deposits of, Dollars in the London interbank market, then, on notice thereof by such Lender to the Borrower through the Administrative Agent, (a) any obligation of such Lender to make or maintain or charge interest with respect to any such Loan whose interest is determined by reference to Three-Month LIBOR shall be suspended, and (b) the interest rate on the Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to <u>clause (y)</u> in the definition of Three-Month LIBOR, in each case until such Lender notifies the Administrative Agent and the Borrower that the circumstances giving rise to such determination no longer exist. Upon receipt of such notice by the Administrative Agent and the Borrower, all Loans of such Lender the interest rate on which is determined by reference to <u>clause (y)</u> in the definition of Three-Month LIBOR shall be determined by the Administrative Agent without reference to <u>clause (y)</u> in the definition of Three-Month LIBOR, until such Lender notifies the Administrative Agent and the Borrower that the circumstance giving rise to such determination no longer exist.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">10.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Survival</u>. All of the Borrower&#8217;s obligations under this Article X shall survive termination of the Commitments, prepayment or repayment of all Obligations hereunder and resignation of the Administrative Agent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="text-transform:uppercase">Article&nbsp;</font>XI<br>
<br>
ADMINISTRATIVE AGENT</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">11.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Appointment and Authority</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each of the Lenders hereby irrevocably appoints Athyrium Opportunities III Co-Invest 1 LP, a Delaware limited partnership, to act on its behalf as the Administrative Agent hereunder and under the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions, powers and discretion as are incidental thereto. The provisions of this Article are solely for the benefit of the Administrative Agent and the Lenders, and neither the Borrower nor any other Loan Party shall have rights as a third-party beneficiary of any of such provisions. It is understood and agreed that the use of the term &#8220;agent&#8221; herein or in any other Loan Documents (or any other similar term) with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law. Instead such term is used as a matter of market custom, and is intended to create or reflect only an administrative relationship between contracting parties.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Administrative Agent shall also act as the &#8220;collateral agent&#8221; under the Loan Documents, and each of the Lenders hereby irrevocably appoints and authorizes the Administrative Agent to act as the agent of such Lender for purposes of acquiring, holding and enforcing any and all Liens on Collateral granted by any of the Loan Parties to secure any of the Obligations, together with such actions, powers and discretion as are incidental thereto. In this connection, the Administrative Agent, as &#8220;collateral agent&#8221; and any co-agents, sub-agents and attorneys-in-fact appointed by the Administrative Agent pursuant to <u>Section 11.05</u> for purposes of holding or enforcing any Lien on the Collateral (or any portion thereof) granted under the Collateral Documents, or for exercising any rights and remedies thereunder at the direction of the Administrative Agent, shall be entitled to the benefits of all provisions of this <u>Article XI</u> and <u>Article XII</u>, as though such co-agents, sub-agents and attorneys-in-fact were the &#8220;Administrative Agent&#8221; under the Loan Documents as if set forth in full herein with respect thereto. The Administrative Agent is hereby authorized to enter into the Intercreditor Agreement and any other intercreditor agreement or subordination agreement contemplated by the terms of this Agreement, and each Lender agrees to be bound by the terms of the Intercreditor Agreement and such other intercreditor agreement or subordination agreement and directs the Administrative Agent to enter into the Intercreditor Agreement and such other intercreditor agreement or subordination agreement, in each case, on behalf of the Secured Parties and agrees that the Administrative Agent may take such actions on its behalf as is contemplated by the terms of the Intercreditor Agreement or such other intercreditor agreement or subordination agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">107</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">11.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Rights as a Lender</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Person serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent, and the term &#8220;Lender&#8221; or &#8220;Lenders&#8221; shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity. Such Person and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with any Loan Party or any Subsidiary or other Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">11.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exculpatory Provisions</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Administrative Agent shall not have any duties or obligations except those expressly set forth herein and in the other Loan Documents, and its duties hereunder shall be administrative in nature. Without limiting the generality of the foregoing, the Administrative Agent:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in the other Loan Documents), <u>provided</u>, <u>that</u>, the Administrative Agent shall not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent to liability or that is contrary to any Loan Document or applicable law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any Debtor Relief Law or that may affect a forfeiture, modification or termination of property of a Defaulting Lender in violation of any Debtor Relief Law; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shall not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to any Loan Party or any of its Affiliates that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Administrative Agent shall not be liable for any action taken or not taken by it (i) with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or as the Administrative Agent shall believe in good faith shall be necessary, under the circumstances as provided in <u>Section 12.01</u> and <u>Section 9.02</u>) or (ii) in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and non-appealable judgment. The Administrative Agent shall be deemed not to have knowledge of any Default unless and until notice describing such Default is given in writing to the Administrative Agent by the Borrower or a Lender.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">108</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Administrative Agent shall not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in <u>Article V</u> or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Administrative Agent.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">11.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reliance by Administrative Agent</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Administrative Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of a Loan, that by its terms must be fulfilled to the satisfaction of a Lender, the Administrative Agent may presume that such condition is satisfactory to such Lender unless the Administrative Agent shall have received notice to the contrary from such Lender prior to the making of such Loan. The Administrative Agent may consult with legal counsel (who may be counsel for the Loan Parties), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">11.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Delegation of Duties</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any and all of its duties and exercise its rights and powers by or through their respective Related Parties. The exculpatory provisions of this Article shall apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and shall apply to their respective activities in connection with the syndication of the credit facilities provided for herein as well as activities as Administrative Agent. The Administrative Agent shall not be responsible for the negligence or misconduct of any sub-agents except to the extent that a court of competent jurisdiction determines in a final and non-appealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the selection of such sub-agents.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">11.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Resignation of Administrative Agent</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Administrative Agent may resign as Administrative Agent at any time by giving thirty (30) days advance notice thereof to the Lenders and the Borrower and, thereafter, the retiring Administrative Agent shall be discharged from its duties and obligations hereunder. Upon any such resignation, the Required Lenders shall have the right, subject to the approval of the Borrower (so long as no Event of Default has occurred and is continuing; such approval not to be unreasonably withheld), to appoint a successor Administrative Agent. If no successor Administrative Agent shall have been so appointed by the Required Lenders, been approved (so long as no Event of Default has occurred and is continuing) by the Borrower or have accepted such appointment within thirty (30) days after the Administrative Agent&#8217;s giving of notice of resignation, then the Administrative Agent may, on behalf of the Lenders, appoint a successor Administrative Agent reasonably acceptable to the Borrower (so long as no Default or Event of Default has occurred and is continuing). Upon the acceptance of any appointment as Administrative Agent hereunder by a successor Administrative Agent, such successor Administrative Agent shall thereupon succeed to and become vested with all rights, powers, privileges and duties of the retiring Administrative Agent. After any retiring Administrative Agent&#8217;s resignation hereunder as Administrative Agent, the provisions of this <u>Section 11.06</u> shall continue in effect for its benefit in respect of any actions taken or omitted to be taken by it while it was acting as Administrative Agent. If no successor has accepted appointment as Administrative Agent by the date which is thirty (30) days following a retiring Administrative Agent&#8217;s notice of resignation, the retiring Administrative Agent&#8217;s resignation shall nevertheless thereupon become effective and the Required Lenders shall perform all of the duties of the Administrative Agent hereunder until such time, if any, as the Required Lenders appoint a successor agent as provided for above. In the event that a new Administrative Agent is appointed and such Administrative Agent is not an Affiliate of the holders of a majority in interest of the Loans, then the Borrower shall agree to pay to such Administrative Agent the fees and expenses (such fees to be payable annually in advance) that such Administrative Agent may reasonably request in connection with its appointment and service.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">109</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">11.07&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Non-Reliance on Administrative Agent and Other Lenders</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Each Lender acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that it will, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">11.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Administrative Agent May File Proofs of Claim</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">In case of the pendency of any receivership, insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other judicial proceeding relative to any Loan Party, the Administrative Agent (irrespective of whether the principal of any Loan shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have made any demand on the Borrower) shall be entitled and empowered, by intervention in such proceeding or otherwise:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and the Administrative Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders and the Administrative Agent under <u>Section 12.04</u>) allowed in such judicial proceeding; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">110</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such payments directly to the Lenders, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due the Administrative Agent under <u>Section 12.04</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Nothing contained herein shall be deemed to authorize the Administrative Agent to authorize or consent to or accept or adopt on behalf of any Lender any plan of reorganization, arrangement, adjustment or composition affecting the Obligations or the rights of any Lender or to authorize the Administrative Agent to vote in respect of the claim of any Lender in any such proceeding.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">11.09&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Collateral and Guaranty Matters</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">The Lenders irrevocably authorize the Administrative Agent, at its option and in its discretion,</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to release any Lien on any Collateral granted to or held by the Administrative Agent under any Loan Document (i) upon payment in full of all Obligations (other than contingent indemnification obligations for which no claim has been asserted) under the Loan Documents and the termination of all unused Commitments, (ii) that is sold or otherwise disposed of or to be sold or otherwise disposed of as part of or in connection with any sale or other Disposition permitted hereunder or any Involuntary Disposition, or (iii) as approved in accordance with <u>Section 12.01</u>;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to subordinate any Lien on any property granted to or held by the Administrative Agent under any Loan Document to the holder of any Lien on such property that is permitted by <u>Section 8.01(i)</u>; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to release any Guarantor from its obligations under the Guaranty (i) if such Person ceases to be a Subsidiary as a result of a transaction permitted under the Loan Documents or (ii) upon payment in full of all Obligations (other than contingent indemnification obligations for which no claim has been asserted) under the Loan Documents and the termination of all unused Commitments.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Upon request by the Administrative Agent at any time, the Required Lenders will confirm in writing the Administrative Agent&#8217;s authority to release or subordinate its interest in particular types or items of property, or to release any Guarantor from its obligations under the Guaranty, pursuant to this <u>Section 11.09</u>. At any time that a Loan Party desires the Administrative Agent to take any action pursuant to this <u>Section 11.09</u>, such Loan Party shall deliver a certificate signed by a Responsible Officer of such Loan Party stating that the action is permitted pursuant to this <u>Section 11.09</u> and the terms of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;">The Administrative Agent shall not be responsible for or have a duty to ascertain or inquire into any representation or warranty regarding the existence, value or collectability of the Collateral, the existence, priority or perfection of the Administrative Agent&#8217;s Lien thereon, or any certificate prepared by any Loan Party in connection therewith, nor shall the Administrative Agent be responsible or liable to the Lenders for any failure to monitor or maintain any portion of the Collateral.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">111</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><font style="text-transform:uppercase">Article&nbsp;</font>XII<br>
<br>
MISCELLANEOUS</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Amendments, Etc.</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">No amendment or waiver of any provision of this Agreement or any other Loan Document, and no consent to any departure by the Borrower or any other Loan Party therefrom, shall be effective unless in writing signed by the Required Lenders and the Borrower or the applicable Loan Party, as the case may be, and acknowledged by the Administrative Agent, and each such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given; <u>provided</u>, <u>further</u>, <u>that</u>:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;no such amendment, waiver or consent shall:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;extend or increase the Commitment of a Lender (or reinstate any Commitment terminated pursuant to <u>Section 9.02</u>) without the written consent of such Lender whose Commitment is being extended or increased (it being understood and agreed that a waiver of any condition precedent set forth in <u>Section 5.02</u> or of any Default or a mandatory reduction in Commitments is not considered an extension or increase in Commitments of any Lender);</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;postpone any date fixed by this Agreement or any other Loan Document for any payment of principal (excluding mandatory repayments and prepayments), interest, prepayment or repayment premiums, the exit fee, fees or other amounts due to the Lenders (or any of them) or any scheduled or mandatory reduction of the Commitments hereunder or under any other Loan Document without the written consent of each Lender entitled to receive such payment or whose Commitments are to be reduced;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;reduce the principal of, the rate of interest specified herein on or the prepayment or repayment premiums or exit fees specified herein for any Loan, or any fees or other amounts payable hereunder or under any other Loan Document without the written consent of each Lender entitled to receive such payment of principal, interest, fees or other amounts; <u>provided</u>, <u>however</u>, <u>that</u>, only the consent of the Required Lenders shall be necessary to amend the definition of &#8220;Default Rate&#8221; or to waive any obligation of the Borrower to pay interest at the Default Rate;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;change any provision of this <u>Section 12.01(a)</u>, <u>Section</u><u> 2.11</u>, the definition of &#8220;Required Lenders,&#8221; change the waterfall set forth in <u>Section 9.03</u> or otherwise or have the effect of changing the priority or pro rata treatment of any payments (including voluntary and mandatory repayments and prepayments), Liens, proceeds of Collateral or reductions in Commitments (including as a result in whole or in part of allowing the issuance or incurrence, pursuant to this Agreement or otherwise, of new loans or other Indebtedness having any priority over any of the Obligations in respect of payments, Liens, Collateral or proceeds of Collateral, in exchange for any Obligations or otherwise), in each case, without the written consent of each Lender directly affected thereby;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;release all or substantially all of the Collateral without the written consent of each Lender directly affected thereby, except to the extent the release of the Collateral is expressly permitted by <u>Section 11.09</u> (in which case such release may be made by the Administrative Agent acting alone);</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;release the Borrower or, except in connection with a merger, amalgamation or consolidation permitted under <u>Section 8.04</u>, all or substantially all of the Guarantors without the written consent of each Lender directly affected thereby, except to the extent the release of any Guarantor is permitted pursuant to <u>Section 11.09</u> (in which case such release may be made by the Administrative Agent acting alone);</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">112</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;advance the date fixed for, or increase, any scheduled installment of principal due to any of the Lenders under any Loan Document, in each case, without the written consent of each Lender directly affected thereby;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;">it being agreed that (X) all Lenders shall be deemed to be directly and adversely affected by an amendment, waiver or supplement described in the preceding clause (iv), (v), (vi) or (vii) and (Y) notwithstanding anything to the contrary in the preceding clause (X), only those Lenders that have not been provided a reasonable opportunity, as determined in the good faith judgment of Administrative Agent, to receive the most-favorable treatment under or in connection with the applicable amendment, waiver or supplement described in the preceding clause (iv), (v), (vi) or (vii) (other than the right to receive customary administrative agency, arranging, underwriting and other similar fees) that is provided to any other Person, including the opportunity to participate on a pro rata basis on the same terms in any new loans or other Indebtedness permitted to be issued as a result of such amendment, waiver or supplement, shall be deemed to be directly and adversely affected by such amendment, waiver or supplement; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;unless also signed by the Administrative Agent, no amendment, waiver or consent shall affect the rights or duties of the Administrative Agent under this Agreement or any other Loan Document; <u>provided, however, that,</u> notwithstanding anything to the contrary herein, (i) no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder (and any amendment, waiver or consent which by its terms requires the consent of all Lenders or each affected Lender may be effected with the consent of the applicable Lenders other than Defaulting Lenders), except that (x) the Commitment of any Defaulting Lender may not be increased or extended without the consent of such Lender and (y) any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender that by its terms affects any Defaulting Lender more adversely than other affected Lenders shall require the consent of such Defaulting Lender, (ii) each Lender is entitled to vote as such Lender sees fit on any bankruptcy reorganization plan that affects the Loans, and each Lender acknowledges that the provisions of Section 1126(c) of the Bankruptcy Code of the United States supersedes the unanimous consent provisions set forth herein and (iii) the Required Lenders shall determine whether or not to allow a Loan Party to use cash collateral in the context of a bankruptcy or insolvency proceeding and such determination shall be binding on all of the Lenders.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Notwithstanding anything to the contrary contained herein, (i) the Administrative Agent and the Borrower may make amendments contemplated by <u>Section 10.03</u>, (ii) the Borrowers and the Administrative Agent may, without the input or consent of any other Lender, make technical, administrative or operational amendments to the Loan Documents as are advisable in their good faith judgment in connection with (A) the addition of Non-U.S. Subsidiaries as Loan Parties and (B) the inclusion of the assets of such Non-U.S. Subsidiaries as Collateral, (iii) if the Administrative Agent and the Borrower have jointly identified an obvious error or any error or omission of a technical or immaterial nature, in each case, in any provision of the Loan Documents (including, for the avoidance of doubt, any exhibit, schedule or annex thereto), then the Administrative Agent and the Borrower shall be permitted to amend such provision and such amendment shall become effective without any further action or consent of any other party to any Loan Document.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.02&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices and Other Communications; Facsimile Copies</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices Generally</u>. Except in the case of notices and other communications expressly permitted to be given by telephone (and except as provided in <u>subsection (b)</u> below), all notices and other communications provided for herein shall be in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by facsimile as follows, and all notices and other communications expressly permitted hereunder to be given by telephone shall be made to the applicable telephone number, as follows:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">113</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if to the Borrower or any other Loan Party or the Administrative Agent, to the address, facsimile number, electronic mail address or telephone number specified for such person on <u>Schedule 12.02</u>; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if to any other Lender, to the address, facsimile number, electronic mail address or telephone number of its Lending Office (whether specified on <u>Schedule 12.02</u> or separately specified to the Borrower and the Administrative Agent).</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Notices and other communications sent by hand or overnight courier service, or mailed by certified or registered mail, shall be deemed to have been given when received; notices and other communications sent by facsimile shall be deemed to have been given when sent (except that, if not given during normal business hours for the recipient, shall be deemed to have been given at the opening of business on the next Business Day for the recipient). Notices and other communications delivered through electronic communications to the extent provided in <u>subsection (b)</u> below, shall be effective as provided in such <u>subsection (b)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Electronic Communications</u>. Notices and other communications to the Lenders hereunder may be delivered or furnished by electronic communication (including e-mail and Internet or intranet websites) pursuant to procedures approved by the Administrative Agent, <u>provided</u>, <u>that</u>, the foregoing shall not apply to notices to any Lender pursuant to <u>Article II</u> if such Lender has notified the Administrative Agent that it is incapable of receiving notices under such Article by electronic communication. The Administrative Agent or the Borrower may each, in its discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it, <u>provided</u>, <u>that</u>, approval of such procedures may be limited to particular notices or communications.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Unless the Administrative Agent otherwise prescribes, (i) notices and other communications sent to an e-mail address shall be deemed received upon the sender&#8217;s receipt of an acknowledgement from the intended recipient (such as by the &#8220;return receipt requested&#8221; function, as available, return e-mail or other written acknowledgement), and (ii) notices or communications posted to an Internet or intranet website shall be deemed received upon the deemed receipt by the intended recipient at its e-mail address as described in the foregoing <u>clause (i)</u> of notification that such notice or communication is available and identifying the website address therefor; <u>provided</u>, <u>that</u>, for both <u>clauses (i)</u> and <u>(ii)</u>, if such notice, email or other communication is not sent during the normal business hours of the recipient, such notice, email or communication shall be deemed to have been sent at the opening of business on the next business day for the recipient.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Change of Address, Etc</u>. Each of the Borrower, other Loan Parties, the Lenders and the Administrative Agent may change its address, facsimile or telephone number for notices and other communications hereunder by notice to the other parties hereto. In addition, each Lender agrees to notify the Administrative Agent from time to time to ensure that the Administrative Agent has on record (i) an effective address, contact name, telephone number, facsimile number and electronic mail address to which notices and other communications may be sent and (ii) accurate wire instructions for such Lender.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reliance by Administrative Agent and Lenders</u>.<b> </b>The Administrative Agent and the Lenders shall be entitled to rely and act upon any notices (including telephonic or electronic Loan Notices) purportedly given by or on behalf of any Loan Party even if (i) such notices were not made in a manner specified herein, were incomplete or were not preceded or followed by any other form of notice specified herein, or (ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof. The Loan Parties shall indemnify the Administrative Agent, each Lender and the Related Parties of each of them from all losses, costs, expenses and liabilities resulting from the reliance by such Person on each notice purportedly given by or on behalf of a Loan Party. All telephonic notices to and other telephonic communications with the Administrative Agent may be recorded by the Administrative Agent, and each of the parties hereto hereby consents to such recording.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">114</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.03&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Waiver; Cumulative Remedies; Enforcement</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">No failure by any Lender or the Administrative Agent to exercise, and no delay by any such Person in exercising, any right, remedy, power or privilege hereunder or under any other Loan Document shall operate as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights, remedies, powers and privileges herein provided, and provided under each other Loan Document, are cumulative and not exclusive of any rights, remedies, powers and privileges provided by law.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:39.6pt;">Notwithstanding anything to the contrary contained herein or in any other Loan Document, the authority to enforce rights and remedies hereunder and under the other Loan Documents against the Loan Parties or any of them shall be vested exclusively in, and all actions and proceedings at law in connection with such enforcement shall be instituted and maintained exclusively by, the Administrative Agent in accordance with <u>Section 11.01</u> for the benefit of all the Secured Parties; <u>provided</u>, <u>however</u>, <u>that</u>, the foregoing shall not prohibit (a) the Administrative Agent from exercising on its own behalf the rights and remedies that inure to its benefit (solely in its capacity as Administrative Agent) hereunder and under the other Loan Documents, (b)&nbsp;any Lender from exercising setoff rights in accordance with <u>Section 12.08</u> (subject to the terms of <u>Section 2.11)</u>, or (c) any Lender from filing proofs of claim or appearing and filing pleadings on its own behalf during the pendency of a proceeding relative to any Loan Party under any Debtor Relief Law; and <u>provided</u>, <u>further</u>, <u>that</u>, if at any time there is no Person acting as Administrative Agent hereunder and under the other Loan Documents, then (i) the Required Lenders shall have the rights otherwise ascribed to the Administrative Agent pursuant to <u>Section 11.01</u> and (ii) in addition to the matters set forth in <u>clauses (b)</u> and <u>(c)</u> of the preceding proviso and subject to <u>Section 2.11</u>, any Lender may, with the consent of the Required Lenders, enforce any rights and remedies available to it and as authorized by the Required Lenders.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.04&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Expenses; Indemnity; and Damage Waiver</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Costs and Expenses</u>. The Loan Parties shall pay (i) all reasonable out-of-pocket expenses incurred by the Administrative Agent, each Lender and their respective Affiliates (including the reasonable fees, charges and disbursements of counsel to the Administrative Agent or any Lender), in connection with (A) the preparation, negotiation, execution and delivery of this Agreement and the other Loan Documents and (B) any amendments, modifications or waivers of the provisions hereof or thereof (whether or not the transactions contemplated hereby or thereby shall be consummated) or the administration of this Agreement and the other Loan Documents and (ii) all out-of-pocket expenses incurred by the Administrative Agent or any Lender (including the fees, charges and disbursements of any counsel for the Administrative Agent or any Lender) in connection with the enforcement or protection of its rights (A) in connection with this Agreement and the other Loan Documents, including its rights under this Section, or (B) in connection with the Loans made hereunder, including all such out-of-pocket expenses incurred during any workout, restructuring or negotiations in respect of such Loans.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification by the Loan Parties</u>. The Loan Parties shall indemnify the Administrative Agent (and any sub-agent thereof) and each Lender, and each Related Party of any of the foregoing Persons (each such Person being called an &#8220;<u>Indemnitee</u>&#8221;) against, and hold each Indemnitee harmless from, any and all losses, claims, damages, liabilities and related expenses (including the reasonable fees, charges and disbursements of any counsel for any Indemnitee), and shall indemnify and hold harmless each Indemnitee from all fees and time charges and disbursements for attorneys who may be employees of any Indemnitee, incurred by any Indemnitee or asserted against any Indemnitee by any Person (including the Borrower or any other Loan Party) arising out of, in connection with, or as a result of (i) the execution or delivery of this Agreement, any other Loan Document or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their respective obligations hereunder or thereunder or the consummation of the transactions contemplated hereby or thereby, or, in the case of the Administrative Agent (and any sub-agent thereof) and its Related Parties only, the administration of this Agreement and the other Loan Documents, (ii) any Loan or the use or proposed use of the proceeds therefrom, (iii) any actual or alleged presence or release of Hazardous Materials on or from any property owned or operated by a Loan Party or any of its Subsidiaries, or any Environmental Liability related in any way to a Loan Party or any of its Subsidiaries, or (iv) any actual or prospective claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by a third party or by the Borrower or any other Loan Party, and regardless of whether any Indemnitee is a party thereto, in all cases, whether or not caused by or arising, in whole or in part, out of the comparative, contributory or sole negligence of the Indemnitee; <u>provided</u>, <u>that</u>, such indemnity shall not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities or related expenses are determined by a court of competent jurisdiction by final and nonappealable judgment to have resulted from the gross negligence or willful misconduct of such Indemnitee, if the Borrower or other Loan Party has obtained a final and nonappealable judgment in its favor on such claim as determined by a court of competent jurisdiction. <u>Clauses (a)</u> and <u>(b)</u> of this <u>Section 12.04</u> shall not apply with respect to Taxes other than any Taxes that represent losses, claims, damages, etc. arising from any non-Tax claim.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">115</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Waiver of Consequential Damages, Etc.</u> To the fullest extent permitted by applicable law, the Borrower shall (and shall cause each Subsidiary to) not assert, and the Borrower hereby waives, and acknowledges that no other Person shall have, any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or as a result of, this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Loan or the use of the proceeds thereof. No Indemnitee referred to in <u>subsection (b)</u> above shall be liable for any damages arising from the use by unintended recipients of any information or other materials distributed by it through telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reimbursement by Lenders</u>. To the extent that the Loan Parties for any reason fail to indefeasibly pay any amount required under <u>subsection (a)</u> or <u>(b)</u> of this Section to be paid by them to the Administrative Agent (or any sub-agent thereof) or any Related Party thereof, each Lender severally agrees to pay to the Administrative Agent (or any such sub-agent) or such Related Party, as the case may be, such Lender&#8217;s <i>pro rata</i> share (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought based on each Lender&#8217;s share of the Total Credit Exposure at such time) of such unpaid amount (including any such unpaid amount in respect of a claim asserted by such Lender), such payment to be made severally among them based on such Lender&#8217;s Applicable Percentage (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought), <u>provided</u>, <u>further</u>, <u>that</u>, the unreimbursed expense or indemnified loss, claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent (or any such sub-agent), or against any Related Party thereof acting for the Administrative Agent (or any such sub-agent) in connection with such capacity. The obligations of the Lenders under this <u>subsection (d)</u> are subject to the provisions of <u>Section 2.10(b)</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">116</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Payments</u>. All amounts due under this Section shall be payable not later than five (5) Business Days after demand therefor.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Survival</u>. The agreements in this Section and the indemnity provisions of <u>Section 12.02(d)</u> shall survive the resignation of the Administrative Agent, the replacement of any Lender, the termination of the Commitments and the repayment, prepayment, satisfaction or discharge of all the other Obligations.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.05&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Marshalling; Payments Set Aside</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">None of the Administrative Agent or the Lenders shall be under any obligation to marshal any assets in favor of any Loan Party or any other Person or against or in payment of any or all of the Obligations. To the extent that any payment by or on behalf of any Loan Party is made to the Administrative Agent or any Lender, or the Administrative Agent or any Lender exercises its right of setoff, and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by the Administrative Agent or such Lender in its discretion) to be repaid to a trustee, receiver or any other party, in connection with any proceeding under any Debtor Relief Law or otherwise, then (a) to the extent of such recovery, the obligation or part thereof originally intended to be satisfied, and all Liens, rights and remedies therefor or related thereto, shall be revived and continued in full force and effect as if such payment had not been made or such setoff had not occurred, and (b) each Lender severally agrees to pay to the Administrative Agent upon demand its applicable share (without duplication) of any amount so recovered from or repaid by the Administrative Agent, <u>plus</u> interest thereon from the date of such demand to the date such payment is made at a rate per annum equal to the Federal Funds Rate from time to time in effect. The obligations of the Lenders under <u>clause (b)</u> of the preceding sentence shall survive the payment in full of the Obligations and the termination of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.06&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns; Transfers</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Successors and Assigns Generally</u>. The provisions of this Agreement and the other Loan Documents shall be binding upon and inure to the benefit of the parties hereto and thereto and their respective successors and assigns permitted hereby, except that the Borrower and the other Loan Parties may not assign or otherwise transfer any of their respective rights or obligations hereunder or thereunder without the prior written consent of the Administrative Agent and each Lender and no Lender may assign or otherwise transfer any of its rights or obligations hereunder except (i) to an assignee in accordance with the provisions of clause (b) of this Section, (ii) by way of participation in accordance with the provisions of <u>clause (d</u>) of this Section or (iii) by way of pledge or assignment of a security interest subject to the restrictions of clause (e) of this Section (and any other attempted assignment or transfer by any party hereto shall be null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in <u>clause (d)</u> of this Section and, to the extent expressly contemplated hereby, the Related Parties of each of the Administrative Agent and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Assignments by Lenders</u>. Any Lender may at any time assign to one or more assignees all or a portion of its rights and obligations under this Agreement and the other Loan Documents (including all or a portion of its Commitments under any Facility and the Loans at the time owing to it (in each case with respect to any Facility)); <u>provided, that,</u> any such assignment shall be subject to the following conditions:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Minimum Amounts.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">117</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:82.8pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:39.6pt;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in the case of an assignment of the entire remaining amount of the assigning Lender&#8217;s Commitment with respect to any Facility and/or the Loans with respect to any Facility at the time owing to it or contemporaneous assignments to related Approved Funds that equal at least the amount specified in <u>paragraph (b)(i)(B)</u> of this Section in the aggregate or in the case of an assignment to a Lender, an Affiliate of a Lender or an Approved Fund, no minimum amount need be assigned; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:82.8pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:39.6pt;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in any case not described in <u>clause (b)(i)(A)</u> of this Section, the aggregate amount of the applicable Commitment (which for this purpose includes Loans outstanding thereunder) or, if the applicable Commitment is not then in effect, the principal outstanding balance of the Loans with respect to any Facility of the assigning Lender subject to each such assignment, determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if &#8220;Trade Date&#8221; is specified in the Assignment and Assumption, as of the Trade Date, shall not be less than $[***] unless each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Borrower otherwise consents (each such consent not to be unreasonably withheld or delayed);</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Proportionate Amounts.</u> Each partial assignment shall be made as an assignment of a proportionate part of all of the assigning Lender&#8217;s rights and obligations under this Agreement with respect to the Loans or the Commitment assigned;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Required Consents.</u> No consent shall be required for any assignment except to the extent required by <u>clause (b)(i)(B)</u> of this Section and, in addition:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:122.4pt;margin-right:0pt;margin-top:0pt;text-align:justify;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the consent of the Borrower (such consent not to be unreasonably withheld or delayed) shall be required unless (1) an Event of Default has occurred and is continuing at the time of such assignment or (2) such assignment is to a Lender, an Affiliate of a Lender or an Approved Fund; <u>provided, that,</u> the Borrower shall be deemed to have consented to any such assignment unless it shall object thereto by written notice to the Administrative Agent within five (5) Business Days after having received notice thereof;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:75.6pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:46.8pt;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the consent of the Administrative Agent (such consent not to be unreasonably withheld or delayed) shall be required for assignments in respect of (i) any unfunded Commitment if such assignment is to a Person that is not a Lender with a Commitment in respect of the applicable Facility, an Affiliate of such Lender or an Approved Fund with respect to such Lender or (ii) any Loan to a Person that is not a Lender, an Affiliate of a Lender or an Approved Fund;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Assignment and Assumption.</u> The parties to each assignment shall execute and deliver to the Administrative Agent an Assignment and Assumption. The assignee, if it is not a Lender, shall deliver to the Administrative Agent such information, including notice information, as the Administrative Agent shall reasonably require.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Assignment to Certain Persons.</u> No such assignment shall be made (A) to the Borrower or any of the Borrower&#8217;s Affiliates or Subsidiaries, (B) to any Defaulting Lender or any of its Subsidiaries or any Person who, upon becoming a Lender hereunder, would constitute any of the foregoing Persons described in this <u>clause (B)</u> or (C) to a natural Person.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">118</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Additional Payments.</u> In connection with any assignment of rights and obligations of any Defaulting Lender hereunder, no such assignment shall be effective unless and until, in addition to the other conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the consent of the Borrower and the Administrative Agent, the applicable pro rata share of Loans previously requested but not funded by the Defaulting Lender, to each of which the applicable assignee and assignor hereby irrevocably consent), to (x) pay and satisfy in full all payment liabilities then owed by such Defaulting Lender to the Administrative Agent or any Lender hereunder (and interest accrued thereon) and (y) acquire (and fund as appropriate) its full pro rata share of all Loans in accordance with its Applicable Percentage. Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Lender hereunder shall become effective under applicable Law without compliance with the provisions of this paragraph, then the assignee of such interest shall be deemed to be a Defaulting Lender for all purposes of this Agreement until such compliance occurs.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">Subject to acceptance and recording thereof by the Administrative Agent pursuant to <u>clause (c)</u> of this Section, from and after the effective date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender&#8217;s rights and obligations under this Agreement, such Lender shall cease to be a party hereto) but shall continue to be entitled to the benefits of <u>Sections 3.01, 10.01</u> and <u>11.04</u> with respect to facts and circumstances occurring prior to the effective date of such assignment. Upon request, the Borrower (at its expense) shall execute and deliver a Note to the assignee Lender. Any assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this clause shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with <u>clause (d)</u> of this Section.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Register</u>. The Administrative Agent, acting solely for this purpose as a non-fiduciary agent of the Borrower, shall maintain at the Administrative Agent&#8217;s Office a copy of each Assignment and Assumption delivered to it (or the equivalent thereof in electronic form) and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts (and stated interest) of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the &#8220;<u>Register</u>&#8221;). Notwithstanding anything to the contrary in any Loan Document, the entries in the Register shall be conclusive absent manifest error, and the Borrower, the Administrative Agent and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement. In addition, the Administrative Agent shall maintain on the Register information regarding the designation, and revocation of designation, of any Lender as a Defaulting Lender. The Register shall be available for inspection by the Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Participations</u>. Any Lender may at any time, without the consent of, or notice to, the Borrower or the Administrative Agent, sell participations to any Person (other than a natural Person, a Defaulting Lender (or a holding company, investment vehicle or trust for, or owned and operated for the primary benefit of a natural Person) or the Borrower or any of the Borrower&#8217;s Affiliates or Subsidiaries) (each, a &#8220;<u>Participant</u>&#8221;) in all or a portion of such Lender&#8217;s rights and/or obligations under this Agreement (including all or a portion of its Commitments and/or Loans owing to it); <u>provided</u>, <u>that</u>, (i) such Lender&#8217;s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Borrower, the Administrative Agent and the other Lenders shall continue to deal solely and directly with such Lender in connection with such Lender&#8217;s rights and obligations under this Agreement. For the avoidance of doubt, each Lender shall be responsible for the indemnity under <u>Section 12.04(d)</u> without regard to the existence of any participation.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">119</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; <u>provided</u>, <u>that</u>, such agreement or instrument may provide that such Lender will not, without the consent of the Participant, agree to any amendment, waiver or other modification described in <u>clauses (i)</u> through <u>(vi)</u> of <u>Section 12.01(a)</u> that affects such Participant. The Borrower agrees that each Participant shall be entitled to the benefits of <u>Section 3.01</u> (subject to the requirements and limitations therein (it being understood that the documentation required under <u>Section 3.01(f)</u> shall be delivered to the participating Lender)) and <u>Section&nbsp;10.01</u><i> </i>to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to <u>paragraph (b)</u> of this Section; <u>provided,</u> <u>that</u>, such Participant (A) agrees to be subject to the provisions of <u>Sections 10.02</u> and <u>12.13</u> as if it were an assignee under <u>paragraph (b)</u> of this Section and (B) shall not be entitled to receive any greater payment under <u>Section 3.01</u> or <u>10.01</u>, with respect to any participation, than the Lender from whom it acquired the applicable participation would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a Change in Law that occurs after the Participant acquired the applicable participation. Each Lender that sells a participation agrees, at the Borrower&#8217;s request and expense, to use reasonable efforts to cooperate with the Borrower to effectuate the provisions of <u>Section 12.02</u> with respect to any Participant. To the fullest extent permitted by law, each Participant also shall be entitled to the benefits of <u>Section 12.08</u> as though it were a Lender; <u>provided</u>, <u>that</u>, such Participant agrees to be subject to <u>Section 2.11</u> as though it were a Lender. Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Borrower, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant&#8217;s interest in the Loans or other obligations under the Loan Documents (the &#8220;<u>Participant Register</u>&#8221;); <u>provided</u>, <u>that</u>, no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant&#8217;s interest in any commitments, loans or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan or other obligation is in registered form under Section 5f.103-1(c) of the Treasury Regulations. Notwithstanding anything to the contrary in any Loan Document, the entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Certain Pledges</u>. Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement (including under its Note, if any) to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; <u>provided</u>, <u>that</u>, no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.07&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Treatment of Certain Information; Confidentiality</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Each of the Administrative Agent and the Lenders agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its Affiliates and to its Related Parties (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (b) to the extent required or requested by any regulatory authority purporting to have jurisdiction over such Person or its Related Parties (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (c) to the extent required by applicable laws or regulations or by any subpoena or similar legal process, (d) to any other party hereto, (e) as may be reasonably necessary in connection with the exercise of any remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder, (f)&nbsp;subject to an agreement containing provisions substantially the same as those of this Section, to (i) any Participant, assignee or transferee (or its Related Parties) of, or any prospective Participant, assignee or transferee (or its Related Parties) of, any of its rights and obligations under this Agreement or (ii) any actual or prospective party (or its Related Parties) to any swap, derivative or other transaction under which payments are to be made by reference to a Loan Party and its obligations, this Agreement or payments hereunder, (g) on a confidential basis to (i) any rating agency in connection with rating the Borrower or its Subsidiaries or the credit facilities provided hereunder or (ii) the CUSIP Service Bureau or any similar agency in connection with the issuance and monitoring of CUSIP numbers or other market identifiers with respect to the credit facilities provided hereunder, (h) with the consent of the Borrower, (i) to the members of its investment committee (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential) or (j) to the extent such Information (x) becomes publicly available other than as a result of a breach of this Section or (y) becomes available to the Administrative Agent, any Lender or any of their respective Affiliates on a nonconfidential basis from a source other than the Loan Parties.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">120</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">For purposes of this Section, &#8220;<u>Information</u>&#8221; means all information received from a Loan Party or any Subsidiary relating to the Loan Parties or any Subsidiary or any of their respective businesses, other than any such information that is available to the Administrative Agent or any Lender on a nonconfidential basis, <u>provided</u>, <u>that</u>, in the case of information received from a Loan Party or any Subsidiary after the date hereof, such information is clearly identified at the time of delivery as confidential. Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.08&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Set-off</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">If an Event of Default shall have occurred and be continuing, each Lender and each of their respective Affiliates is hereby authorized at any time and from time to time, after obtaining the prior written consent of the Administrative Agent, to the fullest extent permitted by applicable law, to set off and apply any and all deposits (general or special, time or demand, provisional or final, in whatever currency) at any time held and other obligations (in whatever currency) at any time owing by such Lender or any such Affiliate to or for the credit or the account of the Borrower or any other Loan Party against any and all of the obligations of the Borrower or such Loan Party now or hereafter existing under this Agreement or any other Loan Document to such Lender or its Affiliates, irrespective of whether or not such Lender or Affiliate shall have made any demand under this Agreement or any other Loan Document and although such obligations of the Borrower or such Loan Party may be contingent or unmatured or are owed to a branch office or Affiliate of such Lender different from the branch office or Affiliate holding such deposit or obligated on such indebtedness; <u>provided</u>, <u>that</u>, in the event that any Defaulting Lender shall exercise any such right of setoff, (x) all amounts so set off shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of <u>Section 2.12</u> and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in trust for the benefit of the Administrative Agent and the Lenders and (y) the Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Obligations owing to such Defaulting Lender as to which it exercised such right of setoff. The rights of each Lender and their respective Affiliates under this Section are in addition to other rights and remedies (including other rights of setoff) that such Lender or their respective Affiliates may have. Each Lender agrees to notify the Borrower and the Administrative Agent promptly after any such setoff and application, <u>provided</u>, <u>that</u>, the failure to give such notice shall not affect the validity of such setoff and application.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">121</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.09&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Interest Rate Limitation</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Notwithstanding anything to the contrary contained in any Loan Document, the interest paid or agreed to be paid under the Loan Documents shall not exceed the maximum rate of non-usurious interest permitted by applicable Law (the &#8220;<u>Maximum Rate</u>&#8221;). If the Administrative Agent or any Lender shall receive interest in an amount that exceeds the Maximum Rate, the excess interest shall be applied to the principal of the Loans or, if it exceeds such unpaid principal, refunded to the Borrower. In determining whether the interest contracted for, charged, or received by the Administrative Agent or a Lender exceeds the Maximum Rate, such Person may, to the extent permitted by applicable Law, (a) characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b) exclude voluntary repayments or prepayments and the effects thereof, and (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the Obligations hereunder.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Counterparts; Integration; Effectiveness</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">This Agreement and each of the other Loan Documents may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. This Agreement, the other Loan Documents, and any separate letter agreements with respect to fees payable to Athyrium or its Affiliates, the Lenders or Administrative Agent, constitute the entire contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. Except as provided in <u>Section 5.01</u>, this Agreement shall become effective when it shall have been executed by the Administrative Agent and when the Administrative Agent shall have received counterparts hereof that, when taken together, bear the signatures of each of the other parties hereto. Delivery of an executed counterpart of a signature page of this Agreement by fax transmission or e-mail transmission (e.g., &#8220;pdf&#8221; or &#8220;tif&#8221;) shall be effective as delivery of a manually executed counterpart of this Agreement or such other Loan Documents or certificate. Without limiting the foregoing, to the extent a manually executed counterpart is not specifically required to be delivered under the terms of any Loan Document, upon the request of any party, such fax transmission or e-mail transmission shall be promptly followed by such manually executed counterpart.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Survival of Representations and Warranties</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">All representations and warranties made hereunder and in any other Loan Document or other document delivered pursuant hereto or thereto or in connection herewith or therewith shall survive the execution and delivery hereof and thereof and shall continue in full force and effect as long as any Loan or other Obligation hereunder shall remain unpaid or unsatisfied and until all of the Commitments have been terminated in accordance with the terms hereof. Such representations and warranties have been or will be relied upon by the Administrative Agent and each Lender, regardless of any investigation made by the Administrative Agent or any Lender or on their behalf and notwithstanding that the Administrative Agent or any Lender may have had notice or knowledge of any Default at the time of any Borrowing, and shall continue in full force and effect as long as any Loan or any other Obligation hereunder shall remain unpaid or unsatisfied and until all of the Commitments have been terminated in accordance with the terms hereof.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">If any provision of this Agreement or the other Loan Documents is held to be illegal, invalid or unenforceable, (a) the legality, validity and enforceability of the remaining provisions of this Agreement and the other Loan Documents shall not be affected or impaired thereby and (b) the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions. The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. Without limiting the foregoing provisions of this <u>Section 12.12,</u> if and to the extent that the enforceability of any provisions in this Agreement relating to Defaulting Lenders shall be limited by Debtor Relief Laws, as determined in good faith by the Administrative Agent, then such provisions shall be deemed to be in effect only to the extent not so limited.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">122</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Replacement of Lenders.</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:39.6pt;">If the Borrower is entitled to replace a Lender pursuant to the provisions of <u>Section 10.02</u> or if any Lender is a Defaulting Lender or a Non-Consenting Lender, then the Borrower may, at its sole expense and effort, upon written notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, <u>Section 12.06),</u> all of its interests, rights (other than its existing rights to payments pursuant to <u>Sections 3.01</u> and <u>10.01)</u> and obligations under this Agreement and the related Loan Documents to an assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment), <u>provided, that:</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such Lender shall have received payment of an amount equal to one hundred percent (100%) of (x) the outstanding principal of its Loans, accrued interest thereon and all other amounts payable to it hereunder and under the other Loan Documents (other than repayment or prepayment premiums or the exit fee) from the assignee (to the extent of such outstanding principal and accrued interest) or the Borrower (in the case of all other amounts) and (y) the repayment or prepayment premium required by <u>Section 2.03(d)</u> and the exit fee required under <u>Section 2.07(b)</u> in each case, from the Borrower, as if such assignment was a prepayment of one hundred percent (100%) of the outstanding principal amount of such assignor&#8217;s Loans on the effective date of such assignment;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;such assignment does not conflict with applicable Laws;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in the case of any such assignment resulting from a claim for compensation under <u>Section 10.01</u> or payments required to be made pursuant to <u>Section 3.01,</u> such assignment will result in a reduction in such compensation or payments thereafter; and</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in the case of any such assignment resulting from a Non-Consenting Lender&#8217;s failure to consent to a proposed change, waiver, discharge or termination with respect to any Loan Document, the applicable replacement bank, financial institution or Fund consents to the proposed change, waiver, discharge or termination; <u>provided, that,</u> the failure by any Defaulting Lender or any Non-Consenting Lender to execute and deliver an Assignment and Assumption shall not impair the validity of the removal of such Defaulting Lender or Non-Consenting Lender and the mandatory assignment of such Defaulting Lender or Non-Consenting Lender&#8217;s outstanding Loans pursuant to this <u>Section 12.13</u> shall nevertheless be effective without the execution by such Defaulting Lender or Non-Consenting Lender of an Assignment and Assumption.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:43.2pt;">A Lender shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Borrower to require such assignment and delegation cease to apply.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law; Jurisdiction; Etc.</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">123</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>GOVERNING LAW</u>. This Agreement and the other Loan Documents (EXCEPT, AS TO ANY OTHER LOAN DOCUMENT, AS EXPRESSLY SET FORTH THEREIN) and any claims, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement or any other Loan Document (except, as to any other Loan Document, as expressly set forth therein) and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, THE law OF THE STATE OF NEW YORK.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>SUBMISSION TO JURISDICTION</u>. EACH LOAN PARTY IRREVOCABLY AND UNCONDITIONALLY AGREES THAT IT WILL NOT (AND IT WILL NOT PERMIT ANY LOAN PARTY TO) COMMENCE ANY ACTION, LITIGATION OR PROCEEDING OF ANY KIND OR DESCRIPTION, WHETHER IN LAW OR EQUITY, WHETHER IN CONTRACT OR IN TORT OR OTHERWISE, AGAINST THE ADMINISTRATIVE AGENT, ANY LENDER OR ANY RELATED PARTY OF THE FOREGOING IN ANY WAY RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS RELATING HERETO OR THERETO, IN ANY OTHER FORUM OTHER THAN THE COURTS OF THE STATE OF NEW YORK AND ANY UNITED STATES DISTRICT COURT IN THE STATE OF NEW YORK, AND ANY APPELLATE COURT FROM ANY THEREOF LOCATED IN NEW YORK COUNTY, NEW YORK, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY SUBMITS TO THE JURISDICTION OF SUCH COURTS AND AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION, LITIGATION OR PROCEEDING MAY BE HEARD AND DETERMINED IN SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS AGREEMENT OR IN ANY OTHER LOAN DOCUMENT SHALL AFFECT ANY RIGHT THAT THE ADMINISTRATIVE AGENT OR ANY LENDER MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT AGAINST THE BORROWER OR ANY OTHER LOAN PARTY OR THEIR RESPECTIVE PROPERTIES IN THE COURTS OF ANY JURISDICTION.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>WAIVER OF VENUE</u>. THE BORROWER AND EACH LOAN PARTY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT IN ANY COURT REFERRED TO IN PARAGRAPH (B) OF THIS SECTION. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>SERVICE OF PROCESS</u>. EACH PARTY HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN <u>SECTION 12.02</u>. NOTHING IN THIS AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Waiver of Right to Trial by Jury</u>. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">124</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Judgment Currency</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, for the purpose of obtaining judgment in any court, it is necessary to convert a sum owing hereunder in one currency into another currency, each party hereto agrees, to the fullest extent that it may effectively do so, that the rate of exchange used shall be that at which in accordance with normal banking procedures in the relevant jurisdiction the first currency could be purchased with such other currency on the Business Day immediately preceding the day on which final judgment is given.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The obligations of the Loan Parties in respect of any sum due to any party hereto or any holder of the Obligations owing hereunder (the &#8220;<u>Applicable Creditor</u>&#8221;) shall, notwithstanding any judgment in a currency (the &#8220;<u>Judgment Currency</u>&#8221;) other than the currency in which such sum is stated to be due hereunder (the &#8220;<u>Agreement Currency</u>&#8221;), be discharged only to the extent that, on the Business Day following receipt by the Applicable Creditor of any sum adjudged to be so due in the Judgment Currency, the Applicable Creditor may in accordance with normal banking procedures in the relevant jurisdiction purchase the Agreement Currency with the Judgment Currency; if the amount of the Agreement Currency so purchased is less than the sum originally due to the Applicable Creditor in the Agreement Currency, the Loan Parties agree, as a separate obligation and notwithstanding any such judgment, to jointly and severally indemnify the Applicable Creditor against such loss. The obligations of the Borrower contained in this <u>Section 12.16</u> shall survive the termination of this Agreement, the termination of the Commitments and the payment of all other amounts owing hereunder.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Electronic Execution of Assignments and Certain Other Documents</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">This Agreement and any document, amendment, approval, consent, information, notice, certificate, request, statement, disclosure or authorization related to this Agreement (each a &#8220;<u>Communication</u>&#8221;), including Communications required to be in writing, may be in the form of an Electronic Record and may be executed using Electronic Signatures. Each of the Loan Parties agrees that any Electronic Signature on or associated with any Communication shall be valid and binding on each of the Loan Parties to the same extent as a manual, original signature, and that any Communication entered into by Electronic Signature, will constitute the legal, valid and binding obligation of each of the Loan Parties enforceable against such in accordance with the terms thereof to the same extent as if a manually executed original signature was delivered. Any Communication may be executed in as many counterparts as necessary or convenient, including both paper and electronic counterparts, but all such counterparts are one and the same Communication. For the avoidance of doubt, the authorization under this paragraph may include, without limitation, use or acceptance by the Administrative Agent and each of the Lenders of a manually signed paper Communication which has been converted into electronic form (such as scanned into PDF format), or an electronically signed Communication converted into another format, for transmission, delivery and/or retention. The Administrative Agent and each of the Lenders may, at its option, create one or more copies of any Communication in the form of an imaged Electronic Record (&#8220;<u>Electronic Copy</u>&#8221;), which shall be deemed created in the ordinary course of the such Person&#8217;s business, and destroy the original paper document. All Communications in the form of an Electronic Record, including an Electronic Copy, shall be considered an original for all purposes, and shall have the same legal effect, validity and enforceability as a paper record. Notwithstanding anything contained herein to the contrary, the Administrative Agent is under no obligation to accept an Electronic Signature in any form or in any format unless expressly agreed to by the Administrative Agent pursuant to procedures approved by it; provided, further, without limiting the foregoing, (a) to the extent the Administrative Agent has agreed to accept such Electronic Signature, the Administrative Agent and each of the Lenders shall be entitled to rely on any such Electronic Signature purportedly given by or on behalf of any Loan Party without further verification and (b) upon the request of the Administrative Agent or any Lender, any Electronic Signature shall be promptly followed by such manually executed counterpart. For purposes hereof, &#8220;Electronic Record&#8221; and &#8220;Electronic Signature&#8221; shall have the meanings assigned to them, respectively, by 15 USC &#167;7006, as it may be amended from time to time.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">125</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>USA PATRIOT Act</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Each Lender that is subject to the PATRIOT Act and the Administrative Agent (for itself and not on behalf of any Lender) hereby notifies the Borrower that pursuant to the requirements of the PATRIOT Act, it is required to obtain, verify and record information that identifies each Loan Party, which information includes the name and address of each Loan Party and other information that will allow such Lender or the Administrative Agent, as applicable, to identify each Loan Party in accordance with the PATRIOT Act. Each of the Loan Parties agrees to, promptly following a request by the Administrative Agent or any Lender, provide all such other documentation and information that the Administrative Agent or such Lender requests in order to comply with its ongoing obligations under applicable &#8220;know your customer&#8221; and anti-money laundering rules and regulations, including the PATRIOT Act.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Advisory or Fiduciary Relationship</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">In connection with all aspects of each transaction contemplated hereby (including in connection with any amendment, waiver or other modification hereof or of any other Loan Document), the Borrower acknowledges and agrees, and acknowledges its Affiliates&#8217; understanding, that: (a)(i) the arranging and other services regarding this Agreement provided by the Administrative Agent, Athyrium and its Affiliates, and the Lenders are arm&#8217;s-length commercial transactions between the Borrower and its Affiliates, on the one hand, and the Administrative Agent, Athyrium and its Affiliates and the Lenders on the other hand, (ii) the Borrower has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate, and (iii) the Borrower is capable of evaluating, and understands and accepts, the terms, risks and conditions of the transactions contemplated hereby and by the other Loan Documents; (b)(i) the Administrative Agent, Athyrium and its Affiliates and each Lender is and has been acting solely as a principal and, except as expressly agreed in writing by the relevant parties, has not been, is not and will not be acting as an advisor, agent or fiduciary, for the Borrower or any of its Affiliates or any other Person and (ii) neither the Administrative Agent nor any Lender has any obligation to the Borrower or any of its Affiliates with respect to the transactions contemplated hereby except those obligations expressly set forth herein and in the other Loan Documents; and (c) the Administrative Agent, Athyrium and its Affiliates and the Lenders and their respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Borrower and its Affiliates, and neither the Administrative Agent, Athyrium or its Affiliates nor any Lender has any obligation to disclose any of such interests to the Borrower or its Affiliates. To the fullest extent permitted by law, the Borrower hereby waives and releases any claims that they may have against the Administrative Agent, Athyrium or its Affiliates or any Lenders with respect to any breach or alleged breach of agency or fiduciary duty in connection with any aspect of any transaction contemplated hereby.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Acknowledgement and Consent to Bail-In of EEA Financial Institutions</u>.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">126</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Lender that is an EEA Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the write-down and conversion powers of an EEA Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by (a) the application of any Write-Down and Conversion Powers by an EEA Resolution Authority to any such liabilities arising hereunder which may be payable to it by any Lender that is an EEA Financial Institution; and (b) the effects of any Bail-In Action on any such liability, including, if applicable: (i) a reduction in full or in part or cancellation of any such liability; (ii) a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such EEA Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document; or (iii) the variation of the terms of such liability in connection with the exercise of the write-down and conversion powers of any EEA Resolution Authority.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Publicity</u>. The Loan Parties will not directly or indirectly publish, disclose or otherwise use in any public disclosure, advertising material, promotional material, press release or interview, any reference to the name, logo or any trademark of the Administrative Agent or any Lender or any of their Affiliates or any reference to this Agreement or the financing evidenced hereby, in any case except as required by applicable Law, subpoena or judicial or similar order, in which case the Loan Parties shall endeavor to give the Administrative Agent prior written notice of such publication or other disclosure. Each Lender and each Loan Party hereby authorizes each Lender to publish the name of such Lender and each Loan Party, the existence of the financing arrangements referenced under this Agreement, the primary purpose and/or structure of those arrangements, the amount of credit extended under each facility, the title and role of each party to this Agreement, and the total amount of the financing evidenced hereby in any &#8220;tombstone&#8221;, comparable advertisement or press release which such Lender elects to submit for publication. In addition, each Lender and each Loan Party agrees that each Lender may provide lending industry trade organizations with information necessary and customary for inclusion in league table measurements after the Closing Date. With respect to any of the foregoing, such authorization shall be subject to such Lender providing the Loan Parties and the other Lenders with an opportunity to review and confer with such Lender regarding, and approve, the contents of any such tombstone, advertisement or information, as applicable, prior to its initial submission for publication, but subsequent publications of the same tombstone, advertisement or information shall not require any Loan Party&#8217;s approval.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:36pt;">12.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Conflicts</u>. Notwithstanding anything to the contrary contained herein or in any other Loan Document, in the event of any conflict or inconsistency between this Agreement and any other Loan Document, the terms of this Agreement shall govern and control.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">[SIGNATURE PAGES FOLLOW]</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">127</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;text-indent:40.5pt;">IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:180pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">BORROWER:</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">BIOCRYST PHARMACEUTICALS, INC.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">By:<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>/s/ Anthony Doyle</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">Name: Anthony Doyle</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:144pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">Title: Chief Financial Officer</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-180pt;">GUARANTOR:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 180pt; text-align: left;">BIOCRYST IRELAND LIMITED</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 180pt; text-align: left;">incorporated under the laws of Ireland</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">By:<u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>/s/ Alane Barnes</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">Name: Alane Barnes</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:144pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">Title: Director</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:144pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">In the presence of:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:144pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">Witness signature:&nbsp;&nbsp;<u>/s/ </u><u>Matthew W. Barnes&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:144pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">Name:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Matthew W. Barnes&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:144pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">Address: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[***]</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:144pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;">Occupation: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Attorney&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</u></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:180pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">ADMINISTRATIVE AGENT:</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP, as Administrative Agent</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:202.5pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">By: ATHYRIUM OPPORTUNITIES ASSOCIATES CO-INVEST LLC, its General Partner</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">By: <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>/s/ Rashida Adams</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">Name: Rashida Adams</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">Title: Authorized Signatory</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-180pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:144pt;margin-right:0pt;margin-top:0pt;text-align:justify;text-indent:-144pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:180pt;vertical-align:top;">LENDER:</td>
			<td style="vertical-align:top;">ATHYRIUM OPPORTUNITIES III CO-INVEST 1 LP</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:234pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">By: ATHYRIUM OPPORTUNITIES ASSOCIATES CO-INVEST LLC, its General Partner</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">By: <u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u><u>/s/ Rashida Adams</u><u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">Name: Rashida Adams</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:180pt;margin-right:0pt;margin-top:0pt;text-align:left;">Title: Authorized Signatory</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>15
<FILENAME>ex_230510.htm
<DESCRIPTION>EXHIBIT 21
<TEXT>
<html><head>
	<title>ex_230510.htm</title>
	<meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:right;"><b>Exhibit 21</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>Subsidiaries of the Registrant</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0">&nbsp;</p>

<p style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="margin-left: 16.25%; width: 67.5%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Subsidiary</b></p>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Jurisdiction of Incorporation</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">JPR Royalty Sub, LLC</p>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Delaware</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">BioCryst US Sales Co., LLC</p>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Delaware</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">BioCryst UK Limited</p>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">England and Wales</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">BioCryst Ireland Limited</p>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Ireland</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">BioCryst Pharma Deutschland GmbH</p>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">Germany</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 53%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">BioCryst France SAS</p>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 44%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;">France</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>16
<FILENAME>ex_227978.htm
<DESCRIPTION>EXHIBIT 23
<TEXT>
<html><head>
	<title></title>

</head>
<body style="cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Exhibit 23</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:center;"><b>Consent of Independent Registered Public Accounting Firm</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">We consent to the incorporation by reference in the following Registration Statements: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:33pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Registration Statements (Form&nbsp;S-8 Nos.&nbsp;333-231108, 333-239078 and 333-245024) pertaining to the BioCryst Pharmaceuticals, Inc. Inducement Equity Incentive Plan;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:33pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Registration Statements (Form S-3 Nos. 333-145638, 333-153084, 333-217859 and 333-237820) of BioCryst Pharmaceuticals, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:33pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Registration Statements (Form&nbsp;S-8 Nos.&nbsp;333-120345, 333-39484, 333-30751 and 333-136703) pertaining to the BioCryst Pharmaceuticals, Inc. 1991 Stock Option Plan, as amended and restated;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:33pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Registration Statements (Form&nbsp;S-8 Nos.&nbsp;333-90582 and 333-239077) pertaining to the BioCryst Pharmaceuticals, Inc. Employee Stock Purchase Plan, as amended and restated;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:33pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Registration Statement (Form&nbsp;S-8 No.&nbsp;333-145627) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated, and the Employment Letter Agreement dated April 2, 2007 between BioCryst Pharmaceuticals, Inc. and David McCullough;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:33pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Registration Statements (Form&nbsp;S-8 Nos.&nbsp;333-176096, 333-211529, 333-218360, 333-228296, 333-231942 and 333-239076) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan, as amended and restated;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:33pt;">&nbsp;</td>
			<td style="width:10pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7.2pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Registration Statements (Form&nbsp;S-8 Nos.&nbsp;333-152570, 333-167830, 333-187193 and 333-195869) pertaining to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan and the Employee Stock Purchase Plan, each as amended and restated</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">of our reports dated March 1, 2021, with respect to the consolidated financial statements of BioCryst Pharmaceuticals, Inc. and the effectiveness of internal control over financial reporting of BioCryst Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of BioCryst Pharmaceuticals, Inc. for the year ended December 31, 2020.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">/s/ Ernst &amp; Young LLP</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">Raleigh, North Carolina</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt 7.2pt;text-align:left;">March 1, 2021</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>17
<FILENAME>ex_227979.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title></title>

</head>
<body style="cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Exhibit 31.1</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><b>CERTIFICATIONS</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">I, Jon P. Stonehouse, certify that:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">I have reviewed this annual report on Form 10-K of BioCryst Pharmaceuticals, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-17.6pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:11pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:11pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-17.6pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:9pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:9pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-17.6pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">4.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin-right: 7pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; font-size: 10pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:18pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin-right: 7pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; font-size: 10pt;">c.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:33pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">d.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:10pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">5.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:10pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:4pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">e.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:4pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:1pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">f.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:1pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date: March 1, 2021</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Jon P. Stonehouse</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; border-bottom: 1px rgb(0, 0, 0); width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Jon P. Stonehouse</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Executive Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Principal Executive Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>18
<FILENAME>ex_227980.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title></title>

</head>
<body style="cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Exhibit 31.2</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><b>CERTIFICATIONS</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">I, Anthony Doyle, certify that:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">I have reviewed this annual report on Form 10-K of BioCryst Pharmaceuticals, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-17.6pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:11pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:11pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-17.6pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:9pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:9pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-17.6pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">4.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7pt;margin-top:0pt;text-align:justify;margin-bottom:0pt;font-size:10pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin-right: 7pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; font-size: 10pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:18pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin-right: 7pt; margin-top: 0pt; text-align: justify; margin-bottom: 0pt; font-size: 10pt;">c.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:33pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">d.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:7pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:10pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">5.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:10pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:4pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">e.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:4pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:36pt;">&nbsp;</td>
			<td style="width:18pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:1pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">f.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:1pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date: March 1, 2021</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Anthony Doyle</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; border-bottom: 1px rgb(0, 0, 0); width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Anthony Doyle</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Financial Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Principal Financial Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>19
<FILENAME>ex_227981.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title></title>

</head>
<body style="cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:right;"><b>Exhibit 32.1</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><b>18 U.S.C. SECTION 1350,</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:36pt;">In connection with the Annual Report of BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Jon P. Stonehouse, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:46pt;">&nbsp;</td>
			<td style="width:26pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-26.1pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:46pt;">&nbsp;</td>
			<td style="width:26pt;vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:20pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Date: March 1, 2021</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Jon P. Stonehouse</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; border-bottom: 1px rgb(0, 0, 0); width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Jon P. Stonehouse</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Executive Officer</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Principal Executive Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:36pt;">This certification is furnished with this Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>20
<FILENAME>ex_227982.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head>
	<title></title>

</head>
<body style="cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:right;"><b>Exhibit 32.2</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:right;"><b>&nbsp;</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><b>18 U.S.C. SECTION 1350,</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:27pt;">In connection with the Annual Report of BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ending December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Anthony Doyle, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:46pt;">&nbsp;</td>
			<td style="width:26pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:72pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-26.1pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:46pt;">&nbsp;</td>
			<td style="width:26pt;vertical-align:top;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:20pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);">Date: March 1, 2021</p>
			</td>
			<td style="vertical-align: top; border-bottom: 1px solid rgb(0, 0, 0); width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">/s/ Anthony Doyle</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; border-bottom: 1px rgb(0, 0, 0); width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Anthony Doyle</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Chief Financial Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50%;">&nbsp;</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">(Principal Financial Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:27pt;">This certification is furnished with this Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:27pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:27pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>21
<FILENAME>bcrx-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:14AM UTC 2021-03-01--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:bcrx="http://www.biocryst.com/20201231" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biocryst.com/20201231">
  <xsd:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bcrx-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.biocryst.com/20201231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-comprehensive-loss" roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity" roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-equity-parentheticals" roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk" roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-property-and-equipment" roleURI="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 2 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-royalty-monetizations" roleURI="http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 3 - Royalty Monetizations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-credit-agreement" roleURI="http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 4 - Credit Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-senior-credit-facility" roleURI="http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 5 - Senior Credit Facility</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-lease-obligations-and-other-contingencies" roleURI="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 6 - Lease Obligations and Other Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity" roleURI="http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 7 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation" roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 8 - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes" roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 9 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-employee-401k-plan-" roleURI="http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 10 - Employee 401(k) Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-collaborative-and-other-research-and-development-contracts" roleURI="http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 11 - Collaborative and Other Research and Development Contracts</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-quarterly-financial-information-unaudited" roleURI="http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 12 - Quarterly Financial Information (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-property-and-equipment-tables" roleURI="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 2 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-lease-obligations-and-other-contingencies-tables" roleURI="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 6 - Lease Obligations and Other Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-tables" roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 8 - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-tables" roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 9 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-quarterly-financial-information-unaudited-tables" roleURI="http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 12 - Quarterly Financial Information (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details" roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk - Fair Value of the Company's Investments by Type (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details" roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk - Summary of Receivables (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details" roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk - Summary of Revenues (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-property-and-equipment-details-textual" roleURI="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 2 - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-property-and-equipment-property-and-equipment-details" roleURI="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 2 - Property and Equipment - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-royalty-monetizations-details-textual" roleURI="http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 3 - Royalty Monetizations (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-credit-agreement-details-textual" roleURI="http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 4 - Credit Agreement (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-senior-credit-facility-details-textual" roleURI="http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 5 - Senior Credit Facility (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-lease-obligations-and-other-contingencies-details-textual" roleURI="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 6 - Lease Obligations and Other Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" roleURI="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 6 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-details-textual" roleURI="http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 7 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-details-textual" roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 8 - Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details" roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 8 - Stock-Based Compensation - Stock-based Compensation Allocation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-stock-plan-activities-details" roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 8 - Stock-based Compensation - Stock Plan Activities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 8 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 8 - Stock-based Compensation - Number of Stock Option Awards Exercisable and their Weighted Average Exercise Price (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note 8 - Stock-based Compensation - Changes in the Number and Weighted-Average Grant-Date Fair Value (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-details-textual" roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Disclosure - Note 9 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">046 - Disclosure - Note 9 - Income Taxes - Loss Before Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">047 - Disclosure - Note 9 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">048 - Disclosure - Note 9 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">049 - Disclosure - Note 9 - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">050 - Disclosure - Note 9 - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-employee-401k-plan-details-textual" roleURI="http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">051 - Disclosure - Note 10 - Employee 401(k) Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual" roleURI="http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">052 - Disclosure - Note 11 - Collaborative and Other Research and Development Contracts (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" roleURI="http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">053 - Disclosure - Note 12 - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="bcrx_AECOMAndIRLMember" name="AECOMAndIRLMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ASPRBARDAContractMember" name="ASPRBARDAContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AccruedDevelopmentCosts" name="AccruedDevelopmentCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AccruedExpensesPolicyTextBlock" name="AccruedExpensesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AccruedInventoryExpense" name="AccruedInventoryExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" name="AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AccruedLiabilitiesCurrentMember" name="AccruedLiabilitiesCurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AdditionalDevelopmentOptionsMember" name="AdditionalDevelopmentOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AfterFourthAnniversaryMember" name="AfterFourthAnniversaryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" name="AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" name="AmortizationOfDiscountAndPremiumOnInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMaximum" name="AnnualLicenseFeeMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AnnualLicenseFeeMinimum" name="AnnualLicenseFeeMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_AnnualNetSalesBetween150000And230000Member" name="AnnualNetSalesBetween150000And230000Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AnnualNetSalesBetween350000And550000Member" name="AnnualNetSalesBetween350000And550000Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AnnualNetSalesOver230000Member" name="AnnualNetSalesOver230000Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AnnualNetSalesOver550000Member" name="AnnualNetSalesOver550000Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AnnualNetSalesUnder150000Member" name="AnnualNetSalesUnder150000Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AnnualNetSalesUnder350000Member" name="AnnualNetSalesUnder350000Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ArbitrationProceedingsOfSulAgreementMember" name="ArbitrationProceedingsOfSulAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_AthyriumMember" name="AthyriumMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_August2013Member" name="August2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" name="AvailableForSaleDebtSecuritiesAccruedInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_AverageMaturityForPortfolioInvestments" name="AverageMaturityForPortfolioInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" name="AverageMaturityPeriodOfHighQualityMarketableSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BCX9930Member" name="BCX9930Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BaseContractMember" name="BaseContractMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BetweenTheSecondAndThirdAnniversariesMember" name="BetweenTheSecondAndThirdAnniversariesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_BetweenTheThirdAndFourthAnniversariesMember" name="BetweenTheThirdAndFourthAnniversariesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CSLLimitedMember" name="CSLLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" name="ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CollaborationReceivablesMember" name="CollaborationReceivablesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" name="CollaborativeAgreementContractCovenantMaximumAmountOfFunding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CollaborativeAgreementContractValue" name="CollaborativeAgreementContractValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" name="CollaborativeAndOtherResearchAndDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CollateralForCreditMember" name="CollateralForCreditMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" name="ConcentrationOfMarketRiskPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ContractTerm" name="ContractTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CreditAgreementMember" name="CreditAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_CurrencyHedgeAgreementMember" name="CurrencyHedgeAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_CurrencyHedgeAgreementPolicyTextBlock" name="CurrencyHedgeAgreementPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DebtInstrumentCommitmentFeePercentage" name="DebtInstrumentCommitmentFeePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" name="DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DebtInstrumentExitFeePercentageOfPrincipal" name="DebtInstrumentExitFeePercentageOfPrincipal" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DebtInstrumentLiborCap" name="DebtInstrumentLiborCap" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DebtInstrumentLiborFloor" name="DebtInstrumentLiborFloor" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DebtInstrumentMinimumLibor" name="DebtInstrumentMinimumLibor" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" name="DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" name="DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_December2014Member" name="December2014Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_December2019Member" name="December2019Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_DeferredTaxAssetsLeasingObligations" name="DeferredTaxAssetsLeasingObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DeferredTaxAssetsRoyaltyIncome" name="DeferredTaxAssetsRoyaltyIncome" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DeferredTaxLiabilitiesRightOfUseAssets" name="DeferredTaxLiabilitiesRightOfUseAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_DescriptionOfCompanyPolicyTextBlock" name="DescriptionOfCompanyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" name="EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" name="EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange01Member" name="ExercisePriceRange01Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange02Member" name="ExercisePriceRange02Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange03Member" name="ExercisePriceRange03Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange04Member" name="ExercisePriceRange04Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange05Member" name="ExercisePriceRange05Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ExercisePriceRange06Member" name="ExercisePriceRange06Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" name="ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_FutureRoyaltiesPayable" name="FutureRoyaltiesPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_FutureRoyaltiesPayableMember" name="FutureRoyaltiesPayableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_GreenCrossCorporationMember" name="GreenCrossCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_IncentivePlanAndInducementPlanMember" name="IncentivePlanAndInducementPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_IncentivePlanMember" name="IncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" name="IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_IncreaseDecreaseInFinancingLeaseObligations" name="IncreaseDecreaseInFinancingLeaseObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_InducementPlanMember" name="InducementPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_InterestAndOtherIncomeLoss" name="InterestAndOtherIncomeLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" name="InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" name="InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_InterestReserve" name="InterestReserve" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_JPRRoyaltySubLLCMember" name="JPRRoyaltySubLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" name="LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" name="LesseeLeaseLiabilityMaturityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_LongtermInvestmentMaturityMinimum" name="LongtermInvestmentMaturityMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" name="MaturityPeriodOfHighQualityMarketablesecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaturityperiodOfShortTermInvestment" name="MaturityperiodOfShortTermInvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MaximumAggregateOfferingPrice" name="MaximumAggregateOfferingPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_MaximumCustomaryReductionOnRoyaltyRate" name="MaximumCustomaryReductionOnRoyaltyRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_MidCapFinancialServicesLLCMember" name="MidCapFinancialServicesLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentMaximum" name="MilestonePaymentMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentMinimum" name="MilestonePaymentMinimum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_MilestonePaymentReceived" name="MilestonePaymentReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_MundipharmaInternationalHoldingsLimitedMember" name="MundipharmaInternationalHoldingsLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_MundipharmaMember" name="MundipharmaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ORLADEYOMember" name="ORLADEYOMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization" name="OperatingLeaseRightofuseAssetAccumulatedAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" name="PercentageOfCarryingAmountInExcessOfFairValue1" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_PercentageOfCommonStockSharesBeginning" name="PercentageOfCommonStockSharesBeginning" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfCommonStockSharesEnding" name="PercentageOfCommonStockSharesEnding" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" name="PercentageOfSalaryToPurchaseCommonStockMaximum" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PeriodOfAgreement" name="PeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_PhaRMANotesMember" name="PhaRMANotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_PikInterestPaymentIsMadeMember" name="PikInterestPaymentIsMadeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PotentialMilestonePaymentsReceivable" name="PotentialMilestonePaymentsReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" name="PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_PriorToTheSecondAnniversaryMember" name="PriorToTheSecondAnniversaryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_PrivatePlacementOfSeniorSecuredNotes" name="PrivatePlacementOfSeniorSecuredNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" name="ProceedsFromAwardsForResearchAndDevelopmentContracts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ProceedsFromRealizedGainOnInvestments" name="ProceedsFromRealizedGainOnInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ProceedsFromRoyaltyFinancingObligation" name="ProceedsFromRoyaltyFinancingObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RAPIVABMember" name="RAPIVABMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RenewablePeriodOfAgreement" name="RenewablePeriodOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyMonetizationMember" name="RoyaltyMonetizationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyMonetizationTextBlock" name="RoyaltyMonetizationTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" name="RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" name="RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" name="RoyaltyRateIfMaintainsSakigakeDesignation" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="bcrx_RoyaltyReceivableMember" name="RoyaltyReceivableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Rpi2019IntermediateFinanceTrustMember" name="Rpi2019IntermediateFinanceTrustMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" name="ScheduleOfReceivablesFromCollaborationsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SecuredCreditFacilityFirstTrancheMember" name="SecuredCreditFacilityFirstTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SecuredCreditFacilitySecondTrancheMember" name="SecuredCreditFacilitySecondTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SecuredCreditFacilityThirdTrancheMember" name="SecuredCreditFacilityThirdTrancheMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SeniorCreditFacilityMember" name="SeniorCreditFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_SeqirusUKLimitedMember" name="SeqirusUKLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="instant"/>
  <xsd:element id="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ShionogiAndCoLtdMember" name="ShionogiAndCoLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_TermALoanMember" name="TermALoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_TermBLoanMember" name="TermBLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_TermCLoanMember" name="TermCLoanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_TermLoanAAndBDrawnMember" name="TermLoanAAndBDrawnMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_TermLoanADrawnMember" name="TermLoanADrawnMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" name="TermLoansABAndCDrawnAndCureRightExercisedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_TermLoansABAndCDrawnMember" name="TermLoansABAndCDrawnMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_ToriiPharmaceuticalCoMember" name="ToriiPharmaceuticalCoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_TransactionCosts" name="TransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_UABMember" name="UABMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_USDepartmentOfHealthAndHumanServicesMember" name="USDepartmentOfHealthAndHumanServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="bcrx_UpfrontPaymentsReceivableAmount" name="UpfrontPaymentsReceivableAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_Vest25PercentEachYearUntilFullyVestedMember" name="Vest25PercentEachYearUntilFullyVestedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" name="VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_WarrantsIssuedInPublicOfferingMember" name="WarrantsIssuedInPublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" name="statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details" name="statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details" name="statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details" name="statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" name="statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" name="statement-statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-tables" name="statement-statement-note-12-quarterly-financial-information-unaudited-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details" name="statement-statement-note-2-property-and-equipment-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-2-property-and-equipment-tables" name="statement-statement-note-2-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" name="statement-statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-tables" name="statement-statement-note-6-lease-obligations-and-other-contingencies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" name="statement-statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" name="statement-statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-8-stockbased-compensation-stock-plan-activities-details" name="statement-statement-note-8-stockbased-compensation-stock-plan-activities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details" name="statement-statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-8-stockbased-compensation-tables" name="statement-statement-note-8-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" name="statement-statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" name="statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" name="statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" name="statement-statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" name="statement-statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-note-9-income-taxes-tables" name="statement-statement-note-9-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="bcrx_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>22
<FILENAME>bcrx-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:14AM UTC 2021-03-01--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details" xlink:href="bcrx-20201231.xsd#statement-note-2-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets" xlink:href="bcrx-20201231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_FutureRoyaltiesPayable" xlink:label="bcrx_FutureRoyaltiesPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LinesOfCreditCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="bcrx_FutureRoyaltiesPayable" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:href="bcrx-20201231.xsd#statement-consolidated-statements-of-comprehensive-loss" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InterestAndOtherIncomeLoss" xlink:label="bcrx_InterestAndOtherIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="bcrx_InterestAndOtherIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" xlink:href="bcrx-20201231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedDevelopmentCosts" xlink:label="bcrx_AccruedDevelopmentCosts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedInventoryExpense" xlink:label="bcrx_AccruedInventoryExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="bcrx_AccruedDevelopmentCosts" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="bcrx_AccruedInventoryExpense" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_TaxesPayableCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:href="bcrx-20201231.xsd#statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DeferredTaxAssetsLeasingObligations" xlink:label="bcrx_DeferredTaxAssetsLeasingObligations" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DeferredTaxAssetsRoyaltyIncome" xlink:label="bcrx_DeferredTaxAssetsRoyaltyIncome" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="bcrx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="bcrx_DeferredTaxAssetsLeasingObligations" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="bcrx_DeferredTaxAssetsRoyaltyIncome" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="bcrx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows" xlink:href="bcrx-20201231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ProceedsFromRealizedGainOnInvestments" xlink:label="bcrx_ProceedsFromRealizedGainOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ProceedsFromRoyaltyFinancingObligation" xlink:label="bcrx_ProceedsFromRoyaltyFinancingObligation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="bcrx_ProceedsFromRealizedGainOnInvestments" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="bcrx_ProceedsFromRoyaltyFinancingObligation" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>23
<FILENAME>bcrx-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:14AM UTC 2021-03-01--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited" xlink:href="bcrx-20201231.xsd#statement-note-12-quarterly-financial-information-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-document-and-entity-information" xlink:href="bcrx-20201231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:href="bcrx-20201231.xsd#statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:href="bcrx-20201231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollaborationReceivablesMember" xlink:label="bcrx_CollaborationReceivablesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="bcrx_CollaborationReceivablesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment" xlink:href="bcrx-20201231.xsd#statement-note-2-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations" xlink:href="bcrx-20201231.xsd#statement-note-3-royalty-monetizations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesBetween150000And230000Member" xlink:label="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesBetween350000And550000Member" xlink:label="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesOver230000Member" xlink:label="bcrx_AnnualNetSalesOver230000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesOver550000Member" xlink:label="bcrx_AnnualNetSalesOver550000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesUnder150000Member" xlink:label="bcrx_AnnualNetSalesUnder150000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesUnder350000Member" xlink:label="bcrx_AnnualNetSalesUnder350000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BCX9930Member" xlink:label="bcrx_BCX9930Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_FutureRoyaltiesPayableMember" xlink:label="bcrx_FutureRoyaltiesPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_Rpi2019IntermediateFinanceTrustMember" xlink:label="bcrx_Rpi2019IntermediateFinanceTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_Rpi2019IntermediateFinanceTrustMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_FutureRoyaltiesPayableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesUnder350000Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesOver550000Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_BCX9930Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesUnder150000Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesOver230000Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement" xlink:href="bcrx-20201231.xsd#statement-note-4-credit-agreement" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AfterFourthAnniversaryMember" xlink:label="bcrx_AfterFourthAnniversaryMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AthyriumMember" xlink:label="bcrx_AthyriumMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:label="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:label="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CreditAgreementMember" xlink:label="bcrx_CreditAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PikInterestPaymentIsMadeMember" xlink:label="bcrx_PikInterestPaymentIsMadeMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PriorToTheSecondAnniversaryMember" xlink:label="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermALoanMember" xlink:label="bcrx_TermALoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermBLoanMember" xlink:label="bcrx_TermBLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermCLoanMember" xlink:label="bcrx_TermCLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoanAAndBDrawnMember" xlink:label="bcrx_TermLoanAAndBDrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoanADrawnMember" xlink:label="bcrx_TermLoanADrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:label="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoansABAndCDrawnMember" xlink:label="bcrx_TermLoansABAndCDrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_CreditAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_AthyriumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_TermALoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_TermBLoanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_TermCLoanMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_PikInterestPaymentIsMadeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AfterFourthAnniversaryMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_TermLoanADrawnMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_TermLoanAAndBDrawnMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_TermLoansABAndCDrawnMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility" xlink:href="bcrx-20201231.xsd#statement-note-5-senior-credit-facility" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:label="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:label="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:label="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies" xlink:href="bcrx-20201231.xsd#statement-note-6-lease-obligations-and-other-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedLiabilitiesCurrentMember" xlink:label="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity" xlink:href="bcrx-20201231.xsd#statement-note-7-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_WarrantsIssuedInPublicOfferingMember" xlink:label="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation" xlink:href="bcrx-20201231.xsd#statement-note-8-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_December2019Member" xlink:label="bcrx_December2019Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncentivePlanAndInducementPlanMember" xlink:label="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2019Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-" xlink:href="bcrx-20201231.xsd#statement-note-10-employee-401k-plan-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts" xlink:href="bcrx-20201231.xsd#statement-note-11-collaborative-and-other-research-and-development-contracts" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:label="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeMember" xlink:label="us-gaap_OtherIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20201231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:href="bcrx-20201231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-tables" xlink:href="bcrx-20201231.xsd#statement-note-2-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-tables" xlink:href="bcrx-20201231.xsd#statement-note-6-lease-obligations-and-other-contingencies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:label="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables" xlink:href="bcrx-20201231.xsd#statement-note-8-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-tables" xlink:href="bcrx-20201231.xsd#statement-note-12-quarterly-financial-information-unaudited-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:label="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AverageMaturityForPortfolioInvestments" xlink:label="bcrx_AverageMaturityForPortfolioInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollaborationReceivablesMember" xlink:label="bcrx_CollaborationReceivablesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="bcrx_CollaborationReceivablesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNet" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterials" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcess" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoods" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryValuationReserves" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvertisingExpense" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AverageMaturityForPortfolioInvestments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-2-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-3-royalty-monetizations-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesBetween150000And230000Member" xlink:label="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesBetween350000And550000Member" xlink:label="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesOver230000Member" xlink:label="bcrx_AnnualNetSalesOver230000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesOver550000Member" xlink:label="bcrx_AnnualNetSalesOver550000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesUnder150000Member" xlink:label="bcrx_AnnualNetSalesUnder150000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesUnder350000Member" xlink:label="bcrx_AnnualNetSalesUnder350000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BCX9930Member" xlink:label="bcrx_BCX9930Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_FutureRoyaltiesPayable" xlink:label="bcrx_FutureRoyaltiesPayable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_FutureRoyaltiesPayableMember" xlink:label="bcrx_FutureRoyaltiesPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InterestReserve" xlink:label="bcrx_InterestReserve" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_Rpi2019IntermediateFinanceTrustMember" xlink:label="bcrx_Rpi2019IntermediateFinanceTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_Rpi2019IntermediateFinanceTrustMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_FutureRoyaltiesPayableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesUnder350000Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesOver550000Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_BCX9930Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesUnder150000Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AnnualNetSalesOver230000Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_InterestReserve" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecuredDebt" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_FutureRoyaltiesPayable" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-4-credit-agreement-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AfterFourthAnniversaryMember" xlink:label="bcrx_AfterFourthAnniversaryMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AthyriumMember" xlink:label="bcrx_AthyriumMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:label="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:label="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CreditAgreementMember" xlink:label="bcrx_CreditAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentCommitmentFeePercentage" xlink:label="bcrx_DebtInstrumentCommitmentFeePercentage" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:label="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:label="bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentLiborCap" xlink:label="bcrx_DebtInstrumentLiborCap" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentLiborFloor" xlink:label="bcrx_DebtInstrumentLiborFloor" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PikInterestPaymentIsMadeMember" xlink:label="bcrx_PikInterestPaymentIsMadeMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PriorToTheSecondAnniversaryMember" xlink:label="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermALoanMember" xlink:label="bcrx_TermALoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermBLoanMember" xlink:label="bcrx_TermBLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermCLoanMember" xlink:label="bcrx_TermCLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoanAAndBDrawnMember" xlink:label="bcrx_TermLoanAAndBDrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoanADrawnMember" xlink:label="bcrx_TermLoanADrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:label="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoansABAndCDrawnMember" xlink:label="bcrx_TermLoansABAndCDrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_CreditAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_AthyriumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_TermALoanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_TermBLoanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bcrx_TermCLoanMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_PikInterestPaymentIsMadeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_AfterFourthAnniversaryMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_TermLoanADrawnMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_TermLoanAAndBDrawnMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_TermLoansABAndCDrawnMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentLiborFloor" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentLiborCap" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentCommitmentFeePercentage" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-5-senior-credit-facility-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentMinimumLibor" xlink:label="bcrx_DebtInstrumentMinimumLibor" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:label="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:label="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:label="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentMinimumLibor" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-6-lease-obligations-and-other-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedLiabilitiesCurrentMember" xlink:label="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization" xlink:label="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-7-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" xlink:label="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_WarrantsIssuedInPublicOfferingMember" xlink:label="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-8-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_December2019Member" xlink:label="bcrx_December2019Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncentivePlanAndInducementPlanMember" xlink:label="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="bcrx_December2019Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-10-employee-401k-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:label="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:label="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ContractTerm" xlink:label="bcrx_ContractTerm" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MilestonePaymentReceived" xlink:label="bcrx_MilestonePaymentReceived" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PotentialMilestonePaymentsReceivable" xlink:label="bcrx_PotentialMilestonePaymentsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeMember" xlink:label="us-gaap_OtherIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementContractValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ContractTerm" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentReceived" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalFees" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PotentialMilestonePaymentsReceivable" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="bcrx-20201231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details" xlink:href="bcrx-20201231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details" xlink:href="bcrx-20201231.xsd#statement-note-2-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_LaboratoryEquipmentMember" xlink:label="bcrx_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="bcrx_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:href="bcrx-20201231.xsd#statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncentivePlanAndInducementPlanMember" xlink:label="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:href="bcrx-20201231.xsd#statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets" xlink:href="bcrx-20201231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_FutureRoyaltiesPayable" xlink:label="bcrx_FutureRoyaltiesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LinesOfCreditCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="bcrx_FutureRoyaltiesPayable" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:href="bcrx-20201231.xsd#statement-consolidated-statements-of-comprehensive-loss" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InterestAndOtherIncomeLoss" xlink:label="bcrx_InterestAndOtherIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="bcrx_InterestAndOtherIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20201231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" xlink:href="bcrx-20201231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedDevelopmentCosts" xlink:label="bcrx_AccruedDevelopmentCosts" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedInventoryExpense" xlink:label="bcrx_AccruedInventoryExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AccruedDevelopmentCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AccruedInventoryExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:href="bcrx-20201231.xsd#statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:label="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details" xlink:href="bcrx-20201231.xsd#statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DeferredTaxAssetsLeasingObligations" xlink:label="bcrx_DeferredTaxAssetsLeasingObligations" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DeferredTaxAssetsRoyaltyIncome" xlink:label="bcrx_DeferredTaxAssetsRoyaltyIncome" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="bcrx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DeferredTaxAssetsRoyaltyIncome" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DeferredTaxAssetsLeasingObligations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:href="bcrx-20201231.xsd#statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details" xlink:href="bcrx-20201231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:label="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows" xlink:href="bcrx-20201231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ProceedsFromRealizedGainOnInvestments" xlink:label="bcrx_ProceedsFromRealizedGainOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ProceedsFromRoyaltyFinancingObligation" xlink:label="bcrx_ProceedsFromRoyaltyFinancingObligation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromRealizedGainOnInvestments" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromRoyaltyFinancingObligation" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity" xlink:href="bcrx-20201231.xsd#statement-consolidated-statements-of-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details" xlink:href="bcrx-20201231.xsd#statement-note-8-stockbased-compensation-stock-plan-activities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:href="bcrx-20201231.xsd#statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange01Member" xlink:label="bcrx_ExercisePriceRange01Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange02Member" xlink:label="bcrx_ExercisePriceRange02Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange03Member" xlink:label="bcrx_ExercisePriceRange03Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange04Member" xlink:label="bcrx_ExercisePriceRange04Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange05Member" xlink:label="bcrx_ExercisePriceRange05Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange06Member" xlink:label="bcrx_ExercisePriceRange06Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange01Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange02Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange03Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange04Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange05Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="bcrx_ExercisePriceRange06Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>24
<FILENAME>bcrx-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:14AM UTC 2021-03-01--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DocumentAndEntityInformation" xlink:label="bcrx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DocumentAndEntityInformation" xlink:to="bcrx_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLossOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeLossOnDerivative</link:label>
    <link:label xlink:label="us-gaap_DerivativeLossOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Loss on Derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLossOnDerivative" xlink:to="us-gaap_DerivativeLossOnDerivative-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Dividend Yield</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Next Year</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share-based compensation nonvested awards compensation cost expected to be recognized next year.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:to="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentMinimumLibor" xlink:label="bcrx_DebtInstrumentMinimumLibor" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentMinimumLibor-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentMinimumLibor</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentMinimumLibor-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Minimum LIBOR</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentMinimumLibor-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum LIBOR interest that will be added to the basis spread.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentMinimumLibor" xlink:to="bcrx_DebtInstrumentMinimumLibor-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="bcrx_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="bcrx_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Significant Accounting Policies and Concentrations of Risk</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax benefit at federal statutory rate (21% for 2020, 2019 and 2018)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-2-property-and-equipment-tables" xlink:label="bcrx_statement-statement-note-2-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-property-and-equipment-tables" xlink:to="bcrx_statement-statement-note-2-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-Free Interest Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-tables" xlink:label="bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Lease Obligations and Other Contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-tables" xlink:to="bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-8-stockbased-compensation-tables" xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stock-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-8-stockbased-compensation-tables" xlink:to="bcrx_statement-statement-note-8-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeGainOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeGainOnDerivative</link:label>
    <link:label xlink:label="us-gaap_DerivativeGainOnDerivative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Gain on Derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainOnDerivative" xlink:to="us-gaap_DerivativeGainOnDerivative-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-9-income-taxes-tables" xlink:label="bcrx_statement-statement-note-9-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-9-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-9-income-taxes-tables" xlink:to="bcrx_statement-statement-note-9-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NondesignatedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NondesignatedMember" xlink:to="us-gaap_NondesignatedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-tables" xlink:label="bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-tables" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Quarterly Financial Information (Unaudited)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-tables" xlink:to="bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Significant Accounting Policies and Concentrations of Risk - Fair Value of the Company's Investments by Type (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Significant Accounting Policies and Concentrations of Risk - Summary of Receivables (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Significant Accounting Policies and Concentrations of Risk - Accrued Expenses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Significant Accounting Policies and Concentrations of Risk - Summary of Revenues (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details" xlink:to="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on available for sale investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HedgingDesignationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details" xlink:label="bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Property and Equipment - Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details" xlink:to="bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_HedgingDesignationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingDesignationDomain" xlink:to="us-gaap_HedgingDesignationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:label="bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:to="bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:label="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ArbitrationProceedingsOfSulAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arbitration Proceedings of SUL Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_ArbitrationProceedingsOfSulAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the arbitration proceedings of several terms under SUL Agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:to="bcrx_ArbitrationProceedingsOfSulAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details" xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stock-Based Compensation - Stock-based Compensation Allocation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details" xlink:to="bcrx_statement-statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-8-stockbased-compensation-stock-plan-activities-details" xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-stock-plan-activities-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-stock-plan-activities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stock-based Compensation - Stock Plan Activities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-8-stockbased-compensation-stock-plan-activities-details" xlink:to="bcrx_statement-statement-note-8-stockbased-compensation-stock-plan-activities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:to="bcrx_statement-statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stock-based Compensation - Number of Stock Option Awards Exercisable and their Weighted Average Exercise Price (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:to="bcrx_statement-statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Stock-based Compensation - Changes in the Number and Weighted-Average Grant-Date Fair Value (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:to="bcrx_statement-statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" xlink:label="bcrx_statement-statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Loss Before Provision for Income Taxes (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" xlink:to="bcrx_statement-statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:label="bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:to="bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:label="bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) (Parentheticals)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:to="bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:label="bcrx_statement-statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:to="bcrx_statement-statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:label="bcrx_statement-statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:to="bcrx_statement-statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:label="bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:type="locator"/>
    <link:label xlink:label="bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 12 - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Information (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:to="bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NotesToFinancialStatements" xlink:label="bcrx_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatements" xlink:to="bcrx_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="bcrx_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</link:label>
    <link:label xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Amount Awarded from Other Party</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales and maturities of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Awards available, Restricted stock awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-recourse notes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</link:label>
    <link:label xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignExchangeContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignExchangeContractMember" xlink:to="us-gaap_ForeignExchangeContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LinesOfCreditCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LinesOfCreditCurrent</link:label>
    <link:label xlink:label="us-gaap_LinesOfCreditCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior credit facility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LinesOfCreditCurrent" xlink:to="us-gaap_LinesOfCreditCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option awards granted (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option awards vested (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option awards forfeited (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock option awards vested (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Non-vested stock option awards (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Non-vested stock option awards (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, beginning balance (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinancialInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, stock option awards cancelled (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxesPayableCurrent</link:label>
    <link:label xlink:label="us-gaap_TaxesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Duties and taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, stock option awards granted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price, stock option awards exercised (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeRelatedLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation and benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MilestonePaymentReceived" xlink:label="bcrx_MilestonePaymentReceived" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentReceived</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Received</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentReceived-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of milestone payment received.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentReceived" xlink:to="bcrx_MilestonePaymentReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, stock option awards cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CreditFacilityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CreditFacilityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherAccruedLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireProductiveAssets</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisition of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Awards available, beginning balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Awards available, ending balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedProfessionalFeesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">(Decrease) increase in lease financing obligation</link:label>
    <link:label xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the period for financing lease obligations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:to="bcrx_IncreaseDecreaseInFinancingLeaseObligations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards available, plan amendment (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SeqirusUKLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Seqirus UK Limited [Member]</link:label>
    <link:label xlink:label="bcrx_SeqirusUKLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Seqirus UK Limited.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SeqirusUKLimitedMember" xlink:to="bcrx_SeqirusUKLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseExpense</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:label="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SecuredCreditFacilityThirdTrancheMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Credit Facility, Third Tranche [Member]</link:label>
    <link:label xlink:label="bcrx_SecuredCreditFacilityThirdTrancheMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent the third tranche of a secured credit facility.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:to="bcrx_SecuredCreditFacilityThirdTrancheMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:label="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SecuredCreditFacilitySecondTrancheMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Credit Facility, Second Tranche [Member]</link:label>
    <link:label xlink:label="bcrx_SecuredCreditFacilitySecondTrancheMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the second tranche of a secured credit facility.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:to="bcrx_SecuredCreditFacilitySecondTrancheMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:label="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SecuredCreditFacilityFirstTrancheMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Credit Facility, First Tranche [Member]</link:label>
    <link:label xlink:label="bcrx_SecuredCreditFacilityFirstTrancheMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the first tranche of a secured credit facility.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:to="bcrx_SecuredCreditFacilityFirstTrancheMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardDateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardDateDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of premium/discount on investments</link:label>
    <link:label xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of amortization expense attributable to the discount and premium on investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeasesOfLessorDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases of Lessor Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLessorDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (loss) on foreign currency</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeContractTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ExtinguishmentOfDebtAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ExtinguishmentOfDebtAmount</link:label>
    <link:label xlink:label="us-gaap_ExtinguishmentOfDebtAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest payable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInterestPayableNet</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentTerm</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term (Month)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalFees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LegalFees</link:label>
    <link:label xlink:label="us-gaap_LegalFees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollaborationReceivablesMember" xlink:label="bcrx_CollaborationReceivablesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborationReceivablesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Receivables [Member]</link:label>
    <link:label xlink:label="bcrx_CollaborationReceivablesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents receivables from collaborations for reimbursable research and development costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborationReceivablesMember" xlink:to="bcrx_CollaborationReceivablesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities</link:label>
    <link:label xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity Period of High Quality Marketable Securities (Month)</link:label>
    <link:label xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:to="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInDerivativeAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of foreign currency derivative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityperiodOfShortTermInvestment</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of Short Term Investment (Month)</link:label>
    <link:label xlink:label="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maturity period of short term investment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityperiodOfShortTermInvestment" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementContractValue</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Contract Value</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative agreement contract value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementContractValue" xlink:to="bcrx_CollaborativeAgreementContractValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateEffectivePercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:label="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MundipharmaInternationalHoldingsLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mundipharma International Holdings Limited [Member]</link:label>
    <link:label xlink:label="bcrx_MundipharmaInternationalHoldingsLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Mundipharma International Holdings Limited.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:to="bcrx_MundipharmaInternationalHoldingsLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WriteOffOfDeferredDebtIssuanceCost</link:label>
    <link:label xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Write off of Deferred Debt Issuance Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentFaceAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AverageMaturityForPortfolioInvestments" xlink:label="bcrx_AverageMaturityForPortfolioInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AverageMaturityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AverageMaturityForPortfolioInvestments</link:label>
    <link:label xlink:label="bcrx_AverageMaturityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average Maturity for Portfolio Investments (Month)</link:label>
    <link:label xlink:label="bcrx_AverageMaturityForPortfolioInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Average maturity for portfolio investments during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AverageMaturityForPortfolioInvestments" xlink:to="bcrx_AverageMaturityForPortfolioInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossRelatedToLitigationSettlement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainLossRelatedToLitigationSettlement</link:label>
    <link:label xlink:label="us-gaap_GainLossRelatedToLitigationSettlement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ServiceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Department of Health and Human Services [Member]</link:label>
    <link:label xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">United States department of health and human services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableRateDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AECOM and IRL [Member]</link:label>
    <link:label xlink:label="bcrx_AECOMAndIRLMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AECOM and IRL</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AECOMAndIRLMember" xlink:to="bcrx_AECOMAndIRLMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UAB [Member]</link:label>
    <link:label xlink:label="bcrx_UABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UAB</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UABMember" xlink:to="bcrx_UABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccountsReceivableNet</link:label>
    <link:label xlink:label="us-gaap_AccountsReceivableNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInReceivables</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of pre-funded warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableRateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents proceeds from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Receivable From Awards for Research and Development Contracts</link:label>
    <link:label xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents expected receivable from awards for research and development contracts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedLiabilitiesCurrentMember" xlink:label="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedLiabilitiesCurrentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current [Member]</link:label>
    <link:label xlink:label="bcrx_AccruedLiabilitiesCurrentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Primary financial statement caption encompassing current accrued liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedLiabilitiesCurrentMember" xlink:to="bcrx_AccruedLiabilitiesCurrentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllowanceForDoubtfulAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Contract [Member]</link:label>
    <link:label xlink:label="bcrx_BaseContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The base contract of ASPR/BARDA to support BCX4430 drug manufacturing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BaseContractMember" xlink:to="bcrx_BaseContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Development Options [Member]</link:label>
    <link:label xlink:label="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The additional development options that can be exercised by the Government.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AdditionalDevelopmentOptionsMember" xlink:to="bcrx_AdditionalDevelopmentOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASPRBARDA Contract [Member]</link:label>
    <link:label xlink:label="bcrx_ASPRBARDAContractMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The potential value of the ASPR/BARDA Contract.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ASPRBARDAContractMember" xlink:to="bcrx_ASPRBARDAContractMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Green Cross Corporation [Member]</link:label>
    <link:label xlink:label="bcrx_GreenCrossCorporationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Green Cross Corporation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_GreenCrossCorporationMember" xlink:to="bcrx_GreenCrossCorporationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMinimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Minimum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMinimum" xlink:to="bcrx_MilestonePaymentMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_TransactionCosts</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction Costs</link:label>
    <link:label xlink:label="bcrx_TransactionCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents transaction costs associated with royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TransactionCosts" xlink:to="bcrx_TransactionCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdvertisingExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdvertisingExpense</link:label>
    <link:label xlink:label="us-gaap_AdvertisingExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InterestReserve" xlink:label="bcrx_InterestReserve" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InterestReserve-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_InterestReserve</link:label>
    <link:label xlink:label="bcrx_InterestReserve-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Reserve</link:label>
    <link:label xlink:label="bcrx_InterestReserve-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest reserve established as part of the royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestReserve" xlink:to="bcrx_InterestReserve-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MilestonePaymentMaximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Maximum</link:label>
    <link:label xlink:label="bcrx_MilestonePaymentMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payment maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MilestonePaymentMaximum" xlink:to="bcrx_MilestonePaymentMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the royalty monetization transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationMember" xlink:to="bcrx_RoyaltyMonetizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents National Institute of Allergy and Infectious Diseases.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInventories</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:label="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Agreement Contract, Covenant, Maximum Amount of Funding</link:label>
    <link:label xlink:label="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents collaborative agreement contract maximum amount if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:to="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan sales, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of stock options, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, stock option awards exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</link:label>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnDispositionOfAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainLossOnDispositionOfAssets</link:label>
    <link:label xlink:label="us-gaap_GainLossOnDispositionOfAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss (gain) on disposal of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Hedge Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementMember" xlink:to="bcrx_CurrencyHedgeAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumAggregateOfferingPrice</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Offering Price</link:label>
    <link:label xlink:label="bcrx_MaximumAggregateOfferingPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumAggregateOfferingPrice" xlink:to="bcrx_MaximumAggregateOfferingPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan sales, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMinimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Minimum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represent minimum annual license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMinimum" xlink:to="bcrx_AnnualLicenseFeeMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise of stock options, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AnnualLicenseFeeMaximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual License Fee Maximum</link:label>
    <link:label xlink:label="bcrx_AnnualLicenseFeeMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual maximum license fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualLicenseFeeMaximum" xlink:to="bcrx_AnnualLicenseFeeMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option awards granted (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Stock option awards forfeited (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options outstanding, stock option awards granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ProceedsFromRealizedGainOnInvestments" xlink:label="bcrx_ProceedsFromRealizedGainOnInvestments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ProceedsFromRealizedGainOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized gain on investments</link:label>
    <link:label xlink:label="bcrx_ProceedsFromRealizedGainOnInvestments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash inflow from realized gain on investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ProceedsFromRealizedGainOnInvestments" xlink:to="bcrx_ProceedsFromRealizedGainOnInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCreditFacilityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Salary to Purchase Common Stock, Maximum</link:label>
    <link:label xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of salary to purchase common stock maximum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCommonStockSharesBeginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Shares, Beginning</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of common stock shares beginning.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesBeginning" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCommonStockSharesEnding</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Shares, Ending</link:label>
    <link:label xlink:label="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents percentage of common stock shares ending.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCommonStockSharesEnding" xlink:to="bcrx_PercentageOfCommonStockSharesEnding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee, Amount</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:to="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ProceedsFromRoyaltyFinancingObligation" xlink:label="bcrx_ProceedsFromRoyaltyFinancingObligation" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ProceedsFromRoyaltyFinancingObligation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from royalty financing obligation</link:label>
    <link:label xlink:label="bcrx_ProceedsFromRoyaltyFinancingObligation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of cash inflow from royalty financing obligation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ProceedsFromRoyaltyFinancingObligation" xlink:to="bcrx_ProceedsFromRoyaltyFinancingObligation-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense and Royalty Financing Obligation [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for interest expense and royalty financing obligation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:to="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpenseDebt</link:label>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization" xlink:label="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization" xlink:type="locator"/>
    <link:label xlink:label="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization</link:label>
    <link:label xlink:label="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:label xlink:label="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of accumulated amortization on lessee's right to use underlying asset under operating lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization" xlink:to="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of Agreement (Year)</link:label>
    <link:label xlink:label="bcrx_PeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PeriodOfAgreement" xlink:to="bcrx_PeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DeferredTaxAssetsRoyaltyIncome" xlink:label="bcrx_DeferredTaxAssetsRoyaltyIncome" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredTaxAssetsRoyaltyIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty income</link:label>
    <link:label xlink:label="bcrx_DeferredTaxAssetsRoyaltyIncome-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from royalty income.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredTaxAssetsRoyaltyIncome" xlink:to="bcrx_DeferredTaxAssetsRoyaltyIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RenewablePeriodOfAgreement</link:label>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewable Period of Agreement (Year)</link:label>
    <link:label xlink:label="bcrx_RenewablePeriodOfAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents renewable period of agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RenewablePeriodOfAgreement" xlink:to="bcrx_RenewablePeriodOfAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NotesPayableFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_NotesPayableFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableFairValueDisclosure" xlink:to="us-gaap_NotesPayableFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Plan [Member]</link:label>
    <link:label xlink:label="bcrx_IncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Incentive Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncentivePlanMember" xlink:to="bcrx_IncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncentivePlanAndInducementPlanMember" xlink:label="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncentivePlanAndInducementPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incentive Plan and Inducement Plan [Member]</link:label>
    <link:label xlink:label="bcrx_IncentivePlanAndInducementPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the incentive and inducement plans.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncentivePlanAndInducementPlanMember" xlink:to="bcrx_IncentivePlanAndInducementPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xlink:label="bcrx_EmployeeStockPurchasePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan, (ESPP).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeStockPurchasePlanMember" xlink:to="bcrx_EmployeeStockPurchasePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_December2019Member" xlink:label="bcrx_December2019Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_December2019Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2019 [Member]</link:label>
    <link:label xlink:label="bcrx_December2019Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of December 2019.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_December2019Member" xlink:to="bcrx_December2019Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseLiabilityNoncurrent</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Monetization [Text Block]</link:label>
    <link:label xlink:label="bcrx_RoyaltyMonetizationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyMonetizationTextBlock" xlink:to="bcrx_RoyaltyMonetizationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="bcrx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredTaxLiabilitiesRightOfUseAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DeferredTaxLiabilitiesRightOfUseAssets</link:label>
    <link:label xlink:label="bcrx_DeferredTaxLiabilitiesRightOfUseAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Right of use asset</link:label>
    <link:label xlink:label="bcrx_DeferredTaxLiabilitiesRightOfUseAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of deferred tax consequences attributable to taxable temporary differences derived from right of use assets.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:to="bcrx_DeferredTaxLiabilitiesRightOfUseAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DeferredTaxAssetsLeasingObligations" xlink:label="bcrx_DeferredTaxAssetsLeasingObligations" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DeferredTaxAssetsLeasingObligations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasing obligations</link:label>
    <link:label xlink:label="bcrx_DeferredTaxAssetsLeasingObligations-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from leasing obligations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DeferredTaxAssetsLeasingObligations" xlink:to="bcrx_DeferredTaxAssetsLeasingObligations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaximumCustomaryReductionOnRoyaltyRate</link:label>
    <link:label xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum Customary Reduction on Royalty Rate</link:label>
    <link:label xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum percentage of customary reductions allowed on royalty rate.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:to="bcrx_MaximumCustomaryReductionOnRoyaltyRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseLiabilityCurrent</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyRateIfMaintainsSakigakeDesignation</link:label>
    <link:label xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Rate if Maintains Sakigake Designation</link:label>
    <link:label xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:to="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021</link:label>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2021</link:label>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of potential milestone payments receivable if regulatory approval is granted before December 31, 2021.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:to="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease financing obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FinanceLeaseLiabilityNoncurrent</link:label>
    <link:label xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease financing obligation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial</link:label>
    <link:label xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Payments Receivable, Expiration Term From First Commercial (Year)</link:label>
    <link:label xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The expiration term of the royalty payments from first commercial date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:to="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseRightOfUseAsset</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards available, stock option awards cancelled (in shares)</link:label>
    <link:label xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award options forfeitures in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PrivatePlacementOfSeniorSecuredNotes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement of Senior Secured Notes</link:label>
    <link:label xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents private placement of senior secured notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_LongtermInvestmentMaturityMinimum</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Investment Maturity, Minimum (Month)</link:label>
    <link:label xlink:label="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents long term investment maturity minimum.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LongtermInvestmentMaturityMinimum" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JPR Royalty Sub LLC [Member]</link:label>
    <link:label xlink:label="bcrx_JPRRoyaltySubLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents JPR Royalty Sub LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_JPRRoyaltySubLLCMember" xlink:to="bcrx_JPRRoyaltySubLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Receivable [Member]</link:label>
    <link:label xlink:label="bcrx_RoyaltyReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents royalty receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyReceivableMember" xlink:to="bcrx_RoyaltyReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PhaRMA Notes Member]</link:label>
    <link:label xlink:label="bcrx_PhaRMANotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents PhaRMA notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PhaRMANotesMember" xlink:to="bcrx_PhaRMANotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseTermOfContract</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral for Credit [Member]</link:label>
    <link:label xlink:label="bcrx_CollateralForCreditMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted cash and cash equivalents required to maintain as collateral for a letter of credit.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollateralForCreditMember" xlink:to="bcrx_CollateralForCreditMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RAPIVAB [Member]</link:label>
    <link:label xlink:label="bcrx_RAPIVABMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents RAPIVAB product.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RAPIVABMember" xlink:to="bcrx_RAPIVABMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity Period of High Quality Marketable Securities (Year)</link:label>
    <link:label xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents maturity period of high quality marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Interest</link:label>
    <link:label xlink:label="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of accrued interest in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:to="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value; shares authorized &#8212; 450,000; shares issued and outstanding &#8212; 176,883 at December 31, 2020 and 154,082 at December 31, 2019</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CertificatesOfDepositMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasePayments</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Receivables from Collaborations [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure representing receivables from collaborations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShionogiAndCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shionogi and Co. Ltd [Member]</link:label>
    <link:label xlink:label="bcrx_ShionogiAndCoLtdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shionogi &amp; Co. Ltd.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShionogiAndCoLtdMember" xlink:to="bcrx_ShionogiAndCoLtdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.01 par value; shares authorized &#8212; 5,000; no shares outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CSLLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CSL Limited [Member</link:label>
    <link:label xlink:label="bcrx_CSLLimitedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents CSL Limited which is a company organized under the laws of Australia.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CSLLimitedMember" xlink:to="bcrx_CSLLimitedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsOther</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOther-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:label="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xlink:label="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of undiscounted cash flows of both operating and finance lease liabilities. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating and finance lease liabilities recognized in statement of financial position.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:to="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredIncomeTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromCollaborators-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromCollaborators</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromCollaborators-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWorkInProcess-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryWorkInProcess</link:label>
    <link:label xlink:label="us-gaap_InventoryWorkInProcess-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryValuationReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryValuationReserves</link:label>
    <link:label xlink:label="us-gaap_InventoryValuationReserves-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Valuation Reserves, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryValuationReserves" xlink:to="us-gaap_InventoryValuationReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryFinishedGoods-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryFinishedGoods</link:label>
    <link:label xlink:label="us-gaap_InventoryFinishedGoods-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ContractTerm" xlink:label="bcrx_ContractTerm" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ContractTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ContractTerm</link:label>
    <link:label xlink:label="bcrx_ContractTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Term (Year)</link:label>
    <link:label xlink:label="bcrx_ContractTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period of time between the contract date and its expiration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ContractTerm" xlink:to="bcrx_ContractTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryRawMaterials-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InventoryRawMaterials</link:label>
    <link:label xlink:label="us-gaap_InventoryRawMaterials-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromLicenseFeesReceived</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:label xlink:label="us-gaap_ReceivablesNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ReceivablesNetCurrent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator"/>
    <link:label xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Awards available, stock option awards granted (in shares)</link:label>
    <link:label xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents share based compensation arrangement by share based payment award options grants in period awards available.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" xlink:label="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant</link:label>
    <link:label xlink:label="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Warrants Issued, Price Per Warrant (in dollars per share)</link:label>
    <link:label xlink:label="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Per share or per unit amount of warrants issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" xlink:to="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenuesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_WarrantsIssuedInPublicOfferingMember" xlink:label="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_WarrantsIssuedInPublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Public Offering [Member]</link:label>
    <link:label xlink:label="bcrx_WarrantsIssuedInPublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents warrants issued in public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:to="bcrx_WarrantsIssuedInPublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Company [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The description of company policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net federal and state operating losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of year</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LicenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued expenses policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedExpensesPolicyTextBlock" xlink:to="bcrx_AccruedExpensesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense and Deferred Financing Costs [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents interest expense and deferred financing costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency Hedge Agreement [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents currency hedge agreement policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</link:label>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration of Market Risk [Policy Text Block]</link:label>
    <link:label xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents concentration of market risk policy.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsAndServicesSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingStandardsUpdate201409Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestPayableCurrentAndNoncurrent</link:label>
    <link:label xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingStandardsUpdate201602Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfAdoptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fixed assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfDebtExtinguishmentCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for Debt Extinguishment or Debt Prepayment Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MidCapFinancialServicesLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MidCap Financial Services, LLC [Member]</link:label>
    <link:label xlink:label="bcrx_MidCapFinancialServicesLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents MidCap Financial Services, LLC entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MidCapFinancialServicesLLCMember" xlink:to="bcrx_MidCapFinancialServicesLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:label="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts</link:label>
    <link:label xlink:label="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Debt Financing Costs and Original Issue Discounts</link:label>
    <link:label xlink:label="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of amortization of debt financing costs and original issue discounts.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:to="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_SeniorCreditFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Credit Facility [Member]</link:label>
    <link:label xlink:label="bcrx_SeniorCreditFacilityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents senior credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_SeniorCreditFacilityMember" xlink:to="bcrx_SeniorCreditFacilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CostsAndExpenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InducementPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Plan [Member]</link:label>
    <link:label xlink:label="bcrx_InducementPlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the Inducement Plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InducementPlanMember" xlink:to="bcrx_InducementPlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedDevelopmentCosts" xlink:label="bcrx_AccruedDevelopmentCosts" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedDevelopmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AccruedDevelopmentCosts</link:label>
    <link:label xlink:label="bcrx_AccruedDevelopmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development costs</link:label>
    <link:label xlink:label="bcrx_AccruedDevelopmentCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents accrued development costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedDevelopmentCosts" xlink:to="bcrx_AccruedDevelopmentCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of pre-funded warrants</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedInventoryExpense" xlink:label="bcrx_AccruedInventoryExpense" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedInventoryExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_AccruedInventoryExpense</link:label>
    <link:label xlink:label="bcrx_AccruedInventoryExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label xlink:label="bcrx_AccruedInventoryExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of accrued inventory expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedInventoryExpense" xlink:to="bcrx_AccruedInventoryExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from common stock issued under stock-based compensation plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_MundipharmaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mundipharma [Member]</link:label>
    <link:label xlink:label="bcrx_MundipharmaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Mundipharma.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_MundipharmaMember" xlink:to="bcrx_MundipharmaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of common stock, net</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PercentageOfCarryingAmountInExcessOfFairValue1</link:label>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Carrying Amount in Excess of Fair Value</link:label>
    <link:label xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of carrying amount in excess of fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_LaboratoryEquipmentMember" xlink:label="bcrx_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label xlink:label="bcrx_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to laboratory equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LaboratoryEquipmentMember" xlink:to="bcrx_LaboratoryEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebt</link:label>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNoncurrentAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentAssetsMember" xlink:to="us-gaap_OtherNoncurrentAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred collaboration revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest Upon Successful Completion of Specific Development Milestones [Member]</link:label>
    <link:label xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vesting upon successful completion of specific development milestones.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_December2014Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2014 [Member]</link:label>
    <link:label xlink:label="bcrx_December2014Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of December 2014.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_December2014Member" xlink:to="bcrx_December2014Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_August2013Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">August 2013 [Member]</link:label>
    <link:label xlink:label="bcrx_August2013Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents award date of August 2013.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_August2013Member" xlink:to="bcrx_August2013Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LineOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior credit facility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest 25% Each Year Until Fully Vested [Member]</link:label>
    <link:label xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents vest 25% each year until fully vested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredFinanceCostsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredFinanceCostsNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SecuredDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SecuredDebt</link:label>
    <link:label xlink:label="us-gaap_SecuredDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebt" xlink:to="us-gaap_SecuredDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ForeignCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfLongTermDebt</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OfficeEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ORLADEYOMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ORLADEYO [Member]</link:label>
    <link:label xlink:label="bcrx_ORLADEYOMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents ORLADEYO.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ORLADEYOMember" xlink:to="bcrx_ORLADEYOMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InterestAndOtherIncomeLoss" xlink:label="bcrx_InterestAndOtherIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="bcrx_InterestAndOtherIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and other income</link:label>
    <link:label xlink:label="bcrx_InterestAndOtherIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of interest income and other income (loss) recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income (loss) from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_InterestAndOtherIncomeLoss" xlink:to="bcrx_InterestAndOtherIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesUnder350000Member" xlink:label="bcrx_AnnualNetSalesUnder350000Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualNetSalesUnder350000Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Under $350,000 [Member]</link:label>
    <link:label xlink:label="bcrx_AnnualNetSalesUnder350000Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales under $350,000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualNetSalesUnder350000Member" xlink:to="bcrx_AnnualNetSalesUnder350000Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesBetween350000And550000Member" xlink:label="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualNetSalesBetween350000And550000Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Between $350,000 and $550,000 [Member]</link:label>
    <link:label xlink:label="bcrx_AnnualNetSalesBetween350000And550000Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales between $350,000 and $550,000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:to="bcrx_AnnualNetSalesBetween350000And550000Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesOver550000Member" xlink:label="bcrx_AnnualNetSalesOver550000Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualNetSalesOver550000Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Over $550,000 [Member]</link:label>
    <link:label xlink:label="bcrx_AnnualNetSalesOver550000Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales over $550,000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualNetSalesOver550000Member" xlink:to="bcrx_AnnualNetSalesOver550000Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComputerEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement, Royalties, Percentage of Global Annual Net Sales</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of global annual net sales of royalties to be paid under the royalty purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Key Territories</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of net sales in key territories for royalties to be paid under the royalty purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SoftwareDevelopmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Development [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesBetween150000And230000Member" xlink:label="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualNetSalesBetween150000And230000Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Between $150,000 and $230,000 [Member]</link:label>
    <link:label xlink:label="bcrx_AnnualNetSalesBetween150000And230000Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales between $150,000 and $230,000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:to="bcrx_AnnualNetSalesBetween150000And230000Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesOver230000Member" xlink:label="bcrx_AnnualNetSalesOver230000Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualNetSalesOver230000Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Over $230,000 [Member]</link:label>
    <link:label xlink:label="bcrx_AnnualNetSalesOver230000Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales over $230,000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualNetSalesOver230000Member" xlink:to="bcrx_AnnualNetSalesOver230000Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OpenTaxYear</link:label>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Tax Year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BCX9930Member" xlink:label="bcrx_BCX9930Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BCX9930Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BCX9930 [Member]</link:label>
    <link:label xlink:label="bcrx_BCX9930Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents BCX9930.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BCX9930Member" xlink:to="bcrx_BCX9930Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement, Royalties, Percentage of Sublicense Revenue in Other Markets</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of sublicense revenue in other markets of royalties to be paid under the royalty purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:type="locator"/>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Other Markets</link:label>
    <link:label xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of annual net sales in other markets of royalties to be paid under the royalty purchase agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesUnder150000Member" xlink:label="bcrx_AnnualNetSalesUnder150000Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AnnualNetSalesUnder150000Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual Net Sales Under $150,000 [Member]</link:label>
    <link:label xlink:label="bcrx_AnnualNetSalesUnder150000Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents annual net sales under $150,000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AnnualNetSalesUnder150000Member" xlink:to="bcrx_AnnualNetSalesUnder150000Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermALoanMember" xlink:label="bcrx_TermALoanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TermALoanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term A Loan [Member]</link:label>
    <link:label xlink:label="bcrx_TermALoanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents term A loan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TermALoanMember" xlink:to="bcrx_TermALoanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermBLoanMember" xlink:label="bcrx_TermBLoanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TermBLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term B Loan [Member]</link:label>
    <link:label xlink:label="bcrx_TermBLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents term B loan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TermBLoanMember" xlink:to="bcrx_TermBLoanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermCLoanMember" xlink:label="bcrx_TermCLoanMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TermCLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term C Loan [Member]</link:label>
    <link:label xlink:label="bcrx_TermCLoanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents term C loan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TermCLoanMember" xlink:to="bcrx_TermCLoanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_FutureRoyaltiesPayableMember" xlink:label="bcrx_FutureRoyaltiesPayableMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_FutureRoyaltiesPayableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Royalties Payable [Member]</link:label>
    <link:label xlink:label="bcrx_FutureRoyaltiesPayableMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents future royalties payable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_FutureRoyaltiesPayableMember" xlink:to="bcrx_FutureRoyaltiesPayableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_FutureRoyaltiesPayable" xlink:label="bcrx_FutureRoyaltiesPayable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_FutureRoyaltiesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty financing obligation</link:label>
    <link:label xlink:label="bcrx_FutureRoyaltiesPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Royalties Payable</link:label>
    <link:label xlink:label="bcrx_FutureRoyaltiesPayable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying amount as of the balance sheet date of obligations for future royalties.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_FutureRoyaltiesPayable" xlink:to="bcrx_FutureRoyaltiesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CreditAgreementMember" xlink:label="bcrx_CreditAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CreditAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label xlink:label="bcrx_CreditAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the credit agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CreditAgreementMember" xlink:to="bcrx_CreditAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to current period tax positions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AthyriumMember" xlink:label="bcrx_AthyriumMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AthyriumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Athyrium [Member]</link:label>
    <link:label xlink:label="bcrx_AthyriumMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Athyrium Opportunities III Co-Invest 1 LP (&#8220;Athyrium&#8221;).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AthyriumMember" xlink:to="bcrx_AthyriumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentLiborFloor" xlink:label="bcrx_DebtInstrumentLiborFloor" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentLiborFloor-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentLiborFloor</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentLiborFloor-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, LIBOR Floor</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentLiborFloor-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum LIBOR interest rate for debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentLiborFloor" xlink:to="bcrx_DebtInstrumentLiborFloor-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfLongTermDebt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentLiborCap" xlink:label="bcrx_DebtInstrumentLiborCap" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentLiborCap-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentLiborCap</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentLiborCap-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, LIBOR Cap</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentLiborCap-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum LIBOR interest rate for debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentLiborCap" xlink:to="bcrx_DebtInstrumentLiborCap-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivableTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TradeAccountsReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAccountsReceivableMember" xlink:to="us-gaap_TradeAccountsReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PikInterestPaymentIsMadeMember" xlink:label="bcrx_PikInterestPaymentIsMadeMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PikInterestPaymentIsMadeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PIK Interest Payment is Made [Member]</link:label>
    <link:label xlink:label="bcrx_PikInterestPaymentIsMadeMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents PIK interest payment is made.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PikInterestPaymentIsMadeMember" xlink:to="bcrx_PikInterestPaymentIsMadeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeMember" xlink:label="us-gaap_OtherIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeMember" xlink:to="us-gaap_OtherIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percentage of Accrued Interest</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of interest that would have accrued on principal voluntary paid for prepayment fee of the debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:to="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billing Status, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AfterFourthAnniversaryMember" xlink:label="bcrx_AfterFourthAnniversaryMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AfterFourthAnniversaryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">After Fourth Anniversary [Member]</link:label>
    <link:label xlink:label="bcrx_AfterFourthAnniversaryMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents after the fourth anniversary.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AfterFourthAnniversaryMember" xlink:to="bcrx_AfterFourthAnniversaryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesBillingStatusDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables Billing Status [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesBillingStatusDomain" xlink:to="us-gaap_ReceivablesBillingStatusDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:label="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BetweenTheThirdAndFourthAnniversariesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Between the Third and Fourth Anniversaries [Member]</link:label>
    <link:label xlink:label="bcrx_BetweenTheThirdAndFourthAnniversariesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents after the third anniversary and before the fourth anniversary.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:to="bcrx_BetweenTheThirdAndFourthAnniversariesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnbilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unbilled Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledRevenuesMember" xlink:to="us-gaap_UnbilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BilledRevenuesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Billed Revenues [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledRevenuesMember" xlink:to="us-gaap_BilledRevenuesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from secured term loan</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percentage of Principal Voluntary Payments</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of principal paid voluntarily for prepayment fee of the debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:to="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants issued (in shares)</link:label>
    <link:label xlink:label="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:to="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity of Counterparty, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity Type of Counterparty [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:label="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_BetweenTheSecondAndThirdAnniversariesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Between the Second and Third Anniversaries [Member]</link:label>
    <link:label xlink:label="bcrx_BetweenTheSecondAndThirdAnniversariesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents between the second and third anniversaries.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:to="bcrx_BetweenTheSecondAndThirdAnniversariesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PriorToTheSecondAnniversaryMember" xlink:label="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PriorToTheSecondAnniversaryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior to the Second Anniversary [Member]</link:label>
    <link:label xlink:label="bcrx_PriorToTheSecondAnniversaryMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents prior to the second anniversary.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PriorToTheSecondAnniversaryMember" xlink:to="bcrx_PriorToTheSecondAnniversaryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:label="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Minimum Unrestricted Cash and Cash Equivalents</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum amount of unrestricted cash and cash equivalents required under the covenant of the debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:to="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoanADrawnMember" xlink:label="bcrx_TermLoanADrawnMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TermLoanADrawnMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan A Drawn [Member]</link:label>
    <link:label xlink:label="bcrx_TermLoanADrawnMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents term loan A drawn.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TermLoanADrawnMember" xlink:to="bcrx_TermLoanADrawnMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoanAAndBDrawnMember" xlink:label="bcrx_TermLoanAAndBDrawnMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TermLoanAAndBDrawnMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan A and B Drawn [Member]</link:label>
    <link:label xlink:label="bcrx_TermLoanAAndBDrawnMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents term loan A and B drawn.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TermLoanAAndBDrawnMember" xlink:to="bcrx_TermLoanAAndBDrawnMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoansABAndCDrawnMember" xlink:label="bcrx_TermLoansABAndCDrawnMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TermLoansABAndCDrawnMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loans A, B and C Drawn [Member]</link:label>
    <link:label xlink:label="bcrx_TermLoansABAndCDrawnMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents term loans A, B and C drawn.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TermLoansABAndCDrawnMember" xlink:to="bcrx_TermLoansABAndCDrawnMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:label="bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentExitFeePercentageOfPrincipal-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentExitFeePercentageOfPrincipal</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentExitFeePercentageOfPrincipal-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Exit Fee, Percentage of Principal</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentExitFeePercentageOfPrincipal-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of principal for exit fee of the debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:to="bcrx_DebtInstrumentExitFeePercentageOfPrincipal-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:label="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current and Other Noncurrent Liabilities [Member]</link:label>
    <link:label xlink:label="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to accrued liabilities, current and other noncurrent liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:to="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentCommitmentFeePercentage" xlink:label="bcrx_DebtInstrumentCommitmentFeePercentage" xlink:type="locator"/>
    <link:label xlink:label="bcrx_DebtInstrumentCommitmentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_DebtInstrumentCommitmentFeePercentage</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentCommitmentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Commitment Fee Percentage</link:label>
    <link:label xlink:label="bcrx_DebtInstrumentCommitmentFeePercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The commitment fee percentage of the debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_DebtInstrumentCommitmentFeePercentage" xlink:to="bcrx_DebtInstrumentCommitmentFeePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:label="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loans A, B and C Drawn and Cure Right Exercised [Member]</link:label>
    <link:label xlink:label="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents term loans A, B and C drawn and the Cure Right has been exercised.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:to="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxCreditCarryforwardAmount</link:label>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfLinesOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfLinesOfCredit</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfLinesOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfLinesOfCredit-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of senior credit facility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromLinesOfCredit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from senior credit facility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_Rpi2019IntermediateFinanceTrustMember" xlink:label="bcrx_Rpi2019IntermediateFinanceTrustMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_Rpi2019IntermediateFinanceTrustMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RPI 2019 Intermediate Finance Trust [Member]</link:label>
    <link:label xlink:label="bcrx_Rpi2019IntermediateFinanceTrustMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents RPI 2019 Intermediate Finance Trust (RPI)..</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_Rpi2019IntermediateFinanceTrustMember" xlink:to="bcrx_Rpi2019IntermediateFinanceTrustMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange01Member" xlink:label="bcrx_ExercisePriceRange01Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange01Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 01 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange01Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the first exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange01Member" xlink:to="bcrx_ExercisePriceRange01Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange03Member" xlink:label="bcrx_ExercisePriceRange03Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange03Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 03 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange03Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the third exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange03Member" xlink:to="bcrx_ExercisePriceRange03Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange02Member" xlink:label="bcrx_ExercisePriceRange02Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange02Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 02 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange02Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the second exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange02Member" xlink:to="bcrx_ExercisePriceRange02Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange05Member" xlink:label="bcrx_ExercisePriceRange05Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange05Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 05 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange05Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the fifth exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange05Member" xlink:to="bcrx_ExercisePriceRange05Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange04Member" xlink:label="bcrx_ExercisePriceRange04Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange04Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 04 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange04Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the fourth exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange04Member" xlink:to="bcrx_ExercisePriceRange04Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange06Member" xlink:label="bcrx_ExercisePriceRange06Member" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ExercisePriceRange06Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 06 [Member]</link:label>
    <link:label xlink:label="bcrx_ExercisePriceRange06Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to the sixth exercise range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ExercisePriceRange06Member" xlink:to="bcrx_ExercisePriceRange06Member-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="locator"/>
    <link:label xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration of attribute carryforwards</link:label>
    <link:label xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income tax reconciliation income tax expense benefit expiration of carryforwards.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:to="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount" xlink:type="locator"/>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_UpfrontPaymentsReceivableAmount</link:label>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Payments Receivable Amount</link:label>
    <link:label xlink:label="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents upfront payments receivable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_UpfrontPaymentsReceivableAmount" xlink:to="bcrx_UpfrontPaymentsReceivableAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PotentialMilestonePaymentsReceivable" xlink:label="bcrx_PotentialMilestonePaymentsReceivable" xlink:type="locator"/>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_PotentialMilestonePaymentsReceivable</link:label>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments Receivable</link:label>
    <link:label xlink:label="bcrx_PotentialMilestonePaymentsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents potential milestone payments receivable based on possibility of future event payments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_PotentialMilestonePaymentsReceivable" xlink:to="bcrx_PotentialMilestonePaymentsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative and Other Research and Development [Member]</link:label>
    <link:label xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Collaborative and other research and development.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfDebt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment, Office Equipment and Software [Member]</link:label>
    <link:label xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to laboratory equipment, office equipment and software.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GovernmentContractReceivable</link:label>
    <link:label xlink:label="us-gaap_GovernmentContractReceivable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Contract Receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GovernmentContractReceivable" xlink:to="us-gaap_GovernmentContractReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCommitmentsDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationOtherAdjustments</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax benefit at federal statutory rate, percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rate change</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased</link:label>
    <link:label xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:label xlink:label="bcrx_ToriiPharmaceuticalCoMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Torii Pharmaceutical Co. [Member]</link:label>
    <link:label xlink:label="bcrx_ToriiPharmaceuticalCoMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to Torii Pharmaceutical Co., Ltd.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_ToriiPharmaceuticalCoMember" xlink:to="bcrx_ToriiPharmaceuticalCoMember-label" xlink:type="arc"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:type="locator"/>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</link:label>
    <link:label xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; (deficit) equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Permanent items</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured term loan</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Weighted Average Remaining Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable Number (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upper Exercise Price Range (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Number (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeForwardExchangeRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeForwardExchangeRate1</link:label>
    <link:label xlink:label="us-gaap_DerivativeForwardExchangeRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, Forward Exchange Rate (in JPY per USD)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeForwardExchangeRate1" xlink:to="us-gaap_DerivativeForwardExchangeRate1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and local income taxes net of federal tax benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign rate differential</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lower Exercise Price Range (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>25
<FILENAME>bcrx-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:14AM UTC 2021-03-01--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited" xlink:href="bcrx-20201231.xsd#statement-note-12-quarterly-financial-information-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-document-and-entity-information" xlink:href="bcrx-20201231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:href="bcrx-20201231.xsd#statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:href="bcrx-20201231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollaborationReceivablesMember" xlink:label="bcrx_CollaborationReceivablesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="bcrx_CollaborationReceivablesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_TradeAccountsReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment" xlink:href="bcrx-20201231.xsd#statement-note-2-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations" xlink:href="bcrx-20201231.xsd#statement-note-3-royalty-monetizations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesBetween150000And230000Member" xlink:label="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesBetween350000And550000Member" xlink:label="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesOver230000Member" xlink:label="bcrx_AnnualNetSalesOver230000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesOver550000Member" xlink:label="bcrx_AnnualNetSalesOver550000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesUnder150000Member" xlink:label="bcrx_AnnualNetSalesUnder150000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesUnder350000Member" xlink:label="bcrx_AnnualNetSalesUnder350000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BCX9930Member" xlink:label="bcrx_BCX9930Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_FutureRoyaltiesPayableMember" xlink:label="bcrx_FutureRoyaltiesPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyMonetizationTextBlock" xlink:label="bcrx_RoyaltyMonetizationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_Rpi2019IntermediateFinanceTrustMember" xlink:label="bcrx_Rpi2019IntermediateFinanceTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_Rpi2019IntermediateFinanceTrustMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_FutureRoyaltiesPayableMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesUnder350000Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesOver550000Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_BCX9930Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesUnder150000Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesOver230000Member" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="bcrx_RoyaltyMonetizationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement" xlink:href="bcrx-20201231.xsd#statement-note-4-credit-agreement" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AfterFourthAnniversaryMember" xlink:label="bcrx_AfterFourthAnniversaryMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AthyriumMember" xlink:label="bcrx_AthyriumMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:label="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:label="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CreditAgreementMember" xlink:label="bcrx_CreditAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PikInterestPaymentIsMadeMember" xlink:label="bcrx_PikInterestPaymentIsMadeMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PriorToTheSecondAnniversaryMember" xlink:label="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermALoanMember" xlink:label="bcrx_TermALoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermBLoanMember" xlink:label="bcrx_TermBLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermCLoanMember" xlink:label="bcrx_TermCLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoanAAndBDrawnMember" xlink:label="bcrx_TermLoanAAndBDrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoanADrawnMember" xlink:label="bcrx_TermLoanADrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:label="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoansABAndCDrawnMember" xlink:label="bcrx_TermLoansABAndCDrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_CreditAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_AthyriumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_TermALoanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_TermBLoanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_TermCLoanMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_PikInterestPaymentIsMadeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AfterFourthAnniversaryMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_TermLoanADrawnMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_TermLoanAAndBDrawnMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_TermLoansABAndCDrawnMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility" xlink:href="bcrx-20201231.xsd#statement-note-5-senior-credit-facility" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:label="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:label="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:label="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies" xlink:href="bcrx-20201231.xsd#statement-note-6-lease-obligations-and-other-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedLiabilitiesCurrentMember" xlink:label="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LeasesOfLessorDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity" xlink:href="bcrx-20201231.xsd#statement-note-7-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_WarrantsIssuedInPublicOfferingMember" xlink:label="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation" xlink:href="bcrx-20201231.xsd#statement-note-8-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_December2019Member" xlink:label="bcrx_December2019Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncentivePlanAndInducementPlanMember" xlink:label="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2019Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-" xlink:href="bcrx-20201231.xsd#statement-note-10-employee-401k-plan-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts" xlink:href="bcrx-20201231.xsd#statement-note-11-collaborative-and-other-research-and-development-contracts" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:label="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NotesToFinancialStatementsAbstract" xlink:label="bcrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeMember" xlink:label="us-gaap_OtherIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_LicenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ServiceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_OtherIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies" xlink:href="bcrx-20201231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedExpensesPolicyTextBlock" xlink:label="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:label="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:label="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:label="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:label="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-significant-accounting-policies-policies" xlink:label="bcrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_DescriptionOfCompanyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_AccruedExpensesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_CurrencyHedgeAgreementPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bcrx_ConcentrationOfMarketRiskPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:href="bcrx-20201231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:label="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-tables" xlink:href="bcrx-20201231.xsd#statement-note-2-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-2-property-and-equipment-tables" xlink:label="bcrx_statement-statement-note-2-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-property-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-tables" xlink:href="bcrx-20201231.xsd#statement-note-6-lease-obligations-and-other-contingencies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:label="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-tables" xlink:label="bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="bcrx_LesseeLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables" xlink:href="bcrx-20201231.xsd#statement-note-8-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-8-stockbased-compensation-tables" xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-8-stockbased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-9-income-taxes-tables" xlink:label="bcrx_statement-statement-note-9-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-9-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-tables" xlink:href="bcrx-20201231.xsd#statement-note-12-quarterly-financial-information-unaudited-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-tables" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-tables" xlink:label="bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts" xlink:label="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AverageMaturityForPortfolioInvestments" xlink:label="bcrx_AverageMaturityForPortfolioInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities" xlink:label="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollaborationReceivablesMember" xlink:label="bcrx_CollaborationReceivablesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollateralForCreditMember" xlink:label="bcrx_CollateralForCreditMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:label="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_LongtermInvestmentMaturityMinimum" xlink:label="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MaturityPeriodOfHighQualityMarketablesecurities" xlink:label="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MaturityperiodOfShortTermInvestment" xlink:label="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RAPIVABMember" xlink:label="bcrx_RAPIVABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyReceivableMember" xlink:label="bcrx_RoyaltyReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryValuationReserves" xlink:label="us-gaap_InventoryValuationReserves-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_RoyaltyReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="bcrx_CollateralForCreditMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="bcrx_CollaborationReceivablesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_RAPIVABMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_TradeAccountsReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityPeriodOfHighQualityMarketablesecurities-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaturityperiodOfShortTermInvestment-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_LongtermInvestmentMaturityMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNet-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterials-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcess-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoods-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryValuationReserves-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdvertisingExpense-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AverageMaturityForPortfolioInvestments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-2-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-3-royalty-monetizations-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesBetween150000And230000Member" xlink:label="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesBetween350000And550000Member" xlink:label="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesOver230000Member" xlink:label="bcrx_AnnualNetSalesOver230000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesOver550000Member" xlink:label="bcrx_AnnualNetSalesOver550000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesUnder150000Member" xlink:label="bcrx_AnnualNetSalesUnder150000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualNetSalesUnder350000Member" xlink:label="bcrx_AnnualNetSalesUnder350000Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BCX9930Member" xlink:label="bcrx_BCX9930Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CurrencyHedgeAgreementMember" xlink:label="bcrx_CurrencyHedgeAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_FutureRoyaltiesPayable" xlink:label="bcrx_FutureRoyaltiesPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_FutureRoyaltiesPayableMember" xlink:label="bcrx_FutureRoyaltiesPayableMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InterestReserve" xlink:label="bcrx_InterestReserve-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_JPRRoyaltySubLLCMember" xlink:label="bcrx_JPRRoyaltySubLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ORLADEYOMember" xlink:label="bcrx_ORLADEYOMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PercentageOfCarryingAmountInExcessOfFairValue1" xlink:label="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PhaRMANotesMember" xlink:label="bcrx_PhaRMANotesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PrivatePlacementOfSeniorSecuredNotes" xlink:label="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyMonetizationMember" xlink:label="bcrx_RoyaltyMonetizationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets" xlink:label="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_Rpi2019IntermediateFinanceTrustMember" xlink:label="bcrx_Rpi2019IntermediateFinanceTrustMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TransactionCosts" xlink:label="bcrx_TransactionCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeForwardExchangeRate1" xlink:label="us-gaap_DerivativeForwardExchangeRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="us-gaap_DerivativeGainOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLossOnDerivative" xlink:label="us-gaap_DerivativeLossOnDerivative-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="us-gaap_ForeignExchangeContractMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="us-gaap_HedgingDesignationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="us-gaap_HedgingDesignationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="us-gaap_NondesignatedMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="us-gaap_NotesPayableFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="us-gaap_OtherCommitmentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SecuredDebt" xlink:label="us-gaap_SecuredDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_HedgingDesignationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="bcrx_JPRRoyaltySubLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_OtherCommitmentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="bcrx_RoyaltyMonetizationMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_PhaRMANotesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="bcrx_CurrencyHedgeAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_ForeignExchangeContractMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_HedgingDesignationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_HedgingDesignationAxis" xlink:to="us-gaap_NondesignatedMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_Rpi2019IntermediateFinanceTrustMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_FutureRoyaltiesPayableMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_ORLADEYOMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesUnder350000Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesBetween350000And550000Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesOver550000Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_BCX9930Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesUnder150000Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesBetween150000And230000Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AnnualNetSalesOver230000Member" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_TransactionCosts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_InterestReserve-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PrivatePlacementOfSeniorSecuredNotes-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecuredDebt-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCarryingAmountInExcessOfFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableFairValueDisclosure-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeForwardExchangeRate1-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeLossOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DerivativeGainOnDerivative-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_FutureRoyaltiesPayable-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-4-credit-agreement-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AfterFourthAnniversaryMember" xlink:label="bcrx_AfterFourthAnniversaryMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AthyriumMember" xlink:label="bcrx_AthyriumMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:label="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:label="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CreditAgreementMember" xlink:label="bcrx_CreditAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentCommitmentFeePercentage" xlink:label="bcrx_DebtInstrumentCommitmentFeePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents" xlink:label="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentExitFeePercentageOfPrincipal" xlink:label="bcrx_DebtInstrumentExitFeePercentageOfPrincipal-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentLiborCap" xlink:label="bcrx_DebtInstrumentLiborCap-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentLiborFloor" xlink:label="bcrx_DebtInstrumentLiborFloor-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest" xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments" xlink:label="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PikInterestPaymentIsMadeMember" xlink:label="bcrx_PikInterestPaymentIsMadeMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PriorToTheSecondAnniversaryMember" xlink:label="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermALoanMember" xlink:label="bcrx_TermALoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermBLoanMember" xlink:label="bcrx_TermBLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermCLoanMember" xlink:label="bcrx_TermCLoanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoanAAndBDrawnMember" xlink:label="bcrx_TermLoanAAndBDrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoanADrawnMember" xlink:label="bcrx_TermLoanADrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:label="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_TermLoansABAndCDrawnMember" xlink:label="bcrx_TermLoansABAndCDrawnMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_CreditAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_AthyriumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_TermALoanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_TermBLoanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="bcrx_TermCLoanMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_PikInterestPaymentIsMadeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_PriorToTheSecondAnniversaryMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_BetweenTheSecondAndThirdAnniversariesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_BetweenTheThirdAndFourthAnniversariesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_AfterFourthAnniversaryMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_TermLoanADrawnMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_TermLoanAAndBDrawnMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_TermLoansABAndCDrawnMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebt-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentLiborFloor-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentLiborCap-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentExitFeePercentageOfPrincipal-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentCommitmentFeePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-5-senior-credit-facility-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DebtInstrumentMinimumLibor" xlink:label="bcrx_DebtInstrumentMinimumLibor-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MidCapFinancialServicesLLCMember" xlink:label="bcrx_MidCapFinancialServicesLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:label="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:label="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:label="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeniorCreditFacilityMember" xlink:label="bcrx_SeniorCreditFacilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="bcrx_MidCapFinancialServicesLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CreditFacilityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="bcrx_SeniorCreditFacilityMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_SecuredCreditFacilityFirstTrancheMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_SecuredCreditFacilitySecondTrancheMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="bcrx_SecuredCreditFacilityThirdTrancheMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DebtInstrumentMinimumLibor-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-6-lease-obligations-and-other-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedLiabilitiesCurrentMember" xlink:label="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization" xlink:label="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="us-gaap_OtherNoncurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="bcrx_AccruedLiabilitiesCurrentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-7-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant" xlink:label="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MaximumAggregateOfferingPrice" xlink:label="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_WarrantsIssuedInPublicOfferingMember" xlink:label="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="bcrx_WarrantsIssuedInPublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumAggregateOfferingPrice-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-8-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_August2013Member" xlink:label="bcrx_August2013Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_December2014Member" xlink:label="bcrx_December2014Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_December2019Member" xlink:label="bcrx_December2019Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo" xlink:label="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear" xlink:label="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_EmployeeStockPurchasePlanMember" xlink:label="bcrx_EmployeeStockPurchasePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncentivePlanAndInducementPlanMember" xlink:label="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PercentageOfCommonStockSharesBeginning" xlink:label="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PercentageOfCommonStockSharesEnding" xlink:label="bcrx_PercentageOfCommonStockSharesEnding-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum" xlink:label="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount" xlink:label="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:label="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:label="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_EmployeeStockPurchasePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_Vest25PercentEachYearUntilFullyVestedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardDateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_August2013Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2014Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="bcrx_December2019Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesBeginning-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PercentageOfCommonStockSharesEnding-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_ForeignCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:label="bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-10-employee-401k-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual" xlink:href="bcrx-20201231.xsd#statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AECOMAndIRLMember" xlink:label="bcrx_AECOMAndIRLMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ASPRBARDAContractMember" xlink:label="bcrx_ASPRBARDAContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AdditionalDevelopmentOptionsMember" xlink:label="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualLicenseFeeMaximum" xlink:label="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AnnualLicenseFeeMinimum" xlink:label="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:label="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_BaseContractMember" xlink:label="bcrx_BaseContractMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CSLLimitedMember" xlink:label="bcrx_CSLLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding" xlink:label="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollaborativeAgreementContractValue" xlink:label="bcrx_CollaborativeAgreementContractValue-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ContractTerm" xlink:label="bcrx_ContractTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MaximumCustomaryReductionOnRoyaltyRate" xlink:label="bcrx_MaximumCustomaryReductionOnRoyaltyRate-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MilestonePaymentMaximum" xlink:label="bcrx_MilestonePaymentMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MilestonePaymentMinimum" xlink:label="bcrx_MilestonePaymentMinimum-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MilestonePaymentReceived" xlink:label="bcrx_MilestonePaymentReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MundipharmaMember" xlink:label="bcrx_MundipharmaMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_NoteToFinancialStatementDetailsTextual" xlink:label="bcrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PeriodOfAgreement" xlink:label="bcrx_PeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PotentialMilestonePaymentsReceivable" xlink:label="bcrx_PotentialMilestonePaymentsReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021" xlink:label="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts" xlink:label="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RenewablePeriodOfAgreement" xlink:label="bcrx_RenewablePeriodOfAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial" xlink:label="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_RoyaltyRateIfMaintainsSakigakeDesignation" xlink:label="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_UABMember" xlink:label="bcrx_UABMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_UpfrontPaymentsReceivableAmount" xlink:label="bcrx_UpfrontPaymentsReceivableAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="us-gaap_GainLossRelatedToLitigationSettlement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GovernmentContractReceivable" xlink:label="us-gaap_GovernmentContractReceivable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeMember" xlink:label="us-gaap_OtherIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="us-gaap_ProceedsFromCollaborators-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_BaseContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AdditionalDevelopmentOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_ASPRBARDAContractMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_LicenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ServiceMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_CSLLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="bcrx_ArbitrationProceedingsOfSulAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_OtherIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_MundipharmaMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="bcrx_AECOMAndIRLMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="bcrx_UABMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_CollaborativeAgreementContractValue-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GovernmentContractReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ContractTerm-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromCollaborators-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_UpfrontPaymentsReceivableAmount-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyRateIfMaintainsSakigakeDesignation-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MaximumCustomaryReductionOnRoyaltyRate-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentReceived-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossRelatedToLitigationSettlement-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LegalFees-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PotentialMilestonePaymentsReceivable-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_MilestonePaymentMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMinimum-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AnnualLicenseFeeMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_PeriodOfAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_RenewablePeriodOfAgreement-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="bcrx-20201231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details" xlink:href="bcrx-20201231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ToriiPharmaceuticalCoMember" xlink:label="bcrx_ToriiPharmaceuticalCoMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_RoyaltyMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_ToriiPharmaceuticalCoMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details" xlink:href="bcrx-20201231.xsd#statement-note-2-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_LaboratoryEquipmentMember" xlink:label="bcrx_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details" xlink:label="bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_OfficeEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_SoftwareDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="bcrx_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:href="bcrx-20201231.xsd#statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncentivePlanAndInducementPlanMember" xlink:label="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanAndInducementPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:href="bcrx-20201231.xsd#statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" xlink:label="bcrx_statement-statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:label="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:label="bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:label="bcrx_statement-statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets" xlink:href="bcrx-20201231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_FutureRoyaltiesPayable" xlink:label="bcrx_FutureRoyaltiesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent" xlink:label="us-gaap_LinesOfCreditCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LinesOfCreditCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="bcrx_FutureRoyaltiesPayable" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LineOfCredit" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:href="bcrx-20201231.xsd#statement-consolidated-statements-of-comprehensive-loss" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:label="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InterestAndOtherIncomeLoss" xlink:label="bcrx_InterestAndOtherIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:label="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_RoyaltyMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="bcrx_CollaborativeAndOtherResearchAndDevelopmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_RoyaltyExpense" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="bcrx_InterestAndOtherIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_InterestExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:href="bcrx-20201231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:label="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CertificatesOfDepositMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AvailableForSaleDebtSecuritiesAccruedInterest" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-n8" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" xlink:href="bcrx-20201231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedDevelopmentCosts" xlink:label="bcrx_AccruedDevelopmentCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedInventoryExpense" xlink:label="bcrx_AccruedInventoryExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AccruedDevelopmentCosts-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AccruedInventoryExpense-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxesPayableCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:href="bcrx-20201231.xsd#statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:label="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:label="bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details" xlink:href="bcrx-20201231.xsd#statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details" xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:href="bcrx-20201231.xsd#statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DeferredTaxAssetsLeasingObligations" xlink:label="bcrx_DeferredTaxAssetsLeasingObligations" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DeferredTaxAssetsRoyaltyIncome" xlink:label="bcrx_DeferredTaxAssetsRoyaltyIncome" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_DeferredTaxLiabilitiesRightOfUseAssets" xlink:label="bcrx_DeferredTaxLiabilitiesRightOfUseAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:label="bcrx_statement-statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities-n10" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n9" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DeferredTaxAssetsRoyaltyIncome" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DeferredTaxAssetsLeasingObligations" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_DeferredTaxLiabilitiesRightOfUseAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-n10" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n9" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:href="bcrx-20201231.xsd#statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:label="bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details" xlink:href="bcrx-20201231.xsd#statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_GreenCrossCorporationMember" xlink:label="bcrx_GreenCrossCorporationMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:label="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SeqirusUKLimitedMember" xlink:label="bcrx_SeqirusUKLimitedMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ShionogiAndCoLtdMember" xlink:label="bcrx_ShionogiAndCoLtdMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:label="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details" xlink:label="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BilledRevenuesMember" xlink:label="us-gaap_BilledRevenuesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:label="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesBillingStatusDomain" xlink:label="us-gaap_ReceivablesBillingStatusDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnbilledRevenuesMember" xlink:label="us-gaap_UnbilledRevenuesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_ReceivablesBillingStatusDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="us-gaap_LegalEntityTypeOfCounterpartyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_USDepartmentOfHealthAndHumanServicesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_BilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis" xlink:to="us-gaap_UnbilledRevenuesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_ShionogiAndCoLtdMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_GreenCrossCorporationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_MundipharmaInternationalHoldingsLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis" xlink:to="bcrx_SeqirusUKLimitedMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ReceivablesNetCurrent-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows" xlink:href="bcrx-20201231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:label="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:label="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ProceedsFromRealizedGainOnInvestments" xlink:label="bcrx_ProceedsFromRealizedGainOnInvestments" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ProceedsFromRoyaltyFinancingObligation" xlink:label="bcrx_ProceedsFromRoyaltyFinancingObligation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeAssets" xlink:label="us-gaap_IncreaseDecreaseInDerivativeAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables-n9" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnDispositionOfAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfFinancingCosts" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_AmortizationOfDiscountAndPremiumOnInvestments" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInDerivativeAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInReceivables-n9" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-1" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet-1" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt-n8" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromRealizedGainOnInvestments" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit-n8" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ProceedsFromRoyaltyFinancingObligation" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_IncreaseDecreaseInFinancingLeaseObligations" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity" xlink:href="bcrx-20201231.xsd#statement-consolidated-statements-of-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details" xlink:href="bcrx-20201231.xsd#statement-note-8-stockbased-compensation-stock-plan-activities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_IncentivePlanMember" xlink:label="bcrx_IncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_InducementPlanMember" xlink:label="bcrx_InducementPlanMember" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable" xlink:label="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-n8" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:label="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-8-stockbased-compensation-stock-plan-activities-details" xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-stock-plan-activities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-8-stockbased-compensation-stock-plan-activities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_IncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="bcrx_InducementPlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:href="bcrx-20201231.xsd#statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="extended">
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange01Member" xlink:label="bcrx_ExercisePriceRange01Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange02Member" xlink:label="bcrx_ExercisePriceRange02Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange03Member" xlink:label="bcrx_ExercisePriceRange03Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange04Member" xlink:label="bcrx_ExercisePriceRange04Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange05Member" xlink:label="bcrx_ExercisePriceRange05Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_ExercisePriceRange06Member" xlink:label="bcrx_ExercisePriceRange06Member" xlink:type="locator"/>
    <link:loc xlink:href="bcrx-20201231.xsd#bcrx_statement-statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:label="bcrx_statement-statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bcrx_statement-statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange01Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange02Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange03Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange04Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange05Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="bcrx_ExercisePriceRange06Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>compound1028.jpg
<TEXT>
begin 644 compound1028.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-A=F]I92P@
M2V5V:6X   60 P "    %   $*:0!  "    %   $+J2D0 "     S0X  "2
MD@ "     S0X  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M62UB:YFN;&*#=-AI5G9P[A<?P;1WYW5W]<SJ'@'2-2\1/K5PUS]J>XM+@[7
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M"N=/F"AI%S#(PSY4HY1QCG*L ?PKSM-0O_#?VG44AG?Q#IT$8UG3@N[^UXE
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44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>exh1082_01.jpg
<TEXT>
begin 644 exh1082_01.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" 2; X\# 2(  A$! Q$!_\0
M'  !  ,! 0$! 0            0%!@,"!P$(_\0 71   0,# @,$!0<'" <%
M!@(+ 0(#!  %$1(A!A,Q%")!41468933,E155G&5T0<C0E*!D=(D,W22DZ&C
MI#4V4V)RLK,T=8*QU"5#<Z*TP1=$8^'P@X3"\29%9(7_Q  4 0$
M            _\0 %!$!                     /_:  P# 0 "$0,1 #\
M_JFE*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E
M*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E
M*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E
M*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E
M*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E
M*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E
M*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E
M*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"N4I#CL5YMA[D/*04H
M="0K0HC96#L<'?%=:4&)]6N,/KZ[]TQZ>K7&'U]=^Z8]?K''\9[\I+O"8AK"
M4H4$SM?<6^E"7%,@8ZA"LYSX8Q6?7^6!EMKBSF69:9%ED)CL,]IWFY?4R"GN
M]WO)Z;]:"_\ 5KC#Z^N_=,>GJUQA]?7?NF/5 C\K$B0_ :B6: %2;:Q<29EW
M1&"0X3W 5([Q&.O]U6A_*7'C\5+L-P@I8E>C4SFW$2 XVXX4%99"@GR2K"O'
M!VH)?JUQA]?7?NF/3U:XP^OKOW3'JLC?E%NMRE6^/8^&$S79-G9NZTJN :*$
MN$C0,HPHC'7;.?"O$/\ *U!F<2<-V]FWN"%>8H?[8XZ$F.LEU/+4C&YU-%.<
M^/[PMO5KC#Z^N_=,>GJUQA]?7?NF/66B?EG,RQ^D&+"A!7=6[:TB1/#25!QI
M3B75+*,)& -O;UJSNGY4_0EJMMPO%LBICRY_8UK@W%,M+* C47"4H&<;Y3UP
M,YH+;U:XP^OKOW3'IZM<8?7UW[ICU#N_Y09D>#Q%,M=C:GQK(\I#ZS/#>IL,
MI=UI[ASLK&/9G.]:&QW^2_PN[>K_ &]NU-H:,G0B3VC\R$!>LD)3@]=L>'MH
M*KU:XP^OKOW3'IZM<8?7UW[ICU$MG']P<79)5WX=5;[->GD,0Y7:TN.!3@RU
MS6PD:=8\B<$@&OW@KCZ;Q1<4-MVB#'AEUYM3GI5*WTALJ3GDZ =RD>/0YH)7
MJUQA]?7?NF/3U:XP^OKOW3'J+QG^4)VP\3BR0K9&E24Q1+/:IZ8G-!40$,A2
M3K7W3MM4F;QG='[P[;.'.'57"7$C-29HDRTQ@P7 2AK.E6I9 /D!YT'[ZM<8
M?7UW[ICT]6N,/KZ[]TQZ_>&^/XW$%ULT6'#<2U<8#TSF.+PIE33@;4V4XW(4
M3OGPKQQ%^4%FQW6\P7K>X\Y!9C+9#;@U277UE"&P".[N.N3M]E!Z]6N,/KZ[
M]TQZ>K7&'U]=^Z8]1;IQS>;%8;Q/X@X75%<@MM/-AJ8'67PM81I#F@:5)SN-
M/_G71WC*_HXX]7$<+L*6652TO^DP 8X=#>O3R]CN#IS^V@[>K7&'U]=^Z8]/
M5KC#Z^N_=,>N%E_*'Z;XAX@L]LM97)MZ%*AJ<D:$3M"RVY@Z>Z$KP,][KFJI
M/Y3KLW8.(+Q,X6:9B6=Y<5W3<@LK?0XA!2!RQMWB=7L]M!>>K7&'U]=^Z8]/
M5KC#Z^N_=,>N%SXZN0FWKT%PZ;G;K*LMS9)EI945I2%+0T@I.LI!&<D9.PKB
MS^5.UO<41[2F.L,S+8BXQ)2EX#I4DK#1&.ZHI23U/0B@F^K7&'U]=^Z8]/5K
MC#Z^N_=,>J>Z?E5,3AN'=8]D5)<?MK-P5'$G24<UY#2&\Z#DDJ6<X'R.F^WZ
MS^5N&]?.'(+=O)CW6"B:])Y^T34AQ>@C3WB.4KQ%!;^K7&'U]=^Z8]/5KC#Z
M^N_=,>H$#\HDYUJU7.X<.KA\.71]#$::9:5NIYAPVMQK3W4JVZ*.,BN3/Y2Y
M@0_/F<.EKA]BXJMSL]N:E:FU!WE!:FM(.G41T)QGQH+3U:XP^OKOW3'IZM<8
M?7UW[ICU47'\J+D=\1XUG8<>5=I=J29%P##?YA(45E900-6>G]YS4V3^4=-L
M4WZ;MS<=/HI^Z.+C2Q(2 VX$!"2$@**M0.=L$X]M!*]6N,/KZ[]TQZ>K7&'U
M]=^Z8]3.&^(+[.N#3%[X9<MK#[!?9D-RA(2G&.XYA(T*P<^(.^^U5'"_Y17.
M*47Q%DL_,EP5I5$:>E!M,U@N*0'0K2=([BML'H!G>@E^K7&'U]=^Z8]/5KC#
MZ^N_=,>J>W?E,N4CAYN]2^&FX\%V:B"V4W .*4LO\E61RQ@ @GVX\*D3/RC3
M6V+I=87#JY7#5MD+8D3A+2EU0;.'%MM:>\E)SU4,XH+#U:XP^OKOW3'IZM<8
M?7UW[ICU72_RJP(U\XGM9B$O6F 9\9?-PF<D,!Y21W>Z0%)\]LGPK07[BUNT
M\)P;N8;DB1.+#46&VL:G7G<:&]1V'7KY _900/5KC#Z^N_=,>GJUQA]?7?NF
M/4"?^42;96+PUQ#81$N<&WFY-,-3 ZW):"@DX<T#2H$@$%/CFKW@GB.=Q$V^
MY+M\&*TA*"A46Y)EDE6=E!*1I\.O_P!J"#ZM<8?7UW[ICT]6N,/KZ[]TQZXL
M\<72;,D/6CAEZ=8HTTPG);<D!Y2DJT+6AG3WD).=]0) )Q7*Y<?W!#M[D6CA
MU5PLUE=6S,E=K2TX5-C+H:;*3JTCS(R1@4$OU:XP^OKOW3'IZM<8?7UW[ICU
M!_\ Q4MIXEEVE,912FV)N4207,)D@M<T-XQW3I!(ZYP?*N,K\H=Z2GAM</A9
ME]F_M-+B*5<P@ZU,AU25#EG&-QGQQX9H+3U:XP^OKOW3'IZM<8?7UW[ICU17
MO\J<RU3KVRY88A;LZ6S**[LAMPE327"&T%'?QDC8[X]N*M^)ORCP['=^'H9@
MO/-W1"'GW2K1V)I:T(0M8P>JEXZC&#0=O5KC#Z^N_=,>GJUQA]?7?NF/72^\
M6W%KB"79^&K&+O+@L(D3"N6(Z6PO.A"24JU+(23C8>VH%_XYO=L=LH8X4+C=
MV6VPP)$\,.(>4@J*%HT*QC21G-!+]6N,/KZ[]TQZ>K7&'U]=^Z8];"$MYV&P
MY*92Q(4VE3C25ZPVHC=(5@9P=LX&:[4&)]6N,/KZ[]TQZ>K7&'U]=^Z8];:E
M!B?5KC#Z^N_=,>GJUQA]?7?NF/6VI08GU:XP^OKOW3'IZM<8?7UW[ICUMJ4&
M)]6N,/KZ[]TQZ>K7&'U]=^Z8];:E!\X;M?&2N(G[;Z\N:6XK<CF>BH^25+6G
M&,?[G]]>[9;^(KH98M_Y1E2!$?,=XHM,<A+@2E13G&#@*'3[.H-:1C_7^;_W
M8Q_U7JF6ZWO09MT>06E(F2TOA.XT(##;9'3KEO/V&@R-TMG$]KCI>E\?R %K
M#:$-V5EQ;BCT2E*023L3L.@)Z U7ER^=G8<1^4"<XMY2T)8;X?0I[*#A>6PG
M4G22,D@#<>8SO.(;=(F^CY$%;29D"1VAI+V="\MK;4E1&X[KBL$ X(&QZ57&
MV7Q,V-=>? >N*$.LKCJU(9#:U(4 E8!5E.@;D=[)V&V RL=V[R)*8[/Y2UJ>
M5$,T(]#,@EH**5'!'4%)!3U!&XKBF5>U2D1QQ[="M37/"O5M.@M[=_5HQIW&
M^:N'^ 7W8\U?;FD7!UG6S(0V1RI"GI#JSI_V9[048SDISX[U=M</O(4R2\V=
M%I]'G8[JV[WV;4&2MB[Y<5:6?R@S6B6#*3VFP(8"VAC*TE:0"!J3G'3(\Q7Z
M%7Q5LASFORA2WF9A*6$-6%M;JR,Y'+"=0(P<Y&V-\59>H3C,418DS2Q)A-PI
MBG7%N+2D*3S.259TA:0I)3TR$G&QS,C\+W&UW 2[;,;E%IYUQIN:HC*7@GFI
M*DIV[Z$K!"3U4"-\T&:=EWIOL>./;HX)>0R6N&@O6H!1*=D;* 0K*3N,'(J9
M=FN(+4M:)GY090<2EM6ANQM.*/,<Y:,!*222H@8%:\VN=(78GY\IEV3"DN2'
MBA&E*@IIU 2D>2>8!D[D)R=S4+B;A^9<;@9D)V.'$IBZ$/$@$LR0\<D X! Q
M04,")Q%.BR9#7Y0GVVXQ*7P_9665-$)"CJ2L C8@Y(Z'/2H33]Y6R^ZK\H<U
ME#2$N8>X?0VI:5'2DH2I(*\J( "03D@>(SL$<//3;??V[NZTEZ\-EAP1LZ6F
M^7RP 3NH[DYP.N,;5REVF_7.,$7"7;V5QU,NL!A"E)<=;<2L+7G! .G&D$XU
M$Y)Q@,FJ1>TMY7Q]<4N\U+'9SPZCG:E)4I/YO1JP0A1SC'=.^U#)O?\ )PWQ
M_<7G'PZ4M-<.)6XGEE*5ZT!&I!!6G90'45HI?#]YE75J]+5;Q<6W6=,<+7R@
MVVA\8*].2HF0HYT@8 'F3$E\'7!ZZ-7)PPY,EPR%R&^T/1T)4YR G0I&20$L
M '/4G.W2@ZM</<7NM(<3QX^ M(4 JSL)(SY@C(/L->_5KC#Z^N_=,>ME%2M,
M9E+J4I<" %!*BH XWP3N1[372@Q/JUQA]?7?NF/3U:XP^OKOW3'K;4H,3ZM<
M8?7UW[ICT]6N,/KZ[]TQZVU*#$^K7&'U]=^Z8]/5KC#Z^N_=,>MM2@Q/JUQA
M]?7?NF/3U:XP^OKOW3'K;4H,3ZM<8?7UW[ICT]6N,/KZ[]TQZVU*#$^K7&'U
M]=^Z8]5TZU\91KQ;(0XY<4F9S<K]%1^[H3GR\:^CUG[U_K9PY_\ Q/\ TQ08
M_5?1<UP5?E G)=0^(Q6>'T<H.D A',TZ,G(\>I ZU^H-Z<MCD]K\H[SD=#YC
M=RR-*4IS. E* G4HG((P#D$$9!S6@D\(<Q5YDHD+$^5(4_%4J0[RF%%M*4K+
M6K05)(*@<=<;U'9X*?MC[:[1/*FXZF7V&Y?> <;;4U@Z0.Z6E!.>H*$G?I04
M*I%\"&SZ^W(NK>4QR!PXDNI6$ZR"V$:AW2#G&""*NHMAXNDQVWD<=RDI6,@.
MV5E"A]J5 $?MKG+X1NTEYJ2^^R^42U/IBN3I&AI):*,)=W5U.K& /#%;6UM.
M,6^.T^A"'$("2E#BG$C'DI6Y^TT'SRZHO]KD*8E?E F%QML.N\FPMNAE!SA2
MRA)"1L>OD3T!K\81Q#(N3D&-Q[/>=;6EM;C?#Z%-)44)6,N!.CY*TGKXUK+A
M:KHW<;A(M#T,)N#:$.=I"B65I!3K2!\H8([IQN.N]<N%^$8UCER'PMQQ>ML,
M'FK&E"([3.%)SI)_-DYQXB@S]WA\2VGLPE\>S5+D++;2&+"T\I1"2H[(23T!
M-<8@O<N3"CQ_RCNJ>F-K<90;*RDD(.% Y'=4"%=TX/=5MW3C9<0V(7F9:EN/
M.MLQ'ENKY+[C*U9;4D *001NKSJD/!"FIJYL*:N.\S(9<B,A66TMMY[JR05$
MJUOY5G_WIZ^(4C:[XY+$=/Y0IG>6MM#QL#896M )4E+FG22-*NA\#CH:YL2+
MX];C.''MS1%TMJ2XYPVE',UD)0$91E145)  R=Q6A:X8NK2;?#;G-M0()4&W
M&WG4K=:P<-K:!T$[@%9STR ,U&M7"5PB\.FUN,VW9EELEQ]Z0A[EE.0I"QA
M(!W3NDX(SB@Y6NU\47.,7HO'TK2E9;6EVR,MK0H=04J (_ @]*F>K7&'U]=^
MZ8]7W"UME6N \S,?YFMY3C;8=6Z&$$ !L+7WE#()WZ:L   5<4&)]6N,/KZ[
M]TQZ>K7&'U]=^Z8];:E!B?5KC#Z^N_=,>GJUQA]?7?NF/6VI08GU:XP^OKOW
M3'IZM<8?7UW[ICUMJ4&)]6N,/KZ[]TQZL+#9>(85Q2]=>*W+G%"2#'5 99!/
M@=2=]JTU*!2E*!2E*!2E*!2E*!2E*!3[*4H/E4;\E+[ BW(7R2KB%NYFZ..%
M:NRK<4O*P&L[91W,]=O+:N$C\D*W[_'N2[FV B=,ENMAL_G ZLN-)Z_H+.?;
M7URE!\DC?DQNL"3;WHDCA^68]JCVY:;G;U/IRV5'6D!8QG-6%Z_)FN^HO"[C
M+C-2YL.&VPY%:*!%D,!>'$ DD))7C&<Z<C-?2Z4'S&!P'Q%99MMDV*\6QIV/
M9&+0ZJ3$6YGEJ4>8D!:<=>ASTJLNWY&B]:VX=ONW)4Q;68C#ZVSK2^B2IY3N
MQ_2UJ&/#-?8:4'R67^2B0B"(]NFP"EJYQ9S+<N,7&BAF-R-"T@C.>O6K=O@:
M;,]$)N_H%#$*:Y(7'MT%3#3R%LJ;*5)*CN=77R&*^ATH/FG#_P"3-RR\&\6<
M/LW+FMW<NIC..))+#:F@VA*M^]I  \.E;<6=IWA8628>8RN'V-TIVU)*-"L>
M6V:M*4'SBW<#WY?H"WWR]0I-DL3[;\9+$92'WU-##7-45%("=CL-\5=< \%0
M^%[>E+C$)^Y\Y]PS41TI<*7'%*"=778$#KX5K:4&!X_X-NW$<I\19=I>@28_
M(5&ND+G]F5O^=94""%$'Q\0#4>+P/>^'I0D<)7F(EQ^#'A2Q<8ZG=:F4:$/)
MTJ&%:? Y%?1J4'S&'^3R[6"38I'#-U@\^WPGHKJ[A'6X'E.N\Q:\(6G&59VR
M<9J1=/R>3+W,NDVZ7-AJ=,C1$H=BLD!B0PM2PX$J4<IR1W2>F=Z^C4H/G5[X
M*XCXAL-ZB7WB*.X].9:89:CQE-QV0AP+*RDJ)*U8QG(Q5Y<N')CW&3O$$*8T
MT[Z&=MK2%H)TN*<"TN'S QTK4TH/F/#?Y+!PY.X;G6Z[RW)=NU(E)D.*6T\A
MQ)YH0G/<RLZOMZYJ9/\ R?R)/!G%=D$]I+EZN3TY#I;.&@MQ*])&=R-.,^VO
MH5*#YY<>#+\Q+O[?#=YA1+9?7%/2428RG'8[BT!"UM$* .H ;*&QJ)</R3Q)
M,:=%;EEM@VZ)#@N!/YR,['UZ'<^)[V^,>/G7TZE!\NB_DPDM\+R+8[<F5R%M
M6YAMWEG"6XJPLC&?TE%9_:*C67\D";==#(<GH>CFXO2.44$$1E-.(0R#GJ.:
MHYKZU2@^:0> ;X8=FL=TO4.1PW:9#3S*6XRDR7TM'+3;BM6G P,D#)QX5Q:_
M)U>78LNSS;Q ]7)-S5<76FHJNT. O<T-E97I R!N$YVKZC2@^;,_DS2N]1Y5
MP?B2XB+S.NBXSK&M*TOHTI00=LI.#GV5/XD_)Y#O=U*BIJ+:U6AZU]F8;"2C
M6XE86G&PP4],5NJ4& 5POQ?(ARFIW%3"EB"Y"C"/$+22I8 YSHUG4L ; 8 -
M<^&/R:M\+<0VBXVBYRUM1H:X,IJ4ZIT.-'!0&\_( 6"K'3<U]#I0?/6_R?R$
M<#1+!V]HN,7,3R]RS@CM)>TXSUP<9J+,X O?8;M8;=>HC'#-TD./.I7&4J2R
MEQ6IQMM6K3@DG!(R,^-?3*4'RWBC\DS-[C<1(1,3&=G.,.074H.J-RV RI)W
M[R5)!!'D?96FXAX27=N$;;:VIO9I]M5'?BR@C4$/,XTJ*<[@X(Q[:UE*#YG=
M> +SQ$W>97$5T@FYR[:JV1DQ(ZDL,(4H*4HA2BI2B0/$8 K=6*RP+)$2S;H4
M2*2E(<,=E+?,(&,G W\>M65*#Y\UP3?(#\F%9>(DP;#)FF:MM,8F2T5+UK;;
M<U8"2<[E)(!(WKC<>![\V>((%BO4*-9;Z\X_)2_&4X^PIT8=Y2@H ZMSN-LU
M]'I0?,+O^2>-/BWN.W+Y*)$6"S;W DZXBXR%H2HGQR%X.,;9JZ:X,>1$X%9[
M8V3PXE <.@_GM+'*V\M]ZVM*#YM??R71KQ.XEGO.L(N4]]F3 EI9!=AK;;2D
M;GJDE.XZ$']M1[S^2QWB5^]S>(KP_P!OG1VX[282U-,MA"!C4C/?',RO!Z?W
MU]1I08![A#B&-/5=++?8D:Z383,2Y*?B%U#JVP0EY U I4-2MCD;U8W'A.1+
MC\)MKN;DARRS&Y3K\@:ER=+:DG..A)5FM=2@4I2@4I2@4I2@4I2@4I2@S['^
MO\W_ +L8_P"J]6@K/L?Z_P W_NQC_JO5H*!2E*!2E*!2E*!2E*!2E*!2E*!2
ME*!2E*!2E*!2E*!2E*!2E*!6?O7^MG#G_P#$_P#3%:"L_>O];.'/_P")_P"F
M*#04I2@4JGB1VV.*)BF]>78S:U:EJ5OK7TR=A[!M5Q0*H[ZZXW?^&T(<6E#D
MIU*TA1 4!'<(!\]P#^RKRL_Q!_K%PO\ TM[_ .F=H-!2E*!2E*!2E<)T=J7&
M4R^VEU"O_=K)"5D;X/F/9O\ 90=Z52<*AQMB>P\TVPMF4I/(95J::!0A02@D
M#;"@>@W41C&*NZ!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!7XK.DZ<:L;9Z9
MK]I09YE^_OJ<2R_8G%-JTK""X2D^1P=C7I3G$2%H0IRR)6O(2D\P%6-SC?>J
MO@YA3-QF2UV61; I#<9EA+20E+25*PI2@>\LZB3Y#89.2>/%=LO<Z_\ I2WM
M,Z;0A"HC;@_./K)"W0@Y &I(2WE7FJ@MC*OH;4X9-AT)7RRK4Y@*SC3G/7.V
M/.N(NMU+KC8N'#9<;"BM(=7E(3UR,[8\:Q#O"U[6N5$3!7V!ZZNWDDJ3N[VI
M:0C&>A;+;@]J3XU-%FN1X=XDMRH4Y4B4Q<D-(5&9#:BXITHPX#J.0H=?.@U\
MB7?(R5*DRK TE(!)<4XD $X!W/G1N7?'0R6I5@6'L\HI4X=>.NG??]E9*9P_
M=H5S=95!=GVN&828BTE*UN,(D%9;()W4A)QOU 2>N:\7&PW15X1>K;:'6$1Y
M3DZ/$RA*\A#"5# .$J<"74@9\<G!)H-8_<[O'&7Y_#C0U%&5N+3WAU&YZC(V
MKJB7?5MJ<1)L*FTI"RH*<("2,@DYZ$;UA('#5WMLMAU^+*4I3\EY]V.RT\5.
M.M12I6E>V"XAW?KM[:EW_AR\/(OMQM,5TOS([,1<=S2V7V2TE.< Z4K0O)'A
M@K ZC :MFYW9Z3V=F?PXX_DCEH<659'7;.?"O:9M[4PI],OA\LI.E3@6O2#M
ML3G&=Q^^HEQL\A-TXA?@0TH=EPX\>.^A*04K*G4K6/\ A"PH^8K&3N#[NF-=
M+9#MZA;)4IZ>4A2<%:'' VG&?T@8ZA_\(YH/H':[[VOLO:K!VK3JY.IS7CST
MYSBN;-QO#X=+,[AUP-#+A0XLZ!YG!VJF-HE;P?1#GI$W?MPN>$:.7VCF:]>=
M6>5^;TX]GR=ZIG[#<)G"<>#%L;\6?%M\MI]Y8;3S]<=Q :20K*M2U(5OMW//
M%!L57.[ID*CJG\.!].<MEQ>H8&>F<]-ZZ*EWQ,AN.J58 ^Z-2&RIS4L>8&<D
M53GAR<J/Q2\2=<I4CD1RTWE>ID)20O&H9/MI#MST25(9F</N3Y$B9'D-2LH"
M$)2EL J7G4DME"NZ!O@8^4<!</S+Y'2XJ1*L#26R LK4M(3GIG)VS7F-/O4H
M9BS.'GAONVM:NF,]#X9'[Q5-8K->&KRY<KE&CN-7A+G:F0C*V2,J8YA)(.A.
M6^Z.I%0W>&+@;%8([$ !3%EY,ID%*>8L.1%+9)SC*TM.)R=O,T&F8G7J0R'6
M)G#[K17RPM"UJ!5TTY!Z^RNR5\1K4M*7+*HH.E0',.DX!P=]MB#^VLI?.'7>
M(9BEL6F3;K>ZJ(VZGN-.+*'%*Y@"2<: =E=23ML!6BX%BW:,;ZN^MI3*>GA2
M7$$:7T)CL-AT =-1;)T^&X]M!WY_$&%'GV+"5ALG+FRC@!/7KN-O;7EN7?79
M+D9N58%R&QE;25.%21[1G(K+RN'+O'NDB5!CJ6Q.OC+TMDK PAM]M:7T[_JI
M4DCJ1I/Z.\FT6J6PW8(IL[S,^V.EV7/PC#W<6%J2H'*RZH@X(VSDX(%!IL<3
M>=F_<[^-,<3>=F_<[^-7:3J2#@C(S@]17[04>.)O.S?N=_&F.)O.S?N=_&KR
ME!1XXF\[-^YW\:8XF\[-^YW\:O*4%'CB;SLW[G?QICB;SLW[G?QJ\I04>.)O
M.S?N=_&J^%<N(I,VZ1R+.WV!U+:EJYF%9;2YGV;+Q^RM961:;0[,XQ0Y",]L
MRF=488RX.SLY&^ ?L/7I03VU\1NMI<:<LBT*&4J3S""/8<U'%PO!=6T)O#W-
M1G4C6O*<=<C.V,5TX'BOV^UKBOQWFTF0^ZTIQ"4**%+U94E/=225'8 # S@'
M(K)"RW 6OB6)V*29$KTIR4]D:"5<U;RFSS<ZN\%)Z^>*#3^E+J6RX+APYRP0
MDJYJ\ ^6<^PU^^DKOK0GM_#NI>"D<Q>59Z8WWJNN7"LI8L;+3K*^7-4\\\(;
M0#:.SNI&48PKO* SUWK@FT2H?%S[RHSRXQ$8)6U!:6E>E.%;G=&_ET\*"\5+
MOJ77&U2K '&DZUI*G,H3YD9V'MKFW<KNX%%N?PZL)W)2XLXV)WW]A_=4"Q6S
MD/Q8LWA\NS&Y4AQZX+T!!2O7^<U9)7K"@-!&V=\:17*-PR4Q(3*K:TE!O<MY
M](2D9CK,G23CJ"%IV]M!=2)-^C)U2)%A:3C.7"XD>'F?:/WUY;EWQV.I]N58
M%L)SJ<2IPI&.N3G%9*X6"\R[2[VV,ZX];5Q(,0X0XIYIN4VXX_I)P=2$-DI/
MBV?.M!.@R)/Y/KQ"8BO+DNLNH0TN.AA3A*=L)2<>S-!.:E7YYA3S,FPN,ISE
MQ*G"D8Z[YKF]<;PPL(?G<.MK(!"5N+!P>G4U0W&U3[A-F(L]H%OA3T1XSXD(
M2A"TH4XMQ2D).<%.&L]3K\DYJ3;.'Y6KAUFYV]AU=MD/,./: I*V0TL-*R=R
M,% WWR#06[,Z]//EEF9P^X\,Y0A:RH8Z[9J3CB;SLW[G?QJAX#M\JWRE(F1I
M#:BM\Y5$;2D:G5*!YH.HY!\?.MU04>.)O.S?N=_&F.)O.S?N=_&KRE!1XXF\
M[-^YW\:8XF\[-^YW\:O*4%'CB;SLW[G?QICB;SLW[G?QJ\I04>.)O.S?N=_&
MN$Y_B6)"D25>AU!EM3A2 [O@9Q6CJ#?_ /05Q_HSG_*:"H@RN(Y5NCS";,VA
MUI+N%<SN@C.YS7=:N(T-E:W+*E &HJ/,  \\YJ@XGM5UO/Y.H4&U!E;3D$=H
M:6ZIM3PY7=0D@'8JQD'&0,9P35_=69<S@RY0^SD350%L\M)RE3A:Z))QD9.,
MG'2@B(NEU<CN/HN'#BF&\!;@=64ISTR<X%?OI.[=D,KM_#G9@K27N8O0#Y:L
MXS65NW"]T9:DY:<EN*1 +3L9AI&A#<IM;B%(V"E #4"201D8&#JM%1I;2[=<
M'+1,N+,5$ELQG&&6EAU?+*' @'3C"5HU#<:^F,T%@W#OXOKUQ3)LI<<B-L\O
M#F A*EJ"NOCJ/[JD.S[TRPI]V9P\AE) +BEK"1D C?.-P0?VUG+%&N5K9,DV
M6:I$B-(8;BMA&J,>TNK;:5E0  0M*002D:>N,9X-<.7"#$0A^'*6J/)84A^+
MRW"@I@M,E7+<!"TE06D]%#J/$T&JD3[S&2%29O#S*2 <N+6D;YQU/C@X^PU^
MLSKT^TIQB9P^XVE.I2T+60!ON2#TV/[JSK-@N#UCO;4JULM.O6!F*PPVE(2'
M4F7W4C)"2 XC;) U8!.*E7RPREW%3L:WAZ$B/!+D9&E(?Y;SBUH ) ) *58.
M <8SO07+$R^/M-.L2K XVZ=+:T*60L[G (.YV/[C1Z7?&6BX]*L#;844E2U.
M  CJ,YZ[&LQ=.&95\N[,F/"D6J$N>T^C9*5M.MQI($DI!Q\M;*<'<Z-Q@U%-
MAO\ <K1)1<("&):'W7@@$.-J<<E).M.^X"$*.^#AS'7-!L8\N^24(5'E6!U*
MR0DH4XH*QUQ@[US>N=W86E#T_AQM:B0E*W%@G!P<;^8(^T57JL,BQW:)=D-K
MN"E2%KDHALI:T LA"2EO._R1G<G?R&U$KA.]2FKDXEI$=<B(XH,O-M.:RY*D
MNEK4=00K0XD:@" 3XXH-DY*OK4EN.Y)L*)#@)0TI3@4O'D,Y->P]Q 0@AZQD
M+44IP7.\1G(&^YV/[C5%&MZXTF6V[P[(G&4_&>BNNJ0.4A#;0 6LDJ06U(4K
M !SG;))J&FS7ZWQ+3+:,F8N)<)DD6\I:2E(4W*"#JP%;E:!N3\OV;!IER;\A
MAQY<FPI9;)"UE3@2DC8Y.=L5Q=NEV9::=>N'#C;;HU-K4ZL!8\P<[UFF^&KO
M;+=)M\MA5P8=<CS2_ TI6E]! <<TNZDK42E"])&#W\;XSR3:KLB7;)#MOD,M
M(;FI)C0V5*.MUI25+;4HI2I6E1.G]PS@!KI,Z]16D.R9G#[+2_D+<6M(5X[$
MG>N;]TNT<-E^X<.-!Q.I!6XM.H>8R=Q7CB2TS+M(X?5#/9PSS%+<=80YRLM$
M *0=NNVU9:'9+C D0BN#.;"(BVG2Q'8?!=,AQ:B K 2@E6I. ,)(&!C%!L3+
MOB92(RI5@$E:=26BIS6H>8&<D5U=<XB:3J=<LB$Y"<JY@&2< =?$D"LM>(4U
MKMD<6*0_*E7)$I%R;2E7)1K04K.^K+:1IT@9.D8R"<:3C>V'B#AE4 QW5H>F
M10ZWG2KEIE-E:@<[=U*E9ZX]M!^ORK[';=<?DV%IMK',4M3B0C/F2=JZ-+XC
M=;2XTY9%MJ&4J3S""/,'-9*%:+VQ>')E[@*N+,6:,\O0HR$B.$(D!)(&H;Y3
MX%2B,X%:OA",]#9EAR$Y#8E2G9+$<Z<,(.@:3I) *E:EX'34?&@ZXXF\[-^Y
MW\:8XF\[-^YW\:O*4%'CB;SLW[G?QICB;SLW[G?QJ\I04>.)O.S?N=_&F.)O
M.S?N=_&KRE!E)5QXCCW:#!4FSE4I#JPO\YA.@)_\]52VG.(GDZFG;(M.<93S
M"/\ SJ%QDTX_=[>RR'%.N0IR$AH@+)*$ :2=@?+.U>^!([MOAOQ>S2&H7._D
MQ?C-LN%(;3G6EM*1\K(!(!('CL2$@2;^7RR)%B+PZM@N:A^S-0'(]\N-T@S6
M9EC6J%S.ZV5J!UIQO@[=*BL<*R9=]N<R5V9EA-S$IG$3^4+TMH P]JV02""-
M.XR,[UGK?PA=HUHA-KBH6\JRICA,=E$<A66BZPZ<Y45)1I2K( .O/4&@W;#W
M$$A!4P]8W4@E)*"XH9\MC7@S;VE:4&7P^%JP4I*EY.>F-ZJX:E0;TY=+7P_,
MC6[LZ([[+;"6UN*U[*#8W.@9&?'7MD"J'A>S3;7.@BXP'DJ1%@H.("9 U(:2
ME0YF>[@@C;[:#3]AG(N+DDL\,IG(',6YH4'$CS)Z@==ZF,R[Z_JY$FPN:1E6
MA3AQ]N#518;:VU)BQ)W#RW;@W(D+D3UI2$*2O7E>O_W@6%)&@],[@:14VQV7
ML/"]X9:@-L27WY^E*&PE2T*?=+?3PTJ3CV&@G!?$9TX<LAU#4/YS<>?7IN/W
MU7R(E^N<NVS6I5D4F$ZMQ/+YBDK);4@C.?#5_=633PQ>XZ(-N3$<DVR+;?S8
M*QJ4A3\5;L0Y/72TZD9VTJ )V)K8</,!OB";-AVM^WVY]EEGEJ9#?,=25DKT
M#H DI3J.,[> %!,6OB-L9<<LJ1YGF#_[T0YQ$XI:4.V12D'"@.82D^1WVJKX
M@C2+I>;C%#:G-*8;"4>"6''BI]?_ (DHT_\ @'MKE%@3K5P8VF,S+3.G2>T2
ME))4ZUS%E:LX!4<9""$[C.01C("\QQ-YV;]SOXUY4>)$C*EV4#(&2'.IV'C6
M-MMQORE*,QVXMNP#'#N0 T@!Q3KW,.3DB.MM."3DD$$G)'C3Q+-L\9X,W!]2
MF69+S<@#:4VAUX! \$AQ+",]#D'J%&@VJ3Q(M(4A=E4DC((#A!_OKA-BWR8V
M&)C=A>23J2AQ#AW'B/:,]:HRB^18C[:?2QDLDL$M!(9#/,2A"DC!*E<O+ATC
M.=2<CN@0H\;B)]^*[(1<D3F$.M1'0,) 7+/\Z23L&F6S@DY"L;JQ0:J%'OL9
MCE0T6)MI)/=;2X!G.^?;GK7=)XE4D%*[,0=P0'=_[ZR%K:XBBW!IR2IZ%$4]
MVU8*/S;;:UJ>>YAR!GO%O!R1A) ZFMGP@TZUP_'YZ%-J<4X\EM8P6T+<4M"2
M/ A*@,>R@\8XF\[-^YW\:8XF\[-^YW\:O*4%'CB;SLW[G?QICB;SLW[G?QJ\
MI04>.)O.S?N=_&I%O]-=I'I V[L^#GD!>K/AUVJTI0*4I0*4I0*4I0*4I0*4
MI0*4I0*5EWK[)CW*:RY+MRRQ)0RB($%+[J5)0H8.L[]_]7!T^&=I+UPG!UZ6
MVXT(;4M$7D%&ZTE:4*459V(4HD#IA/MR OZ503[A.;<N4EEQI,6W+2E;)1DN
MIT(6LZL['2O 'F-\YV7.X3FS=),9QI$>V :FE(R7B$!Q6^=NZH >1R3D;4%_
M2JR>_,8NUM2AUGL<ATM+;+1UYY;B\ZM6,=T;:?VU'XENC\)H-P V9 3SG"L9
M2AL'<D9&Y.$C]IWTD4%W2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!
M2E*!6?X>_P!8>*?Z8U_],U6@K-6EXQ[OQ>\EM;I;DMK#:!E2\16C@>TT&EI5
M':KP]*=6MURVN0D-*<<?C2-7)4,80H$>14=6WR=P*F1+O&DNAO2^R5(+B"^T
MIL+2.I&1[>AP?906%*KH=XC2WFVT!]'.!4RMUI2$N@;]TD>6^.I&XVWJQ.<;
M=:!2LO;.)ER)S$9]=N4\Y)=C%AB1J>04*6"K1CIW,GI@&KB-(DF]3(KRF5,H
M:;=:T-E*AJ4L$*)4<_(&X H+"E5JKU$3(+9YW+#G)+X:5R@YG&G5TZ[9Z9VS
MG:O,Z^1(9?+B9*VX_P#/.-,*6EO;.^!Y'PSCQQ06E*II5Y$&Z26)A"FPAE3"
M&6E*=45E8*< DJQHSD 8&<],U<@Y .^_G0*56SY,MBZVUMOD=DD.%I>H$KSR
MW%[;X [@\\Y/2H]]O(@RX\1#\9AUU*G"[(!4E*1CHD$%1._B  E1)VP0NJ54
M*FS'9"(L+LKKJ(Z'W7U92VK45!.A().^A1Z[#'RLU/M[DEZ(A<UA,>0<ZVTK
MU@8) PK SM@]!UH)%*4H%*4H%0;_ /Z"N/\ 1G/^4U.J#?\ _05Q_HSG_*:#
MQPW_ *NVO^BM?\@JQJNX;_U=M?\ 16O^058T"E*4"E*4"E*4"E*4"E*4"E*4
M"E*4"E*4"E*4"E*4"E*4"E*4"E*4&?NW^N7#_P#\*5_Y-UH*S]V_URX?_P#A
M2O\ R;K04"E*4"E*4"E*4"E*4'YI&HJP-1&"<;X__8FOVE*#R6T$+!0DA?RA
MCY6V-_/:O5*4"E*4'XI(4DI4 0>H-?M*4"E*4"E*4"E*4"E*4"E*4"E*4"E*
M4"E*4"BB$@E1  W)/A2AW&#09F!=+3%N$Z0OB*U.-R7.9HYK:2DZ4I'>U;C"
M!X=:XNR[(N4LCB*W)AN/HDK8Y[>2XDI(PK5LDE()&-SG?!(KAP5>DW]Q2I$"
M*PT]'1*CH,=:%\M1/BI.%^&5)\3TQ@GUQ!='85QG0X%LC.J89B.A8CEU20ZX
M\E:N6GO+TAH'2G<Y-!UER[(_(D:>(K<B)*6ER2SSVR5E(2-E:M@0E((P<@;8
M))K]GR[))=DA'$5N:BS !*9#[9YF!@Z3J[N4@)/78#&#O5-+XAD(M\20S%M9
M:*'B]*$5UQH*0O2E"TI&MC(R2I8(001O5HY>6Q!NDA$&$KLMPCQ$:4A25)<#
M!*L^/\\<8\A02+I=+;+EQ7F.)K4PF.OF)27&UY5I4G<ZQMA9VKCQ"OAF\L.!
M=VLZ)"TALOJ=;6K0"2!\H>)/[S5+&XCE.V6Y7'LD+^3LO.(:5:GVT90LI'YY
M1T+^Q.Y\.AK36A;OIB5:[K%MZWVF&Y*'HS)0E25*4G!2HD@@H\SG/AB@F)XC
ML82!Z9MFP^=(_&OWUDL?TS;?>D?C6(X=XGGW:$RXW:H3\EZWHN*&>Q.QBH91
MK:07-G#A>RTG2#ISLH5K>&9+-\@JN*8++4!]68>IK2MQK [Z@>FHY('ZN">N
M $KUDL?TS;?>D?C3UDL?TS;?>D?C4[L<7YLS_9BG8XOS9G^S%!!]9+'],VWW
MI'XT]9+'],VWWI'XU.['%^;,_P!F*=CB_-F?[,4$'UDL?TS;?>D?C3UDL?TS
M;?>D?C4[L<7YLS_9BG8XOS9G^S%!!]9+'],VWWI'XT]9+'],VWWI'XU.['%^
M;,_V8IV.+\V9_LQ00?62Q_3-M]Z1^-/62Q_3-M]Z1^-3NQQ?FS/]F*=CB_-F
M?[,4$'UDL?TS;?>D?C3UDL?TS;?>D?C4[L<7YLS_ &8IV.+\V9_LQ00?62Q_
M3-M]Z1^-/62Q_3-M]Z1^-3NQQ?FS/]F*=CB_-F?[,4$'UDL?TS;?>D?C3UDL
M?TS;?>D?C4[L<7YLS_9BG8XOS9G^S%!!]9+'],VWWI'XT]9+'],VWWI'XU.[
M'%^;,_V8K+19\AYIVZ&%;19VWI#:FM!YX2T5IU@]"2I'R,# /7(Q07?K)8_I
MFV^](_&GK)8_IFV^](_&LE=;[.M%D%RG6^TK3*AOR([;2#EEQ#"GDH63\M)2
MA65#3N!MOD>K[>IMD=,.7$MCLIPLJ:?8AN+3I6YH4"TDE1(V(P3G/08W#5^L
MEC^F;;[TC\:S=OO5K=N/%S;5]@Q5OOH2T^)#9TDQ6@%IR<'!_O%:&PH1+MK;
MTIEA3BB=Q!7&V!Q_-N=X?MZU7V.-'3?.*E=E;7HE-$)2V"3_ "9HX%!P5*M$
MQUU=WX@LSX7%<B$,+0UE#FG5DEQ6?DC'3&3USMP@CAYAP\^Z<,J;Y:FR6&FF
M7% C!RL+/@3G '[.E7UIEVRYLO.,Q4MAHX4'F0DX_6]J3@X/0X->(<ZWRI+3
M*;<XWSFE/,K<C@)=0,9(/A\H;*P?904MH-@M\IAP7;AHI8!"%MM--O'8IR5A
M>,X.^$C/L&U: \1V3&UYMF?Z4C\:CP[C;I);'H]QKF*4ALN1P M2<Y2"-L]T
M]<9QM7[;Y]MFJ8 @+9$C/)4[' "R 20",[X!.#CH?*@IH\BWAMEF7Q/8W6&Y
M1E?FPE"]7,+F HNJP,G!VW&1XU*:NL-%Z=FGB:Q%EQ"6RT-(4$)4HCO<WKW^
MN/#I6D['%^;,_P!F*J8UQMSRDZK>XRVITL!UR. C6%%&DD9QWAC)VS]HH*U<
MNUJ2[%'$MI%N=>4ZMKF(YAU+*U)UZ\8))_1S@XSG>NGI. RZ^(/$]G9C/.%P
MI6I"UH*OE:5:P.N2,I."3U&U63<RW+NZK<J%RWP,A2V0$*ZD 'SPE1QUP,US
M](6U,E]IRWN-I9>##CJHXT)40",D>!"DG/3??%!53W[._=GKG'XBM#$_EM-1
MW=:%<M"5**DJ[XUI5J.1MT2>H!J\1Q'90A(7>K65XW(DH )^S57%^?;6)$EM
MV L-QB \\(X*$92%9)&^,$;XV\:]2IEMBW)B$]#TJ>&4.\D%OJE(R?#O*2/M
M-! NMV@2I<-V)Q)9&$1EET)<4EPJ44+1U#J=L+Z8ZCK7[<+E:'I[$^'?[,S-
M::6QK=<0XDH44DC 6D]4#Q\]O+0]CB_-F?[,4['%^;,_V8H,PS,M,%$;T9Q'
M:FEM1FXJB^ZAP+0C.DX"TX(U*Z'&_3IBTB\06AJ.A#]_MK[H'><,AM.3[ #L
M/+_S/6K/L<7YLS_9BG8XOS9G^S%!!]9+'],VWWI'XT]9+'],VWWI'XU.['%^
M;,_V8IV.+\V9_LQ00?62Q_3-M]Z1^-/62Q_3-M]Z1^-3NQQ?FS/]F*=CB_-F
M?[,4$'UDL?TS;?>D?C4&^\165=DN"4WBW*48[@ $I!).D^VKSL<7YLS_ &8J
M!?H<86.XD1V0>S.?H#]4T$#A[B&RHL%L2N\6Y*DQ6@09* 0= ]M6'K)8_IFV
M^](_&N?#\-@\.6TICL:S$:P5-@[Z!UJ-PT7YJYYGL6U;++W(:<CL% 6I.0YL
MHG8*[OVI5[*";ZR6/Z9MOO2/QIZR6/Z9MOO2/QJBNG$=M@\:0;&INW .A*7=
M:DAT+<U<L)3XC\V0?^-'MJHE\23;?PZB\2H%J>8DM22PVVRI"FW&F774A62=
M22&5 XP02/V!M/62Q_3-M]Z1^-/62Q_3-M]Z1^-86X\:J8906+5!+K5JD3)8
M4G9N0VE?YH>P*:<!\<:?.K!7%*&KE.A2+9$;<1<68L593W7VE/--.'V+1S,X
MZ84D^> U7K)8_IFV^](_&GK)8_IFV^](_&L>.)9"FK=)7 MT:(]':>6Z['6I
MM2E+4%(+B<AG "2%+!"M6/ UVO%SN=L=OZELV9QFV1$RDI3#7J7KYFD?+/0H
M&<#?.V*#5>LEC^F;;[TC\:>LEC^F;;[TC\:R4Z^2(D&"XIJ(5RIW9=:[));T
M)##KA(:)UKW; R-AD^51FN)Y,D6T-PX;:93#SX>1:I$H.H0Z$H6E".\@*20K
MO?90;;UDL?TS;?>D?C3UDL?TS;?>D?C6;D729'?NTDQ+6NWVV6S&=;Y"DNK2
MIIE:EA62,CFG"2-].,[YKEQG?W+)=)+,2!%<:C04S"DP77.82I8TEQ'=:'<^
M4O;<GH#0:GUDL?TS;?>D?C3UDL?TS;?>D?C5/'N#KO$1LWHJ-SFUE]<@-_FC
M$.="DG]<J[FG_=4KI@'W=+HTQ->8AP(SH9DL1%:D#*G%E*U@=,:63JR>I(Z8
M-!:^LEC^F;;[TC\:>LEC^F;;[TC\:IK/=TOV&V3IMI2J7<R5QH<=I 6&RDK&
MHJ7IV2,DDCJ!@':H/K4Q)EL"VV7GQ'EL(;<TMA2RME;ZQ@J&-+81\K RK[,A
MI_62Q_3-M]Z1^-/62Q_3-M]Z1^-9QCC?AEY: A@!):YI44-@H_,\[24ZM60C
MJ<:<[9S5C.NK$>%:GQ95-F=(2URWTMI4VC0IQ2U84<80A1QG/LH++UDL?TS;
M?>D?C3UDL?TS;?>D?C6:@\76_P!#L2;G:3&E*;94IE090/SC96,*4L 8"3LH
M@]-MQ5C!XAM$Z;%8CVYTHD.(90^64! 6J/V@).3JSR_9L:"T]9+'],VWWI'X
MT]9+'],VWWI'XUGKQQ)$M=XD,O6Y@P(RR)#X0G+24,<U:B/'Y;(  _2/C@5^
M'C.Q=D>>;MKKJF4NN.-M)864(;0E:U%0648 6GHK.3CK0:+UDL?TS;?>D?C3
MUDL?TS;?>D?C58_?+<U9+U<%6MQ!M94EQAQI&M:N6EQ(3I)ZA:1YY."*B6"[
MJEOQ69\&"EQZ2Y&6EMA;:FU):#@"DK (VS]H*3MG "^]9+'],VWWI'XT]9+'
M],VWWI'XU.['%^;,_P!F*=CB_-F?[,4$'UDL?TS;?>D?C3UDL?TS;?>D?C4[
ML<7YLS_9BG8XOS9G^S%!D[IQ!9E<76%:;M;RA+4D*4)*,#(1C)S5]ZR6/Z9M
MOO2/QKEQ$ZQ:K4N2S!CNO*=:8:0I(2DK=<2VG4<;#4L$^S-54EZXQ'8UO>BV
M=R?+D<IB0AHAM* VI:E*;R3D:"  K?(.1O@+KUDL?TS;?>D?C3UDL?TS;?>D
M?C69:N=PDWH65F+:&IS*GTOO+CJ6VO0AA:2E(4"G*9 R"3@@]>M1(_$K\ZZ(
MBLPHD8ICMK= MC\P<TOOM+ 4W@)2"QD%6,@Y\#0;'UDL?TS;?>D?C3UDL?TS
M;?>D?C4[L<7YLS_9BLM978=OM,IYZ$74JNDIH<II*B"J2M*1^\@4%WZR6/Z9
MMOO2/QIZR6/Z9MOO2/QK\7(MH@Q93<5+R96GD(;9&IPJ3J  .,; G?&,'-<#
M<+<(;D@VYT%M],9;1C@+2XK2 ,=",J3N"1OUQ02/62Q_3-M]Z1^-/62Q_3-M
M]Z1^-1GKC;FF5+7;W.8EQMM;/9P%I*SA!P=B"=L@D9SY'$R J#-#@1$2VXTK
M2XVZR$J22,C[0?,9'[C0>/62Q_3-M]Z1^-/62Q_3-M]Z1^-=+GV*WPG)3L-*
MVV]U!MH$X^RN4=^$_P ](MZD/LH"U,K8 64G."/ YP?'[:#]]9+'],VWWI'X
MT]9+'],VWWI'XU&C7.U2;1(N+<,\EA.M:2P O3I"L@>(TD&N\:1!?<4T;>MI
M\-EU+3C !6D8R4GH=R!UVR,]10>O62Q_3-M]Z1^-/62Q_3-M]Z1^-<;=.MLX
M,%,)3/:$<QGG1PD.C&=CTSC?'7&=MC7JTR[=<W7VV8?+<9.%)=9"?TE)V\#@
MI4/M%!T]9+'],VWWI'XT]9+'],VWWI'XUPB38$B2TV+<IME]2D,2%MHT/%.2
M0G!)W"5$$@ @$^6>\-R))G2HIMQ96PE*M3C: '$J*@"G!)QE!Z@4#UDL?TS;
M?>D?C3UDL?TS;?>D?C4[L<7YLS_9BG8XOS9G^S%!!]9+'],VWWI'XT]9+'],
MVWWI'XU.['%^;,_V8IV.+\V9_LQ00?62Q_3-M]Z1^-=H=YMDUX,P[C"D/$9"
M&GTK5C[ :D=CB_-F?[,5Z;C,-*U-LMH5YI2 :#K2E*!2E*!2E*!2E*!2E*!2
ME*"IM_#UNM[RG8C;R%$)2,R'%!"4G(0@%6$HS^B,#H,8 KU<K!;KB^Z_*97S
MW$M)+K;JVUIY964%*DD%)!<7N,$A1!R*M*4&?<X/LZV4-\J2@I"TJ<;F/(<=
M"SJ6'%A6I8)W[Q-=E\,6I4U,GD.)(6VX6D/N)94ML)"%*;"M!*0E."1^BGR&
M+JE!GT\(6E,61&"9QBOI6A;!GOEO"R2K"=>$[D],8\*L+59X=K6\Y%2\IY[2
M''7WW'W%!.=(U+43@9.!G&Y\S5A2@IK)PS:[*ME<!N0"RSV9GG2G7@TUW>X@
M+40D=U/3'R1Y58VZ&Q;H$>%#1RXT=M+32,DZ4I& ,G<[>=2*4"E*4"E*4"E*
M4"E*4"E*4"E*4"E*4"E*4"J=/#5K3<>VAEPN!U3X;+[A9#BLZEAK5H"CD[XZ
MDGJ2:N*4&?'!UE$=YA4=Y;#L=<4-.275)::6,*0V"K\V"-N[C P!L*]+X2M*
MVG$.(EN+<4VLO+FOJ>!0248<*]0 ))P"!N?.KZE!&M\)J!'Y+*Y"T9)R^^MY
M7]99)_9FLY'7*1-XR-N:4[,,AM+24E((48S0![Q VZ]?"M96==LUV9NUQEVJ
MZQ&&YKB'5M/P5.E*DMI1LH.IVPD>%!PC6V=:)+!@)ES&C!,<ID%E*6R@9:!T
MA)/50.,_*Z[5(M$62Q,9+$*7!C(;4'679(=;)VTI:3J.D#?]48VQY?O8N)_I
MRU_=:_CT[%Q/].6O[K7\>@Y\/VYU*"]/CSDNLO.O,M/.ME *U+/="%$9PK'>
MZ9VJ/9K3+BBVRUL2RXTI3;L5]]*PC5D<UL:BD$9QU^258WV,SL7$_P!.6O[K
M7\>G8N)_IRU_=:_CT$MBQ1V9HDIE7)2PHJT+G/*1_4*L8]F*H6K5*=4@FWW%
MF2)ZY*7'):2PE)>4O);#A![IZ:?E;@@]X6?8N)_IRU_=:_CT[%Q/].6O[K7\
M>@@*MUS4R]<@B>F=V[M*86J/I(&$ :O#+0TGO]2=J]/6F7)FW.7R);:Q+;D-
M,./IY,E*6T)TE*5$#=!()QOI)SN*F]BXG^G+7]UK^/3L7$_TY:_NM?QZ %7!
MN5= S;'292DEIQQQL-C\VE/>PHJP"#T!JN<L<U]JXIYMPC\IAJ-%Y?(5S4MI
MRE?>R0K65'<IVT^-6/8N)_IRU_=:_CT[%Q/].6O[K7\>@NH3CKL1ER2R6'U(
M!6T5!6A6-QD;&NU9_L7$_P!.6O[K7\>G8N)_IRU_=:_CT&@I6?[%Q/\ 3EK^
MZU_'IV+B?Z<M?W6OX]!H*5G^Q<3_ $Y:_NM?QZ=BXG^G+7]UK^/0:"E9_L7$
M_P!.6O[K7\>G8N)_IRU_=:_CT&@J#?\ _05Q_HSG_*:K>Q<3_3EK^ZU_'J%>
MX?$HLMP*[U;%($=S(%L6"1I/CSZ"\X;_ -7;7_16O^05WBP(\1EIJ.E;;;2U
M.)2'%;J5J*L[][)43@YWP? 5PX;_ -7;7_16O^058T%<[98#K,QIQ@E,QY,A
MXZU94XD)"59SD$:$8QC&D57HX,LB6'651Y#K+C3K/+=EO.)0EP$+"$J40@D$
MC*<'!-:&E!0N\(6-T3=<$'MJGE/X<6-9=1H<\=LI\L;DD;DFI$GARU2N69$1
M*RW-3<$$J5E+X((6#G;ITZ>RK:E!0+X/LJTMH[,ZAM#262VB2ZE#K:22E+B0
MK"P,GY6>I'0U.G62!.3/$EDJ[<RF/(PXI)6A.K R#MC6K<8.]6-*"JBV"#'<
MCN RWEQWN>TJ1,>>*%Z%MY&M1_1<4,=-\]0*C.<)VE3R76T2X[B2X08TUYG'
M,5K6.XL;%6^.F:OJ4%'ZJVHSEREMR5N+=;>6A<QY3:W$)2E*U-E6E1 0C<CJ
MD'KO72[<-VV[2ER)J)!<<9$=P-2G6DN-@J.E24* 4.\KJ#U-7%*",W!C-SE3
M$-A,A326"H$XT))(&.FQ4?WU /#\1V3,=E9=#\DRDIR4\M1CA@X(.^4ZOLU>
MP&KBE!73;+!F1XK+C;B$1AADLO+:4@:=. I)!QC;&?\ R%1V^&+0TIPM12@+
M24Z4N+"4@M):[H!PGN(2G;&,5<TH*1?"UH6F0A49?*?;4VMD/N!O"D!"B$:L
M E(QD#/7S.9EWM$.[(;1.;6M* L#2XI&RT%"ODD=4J(J?2@I9O#%JF....L.
M)6X25J:?<;)!;2V4Y2H=W2A(QTVSUWKO#L5NAK85'CZ5,N*=1WU'"BC03N?U
M1CV"K.E!3R>&[5)>==>CJ4MX.I</-6-0<" O.#_^C1CRTC&*_#PU:U-N)=9<
M=+C:VEJ=?<6I:5E)4"2K)SH0/L2!TVJYI00'+1!<AS8JV,LS%*6^-:LK4K8G
M.<@[#&,8P,8J+;>'HEOGHD,EQ0;0L(#BU.*UK(*UJ6HDJ40E(!/0# V-7-*!
M2E*!2E*"/<(<>X0W8LQL.L.C2I))'[B-P1U!&X-5:>%;4&'&RW)6XMQ+QD+E
M.J?"T@A)#I5K& 2-CC!/F<WE*"A5PE:2EG2B6VXT7%!YJ:\VZHKTZRI:5A2L
MZ$]2?DCRK]/"=I#K;C")<52&$1AV6:\P"V@J*00A8S@K6<G)[QJ]I0*Q-KC2
MIW+8:[2S&;NDU]R0R6CA0><"$E*\Y&Y.0DX*4_LVU9F-9;["5)3!O,!$=V2[
M(2AVW*6I/,65X*@\,XU8S@4')N)-8B&&[;9,V.U-6I#JGFVWBVH*5K04J2 0
MM12!W>X?M%=)42X*L;K26)BBJ8TXRT7D*>::2M"CE:E8)RE9'>5U ^SOV+B?
MZ<M?W6OX].Q<3_3EK^ZU_'H.5TMCAM'YB-/?ER'XZWB7T!Y*4.)7C5J"1@ X
M"3C)]I-2(5G4T)\)Y<M<=]0>3+$A27O#N%8.K;&Q&VDXZYSX[%Q/].6O[K7\
M>G8N)_IRU_=:_CT'FY6;LUBN$>#Z1F.24!&AV8IQ0]J2XON]? CPJ"[ GM">
M];(5Q97)CB.H/RT.NZLX2M!4XH ("EG&H DC;J:L.Q<3_3EK^ZU_'IV+B?Z<
MM?W6OX]!!F6J=#$QB$W,FLRK<J/WRP@-J2"&T@#3X*7DX/Z-3K?!?@STRTLS
M)"'F"DH??"W(ZAOI22K&E6-\'J$^'R78N)_IRU_=:_CT[%Q/].6O[K7\>@BP
MVKFFU6A'HQU#ML9"BAQUO+S@94V$IPH@#*B221T&QSLMMJG6Z19GDKG2B$K:
MDI=Y"0VE>%*4=."5:PD[%6Q5XU*[%Q/].6O[K7\>G8N)_IRU_=:_CT'Y;X<U
M!M$-V,6V;8H_R@K24NI#:VT:0#D$A0)R!C!&_6I,54KUCE.+M\EN.XRVREY2
MVM.4*=). LJP=:<;9\\5'[%Q/].6O[K7\>G8N)_IRU_=:_CT&@I6?[%Q/].6
MO[K7\>G8N)_IRU_=:_CT&@I6?[%Q/].6O[K7\>G8N)_IRU_=:_CT&@I6?[%Q
M/].6O[K7\>ND>'Q$E]M3]YMKC(4"M";:M)4G.X!YQP<>.#]E!>4I2@4I2@4I
M2@4I2@4I2@4I0C(Q09)B\J;XE<0NZ%Z*J488C+#8T'3G6"$A7R_S>"3YU(G/
MSVK@I3\R7$9[2V&U(9;<CK;U)RE1P5I)[PR2 "=MA5CZ#B>B_1^J3R.9S<\]
M6O5JU9U9S\K?[:_$V&(EQ1"I/*4\7U,E]1;+A5JS@GSWQT]E!4W69.:NUQ9B
MS+@IU#+;D:.W%2MHK.KNJ5R]@2D=5CJ=Q7&XW.7&GW!"9\[GID-M1F1&08^I
M2$$)6YR]@5$C=8.XQN1G2-6UENY.SDK?YSH 4DNJ*" #CN]/$UX]$12J>5AU
MQ,[^?0MQ12>Z$[#.VP V\J#G<+TU!DEE<2XND '4Q$<<3^\#%5-VFS&[M,2S
M(NW*3$:?;8BQFEX4HN @ZD$[Z!L3YUJ&4!II#84I02D)RI143CS)ZFJ^19V'
MYSLLO2T.NH2A7*D+0"E.<# .WRCT\Z"@O%YD!%M=CW-##RH9EK:0$%IX@#2C
M*DZ@%$G?(V2?&NU[NP;E0Y+=RN+5O?A.20(D5+V<%O"OYM1&RSUP*NX5HBPG
MW'8W-05LH8T\Q12E"!W0 3MC)_>?.N<"Q1(+\=UA<G5';4TV%OJ4D)4<D8)Q
MU ^S \J"$E=PEO6=MR<[%6]$6Z\(Z6E!2QR\'*DJ'Z1Z''M-0KG<I"68\5=V
M5"D"6N.J0A#9"T)3JU$*21G&E)Q@:E>6U7!L$,%CE+E,A@+2V&I"TA*5$$I&
M#TV&!X 8%=H]GB1I;$A@.I6RVIM(YJB"%*U*)!.Y)P23N2*#U8IXN5HBR\IU
MK1A81T"P<* ^Q0(J=46!!9@A\,%TAYPNJUK*N\>N,]![!4J@4I2@4I2@4I2@
M4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@
M5!O_ /H*X_T9S_E-3J@W_P#T%<?Z,Y_RF@B6MU$?@Z(\Z\IAMN A:G4@$H ;
M!*AD$;==P:K^%[K)D,OQGIS<R:(Z)*%+T@)*@0ILZ  0E0&^.BQ4^VPFKCPE
M;HT@N!I<5G5RUE!.$I.,CP]GC4F?9XD]Q*Y7.7AAR,4AU0"D+&% @'?.!O[!
MY4%;9W9AN+;,R=/0XN.LKCR6&AE>4=]"T)T[9(TY/R@?"HUAF3Y78P)MPD%P
MK3(4]%2VAM("L*0KEI!.H)'50P3MXB\BVEB.[S.;)=6E!;0IYY2RVDXR!D]=
MAN<G;K7JW6QFWQ%1H[D@M$8&MU2BG["3M09[AFZ2I3]K;5-FR77HP>DIE1DM
M( T_*;(0G4=92-M0P=\93FZBWMJ3,3'3#N2%*)&MR&XA QYJ(Q72-9HD>+"C
MHYQ1#4%,%3JBI&!C&<Y(P<8/A5C08V%<YS+S/-EW%\&>Y%4IZ.V& @/*0"5)
M0"#@ #?=1 .QKJQ>5-\2N(7="]%7*,-,98;&@Z<ZP0D*^7^;P2?.K9CA^&R$
MIYDM: Z7@A<E:DZ]6O41G?O;[^->_0<3T7Z/U2>1S.;GGJUZM6K.K.?E;_;0
M4:KG+:O#T=,^<Z]V]++;3D9 8*"E"E N:!N$E6.]G(&QZ&:\J?S+W(;N;R1#
M=_-,K0WRL!E"\*.C5C*COJS5B++$#4QM7/6F6L.N:W5$A8QA23GND8&",8P/
M*O"[##6\^MQ4E:9"@MUM4A>A9TA.Z<X(PD CH?&@H[G?E1KQSA<E-166V5NQ
M'$MX5K/>WTZ@4([_ %W)'AM6QJO%HC!F>WEXIG**GM3JCDD8./(8 &!X 5,C
M,ICQVF4%:DMI"05J*E$#S)W)]M!TI2E I2E I2E I2E I2E I2E I2E I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
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M0AUE;S;C:7=.$J0-E+0D*!U@@C_]=?D.]RG[LW$D1$L)<6M&'.8A0T@D:5%
M0X3C.$JV&^X!-3(UB@QYC,IL25/LI+;:G)3J]*3C*<*41@X&WL'D*]0K)!A+
M94PE_# PTAR0XXEO;'=2I1 V)'L!(H*RPSY[:8K4II"HSTM^,TLOJ6[A!=*2
MK(WV;QU)Z;GPL8;KRN(+@T\G2E+#"D:7E*24E3N^@@!*MMR,Y&/*O35DA--Q
M4(2_IC/*D-9DN$A9SDDE659U*V.1N:]-V>(W<%S4F5VA>-1,MTI(!) TZM.
M5';&-Z" W=Y_-><>B1DQ&Y@B92\5+5J6E 7C2 -U#(SY[^?F=>I[;"Y42'&=
MBB6F& X^4+*B\&BOY)& HG;J0,]=JL#982F7&BE_0Y($I0[2YGF A0.=60,@
M' VVZ5!NEA3-N#2TLLH9#[4E:RZLY6A85GE?(U=T#6=Q^R@Z(DW0\22HZ6XI
MB(886 IU04-2G H@:>O=Z9\!YFNDFXS2_-$&*RXU#(2YS'2E3BM"5D)V('=4
M-R=SD;#>I,RUQI<CGN&0AW2$%3,AQK4D$D Z5#."3^\UYF6:%+>6X\AW+@ <
M2AY:$N@;=]*2 K;;<'(VZ4%=*O<WG250HD9R&Q#;F\QQY25+2K7W0G3L>X=\
M^(V\M VH+0E8Z* (J"]:8;SLMQQ+I5*9##N'U@% S@  X3\H[C!W-3&&DL,M
MM-ZM"$A*=2BHX&VY.Y^TT%3<FWWK]#9;G28[2XSRU):TX*DK; .Z3^N:AV]^
M5=9*HKTMQE,5"@M3.$J?4'G&P2<;8Y62!XJ\A@VTZTQ9LIN2^9(>;06TJ:DN
MM822"1A*@-R!^X4=M$-QIAL-J:#"2EHL.*:4E)QD920<' VZ;#RH.UN8?C1$
MM2I2Y;H4H\Y:4I44E1*00D 9 (&0!G&:CWM+/9DN2Y+[$=M65)86I"G"=DI!
M3WCN=@G<G ]AEPXS,..EB.G2VG)P2222<DDG<DDDDG<DUPN-KBW!QA<D/:V"
M5-J;?6V4DC!/=(\-OVGS-!5J3+[!:(DMU]LR92D.8=(=#80ZXA!6#G4 A )!
MWP=SG-?K..Q3V)<Y]N)"DE)>YI"U-Z$K"2O.K8KTY!R=.YR35FJUQ50D15!Y
M3:%:TJ+ZRXE62<A>=6=SX]#CIM7)VQP'8;,5;;H:9=YZ-+[B5<S<ZBH*U$Y4
M3N3OOU%!6DRF[*E"G)++<B6VVV7%GG-LJ6D84H[A1W .=0U#Q%2[>RLKNEO$
MF3R6G$\MSFE3B I"24ZU9)WR<G<!6V,"I@M<7L3D50><9<4%GF/K6K4,8(42
M5 @@$8.Q&11FV1F8CL=OG)2ZK6XOGKYBE;;E>=6< #KT '2@Y\-K6YP];%N+
M6XM49LJ6M14I1TC<D[D^VK&HELMT>V1DQXG.#*0 E+CRW=( P "HG ]E2Z!2
ME*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2
ME*!2E*!2E*!2E*!2E*!2E*# HN\TENW]KDDIDI:7,U)U%T2$MJ:QIQ\@ZZOY
M-_6S<PTEI#L;GHCE;:7584I03NK1H!"C@IU?MSM4X6.W @]F3D2S.'>5_/'(
MU]?;TZ5R?X?M[ZRIQ$C'-YX0F4ZE*7-6K4$A6 =6^P\3YF@BW6]RH5Q+(B)#
M 6A(<=#@2L*QE7,""A.,D84021X9!KB9TZ#)OSR&D/0(KP=477U%>GDMJ4E
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M"\I5'ZV63Y[_ (2_PIZV63Y[_A+_  H+RE4?K99/GO\ A+_"GK99/GO^$O\
M"@O*51^MED^>_P"$O\*>MED^>_X2_P *"\I5'ZV63Y[_ (2_PIZV63Y[_A+_
M  H+RE4?K99/GO\ A+_"GK99/GO^$O\ "@O*51^MED^>_P"$O\*>MED^>_X2
M_P *"\I5'ZV63Y[_ (2_PIZV63Y[_A+_  H+RE4?K99/GO\ A+_"GK99/GO^
M$O\ "@O*51^MED^>_P"$O\*>MED^>_X2_P *"\I5'ZV63Y[_ (2_PIZV63Y[
M_A+_  H+RE4?K99/GO\ A+_"GK99/GO^$O\ "@O*51^MED^>_P"$O\*>MED^
M>_X2_P *"\I5'ZV63Y[_ (2_PIZV63Y[_A+_  H+RE4?K99/GO\ A+_"GK99
M/GO^$O\ "@O*51^MED^>_P"$O\*>MED^>_X2_P *"\I5'ZV63Y[_ (2_PIZV
M63Y[_A+_  H+RE4?K99/GO\ A+_"GK99/GO^$O\ "@O*51^MED^>_P"$O\*>
MMED^>_X2_P *"\I5'ZV63Y[_ (2_PIZV63Y[_A+_  H+RE4?K99/GO\ A+_"
MGK99/GO^$O\ "@O*51^MED^>_P"$O\*>MED^>_X2_P *"\I5'ZV63Y[_ (2_
MPIZV63Y[_A+_  H+RE4?K99/GO\ A+_"GK99/GO^$O\ "@O*@W__ $%<?Z,Y
M_P IJ#ZV63Y[_A+_  J#?.*K,NRW!*9N5*CN #E+ZZ3[*"YX;_U=M?\ 16O^
M058UD^'^*K,W8;:A<W"DQF@1RE]= ]E6'K99/GO^$O\ "@O*50)XPL*U+2FX
M)4I!PH!M9*3@'!VVV(/[:]^MED^>_P"$O\*"\I5'ZV63Y[_A+_"GK99/GO\
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MD9UL93C(RI(&1D;4%E2BCI22<X&^PS5;!O<&:XVAA;P+A(1S8[C061G(!4D
MG8[#?8^5!94JNCWF%($,M*>Q+4I+)5'<2%%().<IVV!ZXSC:O4*[PYLQZ*PM
MSM#.=:'&5MG;!.-0&?E)Z?K#S%!/I59%OD"4ZAMM;Z2M:FDJ=C.-I*P2"D*4
MD#.01C/A7X>(+8+:J>9)[,EWD$\M>H.:M.G1C5G/ACV]-Z"TI4 7>&;IZ.*W
M$R\ A*F5I2<A1&%$:3LE70_HGR-<[A?;?;R^)3K@3'&IY:&'%H:&,]]24D)V
MP=R-B#XT%G2JJ7?X$1R2A\R@8PU/%,1Y:4#&<Z@DC&/;79V[1&WI;2B_KBI"
MW=,=Q0 /3!"<*_9GQ\J"?2JASB*W(4T"N2HN!)2$1'E?*&4@X3L2-\'>NCU\
M@LQHTA2I"F9 26U(BNKSDX .$G!.>AP:"SI4*5<XL4,\TNE;R2I#;;"UN$#&
M3H2"H 9&<C8D#QJ,_P 16QB U-6\Z8SBE(#B8[B@%)5I4%82=)!!&^.A\J"V
MI4*X7.- #)D%XAXZ4%IAQW)\NX#C]O6NLV:Q";0N0I8"U:$)0VI:E'!. E()
M.P)V'0$T$BE1K?.CW!E3L5:E(2LMJ"D*04J'4$* (-2:!2N<EY,=E3K@<*4]
M0VVI:OV)2"3^P57'B"W"VHN"W76X2E(2'7([B!WL:3ND82<CO=/;06M*@N76
M&U(E,NN*;5%;#SJEMJ2A*#G!U$:3T/0^!\J_(=WB2Y79FE/)D:"YRWF'&B4@
M@$@+2,C)%!/I2O+JPVVM9"B$@DA(R3CR'C0>J57P[JW)F(C&/*8=6VIU(>;T
M@I24@^/^\FOR%=X\M]#:$/H#J2MEQQ&E+P'4I/[<[X)&XR-Z"QI4)%R:=FJC
M,-O.Z%:''4(_-MJQG!4>I^S./'%#<FC.5%9;>>6A02ZMM&4-$C("B?'!!P,D
M @G -!-I4./<6'[@_#0EX/,I"E:VE(2021W20-73J,BO#UT:9EAEUF2E&M+7
M/+9#>M6-(SU.20,@8R<9S03Z4I0*4I0*4I0*4I0*4I0*@W__ $%<?Z,Y_P I
MJ=4&_P#^@KC_ $9S_E-!G+#:+NNU6F2+O&#J(:$(48 *DH4E)*<Z^G=3^X58
M*L]X5)1(5>8Q?0A2$K, 92E1!('?\=*?W"K#AO\ U=M?]%:_Y!5C09KA!N0S
M<>)43)"9+PGHRXEOE@_R5C&V36EJCX?_ --<3_T]O_Z5BKR@4I2@4I2@4I2@
M4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@
M4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@51<4)>6]:N2F;AN2
MIU;D5"5*0GE.)\01N5CPJ]J).N4&WEL3YL:*7<A >=2C7CKC)WH,]V>5'X6O
M#'9YKZY)># <"5/+UHZKQL.]J Z82$BK*<IUY-NG-1'U)C/%2V5)PX$E"D:D
M@]2-7[BK&3@&<[=+>U!3-=G140U='U/)#9Z_I9QX']U>A<H)A&8)D8Q!U>#J
M2CKCY6<==J"C=CRI%R]+MQ' AIQO1'5A+CJ4H=25X)V/Y[8'!PCPR,=+T^].
MMSAC09K9Y\?2X&P'%!+H4HA*O!(!(U#<GH?&X1<82X:I:9<<Q4YU/<P:$XV.
M3T%<!?;3R5O>DX0:0I*5J+Z0$E70'?8G!P*"';8KT25<!.#\Y+[86F0XE.I2
M!G\RI( &1DXP "%;Y(),2UL*9X8N#1MLN0XI;J2P\K2X^V5%*!J)_P!F$#)/
MAN:NQ=[:8:Y8N$/LJ%!"GN<G0E1QL59P#N/WUU[;%[0Y'[2QSVD!Q;?,&I"#
M^D1U ]M!4VQIQZ6XE2)CEOY6"F<@:@O(PE)(U*&,Y*LC.G!ZUTX?!<<EK>AO
M,K$A;C:GF\'2KR/[-ZE-7NUO(>6U<H:DLIYCA#R<(3^L=]A[>E>H=XMDY_DP
MKC#D/8)T-/I6K Z[ ^T4$Y1PDG!./ 5F>'(+BFFWIJK@%1G7'6X[R$)2DJ*\
M$:4@GNJ(W)Z^>,:91"4DJ( &Y)\*@PKO;9SG+@W"')<P3I9?2LX'4X!H,W;8
MLF,FR/+:N:RVZXIQE:04M#EN ;?:H ;GK7["8NC MUR=;*G')"UOQDQB'4I=
M)U)4O604I[AZ;AM-:1F[6Y_L_(GQ'.TE26=#R3S2GJ$X.^/'%>H=S@37G68<
MV+(=:_G$-.I6I'V@':@S4.'.THE."<MAJ>\ZNWNH0D%*GE*0XG !)3D*PHD=
M=LA.(:K2\8#LSL\S67UK$/E#)<+AP]UZ\LZ?_P"E:V+>;7,?#,2Y0GWB2 AI
M]*E$CKL#X8->_2MN[ 9W;XG8@K09'.3RPK5IQJSC.K;[=J#,RF;H\B?=&VE)
M=1*2XU&5&)>4EO 2E*]> %C5X;<Q56C#KL!$MA=ND2>>ZMYHH2"'0LYTK).$
MD9T][; &">@LT7. N<J$B;%5,3N6 ZDN#_PYS7B;=[;!=Y<V?%CK U%+KJ4D
M#P)R=J"AEID(OTR28]R6VG24L-H!9?/*4DA7CC*OLV&U2Y:I3+LY78GW5S8Z
M V&@" YI(*%']'J#D[582;[:(KKK4FZP&76OYQ#DA"2CQW!.U=7+I;VG)#;D
MZ*AR.D*>2IY(+0/0J&=AN.OG05=Q95";M:&HCSZVW&U.K8;SLA!3D_OVKK?L
ML1H;$6$^XE#[3FEAO*4I2L$_W"I+M^L[10';K;T%Q(6C5)0-23N"-]P?"O;]
MZM;#3+K]RA-M/I"FEK?2D. ]"DD[C[*".^MR+=#/,9]UA^.AI7+1J6T4J4=T
M]2#KQMT*=_,0I(GS[E;TLQ3!;:#D@E]D.)UG*4@Z5C?2I9.Y^4.M74JXPHK+
M;LF6PTV[_-J6X %[9V\]MZXO7NU,1FI#US@MQW<AMU<A 2O!P<'.#@[4%#'7
M+8LULC/0I;BXDH(RAK&6FSA*L9/5)3^T&I<V2_,TJDVR<([<DEIUDE#K(#0_
M.%(.594I:<#.W@15S.N4&W\OM\V-%YAPCG.I1J^S)WZBNDN7'AL\V6^VRUD#
M4XH)&3T&_C04$FZRK)PU-N$F._+<2Z$QF5A+;SY6I*$)5I& 2M6!MG&,C.:T
MB"HH25@)7C< Y /VUPB2HL]@.Q'V9+.K&MM86G(/F/$&I%!SDN\AE3G+<<T_
MHMIRH_8*S"$O+X-M\9RWRBZP8B'65-@DA"VRO;.XPDUIY,AF*RIZ2ZVRRGY2
MW%!*1X;DU$1>K6Y&3(;N4)4=2TM)=2^DI*U?)2#G&3G8>-!0MVN>EZX-<HN,
MLHAF(M2AEU#3RW.6<G90&$Y/78D[G%_#F&7)V@R&DH0<NO("2%$CN@=3TW(V
MV&"?#KZ0A]I?C]KC\]A',=;YB=3:?-0SD#VFO$*Z0)SA;AS8S[@&HH;="CCS
MP/#<;^V@\VB:_.8><DP)$%2'EM)0^4DK2DX"QI)V/45.I2@KXS+OI:=*>00D
M)0PR.N4@:BH>65+(_P# *K[0^_-N*94^%+9=*5!IM: $1T^.3GO+.!DCIT&V
M2K04H,G:($R#<4M@SE.F:^\ZXIP]G+"U+4D!.=.>\D=-6H$G;JB0)D.Y.H09
MRGUSU/I<YA[.&%KUJ!3G3G"E)W!5JP?D]-92@I4/N>LSA[)*Y182R'>7W-04
MH]?+<;UPO*%SIT1#<6<B1&DMK2HJ_,*0%#4I0"M*MLXR-0." ,9K0TH%*4H%
M*4H%*4H%*4H%*4H%0;__ *"N/]&<_P"4U.J#?_\ 05Q_HSG_ "F@\<-_ZNVO
M^BM?\@JQJNX;_P!7;7_16O\ D%6-!1\/_P"FN)_Z>W_]*Q5Y6$><5$O?$4A=
M[E0&EW!II#+$9#Q<7V1D[#0I1. 3MT"2?.NB;DA<Q,9'%TY2E*;0'$P&RUJ<
M2E2$\WE:,J"TX&=]0\Z#;TK+75N7:HHD3>)[@EM2TMIY<)IQ2E*.  E+9))]
M@J*9H3:EW%SC"6W$;<#+BG(C2%-K) TJ26]23N-B!@'/3>@V=*Q$BX*C7)<%
M[B:\)DI!41Z)!2$CJK4&=.D9^5G'MKPBZ:H*IGK->DQP6P%KL^G65J"4! +&
M5DDCY.>M!NJ5EK6W*NC"W87%$Y8;66W$JALH6VK .E25-A23@@X(&Q!\:AOS
M@RI 7Q=.(4D+UH@MK0A!44A:E!HA*24JPI1 ."0<4&UI6+3,<5+=CIXFNRE-
M*6A;@M:2TDISJ!=Y.C;!SOU&*ZVA<F[9[%Q%>-.D+"GK6EE*@>A!6R ?V4&O
MI6&?N@9<80>*+PX7\\HLVD.A>,YP4LD'H?V;]*&Y@(E.'BF[!B,EU3KYM0#2
M0WG6>9R=)QI/0G.-LT&YI62:6X],AQ6N+I2Y$M@RF4)C,DJ:&.__ #>P[PZX
MS7IPK:?F,N\8NH<AMI>DA34<<E"LX*SHPG.D]?*@U=*S$)F7-($7BJ6X2RW(
M $5@?FW,Z%;M^.E7[JE^B+K]9)ONS'\%!>4JC]$77ZR3?=F/X*>B+K]9)ONS
M'\%!>4JC]$77ZR3?=F/X*>B+K]9)ONS'\%!>4JC]$77ZR3?=F/X*>B+K]9)O
MNS'\%!>4JC]$77ZR3?=F/X*>B+K]9)ONS'\%!>4JC]$77ZR3?=F/X*>B+K]9
M)ONS'\%!>4JC]$77ZR3?=F/X*>B+K]9)ONS'\%!>4JC]$77ZR3?=F/X*>B+K
M]9)ONS'\%!>4JC]$77ZR3?=F/X*>B+K]9)ONS'\%!>4JC]$77ZR3?=F/X*>B
M+K]9)ONS'\%!>4JC]$77ZR3?=F/X*>B+K]9)ONS'\%!>4JC]$77ZR3?=F/X*
M>B+K]9)ONS'\%!>4JC]$77ZR3?=F/X*>B+K]9)ONS'\%!>4JC]$77ZR3?=F/
MX*>B+K]9)ONS'\%!>4JC]$77ZR3?=F/X*>B+K]9)ONS'\%!>4JC]$77ZR3?=
MF/X*>B+K]9)ONS'\%!>4JC]$77ZR3?=F/X*>B+K]9)ONS'\%!>4JC]$77ZR3
M?=F/X*G6N'+B\SM=R>G:L:>8VVC1USC0D9S[?*@G4I2@4I2@4I2@4I2@4I2@
M50<5.J;?L_+7(:4F4I:G&HRGM*>2X-P <;J W\ZOZ4&/U.L\)7Q+PE/J>4^E
MISLJTK?*V\@\L#(W)3T .G/C5I<7T/"USDM/N16'RIP<E84CN*2%Z"-1 )\O
M'/A5LY+C-QA(<D,HCJ (=4L!)STWZ41*CKC&2A]I4< JYH6"C ZG/3PH,T\D
MR+FNYLQGE6Y#[*UHY2M3I2AP%T(QE6"MK?&3RLC.$YZ7R6Q(@O2(+#_.Y\1)
MD=D6K5I>"N@ 4H)&HGPWQG.<: 3(QB"4)#)C$9YVL:,>>KI7J-)8E-\R,\V\
MWG&IM04,_:*"B@,K$JZ(O(,E<AD'F-L*2TM@:L("=R%#4K()).01^JF+;N4O
MABZ*F-W&6MPNLO%3"TONM J0C2"D$]S!V'4D]2:UE*#.6\"=-=;=4N=%+&%2
M'HQ9<2=0(02 D*SN< #3IW^4*Z\/*8E/RW>4^EUN2XI"G65M]U>-QJ SG%7U
M* HA*23T&^PS65X;9>ELQWI+RDLPWW7FV3#<97E7, R5GO#2L_) \/L.JI08
MFV*=9;L#KSLY;0>=4650U#E#EN#)PC(Z@#/7/C7[ =FM.6^\/,$(E2%\Q*67
M2^E#N $J3IVTZ&@3ML@^=;7(SCQI08N'VMQ#;[O,7;&KB\XN.F&M#PR\I3:\
MG)4D$@D) V/4@$&O5!4;:]+Q([(92WNS=E=YA?YA 7C3G3RR/#&0#UKZ)2@Q
M,MZ:ZN;>FF"6X\I!;0IAT/EMO*2E*-.^H+=P?)P>6UFV_&C,7&-<8K[QEN..
M%(CK7VE"QW1TZA.$$'&-.^!@UHZ4&/G/Z;[<%/&7V3"0[&$)Q:9 Y2@4A02?
M$CH<;5,ERNSO7%3L>3JF1D%E*&5+*E:5 HV&R@<=<=<^!QI*4&:N"&K:W:M;
M3Q>YK1=4RRXZ,(04Y.D''45VOJX\"%!C-,OZ$2&5)2TPX[I2E8)R0#T'G5^2
M!U-*"E??1%O/;I*'3&=BH;:=#2E<HA2E*! &4Z@4?U,'?&:^4HSIEOB6^"6H
MX+TMQ$F.M"%%14D [8RK6M>#OTR :U5*#'LSU)LMJ:EM3%/QI096H175:@V<
M:_DYP1I.?:?(U*N%R:F*:4MNXQD,RCR)3<91TD,[J4E2#A)UK3DC&1U%:&3(
M8BLJ>E/-LM)ZK<4$I'[31V0RU',AUYM# &HN*4 D#SSTQ04 O"+-PY<+I/8<
M6RTX5)+$<MN2<Z0"&U$=Y2CI&2,X!V!%:-"BI"5%)02,E)QD>PXJ/(,-^&'9
M!8<B)TO!:R"@:2%)7D[;$ @^P&NS+K;[2'6'$.-+&4K0H$*'F"*#\DOHC,J=
M=UZ$]=""L_N )-9(K9D<!VZ._&DK2CL;3[*HKFK 6V5@ITY( !SMBMC2@QIC
M3EO7-B0P\^&&H82XI)/:FD/.+(WV*M'=4/$^04*T,.9$G3@MAAY3K;127EL*
M0$@D91E0!R< X'3&^-LV-*"#:+DW=&'G6F)3(:>6P1(94T24G!(!ZI/@?&IU
M*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"H-_\ ]!7'^C.?\IJ=4&__ .@K
MC_1G/^4T'CAO_5VU_P!%:_Y!5C5=PW_J[:_Z*U_R"K&@PTRVR[A<;VJW!OM<
M:[-NH4I]3! ,)I)PL)5C970I((ST."*ZW\!W*#(9;0XRXRV]"=$DSGQCDMLI
M5F-I+:R>4K"E*R-0/5(K7</_ .FN)_Z>W_\ 2L5>4%'Q'"N$^WPS$;B]LCRV
MI'+=>4EM00K)&L()Z?[M44CA"X7:8\[=)C<-F2\Y)>:A%+F%EE#"$Y<;(4GE
MAPDE(.5)Q\G-;FE!E8U@N6EHS9+#SR+4Y;U.:CEQ94-*SMXA.3[2<9JJA\-7
MF/868:8\4/L.1'4EV\R9"'"RXE1&%MGE@A)^2#X;;5OZ4&4?MEU19.*)1Y3=
MVN#*RRU%<*TMJ2SH0 LA)4K(SG Z@>&3XGV*<]<([MM;BQF6PRAF0EYQIQMA
M.,LK:"2EU/RL!1&-9V!&3KJ4'SUCA6])L]TBJ:C)DS&I(+PO,E396\I14>26
M]"/EJ.0#@^=:/A^W3;?!EH+"&'U)PRE5UD349 .,EU(*!GP2/_*K^E!G;;8G
MH"[*$+:6U;+<N*D*)RMT\L:CMY-G?KWC5%9^$KFQ96[?+;90=+"'G!=Y,A#H
M#J%.X:6@(1J2E>,=-6.A-;^E!B^"N$I=EG-2[C(8??:A"$A3>=FTE(2G<= E
MM!_XEK\,5-N7#CDIGB7E"*AZY-)9CDIV1I0<+5M\H.+<5X^&_EIZ4%+:H2TW
MZ?+#19BH89A,((QJ#96HJ^S*PD?\)/0BKJE*!2E*!2E*!2E*!2E*!2E*!2E*
M!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*
M!2E*!5/Q0J0;>EIB*](9=7ID\I:$J0S@E7RU)&^ GKD!1/A5Q0@*!! (.Q!H
M,C:C'F\(V-:Y*+?A2>45EM65 *&D;E.<9(Z_9X5U=E!^W,*E.-O06+@E"Y"0
M AU /=40-MG"D$C;*2=AM6E++19+1:06B,%!2-)_97K0CE\O2G1C3IQMCRQ0
M9DIBR(UX':VHT95R:6V^<%O6D,J.,['*TJ!_WL^-6=AD*=,UDOHDMQWN6A]*
M0-7=!(.-B03C( _>#5DEIM+7*2V@-8TZ -L>6*_6VT--I0TA*$)& E(P!^R@
MI>-4L*X9FB2EA2-(P'\:-61C.:SDR/9O1;S$A%L;D2'HZ9 AE*6N4)8"#D=%
M:5]>O[JWJT(<3I<2E2?)0R*\",P 0&6@#U&@;T&0A,ZN)F'+^N*Y(,!]D!2D
MD*92IH:R.@UY6H^P@'I7'A: PY8(<LQ[5'AI@:'NSK"^?E"=G.ZD#'7!R<GJ
M-\[=3+2CE3:"<:<E(Z>5$LMI04);0$'JD)&#08CA%JU-Q(BI;5H3(<9Y;?90
MG"F2RA2^;^U*LYVZ5PX70J/%M#T>+;H0=@:8[T984)3V@=QPZ4@';4!WLD'<
M8(5O$QF$YTLMC(P<)'2O:6T)2$I0D)!R !L*#(146M,:SN6SE&Y..("U;<U:
M?_?<[Q.!JSJZ+"?'%0; VPQ*@2&HMMB01+D([9%4"I:BM82VO"0$I.1C=0R$
MC8D&MVAMD.N+0AL.*P%J &3Y9-?J6FT(T);0E.<X"0!F@]U\Z"8K"WI$-%F0
MIJY%>6\"4L![=",>*ODX\02/&OHM<D,L(<RAMM+G7(2 :#,JEV6U7Z^3E=B0
M\U&0M91H#BB"X5#PR3@?W5RNT&*BXS+1V5C1>W$.G+8[^/Y[/V)2"#^LY6J5
M'CJ6=3+16=SE(S]M=3IUC.-0&WGB@R4IBP(O]T]((@-J1'8&HA*7$_+ TD=X
M'&G&-^F/"M'9S(5:81FY$HL(+VH8.O2-6?VYJ1R6^9S.6CF?K:1G]]>Z#+\0
M(@OWAU+[MK>?:B)6N)<$[);*E]]*C\G)!"C@_)3TQO"ND"S&T6N;+CL-J=3!
M9;;EZ5*0VEU)TY5OG"R#6Q=8:>*2ZTVLI.4E20<'S%?KC3;N.:VA>.FH XH,
M3>K=;XEWM4=AJTJQ'?5B:$;-EYI6$[>&I>GPK56/L0MJ$VS3V1*W$(T]!A:@
M<>S(./94MQAEP@N--J(& 5)!VKVA*4)"4)"4CH ,"@JK_.AP3%<D):<F%1$5
MM:PGO8P59.R0 =U> .!DD UP1&C0K%F0P]%3.6IQU!')"RETX&^  X0E(SL0
MD=:TCC3;H'-;0O'34,T++19+1;06B,%&D8(^R@RJ%,<AEPE'HGTLI63_ #>,
M*P?LY^"/;@]*MN'RVIV[*CD&,J82V4?)/YM&O3_X]>?][55J6T%OEE">7C3I
MQMCRQ7ZA"6T)0A(2A(P$@8 %!^TI2@4I2@4I2@4I2@4I2@4I2@4I2@4I2@4I
M2@4I2@4I2@5!O_\ H*X_T9S_ )34ZH-__P!!7'^C.?\ *:#QPW_J[:_Z*U_R
M"K&J[AO_ %=M?]%:_P"058T%'P__ *:XG_I[?_TK%7E4?#_^FN)_Z>W_ /2L
M5>4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"
ME*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"
MJ6\PX\R\VM$IE#J-+VRAD=$U=5%FVZ%.*#.AQI)1G27FDKTYZXR-J#.V]#2[
MY$*CSHK3DAJ(ZXK5J(#9P%'J00Z![$GRJ(J"RJ-;A&A1I&J[2DAMQ>A*DZ7A
MC(!V[B?#]$5L'X<61&$9^,R['& &EH"D[=-CMM7ARW0G1'#D.,L1_P"9U-)/
M*Z?)VVZ#IY4&5;2\[:K>DL-F0BY'^1O/*TQR$J_-E>"2!\H'&-QCNXK\E-J7
M:;M%=A(5*EW -)8CK"L%3:"I2%*TC(1K7OC<5JW[="?=#K\.,XZ%!86MI*CJ
M'0Y(ZBO M-N#H=%OB<T.<X+Y*<A?ZV<=?;UH,H\A^0S&MR4/0I4>X%<8.J&0
MDM.+;)TJ(T!0*<9W"*L^'$25W^Y2K@VMF0_'86&%+"N0G6Z D8)&<)23CQ)J
MX>M-M?DF0];X;D@D*+JV4E1(Z')&=J[-PXS<IR4W'93)< "W4H 6H#P)ZGH*
M"NXM81(L+[:RH J1A2%%*DG6!D$;@[]:S[SSJ9UR2Z2BY1X:&Y#S8PHMES!>
M3CIE )VZ%)&^FMG*C,2V%,RV6GV58RAU 4DX]AKTVRTVH%MM"2$A *4@82.@
M^SV4%7#MUKB7)AZ$I#+ZV%A+3;G=>22@EPI_2(PGO]>\=]ZMED!"BHZ4XW.<
M8J/$@0X:G%0XD=A3FZRTV$E7VX&_6I"TI6A25I"DJ&"",@B@S]BB1!<$2K;'
M;C0TL*:;(&%2]TGF'Q*1C91R3K4>A!4MUIM\;B,>CX,6,B%%T$LM)3E3A&!D
M#JE+?_SU:P[5;X3I=AP(D=TC25M,I0<>60.FPJ6E*4E12D J.5$#J<8W_<*#
M/L6FWL\21DPH,5CL;!=4IMI*5:EY0C<#)V2[G]E0HK,=*H<M"$"YN71YM3F!
MS%C6X%))ZE(0G8';"4^0K6A*0HJ"0%'J<;FN*8<5,M<M,9E,I8TJ>" %D>15
MUQL/W4%!>(S+=R@38K4+09B4/.MI':%+)*,)5XC.R@?T0KRJ \TYZ7=D\F)R
MA=&T=H__ #0^2-(V^3DXZ_S9.WB=8FWPT3%2T1(Z9:NKP;2%GP^5C->C"BF8
M)9C,F4!I#W+&L#RU=:#,7YY3G$4(R8\D-QI32(Y#14@J4,J<U#;H=(\1A?G7
M6]0VV)\V\)]&2%,!O+3T;6ZE21D(2O5W5*U# TG<CKFM%)AQI2FE28[+RFE:
MVRX@**%>8ST-?CL"([+1*=BQUR6_D/*;!6G[%8R.IH*;B>TV^4A*'(,5R7.>
M0QS%M)4O3C*\*(R"&TKQ[16AK\4E*BDJ2"4G()'0]-OWU^T"E*4"E*4"E*4"
ME*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4"H-__ -!7'^C.?\IJ
M=4&__P"@KC_1G/\ E-!GN'[Y<4V&VI3PM=U@1FP%)>B85W1N,OYJ?Z=N7U4O
M/]M#^/7>PSHK-HL\9V0TB0Y"0XAM2@%*2E"<D#R&:LX4J/.BMR8;S;\=P90X
MVH*2H>PB@QEBO5Q3=^(BGAB[+*IJ"4AZ)E![,R,'+W78';/4>.15SZ=N7U4O
M/]M#^/5)?4RC:./UP)<B)(:<+J'(^-9*831 !(.,D#<;^1!WJ/>;NNV\42Y#
MLF:I^/*U"&AQ92N&(>HD-YTG\[D!>,ZL)SX4&C].W+ZJ7G^VA_'IZ=N7U4O/
M]M#^/57P/,N<1V5 XE3(:E.:)32I#J5A2E[.(003W0X#A.=@M(Q@55\5S[M"
MXSFIA/2RQ,A,6]E"2HH9D.J=T/8Z#3H.3[4Y\*#4>G;E]5+S_;0_CT].W+ZJ
M7G^VA_'K#6N5_P"Q&_6*Z75B4FVL&WE,EU*WE<OO* !_/.Z]BE6HX"=L*.>\
M>;(5)F&1/F)XH3/BI;AMRW2C26V.8.3JT<O=W*M.VYSD9H-EZ=N7U4O/]M#^
M/3T[<OJI>?[:'\>LC9(]UNMZ2EUR4ZPTQJ5S+E)CZ<RY(R WLLZ4I'>\ D=*
M_6IB5/.IXGN4^);]4SLKB)+K.MP3'P1J205%* UH0<[$X!QL&M].W+ZJ7G^V
MA_'IZ=N7U4O/]M#^/68>N=R?O;$P,W4V1@-6]]:W T3S$X<<4E)!"TK6T-21
MW=#F",FO4.-)A,H=BR;DMXWQ<<"1-?=26DJ7I20M1&G8;^-!I?3MR^JEY_MH
M?QZ>G;E]5+S_ &T/X]865->3P^RY:[C<W;ZJ#(5=6E2'%*9(C.$E2"<-*#P;
M"=(3UVR.FBX4E75'%/HJZN27>QV_NOJSHDI*QH</AKQE*O'*2>A%!<>G;E]5
M+S_;0_CT].W+ZJ7G^VA_'K)1Y;O+A*9GSU\3J?4+A%+[A2VC"M>6B=*$#;0H
M 9(3@G4<W_Y/(4YCA^/)G:S)?BM*"G+C(DE1*,DJ#FR#D_H__:@G>G;E]5+S
M_;0_CT].W+ZJ7G^VA_'K(0YJO0)<MT^[O\3*MZE3F XMWDNX3K*FU9#:P=6A
M*0,] "*YWEPO(5&X1O-R,)XQ$/RDRG'RP\J8PE.E:R3J*"[K1G& -0WW#9^G
M;E]5+S_;0_CT].W+ZJ7G^VA_'K'/O7&[6^_N7$W*)/A3(S&B/*>90"0T%E&A
M0U(4"5#/@KP.:_+]%N46Z7941V>F!$<C($HW22514%*2IP-9*70,Y5J/3.<X
MQ0;+T[<OJI>?[:'\>GIVY?52\_VT/X]99Z\7_P!)W*X0H\LQ9R)$6WZUI4T'
M6T'D*",Y3K4AW)(&=;8\!4^UHM%P9D,VVZ7J43$YC_\ +G\-N#IJ5J"FW#DY
M0"!@'*=A077IVY?52\_VT/X]/3MR^JEY_MH?QZR".W-6"V"/*NH:;@Q9%P<,
MAYUT\];8<4"HE0*6VW3@?)UY !Q7B<M^3<&HO#4N7-L[DJ.$K5<7TH4X6Y!<
M0)"2I>G"620"0%;>)P&R].W+ZJ7G^VA_'IZ=N7U4O/\ ;0_CUB84AM$RV,<2
MW.?"92BX!QDW%]'*=2['T-\T*"G<)4LI)ZA60!7*USY2KW'%]GEI79HJDIF7
M1^&L@E?>Y2,)4L@)U XWV-!N_3MR^JEY_MH?QZ>G;E]5+S_;0_CUD["+JCB&
M#)EKE-1'KI/;YYGOO!P)=>2AE3*NXV" "E0S_-@;%0KQQ1-O=ON'$TF.]-=M
MZY#$0-ME68JBTR4N(QN$E2E)5CQ*3MA5!K_3MR^JEY_MH?QZ>G;E]5+S_;0_
MCUF692^ULD3IQXG-T"'89?<*!'Y^%?F<Z V&,D+QN0#G4=_H;+J'FD.LK2MM
M8"DJ2<@@]"*"B].W+ZJ7G^VA_'IZ=N7U4O/]M#^/6@I09_T[<OJI>?[:'\>G
MIVY?52\_VT/X]:"E!G_3MR^JEY_MH?QZ>G;E]5+S_;0_CUH*4&?].W+ZJ7G^
MVA_'IZ=N7U4O/]M#^/6@I09_T[<OJI>?[:'\>GIVY?52\_VT/X]:"E!G_3MR
M^JEY_MH?QZ>G;E]5+S_;0_CUH*4&?].W+ZJ7G^VA_'IZ=N7U4O/]M#^/6@I0
M9_T[<OJI>?[:'\>GIVY?52\_VT/X]:"E!G_3MR^JEY_MH?QZ>G;E]5+S_;0_
MCUH*4&?].W+ZJ7G^VA_'IZ=N7U4O/]M#^/6@I09_T[<OJI>?[:'\>I5NNDV7
M*#4BPW&"V03SGW(ZDCV80ZI7]U6U*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!2E
M*!2E*!2E*!2E*!2E*!2E*!2E*!2E*!4&_P#^@KC_ $9S_E-3J@W_ /T%<?Z,
MY_RF@H!:Y-WL5DCY;:@IB(6MY#A2^%\L!(3W2 GKG?<'&,9!T5I3*1;V$3VX
MS<E*=*DQE$M[;#3D @8\/#ID]:X\-_ZNVO\ HK7_ ""K&@QK[S[#O$SD1Q]#
MOI:(C\SHUJ"FHJ2!KVW!/6NK\ZX+A7ET+G,.(GL,M-$,E:$*Y.4IZIWUJ^43
M^RN\" Q<;GQ*S*#A;3<F7!RW5MG4F,P0<I(.Q ./95F_8X+_ &KF)D?REU#[
MNF4ZG*T8TD85W<:4],=!Y4%<U*N3[E[#1D,O)0T&&9'*R@D')24Y&3X:B=_9
M7 3)41,U(ES4O+[,VVQ-;02P7'2@N!2=ECO Z<G!3X9JYD62#(5*4\AY1DZ.
M9_*'.J""DCO=T@@'(Q7IJSPT-R$+0X^)".6X7W5.E21G"<J)P-STH(S*9$2[
M-0C-??:DQW'-3H25MJ04#(PD#!U]"" 0,=:\VQUV);;F2X[)5&>=TEU94HX
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M%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%*4H%0;_ /Z"N/\
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MH64)1CJO;Y &1E?4;!.YP5YA--6@R)B>V3F6$M(4HE(=<Z)[H. 5*(_?07M
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M:)\EZ34WB6\W2&U'M]R]"17;JLPHV9+Q*W%).PPU_P">!T'B*#2<-_ZNVO\
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M"A"D+RD?_O'7%?MJVF<'7-Y5PMS4V&FQ3[B+BZ5-J[0@\Q+BFT[Z2"I.RCN
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M7@?.;S][R_B4]5X'SF\_>\OXE!DKM^3V5Q)<.V\2/PEJ=?:YT>,E00&6V9"
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MLO%T.XVMB6ZR_&6XF.5-+3DIY[A;;W\<J'7RWH(,#A)UKA.X6I[LZ5S'^:I
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MPPV=#9 E_)R.N9*#G R4DX&PJ"K\G,M4E]2I4<A;:@'E%1426 URU( &4?\
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M.J<""7)2%RFWREW;&P04C<YR#W1M7&9^3Y]RXMNL.QA&YJREK*D".DR%.A2
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M(1C*.<2M.H1>S#4 02.6!D C/F*JAQW)89,BXV=#,5"0MQ34OFK 5'4\G"=
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MY64@* (U DC5GPQ5-!O5UO";0I$CT<Q>@Y*CJY:%.-,)0DH0,Y27%A16<Y
M( VS0::!98D%YEV.E86RVXTG*L]U:PM7]X%5R>$(+:&TLRK@V6% Q2F0?Y,
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MMOAL2I4@R(I2XW*;5H<#@24E7EN%*!!!'>-5L$W(\:SXCMV?<A1XS$I+)9:
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M'YT5F&[ MC\>,#RF2TA26AXX3C 'G4L0[;(CNH$>(ZQ*3H<2$)*7D@8P?!0
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MDW*$R\MSE)0X^E*BO;NX)Z]Y.W^\/,5):F17G$(:D,K6L+*4I6"5!"@E>/\
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M_,A Y1*M(U;[=[N[^.W6OT<164JB)%WMY5+QV<=H1E[*M(T[[Y5MMX[5FF>
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MAUST2YE>4A)S_*/U4@?8!Y5XC\,W&-/[='D</MR].GFIM"PK& GYQUP ,^0
MH/+W&O*N<V";<L/MN!F.E;F@ODNI:U;IQHRL'4DKP.N%828+W'2X\Y]<N.IF
M/&1^>900LI6@2RYA6VH'LXQT.^^-Q4QWA*8Z]*=<=X=4Y*&'E&SK)7DA1_\
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MS'"X$K<4]I"4\M"RKH<G"\ >)\NM5[?"4QM]#R'.' XAH,I/H9>R G0!_/\
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MSS"049PI*D#?.HY!'@/VS/5*W?.;W]]S?BT]4K=\YO?WW-^+0?L6V2[=V9R
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M5^M-]P?_ (*O*4%'ZU6K]:;[@_\ P4]:K5^M-]P?_@J\I04?K5:OUION#_\
M!3UJM7ZTWW!_^"KRE!1^M5J_6F^X/_P4]:K5^M-]P?\ X*O*4%'ZU6K]:;[@
M_P#P4]:K5^M-]P?_ (*O*4%'ZU6K]:;[@_\ P4]:K5^M-]P?_@J\I04?K5:O
MUION#_\ !3UJM7ZTWW!_^"KRE!1^M5J_6F^X/_P4]:K5^M-]P?\ X*O*4%'Z
MU6K]:;[@_P#P4]:K5^M-]P?_ (*O*4%'ZU6K]:;[@_\ P4]:K5^M-]P?_@J\
MI04?K5:OUION#_\ !3UJM7ZTWW!_^"KRE!1^M5J_6F^X/_P4]:K5^M-]P?\
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M5'Z8NGU:N'O$?XE/3%T^K5P]XC_$H+RE4?IBZ?5JX>\1_B4],73ZM7#WB/\
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M*$E8[R5:5:AOI20 1FK=@VU-FMTMV1<9"8UV*$NNE)<<D%]<<E7AIU+.R<8
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M5YJ.%-<E:5)4LI;! '+2,DG(6/,$!K;#Q,FZPKD_RHZNQ=7(DD2&7>[JPEP
M9(Z$8VV\ZB1.,NTW:)#1":0'T,KTNRDH>4'$!6IMLC\XA.K"B% Y!P#C>6@6
MR+?YMH:7)2_=&ER7&DI_--X 2I0.,!2M0)&3G&<#))J[):K3>M8M]SN+L"WR
MV6UQU%!:<>80V4+22C4!LV>Z4I403C!.0L;KQ?'MG$$ZV28ZPF+;#<N>%;+
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ML7O_ "WQJ>L,SZL7O]\;XU9:R\,R(#'#GHB&Q:Y"79*I+HA@X!"@G6 4YV(
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MQ>_\M\:GK!,^K%[_ ,M\:M!2@S_K!,^K%[_RWQJ>L$SZL7O_ "WQJT%*#/\
MK!,^K%[_ ,M\:I5NN\B9*#3MDN<-)!/-D<G0/9W7%'^ZK:E I2E I2E I2E
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M\L@U[JJ09*>('%")+[,MH)+I=26]0/4)*\C;R353;(UY93(,I<MQ[LS@6$8
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M;Z-LWW@[\"@O*51]HXF^C;-]X._ IVCB;Z-LWW@[\"@O*51]HXF^C;-]X._
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M< [^S'7:K$\/6\Q(,53:U1X<=45MM2B06U(""%'J>Z.M53?!$)B(41IDYJ0
M4HD)6A*TI*=.C9(!!'4D:LX.<@&@E2N+K8U:G9S;VI"0H)U)4D%0C&3@X!('
M+&<X/EUVKG,XVLT/F=H<DI"'76LB.LZBTK2X4[;A)V)'B0-R:B,\!PEP6V)D
MJ6H%D(=:;< ;+AB]F4L#&<ELXZXVSCKF;<>#[=.:90I;[2VG9#B7$%)5^?<+
MCB>\DC!5C?&1@8(H/;'%4.5>XEOA(=?2^71VD(4&LH&2$JQA6YP<'S\CB.WQ
MM;@B0J4U+8Y#S[:_Y.M>EMI>E3JB!LCIO]OD<3(7#,.%=&YC#TH):4XMJ,7
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MVME#\Y$5Y!3(82_A,A1!!6LXU%1U'." =L@X%?K7!T$"29$F=*=D-N-..O.
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M"A\K QFOPVKB1%Q@-Q),\1&FXY0N2]K((45.\XA[O*5LG&E8 (TXW(#1F#>
MZEL\1(#B@5!/8T9(&,G&>FX_>*-P;PZG4UQ$A:<D93#01D'!'7S!%5?"5ON3
M$Y^X7*-/YZ;>RT!*DI<+C^5J>*<*(0"0V !@;; "J"*Q?+'"@MQR^S.<,9IJ
M')E:Q(D?G!(<"0HX;',2L@8_FR<#8D-FN#>&RD+XB0DK.E.8:!D^0WZU'E]M
MAM*=F<5Q6&D+Y:ENQVD@*QG225=<>%>[K#EQ?0"VF95S;M[JENZ5HYRU<E:
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M6LW8P79CJF4KGZ@EL%#>Z^;G'<6XD_G$D+(*3E-!L78-X:05N\1(0@=5*AH
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MR3LK/_\ 0T%HS/8>M;4]L.JCNM)>3AM164J ([H&<[],9KG'N;+S;ZBA]M;
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ME >2TI(=6%N*42HG!)*\GVG[:T] I2E I2E I2E I2E I2E I2E I2E I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
MI2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E I2E
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MM1^W'A72XVA^XOS4O+;;CR80CE3:E:T+R3D=-N]Y^%6<.?#FI)A2H\@#J6G
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M(=!TJ*00-(SI(P=\9.^<[8X6FYR.TW-B$ZU(<$/FQTIF+E(6Z-60%K S^CD
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M->L\*+)MP6\Q:%0UE2VU K_-C2#GH>7GH!N,XZ"R3!EL7$S!#+[;;[JDLA:
MHA:48<3DXU#2I."1LI6#X$+Y,J.KD:7VCSQEK"Q^<&,]WSVWVKF;C"#(>,R,
M&B2D++J=)(R2,Y\,'/V53H@2V4,RTQ>\B<J7V-I:<H2IM2"D$D)U95K.X&2K
M<]3P3!FOALR[8#FYB24<Q"PE&G96Y&X.#@="-L[$A=3+Q;XEM](.RV.QG #H
M<24J.<;'.#4F)*CS&N;$?:?;SC6TL*&?+(JF>@2GHM]:3'T%]\.,!2DX6 A
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M2H@9"1U/LH.#,^(^MM+$J.XIQ)6@(<!*D@X)&#N,^-?B+A"6I]*)D=2HX)>
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M<N6A,%3SJ4I=,N&E_)2,!2=P0<;>(V&W7,@VJ0PHFVS$Q@MI#3@+ 5\D8"D
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MLH*1CVY)KE&M<2.EX);4YSDZ'%/.*=4I._=)62<;G;IN?.O4&WQX146.<2H
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M*PTXE3:DK2L@$)T$:M1!&!C)R*[QI\:3&<?;= ;;)#FL%!;(&2%!6"DXP=_
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ME:2$K0$A14""<;@ X.":Z2.-XL=;R';7=0IH+*\-MG!0E*W$YUXRE*@3X'!
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M+:FDERZ)6E"5%)4$@KP,E*3^SVFH<1/ ,62E]J^VXK0H*0%78*2C#B70 "O
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MEX@&MS2@S,[B+A*=;9$"3?[.J,^RIAQ(GMC*%)TD9U9Z&JRZ/\#7.4\_+O\
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M9>!",1]#A;.LZM\D'&G.0#4:3QG#C+=#D*?H2MUMI:4H(?6VZEI24#5G.M0
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M4X[&B/B.0EHZW7#C0&T]5:LC&.M!=^A+=V21&,5"F)"4H=2HE6L)  R2<Y
MWZ[5V,%!NR)X4H.)84P4^"@5!0)^S!_K&L=PMQM.O4]KM<"%;(;DIR"&7Y*C
M+#R$E6@H"-(.!GY73SJ]O5W4](N=BL[FF_)MRI3*E)[B"K*49/GJ'3RH.RK!
M%,ZWNH*4-6YE3<1A*!AE1&G7GKG3L!TW/7PY6[A*T0;8U";C:DH0VCF%2@ON
M?)(4#E.Y)[N-U*/B:^:PN(+-PIP^F5;VBSQ5+>3;Y:[O(45-.A.I:W5$GN =
MX:=CD 5J/R=W7B.ZW22]-E)G6#E?FI:X/9%..Y'\TG426\9[R@,G&*#9.VB
M[;V81C(3&9P6D-DHY9'0I(P0>NX\SYUZB6R+!9<;M[+<4+2$_FT@8PG2G;V
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M57'G^HW$7_=TG_I*J\H*6)PO:(DMJ2S&7S65A;6M]Q:6L!0 0E2B$I 6K"0
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MTJ"=735L=\U-NTJ\>N N<>*^JTV]UN&O#A&M*Q^=6&\=X K:.?#DJQU-!?\
MI&^_0+7OR?X:>D;[] M>_)_AKYM:A?>59[<Z+D&HMP8N"G5:\K0X\VGEJ/B
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M1^D;[] M>_)_AJ+(OUW8FQ(KEA1S9.H-XFIQW1DY[OE6FJCO'^L_#_\ Q/\
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MG+7@$ATY#+>?#Q6?8!0;RE*_ I)44A0*AN1G<4'[7EYQ#+*W7%!*$)*E*4<
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M5I)#ZVGHR$1W74O.%"EHQAH:5'4K)Z9 3MG=0\*#O2E*!2E*!5'>/]9^'_\
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M.H0DZOM4/*JR7P/QIQ#;'(?$_&3*6'""IB#"2$K'ZJE;$CV>/C08S@W3*?\
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MG^$X_(;F)A.33%CE'-6$D9&=>"5I&=/4^634IE' 3RHX:C\.K,@99PPUWQG
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M'&4)89)<202,;>.#CSP:#.<,,3+_ &%B!/EL=NL_-M,E;JB5(6DHTR6_-90
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M/8>*GQ(7&85_/*+@*LE1'<4E3H*25$!6 5 !(UOJKP]] VGW-O\ "GJKP]]
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;"E*4"E*4"E*4"E*4"E*4"E*4"E*4"E*4'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>exh1082_02.jpg
<TEXT>
begin 644 exh1082_02.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" 2; X\! 1$ _\0 '  !  (# 0$!              4& P0' @$(_\0
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M5_S21_+T^*Z@?U1BO^:2/Y>GQ74#^J,5_P TD?R]/BNH']48K_FDC^7I\5U
M_JC%?\TD?R]/BNH']48K_FDC^7I\5U _JC%?\TD?R]/BNH']48K_ )I(_EZ?
M%=0/ZHQ7_-)'\O3XKJ!_5&*_YI(_EZ?%=0/ZHQ7_ #21_+T^*Z@?U1BO^:2/
MY>GQ74#^J,5_S21_+T^*Z@?U1BO^:2/Y>GQ74#^J,5_S21_+T^*Z@?U1BO\
MFDC^7I\5U _JC%?\TD?R]/BNH']48K_FDC^7I\5U _JC%?\ -)'\O3XKJ!_5
M&*_YI(_EZ?%=0/ZHQ7_-)'\O3XKJ!_5&*_YI(_EZ?%=0/ZHQ7_-)'\O3XKJ!
M_5&*_P":2/Y>GQ74#^J,5_S21_+T^*Z@?U1BO^:2/Y>GQ74#^J,5_P TD?R]
M/BNH']48K_FDC^7I\5U _JC%?\TD?R]/BNH']48K_FDC^7I\5U _JC%?\TD?
MR]/BNH']48K_ )I(_EZ?%=0/ZHQ7_-)'\O6O<;IGL"WR9;MGQ=3<=I3J@FZ2
M-D)!)U_J_GM7BT7C/+I:85P8LV,)9EL(?0E=T?Y!*DA0!U'\Z-;?Q74#^J,5
M_P TD?R]/BNH']48K_FDC^7I\5U _JC%?\TD?R]/BNH']48K_FDC^7I\5U _
MJC%?\TD?R]/BNH']48K_ )I(_EZ?%=0/ZHQ7_-)'\O3XKJ!_5&*_YI(_EZ?%
M=0/ZHQ7_ #21_+T^*Z@?U1BO^:2/Y>GQ74#^J,5_S21_+T^*Z@?U1BO^:2/Y
M>GQ74#^J,5_S21_+T^*Z@?U1BO\ FDC^7I\5U _JC%?\TD?R]/BNH']48K_F
MDC^7I\5U _JC%?\ -)'\O3XKJ!_5&*_YI(_EZ?%=0/ZHQ7_-)'\O4C@U\EW^
MS/2;C%8BRV)DF$ZVPZ7&^3+JFR4J*4D@\=]P*L%*4I2E*4I2E*4I5.ZG?]"Q
M_P#X] _]9-7&E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2J=T>_^&6/?]V'_ )FK
MC2E*4I2E*4I2E*4I2E*4I2E*4I2E*4J+RO\ ZK7G_N3W_P PUKX'_P!1\=_X
M='_])-3E*4I2E*4I2E*4I2E4[I=_[GO'_'KI_P#1CM7&E*4I2E*4I2E*4JG=
M3O\ H6/_ /'H'_K)JXTI2E*4I2E*4I2E*4I2E*4I2E*4I2E*53NCW_PRQ[_N
MP_\ ,U<:4I2E*4I2E*4I2E*4I2E*4I2E*4I2E1>5_P#5:\_]R>_^8:U\#_ZC
MX[_PZ/\ ^DFIRE*4I2E*4I2E*4I2J=TN_P#<]X_X]=/_ *,=JXTI2E*4I2E*
M4I2E4[J=_P!"Q_\ X] _]9-5S(>NN(6:[3(*4W6Y? JX3)%OB%UF.1Y"U[ [
M?ANNAX[>[=D=EB7:RRD2[?*1S:=1O1&]$$'N""""#W!%2-*B7,CM+>3LX\9B
M#>78ZI0B@$J#0.N1]@-]AOS_  J6I2HF;D=IA9%;K%(F(3=IZ5KCQ@"5*2A)
M*E'7@?*>Y\FH;J%U#L6 ?9:LB<?:;N#Q9;<;;Y)01K97W[ ;_&MK(<TM-BOV
M.6B87UR;\XMN&II 4@E 225'?8?.->:LM*^+4$(4H^ -FJMA^=V?+,/=R6U"
M2+:UZO+U6PE?[,;5VV?_ #J'3U=QI6*X_D $_P" O<WX"+^Q'/U.:D_,.78;
M0>_>IW+<SM>+7*P0;H)!?O<M,*+Z2 H>H2D#D=C0^8=^]5K,.L^,8Q?I-G<9
MNMRG1$A4M-MB%X1@1OYSL =OIO56.V9YC=RPHY9'N;2;$E!6Y(<!3Z>CHI4G
MR%;[:\DD:WL528/Z0.%R94=+Z+Q!@R%^FS<9<(HC+/X+V3K\2!KWU70\MRBT
MXICLB]WJ6AF RCER!!+A/A*!^\H^PJ/G9]8+?@4?,)\E<:S/L-OMJ<1^T4%@
M%*0D;VH[\?\ U*U\'ZD8]F35P-M??COV\!4J/.:+#K*2-A9!_=T/._SJ+Q;K
M+B&39"S9[=*EI?DE:8CS\93;,HI^\&U'SX]]?WUBR3K7AV/WR7;);\YY<)8:
MFR(T1;K,51.M.+'OOZ;[]O/:I+,NJ6,8HU;%3)#\QVY-?$168#)?6XUK?J #
M]W7??YZ\&I['\JLM_P 8:R&VSVEVAQM3GQ"SP" G?+ERUQT0=[^E:F"YO9LW
MLTNZV)UU4&-)<C*<=1PY*0 2H=_NZ4#NJEC?7;#<CO4&V6Q5S7(F.AEI2X:D
MH*B==U>PK;OG6G#;+DK]EFS)/J1GDQY,IN.I4>,X?"%N#L#_ 'ZT=^#J3SWJ
M9CN$2(D6[.2GYLI!=;C0F"\YZ8\N$#PD:/?\#]#62;U*Q:'@C.7N7(*LC^@R
MXA"BMQ9)'IA'GEL$:]M'?85\Q#J5C>4VRZ384IV*+4"J>S-:++D9.B>2TGP-
M ]_P-1^%]7L4R^^(M-K?EMRWD*=C?%1E-)E(3O:FR?O:T?H>Q[=C4!,_2)P:
M(ZZB0J[H+:BA1,%6M@Z\U:LPZGXYB=LM<NYNR5O7-"7(<*.P7)+H(![(]O(\
MD=^U?>GW4W'LZDS(=J5+C7.(.3\"<R67T)\<N.R"-D>#VV-ZV*R]'O\ X98]
M_P!V'_F:N-*4I2J-G_5#'\)N,6VW!,^;=9*/5;@V^.7GN&R.1&P -@^_L:\6
M+JMC-\P^\9% >DF-:$J5.CK9XR&.()T4$^2 ==]=CW[&J[$_2#PMY454IN]0
M(DE02W+EP5(9._!Y GM^-3&8=8,>Q;)E6&7%N\NX)83(*8,3UAP5X/8[_P"7
MO4GA_4:SY/!NLUJ/<K;%MJ$N2';I&,=(20H\@2>X 0=_3M559_2#PER8TE?V
MNS;G7?1;NCL%28BE;U]_S_\ @_G5W<S:THSR)B6WU725"^/;4E +1:VH?>WY
M^4^U1V5]3L;Q?,;3C-V?>1<KEP]+@@%".:RA)6K?R[(-2669G:\6N=@@W02/
M7O<L0HOI("AZA*0.1V-#YAW[U9:Y)/Z^8I"N-SAJA7YTVY]R/)=9@\VT*0HA
M6U!7CL?X5,WOJ]BMJPVU90'Y4VU7)_X:.8C/-9<TH\2DD$$<2-?6M2P=:\5N
M]^A6=QN[6R9-7Z<87&$IE+J_9(/?N>P[^Y ]ZW\[ZKXWAMW:M,SXZ?>'$>I\
M#;8Y?=2GV*AL ?76]Z[ZU7RQ=6<8ON,WB\VYR6L6=M3LZ$ICC)92 224$]^P
M/<'78^]3<+-+-,P/]<&GE_8OPBIA6I.E!"02H:_I @C7U[5#6?JI8+K<,7AL
M-7!M_(V77X(=9"?D;Y;*OF[;""1YV"*A;WUZP^U72;##=WFLP72S*FPX9<CL
MK!T0I>QX/T!_#=6:[]1L>MD7&9)?=DQ<BD-QH#L=')*E+UQ*MD$#N-^X^E:.
M==6<;PZ\-V>7\?<+PI'J&#;8Y?=0D]P5#8 [=];WKOK5;F&]2L<R^T7&=9Y#
MQ5;DE4N*\V6WV- GYD'\CW!(V-;KSB/4S'<LQ"Y9':'7U0K<EQ4EM;82ZC@G
MF?EW[CQW[_WUJ3^KF+0,(M642798A7111"CI9Y2'U D%(0#^'UUX^HK+@/5/
M'LVNDFUP$SX-VCH]5<&XQRR[P[?,!L@CN/??>KW2E*4J+RO_ *K7G_N3W_S#
M6O@?_4?'?^'1_P#TDU.4JFY1U!@8_DB+$;5?+E<51$S2W;89?XM%:D G1[?,
MD_\ *MW$,TMF4OS8L1N=#N,+B9,&?&5'?;"M\5%*O(.CW&ZLM*4JCWGJ;8[7
M/N$<Q[M,9MJN$^9"@K>8B* V0M8'E(() WKWU5SAR69D1B5$=0]'?0EQIQ!V
ME:5#8(/N"#66JQ(S.$WFB,8CPKE,GAM#LAV.QR9BI7RX%U9(UOB=:!K9RK*K
M?C7P3<M$J3-G+4W%APV2\^^4C:N*1[ =R3H#ZUEQ;)+?DT%Z3;2\DL/*CR&)
M#1:=8=3K:%H/<'N#^1!%3-*4I5.Z7?\ N>\?\>NG_P!&.U<:4I2E*4I2E*4I
M2J%UE$A6-VQ,$D2S=X89(_I^J./_ #U5*_1>GV6)T34F6]%9<B/23=@\0"@\
MU=W ?]SB._TU4-FF56N1A>"VWIO(<Q[&<@N_P4B9$9,5;*>0"TI) T22?F'G
MB>_FMJU*G8+UFD8=:KW=+I9)MD<G.,SI)?7"=2%Z4%>4[XCM_OC\*YH#?(_Z
M/5LSX97D*KY&G>FP%3EEI+?K*24E/[VSLDG?;0\#5="E8XQ-_2R84N?<VRJT
M-W/]G**?G2X/V?\ ]J/'NCP=FHSI4R_,M&6YMDF79"RQ8+C.88:1)*VFTAO9
M46SOF07$E*=ZV@#QVJ&QFX7>T]0.G$V!(RENWWY]:7'[Q<DNFY-D)^?T$J5Z
M8 6"-GW&O&S8+)%>SXY]D.29I>,?DV:ZNQ8WP\M33-O9;(XJ+8(!WW!WK9!]
MZ^9'88M[_2&P1?V_<9B+A:/B3.BR?3]0MMJTIOCV0E?#92.QY*^M3?Z4-GCY
M!?.F]GF%:8T^ZJC.*0=*"5^FDD?CWKFMEN=XB]5>G&$9*A:KEBUS?CHDGP_&
M<2V62/X(.OPX^X-6N&S.SZ/U)R.\Y9>K3.L$R2Q!BQ)A8:A(:22E2D#SR(T3
MVWQ5_"^8&Y,Z@].,!ON07R;:[BS(#ZA'>#(GJ;=*0E8_>2L(!('GE76Y/_1G
M?^P?_*OR7T6M.>RNBTR1CV26V#9!\5SB/0@XX= \_G_'_E43(1(<_1TZ5(A.
MI9E*R)89<4GD$+]9_B2/< Z[5;NI-LS6!G_2]69Y! NS*[^P&$Q8@8+:O4;V
M2??8U4TJSS)O4C,KCTCS./;KLE\)O-JN<4^DIQ/(<@I22>.^7<#W.CH@50\F
MOOV_^CK)#%D@6QFV9&VQ=46E'&.^@)[N)U]5*;'D]P#[C7;>MUTQM?0B\."1
M!7;),$(MX;*>*U]O2#8'T.CV\ 'Z53LHPR%<?T=;?>LDBN/WJU8UQC!Y9TR2
MV"%%/CF!H;/C7UJ&ZA'CT&Z/K?($!$VVF03]T)]%7G\-;K+U!#[O6'JA]EDD
MIPEU,CA_2XHT#_O<?'X5&R5LNX3^C\BW%!E_:;)0$'N %I]7^'+S5NZESXMX
MN=WZ:].+= :N%T7ZU_N(0$,Q4J(Y%1'WG3[^_?Z[X^,>M<;'?TE;-:BYRB0\
M1;C05N'NI*%:)'XZ2X3_ !K7_1\Q.UYCTJN4&^L+D6<9&_*CLI<*$.(2E 2#
MKRGD5'7U%>^@26F>B&<-_%LVUD7"X-B2X/V<<>B@!9 ]D^?X5$6!V_=+%=-F
M;7F#.18[?)*87P"(R4("%J&W&B/F.BLG9UW\^="O1ULH_1^ZO-7%2!<!D2PZ
M%GYN1=9X_P#X07_<:N?3XNQ^O]L%[(2\<)C!OU3KY@&^?G\0[O\ C7,L<YHZ
M>=/GI':R_KSR!5]P-[1K^'9W_G5JZGA]WJ#UH5;=EM./QQ(*/'/]AO?X\ O_
M )U+3ELO7C]'--K*%/B*"H-GN&PRQSW_ '+_ +E?C5SS)?Z\]<;/A[OSV.PQ
MA>;@S^Z^]L!E"A[@<DJU[@FM%YUF+^EPE=\4A"'[ &[4ITZ'J<QL()_>UZW]
M_P"-7V)>,-D=59=NBM1G,R:A!3S[<?DM+._N%P#Y2-IV"1Y3YK+T>_\ AECW
M_=A_YFKC2E*4KAG42TL7CK(PK#<M./Y_&MP2IJ1%YL26-[ !4-$_-W Y=D^!
MQ)JHQ[],=QOK#C^06VR)R*';E.R[I:&^*)FT'_:'W4.7X>5#0(._F/XCU&Z@
M](<=QUY>-0,3>887\2GU5RRTDA2>QVGEV]M?F!NMR]6N_P#_ .4M)@X9=HUJ
MF,8ZTCUY;(>26DJ0..C[D\3O\#4[U=MV:1N@V7-Y%>HEXEDLK2N%&]'@P'4%
M8('GL"2?INK7(ON#0^BEJEWTP7\5,2,V&2@.I61QTD(]U)(V1Y'$[\&JFX_"
M/Z46-/P0AFW'% MD</22AKDZ4_*0.( UV(&JXUD-V8SI[/[Z]8<CG3KB\VW8
MYD* IUF.VPKMM>QHJ"4@Z!UW-= R?+$YI"Z%7M2P9#E[:;E?@\AQI*_RV1L?
M@17Z>"TJ.@H$_@:_+73(]0%W_J4Q@C./&,[?I*7W;H7.:%E:@"D)[$:^H/>L
M/4W!I73_ *08)86IC,BZ#(VWE/$'T@\M*]:'GB/E'U.B>V]5(S_UDO/6K%\<
MZLW*%&:A/)N-J5;HQ#,]U)!""XH[2=IUK7?Q[I)LG1YZ-%Z[=4HUW4VW?7Y3
M:XH=("UQOF("-^W$M; _W?I6.$(5W_2MNJ;.&I$,6 Q[N6^Z%N%0'%1'8G7I
MC_PGZ&N6OSKA;,:N_1-A;GVD]D3<.,L@_P#0G%>IR_+82H_@X:ZIEUOCVG](
M/I+;H2.$6) DL-(^B$LK2!_<*JUIM,]NQ95=^DV7VV3BKC\AVX62^1.*$J*?
MVB"5#D 4]AOCL=B3K=:]\OT;),/Z)7&%:H]I:5D3;?PD9/%I"DO!*B@?T203
M_'W\U<^BST:+UKZIQ;LIMN_/3TKCAT@.+B[64A&^^@DMDZ_W?I49)>C3?TB\
MQ?L"D.1F<8=:N3C)V@O:&@2.Q5H('U^4_0UR/%6KCT_Z9V[+X(=D6+)H$RU7
M5D'?IO<WD,N#Z=@/[E#]X5?;9!LMTZ1])X<O(7L>R4./.V::&"XV' Z>25GL
MD;/#R?.O/<5:L2N^06/KE:\>SUG'[U>)T%SX6]06 B2TVE*U<7- :2>*NVO<
M=S7?Z4I2E1>5_P#5:\_]R>_^8:U\#_ZCX[_PZ/\ ^DFIRE<=R561I_2"5^JC
M=H<E?JNWZ@N3CB$</BW/N\ 3O>O-9;I:+K8H&6YIFE\C0+E(M[<!I=F84L1&
M@HZX<^ZW%+7H$ZT=?P@;0)UAZBX6(=JR2SQ;D\^Q)%WO/Q2IP$=:P5->JX$J
M"D@[^76]:[U W]F3-Z 3\_<R"\QLFDA3SCK5P=0VC<CA\,&@K@E('RC0Y<AO
M?M5IOKUUR;J9E5O>M%XNL&SB,S&CP;P("62XT'"ZH!:"M1)(!.P GZ[J_P#2
M23=I&$QAD#R)$YAYYCUA);D*6A#B@CFMLE)6$Z"OQ!WWJOY=<5SY=TP?I]"C
MHN4PJ7=YZ6@F/;P\/G6O7WWU ["?/N>PJ^VBW-8[C$.VP$+<8MT1$=E*CM2D
MMH"4@_B="N&^A)_T)_Z2?U@NOZU>A]I?$?&N>ARY_P#1O0Y>GZ?[G'CO?O5I
MP.RQ/].&;3R)J)+<6WR A4QXI"WD/E84DJXJ ]@00G]T"NAWI^!]HQH29,*-
MD,AA_P"SG'V@XM.@.:DC8) VDD C?:J9TC2_;<ESBQW-Y,Z[L3&9LJY(3P3)
M]=OY!Z?ALH2V$\03VT?>NFTI2E4[I=_[GO'_ !ZZ?_1CM7&E*4I2E*4I2E*4
MJG=3O^A8_P#\>@?^LFHO)>BN!9)>W+K=+$@S75<WE,ON,I=5]5)0H D^Y\GW
MJQW?"<;N^+-XW/M$5RR-)2EJ*E)0EOCX*2G12>Y[@[[GZFM'#NFV+8>B;]A6
MWTGIB/3D/NNK==6C^CS420/P&O KPOIEB:\'1B"K8HX^ASU4QOB'=A7(KWSY
M<OO$GS67(NG.,9#DELOUTMZG+K;@@,/H?<;("%<DA020% *)/>MFS8-CMGL=
MUL\&W)%MNKSK\QAQQ;@=6XD)63R)(V$CL- >U0%IZ,X/:9=OE0[4\),!]+\5
MU<UY:F2D["4[7]W9^[X/ONLF1]'L'R*^NW>ZV4+F/J"G_3?<:0^1X*T)4 3^
M.N_ONM_*^FN*95(M;]XM84Y;$AN*6'5L^F@:^3Y"/E[>/;V\U+9#BMGR&X6>
M;=HI?DVF1\5#6'5H]-SL=Z20%?='8[%:MXP;';OE=MR2?;DN7JW "/)#BTE(
M!) (! 5K9\@^:ALFZ081DM[<NUVLH7->(+ZFGW&DOZ\<TH4 KQYUL^]3EWPO
M'[LBQHF6Y'IV1]N1;VVEJ:2PM&N.@D@$#0['8JPJ2%)*5>"-&J_C6&V+&<:<
ML%EAF/:G/4Y,EY:]\^ROF42>_P"=1B>F&))QZS606Q7V9:)7QL)KXEW]D[R4
MKERY;5W4>Q)'>IC(\3LV1SK/,O$0OR+1)$N&H.K1Z;H((5I) 5W2.QV*KF9]
M(,)S&[&YWRS!RX* #C[+RV5. #0Y<2 >W;9[Z]ZL5GQ#'[-C)QZW6J*U9E)4
MA<4IYI<"OO<N6RHGZG9JGVSH5TZMMW1<8^/-J>;7S0V\^ZXTE7UX*40?R.Q5
M^OMHA7VS3+5=&?6@RVBR\V%%/))\C8((_A4;+PRP3,.:Q:7;FW[$TRB.B,XI
M1XH1KCI6^6QH=][_ !K5PCI]C.$Q9;&/6U+ EZ^(6XM3JW0-@!2EDG0V>WCN
M:C\9Z285C.1?;=FLJ&+@GD6E%U:TL\OO<$J)"=[/@=MZ&JBKCT%Z=7*X2ITV
MQNNRI+JGG7#.D;6M1)4?O^Y)J7R#I3AU_LUIMESM/./:F1'AJ0^XAQIL #AS
M"N1&AX)-6C'K);L=LT6U62(W#M\9/%IEO>DC>SW/<DDDDGN2:T,:PZQ8W9YM
MKM$!+=OFO./R&7%J=2XIP +WS)[$ #7BH'%^D.$8Q?DWBS65+4YO994MYQQ+
M._/!*E$)\GO[>U?;STBPB\Y.;_<;&T[<%.!US]HM+;JQX4ML'BH_F._ONM_.
MNG.+YT8R\DMHD/1@4M/-NK:<2D^4\DD$I_ _4UL3<#QB9AS>*R+1'586TA+<
M4; 1H["@H'D%;)/+>SL]^YK'B'3[&,1M4VW62UMMQIV_B_54IY4@$$:65DDC
M1(UX[GZFM'#^E.&X?>EW6P6=,><4J0AQ;SCOI)/D("E$)WL^/J1XJ=M^*V>W
MY1=,BB12B\7-#;<I\NK5S2@!*1Q)T- #P!XK5SC!L<SB"U%R>V-S4,DJ:7R4
MAQLGSQ6D@C>AL;T=#=8L$Z?8S@C#[>,6Q$13^O6=4M3CCFO *E$G7X#M6#H]
M_P##+'O^[#_S-7&E*4I50SSIOBN=J8<R:U(DR&$\6GT.*:<2G>]<DD$CSV.Q
MW-8['TQQ&QXS<K!:[0ABW7)!;F)#JRX^D@C2G">7@G6CVV=:JRV&TPK#9H=J
MM;19@Q&PRRV5%7%(\#9))_B:J.9=(\+S*]*NV16A4N>IM+9<$IYOY4^!I*@/
M^5;>%=,\3PI-P3CMJ$=%P0EN2AQYQY+B1O0(6HC7S*_/=0D7H7TZBWI-S:QU
MKUDK]1+2GG%,I5O>_3*N.OPUK\*LMZP3'KU?G+S<(2UW)<!=M+R)#B#\.OER
M0 E0 ^^KOY[^:D\8L%LQ>Q1;/8XPBVZ,"&F@HJUM14>ZB2=DD]S[U3)?1/ I
M=M^SW[*LPA*<F!E,Q]*4NK "E#2^VPE(T.W:MS#.DN&89>?M7'+2J).]-37J
M&4\Y\JM;&E*(]A[5/XSB=FQE^ZO66(8[ETDJF2R75K]1U1)*OF)UY/8:%,KQ
M.S98S!:OT0R409*9C #JT<'4[ 5\I&_)['M6',,,L68(@C((1D*@O?$1G$.K
M:<:7]4K001X';?L/H*C\ZZ98EG+K+^26E$B4TG@B0AQ33H3]"I)&QY['?FI#
M"<)Q["+>Y#QBV-06G"%.*!*UN$>"I:B5'WUWT-]JQ/8'C;V<-9>Y;4JR%I'I
MIE>HOL.)1]S?$GB2-ZW6W<L3LURRBUY%,B%R[VQ*T1'_ %5CTPL$*^4'B=@G
MR#52R#HAT_O]Z>NEPL*?BWUEQ[T9#K275'N24I4!LGR1K=6&?@.-3HMAC/6M
MM,>Q/(D6]II:FTL+200=)(WW'OO?O6IG73#$<YD-2<CM"'Y;:>"9#;BFG./T
M*DD;'GL=ZK=Q7!,:Q2R2;38+6U#AR4E+X2I2EN[!'S+)*CV)UW[;[:KS'P'&
MH^#*P]%M2<=*5(^%6ZM792RL_,3RWR)(.]@^*UIO3/$9V'0\6F6=MZRP]F.R
MMQ94T22=I<WS![GW_"L6"]+<0P:8Y,QVTI8FN)*%2'75NK"?H"HGB/RUNKM2
ME*4J+RO_ *K7G_N3W_S#6O@?_4?'?^'1_P#TDU.4J-%CMXR55_#!^U51!!+W
M-7^Q"RL)X[U]XD[UNLE]M$"_6B5:[O&1*@2D>FZRO>E#\QW!WH@CN"*KEOZ;
MXY"N4"X^C.E7& YSC2IEP?D.-?*4\4E:SI.E'Y?![$C8%<MO_3*[9$U-MD[$
MK?%F3996_>(]S6(7$N;4^B&5'3Q1V\?>)/*NN9%@UDOUS%QEMRX]P]+T%R8,
MQZ*XXUO?!9;4GDG\#O7M4S9+3 L5JC6RT16XD&,G@TRV.R1Y_B2222>Y)V:I
MDKH_ALFX39JX4],B8^N2^IJZ2FPMQ1VI6DN 5=[5 8M=MBP(86F-&;2TV%N*
M6H) T-J422?Q)W56_P!&6+?:'Q/P+WI?$?%_ _%O?!^MO?J?#\O3Y;[_ '=;
M[U88=D@0[Y<;O'8*+A<$--R7>:CS2T%! T3H:YJ\ ;WWK6RG%K3E#$9%W8<4
MY%<]6/(8>6R\PO6B4.((4G8\Z/?WKUB^,VK&(;L>SQU-!YPO/NN.J==></E2
MW%DJ4?S-3-*4I5.Z7?\ N>\?\>NG_P!&.U<:4I2E*4I2E*4I2J-U><4U8K0X
MV=+1>82DGZ$.BN0?H^=6;_/-[.>7(S&4VI=WB+4TVWQ:96M#H^5(WL@>?Z-;
M'Z/G4C)KO?\ )%9Y>$FW0[:W<0%M-MH8;6 L*VE(.N"AYW70[!ULQ.]7B# 0
M+I#1<%EN#,FPU,QY:MZTVL^=GMW []O-?<SZNV&R7*[65@7.3<(,=2Y,B'#4
M\S!44[275#[H\=]$#W]ZI&)9[=YW3CII<[UE$J)<+M>%1GE-6]I[XT"0I :5
MW2&P0 .:02/I4=$ZCW[(NK&4Q4WF^6>S6MAPQX[5J0XE 0PM2E/E7=)V@E.S
M\W8#57ZQ=3K39.FF-W2]W:??)=T*VXJFH 1*G+#B@>+""0-=AYUX]SJI2!U?
MQ25B]XOCS\N$U:%AJ=%EQU-R6%J.DI+?G9/8:^A\:-><>ZN6*]R;G#1;[[#N
M<"$JX*@3("FWWF4C>VT;/(G8T/)WVKFMHZR7#(^D^1W:X39N/3HDI'"X1+6'
MVFFE.H2E" M0"U=R%;.QRW]!73LEZH6+%56RWS/M*ZW>5%3(3$MT0O/EO7^T
M4D'20='MOZT>ZN8HC CE[4I]^T)>3&<#;7[5ITD#@M!(T1L?P((V*^XSU8QW
M(<K1CT5NYQIS[)D1%3(:F$2VP">;15W(T"02!L U1_TF,_R7!;MAKF,OGTWU
M279<7TDK$A#7I*XDD$@<2ONG1[_A6])ZD2;UU(Z8#'+@I./7^-)>DQ^""5*0
MV2$J)!(*5 @Z([BIN^];L2L]WFPG!=)34!T,SIT2$IV-%7O7%:Q[[[=@?I5F
MNN<V6W2\:8+CTE.0KX07HR.;:NR2%*5OL"%CO50_24R>]8I@,2=CEP-OFNW)
MF.7@VA>D*2O8TH$>P_NJI.Y)F.#]1\0M5PSF%F$&^2OA7HR833#K )2 Y^S)
M.ARWW.OE/;W$1=NHV>3;/EF>V2\1(^/6"Z_ M6=4-"Q*;2M"5*4X?F!(<2>Q
M^NM:[VO(<PRC-.H4'%L#O+5A9%D3>7Y:XJ)"UE?'@WI78#YT;([]SYUH[6$=
M4K]>ND<&\Q[ ]><F<F*M:H\4!#?K)"B'7#X0CB!L^-G7;?:1_1YRZZY-TWDW
MG*YR'9+4U]+CRDI;2VVD).NP  '?N?[ZJW3_ *GWS,.NQB(4[&Q)^W.OV^.M
MM(^(0A? /DZY?,I*]#MVUV]SWZE*4I2E*4I2J=T>_P#AECW_ '8?^9JXTI2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*B\K_ZK7G_N3W_S#6O@?_4?'?\ AT?_ -)-
M3E*4I2E*4I2E*4I2E4[I=_[GO'_'KI_]&.U<:4I2E*4I2E*4I2J+U@0IRPVE
M" 5+5>80 'N?5%?F^;TOS$]*\,%MM,Z/>DNS;;.9]/2TQWUD@K'L@?-W_P!Z
MKW<.F-WFY7U-M=MAO1;=,LD*%;93@XM.J9:9 0%?FWQ/T[UKW*W99G>.X/A3
MF&W&QJLDF,Y.N4GBEA"6$%&V5 _,5 [T/?0[CN)1%OR;#,PZC0H^*3[VQE3B
MGX,R-Q+*%+2L%#RB1P2"L_W=@=U VC"LD:Z<='X3EEFIEVO(?B9K1;/*.U\2
MI7-8]AH@U<+1C5Z:S/K3)<MLE,>ZQ$(@N%':0H,.#2/KW('\:J5GQ'*<<Q[I
M1DB,?FSW\>3+:GVI  D(2ZM>EI2?)TK>O^S[;(L^37OJ;?,$R.=8L978UKEM
M"(REL"X.Q^_JK4DD@+^[KMO15KP"8SICCUW8ZXLWY=FRIBSR+0N.)=^=]:0I
MSD"?4.SPWH@)[>-Z&ZJD3&\K1T'RW"',4NZ;FW/3):=]+;<@%]OLV?WM!))(
M[:J]R8&08)U35ES.-W&_VRYV9B$XBWI"WXKJ$H''@3OB> _O_#1IU[Z>96_T
M<S"0Y97T7C(KZFY-VEC]HN.T5DZ.O?N>WT WW[#I^48_<W^OW3V[1;>^NUP8
M,IJ1)0C]FR5-.!(4?;9('\:]=6,?N5VZI],9L.WO2K?!D2S,=2CDAI*DM <_
MP.C_ '5SNQ]++YB'Z1-D<ML24_AK+TB7&=2.3<3U65A39/MI02!]1Q/DFO<&
MVY=A>'9G@3>&7&\.WB1)^"N<?B8ZT/I".;JB?E4D#??W[=M;/4L3:O/3_%\$
MQA-F?O!6GX>=,8<TW"[@E1^4\D[40/'9-1?Z3V/7/)NGT*#9K>_/?%T8<6TR
MGD0V$K"C^7<?WU:<5Z785BER3<+#C\6+.2"$/E2W%(V-'B5D\>W;M]:X1<\5
MS*T8QF73BWXO-F-7V\?%P[L@CX9#*EMD^HK]T@-@:/U/T&[=>+%?NF_4V#DU
MDL$[(K8[8&[.XW" +K;K?#B2GSQ/IH[^VS]!NY?H\XE<<.Z;1X=[;#-SE2')
MK[.P?3*R-).NV^*4[_$D52>FO3F^7/H)=\3N+TK')LZX.J4XXP5*](J02./)
M.PH CSX)J/L'3?.;/URL;[M_=E6Z%;6VU7)%J;99+"'#N&$@Z3M(^\.XY?A7
MZ1I2E*4I2E*4JG='O_AECW_=A_YFKC2E*4I2E*4I2E*4I2E*4I2E*4I2E*4J
M+RO_ *K7G_N3W_S#6O@?_4?'?^'1_P#TDU.4I2E*4I2E*4I2E*53NEW_ +GO
M'_'KI_\ 1CM7&E*4I2E*4I2E*4JG=3O^A8__ ,>@?^LFKC2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I5.Z/?_#+'O\ NP_\S5QI2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*5%Y7_P!5KS_W)[_YAK7P/_J/CO\ PZ/_ .DFIRE*4I2E*4I2E*4I2J=T
MN_\ <]X_X]=/_HQVKC2E*4I2E*4I2E*53NIW_0L?_P"/0/\ UDU<:4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*IW1[_ .&6/?\ =A_YFKC2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4J+RO_JM>?^Y/?_,-:^!_]1\=_P"'1_\ TDU.4I2E*4I2E*4I
M2E*53NEW_N>\?\>NG_T8[5QI2E*4I2E*4I2E*J/4R--?L]M=MT"1<'8ETB2U
MQXY0'%(;="E<>:DC>A[D5X_7.X?V%RK_  P_YBGZYW#^PN5?X8?\Q3]<[A_8
M7*O\,/\ F*?KG</["Y5_AA_S%/USN']A<J_PP_YBGZYW#^PN5?X8?\Q3]<[A
M_87*O\,/^8I^N=P_L+E7^&'_ #%/USN']A<J_P ,/^8I^N=P_L+E7^&'_,4_
M7.X?V%RK_##_ )BGZYW#^PN5?X8?\Q3]<[A_87*O\,/^8I^N=P_L+E7^&'_,
M4_7.X?V%RK_##_F*?KG</["Y5_AA_P Q3]<[A_87*O\ ##_F*?KG</["Y5_A
MA_S%/USN']A<J_PP_P"8I^N=P_L+E7^&'_,4_7.X?V%RK_##_F*?KG</["Y5
M_AA_S%/USN']A<J_PP_YBGZYW#^PN5?X8?\ ,4_7.X?V%RK_  P_YBGZYW#^
MPN5?X8?\Q3]<[A_87*O\,/\ F*?KG</["Y5_AA_S%/USN']A<J_PP_YBGZYW
M#^PN5?X8?\Q3]<[A_87*O\,/^8I^N=P_L+E7^&'_ #%/USN']A<J_P ,/^8I
M^N=P_L+E7^&'_,4_7.X?V%RK_##_ )BGZYW#^PN5?X8?\Q3]<[A_87*O\,/^
M8J P&]WC'\.M5JFX1DJY,5GTUJ:^$*2=GP2^#_RJ?_7.X?V%RK_##_F*?KG<
M/["Y5_AA_P Q3]<[A_87*O\ ##_F*?KG</["Y5_AA_S%/USN']A<J_PP_P"8
MI^N=P_L+E7^&'_,4_7.X?V%RK_##_F*?KG</["Y5_AA_S%/USN']A<J_PP_Y
MBGZYW#^PN5?X8?\ ,4_7.X?V%RK_  P_YBGZYW#^PN5?X8?\Q3]<[A_87*O\
M,/\ F*?KG</["Y5_AA_S%/USN']A<J_PP_YBGZYW#^PN5?X8?\Q3]<[A_87*
MO\,/^8I^N=P_L+E7^&'_ #%/USN']A<J_P ,/^8I^N=P_L+E7^&'_,4_7.X?
MV%RK_##_ )BGZYW#^PN5?X8?\Q3]<[A_87*O\,/^8I^N=P_L+E7^&'_,4_7.
MX?V%RK_##_F*?KG</["Y5_AA_P Q3]<[A_87*O\ ##_F*?KG</["Y5_AA_S%
M/USN']A<J_PP_P"8I^N=P_L+E7^&'_,4_7.X?V%RK_##_F*?KG</["Y5_AA_
MS%/USN']A<J_PP_YBGZYW#^PN5?X8?\ ,4_7.X?V%RK_  P_YBGZYW#^PN5?
MX8?\Q6E?,INDZRW"(S@^4!V1'<:25"( "I) W_K'CO6+&<ENMKQNU0)&#Y.I
MZ+$:864"(4E24!)UN1XV*DOUSN']A<J_PP_YBGZYW#^PN5?X8?\ ,4_7.X?V
M%RK_  P_YBGZYW#^PN5?X8?\Q3]<[A_87*O\,/\ F*?KG</["Y5_AA_S%/US
MN']A<J_PP_YBGZYW#^PN5?X8?\Q3]<[A_87*O\,/^8I^N=P_L+E7^&'_ #%/
MUSN']A<J_P ,/^8I^N=P_L+E7^&'_,4_7.X?V%RK_##_ )BGZYW#^PN5?X8?
M\Q3]<[A_87*O\,/^8I^N=P_L+E7^&'_,4_7.X?V%RK_##_F*?KG</["Y5_AA
M_P Q3]<[A_87*O\ ##_F*R=,HLV-8)B[E!?@/2KI.EICOE)<0AV0XM'+B5#?
M%0\$U;:4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4JE]3<_BX+$MP5;Y=TNES?\ AH,&
M*!S>7VWW/@#8^OD=JB<$ZI&_Y8]B^08]/QR_I8^*:CR5AQ+S?N4J '?^'L>_
M8U,=+LZ9SZU7.='@N0DP;@[;RA;@65E"4'D- :!Y^/PJEGKM#_T5HS86*265
MW#[/$3XA/+EHGERUKV\:K=M?6%U&4VFR9;B%XQQRZN>A#D25)<;<<[ ))&M;
M) ]^Y'MWK5D]9;BYDN06BQ8)=KS]BR3'D/17TGOL@'CK??B=#\*SR^N-G3TU
MBYA"MLM]IRX)MKT1:@VXP\0203W!T-'\E#QXKKE<1Q_K=>LCAN3+!TXO%PAH
M=4R7F92./).MCN/Q']];W43K7^HELQV1>,8FIE79IUU<3UTA<;TRG85V[]E;
M_A4AU9ZQ6SI[;K)*^!=N@NR%.LI9<"--I"3S.P>QYC_G6KDG6%^VY%9[):,3
MG7F?<K6U=4-QWTI*4+Y;3HCOKCY_&I2W=0[N<?R*[7["KE96;3"7,2F2^D_$
M\4J44)('8_+Y_&M?'NL-JOW2RZ9G"B.?^S$+,F 7!ZB%)[@<M:T000=?^1K1
MR+J]<+3CMOOT?";E.LTFV,W)R6W(0$,!8V4*V.Y UW_&IOIGG]TS5Q#LG$+A
M9[8]%$J/.?>2MMX$IXI&@#W"B?X5'M=9;.YU>5@@BNAP++ G^H/3+P1R+>M>
M?W?/GM4_><Z9MG4W'\-5!<<>N\=U],D. );"$K5HIUL[X?7WJY5"9ODD3$,3
MNE^N *H\%DN% .BXKPE /U4H@?QJ%Z2]0874?&G+K"C.0W&9"HS\5U84IM0T
M1LZ'8@@^/J/:JK.ZSOS+K<(V#X;=\HB6]PLR9L90;9YCRE!(/,_EK?MV()D8
MO6*T3NEMUS.##E+%L5Z4JWND-O-N<D@I)[C]X$'_ ,CL" =ZYSK?:(U[OG3^
M^P<?=#:S/2XAQ*4+UQ5KMV.Q[CR*G,VZLJL.5VFPV3')F02KE %P8,5Y*.39
M*O8CZ)W_ !K=L_4"\O6F_7"^X3<[(Q:X+DU)DOH5Z_!)44)T.QT/-5NR=9,B
MOEKCW*T],KW*@R 5-/-RF^*P"1L=OJ#6[F?6J'B6<V7&[G9I(5<&8[SLCU@!
M&#JR@\AKOQ([]ZR]4.LT# \OMN/N6M^?(EMMN*<;=" R%K*$[V#W[$UCOW5V
M?$SR\XM8\+N-\E6L-J><C2$)'%:$J!T1V^]K^%;ESZH3[+T[N^4Y!B%PM9@/
M-M)A/OIYO!:D)Y!0&@ 5?\J7CK#:H726-GD*(Y-AO*;;5&2X$K;6I7%2%'1[
MI._S\^]:/4CJ]<,&?ENS<)N3]G86A";DF0A+3A4 1H:)\DC^%6_ ,HNV2M3%
MWC%IV/>CP](2G4K]<*WLIT.VM#^^K;2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2N.?I$N8JZC&8&8"YP4R9:O@[
MU#6E M[H [K4? .Q[?ND[&MU5>G>172S]9K7BT3-&<ZLTV(XXY*(2Z["XI4H
M;>25;[@#NK][P#K>3]'O*[#B-GS:UY+=H5LGQ;]*D+8E.I;64<4)VD'NKNA0
MT-GQ]17,'HS[/Z(UN6M);^(R'U&B1Y3\R=_WI/\ =7=XG2S);OEECO/4#,A>
MF;*_\3$AQX"(R?5!!"E%)[Z*0?'MY'>J#@]FR^[]4>JB</RAFP(3=0))7!1(
M+FU.\2.7W=:5_?\ A7SK-@T7IWT&@VIF:Y-=<OS4N5+='$NNJ2H*5K9T-)2/
M)\>:[];<XQ.Z3FH5LR>QS)CITVQ'GM..+.M]DA6SV!K\M]$XT%W$Y2I75=S$
MG/CWA]GIFLL@CY?VG%:@>_C?X5<^JMNA9'E_26TMW9%YAS(<^$;B'$N?$;92
MV7.2203O9.O>N2N.W#*,#R.5>&E(.'V.-94)5[.F:D<A^/IH*3^57O*VV7>K
M^$)DY2K%6_U0C?\ M)+R&BG_ &GR\ED#OXJ_N_ ,=+>H;$7J+^N3R[,^OBN8
MT\J,D-. D!!.@2H>?H*XC>K-<,&Z76S([(A3ECRNS"!=6-]FY&CZ;OX;U_?R
M'[PKNMY_^Q%;_P#N:8_])%3^*9"QB?Z/%EOLK1;@V%AT))US5Z20E/\ %1 _
MC7YM^R\Q:Z8-7<8;-%P;N/ZT?K"93>SL<M^GKEQXZ5Y\C==-O68VFY=;^E.5
M2IL6#;)-F?>6](>2VVTI33P*5*40 0L\?SKO5BRBP9 XZW8;W:[FXT IQ,.6
MV\4 ^"0DG5<7_2=N4V\W7&,$LL!VZ29;WVE-A,N!M3K#9.D<CV2%:6=GP4#S
M4)@=UO%CZVW>%>+ ]BL7-(RE1HSCZ74HE-H^^E2=#N2OMK>U#\*^]'<FC6'I
M)<L25D5LQ',;9,=2ZNZ!  _:A14$KT%[3M/;9[ _2HE&67;*>A/5,W6=%N#$
M*2AF-+C1$QT/I]5.U@ #[W97?OWK0R^SY!9\'PF1E^276[=.;@Q$$Z+%;0RN
M("A*FTD@$K0.W?L=I]B0:L75INWN=>,.1'R=.,VW]7_V-T9?0VEMO;W$)6HZ
MTH:'GONK?$%OC]/\^8C=2/UR?<LLA?I+F-/*CI2TX"H!!) )4 2?H*YWTJB6
M]SI]9E/]:7; X6E<K8+@PV(_SJ^7BI0(WY[_ %K;ZU6=O+>K5WC0UHD>KAAE
MQ7&U!06IMTNH*2/.^([CZU1+K-E9CCKF=W-!#\S(;7;6M_NAF.OU-?@I1!_.
MKS=V8SWZ1F?"7G2\-2&8NGTR6V?7_8M?)M9&]>>U3G54PT?HXY1'AYH,O4B5
M'6N89+;RF^3S6D$H) '8D?F:Y7UDLUPZ>6*1982%+Q+)T1[A'&^T62CB7$C\
MP?[N/]$UW7]+7_X)O_\ >H__ )UV>+_T5G_L#_RK+2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2M.[VJWWJ"N%=X
M,:=#7]YF2TEQ!^G8C5:&.8GCV,^J<?LMOMJG1IQ49A*%+'T) V1^%:U\P7%+
M]/\ CKSCMJG3.P+S\5"UJUXV2._\:D+CCUFN=K9MMPM4&3;F2DMQ76$J:04C
M2=)(T-#Q4I6A;K-;+;+FRK=;XL63.6')3K+24*?4-_,L@?,>Y[GZFOE\LEKO
M\(0[Y;HEPBA8<#,II+B.0WHZ(UON?[ZBK7@6(VF>S.M>,V:',9)+;[$-M"T$
MC790&QV)K65TRP92B58?8"2=DF UW_\ P:E8^*V",;:8]EMS1MG+X$HCH'PW
M+NKT^WR[]]>:^*Q/'E1+C%59+:8UR=]::U\,CC)7OER<&OF.^^S[UKW;",6O
M#K#EUQVT37&&4QVE2(B%E#:=\4#8[)&SH?C2VX1BUL:F-6[';1%;F-%B2EF(
MA >;/E"@!W2?H:WG<>LSUB%D=M4%=G"0@0E,)+(2#L#AK6@0#XK*Y9K8Y919
MUP(JK4&@Q\&6DEKTP-!'#6N.@.U8I>/6:98V[-*M<)ZT-I2A$)QA*F4I3KB
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M ;*_%CR^+6]+D</3X_4?M$[^E6NE*4I2E*4I2E*4I2E5/JY_\*LQ_P"#R_\
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MU1YLD/O#U%D\EJ  "E?>*>^B2-UQ3*8F37[IY>H-QAYJ_D[B70NUQ8OP]M:
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MXI#*I00%<CK7 <?&O%?L^VS&+C;HLV(HKC26D/-*((VA0!!T>X[$5^6/T?\
MJWB^$].)%KNCTMR\?&//-0V(RUJ=V$\0% <=DCW-8W(U[Q#]':!C"V%Q\ES2
MYJ;:B*!2MIMTI"@1[;2$@CV]3OXIE5DSOITO"LLO<3'4VW%E-0";.IXNKC+^
M57J<^QWM0V-?,YX[]N@_I$O-RIW2V1&6'&7<AC.(6GN%))201_"M[])V[R_U
M2MV(V8@WC*)B(+2=ZTV% K)/L-E"3^"C7-,FMF;].;UA.89'%QUNUV+TK0O[
M&+Q68J@4GU OL=#EHC]Y0_A^C,9S.T9+>[Y:[4XZY)LZVT22I&D;<"BDI/[P
M^4]ZY#^D0Y=,QS7%NG^-HB/24DW>6B65!CBC?!+A3WXG2]@?TD^/-1=E<RO!
M.OEONF;MV9EG,$&"Z;27/0]9 2&U$+[A1/$>=?,3]:I6 ],).8])\EN=EN-R
M8OC%TD(:B(DJ3'DI2E!+:D#7S*!(WOZ;[5WSH)?;->NED5%BM[5K,%*XTJ C
M?[!X=U?>)4>6^6R2>_<[!J!_1(!'19G?_P"ER/\ S%<AQ*S7.3T"Q:_6B&[.
M<QW(U7%Z*T-K<:2I)40/?1 _@2?:NQ)ZZP<BO=CM/3RVR;W-EOI$U+S2V$PV
M?WE*41V(.CVV.Q'DBJDSG>/X)^DAU#E9-+<BLRF(C;2DL+=Y*#+9(^4'7:M?
M](?,<;SCIYC5SM<MV19FLB;CR7/2<;4D!I2EZ! 5]U0[BI+I;<.C,3.;:<0N
M%T7>W2IF.E_XI2"5)((/,<?&_-4S+KAT_G7?('L[M%SP[.(\ASTE6HNGXH_N
MN).N!*COOI.]@[[]N^= Y&0RNE=F>RXR%7-25Z5)WZJFN1X%>^^^.NY[D:)K
ME\&]1^D^9]0+5F2KC;+3D<IR=;[U%:4L)+G+8"D@D+3R&NW8IWX()=#K]<#F
M.4W<7K++S@L&V*6S,O"EJ"W$E"E% /8G25ZT-Z\ZW76KG?+;EO2>Z7^U)4N+
M)M4LL+=;XK">"TD:]ME/_(5%_HV=NB.+;_\ I3O_ *SE<TZP7QM?52^6F4BW
M618M*41YR[29LNZ<T@^BUO:1\QX^"=I/\*<TTQ<.@O2.'(2EYI62EA]I7<:+
M[NTD?]E0_OKH%TM*F_TALK@8ZPU$DRL-=0REA(;'JDI2D]M#>PG^ZN29/=,8
M5^CO;L>CVU3>76V7RG(,-278Q]104MQ93X5R0G1/D@:[=OV3E]I5?\-O-G;6
M&UW" ]%2L^$E;92#_P Z_.%ISRT67I?#P?,[GDN'Y%9W"A7V:VM+LA*5*X\%
M@$%*@H>2 2-@ZJW]'<SG8GTJ1=NHSU]<,^]&-"<GA;KZFUH3Z>PH["=I7^'T
M\U6NN/5*!><S?P23=WK+C$8\+O-894X])4-;8;"0=#V)/T/D#2NMXKG6'Q(.
M&6:P>NB%>&7&K4E+"@G@SV5RWW'@]SY\U[ZW7%%LQ2$\[#@OMJN<9"I$]M3D
M>#\Q(D.)202$D#ML#9&^U<\M=T-RZJ/OJR2/D(5C$YH38D-+$<J#C2BVA0*N
M9 [GYE:V/'>L<ZW.L] .FTF /AH421!FW!UN*'PVUP62ZIO]]*7%I61_'VJR
MX,]'O751NY1,J.1O1;8XR_*@P&VXJ4+6DI;<=2L[7L<@D Z'+>JFNHD=J3U4
MZ8(D-(=0F5.< 4-@*3%4I)_,$ C\17/NH,"9)N/5=NV-++:)MEE2FF6?5*VD
MH2IT^G^_V3R(]PDBIS')<7(.IF,2HF8C))$%F0X56ZVMMM,-+;X\'W O:=GC
MQ1HGDGP/-5J):WE?HTXZ[;V2EIFZ)F7 MQ_746$S%E:BW_\ *!.D**?<(^@J
M;AR8U^S2-.BY=^LDB%:9GJ.VZWMML--+0 &WW4K\E0!2C1.TG8'FJ_9;M9+K
MT,Q#%L?+9RLOPEL0VT$/L/)?0XY((UM*.'-7/P0KSWJ>ZEQ)UNSJXXS;4.)B
M=04L(+B/#"VR$2S_ .*/H_F*[M'9;C1VF&$);9:2$(0D=DI T /X5DI2E*4I
M2E*4I2E*5YX)Y\^*>>M<M=]5ZKXH!22% $'L0?>OBUH:">:DH!(2G9UL^P%8
MP['::=4'&D-M;]0[ "/<[^E?8\EB2GE&?:>3H';:PH:/CQ6120I)2H I/D'W
MKRI3;+8*E(;0- ;( 'T%>Z$ @@C8/D&OB4I0D)2 E(\ #5?:5K*E0E22TI^.
M9#9&T%:>22?';R-ULTI7Q2$J4E2DI*D^"1XKXAQ#G+@M*N)XG1WH_0U]4E*T
ME*@%)/D$;%?0   !H#VK P_%E*4N.ZP\II10HH4%%!]P=>#61QYMH@..(02"
M1R4!L#R?X5Z2H*2%)(*2-@CP:^U\6I*$*4M02E(V23H 42H*2%)(*2-@CWK[
M2OG!/,KXCF1KEKOJOM*4I2E*4KXM*5I*5I"DGR"-BOH    T!2E*4I2E*4I2
ME*5%VNQQ;==;I<6E/.3+BM"GG'5\M)0"$(2/ 2-JT/JHGWJ4I2E*5\2A*22E
M(!4=G0\U]I2O*D)4I)4E)*>X)'BO5?%I2M)2M(4D^01L5] T-#L*4KX4I*@H
MI!4/!UXK[2O@2D*)  )\G7FOM?%(2HI*DI)3W!(\5]I2A (((V#7Q*0E(2D
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M;2$J"@..B5$G7(=C5CZ>Y,O*L>,R3$^#GQY#T*9&"^8:?:64+ 5[C8V#]#5
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M%%Q+:F^270E22-_=7Q5_V3X[52>DLN^P[+:L:P^VXS$EIM,6Z3YSC#@;(>;
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MZT)<1"4J0XKTDN<N0T5'>^:O.];K?N&)V:?DT'(9$4_;$-/!F0VZI!X]_E4
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M*S!A1XD9/!AAM+3:=DZ2D: V?P%4S).E&&Y'=EW*YV@&8X=NK9>6T'3]5!)
M)_'S5D3CMG3CPL0MT;[']/TOA.'R<?/CZ[[[\[[^:JMFZ/X19[JW<(EF!D-*
MYM!YYQU#9\@A*B1_?NK._C=K?RB-D3L<F[1V#&;>]10"6R22..]'[Q[ZW6O%
MPZQQ<MD9-'@AN\R&_3=?2M0"AH#[N^._E'?6ZV#C5J.5#(S'/VP(_P +ZWJ*
MUZ>]ZX[X^??6Z?JU:OUJ_6/X<_;'P_POK>HK7I[WKCOCY]];J.NN!8]=+S,N
MLJ&X)\R,J'(<9D.->LT1Q*5!*@#VT-^>P^@J:L=G@V.SQK5:V S CHX-M;*M
M#R=D]SW)\U!1NG>+1\:D8^FU(7:'WB^J.XXM82L@#DDD[3X_=(]_J:PXATTQ
M7$IZIUEM@;FE)2'W75NJ0#Y">1.OIV[U-7K&K5>KI:;C<8Y=EVIQ3L18<4GT
MU'CLZ!T?NCSOQ2]XU:KW<[3<+E'+LNU.EZ(L.*3Z:CK9T#H_='G=?+-C-IL\
MR[2H$7@]=7?7F%2U+#B^_?1) ^\>P[5K8QA=@QB#-A6:WH9B35E;[*UJ<2LD
M:(THGMKMKQ5;/17 C/\ BC9!][EZ7Q#OI[_[/+7\/'X5T"'%8A16HT-EMB.T
MD(;:;2$I0D>  / JIY=TSQ3+)XG7FUA<W027VG%-*6!VTKB1R[=N_>I&V898
M+7C,JP6^W-Q[7*;6T^TA2N3@6GBKDO?(DCMO>ZD[%:8=BM$6V6QHLPHR.#2"
MHJXCSY))-:MOQJU6_(KE?(D<HN=Q2A,EWU%$+"0 GY2=#L!X%,CQJU9&8!N\
M<OF!(3*CZ<4C@XGP?E(W^1[5%YET]QG,7FG[[;4O2FT\4OMK4VYQ^A*2-C\#
MNLUOP7'+=B\K'H5M0S:I22E]M*U<G-^2I>^1/X[JL_Z#.G_]2N?_ 'X__P#M
MU<8^+6B/DOV^U&*;K\*(?K>HHCTAK2>.]>P[ZW7EO$[,UEKF2LQ2W>7&O1<>
M0ZI(<3K6E)!XGP.Y'L/I4[2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I7.Y_5_&8$Q$66S?6WW'"TVDV>3^U
M4-["/D^;L">WM4[:\XL]Q>M#+?QK#]U<>:BM2H;C*U*:1S7L+ (''P3Y]JL]
M*ALLR6VXI:?M&[N.I94ZAAM#+2G7'7%G24(0D$J43[5(6N:BXVZ-,;:?90^V
M'$MR&BTXD$;TI)[I/X&M6??($"]VJTR75)G7,.F,@()"O22%+V? T"/-,9OD
M#);'%N]H=4[!E J:6I!02 HI/8]QW!J3I6BU=([MZD6M(>^*890^LEI01Q42
M!I>M$_*=@'8[?6MZE*H5QZLXM"E2FP]<)<>(LMRID.WO/QHZAY"W4)*>WOHG
M576W38MR@1YL!]N1$D(#C3S:N25I(V"#6Q2M*T76#>(AE6R2B3'#BV?41XYH
M44J'\% C^%;M*TKU=8-DM4JY762B+!C(+CSR_"$_6OGVK'^W!:=/?%_#?%;]
M)7I\.7'[^N/+?[N]Z[UO4I5&NO5+&K?<I4)"[C/7#442W+=;WI3490\A:T)(
M!'N-DCWJ8D9IC[.'+RK[2:=L26_4^*:!6"">(  &^7(A.M;WVJ,:ZD65R;:(
M0C7@7"YI]1N(JW/!UEOU"WZCJ>/[-'(?>5H:[^*LUCND>]6F-<80>$>0GF@/
M-*:7K\4J (_C6]2E1SEYB(R!FRA2USW(ZI10E.PVT%!/)1]MDZ'UTKZ&JE<.
MK.*PY,E >N$N-$66Y4V';WGXS"AY"G4)*>WOHG56.Z998K7C:+_.N<=NSK0E
M;<D*Y)<"ON\ -E1/L "34-8^I>/7:[1[857"W396_A6[E!=B_$Z_^EE:0%'\
M-[_"K&Q>8CU^EV<*6B?'91(*%IUS;62 M)]QM)!^A\^1N1I5=N>8VBV)G*G+
MD-(ARF(;JC'7HN/%(0$G7S#:T@D=A[^*W[9?(%SNEVM\-U2Y5K=0S*24$!"E
MH"T@$^?E4/%2=*4I2E*5I0;K!G39T2')0](@K2U)0G_Y)2DA02?QT0?XT?NL
M%B[1;8])0F?*0MUEC]Y:4:Y*_(<A_?6'&[Y R.T-W.TNJ=AN+<;2I2"DE3:U
M-J['O]Y)%2=*B[/?H%WFW6)!=4M^V2!&D@H*>+G$*T"?/90[BM1>7V1M[($/
MS4L"P\/M!;J2E+/)L.)[GS\I'C\O-0MIZIXU<;C#AE5RA&<L-PWI]O>C,RE'
MP&UK2 2?8'6_:I7+,ULF+/1H]S?>7/E F/"B,+D2'0/)#: 3K\3H5YQ+-[)E
M,B5%MKLAJX10%/PID=<=]M)\$H6 =?B-BMS+<FMN*6I,^[K=#2WD1VFV6E.N
M.NK.DH0A()*C]*D;;,1<+?&F-MOM(?;2ZEM]LMN)!&]*2>Z3]0>XK9K!<)D>
MW0),V<\AB)&;4\\ZLZ2A"1M2C^  )J-3DMK7=K7;D/J5)N<9<R* A6EM)X[5
MO7;[Z>Q[]ZF:4I2E*4I2E5_,,MM>)L1%W0RG'9COH1H\2.M]YY>BHA*$ DZ
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MZ1-9\QES%P\SM\J;)E1[?D5E8CA]PK*$_P"K$ZW]223]235_Z=__ !'ZF_\
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M5$<5"L,I,R&DN$D.))5\Q_>!*B2/>MV^8/9KU(O;TY#Y7>(*+?*X.:VTDJ(
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M,3N,:9<I+BOB(UVX6<E2NTI3/J<O4 T2G@=J&_QK] Q&!&B,L))*6D)0"?<
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M3;"TH2XI/XK#:-_]FM.V]+8<# ;;C"+C(<$6X-7%R8M +C[B'@[\PW[Z"?R
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M:EM=T$I!*/R^E?$_#J"XZ/2(2-*;&NP/L17EMN-'+3+:&6B ?30D!.OKH?\
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M:L9BQ-AJWRU17%/;)6XZX #P"0-#>O)-<]MF3WZXX-9+>Q=IA3><C<M<*\*
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MHT=C1^FZYCU:MN6W[)84&/CCEWPYAH.R(K5R:B_&O[V$NE1Y%M( ^70V3WV
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MW%R%J)"6T-I'(K)!''6QH[UHU]LV;62ZP;I*3(=B?98Y3V9S*X[L4<>6UH6
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MH2YZR6/NJ=2E6BD=O?50U]R1R^=*.HK!R=F_,1[?ML/Q/A)T<D'DEYH(0-;
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ME7I)*4=W$DC[RO'UK)-P2XW?%[A9<CRN;=427H[R'EQ&&E,^DZES0#:0#R*
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MH_A]:^/OLQTA3[K;22= K4$@G^->RI(UM0&_&SYKRRZV\V%LN(<0?"D'8/\
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M*4@D=D $;!W6*1:1(Q>SV2=+M\JU?KTS&3%MSSJV8S1;5ZD8+6E)*02H:3L
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MCT%E326P)/%+9/?@!XW[:K:AM*MV$IR^.DE_&\LGR7>([JB.25MR$_X%<O\
MP5T?I$#=F[_E[HVJ_P Y2HQ/_P"AL_LF/[PE2_\ QU2K19L5O6-9S>\[2T+G
M%NLQ,N>L_P"LP$-+/HAE7=2-(""D)^\3[[K;QJSXYF&4YL]F;+-R=B%AN*FY
MC1CP3'0M+B0K7IE1*RI0 .P?&JK6-PDY4OH_&R/U+C#6W> $R23\2PVI(9]0
M'[P*4MGOV.AO=9FL*QURQ=7@[:HZV[6])3;FU)VB#_JJ7=LI\-GFK>TZ\#V%
M2EALEORSJ3CWZRQF[FT,(AR%,RAZC;CI=4.:DGLHCDK6]ZY$^:JAQJTQ>A%U
MOC41)O-NNRT0IJR5/14-3PVA#:SW2D)_=';N:D>K,.-+;ZTJEL-/&.FT/-%Q
M(5Z:_3UR&_!TI0W]":[-E=GM(Z:W>VQH,/[*1;W?2C(;3Z0 25)TD=NQ (_&
MN.V+&;%<O]!\!V!$<@/VF5)DQT) ;?>^&CE1< [*)5W(/DCO6#)0YCMEZCV>
MP);@V5J_V]MQE+BF68\=Y#)>&T[+:%$Z/$=@HZ%6G&K'(L/4_'/AX^)6%,F+
M(#T&RO/*,YD(VE:D>DE'R+XD+403L@$^*G>JLEFUYWTVNT]Q#%NCW&2P[(</
M%#:G8RTHY$]AL]MFL74*X0[GU&Z<6VWR69,QNXNS7&VEA9;91'6"M6O VH ;
M\FHBWP+7?+UD=PQ#*KKAUZ9GNHN4%Q;3C*GD]B^J.O8TL 'D"-C\:B)V1SKW
M@^*Y+>TL2(-@RG_7ID1LAB0PVIQH3$I[_*%*23K?@FK;U;R>?;,9DW_'LIQU
MJVM0U.(C26$R#,<&R$H6' /F^4  &K-D"$7OI7,-VC-/&1:2\ZRXWM//TN7W
M3]%=Q]-5R3%[39I<7I%9;A&B#'IMH7,=B@ ,3+@&6=>JD=EJT5JT?)WYU5YZ
M91XMJZB9S9L?"6\>B_".(C-']C&DK2OU4-CPG8""4CP3[;JK9!9[0UG_ %6D
MB#"1.3CB'FG/32' M;,@.*2?.U  $^_;=8(V,VC';#T>O%GA-1;M*GPF),Q
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MH%KM35MMT1F/;VD%M$="0$)2?(U].YK0L^(X]93&-ILL"&8RW%L%EE*?24X
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MRU+E)0B0%[;4E7!UIU&M_,D@^""*VF,RMMCN=ZEW9ZYD6ZQ0ID@J?+C2@KF
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M8(2E2SM6B21V%5&S],YK%KMEC?P.Q_&QEM-2+X])#D=UI!&W T%!PN*2/ND
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MW?E*5M+([A*DJ(V/!U4+)?Z@Y1(@07+,C$X")#;TV:FXHD.NH0=EID(';D0
M5*UVWV]JQ0H&6X?.R:+8K$Q>(MVGO7*)*,Q#(CN/ <D/)5W*0H$@HY$@ZT*\
M8=T_N&,WW!TI4B1"L]EDPI,@* V\XMM79)[Z)"_^51M_PC(7+#F0APFGY<O)
M6+Q#8+Z4>NTV6"1R/9)/IJ\U;,4M%V3G]_R"XPA"9N=N@-H;+J7%-NH#A<0>
M)[\2L#?@^U<FO?37)[OAD^VS\7:N&5+YE=^G78.MNGGL*9;))02G20"E 3]>
MW?I;L#(\8S3(KO9;&F]P[\EAXM)EML.1GVVPV0KGV*" D[2200>Q[5J1[-F$
M7-<0OMSBQKM(3;WK?='(SJ&4QBZZA86E*M<TI">/;N=;UWK0PW!K[:U=.C,C
M-H^QI=V=F:=2>"9!>](C1[[YI\>-]ZP9YBTEN1GMWFRX=M8ES+5+MDJ4Y^R4
M]'" $N:[I25@)V?Z6Z^FX9!=NN&%?;EIBVL1H$]Q,9J8)+@"DMI4XHI "4$\
M0GW)"MZJ]]2,9E9':82[1(:BWJUS&[A =>!+?JHV."]=^"DJ4DZ^N_:JO?U]
M0<OLLC'G<;B8\S.;,>9<UW%$D):4-+]%M(Y%1!('+CK=3-JQ21:^IL2X0V$H
ML<7'$6II7,;"T/<@G7G[@'?Q58L^#7V-T_Z>VIZ,V)MGOJ)TQ =20AH+?)(.
M]$Z<3V'?O6U:[;FV)V>YXWCUIBRD.RY#UON[DI"6HZ'G%.;>;/SE2"M79((5
MH>*@Y73F5:[[D#KV'0<M^TY*IL>:J4B.IIQ:1S0ZE1'R<P5 HY'2M:JT6'"[
ME:LFP>1\- ;BVJURX\OX(>FRAYTMJ ;0HE7':5=__+=6?J3CCF6X-=[)'?2Q
M(E-#T7%C:4N)4%HY?AR2-_A4"Y)Z@WQ2([=MC8TAN*^'I#DAN3ZSY;*6O2"=
ME*$K(42K1(&M5SS_ $=WV5"Q\_J>AF]6^?#E3[I.NXE/2?3=27"R2HZY:*CR
MX=AH [KHMHQFYQD]1P\R@?;4IQV%^T!YI,9#8W_1^9)'>K#T\MDJRX%CEKN"
M B9"MT>.\D*"@E:&TI4-CL>X-<]3@U]'0MG&?AF_M=-Q$@M>JG7#[1]??+>O
M]GW_ .7FIW,\9O\ <,W?NMA=;BJ.-2[='EJ6!Z4I;B%-G7G7RD[T=:JBQ^GU
MW?EXI)9PU$"=;;E%E7"X3;L)<A]*%?M"V2I78]U'92>P 3])%OIK>+=<;[E5
MFBL,Y:C()$Z(2\ F="7Q!8<.])"AR(WX4 >U>[U@+S.97R[O87&R:->"W);2
MN8AEZ&\&PE;:^1XJ02D':22._8]JZ1T[LCV/8? M\J-;XLE 4MUFWH4EA"E*
M*B$\B2?/<^YV>V]5R*_]/\BNT')8=TQIJ\WJ8Y)^%O4VZ;CMMKY>EP8))0I"
M2  $:Y 'EJKYBF,W6#G-MNLR.EN*UBT:V.'U$J*9"'2I2= ]P ?/BH.=B+T3
MI+G,*^.-07'KA/NL5\N AO\ :EYES8\=TI.O-63HK F,8.U=+ND)O%]>7=I@
MUK2G>Z4Z]@EL(3KVU5\I2E*4I2E*4I2E*4I2E*4I2E15]OT*QNVIN>IP*N4Q
M,"/P3RVZI*E 'Z#2%=ZW+E!BW.!(@W".W)B2$%MUEQ.TK2?((]Q6=IM#3:&V
MTA*$ )2D> !X%>J4I2M"ZWB#:5P47"0EE4Z2F)'!!)<=4"0D:_!*C_"M^E5N
M3FUC9A,RTRE/1W;FFSI6TV3_ *R7/3XG>NP5V)\59*5$/JLV)62?-6EBW6UD
MN3)*T(TD%1*EK('<DG9^IJ59<2\TAUL[0M(4D_@:]4I2E*4I6&;);APWY+VP
MTRVIQ>ALZ V?_*H:TY5 NK5H>AMS%1[I#,YA\L*#:6]).EJ\)40H:!\Z/TKW
M$RFVSHEFEVXR)D.[+*([[#"E(  4>2SKY4_*>Y]]?6IRE:EUML*[0E0[G&:E
M15*2M33J>224J"DG7X* /YBMNE*4I2E163WZ%C5H5<KHIQ,5+K3)*$\CR<<2
MVGM_VE"I6E*5\4>*23LZ&^U:=DN3=WM4:>PS)8;D(YI;DM%IQ(^BD'N#^!KY
M<;FW DP&7&93BICWH(4RR5I0>)5M9'W4]M;/N0/>MZE*4I2E:$^\08%QML"7
M(2W+N+BVHK>B2XI""M7CQI*2=G_ZM8;!?H5]-S%O4X?L^:Y ?YIXZ=0 5 ?4
M?,.]2M*4J"CY5;)ENMD^W*D3H=PE&(R]&84L!0*P5*[?*@%"AR/;Q]14K<8,
M6Y07H=PC,RHCR2AUEY 6A:?H0>QJ*QG$,>Q=3RL?L\*WK> #BV6P%* \ J\Z
M'T\5L7J_0K-,M,::IP.W25\)'XIV"YP4OO\ 0:2>]2M1CE]MZ;I,MJ7BY<(D
M82W8[:"I26U%02?&B24JT//:MFTSD7.V19S33[3<AM+J6WVRVXD$;TI)[I/U
M!K:I2E1N27N#CEBFWB[.EF##;+KJPDJ('X >23H?QK#9\@CW''C>'HLZVQ4I
M6XM%P8+#B$IWM2DGN!H;_*L#>6VEV7CL=EYQPW]A<B M+9"5MI;2X2=]T_*H
M'O4C?+FW9[6].?9E/MM<=MQ62ZX=J">R1W/G9_#9K>I2E*T)%X@Q[S$M+LA*
M;A+:<>99T25(1KDK?@ <D^?K6_2HO(<>M&1QF(]^MT:X,,/!]MN0@+2EP @*
MT?P)_OK+;+O N4FX1H#Z77;>]\-)2D$>FYQ2KCX[]E)\?6M^E*4I2E*4I2E*
M4I2E*4I2E*YUFRI%ZZD8_BSDZ;!M+L&3<) AOJ87*4A3:$M^H@A02.940DC?
M:J;GME^'3C%@8RN7.",OCI2HO\Y=O;7&>5Z1<)4HG6RE2NX"AYT*D4RE8;D6
M=VK]8KC&LT>R,W%J3.=7-7"<474*4CF2I6^*3Q)/?\ZA($BY67*<)D0H^9PV
M;A<$PY3]]N0<3-2IEQ1_U?U5E"MI"@=)UX]ZQ2XEQF8+U'R5W),@1<;/=[F;
M<&K@XAN.EEPE*. .E)[:TH$ =AJK5#1)SS/+G"NMUND&':K9!>CQ[=+7%]1U
M]*U*>)005<2D) .TCOV[U2+5D60OXKBUE$Z\WARYWNYLR9$28AF5);84LI;0
MZM20@*['L0>*2$ZJPQ_UM@Q\NM<!<RP1'+4'X"K[>&)+L205E!XK#JUI;4-:
M*R0% Z^E;_3J6NUYQ$MET:RJR3ID1P?9]UFFX19CB.*E.-/E:M+ WL#B"#XK
M>ZY6AFYW/I_ZTB<SSR!N.?AI;C.@IETE0X$:4.(TKR 2 >YK1L]JDYLK,+G<
MLBO4"1;KI*MT!,.<MAN$AC02LH20%J5]Y17O8('BKOTQO$O*.FMANETVF9.A
M(4\I'R$J(T5#7C?GMXW7"X]B2ST\;;B3[DV])SMN,'ERENEGC-6E*T!9("^^
MRK6U$ JWJKK=9D[I]E>41K1/N<Z&UBCUY;CW"6Y*XR6W"D*"EDD CR ==JB;
M2<IB1<:O4&!DPFOOQE3)MSOT9<2:TX1S'HE\I3L*)0$)!!T*O_Z0$5$KH]E'
M-QY'I1%NCTG5(V0/"M$;3]4GL:I-R5<G,OAXI%B9-=+1;K,S+^'A7@1WGG'5
MKVMUYQU"UI3Q "0H@'S[5KSYF5?J?;[7/N%TMCJLNCVUF0+@T[,3$<\H=<:6
MH%:>2A\QV=))'O4XO&UN]5F<5-_R)-ACX\)2F1='@MUTRG "ISER[!6NQ&PE
M(/8:JH\;LQT@FY8YDM^>O-HN2HT1:YRP@--S SQ<0"$N<D[VI8)._.A4]GR+
MRC*,DG33D4VTMI0(4S';GI5I(:!4'8@6GF>6U$GEM) [>*['CDYFZ8_;)\65
M\8Q)C-O(D\.'JA200OC[;WO7M50ZF29<G(\-QMB=*M\*\RG_ (M^(Z6G5(99
M4X&DK'=/(ZV1HZ!T:K&7MR<42FP67+IA;O-W@PRR[)+TNU,N\PM2'5J4O2^&
MDE7W23HUNR(\C"L^MMIM5UNDJV7BV37'8\Z8Y)5'=82@I=0M9*D\N9!&];[Z
MJI6=JYV_IWT\RTY%?I-YF3X#,DR)[BV7F7G A3:FB>)^4_>URV-D[J?3;9.:
MHS^YW&_7:$_;9TJW0F8TQ33$5MIL:4IL'BOGLJ5S!V" -5&XFY(DQ.FMH^.G
M,0)>'OJ>:CR5M!2@A@)5\I'S#9T?(V=5J=.O7L^&='409]P2U<IJE26U2W%(
M6/AG/DXDZ"-I!"!\H/?6ZRQD7*Y='9O4=W)+Q'R-+,BXM!$Q8BL^FM7&-Z&_
M3*=("3L$DDG=3=JARLXZB9*Q=+O>X=O:MEM?1"ASW(Z6W76W"5 I(((UX\$Z
M)!T-0<&9D^0].\#D_$3+ND&6FXP(US^!FSTMK4VVM+@4DJX\=J 4.1(W71>C
M]R9F62XQ6YEZ>>A35M.1KTG4J&"$J2TI6R5@ ["R3L'SVKWUBNDZVXFPW;93
MD%VX7&);ES6_O1FWG4H6X"?! ) /L3NJ;=&).#]3;2Q:[S>9MO59;A,5;ID]
MR0DNMI00KYB2>7L#V!!UK9JM6R7ESN'VG*H,')5WM\,3%W"7?8R;>^E:DE39
M84^$H;(44I 0% Z]]U:U6B3E&>=2F9U_OS$2W+BB$Q#N#C"&%JB(45@)(]^_
M'[N]D@DU7HN49!DL+I_:WV;Q<6YEB5<IK=LFMPWI;B5(;')U2T'B-E1"5 DJ
M'L#7J^W#*[5T[S6*I^ZVD1)MN^S')5R:DS8Z77V@MM:VW%GB/;F=E*]=Q5BR
MRV1K+/LV.1[IF=V+B'YB[9 F+5)D#:$^H[)4X@H:2?W0H J5_"J;/FW%?3S-
M+7<?M!#5MR"VMQV+A+$I^.A;L9?IJ=!5RT2==SK>M]JZ9USD3V;%CS-LNLJU
M.S+_  HBY49PH4E"U$*_ C\#L'7>H6ZIE8=EL^SVFZW61;YV.3)RFY<UR0N,
M^R4A+J%K)4GES.QO6P"-5!V^/<XV$X#K)+Z9>8NPV[C.=FK6IM!CK=*&=]FU
M*T$<AW.OKWJ7N]FN5NRJXX9C]^O C7:P/S(_KSW'78,IMQ"4+0ZH\PA15HIW
MKL?KJO6-Y=-SS(<2$.5(C,P+2Y<[PVRXI 5)5MA+"]:^ZM+RN)_HBJU9W<CO
M6&X'+=<NU_@FTK=G0(-X5%G+<+@"9!/-*G4@ IX\AW/O4W;<A=?B=/6;?>KV
M^!D+T"8+AMF2.+3Q]"0 ?G*?E[G>] ^:T(K=QNW2*Y=17LDO$;(D-2K@REN8
MM,9CTEKXQ_0WP*=("3R!)))W4U"8EYMU)G1[G=;S#MOV! EF!"G.1TAYPN;.
MTD$:UX![]M[T*A(,G)[WTYQ(-S)EV+,^<Q-AM7/X*;<667'6T<7=I*BD)25
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M3#T9]3+K+J00%I6D@@Z4H?QJ)N_3;'[I-E27A<63-2E,YJ+/=8;F@#0]9*%
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MQ<2=Z5R.P=@]NW85XDX%"CXR]:K*Y(CNR)K4Q^6[)<6\ZM+B"I:W"2I1*4Z
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M\M2U2%A04XXHDE:CS5LJ)_Y"M&5TPQF5,?=<8F"'(?\ BG[<B8ZF&\[O?-3
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MK29TMV*TIB(F?-=DHBMJ&E):2M1"01VWYUVWJL-NZ98W FQ'F69JXT)[XB)
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M:]W6[3;<Y<G880M#,;U%*7Z*OE2Z4H2.)&@2>U8NL=GRJ)TWOK%UR03K<B9
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M^^H6-B<9CIVG$4R'C$%L-L]<@<^'I>GR^F]=ZPS,,BR;?B<14I]*,=D,R&5
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M"_JGDVA7YIKQ9L"MMIR[),@CNO*E7M*$K;5K@P G2N'_ &B H[]P*C(O3-N
MQA@M=ZF19&,MKCM.^DVOXAE?'FA8(T-A &QHCO\ PVU]/(2L#O>+&;)^%NKT
MAYQ[2>:"\X5D#V[$Z%71IH(80UY2E(3W]^VJY[CO3!NSP,?@N7N;,B6&>9D!
M#C3:2V@MJ0&E%('(#FH[/?\ A4K>.G]JO-QR21<UO/-7V&Q#?9!"0V&BHI4@
M^0K:M[]BD5CM&%36;O;IU\RBZ7E-M"OA&'D-M)"BGCS<X)!=4$]@3V[DZWWJ
M2SC%VLJML1A4R1!E0I;<Z)*8"5*:>;WQ5Q4"%#N001[U#P.GNLE^W;W?9]WG
M.0';:\EY#;;2F7"D\4H0!QT4^>Y.SL^-1D'I066K!%EY1=IEML$MF3;8CB&D
MI:](_*E:DI!7H?*"3V!/:MF\=,&KDO+V3>YK5LR5(5(AI:;(:>TV/50LCEX;
MUQ/;N?PJS7C&8]TR3'[P\\XEVS_$>FT "ESU6_3/+\A54'2IG[.38E7^YJQ!
M+OJBS%+?'CSYADN\>9:Y?N[WKMO56RTXVQ;<IOU\:><6]=TQTN-* XM^BA21
MQ]^_+O578Z7M0K3BD:U7N;#EXZ\\Y&E!IM96EXJ]1"DJ&NX41OVJ,C61&3]=
M!D:;9<8D.QQ%1ENRV5,HER@I:4*0#]\(0MSYQV^=.JZ5?K8S>['<;5+*TQYT
M9R*Z4'2@E:2DZ_'1JEL=.)#$&R+9R:<W?;.RJ+'N:8[0*XRM?L7&^/%:1Q3H
M^=C>][JP8=BS.-HGO*F2;A<[B]\1-G2>/-Y82$@:2 $I2D !(&@*CKMA,AW*
M9E]L>0S;-)GL-,34M,M/)=#?+@I/J)/!0"B-]Q^%1\3I9 A8^Q;HEUN+4J'<
MG;I!N/)*GV'5D\@200M)"E A0[@]_K7F=TN9NMHOS-ZO<^;=KPEA+MQ*&T%E
M+"PXTEML#BE(4-D=R=G9JYM6Q;V/?9=WE+N"G(YCR)"D):4]M/%1TG023OVJ
MA+Z4O/V*WV6;EMV?M5L6PN#']%E'I^BI)0'"E(+F@G7?0]]; (W[UTY=N"[U
M&C9-=(=EO2U.3K>E#3@45@)<#:UI*FPH#N!O6SK56^79H4K'7K&MLIMSL54(
MMI400T4<- _]GWJBGI=(D6^T0+EEMUEPK._'?@,^BRVE!94"CU"E(+F@GCW(
M'?>M]ZH^;0)7Q.96R#"S2W.71U[_ -FVZ,'X=R6I "7@_P"F?1"^WJ)YCP:O
M\'IX^Q;,8DP;O(L^16JTLVMV3'0AU#S:4IVA:%@A0"@2"-$;-;8Z=1EVB+$E
M76X2Y2+NS>GYCZDE;[S:PH#0 2E'R@!*0 !_?4Q+Q6+*R]R_NO.^JY:U6I3(
MT$^FISF5;\[]J\=/L9=Q#&F+*NZOW./%/",M]I"%-,@ );^4#EK1[GOWJ"G]
M-U..7=BU9'<[79KPZM^= 80TH*6Y_M"VM22IOG[ZWW)(U4W;\-M]NR>WW>"I
M;*8-H^QV(J=>FEGFA8._.QP K)GF+HRVQH@F:_ ?9DLS(\IE*5*:=:6%(5Q4
M""-CP:\X[BR;/>+U=')STN9=D1A(4M"4CDRUZ?(!([<O)'@>U0$;IA&@6+&X
MMIN\Z#<[ TMF)<6TH4M2%_?0XA0*5I/;MKL0""*L6)8TJPKN$F7=)EUN=P<2
MY)E2>*=\1Q2E"$@)0D#V ]R236IFN%M9)-MUSB7.;9KW;N:8T^'Q*@A>N2%I
M4"E:3H'1'D?G6#$L%%GO4J^7F\3K_?)$<1#*F)0A+;/+D6T-H 2D$]S]=5#,
M=+I5MC/6S'LSOEIQYU2C]G-(9<]%*B2I#3JT%;:>YUHG53EQZ=V.7BUJL4=,
MF U:>*K?)B.\'XJTC06E??N=G>]@[[BHI?3:7=7XPR_+[S?8$9U#S<)3;,9I
M:D$%)<])(*]$ ]SY%7;(+3%OUBN%IN"5*ASF%QW0DZ/%22#H^Q[U2[7TV>8N
M^/7"[9/=+JNPJ5\$V\VTVA*"TILA00D%2M$?,3OY1XV=[J^GD)6"7S%S-D_#
M79Z2\X]I/-!><*R![=B="O5TP9Q=[=NUAOTZR3)4=N--,=MMQ,A+8(0K2TD)
M< ) 4/;V-:$3I;!@XQ8[9;KK<(TZR2'Y,"YI*5/(+JUJ6E04"E:2%Z(([@"L
MS_3E-PL>11+U?;A<)U\8$9^8M*$!IM.^*6FT@)2.Y/N23W-7F.T&([3222&T
MA()]]#59*4I2E*4I2E*4I2E*4JE9=U"MF,YICF/S78Z%W7U%....\2RD)/#M
MKOS6.([^QJ+Q[JM9%RKO$R:[6JVS(UXE6]AI3G$J:;<X(6O9.B>_<Z!([5:W
M[U\-E4F'*G6IJWL6T35MK6I,A'[10+BM_*&M#SYV#[5YQS,\<R62['L5YAS9
M#:/44TTOYN&]<@#W*=^X[5)7J[V^QVYV?>)L>%#;US>?6$)&_ V?<^P]ZT+7
ME^/72T2KI!O,%VWQ"1(?]4)2QH;//>N/;ZZKYC>8X[DPD?8-XASC' 4ZEIS:
MD ^"1YT?KXK3@=1,0GW*) A9';'YDL#T&T/ EPD; 'MLCP//<=JBK'U1L5QR
M'*[<],B1FK$05/*>WZC82DN.'M\H2I7 ^>XJ7'4'$3;9=P_6&V_!17_AGGO6
M'$.^> /N?P&ZWK!E=AR"!(FV:[0Y<6,2'W$.#3.AL\]]T]N_?51;/4?$I42X
M/P;];Y/P3"I#J4.C[@[<A]4[T.0V.]9NFN7Q<XP^#>XI:2MY(#[+:^?H.:!+
M9.AL@$>WO4IE%\AXSCMPO5S4I,.$RIYSB-J('L!]2= ?B:H[5TZI2+<+NU:,
M9:94CUD6=UQ[XHH\A!>^X'->W'6_>IRT]1L;F8O:KY,N+%MCW%MQ3:)BPVI*
MF]^J@[_>200?RK1RWJ+!C]-+SE.)3(%U, !('(J0%\T@I6 00=*WKM[5<8=U
M@3)$YB++9=>@K#4E"5=V5%(4 H>W8@U"9-FMKLV 3<L8?9EP&HJI#"DN<4R#
MH\$I5H_>5H Z/FJN>K%M1<L7=?FVUFQW6VORWY2UGY'6U-I]-)WW^9:AK1)(
M[5=X&46*X6!=\AW:$[:$!17+#P#:./GD3]W7T->,;RVP9,7DV&[19RV=%Q#2
M_F0#X)2>^C['P:B<WRJ?;;O:\>QJ%'FY#<DN.H$EPH8C,HUR==*05$;(  [D
MGR-5JV6\9K;\GA6O++9;YL&<A9:N5F:="(RTC?%]"RKB%#L%;UOMKO4N]GF*
ML7\61V_VY%T]0-?#EX;#A\()\!7^[O?X5ZO^<8SC\AZ/>KW!AR&DH4MIUS2P
M%;XGCY.^*O'T-0F8=4+%CKF,J,V$]$O3_$2?7'!MC@I1=! /(; 3[=U5/*S3
M&TWY%D-ZA?:RW5,B)Z@]3FE(401[?*0>]:UMZAXC=+PBUV_(K;(G.**&VFW@
M?44/(2?"C^ )K->LYQ>QW,6Z[WVWQ)IXDM.N@% 5]TK_ *(/MRUNH,=2;<_G
M%]QAB3!:EV^$'VG7G20X[Q6I:2 .P0$ G1\&I)O.K';K+;'\BOMH8ER8#<Q1
M9=(:=2KB"MH*^92"I7;WT14DC+<?7C7ZPIO$$V0)Y?&^L/2\ZUOZ[[:\[[>:
M\8]F&/9&^6;'>(<YX->L6V7-J2CEQV1Y'?MWJ(S/*KG$R"!C.)PHTS();"I:
MUS%J1'B1TJ"?5<X_,K:CQ"1Y.^XU4?'RG*,=R&TV[.XUH=@W9[X6+<K5ZB$-
MR""4M.MN$D<M$!0)[C1%4BY==5,HRVY0YF/.6NUK5&@1%%PR9CO%/%SD#Q],
MDJ[ ;^4]ZZ%@V27*Z2X;5SN^,S4/V]<S_P!F!U*U:>X!:0LD>F!L$[WR_"I>
MRYQC%[NAMMHOL"9- 40TTZ"5A/WBD^%:]];U7QO.L6<OOV,W?K>JY^IZ/H!X
M;+G] 'QS_P!W>_PK).S/'(%]:LTR\PF;JZZEA$13G[12U %*=?B%)_O'UJ*S
MC-VL4RK&8=P>A1;5<DRU2I,E126_20E2.)WKN5:UH[[ 5-6O*[!=+&]>8%WA
M/6MCD'I(= 0T4^0LG[I';SKS6OC><8SDTMR)8KW"FRFT>HIIM?S\-ZY 'N4^
M.X[=Z^6S.L6NEX^RK=?K?(N!*DI9;=!*RG[P2?"B.^P-ZU4M>KM;[';G9]XF
MQX4)K7-Y]80D;\#9]S]*B[+FV-7R'.E6J]0I+$%!<E%"^[*=$\E ]P- ]]>Q
MJ1<OEL;BVV2Y.82Q<EH:AK*NSZEI*D!/U)2"1^5<QN'66,]BV:7"R? NS;#,
M##+2W"L/L\F4^L0-$ J<6!W_ ':O]@S/&\AN+\&R7J#.F,)YK:9="CQWKD/Z
M2=]MC8K$QGF*OW_[$9O]N7=/4+7PZ7@25CR@'P5?[N]_A66=F>.0;XW995YA
M-79QU+"(BG/VA6I(4D:_$*2?XBJA'ZJ0HMRPRUW6=9WY=\9==>E07E>@C79O
MTPH;(6K:1L^4FKRG)+,JP.WM-RB_9#065R^?[-/%12K9_!0(_.H3J5G<'![3
M F2RRHS)C,9"7'. "5+ 6YX.^*25:K<O6>8K9$0UW6_0(HF-!]@..C:VSX7K
MSQ_WCVJP19#,N,U(B/-OQW4A;;K:@I*TD;!!'8@_6JQ9LI5<)V3S%^FWC]F<
M5%#H0I3CKK22I]7;]U.P@ #9*5?@*C^G><R<OR')HCMJ?ML2VF-\.F4@H?<2
MZA2N:TD_+L $#SH]^_82^(W^1<;A?;1=$M(NMIDAMST@0EUEP<V7 "3K:>Q&
M_O(56?(LQQW&I,>/?KS"@/R!R;;?="5%.]<M>R=^Y[56<,S>=D%BQFX/.V>*
MJYSY<9QI96%.H:6\E(8[G:]-I4=G6N6O:K#!SG%Y]P=@P[[;WI;+3C[C:7AM
MM"%%*U*/@ $'>Z]X[FF-Y)+<BV.]0ILAM/J%MIS:BC>N0'NG?N-BL:\ZQ=%^
M%E5?K>+H7?0]#UAOU/\ Z7OQS_W=[_"H[!>H5LRZ_P"0VN&[']6UR2TV$.\E
M/-A*-NZT-#FHI_A4MDN9XYC#S+607F% >>')#;SFE%/]+7GC^/BO=VRW'[1;
MHL^Y7F#'A2DE;#ZWAP=2$\B4GP?E[]O-;7V]:_U?%]^.8%H+'Q/Q95IOTM;Y
M;^FJC[/F^,WJ\+M5JOD"7<$)*BPTZ"H@>=?77OK>O>O,K.L6B7S['DWZWMW+
MF&BPIX I6?""? 4?9).ZS9%F..XW)CQ[]>84!^0-MMONA)*=ZY:]D[]SVKZ_
MF&.L8^+Z]>8*+05EM,M3H#:E!124@^YVDC0[]C4+D'4FP0, NF4VN?#N4:&A
M02EM[7-X#LT3HE*B==B-]ZVK%EC5\N-G5;[A:7;=-M[DHMI6HOJ6E:4DH_=]
M-)*DG??>JR6WJ'B-SO"+7;\BMLB>M10VTV\#ZBAY"3X4?P!-1V)=2;/D-^R>
MW(E1&1972.9?'[1I*$E;IV $I"E%/\/-3>.9GCF2R78]BO,.<^VGFIMIS:N&
M]<@/=._<=JW;_?;5CMO,Z^7"- B!01ZCZPD%1\)'U/X#O6C:\TQNZV>;=;?>
MH3]OA F4\ESLP -GF/*>PWW%>;1G&,7F\*M5JOL"7< DJ]!IT%1 \Z^NO?7C
MWK<1D=G78G[TFY1C:F.?JRN?R(X**5;/MH@@U(/RX\>&N7(?;9BH07%NN*"4
MI2!LJ)/@:^M5&3U#L4S'+_-QFZP+C-MD!Z9Z*5[WQ02DD=B4$@#8[?C3"NHF
M/Y&S:XB;Q;57V3$;?<ALN]PLH"EI3W[E.SL;)&N];=WZA8C9KJJVW3(;=&FH
M(2XTX\!Z9/@+/A/\=5M7[,L=Q]WTKU>84)TM!\(=< 4I!/$* \GN#X^AK(K+
M,?3C0R$WB"+(4\A-]8>D>^M;^N^VO.^WFO%AS#'L@6M%EO$*:M#7KK2TX"4(
MY%.U#V[@CO\ 2L5CSC&+[<E6^SWV!,F %0::=!*P/)3_ $@/<IW7Q&=8LN_?
M8R;];S<_5]#T/5&R[_\ 2]^.?^[O?X5M9G<WK/C4V?&DVZ*\R$E+UQ4H1T[6
M!\Y3W]]#7OJM2^YYBUAE/QKQ?8$22P4AQIQS2T\D\AM/G6N^ZL$.2Q-BLRH;
MS;\9Y <;=;4%)6DC8(([$$>]9:4I2E*4I2E*4I2E*5S'J;<(EGZF=-[A<WTQ
MH*'IS*GW.R$K<8"4))]B3V%5)N$Q_HAZRK,=!<=NMY6HE/=123Q/\-#5?;]'
MC3<CN;5TBW"9#=P!@/-00#(6/77OT]D J'G1\Z]_%;& 7U<GJ!8(<2^6O,XA
MAO@3T0@U,M382"$NJ0>.E$!.B$JW[=C5JZN*1"O>$7BYH*L?MMS6[/5P*D,E
M3"TM.K \)2LCYO;8JGY_<['DPFW/';6JXVN%<[9(O=RBH]1J<PVX2IL ?[7T
MQQ4K0(UVJ:D7:UY;U6QZX8?(9GL6ZVS4W.;%[MAMQ*0TRI8[%7,%03Y&B=55
M8,-EC]'# "RPA"TW*W/ I3HA9E)VK\SL]_QKWF,^*R>N=I>>2BXR(S<MF.K8
M4XT(C:2M/U /:K+G\]C'H> ,LMVBULZ*47FX1BZQ;2E@!("0I("U@E(*E #1
MJ@R1.O[75=%MN#U_D2;=;7$R&8@CB:TAQSU0TE/WT\ I .SL]MGM73EY5B.3
M7BTQL:BM7BX,PI/IR(B.UL;+6N+GC@5=D!![[]NU>.B65V1OI5B$==P;]<AN
MTEL)42F6$<BT=#LK0WW[59.KN/R\HZ;WRT6WB9KS(6PE1T%K0M+B4G\R@#^-
M0;76C$Q; J6_*CWH)XKLBHSAF![7^R#?'9.^P/CWW5+QS')5KO/25B_14HG/
MSKM<7HZOF##CC2W4I_-.T_Q%:O4AKA#ZY);1Q2K[+7I([%1:1L_G4OU@%RQ_
M+Y";$VOEG,)%F*D#LU+2L(2Z3[?L''/_ .F*OO4"U-V_HSD5IMC*O1C6*1&8
M:2-GBEA24@#W.@*H^.S;9D&=]+YT!UF;'9L,L(=2-A#J0PA7Y$?,/[ZKF30I
M:[7FRH(<;A1,W8FS0U']?BP&F2M?I?O@**5D>_$[JTX?(C7[JE;+A$RQ>2OP
MH#Z79$&WM-QVVUE.FWG4J[J*@%)1HD<5$ZJ8SR0,2ZF67,I[3R[&NVO6F:^T
MVISX/;B'6W%!()XDI*2==NVZWH'4J%DF46VTX2$7F,HK<N,]L*#$-L)^7Y]:
M4M2M )'X[U7+X]RLT7H/<<)N+85FJTOQEVHMDRGIRG%%#P3K:@24K#@[: []
MJOV%05(ZQY&NX)2[.9L=M96\1LDGU>>C^)2-_D*Y_9IL6R=.>EUQN3B8ELA9
M),]9Y8(0RGU)B4[^@\"KIBR6HSG6"X(MHN,@3W2(Z1\TE*8B"EL'SWY*';^D
M:Y_)OZ;C;>GZ&LEM<MEB]6QPVBT6WTVK:@.I&G'"I2D<=\>_$DGQYJX6R_8]
MB[/4*UYLEO[1G767($)Y!+ESCN >BEH:_:;3I  WQ(.]5B^T(<'-\I@R63:Y
M%RQ.-\% >^_IMI\K;'L2@=CW]C3I?&;=S3IXX\TE2F,!;6VI2?N*YL)V/H=*
M4/XFHA+/PC$JXR(RW+%:NH,N5.;;:*PTWP(2Z4@=TH6I*CH=O/M5GPV]6;(/
MT@KM<,?T[&7CK27)26RE$A8D'YDD@<@!Q3R']'7M4IE\H8;U4CY;=&GCC\VU
M"UR933:G!"<0Z7$*<"02$*"B-ZT"!O6ZC\FR.W=2KWC-FPYXW*/"NT>Z3Y[*
M%>A&;9)4$<R-%:U:  V=;)U58R1)_P!$G6@:.SD,C7;SVC5.]4(-PN/4#((=
MG2M4]_!I+3(1Y4HR!\H_$^!^=;47)\5O5KQ2SX[%1.OK#?"*PRCBY9U!A25.
M.CMZ82?E(/DD:!KF]N4V_P!,;=BL_*9#5S0IJ,O'8MH:,]J2EP$J3M0/90Y^
MJ2!K9WWKK^#Q6O\ 3'U*D+:2I[_V:@.%/?0C[T/X]_X"ON>1FI'6#IGZS27
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MG?\  I-,)!'5WJ42#HFVZ_\ O<TLP+W7;)G8_P#L&++"8D:\>L7'EI_CP/\
MSJ(^U[1B?5?,I.8OLPFKK&B&WR)*?D>90T4N,H.NZ@O9*!W/('1JG8&EL6#I
M'\-'7'8&073@RM)2IM.Y>DD>Q T-5D8L\J7^CCD"+/%4N8]=)3SZ&6N;CS:)
MY+@X_O'TT:U[@:J3LLR)D>>8BN%F2L@DP2Z^A-OM;3:8C9:*5)D+"@6TG8'
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MI2E*^$!0TH ^_>OC;B'.7IK2OBHI/$[T1Y!_&O5? D#>@!L[.O>OM$@) "0
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MEK<7KN4I2D]AW)(KGO5^9EB.F.41<DM\![T'8#D2; 46VI),MK;9;6I2D*!
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M*"&(A:VM3" DI ]3F%*'<$ 5YQ9+B#TH;-RCW*.W>;@B,_'+A;#09>"4)4X
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MX'UNR0V0L'D=:&^WULN*9!=+I,F0[UC[]J?80AU#J'A(C/H5O[CH2 5#7=)
M(V#W!K6RK+W[9?H=@L=H<O%\DL*EECUTL-LL)4$^HXX0=;4=  $D[\5SWJ9G
M=TN_3R;'M=NF6RZM72/:[HR)@:>BE3C>@AQ/WDN)4 %C791-=(:9E8]T\4FV
MP71,BPU+1%>FEY2%Z*BDO+WRT2>Y^E<DMV79,Y8NDEQDQ9LJ=,>=2IAJ6-W
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M+J+=;G.BVR!/1:G(4UY14A#T=9(]0#N$E90"?H2?:M:;,R"^]8<":O\ ;K?
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MCA'CM-.H<+OJ;T5$(^X/FY$[':LKUAF8]D.6)N$/-Y(GW%VXP'+#*=2P^ET
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M&FR^9!4&RKVV-;_ U),91D5RC6NW6;$)D6>RTHRW+JQZ<>,4M$!+:]Z<)7Q
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M6>6TM"T#02$I2/3"0D#0&_SJQ3\<CS,NM60.//)DVZ._';;3K@H.\-D]M['
M:_,U5[/TOBVVWVJWF\W"1 M-V3=8++B6_P!B0'/V7()!4DEU1V>_CO4C=\(<
MD91*OMFR"Y667.8;CS4QFV7$OI;Y<"/40KBH!2AL?W5H1>EELAX\U;(ERN;3
M\:Y.72%/]1*I$9Y9._F*2%@\E A0.P3OZUYF=+HESM-^9O5XN,^Z7A+*'KDL
M-H<;2RL+:2VA*0A*0H;UKN2=FLMTZ:Q[NU=#=KO.DR[E9V[/)D<6T%2$K4KU
M  G042L^VOPJ?N.+Q9]YQNY./O)=L2G5L)3KBYS9+1Y=OH=]M=ZX+D.+W"]X
M[,Q:WVO,[8[*F$ILZDI5:HRB]R4Z)/ <F@-K".7WB/EK])SHC$^$_$F,H?BO
MMJ:=:6-I6A0T01]"#7.T]+'6H1M,7,\E8QS7 6Y#K9*6_P#Z6EXH+@1KMKEX
M[;JQR<)M2V\89AI5"BX]($B(PQKB=-J;"5;V=:63OSOWK4GX! FP<QBN2Y24
M9.>4DIX[:_9);^3M]$@]]]Z\7+!"JZFYV&^W&QSW8S<24Y&0TXF2VV"$%27$
MJ 6D$@*&CHZ[UIM=+H%L1:W<7NEQLMR@1U1?C&N#RI+:EEQ0>2XDI62M2E;T
M""HZ^E;+?3F +5"B/W&XR7V;PU>WI;RTJ<D2&U!0Y=N(3V XI   [5.S(ES7
ME]ME1Y3J+4W%?3)8Y)X+<)1Z9UYV!S[^/[ZT^HV&0,\QI=FN;TB.T74/)>CJ
M <0I/T)!\I*DG\%&L*\#M*L^M^6)]5$V%!^!:920&N(Y!*R-;Y!*UI!WX57Q
M&"04XSE-D$J3\/D#\N0^Y\O)LR!I01VUH>V]UY=Z?VF1<')$U3TEIVR)L+L=
M9'!; 45<NPWR._(-:MJZ>"/<;4_=L@NMXC6<DVZ++#02RKB4!:BA +BPDD J
M/;9/GO61KIU;F^GUKQ$2Y9A6]QAUM[Y?446G0Z-]M=R-'MXJ;S7'(^6XS,LD
MUYYF/)X%3C6N0X+2L:V"/*129CD>5F%NR);SPE08KT1#8UP4EPH))[;V. UW
M]ZKLWIG D0I;;%RGQ9;M[5?V)3? KCR2GCV!24J3K8TH'>S6:TX5]CY,YE<^
M]7:\79,!R&YZJ6PE;14E82AM"4A)!1V \\CO=0G2?'@<OR_,EVR;;$7A]*(<
M6<V6WD-I2"XX4'NCU'-JT>_R@^]6;-L*9RFYV2X_:D^VSK.MUR*]$*-A:TA)
M)"DD$=O&M$$@UI-=-K8_9[[$ODN9=I=[*%3ISRDMNDM_[+@$ )0$$;2 //<[
MK/9L)?C7N%=+WDEUO;UO0M$-$D--H:Y#B5J#:$\UZ[<E;\GMOO4O?L<CWF[V
M&X/O/-NV>2J2TE&M+4IM39"MCQI1/:HF]80J1D4F^6&^W"Q7&8TAF8J,AIQ$
ME*-A"E(<2H!:0=!0UV[=ZPN].+<FR6>';Y]QAS[0ZN1$N@<2Y(#CF_44LK!2
ML+Y'DDC7TUH5JKZ76Z5"GFZ7.Y3+U,DLS%7?DAM]IUD$-%H)2$("05 #1^\K
M>]UO6_!E"5.FWR_7*\7"3"7;TO/);:0PRK[W!MM(3R)T2H@GL!V':M+(NE=G
MOV#6'&)DF:B-9TM-LR&E)2ZI"&RVI*CK6EH)"@!4OE&',7F9;+A G2K/=[:E
M3<69#""0VH *;4A8*5(.AV([$ C5: Z<6^18KM!N]PN5QF71Y$F1<77$H?2Z
MWKTU-\0$M\"D<0!KZ[W7VSX&Y%RN%D5VR*Z7>Y1([L5OXA+3;8;7Q_<0A(W\
MNR?)WW\ "<ON.1[Q>K!<WWGD.V>0Y(92C7%96VILA6QXTHGM[UK6S#[="8R5
MATN2XU_E.R9;3VN/[1M+:D#6OEXI_/N:A+=TU0R[:6KED-WNEIM#J'X%OD^D
M$-K1_LRM:4!;G#]WD?8;W6X[T_@.8ME%B,N4(^02I,I]SY>;:GB"H([:T-=M
M[J3FXM%EW['+JM]Y+UC0\AE UQ<#K80>7;V V-:K%F6)HR-ZU3&;C*METM;R
MGHDN.$**"I!0M)2L%*DE)UK507^C",\K(7KA?+K.EWZVFVS'WBV#Q^;2D)2D
M)1H*(  U[]SLF>G8E$F.XPM<A])L#H=8UK]H0TIK2^WT43VUWJFV:QC(>MTK
M+56BXV^);(/P25S62S\5*Y+3ZJ$G[R4MJ4D+]^?;Q4EUML,K(K-CL&&W,4/M
MZ&MYV)OU&&@H\G0='CQWO9["I*V8%'3,N$W(KC+R"=-AFW+<F);0E$97=3:4
M-I2!R/=1\G0\:K2MG3@Q5VJ/,R6]3[-:G4/0[>^6@E*D?[,+<2@+<2GV"C[#
M>]5,0,+M\6!D\)QQ]Z/D$MZ7)2I7$H+K:6U)01H@:0"#YW49:.GQCW2TR[SD
M-TO;=G"A;V):&4I:*D%')90@%Q7$D;4?<G6^]:2>E400D695]NR\20\'DV17
MI^EH+YAHN</4+05^YR_#>JMEIQR-;<GOU\:>>7(NXCAUM6N*/104IX]M]P>^
MZ83CD?$<6M]BA///1X2"A#CVN:@5%7?0 ]ZFZ4I2E*4I2E*4I2E*4I2E*4J+
MR'(+3CD),N^7"/!84L-H4\O7-1_=2/*C^ K78RW'Y%A^VV;Q"7:0XEHR@Z."
M5E00$D^QY* T>_>HQOJ9A3K$MYO)K6IN*4ATAX?O'0XCRK>NW'>ZWU9KC2;'
M$O*KY;TVJ6LM,2U/ -K6 HE/+V("%;!\<34=/SNU2L*R.]8O<(5Q>M,)Z04!
M1(2M#:EI"T]E '7X;'BO2L^L5KQZR3LGNL&W2+C$;D!I2]$\D!2BE/<\1OS[
M>YJ;:R"T/+M:6;E%<-T"E02AP*$D)3R5P(['0[TEY%9X2[BF7<HC!MS:'IGJ
M.!(80O?$K)[#>CJL&-Y78LF#YL-TBS2QKU4-K^9&_!*3W /L=:-5')>JME9E
M6J%C5UM5QG2+Q$M[[(<YE+3CH0M2-$;(WY&P#K=3G4S*'L2L,2XL",0Y<(L5
MU4C80AMQU*%JV"-$ D[/;ZUMVC-\9O$:=(M=ZA26H+9>DEMS9:; )YD>>.@>
M_@U(NWRUM08$U<Z.(L];3<5WG\KZG/\ 9A/UY>U5K.^H5MQ"_P".VR>['0;H
M^I#CCKG'T&PA1"]:[[4 GV\U&6CJK9FKED,/*KI:[8[!O#L",A2RE2VDH;(6
MO9.OF61R[#M5PR'*+'CD=A^]W2+#;D'3/J+[N]MGB!W5V^@K=M%T@WFW,S[3
M+8F0GAMMYA86A7L=$?CVJOX?DLN]Y)E]NDM,(9L\Y$9A38(4M*F4K)5LGOM1
M\:J#NG45^T2NI"YD)MZ)BS<9;"&=AQ[U& X0LDD?>.M@=A]:UT7[J-;XD"\7
M"!C]XM4A;7K1+,A]4EIMP@<T*)*7>.]G0&P">PKIDA]J-'<?D.H:9:25K<6H
M)2A(&R23X 'O5<LF?XI?9K,.T7^WRY;RE(:9;=VM92DJ.AY(XI)WX[&O3F>8
MJW?_ +$<O]N3=/4]'X<O#8<_H$^.7^[O?X5+P[M;YJYR(LMEU4%TLR@E7=E8
M 40KZ=B#_&HB?G>+P+9!N$N^0FXDY)5%65[]9(\J2!W('UUJMF7EN/P[)%O$
MF\P&[5*.F99>3Z3AXJ5V5X\)4?X&HUWJ3AK,-F4[D5O0P\R)#1+FBXV5*0%)
M'D_,A8[#]T_2I%[,,=9LT.[NWJWHM<PE+$M3R0TX0E2B KQV"%;^G$U%GJ?A
M(MQG')K;\,'"T3ZOS!0&R./WO'?>O%2]TRNPVJSQKK<+O#9MTGC\.^704O<A
MM/#7WMCOVW7EG+L?>Q]5]:O$)=H2L-JEAT%"5%02$D^QY* T>^S6M;,\Q6Z&
MX"W7ZWR3 :4_)]-T'TVD^5_BD?TAL5J]+<WB9[BS=VB^DV]ZBT/1VW.99(6H
M)!.AW*0D_P :MKBT--J<<4E"$@J4I1T !Y)-5VPYUBV03W85EOT";*;25EMI
MT$E(\J3_ $@/J-BJ$YUGBS,>N=QM"K>5P;XU;E)<<*TF,I]+8?)''7(<E#V&
MN^ZZ'C>88]DSTAFP7B'/=CZ+J&7 2D'PK7N#]1VK# SK%KA>OLF%?K>_<>2D
M)90Z"5*3]Y*3X41[@$D5D<S/'&[^W8U7F&+NXZ6$Q/4_:<PD**=>W90/\:V<
MDR6RXS%;D7^Y1H#3JN#9>7HN*^B1Y4?R%5G->IMDL&$-9' F0KC&D/M1XZD/
MC@LJ6$J[C?W05*(\_*1VK3'56S1,MNT.[W.VQ;*U"ARH4DJ(7(]8.%6N_P P
M 0D]AV![U<9N46.#86KU+NT)JTNA):E%T>FYR^[Q/[Q/L!WK##S#'IMADWJ+
M>(;MKB[$B0ESY62/(7[I/<=C]:\6'-L:R"Y/6^RWJ%-F-<RMIESD0$$!1'U
M*D]Q]16R,HL9M4VYBZ1#;X3JF)#X<!0TXDA*DD_4$@:_&HN-E\*#;KM.R*\6
M9J+&N3L-MQA:@$Z(XM+Y=R]YV$_PJ3MF4V*Z69^[0+M">MK'(/2 Z ADI&U!
M9/W2!Y!U6+&\PQ[)G7FK#=XDYUE(4MMI?S!)\*XGOQ/U\5/56W,[Q9J^_8SE
M]@)N?JACT"Z-AP__ ">_'/\ W=[_  JO*ZGVNU9GE-HR>XVZVQK:[&1$4M1#
MCH<82XLJ&SL J V   1NK3>LMQ^R6V+<+K>(4:'* ,=U3H(?V-CAK[W8@]M]
MJK^5]08C& N9'B<N!=&TRX\7D%%: 7'VVU @$$* 7O1_"I/%,CE7C*,NMDAI
MA#-GELQV%(!"EI6PAPE6SK>U'QKM4#;^J5HCW_)+=E%SMEM-ON/PD8*64J6W
MZ;:N:]DZ^99'+L/%6^_Y-9,?A,2[S<XL2.^0EE3B_P#:G6]( [J[=^VZVK+=
M[??+<U/L\UB;#<WP>86%))'8C8]P?(]JBK[G&,6&XI@7F^0(<P@*+3KH!0#X
M*OZ(/L5:KWDF:8WC*V$7Z]0H3CZ>;:''/F4G^EH=^/X^*RW'+<?ML.%+GWF
MQ$FH4N,\MY(0\E*>9*5>#\O>O%KS'';I9)5W@7J"[;(I(D2/5"4LD>0O>N/\
M:UH.:V.^6RYO8[>;=)?AL*=7S60EKY24J<3V4$=O(]@=5C=S:RV?';+.R:]V
MJ.[<([;B5M.'TGU% 4I30/S%'?8)\ C=:&&9[&NUAR&\W>7;HMKMUUDPVY:7
M.+2F6U (65$D$JV.X['8T*G+-F&/7J!,F6N[Q),>$DJDJ0ONR-$[6#W2- GN
M/:M:)G^)RXEQE1\@MJXUN"#+>#PX,\_N[/COH@#ZC7FM['\IL>11I#]END66
MW'.GN"^[7;?S ]T]N_>JA<NJ=GD7S'+?BUTMES5/N:84H(65*0V6W%<T:(W\
MR .7<>:O-\O%NL-M=N%YFL0H36N;SZPE(WV _,GP/>HJW9UB]RC2Y$"^07V8
MD8RY"D.@^BT"05+'[H'%7GZ5X9S_ !-ZWW"<WD-N5#MZPW)>]8<&UGPG?N3H
MZ K9MF8X[=++,NUOO$-^W0PI4EY#G9@)&SS'E/;OWK?>O%N95;@[,90;BKA$
M!5_MU<2K2?K\H)_A4'*ZC8=$FIAR<CMC4DO*CEM3P!2XE124J_H_,".^NX-;
MN1YCCN-/QV+_ 'F% >D#;:'G %%/NK7LG\3VJO8CU%@R\%9R')YEOMZ'IDB*
MV4J(0YP>6A 2"25**4;[;]_:K?8;W;,@MZ9UDG1YT0J*/496% *'E)^A'T/>
MN?8YU&=R+J?>K1!N%C;L-I&G OF9,C]F"M:5<@A*$+(2=@^#_"W8_G&,9%/<
MA6.^P)TM"2HM,N@J4D'14G^D/Q&Q7NW9GCEROAL\"\PY%T <)C-N<EC@HI7L
M>VB"-?A7K(LQQW&I4>-?KS"@/OCDVV\Z$J*=ZY$>R=^Y[5!87GT6?TZCY/DT
MJ!;FG)$ADK"N#9X2'&T!.R220@=AO9WJIN)FF-R[.NZQKU"<MZ'DQW'PYV;<
M40D(5[I)*@-'7D5M7^]Q+6D1W)L./<)##SD5$E1"5^FCDI1 [\4C1.O:HES-
M[+9\=LL[)KW:F'I\9MU*F%GTWR4 J4RD_,4=]@Z\$;J,S#JE8;'CMHO$.=!G
M0[E.:BMNH?' (*PEQ>P#]P$DCM4W;,B:D76]EZYV@VJ''CR6U-N*#K*'$*45
MO%7RA) !21[ [K)C6:8WD\AYBP7F%.?:3S6VTYM03XY:\E/XCM6HQU&PY^?$
MA,Y';%RI2N#+8>'S*V4A/T!)! ![GVJUTI2E*4I2E*4I2E*4I2E*X[U:,JW=
M2L7O,F[BRVAN%)C)N+L5+[4:0I2#\_+LCFD$!1^A'O5*R"-&N. Y_/8N<F]Q
M+C<K6VY+,)$>+)6F0TE:F0DGGV*4J5H E/8GN:Z9/A1S^D'8W#';VSCDDMJX
M#Y"'VTC7T[*4/R)KEMZ=@P+-$=NC'.VQ^ITE;C8;*PEM/K'?$#ND>2 / -67
M*IT/);QGE\QEU$NSM89)A2IC'=I^2>2T)"O"U)0%;(WKF!7O";M:\1RIZX9A
M(9@,W&P6Q-MFRNS9;;9(=92L]@KF0HI\G8.JTX]HEM=)I^16V&\P+5D$C(K-
M&6V6U"&ETDH"3W2E;9=(3_O"M.]0I]TZ>1\R_;,INV2LWF8L1O74Q;T<FV"I
MO]]*$AIPC\2?:M_TW,KO]V>Q_*W<BNR,=F142X,%IF,@NI'IMN.I5W7S 4E.
MCK2B=5K7+(<7GXGTQLMM2@W>WWFU)7"2R0] 4AU"7/5&MH[[3W^\2"-^:N_Z
M1GH_Z/HYEQUR8PNT$NLH05EQ'KIY)"1YV-C5:S-RM.9=7+%+Q9UF?!@6N6S=
M)+"=M%#I;])A2O!5M*U</([]JKO3F#-D9U!PZ<VX;?@;LA]+B^X>]7M"_BEI
M;G\4BK;U@N$2S9/T]NMT>3&MT:ZNAZ0O?!OE&<2GD?;9.J@K3"87B?6UU<="
MG7KC<&U**=E:4Q&RD?B 5*(_,U7D/2[1D&'W:X9 C'K?(Q*)&CW*3$2\REX?
M,XT5+[-J4"D[.N7'7M71>B3#/V9?YT2;,G19]T<?3)>AIC-/JXI2IQE*2=MJ
M(^]H;()U[F$@9/:>GW4C-FLODFV1KM(8G0)3S:O1?3Z*4+2% $!25)\'OWK5
ML-QG3(O4[-+%9%W:%<WHX@Q)+2D?'LLLI;<4E)&RE0Y\1KYM:JIW6;A46(S*
MZ.W*XPLN=>;^'LT);WIN+*QS0_'5M*$@<MGY0-;KK_6VWS;ITNO<6W,.27RE
MIQ;#7=3S2'4+<0D>Y*$J&O?>O>J-<LFQS)^L73-6,*2^Y'$]"Y"(ZD)928B^
M+1) [C1/#R->VZK[5RL['067A$MH*S52'8RK3Z9,IR<IPE+P&MJ!5I?J>->]
M2G4UN\8U>Y$*W!QR3G-N8M2G4 D(G(4EI3A/L"RXH[^K?]V2]1?U,ZG$.9"U
MC%H-DBPK9-DPT/,E#)4%L\UZ"%=TJU^]O\*CF;=&<QK%%H=ESX$[/6Y:')<-
M,9#H*'-K;;!.FE*25#8&]GMKST)F*TK](J4^IE!6WB[(0LI^[REN[U^=<[ML
M)EVT8C%=82J.WU!E\6BGY4A*I)3V^@(%=!QB%'7UNZ@O.1VU.&!;4<R@;*5)
M=Y#^/%._R%<FQ4R[;9>EUXEW?[%M+=FDQ47%Z*E]J-(4Z#I?+LWR0G04?Z.O
M>I#((T>?TZZB7"/<I-ZBW&XVQ"Y9A(CQ9*TR&4K4R$D\QHI2I6@"4]B>YKIU
M^90SUQPQ3+:4#[)GMDI3KY06>*?R&SH5$=#,ILMMZ76B'-GMLRX\Y=M>9*5<
MVY+DAS@VH =B=CSVJU=:+?/NG2S)(=H;<=F.Q2$M-?><2""M ^I*0H:]]U3+
MU?<?RZ\]/HF#.-29MON3<E:8S?$P(:6UI=0YV_9[!2C@=;.NW:JA<Y,&5BV7
M6)]3;DU&=!V1#6/F]%V:CBH@^4J&^]7K.H4N1U5?8LX].X2,,GL,+1\I]3U6
MPWW_  4>WTJ@6I^-<L0Q7'E96^Y/8?B(188=G:3,A/M*225;4"@((5R<.MC9
M[[[]2Z8QFAG74J06D^LN[M(+A3W*1&;(&_P*E?WUK9;-A8]UFM5]R9Q$:RJL
MSD.+-?'[&/*]8*4"KP@J1H G6^)%4+)%-R,+ZC7^VM+;QF7?;=*BK#92AP-N
M1Q(?2-=TE22>6N_$FK[A;L"[]9LKNT,LRF'K/;C'DI&PIM?JD\3]#I/]PKF-
MI;E0</Z8W0SS:K/ EW9IZ<J*'VX;BWW$LK6@]DIT%I"CV3R'C=;N0!FX8EU2
MN\*^2+ZEZU-1WIS4)MB(^XDJ(]-25'U%I!T2!H I&ZN?5Q7ZFV?%,QM<3?V"
M3&<9:1V+#[/I@:'T6EG54^R8S-LV5VCI\ZTZN%<U0,@G.>4%3#9^(2K\5OLL
M'_Q&LSJ(#=MN\NY3KC9W(V<SG(UWCLH=:A.%.@M]*^WID$IWKR1LBM.[RKK?
M\2RDQC;KK%AW:W295\M,#Y;FR@@N\FME+JF@E!(22".WL:M>+2HN0=3[!-B9
M<O)7H,605NP+<TVPRVM('!]Q*M@E6BE&B=I[@>:ZY8KQ OUM1<+3($F&M:T)
M<"2G:D**%#1 /922/X5^>+U<XUD3>XEBN34M1NZW',*OL!+C[[ZGPHJ84@\N
M*CI:%?, -$GS71L4AL.]4>JKKT="EN" THJ2#M'P@VG\OPKG>,WTVO%^F;;T
MJTV$FS.J1?[I&+P:/)(,=O:DI2I0[DJ/@: K3=D*E8AU&69CL\N9!:G1(<BB
M.7@7(W[0-@#23HZ/N-'9WNNN].01U!ZED@Z-RC:_^]&JIE@R;%L=R_JDWDJF
MF79=P "76R3,;#"!Z*.WSJV3\@[_ #CMWJO6N%>L5E8#*R.\G'6&\<,)$Z5$
M2^W&?+O(M+*^S2BWP&SK_9E-=,Z+-,N*RBYP[C+N4:?< Y\6N&B,P^XEM*5N
M,)23R2= %6AM221OS5?MM^L&*/\ 42W9OZ:9T^YR)*(SZ"5W**MM(:0UV_:=
MMHXC>COQ7S%[S9L0S?()>6LIQYFY6^WJM@G=@B.A@)7&2KN.2%[V@'9V#HU!
M8E:U)NG3%,J"MBWOWV\38$5]LI+,=3;KC'RG[OLH#VV*D\GAV]^\=8F;K'N*
M[>L6EUW[-0%/((1R]5*3V/$I2I7GLD]C6K;KX_<+CD+#=WM&8,G&Y7*^Q(89
M?C #:6'5))0>1)(2-':22*R8+<K?BUYQ>[Y6\W#M\O#;?%@3I XM-N(3R=:Y
M'LE1"D*[ZV!^%5P(];$/M2S>K L$3.)$QY8A>I\.P4D(>+)'W$J4E6M=M@Z[
M58FG(]YN^572'DSN1N,8S)C/3(D%MJ)I7S);4XE7S.#1( !T"=D;T?F10'HG
M2;I3-B+,*V6_X*1.?;BA\1P8QXO+;_>"5KV3[%6_:H^\PY&6?KE(QO(Y&2W$
MXZY#5)A06VHKFW H,^HA7SN\0O0 .@L@D;U4W?,FQ._WSI@QC19=DQ+JV/3:
M;(5":]!P%ESM^S42$_*=$\#V[5:^KVHESPN\W!I;UAM=T4]/"6RX&N3*T-/*
M2 3Q0M0._;>ZYU>[O:;]D?5F?8$\XKN'*!D):*$R5A+P*T[ Y#0">7U0?I5E
MOS$6SVSI-=9T<)QJU!)F$-\D1U*B\675@#LE*R?F/@JW4;D9:R^\=1+GAR?C
MK:]BBX#LB*G;<R9MPI2@CLXI*#K8W]X"O:LMLV17;I-%LDOXQV++29/IH41'
M4(CB>#AUI*][^4]_E-:IA,?Z"^JROAT>H]=+LXL\>ZE)=/$_PT-?E4Y:;Q:L
M4ZAW^;F4AJ&U=;9 ^SY4H'@ZTAHAUE*OZ7,\BCR>0.C5/L(M4?IQA\Y<VXXR
MJ->+G\!=$QD+8@<GG@$2$+\)4GY1V[$>172^BUT?N:,D+J+7+:1.'&]6V.6&
MKFHMIY.<23M23I)4"0==O%4_)K=<+G ZW1+4RZ]*=DQ"&FM\G4".R5H3]24!
M0U[[U4K>;[8,OR#I]&P=UF5-M]Q1)<^%;T8,-+2TN(<[?L^6T)X'1)]NU3O0
MJ,TSCU]=2TE+KM_N*UJXZ*CZZ@"?X "HW[7M&)]5LSDYB^S#:NL>(;?(DIVA
MYE#12XR@Z[J"]DH'<\@=&N;V=MZ)A732[,2'+)8H-QNX=DNPP\F"I;[@94XV
MK[H "T\C]TJ]JN./V"%G,O.D(OSU\:N5N:@O7%J$VQ#6\GF6U(4E1]1QO8V0
M-#Y1OVJ/P^;<,UB91DEZCNM/V6P+L24N#S+],KE+'X\@A/Y5@M=_%J;P9ARX
M6?&%?JC"*;W<(A><D I3N.T2I*1K040=D\AVJ*AS$,].;E<)<AYR-%SYF7(D
MOQO0(:]1E1=4V . (/+6AYJ5S5M5[NG4J3;6EW"WK%@F.MQTE9DQ$E2UA('W
M@4#>O<"K7*O5FS#J=@S^&2&9YMOQ+LZ5%&T1XRF2E+2U:T"I93I![CB3H:JG
MM0VFOT44J;82ETSDO%03\W/[3 Y?GKMOZ5^C:4I2E*4I2E*4I2E*4I2E89DF
M/%8+LQYIEGP5NK"4]_;9K*D@I!204D=M>-5]J!RG&V<AD6)UZ0XR;3<47% 0
M ?44E"T\3]!\Y_NJ>  &@ !^%" H=P#[]ZKN<X[*RBSFV,7F3:XK^VYGP[:%
M+?94"%-A2@>&P?O#O4Y"BLPH;$6(VEJ.PVEIMM/A*4C0 _("LJ4A(TD #\*^
M@ $D ;/DTK X4NH?8COI:?X_>1HJ;)!TK1_O[^=5 X5BWZN(N+\NXO76[W)\
M/S)SS:6U.D)"$)"4C24I2  !^/UJRD!0T0"/QKREQ"G%MI6DK1KDD'NG?C8]
MJ^J 4"% $'V-?''&V^/J+2CDH)3R.MD^ /QKZI(4-* (^AK[7P) 42 -GR:C
M<EM"+]8IEL<E2XB9".(D1'2VZT000I*AX(('_P!6JO;<57!R6VWC+<J<NTZ(
MEQBW(>:9C(0IP!*U!*0.:R !OZ$Z'>KWH<MZ&_&Z\MN(<Y>FM*^*BE7$[T1Y
M!_&OBEM*<+*E(+FN7 D;UOSKZ;KW2E*$ @@C8/L: :&AXI6G<K;&N3+;4M!4
MVV^W("4J*=K;6%H)UYTI*3K\!6Y0  D@ ;\_C30!) &SY-*^<1R)T-GWK[10
M"@0H @^QH1L:/B@    T!0]QWH      /84I0]QHT      'L*^!(3O0 WW[
M5JVJW1[7#^&B)4ELN./'DHJ*EN+4M:B3[E2E'^-;7$<MZ&_&Z^U\4 H:4 1^
M-?:4(!UL Z[BA 4"% $'V-*$ D$@$CQ^%" ?(!UW[TI7P)"?N@#W[5](!&B
M1^-*^)2$C20 /H*^U\2D)&D@ ?05]  WH ;[FH'+\?>OT:)\#=YMHG0WP^Q)
MC$$;T04K0KY5H(/<'\*U,2Q-=EN=QN]SNLB[WJ>EMIZ4ZVAI*6V]\&T(2-)2
M"I1]R2>YJTT "0   !["@ &] #?>E" =; .N_>A (((V#0  : T!2@ &] #?
M<_C2A .M@'7>GGS0 )    'L*5\(!UL Z[C=?2 001L'V-/'B@ &] #??M2E
M*4I2E*4I2E*4I2E*4I2N.=9;9/O74CI];"U9Y5K>=E+$6X1U.MK<0PHJ+B0H
M!0"=<1KLK9.QVK/'Z@W]A&6W>5#M#.*XS+EPW&T!SXJ1Z2=H"._!/=2 =@[V
M?&N^^G*\PL<C'Y670K+]E7B4U"+<#U0]!=>_V?-2B4N#>DD@)T3L;%0,_J3F
M+.,Y%D[5OL8LUBN3\-UA?J^O*;;?X%2%!7%!T1Y"MD'L!JK3:\FRB'GEILF4
M1K0(]XB/R(WP/J<XRVN!4VX5'2^RQ\P">X\5+]0+U=[-&A&T"TQVWG2F1<;M
M(#<:(D)V"I/)*EE1[  C\2*H#75JXIQ+.Y:7+!=9V-ML.M2[:I:HDD.[T-<B
M04E*@=*/M5EB9/E4#-K%:,DC681;ZS(5&^"]3U(KC2 LH<*CIP:.MI">X\5I
M1NHUR?PR Y\'$3E<B\_83D32BTW(2Z0XK6^7$-)+GGZ5)=5,UEXG)L4:.Y;H
M#-R==0[=+FA:XT7@D%*5!!3\RR>VU)'RFJ?G]ZRBZ8)89(=LK3RLBB,?$0WE
M/1Y:/71Z3B"E>P@G[R%$GMYK;R3-9N+2.HUP8M5K<NUIB6E;CR$+'Q:W>22%
M?-O2=GC[C??=62'DN3VK*[%;<NC6CX6^>JB.N!Z@5%>0@N>DX5$A8*0H!:0G
MN/'>H[_2-<O]"?ZY_"0_M#UO3]'2O2U\9Z'UW]WOY\_W5KL3Y]LZA=59EGA-
MSI[4:UEIAU]+*"?3<!*EJ( 2!M1_ '7>O-AZB7:1FD/''KOA]X?N$:0MIVSK
M6KX1UM'(!X%Q7))[^"D]CVJL8-=+E&Z<8@]?&+9<TR\K##"G$.%;*E2WPIW9
M5W6% \3[#SNK6<WS"Y6.[958+?95XY <?#4607/BIC3"E)<6E8/%!)0KB"E7
MCN:VGLVR"^9?#M&',VE$.98&+VB9<4N*X!QQ20DH0H<M@)[;&NYV>PJQ],\D
MEY1C)F7.,S&N,>4_"DH842WZC3A02@GOQ.M]_K51.<YA<<?NF66*WV5>-PG'
MRU%D%SXN6RPI27'$K!X()X*XI*5>.YJ'CM/99U[M=S=9L\RUIQ^-<H29492U
MLM+>*DK1M6DO<@/F \ #SWJ>ZGN7U/4[IRU:),)MER3*TA]+A"EB,YR*@E0V
M.!/'Z*[^.U5*P7S+,?LO46\V6/9EVFUY!<I+S4OU"])"5\EA!20$:2.Q(5L[
M[#WM=]S P,NN4^!8F9DEG$4W1I2$GXET%Y>F21L</?L-[WY\5M]-LUNV2W%D
M+GXQ>+:]&+KCUH<4V[#<!&FW&G%J40=GYM)[CN!NIG-,CND._P!EQW&V8:[M
M<TO/E^;R+,9EH)Y+4E)"E$E:0 "/?9J$N67Y=:(\6U7"SVY>27"Y? 6]]MTI
MAOM^F7%/E.RX@(2E0*"=DCL2#V\NYMD-BE7^TY+'M;MTB65Z\P9,%+B&'T-[
M"D+0I14E05Q\*.PKVU6M;,WRUDX5<;]#LB;/DKK48,Q?5^(C..LJ<0HJ4>*@
M>)V !K>MJ\U5[#E648IAG42^R1;;B_%R-3*&0EQ/)U3[+2P"5'2.*AQ'D:[[
M':KO>K]FME@0471W$(3KRW%2+I)>6W#CH '!L(4X%K625=P0G2?QU4-:>K,M
M_&;PZ6[3=;O%NK%HAN6UY0B3'7^'IJ!/(I YGD-G[IT>];&<S<_B87EK%R:L
MRFA99$AJYP XTEE24GFT4*<*^?'92L'0([BKITU^/_4*P_:JXRY!AM$&.E24
M\. X[Y$G>M;_ !W5EI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4JLY!C;MTS+%+TW(0VU9ERE.-J227/59+8T?;1.
MZBH73]M>-YG9;K(#L;(;A*E\FAI327@D =_WDE._I6FWAV3W:188^6WBV2+7
M99+4Q'P<9:'IKK7^S4[R40@ Z40G>R/85BF]-Y<CIIE6,">P'[S-E2D/E!XM
MAU[U "/)(':K->,;=GYYC=_1(;0S:F);*VB#R<+P; (/MK@?[ZC.HF'S<@O&
M/W:VN6UR1:5/:AW-DNQW@XE(Y'7<+3Q['1\FJW.Z87NY6S.6KA>+>J5DL2*R
MGT(RFFHI9Y#BE.R2G2AWWO>S[Z%VON-.W+,L4O2)#:&K,97J-E))<]5K@-'V
MT>]<]PRVV[(NN5ZR2QR_B[#":2O:!^Q^TG$!MPH/N0RA(5]"NNA9I:+Y<'8$
MC'[A$:,<N)D09[1<C3$+ &EZ[@I(V"-^3L&J2.E4]G$I\:%-MD6\2;RS>VVF
M(RD067&E(*6TH!Y<2$=SV))\"HGK!C$^#A'4*]W"5'4_>8MK:4B.E0#3C+@2
MLC?L2O8]]#O5VM^*Y!/R:S73+[G;I*+*EPQ&X,=;?K.K1P+SO)1T0DG24]@5
M$[\55Y72_)UX=(PYB^VM&."49+"S%69*DF1ZX:6>7$ */W@-G0&AWJ8RWII)
MOTC,W47%AD7S[/4RA;16A)BDDI=3L<D+.@0/:LELPJ_JS#'+W=)5CC1[0)"$
MVZV15-MZ=;XE7(GNK83VT  #YW6A:>FUZBV:UV>3<K>N!:<@1=XCC;2PXMKU
MG'5H<V=<MN:!';0K,O LEA6>ZXS8KU;H^,W!U]25O1EJE0VWE%3K;>E!*NZE
M<5'1'+WU5ALF%IL^:LW:&\D6]BPL65F.02M(:<4H*)\:TH#^%;> 8V[C%KGQ
M7Y"'U2;E*G!2$D!*772L)[^XWJJFK <DAV2Z8O9+U;F,8GN/E*W8RU2XC3RE
M*<:;TKBKNI7%1[CE[Z%6*SX8FTYNS=XCR$V^/8F;,U'()6D-NJ4%$^-:('\*
M\Y[C5TN]WQF[V&5"9GV62XZ$34*4TZAQI3:Q\I!! 5L?C6@C I*<)SBQ_&L^
MKD,J?(:=X'BR)&]!0]];[ZH[@4Y5Y<G1KP8+IQQNRMO,(_:-.H<*PZ-]B.X[
M5K67!KP[G%JR3(W;$B7;6G4!=JBJ:<FJ<1Q*GE*/@#9"1ON=[J<S+&9]PO=G
MO^/S(T6\VL.M)3*;*V9#+H'-M?$A0[I20H>"/!W4#,P/(+BVB[3\A:.3Q[@F
MX0REI:H48);+982V5<N"DE7)0())W[=\KF#7F\R+]=,DN$ W6=9WK-$:AM+#
M$5MS94HE1*EJ*N)/C03JMZ=A4B38\$@)EM)7CDN+)=64G3P986V0GZ;*M]_I
M4!<.FUZDVK,+.FY6\6R\W5%VCK+2_6:<]=IU:%]]%.F]#7?9[U-YQAMPNV66
MG(;4NTOOPHSL4P[LPIUD!:DJ]5'$[2X..MZ[@Z[5#-]+[E(AY%]IWN.JY7"X
M1;K$EQXI0F+(82D)'IE1V@%  &]\?)WWJ3EXGE&0L7=&47R(RU*M<BVLQ+8A
MQ+ 4ZGB7W M6U*'@#P!ON=[J7Q.V9/;+5CT&XS+0MN$VIB9\.RY^V0E 2R4%
M1^56P"K>P?;56RE*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*^(0EM/%"4I&]Z U7VE" 1HC8I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E?F7](S.[Q/G?9V*R7XUFLLYAFYS6'"@NRED\6
M$J'D)2%%0^I /@;Z-F%UD8QUOQ!Y+[GV9D<=ZV2&"H\$NMZ6TX!XY$KX[^E=
M4JD=3<5B7>TS[H[.N\:5#@NEH0K@]'1M*5*!*4* )W[FJ1C5@1 Z(.Y2W=;Z
M[>)&,./K<?N;[B XJ-R*DI4HA)![@CQ[5,85G]S9M^%1K]C\J- O##,6+<G)
M:'%N/>CR!<;'=/,)40=D_4"I"3U(FF'<;Q:\8DS\8M[CJ'IZ92$..):44NK:
M9(^=*2E7<J23Q.@:L>7W!+_3F]7&VR%<'+4_(COMDI.BRI25 ^1[&HW&)4AW
MHO:9;K[JY2\?9=4\I9*RLQ@2HJ\[WWW7-94V[2.FG3.3<7[^]C3L/G?'[6MQ
M4I1])/I%:D?M/3Y<N1'X;JR=,I=C3>)\W#<O=N6-MPRJ3:IDAUY^,\E6PX@.
M_.A)3R!2>Q-:&-6>+EV'-YOU!R&XQ&YX,EIINZKA1+>RI6FDIXJ2"K13M2M[
M)U5VZ5O$V27%&50\G9C2EIC3&9*7W4L'10AY:>Q<'?O[C515XZDW%B[Y1!L^
M*OW(8[Q5,>,Q#*2A3(=^38)4K15\O^[Y[@5]MG4Q^7,QQZ1C<J)8,@<#$">Y
M(05J6I"EHYLCNE*@DZ/(^VP*^W[J'>;7%N]T;PR:NP6M;B7Y4B4B.\M#?WW&
MV5#:D]B02I/(>*L$'+X\K,!8E1U-!ZV(ND62I7ROME7%0UKL4DIWY[*%9L.R
M9&38PF^,Q5L1'5/&.%+V76D+4E+GCMR">0'?L14(CJ*RKI[8<J^SG/3NKT9E
M,?U1MOUG V"5:[ZWOQ6I<NHET3>LFMUCQ1^YFP*1\2\9J&4J2IH.?)L$E6B?
ME\=O(V!7EW+(%YO6(2H:)Z3=[-+FQB)!0VA(0T2'&QV4KYAH[^71UYJ-Z?97
M>VNG&%,6^RS\@NLVW!]V0\_Z3* G0)<?4%?,21I(!)T3XK1SGJ+>I/3NZR;3
M;'K;>;==X]MG-B6A7HDN-'Y%@:4E86$[T".1/M5PE9G=G+LJT67&S/NT6,U(
MN+:IR&68A<!*6O4*3S6=$]D@:T21NH^?U3;19+)+MUCF3)]SN#EJ-O4ZAIR/
M*0%\D+)VG04C1.]:/+\*W7\ORA4CX2#@\AV8Q'0]++\]#+#:E;(;;=*2'5 #
MN0 !L G=0*\O.37SI7=+:J7#B7&7.0_&4YK9;CNI*%A)TH)6@Z_(&L72;,7H
MV.8? NPD257J5<V43W7BKBZU)>*6U;[]T A/?]S7TKH&,Y&B_P!POS,:,I$6
MUS3 $@KV'W$H27-#78)4KC[[(-5A74>>^S+N=HQ2;<L;BRE1ES6'TEYW@O@M
M;3 !*TI4"/()T="J[;\OR"V9AU&%NL<N^18,QIY7J34LH8;^&02AL*WM1TH\
M0 /J=FKE(S>5,M]@D8KCTV[KO$036U+6([##12D_M72" H\@ D DZ/L*B9'5
M5,+$[O=)]BDM7"TW%JVR[>V^EP\W%-@%"QV4-. CL#Y':I"VY](;R*3:,JL:
M[&XBWN71ITRD2$+8;4 OD4@<5)V"1W'XU#JZJW!F+8KC,P^9'LU\F1XL&49;
M:E:>4 A;K8&T;2>0&S]"02*F)N=7)Z==TXUC#]X@VEU4>7)$M#)4ZD K;900
M2X4[ .RD;[ FK%#OK=XQ%J^8^W\:B3%$F*VI8;]3:=A))WQ/L?I7#[7F.3/X
M-TNNDQB;*GRKJ4%#,H<KBE3+NBOPE*>7L>P"=_2NDP^I+<:/DXRJU.V>9C[3
M4B0RV\F2EUMP'TRVH ;)*2G1 [ZK8@YM<V+O:8F48T[9F+LX6(;_ ,8A\>MQ
M*@TZ$@<%$)5K14-C6Z\=5[M<HS-@L=DE*@SK]<4P3,0 5QV0E2W%HWVY\4Z&
M_KOVK47TW?M$J#<,1R"[L7!E]"I(N,]Z4S-:W\Z7$*) 41O2DZT:T&X3_4;-
M<E8N5SN,;';%(1;V84&2N-\0]Z:5N..K00H@<@$I! [;K/943,'ZE6W&TW*=
M<,?OD1]Z(W.>+[L1]CB5)2XKYBV4K'8DZ([59,NRYVSW>W66SVIR\7R<AQYN
M,EY+*&V4:"G''"#Q3M0 [$DFH"=U4:MN*7^Y7.R2X]TL4EB-.M@=2M8]9:$H
M6A8[+20OD#VWHCM5QL%SN4FS.S;_ &@V=]!43'^)3(/ #85R2 -^>WMJN;X/
MC*^HN,1LJRJ[WL2[IRD18T*X.QF8+140VEM+9 *@D E2MDFLV8P<SLW3.)"<
MN5PNKK%R0B=,MB2)R[;R.RG7<O:X@E/?6S]36AT_>QR3E]O5@.831Z8<%SLE
MUDR%K>1Q[*2V_P#,E:5:)*>VJZ1G&4(Q>WQ'$0WKA<)TE$*%#94$J?>4"0.1
M[)2 E1*CX J@V_+KBQU7O#^51)%DAVW&/BGXQD^NP0E]1+R"G05\OR[XA6TD
M?3<_$Z@7!MVT2+]C$BU6:[/-QXLM4M#JT+<_V0>; _9\NP[%6B0#JL#?4F;,
MG715HQB3<;3;+@JW2GH\E*I25I6$+6F, 5%()_I D#>M5YN&:V['<BSAYZ/<
M7Y$$V]H,ID>H)#KR2&FV6SV022 ?KY/BMNT9Y<UYK;<9O^,.VJ=.C.RD.IF(
M?:X(UV"D@;5LD$:&NWG=0MIZNRYU@LN1/XG*C8W<9#<94Q4Q"EM*6YZ85Z6M
ME'+0WL'Z C1-DOF67YB[7")8<0DW%B E)>E2928;;A*>6F>23ZFAV)[#?;=5
M.?GUVO&5=,Y.-PG5V6],2)#C*Y"6BZ0WW2L:/^S^]YTHG\ :WK=G<6V0KBBW
M6ZY7"Z2LDF6V+!7+YJ>>0HE:@M79MH!).NX2/K4B.HSL*+DC5_L3MMO-EMJ[
MJ88DI=1)CI2H\FW0!^\DI.TC1(\UXM/4:;(NF.MW7&)%MMF0?+!EKE(<5S],
MN!+C8&T<D@Z[G\0/;HM*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4K\X]0/T>"+ 6L.O-_DR'9Z9+L29<$"/W)YN!(0/G';1\U/YA9>?5'I1B\25
M,G?8R7[E(DRW/4>]- 2$+<5H;*EI(WKS7;ZCLCB.S\>ND2. 7I$5UI )T"I2
M"!W_ #-56#C5Q9Z'HQA:&_M86 V\HYCCZWPY1KEXUR]ZU;GBETD63IO&;;;+
MMCFQ'YH+@TE+<9;:M?7YE"J*CI7*M,6Y6F/@^.WIYV0\N%>YCJ0&T.+*AZ[9
M')2D<B/EV% #Q7:561ES$S8G."(ZH7P2O11P2$^GP^5/L->![5S&%$ZEVW"D
M88Q8;0^68GV<S?#<>+0:">"7%,\.?()UV!UL5-RL9R;%[=B?ZF2&[@U980@R
MK7)?+#<U'%(#B5:(2X"DD;&M*(_/'8\?OM]ZB,95D5E@V)J)!=A)C-24R'I9
M<*=EU:4A/!(3V3W.R36E:[/EV&696,P\=MV68ZTI0@J>FICN--%7)+;R5I*5
M<2=!0]@.VZG>E6*7''?MZ?>&[=%EWB6F485O!]&*E* @("B!R.ALG0&]UCB8
MM<VIW4IU;;?"^E)A?./FU$2U\WT^8&M-6'W<XGTM@!MKXG'Y,)V</4&DI:BK
M;7Q/[WS*'BJ5?.FV072U9%!N&-6^[7V8N46+_/N/- 0LJ+?!D@EM:4D)  "0
M0#NI3K+:YS>+X8FU26HF5)4BT-M\N2E(DLEET#7GCH+WX'I[KK]KM4:UV&+:
M(:?3B1HZ8K0'LA*>(_Y"N,Q\0SC]1L>P]RT6]$>RSXKJ[@)H4)333X4.#>MI
M.NYY']W0WOM>[)C=QB7OJ#)>0V&KR\VN(0L$J C);._I\P-5[&\&O< ]/_B&
MF1]C6*5 EZ=!XNN(:"0/J-H5WJ$8P#(8EFPV)=;.B_6RW6HQ)-H1<?ATMRN0
M(>/<)<'':='QY KXUTWR%C LRML6TVJ')G76+<H,*(^$L<&RPHM!7$:(](CD
M0 3W\&MZ^8)+EY?+R:X81;+^+Q%C^O DR6P] D-HXD)6H<5H(X[([[3O52%M
MP.Z1(N$\;?:(2X%Y=N,R/;AZ;+*%M.)"4[[K4.2 3H;T36++,/NUPSN[3;CC
MD;*;9)0R+<B5<2TQ!XHTM*VB""%*^;D$J/?58<*P&^VB'TY8FL1$*L$^XNR_
M16 @(>#_ *90/I^T3V]JT+_896*= FT7)V/%OMDG.W:%\_(%X3%N-I&OO%:7
M.&A_3U73.F=A=QO![5;Y9Y3_ $R_,6?*Y#A*W23[_.I7\-53K/:,YQ;'Y&*X
M]!@K9$EY4&]N24\8[+KJG-N,D<E+3S4 !L'MW'>IJPXQ<X4WJ Y)"%"\O!<5
M7(;6!&0V2H#[OS)-4YW!,@9M&%1;C:$WZUVVSIA2K0FX_#I1*'']L>X2X- I
MT3VWL"L,/IM?F<9R.WM6JUV\SKY!N,:+">'HMLMJ9*T@Z'S)#9V=#D=D>:N.
M<XNY=<N5<IJDM6(8[.M\MX*VMOU2@["?)^5*C_"N;WF?D4K%NG%J?:LSEM1>
M+8ABX1)I=5<4-K3Q4VUQ!1\HY*V>VM?E-7#IH];[[DCB,(L>3BZS79\2=*>0
MVN.MWNIMT*&RA*MD%.SHZT*ZSBEH59<5MUK<3$0Y'CI;6(C7ILA>OFX)]D[)
MT*Y?B&&9/'L'3^VW.VL1EXS<U*=<1*2XE]GT7$AQ.@"-J6!Q/?WJ4S'IW/R>
MZYZA:VH\2]6V%'B/*/+3S*EK^9/GCR*/X$UHXQ@SXR*RR#@&-X\(+GK2IC:T
M/K=4E)XA@) *?FT>2M$ :T:NO4G&9F16N ]9I#,:]VJ8W<(#CX);+B004+UW
MX*2I23KZ@^U0$U743*?A+:_:X^*0P\VY-N#%S#[SB$J"BAD)2"GEK1*O )[&
ML\^S9+BV77:]XC B7BW7DH=F6UZ3\,XT^E(1ZK2R"DA20.23KN-@UFQNPW^[
M9JWEF8,1("XD5<2VVR,]Z_H!P@N...: *U<0-)&@/QK-EMFO,7-[9EN.Q&;D
MZS"=MLN"X^&5+:6M+B5MK(X\DJ3W!UL'S54O>"Y'?;#F$^7'BQ[U?YEN6W!0
M^%ICL176R IS0!60%J.NW@"NR*2%)*5 %)&B#[URG'X.<8#;E8]9;#!R&S,+
M7]FR57$1G&6E**@V\E23RX[UR2>X [5M+QG.H^*0Y#&0(DY2S<E7)]E;JTPW
MD*V#$'N&P".)(\C>AOM@?L^4YEEN-3[[CL''HUDE&8I],Y,J0^>"DAI!2D<6
MR5;5L]]#M5CZCV"XW5NR7*Q)8<NMEGIG,L/KX(D)X*0MOEH\24K.CHZ(%5.=
MB61YGD&02<A@,6:WW''EVAA")*7W6UESES7QT/)WH$C0'?9-1F/=/);<NQ,/
M8#B]L?@OM.3;L%(>#P;]V$ !25*(!VK7'\:^9E@=^O-RN:F<<MK=\=DE4#*(
M,SX-;#14"DNH3\ZUI'8_>"M#Q6;/,5E1IF77NX7"' 2_+L\FV3)2OV2I,?L
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MMZW1'+NPUZ#4Q30+J$=_E2KR!\RO[S]:DJ4I2E*4I4;=;#:;O+@R;I;HDR1
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24I2E*4I2E*4I2E*4I2E*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>exh1082_03.jpg
<TEXT>
begin 644 exh1082_03.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" 2; X\! 1$ _\0 '  !  (# 0$!              4& P0' @$(_\0
M6!   00" 0,"! (%" 4)! 0/ 0 " P0%$08'$B$3,10B05$R8146<8'4""-"
M55:1DI47,U)B=20T-C=R=*&QLS6RM,$8)3A#@J+1\&-S=I1&4U2$PL/Q_]H
M" $!   _ /U2B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B*O<XSES X
MNK+C:M>U<M78*43+$IBC#I7AH+G!KB -_0%1_P 5U _JCBO^:6/X=/BNH']4
M<5_S2Q_#I\5U _JCBO\ FEC^'3XKJ!_5'%?\TL?PZ?%=0/ZHXK_FEC^'3XKJ
M!_5'%?\ -+'\.GQ74#^J.*_YI8_AT^*Z@?U1Q7_-+'\.GQ74#^J.*_YI8_AT
M^*Z@?U1Q7_-+'\.GQ74#^J.*_P":6/X=/BNH']4<5_S2Q_#I\5U _JCBO^:6
M/X=/BNH']4<5_P TL?PZ?%=0/ZHXK_FEC^'3XKJ!_5'%?\TL?PZ?%=0/ZHXK
M_FEC^'3XKJ!_5'%?\TL?PZ?%=0/ZHXK_ )I8_AT^*Z@?U1Q7_-+'\.GQ74#^
MJ.*_YI8_AT^*Z@?U1Q7_ #2Q_#I\5U _JCBO^:6/X=/BNH']4<5_S2Q_#I\5
MU _JCBO^:6/X=/BNH']4<5_S2Q_#I\5U _JCBO\ FEC^'3XKJ!_5'%?\TL?P
MZ?%=0/ZHXK_FEC^'3XKJ!_5'%?\ -+'\.GQ74#^J.*_YI8_AT^*Z@?U1Q7_-
M+'\.GQ74#^J.*_YI8_AT^*Z@?U1Q7_-+'\.GQ74#^J.*_P":6/X=/BNH']4<
M5_S2Q_#I\5U _JCBO^:6/X=1G&N1<YY#@:66IX7C4=>W'ZC&RY.<. W]=5R/
MI]U)_%=0/ZHXK_FEC^'3XKJ!_5'%?\TL?PZ?%=0/ZHXK_FEC^'3XKJ!_5'%?
M\TL?PZ?%=0/ZHXK_ )I8_AT^*Z@?U1Q7_-+'\.GQ74#^J.*_YI8_AT^*Z@?U
M1Q7_ #2Q_#I\5U _JCBO^:6/X=/BNH']4<5_S2Q_#I\5U _JCBO^:6/X=/BN
MH']4<5_S2Q_#I\5U _JCBO\ FEC^'3XKJ!_5'%?\TL?PZ?%=0/ZHXK_FEC^'
M3XKJ!_5'%?\ -+'\.GQ74#^J.*_YI8_AT^*Z@?U1Q7_-+'\.GQ74#^J.*_YI
M8_AT^*Z@?U1Q7_-+'\.GQ74#^J.*_P":6/X=/BNH']4<5_S2Q_#I\5U _JCB
MO^:6/X=/BNH']4<5_P TL?PZ?%=0/ZHXK_FEC^'3XKJ!_5'%?\TL?PZ?%=0/
MZHXK_FEC^'3XKJ!_5'%?\TL?PZ?%=0/ZHXK_ )I8_AT^*Z@?U1Q7_-+'\.GQ
M74#^J.*_YI8_AT^*Z@?U1Q7_ #2Q_#I\5U _JCBO^:6/X=/BNH']4<5_S2Q_
M#I\5U _JCBO^:6/X=/BNH']4<5_S2Q_#K7R.4Y[0Q]FW+A^+NCKQ.E<&Y2QL
MAH).O^3^_A>,1F.>93$TLA!AN,-AMP,G8U^4G[@US0X ZK^^BMOXKJ!_5'%?
M\TL?PZ?%=0/ZHXK_ )I8_AT^*Z@?U1Q7_-+'\.GQ74#^J.*_YI8_AT^*Z@?U
M1Q7_ #2Q_#I\5U _JCBO^:6/X=/BNH']4<5_S2Q_#I\5U _JCBO^:6/X=/BN
MH']4<5_S2Q_#I\5U _JCBO\ FEC^'3XKJ!_5'%?\TL?PZ?%=0/ZHXK_FEC^'
M3XKJ!_5'%?\ -+'\.GQ74#^J.*_YI8_AT^*Z@?U1Q7_-+'\.GQ74#^J.*_YI
M8_AT^*Z@?U1Q7_-+'\.GQ74#^J.*_P":6/X=/BNH']4<5_S2Q_#J1X-G+>?P
MTUG(U8*MN"Y9I2QP2F2/NAE=&2UQ:TD'MWY 5@1$1$1$1$1$14[J=_S+C_\
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MX 1XITIT/4[QL,)_I:];^_\ -7VIF.&V.JMO'58JTG,HJ0=-/'7[GMAW^ R
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M _,7 [T/KH>1Y$HS'\FX9S#J-2K\4OYN#E4CIZ-RMVF%CGM>"R9Q([&@O/\
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M?^95Q1$1$1$1$1$1$1$1$1$1$1$1%%\K_P"BV9_[E-_[A6OP/_H/QW_AU?\
M])JG$1$1$1$1$1$1%3NEW_L?,?\ 'LI_\9*KBB(B(B(B(B(BIW4[_F7'_P#C
MU#_UFJXHB(B(B(B(B(B(B(B(B(B(B(B*G='O^K+CW_=A_P"95Q1$1$1$1$1$
M1$1$1$1$1$1$1%%\K_Z+9G_N4W_N%:_ _P#H/QW_ (=7_P#2:IQ$1$1$1$1$
M1$14[I=_['S'_'LI_P#&2JXHB(B(B(B(B(JCU,K79\/C9<=0L9"6IE*EM]>N
M6"1S(Y0YW;WN:-Z'U(7C]<\A_87E7^&G_$)^N>0_L+RK_#3_ (A/USR']A>5
M?X:?\0GZYY#^PO*O\-/^(3]<\A_87E7^&G_$)^N>0_L+RK_#3_B$_7/(?V%Y
M5_AI_P 0GZYY#^PO*O\ #3_B$_7/(?V%Y5_AI_Q"?KGD/["\J_PT_P"(3]<\
MA_87E7^&G_$)^N>0_L+RK_#3_B$_7/(?V%Y5_AI_Q"?KGD/["\J_PT_XA/US
MR']A>5?X:?\ $)^N>0_L+RK_  T_XA/USR']A>5?X:?\0GZYY#^PO*O\-/\
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M)[+('B-D+3K6W$'SH@^WU"QT>JE"[P',<CCQ]J.;$O,5O'S$,DCD! [=_O\
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M>4AQ&.@RL^3AHUH\C8:&36FQ 22-&M!SO<CP/?[!?:&)Q^.L6YZ%*M6FMO\
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MHB?P.;[C7@C[;(]@%J\MI<\QO,+&4XTVOG<+;@;%)B;<XC;"\ #N9OQYUO\
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M&=I=KYGD:T.WR?"N=3J)QZQQFYG'V+%>M3L&G8AGKO98CL; ]$Q:[B\ES=
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M^HU=#A_U3/\ LA<PZZT*F4DX%1R->*S3GY+ R6&5O<U[3#-L$?4*,ZA<4PO
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M/D*6Y]D\C<CYS'>F<&NX-#8?6CF[X63.,W>6Z):?MW#W 'E6K@7_ %L9;_\
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M9CGM$.L69I7S33$>W?(\EQU]MZ"W;^"Q]_-XK+6H"^_B_5^%D[W#T_5:&O\
M .CL >^]+6R?%,+D^38KD%RDU^8Q8>VK9#G-+ \$$$ Z<-$Z!WK9U[J'R'3'
MB]^]:L3U+38KDWQ%JG%=FCJV9-@]\D+7!CB2!O8\_7:D\KPW!Y6?)S7:9>_(
MT!C;/;*]H?7!<0P $:\N=Y&CY6WC^.XS'Y>;*5*Y9=FK14WR>HX[BCWV-T3K
MQW'S[E>[>"Q]O/T,U/ 79&C%+#7E[W#L;)KO';O1WVCW"VLE0JY3'V*.1KQV
M:=AACEAD;MKVD:((5<P'3[ 8/)U[]6*[/9JQNBJ.NWIK(JL(T6Q"1Q# 1X\>
M=>/9:.5Z4<2RCK@N4K1JVY'334F7IF5C*[WD$37A@?\ F![^??RI/D7!\+GL
MFW)667*V1$7H.M4+DM622+>^Q[HW#N;^1WKZ+-5X9@:D6"BJ8]D$6$>^2@R-
M[@(G.:YKB?/S$ASM]V_)W[^5J9GI_@<MFK&4L1W8;5IC8[8J7IJ[+36C31*U
MC@'Z'CS]/'LLV*X+Q[%,PS,?0]&/#S3V*+&RO[87S!PDT-^0>]W@^!OQI3V0
MI5<E1GI9"O%9J3L,<L,K0YCVGW!!]PJ70Z2\0IVZTPHVK$=5XDK5;5Z>>O X
M>Q;$]Y:-?3QX^BM3\)0?R./.NA/Z4CJNI-E[W:$3GM>6]N]?B:#O6_"C8>$8
M&'#X[%QTW"EC[PR5>/UG_).)72AV][/SN<='QYUK2T\QTWXUE\C:MVZMEOQC
MP^Y7AN315[;AK1EB:X,>? ]QY^NU[SG3WCV8R,EZ6&W4LS1-@L.H79JGQ$;1
MH,D$;FAX \>?IX]E8\7CZF)QU:AC:\=:G6C$44,8TUC1[ *EV.D?$9[UVTZM
MD627;$EFPV'*6HF/D>XN>>UL@ V3] I>[P+C=KB]3CQQK(,73D;-5CK/=$Z"
M1I)$C'M(<'[)/=O9V=[V5K4^F_&:E;+PLISR?I>K\'?EFMRR2V8_F_&]SBXN
M^=P[M[UH>P&I)O$,'\3:G?19(ZU09C)FR.<]LE=G=VL+2=?TG>?<[45B.FG&
ML7E<?DH(+LMS'$_!/M7YY_AFEA86,#WD-;IQ\?L^PUOU.$8&HZ@Z"FYIHW9L
MC!_///9/+W=[O?SOO=X/@;\!:W*N,"6AR2[@J-"?.9:K'7E9D2]]>PV/N#8W
MM!\ M>\;'U()WI4/AG3^RWGF"S;N,OX]6P\<W_.<LZ_+,Y\9C;'&2YW9$T.>
M?<;)'RKM*(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(N<8SEUO$6^I,7(+/Q#,!)^D*Y<UK=5)(/48P: WIS)&[.R?N57N(\VY!
MB>GW,W\SN"SR# UVV_4])K 6S5FR1-TT >).]F]?T5::O,7\=PW'L7G69/-<
MKL8]EFQ7H51)*= !\C@.UK&]Y[1O6_HMEO4O!/P$>39'D7227CC&X\57"W\4
M!LPF,^S@ 2=G6O.U7N?=26MZ<<AR6$DNXG+8BS4BM0W*P;-7$D\0.VGN!#HW
M.T1O\O*M7'>>8W-YXX?X/*X^^Z VH&9"HZ#XB($ O9O[$C8.B-^RK^!ZEXJK
MQ[C+)[.8SE[+UI9ZKXZ ]:UZ;M.W&SY6GS^0T"20IFOU)P$O%KN<E-RM%3LF
MC/4FKN%EEG8 A],;)>>YN@-[W^U:M?J?C;-ZYC(\7FZ^:KT),@:-FD62F-I:
M 0-Z=LN&M$^Q]B-*-X;U1BGZ<8+-<AK7OTID7""*K7J$R7)>WN)@8"=LT?Q$
M@#1V5.0]2<([!YS(V(\A3DPC!)?HVJYCLPM(VT]A.B"/8@D'[K[A.HN(RV>H
MXIM7*U),A&^6A/<INBBN-:.YWIN/DZ;\WD#QY5S7+,[)R/-]7;V Q?*;F%Q]
M7$07 RO5@E+I'2R-))D83[-']RW^*Y;/X;GS^(\GR3,PRS1.0Q^1^';!(0QX
M9)%(UGRDCN:00!XWM;O4?D&4HW<!Q[C;X8<UGIY(H[4\?J,JPQL[Y9>W^DX#
M0 /@D^5J5\)S? 9K%SUN1S<DQLTXBR-:_#!"Z*,@[FB>QK?PG7R'>P?"Z$J=
MR2ARO+<C;7QF7."P,-4/=:KQ133SSEQ^34@<&L:T [ULD^ZI%'GO(+W#*%:M
M=K29B_R&3 ULNR >G+$QSBZVV/\ "3V,<-?A[A]O"F*_(\MQ#D6;P_(\L[,U
M8,))G*MR:".&5K8G%LL;_3 :[W800 ?)!VH'I)RB]GLAA/TCU-CR%Z>L+$^'
M_1D,(D<8]N8R4-'=V$^2TG\/V5AY/RKDU?J7Q?%P4!C^/6;\E:6Q*YKI;I$#
MW_*T;[(P1[DAQ('L-[B^JG,[..Y[3P</+QQBI'C'79Y6T&7'S/=+V,:&%KB
M R0DCV\;^BZ)P>=UGBM"=V>CY#ZC7/&2CB9&)P7$CY6?*-#3?'^SY\[4ZB(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(BY!U5
MXQE<ESO%#&4I9\5G((L?EY6#Y88H++)@YW_:896?O6+JOQ3+93J!B!C*<L^'
MSD<%/,/C'RQ1U[+)VN=_VFF1BDNHS\T>:U(YAR5G&#0^63CT0=,^UZAVV5P!
M>UG9VZUH;)V?"IN)XU=BX=F(<UQ'-VH'\H=>$9MO=D*\+H8PRS'('$R2 C1
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M3CSXJ7HR$=_HR"(.;V!VPYSW!P;Y]UVNC4N09+(SV<B^S6L.8ZO6=$UHJ@-
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M>"6G\;'@#O8?<.T/V*N3\ZR,G/<EQS&<>%F#%FN^]?DNMB9#%*WN[@TM)<0
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MD?*#RW+Y2I4Q]Z]Q^;!XZ@RQZO:']SB^630&RXM&AL !3>6XMDK3.G@B$/\
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MU2*T8H*TLCY&/!T]K&M+B#VN.O.A[Z43R_JKB,1CN*9#&3QWJ&<OL@$[(99
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M8US7#;2"-D;!^H\%?41$1$1$1%"\<X[4P%G-3U))WNRMYU^82D$-D<QC"&Z
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M"G++79W799'=HAB8'DN?W>/H/!.]>5+X?G5:SDK&.S6,R& OQ5771%D/3U)
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M1$1$1$1$1$1$1%QB3IWRO&\DXQ-4Y&+L$>6L7K4[L=&U\;I()0Y[SW[?O8C
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M6?'%7EF,4>]=\G8TB-OYNT%#=,N=QYSBG&9\Y:A&7S;K0KLBC=VR^C(_>M;
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MK H-CT[N:-?-['V/TVOENT,IT7QG3ZEB,C#RQD56B^HZE(UM:6)["^PZ7M[
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M:U'+2DB;19!VNDE<]S0WR >W1V[O_:M#,X3+&/+9&*/+05:'.Y[T[J4 ?.V
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MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(N!]7L/R7GO5W X3
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M/:&'7?MS=$DCY#]-^1X5.;_*!Q?H#)/XIRIG&B_M&8-+^8UO7=[_ (=_GO\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>exh1087_01.jpg
<TEXT>
begin 644 exh1087_01.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" 2; X\! 1$ _\0 '  !  (# 0$!              0% 0(& P<(_\0
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MSV?:_P \5GVEC_CF_P#.%/:6?^-1_G"GM#/_ !J/\ZGM+/\ QK?^<*"0R?\
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M%?90V3Q@6H?^=6G6QYXAD_PBMCI[Q</]FEA'Q^CO_I6/N<\71VUM8S\[=_\
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M[ZTAQP(7SDH'?)JPB ZBTSI*[HO-\ N-U7'4MBY/LAV.79!2"D*&#@)&<9P
M/*J[5+UY@:DNOL,N[LQ(UX@P&;@N[.EB(DQXQ(>8.0M*BLY4>ZE\D=ZN8NL[
M@YXF&0INY'3+\E=H8661[(IQ(&UT+[[B\%M^A!'I7OH5*[G:M/W:YZIN;5TO
M(?;?AA_*%K4VXHMH1C#2FMA(*0#[F%9S5_X>P7TS[X[)NUTF"+.=AM-RI&]
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MG.3\U?+'4Z8B:<\,=+:J=M%[7/@V];DER"J4AP0UC.&0!RDDX&%<D_'-?$?
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M7/Z[?M5W\99,C4MMO\RV*LD=_P!FM25J<9<5LP5A)&!@J'S(K[WX8PK7"T7
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M$M4%AR"E:(JFV$I+"5YW!&![H.3G'?-'-.V9RX3)[EKA*FS63&DOEE)6\T0
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MU27M5:G8;ZC]CLK;>SJE2KVD#9G&[);[?&O.)K*_S-OL=GL<C<HH3T;XE>5
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M4JPE1"@Z4H0 D_CJ/ ["RUK LD"5%=MNGM,Q+'(@)E-7*=:W'F'G%'AI2VR
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MU)22 5$]SYUUD9*D-(2XX7%A(!61@J/KBO6E*5JYVX]:XO1G^^[7/_2+(_\
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MK8#A 4G<HJ<0!S@#)YJJ5>=52;G"T^@6F#>?979DN2IM;S.Q+O3;Z:-P/O\
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M.,I<E35Q6I<C+Q))(P<'R& !CT %>:M-0EJE%;LQ:)00)"%/J*7=B0D;A\0
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M.X-%8W$>N.^*R93"9"8Y>:$A0W!HK&XCU [XK93[27TLJ=0'E J2V5#<0.Y
MK>E9S6I2"H$@9'8^E9I2M5-H4M*U(25I[*(Y%0+Y:V;O#,1YYUD*()4SMW$
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MD(4$' 5@!2@5$ @^Z#WJ\S51.O*HDAT*@R#%94A#L@X2D%6,%(/*P-PR1VY
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M[I((SC..Q/Z:C_0D'Z3^D F0)?FI,ET C.<%.[:1\,8JR%5:;# 3<!,2V[U
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ME*4I2E*4I2E*4I2E*4I2E*4I2E*5%NIQ:YA]&5G_ +)KGO"@8\-M,_"WL_\
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M2UM">^0I8(''I5?;M6WRXM2WHE^TDI$5KKO%R-)9VM_EX4<[?B,BM8^M;Z_
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M2?.LA0/8UG(K&X>HIN'_ .#6H<03@*!^1K>E*4J/,'N(_;?Q&H]B_P!R8/\
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MZ!R2 $J&]AQ*\(4">Q/()J"]8M1JMMN<GVJ=(?;<E*8?BS$-SXP61LWJ!"'
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MVVF#%E.20^',E:2I:DHVXX(*^3VPGCOQE5K>=N[#J+9#B*1*,AV:TL;W$X(
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M)^LM/N@$*\^W/( YST$LD,JQ7(>#J0?#6QDC)Z:^_P"W56;_ *HDVB\W1J3
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MZ?MK<76WD9$V.?DX#6R;C"4,B4QC_G!61<(9.!+CD_\ .#[:V]MB_P#*6?\
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MWL>3N1_774$\<]N*Z[V2.>[+9_P!0P8I[QVC_@"M3;XA&#&8Q_S8K7Z,A?\
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M<9EE)P5J4>3\DI"E'X)-1Y>H8\::M@L27&FGD,/R4!);8<7MVI5E6[\='(!
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M/20@_P =>@O%M(XN$/\ TR?MK(NMO/:?$/\ UR?MI]*0/^71?],G[:"ZV\G
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MKA*=8>;Z"-N<(;4.>#P:^LHSM&\ *QSCD9K;(ID5@J [D#YUD'(R*4K 4"<
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M2E*4I2E*4K5:<C@D&MAV%*5 DKVW*,WO."A9VXX/:I]*PH9]/SUKL/J/T?\
MUK.S_P#'--I_*/[U8V>JC^@5G:KR56-JORJ;3^4?WJ;,=B<_&FP^>*P&^><&
MMM@]$_HITT^B?T5CICS"?T5@M)/XJ?T4Z#?FA/Z*=!O\A/Z!6I83GA+8'Q16
M#$:(P4(/S36IA,^337^8*U]@CGNRUG]HG[*U7;(BQA<9@C_FQ6OT-;O.%%)]
M2RG[*\S8+2>%6R"1\6$?96#IZSG_ (*@?N='V5YO6"Q,LN.O6NV(;0DJ6M<=
M "0.Y)QVKE=+771.IV+S*@6VVBWVM[I.RWHK:&E@("RM)(^I@]SC/?MS7OI
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M9-9\XU?$./6U)_7K55DUJI)2K5L$@\$"U ?RZK;#I'6%CL\6V6[5=O\ 9(J
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MZ-BSBI4C2EP@Q)9"N#+5-2SD^IZ;"E?)T&NET+9;E.9N#L.Q:0G1C>9P=>N
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M\RTF.4M);CK< ;*FB1DH&<D]S59'U_<].S[@W?X3DNQLW1RWMW,OIZV4L=0
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MNC)[^\GCOR/6O21-BQW6VI$EAIUSA"%N!)5Y< ]ZPW/B.R5QVY4=<A&=S27
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MA2^%.E!00>/J[2>/WZSIC1T33\P269]UF+;C^R,IFRBXEAG<#M2,#T')RK
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MCS&W9"G'F0A.3[[1 <3GME)4,U.EQF)L9R-,8:?CNI*7&G4!:5@^1!X(KT
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M04MI4EH;]@5U^W'4!SS42X"X_=):[K,AZJ4W$4ZF&AYQP2"KZ.:* 2,HZBG
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MR4J2^%,)/5"B"H*XYR0"<^8K2)IRRQ+?$@QK3 ;AQ'0_'93'3M:<!R%I&.%
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MJ4I2E*'L:K'"V+Y'"D NEE92OT&4\59TI5)JK4+.FX F28-RF-9.X08Q>+8
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M?3T&%NYWJ2-N?QE8!) )) YJ'.\([7*F*?3=;HRDNR5AM!:(2W(4%NM@J02
M5@D*^L,D ]JDV_PMM4);21.GNQ$MQD+C+4C:X6(YCI42$A0)1WP>_;%>EO\
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M0%I6'7" %%..1@\@>=5<72^K/N'\2X5YCJEW6:E#$9UO_P!M2W'0TEP<]U!
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M*%M&6"@-;,8()>^L.<''%3V;EIFT6W6-KU9;U2KW.N,ESV/HJ+]Q;6HECHJ
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M?,Q,!<!,-9E-O%!6$EKORE)((R".Q-63&JXJ]-3+V_ NT2+$W%UJ5"6V]M2
M2H-GDIP<Y'H?2M+AK:PP7D(?FI*%0%7-3J$E2&XXQAQ1'8*SA/F3VJ%!\1+)
M)+XD-W*W]..Y+1[?!<8Z[3:=RU-[A[^!S@<X/:K6=JFT0F+:])DJ2W<6UNQC
MTU'>E#1>4>!Q[B2>?EWJMLOB'I^\7"%#BO36GYJ-\7VJ"\PA\;=WN*6D)5[O
M/![5*U'K2RZ>G-0K@](7-=;+P8BQ79"PWG&]26TDI3GC)KPE>(.FXXMY3.=D
MB>S[0Q[)%=D;F\[2L]-)P >#G&#Q6#X@Z<$ER.)4Q<AM*%N-HMTE2FPL93N
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M.WJ)V]BH@^9K?57AEJ.1+ENQVG9;<T3&>DQ-:92R')DAU*E]1M6Y!0\,A.%
M@CGC$"*H-Z^LNFHT&%*FQ=1.3'YR'LR0D-KRE;:DA02 H +SM4$IQR<"=J+P
MXU*O25DM-HMD9I3=@3#D%DQTGVD@=4.*6E1VG (+?)(.2!@CHK1X>O.%AZ[V
M6$IY6I7+F[U.FL] M*"<GSPHIX_>J8K1EU'A;+LB(S!DBYNS$PRX A]@32\&
M<]DA2,#T&<'SJ-9-&RI^IX]WN>GX\&VNW!R7]&.EMP1\1@T'%)!*-RE#.$YQ
MP2<YJ#XNZ)OU_P!9)N5LCO/6YJ-#2ZVRI@K>*'9!4D)=R@E/40K"A@^N1QS
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M=\NJ&?, >>2=HGA_ BZDC79%QNI:B27ID:WEU)C-.NA8<4$[=QSO4<$\9.,
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MB-(1=6[?<Y5N:FW!BZ(;90A28TELA16@*!'O*2DD'(R.W)KU:T$7URY%^O\
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M0XU'0S;VHKS8;;"EAY"P$H(.!\=PK+6JO#^1<(3#>EH'0?#06\J*R.DIQ(4
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MI2E*4I2E,"L;1C&!BLD ]Q3 ]*QM'H*;1Z"LX ["E*4I2A /E6-J?04"4@<
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M'B".[^EC\HTC^DK9)U]CE>ES_P!6^/Y1H5:^ _L9/YGQ_'6A=\0!]5O3*O\
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M]-;)6E1P% GX5L*5C-9I2E**[&N9M+ZD2+D4K&3.<3C'D$BNFI2E*X?5I_\
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M@B-PHL=26U[?:F6EK"B< K4IU )P!M_1;)O-^66[2J1>C)1?S',5,UCVH,&
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M.X)5P<^0SDYJ/JS4>I+#>M0Q&K_>G_HR+%:C.)AQ5,K?>!"3(6I(" 5[1D8
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MC8[%>6IQ;Z,J"2E6  >V?7O7C</$BXMWUJWI<M,!M1GY?E,O.@^SRRPE("%
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MQYUBC0G2&WBA*$(7P>%8&#QGO5C8[AI&W::D3[&Y:(=B:42ZY$0AIE)XSG:
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MI2AKDM*QDB?>$N)][VQQ>W)QR>]=;2L%(/>L!"1Z_G-9VBN)U&,>)ND  #^
MG$9[9V(KBM'C3;"[$NY0Y2M<F:Y[:MMLB2EWWNHIY7_$8[9.W;MVBOL&V+<[
M80"E^'):(_8K0H?P$5\3NE@A6_3GB!(M\$,2F;@&(JT@[FT%+'"<=DY]*WU<
MJ[-W^8+JY&+HAVO9[&AQ" #/YSDGGRXK323T-KQ!A+96W/DR9\G<XDK:G1\[
M\ID-Y*5-C& >/Q.*V\3)$1K5-SE27V7W64QQ[&\M;$A!'(5$4.%$G@C')'>O
M2;=4BWW>SF6\F[/:D;#,12SUBVIYI0PG.=NP*/IBO/3]ENUQ?>NT5L1V6;M.
M>=GF<XIQUI+CJ>ETOJXY]?*J6%:+RUX=+OK21 938WG'GFIRW7)BUM@)60>$
M8*<Y!KK?$6\P;F_I1$2?;I<93KW62Y<2RRI26#@+6@Y'/EZU13;W]S.HH%SC
MR6_HN#;DH=C1Y2I#!#JWDY22<DAQ#0R>V:J;>Y,0];+;=)JI"Q*N8D(FW5R(
MV5@L'&]/!VE2L#RR:MK]=[C9[C=+A!F+-EAV9AN3'CR52$HZW7'6;7W)0M">
M?,$^E7K%J9D:@TA[7/NB3,M*Y4L)N3R$+<0ECWL!6/QC4"PZINCM^DW&8;DW
M:+XF2S"6]GHIV EA3?/!6A*R<@<XKZ#X>7B/(T%9Y,J<VZXW;FGI*U.[E)]P
M94KGX<YKYK UEJ*+&U'<'8=T2N\6R3<+4W+PIM"VBLH2RG)[L*:64D DH7P<
MU,N$Z+IQTM6>[7J8N=8I;J)CD]$IE]U#)<#PRX5-*&#]5 2=P]*H5WJ_0K)=
M%&;=+>\C2ZYX$R:9!DN$(VO,''N;?>W#.??3QYUTVH_IRTZ%FRDIOD.4[(@L
MMJ>O'74X%R$)6$'/X,D'&?V7PJ)K:5J/3T"QJA+NT)]5R7(=9E7'VM3[+$=Q
MY385Y)4$$8]<&J6_:TOD[5=P?M%SE+M$YV$W :B*0"MHS#'66ROW0I90O"C@
M8*3VKHKV]J2PPK$BU)O(E.7%U3D.\OL/N26D,J66PMHJ !P<9.01Z8J,_>YM
M]T7=]0VV^3HZ&;FEB,AK:@!I;K22E22G.4[U#YUW&KQ)T_HZ,F+.??E"=$9+
M[P2MQ25R&TJ!.,<I)%<KINX7).JX1NMPE+8N#[Z(ZFTM/0)*,**$ME/O-J2
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MJ+4P_P HJK4Z$)&$:GU.CXB?G^$4&AUC^RS5/[L'ZE;IT6\GZNJ]3_GDI/\
M"BLG1LD_5U?J88_]^W_1UC[CI7EK+4O^D9/\W6#H^;V3K+48/Q+)_FZR-(W/
M^[34/^:Q_15G[DKJ.VM-0CYB.?YJATM=<8&MKX"/5N.?YJM?N5O9^IK>\ _&
M/'/\W6%:3O\ MXUQ= ?4QHY_D4^Y;46/=UO<<_&''_4K(TQJ8?V;33\X+'V5
MG[G-3#^S25QZP6/LK/T%JC\76;A/_1K/VUJ;%JSRUA_G6ML_P*K/T3K$=M6Q
M3\[0/UZR+5K/RU7"/[:T ?SE#;=:C^R>VGYVD_TM>9M^N/Q-26I1]%6L@?\
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M;8[DM)3(4U&0DN@]PK Y!]#4F3:+;*;:;DV^&\VTVIEM+C*5!"" "D CA)
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MY<$O)7AQIY3A<WI/EA1X^'!KULNDVK:Y<)+LV;-N$UL-+EOK3U$H2#M2D
M J)[=S4"-X=6.(W9Q#BAAZVJ)2^VE(6\"DI4EPX]X*!R?B*QI_0;=FFPGE7*
M;.9MS*V8##Y2$QTJ !Y !4<  $]AFI"-$Q4VWV0OOD?2OTKNR,[P[U0G]KD
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M9M2I/H;0_P#JT.OX([VC4G^J'_U:P/$&V_C6S4*?VUI?_5K!\1+2#@P;\/\
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M%,TS6B%H4I82I)*#M4 <[3@'!_,0?SUOFE0Y=RA0WFVI<N.PZY]1#C@25>7
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M49QAU2KDZ^7%J*#O2A2 E(RCL"._P%6UI9N,9;T1V,P(JGY#OM"7R3A;BEI
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MM3657I3Z[JIK\*)"ATMQ&"E?XFT@YQC..:L;<Q$@ZBN(>^E \[+2MGWY*VE
MLMC)P2C&0H<]L>0 KJJXQ#LA4@;G+D+V)H!9W.='H]3N$_UO9T\^]WSY[N*D
M,MQ1K>8ZI=R"U,L(21U^D5A;I*?R<#*?AS76"N/0;8B/,@7:(XN4].6X6@T5
M+>R\5-+21W 3MYS[H20<8KQ>ERMSY,F2F_"8I#,0*5TBWU,(]W&"DMX45=P2
M>1C U,H1GITP768KI71IE#2W"IM+:E("QC'(P7#DYQMXQBO2.&(&L[NN7<)$
M=3[C"F6"YD/#;@X2020%9'':MW9!DZOG0'+T_%BI984RVA:$E3ZE.A24DCG
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M_P!7.?965:X0>^G]3#Y6MT_P"M?NW;_M#J?_ %4[]E8.O8J>39M28_Z'?/\
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M"^8*&+3);@% 2E!#(6E*0,;0G@ 55?1FI$_5U#&/SMX_B56#;=38_P!WX?\
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M.8]+N-LBR9#T?V1Q;J-V]K).PCL1DDUOI_3MHTZPZS9+?'A-NJ"W TG!60,
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M.NPX][4JXR$MG;MRE/X3*C[PSY"HVF+)I34%TN\6%#N8CP%-I1)5=9>V1NW
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M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4/:J;3
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M%+ +AQG"?4XYXJ1FF:\52&4N+0IU 6A.]2<\I3ZGX<'FHPN]O,3VH38YB_\
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MU/!^:JU(6;(O=UQDEL^_D?5)YX[>HK/W1:@Z%^>&K[*INQ%0N'^Q#GX' )/
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M]+:%*4 C>M>T G@;G%'\_P *@?>XT][-T#"WM;V5X6ZLG\$I:F^<]@7%\>A
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MMPC&2J0X7%NK=* @K4I1420/G^\*N:^,:K\/KS?O%>:]OZ.EY\9GV]06,O\
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M<=*ZH'&<>R(S\OZYW^%9.O4\G[F-3X!QQ"3_  ;_ (4.OFP ?N:U0<^D#_\
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MJ4H '*CDGOP/2JH:$><O4"3,ODF5 @353HL=UE*G6UG=A!?/O% *S@=\8!)
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M2'&1[NWJA"@GW![I(J1)\.KK<[*_$EV[HL-Q7_HZ'[2%)AN2)!X^M@EIM*%
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MY3FS_)J(]K+4K\^/.E>$4IZ='R&9"W&5N- _DK*<C\U2G_$;5+Z F3X67EU
M4E827&U84D@I(&.X(!!\L5Z#Q.U5Y^&&HA\EH^RGWT-2 ^]X8:FS\ D_Q4'B
MIJ $[O#+5 ^2 ?XJQ]]J[?C^'.K4J] QG[*P/%RXYY\.]7@?",:V^^Y,'UM
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MTQ#'^&Y^M6A\%O#X_P!C<<?)US]:L?>4\/\ ^YYG_3.?K5K]Y+P^SG[GF_\
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MDD9!!]"*]:4I2E*4I2E*4I2E*4I2E*4I5!JZTS+M:NA;YB8KZ7$N?A6PXTZ
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I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>exh1087_02.jpg
<TEXT>
begin 644 exh1087_02.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" 2; X\! 1$ _\0 '  !  (# 0$!              0% @,& 0<(_\0
M3A   00" @$"!0(#!@,$!P(/ 0 " P0%$082(1,Q!Q0B05$R814C<19"4F*!
MD20SH31RDK$(%S5#4V-S@L$ET>$FHS=$=8/PE+*SPM+_V@ ( 0$  #\ _45/
M_EG_ +Q6]$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1%HI_\L_\ >*WHB(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(HF.<Y\!+AH
M]BI:(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B*-CS_PX/Y<5)18-:0\DNV#]EFB(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(BBX[_
M +*S_=2D1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$4;'_\ 96*2B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(BCX_\ [*Q2$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$7)\OY=8XZ;,
MC./Y+(4ZL!GGM0.B9'& "2/K>TD@#?@'W'W6=[ESHLA2HT<1<OW9X&6)H8I(
MF.K,>= O#W@GV=^G?Z?W&XXYI8?R++XFMQO)VI,7T,\D$D.B'M+F=0Y[220/
M;W"V?VXK6N-U\Q@\;D<LR;ON"O&&R1=#IX?W(#2T^.N]G[ CRO9>;U'U,1)C
M:5V_:RE4W:]2-K6R>B&AQ<[L0!^IK0-^2X:_*WV>8X^/&X+(01V+-/,S0P5Y
M8FC33*0&E^R"/?\ !/@J?F,[7Q.0Q52S%.YV2L?+0O8T%K7]'/TXD^/#'>P/
MLJG/<]Q.$O7Z]IEE[,<V!]Z>)K2RJV9W5A?MP<=^_P!(=H*9;Y1 S+6<9CZ-
M[)W*K&OLLJ-9J'L-M#G/<UO8CR&@DZ\Z4/\ MWC75:4D57(2SVOF"VJV#^<Q
ML#RR5SVDC0:X:]]G8 !)TL<MS_#XZK#<:R]=H.A;9EMTZSI8H(G#;7R$>P(\
MZ&R!Y( 6_)\WP^/EG:]\T\5:.&:U/!'WCK,E_0YY'V(!/@'0\G07F6YSA<7D
M9ZEF68_+.A9:F9&715W3'48>[_-L>V] @G2M,EGJ&.RV+QEF;5[)/>RM$!LN
MZ,+W$_@ #W_)"M/LJ#&\LQ61R9HU99"]QD;#*Z,B*P8R!((W^SNI.CK\'6]%
M,;R[#9%S_E[>F-B?8;+)&Z..2)ATZ1CG !S0?<@D>0?8A>4.886[3MVFVG0P
MU:[;<IL1/AU X$ME < 2PAKO(_!4G#\BQV7K3S4YG@0:,K)HGQ21@C;26. <
M 1Y!UHCV4K#92GFL;!D,9.VQ3F!,<K00':)!]_/N"IJ(B(B(B(BC8_\ [*Q2
M41$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$7-\VJSY
M.#&XJ*"1]:Y<C^;D:W;60Q[D<'?LXL:S_P"VN>YEC*&<Y%$RCB+L')J%JM+#
ME&U71M,?8%_\_6G,#"YI83LGP 4QV3=B.=\SL6<9F'Q6?E75G08^:03](NK@
MTANO!\>2 J_!8^3$\4RM+D$>5HVN1W;F1ZXR&25]02$$1E\;2&OUKW\$['G2
MQQ%?+\=R7&LOGZ4]I[,"^A.:M<ROBF#FR-:6L!UMK2W8\=A^X4:#!WL!\.>
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M[UWC;RR)S2WJ-&1VW!QV !KSM7G,^.W\UR+C%VJVFZMBK+YYFSR.:Y_9A9H
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M4KMC:QCQ"\.D:='Z=-\?;\#:U\EXS/6L<MLT.-/<Z7*8RQCW05QMS(O2]0-
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M4CR_WW^DZ\-\8_$O)'C,^0HXC-9*.;'5:DT)M9*4N?WL%SG1M!_F -<>SG[
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M)Y?K#?;W\Z]ES4?*<]A^#X+Y/)-N6SQ]V8D;Z EF)#&N_FES@T1?K!=OL3X
M.ETO]K\O_:G%UKOR]/'7S7$#G0.?%/WC[/890?Y<O8_2UPT0!Y\JJ^">:L7J
M53#59(J=?&LFDFAEB/J60^=_5T?V$8T03Y/;QH:!/4\BY#DW<EMX3 OJ0V:6
M-_B,C[43GMD)<6MC&G#0^D[=Y]QK[KG\7S[-Y:Q!:KQXVMBF8BOFK398I#*(
MW.D$L;2':)_EDM=K\>#O:K<AR&Y3Y#@>699M"6)W';M^.&G&YK@W4+PQTA<>
M_@M < WSV.O*MLES+EV.P\]RQB:#0YU/Y5TA:SU?6E;&]I:R9Y&N[2'^W^5=
M5EYLG6^'^7GST6-L78J=A\L4 ?Z$C0UQ#=$]O+= ^?<E<YC^6VL=?X[B?DZF
M.QMFI2;4,D3_ $YR\:?'')VZL<QH'5CMEWV/MOH.6YS*X_/\?QF(@I2.R;YV
M%UES@&>G$7[^G^@\??V\>XYC#_$;).@Q%_-4*,&-O5KDKC7E>^2,U@2\Z( (
M/5VA[CQY*W/^),N*K8F]R&I!'C\MC)<E6-9Q<^,QQB0Q.W^HECAIPT-@C7W5
M7D+>3BYAG+>9J4I >*/L?*PS/:US>_U,<[SYUMO9OOX/A;;L4^8R_"L/\M7_
M ()9PTDWRCK$@ ZM@ .]$]F!QZDDGR3O:<9YBW&\8Q6-X_@I'VC#<L"H)IK
M:V.P^/7J=7.)>_9VX #S^P7GQ%Y7D<IPCDT.-QLE:6CCHIKGK6'0S022L[]6
MAH\EC?)V0#[?E=SG<S-A.+UKL44,SCZ,;C8L"&-@<0"]SC]AO>ALGV'DKCQ\
M5G'#TK?\+BB?/;LTG/L6'10"2'75OJ%GTF3?T]PWV._;S]/KO=)!&][.CG-#
MBW>^I(]MK8B(B(B(B(B(H>*_[##_ $4Q$1$1$1$7,\^Y*.+X6*T&=YI[,-6/
M<;GM:9'AI<0WR0 2=>-ZT#Y6G%<I@K]*F?R=!UZ2<1,?6ADCC^OS$U_;8CD<
MT@]'.WY\*BS/-,S0;R'T8:,S\;F*E")IC<WU(YA%X)[^'#U?U>WCV\^.SGY%
MB:^39CYK\++;Y!"UCCH&0CL&;]NQ'GKO>OLM-3E>"MB P92L1/8=4CV[KWF;
MK<8W_>\^WO[_ (*V3<EPL,\,,F3JMDF=U8/4'D]^FM_;ZP6^?<^/=3*&2IY!
M]ME*S'.ZK,:\X8=^G( "6G]]$?[J9I$32(FDTFDTFD(!]PFDTFEJM5X;5:6O
M:BCF@E:6/CD:'->T^X(/@A5F#XUA, Z5V%Q5*BZ7];H(@TN&]ZV/M^WLKA-)
MI-)I-)I-)I-)I-)I-)I-)I-)I" ?<+PL:=[:#O\ (0L:?=H/V]ECZ4?9SNC=
MNULZ]]>VUX:\)F;,8HS*T=6O+1V _ *US4JLS@Z:M!(X$.!=&"01]_ZK3BL9
M6Q<,L51I EE=,\GW<]QV3X_T'] %ZW%8]A!;0J-(<YXU"T:<X[<?;W)\D_=8
MOQ&-DCAC?CZ;F0R>K&TPM(8__$T:\']PM]ZE5OUG5[U:&S7=KM%,P/:='8V#
MX4:;"8J>"2&;&49(9)/6?&^NPM<_V[$$>7?O[K*UB,;<J15;>/ISU8M&.&6!
MKF,T-#32-#PMSJ-1U6*LZM":\188XN@ZL+""W0]AH@$?C2CY#"XO)6ZMK(8Z
MG:LU3V@EFA:]T1_+21L+/)8JAE/E_P"(TX+7R\@FA]5@=Z;Q[.;OV(_*C7>-
MX6]F*^5N8JE/DJ^O2LR0M,C->VC^WV_'V6$O%\%+#?BDQ-)T=\[MM,0U.??;
M_P GP/)\KRCQ;!48J$=3$TXFT'.?5ZQ#<+G>Y:?<$_<_=)>+8*7-OS#\54.4
M>PL=:$8$A!&O?\Z\;]]>%KH\1P5!U%U3'1Q?(M>RL&N=J)K_ -8 WK1^X^ZP
MI<*XU2Q]^C5PE&*I?\68FQ#K*/L#^P^WX^RP=P?C3L-#BOX/6;0AE]>.-@+2
MR3_$' [!^WO[>/966&P>,PN,..Q=*&M1+G.]!@^G;CMW@_G?LJ:3X><5D@AA
M=B(_3AA?78WU9!_*?Y+#]7EN_(!V!]M+?3X/QZE)$^M1>P12,F9'\S*8Q(Q@
M8Q_0NZEP:UNG$;\ [WY7M#A/'Z%C&SU*+XYL=ZGRL@L2ES!(=O&R[ZFD^='8
M\G\E;\]Q7$YR[%;OP2_,QQ.K^I#.^)SXG?JC<6D=FG\%>4^*8BGF)\E7KN9-
M-5;2?&)'>EZ+?TL$>^H \^P^Y_*J,?\ #/C-">*2&M;<R*"6M'#+=F?$R*3?
M=@87:ZG?M[?[+*O\-^.08N3'PP6VUGOB=YN2N<T1N[1M:XN):UKO( (&UU&3
MH0Y+&6:%KNZO8B=#* [1<TC1&_W&U1,X3BFSUG"2Z88'0/\ ES8<8WNAUZ3G
M _=O5OD:WU&]Z5CE<#7R67QF1EFL1V,<9#!Z;@&[>WJ[8(._'A4]+@.*J,Q<
M8FN2PXX3B&.5[7-+9M^HUPZ^0=G_ '6%'X=8.O7^6L&W>IQUI*=>O;E[LK0R
M>'LC\ ^0 -N)(  ! 6JE\.<?6=,Z3*9FT9<>[%_\18:[K7<=]1]/N-Z!.RIT
M7#:\67Q&0BR>29+C*AI01AT188SK?8&/W/5OD$?I'[JL'PQQ<=/&QULGF:UO
M'NF,-Z"=D<Y;*\O>QQ#.I:7.)UUV/L5CE_ACB[_S4=;(Y7'5+E2.G;KU)F]9
MXXV]6=B]KCL#QL'R/!5[R/B\.<PM*@^Y:KR4IHK%>U%U]1DD?Z7:+2T_?P1K
MRJ-GPVK,QMZ@,UE'UKLMB2=DWI2!_K]"_8+/<%FVN]P2?Z+MJ-6*C2KU*[2V
M&"-L48)WIK1H>?Z!;T1$1$1$1$1%#Q/_ &"#_NJ8B(B(B(B+EOB%BK^8Q-*O
MC(HY)(\A5M/]23H R*5LAUX\D]= ?NN5R'"\O8@Y3A_1ADHYW)1Y%MR20?\
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MA'*(8XW,D>Y['AO5HTPZ;O9)&SHJ_P#F\Y5Y'DJC>5>EC,-BZ]V5TM6*4/\
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M-RT)<E"^5]&<6:Y;,^/I(/9VFN&SY/OOW*A/XAAGY;)9!U4F3)1"&[$7GT;
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MNO<*5A<E+<Q,=O)5/X;,Y[VN@DF:_IU>6CZF^#L '_72L))8XAN21C!K?U.
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M7'31BY896A_D/\R.=U:#X^G9_.E/$S3+Z?63MU[?H.M?UUK?[+V*=LK.S6R
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M#^K5D9/PUW^VUYZA_P +_P#PKTR?Y7?Z!8&?1_Y<A_\ LK(RZ&^CO]ECZ_\
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M(B(B(B(B(B(B(B(B(B(B(B(BAW8?5DKGVZ.)W^/I(_\ O7F&_P#9=0_F)O\
MY*:B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(M<P^D:\^5'PX_\ P94'XC;_ .2F(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(H
M>)\XZJ?_ );?_)3$1$1$1$1?./BI0MP8\WJF8R=6Q:R-*M'\O:DC9#&^5D;@
M&M< 2>SCO6_;\+RZ;M#EV*XA5R61-.^)K\UJ:<OG9%&&#T(Y''?EWDGW ) U
M[C:[)9#C7.GX:O\ .96C=QLMZK!--WECFB(!C;(\[ZN#A^HG1^^EWM.22:I#
M+-"Z"5[&N?$X@EA(\M)'@Z]EN1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$4/$C6-JC_Y;?_)3$1$1$1$14/,L _D6
M.KU8[II^C:AM=Q$)-F-X>T:)'CL!M,_QV/+6\;D&6'5<MCG.=7LQL#@.XZO:
MYI_4UP^V]^Q!!4:/C$PR%_+R9(OS\]0TX+?H#I59[@,C)._J^H[)WH#P  NB
MJ,DCJPQSR^M,U@:^7J&]W >7:'@;/G2VHB(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B%1,5_P"SJO\ ]-O_ )*6B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(A43%_^SJW_ --O_DI:(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B%1<7_[.K?_ $V_^2E(
MB(B(B(BYCXA\MBX;QUV3DJR6W^H&,@C.G/\ !<\^W]UC7N_^RO.6\OJX##8V
M^#%)%D;$->&663TX6^H-A[WZ/5H )WK\!5').;9?!8+(7[&#KF2I;@K "X[T
MYVREH:]C_3^Q> 01]BM.>^)+\)7Y&V[A_P#C<*ZNY\3+6V313O#&/:_KL'9\
MM+1[>Y5]@.42W^3Y7 9"@VI?H113]HI_6BEC?O1#NK2"""-$#\KSF')[. R&
M#J5L?'<=E;/RD;GV3$(W]2[9^AWC0/M_LMG%>3_QO(9C&V:3Z.3Q,K([,)D$
MC"'M[,<UXUL$;]P#^0O,!S"CFN49S!UVO;8Q99M[O:8'8<6_LU[7,/[A463^
M)(QAY#)9PT[JN"GCBNRPS-<0'@$.:TZ)&G#8\'^JO,GR:>MR.CB*>--N2[6D
MM12B<,;T86AV]C8/UM_W6_C7)ZV<LY"D8+%+*8][66J=@#NSL-M<""0YKO.G
M _[+'CW+<=GLYG<51<XV,1,V&8GV<2#LM_HYKVG]VE="B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(A4;'_]D@_^FW_R4E$1
M$1$1$7&9K 6^1<GL_/\ S=/%5J1KUWQ.A<+#I=B;;7!Q&FAC02 ?+_.BJ3CF
M*S53X>4./Y_CQR4%:P:D\,CX7F:F._IO;]>NS?Y>Q[^#K\KFLKPS,P\&SN'Q
ME/*2XN?(U7XVC8G:Z6O$Q[72_5V^EFVGJ.V_'L"=KIOB3PV)WP^SE3C.,L3Y
M/*2UY)2Z9TDTI9*QWU/D<3H-:[0WX]A[KWCW'<IQ_D.>I46VFXW- 6J^7TR6
MQ4EUHQ2&39>![M)!UL@K1S+CF9?/Q2*Q-D^0-IY,V[-EK8X'QQ>F6AHZ=/.S
M]O/DK3@*68XO=YIDL7A[\>-M!CZ%*;^?-+:ZD.>2'.<&;Z_J/]-:TL)..Y+B
M?(^(Y6B;V5C9')0NB*II_H/V\R/U]Q(>VO?R=#W5-G.'97)\BY;E:M.T^2OD
MZU^M3L![:^1CCB ?&6GZ2=CZ21[Z^QVNPM7YY^?X#+'$9=E*+%V(YG?)R$Q2
M2/B(80!O8]-WD;'MY4"3^+5L_P CYM_"+L3Y:,>.QM(0&2:4AQ=ZLC(]EH[$
M>_D-!WKP%"J8+*\(YKQO(-FM9>E9JNQESY3&/#HV;[MFDZEVSW<=DZ/D_NOL
M*(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(BQ
M<X >5IQ__8X/_IM_\E(1$1$1$1%RF;YM2PV3%:WC\H:@E9!+D8ZX-:&1Y :U
MSM]O=S1L-(VX#?OK=<YEC*N6FI2"P65YXJMBVU@,,$TNND;CO>SV;Y ('8;(
MVO1S#&G,F@UM@L%OY VPUOH"SU[>EO>^VO&]:W].]^%(Y-R2KQY^,;<ALRG(
M6FTH/0:UVY7 EK3LC6P#Y]O"NU597.U\9E\1CYX9W29.5\,,C "QKFQN>>VR
M"/#3[ JU1%XYW5I.B=#>A[JKXQGJ7),2W(XPR&LZ22(&1A8[;'%I\']P5:KW
M:;4/+9*IB,99R&2G;7IUV&265P)#6C[^/*E,>U[&O80YKAL$>Q"RVFU4Y;D6
M*Q-@09"['#,8S,6:+BV,'1>[0/5H/]XZ"1\DP\KZ[(\E6<^Q6^=A;W\O@UOU
M /?KK[KV+D6(FQ462AR563'RR"*.PR0&-[R[J&@CP27>/Z^%:CR$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1%JF_2/ZK"C_V2#7^
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MB@YO(QXC$7<C-'++#4A=.]D6NQ:T;.MD#V!^Z8/)19C"X_)UFR,@NUX[,;9
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M<Z[3CCEF9T< &R=NA!(T=]3[;]E8J)E,C3Q=-UK(6(Z\#2&]WG6R3H ?DD^
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M;)\P(['=X>YQVSJ-Z:P N)\D@:6B;CTC;E^[%@;$=D\NJWHY&TSW%9HB[N!
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MD'R\L[-=92TC>QH$@$ D#8*T4_AWCZCL&YE^_([$R6I(O5,9[_,]O5[:8/\
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M&&P-=&6.[-:WZ2>I._(\E98+AU2SRC"U+..S,U&KA9'0SY%KV$2"TU\+7N:
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MAUJ?U)G2=I7:[.^HG6]#V\>%7G@N!?C<Q0FJR35<M,;%MDLSW=Y3KZP=[:?
M]M>P6^QQ2C+;J7(Y;L&0K0FLRW'.?5=$3OH\NWW&_/U Z/D+$\1QPH5ZD+K,
M38K;;SI!)VDFF:>P?(YP)<=@>_X ]AI:<GPC#WZ&6J%DU>+*V6V[9@?U=)(
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MV5@_OAP('T[\C7NJ&'&Y#%?"OC$;J\E;(2\@AL5*T@^J!LEESFL_;^6XDC[
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M(B(B(B(B(B(B(B(B(B(B(B(L9'!K23[+Y+\&\O%E.4<NGB+G^I8[%Q&M#N\
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M-JRXS1Y9A\75P;V8N6M3:V"+)F9_=T+?#=P]?U]0!^O7W_91.5<0RF9X:,?
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M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1%RF&81\0>1'NXM%:H
MW7@>)%U:(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B'R%SV*C Y?FY/I!=#6'4>_@/\ =="B(B(B(B(B
M(JBOR3#V<[-A8,E6?E86]GU@_P"L >_]=;&P/;[JW11<CD*>,K&QD+4%6 $-
M[S/#!L^PV?N?PJQO+N/N:]S<Q2=TDCA>&R@EKY"0QI'N"X@ZW[Z5[M-IM-IM
M1JE^I==.VG:@L&!YBE$4@?Z;Q[M=H^#^Q4G:T/MUX[<562Q"VS*USHX7/ >\
M-ULAON0-C?\ 5;T6$\T=>)TL\C(XFC;GO< !_4E9CR$6!EC$WH]V>KU[]-_5
MK>MZ_"S0HB%$1$*($1$3:;1$0(B%-IM$1$"(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B+G<7YYGG3U:/Y%;SOR?U^X71(B(B(B(B(B'V7"9H3P_$/BDD+,?+C97
MVXVMC:6S12F)SWR[!T6[:6GQ[O&]G2[:M8ALQ^I6FCFCV6]HW!PV#HC8_!&E
MM7SCDLI'QKXI'DNHQPH6'4R_PTV]@'7V[>G[?U.EC\7:U/\ @]N6C)!'F9;6
M+CE?^HM:+8](N;L>-N?^-^1OPJ_^/YR&>_B'YRQ/<ASK:4#VUH!8L1&LV4L'
MTB-NB=EY;X:#[G2C<=Y)R/D53AC(\V:DF4BR,=B:.M%)V->0M9(W;=!Q'D^.
MO^4+*MS'/Y# <8D^8GBL7\19MODH4A8EDL1EC6 Q]7=6'L23H>=#8VI$_(.9
M36X\9'/CZN6JX>#(V1/UCC=*]SN[7;#CZ;.A:>I!\[W]E>?$FS?=A..OI7GT
MG6<O0CE,(:[;7RM\ N'L#H^WG6B-'2Y.KE,CA>39B]2N0LQ]GE5?'3Q20-[2
MET,3'N+@?I.]$: \[WO>AT?%.2YS/97'WHVPQX6S8LUY8I3&"ST^X8&>?4,F
MV?4'#V)( TI/*\G?J\[I5Z46/T,/<M">:OWEB<PL&@[L#U)<W;1KV]U3<>Y/
MRS)BG 9L8^SD^-_Q>ITKN:(IP8QT=MQ[-/J#SXTM-?XD7YN)_P <KFM*RO2K
M0V621EH9D)91&YKCOPUGN6^^G-\^5GS3D>8QV.Y=BLI'BLC\CCX+T+Y:IZ31
MR/<QS)(^^M@L.B#K6MA=!6Y#E,CE[[\9+CH<5B<B*%J"=KO4D:&-+GM<#H';
M@&MZ^=>_D :N$\HY#R"QCKMC%P0X'(5WS1R]V-?&[>V-\2N+]MWOZ&:(]E7\
MYY#<P7*\Q9IT,7)-0XW)=CM2Q.,OB8?RB0X;8>KCH??7^N4G,^1U!G8;5&G8
MM4JE*W&VE#))T9.]S7[;VW)Z8:YWCKV UX4>OR;.9KD'#OX;D\7)2NMO3/,$
M;^DXBZM;V!=MIU(#U/EKAYWI9XCG/([6.P.4N4,5%C\I?BHM;%)(Z0%TDC'.
M\Z UT!'OO:G4.;9&[D68B*O3&3ER5RFR5W81-CKAI<\MWLN/=H#0?OO?A88[
M/\HM<RAH9&E0J,&&=;EJ"8O(D,G3R\ @^6^-#P''W*C\/Y-/-Q_!X[C6+KQ3
M'#C)F":9[F,87%K(FN.W%SB'?4?;6]'>E@[XEY"Y698P^$KR0OPCLS_Q%LQN
M:&.ZOC(##YV" ?8_LK2+GQL<BQN-BK5XOG:]:RQEB?I+*R4$N,8(ZOZ>-CMO
MWT/ WTV5Y'@\/.(,OF<;1F+!)Z=JTR)W0G0=IQ'C8(W^5LQV4Q6?IROQ61J7
MZVS$^2G8;(&G7MV8?!T1]]KY1\,;+K& PMG*39\6V26[3[\MV5T+XXI7?0YI
M>0X%A \CQK?N%U=;XAF2/$SSXHQ5<S6EL8Z06 YSRQA>&2#J.A<T;&BX?97/
M!>17N38F+(VL,_&5;$,4]9S[#)3,U[=GPWRW7[^X(/CR!3TOB+'8L8]\F,E9
MCLA'9FKV&S-<YL<!U(Z1A Z^/( +B?V/A9P_$.O"RC8S-";'T,A1DR%2P7^I
MN.-G=S9 !]#^GU #L"-^=C2]?\0ZU"25F?HRXX_P\Y.#4@E,L(<!U\:U)MS?
MI\CS[GRJ&US"YA>:YJYFZMJI4AQ-244W6A)&U\D[F=]_I8/8./L.I/G[]/9S
MT]ZEBM1/I2SVG22-CD]4FO 2]SVEOZF/ZQM\>XE 4/'?$BA;P0RLM8P5IG0M
MK/-B,QRNE[::7[TQS>I[@_I_?8WIC^)]2=E*.CA\E<O6OF6,KUS$_P#F0!I>
MWMWT00YI#AL$$:\^%:X_F]2Z9XA2MQ7(<FW%OJR%GJ=RT.[C3B"WKMWOO33X
M\*!A.65XJDC:T>9R5ZSD+C65)G1&5GHO(D#3V#1&TZ#?)/D#SM8Y;XI8/&4X
M+%F.VWM!%9GB>UL<M:.0D-+F.<'$^#L-#B -^Q&[S$\KJY7-VL?3KV7QUY'0
MFV"PQ&1H!<WP[L#Y\;: =$C84+G?)SB\;EJV-CNS92OCY+9=4CC>:S='H]_<
MZ\EITW1)#7>/"@5OB!C<7@<4_,2SR2_)U)+MAH:6P.F:T-<_R#Y)W](.O<ZV
M% N<EO5+G+X;>7MQUJF5I5JUB&I%(Z!LK8G&/6@""7EG9VR.P/NNI9S'&.L9
MBOJRV?%3106(W1Z)?*0(PWS]7;8U_51Y.?8&.^:KK$Q_YX9*R%SV2.A!,C6E
MNR2 UWV\]3K>EIQ'Q%P>7JMFQPR$QD($,8IR!\^V]B6 CZ@ #L^P\?D;\RW.
M\2[CK[N)N/GDEH27X70UWR](F['J/:!MH[#6CH^#^#JPXYG0_P"'^)SN;L1Q
M^IC8;=F8CJT%T;7..A^Y/@+38YYQ^K5O3W+<]9M%L;[#9ZDT;XVR'3'%I;OJ
M3XWK6_"F-Y9B#QRUG38E&,J]Q-*ZO('-Z'3CTZ]M _?7[JNC^(W%I:N0LMR9
M$%!K'V'.KRCJQ_Z7C;?+3_B&Q^ZVCGW''4H[;+TDD$@D=N.K*\M8QW5\C@&[
M:P$CZSIO[JPBY-AY;=BM'>8Z:"JV\\ .(]!PV) =:<T_L2H%'D]2QG+H&5I?
MP^&A%;,3HWQRPM<7'U'N=H=2W7C0(TH&%YS7NY[D\5F:*'%8J*H]DLD,D,FY
M@_8>'^3Y:WKH#?8>^PKIW*\+_"OGQD(_0,KJX^EQ?ZK=[C]/7?L-$ENMZ"K>
M'<FM9[X>-S[VUQ9>RP]HC:X1GTY'M:=$[\AH)\_<J-PWXB8;-\;ANWLECZ]Y
ME-MN[6CF#OEVD [(]]#8W^-^5T]/,XZY+5CJVXI7VJ_S4 :?^9%X'<?M]0_W
M"Y7(<[DJ3Y*R*#'X;&Y&/&VI1*?6:]P9N0,ZZ+0Z1@]]GR?L ;3*YO+?Q.]2
MP..@O25F0@F:?TF"1_9Q#G:.@&-:? ))>W[;*JJ7.[%C!865^*]+,92Y)1BJ
M&<&,.C+P^3N!YC 83L#SX'WVIU3F'SG'77(*P;D8[_\ #)*G8OZ6!*&/ ( [
M #;]Z'TC[+13YG>CSM*AGL$_%P7JTUJO.;392!& YS9&AHZ.#2#X+A]MK;QO
MFK<O;Q<4]%U2++U7W,<_U>YFC81L.&AT=U>QVO(T??8TLJ?-8W\>Y'E[U">K
M'A9YX9H0]LCW>DQKB1KQL]O;9_JMO#N6MY#<N5'UF06*T%>R?2G$S"R9I<SZ
MM#3M-\C7XT2"KC.YK'X.HRSE+4=>%\K(6E[@.SWN#0!^?)_V!/V5;Q[E$&6O
M92I*V*M+3NFG&#.'?,:B9)V;X'V?[>?97PGB,QA$K#*!LL[#L!^=*):N68<M
M0K14Q+6G;(9;'K-;Z): 6CH?+NVS[>VO*EQSQ2DB.5CR "0UP.@?9;%#S%N>
MCC+%FI2EOV(V]F5HG-:Z0_@%Q "EL)+02"TD;(_"]7J(B(B(B(B(B(?9<[B&
M,',<])VW*Z*L"-?8!^ET2(B(B(B(B(BK<?@<3C;EBWC\92JVK!)EEA@:Q\A)
MV=D#9V?*DT*-7'P&&C7AKPE[I"R)@:.SB2XZ'W)))4E5^8H8S*1,I9>M4MQO
M/9L-AC7@D?< _<+0[CF%=1^2=BJ1J>J)O1]%O7U![.UKW\#S^RU7.)X"Z9#;
MQ%*5TDS;+RZ(;=(T:#R?N=>/Z>/9>4>)<?Q[(FT</2K^EZGINBB#7,]3]>B/
M(WXW_0?A<=R;X:LM7L>[$4\))CZD'R\5+(1REM?;RYSXW,=O9V!U(\=?!&RK
MZIP#!OQ^.AS5&MD[%(O,4TS">G9Y?T;V)/0$Z#23H >ZZ',8FCF:8JY.LRQ
M'MD#7;\.:=M<"/((/W5:WAO'VQOC;C(FQNL,MEK7. ]9@TU^@?!&AK^@_"RH
M<0P&/SUC-4\9##DYW.?),W?ESOU.#=Z!/W( )^ZVY7C6*RN19>O02OM,KOJM
MD98DCU$_]3=-<!Y_/OX'X"QQ?%,/B[E.U1K21SU*GR,!-B5P9!L'H 7$:V!]
MOL/PLO[+X4XK(XPX^ T<C+)/:B(.I7O.W./[[UY'MH:UI1)^$X6QB+V.GBLR
MPWFL99DDM2.FE:S]+3(7=M#\;UY/Y._!P?!#D?\ '/EI?XBXL=([UY.DKF#3
M'O9OJYP^Q(]_/OY6>!X5@\#D9;N+JR0R/+BV/UWNBB+CMWIQD]6;_8!>YWA^
M)S=ZS;R$<SIK-)V.EZ3.:'0.=V+-#\GSOW_=)N(8V2Q8LAUN.U-%!"Z:.PX.
M A=VC(^VP[9\@[V0=@Z49G!<3'-0G@?=@M4YI[#9XIRQ\CYB#*7Z\$.+6^-:
M\ >WA>.X)C3Q>I@X[-^*"G8%JM.R4":&0/+@0>NCY)]P?=09OACAGUPV*YEH
M+++TF0BN1VOY\,K]!X:\@_2X  @[VK"#A&/K9"E<IV\A7GK4W4MLF!]5KG%W
M:3L#V=V)=L^Y/D%0Z7PYQ]"+%?(9+*UK6.INH1VHY(_4DKDDB-^V=2 3X( (
MU[K:[X?8QKWBK:O5(78LXAL,+H^D<!.SKLPGL3OR2?=9'@E1QQL<N1OS5*$E
M>6.O*8R.\+0UC@>FV_I!(:0"1]MG?7%H/N ?ZA:YHBZ"1D+_ $7N:0U[6@EI
MUX.CX.OW5#Q#BT/'.,#!&S)?J R#<[&M):\DN:>H /ESO]U48WX>PTX*5>3)
MV;-;&PRPXUDT;":PD;U)+@-O(:2T;T #[$^5TF QG]G^-4L97>^TVA6;!$7:
M:YX8W30?MO0 VOD_!..YV&>LR>O98ZR'-R<=O%P1-+)-^J!8:[NX[.P?/;0V
M /;L:WPYKNH5:&7R5C(4:-.>C38YH8^..5O1Q>X>'N#--!T-#?@[6NS\-HLE
M0=!F\I-<G9C?X77L,B$;HV=@[N?)[/VUGGP/'MY*SAX1F/XM;R=SDS+5VQ3B
MIGOCVB/HR4OT6!_EK@7-(WY[$['@"3Q3@S>.QV17O#N^&6.N(X>D=4RR.>_T
MV]CIN_3 ;OQZ?N=JI_\ 5E+UN68\Q%2RTLE>Q'8H4O1B;-#W_FNB+W![G!Y#
MO(V-*XJ\3RHS^$RV1S[+MB@+(E#J?02^MU&F:?J,-$;=#3ON2?/B5'Q"M'\0
M)^3ME?WEJMB-?ST]5NVB;_O=#T_H3^5SA^'F6I6*N0P^>KPY>O=MV1(^F3$^
M*R_N^)S.Y)T0-$$>W^JL7\1SL&:%_'\B9_Q=6.MD/F*@>Y[F%W\V+3@&.TX@
M @@>-@Z3&<+MU^;,STUJG&]DECNZK$Z.2W$_8CCG\]7= 0>VMDM'[K'E7$LU
M<S67NX'(T8(LOCA0M16X7/+2T2='L+2/_B$$'^OGV594^'N7Q^1CEI7\5)!9
MIUJMWYBGW?&Z%@C$D!WX):-:=X!\^?92LSPS+6:7(JU66@1E,M7R3#)(]O01
MF(EATT^_H-\_YC^/-M?X<+/Q I\B99,==L ;:JCVGECWZ+SX_NA\GX\AJY_%
M<$S>.^>QT<V&?B-V)*EAT!^<_FA_\M[]$!H+S]0V2!KQM>7N 9,<=X='59A[
M.1X_$:[ZUUKGU;+'-:UWDM+FN^AI!T='8\K;+Q#D-&[);Q P;S<Q3L?9K%KJ
MT4#N\CVNBZ-=MH]4C1 )UO>R597.'6\A\(Z_%+%B*O>BH05A-$XNC]2'KU/L
M#U)8-C7L2/*J>5<*SG)(\E>LQXR'*3X^O09"V=[HB&3B9[G/],'1(T&]3KR=
M^=#H/BNXCX7<F,H:QQQLVP#L EA\;^_E<GR7B>;Y+CK>0;CZL%V;%5\=#7^9
M#N[1,V5[G.ZZT.H#1^YWK:O\[@<RWE5[,8R"&U#D<1_#Y*\L_0PR-<XL<#HC
MI];@=>=^=':K+GPWM0T^)08ZZ ZC5&*R<A^DV*;@"]H/O^IHT/L''\><N7\0
MS&3R_)9\=#7:VW4HBJ^5XZO?7E,AC<!Y#7[ W^RJ\OQKE6<O9O*/P\5*:9V.
MLPU'WFGUG5G/+HG/9^GMW\._8'Q]IU7 9S&Y7$Y['\<K1ELU@V<7'<#I1ZK(
MV^J97'JZ3<9WY'TNU[[*O^ X;)4OAV<5DZHJ7C\T/3,K7@>I(][3MNQ_?'^R
MYOCO&Y(J?&'<DQL.(J<>QLU*W+8FBZ62^-L9+7-=^@Z<XEW4[(&CY(O/A-C)
MJV(?/9M-N11%V/Q\P\]J<,CQ&=_<G?N/!#6%5_)>"#-<I;\G6LTL;/;BNY24
MV2(K3HM%K61!WZG'79Q &F^-GR.@@BLTL(]UW$6K\^4M226X871]HF/WU#MN
M:"&L;&PZ._&_*Y;$\5RF"H<:N0UI7Q8G(V96X_N)98*<S7L:P'?U.8"#H$_<
M#>AN?PGCF0I7'7,E4=&);U[-.@[-<63S.Z1L!!T2(N^_MMX\^%C%_$.09RXW
M*<<RU.>S4FIPSV/1]"E"YKMD.;(XOD>X,WH#0T/9I+M/&,%E+&;X6[(49*8X
MQCIJT[R!TGE>QD0$?Y;UC+]_YFCWV!GCZF;'%>?,QU!\62N9"U-2CN1:;*U[
M&M:[1\'?5V@?VV%4\(BD^'M+D=N/$Y9O%HHJ]B.!\#39$Q:&S$ D$L: TDDZ
M&CU\!=;\6*,E[BT#H:,MYT&0IV'111>J_HV=A?IH\GZ=^!]EPEK"NEOY3)-P
M%UES^U%&>*0X]_J,K-$/<M(:?I'20'J=>/OL;G\+PUE_+('YO&9QN:H7[<QO
M.:QE26.0OTX2!O9X+2P!A.QH>P'BS^)6*EN<UP=J+'V;$<>+R4,LD55TC=OC
M:(V.('W/?0\^?MY7/_#KC(KWL-2MX2U7@N\7=3R+S5=&#*7MVV1Q'ZNH=K?V
M_P!%J@P')O\ U?YB*:K(_(XF(8>JV,?S+-9DH=*]FM'<D?5OOYZ'[E:N6X^6
MSB>=6>.8RPS"W,96;%5^4DC[V^WDLB(!#@PMV0-;]]D%7,$E8\XM5^08C(W,
MJZ[5M8>S%%)Z;:X8P "0>&-:[U"\'0/;[K3\,X9)>3UI+[LM'R*HZU'DHG5?
M3B>'N+@^27J/5;L-Z#>P#X&@5]E1$1$1$1$1$1%S>)D[\WSS"->G7K#>O??J
M'W72(B(B(B(B(B(B+BN7W7U>:\=C%.C-(^O=DKSS,)D@>R(;ZD'P' @'[Z!_
M*YGCWQ%Y%>BQ+[&)HSRY7#V,A4K5B]KS+%K3"YQUI^_'CQOW/NO6<XS&6JX%
MV.MXYLEC,1T; ^7DC>W<#I"Q\;G=F$.80?)V-$'29+GO*,?@.39B6AAI*>%L
MS53U?('RO8^-H\>P!#W'W]P%<Y?G-O&9K+XXTZTLL,F/AI'U"P/?:<]O\P^=
M!O0G8]UKS.<Y=7Y#QO'?+XN V\C/"]_J.<V>)D#WAP \L\ ^#OZFCSHK5A.1
MBO<M4,7C8H<EDL_;K?S)WOC[1,#I)G$^?+6^&-T-Z]O)7D'Q S%V_1QE'"5/
MXE)<N4)VSVW-CCE@8';!#"2PAS3O6_MK[K#_ -9TAP^"LG'UH+&3KOD;\U9,
M4+I6/Z&%LO4M['R1VZCV\^?%I\6'3,I<<=3:Z2U_'*GI1"4QB0]B2TD?;0)\
M@Z )44_$"Z,,RR[$UF667;5&PUUL^DV2 N #"&%\A>1X 9OW/V4BA\1()Y<
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MTC \]R[V)V/'L/?=WQ# 9'$Y/.WLI=J69<I-'.YM>!T8C<V)L9 VYVQ](_\
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MMT0-$'1W^/W\3<-Q//8?.VWTLS59A[T\=RS *SO4;, T2-B)<0UC^HV#L@;
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M3MP0.;&7RR.!;&7@^[@UVCY )!77\".9PD=F*SC\A>J3Y"&M7L30,AL-A](
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M%)3#_3D8QSMEK3MWTM'U'V!W^RDW>;\9HLA?:SE!C9H/FH_YH/>+_&->X_\
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M$1%XX;:1[>%PWP_BC;R/F<C7;D?D@U[-[ZZB: ?]0NZ1$1$1$1%B\]6N<=Z
MWX&S_LOD6$XEDLM\"\EQN6*6CDIWV7,9.TQ^38=(P']G#6_ZJPY4ZYS+@3.-
MU\3D:N1O"*&Q\U5?'%5#'-,CC(1T=KJ>O4G9(^V]=IQ^.E%>RXI8V>G+\R/7
MEEAZ"T_HW^8T_P!X:T-_D%7:(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(A]BOF_P *7.DY#SV1P8 <RYH+7;WIC??\
M+Z0B(B(B(B(FDTFD1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$=X!7SCX4_+-R7,A6CD:\9B1LLCB/YKNH)( ]O<!?
M1T1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$/L=>Z^5?!-I;9YJ3(V3U,V^0.!WX,;/'[>Q7U5$1$1$1
M$4+)Y2IBX#/D+$-:#8;ZDKPUNS[#96NCF:-Z>:"I;@FF@UZC&/!<S?ML>X]C
M[J._DN)8=/R--NY#""9F@>H!LM]_?]E,DR5:*W#5DFA;8F!,<;GZ<_7OU'WU
ML+2<YCAD/DOG:AM;UZ/K#OO\:_/[*0,A6=9=6;/";#1V,0>"_7YZ^ZT-S5 V
MA6^<J^N3U]/UF]M_C6_?]EX_.8YCRQ]^HUP.BTS-!!_&B?!6ZQDJU=[&3V((
MG/\ TA\@;O\ <;/D*7&\/!(]EDXZ:3X\?E0CD:XG$!FB]?\ ^'W';_;>ULDM
MQQN E?&PN\-[.UL_CRL_F&]VL):'N]@7>5DZ5K=$N:&G[E>B0'>B"0=:">H-
MD;&PL6S!Q<&EI+3H^5DU^]>V_NCY&M'N/QY.EX)-^->?PO>Y\;;_ %(*=S^!
MM9HB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(O'G33_1
M?)_@2^*0<Q? WJPYE_C7W]-F_P"OE?641$1$1$1?.OCOU'PUR(<6]C/6 W]M
MSL__ "JBY1CLDWGV5S_&W%V6Q52IVJ CK<A<9>\1_P VAX/V(6J*G'S?X89V
MUA6.CM/R,M^B7LZNCFC>'-!'V.VEI_J5OQF9L\NQ65Y=B(-S5,0ZM0#QY%ES
M.\VOZ'TV?U:Y0[U;%,_]'IMV QFU_#6V8;(UZKK6@0>WOW]3Q^?=5V>LY&KE
M.7Y"%G3-1\1KRES&[<V1QD[D:\[\?]%W^+X_QJSPG$1EE9M-H@GBLM+6.,GA
MP?W_ ,1=[_E<=QRG+:S'/FU\1B[L3\X8Y#9=U(88X_4U])]F]C[CSM.8XZ2E
ME\OFJ5*IR;CMJK'#=J!P=8JM;']+H3[$%A[:_P!0OH\'(*-/A]'*5([]J@ZO
M$Z)L$)EE<TM'7Z1Y]M;_ -5&Y5R.RWX9YC.8:O9;:CH330,L0.CD:X-.B6$;
M\:WK[JKP/%>/W^ X\3B*3U:\5@WB093(=.,G?WV3^ZKOAS0K<DFY7<Y'!';O
MC*V:72<;,$$;M1L;OR 6Z=X]][7S^Q'E<QQG#RTIII\EALAD7XV<N)=8BKN)
M8UQ^X+01^^P5>\MY WF&5X=D\?-*<*S+586AI/66:1CI'AVO?HU@;_WG%;J>
M5_L?\3<YD[4L@P&3M259!V);#/% R1A'V^L.>/W.@JEC;DT'Q8NY9\IO.Q$%
MGTW./_#%T<KFM:/MH!O^H_9=OPW&PN?B7S82>DYF.#OFC-MLY<T-+7 $[_5O
MS^%\]^&5V:SD>#TJDEBC?'KVK-R>4EEZ!KWM,3!LA[AXV"!H>5]%X9%%S')<
MGNYP/F=5R,F/K57/(;!'&&_5H'PYQ)._QI1I\:[$_$3@>.;;L6(8:UXO<^9Q
M[AH;U[>?)&_<JKY?R^:I\1L;?@R(;A\=<9C;4'V?ZP(?*?V8XQMW]CV_"ZC*
MR./QAP$(EE;7?B[4LD;9#U<YKXPTD?D;<%]":X'V<#_JLD1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1%A+OH[7OHKYQ\%J3:F&RSXWL=
M'8R$DHTTAP^EH(=O[[7TI$1$1$1$7/<PXZ>1THZLDM<0-?W='/6$S'_CP2/8
M^55P\3RM>Z^Y6S5:.U)&V*25N/:'/:WV&^WL//\ NMM+CN=H,<REFZ,+'O=)
M(UN- #GN.W.T'^Y6K&<9SV+K"MC\QC:];N7F-F-.MN)+C_S/R561?#JS#.V:
M*UB ]LOKM:<:XL;)_C#/5ZAW[@*4.&9=F8L95F4Q@R%B(0RRF@\]V#R&Z,I'
MW/V^Y43'?#R]C;,<]"]B8',<9 T4)2QKC]VL];JW_0+5)\-;/J7',MXT"[(Z
M2TUM>=@F<1Y<[4_DK;8^'UV>6=S[.+'S#!%,V.&Q&V1@;U#7!LX!'4 >RO:F
M+Y+4KQ0P7,(QD;0QK6U) T #0T._@: \+9)4Y5)&YC[6#<QP+2TUI-$?C]:Y
MBA\/LC0#!4=B60L?ZC:W:V8&G>_$9EZZW]M$?LI%OA67LW[5LRXN&2V.MGY9
MUB'UAK7U=7Z)^V]>RV1<3S5>WC)J\.#C;C6O;6CCDG8QH< ""WR/(WY\J!-P
M'*.IXRI7K86K6QMHW:T<-B9H;-LGN?I\^7._T6\\,S$L4\=RGA+39[S,A();
M<Y'K-((<!U\?I U[:6B_P?,7)L_)-4QCCG(FU[O3(3-[L:TANAZ9UKL1X_*V
MU>,<CK2TG>E4E^38YD#9,M*6Q[:6[ ]+W#? /V42+@N2AP6.Q<6+I1Q8Z;UZ
MD[<K)Z\#MD_2_P!'VT=$??94J7B^=9FK&3HU(J-JT&MLFMEW-;/U&@YS70$=
MM#]0\KU_'<S_ !;&9"+%5H[&-BEB@;'ECU(D_47;A.R=#R5JL<;S4W"[/&I\
M)')4L=_4E=E 93W=V)#O1T#LGSI:I..<E=EL9DF4Y67:%,TXY1DXW=F.T3V!
MA^H^/V78\(H7,?1F9DHI&6I;#Y7ODL"5TA/W):UH ^VM+ID1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1%C)_RW?T*^9_!&PVQ@\J&$'T
MLC+&=-UY ;O^J^G(B(B(B(B:32:32)I$TFD32:32(B:307FDZC]_]#I.HUKS
M_NO.C=>P3HW\+T- .QO_ '7J(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(BU6CUK2D^P83_T7S+X$S>MQ_*%LSY8QD9.H<SKTVUIU^_O[
MKZDB(B(B(B(FTVFTVFTVFTVFT3:)M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$47)NZ8ZT[\1./_ $*^:? 1LK<#F#/!Z1?D
M7N;OP2WTV>?_ #7U5$1$1$1$7+<WS$U*?"8FE*8;>8N?+"4?JBC:QSY'-^W;
MJW0W]W _91IN:04^2U<)8Q]N%DUGY&&>61H=(\1]^P83W='H:]3V[>%OX=D[
M+\OR# W9))Y<1-$(K$FNTL,L8>SL0!LM^II/WZ@GR2N6@Y9:P'(.>6\K)D\A
MB\;;J00P1ACO2$K&DD;ZD_4\#6R=$>%=6?B-4J1676\/E('U;\-"S&\1;@,H
M:8Y'$/(Z'L/.]C[A6U[EU.O=92@K6K5V6R^M!#$& S.C8'R.:7. ZMWHDD?5
MX\E5#>7T,O=XM8J6<E7BM6[$#H0QC6^K'$_O%."=MZ]2?&QL#[:*DT?B!B[,
M#K<U:_5QAJONPWYHAZ,T3':)!:20?((#@"0?"F<4YEC>2W\A2IMEBMT>CI(Y
M'1NVQX):YI8YP(\>?.P?!7'Y/EF2'+LGA[68=@\BVPS^%UIZ\?R]Z#3=_P Q
MP)+W$N&@YNCH:/E=78YUBZT5Q]F*W$RKDVXJ4EC3J9P:6GPX[:>[?/OY\@>5
MR_%OB'\ID<Q3Y/+=D8.06,;5N?*@00L'41QO>T ;)+@#Y/YUX5V?B=@?FHH!
M%E#WN28_U!2DZMLLW_*)U^LZ.@-_OI9V^5U<E6X_9QN3MT([64^4<QU$N,KF
M%P? _L/Y9):?J]_'A26<^PAI6[CG6F4Z\?J>NZ!P9(/4],=/R2_QK^BUW.31
MV;V";6N6<?Z^1?5D@FHEQG+&/)C+CXC]NP=OR!XV%)BYU@9+;8!9E E;*Z"8
MP/\ 3LB($R>D[6G]='V]_MM9<;YSQ_DEN.MB+LDTTL!M1A]:6(21@AI<PO:
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M.8(RWVCT/!=_5Q:T?U_9="][(V.?(YK6-&RYQT %I9?J/$A9:@<(@'/(D!Z
MC8)_'A'W:L<1E?9@;$'="\R  ._&_P K*:U7A&YIXHQK?UO \; W_N1_NMI<
MT:VX#?M^Z=F[UL;_  H+;TO\:?1-*<0-KB87"6^F7%Q'IZWOL -^VM%3@X'>
MB#I>[4'+WWX^.N^.E:N&6>. MKM#C&''7=VR--'N2IR;3:*LQ^7BMQ!\T%BB
M]UA]:..XP1OE<W?EHV=@AI</R!M><;S=;D.*9D*+9FP.EEB E;U=N.1T;O&S
M]VE6A7-Y7F.*Q<^8BM_--=B:K+EDB!Q'I.) +?\ %^D[U[:*Z&&1LL3)&[ZO
M:'#?X*S*\10L=DZV1ENQUO5[4YS7E[QN8.X /@D?4-$>1X4U5^1S-#&W,?5O
M6!#/?E,-9I:?YCP-]=@:!T/OI939.G#EJ^,DG#;UB-\T46CMS&D!QW[>-C_=
M3D4/&9*EE8'SXZS'9A9(Z)SXSL![3IP_J"IFD  ]AI4?&>/MP4F4<RW+9%^V
M^ZX2-:/3>_\ 4!H#QX'NK"?(T(,C7H3VJ[+UEKG0UW/ DD#1MQ:WW("F  #0
M&@O.K?P/]EKGK06(_3L0Q2Q[WU>P.&_SHK7-0ISO<^:I7D>\=7.?&"2/P=C]
M@L3C*!WNE5.V"/S$W](.PWV]@23K\KQV*QSPX/H5'-<&AP,+3L-(+0?'V+01
M^-#\*;M:K%B&N&NL31Q-<X,:7N#07'P -_<_A;=IM%BV1CBX-<UQ:=. .]'\
M%9;7@<TZT1Y]E[M-IM-IM-IM-IM-IM-IM-IM-IM-IM-IM-IM$1$VB)M-IM$1
M$1$1$1$14'.G^EQ#,O V15D.O_LKA/@#(Z;CN2?)T#SDI=M8W0!Z,W_U7UI$
M1$1$1$1<3E8'UOBS@\A.=U+&,LT8MZTR?O')_NYC'?\ @*A5<G:RG-:TN2XY
MFH_EWOCHE\#?0A:1IT[W]C]9:" -> =>[CJ5PR"23G_.,E&XNHS35:T9UX,D
M46I"/SHN#3^[2/LN7Y?@,ERW$<IRS6VJEAA:S'UY*#O7U7/>,L)T1WD+CL#V
M< ?;QU'*;TN4^#>:NWJ,E:T_#SR2UK4.C'*V)Q(+7#SIP\'[^"OF4W%1:XW+
M8P.!G@:>+&G;B;0=&ZU<?TZ::0.[FD.<9!O[>3M=;)A*N#Y+A;#\%+)Q>7%R
MQ25Z]%\HBMNZETDD+6EVWL:6;Z_D'W7'X7CE"EFL31YIA[%UW]GYRVNRJ^S)
M&WYAWI,=T!^IL;@T$_I/@$:"D1<=RL!I8SEE+/67.Q-*.G)C862B&>(N[,,Q
M8XPNV6?6" ='9.@NW^'/':#.5<IRTV+EAOLRD@K6)H9(]Q.AC#BSL ' N#_(
M'G7]%SOQ3Q=R;DG+IZ6,M6/7XTR"(Q5'O;)/ZY]B!HO#0P_GP/PLXN(ULM<Y
M5B<?7EJU\CA:<L4H:]K#; >>X<?!> Z+L1YT[S[E",Q=XUB,_E,=+#';R-6/
M*5!&7.CIQ LTY@&RPR@O(\_2X;V 5K=#/6>U];UH\'_:NL_'LTYH9" #,6C[
M1=^W^4>?L0F+FEFL92-E+*?^L&E-D7MD]-XC<Q[9/1<YY'1T6O3#6 _J&P/<
MK?\ #W,8C$P6>16KV1AK1T8H,FR2C+''#8#V@=P=E\I+G;<-^/+M;&^\^)F-
MMY+AM\8Q\K<C6 MUO3<6ETD9[!GC[. +?_M+A^,09G(\S=\Y6LU\7E_1SK6E
MS@*[&=V^@?J_4XF%Y \>7_A5&-DI6F<-M7IY+45;D>1@,KY7REK7>N8P3LD[
M_EZ_/C\J1P3TZN2X=8K6IA)=RN6AL,^8<6.C!G>P=-]0.W1P('DN'Y4OXX98
M5KUNO#D;5&[7PTERN?F)(V%X>0#&R,@OE\$$DZ:T@D$$Z@<MRU6^WG$XN02/
MDXA6+B'@$N)F/M]OUM\?YA^0NV^)]U]7X3V[E*_)3E;# 8K,$QC+=O8-AP/X
M)7'\NGGP_(9L3-RRYC<;-C_FL?>MV9I3).Z5Q=T<UP[EH],",]AH^WE:\WRB
M=]?-&]F[5/D='(TH*M(3NK%T#G0AS_1!T_N))"=]NO@>-!2\CR=]+)7*<N;E
MBM1\PK5XH7VCV%5S8"]I!/\ R_J?[^/*QMY'(V;(KLS^0@:[F+\9ZD<XV*YK
M]O3\@CPX>/P3^5JBS.:9RVQBIN314K&+R-:M##=E+K%VOU8-B( -D]0EQ+M=
M@?NT!:*61CY!D^"Y'*9:5^3ESECUZ+I@UM5S&3=8Q']NNF#?N>WD^1KL><5W
MV_B5Q2O'DIL:^2AD )X.G?P8#H=P1]M^WL"N"R7-N01\/BL#-/\ XE6Q,MLN
MU'"U_6R^..<[!]3U&L&F  >Y)\A=97Y-;R/(LO'?Y$W#38VS4$%)C8Y&V(7,
M8YY#=%TG<N<T%I^G0T-[W!X#G9V<JR>$EGFQ\+\ODYZ[@V,C(/%A_:(.<#U+
M1YUX)WO8 \W6=Y7R .P?JXRSQTRYRK3F%E\,S;$,@>7-!;V _2!L$'95'0Y-
MR+*9F&E5SSX8I.2WL7ZAKP//H10%[=?0!V!:=']QOMK1[/A.;R4W&<Q-EWB_
M8Q=RU6;/$P--ID1.G=6C78_I('C8*^=7,Q??D^"\LGOC*RC#Y/(FK&UC8XW"
M!A,<?5H=[N#3V)/T']U9Y+G.=X]C,??=;;FH\C@I<B/Y+&MKS,$9V.@!,7\S
MR#L^/=7%[-9C#FDX<DK96"WD,<QG\B,/;#/(6/V6@#J='J?<:.R5HL<HSS[)
MKU;T$;G<J=AP]]=K]0>AZ@\ CR"#Y_W6G%\KY'#9QDV0O5[=9V;N8>6%E81N
MD$0F+9.VSIVXQX U_P":BT>9<NGXA<Y _P"3BJR8:?(P"1L;NLK-.#6-:_L6
M]20>WD$#\Z6OD_).30XW-TILI V9M?&6XK%>OZ98VQ/Z3X]$G8\;W[^3_I=Y
M3EN;H\MJ8^&>G;IG)5\=-)'6=IA?%V<'N+@!)OR&M[ -(V02JG'9+)R<9QTV
M9FIY8S<J^4/S-7?0"T]@<SZM!PZ@CQX'C]U9R\\RGR;\U%'5.,CSG\(?3,3O
M6Z>H(O4[=OU]CVZZUKQ[^4PG,>0SY;$&]_#'T+F6N8E\<,+V2 Q>H6R EQ'G
MTB"W7W]_Q:_$KE62XS-4?7^7K8]\;S)=LUI)XFR[ CCD+' Q-=L_601L?9<S
MB\Q?P.>Y#/CHL>[&VN5059FN:[U'&>.!I>T@@#78.\@]MGV]S=8GFU^]S"GB
MK,%&?'WK%RL'01O(C,([-W*3UD+F@]@T#J3HG8(7-<-BC;2^%+FL8"V]D&M(
M'L/2L^!^W@?[+J.6OR<?Q1P9P45.2X_$VP1:D<QFA)"1OJ"3Y.@/\Q/]:^A\
M2<MEL?6_A&!];*"B;D];L7-["62(1M<- ;=$_P"H[UX\%=CRCD$^'XO'E8Z3
MRYQB]5A8Z3Y=CR.SW-8"7!@)) _'NN7/Q"NS5JT.-IU;^1?1??(J"6>*1HE<
MR-K#&UQ'?H[R[77V()V!IM?$K*17,JT8*"*MBWX\VA-9<V8-M==-#.FNS2[S
MLCV*Z+A.7RV3S/*8LDVM\O1R)K0^DX[:!%$X#1'G]1)._<GQI0Z'.ILER!U2
MAB)[.-9??CY+43928W,&C(3TZ=.PZ_KW['2YSB?,9,/QRAC8(I<CD[%C)2,;
M+)+(1'%:>T;+6/>=[:T>/L23X\WM?GU_)>I'AN.69KE6G!;NT[$OH31&4D")
MK2WR\!KG>>HUK\^(3N?9>C;Y)+;Q<%JI2R\&-AB@L=9!Z@C _4P [+]^2/)U
M[#:GVN?7*T.5=+@?YN%K,M96%MQKG0!W9P:S3=/(8WN=EHT0-[6BW\3/1ER$
ML.%EGQE%U0RVVV&CM%9 +'M9K9_4TD$C^JDR<FK8OD'(]1Y">Z+E.C'6DL[A
M?+)&"STP?$8(=MQ^^M^3X6>9YU:P^)-K(8&:M)&; E$]AL<6HNOZ)"/J[AWT
M#0+M'VTJ//9FQ:RV5N8^[?AJV.(/R4,7KN:(Y.Q+7AH.FNT!O2NL%S..K%7H
M9:&>-T&#BRGSDCPX6&!C>^ON7 ^^_P C\KMJLKIZT4KXGPN>T.,<FNS-CV.O
M&PN;DYI39?S-%].X+N,E@B,)# ;!F.HS']6B"?SK6COV57C>514I,V7P9FT]
MN8?4='.^(M@/H-D\.[!K(>OD=CO9_)TK_!<JQN8X?%R6)[X,8^%\[G3#3HVL
MV'; W[=3[;]ESI^*F&&/R-L4[TC:,$5E[83%(71O=U!!;(1L'0+20X;'A;I_
MB13JS78[>&S-<T9XHK9?%'JNR4@1RN(>=M._9NW#1V K!O-:9Y-#AI*.0A?/
M/+6@L21M;'+)&TN<&CMWUH'3NO4_8E<F[EEF2AQFQC<O?F9<Y*['S_,5XV.>
MSM)VC( \!O70(T?ROJDK_3B>_JYW4$]6C9/[#]UQG'^?U\G@L?=EQ]QEN_--
M'6I1L#I)!&YVR-D#0:!LD@;\?A7M+D='(<:?F\?ZUJHV-[^D<9$FV;#F=3HA
MP((T?N%PM+XBS2Y/!W;4-R/%W\)+??4BJF5XD:^+3AU!=UZO=YWK_HNJR'/>
M/T,?7O3VWFI-7BN>JR)SA'#)^A[O&P#_ +^#X\%9<[Y,_CV+I&C RSDLE:CH
MTHWG3#+)[.<1YZ@ DZ_'V]U&RN1SO&XGY++6:5W#5JDT]MT-9T4K'L;V:&_6
MX%IT1[;!UY55?Y-R+%</K\LOQT9*7I1V+6-AB=ZD4+]>62]M.<T'9VT ^?;6
MS%Y%SK*8R_R9\,^&=0Q5*O=@9+$]LEH2A^HP_P!37;;  0T[[#POH6$N/R.&
MH79JTE22S!',ZO*-/B+F@ECOW&]?Z*:B(B(B(B(BY_GCBWB&8<" 16=[_P!%
MQOP$<).'V'?<7IF;']XC0)_U(VOJ2(B(B(B(O%HNU*]V#T;<398^S7@.'LYI
MV"/P00""M>6M?(XVU:->S9$,;G^C69WEDT/TL;]W'[!<M>YAA>+U[U/^'W((
ML71CNOBB@  B>XM&MD;.VG?[_==H%%RN/K97&VL??C,M2U&Z&:,.+>S'#1&P
M0?(_!6RC4AHTH*M8.$$+!&P.>YY#0-#;G$D_ZE;U5?P*F>2#.?SOGQ6^4WZI
MZ>GV[:Z^WOYVK72:32:32:32C9&C7R-.2K<C]2O)H/9V(#AO>CH^0?N/8CP=
M@J2FDTFEBYC'';F@G6O(^R\,,1))C82?!^D>5Z8V%G0L:6_C7A:Y:T$IB,L,
M;S$>T9<T'H?R/PJ3F?&V\CQ$E-DL569\D+S8,'J.U'(V0-]QX[-'W]M_U5N:
M-5TQFDK0.G=KM(8QV)'MY]_"U'#XTR>H<=3+^W?MZ#=]OSO7O^ZW/H5)+T=U
M]6!UR-I8R<Q@R-:?<!WN!^RC.P6)=>-UV+HFZ7B0V#79ZG8 @.[:WL;/G]UM
MR6+H91C&9.C5N,8=M;8A;(&G]M@K7=P>*O=/G<92L%D3H&F6!KBV,C18-CPT
MCQI8_P  Q'SE2W_"J/S52/TJ\OH-[0L^S6'7TC]@O&<?P[.G3$X]O24SMU68
M.LA]WCQ^K]_=;\MBZ.8I.J96G!<JN(<8IXP]NQ['1^ZY3,\ QMK)X1]#&XNM
M0IW'W+,#80WUW.C<P>&C6QV[ G[@+L*-2O0J15:4$=>M$WJR*-H:UH_  514
MX=QNG>;<JX'&0VFN<YLL=9C7 N&G$$#[K=C.,87%QSQT,75ACG88Y&AFP6$D
MEFC[,VXGJ/'D^%%K\(XU6PUG%5\+3CQ]EXDFA:S0>X$$$GW\$#7X^RR@X9QZ
MOZ?RV+A@].P+3?2+F:E#>H?X/N 2/]3^5G7XCA*[ZSXJ.G5[+[D1,KSUF?\
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M3#*.M?YICFM:S>B[KV&SK['^BPAX?RJ[P*;B]^IAZ_R5$TZUYKRXVNKFF/P
M#&TA@[>223O[*XQ;\GQR!E^7C&,I7,C;K4Y:U6UWD>WZNTG;K]9&_#/LT.)/
MOJWYIA[^2Y#Q*Y2@9+#CKSK%@N<T=6&-S-@$^3MV_P#1<?QGB6>X[>PV6&.^
M:?5=?AL4V6&=RR>8RLEC+G!H/Z6N!(\#QM2^'<0S7&LWQZQ\G#-%\K=AM".<
M!M0S663 #?EP !;XWY'D@>5:\YQ.5O<HJ6:&-ELUF8B]5=(V6)H$DH9T&G.!
M_P#=GSK7D?OKDKW",_?Q$5.#&?)2-XK'C2Z22(L=89*Q_IGJ\DM<&N&_;ZE<
M9ZCG,]Q'*3?V29C\G=FI>I%'-$Z:3T90]SWNV 6AK=-&R[W\:*B9G#YYF5R4
M%;!6K4,W)*>998CEB:PPL$/9OU/![ QN&B /W6B'%\BKS8/&6..VK$M#D4F0
MER4<D19/"XRGU/+PX._F $$>S/Z!94..WGYO#/NX.P^K!R3(7WA\;2&12B3T
M7ZW_ (G,.O<:]O"HW0Y;C];B=>OA[\V3K3Y69]1E=MD""230<8^[=-(D9H]A
MHAPUY*^@\2@IL^%4N-PU*\14K34_E[4+8YW2@$$.;O6R3OWUY]UQ,G#,U_"H
M*V'Q1HWCQ%M":4!L;9+0?&YT;B#LDAKQV]OJ]UGS/!7LS2SV1Q>!N5(+6"BH
MFD:_5\UKU YNF#_X;=COK7GP=!=-B<'>CY5RAO''28"M9BHN@L'']HW]&2!X
M#7:&_J9O[^/V*J^>86\^YFGS5+&3G?Q.Q2=:AHN/S%DO!8 UH/G?D ;U^R83
MBU&[FLKBCA[%3&93CE6*5[J,D3'3@R=BYQ:!ZK0]A\GML?D'4&/#<BL\$GR&
M1QDDF7K?*XN6M"TB2U2K3_SNOL=2?6=#]30-;WI:^0XJ2U0YC;P>,N?P:V:#
MJE9E&0%UAKQZLD<77;1TT">OD[\^"K:%HEYQDJN8X_DK>7=DX[V,O"-S8F5P
MUK6[E'Z&L_F$L/N3K1)43X4XYXSE&7)5L_#R*C'/#D3- V.N\N.^[I0P&;L=
M%NW$C9/M[W67P<64^*F1FDJ32.@Q$,E1^GMB^:9)(=[\,<]H='[[T'?A<CQV
MHQW#L]8,/(&9D\=GIY&*U6$4)LZT!X:#+*YQ?I^W'1/8[(4;DER1EBO*RG?K
MV:+<08['RLTKI&[9ZGI/ U$P!SFN;Y+G'2V!O\#BS'H5KM:L.3SRY5S*<CRR
MJ]K_ $G:\!T>^CB 2?8_LIK)H*4F.K9J?,7.+RTK8H3SQ2#U+!DV 6M';738
MC[>=;U[A=+AK&3@_]'VI)@63?Q6+#-;"UD9[B0, /4'W(\Z_<+A+V0@CSV?O
M<%%V6'^!U.SV&5T@9\P/7 [>?4]/R=$$?4??RK;D&1GHVLI8P<UN7A'S./==
M?5D>X1L)=ZXC(\AO7TNX;Y&S[$E;Y,KC\;R?B]K'YC*-XO9GR37RVIWM@>70
MQNC9'[;8'%X9O9V':WX7+\>RUO)8WCD=_/Y-I?QJ]9FZY&2-SY62.+'.(<#L
M ;W]PW[C84S'<ESE6K5GQ>4MWLG?X@^^Z.6<S[M-> ',C)T' =O#1YZ^03M;
MY<O*_C5RWC^:2V*-F[CV"6H9XA4+Y V1H?+*]Q<6;+F$Z&@=#:W9*Q49+8JW
M<S;?3QO,(8@Z;)2$PP.A:[ZG]]Z[AVB3X(.B/*ZCC^4G'Q+->6_)?@MSVQ#+
M5O/>QC8__=3UW'499[![?U;&]D[5UCI)Y_C#G&6MAE?$UVU/.OH?(\R$?U<U
MH)_RA1>#<D>.!5GVKHN9J=^0^4BGEW)9,,TNFC[G30T>/8:51\,^1R69&97(
M<KIV:$N,$]R!\W;Y:9KFASWD@"$>7#IX!UL>Q76_$O.RX3B+KU6Q\NR2Q7AD
MN-:'"M%)*UKY?N/#22-^-Z]_9?-;V>_L]G.6RXW+>O!/?QD$]Z6=K_0A=&[L
MXO .@#U;O1UV_HKVU-:ECXBV[EZ^6<SE($4\![ 1_+3$,[Z >6]M=A_0^05I
MDY'F\9Q@YZ3)3RTL9R&S7R+?2B)DIB=T>_T;!;])^G6QO_3+)<EY$^[C,>W*
M18JQE*5G(P27'Q0AA+QZ4.S"\'HP@N;H.))^KPLL=G<_=RF8FL<F97HXS&4L
MB\PTV/A?WA>Z36V=^A+>P'ZO_)<=RSDF8RO"^3XG)WOFHY<-1NP&?T62=GS
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MB(B(B+Y#_P"D!%+*>,&N[J]MN0[)T!_+^Z[+X8TOD.'XZ!G41L8>H!/T@N)
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C1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1"-_G_ '1?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>exh1087_03.jpg
<TEXT>
begin 644 exh1087_03.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" 2; X\! 1$ _\0 '  !  (# 0$!              0% @,& 0<(_\0
M5!   0,# P(% P($ P0( @$5 0(#!  %$082(1,Q!Q0B05$5,F$C<4)2@9$6
M,V(D<J&Q%S0U0X*2P=$()5-C<Q@V-X/A\/$F1%5U=I.SE*2TPL/_V@ ( 0$
M #\ _4%O_P"JHJ32E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*5'M__545(I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E
M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*AVI17!:*A@XJ92E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*5%M?_4&?RG-2J4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*
M4I2HMK_Z@Q_NU*I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*BVL?[ S^V:E4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E1K;Q"9'^FI-*4I2E*4I2E*4I2E*
M4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*Y+4NO+=I^5
M+9DPKO)3$;#DAZ)"6ZTR"-V%+' .,']B*E3]6Q(=RAP3"NC\B0EM:O+Q%N".
M'%;4]4CA'.>_P:Q>UI:FI]TAA,]U^V%*988ANN!K<G<.4I.<IYXI.UO8HEIB
MW(2G)4.2VIYMR&PY(_33C<LA )2E.0"3C!.*D3-5VB+'@/*D+=1.9,E@,,K<
M4MH)"BYM2"0D CDCW [FM\G45KC_ $HN2DE-U6EN&I"5*2\2G<,$# R.>:V3
M;U!A7:W6R2Z4S;@5ICHV*(64H*U<XP,!)[FH4[5]F@W55ODR5)?0XTRXI+2U
M-M.._P"6E:P-J2KC )]Q\BLYVJ;9$GOPM\B1*CI"WVXL9Q\L@C(W[$G;D<@'
MDCVK2YK.Q(C1)'GLLR8_FT+2TLA+&0.JOCT)R1RK'O\ !QA<]<6"UWANVSIW
M2D+<2UOZ2RTAQ0!2A3@&Q*B"#@D'!!J6YJBSMW,0%S )!?$7);7T^L4[@WU,
M;-^/X<Y_%>-ZIL[EV^FHFH,OK*CXV*V%U*=Q;"\;2L#G;G/XJ:;M!%[3:#)1
M]25',H1^=W2"@DJ/P,J _/\ 0U,<6EMM2UJ"4)&2I1P /DU4VS4MHN;4AV'.
M:6W';#KJE H"6R"0YZ@,H(!PH<'!P:\BZFM$J#,F-3FA&B)WR%N M]).W<%*
M"@"$D<@]B.1FLV-16I^WR9S<YGRL4X?6H[>D< X4#R#@@X]\CYK8U?;8Y:WK
MD)T=,%DJ#KRUA"6R#@A6<;2/@U+@RV)\*/+ANI>C2&TNM.)[+0H9!'X((K?2
ME*4I2E*4I46V?]08_P!VI5*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I
M2E*4I2E*4I2E*4I2E*4I2E*4I2E*Y;6R3-<M%D0G(N,Q*I''9AK]1>?W*4(_
M\=<QJ>+:I>LD3=,2WV=8QIL=$IMKJ!+[.4A:74GTEL-DG<.Q'!SQ4;3&I+/:
M?$#Q%?G3V4)7)C%M*3N6[M8"5!"1DJ(4", 'FHMC2NU^'MP@W*\?X7FWB3,F
MP&'-J76&7%$I;"5>_.<#U#=C@UMMKSMDU+8KOJEEF!%=TH(BF2D)0A]"TK6T
M > 2DC"??:1[5K:8=L^B?"F)=B(TEJYQM[;RMJD?H/  Y[8W)'X) KJ-:R6&
MO$#0"'7FT+,N5A*E 'F*XD?W) _<U\ZU>^&_$V=,80/T+I :DV1Q9W7+TX1)
M0G/)02, <?IY5VQ78Z N\'3T[5%LU'-9@W9=VD3"J6X&_,LKP6W$$G!2$@#
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M";TDV'NCZ@$F0E:4DC(STTN''P?S4GQ1>\_=[O*LZ@[:V+=;?..,X+91YO>
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M2TB3#+.V6VZI7<CTK[$*[\_N*Y9BU7]Z%*%LL5TBK?T\EA481%1VD+0^E2F
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M#M\W/;92O)&Q10O:KCX5@_TKY_J2]RM9:'C+G(=:=L<B(U<4'@*G>;;:*?R
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M1;=$:GM!L$F(U;GID2%-@NI5*4E".LYU$. [#NQV*<#G'..0B:!OZ+&F$XB
ME8THY8PH2%']99^X^C[1\\G\5,OFA[W=8]W;"8#)FV"-;4Y?4H)>:6I1SZ/L
M._OWX[4U5HN\ZE<EW=46#$N*6(;<>$X[O;<++_64'% #TG[1CVP3CL-C.F+M
M]0T_-%@MEOZ-U,R3'AO!6Q'04UN4LA.]>5YX' 2!G-=)XB62?>(%I<M/35*M
MES8N"6'%[$OAO(*"KG'"LC\@5R=^T;>IK%\EQX;0DW:[PIOE>JG##3 ;RK/;
MJ*V'.,]QS76^)]JN%^T%=;9:&T*G2VTMH2XH)2!N!5D_L#_6N0NVD+W)&L"S
M!0HW:Z09<?<\@%+;*FRHGG@_ID ?ZA^:O#I":CQ*=N3"VT:?E!N=)9/W*FM
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MG([,WH^5>;4O=U E8!;5N"MW.,=J^A>(-AN%PL-D<M;2)$^RSX]Q1&+FT/\
M3!"D!:NQ(4<$^X&:\U%,N^IM*W:#9K7/M\E^&\VEZ9AA27"CTI2 2223C=P!
MSS7#:NL=QO=IG3;?89<-:M/"VN12T0IQ\N(4E"4CN$!*_7V]8P3SB1J2P/+<
MUBFT6*0F/(^D/Q6VHA0'.BZ%.;1@>H)/;OW'L:WR-/*>N/B5<AICSDF4RV;>
MB5'V!T>5"%I0H84DD[@=I!/&#[USC=NO[<B_NMV.\2K=YBTS2PY#2P9330(>
M;2V.#V3ALY.$\\]^LEV]EV]:5O,32DZ/#-UDOOM+C[G<NL*2'%MY/3!<(X.
M,;C@FJ^PV6<(NF8TJU3&;W:+E(=N,PLK*'F%!PK4',8=ZFYOTC)SQ@8KHO N
MQ,VC05N<=M*[==EH4W)Z[!;>(#BRD**@"0 H8KB+U;;HY:]3L0+3<9,63;IJ
M6O,6]U,MAUQ])+06!AY"U94D\D <D#O-NUK\E-U*BU:<EJM\M-H6A*;>]L!0
MM:G'2A(!<4G*"I.<GL>QK"PL7+Z7$AKMEUPQK,R6RN M&(Q4I8<("0$CU'L
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MDA.5''). /ZD@5F*\J%=[G$M$/S5P=+3'4;:W!)5ZEK"$C !/*E 5-J!>;Q
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MWI$MEMET18WET.J022\XG<07%9Y(Q784I2E*4I2E1'(W4EM/;W $;@4)5Z5
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M7]!3J_Z5?^6O>I_I-8E[G'3<_P#+0O8_@6?_  UYU_\ ZFY_Y:=?_P"IN?\
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MWR^0ZE>_I]7;MQLW\=\XY_%1;;K^\R8[CTG3\1E*YZ[5& G[M\I+Q;PKT<(
M"E;AD^D\<BH-CO=RLLW5[TJ-$7(5>VF%;YB@PPE4=LA6Y2=Q!. $)3G<L "I
M5O\ $FX7:)9E6JP-.2+C%EO['I9;#2H[@0L'T9P2>#C//(')JPAZ^EW>)'=T
M]9%3GOI[%RDL*D!M2$O;MK:#M(4OTJ/)2,#OS4MO7)D:A\A#L\Z5#3.5;W9;
M+3B@TXD'<I6$; V%#:3OR#_#CFK+4&I19KW;+>[%*DW!#W1D%P)0'&T%>Q7'
M&0#@_@URTGQ C7S0LZX0XLL,?2GIDGH2>D]& 4I&T*QPL['"#[;#^,U>J-2W
M=ZQZX@LH7%BVNSL/1Y+<M772I3:U!14 "2=H!Y_A]]QKN-*ZE<NMQG6N5;I$
M*7"88>/5<0OJ(="MI]).#Z%9%<7K?55V=L^LDMQW(J+/.BL,O1I!#J]RV"1@
M 9W)</OCV_-7_P#TBQ&/J3%QM[\*XPY;$,Q5N(45*>1O;.Y)( VY)[XVG&3Q
M70::O[=ZL[D]R,_"#+CC;B'QC&SNI)]TD<@_%4T?7K)M;EVF6N=&LIA*N#$P
M@*2XV% )20/M6H*2I*3W!YQ@BM%V\16K,W<&[K:)K$^'&:F>62I"RXRM80%!
M0.,I40E0[@]LCFHMX\0Y3++T>)8Y35U:N<6 N/(<;X#Y"DJR%$<HR,9X/?BI
MX\0&S/NL9%@O;GTM2T2W&VVUI0H-!P 87E15D  9.2,XS2)XB6N0F>VJ+*1/
MB2V81B#IK6XZZG<A*5)44'C.<J&W:K.,5X[K26+[8K>C3UP9,]^2R[Y@-H4@
M,I.2G*P% ^E6X9!3G&3VGW_4[]JU=8;.BWN/,7!+SCLD*0 VEL#. 5 \9!/X
M[ GM3H\5K MN:XE$E:&(BI[>PMK,AA.-RT@+RD@'.U>U6.<5M7XDPFRTERQ7
M]MQYMYYE"XB4EQIL(*EC*AA.%I/./<=^*W0_$FQ269#Y3.8BM6_ZFA]]C8EY
MC.TJ1SGN0.0.^1D<UT=ANZ;PP^ZF)*B])WI%,@)]7I2H*24J4E22%#D'Y^*A
M:FN*85UTZT9LF-YJ:6@AIE*T/GI+.Q9/VCC=D<^FL]2ZG@Z>Z*98>=?>0XXV
MRPD%90V 5JY(  R.YY) &2<58V>Y1;Q:XEQM[H>ARFDNM+'&4D9''M^U<W<_
M$2PVVYSH4M<U*X+K;4MT0W"U'*\;5+7C 2=PP?\ TJ7_ (QM1N:H*?,K<ZSL
M9M:63L=>;1O6V@^Z@ ?P<$9I#UI9I6GXMX0X^F))2ZMM)847"&@HK.P D8V'
M_@.Y%5B?$_3:FE+"[AQ$3.2CR#VY;!!)<2-O*1@Y5V'S5G<=:6*WAI;\E996
MAEQ3[;*UMM(=.&U.+ PD*/ S\CVYK4C7NGU7=5M$J0)29?D5 PW@A+Y&0@K*
M-H)';GGVS4G1NIV-40I4F-&E1TLR7(^'VE()V+*<\@#.4G([CL>:\8UE8WO,
M*$M:&6&EOJ><8<0TIM*MBE(64A*QNP/23G(QW%4.H_$"+&;MK]MDA#(N[-ON
M")45QMQI*T*5]J@""1M(.#G/%7D?6EBDVANXL2G'6''%LH;3&<+Q6C.]/2V[
M\@ DC;VYJ/>]96QC3BI]KFM2'7X;DN)TV%OA24C[E)1R$@X!)Q@\$BHVE=;P
MY>E;;+O4A+=P7:F[G)0VPO:EL@;EC .0"?8G%9-ZIQK%UAZ3#%@^C(NC;Y04
M%(*]N5*)QC SV'>NAM%YM]W,@0'M[D980\TMM3;C2B H!2% *&001D<BM5^U
M#:-/".J]3F(0D**6BZ<;U 9('YQ[>_M58[X@:3:ML:X.7R&F))2M33A)]01]
MW&,@CX(S4]&J;&NYM6]%SC*EN'8A(5PI6,[ KMOQSMSG'.,5ZYJFQ-2Q%>O$
M%M\K4VE+CR4[EIQN2"3@J&1D#D>]:(NM--2VG7(E\M[Z6MF_I/!1&\$I&![D
M \?BMJ]5V%+<)PW:(43$I5'4EP*#@*@D$8]BH@?OQ4F'?K7,NCMMBSF'9S06
M5LH5D@(4$J_L5 'X)Q46XZNT[;9RX4^]VZ/+0I"%,N2$I4E2\[01G@G&?VYJ
M2Y?[2U=DVMRY1$7%0R(ZG0%GC.,?..<=\<]J]8O]G?@HFL7:WN0EK+:7T24%
MLJ )*0H'&0 3C\&HHU=IOINK&H+/L90EQQ7G6\(0K&U1.[@'(P??(J=(O-LC
M>5\Q<8;7FL>7ZCZ4];.,;,GU9R.WS6'UVTF:F']4@^;4ZIE+'F$;RXD9* G.
M=P!!([XJ#;=7V"Y-S78UUAEJ&\6'7%/("0H8Y!SVR< ^Y!Q5W&>9DL(>C.-N
MLK&4.-J"DJ'R".];<4I2E*8'Q2F*8'Q2E*4KF?$"28ME:6E12HOI2"#C^%7_
M +58:3V_X;MNT8'03@?TJVI2E*4I2E*5Y5#(TW%=O4V9AM4>XLAFX1'6@XW)
M"00E7)X4 =I[@@ 8X!&V/8HUIM3T33;$6VN+  <2UNQ[9(_B(';)^/:MVG[-
M#L=DCVF$"8[*"DE9RI9))4I7R5$DG\DUI:TO8V&8;3%KB,-PWB_'2T@(#+A[
MJ3C&"??YR:,Z7LK%E>M*+>R;:\LN.1UY4A2BH*).2?< _OS6Z\Z?M=Z4RJZ0
MFI"VDJ2A:LA24J&%)R.<$=QV->.Z=M+LQ,IR"RIY,8PQD>D,'NWM[;3\8]A5
M;'T#I>/895F9LT86V40IYD[CN(.1ZB<C![8/'MBO5:$TXJ-&CBWE#,=IQE"6
MY#J,H<(*TKPH;PH@9W9S5Q<+5#N$5J-):/2:4E;?26IHMJ3V*5)((Q^#54SH
MNPL+W,PUH/E5PO3)='Z*SN6G[NZCR5=R><YJ'(\-]+2$!*[<L8::9RF4\DE+
M1RWG"^2GV)Y X!J:_HNQ/HGH=B.J1/=;?DI\TZ XMO&PD;N,;4]OY1\"IU_L
M4"_0FHMS:6XVTZB0TI#BD+;<0<I6E22""#[U67'0M@N-J$"7$<6V)/G>MUW
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M"$C./TUJ*5%. M) 00<8[_FK%OQ/@+<>=3 E/6X1GY34F..H5)9!*@I./1N
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MC:PRVF4RG:I*VBE2%@9/92$G&?Q5;(T7<Y9M4B;J:1(N$&0I\O.14=-8*"@
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M<Q5R6R%)!"RRXDE*A\'"@1^<5S6D-<I&E]/R-1/2)%TO'5+28L):@HH)]("
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MZYN-JB>3I5QF= N$2ZW*1$<=;BK;]"4NJ2$Y5P4EK:<@Y[U<Z*O<R]Z:?FS
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MMK=GD+<8;:+QV#DI SD9Q[5S]EUW:KK+M,=+4R*J[,&1 5(: 3)2!N.T@G!
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M0VY-:V2(YP4O[>$KP?< X)'<$ ]AC!^UP$6AZWVU4>V1GE%I?E$(;.3P0G'
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M/D@U=4I2E*4I2E*4I2E<GXA,*>AVX)4I($O)(&?^Z<'_ +5?V48M<0?#2?\
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M+:"7TDM265XW-KQR.0"%#.#[&H6I-,WG4EG;\],A1[E%EL38;3*5*80XTK<
MM1 4K=R"0!@8P#@DUMUT1=)MR=O"3 3<I-R@S'FB^OIH:B\I0E6S*E*.224C
M&<8.,G6O15^BW==YMKUN,]J\2)[++RU]-QEYI+:D+(3E*@$ @@$>U96O15]C
MJLYF2+8LQ;[)N[Y:+@W!T.82@$>W55W^!S7MNT7>V+1IZWO.V[IVJ\N3RI*U
MY<:*G2 /3PK]7MV&WN<\1K1H*\0K79;,ZY!7;;#,=FPGTNK#LCTN!IMQ.W">
M75;B"K.T<<FM=DT3J"VP;$V(UG<<M]DEVYQ#CRU-./.J2I)(V<H)0-PX^XX!
MQS9Z?T"M$&="N<B9$MJI*7H4*%<WSY5(1A20Z-JBDJ).T\#BI#&GKQIG4]PN
M.G6H]QM]S2UYF+*DJ:<:=;0$!Q*]JMP*1Z@><\@^U;9MHU -1V?4(3"D26&G
MXLF&A90E+3I0I.Q9'J*2VG)(&03@#@5S=FT)=K$[&:8::E-HLDV(XXET)'F'
MW@[A(/.T$%.>.X-82-'Z@59VXR(+9<&D%V(_[0D#KJ"4Y_W<))S66HM):@N,
M>_-L0&4F9IZ-:V2MY!!=0I143\ =0X//VY^*W0])WJ+JI]UVRVN=#G/1Y@G2
M7078#B&VTK3LP=YRWE)!&"<DUA'T??XF@X;$.,PF\VV]*NK;#CXV24]5:]A4
M!Z<I7C\$5;3+5?[HG3LA^TPX+K-Y^I/QV7DJ#" TM&"K ZBU*65$@#CCG&3S
M^F=,ZIA:CBW&?:D)*;9,ARBS-24K6I84@--9"4-G "4X21DE1R,GNM$0[A9?
M#JT0I,)?U*% 0RJ-U$$J<0G& H';@D=\]C[5QM@TYJ&WVWP\0JU$/VEN1$F)
M,AL=(+;"0X""<C@G Y_:H%BTE?XFG95N?TY%^IP+9(A1[BN<7?-E;92@-I*A
MTP3@JSCMP.>-ZM'WP.RUFT]3?HYNS)27FN9(SE/W=N1SVXJ8QIN^,WRS28D*
M3&DH\DU-4X\V]%D--MIWE:"2I+J"%!"D#D[3GOCO],WAR\Q)3KT)<-;$ER,4
M*<2X%;#C<%)X(_Y$$'D5\WTS8KU"F:,:GV*1T[._<.L[O:6G]3<4+3ZLX.<?
M/X%55ITM?(D&R&XZ<G7"$;>];)<!F>([C14\M>\[7 E:%I4 1GV[>U=[K+2T
MRZ>'L2V6Q$9BYV_RS\9O>HM!UDI(1D\E)P0"?P34]JZW6]0U1$62=:WW65I>
M>E+0$L**#C84J)6=Q'(P, G((P>";TY=KA9["W](>A3K-9YEOE;L 2%*9Z2$
M(.<+2I0#F3P,?)XCS=+7$69^-$LSS9<T:;>$); !E DE!Q[Y).??/!-6T6TO
MS;_?K@[II2W?H3#<-N:P %/(ZI*-P^TG<WV(//R#CDTZ?U(Y'N2HUFN9WVJW
MGHR4MM(?5'?W.,)2GA(VY2E*LDC)).<GL;A'+LRPWR-HZ=' O)D/L;$&0K=&
M<:ZBT!6U(WE'.> D$XS5?;K'=%-V6U2K?)1=+;?GITJX%@EI^,I3JU*"^RMZ
M7$HV<JXY&!70^">F6-/Z(@]6U>1NZT*3,4XR$.K(6H@*/N #Q^,5Q=SM-V;L
M>JXL2W7!^'(M<D--.P%"3'D.O ]!"TC#R"5*4% ': ,D9YDW:V.0[K>3:].R
M50%IM#B0W;W=B%(6O>ZEL =1: ILE'.<8(."*\L4&XLM6:&Y:[RGR^KGIF]^
M&1^@4.X<.Q.P#+B>P R3CL<=[X7LOL6J[B3&D1U.7F<\A+[*FRI"WE*2H!0!
MP00<UV-*4I2E*4I2E*4I7+>("%N6Z EM>PF6.?\ [VY5]:N+;%Q_]&G_ )5+
MI2E*4I2E*5\Z>\1'TS]01FK=$WVAN4XXR[,+;Y2T,H5L*.4. $A22H#C/>JK
MQ&U.[<](Z@MZHICYTZW=VWFI"MP*R1L( '8I[YY^*GW/Q#N=DCWENZZ?;:EV
M^ BXLH1-WHD,E6T^K9Z5A1 Q@C\XY/EZ\1KM9UZ@$K3K!194LR)"T3\@LNGT
MX_3Y<&"2G[>#ZNV=&L-3OVF=JN;:(#7U.)"@[9#TM90MMUQ:4GI[=J5).3^<
M\GC%=W>;G,M>G7IZH33TMI()CHD!+8)4 27%)&$@'))'8'BN0C>)+TEJ.F+:
M6Y,IR[FT%+,O],JZ/5#B5J0,I*?P/QNXSTNE-2B\Z<<NDR/Y!4=Q]F2V7.HE
MM3*U)7A0 R/23G KD)FOO\0:;OS42'-ADV)ZYQ9:%K3M3L](*L)VK]22-I4"
M,X4<5O3XB,6F#"B"*]/=BQ87F]BR7<O)3C8G!WD A2LE. 1WYJ]8U9)FSE)M
MMF>EVX2'X8EI=  =:2K)4G'#94DHW9[^V"">9L7B/>'K!8'I6G'9EPO+#\B,
MW%?;2E01ZMIW$8]) ]\D?-7W^/X@<:=5"D"UN7$VI,W<DIZ^=O*<Y"-X*-WS
M^.:TV;Q#1<IT!A5DN$9N;(DQ&77%M$*>8WE2,!1[A"N3@9']:BZ6UDQ]!MS%
MMAWJY3GQ,?$>6\A<A+;+ZD**UYQ]V$I )]AV!-=!J:[M_P#1[<;LXBYQ&3;U
MOJ2T U+9249) 4<)6D<_@BN:7XFPK5 <0JW7:4W;X,25*D*4T2EIU/"R2H;E
M=L@#).:OG]<0F+C>8+D*<'[:TR]C#?\ M273M;Z7KYRKT\[>2*\?UW;F)"@Y
M&FB"B>+:N<$H+*)!XVGU;L!1"-VW&3WQS42V:KB1ESTI-WFRI%Y=@M0W>D5A
MQ* I26_4 &DI!5E1XY_%8W7Q,L]JM[$BX1IT:0XRX^8<D-,/(0A6T\.+2%$D
M' 25%7<9JPUAJKZ-HL7ZVQ7)R'>AT0G">'5)2E1"B./4..^2.PR1A=M<P+6J
M9YF'/+4!#2[@XVA"DPNH,I#F%9)P03L"L @FM^M]2KT]9(T^)#7/\Q*8CIZ:
MD[0''$IW$E0^>/R1G R:YNSZX7!U!>X=Z3<7F3>FH3#@8241 ZTV4(6I.!]Z
MBGC<1D9."";]K7EC<O[%I2\KJOON16GO26UO(SN1P=P.0H9( )! )J5J?5ML
MTXM+<TN./EE<DM,A)6EI'W+()' ^!DGG .#BJG>)FGXBY(*ICS49N.^Z\S'4
MIM#3WV.%7\O(_// .#B6WKFU+:E?I3TR&)#47RJXRDNK6Z 6L ]@H'NHC&#G
M%15:NAW)>G'X-QE0FYD]R*N.N%N+CB$K"F'"?\I0*2<YYVG&1S4SP\N<VZVB
M>Y<G^N\Q<Y<5*]B4Y0V\I">  .P%>6W7E@N!=Z4Q;;;<0SPZ^TIM"XX44EQ)
M(Y&1^_XJFAZY0O6]T9E/OQK)$M3<PIE1%-*2M3A&1D;E9&,#'<D8SQ6J%XAL
M,:FU,F[NR(UI@)@I:2]"6AQMQ\K&" ,D$A&">.:O5:]L"([#[K\EMIPI"U.1
M'4B/N64)ZN4_IY4D@;L?VYJ7_BZRA4P*EK"8B'ENN&.X$ -+"'-J]NU12H@$
M)).:S5JJTIBE\NR1^JICI>3>ZQ6E.X@-;-YPD@YVXQ6H:RL*DQ%,S^NB4EI;
M:V&7'4@.KV-E2DI(1N5D#=CD'X-6=VNL.TLMN3GB@.N!IM"4*6MQ9[)2A(*E
M'@G !X!-<AI'7K4K2ZKKJ!Q#.^7*;8#$=TK<::6H;^D I8P!ZLCCWQFNB3JF
MS+>BM-3T/&4EM32FDJ<00X2&\K2"E.X@@9(S@XJ+9M1L.MW-V;<H3[;5S5!9
M$9M84DX3AI0.2IP9).WC'[&O?\<Z:Z#+WUF+L><6TWR<J6E.Y2,8SN ]N^>.
M_%;'=9Z>;MD:X*NC!AR4+<:<0%*W)0<+5@#("3P2>![UJ8UK97=03[5YI*5P
MHK<MQY0(;V*"U'U8P $I!SG'J'P:F1]4661;Y4UJXL>6BJ"'U*)26U'& 0<$
M$Y&..<C&:J= :J>U3(U"HH9\G N!AQW6TJ27 $)4=P5R% JP>!6^)JR"P[</
MK-XLK+2)RXL8MOX/I0E10O=QU!DY"<@<>]74*[6^=:A<X<QB1;RE2Q(:6%(P
MDD*.1\$'^U<<CQ*MDB?87H\F,W8[BS+<7)DJZ:FRSLP.3@9"P>>:ZJ9J*S0F
M(K\NZ0F690"F%K>2 X#C!2<\CU#GMR/FK"5*8AQER);[3$= RMUU82E(^23P
M*@B_V?Z<W<#=8*8+A*42%/I#:B,Y 43C(P>/P:2-06:,RAV1=[<TTXWUD+<D
MH2%(SC<"3RG) SVYJ$]K"Q,WUJTN7**F2Y$,T$NH" WD8.2?<$D8]DD_O+5J
M*R(9+R[Q;4LA8;*S*0$A1 4$YSWP0<?!J5)N<"*]'9DS8K+L@X90XZE*G3\)
M!//<=JC674%KO;LUNUS69*H;Q8>"%@[5@#/].<9^0:PM>I+/=(TR1"N,9V/$
M=++SH<3M2H''?/;/&??%6;#S3[*7F'$.-*&4K0H%)'R"*TBXP2VZM,R,4-#<
MXH.IP@9(R>>.0?[&LES8K<=N0Y)82PYC8XIP!*L]L'L<UFY(9;>;:<>;2ZYG
M8A2@"K'P/>H5NN+TB9<&9<5,5$=\-,K+Z%]<;0=V!RGDXP>>*GJ=;3NW+0-O
MW9/;]Z\>6I#"UMH+J@DE* 0-QQP,GCFHUMF.2+;&D3H_D7W&PMR.XXE9;/N-
MR3@]^XJ8E*4I 2 $CL!VH5)"@"H J[ GO4./,?=NLR*Y!>:CLH0IN4I22AXJ
MSD) .04XYR/>IM*]]JIKIJ.VVR^VBT2WBF=="X(R,<'8G<K)]OQ\FKBE*4I4
M&WW%,V3.93&E,F([TBMYHH2X=H5N0?XD\]_G-3J5">N2&KO&MY8E*<?;6X'4
MLDM("<<*7V!.>![X-3<UZ*4I2E*4I2E*4KG-9NL-18!DC*3*PGGWZ;G_ *9J
MYM?_ &=&_P#K:?\ E4JE*4I2E*4I7(2M!0)UQ<EW*9.FDHEM-H=4@!E$C/42
ME24A1 !(2%*( /X&(3?AG ,>0S,NUWF(?M@M+G6<:Y825%/VMC!&[O[XYSSF
M3== 1+K N+%QNER?D3HR(;DM72#B64JW;$@-A !.23MR?G@8]NV@XMT5J R+
MI<DB]QVHTH-EH82WD I]&02"H'.1ZCQVK&[: AW1-XZ]RN 5<XK$5PIZ8V!E
M14A2?1WR23['/[5::CTT+[IGZ1)N$M"PIMP2T[.H5H6%A1!&TC(&1C&.*IX/
MAZRQ<_/2+U<I+PN:;KA:64@O!KI'.$=BD]ACVQCWNM/:;8M%IG6Y;RY<:7(?
M?4'0 </**E)XQD94K^]4=N\/E0K#+LYO]RDP%Q'(,5I\((BLK&"!@ K(3@ J
M)P.P[UFWH)4>:)$&^W"(AZ,Q&G,LI0$R0TD)"LD$H44C:2D@X[8/-;K-HI5I
MO<N1%O4Y-I?DKF_3!M"$O+SN._[B@DD[.V>>:T:<T$JS*TX57=Z2BQI?:CH4
MPA(4VX G:<<\ #GW.?VK6SX=M-.&,+BM=C%R^JH@J9!*'LE6T+S_ )>\[MN,
M^V<9SY:M!2H!L9-X:=-LG2I^3#QU5O[\@_J< =1>/Z?',"!X92[8U:'K9J1V
M-=;>)+?F_*)6EYMYPN*2M"E$9"R2"#77WFPJN>C9EA7-=S)AJB+E.IWK.Y.T
MK(R,GDFN4E^&2I-KO4%5W2&[G;XL!2A$Y0&!@*'KYSDY'[5>7+1D>?JBQ7I^
M0L.VUDLN-(&$2<$*;W#/9"QO YYQ\55J\.R?-P1<DFPRKJF[+BJ8RX%[PLMA
M>[&PK2#RG.,C/.:T/^'MQ+KLN+?&HUQ1>'+M$>1%*DHZB-BVEI*_4DIXR"#4
MBXZ)O#MR@7:)J-";NTPY'DNR8*7FGD+7OPEO<-FT]N3P!G/.;O5.FUWK1RK(
MU-+3N&"F2\CJ$EIQ"P5 $9SLYY'>N?N.@9LI5_:3<V!%U"RVFX@L$%#J4A*G
M&ANXW)&-I)P0#D]JOM8Z<=O&FV+;;9#<5<9^.^T74E:3T5I6$JYS@[1SWKG9
MFB;R^+H1,MY<EWJ+=DG8M('1#>4D<]RTGWXR>^*FZ9TA=K%='6&KG#5IX2G)
M;+7EO]I1O45EKJ9QLWJ)S@J(XR*SUCI"?<]30[W:7[7UVXRH;S%SB>8:4@JW
M!20""% Y]^<U4W3P[G2&]1ML3(G_ ,SAPHK;KB2%(\O[J2D;<*^!C%2;WHV]
MS+A=YD27"1]0DPGG(RU.!#J&4%*VE*2,A*L@Y'\N""":KK/H&_V_Z,T7K,8L
M*^O79;<<+93L6%!*4)VG& XKC( P!D]QUVBK)<+-9[E&F+C(D29\J6VIA9<"
M0ZX5C.Y*>058_./SBOGG_19J"2RXB=,M76>M#]N?DI4XMQUQ3B7$NJ*DY/*
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MX(&T?*OR:LXLN[2]6JBZAN4J!?F)D9QEF/$=/78Z2-Z4N!8;#9/5*LCCDYX
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M,4Q3%,4Q3%,4Q3%5VH;1&OUEF6N<7!%EMEIWIG"BD]P#[5,C-=&.TT7%N%M
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ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2N;UL$F'!WK"0)7<IW?\
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MO*8IBF*8IBF*P>:#K2VU[MJ@0=JBDX_!'(KUAEN.RVRRA+;3:0A"$C 2 ,
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M1)]#BVPH_<C;P>2E65#)X^CZ-DVR78T.V2>Y<(9>=P\ZXI:MW445))5S@$D
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M:M],TI2E:TO-+>6TAQ"G4 %: H$I!SC(]LX/]JV4I2O"H;@G(R>0,T40!DG
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M4I_SCUOVIZ:Y& -^X *"20"4 @$CXXJVT583IC3,.S^;,M,4%*'5-A!*2HD
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MVI45N(WM;PM2DY0@YRGID[L J[5$1XC21'N[SD>$ER XVV[!<6MI]DJ?#>%
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MFYNW9QA+"%()&%E(.$C&XGV''YQ-=\1M/,1)TB0_):3#91(=2J,O=TEG"5@
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M#\A8/K0VXE>U6._VX'QD_P!;$Z1L2[4];G;8PN(^M+KJ%DJ*UIQM45$[LC:
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MN2+>+E#,Y:2I+ >25D8"NV?@@_L<U!L^H&'+/YZ[S+5'29#K*7&9:5LG:I0
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MVZ-*=C/1''FTN*8> "VR1G:K'N*A7^]-VGR30:5(FSGBQ%CI4$EQ80I9R3P
M$I42?Q[D@5SKNO)"V%KM^F+O.<8<1'E,LEO?'?4A*]B@5<@!0RH<#([\XZRY
M6^)=(R6+A'2\R%I<"%]@I)RD\>X(!'Y ->6J<N>R\MR'*AEMY;.R0D K"3C>
M,$Y2>X/Q49^^,,:HB6-;+_F),5R4AT!/3VH4E*D]\Y]:?;'YJQ\PUYGR_43U
M]G4V9YVYQG]LU$NMG@79<)=P8ZRH;XDQSO4GIN#("A@CD9/]S5A7.:E=M,2]
MZ=?N<9]R8[*5%A/-DX:<6A1.["@,%*#['M71U60+#:X%UFW.'"::GS2#(? ]
M2\ #W[=AV[X%68KTUY2E*5B%H+BFPI)6D!13GD YP<?T/]C45-QC*NR[:%.>
M;0R)!3TE;=A44@[\;2<@\9S4EYM+S*VG,[%I*3@D'!_(Y%8Q&V68[;45+:&&
MATT(;P$I">-HQVQC&/Q7LJ0W%C.R'R4M-)*UD)*L <G@<FM=MGQKG;XTZ Z'
MHDAM+K3@R M)&0>?Q4G-,TS3-*4I2E*4I2E*4I2E*4I2E*4I2E*4K!+B5+*1
MW'?GM^]9TI2E*4I2L5A1*=IP/>LO:OG.J1U?&#1S>]*2B/+7@ISGT*%?1J4I
M2E*4I2E*4I2E<9XJL/*L,":RUU6[9<XL]]&,GI-N#>0/P"3^P-0M=Z:FWB^6
M>YV)Q 1*:7;;DL*&%07/65 Y[@@A./=S-5FJ;+='IGB W#M$AUFY65B%"4@M
MA+CB4NI(&5#&.JGD@=C^,V$J*_.UQH5MM+K;EJB/R9B#_P!VE;0:0E6#W*MV
M!_H/Q5CJ2PHOVJVF+E;UR+.]:I$1]PXVA2W&E)'?(.&R00."!SFN1-EU5:[%
M/CS67+S(CW6(8\MMM"WUQD;</)2L[2\D9&3QD9.>]1=.:<NBKG93<]/S/*Q+
M[<I;RY?1</2=0YTR0%'<2I:>PQD9_-1;+I6Y1K?I5F)97[=/2;LF0\EH)Z =
M2X&0M:?;U-XQG&WVQ74^%=J>8=CRIEBN5MGQ[<B!)=F2 I+A200&DI)!1]QW
M$#&0!G)Q2WNVWJ1K4R$V.<AAC4$>5_LZ&U-/-);".NI:CN*NPVIPE(3R,\G1
M9M-28+UCE1;(['F)U#/D//"(0I#+B7DM+4<?9ZV^/_8ULTC&N#5\T*U+TY<8
M\VV)F,7*48_Z:G%H'ZO5)]86K*LCW-2/&NW3[B]<6(%GFOK=LRFVI,6-UBXO
MJ[BR200@  *S]RN #D8-7JMB=-C:D:EZ8NDJXS)D*7 DIAES;'26OT]W_=J1
MAS*<]UGY->7J/+=ERV+EIBYR;F=3L3FYB("GD+AAU!3AP [=K8VE.>^?DUD-
M*9TSJN;:[%*9NJ;RXXUMB*:==A%YM:D-)6 %!2$'"<8)R,<\KE:FOI"I%NM]
M\AAR8[-93<K5UF5.]$-J0Y';1EM"]V H#)5N/QFP@1[@G5=CDIM;R'L0F94.
M5"<(C@1P2Y'D#@)05E"DJ)R0KW(ST>O&D'66GG+U;G+AIPQY+;J1'4^VS(.P
MH6M !SZ0M(.."H]JY.R6546Y^'#-[MS[ZVA.3NE1BXIADDF,EU6"$D#  )X-
M=?KYIQ6JM,KN45<O30\PB6V&"\A+Q0.DIQ !RG[P#@@$^W%<7;K0X4Z':OL%
MV0PFZ32T),=3BF82FW0REPD$I'J1@*[9'QPO5M:18O$ER+ =3.D71'0+;"M[
MK>&,[,#*D[@OMQP:N(3T>3KJ=%O\*YJOC=V1(MK\=M82J'M2$CJ ;0V 5E:"
M<$_).*YYR2DA,&2F6&W+Q=>DX\T\\VA.?TTEI.%*4I*OTR2 .2,\"K?P]G+F
MWK0"Y+CRY2-.R&WB\E07OWLC!W#.3TU_OM)K/6[3\3Q#OLFT,._7GM/)-L4E
M"U;GDJ>"]N 4[@DIX/&2GYJPT+)3*UC$=TZ\Z[95V=)N 6M:@B5O&W<#V>QO
MW#OQZN<5I\0+?>CJ>3;K,Y-Z>HX6Q#R9"PB"^PK)6.?3N0K&!C*DC/OBL>4_
M?;5I"\W<28SMVOS#RV.LI'00F,ZWZ<'T JYX(Y< [U&L%];=DVB+=[M(&FTS
M;K%$E4M:4J6AW+"770K/^65E.X\X'? J+;GY\U5GCZBN]P:/T&>^!YYQA3J6
MWT]!Q>TI]6SG/<@<YYJ]\-9ZE:FTT7+M)DN7/3"9<E#TM3@7("VAD()PD@=0
M8 '8Y[&LO$!R.YKRZPI^HKA:F$Z?3,80Q.4R.L'71O2,\D!*?2.#[@US5UU1
M.8=@N72Z/PKM$-H5,0_,4UMZFSK!#*<)V8)WJ7GGC P*[2)]4C:XFZ95+N+\
M2:^W=X\PR5J+,5/^8SNSD#J)2D#W2Z?BN;M$R5+DV)9U)=%)GZ@GV]83.)28
MZ>L4)3^?2C"ON&X8(].-;>I)J+3IR+<M1K@VUZ5<X[MQE.+.5-/%+"%NH6A0
M.W<02H9VC.:W7&7.<D*AN:LN2_+:5?GF4RLQ@\M#FU#VW)X(3G@\COP<5=>'
M$Y,S7EQE3YR_/3;/:WD,J?.'%*;>4O:@GL.3@=LGYJ3J^Y7)&L;W!MUY$0_1
M&G&@\[AIEY4@HR< [2H8&[VSFKSPYGNW.TW1J4)S,F-.<BNM29 ?4PH(02E#
MH^](W9"CSS@\BN T/>E>2TC9_JTA+%RE7 S'DR,N)>0M2FVBHGT;LJ5CNHC\
MFN\T/<)URT))<N;QDNM.2X[<HI \RTAQ:4.<<<I Y'?O[U\RM-YOFD]&Z=EV
MFY2+FU)TX])<@NI;4B(6FD;'$[4@A()VD$G.??V^D>'UQF3KC/+EZ@W* ZPS
M(CML2#(6UNW E3G30,**<A..,'L*YJ^ZNO%ED7^6IY]\(CSG+?TMCL5WHG@*
MP-S;C>%;@>%<\\"M=QONH&+6X]$U+$>0]*MW05'6W*6VAYX-KWJZ*$E*@<@8
M"@4GG%:[E,NTA]N!*O<UU,'5T>$A[#25N-%I#@"PE 2K:HY'&.!D'%?5;2V\
MA^X*<N9G(6_EM!2@>6 2 6\I[\Y///-6-*4I2E*4I2E*4I2E*4I2E*4I2E*A
MQ[?&8G29;2"'Y*DJ<5N/)2G:./;BIE*4I2E*4I0]C7SC5B,^+&EE!80I,:1A
M6/\ 2KBOH]*4I2E*4I2E*4I2HEVN$6U6]V9.<#<=L#<<9)).  !R220 !R20
M*]M24HMS 1#$).W(C )'3S[$)XS\XR,^YJ!<+M+BKN26K--DB*PEUI311B2H
MYRVC)'(P,YXYK4Y<D6YR>Z+)+;:2VW)=?:;1^J59"N K*E( !/N1VSP*G2[H
MTS9E7.,VY.C](/)$;:I2T$9RG) /'/?]JJ(VMK7.T@SJ.UIDSX#A2-D= +J2
M5;=I22.02 1_Z<UTK:BI"5%)02,E)QD?@XK+-,UY5;=+NQ!@W"0AMZ:Y"3N=
MC1$]1[MD)"?<D'.*UW>_P;5;;A,?4XYY".)4AAI.YU#9S@E/<?:KO_*?BI\&
M2W-A1Y3.>D^VEU&X8.%#(S_>M]*56Q[S#D7V7:&U.>>BLH?<2IM0&Q94$D$C
M!Y2>WQ5E599KY O+MQ:@.J6Y D&+(2IM2"EP $C! )&%#GL?:K.O2:\I2E5]
MPO,"W3[?"F2 U)GN%J,C:H]1025$9 P. >^*L*5Z:K+U?;99$(7=9C<9*PI0
MW9/I3C<HX[)&1E1X&1DU8H4E:$J004J&01[BO:52?X=C*U:Y?W5J<D*BHB);
M4E)2A*%J6%#C.[*CSGXJW4PTM>];3:ED ;BD$X!R/^/-55BL:[;*F2Y=PDW&
M7(40'7PD=)K<2EM(2 ,#<>3R??V L$P(B"DHBQTE)W)(; P?D<=^!7H@Q T6
MA%8Z1.XHZ8P3\XKUR%%<65N1F5J(VDJ0"2/BC4.,T\'6H[*'0CIA:4 *",YV
MY^,\XJ,X;5)?FMK\BZ\RD"4D[%*0DIR X.X!'//M2QNVIR%LL3D%41I91MAJ
M06T*SDCT\ \\BL9\"SMV]\3XL!,'>7W0^V@-[SW6K(QG\FI[;3;326FT)0TE
M(2E"1@ #@ #XJ);[1;;<7C;[?#BE[ETL,I1O_P![ Y[G^]>VJTVZT-+:M4")
M!:6HK4B,REL*5\D) R?S6#%EM4>8_*CVV$U*?"DNO(82E;@4<D*(&3GWSWJ*
MC2FGD1!%18K4F,'0^&DQ&P@.#LO&,;OSWK8_INQR$R$OV:W.B0Z'W@N,A75<
M'9:LCE7Y/->62P0[1<;M-C) ?N;X??VI"1D# X'OW))Y))]L 6W41U-F]._&
M=N><?M7I4!C) R<<U[FO$K2HJ"5 E/! /:O<TS3-,TS3-,TS3-,TIFF:4I2E
M*4I2E*4I2E*4I2E*4I2OFU_4IWQLTP@+2 U D+V$9R2" ?[&OI-*4I2E*4I2
ME*4I2N%\6VW50=-.#'E&;_!<E9[=/>0,_P#C**J]>VJX,:VA2;.RI36H(J[-
M-6@?Y/\ &'OW#8=']$CXJBUO;NDCQ)C6Z,XEM5I@MQT,H5A2T%T$(QW(!0"!
M\BNML\J,KQ;U%TW1T_I,12\DXW!3A4>?A*F\X^16GPPZD3P8@*GN)2!$?<"E
M>D!I2UJ;_IL*:Y*+9Y=@T_IZZ:<:+]IN[<!FZPVSPR\"V!(0!V.4[5C]C[''
MMUNC*?$:,O>]&6WJ'R[W42X75MF,H?>,!+)5C:CG)R<^PBZ:A1I2]%&5+FGS
MDFYM3,SWAO92ITMI5Z^$Y"#[9S^>:N-<5R+3IN/J"^3+?9WK=(:8D*;=6I4A
M+ZPE(*2"'0V$%)4"?8=SG[EIN\Q)J3;4RE.W6 PQYQEU.UULK;"@5CMDCG@G
MG-?(M5.0K9$\7"Q-=BW%+K+B-DMQ"P%,LX/W>ZR0/GD#CBIFH7[/;[AXKOF2
M?.2;8AUM'55AQM4;;N2"=JD[E=_8JP*C-WF0_=TVJ3?W;2\ABW.6EMEIQ;DI
M'205!O#@0K*]Z5;DGCN1C(^S6J[P+LS)=MLIN2B,\N.Z6SG8XC[DG\BOSZG5
M?Z3RXNHI"42[%<WTH<N+BI ?00IO?DA*' =V$( P <[@:GJO<^S6U3MLO=P?
MD/Z3C39 =E*DJ;=+J MY*5$[5!M2SP,>D'!P:[#03UF7XJW\6*Z?4&%VF(O<
M9JI.#O<R I2B<8*"1G@J_-4.LI$PW;7SL/4=SC7*TOQ%VV$W+.PK6RV=O3/W
MA:R1MY'/ KUB0_ O5UN,>Z2(ZSK)F*\PAX):+;B&0O>GWR.,GMMXP<UN@7ZZ
MS&;1<69\KZ\]J5RWS;=UR4-L!:TJ;Z6<#8V$KW 9]R>:U:;NEX93I2>W=;C<
M9$QZ[,KC/2-S;P9ZY:3CYRA//?G&<8 L?".]W&[W"W2Y6I8L_P Y;U.28#:E
M.+;=!3E:P3AH@JV[0 #[#WK5KFY7>-=-;2HM\GQTVA%N>C1VUI#84L^K<".4
MD9!'8YYS@8W:CU/,A3=2,"[*9=CWZW,16RX KI.!@N) /)2=SA_'/Q49ZX7X
MRWW$:CN*-NJ_I*4!+)2EA:4YX*.2,\$\#';OF&X9UWU!I^W2[U*0[%U!<H3,
MXALOA"6%%(R4[=W) .WCCXK9&U+J-]Z+I]^ZMM[W+BPQ='W1&5)+#J4-G?TU
MI40"HD #=M[\$*O]+2K]>-7(8F:B*F(MMA3%IA-(Z,E:E.I7@J1NV*" ?;OQ
M@<59ZDN<^9KP:<CW%VT,)M"KBB6ULRMT.[-IWI(*4@;B!WW#/%<[I27.U)K+
M2=RN3[S+LO3+K[S"$(Z:LO,;AA22=J^"><]L$#O=ZI?OCNMU6FU7]VUQ?HKL
MU.V.RM*'4.)2#ZTD[<'D9[=L=ZY:!K75E[0509-MAR(=O@SGD2'0VEQ+C86Z
MM2"TI2D<[1L4G!QWSBK=B=JZ3%U5+@7M+ZX%Q=@183K++>\;F<8<VX"\*6E.
M01N4,@TLNJ+C>Y]JLC=VFPW7U32])=BM(DH6PI #!24EO< O)4 <A/&,\5D/
M56JKRY#CLW5J"M%LN#TAUF,A8=7&D!I+B H'&[OCD<GCMCI]17N=*\#7KYUU
MQK@_9$RU.1\)PM3(4<;@<#)_?'8@\U70[Q=UQY5I@70QI%JL3$YIUUMM9DK6
ME9 6-N A.P)]."=W>KJ]:DN)\('-2P^G#N1M29X2I&]*%%L+*<'^HYKGYNL;
MY99MU@SID62X56WR\E4?8B/YIQ3:BI(/*4[21DY^36G4E]OZ+TY8OJ13Y2\V
MQ"9:&DA3S3Y)V. <924<XQD$9&#SIUU,FKLGB5&#L=I<5<1LO-1TH6\A;39(
M61RHX5C/P,8Q5K<[O/T=J2?%?$-SZO$+MO=9B!M<B<DA'37@^HX+9'XS\5>^
M)4J5;/#:Y27$PIDAAA)=3)8WM.G("O1D>_([X_-4%[U=J&!>M0+;=MRK;:+E
M!BE@QU!QUN1TL^O?@%/5[X.<=AVKIM;W^9:9-FM]K9ZDVYOK:2K:E6Q*&U+4
M0%+0DJX &5?/!Q@T2]97RS,::E:JBP(,.6X_$N);/4++R0LMD*2LI 5L.1ZL
M'C-8RM6ZK<=5$M=HB/7&-"8FR&%E*1^JI1Z>5/)*,)1C=A8*L\ #G7.UM?8]
MTN:FT6I=L@WB);R.FX776WPUR%;]H*>KWP0?@>]QX<SKS.EZH5>)K$EJ/=G8
MS"6V"@MA 3QG<1MP1QC.<DDYXK?\>S2U&NZ6(AL;UY^D=+8OK@=0M=;=G'WC
M.S;V]\\5YX=VU<_4&HKG>!#DS85Y?;8D):4EQL])"<!14?T]JB @Y&>:J=0W
M2=J&9I*[!N"+2-2B-' ;5YA/36ZV5%9.,*+9.T)&..3[6]NUC?[Q;_.Q;8B/
M;ID)Z1'EJ2#T%)&YL*&_U[DY[ 8(QR.:Y335ZF6&TVA5JLR+AJ*=8V9[[C#3
MJC(00-@=P<=12BYEP_CC!X[B#JV\7F:\;):XRHL*1'CS&GWPEY)<0A;A'\(#
M86/G<0H#MSR[&H;K/TVY+U'!B3 SJAN&E =<:Z.V0&P0 .=IVD GG)S\'K(V
MLI3EXN=G=@LHNL:Y-1&6NJ=KK"T=0/$XX]"73CGE&,\UKTEK>;J*? 4S9) M
M$U#JT3 E8#.T^G?N2$G< ?M)P>/S6S4-T;@ZX!1;4/S8UCDS&GU2EH!2EQL*
M;*0"D9R#NP3QBJZWZ_N\B.I;E@84\[8TWN*RS,)+J.-S9.SA7(Q@$'L2*DO^
M)$86UJ=$A&1'>CQ%,D/!)7(DJPVSVP,#E2O8$<&J_5FKE+LNJ[9=[9B9:1'<
M=1&FK0EYIQ0*%H<"0H$$8*2/;O@UTHU/-E7>;'M-F5-AP9K<&2^)*4+2M24J
M6I*"/4E 6C/J&<G&<5#LVN'KM<V&8EBG+@R4O]&7TW0D%O[>H5-A"0O!P0M7
ML#@FND;GRT:>\],MSC<U,<O.06G$NK"PG/32K@*.>,]JX1OQ3"H=P<%I1(?A
M/0FU(B3$NH<$E12G8LI2"H*!!';_ %5:Q==./*<A+M73O8N1MB(GF04*6&NM
MOZFWA(;Y/IR#Q@T\)Y<^9;KZ;IU4R&KS*:Z3D@O])(*<(2L\E(]NW[5W%*4I
M2E*4I2E*4I2E*4I2E*'L:^57M[I>/FF4*4D]2 ^CCVPE9_\ ]:^JTI2E*4I2
ME*4I2E*A7L0#:98O 9-N+9#X? *"C'.<U#M-PB)D1[3&:G IAID(4^TY@-[M
MH"EJYW\?:?5CFIMTN,:UQ#*G.%N.E0"W-I(1GC*L=A\D\#WJ)JE=M18I)O2W
M$VX[4NAO>2L*4 $81ZE;B0,#OG'O42V:OT_+4B/!F [71%VAAQ ;<X ;.4@)
M5R.#@\BNBKPTH0#W%16($=B=)FH2HR9"4I6M2B?2G.U(!X &2<#W)J20#W J
M";K;A=Q:C+C_ %(M]41=PZFS^;;WQ^>U>+N-M%[:MBWV?JG15(;9/WAL$)*A
M\#)Q6Z!;XT#S!BMA"I#RGW3[K60 2?Z #]@*V&+'R%%AK.2K.P=R02?[@?VJ
M#]5M"C/>,J)_\L46Y+BB!Y<[0HA1/;@@U!TW?M-7&?,@V&1$,V.,R&&F^FM'
M./4" >]+3IEN%J2]7=]UF2Y<7FWDI4P 6"AM+8VJR?X4I^.?[5;JMD!6_="B
MG>K<K+2?4>>3QWY/]ZC6PV:Z@W:W(A2B[N:,MI"5%>TE)3N[D @BI MD !L"
M%%_25O1^DGT*R#D<<'(!S^*Q1%MEJ,B6AB'"+IW//!"6]Y^5*XR?WJ'-M^GU
M-NRIT2U%N9MZCSS;>'_=.5$>KL",_%;W;%9I*@Z[:[>ZHI0D+5'024I(*1G'
M8$ @>V!7OT*T=0K^EP-Y=ZY5Y=&2Y_/G'W?GO4>;:-.K+<&9 M15(>+[;#C3
M8+CHY*PG'*AC)(YK?-T_9YUN8@3;5!D06""U'=82IMLC@;4D8']*VQ[1;HUQ
M<N$>#%:G.-AE<A#0"U(&,)*N^!@<?BM=[M5IN;;1O,*'*0V2$&2VE025>DXS
MVSV_-#;;2;BS/,6'YUEOI-O[$[T(_E![@?BN>O.D8MYURS>+H8DF"S 5#3%7
MG.Y2]Q4?8@CT[3Q@G]JO)^G++<+E"GSK9#?G0_\ J[RVP5-XY&#\ \CXK6SI
MJR*A3&6831C3WA*?"5'#KFX*"\Y[Y .1\"CFE;&Y$8C*MK'38=4^T1D*0XK.
MY85G=N.3DYR:]7IBR]9E\P6T+8CJBME*E)"&2,%  . #4EJR6UNPFRHB-_2R
MR8_EB24],@@I_;!Q4![1M@=:C-KMR-L=@QD;7%I*FB<EM9!RM)/)"L@GFK2X
M6R%<+8[;ID9MV"ZCIK8(PDI^,#VJJD:-L,E4Y4F"7_.QVXT@.ON+#C;>-@(*
ML9&,@CG))SDFLG-(6-V N&["*VEOHDJ6IYPNJ=1C:LN;MY(P .>!QVK7*T38
M)3%Q9?A.*:N!;,I DN@.;  C@*X   P,#@?%:'+%<)VJ(KUR$!5DM:P_;PE3
MBY"G2V4$N%7&!N7C&3]O;%7MZM4.]VQ^WW-GK0WQM<;WJ3N&<]TD'VJHG:)L
MDX7 /M2?]O=9?D8E. K6UCIJSNXQM3V_E'Q4W4VG+7J6 W$O$<O-M.)>:4EQ
M3:VUI[*2M)!2?R#6N3I>TR;"S9GXO4@-.-NA"UE1*T+"PHJ)R25#)).3DY[U
M'O\ HVT7VZ,7":W(3*;;Z"U,/K:#[6<])P)(WHR3P?D_)KQ_1EH?5-4XB03,
MEM3GOUU>IYO;L4.>,;4\#CTBIUFL$*T3KG*A%\+N#QD/(6Z5("SW*4G@9]_V
MJ SHNT,W%<IM+X;5,^HF+U3T?,X_S=OS[XSC/.,\U,TYI^-8#/\ */RG?.R5
M2WNNL+RXK )!QD< <=N*I_\ H[LJ;DW+:<GMI:G?4FXR)*@PA\]U!'89R3C\
MG&*RL_A_:+0J6F"[/1&>#H:BJ?W,Q>H,++22,))_.<9.,9.=;WAY:U-V8,3+
MI%>M3'E&)$:3TW"Q@#I*('*>!^1['-;%>']H3?/J45Z?$2M+27X49_9'D=(8
M;*TXR< )'!&0 #GG.D^'=M$9^,W/NC49VYINO22ZC:ET++F!E!].[D@Y/ YX
MJ]5IRVJU8C49:/U1$0PPO/'3*MW;YSD9^#51IG0D'3UR,B)-N+D1M:W(L!Y[
M<Q$4O.XMIQG^)0&2<!1^:L;MIB+<[NNXNR9;3Z[>[;2&BC:&W""H\I)W92"#
MG'':H]GTA%M-UMLV-,EK\C;!:FVW-A"F@4D$D)!W>D?^U0VO#JR,Z6FV)CKL
MQI,I4T.MJ"7&G=X4@H..-FU(''9->7#04:X6R],3+A*<FW<,HDS=J O:T1M2
M$A.T#@YX_B/XQ[_@5I&JY-YC7:X1V9JD.SH#93T9#B  E7;*>PS@\_\ /&S:
M)-BD2EPKO<G+>%.OP[=E!3&=6%;BDD9/W':E1V@DY^1/:L<VYZ$79=13GG)D
MJ,MB1);VH7ZLC/I&W(! ..,@USCWAF^Z7UJU'(6\^(065Q&]F8JRMO:E.,#.
M.,]L]\C;-EZ <>N$RX,7ER+<'+F+G&?:82>@KI=%2""2%I4V #VYY_%76BM.
MNZ<BSVY%R7<'IDQR8XZMI+>%KQD #VXKHJ4I2E*4S2E*4I2E*4I2E*4H>W-?
M(+LW*=_^(BTJ:2A49J LN%0SM&Q8X_.5)_H:^OTI2E*4I2E*4I2E*XGQ142W
MI9A:E"(_?HB)  R%)&Y20?P7$MU7ZEGI1KF]0IEYDVZ -/ID%;<@IZ#G66.H
MD9^[ 2/SV]ZU>'ER?NMIOD+6$AT7F*T(TZ(X>$,]+AT(!(.\$J)'OQ[5>>%B
MGYGAGIE=QW.O*A,J)=&2< %).??A)S_6N?\ #UUAACQ&D2".E'U!*?*M@7LV
M-MJ"@#W((R/R*YS3EZE71B[PI>II$1A=AC3FY:9G5=:=4M8ZA ^U1PC+220-
MP [UFYJ*\N:.=<EWB3:-0,W># GLE22F(-R$%0W9RA:3OR3@YQ[$F4]<;C;;
MA<["[J"XRF!=X[,5];B4.N;V5..,*? PA*<!1(&X#@#)%86C5-XA:5TIJJ=.
MDW&WDOPK@TUM5N47%I8=X R<A*#\[TG%;+O>]0(NDJSO:AAV>=!@1Y:793FT
M.K65*=4$[3U$C;LV@C ^2:O]!R+O=M7ZF<G7N8Y$M=Q5'9B!#26U)4TD^K"-
MQP3QR/SG-0-3SW+5XN7&X,-AUZ)HV1(0@]E*1("@./DBN6O%^EVJ? U+%NSM
MXF*TK(EA)""EM96SE:0D#"<D^DYQT_WJ[DWG4K"66V=20GFY=SMR&%1UHE+0
MR\5A86KI(20HHRG R.1VQ4!%RO$ZX0+?+O\ /_V#5KEM\QAD*=:$=3B2L=/:
M2"..,<]L@$3=839UST-KIN1.<'D;XW':+;;:26O]F(2KT\\K)SWX SCBI>K-
M3W#2EWU T)G599A0%ID/1V\LJ>D+:6ZLH2G( &[!XS^]6-SNUQ@*CP&]4)G/
M2[@E$;H1V3*4T6BKIYP&LY&[<4CT_)(KF]+7N]7[5NAWKA='4J=@SB\VVA 0
MM;3W3W$;>Z@!GX_AQFM^B-67>]1=.6@2D6]^XIN$A4QB.V,EF0I*6T(*=O8Y
M5QG ^237MIU=J>^+M:&IT> IVW3W'R(@6%NQGDMA:,G@*SV[#GOP1VUOGNWW
MPI8N%P2VM^;9P^\ GTE2F<GCXR:^<V9V5I:RV33-YWR[%=78#MJDN#?L47FE
M+BK_ &RHI)]LCVP.L>UA=&URAF.>CJIFS)RWW86&B??[O6>?P.*K&M4:L<FQ
M5(G6SHOZADV0-JAJ.$H#A2Z3O[CI?;[Y[_$5VYWB_7C1RP]":N\>[72#YDL*
M+9#3;J-_3W9Y2GMN[^]2H6N=47#I6>/#AF_H$U#KC026G'&'$M@I2MQ!VDJR
M>21CM\6UEO\ JJZZN1;S]&CQ6(D29*0 IQ0#G42XA"PHI4=R,A7''&#5A+6J
MX^*T>W2=JX5MMB;@VV>Q?<=6V%D?*4H5CXWFJ'_"&GSXE+M!M$'R TXEL-]%
M/ ZQ3G./NQ[]ZYV[V:VN7'QI+L"*ZN+;V%LK6TE2FU""5;DDC(.X Y'OS5M#
MN#T&5;M(:L+<FXQID9VUS7@%&;'Z@&<G_O$#A7R.>>3756-]5N\2;U9&N(+T
M)FY--@C:TLK4VX$CV"MJ58^=Q]S727>SP+P8WU*,W);CK+B&G4A2"HI*<E)X
M/!-?$K/9;=-_^')^\2(K/U'Z9-4IY* DN'>O&[ YP4IQ\8&*ZX:ZN=E$VWW.
M%%>E,I@"'Y7<4J$E9;2%@\DI*2>,;O@9KK=&W2[W&+,%^MPAR([Y;;6E)2F0
MW@$.!))*>Y&"3V[FN1\.+9$UMHM5\U$E4JY7-UY2UJ40J& XI"6VCW;VA(Y3
M@D\FI<S5<^S0KU&M[+%Q1I6&PJ<X^X4.R?T@M10!PG#8W9.<DX'8FM#WB%=!
M.FK:M</Z7$N4.$IU4A75<3(#9!2G;@$!U).3CV'S4=.M-20VKQ)<B6Z8VC42
M;4T@OK;*$J4T@ >DY^[.2>Y/'&*EWC7=XLDJ,Q=;9;T/;XK;S3,E3JEEYP(*
MDX3Z$IRGEP#<20/DV\/5-UNSDEZS6AA^VMRGX?F%R@E25-!0+BD8^PK3MP"5
M8YQ5+I'6]WN-HTY&<B0Y-]ND%=PY?4VT&D[>3A!(45* "0"  >>.<;9XFS[W
M.M46Q:=\P[-AJE+2[,#98+;_ $G4'*<$I/;')R.!5_KW5SNF%P6F8C#KDM+G
M37*?+#2EIV[6M^T@+7D[<X!VGFN5CZFGZ?U?JI:H+DFU?5H++SCLPDQNNRR/
M0DY*@%KR1P ",?CHXFMQ*U8S8),%#*I3DEE!;E[W4=(9W.)2GT;D\CU$\C@5
MR.C)$HQO#!;DV8ZJ1+N/6+LA:^K^G(4-^3ZL$#!.<5W&JIJ6-6:7CEB4Z\\N
M2IGI2BT@K2RHX6G^($=L\ \U1VCQ2:D0XTZ[6=^VV^5;'KFP]UDO%:&MN])2
MGD'"@1\_BM'B!?[Q)\/=1+5;I]FE,,QW8\B/*^\.+3PEQ.,+'(4.0,CD@YJ]
MF:W:A*N*%P75?3[E&MKI#@R2\&]JQQ[=5.1^_>J75NIY,V?IU5I1+;MW^(6X
M*YC3^U+VTJ2X@I'=&Y)&3P2G\\W6G=?0[[>8\*+$?Z$I#BX\D$*2K8<84!R@
MD<C/<?!XJ+K#42['J*8Y&BW&3,C6)^:VR9*41'$H<1DE.<[QN^['VY SFO(&
MOUN2+- =M,A=QEQHTA]"7&P4(=7LWI3N)6D$;E8SM21GWQT&J8<M]@RHUSDP
MV8T9]2FF-H+J\)*"20>$[5<#ON_%<"^Y?6?"+_$S>HIYDKL EK2L(.)!0AP+
M2=O ^\%)!R".V.<KKJ>^Z<E:<G^9D7.T*M?G+I'4A!<0@%L*?04H"CMZF2">
MV?C-=EI6YNW2]Z@4FX>;M[+K(B!(1L"%L-N9"DC)Y4>23Q6FXZ[ML"3)ZK$M
M5OBRD0I-P0E)88>40-JO5NX*D@D)(!4!GOC3'\0H#UU;A?3[FVA5Q5:E27&D
M!I$@ D)SNR<X/*00/?&:FZEU$_;-0V&T1[?(D&Z%X*>:4V"T$(SD!:ADY*3[
MC /<USGA[K@/0($*_.35SI$B<A$YYD(9<Z+KIV[A@9#:1V&.",Y!%7^F-=V;
M4=T^GP%NB2J,)C8<"<.,[MN\;2<<D>E6%<CBH5TU;$L-^U$]<9=Q7%@1(SJX
MHC)*&@I2T[T*'*MQ&#GMM_M(5X@6=J#=)<MJ?%:MKC2)(?CE*D)< *',=]IS
M[\CW JRGZIMT*3(CN=9;[3C3"4(1DO.N)*D-HYP58!)^!R<#FJB9JR'<&K4N
MWW61;U*NZ8+[1A]1:G!G='<R/T\\'=\=LYJ>WK:QKD],R7$-$/J1)6TI+*^A
M_F[5D8.WGGL<'&<5*L.I[;?)<F+#4\F5'0AU;3S2FU;%YVJ /<'!'X(P<5JE
MZNM$6X>4>?<XDIAJ?2TI3*'U8VM*6!@*.1W]R!W.*C6S7=AN=RCP8;\A3K[[
ML9"E17$(ZK8)6V5*2 % ))P><"H.BM8MS8-M8O4G%UN$N:Q&"6%!#@9>=&-P
M&T$(1GD@FNF;NL69:9,V*\L,-%U!<+*\I4V5)5Z2 3@I/8<XXKAWM5S7V=*V
MN!<5KFW>"N6+FBVK4A6$IV$(P0D$K25?R@<[=P-?18H=$=H22@O[!U"@$)*L
M<XS[9K;2E*4I2E*4I2E*'M7S53;LGQO4L*;#4:U#(4<'*UD<?/V<_P!*^E4I
M2E*4I2E*4I2HHN$3ZG].\RSY_H^8\OO&_I[MN_;WQGC/S4JJO4[%KD6.4W?G
M&6K=@%QUUP-AO!!2K>2-I!P0?8XJ3'B,JAMH>4)F6PE3SJ4E3HQW.  <_@ 5
M7Z@AVN2QY.=):AF>>B=JT-N2 <!30)&3N  .WG'8BKAEIMEI#32$H;0D)2E(
MP$@< "M,6!#B%PQ8L=DN<KZ;83O_ 'QWJ.JTVEA!<-O@MI0C!464 )3G=C..
M!D9_?FJ;5.FK?JZUM=!R%L<D,2EOAA+R9"6U!00K!&Y)P!W[5<&PVCR#<(VN
M 8;:^JACRZ.FE><[@G& <D\U5R=+ARY1?+RFXED9<3(7;&(J$)=?2K>'"L<_
M=M./<I'YJTN<"TOOQIETB0''F%@,/R&T%3:B1C:I0R#G&,>];X5M@P7I#L*%
M&CNR5;WUM-)0IU7RH@>H\GD_-8*M-N-Q-P,"(9^W9YDLIZNWXW8SC\5 MNF-
M.1%K=MUFM32SO0I;,9L'U<+3D#L>Q%(6F-.M6X185GMB875ZP0TPC;U!_&,#
M[A\]Q7KFE+ ZA]#UG@N(?D"6ZEQE*@MX?]X0>ZN3S1_2=AD-3&G[3#<:FNAZ
M2A38(>6.RE#W(K<]IZT/N2G'[='>7*8$9]3J-Y=:'9"L]Q4,Z*TR;6W;18K>
MF V\)*6$LA*0YVW8'OCC\CCM7L;1FG8PA"/9XC0A.+>C!",=):R"HC]R ?Z#
MX%9JTE83%C1T6QAIJ*XMUCHY;+*E?<4*204YR<X/.3FLAI2R)?8>;@(:6Q&5
M#:Z2U("&5=T  @ '_G@]P*EQK-!C65-H88*+<EKH)9#BO2C&-H.<@8X[]J\-
MEMZK=%@+C)<B15MN,(6HJZ:FU!2""3G@@8Y]L=JJYNAM.S;J[<I-N"YCCR)"
MG \XG]5 PE8 5@*  Y !XYK-O1EB;,<HBO L357%O_:WN)"@07#Z^2<G.<CD
M_)K%&B+"AEIM$5]/2E.36W$S'@XAYS.]25[]PW9.0#@Y/'-87'0>FKC"@Q95
MK3TX)4J.IMUQIQ!5]QWI4%'=DDY)R>3DU86S3EKMES>N$&,IF2ZPW&40ZLI#
M3?V)""=J0.<8 [GY-:;A9%*U1 OL)3:933*H<A+F<.QU*"L CLI*AD>QR1QG
M(DBQ6\:A-\Z3OU,L>6+O7<V]/.=NS=M[\]N_-5C^B;2^]J!UQ4S??6PU/Q(4
M XD)V@#^7T^GCV-6DRQP)HMIF,]=VW.I>C.K.5H6D8SG\CO\U2HTBFX2[S.O
M;BQ*N0::"8CRD%AEI6Y"$K&%9*LJ4>,YQV'/6.HWMK0%*05 C<GN/R*YEC1%
MG9T:YI9")'T5:2CHETDA)5N("N_<D_UK1</#^S7$W(SU3'S/:8965/8+89.6
MRV0!M(.3D>Y.:NM/62/8X:F&'I<E:U;W'Y;Q==<. !N4?@ #^E5;6BH$:5.<
MMLRY6]B<X79$6*_M:6LG*E $$H*O<H*:PFZ$M$F5)=:,F(W+CMQ)<>.L):DM
M(&$H6D@_P^G*<';QFDK0EL?-Q/F)K:9TIB8M#:D!*'&=O3VC;P!L1Q[[1^<Z
M9'A_;WGIBQ<+FVF3/1<BVEU&Q#Z2E04D%!_B2D\Y[8X!(..HO#V!?+A<);ER
MND4SC'6\W&<0E)6PK+:QE!.1\9Q[XR :VV[0=MM]\DW"-+N269#YEK@=<>6Z
MY3@N[<9W'OR<9YQP,1[=X=0K:S9Q!NMU9DVIMQB-*"FBYT5@9:4"WM4D8!&1
MD'G-3++H:VV6\6^?!D34F%#<A(94M*FUI6OJ+6K*<E94,D@C]JEZMTTG4<5<
M9V?)CQG6'(S[*$H4AU"\9)"DG"QM]*AVR>#53+\/8+L2Y,,3YK0G28LI6=B@
M@QP@-I'ISMPVC.3DX[]ZPMWA\B!>HD]B\SBF)+DRV8ZFVBA)?R7$D[=Q!*O<
M]N!\ULLNA$VMK3;:;F\\FQOOO,[VD@N=5*DE*L? 6K&/Q\<W%]L*KE>K/<FY
M98>MBG5-IZ86E9<1L.[D=@3C'O7.,^&D,6RUVZ3.>?AP+=(M@24!*EMO8W$D
M?Q#:G''L?GC8-!27])S++==23YZGVVF$R7&TA33;:MR0$]BK/=2LDX'Q6-Y\
M/W;C<KC(:OCT:/.E19SL=,="AUV-F%;CS@AM/'R._<'3_P!'4AN=&3&O[R+1
M&NWU=J"N,E10X5%11U,@[-RE'&,\]ZM-):/E:=D(:3?Y<JSQU+5$@+;2.CN)
MX4X/4L)!( / R/@8W:ATD;U>9$UR;TFWK3(M732UDA+Q22O=N[@I'&/FJF3H
M&5.BV6/<+K'>3;C&4EX0MKS:FE9):6%^C> $G(5P/FNSO<5^;:)D6&\VQ(>:
M4VAUQLN)02,9*01G^XKF'=(37/"X:1-QCAT01;_-^65CIA(1G9O^[:/YL9YQ
M[5-@6"6Q=K?)DR8;L>-;C 4RF*4E>2@E0.X@#T#TX_KVKS1&CX>D#=F[:XLP
MYLGS#;"NT<; G8DY^WCCX''M5)+\/')*;U;53VO\/7:XIN<ACHGK)<WI6M"5
MYQM4I"3DC(&1[@C,Z"DJZ>^XQE!&H3?@#&/?G]/[_;.=WX[5=ZFL4RXWRP72
MW2F&7K:X[N2^V5A:'$;58P1A0P,>U<Q!\/K@F#88DV7$6U D3W7RT% N)E!P
M$)R."GK*[_ JZT'IR]V%IB-=KK#F0X<?RL41XO26M(QA3I*CE0"0!C Y.<\5
M7ZNT3<;Y-U(ZU*B-(ND*-#:W;B6^DXI94KCG.\CCM@59)THN3==6.70L.0+[
M':84T@G<@);*#W'.=Q.?;%4L?P^G1M,6!I%P:D7^U3D7!4EX$-R5A)04JP,@
M=/"0<$C:.];9&C+HM4>2AR"93M^1>I:2XM*$!" @-MG:2H[0,J.,G/ S@:;5
MH>_,:?N&EI5VA_X;6U)9CN-M*,DH=2H)0YN].$%9.1R=J>PR#>:"L5UL[*A>
M4V5+B&D,(-MCEOJ!/=:R1G)X](X&#WSQ32]"7%]N[6GS$55CN5W1=7'2M8D-
MC>AQ;0&,'*D !6X8!/!P*QMFC+U#=LBE&VJ$"]2[BO#Z\J;>ZF /1]PZI_'I
M'//%3>K6BU:6MNF9$YMK5;ER=N%I,5*G"%JDJ7NY2 $I2X0K./3FOI7TL0],
M*MEO2%%N*66NHK&Y6W *E8/)/)/Y-<AI[2]ZMTS0RI#4,M66U.0)*D2"25J#
M:04C:,C]('DC[OQS]%I2E*4I2E*4I2E*$ @@]J^7/K2GQPCI6RIX.6_:-K>=
MN 3N)]LYQ_:OJ-*4I2E*4I2H=X6ZU:9KC#A:=0RM2%@ [2 2#@\5\J@ZBU.+
M5HY<J]L./:C92[O6VU&#"@SOV)44+!*RH=TGE) QGB0C4]^?\U;9EWB1;C;;
M*Y-<>@H2M,MY+CB,I+B,;$],;@$CU*X.!S!@:SODBSRG9%V2PY_A&/>4NEMH
M;)!*]Q *<%*MJ00>V>,9&-U\U3>HL:XS&);29"-)M71M?ET$H=*O4,D<I.WL
M>.:W3[SK.'<H5A1<X<RZS8CMP0^$-Q4IP4A+*0H+WI2=Q/\ $01R,<P-87ZZ
M:CT9K&(N?'ANVVS,.OM14I<1(4ZR5N<J!.PCTI(P<Y.3VKNM77Y_3VC8,J*$
M=9YV+$2M9 2WU%I05'/' )[\?/%<S>)5W?<TZS?C%5(CZH92V65@JZ19<4D.
M <!>#[=Q@\9J+)\0KO;&[L;ETV;@RPEUJ(\T R4+DH:0^V\DX6V X,Y(.?\
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MA:=N0H%.-I /)/8$UOM>I8PB2WYUS9E#ZB]$81&BN!P%!/Z/3Y4M:0E62!C
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M2I6>JHI.Q"E E.,X'OFLD7W6!UBG3BG["F6;*+FI8A.E(=ZG3+?^=]N?XO\
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MBH4\&VU$(4LJ4O!P,)/L<D@5M9U TQ&M OC:+7<;BHMMPUO)<4%A)40%)X(
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MV^M7PW,-1WF# FKA+#NW*E)2DDC!(QZJMZKY]U9C,W LMNS),)D/+BQD[G5
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M(2I)3GW)[$FIVF+1-_QJXB\0K^;C'NS\UF4$H1#6RYNPKJ!.X^@A'3*O9/
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MH_)P:["W3HESA-3+?)9E1'1EMYE84A8SC@C@]JX/QV0VWX>3%A*$*7,AE2L
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MML-';M[)(!]/&#G@D>YJLA: TU"NC%PC6WIR6%N.,X?=Z;1<SOVM[MB0K)R
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MB0F0B'*?;4V$)4"$],$E7322=N><#CC!KGK)=843P>1I^2R$7QJW*MR[0?\
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M:N,RD1TB0Z.H"$C*REO:,\>H<'%7_A,T^U<M;B3*=EJ%Z4V'W=N]82RV!G:
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MGQT$*"B@)*DY)[8'?V%5\WP_FWB/)7>KHR9QLJ[.RY&9*$C?]SJ@3R20/2,
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M*4I2E*4I2N=\0M.JU9HVZ61$@1ERVPE+I3N"2%!0R/C(KF[UHF[W9O5/7EP
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M%VN$WIW.;#:0Y.6\RED/ HPDDC( &%=\*/MBH%OD*1:/%=^YK;:>3-D-[G%
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MH?=:#3R4D;'@/M*@1W3DX(QP<'/&)Z6TH^Q*4_L,5JD1(\E39D,-.EL[D%:
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M2E*JY-PEIN;,:)!4\SO"7WBH)#8([@'[OZ?-6E*4I2E*4KBYIW>*5H0IP_\
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ME*4I2E*4I2E:949F5'=8DMI=9=24+0H9"@>X-91V6X[#;+* AIM(0E([  8
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MK/!XS_RJ#=;NQ;F&5E+DAZ0K9'88 4M]6"<)Y [ DDD  9)JN5J)V-*:;N<
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M7-\LLQ4.JQM0IW&T$Y'X!X)!J]NUQC6FWNS9JEI8;P#L0I:B20E("4@DDD@
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M*4I2E*4KRF*8IBF*8IBF*8IB@2!V IM&,8&/BO0,# KS'.<<UX$)"RL)&X@
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MV\//PW&"^E"48<(&<IVG^($$8SW%4Z?$&T*C1I"6IRF9-M5=65)9SO93MW
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M"R\SMV.H5MR%#8G\=^.1C-O1*52+5*G7JY3)D"5YLO.!H==804 * 1@)"5*
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/E*4I2E*4I2E*\  ["O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>exh1087_04.jpg
<TEXT>
begin 644 exh1087_04.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" 2; X\! 1$ _\0 '  !  (# 0$!              4& 0($ P<(_\0
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MHYSHCW=/6UI^'97#FUB&+T@<!;)+&QWK=KLYP![U9&C[[B /K("^><Y@=_\
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MNLN#*\ C<Z:9Q\FMC ZB?N=O>O+#<QP^6O6:%>>:+)5V>)+2LP/AG#?SPC<
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MT0QQ#6C>R2= ?:?)1F5YIS;"93CIRV QK,7D;D&.D\.9SI_%>#M[6@D!O9Q
M.SH=]$]LVO2A/'FK4D=2'Y"J9R/ S.>UWC.E<#U2-.]=+7:'3K9'???2G:_,
M;G_Q&R_'[E.O%2H8WU\2QR%[Y/: ]X ';?;OW]Z@>$^DN_F<IQ>/)4ZK*G)(
M+,E0U^KJ@?"YVV/))ZO9 .P&]SK2^KZ0(@1$1$1$1$1$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$4=G; K5&2$Z >/W"O?%G_Y?7^M@/[2ZD1$1$1$4'EN
M58?$V_5LAD:U>?0/0]W?1WW/P\C]Y4;TFV>,\YP$>*?RFC2B;.V=SPWQ'$MW
MH#N->?UJNY3"\>R>2Y%E['/8H\WEJHILL56B*.O&.CL&=1)V& ';O(GW]UY8
M/!<>Q3LX&\QPD\.5%82UI*($);$QS>@L#Q[)ZM]B"" =DKQJ\8XUBIN/W,%S
MK'U,ABF31%\\?CQ21R/<[H#'/]D#K('<_?[J[\IS''LWP>WQ]G+<=')9K^KO
MMRD/)'D7=(+1L_<"Y<)/Q>KZ-AQ"_P HQUF'U-])T\+A&2QP(WHDZ/?XJNQ8
MS&#T<V^)V?2!B98WPMK0R^K,9X<8>'>T!)MSNV@=@ >XGNIWDKL!FJO$86<N
MQ,+L#;@MDGI<)W1 #0'6.D'O\5"8WC'%8'T:,W*L2[ 8^]/?KU_%:V5SI&Z#
M'.ZM:9LZ('?MY:[[<7X_0P^7XM9?SC!3U..^LQ58^EO7+%-U?3=X@ < [0T-
M=M]]J_\ %N05J=&://<NP^2LNGD?'+')'%TQ$^RP@'N0/?\ _P!32*7$,#!F
M*9CY)AG82GF),U##XS?$\5S6ZC)ZM=+7#8/GH ?6I$X7$2<CN<E.0XQ!G&UY
M(\='6E8V.*5[2#+*_P"E(\DZWH:'D-]TR7'L=5N<9O<?S.(CO82E)0#;4X F
M8^/IZBX;(<"2[R.]GRWM<63XE2^8/&N,8?D&)8S$VH[CYYYFGQGM+G$!H/8%
MSR?/MY?6K8^7IR'(<I5R^(&3N015J)DG:YD#&-)'5W[_ )(^0D#S ;]RA4.%
MY7)\6S>$Y;RO!35KC"^%U4MZO63('F:0Z!<=M \_(D=NRM&"P7J.0Y5FGY##
MOS>9@BKQ1-LDPQ-CA$8V[I!.R.H]O<!]:C:'"[T7HOP7''9+$2V,3=9:?&)W
M&"ZQLCW^%(=; /4/<X;:.RG?1EQ6'BU//,GFIP,RMQ]AM.G.3'681H,:_P!D
M[^L :[:\E,UN*X.*>.6&SDG21N#P'9NVX;!WW!E((^HC2B^=<;MY/D>'SN)=
M0ELTH+-62O:F+&21RQEH/4 ?(^[7<$]PJ3/Z)+-?#T\6R;'Y>C#AY:+8K=@Q
M"O:?*9?6(]-=[SKXZ&MZ[*R<>XMR3C?'[@QN0Q5K.,K5:5.6VY[HO!B&W!VN
MXVY\NO/L&;7=QOB^0KY[.<DOT\;6R>1IQU?5J,SG1.<W9=(YY8.[B1[NP;YD
MJ)X-P7-8;@F#XUDO4WQP9/UJX^&8N:^)KC*T#8![R",$?#:<II>D7(<XBMX[
M&848FJ[PZDEB4ODA#NSYVMWKQ"-ZV#H=@.[M\UKT;9:3(W:#?5SB+7)6<@=9
M\3VVMUM\73KZ74  ?+1WO?93^.P>;C],64Y!/0C;BK&/;1C>)FEQ+7!W46[\
MCHC[VUY\8]'L-/F4?()*5?&P4XGQ8_'5Y'/9$9-F25P^BUQWKI9V ]Y7T7J<
M?(#[Z=>O/6TZ_AK:=1]^@L]2R#]BSM-HB;3:(40(B;3:% FTVFTVFTVFTV@1
M$1$1$1$1$1$1$1$1$1$1$1$1$59]($KH<+$6:V9VCO\ VKE-XH[QU77]3;^X
MNM$1$1$1%6<9WY]G=_UI5_=E6.<9F_A689V.%4F[DH*,GCQN=TMD)'4-.'<:
M4;E,QR2IR'"X]SL3"S*VK,,?56?(Z)D;'O:XD2@.+@P=M#75[]+R9G.2'EU?
M!69<+4>[&F[)(8))/:$OAZ:/$;V(]KOW'EW\UP<BY_D.-P\=M9*G4LT+[W^M
M3U]@10B1K6SMV3[+FR1GI/<;/<J4YQRZSA\]Q_#XB"O+9R-F..>:9I>RO&_J
M#20' DN+7:[_ )ARN_2/@$+&GS:/O+4P1$:=$PCZVA8%>$>4,8^QH6CJ-5Q)
M=6@)/F3&%J<=2=]*G6(^N)OX%YNQ&-<=NQ],GZX6_@59](6(QK.. LQ]-I-R
MJ.T#1V,[-^Y35G$8:M4GL28FDYL3'/(;6820!OMV5-XQD:W(JF)O5.*X!^/R
M3)"V6*9LCH'AA<UDH\$=).M'1.C\>V],+E<?E?1=/R]O$<2V1D,\[*0#7=38
MBX$=?A]B>@_F3[EID+C(.4WL+7X1@+,]3&LR+W>*UI>"XM+&[A\]M=HD@'MY
M;[<M+-X/,6\7!@N&XNX<CC'92(3".$]+7!IC/Y&1U=1T.^OK"VQ66XOFK?$6
M4>)8TP<AAL2QR2Q,:Z P_P T:YH8=]SH:/?ZE-\MQV"P)Q(AXIBK7RA=91V6
M-B$;G[Z7'V#L=CY=_)1<,..NYSD.,H<*P4K\*Z-LKI9@SQ.N/Q&]/Y$1Y=CL
MCO\ ?6)F<>FRD^.QW#,;/D*U**]8K3-C@D#7[TUC2T]3AKOOI ) WW5DH\2X
MM<QM>X>/8V*.:)LVGUF M! /?[% WJG#\=P23E-WC-%E-L/K#8V0-+WL<[4?
MF!HN!:='RWKW+QL8[ TZ64LW^$T8Q1H_*'5%(R1DT>G$AC@![0#?(@#9&B1W
M7OA<5A,G6QEF/A$45?(P>/#+U-<&@Q];0_I^CL=M^6]#WA0_';_#LQ%@+$W$
M7TZN<>^*E,XM<TO9U;:X-=MI/2==B.W?2E\'B^,Y3E&:P4O%8:EK&"-[G2N!
M;,Q^^E[-'N.WW#V\U&[XTVK@ISQ")K,S=-*M^2CW;U(>_P! AI(([ZUV[J0^
M3N.6;61CPW$3DHL=(Z&Q-"YK&F5HVZ./J<.MP]_D-]M_#@C;A+&5HT:/!IIY
M;>.CR;/R=D9;$[I!#@YXTX%P!"D9ZG&XI,759QBRW)9%U@0TI)1$X"$Z>YQZ
MRW7T=:)WU ^6R)/CO'N.9K&B[%A+-,^++"Z&Q(YLC'1R.8X'I<1YM/D3L*5;
MPK!_F:LK?LLRC_>6#PC"'?Y#:'V6YA_OH.$8<'V?7V_6+\WXR'A>*!_IF[Z_
ME&;\=8^9>+]WRD#\3D9_QT^96-_JF1_TC8_'3YEXW^JY/_2,_P".L?,K'?U;
M)_Z2L?CH>%X\?_?ROW,E8_&6_P SJ.NUS+C[,E/^.L?,ZG[KV9_TC-^.LCB-
M0=O7\U_I&;\9'\3@:!T9',@['],I3_&H/$8)UO,9RM)F,TV.I8B9$&WGG0,4
M;CO?U[7OEL3C\5)6BLY_D)LV7%L%>*V^264@;/2T G0'F?(>\K@=\CBG:F^7
M^3F6K*R":H)9?6&O>=,'A=/4=[V"!HC9'8+DI7\'<L.B@SO+^J.R^G(2)^F*
M9HV8W.Z-=7EH;V=CXKMIRX.YQQV>J\HY#-B@_P /Q622D]75T:Z.CJ/M=O)3
MAXT!!XQS_(8XNGK)=:#=#6^X(V/NJ(R+,?C..PYS(<CY-5Q\K8W![I"\MZ]=
M/4UK'$>8'EYD!=&1I5\<ZBVWR3DS7WG%E=C>I[GN#"\MTV(D'I:XZ.O(_!>&
M/CHY'$6LI1Y=R*6G5=(R<M(ZXG,^FTQF+KZA\-;7D+&+_P";;YMR)ALU#>BZ
MVL:70 ;+^\'8 =SORV/B%H;^+9)+&[FO(VOA8)90^$ QL.].=N#V0='N?@58
M_FU>]W*,[_Z?^361QS(#Z/*,U_YA7/\ PU"9BGF*6>P5*/DV5,=Z:1CR8X"0
M&1.>-?D?Q:/OKNS56UA,;+?R/,,I6J0]Y)705W!@^)U#V'UKG?X[<?2OOYOD
MHZEQS&5Y'58 )"[Z/_V??[M^?;XA;8QEW*,L/QW.)+3*SS'-X4%=YC<!LM<
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MT=?E6A_N]@_[>169$1$1<6&_H53_ +DW?WEVHB(B(B(JO@A_TXY,?TE8;_\
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MFDTFDTFDTB(B*J<@_+SQ3^VM?P15K1$1$1$1%S9(ZQUDC^IN_<4/Z/!K@V!
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MZ"YKPUKO-CG-(T]O<%?+>0<QR^*QG+K)Y#D1=QN4=6HQ/Q\3ZSVAL9#))!$
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MI3Q/TI6!(=_1=]Y9,FOS)3Q/TI1KR?<1]HTMMIM8+M>XE.KMY)U_I2L&3O\
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M/[<2LHE_2N^Z-+/B?I2GB?I2GB?I2L]?U%"[7NVL>)^E*P9/TKOO)XI_./\
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M*/PK7Q.9CSCP&O[:;\"V;)S)W_VL!^N3#_=6>OF/]1P!_P +-^*LF7F&NU;
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M4!L4G9[>SN^QYD]^P^ UP\@X!CK&"GK86%E>WZBW&Q.FGF=&*P<"82.KR(V
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M'W'2CQ6,!)#6:'2T;)/8>9WYZ7!=X)B;> Q6)<^W%#C)6S5IHI R9KV[]KK
MWL[.SYG??:E<]@X\WC&4;-R[%&US7.?7E$;Y.GW.('<$]R-:/V=E&V.%4K%%
MD-F]E)K$5IMR"Y+9ZYH)6C0+"1H#6^VB#L[!77C>*XNCCI*KH?6W2R232SVF
MM?+)(\^T\G6MGMY     :"@Y/1Q2%/"U:6:S="'$0>#7;5EB;LZT9';C.WD=
MM_#>M;.[)%AO"X\<5'D<B"8W1FZ90ZQL[)?U$:ZNY[Z[>[2@<5Z/:%+&V<;:
MR>7R>-GJNJ&K=G:Z-C':V6AK6Z=V^EYCW>:EL-QJOBYKUEENW8R%R..*2Y.6
M&0,8TA@&FAO;;C]'N2=[4;\PL>WB>+P4=N\(\5-'8HVB6&6"2/?2?H])\R.X
M[@E2_&,!7X_6ML@DDFFN67W+,TF@Z65^MNT  .P   \@O?/XF+-X\4K+WL@,
MT4KPS7MACVOZ#]1Z='ZB5RYK!SY.XV1N:R%2HZ$PS5(/##)0=]^HM+FGOK;2
M#KRT>Z[&XJG##&VI6@@DAB$4$@B:3$ --UOW >Y5?)>CZOD>-18RQD[?K<=X
M9 9-K6"SXP.P_>M ZTWL/H@!6>3$U+$+VW8(+$TD1BEF,0:^0%O2>X\MCLH/
MC_#68>S!9]?EMSTZ7R?0=.P$00[!T=:ZW>RT$[&PT>7<GICXRZO!E9J61F@S
M61<U\N2,;'O'3]%H81T] &VAOP).]G:Y,CPB#*XJ]!E+LT^0MNAD==8QK'1O
MA.XBQNM -.SH[WU'9UY2/'./-Q60RF1L6/6LGDWQNL3B,1M(C;TL:UNSH ;]
MY[DJ>1$18>-@?;M5?T?'JJYL_P#C%S^$*M*(B(B(B(JO>_\ J-BO[W6?X2)6
MA$1$1$1$43RWMQ7,_J*;]X5MQ;\KF,_4L7[P*41$1$1$1$1$1%Y7/YTF_M#^
MXH/T?#7"<)^HXQ_JJPHBU =XA._9UY+9%I*P2- .];WV7AC>U"L!^<;^XNI$
M1$1$1%5.#'=CDQ/G\L3#_58K6B(B(B(B*K\I/_2#B8^-^3_V\RFLLZ\,3<.)
M;"[(^"[U<3$AADT>GJU[MZVOD^.Y3E>/<3SC98,Q8Y9%:KTA3R-EMAGBS.Z8
MGQ. :#&[9/N[MT=>:]+O-K&)PLN,Q<.7EYA)?@QTD.1?')(V21I?XK6B0Q!I
M8'$!I#=ZWV!4[B.6PNP;Z6+-YF<%M] Q9>4.DCF: Y\CR'%O0UK@[V2 =AHU
ML+BXS!>Y1Z-\'D,ARG)T1!#/+<L5)&LDE<''1<[1T&M#NVO>/@O.Y8S6,]#%
M3('+9!N0=)!/XLKVOE,<UANHWN(]S'@;&CL>>NRL_I(NW:%##34+DU8OS%*"
M41].I(WSL:YIV"=:)\B%CGUN[2O\4=2NS016,Q%6GB8&],K',>[1)&_-H\B/
M,[VJQRGD66=>YQ=H79*T/%H(7UX6@=$\A9XLGB@CV@6Z8._;9([]U8;N7M3<
MUX7ZK:F9C\E4M325^W2XMC8YI/;>_;/OUY=ES^FFYFJ'$76,(+7@L<\W74]>
M,R+PW@.;OW!_07$=PT'2A\AS*W7Q>)J<?R;LS-G;$KZ%N* 2R0U6,#GDLTT.
MD!VT!VM$CJ\CNSX[D4,_H[LYO!2V<F8:L\L8LC\E?(P.VQPT-'J;K2J/$>5W
MLAE<)2H\CAR4F8PLEJ4R-8\T[3>CV@UH&FDO<.@_G/=WW)\2OY/)6^58:ARE
M]R6G) R*U:KQB> NV9?8#6AP[>P2W6]CN!WF."2Y:/+\AQF0R,F5H49HF5KL
MS&ME+G,ZI(W= #7=.V]P/S6O<J_=YADZXO9MUHLQM7D#<1ZF8V%CH0\0O>7=
M/7U=;BX=]::!KNM*7+\N(L3G[5GJQF1S,^.-$1L#8H6F5C'AP;U%_5#L[<0>
MHZ [:]>*\KS%P\0R=RR):G(Y;##5Z&!M8!CY(N@AH<?9C(=U$[+NWDI7D>:R
MECE]K"8:[ZHZCB79%Q$37F64N+8V.Z@1T>R2=:/<:(5;'/LMGJ&5R.%D%1F(
MP=?*NK^$)/6)I6.D,;B1OH#6:]G1V[>^VE]4Q%UF3Q-*_&TMCM0,G:T^8#F@
M@?MKKTFDTFD1$1%AWDJMZ//YQS)^.8N_PI5J1$1$1$1%5[W_ -1L5_>ZS_"1
M*T(B(B(B(BB.8G7$<V1YBC/_  97IQD:X]C!\*T?[T*31$1$1$1$1$1%Y6_Y
MUF_M'?N*%]'_ .4G"?J2/]Q3Z(B(A\ES8_\ G2#^YM_<72B(B(B(BH6 RPPE
M[D4-W'9<NER<LT;HJ$LC7L<&@$%K2".Q4Q\\*8\\=G1_DJQ^(GSRH>^CG!_D
MJQ^(LCF%#WT\T/\ )5C\19^>&//_ %3-?Z)L_B+/SPQNN\&7'U?)5G^36KN9
MXI@VZ+*M'Z;&61^ZQ:_/7#GS^4!]N.L?B+/SVPOY^\/MQ\X_W$'-L'[Y[0^V
MC/\ B)\]L#[[<P^VI-^(GSWX_P#UY+^Q9OQ%CY\<?_KV7]BS?B*O<DY9AI\]
MQF:.U(8J]R225YKRAK&FO*T$DM[=W ?=4KD^782]C9J]/D1Q\[@ VS%%U.C[
M[[![2T[\NX]Z@KTG$LABK=?(\E?->LR0S.O^RR:.2(AT98 P-;TD; U[SOS7
M+=@XC<%FU+R<?+<MR&\W(=(#HY86],8#-:Z W8+3Y]3N_?MWXWYBQP63E\AB
MLO:M676YIKL3';D<&M]EI!Z0&M: ![AYE>..@X7B^"OXO0Y!CH*DNVV)0Z,.
MF:YWMAVB.[F[9OW#7P4AS7+<=Y)QZ3%1<IQ5-LDD;W2%[9" QX> !U#7=K>_
M?MOMWV->6Y7 \@QM&LWEF'K2UK<%PR=37ASXG!X ;UC0+@/>>W;ZUZ<HRG'\
MY/AGQ\JQ-<8ZZR]T^(R3Q'-! 'TQH:<[X^[[L?R"'BV7NY21G*J%:IEXXHLE
M V9A,[8SVZ7=0Z"6GH<='8UY$;4CD;_'KG)L'E(.3XB%F+9-&V#Q&NZQ(&@^
MUUC6@T:['[J<WRF.S>&EK8KEF(IS/CEC<V69KXY6OC<SI< X$?2!!&]$>1\E
M 4<7QV@^I?I\LPS,[!=L7C.3'X#G3M#98_"#P0S0:1[6P6@DGN#V8>[2X_9P
M]/%<HQ4F.+[4^2,DD(\663J>'@]>V_DCNS&C73O9[#?O0@P%3(93-5.1X)N?
MN0^!'9:(Q#78#OI;&'[.S[3B7;)^  "V$L)CRMQG,L!'R*]!'6;<AB:(H8V%
MQ&HC*2YWMO[E^O+MH:,?!8R&$XW;@H\UPEFXT1BFR.O&QC7=>WF3JF)<7;[N
M+MCN=$KH?@\)+D)Q\YL?\BV,JW,24PYG69QHZ$G7KH+VAY'3O>QONO6C@<)!
M9HPGD-.7$4<A-DJ]1SQU"63J(:7]6BQKI)' =.^[=GL=^6!P%'&3XN.3DF.E
MQ^%,[L7$" YID!#3*>OVNAKG-&M;!V5Z9''>NSQ7V<GQ,68GQK\7>F '1(QQ
MZA(QO7[+FDNT"2/:[^2Y;7$<3#6N4\!G*%2CD,9#BKHD>V1_A1@M#V$'Z98]
M[>_;Z)]VC]!H7<33I5ZE6W5;!!&V*-HF:=-:- >?P"ZOE&E[K=?]=;^%/E&G
M_74'ZXW\*?*-/^NH/UQOX5D7ZA_ZU!^N#\*SZ]5_KF#]<"V;;@<=-FC/_G"V
M]8A_JC/OK/C1?U1GWU@SQ#_[C/OA9$K#Y.!^ZDCPUNRJOZ/7 4,OL@?_ #>[
MY_W9RM74/_T$ZA__ %[)U#XA.H?$(' ^]-_44+@/-.H:\PL%[?B@>/BG6/K^
M\5GJ'_\ 7LJQ>_\ J+BCL?T.L_PD2LY<!Y_N+'6WXA9ZF_$)UC[?L&TZA]?W
MDZA[R L%X^.UGJ";'O[)L)U#Z_O+(*A.:/'S0S@\CZC/_!N73QYX^0L?Y_SO
M'Y]OS(4AUM^*SUM^*=;?B%@/:3KO]Y;;'Q"QU#Z_O(' _'[RSO[5KUA.MOQ3
MK;\4\1OQ">(U!(TG6UG8^O[R=0^O[Q3J'U_>3:\K;AZI/_:._<4+Z/COA.$_
M4D?[BL"(B(L/&QV7AC_YS@_N;?W%T(B(B(B(M#'L[)*VZ1\%CH"= 6>D)TA8
MZ!\$\-OYT)T#_P#00M^LIT#XN^^4Z!]?WTZ!]?WT:P#R62T'S[_:L&-JP8FG
MS'[03PF_ +!@C/FQI^T+'J\7]39_FA:FI7.]PQ=_T@6HH51YP1'[6 K)HU?Z
MWA_6Q^!8-"H?.K ?\&/P+'R=2_K2O^MM_ L''4S_ -5@U\/#;^!:_)-#WTZ_
MZV$^2<?_ %C6_6F_@6#A\:?.A4/^!;^!8^1<9^AU/]9;^!:G!XH^>.I_K+?P
M+'R#B3YXRD?M@9^!/D#$?H71_8[/P+!X_AB-'%4"/KKL_ O-W&L&[SQ&/_8S
M/P+0\4X\[?5@\82?>:K/P+4<1XZ/+!XL?XJS\"?-+CWZ"8S]BL_ AXCQT]C@
M\81^I6?@6IX=QL_TBQG[%9^!:_,OC6]_(6,_8S/P+)X9QH^>!QG[&9^!!PSC
M0\L%C@/JKM_ L?,OC?Z"4/UEOX%@\*XV?Z2TA]D8'[BU/!^-'^D]7[@*U/!N
M-D$?)4 W\"?PKS;Z/^,,ZNC$PMV>H]+G-V3YGL?-;?,3CP\J+ON6)?QELW@_
M'Q_U*3]DR_C+/S(X_P#UE)^R9?QD^8^ ]U.4?9:E_&6IX-@#_P!4F_9<WXRS
M\Q\"/^K3_LN;\99^9.$'T8KC?[2].W]QZS\S,2/HNR0'U9*S_*(.'XT?1GRP
M/U92S_*+#N'8YQWZSE_])V#_ +ZU^9N/]US-#_*EC\=9'#Z0^CD,XW[,I/\
MC+Q?P?'NM-L&_G/'8TL:_P"5)]M:2"0/:]Y:%Z?,ZM[LMR#_ $K,?W7+(XA
M/+,9_P#TE(?XT^:,/Z,9_P#TC)^%/FC%[LUGQ_E!Y_=3YI-UVSF>'^.D_P 2
M?-+_ ,>SW[+_ /X)\TS[L]G?V4/Q5N>,2Z[<@S8_PL?XBU^;$_NY'F_UV/\
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MRY[&&IL$.(/5X6AY_1Z?+X*Z<C9PZ?TH<?AK6<93MXBVZ>UX#FBQ9LRN 9$
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M2\=;&@AK7>SW !( /ELKQQN+S.,@E@QN XS3@EWUQUR8VO\ M 9HK$.-S58
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M9!%3;([R:\?N%=S?-;(B(B(B+4^:^?<6OYR"I<90PL=JO\H6]2FXV/?Y._\
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M8L ;\F0CBA)IW -^%U-9X;MC?LD$CI/==5O-9_$4?1[FKN;GGQ=TPP9=I@A
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MY#^H9OWA4Q2<139H;Z6  ?'LOA^"K7I^2Y6#AE?)8JGD8IQD,?8K/CBIRNJ
ML>TN #7^,[1#=@COK0!4AP+'NX[/B+F-QV7J5J.%E;FZKHY"'SLZ>D,:>SY"
MX2GV.VB._<;[^:XB;/,FR?#K=QM[DF-CJR1.@_('0.WJ61SA^1EK'.[>9[ #
M?==7):\;H,!@L%+F(\I@[-1D+&5)17D8WH#B][F^&YHC+COJV".VSV7MF.14
M\QS&G0MT,SZIC;C'0AN.F++-D>RUY?T](C87$[)[D;[!HZM<_DH,KRCC.=J&
MT*6!R5FID(WP/:Z)TE<M;(6D?0VYIZO+3P?BH+C=.UA>3T^3Y2C+#CKMC*/'
MY"\OKB:2-T3G,#207B,C7Z8#S.ES<2HWN+/I9',T[(CN<?FA9!X3I.F<V'S"
M%P )#G-E UKN6D>Y2N2QUIGH:;PWU62;/P82&P^J(W%K@QS>I@> 6EVVD=.]
MG[%$<VIW.1\BO<BPL5F7&8^ICFR,9&1X[H[7CR-:#W)8P@GMO?;SV%>.$QNO
M<]Y;G:_7\EV6U*T$FB&SNC8[K>-^8!>&[^H_!7U$1$11/+CT\4S3AYBE,?\
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MB(B(BJ>2[^D? _J&W^["K8FDTFDTB\[%>&S'T6(HY6;WTO:'#?V%;M:&M :
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M*&0'_A%?^&F_ K6B(B(B(B*K>E$ZX#F?KB _UFJSQC31]BV1$1$1$1$1$1%
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MX5/P_0;]@6Z(B(N'+LZX(QX@C]O>R=>XKN1$1$1$1>5KM!*?>&']Q5WT:#7
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M@_%3Y$S?NY-;^[6A_%6S</G-]^2S?=J1?@63A\[[N2R?L.-:G$<@'=O)G$_
MT8R/XD&*Y)_9)&/MQS?QT^2^2#_M'"?\G-_'3Y+Y+[N1P?=QS?QT^3.3_P!D
M=7_1P_'4?FN,<@S&.DI6N20B)[F./3C1O;7AP_\ N?%H7;\F\H:3T\AI]_/>
M,W_Q LC'\J_L@H'_ "6?Y9;&ERD?T\QQ_P F._ED]3Y7[LSBS]N.>/\ BH*G
M+-_T7Q1^W'O_ )5;>J\L_17#_L"3^56/5^6#^F6'/U^HR?RJP*_+OT1PGW:,
MG\JABY<WMZ]A'?7ZG*/^(M?"Y@.XL8,_;'-^,@',/>_!'[&3#^-9UR[\]@O\
MV;\*Q_TO;WU@G?5N8+(DY?\ UOA'?X:4?[I6?&Y</.C@S]EJ4?\ #6?6.6_H
M?AOV9)_)K!M<M']*\0?LO/'_  UCUWE?Z"XL_9DGC]V%<65Y%GL5 R7(XG&P
M1/D;$UQR3CM[CIK?YE[RO+D<?*,W@K6.=AJ,#;+0QT@OE_2-C9UT#:ND((!W
MO[3[UZ(B(L/;U-([=Q[U7;=&P(L?ZPV*22&5_8'I8 6NT>^SOW>?O*L:(B(B
M(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B+RGA;, 'M8[1!'4-Z(\BO4#0 'D$1$1$4)RW)OQ6.BGC#273!AV-]NEQ
M_B4VB(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(B(
MB(B(B(B(B(B(B(B(B(BA^2P.LU:\8BCE:9MN#SK0Z7=Q]>]?MJ81$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1
M$18+@#K??X+*(B*K>D:R*V#A<>GVK#6C8W^9<?XE:41$1$1$1$1$1$1$1$1$
M1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$7%;%PVZQ
MK/B97:\F<.:2Y[>GL&_ [U]Q=J(B*G>E,;P%;]5-_>/5Q1$1$1$1$1$1$1$1
M$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$1$11]J]
M'7R%:J62NDL%W261N+6](W[1'9OVJ01$14_TGG6$J ^^VT>6_P#[;U<$1$1$
M1$1"=#:XKV5HT'-%RW!!O^J2-;^Z5TLF:]@='[0(!!'<$?45NYP:-GR7DRU"
M^1T8D9XC0"YO4-MW\1[E[;3:\3:@#^@S1=6]:ZQO:]MIM:L>UXVQP</+8.UM
MM-K&UG:QM9VFTVFTVFTVFT3:;3:;3:;3:;3:(B(B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B+4MV=K9$1%3/2D\,P^/W[[H'^RD5S1$1$1$1%AW9IWK6
MO>OAGH@B;GN=>D6?D\3;&0@N-KL;8:'>%7]L=+0?)I 'DJEP3EV?P7$YH<18
MB]2=R<8RBZTPR-$+B00WOV#5-\RYER6UA\KB)+\++%+D57&/LP0!OCQ2 .[^
MUV(UHZ\PNKD_-+O%^8<WFAJ4IKE.E1CBM>"6N>Z4Z'B>UW:"2=!=G*/23G^/
MU^84HC4LWL)'4GAL/AU'(V;S:X CR]VCM6WT:<JR^;Y'RC%YAU:08QU<Q201
M]':6/K+2-GL#Y'WKYSRW!RYOTV\OQ5#%T[D]S M8TSO$;8'N,>I]Z)):='L-
MJ9BY'RKBMBEP?&,9F,OB\2RV^5[>OUIWB ='47-Z&-:2 X[/9O;SW8JO*>69
M;TCY; XQF&@H8PTYYGV&2&4Q2M#GL!#BTN\P#H#M]?:L>CGFEMU'BV$PF.Q>
M-FS-O(O<[PY9(8A$7..F&3JVX_IM#W#W#TH^E#(\OQ^.Q=*K2J7+V'MW+CYX
M7R1_D9?&&Q@/'8ECCLDZ&NQ5L]"D3[OH7P<)GFB?-5E9XT;M2,V]XZFD[[CS
M&P5"<)XQ'@N?Y^YQ2:6/#NI^JPP6K+GQV[K22YS2XDN:W6B?BYX'D=?0:%S-
M1<-=;SD%2'-QUI))8JQ+H@\ D:V=Z[#WK\_\0LYR2GPN7&3SMSF?QF:;8G<X
MAUB1OB.@>\GS(=TZ<?(?4I/@.7M\:Y<1)7N5:N/XNVQFJL[2W=MI/MZ\B]P#
M=.\R"5R9ZMDVW^05,O*\R8CC#\BP!Q:8KTTHF=*W1^D'%[>H>X ?%6#-9?)V
MLGZ&KL]NW%+E"Q]N)LSA'(0R,@EF]=^MQ\O>KUFZ!Y5R^]4=>MTZ&)J,BDDJ
MRF-SI9G![V]0\M1L8-^8$IUI?++D>7X_PO,,QV6R+<-F,[6J8U]B9SIFUG./
M7(T[V&O(T/+;1OW[5HPD S.1Y[@LKE+U'CN'OMF:8;)C+8W1.)CZ]]08" [0
M[;[>6PH"I+R/#\7X'@<Y:NN;ELZ&RMFD<)FU-CH@D=O8ZM]1'8Z]GR!"NWH5
MY#-+P[-OS-AWJN)R=FK%-*2XB!G26@D]SKJ(]_8!6^IS;CMRU#6K9:"2>9X8
MQ@!VYQ.@/)?._23DKMKG.;QHN6J]7%\5L96NVO,Z,BR'Z$A+?/0'8'MY_%4#
MEW->0B"GDK%RU9K6\!6<]]*Q)#\F6)![,T@C['J<"=$=P=#7;?V6I)8Y%GZU
M5F2M2X_'8F)]B>I(83:GFZ2/(C7Y&QQ]VO&V"#HBG^C^_E8\=Z2,9;NYVC?H
MN=8K0W91/)5B+'%A;*[JZM]/?S'EH[)*FL!F<C8]"&#=ZY._-9>-E**RYY,G
MB2O+3)OSVUO4_P#\J\I<+F\3Z5L(['\ERV0BG;-/E*L\G57@K@:CZ6 >SL^R
M-[<2TG?8JG\:YCG+.0X?DHLA8\?D60R-6=DKW21,:"T0],9/2T,V#V )[[/=
M7/B&*SN*]*60HP\CRV7P[<>'WI+S@\16WG;6Q]M-/3IW2!H C>]A2?H<R>2R
M#N8Q97(6+[J.>LTX9)^G8CC#0T:: T?'L -DKZ*B(B(B(B(B(B(B(B(B(B(B
M(B(B(B(B(B(B(B(B(B(B(B(JGSUP+</%( Z.2Z001\()3_$K8B(B(B(BY,M;
M%#&VKCVES*\+Y7-'F>EI.A]Y5ZGG,[;IP6(>./\ "F8V1G5=B!T1L;4/E,1-
MD[KKESACO6I&&*26+(1L=(P^;7D$=0^H["K_ #GBV=S6$PF*PW%JU*ECK\5K
MP77(FL+&'NP=(\S\5*S<7AFPL^,DX.YU2:?UJ5IR$?7)*._7U]6^KL/>O9^
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MY^R0%9^4*GNLPGR'TQ_^O>MO7*W]<1?YX61;KGRFC/V."R;$(&S*S7VA8%J
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M7?X;WD.;TGN/#<"-COI<F NPYOY2&.XABO$I92;&R&68!GY$/:D)\(D;):
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M8C:V1DS)*\IC?&]CNIK@1[P0#WV%YX;!P8R5\YGM7+;VB,V;<G7)T DAH[
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MOHR(B(B(B*J>E(D<!S7?0-<@_8K4SZ#?L641$1$1$157BP_Z5\N.O^MPC?\
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M(H/G;NGA'(7'R&/L'_9N7=@1TX:D#[H6_N+N1$1$1$1%5N'_ -$^3?WU>?\
M8Q!6E$1$1$1$57YI_-\"/CE(_P!X[\"L[?+[JRB(B(B(B(B(B*K<\[U,:/\
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M2X[?!U-=W!!+?>-^\#:QQCF\U9PQ^*H58K^4Y+:I=;GR/8WH +Y2"=D^6@"
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MRYCI_59Y)81XK"9F-Z'=0^D&/^EY[]^POIN3R>1?C>)T,;8#<ED3'*^1_?\
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M[+W$]O-7F7E>"L5Q%<\:=O;J#Z$I:3\=%B\:_)>+59/$@B$$FM=3*#V'7V]
M5-SF/X;ELSD+<V4LQ5<E-6L7ZHJ/(F?!OHT[I]D'?M#OO7N[[Y;V&X=?E?!)
MG)3BGY?Y:=5--_5XY'M-\3I^@3OMK??S4G)+BX<-B*F(YG=QUFE,^>:=E5SA
M;>\ESS(PMT=N)/U;^S7#F:'%;_!<EQT\A='\IV?7+UUU9SI)I2]KRX  -;W:
MT:^ ^/=3=#,<>KWH;K^1P.LUL8,=6)KN:(N^W2:.]EW3%V_2?7VK6 Q& I6;
MIR_/[.6I763>/5E9X;9'RL+'/)'F>DD#?EVUY!>V'Q_&\5"^2#F<;<C%C&XB
ME<;7Z75JX<7>7<.>=_2[>0T N/&4*V,PF0H5/2G)U3PMKUY9*^_56;)D+6AP
M!<[V?:\QH^9.Q8?1O;Q/$J,]?)\YBS)<&,A+X_!;!&P'3&M!(]Y[_9\%<'<[
MXP/Z=4_NOU^ZLCG?%B!O/XT'X&PT?QK<<VXP3VS^+/\ C+?PK;YZ<:_1[%_L
MIGX5GYX\<]V>Q9_QIGX5D<PX\?+.8O[MM@_C7H.5\?(W\N8O]EQ_A3YU\>_1
MW%#[;<8_C0\JP1^CFL2X?'UR/\*]/G%B/T5Q^OU0S\*R.0X?]%*!^RPS\*S\
MX<0>WRG1W^J6?A6WRYC"1K(T?V0W\*V&:QWZ(4OU]J?+.-]U^H3]4S?PK(R]
M ^5RN?\ "-_"O5M^JX ML1$'WAX6PN0'REC/_F6?6HOZHS_.639BUV>W[ZP+
M+3Y%I_\ ,/PK/K#/>?VPGK$?O('VD)ZQ'^>;]]9\=GQ;]]9\8'R+?NG2SXK?
M>YN_M3Q![BT_=6>L>_2=8^I"_P"&OOK'6?A^V$ZS[F_MA9#C[VG]I.H_G3^T
MG4[\Z5CJ=\%GK^#3]\)U'\Z?VDZ_J6.H_ ??6P=V\NZ;/U)L_4F_J*SOZDVB
M(FTVB(B(FTVB(L%918Z1W^)7SWT@PRS<QX7&PD,-FT7DN '\[/UYKZ&B(B(B
M(BJOI"'_ ##&:'],Z8/Z^S_^*M#FA['-).B-=CHKY3PJ;+YKT<',6\Y>%B#U
M_J+.D&1S)'-CV=: :&'L!W+M[7$ZSFQZ&!REN?O>O'#&R[JZ#J?V7![?9[#0
M<".X/4/(A66*9UHY/U#,YUIJXTR2,LPF,=;]ECV%[ =M\)X/8C3E"\"YMDYN
M 6XLNYMGE5.1E6-KP ;#YP'5GD#6FD/&S\&./N*G_0ID+^7]'.-R.9N27;]A
M\YDE> /HS/8    !IH_;5[T/@F@F@L%H/N6=!-#X!-#X!5C@[&].;=TC?RK8
M[_>5?YURF?"\PIT<EDY<%@[%7<&1;79)&^UU'<<CGM(8 T CRWL^T-+IJ97*
M_/#B^+LY&*06L0^W<;"QA:^5GA#J:[79KB]Q[?#LN/G.;S6'QW-;E&ZY@Q=:
M":H'0L<T.=LO:?9V1Y>_MM1$G-,L9N04J&5K7XZ6 =EFWHHF.=!.WOX#]>P0
M1L^0('WUMQCF^8N7,71.4I91U["')3R0P@/HRAK2&OZ3T]))(T0#V\U>^ 7;
MF7X3A\GDI627+U5EEY8SI:SK;U!H'P&]=]^2HN2YMGJ'#LGE9K-!DE7D#\6U
M[X-1^ V?PB]PZNSO,^>NRF[G*;L. SV4P&1QO)10K[;'2CV6R[!\VN(> TEW
M2"#VU[U(<&Y!-R&;UFGEL=E\*^N'">O%X4L4VQ[$C"XD=NX[#W[]VYJQ=G=R
M>GCJP9X+*[[-IQ&R 2&QM'PV>L[_ .[/Q52SW,+L'-[O'H;E#%66UXY<<+T#
MG,R#R"7 /ZF@:.FZ'?>SW\EC*\FR]7T@0XB;*8?&4'8EM][KD/41)U]!C'Y*
MW8[%V_=K2UR'+\Q6R?$*HM86.#-QVY7W'0R.C;'$WKCD:#(W0>PM)!/8D]RO
M&'FW(;_HNR/(\=1HNOT99@ 6N=#<AB=ITL6G@@%O41LGZ.N^P58G<@LW\EQF
M+ RTIJV1@?=LRR1.)$ :W3F .'22YX'??F?AWKM?G]]V*L/=!3M9&?.R83'Q
M1L?$QSFN(ZY"7..@ 2=?#0\U/9*URO&>L/E?B;-1M":831U)&>%.SI+6N:93
MMCAU^1!! 7)PW/9[+MP-FW<P,T&1JBW+6K0O9-"PQ@[!,C@=/<QI[#Z7U+DX
M3S+)\J]0M5?DIT+K#X<C0:QXM8\!K^GJ)=[1ZF@$]+1W[;7T;H;^='WDZ6CR
M:/O+'0W\ZW[R&)A\V-^\L>%'^<;]Y:&K ?.",_:P+4TJI\ZT/ZV%H<=2)V:=
M<G^Y-_ L'&43YTJQ_P $W\"U.)QQ\Z%0_;"W\"U.%Q7Z&4?UAGX%CY$Q7OQE
M']CL_ AP6(/]*Z'['9^!5KTA83$Q</R+V8RBQS0S3A78"/;;]2GG<?P;8R^3
M%8YK6MV7.KL   ]_94@7\=9P$W(\?P[&6>/1M?*)?898EB8=.E9$8]=.@X@%
MX) \NX"\,_EL11Q<.7H<2Q%W#V):T5:RYXB=-XW3IP;X1TT%P!V=]CV[+/(;
M%/C\4%C,<$PT=-V0CI36FR,<R)CPSIF),0)9MQ:?+1;]:G*F(PESD]W&P\6Q
M#Z5.-AEN=+>TKAOPNCH^D!HGVNP<WXZ718P7'(\_3Q<7',8]TL,EB5_@,'A,
M:6M';7<N<[M_:N^"CZ%+C=OF>2X\.+X]DE&O'8=/X;-.:_?2 -;WV.U%<AM\
M;X]0FR&4XC1;CJ]X4IYH@UYCWK\DZ>D$M]KW=^Q[*7GQ?&W9G'4J?'<999D*
MDMN"=N@TMC\/]*?/Q6:(]V_NU_'7<#D.'1<EI<'A=1=4GN/VYC2QD9(Z=Z[N
M/2X@#W#N>X5@XYB,/EBQUGB%>G#+6CLQ2GID:\/V>G8\G#0V/K"GOF5QK]!:
M7ZVM3PSC@<W6&IC?P8J[PGB^&MT+S[6/AD<S(VXVEV^S6RN#0._D %T'&<;'
M,!QX8&3UCU/UWU@$>$&=?1KZ75O?NTH3D%OC.%CS=BUQ:^^EAYF06[$4D9:T
MN:QP<&^*'$=,C#Y;[_4I:W2XO&S!RTL5)?K9>5L5>>M-[ VQSPX]3P==+7'M
ML]O+:C,9-@,I%;-'BN5DEK9)^+=$V9H)E8"7G?BAH: WS)&]@#9*]^+C!\@;
M5DAXSEZU2R^:-EB6<%C7Q.<US7=$SB.[' '6CKS[A>>6?QW'YZ_B'X',S6*=
M,9![J\^PZ#9!<-S G1!'3K?;L"M!/Q22W6CQF)S>1-FA\I0R5++PU\ (!(#I
MFG8+@.G6^_DMY)N)?(&'S=.KE[E+*3LKP.@MR]0D>[I:UP=*-'JVT_ CNNRS
M5P R=O'T<=G<C;IL:^TRI<E AZAMK7.?*T%Q'?I:2?J[A1D&0XW9GQ%>KB>3
M2SY2&6:O$+CV.U$2) [JG'21\#\>W=6'!8+#Y:M+*VIG:CXI#%)#9OSM>UP
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M=+WJ6([=6&S [JBF8V1AUK;2-A>J+E9D:TF2EH!Y;;C8)/#<TMZF=O::3V<
M2 2-Z/8KKTB:32:4-R7C]?/15!-9N5)ZDWCU[%27H?&_I<W8V"T^RYPT01W7
MKA<-#BW3R">S:MV->-9LOZI'@;Z1V   V=  #N?BI32QI9TFD(!&BM2QI.R
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M6^IP/Q!(/F5+5X8Z\$<,$;(X8VAC&,&FM:!H #W !;HB(JUR'\M/%Q\+$W\
M]3&8Q=/+TC4R$1E@+FOT'N80YI!:X.:0000"""H?&\(P-#!OQ<=(25Y.@RR2
MO<Z61S  QYDWU!PT-$$=.O9TO*]PO'RNQ(J,]7;2OC(%_7(Z1\GO)<7>T7:
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MH[?G?/[JOB(B(B(B*K<Z.IN.:\SEHA_JO5I"(B(B(B(BJOH[[X:[OS^4KO\
M[B1=>0XO5N9"W<9<R-2:VQL5@5K!8V1K1H#7?I.C])NG?6N"[Z/<#8MU9X8K
M-(05VU'14[#H8YX6_1CD:T^TT=_OE>U7A.)J\BFR\!N,?+,;+ZHL.]6,Q&C+
MX7EU_7\>_FI+*X2+(7JMUMNY4MUF/C9)6D VU_27!S2"UPVUOF.VNR@LAZ.L
M1;AIF&?(T;]6>2RS(5+'18<^0[D+G$$$.[;&M=@!H+-WT=86Q?IVX),C2?!7
M%21M2VZ,6H0=ADWO>-D]]@G9V2M[O <7;^6VOL7V5\NYC[%>.4"-KFA@ZFC7
M8D1L'?>M=M;.\W.!8RW=R$TMB\(,DZ)]^HU[!#:=&  7CIV-Z&^DM#O?M<\O
MH[HR,R#1D\HSUW*1Y:0M=#L3,(+0-Q_1VUIUY^R._GN6YAQ>#E$./CLW;M3U
M&W'=B=5,8/BL.V$];'>1]WW]KD;PN 7<ED),KE)<O<J.I-O/D8)*\9[ZB#&M
M:WOH[UO87A=X,;61DNCD_(H9GP,K'PI8!IC==FN,1<TN(VX@@D_8-37*<!!R
M/CMO"V[%F"K:9X4CX"WK+?>-N:X=_LVH;)<#JW<E>N#(Y"!V2J"GD6Q%@%M@
M! +O9]EVB6[;KL3Y>:D<#Q6C@\UELE1DL=>2$#9(7%OAQB%G0P, :"--[=R5
M#<H]'=7/9#*6AE<C2^4XZ\=F.#PRUYA=U1N]II(UOR! /O7G+Z.(3;ZZV;R=
M>I\I-RPJM$3FML [<X%S"0''9+?+9.@E'T<04;V/?5S639C\????J4"(C'$Y
MX<',!+.KH]MVAOML^_NO6KP!M4XQ]?+VHYZ%ZS<9*V-FW"<N,C"""-$N.CY@
M??6D?H]97L5KU3*3192M?LWX;!A:YN[!)EC<S\TP[[#8(T.Z]Z'!(<?>QMNI
MD)VSTF6CU.C8?%FL'JEE=V'?8&AY#6E!3^B6-V+^3JV>MP5CC&8Q_P"01N<Y
MC)'/8[9';N[N!K>AW"N&"X]-C.097*37S:?D(J\;PZ$,(,3"WJV#KOLD@ ?4
MJ[G/1Q+>FOMQV>L8^A>OQY*:L*[).FPQS7=3''RV6-)!V-CZR%(XGA<V+R=L
MULY=&%GGDM#&!C UDKR2[4FNKHZB7='EL_#L8*+T6V(\5CJ3>12'U&G9Q\+W
M4HSTPRAH&AOLX!OTNY.SY;4C%P"=L/ARY=LF\%\A.=ZKH]']4'M^??R_;/FO
M*?T<.GIX*G-DH9*V*94;%(ZG_P X88.GO%*'_D?6&@.&G#SUK:NV+@NUXIVW
M[C;;W3/?&YL(CZ(R=M9H$[Z1VZO>NU$5:](1 X]'L_\ 7J?_ +B-61GO^U91
M$1$1$1:O_,_;_$56O1[^5WOY>MVOX=ZLZ(B(B(B(JMF^_.^,;]S+9_U&*THB
M(B(B(B(B(B*KYW\NO%Q[MVC_ +(?A5H1$1%X2B7QFF-PZ/S;2/W%\ZY1=?4]
M,'$:@C8:LT%GJ.SL'PW'7W2-_<7TQ$1$1$1%5>==[7&&^\Y>+]IDBM2(B(B(
MB(L$Z*JOHW.\%8=[S?N'_P!1(K6B(B(B(B(B(B(B(B(B(B(BJWI)[\>@'QR%
M,?\ J(U:&?1641$1$1$6K_)5OT?_ )66?JFQ_#/5F1$1$1$1%6,SWYWQL_\
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MU<88?C9M'_;R+C^0\GA.6Y7,X**M<KY=K'6ZL\QB<R:-O2U['=+AHCLX$=M
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M7^]!_)K4X#)?F>5Y=O\ @ZQ_X:Q\@9;\SRS*Z^N&M_)K)P>8/ERO)@?J>O\
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MFA*Y]N!S^MW63$=.+MGJ'?N?->?(,)@<EDJUFGRWDN)KU:PIU:U*I,QD$72
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MW#K</L#'1_YQ^"I-?F64R/)<OB:EG'5LG1R A9C+<#A+/5#F[F8\N <2WJ<
M!KM]>UT/Y+D&\EY3C[.<PU)F,DA;6;-5)?()(P\ _D@)[N#>P[Z7CR7F.5Q'
M*+&)GM8.BV'!C*F2U$\ATO66&($2#MMI((!.O<5[9CF>8H<+XYR1]"&G5M2P
M-R<-B-[GU8Y" 9!W;Y$CL1[PK!;RF1?R:Y2HNJ&C2HB>P^2-SG>,[JZ& AP&
MM-ZC[]$?'M6N/\YR.;Q'$X8:]!N:ST,MDN,;O!K11^;NGJV\]P .H=SOL%T\
MGS')^,X'.W;C<1:%*&&:M8;5?&R7;RV1CV^(2"/9((.N_P![ML\@OTJN7N13
MXG.PT,>^R8<?"YDOB?F&_P T>"'!K_+N.GR.UKP7D5SDCZ5N*?"Y#$3U'22S
M4F.8^O."S43VN<?<YQV='V?(>^Z>J0GSC9]Y/5(/ZDS[H3U2'^I1_P"8%@TJ
MY\X8O\P+'J%;^H1?Y@_ L?)]7^H1?YC?P)\GU/ZVA_6V_@3Y/J:[UH?UMOX%
MCY,H_P!9UOUIOX%H[$8]YVZC4)^N%I_B6OR-COZPJ?K#/P+/R-COZQJ?K#/P
M+4X3&'N:%3?]Q;^!5SF>(Q[!A>FC4'5DX6G\@;Y>U]2D\O1X]A\3;R.1H465
M:D3I97^KM[-:-GMKS^I5&]>IX_!09W+\0QL. D+'/<T-?8KQO(#9)(^CIUW!
M< XEOUZ*9F>ICLMBJ/S+P;V92W+5JO>]K=] <>MP$)TUP;L:)/<+-B;'8[-8
M&CF.%8FE!E)I*PL_D;V12M+NEA_(QOK#06GMO>NVE-8''8;+W,D&<:Q+*%6=
MU>*R(V.\=S=!Y#>@: =MN]GNT_:O>'#8"QG[>/9Q[&%E6".22;U=GTWEVF :
M\P&[/?\ --^*B>+18?/7N05OFIAZ[L3:=3V0UWBO#0[?\S'2W1'?N?/M\86U
MF./XMV$EY'Q##4<=E)70LM,+)1"\'0\0&-NFG\\"=>]=_(VX3$3\B XAAIXL
M1C8\F7:8TRL<9!T@>&=$>#)[S^9^)UXY"Q@Z. CS+N#4W4715G]?@P#O.YH:
MT;;WUUMV?+N?/2LN)XWAKHLB]Q+'T9(9?# =7B>)!TM=U-('<=]?:"I!O#N/
M-<"W"8P$?"LU:3<0P AE:W$8]H?[3O\ F[>Z@N!\4P-WA.#LV\33FGEIQO>]
MT0V26CNM</C>/Y+DV;P_S7K0_)1C#YW!I;(9&]3>D#O]'N=^7UJ!O9'B-#%Q
M9#.<7-+'29"3'&PSH>R.1DCXW.< X.#>J-W< ]AOLK'8X_QN/*5Z$?'G6/'K
M268YHG,\,M86 C9>#L];==M=_-0&(GXKE..U<UC^'Y62E9AFL CPVED<1 )<
M?% !))T-[.CV[*7XWBN.YV.K+'QF_4KVZK;D$UAXZ'L=H@;9*[3M.!T=?M%0
MF1O\/QUG.,L<;R@@PLL<5ZRQP<R(/ +7Z$W66Z()TTD?!>V0L\6HV\S$[C67
MF@Q$4=BU9AE!C$3VEP>!XW41II)]G8UY*3LUN+0Y#C]6OC,A99FVN?5L5[+@
MP ,\3;B9 X>SW[ KQD''G"])C,3G\C3HN>RQ:J6Y#&',^DUO5,USR.X]@'N"
M/-:0/X_:RYQM#'<CM6A4BO=,60>UOA2?1=[4X^L:\^RL6+XWB,C1BLM9F( _
M?Y'-D)VO:02""!(?>/BNH\-Q?NDR8^S)6/QU79>.UF<]J8YMO*BI)C9IW,&1
MG^FV2)H/T_@X_?7MR['X;C&+;?NR\B?7\1L1]6R4Q(<XAK=@R#>R0.V_->4=
M7%>#,9&<MBEAB\=\,ERQXG1L@N $AZM:\@2>X[+%,8"_3Q%FCDN26(\KU&MX
M61L%Q#?,N'7[('O)\CV.B0%S,M8)]ZM3CM\P=8LPNL0L%NUN2,:VX>UY=Q]]
M;UCA;=Z6K3O<NGGCABL.$=RPX".0$L=]+7< _>7I4."LY>CC1G.2PV[U?UFJ
MV:Y.P3,T">DDZZ@#W;YCNF5^2,5!DY[N1Y6V''/8RQ(+,K@"[1:1WVX>TWRW
MK??2]:D>&FRL6-DRW)JF0F87PPVK,T1F &ST%W9Q'O .Q\%'T\I@[;7R09'F
M/J\<YKR3]5CPHWAW20Y^M#1\S[EUS6>/QRY")V?Y0YV/=T6BSUJ1L)UOVB&%
MOD=[\M=U-4\'6NT(KM#D67FJ2L\2.2*R'A[?B--[J$Q60P63?5;2Y9G3ZTY[
M*YE$D0F<TD.:POC <X$'L-GLM*.5P>0DKQU^79UOK$YK0OFB=$R24'1C#WQ!
MI=OMK>U(115GYZ;"Q\GY",A%&)GQF(AK6'>G=9BZ='1&]^8(7'';QKY(#'S+
M.&.>800SB &&20N#0ULO@]!))UV*S+>I1MN./,L[T4W.99?ZH'-A<T;<''P=
M-T""=^XJP#CN0_LGRO\ F0?R:RWC^3:=_.?)'[8H?Q%M\AY4>7);I^V"$_[J
MY,;\H4.9PXVUDI+U>6C)9_)(F,+7-D:.W2!V]I6Y$18)^":6LI(8=>9"^:>*
M3Z;JT9G+X8\*>D%N^YD[GJ^/L_'X+Z<B(B(B(BIG,[U7'\LXM8OV(JT#39!D
MD>&M!+!H;*\>59W 9[C.1Q4?),76%ZN^N^5TC7]+7M+7$#J'?1.N_P!]0V?;
M@,WZ.X^*'EV+B:V&"%]D%IVV(M(TWK[$] ]Y]ZDN3W<5G8,1X?*L/7FH7([O
M6=2-D>P$ :\0:'M'WD_6N?)ST\I!8CO<TPQ,LE=[61,#(V>%*)">DRDESBUH
MV7=@WL%$Y3 \7FAY>['\FQ=>UR)GAO=+*V1D'4 )"QO6.[R.H]_,#STKIA.0
MX3'X>C3GY!B99:\#(72,G:T.+6@; +CKR\ME=XY7@'>6;QG[)9^%#RO C^G>
M,_9+/PK(Y3@2=#-XP_XRS\*V')\&?+,XX_XRS\*]6\@PS@-9;'G?_P"2S\*V
M^7,3^BE#]D,_"O.QFL689-9*D3TG6IV?#[5">C[*XYG"<&PWZC2VG&T@S-V#
MTCMYJ#Y+@Y>1XW*XG(YG!VL=<L.EKRR^U-2:3^8]K1</S)[:WKN%),QTV-Y5
M=R^%RV-EBOUH89Z]N31#X@0Q[7M^(<001]>UPYGBK[N*P56')8Z6:EF&YFU)
M([H;/)UO>YC6C?2"7D#9.@!Y^:E?2#A#R;CL.,H6:%?5F&PXO?[(\-X?T@ =
M]ZTM_2!@CRC@^0P5*>G4FNM:TO+ML9IP<2 !W^CKW+>Y#R"Z9H+$^(@I.J21
M!D4KRZ25P#07$M[-:.HZ'<DCRUWK=#BF<QM?@\-63#6&<=;('F2T]AG+HG1#
M6HST]G$^_OV^M6)]7DD@=*'X>+5H/%!LKG0R0ECP\.D\,.ZW.>'?1('0.W<K
MQX#Q0<:R/(+FJ=2/*3LE9CZ;RZ"OTMT2TD-[N)V=- [ #R4_QNC-0Q8;<,9N
M32R6)RP[;UO>7$ D#8&PT?4T*F<JXAF.30.J7XL8V:*^9Z.8BF<+-2'QNL -
MZ/IAOL_2Z?>?+OVQ\=S,/(.37GX_"W8,M)$^-LUJ1AC$<36#?Y$[SZ=]BH[-
M^CJUR7D<UKD4E2:I/@V8R1\3B)6SME\7QF#IT-./8;]WW%8,=A,ID^$V<#S-
MU2U+) ZJ^S7<XB=I&A(6D#I=Y>\]QO:\>%\;R. X/+3O31W\[-&XSS=72V5X
M8&,&]=@&-8W>O<2JY@."YS#8;B%JL:1SF!AEJR5WS'P+4,GTAU])+7#0(/3[
MB"I?G>'Y/R?AF6QT<6/JV+?A1PPB=SFM#9 Y[GR= ^D!TAH;V\]]^TBZEGGS
MWYL?1QF)GFI.8V9LOBF2=O\ ,>H=  8WJ?LZ)._J49Q_BUF+G7SA^2ZF#)K2
M06XJECQ&WGDM+7D - #=.T2.H]7<#2^@;^M.H>\A.IOQ'WUD$'R(1$1$V!YE
M$38/D56><'O@!OSRL/[CUU\QPC>2\5RV'\8PB[ Z$2@=702.QU[QOW+Y[RC(
M6\W@*_H^MTG8_.WZ[(9)YR!6\-FNN2)^_;)#3TL^D/S0 !4[SC&WI.3<&DQ]
M"S;JXZV^2Q)'TZC88BP$[(WW/N]P*[O2]B[&8]'N6I4*<ER^]C369'H.;*'
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7$1$1$1$1$1$1$1$1$1$1$18#0/)?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>exh1087_05.jpg
<TEXT>
begin 644 exh1087_05.jpg
M_]C_X  02D9)1@ ! 0$$L 2P  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +" 2; X\! 1$ _\0 '  !  (# 0$!              4& 0($ P<(_\0
M8Q !  $# @,$! 4+"PX,!@,   $" P0%$082(0<3,4$4(E%A%18R8G$C-%*!
MD:&QL]'2TT)5<G-T=9.4H[+!""0E,S4V5%:$DI6BPL,7-T-%1E-C98.%I+0F
M)T2"X?!'9.+_V@ ( 0$  #\ _4.G_6=G]BZ
M            )\.CCHPHIU2K-FY=FNJS%GDY_4B(F9WV]O7Q>FG_ %G9_8N@
M                                     <NF535@V9JC:>5U
M                             $^#GT_ZSL_L70
M                   .73=_0K&_V$?@=0                   !/2-VE-
M<3<JHZ[TMP               "7/I_UG9_8N@                    (
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MV8V\S"[0N)\2[I5_'BK%PZ[]V]D6[E?>?5IYZN6?6FN:JIZ>&WT)OMJM7;G
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MX'4   -:JMIVF8B?><WSJ3F^=!S2SS1YS!S1[89@"0-S<@W)-S<W-S<
M               V      )<VG?6EC]KI_ Z0  !1;&D8>L\9<1?"-%R]%BJ
MQ31M=KIBG>W$](BJ'/Q%A\.:-FXF%&DZAGYN1;NWZ;&+?JFJFW;B)JKGFN1&
MV\TQ'G,STA&YF9P?:L8M_%P-0SK5[ ^%*JL6]7/<XO\ UE?-<I]_JQO5/+.T
M3LSJV5P=IUVJ(Q=2R+%K'M9>1E8^575:QK-VK:BNN>\B=IZSM3$SM$SLZ=9L
M:%INMXNEX^C\0:G?OTT5UUZ??N7+>/355,4U7*INQRQ.TS]$2LOQ,TCRIS/X
M[>_.)X-TJ/",^?HS[WYS7XFZ9/A.HT^[X0O?GGQ-TWRKU&/_ #"_^>?$[3HG
M^V:GO[8U'(C_ &VT<(86WUWJW^D;_P">?%'$\LS5X_\ ,;WY[:.$L6(^OM8_
MTE>C_:0.J:+./Q'H&':U/5J;.7<OQ>B-0N[U13:FJ//IUB'3Q/IVF\.Z/D:I
MJ.JZ];PL>.:[5:S+MR:8WVWVWF?N.+0:='UK/NX.)KO$EG/M6J;]6+DWKMFY
MW<SM%<4UTQO3OYQO[T_/"NWR=;U^/HS/_P 'Q7N?J=>UZ(]^7'YLM:N%;VWJ
M\1:]$^V,FF?PT.+)TKT'-P<2_P 2<23>S:ZJ+7+-%=.]-,U3S5=W,4](\]MT
MA\7<V.E/$NM[>6\V)_W;AT3#NZQIMG4--XLUJ[B7N:**ZK5JB9VJFF?5JM;Q
MUB?)[9^G9>GXTY&5Q;JMJS$Q3O-K'JF:IG:(B(L[S,S,1$1UE!U:YIUO4+N%
M<X_SK.5:NQ8N4WL>S;BBN?"FJ:K,1$SY;SUWA-ZE@:AIN#?S<SB_,L8EBB;E
MV[=L8^U%,=9GI1#QU.G+TK38S]1XUKQ<+U?J]['L11U\-YY=NKBJU+^Q^1G?
M\(6/Z)C511?NQ8Q]K54^$5=/5^VQB9M>;GX^%B<?VKN9D6^]M6:<:Q-=='7U
MHC;K'2>KKPZ=0S=0R\'%XU[W,Q)B+]FC#L37:W\.:-NCWQ,75,JG)G'XRKNQ
MC7*K-Z:<.Q/=UTQ$S3.T=)C>$/A:YCY^71C8?:1B7<BNKDIMTVL;>JKV1'G/
MN\4MJ6+JVDX5W-U#C*G%Q;4;W+N1B6:**8]\O#$R<O)T:O5<?C?$O:;1$U59
M5&-9FW3$>.]45;1L])OY].DSJE7&6#&G1&\Y,XMN+<==OE<WCOTV]O1T8%G6
M=0P[67I_%6+DXMV.:B[:PZ*Z:H]TQ4]_@WB3RU_&GZ<#_P#VV^#^)OU]PO\
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M]JX< YF1:XEXNX?NY%_)QM*R;%>-<OUU7*Z;=ZU%?)-=4S-7+.^V_7:8ZKP
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M<O+LU6:\++IL4V_1ZK57-17-$3Z]7E,S/6(CPG>9[;O!NJW[NCYF3Q+7?U7
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MJ/&IL     "K\>]=*Q(]NIX<?R]M9;7A/T_T-P :7/DO'3OK2Q^UT_@=(
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MO+,S5S;15TFJ*=M^F_1<MS<  $9Q/.W#FJ?N6[_,EY\'SOPIH_[CL_S(2X
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M34/[71^S_HEG38VPL>GRBW3^!U   "J\#QZ^O^_5\B?P1_0M4FYN;FYN;FX
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MHTZUQ)H5G0<_)JU33-3M3D:;5C[V^2>ERNN9IZ3315.U7-MOTCUMGTP
M  0O&\;\':Y^X;_XNIU<.QMH&FQ[,>W'^K"0   !5<*/_F;J_P"]6)^-R%J
M  !4N/.LZ!^_&-]Z9E:[?G/MZM@     5CCG^YV#^^F)^.I66CY5388FG>=]
MY\"(B)9')J$3-NWMX\_]$M]/^L['[73^!T   "MQPM:M9.7=Q=0U3&])O59%
M=-F_$4\]4[S,1,3XO3XOWOU[UK^'H_,8GAZ]^OFM1]%^C\P^+U[RUW6M_?>H
M_,/B]D_K[K'\+;_,/B_E^7$.L1[N:S/X;9.@YOZGB'5X^U8_1GP'J,>'$6I[
M>^BQ^C9G1]3VZ<0:EO\ M6/^8Q\#ZM/AQ%FQ^RL69_!2Q\#ZWY<2Y&WOQ+4_
MT,3H^N>7$U_^)V?R,? VN_XSW_XG9_(X9X5U:K6+>ISQ)?G*MV*L>FJ<2UM%
M-5453TV]L0[O@C7_ /&:Y_$;7Y&DZ/Q#UFGB>OW;X%K8ITKB7?\ ODM3].G4
M_G0S.E\3[].(L3;WZ;'Z1F-/XIC_ )\P)^G3YV^]</0>*OUYTS_1]7Z5B</B
MWRU?2I^G K_2M9P^+H_YUT:?\@N?I2,;B^/^<M%GZ<*[^E8[GC#_  [1)_R2
M[^>SW/&'^&:'_%;WY['<<9;_ %WH,Q^Y[T?[;,VN,?\ K]#G_P .[^4Y>,HZ
M<^@S_P#9=_*1'&7G.@;>Z+S.W&'_ '']VZ;\8Q^IT*?MW3?C'[#0ONW3?C'[
M#0ONW6LU\9?]3H<_^+=_-*;O&5/CB:'5_E%V/]EK-[C*)W] T6?\KN?HV8RN
M,)\=,T;^.7(_W9Z3QA^M>C_QVY^C9C)XPW_N9H_\=N?HV9RN+_/2M(J^C-KC
M_88]+XNBK>K2=+F/9&?5^C>DZAQ+$=="Q)GYN?\ EH8^$N)O+A_'_C\?FL?"
M7$_^+^/_ !^/S2=2XF_Q>L3]&H4Q_LGPIQ+'_1RW_I"G\CAX@RN(]1T+4,*C
MAO:[D8]RS3/IUO:)JIF(W^Z]=.U'B'$T_&QZN&+]55JU31,T9MG;>(B/.?<Z
M?AG7_P#%;*_CMC\YF-9U[]5PME_:S+$_[1\.:U'CPKG[^[*L?GGP[K/^*FH_
MQC'_ $C$Z[K'GPKJ43[KUB?]X4ZYJD3$_%C5_P"%QOTCT^']3_Q6UC^$QOTK
M'QAU&/'A;6M_V>-^E:_&'4/U7#&L[>Z;'Z4^,N93TGAC7=_=38G_ 'K'QDRO
M/AW7]OVNS^>?&7(CPX>U^/ILVY_VT+C:KF6^+\_4J^'=;[B]AX]FFJ+-/-S4
M5W9F-N?P]:/NIJ>*+L?\P:]/^2Q^>Q\::_U6A:_3/L]$W_!4V^-GMT/78CVS
MA5$\6VX\='US[6#5)\;+'C.EZY'NG!N,QQ;C^>G:S'^07/R,3Q;A[^MA:S3/
ML] N_FM9XPP8CZTUG_1U[\UF.,--F.MO5J9]GP=>_,/CEI7G1JN_[W7_ ,P^
M..E?]Y_Z/O\ YA\<M)_[R_T??_,0'%?$>%FU:/Z/;U&NFQJ%J]<GT"]ZM,1/
M7Y'O3L<9Z1'2JK4(_P#+[_YC,<::1Y5Y_P!O!O?F,SQKHT5;57\FF??BWH_V
M6U/&FB;?7-W[>-<_-9^.F@^>95_ U_D8^.N@?X=/\%7^0^.N@?X=/\%7^0^.
M^@>>HQ'_ (5<?T,QQMP],?W3M?\ W15']!''/#.^WPUB1/LFIF>..&8\=;PH
M^FXQ\>.&/U]T_P"W>AM'&O#,_P#/VG1].13']+>.,^&?U_TO[>51^5M\<.&_
MU_TK^-V_RMJ>+>':ODZ[I=7T95$_TL_&KA_]>]-_C5'Y6U'$^A5SM3K6FS/N
MRJ/RM_C%HOZ\:=_&:/RJ[QCK&FY.#IMK'U#$O7:M4Q)BBW>IJF8B[3/A$^R)
M76GY5388HWVG?VL@Y\RJFBBB:YB(YO/Z)-/C^L['[73^!T
M   !L;&QL;&QL&P&P; ;!L!L;,<OODY?9^$V]K'+/M@Y/9.S'+5Y2SRU>=4G
M+/V4G+5]E)M5YU'+5]E/WF.2?.K?[4')/M^]#/(<D>PY(.6?=]P[NF?E13,_
M0QW5/O\ NM9LQ[F>Z]_3Z(8FQ3/CM/TQ!&/;^PIG[37T6S_U5'^;#2[@8US;
MGQ[-6WAS41+S^"<"?'#Q]_VNG\C$Z/I\Q]8XOV[-+'P+IOG@8<_^!2Q:T73;
M5Z+MO3\.BY3,33538IB8V]^R0B-IED ''J-,56K<3/3G_HEOI\SZ+8C_ +.G
M\$.D   "98WWCQ9 W @ #<   -X]IO'M-S>#<
M<6J3$6;>_P!G_1+VQ/K:Q^QC\#W   "?"7Q?6]2R>*.W">$<V_>L:'@8495>
M/:NU6O2KD]8YIIVF:8]FZ;XBR*. ;MJ_IO?9%S6<K'PL7#OW:ILV;L\W-5$S
M,\M,QXQ'G"+R^U;(LVK5FSI5F]GT:[\!Y%KTF::>>:=Z;E-6T[Q[ICHB]8[2
MM<S>%M*RM-QL?"RLCB.G1<CFNS-,[5=9HGEB=JMMI\X6KX\ZQ=XZU/AO3M!M
M97P97C59-^G*Y=K5VF)JJBF8WFJG?P\T9IG:S:O:YD8VIZ?&/;MZ?>U"KN[O
M>5V.ZJJIJMW/+FF(B8Y9GWNFWQ[KF7PQF:M:T*,?&JP;69B9=5_GMU4W)CU9
MB(^73$Q.WA[UZQ[.7JW#&-1DWJ\/)O6[=5=S'NS-41$Q,[5;1M-41[.F_GLI
M_#%G+U#B?B:Q7J^I46M-R[,V(G)KJIBCFJFJF8F?6B8IVZ^U+:=QS3G7=.Y<
M#DQM3JOT8-VJ]UN56YV]>GE]7>>D=9<&A\;YM7"V-JFH8,7)RLNNU373<FFU
M:IYIZUU<L\E-.VV_7?Q<>K\67M8PN$=1TVO(PJ,G5*<>]:INSM5'-$33.VW-
M$^^/,[>HUO X.^&^'LS(L7=,NTWK]FS.W?V-XBJF??Y[^R'MA\3T:[G5<0:;
M>S+^AX&FQ>KLXM7/W]^N.:*(ICQJII\O;5&Z(R.TNG6M#XMP\*SD:;J.G:+7
MJ%J[1<IJFB*K<S3$[1/+735MO3,,<-]IT8/#NB6=7L967GU\.SK5S(YJ?7IH
MIWJB=_.7?F]L&D8N#IN11B7[E>7IM.JUVHN4179L3$3'29]:J=^D1X[2MVB<
M2?"NNW\&UIN;:QK>-:R;>;=HF+5Z*XWBFGWQYJ_VB:]J.D:_I]JO(R,#1;M-
M&^98MQ5RW.\]:*MXGI%$=(V\9\_+QXXU/5M)X?TW4+.NW:KM55NF+N/C15C5
M4S\JNY.T^.^\;3'LB/-)<;<47\2=,L:3<HVO9N/:OWXGPBN>;DICVS3&\^R)
MC[*$CV@<17N'M(LU8-F+VH9=ZG&QZ)C>.:=^NWG]'MF%=U+C>JSI6G8^C95_
M/U#-OUV:[MW'^J6.3;GGNJ8C>8WZ4_?DS^*<C*N:9AZ'JEVNS>PK^;<SJZ*(
MKF:*:MJ:HFG:F.:-I]7?WNW/XSN8?9-D<55V*9R;6%5>Y)Z4U7(WIC?W35]Y
M\YSNU#6=!QM8MYUZWF94:)C:EC556XI[N[=JBB:9B/&F)JIF(GV;>;WU7M+U
M;0[NMZ+>R*+V=9NZ?;Q<VY;IB8C)^5-5,=)FGK,?2O'9OQ3F:SJW%.B:E7%[
M*T/.[B+\4Q3-RW5&],U1'3>-IB=NDJ=I_:9J5[/PM4FJF=)RN(+VBQBQ1$<M
MNFGU;G-/6:M]_'IM+TX*[2=4U#6.$\C/JM58'$M[+LVK%-N(C%FU5,4<L^,[
MQ'7=]Q                       <V7&_)/SOZ)8PKF^)9F:9^13/WGOWGS
M9.\^;+'>_-J^XSS[>4G>?-D[SYLL=Y/V-7^:1<^;5]N-F>\^;)WGS9.?YLL=
MY\VK[BJ\1<%Z;K6M86L]YEX.L8=,T6LS$KBFN:)\::MXF*H]TP\]1X(P-1T^
M+&;DZC?RJ<FC+HS*J][M%VCY,T].6(\N6(V1U79AHM=C$HJNY_>V-3G5ZKV\
M15>R)_55=-O#RAY3V5Z-\"V].HRM3HHM:M\,V[M%=//1?WWZ3MX)G3>#<'3]
M?UO6*,C.N96K6;=G(YZXG:**>6F8Z;[[>]7]$[*=$TF_CW)RM7RK=G#O8$6L
MBJ*J:K5VJ:JHG:(]OB[]&[/L/2>%<K1?A;6<C3*[<6;5J]5%4X]'-$Q31$4_
M1X[]%PT:Q&+IEG&HO9%Z+-/)%R_3RUS],;1^!&:!P[9T?5M5RK>5DW[NHU1=
MOQ=ICEWWJVY9B.GRIZ;STV<>F<'X6E9^G5^D9-[&P:KM6%CS;WILU7)WJF:H
MC>?'IOMM]]'QP-8QL' P(U74>YP\KTJS3%B*Z8WF9VGU9B9WGQG?Z'GC<$X>
M-@:5B6L_.FUI^;Z;;YL2J9F=XF*9VB.G3[Z[9UG'U+3+^/DVINXU^B;==NNB
M8WIGI,3$]51T#@;!T+LZKX2TO(S+%FNS7:]+HIVN\U>^]?3]5U5W3NR.U@VM
M4IC6,FNK/T:-(N3.-1'+1'3GC:/';VLYO9-:R,73+5G6<FS5BZ-<T6Y<C'IJ
MF]9JC;>-_"6T=E5W%S>'<O2M=OXF7I>GT:9=KG&IKC(LTQ,1.TSM35UZ2N>A
MZ/GXG$6;G7]8R<G NV;=JQA7+<138JIC:JJ*O.:O:YN)]+S-3O9%JUFTSAWY
MMQ<Q\C!N7::.69WJIF/'?V>'3Q1=GA7*LX=S2J-:RJM"NV:+-6-7@5S73$;<
MW+5Y<VT^7GX>;;B7@30]8NV+UBS=Q;U-ZFN]5Z/=J[ZB(VY/=TVZQ[&F;P[G
M:EE94Y>H97=8^;:R],FYBU51;Y=]Z)ICK-/6F.LQ/J[^?7>UP938O8NJ8V97
M&IV,Z]F7*J\6N:+DW=N:F*.DQ$1$;3U\_;TUQN"Z=.P\#X.S;U.7C8]_&KN7
M,2N:;D7=YF8ICPVJG>.KSSN#LC-T^KAJC+O3PY=TJO'O4UV.68N3,\M<3,?*
MWF9V\N7KXPA+O9+\(X6J1K.?1=S,K3+&F6K]FQ---JFS/-37M,S,S-44S,>[
MRW;9W955J?PIFZCFVHUC,NXEZW<MV9FW:]'C:F-IG>8J\9G?IND='X/UG2<[
M+S],U/'LZAJFJ4Y^I?49KHKM1']JHWZQ],[.+$[+9Q=3Q:*\JBO1,;5[NLVK
M7)/>3=KC;NZIWVY8GKOL<*=FDZ)J_#].3D4W=.X?JR:\&*::N\KF[7OO7O&T
M<L;QT\7U3TVU]A?_ ("O\A&;;G]3?_@*_P AZ;:^PO\ \!7^0]-M[;\M_P#@
M*_R/2U>INQ,T17$1.WKT33^&&\U;>6_T,=Y\V3O/FRQWGLIJ^YN=Y\V6>\^;
M)WGS9.\^;)WGS9:3?VW^IW)^BEFF]S1O%%<?32VBY\VK[C$79GKRU1'OAGG^
M;+/-TWV8[SYLG>?-DFY\VK[C'>S]A7_FL=]UV[NY_FMN\^;)WGS9.\^;)WGS
M98[SK\FK[C,W/FU?:C=CO)^QK_S6>\^;)WGS98[WYM7W&>\^;)WGS9(KWGPE
MMNQ->WE+'>?-D[SYLL3=VCY-4_1#$7M_U%<?32V[SYL_<.\^;+$W/FU?:AGO
M/FRQWGLIJ^YNQ-[:=N[N?YK,7?FU?;C8[SYM7W#O/FU?<.\]M-7W-F>\^;)W
MGS99IJYHWVV.;KMM)->WEO\ 0QWGS9.\^;+6J]RSMW=<_1&[/>]/DU?<.\G[
M&O\ S6>\^;/W#O/FR=Y\V3O/FRUJO<NWJ5S]$;O&C*N594V_1ZXM<N_>SX;^
MS9RZEEUXU5N:Z8JM5W.6GEB=X]6J9W^X[\3^T6XCPY8_ ]@V@ VCV&T &T>P
M-H]AM'L@V@ V-@#8F(GQ8BBF-MJ8C;W,Q$1X1!M'L-HCPB  "8B?&#:/9!M'
MLACEC??:-V=H]C'+3'A3'W&0#8 VW  -H]@;1OOMU  VCV0 !M'L#:/9 &T>
MP V #:/8!M'L#;<V-H]AM'L#;8   VCV0 !LX=3Y-K47.L37T^G:71B_VFC]
MC'X'L                                    #GS,NSAX]V_E7;=FQ:C
MFKN5U;13'MERY]RBY&'<IF*K=56\54SO$[T3,)"BF*8B*8VB(V;
M                            X=8TO#UC3K^!J5B,C#OQM<MU3.U4>.W3
MZ&MZQ;HN8MNFF*;=$S%-,=(B(IVC[R0
M        ')DTS-ZU],_@=8                                     Y
M;\_5[7MWF-_M.H                                  !K7533,155$3
M/2-Y\6T=8 "?!PY-7]>XL;^,U[Q]IW
M     .7-P,?,O8MV_;IKN8U<W+54_J*IIF-X^U,NFBGEIBF/"/!D <>3MZ78
MZ;SZVT_:AV                                     $^$N2]']<V>E7
MA5UCP\O%U@                                    $^$N6_-7?V8CY,
MQ5,_>=0                                    !/A+BO7:8S+%NJJ(K
MJIJF*9\9VVW=H                                    !/@XJK.^H6+
MDT53M15&\5>K'AY>UV@                                    #QJB?
M2;>T^KM5O'W'L                                     2YKU4QDVHB
M?&*OZ'2                                     .&_-/PA9CFIYN6J>
M7?KMT=P                                    !/@C\J*?A'&F?E<E<
M1]'1(                                     #@R:(G4\6K?K%%<1'W
M'>                                     (S(GEUG$^1MW5SQGUO&/O
M),                                    )\&E%RFJJJFFJ)FGQCV-T)
MDY&-5Q/@6)N4>DSCW:Z:)^5-.],;Q[MTV
M         #6FBFFJJ8IB)GQGVLU1O3,>Y5*])P:.T;#U7NJOA*[I]W'[SFG:
M;=-=,[;>'C5XK8                                  "/MY.=5K-RQ7
MAVJ<"+<549$7MZZJYF=Z9HVZ1$;==YWW\$@  A<JGEXITZ>3?^M[T17,^'6C
MI]Y-                                   ;1[(  $#?JJ^-6ET\L3OB
MWIFJ:HWB=[?3;Q3P                                     A+L3/$^
M!5O3MZ/>_4]?&WYIL                                     0^11'Q
MFP*N6G>,>[$53,[]9I\OM0F                                    8
MK^3TW^TQ%413O,S,>.[%-VBJN:*:HFJ.LQOU;B&O53'$N#3RT[3CWNOG'6CH
MF0                                   >&9S3CUQ;^7Y==FF-9KMU7*
MJ[M55-6W+1.VU'T(W2N&L#3-=U35\6;_ *;J,TS?FY=FJGU8VB*8GI3'T)P0
MM_FGBC F(]3T>]O/OWMIH                                #>-]MP
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M]0  !$=_OQ!CVJ)B:>XN35$>4[T>*7      !BJ9CPAF/#J
M           //(M1>HY:M]O=.TMZ8VAD:U41-<53XPV   8F8CQ9WWA!TXT4
M\2V+U%NW];W.\KCI,U3-'68\^D)P
M    &MS?EZ.+3K>19INQ?KHKWN5U4<N_2F9WC??SZHZCOOC3A=_$;SAW9]7P
MWYJ%@                                     .B&F:8XEQ8GEBJ<2N8
MZSO\JG?W)D        #S\.@                     $      ,3XHF;$5\
M0XMZ:JXFWC7*8I\IB9H_(EP        :<D=[S]>;;;QZ-P
M             8F$-553\:<6GGN17.+<GEW]6?6HZ[)H
M                     0E4Q\:\..DU1AW/YU*;
M                 $)5<JCBS'L\L<L85=4U;==^>F$V     #$LQX
M                         (.JN8XOM4Q3ZOH57K;^?/3Y)P
M                       #<  )G:.K$3NR@KE&_%=F(IN<WH=4\_-ZGRXC
M;;VIT                                 :UU<L;JS&=K^H9T>BV+&!I
MT5S$W,BF:[UV(\Z:8VBCKYU3/T+-;WY8B9YICQGVM@ 8KIBNF::HWB68C;P$
M#53'QTL5?JO0:X_UZ4\                       3T(G< GK'2=F*8F/&=
MV0       )   !!544?'#$K_ .4C!KIV]W/2G0
M"8W@B-@          <N=G6,*+<Y5ZS9IN5TVZ:KE<4Q-54[13&_C,SY.J)WB
M)  %>JZ\<V>O2G3ZYV^FY3^180                                 !
M&:[HV%K>/;L:C9[ZW;NT7Z8WF.6NB=Z:HGW2D_+J  *[-R8XYLT;T]<"N=N7
MK_;*?/\ H6(                                  ">D/''O=[S_ %.N
MCEJV]:-M_>]@ E T45_'3GFNN:(P-N3;U8GO/&)^TG@
M               '%$Y4ZE'KVO0^28FGE]?GWZ3OOMMMY;;NT F-X:T]:ZFP
M 3X*Y-VJ./+-$79FFO3:IFW]%R-JOOS"Q@
M          "O4<D<<==N>=/Z;1X1%R5A
M         )\)5NW53/:#73UYJ=,B?=UNRL@
M         ,5_(GQ\/)'Z!\)_!U/PY&/&=SU\WH^_)R\\\FV_GR\N_O2( 2J=
MJY7/:=71M5%%.E1/R>DS-Z?/^A;
M    -Q6[5=<=H%RW-OZG\'1537[^]G>%D
M         "9VCJ\8IN3>YHK]3:(Y9CPGZ7K5\F?H5>Y5=HX\IY9I[N=/ZQ/C
MOWD_>6D                                     56F)GM)IG:=HTK:=
M_P!M_P#PM0                                    !5ORSMX[*U:IM?
M'^J8Y.]^#HW\>;;O)^\LH                                    QS1
M$[;QNSNQ*J8O)_PC7]JYYXTVG>FJ)\)NU3O3,^6_2?8M@
M                    3.WB"'UG2\G-RM/OXNH7L6<6_P!]7;IG>B_'+-/+
M5'LZ[_3"3Q[7=1,<U56\[[U3O/W7K5X2J&)9MQV@9<5Y%$W+V#17./57-57J
MUS3SQT]6/+;VK>       $@                           UKIBKQ\FP!
M/AU4W3Z:;7:?J$54U55W-,M317,Q\F+E43'M\5R
M                )\)5/$Q)GM*S,WFJFF-,MV>68C:F>]JG[_5;
M                             "?!6,6:+?:%EV^>9KN:=17-._2(B[7^
M59P                                    "?!4,6K?M2R8F*)B=(HF*
MMO6CZM5TE;P                                    ">D3*J8]5,=IF
M31$5<TZ5;G??IMWM7DM8                                    !/A*
MFXE<U=K.93,U;4Z1;VWCQ^K5>"Y
M    $^"G:?<B>U#.MSR554:9;JWB/6IWN5;Q]$SUV]NZX@
M                      ,3*G:9DV<CM-U2FW-,7+&G6K=<<LQ5.]=4Q/AU
MC;[ZY                                    Q7533MS51&\[1O/C+,
MQ5&\2HFD557.U[59JHKMQ3I5NB(JF/7COJO6A?
M             8N5111-57A"+X9UW#XCTN-0T[O)QYN7+43<HFF=Z*YIGI/E
MO$I5BJ-]MXB=IWZL@3X2^?\ #]R[=[7=<F_1$<FGVZ+=7MH[VK^G=]
M                             !BJF*J9IJC>F8VF)\VMJU19IY;=,4T^
MR(VB&X\[MRFUM-==--.\1O5.ST"?!2-'O=]VIZM$TQ1W6FV::=XF*JXFY5,U
M>S;==P                                !X9<U1;WHY>>(F8YIF(WV>
M6CSFSI>-\*4V*<WD^JTX\S-N)^;OUV=@ -:[=-<QSTQ.W6&P3TB5(T.FN.TW
M6YO4VN\]!L13515._=\]>T51]EOOU\/!=P
M      !PZUIU&JZ=>P[EZ_8IN1M-RQ7RUQUB>D_:=EJCDMQ3O,[><^;8  &M
MVN+=NNN=]J8F9VC>5!X0U+&U/M"UN[1A7L;)HPK%$S=C:J:>:N=ICRG>7T
M                                   !BJ-Z9CKUCR4+0;=%':WKLS35
MSSIN--%4STFCFJ^_ONOP                                    !5X3
MMXJ%PS3ESVG<0UY5,=W.)8BQX?4Z(JJB*=X\IF)JZ]>J^@
M                      -+M=-%.]=44Q[5,T#,M97:=Q';Q<BJN,?"Q;=^
MW^IIN[W)^[R[+L                                     Q5&_DIFC3
M1':?KM,;15.GXN\<L1OZ]WK[_)=
M    "95'AJBY'%^NUWL>S;B;=F+%=N)YJK7K3ZV_GO,K<
M                      UJWZJII-R]/:'K%/>\V/.!C3%$3O%-?/=B?M[1
M'W%M                                     %/T6W33VC:Y7'-S5X&+
M5._AUKN[;+@                                     \K]==%$S11-=
M7V,3$3]]3>'+EVOM,XGIN7+=5NWB8ENB*8G>F(FY/K;^?7R7<
M                         !B?"?:J.A3S]H?$5<VIHF,;%HWWWYH^J3O[
MI]WBMX                                    $SM'E]MB?/91>%,FB[
MVD\5V;611>MV<?#HVIKYN6KZIOS>]>P
M       :W**:Z>6J-X]C:.D*/PQ33;[2N+*+,T1;JQ\.N:8B(GFVN;S/TKP
M    !(                              !/@AM/TN,?B+4]2VHBO,MV:*
MMO'U(J\?\Y,@     Q5&\,6Z8HHBF)F8CVM@
M    :57:*;D4353%<^$;]9;@$^'1"Z1>R;NL:GWLVYQZ)HBU,5==]O6B8^E-
M                             #SN55Q=HIBWS43XU;_)>@    !$[M+E
MJBY,37135MX-P&*IVB9VWV1FETW(RLN;G=Q35<WHBBG:8Z==Y]J4       :
MU3,3&T;[RV                           ):6Z.6JN>:J>:?"9\&X\[EV
MFB[115,1-7A[WH$J1PEEWJ^..+\:]?JN18JQN2WS;TT1-%76(\IG;JNX
M  !L   \Z(N175SS3-._JQ$=8>@                        3X=&EJ:YI
MCO(VJ]S?:-]]NH,3,;3U\/'W*+PE59K[0N,^2:HOQZ)371MTB.6O:8^E>P
M     !K15O55'+5&WG/FV                            >&55<HM53:B
MFJN8]6*ND;^]\ZX%SZ[_ !5QEEW\:NQD^GTX?)Y3;M4SR5__ '15N^F
M   !$;1X[@                          ,5UQ1&]7T,@UN_)VZ=?:H_!V
M):L\4\5\^3%[(KR;5Z:-XF;5$V]J:?N1,_;7H
M&*M^6>7;?;INQ;BKEB;FW-[O!L         $=?  )C<CW UN4\U%43,QO&V\
M>3YYP/R?'[CBFW%6]%W%HJJJ\:MK=77?Z)A]%
M           GK#%-,4QT9 &M%$41,4^<[M@GPE\^X%N57^/N.:YYZ(B_CT1;
MK\?5HJCFCW3MT?00                                    &)\WSO@7
M&MXG:#QU3;RJ[]5R[BUU17.]5$S17TW]GLA]%
M           \P  &)?,>%,CN^/>-;G=54U7,G&B9Z>5NY[WT\
M                       !BJ9B.GB45153$Q,3'MB=X9 )\'S;A*JQE<9\
M8<MJY1<HR[$5S5MM5/<SMM]V7TD
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MM]FS6BKFF=HF-O:V !B8WB7S7LNC_P"*^/HFN:Y^$Z9YIC:)B;<3]V/!]+
M                                >=JFY%=4W*XF/*(CP>@  \KUVJW;
MKJHHFY53X4T^,OGG93155KW&V751-NF]JLVZ:?*8HHB.:)\]_P"A](
M                             >=Z[%KEYM_6GEC:)GJ](G>&EZ*ZK546
MJHIK\IGR;QX1OXAN3,;=7SCLJN7:^(..*<B9YZ=5BB*?93%FC;^E]'
M                             )C?S8ICEIVWF?I9!K1%455355O$^$;>
M#:8?/.S**OC)QS-=7-7\*QO5MMO]2HF/P[/H8
M             203M$3O.T>U\V[),JC*UCC6[1OO7JO-U]DVJ-H^\^D@
M                             3+&YN;FYN;L[L;F['-$[Q^%\P['9HJU
M?CB_1RU4W-7F-Z9WCI;I_*^H@                                !,[
M,;;]38V-C8V-F=F-C9K<HYJ9B)FF=NDQY/DO]3_A3B6N+K-5JNWW>LW:-JH\
M)BFGF^_U^V^N@                                 !(  Y\V_3CX]R[
M7$U4T1UBF-YV?,.P;-C49XRS+57/9OZY?KIJCPGI3UCZ>DOJX
M                       UN5113-54Q$>^=BBNFNF*J9BJ)\XZM@ >-^/4
MJWVF)G:8JG;I['S_ +([%G&S.+K6)1;MXMO5JJ+=-OY.\6Z-]H\NKZ,
M             $3$^$[@               UN6Z;D;5TQ5'LF-X*+=%%,4T4
MQ33'A$=&P -*O&?8HW9?$>D\55T5\]%>KW)B>GCW=&_@O@
M   !/6&*:8IZ1X,@              #$U1%41YRSXP0&Q ,5=:9C>8WCQCR?
M/^R6Y%V.)JXJFN?A>[3,U3U]6FB.OE'AY/H(
M          UFW1-R*YICGB-HEG?;Q(F)\&0!K5YP^>=C]J]3'%-61W6]6LWI
MHIM;\M,331[>N_M?10                                  )(C8 &)C
M??;Q?->Q?)KR9XNY[<4TV]:O4TSUZ^I1O+Z6         &X
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M=9CQ\'S/^I\BF.'];IHBNGDU?(IJHJZ\L^KY_??5
M                GPE'8&IVLO4<[#MTWHN8E5--R:[<TTSS1O'+/A4D6.:G
M?;?K["KR<U=RN+%4UTQ3,;[^?1\R_J>:XKT#7JHB=ZM9R9GIMUB*8?5P
M                              F=@&E%'+UF=Y;H^K#R?A>SE49M5.)3
M;KIKQ8MT[5U3,3%?-XQ,;3&WAU2#EU&*?1JYJC>(B9CKMY/F?]3U%R.']<IO
M;<U.L9,1,1MO'J[/JP                                  ;,1.\])9
M !QZG7;IQ;T7:MHFB8CW='SOL HBGAS6)VVJ^%\F)B9WF(WB(W]G2(?4
M                             8F8B=I9\88B-F0:T413OMYM@W 1^LV+
M63AW:;\1-%-,U1$[[3M'G[8]RA=@5B+/"F=51<HNQ=U/*KWIJWY?7Z1N^F@
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M>X-["TN]Z7I]&GY-V_7=KL47.;V1%7CTWBG?9:@
4               !B*8B=_-__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>footer1026.jpg
<TEXT>
begin 644 footer1026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-A=F]I92P@
M2V5V:6X   60 P "    %   $*:0!  "    %   $+J2D0 "     S,R  "2
MD@ "     S,R  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
M   ! @,$!08'" D*"__$ +41  (! @0$ P0'!00$  $"=P ! @,1! 4A,082
M05$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X
M.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3
ME)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+C
MY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ ^D:*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ;DT9-%% ')'7]3NM4U.VC;["%LU>U%S"T0C;S"FYG92"3P0.1T
MZG-2RZW*D$<<FI"U"QW!DNY#&P>2/9A0VT*RX9N@!^0]"#73LJNI5P&4C!!&
M0:3RTV*NQ=JXVC' QTQ3NA69@6NIWTFJVTEW*(XITC46<<B%XY&CW$.I3=@9
MZANPXQFK$T]X?%#P_:Y(;1+>%U0! '8O(&Y*$GA4X!&/QK7\M/,,FQ=Y&"V.
M<>F:=1<##;5-6,<DB6T("QSR!61B?W;[57W+#GV]ZDCUN>2_N(4A67R9?+\I
M/O@>6'W$GC&3M_K6Q34C2,L8T52[;F(&-QZ9/OP* ,I=5O)&B2*&)F>=8W(8
MGRP59CD#/(P!U[]J+C5KN.%C;VPEFZ>3R#'S@;CSP?8?GUK7HH YGQ1J][IT
M]E%!<"(S6\S,5DAC!=3&!S+D8^8\#G\J9'XM:WMY;N[7S;<-%DH-K1[X%=?E
MZ_,YVC)ZL!74T47069@/KMVVL:?:E+> 27)AG3S]TF1 [D!=OW<@?-GD#IS6
MM=W.=-N9+6Y@C=86999&&Q#MR&;VZ'Z5/Y:>9YFU=^-N['./3-(L4:&0K&JF
M0[G(7[YP!D^O  ^@% &!IGB)!(EK=3R/+Y[0RO<21?NV$8< % %8$'(Z'GD#
MI5>'Q7/<3V#QQQ1174D D$\X"HLEN\F%(7KE0.>OMFNE%M (P@@C" [@NP8!
M]<5+1=!J8^BZ[<:M,ZRZ>;6,('1C<1NQR>C(#E3['WK'@\032VUQ<6FL)=6?
MF6T2SN(LINEVR2 +C"8("EL\@GD=>N6-%=F5%#-]X@<GZTI 92&&0>"#WHN@
ML<R-<F>.)9]2CMH";K;?$)B3RW 3KP<@L3CKL)&!6U;WEU+H4-XUJ?M4ENLA
MM\XPY4$KS[\5;,:%0I52JX(&.F.E.H8696TZYN+JPCEO+<V\S#YHR>G^'TK#
M36I5N4\K44N;AM0>W>P^3*Q^:R;@%&X;5&\DY! /J".EHI+0232M<YS_ (2[
MS([3[+:I--<VXE\L7 &QC+'&%)QZR=?]G\GIKE_#JMU%=V\)M4O4MQ()OFCS
M;I(<#;\PW$\D@\].*WDC2/=Y:*FXY;:,9/K3J>@]3E[;QA/=S)%!80N\LT<<
M3"\RCJ\;N'R%R.(^A&>:NZ5K]Q?2P+>6D-JL\#3(RW&_&UU7!RJ]=PQ6S'&D
M2[8D5!G.%&*)(TE4+*BNH8, PR,@Y!^H(!_"C0-3#O\ 5[VR\2[ !)I\5HLM
MPBIETR[#S >X&WE?3)'(P:MCK%Q?6]JE[JBZ<\FG07"N%C!F=U)=OG!&!@<
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MI+W'V&4!6CG C(W<YQ\S<>BGK5S1=8DO;F[C?S##"55))&B+-(0Q9!Y9*G:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
:*** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>header1026.jpg
<TEXT>
begin 644 header1026.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-A=F]I92P@
M2V5V:6X   60 P "    %   $*:0!  "    %   $+J2D0 "     S@T  "2
MD@ "     S@T  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?#=KH%QHMMH]M#IUT )X(U*^;_O$<GIZUA>-[HWM*UCEO@/_ ,DBT[_KK/\
M^C6KN]4TVVUC2;K3;Y-]M=Q-#*OJK#!_&H]%T/3O#NEQZ;HMJMK:1DE(E8D
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4
M)12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC%
M "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 )12XH
MQ0 E%+BC% "44N*,4 )12XHQ0 E%+BC% "44N*,4 +1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
:444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>bcrx20201231_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bcrx="http://www.biocryst.com/20201231"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="bcrx-20201231.xsd" xlink:type="simple"/>
    <context id="d_2020-01-01_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i_2021-01-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_ProductOrServiceAxis-RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2018-01-01_2018-12-31_ProductOrServiceAxis-RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2018-01-01_2018-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2018-01-01_2018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i_2018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2017-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i_2017-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i_2017-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201409Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i_2017-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201409Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:RoyaltyReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">bcrx:CollateralForCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">bcrx:CollaborationReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">bcrx:CollaborationReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:ShionogiAndCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:MundipharmaInternationalHoldingsLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:BilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis">us-gaap:UnbilledRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-RAPIVABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:RAPIVABMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-ORLADEYOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2018-01-01_2018-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2018-01-01_2018-12-31_CounterpartyNameAxis-SeqirusUKLimitedMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:SeqirusUKLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:CollaborativeAndOtherResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2018-01-01_2018-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bcrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-03-09</instant>
        </period>
    </context>
    <context id="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bcrx:RoyaltyMonetizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-03-01</startDate>
            <endDate>2011-03-09</endDate>
        </period>
    </context>
    <context id="d_2011-03-01_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-03-01</startDate>
            <endDate>2011-03-09</endDate>
        </period>
    </context>
    <context id="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-03-09</instant>
        </period>
    </context>
    <context id="i_2020-12-01_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-01</instant>
        </period>
    </context>
    <context id="i_2019-12-31_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_LegalEntityAxis-JPRRoyaltySubLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bcrx:JPRRoyaltySubLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-11-30_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:PhaRMANotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bcrx:CurrencyHedgeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder350000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween350000And550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver550000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver550000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-BCX9930Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:BCX9930Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder150000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesUnder150000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween150000And230000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesBetween150000And230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver230000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bcrx:ORLADEYOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AnnualNetSalesOver230000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:Rpi2019IntermediateFinanceTrustMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:FutureRoyaltiesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermALoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermBLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermBLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermCLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermCLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PikInterestPaymentIsMadeMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:PikInterestPaymentIsMadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PriorToTheSecondAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:PriorToTheSecondAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-BetweenTheSecondAndThirdAnniversariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:BetweenTheSecondAndThirdAnniversariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-BetweenTheThirdAndFourthAnniversariesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:BetweenTheThirdAndFourthAnniversariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-AfterFourthAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:AfterFourthAnniversaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-07</startDate>
            <endDate>2020-12-07</endDate>
        </period>
    </context>
    <context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoanADrawnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:TermLoanADrawnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoanAAndBDrawnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:TermLoanAAndBDrawnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoansABAndCDrawnMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:TermLoansABAndCDrawnMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoansABAndCDrawnAndCureRightExercisedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bcrx:TermLoansABAndCDrawnAndCureRightExercisedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-07</instant>
        </period>
    </context>
    <context id="i_2020-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:AthyriumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bcrx:TermALoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-05</instant>
        </period>
    </context>
    <context id="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityFirstTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:SecuredCreditFacilityFirstTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-05</instant>
        </period>
    </context>
    <context id="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityFirstTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:SecuredCreditFacilityFirstTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-05</startDate>
            <endDate>2019-02-05</endDate>
        </period>
    </context>
    <context id="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilitySecondTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:SecuredCreditFacilitySecondTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-05</instant>
        </period>
    </context>
    <context id="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityThirdTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:SecuredCreditFacilityThirdTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-05</instant>
        </period>
    </context>
    <context id="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-05</startDate>
            <endDate>2019-02-05</endDate>
        </period>
    </context>
    <context id="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-05</startDate>
            <endDate>2019-02-05</endDate>
        </period>
    </context>
    <context id="d_2020-12-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bcrx:MidCapFinancialServicesLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2019-01-01_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i_2019-01-01_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="i_2019-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bcrx:AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bcrx:AccruedLiabilitiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">bcrx:AccruedLiabilitiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2017-11-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2017-11-08</instant>
        </period>
    </context>
    <context id="d_2018-08-06_2018-08-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2018-08-06</startDate>
            <endDate>2018-08-06</endDate>
        </period>
    </context>
    <context id="i_2018-08-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2018-08-06</instant>
        </period>
    </context>
    <context id="d_2019-11-18_2019-11-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2019-11-18</startDate>
            <endDate>2019-11-18</endDate>
        </period>
    </context>
    <context id="i_2019-11-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2019-11-18</instant>
        </period>
    </context>
    <context id="i_2019-11-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2019-11-21</instant>
        </period>
    </context>
    <context id="d_2019-11-21_2019-11-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2019-11-21</startDate>
            <endDate>2019-11-21</endDate>
        </period>
    </context>
    <context id="i_2020-04-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2020-04-24</instant>
        </period>
    </context>
    <context id="d_2020-06-01_2020-06-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="i_2020-06-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="i_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bcrx:WarrantsIssuedInPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-01</instant>
        </period>
    </context>
    <context id="d_2020-06-01_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bcrx:WarrantsIssuedInPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-01</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="d_2018-01-01_2018-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2018-01-01_2018-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2018-01-01_2018-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-08-01</startDate>
            <endDate>2013-08-31</endDate>
        </period>
    </context>
    <context id="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-12-01_2019-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:August2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardDateAxis-December2019Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:August2013Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardDateAxis-December2019Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">bcrx:December2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2017-12-31_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i_2018-12-31_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PlanNameAxis-IncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">bcrx:Vest25PercentEachYearUntilFullyVestedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2019-12-31_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange01Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange01Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange02Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange02Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange03Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange03Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange04Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange04Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange05Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange05Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange06Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">bcrx:ExercisePriceRange06Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:IncentivePlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bcrx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_TaxCreditCarryforwardAxis-ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-08-01_2020-08-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:BaseContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AdditionalDevelopmentOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-03-31</instant>
        </period>
    </context>
    <context id="d_2015-04-01_2020-12-31_TypeOfArrangementAxis-ASPRBARDAContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:ASPRBARDAContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-04-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-06</startDate>
            <endDate>2018-09-06</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-09-03_2020-09-03_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:USDepartmentOfHealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-03</startDate>
            <endDate>2020-09-03</endDate>
        </period>
    </context>
    <context id="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-05</startDate>
            <endDate>2019-11-05</endDate>
        </period>
    </context>
    <context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-05</instant>
        </period>
    </context>
    <context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-05</instant>
        </period>
    </context>
    <context id="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-05</instant>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-ServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:ToriiPharmaceuticalCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-16</startDate>
            <endDate>2015-06-16</endDate>
        </period>
    </context>
    <context id="d_2015-06-16_2020-12-31_CounterpartyNameAxis-CSLLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bcrx:CSLLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-16</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-03-04_2020-03-04_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bcrx:ArbitrationProceedingsOfSulAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-04</startDate>
            <endDate>2020-03-04</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-OtherIncomeMember_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bcrx:ArbitrationProceedingsOfSulAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">bcrx:ArbitrationProceedingsOfSulAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:GreenCrossCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-06-01</startDate>
            <endDate>2006-06-30</endDate>
        </period>
    </context>
    <context id="i_2011-11-11_TypeOfArrangementAxis-MundipharmaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:MundipharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-11-11</instant>
        </period>
    </context>
    <context id="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2000-06-01</startDate>
            <endDate>2000-06-30</endDate>
        </period>
    </context>
    <context id="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bcrx:AECOMAndIRLMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2000-06-30</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">bcrx:UABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="d_2020-04-01_2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="d_2020-07-01_2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="d_2020-10-01_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-01-01_2019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="d_2019-04-01_2019-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="d_2019-07-01_2019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="d_2019-10-01_2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_DebtInstrumentAxis-CreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bcrx:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000882796</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">bcrx:SeniorCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="Month">
        <measure>utr:M</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="JPYPerUSD">
        <divide>
            <unitNumerator>
                <measure>iso4217:JPY</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>iso4217:USD</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2020-01-01_2020-12-31"
      id="thunderdome-EntityCentralIndexKey">0000882796</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2020-01-01_2020-12-31"
      id="thunderdome-EntityRegistrantName">BIOCRYST PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2020-01-01_2020-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2020-01-01_2020-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2020-01-01_2020-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2020-01-01_2020-12-31">2020</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c69831007"
      unitRef="USDPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c69831008"
      unitRef="USDPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2020-12-31"
      decimals="-6"
      id="c69831009"
      unitRef="Share">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2019-12-31"
      decimals="-6"
      id="c69831010"
      unitRef="Share">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69831011"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69831012"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828094"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828095"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c69828104"
      unitRef="USDPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c69828105"
      unitRef="USDPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2020-12-31"
      decimals="-7"
      id="c69828106"
      unitRef="Share">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2019-12-31"
      decimals="-7"
      id="c69828107"
      unitRef="Share">450000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828108"
      unitRef="Share">176883000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828110"
      unitRef="Share">176883000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828109"
      unitRef="Share">154082000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828111"
      unitRef="Share">154082000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-4"
      id="c69828254"
      unitRef="USD">52420000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828332"
      unitRef="Share">92000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828342"
      unitRef="Share">10455000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828377"
      unitRef="Share">283000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828387"
      unitRef="Share">115000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828397"
      unitRef="Share">43621000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <bcrx:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828407"
      unitRef="Share">11765000</bcrx:ClassOfWarrantOrRightIssuedDuringPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-4"
      id="c69828437"
      unitRef="Share">510000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828448"
      unitRef="Share">246000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828462"
      unitRef="Share">22044000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <bcrx:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828473"
      unitRef="Share">3511000</bcrx:ClassOfWarrantOrRightIssuedDuringPeriod>
    <bcrx:MaturityPeriodOfHighQualityMarketablesecurities
      contextRef="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember"
      id="c69828560">P3Y</bcrx:MaturityPeriodOfHighQualityMarketablesecurities>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember"
      decimals="-3"
      id="c69831136"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2020-01-01_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentMember"
      id="c69828591">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2020-01-01_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentOfficeEquipmentAndSoftwareMember"
      id="c69828592">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2020-01-01_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      id="c69828593">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AdvertisingExpense
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828614"
      unitRef="USD">0</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828615"
      unitRef="USD">0</us-gaap:AdvertisingExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"
      id="c69829093">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember"
      id="c69829118">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2020-01-01_2020-12-31"
      decimals="2"
      id="c69831164"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2019-01-01_2019-12-31"
      decimals="2"
      id="c69831165"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2018-01-01_2018-12-31"
      decimals="2"
      id="c69831166"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-4"
      id="c69830313"
      unitRef="USD">4080000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69830314"
      unitRef="USD">4938000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69830315"
      unitRef="USD">4905000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69830319"
      unitRef="USD">1456000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69830320"
      unitRef="USD">281000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69830321"
      unitRef="USD">18000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69830325"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69830326"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69830327"
      unitRef="USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OpenTaxYear contextRef="d_2020-01-01_2020-12-31" id="c69829408">2017 2018 2019</us-gaap:OpenTaxYear>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69829412"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i_2018-12-31"
      decimals="-3"
      id="c69829413"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <bcrx:ContractTerm
      contextRef="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember"
      id="c69829532">P5Y</bcrx:ContractTerm>
    <bcrx:RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial
      contextRef="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"
      id="c69829552">P10Y</bcrx:RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial>
    <bcrx:RenewablePeriodOfAgreement
      contextRef="d_2020-01-01_2020-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember"
      id="c69829592">P5Y</bcrx:RenewablePeriodOfAgreement>
    <dei:DocumentType contextRef="d_2020-01-01_2020-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2020-01-01_2020-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2020-01-01_2020-12-31">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2020-01-01_2020-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2020-01-01_2020-12-31">000-23186</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2020-01-01_2020-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2020-01-01_2020-12-31">62-1413174</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2020-01-01_2020-12-31">4505 Emperor Blvd., Suite 200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2020-01-01_2020-12-31">Durham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2020-01-01_2020-12-31">NC</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2020-01-01_2020-12-31">27703</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2020-01-01_2020-12-31">919</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2020-01-01_2020-12-31">859-1302</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2020-01-01_2020-12-31">Common Stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2020-01-01_2020-12-31">BCRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2020-01-01_2020-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2020-01-01_2020-12-31">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2020-01-01_2020-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2020-01-01_2020-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2020-01-01_2020-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2020-01-01_2020-12-31">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2020-01-01_2020-12-31">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2020-01-01_2020-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="d_2020-01-01_2020-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="i_2020-06-30" decimals="INF" unitRef="USD">832869919</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="i_2021-01-31" decimals="INF" unitRef="Share">177182751</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828048"
      unitRef="USD">272127000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828049"
      unitRef="USD">114172000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828050"
      unitRef="USD">2221000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828051"
      unitRef="USD">1551000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828052"
      unitRef="USD">28239000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828053"
      unitRef="USD">22054000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828054"
      unitRef="USD">8646000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828055"
      unitRef="USD">22146000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828056"
      unitRef="USD">7039000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828057"
      unitRef="USD">0</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828058"
      unitRef="USD">5528000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828059"
      unitRef="USD">4422000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2020-12-31"
      decimals="-5"
      id="c69828060"
      unitRef="USD">323800000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828061"
      unitRef="USD">164345000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828062"
      unitRef="USD">7113000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828063"
      unitRef="USD">7347000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828064"
      unitRef="USD">3802000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2019-12-31"
      decimals="-4"
      id="c69828065"
      unitRef="USD">3590000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828066"
      unitRef="USD">334715000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828067"
      unitRef="USD">175282000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828069"
      unitRef="USD">18713000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828070"
      unitRef="USD">13988000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828071"
      unitRef="USD">33942000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828072"
      unitRef="USD">21365000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c69828073"
      unitRef="USD">21670000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828074"
      unitRef="USD">14904000</us-gaap:InterestPayableCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c69828075"
      unitRef="USD">150000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="i_2019-12-31"
      decimals="-4"
      id="c69828076"
      unitRef="USD">2120000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828077"
      unitRef="USD">1179000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828078"
      unitRef="USD">1377000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828079"
      unitRef="USD">0</us-gaap:LinesOfCreditCurrent>
    <us-gaap:LinesOfCreditCurrent
      contextRef="i_2019-12-31"
      decimals="-4"
      id="c69828080"
      unitRef="USD">9020000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i_2020-12-31"
      decimals="-7"
      id="c69828081"
      unitRef="USD">30000000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828082"
      unitRef="USD">29561000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828083"
      unitRef="USD">105654000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828084"
      unitRef="USD">92335000</us-gaap:LiabilitiesCurrent>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828085"
      unitRef="USD">124717000</bcrx:FutureRoyaltiesPayable>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828086"
      unitRef="USD">0</bcrx:FutureRoyaltiesPayable>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828087"
      unitRef="USD">3871000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828088"
      unitRef="USD">3406000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LineOfCredit
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828089"
      unitRef="USD">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828090"
      unitRef="USD">41289000</us-gaap:LineOfCredit>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828091"
      unitRef="USD">119735000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828092"
      unitRef="USD">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:CommonStockValue
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828102"
      unitRef="USD">1769000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828103"
      unitRef="USD">1541000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828112"
      unitRef="USD">1002408000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2019-12-31"
      decimals="-5"
      id="c69828113"
      unitRef="USD">877300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828114"
      unitRef="USD">3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828115"
      unitRef="USD">39000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828116"
      unitRef="USD">-1023442000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828117"
      unitRef="USD">-840628000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828118"
      unitRef="USD">-19262000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828119"
      unitRef="USD">38252000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828120"
      unitRef="USD">334715000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828121"
      unitRef="USD">175282000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c69828123"
      unitRef="USD">3301000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c69828124"
      unitRef="USD">17533000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c69828126"
      unitRef="USD">3381000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c69828127"
      unitRef="USD">6303000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2018-01-01_2018-12-31_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c69828128"
      unitRef="USD">6101000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-4"
      id="c69828129"
      unitRef="USD">11130000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c69828130"
      unitRef="USD">24999000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2018-01-01_2018-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c69828131"
      unitRef="USD">14552000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828132"
      unitRef="USD">17812000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828133"
      unitRef="USD">48835000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828134"
      unitRef="USD">20653000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-4"
      id="c69828136"
      unitRef="USD">1550000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828137"
      unitRef="USD">3726000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828139"
      unitRef="USD">122964000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828140"
      unitRef="USD">107068000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828141"
      unitRef="USD">84888000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828142"
      unitRef="USD">67929000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828143"
      unitRef="USD">37121000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828144"
      unitRef="USD">29514000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RoyaltyExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828145"
      unitRef="USD">126000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828146"
      unitRef="USD">375000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828147"
      unitRef="USD">471000</us-gaap:RoyaltyExpense>
    <us-gaap:CostsAndExpenses
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828148"
      unitRef="USD">192569000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-4"
      id="c69828149"
      unitRef="USD">148290000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828150"
      unitRef="USD">114873000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828151"
      unitRef="USD">-174757000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828152"
      unitRef="USD">-99455000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-4"
      id="c69828153"
      unitRef="USD">-94220000</us-gaap:OperatingIncomeLoss>
    <bcrx:InterestAndOtherIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-4"
      id="c69828154"
      unitRef="USD">9420000</bcrx:InterestAndOtherIncomeLoss>
    <bcrx:InterestAndOtherIncomeLoss
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828155"
      unitRef="USD">1933000</bcrx:InterestAndOtherIncomeLoss>
    <bcrx:InterestAndOtherIncomeLoss
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828156"
      unitRef="USD">2252000</bcrx:InterestAndOtherIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828157"
      unitRef="USD">14501000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828158"
      unitRef="USD">11892000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828159"
      unitRef="USD">9176000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828160"
      unitRef="USD">-2011000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828163"
      unitRef="USD">-965000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828164"
      unitRef="USD">517000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828165"
      unitRef="USD">-108000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828166"
      unitRef="USD">-182814000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828167"
      unitRef="USD">-108897000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828168"
      unitRef="USD">-101252000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828169"
      unitRef="USD">-36000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828170"
      unitRef="USD">336000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828171"
      unitRef="USD">-54000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-4"
      id="c69828172"
      unitRef="USD">-182850000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828173"
      unitRef="USD">-108561000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828174"
      unitRef="USD">-101306000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c69828175"
      unitRef="USDPerShare">-1.09</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c69828176"
      unitRef="USDPerShare">-0.94</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2018-01-01_2018-12-31"
      decimals="INF"
      id="c69828177"
      unitRef="USDPerShare">-0.98</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828178"
      unitRef="Share">167267000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-5"
      id="c69828179"
      unitRef="Share">115600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828180"
      unitRef="Share">103185000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828181"
      unitRef="USD">-182814000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828182"
      unitRef="USD">-108897000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828183"
      unitRef="USD">-101252000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828185"
      unitRef="USD">748000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828186"
      unitRef="USD">724000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-4"
      id="c69828187"
      unitRef="USD">770000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828190"
      unitRef="USD">-7000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828191"
      unitRef="USD">14794000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828192"
      unitRef="USD">17719000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828193"
      unitRef="USD">9396000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828194"
      unitRef="USD">2428000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828195"
      unitRef="USD">1278000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828196"
      unitRef="USD">885000</us-gaap:AmortizationOfFinancingCosts>
    <bcrx:AmortizationOfDiscountAndPremiumOnInvestments
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828197"
      unitRef="USD">121000</bcrx:AmortizationOfDiscountAndPremiumOnInvestments>
    <bcrx:AmortizationOfDiscountAndPremiumOnInvestments
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828198"
      unitRef="USD">117000</bcrx:AmortizationOfDiscountAndPremiumOnInvestments>
    <bcrx:AmortizationOfDiscountAndPremiumOnInvestments
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-4"
      id="c69828199"
      unitRef="USD">110000</bcrx:AmortizationOfDiscountAndPremiumOnInvestments>
    <us-gaap:IncreaseDecreaseInDerivativeAssets
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828200"
      unitRef="USD">-632000</us-gaap:IncreaseDecreaseInDerivativeAssets>
    <us-gaap:IncreaseDecreaseInDerivativeAssets
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828201"
      unitRef="USD">-347000</us-gaap:IncreaseDecreaseInDerivativeAssets>
    <us-gaap:IncreaseDecreaseInDerivativeAssets
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828202"
      unitRef="USD">-1049000</us-gaap:IncreaseDecreaseInDerivativeAssets>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828204"
      unitRef="USD">-13903000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828205"
      unitRef="USD">17853000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828206"
      unitRef="USD">-1824000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828207"
      unitRef="USD">7039000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828208"
      unitRef="USD">-1649000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828209"
      unitRef="USD">1649000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-4"
      id="c69828210"
      unitRef="USD">2140000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828211"
      unitRef="USD">1364000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828212"
      unitRef="USD">866000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828213"
      unitRef="USD">17355000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828214"
      unitRef="USD">11741000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828215"
      unitRef="USD">4487000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828216"
      unitRef="USD">6766000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828217"
      unitRef="USD">3056000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828218"
      unitRef="USD">-247000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-4"
      id="c69828219"
      unitRef="USD">-1970000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828220"
      unitRef="USD">1899000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828221"
      unitRef="USD">-7079000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828222"
      unitRef="USD">-137216000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828223"
      unitRef="USD">-89584000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828224"
      unitRef="USD">-92565000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828226"
      unitRef="USD">514000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828227"
      unitRef="USD">343000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828228"
      unitRef="USD">366000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828229"
      unitRef="USD">49818000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828230"
      unitRef="USD">3018000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828231"
      unitRef="USD">62614000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828232"
      unitRef="USD">43475000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828233"
      unitRef="USD">81295000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828234"
      unitRef="USD">67748000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <bcrx:ProceedsFromRealizedGainOnInvestments
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828235"
      unitRef="USD">1000</bcrx:ProceedsFromRealizedGainOnInvestments>
    <bcrx:ProceedsFromRealizedGainOnInvestments
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828236"
      unitRef="USD">0</bcrx:ProceedsFromRealizedGainOnInvestments>
    <bcrx:ProceedsFromRealizedGainOnInvestments
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828237"
      unitRef="USD">0</bcrx:ProceedsFromRealizedGainOnInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828238"
      unitRef="USD">-6856000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828239"
      unitRef="USD">77934000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828240"
      unitRef="USD">4768000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828242"
      unitRef="USD">93279000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-5"
      id="c69828243"
      unitRef="USD">58500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-5"
      id="c69828244"
      unitRef="USD">53400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828245"
      unitRef="USD">14817000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828246"
      unitRef="USD">19882000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828248"
      unitRef="USD">2446000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828249"
      unitRef="USD">1239000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828250"
      unitRef="USD">2852000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828251"
      unitRef="USD">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828252"
      unitRef="USD">19477000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828253"
      unitRef="USD">10353000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828256"
      unitRef="USD">4025000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828257"
      unitRef="USD">119867000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <bcrx:ProceedsFromRoyaltyFinancingObligation
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828260"
      unitRef="USD">124708000</bcrx:ProceedsFromRoyaltyFinancingObligation>
    <bcrx:IncreaseDecreaseInFinancingLeaseObligations
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828265"
      unitRef="USD">-76000</bcrx:IncreaseDecreaseInFinancingLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828266"
      unitRef="USD">302697000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828267"
      unitRef="USD">99098000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828268"
      unitRef="USD">62504000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828269"
      unitRef="USD">158625000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828270"
      unitRef="USD">87448000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828271"
      unitRef="USD">-25293000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828272"
      unitRef="USD">115723000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2018-12-31"
      decimals="-3"
      id="c69828273"
      unitRef="USD">28275000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2017-12-31"
      decimals="-3"
      id="c69828274"
      unitRef="USD">53568000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828275"
      unitRef="USD">274348000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828276"
      unitRef="USD">115723000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2018-12-31"
      decimals="-3"
      id="c69828277"
      unitRef="USD">28275000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:StockholdersEquity
      contextRef="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828293"
      unitRef="USD">984000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c69828294"
      unitRef="USD">714869000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2017-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c69828295"
      unitRef="USD">-243000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c69828296"
      unitRef="USD">-631843000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2017-12-31"
      decimals="-3"
      id="c69828297"
      unitRef="USD">83767000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2017-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201409Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c69828301"
      unitRef="USD">1126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2017-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201409Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember"
      decimals="-3"
      id="c69828302"
      unitRef="USD">1126000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c69828306"
      unitRef="USD">-101252000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828307"
      unitRef="USD">-101252000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c69828310"
      unitRef="USD">-54000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828312"
      unitRef="USD">-54000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828313"
      unitRef="USD">11000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c69828314"
      unitRef="USD">2490000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828317"
      unitRef="USD">2501000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828323"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-4"
      id="c69828324"
      unitRef="USD">350000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828327"
      unitRef="USD">351000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828333"
      unitRef="USD">105000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c69828334"
      unitRef="USD">53295000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-5"
      id="c69828337"
      unitRef="USD">53400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2018-01-01_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c69828344"
      unitRef="USD">9396000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828347"
      unitRef="USD">9396000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828348"
      unitRef="USD">1101000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-5"
      id="c69828349"
      unitRef="USD">780400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c69828350"
      unitRef="USD">-297000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c69828351"
      unitRef="USD">-731969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31"
      decimals="-3"
      id="c69828352"
      unitRef="USD">49235000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c69828356"
      unitRef="USD">238000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2018-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember"
      decimals="-3"
      id="c69828357"
      unitRef="USD">238000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c69828361"
      unitRef="USD">-108897000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828362"
      unitRef="USD">-108897000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c69828365"
      unitRef="USD">336000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828367"
      unitRef="USD">336000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828368"
      unitRef="USD">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c69828369"
      unitRef="USD">832000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828372"
      unitRef="USD">835000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828378"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c69828379"
      unitRef="USD">403000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828382"
      unitRef="USD">404000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828388"
      unitRef="USD">436000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c69828389"
      unitRef="USD">58064000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-5"
      id="c69828392"
      unitRef="USD">58500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c69828399"
      unitRef="USD">19882000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828402"
      unitRef="USD">19882000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-01-01_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c69828409"
      unitRef="USD">17719000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828412"
      unitRef="USD">17719000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828413"
      unitRef="USD">1541000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-5"
      id="c69828414"
      unitRef="USD">877300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c69828415"
      unitRef="USD">39000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c69828416"
      unitRef="USD">-840628000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828417"
      unitRef="USD">38252000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c69828421"
      unitRef="USD">-182814000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828422"
      unitRef="USD">-182814000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c69828425"
      unitRef="USD">-36000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828427"
      unitRef="USD">-36000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828428"
      unitRef="USD">5000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c69828429"
      unitRef="USD">1809000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828432"
      unitRef="USD">1814000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828438"
      unitRef="USD">3000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c69828439"
      unitRef="USD">629000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828442"
      unitRef="USD">632000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-4"
      id="c69828449"
      unitRef="USD">220000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c69828451"
      unitRef="USD">93059000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828457"
      unitRef="USD">93279000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c69828464"
      unitRef="USD">14817000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828467"
      unitRef="USD">14817000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c69828476"
      unitRef="USD">14794000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828482"
      unitRef="USD">14794000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c69828483"
      unitRef="USD">1769000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c69828484"
      unitRef="USD">1002408000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="c69828485"
      unitRef="USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c69828486"
      unitRef="USD">-1023442000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828487"
      unitRef="USD">-19262000</us-gaap:StockholdersEquity>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757829">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &#x2014; Significant Accounting Policies and Concentrations of Risk&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;The Company&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was founded in &lt;em style="font: inherit;"&gt;1986&lt;/em&gt; and incorporated in Delaware in &lt;em style="font: inherit;"&gt;1991,&lt;/em&gt; and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. The Company has incurred losses and negative cash flows from operations since inception.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;Based on the Company&#x2019;s expectations for revenue, operating expenses, and its option to access an additional $75 million from its existing credit facility, the Company believes its financial resources available at &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;will be sufficient to fund its operations into &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; The Company has sustained operating losses for the majority of its corporate history and expects that its &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; expenses will exceed its &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of its products and the progression of its product candidates in the future. The Company also &lt;em style="font: inherit;"&gt; may &lt;/em&gt;consider other plans to fund future operations, including: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (&lt;em style="font: inherit;"&gt;5&lt;/em&gt;) reducing spending on &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more research and development programs, including by discontinuing development; and/or (&lt;em style="font: inherit;"&gt;6&lt;/em&gt;) restructuring operations to change its overhead structure. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates, timing, scope and magnitude of its commercial expenses and key development and regulatory events and its decisions in the future.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 9pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). Such consolidated financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; adjustments other than normal recurring adjustments.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 1pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Restricted Cash&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Restricted cash as of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; reflects $796 and $134, respectively, in royalty revenue paid by Shionogi &amp;amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note &lt;em style="font: inherit;"&gt;3&lt;/em&gt;) and $1,425 and $1,417, respectively, the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Investments&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of &lt;span style="-sec-ix-hidden:c69828560"&gt;three&lt;/span&gt; years and requires an average portfolio maturity of &lt;em style="font: inherit;"&gt;no&lt;/em&gt; more than 18 months. Some of the securities the Company invests in &lt;em style="font: inherit;"&gt; may &lt;/em&gt;have market risk. This means that a change in prevailing interest rates &lt;em style="font: inherit;"&gt; may &lt;/em&gt;cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; collateralized. The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; realized any significant losses from its investments.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 7pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the Company believes that the cost of its investments is recoverable in all material respects.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 14pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair values of the Company&#x2019;s fixed income investments are classified as Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active. These fair values are obtained from independent pricing services which utilize Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 14pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Amortized Cost&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Accrued Interest&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Gross Unrealized Gains&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Gross Unrealized Losses&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Estimated Fair Value&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 40%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;24,986&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;3&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;(3&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;3,225&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;3,239&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Total Investments&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;28,211&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;(3&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;28,239&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="margin: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Amortized Cost&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Accrued Interest&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Gross Unrealized Gains&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Gross Unrealized Losses&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Estimated Fair Value&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 40%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;10,488&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;10,561&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;9,742&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;59&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;9,810&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,669&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,683&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Total Investments&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;21,899&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;116&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;22,054&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The Company&#x2019;s investments at &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; have maturities of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year or less.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Receivables from Collaborations&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 1pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&#x201c;Green Cross&#x201d;), Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;) and Seqirus UK Limited (&#x201c;SUL&#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date&#160;&lt;/span&gt;based on historical collection experience or specific circumstances and no amounts were recorded at &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;At &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2019, &lt;/em&gt;the Company had the following receivables:&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b style="font-size: 10pt;"&gt;December 31, 20&lt;/b&gt;&lt;b style="font-size: 10pt;"&gt;20&lt;/b&gt;&lt;b style="font-size: 10pt;"&gt; &lt;/b&gt;&lt;b style="font-size: 10pt;"&gt; &lt;/b&gt;&lt;b style="font-size: 10pt;"&gt; &lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Billed&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Unbilled&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;U.S. Department of Health and Human Services&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;5,402&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;5,402&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;2,037&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;2,041&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Green Cross Corporation&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;740&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;761&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Mundipharma International Holdings Limited&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Total receivables&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;2,816&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;5,427&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;8,243&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="11" rowspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b style="font-size: 10pt;"&gt;December 31, 2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Billed&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Unbilled&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;U.S. Department of Health and Human Services&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,353&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;15,023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;16,376&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,336&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,340&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Green Cross Corporation&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;2,924&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;2,932&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Mundipharma International Holdings Limited&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;56&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;56&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Seqirus UK Limited&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,091&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;351&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,442&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Total receivables&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;6,760&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;15,386&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;22,146&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: justify; text-indent: 26.75pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: justify; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Receivables from Product Sales&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 3.05pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Receivables&#160;&lt;/span&gt;from product sales are recorded for amounts due to the Company related to sales of RAPIVAB and ORLADEYO.&#160; At &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;receivables related to sales of RAPIVAB and ORLADEYO were $254 and $149, respectively.&#160; There were no receivables from product sales as of &lt;em style="font: inherit;"&gt; December 31, 2019. &lt;/em&gt;Receivables from product sales are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions and the Company&#x2019;s own historical collection experience. &#160;No reserve or allowance amounts were recorded at &lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;At &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; the Company&#x2019;s inventory related to peramivir which is being manufactured for the Company&#x2019;s partners and the U.S. Government.&#160; Inventory as of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;consisted of raw materials of $206, work-in-process of $2,555 and finished goods of $4,548. As of &lt;em style="font: inherit;"&gt; December 31, 2019, &lt;/em&gt;the Company inventory consisted of peramivir finished goods of $276.&#160; Inventory is stated at the lower of cost and net realizable value, determined under the &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in, &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-out (&#x201c;FIFO&#x201d;) method, or market. As of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; the Company had inventory reserves of $270 and $276, respectively, for estimated unrecoverable capitalized inventory costs.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company capitalizes subsequent costs related to the production of inventories.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of &lt;span style="-sec-ix-hidden:c69828591"&gt;three&lt;/span&gt; years. Laboratory equipment, office equipment, and software are depreciated over a life of &lt;span style="-sec-ix-hidden:c69828592"&gt;five&lt;/span&gt; years. Furniture and fixtures are depreciated over a life of &lt;span style="-sec-ix-hidden:c69828593"&gt;seven&lt;/span&gt; years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Patents and Licenses&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 12pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"/&gt;


   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 5pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The Company generally enters into contractual agreements with &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors who provide research and development, manufacturing,&#160;&lt;/span&gt;distribution,&#160;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="width: 27pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="width: 27pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;fees paid to investigative sites in connection with clinical trials;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="width: 27pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance, drug products, and product candidates; and&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="width: 27pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;professional fees.&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-17.15pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2019, &lt;/em&gt;the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Accrued expenses were comprised of the following:&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;9&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Compensation and benefits&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,030&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6,190&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Development costs&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;15,150&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;11,302&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Inventory&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,453&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;29&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;333&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;326&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Duties and taxes&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;67&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Other&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;4,896&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;3,451&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;33,942&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;21,365&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Accumulated Other Comprehensive Loss&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. For the year ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;realized gains of $1 were reclassified out of accumulated other comprehensive loss. No reclassifications out of accumulated other comprehensive loss were recorded in &lt;em style="font: inherit;"&gt;2019.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:14pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company recognizes revenue when it satisfies a performance obligation by transferring promised goods or services to a customer. Revenue is measured at the transaction price that is based on the amount of consideration that the Company expects to receive in exchange for transferring the promised goods or services to the customer. The transaction price includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company has collaboration and license agreements with a number of &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties as well as research and development agreements with certain government entities. The Company&#x2019;s primary sources of revenue are license, service, royalty and product sale revenues from these collaborative and other research and development arrangements.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Arrangements that involve the delivery of more than &lt;em style="font: inherit;"&gt;one&lt;/em&gt; performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort we expend or costs we incur toward the satisfaction of performance obligation in relation to the total estimated effort of costs. Variable consideration is assessed at each reporting period as to whether it is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:14pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Product Sales&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company&#x2019;s principal sources of product sales are sales of peramivir to our licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services under the Company&#x2019;s procurement contract. In &lt;em style="font: inherit;"&gt; December 2020, &lt;/em&gt;the Company launched ORLADEYO and began recording product revenue. The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;The Company recorded the following revenues for the years ended &lt;em style="font: inherit;"&gt; December 31:&lt;/em&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;span style="color:#000000;"&gt;2020&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;span style="color:#000000;"&gt;2019&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;span style="color:#000000;"&gt;2018&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Product sales, net&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3,301&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;17,533&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Royalty revenue&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3,381&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6,303&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6,101&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Collaborative and other research and development revenues:&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"&gt;&lt;span style="color:#000000;"&gt;U.S. Department of Health and Human Services&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;9,231&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4,898&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,552&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"&gt;&lt;span style="color:#000000;"&gt;Torii Pharmaceutical Co., Ltd.&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,899&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;20,101&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"&gt;&lt;span style="color:#000000;"&gt;Seqirus UK Limited&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;12,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total collaborative and other research and development revenues&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;11,130&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;24,999&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;14,552&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total revenues&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;17,812&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;48,835&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;20,653&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Advertising&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed in &#x201c;Selling, general and administrative&#x201d; as the costs are incurred. Advertising expenses related to the launch of ORLADEYO were $6,567 for year ended &lt;em style="font: inherit;"&gt; December 31, 2020. &lt;/em&gt;The Company did &lt;span style="-sec-ix-hidden:c69828614"&gt;&lt;span style="-sec-ix-hidden:c69828615"&gt;not&lt;/span&gt;&lt;/span&gt; incur advertising and product promotion expenses in &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Research and Development Expenses&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Additionally, the Company has license agreements with &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#x2019;s academic partners for modification to existing license agreements. These deferred expenses would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which &lt;em style="font: inherit;"&gt;no&lt;/em&gt; compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Interest Expense and Royalty &lt;/b&gt;&lt;/i&gt;&lt;i&gt;&lt;b&gt;Financing Obligation&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The royalty financing obligation is eligible to be repaid based on royalties from net sales of ORLADEYO. Interest expense is accrued using the effective interest rate method over the estimated period the related liability will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of the royalty financing obligation and records interest expense using an imputed effective interest rate. The Company will reassess the expected royalty payments each reporting period and account for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that the Company make estimates that could impact the carrying value of the liability, as well as the period over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact the liability balance, interest expense and the time period for repayment.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Interest Expense and Deferred Financing Costs&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Interest expense for the years ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; was $14,501 $11,892 and $9,176, respectively, and primarily relates to the issuance of the PhaRMA Notes (defined in Note &lt;em style="font: inherit;"&gt;3&lt;/em&gt;) and the Prior Credit Facility and Amended and Restated Senior Credit Facility (each defined in Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;). Costs directly associated with the issuance of the PhaRMA Notes, the Prior Credit Facility and the Amended and Restated Senior Credit Facility have been capitalized and are netted against the non-recourse notes payable and senior credit facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Amended and Restated Senior Credit Facility (as subsequently amended and restated) using the effective interest rate method. In &lt;em style="font: inherit;"&gt; December 2020, &lt;/em&gt;the Company incurred costs directly associated with its royalty monetization (defined in Note &lt;em style="font: inherit;"&gt;3&lt;/em&gt;) and borrowings under the Credit Agreement (defined in Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;). These costs have been deferred and are being amortized to interest expense over the terms of the respective arrangements. Amortization of deferred financing costs and original issue discount included in interest expense was $1,217, $1,278 and $885 for each of the years ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018,&lt;/em&gt; respectively. In &lt;em style="font: inherit;"&gt; December 2020, &lt;/em&gt;the outstanding principal balance of the Senior Credit Facility was repaid and related unamortized deferred financing costs and original issue discount of $1,211 were fully expensed as part of loss on debt extinguishment.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Currency Hedge Agreement&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The final tranche of the options under the Currency Hedge Agreement expired in &lt;em style="font: inherit;"&gt; November &lt;/em&gt;of &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt;&#160; The Currency Hedge Agreement did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; qualify for hedge accounting treatment; therefore mark-to-market adjustments were recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the years ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; resulted in losses of $632, $347 and $1,049, respectively. Mark-to-market adjustments were determined by a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party pricing model which uses quoted prices in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; actively traded and for which significant inputs are observable directly or indirectly, representing Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; in the fair value hierarchy as defined by U.S. GAAP. In addition, realized currency exchange gains of $662, $863 and $941 were recognized in &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018,&lt;/em&gt; respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under the Company&#x2019;s foreign currency hedge.&lt;/p&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the years ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include 14,957, 2,805, and 2,274, respectively, of potential common shares as their impact would be anti-dilutive.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to the valuation of stock options,&#160;&lt;/span&gt;the royalty financing&#160;&lt;span style="color:#000000;"&gt;and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; readily apparent from other sources. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Significant Customers and Other Risks&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:23pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Significant Customers&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Other than royalty revenues, the Company&#x2019;s primary sources of revenue that have an underlying cash flow stream are the reimbursement of galidesivir (formerly &lt;em style="font: inherit;"&gt;BCX4430&lt;/em&gt;) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS and sales of RAPIVAB (peramivir injection) under our procurement contract with the Assistant Secretary for Preparedness and Response within the United States Department of Health and Human Services. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:23pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Risks from Third Party Manufacturing and Distribution Concentration&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on single source distributors for distribution of approved drug products. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#x2019;s product candidates in development.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:23pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances &lt;em style="font: inherit;"&gt; may &lt;/em&gt;exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assumed credit risk.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"/&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the FASB issued Accounting Standards Update &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &lt;i&gt;Financial Instruments - Credit Losses (Topic &lt;em style="font: inherit;"&gt;326&lt;/em&gt;): Measurement of&lt;/i&gt; &lt;i&gt;Credit Losses on Financial Instruments &lt;/i&gt;(&#x201c;ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&#x201d;&lt;/em&gt;)&lt;i&gt;.&lt;/i&gt;&lt;i&gt; &lt;/i&gt;ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; requires a financial asset (or a group of financial assets) measured at amortized&lt;i&gt; &lt;/i&gt;cost basis to be presented at the net amount expected to be collected. In addition, ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; requires credit losses relating to available-for-sale debt securities to be recorded through an allowance for credit losses. ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; is effective for public companies for interim and annual periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2019. &lt;/em&gt;The Company adopted ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02&lt;/em&gt; as of &lt;em style="font: inherit;"&gt; January 1, 2020. &lt;/em&gt;Given the nature of the Company&#x2019;s receivables from collaborators, investment portfolio and other financial assets, adoption of this standard did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material effect on the Company's financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;In &lt;em style="font: inherit;"&gt; August 2018, &lt;/em&gt;the FASB issued Accounting Standards Update &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15,&lt;/em&gt; &lt;i&gt;Intangibles - Goodwill and Other - Internal-Use Software (Subtopic&lt;/i&gt; &lt;i&gt;&lt;em style="font: inherit;"&gt;350&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;) &lt;/i&gt;(&#x201c;ASU &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15&#x201d;&lt;/em&gt;). ASU &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15&lt;/em&gt; aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service&lt;i&gt; &lt;/i&gt;contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance requires entities to capitalize costs for certain implementation activities in the application development stage and expense the capitalized implementation costs over the expected term of the hosting arrangement. ASU &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15&lt;/em&gt; is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2019, &lt;/em&gt;with early adoption permitted. The Company elected to adopt this standard early, beginning &lt;em style="font: inherit;"&gt; October 1, 2019 &lt;/em&gt;on a prospective basis. Adoption did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material effect on the Company's financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;"&gt;The Company has reviewed other new accounting pronouncements that were issued as of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe that these pronouncements are either applicable to the Company, or that they will have a material impact on its financial position or results of operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"/&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <bcrx:DescriptionOfCompanyPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831137">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;The Company&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;BioCryst Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) is a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was founded in &lt;em style="font: inherit;"&gt;1986&lt;/em&gt; and incorporated in Delaware in &lt;em style="font: inherit;"&gt;1991,&lt;/em&gt; and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. The Company has incurred losses and negative cash flows from operations since inception.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;Based on the Company&#x2019;s expectations for revenue, operating expenses, and its option to access an additional $75 million from its existing credit facility, the Company believes its financial resources available at &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;will be sufficient to fund its operations into &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; The Company has sustained operating losses for the majority of its corporate history and expects that its &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; expenses will exceed its &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#x2019;s liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of its products and the progression of its product candidates in the future. The Company also &lt;em style="font: inherit;"&gt; may &lt;/em&gt;consider other plans to fund future operations, including: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (&lt;em style="font: inherit;"&gt;4&lt;/em&gt;) obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (&lt;em style="font: inherit;"&gt;5&lt;/em&gt;) reducing spending on &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more research and development programs, including by discontinuing development; and/or (&lt;em style="font: inherit;"&gt;6&lt;/em&gt;) restructuring operations to change its overhead structure. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#x2019;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates, timing, scope and magnitude of its commercial expenses and key development and regulatory events and its decisions in the future.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;</bcrx:DescriptionOfCompanyPolicyTextBlock>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-6"
      id="c69828502"
      unitRef="USD">75000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831138">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 9pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The Company&#x2019;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;). Such consolidated financial statements reflect all adjustments that are, in management&#x2019;s opinion, necessary to present fairly, in all material respects, the Company&#x2019;s consolidated financial position, results of operations, and cash flows. There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; adjustments other than normal recurring adjustments.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831139">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 1pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="d_2020-01-01_2020-12-31" id="c69831140">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Restricted Cash&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Restricted cash as of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; reflects $796 and $134, respectively, in royalty revenue paid by Shionogi &amp;amp; Co., Ltd. (&#x201c;Shionogi&#x201d;) designated for interest on the PhaRMA Notes (defined in Note &lt;em style="font: inherit;"&gt;3&lt;/em&gt;) and $1,425 and $1,417, respectively, the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember"
      decimals="-3"
      id="c69828548"
      unitRef="USD">796000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2019-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-RoyaltyReceivableMember"
      decimals="-3"
      id="c69828551"
      unitRef="USD">134000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember"
      decimals="-3"
      id="c69828557"
      unitRef="USD">1425000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i_2019-12-31_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis-CollateralForCreditMember"
      decimals="-3"
      id="c69828559"
      unitRef="USD">1417000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831141">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Investments&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#x2019;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#x2019;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of &lt;span style="-sec-ix-hidden:c69828560"&gt;three&lt;/span&gt; years and requires an average portfolio maturity of &lt;em style="font: inherit;"&gt;no&lt;/em&gt; more than 18 months. Some of the securities the Company invests in &lt;em style="font: inherit;"&gt; may &lt;/em&gt;have market risk. This means that a change in prevailing interest rates &lt;em style="font: inherit;"&gt; may &lt;/em&gt;cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#x2019;s investments are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; collateralized. The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; realized any significant losses from its investments.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 7pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the Company believes that the cost of its investments is recoverable in all material respects.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 14pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The following tables summarize the fair value of the Company&#x2019;s investments by type. The estimated fair values of the Company&#x2019;s fixed income investments are classified as Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active. These fair values are obtained from independent pricing services which utilize Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; inputs.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 14pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Amortized Cost&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Accrued Interest&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Gross Unrealized Gains&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Gross Unrealized Losses&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Estimated Fair Value&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 40%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;24,986&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;3&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;(3&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;3,225&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;3,239&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Total Investments&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;28,211&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;(3&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;28,239&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="margin: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Amortized Cost&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Accrued Interest&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Gross Unrealized Gains&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Gross Unrealized Losses&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Estimated Fair Value&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 40%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;10,488&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;10,561&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;9,742&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;59&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;9,810&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,669&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,683&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Total Investments&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;21,899&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;116&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;22,054&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The Company&#x2019;s investments at &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; have maturities of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year or less.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities
      contextRef="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember"
      id="c69828562">P18M</bcrx:AverageMaturityPeriodOfHighQualityMarketableSecurities>
    <bcrx:MaturityperiodOfShortTermInvestment
      contextRef="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember"
      id="c69828569">P12M</bcrx:MaturityperiodOfShortTermInvestment>
    <bcrx:LongtermInvestmentMaturityMinimum
      contextRef="d_2020-01-01_2020-12-31_RangeAxis-MinimumMember"
      id="c69828570">P12M</bcrx:LongtermInvestmentMaturityMinimum>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="d_2020-01-01_2020-12-31"
      id="c87A4B6EB-0B75-4729-A4CE-C0791CB26B26">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Amortized Cost&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Accrued Interest&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Gross Unrealized Gains&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Gross Unrealized Losses&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Estimated Fair Value&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 40%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;24,986&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;3&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;(3&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;25,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;3,225&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;3,239&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Total Investments&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;28,211&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;(3&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;28,239&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="18" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2019&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Amortized Cost&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Accrued Interest&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Gross Unrealized Gains&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Gross Unrealized Losses&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Estimated Fair Value&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 40%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Obligations of U.S. Government and its agencies&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;10,488&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;23&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;10,561&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;9,742&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;59&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;9,810&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,669&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,683&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Total Investments&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;21,899&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;116&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;(1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;22,054&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2020-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c69828715"
      unitRef="USD">24986000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2020-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c69828716"
      unitRef="USD">14000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2020-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="c69828719"
      unitRef="USD">25000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2020-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c69828720"
      unitRef="USD">3225000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2020-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c69828721"
      unitRef="USD">11000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2020-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c69828722"
      unitRef="USD">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2020-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c69828724"
      unitRef="USD">3239000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828725"
      unitRef="USD">28211000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828726"
      unitRef="USD">25000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828727"
      unitRef="USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828729"
      unitRef="USD">28239000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c69828730"
      unitRef="USD">10488000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-4"
      id="c69828731"
      unitRef="USD">50000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c69828732"
      unitRef="USD">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2019-12-31_FinancialInstrumentAxis-USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="c69828734"
      unitRef="USD">10561000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c69828735"
      unitRef="USD">9742000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c69828736"
      unitRef="USD">59000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-4"
      id="c69828737"
      unitRef="USD">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c69828738"
      unitRef="USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember"
      decimals="-4"
      id="c69828739"
      unitRef="USD">9810000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c69828740"
      unitRef="USD">1669000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c69828741"
      unitRef="USD">7000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c69828742"
      unitRef="USD">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2019-12-31_FinancialInstrumentAxis-CertificatesOfDepositMember"
      decimals="-3"
      id="c69828744"
      unitRef="USD">1683000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828745"
      unitRef="USD">21899000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <bcrx:AvailableForSaleDebtSecuritiesAccruedInterest
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828746"
      unitRef="USD">116000</bcrx:AvailableForSaleDebtSecuritiesAccruedInterest>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2019-12-31"
      decimals="-4"
      id="c69828747"
      unitRef="USD">40000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828748"
      unitRef="USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828749"
      unitRef="USD">22054000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831142">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Receivables from Collaborations&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 1pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&#x201c;Green Cross&#x201d;), Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;) and Seqirus UK Limited (&#x201c;SUL&#x201d;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date&#160;&lt;/span&gt;based on historical collection experience or specific circumstances and no amounts were recorded at &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;At &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2019, &lt;/em&gt;the Company had the following receivables:&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b style="font-size: 10pt;"&gt;December 31, 20&lt;/b&gt;&lt;b style="font-size: 10pt;"&gt;20&lt;/b&gt;&lt;b style="font-size: 10pt;"&gt; &lt;/b&gt;&lt;b style="font-size: 10pt;"&gt; &lt;/b&gt;&lt;b style="font-size: 10pt;"&gt; &lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Billed&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Unbilled&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;U.S. Department of Health and Human Services&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;5,402&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;5,402&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;2,037&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;2,041&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Green Cross Corporation&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;740&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;761&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Mundipharma International Holdings Limited&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Total receivables&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;2,816&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;5,427&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;8,243&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="11" rowspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b style="font-size: 10pt;"&gt;December 31, 2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Billed&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Unbilled&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;U.S. Department of Health and Human Services&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,353&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;15,023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;16,376&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,336&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,340&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Green Cross Corporation&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;2,924&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;2,932&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Mundipharma International Holdings Limited&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;56&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;56&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Seqirus UK Limited&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,091&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;351&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,442&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Total receivables&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;6,760&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;15,386&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;22,146&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: justify; text-indent: 26.75pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: justify; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#x2019;s calculations of its indirect cost rates are subject to audit by the U.S. Government.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Receivables from Product Sales&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 3.05pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Receivables&#160;&lt;/span&gt;from product sales are recorded for amounts due to the Company related to sales of RAPIVAB and ORLADEYO.&#160; At &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;receivables related to sales of RAPIVAB and ORLADEYO were $254 and $149, respectively.&#160; There were no receivables from product sales as of &lt;em style="font: inherit;"&gt; December 31, 2019. &lt;/em&gt;Receivables from product sales are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions and the Company&#x2019;s own historical collection experience. &#160;No reserve or allowance amounts were recorded at &lt;em style="font: inherit;"&gt; December 31, 2020&lt;/em&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-CollaborationReceivablesMember"
      decimals="-3"
      id="c69830429"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock
      contextRef="d_2020-01-01_2020-12-31"
      id="c7C399358-8B24-47B2-9750-A736790F2714">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b style="font-size: 10pt;"&gt;December 31, 20&lt;/b&gt;&lt;b style="font-size: 10pt;"&gt;20&lt;/b&gt;&lt;b style="font-size: 10pt;"&gt; &lt;/b&gt;&lt;b style="font-size: 10pt;"&gt; &lt;/b&gt;&lt;b style="font-size: 10pt;"&gt; &lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Billed&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Unbilled&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;U.S. Department of Health and Human Services&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;5,402&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;5,402&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;2,037&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;2,041&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Green Cross Corporation&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;740&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;761&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Mundipharma International Holdings Limited&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;39&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Total receivables&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;2,816&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;5,427&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;8,243&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="11" rowspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b style="font-size: 10pt;"&gt;December 31, 2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Billed&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Unbilled&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;U.S. Department of Health and Human Services&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,353&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;15,023&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;16,376&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Shionogi &amp;amp; Co. Ltd.&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,336&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,340&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Green Cross Corporation&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;2,924&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;2,932&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Mundipharma International Holdings Limited&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;56&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;56&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Seqirus UK Limited&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,091&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;351&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;1,442&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Total receivables&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;6,760&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;15,386&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;22,146&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c69828751"
      unitRef="USD">5402000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c69828752"
      unitRef="USD">5402000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"
      decimals="-3"
      id="c69828753"
      unitRef="USD">2037000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"
      decimals="-3"
      id="c69828754"
      unitRef="USD">4000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"
      decimals="-3"
      id="c69828755"
      unitRef="USD">2041000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"
      decimals="-4"
      id="c69828756"
      unitRef="USD">740000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"
      decimals="-3"
      id="c69828757"
      unitRef="USD">21000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"
      decimals="-3"
      id="c69828758"
      unitRef="USD">761000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"
      decimals="-3"
      id="c69828759"
      unitRef="USD">39000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"
      decimals="-3"
      id="c69828761"
      unitRef="USD">39000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"
      decimals="-3"
      id="c69828762"
      unitRef="USD">2816000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"
      decimals="-3"
      id="c69828763"
      unitRef="USD">5427000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828764"
      unitRef="USD">8243000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c69828765"
      unitRef="USD">1353000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c69828766"
      unitRef="USD">15023000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c69828767"
      unitRef="USD">16376000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"
      decimals="-3"
      id="c69828768"
      unitRef="USD">1336000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"
      decimals="-3"
      id="c69828769"
      unitRef="USD">4000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-ShionogiAndCoLtdMember"
      decimals="-4"
      id="c69828770"
      unitRef="USD">1340000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"
      decimals="-3"
      id="c69828771"
      unitRef="USD">2924000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"
      decimals="-3"
      id="c69828772"
      unitRef="USD">8000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-GreenCrossCorporationMember"
      decimals="-3"
      id="c69828773"
      unitRef="USD">2932000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"
      decimals="-3"
      id="c69828774"
      unitRef="USD">56000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-MundipharmaInternationalHoldingsLimitedMember"
      decimals="-3"
      id="c69828776"
      unitRef="USD">56000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"
      decimals="-3"
      id="c69828777"
      unitRef="USD">1091000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"
      decimals="-3"
      id="c69828778"
      unitRef="USD">351000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis-SeqirusUKLimitedMember"
      decimals="-3"
      id="c69828779"
      unitRef="USD">1442000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember"
      decimals="-4"
      id="c69828780"
      unitRef="USD">6760000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-UnbilledRevenuesMember"
      decimals="-3"
      id="c69828781"
      unitRef="USD">15386000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828782"
      unitRef="USD">22146000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-RAPIVABMember"
      decimals="-3"
      id="c69828578"
      unitRef="USD">254000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember_ProductOrServiceAxis-ORLADEYOMember"
      decimals="-3"
      id="c69828579"
      unitRef="USD">149000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="i_2019-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember"
      decimals="-3"
      id="c69828580"
      unitRef="USD">0</us-gaap:AccountsReceivableNet>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i_2020-12-31_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis-TradeAccountsReceivableMember"
      decimals="-3"
      id="c69830435"
      unitRef="USD">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:InventoryPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831143">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;At &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; the Company&#x2019;s inventory related to peramivir which is being manufactured for the Company&#x2019;s partners and the U.S. Government.&#160; Inventory as of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;consisted of raw materials of $206, work-in-process of $2,555 and finished goods of $4,548. As of &lt;em style="font: inherit;"&gt; December 31, 2019, &lt;/em&gt;the Company inventory consisted of peramivir finished goods of $276.&#160; Inventory is stated at the lower of cost and net realizable value, determined under the &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in, &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-out (&#x201c;FIFO&#x201d;) method, or market. As of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; the Company had inventory reserves of $270 and $276, respectively, for estimated unrecoverable capitalized inventory costs.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company capitalizes subsequent costs related to the production of inventories.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828582"
      unitRef="USD">206000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828583"
      unitRef="USD">2555000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828584"
      unitRef="USD">4548000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828585"
      unitRef="USD">276000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryValuationReserves
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c69828589"
      unitRef="USD">270000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69830445"
      unitRef="USD">276000</us-gaap:InventoryValuationReserves>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831144">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of &lt;span style="-sec-ix-hidden:c69828591"&gt;three&lt;/span&gt; years. Laboratory equipment, office equipment, and software are depreciated over a life of &lt;span style="-sec-ix-hidden:c69828592"&gt;five&lt;/span&gt; years. Furniture and fixtures are depreciated over a life of &lt;span style="-sec-ix-hidden:c69828593"&gt;seven&lt;/span&gt; years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2020-01-01_2020-12-31" id="c69831145">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Patents and Licenses&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 12pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <bcrx:AccruedExpensesPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831146">&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;i&gt;&lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt 5pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;The Company generally enters into contractual agreements with &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors who provide research and development, manufacturing,&#160;&lt;/span&gt;distribution,&#160;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt; text-align: left;"&gt;&#160;&lt;/p&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="width: 27pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;fees paid to Clinical Research Organizations (&#x201c;CROs&#x201d;) in connection with preclinical and toxicology studies and clinical trials;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="width: 27pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;fees paid to investigative sites in connection with clinical trials;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="width: 27pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin: 0pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;fees paid to contract manufacturers in connection with the production of the Company&#x2019;s raw materials, drug substance, drug products, and product candidates; and&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;td style="width: 27pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;professional fees.&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-17.15pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#x2019;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2019, &lt;/em&gt;the carrying value of accrued expenses approximates their fair value due to their short-term settlement.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Accrued expenses were comprised of the following:&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;9&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Compensation and benefits&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,030&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6,190&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Development costs&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;15,150&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;11,302&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Inventory&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,453&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;29&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;333&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;326&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Duties and taxes&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;67&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Other&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;4,896&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;3,451&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;33,942&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;21,365&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;</bcrx:AccruedExpensesPolicyTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757834">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;9&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Compensation and benefits&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;11,030&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6,190&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Development costs&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;15,150&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;11,302&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Inventory&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,453&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;29&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;333&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;326&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Duties and taxes&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;67&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Other&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;4,896&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;3,451&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total accrued expenses&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;33,942&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;21,365&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c69828783"
      unitRef="USD">11030000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i_2019-12-31"
      decimals="-4"
      id="c69828784"
      unitRef="USD">6190000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <bcrx:AccruedDevelopmentCosts
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c69828785"
      unitRef="USD">15150000</bcrx:AccruedDevelopmentCosts>
    <bcrx:AccruedDevelopmentCosts
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828786"
      unitRef="USD">11302000</bcrx:AccruedDevelopmentCosts>
    <bcrx:AccruedInventoryExpense
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828787"
      unitRef="USD">2453000</bcrx:AccruedInventoryExpense>
    <bcrx:AccruedInventoryExpense
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828788"
      unitRef="USD">29000</bcrx:AccruedInventoryExpense>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828789"
      unitRef="USD">333000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828790"
      unitRef="USD">326000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c69828791"
      unitRef="USD">80000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828792"
      unitRef="USD">67000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828793"
      unitRef="USD">4896000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828794"
      unitRef="USD">3451000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828795"
      unitRef="USD">33942000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828796"
      unitRef="USD">21365000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831147">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The liability method is used in the Company&#x2019;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831148">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Accumulated Other Comprehensive Loss&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#x2019; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. For the year ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;realized gains of $1 were reclassified out of accumulated other comprehensive loss. No reclassifications out of accumulated other comprehensive loss were recorded in &lt;em style="font: inherit;"&gt;2019.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828600"
      unitRef="USD">1000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828601"
      unitRef="USD">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831149">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:14pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Collaborative and Other Research and Development Arrangements and Royalties&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company recognizes revenue when it satisfies a performance obligation by transferring promised goods or services to a customer. Revenue is measured at the transaction price that is based on the amount of consideration that the Company expects to receive in exchange for transferring the promised goods or services to the customer. The transaction price includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company has collaboration and license agreements with a number of &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties as well as research and development agreements with certain government entities. The Company&#x2019;s primary sources of revenue are license, service, royalty and product sale revenues from these collaborative and other research and development arrangements.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Arrangements that involve the delivery of more than &lt;em style="font: inherit;"&gt;one&lt;/em&gt; performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort we expend or costs we incur toward the satisfaction of performance obligation in relation to the total estimated effort of costs. Variable consideration is assessed at each reporting period as to whether it is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be an obligation to deliver services, a right or license to use an asset, or another performance obligation.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#x2019;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#x201d;BARDA/HHS&#x201d;) and the National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;), revenue is recognized as reimbursable direct and indirect costs are incurred.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Under certain of the Company&#x2019;s license agreements, the Company receives royalty payments based upon its licensees&#x2019; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:14pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Product Sales&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company&#x2019;s principal sources of product sales are sales of peramivir to our licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services under the Company&#x2019;s procurement contract. In &lt;em style="font: inherit;"&gt; December 2020, &lt;/em&gt;the Company launched ORLADEYO and began recording product revenue. The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;The Company recorded the following revenues for the years ended &lt;em style="font: inherit;"&gt; December 31:&lt;/em&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;span style="color:#000000;"&gt;2020&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;span style="color:#000000;"&gt;2019&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;span style="color:#000000;"&gt;2018&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Product sales, net&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3,301&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;17,533&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Royalty revenue&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3,381&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6,303&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6,101&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Collaborative and other research and development revenues:&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"&gt;&lt;span style="color:#000000;"&gt;U.S. Department of Health and Human Services&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;9,231&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4,898&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,552&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"&gt;&lt;span style="color:#000000;"&gt;Torii Pharmaceutical Co., Ltd.&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,899&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;20,101&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"&gt;&lt;span style="color:#000000;"&gt;Seqirus UK Limited&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;12,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total collaborative and other research and development revenues&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;11,130&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;24,999&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;14,552&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total revenues&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;17,812&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;48,835&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;20,653&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Advertising&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed in &#x201c;Selling, general and administrative&#x201d; as the costs are incurred. Advertising expenses related to the launch of ORLADEYO were $6,567 for year ended &lt;em style="font: inherit;"&gt; December 31, 2020. &lt;/em&gt;The Company did &lt;span style="-sec-ix-hidden:c69828614"&gt;&lt;span style="-sec-ix-hidden:c69828615"&gt;not&lt;/span&gt;&lt;/span&gt; incur advertising and product promotion expenses in &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757835">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;span style="color:#000000;"&gt;2020&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;span style="color:#000000;"&gt;2019&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"&gt;&lt;b&gt;&lt;span style="color:#000000;"&gt;2018&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Product sales, net&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3,301&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;17,533&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Royalty revenue&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3,381&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6,303&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6,101&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Collaborative and other research and development revenues:&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"&gt;&lt;span style="color:#000000;"&gt;U.S. Department of Health and Human Services&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;9,231&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4,898&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,552&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"&gt;&lt;span style="color:#000000;"&gt;Torii Pharmaceutical Co., Ltd.&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,899&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;20,101&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"&gt;&lt;span style="color:#000000;"&gt;Seqirus UK Limited&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;12,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total collaborative and other research and development revenues&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;11,130&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;24,999&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;14,552&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total revenues&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;17,812&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;48,835&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;20,653&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c69828797"
      unitRef="USD">3301000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c69828798"
      unitRef="USD">17533000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c69828800"
      unitRef="USD">3381000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c69828801"
      unitRef="USD">6303000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2018-01-01_2018-12-31_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c69828802"
      unitRef="USD">6101000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c69828804"
      unitRef="USD">9231000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c69828805"
      unitRef="USD">4898000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2018-01-01_2018-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c69828806"
      unitRef="USD">2552000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c69828807"
      unitRef="USD">1899000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c69828808"
      unitRef="USD">20101000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2018-01-01_2018-12-31_CounterpartyNameAxis-SeqirusUKLimitedMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="INF"
      id="c69828812"
      unitRef="USD">12000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-4"
      id="c69828813"
      unitRef="USD">11130000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c69828814"
      unitRef="USD">24999000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2018-01-01_2018-12-31_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember"
      decimals="-3"
      id="c69828815"
      unitRef="USD">14552000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828816"
      unitRef="USD">17812000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828817"
      unitRef="USD">48835000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828818"
      unitRef="USD">20653000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:AdvertisingExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c69828612"
      unitRef="USD">6567</us-gaap:AdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2020-01-01_2020-12-31" id="c69831150">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Research and Development Expenses&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company&#x2019;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#x2019;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#x2019;s manufacturing and clinical and preclinical studies are performed by &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#x2019;s on-going review of the level of services actually performed.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Additionally, the Company has license agreements with &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, such as Albert Einstein College of Medicine of Yeshiva University (&#x201c;AECOM&#x201d;), Industrial Research, Ltd. (&#x201c;IRL&#x201d;), and the University of Alabama at Birmingham (&#x201c;UAB&#x201d;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Deferred collaboration expenses represent sub-license payments, paid to the Company&#x2019;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#x2019;s academic partners for modification to existing license agreements. These deferred expenses would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have been incurred without receipt of such payments or modifications from the Company&#x2019;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2020-01-01_2020-12-31" id="c69831151">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which &lt;em style="font: inherit;"&gt;no&lt;/em&gt; compensation expense is recognized until &#x201c;performance&#x201d; is deemed to have occurred.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <bcrx:InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831153">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Interest Expense and Royalty &lt;/b&gt;&lt;/i&gt;&lt;i&gt;&lt;b&gt;Financing Obligation&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The royalty financing obligation is eligible to be repaid based on royalties from net sales of ORLADEYO. Interest expense is accrued using the effective interest rate method over the estimated period the related liability will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of the royalty financing obligation and records interest expense using an imputed effective interest rate. The Company will reassess the expected royalty payments each reporting period and account for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that the Company make estimates that could impact the carrying value of the liability, as well as the period over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact the liability balance, interest expense and the time period for repayment.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;</bcrx:InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock>
    <bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831154">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Interest Expense and Deferred Financing Costs&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Interest expense for the years ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; was $14,501 $11,892 and $9,176, respectively, and primarily relates to the issuance of the PhaRMA Notes (defined in Note &lt;em style="font: inherit;"&gt;3&lt;/em&gt;) and the Prior Credit Facility and Amended and Restated Senior Credit Facility (each defined in Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;). Costs directly associated with the issuance of the PhaRMA Notes, the Prior Credit Facility and the Amended and Restated Senior Credit Facility have been capitalized and are netted against the non-recourse notes payable and senior credit facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Amended and Restated Senior Credit Facility (as subsequently amended and restated) using the effective interest rate method. In &lt;em style="font: inherit;"&gt; December 2020, &lt;/em&gt;the Company incurred costs directly associated with its royalty monetization (defined in Note &lt;em style="font: inherit;"&gt;3&lt;/em&gt;) and borrowings under the Credit Agreement (defined in Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt;). These costs have been deferred and are being amortized to interest expense over the terms of the respective arrangements. Amortization of deferred financing costs and original issue discount included in interest expense was $1,217, $1,278 and $885 for each of the years ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018,&lt;/em&gt; respectively. In &lt;em style="font: inherit;"&gt; December 2020, &lt;/em&gt;the outstanding principal balance of the Senior Credit Facility was repaid and related unamortized deferred financing costs and original issue discount of $1,211 were fully expensed as part of loss on debt extinguishment.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;</bcrx:InterestExpenseAndDeferredFinancingCostsPolicyTextBlock>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828624"
      unitRef="USD">14501000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828625"
      unitRef="USD">11892000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828626"
      unitRef="USD">9176000</us-gaap:InterestExpenseDebt>
    <bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828631"
      unitRef="USD">1217000</bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts>
    <bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828632"
      unitRef="USD">1278000</bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts>
    <bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69828633"
      unitRef="USD">885000</bcrx:AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="d_2020-01-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-3"
      id="c69828636"
      unitRef="USD">1211000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <bcrx:CurrencyHedgeAgreementPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831155">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Currency Hedge Agreement&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The final tranche of the options under the Currency Hedge Agreement expired in &lt;em style="font: inherit;"&gt; November &lt;/em&gt;of &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt;&#160; The Currency Hedge Agreement did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; qualify for hedge accounting treatment; therefore mark-to-market adjustments were recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the years ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; resulted in losses of $632, $347 and $1,049, respectively. Mark-to-market adjustments were determined by a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party pricing model which uses quoted prices in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; actively traded and for which significant inputs are observable directly or indirectly, representing Level &lt;em style="font: inherit;"&gt;2&lt;/em&gt; in the fair value hierarchy as defined by U.S. GAAP. In addition, realized currency exchange gains of $662, $863 and $941 were recognized in &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018,&lt;/em&gt; respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under the Company&#x2019;s foreign currency hedge.&lt;/p&gt; &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;</bcrx:CurrencyHedgeAgreementPolicyTextBlock>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="d_2020-01-01_2020-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-3"
      id="c69828642"
      unitRef="USD">632000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="d_2019-01-01_2019-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-3"
      id="c69828643"
      unitRef="USD">347000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="d_2018-01-01_2018-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-3"
      id="c69828644"
      unitRef="USD">1049000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="d_2020-01-01_2020-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-3"
      id="c69828648"
      unitRef="USD">662000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="d_2019-01-01_2019-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-3"
      id="c69828649"
      unitRef="USD">863000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="d_2018-01-01_2018-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-3"
      id="c69828650"
      unitRef="USD">941000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831156">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Net Loss Per Share&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&#x2019;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the years ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; include 14,957, 2,805, and 2,274, respectively, of potential common shares as their impact would be anti-dilutive.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c69828657"
      unitRef="Share">14957</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2019-01-01_2019-12-31"
      decimals="INF"
      id="c69828658"
      unitRef="Share">2805</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2018-01-01_2018-12-31"
      decimals="INF"
      id="c69828659"
      unitRef="Share">2274</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:UseOfEstimates contextRef="d_2020-01-01_2020-12-31" id="c69831157">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#x2019;s consolidated financial statements relate to the valuation of stock options,&#160;&lt;/span&gt;the royalty financing&#160;&lt;span style="color:#000000;"&gt;and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; readily apparent from other sources. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <bcrx:ConcentrationOfMarketRiskPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831158">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Significant Customers and Other Risks&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:23pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Significant Customers&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Other than royalty revenues, the Company&#x2019;s primary sources of revenue that have an underlying cash flow stream are the reimbursement of galidesivir (formerly &lt;em style="font: inherit;"&gt;BCX4430&lt;/em&gt;) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS and sales of RAPIVAB (peramivir injection) under our procurement contract with the Assistant Secretary for Preparedness and Response within the United States Department of Health and Human Services. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#x2019;s collaborative and other research and development revenues. The completion or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&#x2019;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&#x2019;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#x2019;s drug development activities are performed by a limited group of &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#x2019;s ability to complete its drug development activities.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:23pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Risks from Third Party Manufacturing and Distribution Concentration&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on single source distributors for distribution of approved drug products. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#x2019;s product candidates in development.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:23pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Credit Risk&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances &lt;em style="font: inherit;"&gt; may &lt;/em&gt;exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#x2019;s receivables from collaborations are due from the U.S. Government, for which there is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assumed credit risk.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;</bcrx:ConcentrationOfMarketRiskPolicyTextBlock>
    <bcrx:AverageMaturityForPortfolioInvestments
      contextRef="d_2020-01-01_2020-12-31_RangeAxis-MaximumMember"
      id="c69828664">P18M</bcrx:AverageMaturityForPortfolioInvestments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2020-01-01_2020-12-31" id="c69831159">&lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the FASB issued Accounting Standards Update &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &lt;i&gt;Financial Instruments - Credit Losses (Topic &lt;em style="font: inherit;"&gt;326&lt;/em&gt;): Measurement of&lt;/i&gt; &lt;i&gt;Credit Losses on Financial Instruments &lt;/i&gt;(&#x201c;ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&#x201d;&lt;/em&gt;)&lt;i&gt;.&lt;/i&gt;&lt;i&gt; &lt;/i&gt;ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; requires a financial asset (or a group of financial assets) measured at amortized&lt;i&gt; &lt;/i&gt;cost basis to be presented at the net amount expected to be collected. In addition, ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; requires credit losses relating to available-for-sale debt securities to be recorded through an allowance for credit losses. ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; is effective for public companies for interim and annual periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2019. &lt;/em&gt;The Company adopted ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02&lt;/em&gt; as of &lt;em style="font: inherit;"&gt; January 1, 2020. &lt;/em&gt;Given the nature of the Company&#x2019;s receivables from collaborators, investment portfolio and other financial assets, adoption of this standard did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material effect on the Company's financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;In &lt;em style="font: inherit;"&gt; August 2018, &lt;/em&gt;the FASB issued Accounting Standards Update &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15,&lt;/em&gt; &lt;i&gt;Intangibles - Goodwill and Other - Internal-Use Software (Subtopic&lt;/i&gt; &lt;i&gt;&lt;em style="font: inherit;"&gt;350&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;) &lt;/i&gt;(&#x201c;ASU &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15&#x201d;&lt;/em&gt;). ASU &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15&lt;/em&gt; aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service&lt;i&gt; &lt;/i&gt;contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance requires entities to capitalize costs for certain implementation activities in the application development stage and expense the capitalized implementation costs over the expected term of the hosting arrangement. ASU &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;15&lt;/em&gt; is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2019, &lt;/em&gt;with early adoption permitted. The Company elected to adopt this standard early, beginning &lt;em style="font: inherit;"&gt; October 1, 2019 &lt;/em&gt;on a prospective basis. Adoption did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material effect on the Company's financial position, results of operations or cash flows.&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;"&gt;The Company has reviewed other new accounting pronouncements that were issued as of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe that these pronouncements are either applicable to the Company, or that they will have a material impact on its financial position or results of operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757836">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; &#x2014; Property and Equipment&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Property and equipment consisted of the following at &lt;em style="font: inherit;"&gt; December 31:&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;9&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;722&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;602&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Office equipment&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;211&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;184&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Software&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,159&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,159&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3,774&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3,462&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;&lt;span style="color:#000000;"&gt;8,583&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;&lt;span style="color:#000000;"&gt;8,528&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;14,449&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;13,935&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(7,336&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(6,588&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;7,113&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;7,347&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&lt;span style="color:#000000;"&gt;Depreciation and amortization expense for the years ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;&lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; was $748, $724, and $770, respectively.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757837">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;9&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;722&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;602&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Office equipment&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;211&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;184&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Software&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,159&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,159&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3,774&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3,462&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;&lt;span style="color:#000000;"&gt;8,583&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;&lt;span style="color:#000000;"&gt;8,528&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;14,449&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;13,935&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(7,336&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(6,588&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;7,113&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;7,347&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c69828825"
      unitRef="USD">722000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c69828826"
      unitRef="USD">602000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember"
      decimals="-3"
      id="c69828827"
      unitRef="USD">211000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-OfficeEquipmentMember"
      decimals="-3"
      id="c69828828"
      unitRef="USD">184000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember"
      decimals="-3"
      id="c69828829"
      unitRef="USD">1159000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-SoftwareDevelopmentMember"
      decimals="-3"
      id="c69828830"
      unitRef="USD">1159000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"
      decimals="-3"
      id="c69828831"
      unitRef="USD">3774000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"
      decimals="-3"
      id="c69828832"
      unitRef="USD">3462000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c69828835"
      unitRef="USD">8583000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2019-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c69828836"
      unitRef="USD">8528000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828839"
      unitRef="USD">14449000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828840"
      unitRef="USD">13935000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828841"
      unitRef="USD">7336000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828842"
      unitRef="USD">6588000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69828843"
      unitRef="USD">7113000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69828844"
      unitRef="USD">7347000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69828822"
      unitRef="USD">748000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69828823"
      unitRef="USD">724000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-4"
      id="c69828824"
      unitRef="USD">770000</us-gaap:DepreciationDepletionAndAmortization>
    <bcrx:RoyaltyMonetizationTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757838">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;3&#x2014;Royalty&lt;/em&gt; Monetizations&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;RAPIACTA Royalty Monetization&lt;/b&gt;&lt;/i&gt;&lt;i&gt;&lt;b&gt;s&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13.5pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Overview&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;On&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; March 9, 2011, &lt;/em&gt;the Company completed a $30,000 financing transaction to monetize certain future royalty and milestone payments under the Company&#x2019;s agreement with Shionogi (the &#x201c;Shionogi Agreement&#x201d;), pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and Taiwan. The Company received net proceeds of $22,691 from the transaction after transaction costs of $4,309 and the establishment of a $3,000 interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the &lt;em style="font: inherit;"&gt; September 2012 &lt;/em&gt;interest payment&lt;span style="color:#000000;"&gt;.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;As&#160;&lt;/span&gt;part of the transaction, the Company entered into a purchase and sale agreement dated as of &lt;em style="font: inherit;"&gt; March 9, 2011 &lt;/em&gt;with JPR Royalty Sub, LLC, a wholly-owned subsidiary of the Company (&#x201c;Royalty Sub&#x201d;), whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii) the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#x201c;Currency Hedge Agreement&#x201d;) put into place by the Company in connection with the transaction. Royalty payments are paid by Shionogi in Japanese yen, and any milestone payments will be paid in U.S. dollars. The Company&#x2019;s collaboration with Shionogi was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; impacted as a result of this transaction&lt;span style="color:#000000;"&gt;.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13.5pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Non-Recourse Notes Payable&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;On &lt;em style="font: inherit;"&gt; March 9, 2011, &lt;/em&gt;Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due on &lt;em style="font: inherit;"&gt; December 1, 2020 (&lt;/em&gt;the &#x201c;PhaRMA Notes&#x201d;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of &lt;em style="font: inherit;"&gt; March 9, 2011 (&lt;/em&gt;the &#x201c;Indenture&#x201d;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14% per annum, payable annually in arrears on &lt;em style="font: inherit;"&gt; September &lt;/em&gt;&lt;em style="font: inherit;"&gt;1st&lt;/em&gt; of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Royalty Sub&#x2019;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#x2019;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company &lt;em style="font: inherit;"&gt; may, &lt;/em&gt;but is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; obligated to, make capital contributions to a capital account that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be used to redeem, or on up to &lt;em style="font: inherit;"&gt;one&lt;/em&gt; occasion pay any interest shortfall on, the PhaRMA Notes.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;In &lt;em style="font: inherit;"&gt; September 2014, &lt;/em&gt;Royalty Sub was unable to pay the accrued interest obligation due &lt;em style="font: inherit;"&gt; September 3, 2013. &lt;/em&gt;Under the terms of the Indenture, Royalty Sub&#x2019;s inability to pay the full amount of interest payable in &lt;em style="font: inherit;"&gt; September 2013 &lt;/em&gt;by the next succeeding payment date for the PhaRMA Notes, which was &lt;em style="font: inherit;"&gt; September 1, 2014, &lt;/em&gt;constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the &lt;em style="font: inherit;"&gt; December 31, 2014 &lt;/em&gt;balance sheet, and thereafter. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes &lt;em style="font: inherit;"&gt; may &lt;/em&gt;foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to have a significant impact on the Company&#x2019;s future results of operations or cash flows. The PhaRMA Notes had a final legal maturity date of &lt;em style="font: inherit;"&gt; December 1, 2020, &lt;/em&gt;at which time the outstanding principal amount of the PhaRMA Notes of $30,000, together with accrued and unpaid interest of $20,614, was due in full. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the PhaRMA Notes remain outstanding and in default and the Company will continue to record the liability and accrued interest owed until the Company is determined to &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer be the financial obligor.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:38pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Indenture does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&lt;span style="color:#000000;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the aggregate fair value of the PhaRMA Notes was estimated to be approximately 3% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified as Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; in the fair value hierarchy as defined in U.S. GAAP.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Foreign Currency Hedge&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company had&#160;the right to purchase dollars and sell yen at a rate of 100 yen per dollar. The final tranche of the options under the Currency Hedge Agreement expired in &lt;em style="font: inherit;"&gt; November &lt;/em&gt;of &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Currency Hedge Agreement did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; qualify for hedge accounting treatment; therefore mark-to-market adjustments were recognized in the Company&#x2019;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments in &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; resulted in losses of $632, $347 and $1,049, respectively. In addition, realized currency exchange gains of $662, $863 and $941 were recognized in &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018,&lt;/em&gt; respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under the Company&#x2019;s foreign currency hedge.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;ORLADEYO Royalty Monetization&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;On &lt;em style="font: inherit;"&gt; December 7, 2020, &lt;/em&gt;the Company and RPI &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; Intermediate Finance Trust (&#x201c;RPI&#x201d;) entered into a Purchase and Sale Agreement (the &#x201c;Royalty Purchase Agreement&#x201d;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $125,000 in cash (the &#x201c;Royalty Sale&#x201d;).&#160; Under the Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the United States, certain key European markets, and other markets where the Company sells ORLADEYO directly or through distributors (collectively, the &#x201c;Key Territories&#x201d;) in an amount equal to:&#160;(i) 8.75% of aggregate annual net sales of ORLADEYO in the Key Territories for annual net sales up to &lt;em style="font: inherit;"&gt;$350,000&lt;/em&gt; and (ii) 2.75% of annual net sales in the Key Territories for annual net sales between &lt;em style="font: inherit;"&gt;$350,000&lt;/em&gt; and &lt;em style="font: inherit;"&gt;$550,000.&lt;/em&gt;&#160; No royalty payments are payable on annual net sales in the Key Territories over &lt;em style="font: inherit;"&gt;$550,000.&lt;/em&gt;&#160; In addition, RPI will be entitled to receive 1.0% of global net sales, if any, of &lt;em style="font: inherit;"&gt;BCX9930.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;Under the Royalty Purchase Agreement, RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees outside of the Key Territories (the &#x201c;Other Markets&#x201d;) equal to: (i) 20% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets; (ii) 20% of proceeds received on annual net sales of up to &lt;em style="font: inherit;"&gt;$150,000&lt;/em&gt; in the Other Markets; and (iii) 10% of proceeds received by the Company on annual net sales between &lt;em style="font: inherit;"&gt;$150,000&lt;/em&gt; and &lt;em style="font: inherit;"&gt;$230,000&lt;/em&gt; in the Other Markets. No royalty payments are payable on annual net sales above &lt;em style="font: inherit;"&gt;$230,000&lt;/em&gt; in the Other Markets. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; payment will be due to RPI for any achievement milestone which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be payable under the existing out-license for ORLADEYO.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company will be required to make royalty payments of amounts owed to RPI each calendar quarter following the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of ORLADEYO in any country.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Under the Royalty Purchase Agreement, the Company has agreed to specified affirmative and negative covenants, including covenants regarding periodic reporting of information by the Company to RPI, &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party audits of royalties paid under the Royalty Purchase Agreement, and restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness other than certain royalty sales and as is permitted to be incurred under the terms of the Company&#x2019;s Credit Agreement with Athyrium Opportunities III Co-Invest &lt;em style="font: inherit;"&gt;1&lt;/em&gt; LP. Refer to Note &lt;em style="font: inherit;"&gt;4&lt;/em&gt; for further details on the Credit Agreement. The restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness are eliminated after the achievement of certain specified milestones in the Royalty Purchase Agreement.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&lt;span style="color:#000000;"&gt;The cash consideration of $125,000 obtained pursuant to the Royalty Purchase Agreement is recorded in &#x201c;Royalty financing obligation&#x201d; on the Company&#x2019;s consolidated balance sheet as of &lt;em style="font: inherit;"&gt; December 31, 2020. &lt;/em&gt;The fair value for the royalty financing obligation at the time of the transaction was based on the Company&#x2019;s estimates of future royalties expected to be paid to RPI over the life of the arrangement. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration and sales price and are determined using forecasts from market data sources, which are considered Level &lt;em style="font: inherit;"&gt;3&lt;/em&gt; inputs. Deferred issuance costs, which consist primarily of advisory and legal fees, totaled $2,370 as of &lt;em style="font: inherit;"&gt; December 31, 2020. &lt;/em&gt;The liability and the deferred issuance costs are amortized using the effective interest method over the term of the arrangement, in accordance with the respective guidance. The effective interest rate as of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;was approximately 24%. For &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; accrued interest expense in the amount of $2,108 was added to the initial balance of the liability. The Company will utilize the prospective method to account for subsequent changes in the estimated future payments to be made to RPI.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
  </bcrx:RoyaltyMonetizationTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"
      decimals="-7"
      id="c69828846"
      unitRef="USD">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"
      decimals="-3"
      id="c69828847"
      unitRef="USD">22691000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <bcrx:TransactionCosts
      contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"
      decimals="-3"
      id="c69828848"
      unitRef="USD">4309000</bcrx:TransactionCosts>
    <bcrx:InterestReserve
      contextRef="d_2011-03-01_2011-03-09_LegalEntityAxis-JPRRoyaltySubLLCMember_OtherCommitmentsAxis-RoyaltyMonetizationMember"
      decimals="-6"
      id="c69828849"
      unitRef="USD">3000000</bcrx:InterestReserve>
    <bcrx:PrivatePlacementOfSeniorSecuredNotes
      contextRef="d_2011-03-01_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="-7"
      id="c69828852"
      unitRef="USD">30000000</bcrx:PrivatePlacementOfSeniorSecuredNotes>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="2"
      id="c69828853"
      unitRef="Pure">0.140</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2011-03-09_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="2"
      id="c69828854"
      unitRef="Pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SecuredDebt
      contextRef="i_2020-12-01_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="-7"
      id="c69828861"
      unitRef="USD">30000000</us-gaap:SecuredDebt>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i_2020-12-01_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="-3"
      id="c69828862"
      unitRef="USD">20614000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <bcrx:PercentageOfCarryingAmountInExcessOfFairValue1
      contextRef="i_2019-12-31_DebtInstrumentAxis-PhaRMANotesMember_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="2"
      id="c69828865"
      unitRef="Pure">0.03</bcrx:PercentageOfCarryingAmountInExcessOfFairValue1>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i_2019-12-31_DebtInstrumentAxis-PhaRMANotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_LegalEntityAxis-JPRRoyaltySubLLCMember"
      decimals="-7"
      id="c69828866"
      unitRef="USD">30000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:DerivativeForwardExchangeRate1
      contextRef="i_2020-11-30_DebtInstrumentAxis-PhaRMANotesMember_DerivativeInstrumentRiskAxis-CurrencyHedgeAgreementMember"
      decimals="INF"
      id="c69828868"
      unitRef="JPYPerUSD">100</us-gaap:DerivativeForwardExchangeRate1>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="d_2020-01-01_2020-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-3"
      id="c69828874"
      unitRef="USD">632000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="d_2019-01-01_2019-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-3"
      id="c69828875"
      unitRef="USD">347000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeLossOnDerivative
      contextRef="d_2018-01-01_2018-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-3"
      id="c69828876"
      unitRef="USD">1049000</us-gaap:DerivativeLossOnDerivative>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="d_2020-01-01_2020-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-3"
      id="c69828877"
      unitRef="USD">662000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="d_2019-01-01_2019-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-3"
      id="c69828878"
      unitRef="USD">863000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:DerivativeGainOnDerivative
      contextRef="d_2018-01-01_2018-12-31_DerivativeInstrumentRiskAxis-ForeignExchangeContractMember_HedgingDesignationAxis-NondesignatedMember"
      decimals="-3"
      id="c69828879"
      unitRef="USD">941000</us-gaap:DerivativeGainOnDerivative>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember"
      decimals="-6"
      id="c69828885"
      unitRef="USD">125000000</us-gaap:ProceedsFromIssuanceOfDebt>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder350000Member"
      decimals="4"
      id="c69828886"
      unitRef="Pure">0.0875</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween350000And550000Member"
      decimals="4"
      id="c69828888"
      unitRef="Pure">0.0275</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver550000Member"
      decimals="-3"
      id="c69828891"
      unitRef="Pure">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-BCX9930Member"
      decimals="2"
      id="c69828893"
      unitRef="Pure">0.010</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember"
      decimals="1"
      id="c69828895"
      unitRef="Pure">0.20</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesUnder150000Member"
      decimals="1"
      id="c69828896"
      unitRef="Pure">0.20</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesBetween150000And230000Member"
      decimals="1"
      id="c69828898"
      unitRef="Pure">0.10</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets
      contextRef="d_2020-12-07_2020-12-07_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_ProductOrServiceAxis-ORLADEYOMember_StatementScenarioAxis-AnnualNetSalesOver230000Member"
      decimals="-3"
      id="c69828902"
      unitRef="Pure">0</bcrx:RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets>
    <bcrx:FutureRoyaltiesPayable
      contextRef="i_2020-12-31_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember"
      decimals="-6"
      id="c69828909"
      unitRef="USD">125000000</bcrx:FutureRoyaltiesPayable>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i_2020-12-31_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember"
      decimals="-4"
      id="c69828911"
      unitRef="USD">2370000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i_2020-12-31_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember"
      decimals="2"
      id="c69828912"
      unitRef="Pure">0.24</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="i_2020-12-31_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember_LongtermDebtTypeAxis-FutureRoyaltiesPayableMember"
      decimals="-3"
      id="c69828914"
      unitRef="USD">2108000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="d_2020-01-01_2020-12-31_DebtInstrumentAxis-CreditAgreementMember"
      id="c1757839">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;Note &lt;/b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;4&lt;/em&gt;&lt;/b&gt;&lt;b&gt; &#x2014; &lt;/b&gt;&lt;b&gt;Credit Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;On &lt;em style="font: inherit;"&gt; December 7, 2020, &lt;/em&gt;the Company entered into a $200,000 Credit Agreement with Athyrium Opportunities III Co-Invest &lt;em style="font: inherit;"&gt;1&lt;/em&gt; LP (&#x201c;Athyrium&#x201d;), as lender and as administrative agent for the lenders.&#160;BioCryst Ireland Limited, BioCryst US Sales Co., LLC, and BioCryst UK Limited, each of which is a wholly-owned subsidiary of the Company, are guarantors to the Credit Agreement. The Credit Agreement provides for an initial term loan in the principal amount of $125,000 (the &#x201c;Term A Loan&#x201d;), which was received by the Company on &lt;em style="font: inherit;"&gt; December 7, 2020 &lt;/em&gt;and is recorded in &#x201c;Secured term loan&#x201d; on the Company&#x2019;s balance sheet as of &lt;em style="font: inherit;"&gt; December 31, 2020.&#160; &lt;/em&gt;The Company used a portion of the proceeds from the Term A Loan to repay $43,298 of outstanding indebtedness, including accrued interest, under its existing credit facility with MidCap Financial Trust.&#160; The Company intends to use the remaining proceeds to support the launch of ORLADEYO in the United States and Europe and to advance the development of &lt;em style="font: inherit;"&gt;BCX9930&lt;/em&gt; into clinical trials in multiple complement-mediated diseases, and for other general corporate purposes.&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Credit Agreement also provides for &lt;em style="font: inherit;"&gt;two&lt;/em&gt; additional term loans, at the Company's option, in the respective principal amounts of $25,000 (the &#x201c;Term B Loan&#x201d;) and $50,000 (the &#x201c;Term C Loan&#x201d;).&#160; The Term B Loan and the Term C Loan &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be drawn upon if, among other conditions, the Company reaches defined revenue milestones and, with respect to a draw on the Term C Loan, the Term B Loan has been funded prior to or contemporaneously with the Term C Loan.&#160; The maturity date of the Credit Agreement is &lt;em style="font: inherit;"&gt; December 7, 2025.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Credit Agreement provides for quarterly interest-only payments until the maturity date, with the unpaid principal amount of the outstanding Term Loans due and payable on the maturity date.&#160; For each of the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;eight&lt;/em&gt; full fiscal quarters following &lt;em style="font: inherit;"&gt; December 7, 2020, &lt;/em&gt;the Company has the option to make the applicable interest payment-in-kind (a &#x201c;PIK Interest Payment&#x201d;) by capitalizing the entire amount of interest accrued during the applicable interest period with the unpaid original principal amount outstanding on the last day of such period. The Term Loans will bear interest at a rate equal to the &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-month LIBOR rate, which shall be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; less than 1.75% and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; more than 3.50% (&#x201c;LIBOR&#x201d;), plus 8.25%, or for each interest period in which a PIK Interest Payment is made, the LIBOR plus 10.25%.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Subject to certain exceptions, the Company is required to make mandatory prepayments of the Term Loans with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sale), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events, subject to certain exceptions. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;make voluntary prepayments in whole or in part. Prepayments are subject to a premium equal to, (i) with respect to any voluntary prepayment and certain mandatory prepayments paid on or prior to the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; anniversary of the applicable Term Loan borrowing date, the amount, if any, by which (a) the sum of (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) 102.00% of the principal amount of the Term Loan being prepaid plus (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) the present value of all interest that would have accrued on the principal amount of the Term Loan being prepaid through and including the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; anniversary of the date of the borrowing of such Term Loan, plus 0.50%, exceeds (b) the principal amount of the Term Loan being prepaid; (ii) with respect to any prepayment made between the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; and &lt;em style="font: inherit;"&gt;third&lt;/em&gt; anniversaries of the applicable Term Loan borrowing date, 2.00% of the principal amount of the Term Loan being prepaid; (iii) with respect to any prepayment made between the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; and &lt;em style="font: inherit;"&gt;fourth&lt;/em&gt; anniversaries of the applicable Term Loan&#160;&lt;/span&gt;borrowing date&lt;span style="color:#000000;"&gt;, 1.00% of the principal amount of the Term Loan being prepaid; and (iv) with respect to any prepayment made after the &lt;em style="font: inherit;"&gt;fourth&lt;/em&gt; anniversary of the applicable Term Loan borrowing date, 0.00% of the principal amount of the Term Loan being prepaid. Upon the prepayment or repayment, including at maturity, of all or any of the Term Loans, the Company is obligated to pay an exit fee in an amount equal to 2.00% of the principal amount of the Term Loans prepaid or repaid. In addition, each Term Loan is subject to a 1.00% commitment fee at its respective borrowing date.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Credit Agreement also contains representations and warranties and affirmative and negative covenants customary for financings of this type, as well as customary events of default. &#160;Certain of the customary negative covenants limit the ability of the Company and certain of its subsidiaries to, among other things, grant liens, make investments, incur additional indebtedness, engage in mergers, acquisitions, and similar transactions, dispose of assets, license certain property, distribute dividends, make certain restricted payments, change the nature of the Company's business, engage in transactions with affiliates and insiders, prepay other indebtedness, or engage in sale and leaseback transactions, subject to certain exceptions. &#160;Additionally, as of the last day of each fiscal quarter (a &#x201c;Test Date&#x201d;), beginning with the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; Test Date occurring immediately after the Term C Loan is drawn, if applicable, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; permit consolidated net revenues from ORLADEYO sales in the United States for the &lt;em style="font: inherit;"&gt;four&lt;/em&gt;-fiscal quarter period ending on such Test Date to be less than the specified amounts set forth in the Credit Agreement (collectively, the &#x201c;Revenue Tests&#x201d;).&#160; If the Company fails to satisfy the Revenue Tests as of any Test Date, it will have a &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-time right (the &#x201c;Cure Right&#x201d;) to repay in full the entire amount of the Term C Loans outstanding at such time together with all accrued and unpaid interest thereon plus the prepayment premium, exit fee, and any other fees or amounts payable under the Credit Agreement at such time.&#160; In addition, the Credit Agreement contains a minimum liquidity covenant requiring the Company to maintain at all times, as applicable, at least $15,000 of unrestricted cash and cash equivalents if only the Term A Loan has been drawn; at least $20,000 of unrestricted cash and cash equivalents if the Term B Loan has been drawn but the Term C Loan has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been drawn; and at least $15,000 (or, if the Cure Right has been exercised, $20,000) of unrestricted cash and cash equivalents if the Term C Loan has been drawn, subject to certain exceptions.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;A failure to comply with the covenants in the Credit Agreement could permit the Lenders under the Credit Agreement to declare the outstanding principal as well as accrued interest and fees, to be immediately due and payable.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&lt;span style="color:#000000;"&gt;The Company's obligations under the Credit Agreement are secured by a security interest in, subject to certain exceptions, substantially all of the Company's assets.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&lt;span style="color:#000000;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the Company had borrowings of $125,000 under the Credit Agreement. The carrying amount of the debt approximates its fair value based on prevailing interest rates as of the balance sheet date.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&lt;span style="color:#000000;"&gt;The Credit Agreement provides for quarterly interest-only payments until the maturity date, with the unpaid principal amount of the outstanding Term Loans due and payable on the maturity date of &lt;em style="font: inherit;"&gt; December 7, 2025. &lt;/em&gt;The Company has elected the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarterly interest payment to be a PIK Interest Payment and began accruing interest at a rate of 12.17%. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;debt fees and issuance costs totaled $7,764 and are being amortized as interest expense on an effective interest rate method over the term of the Term A Loan. Interest expense of $925, net of deferred financing amortization of $131, related to the Credit Agreement was recognized in &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; related to the Term A Loan.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&lt;span style="color:#000000;"&gt;The Credit Agreement contains &lt;em style="font: inherit;"&gt;two&lt;/em&gt; provisions that, if deemed probable, would create the recognition of an embedded feature; however, at this time, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe either provision is probable.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
  </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="-8"
      id="c69828919"
      unitRef="USD">200000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember"
      decimals="-6"
      id="c69828921"
      unitRef="USD">125000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="d_2020-12-07_2020-12-07_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-3"
      id="c69828922"
      unitRef="USD">43298000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermBLoanMember"
      decimals="-6"
      id="c69828925"
      unitRef="USD">25000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermCLoanMember"
      decimals="-7"
      id="c69828926"
      unitRef="USD">50000000</us-gaap:DebtInstrumentFaceAmount>
    <bcrx:DebtInstrumentLiborFloor
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="4"
      id="c69828931"
      unitRef="Pure">0.0175</bcrx:DebtInstrumentLiborFloor>
    <bcrx:DebtInstrumentLiborCap
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="3"
      id="c69828933"
      unitRef="Pure">0.0350</bcrx:DebtInstrumentLiborCap>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember"
      decimals="4"
      id="c69828934"
      unitRef="Pure">0.0825</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PikInterestPaymentIsMadeMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember"
      decimals="4"
      id="c69828935"
      unitRef="Pure">0.1025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments
      contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PriorToTheSecondAnniversaryMember"
      decimals="2"
      id="c69828939"
      unitRef="Pure">1.0200</bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfAccruedInterest
      contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-PriorToTheSecondAnniversaryMember"
      decimals="3"
      id="c69828942"
      unitRef="Pure">0.0050</bcrx:DebtInstrumentPrepaymentFeePercentageOfAccruedInterest>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments
      contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-BetweenTheSecondAndThirdAnniversariesMember"
      decimals="2"
      id="c69828945"
      unitRef="Pure">0.0200</bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments
      contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-BetweenTheThirdAndFourthAnniversariesMember"
      decimals="2"
      id="c69828948"
      unitRef="Pure">0.0100</bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments>
    <bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments
      contextRef="d_2020-12-07_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-AfterFourthAnniversaryMember"
      decimals="-3"
      id="c69828950"
      unitRef="Pure">0.0000</bcrx:DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments>
    <bcrx:DebtInstrumentExitFeePercentageOfPrincipal
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="2"
      id="c69828951"
      unitRef="Pure">0.0200</bcrx:DebtInstrumentExitFeePercentageOfPrincipal>
    <bcrx:DebtInstrumentCommitmentFeePercentage
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="2"
      id="c69828952"
      unitRef="Pure">0.0100</bcrx:DebtInstrumentCommitmentFeePercentage>
    <bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoanADrawnMember"
      decimals="-6"
      id="c69828957"
      unitRef="USD">15000000</bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents>
    <bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoanAAndBDrawnMember"
      decimals="-7"
      id="c69828958"
      unitRef="USD">20000000</bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents>
    <bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoansABAndCDrawnMember"
      decimals="-6"
      id="c69828960"
      unitRef="USD">15000000</bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents>
    <bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents
      contextRef="i_2020-12-07_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_StatementScenarioAxis-TermLoansABAndCDrawnAndCureRightExercisedMember"
      decimals="-7"
      id="c69828961"
      unitRef="USD">20000000</bcrx:DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents>
    <us-gaap:LongTermDebt
      contextRef="i_2020-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="-6"
      id="c69828962"
      unitRef="USD">125000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i_2020-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="4"
      id="c69828964"
      unitRef="Pure">0.1217</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i_2020-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember"
      decimals="-3"
      id="c69828965"
      unitRef="USD">7764000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2020-01-01_2020-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember"
      decimals="-3"
      id="c69828966"
      unitRef="USD">925000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="d_2020-01-01_2020-12-31_DebtInstrumentAxis-CreditAgreementMember_LineOfCreditFacilityAxis-AthyriumMember_LongtermDebtTypeAxis-TermALoanMember"
      decimals="-3"
      id="c69828967"
      unitRef="USD">131000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="d_2020-01-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember"
      id="c1757840">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;Note &lt;/b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;5&lt;/em&gt;&lt;/b&gt;&lt;b&gt; &#x2014; Senior Credit Facility&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;On &lt;em style="font: inherit;"&gt; February 5, 2019, &lt;/em&gt;the Company entered into a $100,000 Senior Credit Facility with an affiliate of MidCap Financial Services, LLC, as administrative agent (the &#x201c;Second Amended and Restated Senior Credit Facility&#x201d;). Borrowings under the Second Amended and Restated Senior Credit Facility were available in &lt;em style="font: inherit;"&gt;three&lt;/em&gt; tranches, with (i) the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; tranche comprised of $50,000 funded at closing, which included $30,000 of proceeds that were deemed rolled over from the outstanding principal amount under the Company&#x2019;s prior credit agreement, (ii) the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; tranche comprised of $30,000, and (iii) the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; tranche comprised of $20,000, with the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; and &lt;em style="font: inherit;"&gt;third&lt;/em&gt; tranches to have been funded upon the completion of certain contingencies related to the Company&#x2019;s development activities of its product candidates and the establishment of certain financial covenants. On &lt;em style="font: inherit;"&gt; September 10, 2019 &lt;/em&gt;the Company executed the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; amendment to the Second Amended and Restated Credit Facility which extended the commitment termination date for the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; tranche to &lt;em style="font: inherit;"&gt; November 30, 2019. &lt;/em&gt;On &lt;em style="font: inherit;"&gt; November 30, 2019, &lt;/em&gt;the Company&#x2019;s access to the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; tranche expired.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Second Amended and Restated Senior Credit Facility refinanced and replaced the Amended and Restated Senior Credit Facility dated as of &lt;em style="font: inherit;"&gt; July 20, 2018 (&lt;/em&gt;the &#x201c;Amended and Restated Senior Credit Facility&#x201d;). The Second Amended and Restated Senior Credit Facility had a variable interest rate of LIBOR (which was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to be less than 0.5%) plus 8%. The Second Amended and Restated Senior Credit Facility included an interest-only payment period through &lt;em style="font: inherit;"&gt; June 2020 &lt;/em&gt;and scheduled monthly principal and interest payments for the subsequent 30 months. The Company used a portion of the proceeds of the Second Amended and Restated Senior Credit Facility to pay off outstanding amounts under the Amended and Restated Senior Credit Facility and the remainder was used for general corporate purposes.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;In &lt;em style="font: inherit;"&gt; December 2020, &lt;/em&gt;the Company repaid the outstanding principal of the Second Amended and Restated Senior Credit Facility of $40,000 along with exit fees and accrued interest through the payoff date that totaled $3,298. The unamortized deferred financing cost and original issue discount of $1,211 was expensed as a loss on debt extinguishment.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-8"
      id="c69828972"
      unitRef="USD">100000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityFirstTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-7"
      id="c69828975"
      unitRef="USD">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityFirstTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-7"
      id="c69828976"
      unitRef="USD">30000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilitySecondTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-7"
      id="c69828978"
      unitRef="USD">30000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_DebtInstrumentAxis-SecuredCreditFacilityThirdTrancheMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-7"
      id="c69828980"
      unitRef="USD">20000000</us-gaap:DebtInstrumentFaceAmount>
    <bcrx:DebtInstrumentMinimumLibor
      contextRef="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="3"
      id="c69828988"
      unitRef="Pure">0.005</bcrx:DebtInstrumentMinimumLibor>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember"
      decimals="2"
      id="c69828989"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentTerm
      contextRef="d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      id="c69828990">P30M</us-gaap:DebtInstrumentTerm>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="d_2020-12-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-7"
      id="c69828991"
      unitRef="USD">40000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:PaymentsOfDebtExtinguishmentCosts
      contextRef="d_2020-12-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-3"
      id="c69828992"
      unitRef="USD">3298000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="d_2020-12-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember"
      decimals="-3"
      id="c69828993"
      unitRef="USD">1211000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:LeasesOfLessorDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757841">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;6&lt;/em&gt;&lt;/b&gt;&lt;b&gt; &#x2014; Lease Obligations and Other Contingencies&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;In &lt;em style="font: inherit;"&gt; February 2016, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02:&lt;/em&gt; &lt;i&gt;Leases (Topic &lt;em style="font: inherit;"&gt;842&lt;/em&gt;)&lt;/i&gt;. This ASU requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most operating leases. ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02&lt;/em&gt; is effective for annual and interim periods beginning after &lt;em style="font: inherit;"&gt; December 15, 2018, &lt;/em&gt;including interim periods within those fiscal years. In &lt;em style="font: inherit;"&gt; July 2018, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2018&lt;/em&gt;-&lt;em style="font: inherit;"&gt;11,&lt;/em&gt; &lt;i&gt;Leases (Topic &lt;em style="font: inherit;"&gt;842&lt;/em&gt;): Targeted Improvements&lt;/i&gt;, which provides companies with an additional optional transition method to apply the new standard to leases in effect at the adoption date through a cumulative effect adjustment. The Company adopted the new lease standard as of &lt;em style="font: inherit;"&gt; January 1, 2019 &lt;/em&gt;using this optional transition method.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company elected the package of practical expedients referenced in ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02,&lt;/em&gt; which permits companies to retain original lease identification and classification without reassessing initial direct costs for existing leases. The Company also elected the practical expedient that exempts leases with an initial lease term of &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months or less, as well as the practical expedient that allows companies to select, by class of underlying asset, &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to separate lease and non-lease components. Adoption of this standard resulted in the recognition of a right-of-use asset and a lease liability on the Company&#x2019;s &lt;em style="font: inherit;"&gt; January 1, 2019 &lt;/em&gt;Consolidated Balance Sheet of $3,621 and $4,822, respectively. There was &lt;em style="font: inherit;"&gt;no&lt;/em&gt; material impact on the Company&#x2019;s Consolidated Statement of Comprehensive Loss, and the cumulative transition adjustment recorded to retained earnings upon adoption was $238.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of &lt;em style="font: inherit;"&gt; December 31, 2020. &lt;/em&gt;Certain operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#x2019;s Consolidated Balance Sheet represent payments over the lease term, which includes renewal options for certain real estate leases that we are likely to exercise. As part of the Company&#x2019;s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Renewal options for our leases range from 1 to 5 years in length and begin from &lt;em style="font: inherit;"&gt;2023&lt;/em&gt; through &lt;em style="font: inherit;"&gt;2026.&lt;/em&gt; The weighted average lease term for the Company&#x2019;s operating leases was 13.1 years. The discount rate used in the calculation of the Company&#x2019;s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company&#x2019;s collateralized borrowing rate from lending institutions. The weighted average discount rate for the Company&#x2019;s operating leases was 12.7%.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; made any residual value guarantees related to its operating leases; therefore, the Company has &lt;em style="font: inherit;"&gt;no&lt;/em&gt; corresponding liability recorded on its Consolidated Balance Sheets.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"&gt;Aggregate lease expense under operating leases was $1,754 and $1,464 for the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt;-month periods ended &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; respectively. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; months or less was &lt;em style="font: inherit;"&gt;not&lt;/em&gt; material.&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Future lease payments for assets under operating leases as of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;are as follows:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 85%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;Remaining Maturities of Lease Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0.5pt 0pt 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,302&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;758&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;2023&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;619&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;2024&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;577&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;2025&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;582&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;7,327&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 12pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;11,165&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;6,115&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 12pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;5,050&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The&#160;&lt;/span&gt;Company&#x2019;s current lease liability at &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; was $1,179 and $1,377, respectively. The Company&#x2019;s long-term lease liability as of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; was $3,871 and $3,406, respectively. The current and long-term portions of the Company&#x2019;s lease liability are presented within &#x201c;Lease financing obligations&#x201d; on the Consolidated Balance Sheets. Cash paid for amounts included in the measurement of lease liabilities was $1,696 and $1,457 for the years ended &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; respectively. The Company&#x2019;s right-of use asset balance associated with operating leases totaled $3,802 and $3,590 at &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; respectively. These amounts are presented within &#x201c;Other assets&#x201d; on the Consolidated Balance Sheets. Operating right-of-use assets are recorded net of accumulated amortization of $2,641 and $1,386 as of &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; respectively&lt;span style="color:#000000;"&gt;.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


  </us-gaap:LeasesOfLessorDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2019-01-01_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="c69829007"
      unitRef="USD">3621000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2019-01-01_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="c69829008"
      unitRef="USD">4822000</us-gaap:OperatingLeaseLiability>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2019-01-01_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201602Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember"
      decimals="-3"
      id="c69829010"
      unitRef="USD">238000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2019-12-31_RangeAxis-MinimumMember"
      id="c69829011">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2019-12-31_RangeAxis-MaximumMember"
      id="c69829012">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2020-12-31" id="c69829015">P13Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2020-12-31"
      decimals="3"
      id="c69829016"
      unitRef="Pure">0.127</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69829019"
      unitRef="USD">1754000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69829020"
      unitRef="USD">1464000</us-gaap:OperatingLeaseExpense>
    <bcrx:LesseeLeaseLiabilityMaturityTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757842">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 85%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;Remaining Maturities of Lease Liabilities&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt 0.5pt 0pt 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;2021&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,302&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;2022&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;758&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;2023&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;619&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;2024&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;577&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;2025&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;582&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;7,327&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 12pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;11,165&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Less imputed interest&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;6,115&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 12pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;5,050&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </bcrx:LesseeLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829041"
      unitRef="USD">1302000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829042"
      unitRef="USD">758000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829043"
      unitRef="USD">619000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829044"
      unitRef="USD">577000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829045"
      unitRef="USD">582000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829046"
      unitRef="USD">7327000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829047"
      unitRef="USD">11165000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829048"
      unitRef="USD">6115000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2020-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember"
      decimals="-4"
      id="c69829049"
      unitRef="USD">5050000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2020-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentMember"
      decimals="-3"
      id="c69829026"
      unitRef="USD">1179000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2019-12-31_BalanceSheetLocationAxis-AccruedLiabilitiesCurrentMember"
      decimals="-3"
      id="c69829027"
      unitRef="USD">1377000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2020-12-31_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember"
      decimals="-3"
      id="c69829029"
      unitRef="USD">3871000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2019-12-31_BalanceSheetLocationAxis-OtherNoncurrentLiabilitiesMember"
      decimals="-3"
      id="c69829030"
      unitRef="USD">3406000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69829031"
      unitRef="USD">1696000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69829032"
      unitRef="USD">1457000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2020-12-31_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember"
      decimals="-3"
      id="c69829034"
      unitRef="USD">3802000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2019-12-31_BalanceSheetLocationAxis-OtherNoncurrentAssetsMember"
      decimals="-4"
      id="c69829035"
      unitRef="USD">3590000</us-gaap:OperatingLeaseRightOfUseAsset>
    <bcrx:OperatingLeaseRightofuseAssetAccumulatedAmortization
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829037"
      unitRef="USD">2641000</bcrx:OperatingLeaseRightofuseAssetAccumulatedAmortization>
    <bcrx:OperatingLeaseRightofuseAssetAccumulatedAmortization
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69829038"
      unitRef="USD">1386000</bcrx:OperatingLeaseRightofuseAssetAccumulatedAmortization>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757843">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;Note &lt;/b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;7&lt;/em&gt;&lt;/b&gt;&lt;b&gt; &#x2014; Stockholders&#x2019; Equity&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Sales of Common Stock&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:22pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;On &lt;em style="font: inherit;"&gt; November 8, 2017, &lt;/em&gt;the Company filed a $200,000 shelf registration statement on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; with the SEC. This shelf registration statement became effective on &lt;em style="font: inherit;"&gt; December 12, 2017 &lt;/em&gt;and allowed the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;On &lt;em style="font: inherit;"&gt; August 6, 2018, &lt;/em&gt;the Company completed an underwritten public offering of 10,455 shares of its common stock, offered at a price to the public of $5.50 per share, including shares issued pursuant to the underwriters&#x2019; &lt;em style="font: inherit;"&gt;30&lt;/em&gt;-day option to purchase additional shares, which was exercised in full. The net proceeds from this offering were approximately $53,400 after deducting underwriting discounts and commissions and estimated offering expenses.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;On &lt;em style="font: inherit;"&gt; November 18, 2019, &lt;/em&gt;the Company completed an underwritten public offering of 43,621 shares of its common stock, offered at a price to the public of $1.45 per share, including shares issued pursuant to the underwriters&#x2019; &lt;em style="font: inherit;"&gt;30&lt;/em&gt;-day option to purchase additional shares, which was exercised in full. The net proceeds from this offering were approximately $58,500 after deducting underwriting discounts and commissions and estimated offering expenses.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;On &lt;em style="font: inherit;"&gt; November 21, 2019, &lt;/em&gt;the Company completed an offering of pre-funded warrants to purchase up to 11,765 shares of its common stock at a price of $1.69 per warrant. Each pre-funded warrant is exercisable subject to conditions in the warrant agreement into &lt;em style="font: inherit;"&gt;1&lt;/em&gt; share of common stock at an exercise price of $0.01 per share. The net proceeds from this offering were $19,882, excluding any proceeds the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive upon the subsequent exercise of the pre-funded warrants. All warrants issued in this offering remain outstanding at &lt;em style="font: inherit;"&gt; December 31, 2020.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;On &lt;em style="font: inherit;"&gt; April 24, 2020, &lt;/em&gt;the Company filed a $500,000 shelf registration statement on Form S-&lt;em style="font: inherit;"&gt;3&lt;/em&gt; with the SEC. This shelf registration statement became effective on &lt;em style="font: inherit;"&gt; May 14, 2020 &lt;/em&gt;and allows the Company to sell securities, including common stock, preferred stock, depository shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;On &lt;em style="font: inherit;"&gt; June 1, 2020, &lt;/em&gt;the Company issued 22,044 shares of common stock to the public at a purchase price of $4.50 per share and pre-funded warrants to purchase 3,511 shares of common stock at a purchase of $4.49 per pre-funded warrant, for total net proceeds to the Company of $108,096 million after deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant is exercisable subject to conditions in the warrant agreement into &lt;em style="font: inherit;"&gt;1&lt;/em&gt; share of common stock at an exercise price of $0.01 per share. All warrants issued in this offering remain outstanding at &lt;em style="font: inherit;"&gt; December 31, 2020.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <bcrx:MaximumAggregateOfferingPrice
      contextRef="i_2017-11-08"
      decimals="-8"
      id="c69829051"
      unitRef="USD">200000000</bcrx:MaximumAggregateOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2018-08-06_2018-08-06"
      decimals="-3"
      id="c69829053"
      unitRef="Share">10455000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2018-08-06"
      decimals="INF"
      id="c69829054"
      unitRef="USDPerShare">5.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2018-08-06_2018-08-06"
      decimals="-5"
      id="c69829056"
      unitRef="USD">53400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2019-11-18_2019-11-18"
      decimals="-3"
      id="c69829057"
      unitRef="Share">43621000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2019-11-18"
      decimals="INF"
      id="c69829058"
      unitRef="USDPerShare">1.45</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2019-11-18_2019-11-18"
      decimals="-5"
      id="c69829060"
      unitRef="USD">58500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2019-11-21"
      decimals="-3"
      id="c69829061"
      unitRef="Share">11765000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2019-11-21"
      decimals="INF"
      id="c69829062"
      unitRef="USDPerShare">1.69</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2019-11-21"
      decimals="INF"
      id="c69829064"
      unitRef="USDPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="d_2019-11-21_2019-11-21"
      decimals="-3"
      id="c69829065"
      unitRef="USD">19882000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <bcrx:MaximumAggregateOfferingPrice
      contextRef="i_2020-04-24"
      decimals="-8"
      id="c69829066"
      unitRef="USD">500000000</bcrx:MaximumAggregateOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-06-01_2020-06-01"
      decimals="INF"
      id="c69829068"
      unitRef="Share">22044</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2020-06-01"
      decimals="INF"
      id="c69829069"
      unitRef="USDPerShare">4.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember"
      decimals="INF"
      id="c69829070"
      unitRef="Share">3511</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <bcrx:ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant
      contextRef="d_2020-06-01_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember"
      decimals="INF"
      id="c69829071"
      unitRef="USDPerShare">4.49</bcrx:ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2020-06-01_2020-06-01"
      decimals="-6"
      id="c69829072"
      unitRef="USD">108096000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-06-01_ClassOfWarrantOrRightAxis-WarrantsIssuedInPublicOfferingMember"
      decimals="INF"
      id="c69829074"
      unitRef="USDPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757844">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt;&lt;/b&gt;&lt;b&gt; &#x2014; Stock-Based Compensation&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the Company had &lt;em style="font: inherit;"&gt;three&lt;/em&gt; stock-based employee compensation plans, the Amended and Restated Stock Incentive Plan (&#x201c;Incentive Plan&#x201d;), the&#160;&lt;/span&gt;Amended and Restated&#160;&lt;span style="color:#000000;"&gt;Inducement Equity Incentive Plan (&#x201c;Inducement Plan&#x201d;) and the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The Incentive Plan was amended and restated on &lt;em style="font: inherit;"&gt; March 19, 2020 &lt;/em&gt;and approved by the Company&#x2019;s stockholders on &lt;em style="font: inherit;"&gt; May 12, 2020. &lt;/em&gt;The Inducement Plan was adopted by the Board of Directors on &lt;em style="font: inherit;"&gt; April 24, 2019 &lt;/em&gt;and amended and restated by the Board of Directors in &lt;em style="font: inherit;"&gt; February 2020 &lt;/em&gt;and in &lt;em style="font: inherit;"&gt; July 2020. &lt;/em&gt;The ESPP was amended and restated in &lt;em style="font: inherit;"&gt; March 2020 &lt;/em&gt;and approved by the Company&#x2019;s stockholders on &lt;em style="font: inherit;"&gt; May 12, 2020. &lt;/em&gt;Stock-based compensation expense of $14,794 ($12,938 of expense related to the Incentive Plan, $1,494 of expense related to the Inducement Plan, $362 of expense related to the ESPP) was recognized during &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; while $17,719 ($17,164 of expense related to the Incentive Plan, $323 of expense related to the Inducement Plan, $232 of expense related to the ESPP) was recognized during &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and $9,396 ($9,223 of expense related to the Incentive Plan, $173 of expense related to the ESPP) was recognized during &lt;em style="font: inherit;"&gt;2018.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:23pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company accounts for stock-based compensation in accordance with FASB authoritative guidance regarding share-based payments. Total stock-based compensation was allocated as follows:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;9&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;8&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Research and development&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;10,222&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;13,977&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6,867&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;4,572&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;3,742&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;2,529&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;14,794&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;17,719&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;9,396&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Stock Incentive Plan&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#x2019;s stock at the date of grant. Commencing &lt;em style="font: inherit;"&gt; March 1, 2011, &lt;/em&gt;stock option awards and restricted stock units granted to employees generally vest 25% each year until fully vested after &lt;span style="-sec-ix-hidden:c69829093"&gt;four&lt;/span&gt; years. In &lt;em style="font: inherit;"&gt; August 2013, &lt;/em&gt;&lt;em style="font: inherit;"&gt; December 2014 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 2019, &lt;/em&gt;the Company issued 1,032, 1,250 and 315 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;100%, 85% and 100% of the &lt;em style="font: inherit;"&gt; August 2013, &lt;/em&gt;&lt;em style="font: inherit;"&gt; December 2014 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 2019 &lt;/em&gt;grants, respectively, have vested. During &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the Company recognized $1,768 and $684 of stock compensation expense related to milestones within the &lt;em style="font: inherit;"&gt; August 2013 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 2019 &lt;/em&gt;grants for which achievement became probable. Stock option awards granted to non-employee directors of the Company generally vest over &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year. All stock option awards have contractual terms of 10 years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Related activity under the Incentive Plan is as follows:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Awards&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Available&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Outstanding&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Price&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Balance at December 31, 2017&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;468&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;14,452&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Plan amendment&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4,400&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Restricted stock awards granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(13&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(4,272&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4,272&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;7.15&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards exercised&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(1,011&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2.92&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards cancelled&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;222&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(222&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;7.44&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;805&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;17,491&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6.49&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Plan amendment&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Restricted stock awards granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(27&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(4,511&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4,511&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3.91&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards exercised&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(251&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards cancelled&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;701&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(701&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6.82&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;968&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;21,050&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;5.96&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Plan amendment&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Restricted stock awards granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(31&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(7,469&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;7,469&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;8.06&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards exercised&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(510&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.56&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards cancelled&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;3,124&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(3,124&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6.93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;4,592&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;24,885&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6.52&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;For stock option awards granted under the Incentive Plan during &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018,&lt;/em&gt; the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; was $5.48, $2.63, and $4.92, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&lt;b&gt;Inducement Equity Incentive Plan&lt;/b&gt;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The&#160;&lt;/span&gt;Company has the ability to grant stock option awards to newly-hired employees as inducements material to each employee entering employment with the Company. Stock option awards granted to newly hired employees generally vest 25% each year until fully vested after &lt;span style="-sec-ix-hidden:c69829118"&gt;four&lt;/span&gt; years. Each stock option has a term of 10 years and is subject to the terms and conditions of the Inducement Plan. The vesting and exercise provisions of all awards granted under the Inducement Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Inducement Plan&lt;span style="color:#000000;"&gt;.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Related activity under the Inducement Plan is as follows:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Awards&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Available&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Outstanding&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Price&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;171&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,329&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3.60&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Plan amendment&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,900&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(3,002&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3,002&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.02&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards cancelled&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;160&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(160&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.15&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;229&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;4,171&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;For stock option awards granted under the Inducement Plan during &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; was $2.73 and $2.41, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The following table summarizes the key assumptions used by the Company to value the stock option awards granted under all plans during &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018,&lt;/em&gt; respectively. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#x2019;s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on &lt;em style="font: inherit;"&gt;zero&lt;/em&gt;-coupon government issues with a remaining term equal to the expected term.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Plans&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;9&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;8&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Expected Life&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Expected Volatility&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;84&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;81&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;82&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The total intrinsic value of stock option awards exercised under the Incentive Plan was $1,562 during &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; $1,127 during &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; and $4,504 during &lt;em style="font: inherit;"&gt;2018.&lt;/em&gt; The intrinsic value represents the total proceeds (fair market value at the date of exercise, less the exercise price, times the number of stock option awards exercised) received by all individuals who exercised stock option awards during the period. No stock option awards were exercised under the Inducement Plan in &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:25pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The following table summarizes, at &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;by price range: (&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) for stock option awards outstanding under the Incentive Plan, the number of stock option awards outstanding, their weighted average remaining life and their weighted average exercise price; and (&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) for stock option awards exercisable under the Plan, the number of stock option awards exercisable and their weighted average exercise price:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" rowspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;b style="font-size: 10pt;"&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td colspan="6" rowspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Range&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;0&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,514&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2.19&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,414&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;6&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;12,689&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.22&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6,854&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2.48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;6&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;9&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;10,852&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;9.2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;7.88&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,005&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.89&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;9&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;12&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,347&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;10.85&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,129&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.51&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;12&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;15&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;559&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;12.30&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;539&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6.43&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;15&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;18&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;95&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;15.39&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;95&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;10.57&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;0&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;18&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;29,056&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6.14&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;13,036&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3.27&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&lt;span style="color:#000000;"&gt;The weighted average remaining contractual life of stock option awards exercisable under the plans at &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;was 5.3 years.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The aggregate intrinsic value of stock option awards outstanding and exercisable under the plans at &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;was $29,716. The aggregate intrinsic value represents the value (the period&#x2019;s closing market price, less the exercise price, times the number of in-the-money stock option awards) that would have been received by all stock option award holders under the plans had they exercised their stock option awards at the end of the year.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&lt;span style="color:#000000;"&gt;The total fair value of the stock option awards vested under the plans was $18,739&#160;during &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; $12,499 during &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; and $8,952 during &lt;em style="font: inherit;"&gt;2018.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;As&#160;&lt;/span&gt;of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the number of stock option awards vested and expected to vest under the plans is 26,487. The weighted average exercise price of these stock option awards is $6.13 and their weighted average remaining contractual life is 7.4 years&lt;span style="color:#000000;"&gt;.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&lt;span style="color:#000000;"&gt;The following table summarizes the changes in the number and weighted-average grant-date fair value of non-vested stock option awards during &lt;em style="font: inherit;"&gt;2020:&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Non-Vested Stock Option Awards&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Weighted Average Grant-Date Fair Value&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Balance December 31, 2019&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;11,688&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3.77&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;10,471&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards vested&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(4,543&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards forfeited&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(1,596&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;3.96&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Balance December 31, 2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;16,020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;4.25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;there was approximately $56,094 of total unrecognized compensation cost related to non-vested employee stock option awards granted by the Company. That cost is expected to be recognized as follows: $17,758 in &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; $16,281 in &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; $12,484 in &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; and $9,571 in &lt;em style="font: inherit;"&gt;2024.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;i&gt;Employee Stock Purchase Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company has reserved a total of 4,475 shares of common stock to be purchased under the ESPP, of which 2,873 shares remain available for purchase at &lt;em style="font: inherit;"&gt; December 31, 2020. &lt;/em&gt;Eligible employees &lt;em style="font: inherit;"&gt; may &lt;/em&gt;authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during &lt;em style="font: inherit;"&gt;six&lt;/em&gt;-month purchase intervals. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; more than 3 shares &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be purchased by any &lt;em style="font: inherit;"&gt;one&lt;/em&gt; employee at the &lt;em style="font: inherit;"&gt;six&lt;/em&gt;-month purchase dates and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; employee &lt;em style="font: inherit;"&gt; may &lt;/em&gt;purchase stock having a fair market value at the commencement date of $25 or more in any &lt;em style="font: inherit;"&gt;one&lt;/em&gt; calendar year.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;There were 246, 115, and 92 shares of common stock purchased under the ESPP in &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018,&lt;/em&gt; respectively, at a weighted average price per share of $2.56, $3.51, and $3.83, respectively. Expense of $362, $232, and $173 related to the ESPP was recognized during &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018,&lt;/em&gt; respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#x201c;look-back&#x201d; option were determined using a Black-Scholes option pricing model. The weighted average grant date fair values of shares granted under the ESPP during &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018,&lt;/em&gt; were $1.47, $2.01, and $1.89, respectively.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69829077"
      unitRef="USD">14794000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829078"
      unitRef="USD">12938000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c69829079"
      unitRef="USD">1494000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c69829080"
      unitRef="USD">362000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69829082"
      unitRef="USD">17719000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829083"
      unitRef="USD">17164000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c69829084"
      unitRef="USD">323000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c69829085"
      unitRef="USD">232000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69829087"
      unitRef="USD">9396000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829088"
      unitRef="USD">9223000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c69829089"
      unitRef="USD">173000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757845">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;9&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;8&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Research and development&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;10,222&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;13,977&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6,867&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;4,572&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;3,742&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;2,529&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;14,794&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;17,719&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;9,396&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c69829208"
      unitRef="USD">10222000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2019-01-01_2019-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c69829209"
      unitRef="USD">13977000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2018-01-01_2018-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c69829210"
      unitRef="USD">6867000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="c69829211"
      unitRef="USD">4572000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2019-01-01_2019-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="c69829212"
      unitRef="USD">3742000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2018-01-01_2018-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="c69829213"
      unitRef="USD">2529000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69829214"
      unitRef="USD">14794000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69829215"
      unitRef="USD">17719000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69829216"
      unitRef="USD">9396000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"
      decimals="2"
      id="c69829092"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2013-08-01_2013-08-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"
      decimals="-3"
      id="c69829094"
      unitRef="Share">1032000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2014-12-01_2014-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"
      decimals="-4"
      id="c69829095"
      unitRef="Share">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2019-12-01_2019-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"
      decimals="-3"
      id="c69829096"
      unitRef="Share">315000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2020-01-01_2020-12-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"
      decimals="0"
      id="c69829097"
      unitRef="Pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2020-01-01_2020-12-31_AwardDateAxis-December2014Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"
      decimals="2"
      id="c69829098"
      unitRef="Pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2020-01-01_2020-12-31_AwardDateAxis-December2019Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember_VestingAxis-VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember"
      decimals="0"
      id="c69829099"
      unitRef="Pure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_AwardDateAxis-August2013Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829102"
      unitRef="USD">1768000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_AwardDateAxis-December2019Member_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829103"
      unitRef="USD">684000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-IncentivePlanMember_RangeAxis-MaximumMember"
      id="c69829105">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="d_2020-01-01_2020-12-31"
      id="c8E0CFA93-2E69-4763-A357-3334C9545AA8">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Awards&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Available&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Outstanding&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Price&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Balance at December 31, 2017&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;468&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;14,452&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6.06&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Plan amendment&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4,400&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Restricted stock awards granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(13&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(4,272&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4,272&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;7.15&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards exercised&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(1,011&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2.92&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards cancelled&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;222&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(222&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;7.44&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;805&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;17,491&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6.49&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Plan amendment&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Restricted stock awards granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(27&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(4,511&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4,511&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3.91&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards exercised&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(251&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards cancelled&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;701&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(701&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6.82&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;968&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;21,050&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;5.96&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Plan amendment&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;8,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Restricted stock awards granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(31&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(7,469&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;7,469&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;8.06&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards exercised&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(510&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;3.56&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards cancelled&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;3,124&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(3,124&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6.93&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;4,592&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;24,885&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6.52&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Awards&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Options&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Exercise&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Available&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Outstanding&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Price&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Balance at December 31, 2019&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;171&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,329&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3.60&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Plan amendment&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,900&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(3,002&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3,002&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.02&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards cancelled&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;160&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(160&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.15&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;229&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;4,171&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2017-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829223"
      unitRef="Share">468000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2017-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829224"
      unitRef="Share">14452000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2017-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c69829225"
      unitRef="USDPerShare">6.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-5"
      id="c69829226"
      unitRef="Share">4400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829229"
      unitRef="Share">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829232"
      unitRef="Share">4272000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829233"
      unitRef="Share">4272000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c69829234"
      unitRef="USDPerShare">7.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829236"
      unitRef="Share">1011000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c69829237"
      unitRef="USDPerShare">2.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829238"
      unitRef="Share">222000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829239"
      unitRef="Share">222000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c69829240"
      unitRef="USDPerShare">7.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2018-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829241"
      unitRef="Share">805000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2018-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829242"
      unitRef="Share">17491000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2018-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c69829243"
      unitRef="USDPerShare">6.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-6"
      id="c69829244"
      unitRef="Share">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829247"
      unitRef="Share">27000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829250"
      unitRef="Share">4511000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829251"
      unitRef="Share">4511000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c69829252"
      unitRef="USDPerShare">3.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829254"
      unitRef="Share">251000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c69829255"
      unitRef="USDPerShare">3.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829256"
      unitRef="Share">701000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829257"
      unitRef="Share">701000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c69829258"
      unitRef="USDPerShare">6.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829259"
      unitRef="Share">968000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-4"
      id="c69829260"
      unitRef="Share">21050000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c69829261"
      unitRef="USDPerShare">5.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-6"
      id="c69829262"
      unitRef="Share">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829265"
      unitRef="Share">31000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829268"
      unitRef="Share">7469000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829269"
      unitRef="Share">7469000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c69829270"
      unitRef="USDPerShare">8.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-4"
      id="c69829272"
      unitRef="Share">510000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c69829273"
      unitRef="USDPerShare">3.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829274"
      unitRef="Share">3124000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829275"
      unitRef="Share">3124000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c69829276"
      unitRef="USDPerShare">6.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2020-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829277"
      unitRef="Share">4592000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2020-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829278"
      unitRef="Share">24885000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2020-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c69829279"
      unitRef="USDPerShare">6.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c69829112"
      unitRef="USDPerShare">5.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c69829113"
      unitRef="USDPerShare">2.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="INF"
      id="c69829114"
      unitRef="USDPerShare">4.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember_VestingAxis-Vest25PercentEachYearUntilFullyVestedMember"
      decimals="2"
      id="c69829116"
      unitRef="Pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember"
      id="c69829120">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2019-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c69829286"
      unitRef="Share">171000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2019-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c69829287"
      unitRef="Share">1329000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2019-12-31_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c69829288"
      unitRef="USDPerShare">3.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-5"
      id="c69829289"
      unitRef="Share">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c69829292"
      unitRef="Share">3002000</bcrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c69829293"
      unitRef="Share">3002000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c69829294"
      unitRef="USDPerShare">4.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-4"
      id="c69829295"
      unitRef="Share">160000</bcrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-4"
      id="c69829296"
      unitRef="Share">160000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c69829297"
      unitRef="USDPerShare">4.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2020-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c69829298"
      unitRef="Share">229000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2020-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c69829299"
      unitRef="Share">4171000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2020-12-31_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c69829300"
      unitRef="USDPerShare">3.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c69829130"
      unitRef="USDPerShare">2.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-InducementPlanMember"
      decimals="INF"
      id="c69829131"
      unitRef="USDPerShare">2.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c69829137"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757848">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; padding-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;9&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;8&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Expected Life&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Expected Volatility&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;84&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;81&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;82&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;0.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;0.4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1.8&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      id="c69829304">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      id="c69829305">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      id="c69829306">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="2"
      id="c69829307"
      unitRef="Pure">0.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="2"
      id="c69829308"
      unitRef="Pure">0.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="2"
      id="c69829309"
      unitRef="Pure">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="-3"
      id="c69829310"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="-3"
      id="c69829311"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="-3"
      id="c69829312"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="3"
      id="c69829313"
      unitRef="Pure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="3"
      id="c69829314"
      unitRef="Pure">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="3"
      id="c69829315"
      unitRef="Pure">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829140"
      unitRef="USD">1562000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829142"
      unitRef="USD">1127000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanMember"
      decimals="-3"
      id="c69829144"
      unitRef="USD">4504000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c69829146"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757849">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" rowspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;b style="font-size: 10pt;"&gt;Outstanding&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Exercisable&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td colspan="6" rowspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Range&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Life&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Number&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;0&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,514&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2.19&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,414&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1.25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;6&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;12,689&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.22&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6,854&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2.48&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;6&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;9&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;10,852&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;9.2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;7.88&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,005&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.89&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;9&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;12&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,347&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;10.85&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,129&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.51&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;12&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;15&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;559&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;12.30&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;539&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6.43&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;15&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;18&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;95&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;15.39&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;95&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;10.57&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;0&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;to&lt;/em&gt;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;18&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;29,056&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6.14&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;13,036&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 7%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3.27&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member"
      decimals="INF"
      id="c69829318"
      unitRef="USDPerShare">3</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member"
      decimals="INF"
      id="c69829319"
      unitRef="Share">2514</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member"
      id="c69829320">P6Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member"
      decimals="INF"
      id="c69829321"
      unitRef="USDPerShare">2.19</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member"
      decimals="INF"
      id="c69829322"
      unitRef="Share">1414</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange01Member"
      decimals="INF"
      id="c69829323"
      unitRef="USDPerShare">1.25</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member"
      decimals="INF"
      id="c69829326"
      unitRef="USDPerShare">6</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member"
      decimals="INF"
      id="c69829327"
      unitRef="Share">12689</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member"
      id="c69829328">P7Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member"
      decimals="INF"
      id="c69829329"
      unitRef="USDPerShare">4.22</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member"
      decimals="INF"
      id="c69829330"
      unitRef="Share">6854</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange02Member"
      decimals="INF"
      id="c69829331"
      unitRef="USDPerShare">2.48</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member"
      decimals="INF"
      id="c69829334"
      unitRef="USDPerShare">9</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member"
      decimals="INF"
      id="c69829335"
      unitRef="Share">10852</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member"
      id="c69829336">P9Y2M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member"
      decimals="INF"
      id="c69829337"
      unitRef="USDPerShare">7.88</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member"
      decimals="INF"
      id="c69829338"
      unitRef="Share">2005</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange03Member"
      decimals="INF"
      id="c69829339"
      unitRef="USDPerShare">4.89</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member"
      decimals="INF"
      id="c69829342"
      unitRef="USDPerShare">12</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member"
      decimals="INF"
      id="c69829343"
      unitRef="Share">2347</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member"
      id="c69829344">P4Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member"
      decimals="INF"
      id="c69829345"
      unitRef="USDPerShare">10.85</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member"
      decimals="INF"
      id="c69829346"
      unitRef="Share">2129</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange04Member"
      decimals="INF"
      id="c69829347"
      unitRef="USDPerShare">4.51</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member"
      decimals="INF"
      id="c69829350"
      unitRef="USDPerShare">15</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member"
      decimals="INF"
      id="c69829351"
      unitRef="Share">559</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member"
      id="c69829352">P4Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member"
      decimals="INF"
      id="c69829353"
      unitRef="USDPerShare">12.30</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member"
      decimals="INF"
      id="c69829354"
      unitRef="Share">539</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange05Member"
      decimals="INF"
      id="c69829355"
      unitRef="USDPerShare">6.43</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member"
      decimals="INF"
      id="c69829358"
      unitRef="USDPerShare">18</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member"
      decimals="INF"
      id="c69829359"
      unitRef="Share">95</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="d_2020-01-01_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member"
      id="c69829360">P4Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member"
      decimals="INF"
      id="c69829361"
      unitRef="USDPerShare">15.39</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member"
      decimals="INF"
      id="c69829362"
      unitRef="Share">95</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2020-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange06Member"
      decimals="INF"
      id="c69829363"
      unitRef="USDPerShare">10.57</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c69829366"
      unitRef="USDPerShare">18</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c69829367"
      unitRef="Share">29056</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="d_2020-01-01_2020-12-31" id="c69829368">P7Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c69829369"
      unitRef="USDPerShare">6.14</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c69829370"
      unitRef="Share">13036</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c69829371"
      unitRef="USDPerShare">3.27</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-InducementPlanMember"
      id="c69829150">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i_2020-12-31_PlanNameAxis-InducementPlanMember"
      decimals="-3"
      id="c69829151"
      unitRef="USD">29716000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="INF"
      id="c69829153"
      unitRef="USD">18739</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="-3"
      id="c69829155"
      unitRef="USD">12499000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="-3"
      id="c69829157"
      unitRef="USD">8952000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="-3"
      id="c69829159"
      unitRef="Share">26487000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      decimals="INF"
      id="c69829160"
      unitRef="USDPerShare">6.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember"
      id="c69829161">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757850">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Non-Vested Stock Option Awards&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Weighted Average Grant-Date Fair Value&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Balance December 31, 2019&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;11,688&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3.77&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards granted&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;10,471&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards vested&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(4,543&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4.12&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Stock option awards forfeited&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(1,596&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;3.96&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Balance December 31, 2020&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;16,020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;4.25&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69829372"
      unitRef="Share">11688000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c69829373"
      unitRef="USDPerShare">3.77</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69829374"
      unitRef="Share">10471000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c69829375"
      unitRef="USDPerShare">4.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69829376"
      unitRef="Share">4543000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c69829377"
      unitRef="USDPerShare">4.12</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69829378"
      unitRef="Share">1596000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c69829379"
      unitRef="USDPerShare">3.96</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c69829380"
      unitRef="Share">16020000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c69829381"
      unitRef="USDPerShare">4.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829163"
      unitRef="USD">56094000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <bcrx:EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829164"
      unitRef="USD">17758000</bcrx:EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829166"
      unitRef="USD">16281000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829168"
      unitRef="USD">12484000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree>
    <bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829170"
      unitRef="USD">9571000</bcrx:EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c69829172"
      unitRef="Share">4475000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c69829173"
      unitRef="Share">2873000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="2"
      id="c69829174"
      unitRef="Pure">0.15</bcrx:PercentageOfSalaryToPurchaseCommonStockMaximum>
    <bcrx:PercentageOfCommonStockSharesBeginning
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="2"
      id="c69829175"
      unitRef="Pure">0.85</bcrx:PercentageOfCommonStockSharesBeginning>
    <bcrx:PercentageOfCommonStockSharesEnding
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="2"
      id="c69829176"
      unitRef="Pure">0.85</bcrx:PercentageOfCommonStockSharesEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c69829179"
      unitRef="Share">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <bcrx:ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount
      contextRef="i_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c69829183"
      unitRef="USD">25000</bcrx:ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c69829185"
      unitRef="Share">246000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c69829186"
      unitRef="Share">115000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c69829187"
      unitRef="Share">92000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="c69829191"
      unitRef="USDPerShare">2.56</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
    <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="c69829192"
      unitRef="USDPerShare">3.51</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
    <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="c69829193"
      unitRef="USDPerShare">3.83</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c69829194"
      unitRef="USD">362000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c69829195"
      unitRef="USD">232000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="-3"
      id="c69829196"
      unitRef="USD">173000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2020-01-01_2020-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="c69829203"
      unitRef="USDPerShare">1.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2019-01-01_2019-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="c69829204"
      unitRef="USDPerShare">2.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2018-01-01_2018-12-31_PlanNameAxis-EmployeeStockPurchasePlanMember"
      decimals="INF"
      id="c69829205"
      unitRef="USDPerShare">1.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757851">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;Note &lt;/b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;9&lt;/em&gt;&lt;/b&gt;&lt;b&gt; &#x2014; Income Taxes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&lt;span style="color:#000000;"&gt;The Company has incurred net losses since inception and, consequently, has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recorded any U.S. Federal and state income tax expense or benefit.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&lt;span style="color:#000000;"&gt;The components of loss before provision for income taxes were as followings:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Domestic&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(176,613&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Foreign&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(6,201&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Loss before provision for income taxes&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(182,814&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"&gt;&lt;span style="color:#000000;"&gt;The differences between the Company&#x2019;s effective tax rate and the statutory tax rate in &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018,&lt;/em&gt; are as follows:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;9&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;8&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Income tax benefit at federal statutory rate (&lt;span style="-sec-ix-hidden:c69831164"&gt;&lt;span style="-sec-ix-hidden:c69831165"&gt;&lt;span style="-sec-ix-hidden:c69831166"&gt;21%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; for 2020, 2019 and 2018)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(38,391&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(22,868&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(21,263&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;State and local income taxes net of federal tax benefit&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(2,544&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(1,591&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(2,547&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;774&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;691&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;503&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Rate change&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(82&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;625&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(29&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Expiration of attribute carryforwards&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3,774&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3,976&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,183&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:c69830313"&gt;(4,080&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:c69830314"&gt;(4,938&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:c69830315"&gt;(4,905&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Foreign rate differential&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;542&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Other&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:c69830319"&gt;1,456&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:c69830320"&gt;281&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:c69830321"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;38,551&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;23,824&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;26,040&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: #000000; "&gt;&lt;span style="-sec-ix-hidden:c69830325"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:c69830326"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:c69830327"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company recognizes the impact of a tax position in its financial statements if it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that the position will be sustained on audit based on the technical merits of the position. The Company has concluded that it has an uncertain tax position pertaining to its research and development and orphan drug credit carryforwards. The Company has established these credits based on information and calculations it believes are appropriate and the best estimate of the underlying credit. Any changes to the Company&#x2019;s unrecognized tax benefits are offset by an adjustment to the valuation allowance and there would be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; impact on the Company&#x2019;s financial statements. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect its unrecognized tax benefits to change significantly over the next &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;9&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Balance at January 1,&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;7,210&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;5,976&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Additions to current period tax positions&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,234&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Additions to prior period tax positions&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Reductions to prior period tax provisions&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Balance at December 31,&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;8,230&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;7,210&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company&#x2019;s ability to utilize the net operating loss and tax credit carryforwards in the future &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be subject to substantial restrictions in the event of past or future ownership changes as defined in Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; of the Internal Revenue Code of &lt;em style="font: inherit;"&gt;1986,&lt;/em&gt; as amended and similar state tax law.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;9&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Net federal and state operating losses&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;159,939&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;155,190&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;66,331&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;63,275&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Royalty income&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;28,034&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;10,732&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;9,786&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Leasing obligations&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,135&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,070&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Other&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;5,563&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;3,801&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;271,734&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;233,122&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(124&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(114&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(854&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(803&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(978&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(917&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(270,756&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(232,205&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The majority of the Company&#x2019;s deferred tax assets relate to net operating loss and research and development carryforwards that can only be realized if the Company is profitable in future periods. It is uncertain whether the Company will realize any tax benefit related to these carryforwards. Accordingly, the Company has provided a full valuation allowance against the net deferred tax assets due to uncertainties as to their ultimate realization. The valuation allowance will remain at the full amount of the deferred tax assets until it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that the related tax benefits will be realized. The Company&#x2019;s valuation allowance increased by $38,551, $23,824, and $26,040 in &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018,&lt;/em&gt; respectively.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the Company had U.S. federal operating loss carryforwards of $677,109, state operating loss carryforwards of $494,608, foreign net operating losses of $6,427, and U.S. research and development and orphan drug credit carryforwards of $74,561, which will expire at various dates from &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; through &lt;em style="font: inherit;"&gt;2040.&lt;/em&gt; Federal losses, state losses, research and development credit carryforwards began expiring in &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt; The foreign net operating losses have an indefinite carryforward period.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Tax years &lt;span style="-sec-ix-hidden:c69829408"&gt;2017&lt;/span&gt;-&lt;em style="font: inherit;"&gt;2020&lt;/em&gt; remain open to examination by the major taxing jurisdictions to which the Company is subject. Additionally, years prior to &lt;em style="font: inherit;"&gt;2017&lt;/em&gt; are also open to examination to the extent of loss and credit carryforwards from those years. The Company recognizes interest and penalties accrued related to unrecognized tax benefits as components of its income tax provision. However, there were no provisions or accruals for interest and penalties in &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;


  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757852">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Domestic&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(176,613&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Foreign&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(6,201&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Loss before provision for income taxes&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(182,814&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69829418"
      unitRef="USD">-176613000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69829419"
      unitRef="USD">-6201000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69829420"
      unitRef="USD">-182814000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757889">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;9&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;8&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 55%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Income tax benefit at federal statutory rate (&lt;span style="-sec-ix-hidden:c69831164"&gt;&lt;span style="-sec-ix-hidden:c69831165"&gt;&lt;span style="-sec-ix-hidden:c69831166"&gt;21%&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; for 2020, 2019 and 2018)&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(38,391&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(22,868&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(21,263&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;State and local income taxes net of federal tax benefit&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(2,544&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(1,591&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(2,547&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;774&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;691&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;503&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Rate change&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(82&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;625&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(29&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Expiration of attribute carryforwards&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3,774&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;3,976&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,183&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:c69830313"&gt;(4,080&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:c69830314"&gt;(4,938&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:c69830315"&gt;(4,905&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Foreign rate differential&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;542&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Other&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:c69830319"&gt;1,456&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:c69830320"&gt;281&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:c69830321"&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;38,551&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;23,824&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;26,040&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Income tax expense&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color: #000000; "&gt;&lt;span style="-sec-ix-hidden:c69830325"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:c69830326"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:c69830327"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69830298"
      unitRef="USD">-38391000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69830299"
      unitRef="USD">-22868000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69830300"
      unitRef="USD">-21263000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69830301"
      unitRef="USD">-2544000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69830302"
      unitRef="USD">-1591000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69830303"
      unitRef="USD">-2547000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69830304"
      unitRef="USD">774000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69830305"
      unitRef="USD">691000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69830306"
      unitRef="USD">503000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69830307"
      unitRef="USD">-82000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69830308"
      unitRef="USD">625000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69830309"
      unitRef="USD">-29000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69830310"
      unitRef="USD">3774000</bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards>
    <bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69830311"
      unitRef="USD">3976000</bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards>
    <bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69830312"
      unitRef="USD">2183000</bcrx:IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69830316"
      unitRef="USD">542000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69830322"
      unitRef="USD">38551000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69830323"
      unitRef="USD">23824000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-4"
      id="c69830324"
      unitRef="USD">26040000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757890">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;9&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Balance at January 1,&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;7,210&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;5,976&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Additions to current period tax positions&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,020&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,234&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Additions to prior period tax positions&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Reductions to prior period tax provisions&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="color:#000000;"&gt;Balance at December 31,&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;8,230&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;7,210&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2019-12-31"
      decimals="-4"
      id="c69830328"
      unitRef="USD">7210000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2018-12-31"
      decimals="-3"
      id="c69830329"
      unitRef="USD">5976000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-4"
      id="c69830330"
      unitRef="USD">1020000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69830331"
      unitRef="USD">1234000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c69830336"
      unitRef="USD">8230000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2019-12-31"
      decimals="-4"
      id="c69830337"
      unitRef="USD">7210000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757855">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;201&lt;/b&gt;&lt;b&gt;9&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Net federal and state operating losses&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;159,939&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;155,190&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Research and development credits&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;66,331&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;63,275&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Royalty income&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;28,034&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;10,732&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;9,786&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Leasing obligations&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,135&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,070&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Other&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;5,563&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;3,801&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;271,734&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;233,122&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(124&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(114&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(854&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(803&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(978&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(917&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(270,756&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;(232,205&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="color:#000000;"&gt;&lt;em style="font: inherit;"&gt;&#x2212;&lt;/em&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829468"
      unitRef="USD">159939000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="i_2019-12-31"
      decimals="-4"
      id="c69829469"
      unitRef="USD">155190000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829470"
      unitRef="USD">66331000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69829471"
      unitRef="USD">63275000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <bcrx:DeferredTaxAssetsRoyaltyIncome
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829472"
      unitRef="USD">28034000</bcrx:DeferredTaxAssetsRoyaltyIncome>
    <bcrx:DeferredTaxAssetsRoyaltyIncome
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69829473"
      unitRef="USD">0</bcrx:DeferredTaxAssetsRoyaltyIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829474"
      unitRef="USD">10732000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69829475"
      unitRef="USD">9786000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <bcrx:DeferredTaxAssetsLeasingObligations
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69830346"
      unitRef="USD">1135000</bcrx:DeferredTaxAssetsLeasingObligations>
    <bcrx:DeferredTaxAssetsLeasingObligations
      contextRef="i_2019-12-31"
      decimals="-4"
      id="c69830347"
      unitRef="USD">1070000</bcrx:DeferredTaxAssetsLeasingObligations>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69830348"
      unitRef="USD">5563000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69830349"
      unitRef="USD">3801000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69830350"
      unitRef="USD">271734000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69830351"
      unitRef="USD">233122000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69830352"
      unitRef="USD">124000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69830353"
      unitRef="USD">114000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <bcrx:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69830354"
      unitRef="USD">854000</bcrx:DeferredTaxLiabilitiesRightOfUseAssets>
    <bcrx:DeferredTaxLiabilitiesRightOfUseAssets
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69830355"
      unitRef="USD">803000</bcrx:DeferredTaxLiabilitiesRightOfUseAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69830356"
      unitRef="USD">978000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69830357"
      unitRef="USD">917000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69830358"
      unitRef="USD">270756000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c69830359"
      unitRef="USD">232205000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69829395"
      unitRef="USD">38551000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69829396"
      unitRef="USD">23824000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-4"
      id="c69829397"
      unitRef="USD">26040000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="-3"
      id="c69829401"
      unitRef="USD">677109000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2020-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"
      decimals="-3"
      id="c69829402"
      unitRef="USD">494608000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2020-12-31_IncomeTaxAuthorityAxis-ForeignCountryMember"
      decimals="-3"
      id="c69829403"
      unitRef="USD">6427000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2020-12-31_TaxCreditCarryforwardAxis-ResearchMember"
      decimals="INF"
      id="c69829404"
      unitRef="USD">74561</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c69829411"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757857">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;Note &lt;/b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;10&lt;/em&gt;&lt;/b&gt;&lt;b&gt; &#x2014; Employee &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;In &lt;em style="font: inherit;"&gt; January 1991, &lt;/em&gt;the Company adopted an employee retirement plan (&lt;em style="font: inherit;"&gt;&#x201c;401&lt;/em&gt;(k) Plan&#x201d;) under Section &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) of the Internal Revenue Code covering all employees. Employee contributions &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be made to the &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan up to limits established by the Internal Revenue Service. Company matching contributions &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be made at the discretion of the Board of Directors. The Company made matching contributions of $1,569, $926, and $724 in &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2018,&lt;/em&gt; respectively.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c69829509"
      unitRef="USD">1569000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c69829510"
      unitRef="USD">926000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2018-01-01_2018-12-31"
      decimals="-3"
      id="c69829511"
      unitRef="USD">724000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757858">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt;&lt;/b&gt;&lt;b&gt; &#x2014; Collaborative and Other Research and Development Contracts&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;National Institute of Allergy and Infectious Diseases (&#x201c;NIAID/HHS&#x201d;)&lt;/i&gt;. In&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 2013, &lt;/em&gt;NIAID/HHS contracted with the Company for the development of galidesivir as a treatment for Marburg virus disease and subsequently, Yellow Fever and Ebola virus disease. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;all options under this contract have been awarded, and the total value of the contract, as amended, is $45,931, inclusive of the &lt;em style="font: inherit;"&gt;$2,897&lt;/em&gt; added to the contract in &lt;em style="font: inherit;"&gt; August 2020 &lt;/em&gt;to support the development of galidesivir. In &lt;em style="font: inherit;"&gt; August 2020, &lt;/em&gt;NIAID/HHS awarded the Company a new contract, with potential aggregate funding up of to $43,908 if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir. NIAID/HHS made an initial award of $6,326 to the Company under this new contract&lt;span style="color:#000000;"&gt;.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Biomedical Advanced Research&lt;/i&gt;&lt;i&gt; and &lt;/i&gt;&lt;i&gt;Development Authority&lt;/i&gt;&lt;i&gt; (&#x201c;BARDA/HHS&#x201d;)&lt;/i&gt;. In &lt;em style="font: inherit;"&gt; March 2015, &lt;/em&gt;BARDA/HHS awarded the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This BARDA/HHS contract includes a base contract of $16,265 to support galidesivir drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $39,120. As of &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;a total of $20,574 has been awarded under exercised options within this contract.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The contracts with NIAID/HHS and BARDA/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress, and the continuation of the contract is based on the Company&#x2019;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;U.S. Department of Health and Human Services (&#x201c;HHS&#x201d;)&lt;/i&gt;. In&#160;&lt;/span&gt;&lt;em style="font: inherit;"&gt; September 2018, &lt;/em&gt;HHS awarded the Company a $34,660 contract for the procurement of up to &lt;em style="font: inherit;"&gt;50,000&lt;/em&gt; doses of RAPIVAB (peramivir injection) over a &lt;span style="-sec-ix-hidden:c69829532"&gt;five&lt;/span&gt;-year period, including an initial base order of &lt;em style="font: inherit;"&gt;10,000&lt;/em&gt; doses. In &lt;em style="font: inherit;"&gt; September 2019, &lt;/em&gt;HHS exercised its option to purchase an additional &lt;em style="font: inherit;"&gt;10,000&lt;/em&gt; doses of RAPIVAB. The Company delivered a total of &lt;em style="font: inherit;"&gt;20,000&lt;/em&gt; doses of RAPIVAB and approximately $13,864 of product sales in &lt;em style="font: inherit;"&gt;2019.&lt;/em&gt; On &lt;em style="font: inherit;"&gt; September 3, 2020, &lt;/em&gt;the Company announced that HHS had exercised an option under this contract to purchase an additional &lt;em style="font: inherit;"&gt;10,000&lt;/em&gt; doses of RAPIVAB for $6,932, which the Company expects to deliver in &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt;&#160; &lt;em style="font: inherit;"&gt;No&lt;/em&gt; shipments were delivered in &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; under this additional &lt;em style="font: inherit;"&gt;10,000&lt;/em&gt; dose option&lt;span style="color:#000000;"&gt;.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Torii Pharmaceutical Co., Ltd. (&#x201c;Torii&#x201d;)&lt;/i&gt;. On &lt;em style="font: inherit;"&gt; November 5, 2019, &lt;/em&gt;the Company entered into a Commercialization and License Agreement with Torii (the &#x201c;Torii Agreement&#x201d;), granting Torii the exclusive right to commercialize ORLADEYO&#x2122; for the prevention of hereditary angioedema (&#x201c;HAE&#x201d;) attacks in Japan.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Under the Torii Agreement, the Company received an upfront, non-refundable payment of $22,000 and is eligible to receive an additional milestone payment of $15,000 upon receipt from Japan&#x2019;s National Health Insurance System of a reimbursement price approval for ORLADEYO in excess of the threshold specified in the Torii Agreement.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;In addition, under the Torii Agreement, the Company is entitled to receive tiered royalty payments, ranging from 20% to 40% of annual net sales of ORLADEYO in Japan during each calendar year. Torii&#x2019;s royalty payment obligations are subject to customary reductions in certain circumstances, but &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be reduced by more than 50% of the amount that otherwise would have been payable to the Company in the applicable calendar quarter. Torii&#x2019;s royalty payment obligations commence upon the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of ORLADEYO in Japan and expire upon the later of (i) the &lt;span style="-sec-ix-hidden:c69829552"&gt;tenth&lt;/span&gt; anniversary of the date of &lt;em style="font: inherit;"&gt;first&lt;/em&gt; commercial sale of ORLADEYO in Japan, (ii) the expiration of the Company&#x2019;s patents covering ORLADEYO, and (iii) the expiration of regulatory exclusivity for ORLADEYO in Japan. The Company will be responsible for supplying Torii with its required amounts of ORLADEYO. The activities of the parties pursuant to the Torii Agreement will be overseen by a joint steering committee, to be composed of an equal number of representatives from each party to coordinate the development and commercialization of ORLADEYO in Japan.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;Under the Torii Agreement, the Company has granted Torii a right of &lt;em style="font: inherit;"&gt;first&lt;/em&gt; negotiation (&#x201c;ROFN&#x201d;) to commercialize ORLADEYO in Japan for the acute treatment of HAE attacks if the Company develops ORLADEYO for such indication and to commercialize any additional kallikrein inhibitor that the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;develop in the future for use in HAE in Japan. Under both ROFNs, if the parties do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; agree to terms with respect to a definitive amendment to the Torii Agreement or new agreement, as applicable, the terms of the amendment or agreement would be set by a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party arbitrator.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;The Company identified performance obligations related to (i) the license to develop and commercialize ORLADEYO, (ii) regulatory approval support and (iii) reimbursement pricing approval support. These were each determined to be distinct from the other performance obligations. The Company allocated the &lt;em style="font: inherit;"&gt;$22,000&lt;/em&gt; upfront consideration to the identified performance obligations using estimation approaches to determine the standalone selling prices under ASC &lt;em style="font: inherit;"&gt;606.&lt;/em&gt; Specifically, in determining the value related to the license, a valuation approach utilizing risk adjusted discounted cash flow projections was used and an expected cost plus margin approach was utilized for the other performance obligations. The Company recognized $20,101 in revenue in &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; including $19,344 associated with the license which was transferred to Torii at the execution of the Agreement and $757 related to the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; services provided in the performance of the &lt;em style="font: inherit;"&gt;two&lt;/em&gt; approvals. The remaining $1,899 of the &lt;em style="font: inherit;"&gt;$22,000&lt;/em&gt; upfront payment was recognized as revenue in &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; as the services were delivered.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Seqirus UK Limited (&#x201c;SUL&#x201d;). &lt;/i&gt;On &lt;em style="font: inherit;"&gt; June 16, 2015, &lt;/em&gt;the Company and SUL, a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia,&lt;i&gt; &lt;/i&gt;entered into a License Agreement (the &#x201c;SUL Agreement&#x201d;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &#x201c;Territory&#x201d;). Under the terms of the SUL Agreement, the Company received an upfront payment of $33,740 and has achieved all development milestones under the contract totaling $12,000.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;On &lt;em style="font: inherit;"&gt; March 4, 2020, &lt;/em&gt;the International Court of Arbitration of the International Chamber of Commerce (&#x201c;ICC Tribunal&#x201d;) delivered a Partial Arbitration Award (the &#x201c;Partial Arbitration Award&#x201d;) in an arbitration matter between the Company and SUL with respect to the SUL Agreement. In the Partial Arbitration Award, the ICC Tribunal found that, during the term, SUL materially breached and abandoned its core duties to the Company under the Diligent Efforts (as defined in the SUL Agreement) requirements of the SUL Agreement as applicable in the U.S. The ICC Tribunal granted a declaratory judgment in favor of the Company terminating the SUL Agreement and restoring all rights to peramivir to the Company. The parties agreed on a transition process for the product, with a full transition of commercialization of the product in the U.S. and Australia returned to the Company as of &lt;em style="font: inherit;"&gt; August 1, 2020 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; November 1, 2020, &lt;/em&gt;respectively. The ICC Tribunal also awarded the Company its attorneys&#x2019; fees and expenses incurred in securing the declaratory judgment as well as the costs incurred by the Company in the arbitration. Finally, the ICC Tribunal found that SUL breached the SUL Agreement by failing to pay the milestone payment due to the Company within &lt;em style="font: inherit;"&gt;30&lt;/em&gt; days of the approval of peramivir for adult use in the European Union and awarded the Company $5,000 (plus interest) for this claim. The ICC Tribunal retained jurisdiction for further proceedings relating to the award of attorneys&#x2019; fees and for any dispute relating to the return to the Company of all rights to peramivir in the Territory. The Company recorded the settlement gain of $8,893 in other income and legal fees and other expenses of $5,026 in selling, general and administrative expenses for the year ended &lt;em style="font: inherit;"&gt; December 31, 2020.&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Shionogi &amp;amp; Co., Ltd. (&#x201c;Shionogi&#x201d;). &lt;/i&gt;In &lt;em style="font: inherit;"&gt; February 2007, &lt;/em&gt;the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially&lt;i&gt; &lt;/i&gt;life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to UAB on any future milestone payments and/or royalties received by the Company from Shionogi. In &lt;em style="font: inherit;"&gt; October 2008, &lt;/em&gt;the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;In &lt;em style="font: inherit;"&gt; December 2017, &lt;/em&gt;the Company, on behalf of Royalty Sub, instituted arbitration proceedings against Shionogi in order to resolve a dispute with Shionogi under the Shionogi Agreement regarding the achievement of sales milestones and escalating royalties. The arbitration proceedings have concluded, with the decision that &lt;em style="font: inherit;"&gt;no&lt;/em&gt; sale milestones had been achieved and that royalties would remain the same. The costs associated with the arbitration proceedings are recoverable from the assets of Royalty Sub in accordance with the terms of the indenture and servicing agreement relating to the PhaRMA Notes.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Green Cross Corporation (&#x201c;Green Cross&#x201d;). &lt;/i&gt;In &lt;em style="font: inherit;"&gt; June 2006, &lt;/em&gt;the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be&lt;i&gt; &lt;/i&gt;responsible for all development, regulatory, and commercialization costs in Korea. The Company received a &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Mundipharma International Holdings Limited (&#x201c;Mundipharma&#x201d;). &lt;/i&gt;In &lt;em style="font: inherit;"&gt; February 2006, &lt;/em&gt;the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and&lt;i&gt; &lt;/i&gt;commercialization of Mundesine, a Purine Nucleoside Phosphorylase (&#x201c;PNP&#x201d;) inhibitor, for use in oncology. The agreement, as amended and restated, provides for the possibility of future event payments totaling $15,000 for achieving specified regulatory events for certain indications and tiered royalties ranging from mid to high single-digit percentages of net product sales in each country where Mundesine is sold by Mundipharma. The Company licensed forodesine and other PNP inhibitors from AECOM/IRL (as defined below) and will owe sublicense payments to AECOM/IRL on all milestone payments and royalties received from Mundipharma.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:27pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&#x201c;AECOM&#x201d; and &#x201c;IRL&#x201d; respectively). &lt;/i&gt;In &lt;em style="font: inherit;"&gt; June 2000, &lt;/em&gt;the Company licensed a series of potent inhibitors of PNP from AECOM and IRL,&lt;i&gt; &lt;/i&gt;(together, the &#x201c;Licensors&#x201d;). The lead product candidates from this collaboration is forodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the agreement to include other inventions in the field made by the investigators or employees of the Licensors. Under this agreement, as amended and restated, the Company has agreed to use commercially reasonable efforts to develop these drugs and to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000 per indication) for future development, single digit royalties on net sales of any resulting product made by the Company, and to share a portion of future payments received from other &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. The Licensors have also granted the Company an exclusive worldwide license of galidesivir for any antiviral use.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;i&gt;The University of Alabama at Birmingham (&#x201c;UAB&#x201d;). &lt;/i&gt;The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific&lt;i&gt; &lt;/i&gt;research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed by UAB with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party partners. The Company has completed the research under the UAB agreements. These &lt;em style="font: inherit;"&gt;two&lt;/em&gt; agreements each have an initial 25-year term, are automatically renewable for &lt;span style="-sec-ix-hidden:c69829592"&gt;five&lt;/span&gt;-year terms throughout the life of the last patent and are terminable by the Company upon &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months&#x2019; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&#x2019; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently &lt;em style="font: inherit;"&gt;no&lt;/em&gt; activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts received.&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts
      contextRef="d_2020-01-01_2020-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember"
      decimals="-3"
      id="c69829519"
      unitRef="USD">45931000</bcrx:ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts>
    <bcrx:CollaborativeAgreementContractCovenantMaximumAmountOfFunding
      contextRef="d_2020-08-01_2020-08-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember"
      decimals="-3"
      id="c69829521"
      unitRef="USD">43908000</bcrx:CollaborativeAgreementContractCovenantMaximumAmountOfFunding>
    <bcrx:CollaborativeAgreementContractValue
      contextRef="d_2020-08-01_2020-08-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-NationalInstituteOfAllergyAndInfectiousDiseasesMember"
      decimals="-3"
      id="c69829523"
      unitRef="USD">6326000</bcrx:CollaborativeAgreementContractValue>
    <us-gaap:GovernmentContractReceivable
      contextRef="i_2015-03-31_TypeOfArrangementAxis-BaseContractMember"
      decimals="-3"
      id="c69829525"
      unitRef="USD">16265000</us-gaap:GovernmentContractReceivable>
    <us-gaap:GovernmentContractReceivable
      contextRef="i_2015-03-31_TypeOfArrangementAxis-AdditionalDevelopmentOptionsMember"
      decimals="-3"
      id="c69829527"
      unitRef="USD">22855000</us-gaap:GovernmentContractReceivable>
    <us-gaap:GovernmentContractReceivable
      contextRef="i_2015-03-31_TypeOfArrangementAxis-ASPRBARDAContractMember"
      decimals="-4"
      id="c69829528"
      unitRef="USD">39120000</us-gaap:GovernmentContractReceivable>
    <bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts
      contextRef="d_2015-04-01_2020-12-31_TypeOfArrangementAxis-ASPRBARDAContractMember"
      decimals="-3"
      id="c69829529"
      unitRef="USD">20574000</bcrx:ProceedsFromAwardsForResearchAndDevelopmentContracts>
    <bcrx:CollaborativeAgreementContractValue
      contextRef="d_2018-09-06_2018-09-06_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-4"
      id="c69829530"
      unitRef="USD">34660000</bcrx:CollaborativeAgreementContractValue>
    <us-gaap:ProceedsFromCollaborators
      contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c69829537"
      unitRef="USD">13864000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="d_2020-09-03_2020-09-03_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember"
      decimals="-3"
      id="c69829540"
      unitRef="USD">6932000</us-gaap:ProceedsFromCollaborators>
    <bcrx:UpfrontPaymentsReceivableAmount
      contextRef="d_2019-11-05_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"
      decimals="-6"
      id="c69829545"
      unitRef="USD">22000000</bcrx:UpfrontPaymentsReceivableAmount>
    <bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021
      contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"
      decimals="-6"
      id="c69829546"
      unitRef="USD">15000000</bcrx:PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021>
    <bcrx:RoyaltyRateIfMaintainsSakigakeDesignation
      contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MinimumMember"
      decimals="1"
      id="c69829547"
      unitRef="Pure">0.20</bcrx:RoyaltyRateIfMaintainsSakigakeDesignation>
    <bcrx:RoyaltyRateIfMaintainsSakigakeDesignation
      contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_RangeAxis-MaximumMember"
      decimals="1"
      id="c69829548"
      unitRef="Pure">0.40</bcrx:RoyaltyRateIfMaintainsSakigakeDesignation>
    <bcrx:MaximumCustomaryReductionOnRoyaltyRate
      contextRef="i_2019-11-05_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"
      decimals="1"
      id="c69829550"
      unitRef="Pure">0.50</bcrx:MaximumCustomaryReductionOnRoyaltyRate>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"
      decimals="-3"
      id="c69829560"
      unitRef="USD">20101000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-LicenseMember"
      decimals="-3"
      id="c69829562"
      unitRef="USD">19344000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember_ProductOrServiceAxis-ServiceMember"
      decimals="-3"
      id="c69829563"
      unitRef="USD">757000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="d_2020-01-01_2020-12-31_CounterpartyNameAxis-ToriiPharmaceuticalCoMember"
      decimals="-3"
      id="c69829566"
      unitRef="USD">1899000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="d_2015-06-16_2015-06-16_CounterpartyNameAxis-CSLLimitedMember"
      decimals="-4"
      id="c69829569"
      unitRef="USD">33740000</us-gaap:ProceedsFromLicenseFeesReceived>
    <bcrx:MilestonePaymentReceived
      contextRef="d_2015-06-16_2020-12-31_CounterpartyNameAxis-CSLLimitedMember"
      decimals="-6"
      id="c69829570"
      unitRef="USD">12000000</bcrx:MilestonePaymentReceived>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="d_2020-03-04_2020-03-04_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember"
      decimals="-6"
      id="c69829573"
      unitRef="USD">5000000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-OtherIncomeMember_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember"
      decimals="-3"
      id="c69829574"
      unitRef="USD">8893000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:LegalFees
      contextRef="d_2020-01-01_2020-06-30_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember"
      decimals="-3"
      id="c69829575"
      unitRef="USD">5026000</us-gaap:LegalFees>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="d_2006-06-01_2006-06-30_TypeOfArrangementAxis-GreenCrossCorporationMember"
      decimals="-4"
      id="c69829578"
      unitRef="USD">250000</us-gaap:ProceedsFromLicenseFeesReceived>
    <bcrx:PotentialMilestonePaymentsReceivable
      contextRef="i_2011-11-11_TypeOfArrangementAxis-MundipharmaMember"
      decimals="-6"
      id="c69829579"
      unitRef="USD">15000000</bcrx:PotentialMilestonePaymentsReceivable>
    <bcrx:MilestonePaymentMinimum
      contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"
      decimals="-5"
      id="c69829582"
      unitRef="USD">1400000</bcrx:MilestonePaymentMinimum>
    <bcrx:MilestonePaymentMaximum
      contextRef="d_2000-06-01_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"
      decimals="-6"
      id="c69829583"
      unitRef="USD">4000000</bcrx:MilestonePaymentMaximum>
    <bcrx:AnnualLicenseFeeMinimum
      contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"
      decimals="-4"
      id="c69829585"
      unitRef="USD">150000</bcrx:AnnualLicenseFeeMinimum>
    <bcrx:AnnualLicenseFeeMaximum
      contextRef="i_2000-06-30_TypeOfArrangementAxis-AECOMAndIRLMember"
      decimals="-5"
      id="c69829587"
      unitRef="USD">500000</bcrx:AnnualLicenseFeeMaximum>
    <bcrx:PeriodOfAgreement
      contextRef="d_2020-01-01_2020-12-31_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis-UABMember"
      id="c69829590">P25Y</bcrx:PeriodOfAgreement>
    <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757859">
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;Note &lt;em style="font: inherit;"&gt;12&lt;/em&gt;&lt;/b&gt;&lt;b&gt;&#160;&#x2014; Quarterly Financial Information (Unaudited)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;First&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Second&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Third&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Fourth&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt; Quarters&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Revenues&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4,823&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,871&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6,102&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4,016&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Net Loss&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(37,599&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(38,607&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(46,115&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(60,493&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(0.24&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(0.24&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(0.26&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(0.34&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;2019 Quarters&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Revenues&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;5,887&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,448&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,775&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;39,725&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Net Loss&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(31,054&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(37,629&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(37,592&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(2,622&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(0.28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(0.34&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(0.34&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(0.02&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b/&gt;&lt;/span&gt;&lt;/p&gt;
  </us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="d_2020-01-01_2020-12-31" id="c1757860">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;First&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Second&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Third&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&lt;b&gt;Fourth&lt;/b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt;20&lt;/b&gt;&lt;b&gt; Quarters&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Revenues&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4,823&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;2,871&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;6,102&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;4,016&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Net Loss&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(37,599&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(38,607&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(46,115&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(60,493&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(0.24&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(0.24&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(0.26&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(0.34&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;2019 Quarters&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: 1px rgb(0, 0, 0); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;span style="color:#000000;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Revenues&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;5,887&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,448&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;1,775&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;39,725&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Net Loss&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(31,054&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(37,629&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(37,592&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(2,622&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"&gt; &lt;p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"&gt;&lt;span style="color:#000000;"&gt;Basic and diluted net loss per share&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(0.28&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(0.34&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(0.34&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;(0.02&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;span style="color:#000000;"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-03-31"
      decimals="-3"
      id="c69829603"
      unitRef="USD">4823000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c69829604"
      unitRef="USD">2871000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c69829605"
      unitRef="USD">6102000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-10-01_2020-12-31"
      decimals="-3"
      id="c69829606"
      unitRef="USD">4016000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-03-31"
      decimals="-3"
      id="c69829607"
      unitRef="USD">-37599000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-04-01_2020-06-30"
      decimals="-3"
      id="c69829608"
      unitRef="USD">-38607000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-07-01_2020-09-30"
      decimals="-3"
      id="c69829609"
      unitRef="USD">-46115000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-10-01_2020-12-31"
      decimals="-3"
      id="c69829610"
      unitRef="USD">-60493000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-01-01_2020-03-31"
      decimals="INF"
      id="c69829611"
      unitRef="USDPerShare">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-04-01_2020-06-30"
      decimals="INF"
      id="c69829612"
      unitRef="USDPerShare">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-07-01_2020-09-30"
      decimals="INF"
      id="c69829613"
      unitRef="USDPerShare">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-10-01_2020-12-31"
      decimals="INF"
      id="c69829614"
      unitRef="USDPerShare">-0.34</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-01-01_2019-03-31"
      decimals="-3"
      id="c69829616"
      unitRef="USD">5887000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c69829617"
      unitRef="USD">1448000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-07-01_2019-09-30"
      decimals="-3"
      id="c69829618"
      unitRef="USD">1775000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2019-10-01_2019-12-31"
      decimals="-3"
      id="c69829619"
      unitRef="USD">39725000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-01-01_2019-03-31"
      decimals="-3"
      id="c69829620"
      unitRef="USD">-31054000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-04-01_2019-06-30"
      decimals="-3"
      id="c69829621"
      unitRef="USD">-37629000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-07-01_2019-09-30"
      decimals="-3"
      id="c69829622"
      unitRef="USD">-37592000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2019-10-01_2019-12-31"
      decimals="-3"
      id="c69829623"
      unitRef="USD">-2622000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2019-01-01_2019-03-31"
      decimals="INF"
      id="c69829624"
      unitRef="USDPerShare">-0.28</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2019-04-01_2019-06-30"
      decimals="INF"
      id="c69829625"
      unitRef="USDPerShare">-0.34</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2019-07-01_2019-09-30"
      decimals="INF"
      id="c69829626"
      unitRef="USDPerShare">-0.34</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2019-10-01_2019-12-31"
      decimals="INF"
      id="c69829627"
      unitRef="USDPerShare">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766302141960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000882796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOCRYST PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-23186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1413174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4505 Emperor Blvd., Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Durham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">27703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">859-1302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BCRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 832,869,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,182,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766302973128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 272,127<span></span>
</td>
<td class="nump">$ 114,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">2,221<span></span>
</td>
<td class="nump">1,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">28,239<span></span>
</td>
<td class="nump">22,054<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
<td class="nump">8,646<span></span>
</td>
<td class="nump">22,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">7,039<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,528<span></span>
</td>
<td class="nump">4,422<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">323,800<span></span>
</td>
<td class="nump">164,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,113<span></span>
</td>
<td class="nump">7,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,802<span></span>
</td>
<td class="nump">3,590<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">334,715<span></span>
</td>
<td class="nump">175,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">18,713<span></span>
</td>
<td class="nump">13,988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">33,942<span></span>
</td>
<td class="nump">21,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest payable</a></td>
<td class="nump">21,670<span></span>
</td>
<td class="nump">14,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred collaboration revenue</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">2,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Lease financing obligation</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Senior credit facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Non-recourse notes payable</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">29,561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">105,654<span></span>
</td>
<td class="nump">92,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Royalty financing obligation</a></td>
<td class="nump">124,717<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Lease financing obligation</a></td>
<td class="nump">3,871<span></span>
</td>
<td class="nump">3,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Senior credit facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">41,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Secured term loan</a></td>
<td class="nump">119,735<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; shares authorized &#8212; 5,000; no shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; shares authorized &#8212; 450,000; shares issued and outstanding &#8212; 176,883 at December 31, 2020 and 154,082 at December 31, 2019</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">1,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,002,408<span></span>
</td>
<td class="nump">877,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,023,442)<span></span>
</td>
<td class="num">(840,628)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; (deficit) equity</a></td>
<td class="num">(19,262)<span></span>
</td>
<td class="nump">38,252<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 334,715<span></span>
</td>
<td class="nump">$ 175,282<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_FutureRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations for future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_FutureRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766387055816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">176,883<span></span>
</td>
<td class="nump">154,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">176,883<span></span>
</td>
<td class="nump">154,082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766297940488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 17,812<span></span>
</td>
<td class="nump">$ 48,835<span></span>
</td>
<td class="nump">$ 20,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">1,550<span></span>
</td>
<td class="nump">3,726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">122,964<span></span>
</td>
<td class="nump">107,068<span></span>
</td>
<td class="nump">84,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">67,929<span></span>
</td>
<td class="nump">37,121<span></span>
</td>
<td class="nump">29,514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty</a></td>
<td class="nump">126<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="nump">471<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">192,569<span></span>
</td>
<td class="nump">148,290<span></span>
</td>
<td class="nump">114,873<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(174,757)<span></span>
</td>
<td class="num">(99,455)<span></span>
</td>
<td class="num">(94,220)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestAndOtherIncomeLoss', window );">Interest and other income</a></td>
<td class="nump">9,420<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
<td class="nump">2,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(14,501)<span></span>
</td>
<td class="num">(11,892)<span></span>
</td>
<td class="num">(9,176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(2,011)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (loss) on foreign currency</a></td>
<td class="num">(965)<span></span>
</td>
<td class="nump">517<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(182,814)<span></span>
</td>
<td class="num">(108,897)<span></span>
</td>
<td class="num">(101,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on available for sale investments</a></td>
<td class="num">(36)<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Net comprehensive loss</a></td>
<td class="num">$ (182,850)<span></span>
</td>
<td class="num">$ (108,561)<span></span>
</td>
<td class="num">$ (101,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in dollars per share)</a></td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="num">$ (0.98)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding (in shares)</a></td>
<td class="nump">167,267<span></span>
</td>
<td class="nump">115,600<span></span>
</td>
<td class="nump">103,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 3,301<span></span>
</td>
<td class="nump">$ 17,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,381<span></span>
</td>
<td class="nump">6,303<span></span>
</td>
<td class="nump">$ 6,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember', window );">Collaborative and Other Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 11,130<span></span>
</td>
<td class="nump">$ 24,999<span></span>
</td>
<td class="nump">$ 14,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestAndOtherIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income (loss) recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income (loss) from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestAndOtherIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766303031992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (182,814)<span></span>
</td>
<td class="num">$ (108,897)<span></span>
</td>
<td class="num">$ (101,252)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">748<span></span>
</td>
<td class="nump">724<span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss (gain) on disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">14,794<span></span>
</td>
<td class="nump">17,719<span></span>
</td>
<td class="nump">9,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">2,428<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
<td class="nump">885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AmortizationOfDiscountAndPremiumOnInvestments', window );">Amortization of premium/discount on investments</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeAssets', window );">Change in fair value of foreign currency derivative</a></td>
<td class="nump">632<span></span>
</td>
<td class="nump">347<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="nump">13,903<span></span>
</td>
<td class="num">(17,853)<span></span>
</td>
<td class="nump">1,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(7,039)<span></span>
</td>
<td class="nump">1,649<span></span>
</td>
<td class="num">(1,649)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(2,140)<span></span>
</td>
<td class="num">(1,364)<span></span>
</td>
<td class="num">(866)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">17,355<span></span>
</td>
<td class="nump">11,741<span></span>
</td>
<td class="nump">4,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Interest payable</a></td>
<td class="nump">6,766<span></span>
</td>
<td class="nump">3,056<span></span>
</td>
<td class="num">(247)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(1,970)<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
<td class="num">(7,079)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities:</a></td>
<td class="num">(137,216)<span></span>
</td>
<td class="num">(89,584)<span></span>
</td>
<td class="num">(92,565)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Acquisition of property and equipment</a></td>
<td class="num">(514)<span></span>
</td>
<td class="num">(343)<span></span>
</td>
<td class="num">(366)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="num">(49,818)<span></span>
</td>
<td class="num">(3,018)<span></span>
</td>
<td class="num">(62,614)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of investments</a></td>
<td class="nump">43,475<span></span>
</td>
<td class="nump">81,295<span></span>
</td>
<td class="nump">67,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromRealizedGainOnInvestments', window );">Realized gain on investments</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities:</a></td>
<td class="num">(6,856)<span></span>
</td>
<td class="nump">77,934<span></span>
</td>
<td class="nump">4,768<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Sale of common stock, net</a></td>
<td class="nump">93,279<span></span>
</td>
<td class="nump">58,500<span></span>
</td>
<td class="nump">53,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Sale of pre-funded warrants</a></td>
<td class="nump">14,817<span></span>
</td>
<td class="nump">19,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from common stock issued under stock-based compensation plans</a></td>
<td class="nump">2,446<span></span>
</td>
<td class="nump">1,239<span></span>
</td>
<td class="nump">2,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from senior credit facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,477<span></span>
</td>
<td class="nump">10,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Payment of senior credit facility</a></td>
<td class="num">(52,420)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,025)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Net proceeds from secured term loan</a></td>
<td class="nump">119,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromRoyaltyFinancingObligation', window );">Net proceeds from royalty financing obligation</a></td>
<td class="nump">124,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_IncreaseDecreaseInFinancingLeaseObligations', window );">(Decrease) increase in lease financing obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities:</a></td>
<td class="nump">302,697<span></span>
</td>
<td class="nump">99,098<span></span>
</td>
<td class="nump">62,504<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">158,625<span></span>
</td>
<td class="nump">87,448<span></span>
</td>
<td class="num">(25,293)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">115,723<span></span>
</td>
<td class="nump">28,275<span></span>
</td>
<td class="nump">53,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">$ 274,348<span></span>
</td>
<td class="nump">$ 115,723<span></span>
</td>
<td class="nump">$ 28,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AmortizationOfDiscountAndPremiumOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to the discount and premium on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AmortizationOfDiscountAndPremiumOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_IncreaseDecreaseInFinancingLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period for financing lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_IncreaseDecreaseInFinancingLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ProceedsFromRealizedGainOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from realized gain on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ProceedsFromRealizedGainOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ProceedsFromRoyaltyFinancingObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from royalty financing obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ProceedsFromRoyaltyFinancingObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766303279144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Cumulative Effect, Period of Adoption, Adjustment [Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance (Accounting Standards Update 2014-09 [Member]) at Dec. 31, 2017</a></td>
<td class="nump">$ 1,126<span></span>
</td>
<td class="nump">$ 1,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 984<span></span>
</td>
<td class="nump">$ 714,869<span></span>
</td>
<td class="num">$ (243)<span></span>
</td>
<td class="num">$ (631,843)<span></span>
</td>
<td class="nump">$ 83,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101,252)<span></span>
</td>
<td class="num">(101,252)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">2,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">53,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,396<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance (Accounting Standards Update 2016-02 [Member]) at Dec. 31, 2018</a></td>
<td class="nump">$ 238<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
<td class="nump">780,400<span></span>
</td>
<td class="num">(297)<span></span>
</td>
<td class="num">(731,969)<span></span>
</td>
<td class="nump">49,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(108,897)<span></span>
</td>
<td class="num">(108,897)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436<span></span>
</td>
<td class="nump">58,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,882<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,541<span></span>
</td>
<td class="nump">877,300<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="num">(840,628)<span></span>
</td>
<td class="nump">38,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(182,814)<span></span>
</td>
<td class="num">(182,814)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">1,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,814<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee stock purchase plan sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="nump">93,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of pre-funded warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,817<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,769<span></span>
</td>
<td class="nump">$ 1,002,408<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (1,023,442)<span></span>
</td>
<td class="num">$ (19,262)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121640130&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766295893096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parentheticals) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares (in shares)</a></td>
<td class="nump">510,000<span></span>
</td>
<td class="nump">283,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee stock purchase plan sales, shares (in shares)</a></td>
<td class="nump">246,000<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
<td class="nump">92,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares (in shares)</a></td>
<td class="nump">22,044,000<span></span>
</td>
<td class="nump">43,621,000<span></span>
</td>
<td class="nump">10,455,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Warrants issued (in shares)</a></td>
<td class="nump">3,511,000<span></span>
</td>
<td class="nump">11,765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766297077000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>Note <em style="font: inherit;">1</em> &#8212; Significant Accounting Policies and Concentrations of Risk</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>The Company</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 27pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was founded in <em style="font: inherit;">1986</em> and incorporated in Delaware in <em style="font: inherit;">1991,</em> and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. The Company has incurred losses and negative cash flows from operations since inception.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">Based on the Company&#8217;s expectations for revenue, operating expenses, and its option to access an additional $75 million from its existing credit facility, the Company believes its financial resources available at <em style="font: inherit;"> December 31, 2020 </em>will be sufficient to fund its operations into <em style="font: inherit;">2023.</em> The Company has sustained operating losses for the majority of its corporate history and expects that its <em style="font: inherit;">2021</em> expenses will exceed its <em style="font: inherit;">2021</em> revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#8217;s liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of its products and the progression of its product candidates in the future. The Company also <em style="font: inherit;"> may </em>consider other plans to fund future operations, including: (<em style="font: inherit;">1</em>) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (<em style="font: inherit;">2</em>) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (<em style="font: inherit;">3</em>) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (<em style="font: inherit;">4</em>) obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (<em style="font: inherit;">5</em>) reducing spending on <em style="font: inherit;">one</em> or more research and development programs, including by discontinuing development; and/or (<em style="font: inherit;">6</em>) restructuring operations to change its overhead structure. The Company <em style="font: inherit;"> may </em>issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#8217;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates, timing, scope and magnitude of its commercial expenses and key development and regulatory events and its decisions in the future.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Basis of Presentation</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 9pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Such consolidated financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations, and cash flows. There were <em style="font: inherit;">no</em> adjustments other than normal recurring adjustments.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Cash and Cash Equivalents</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 1pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of <em style="font: inherit;">three</em> months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Restricted Cash</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Restricted cash as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> reflects $796 and $134, respectively, in royalty revenue paid by Shionogi &amp; Co., Ltd. (&#8220;Shionogi&#8221;) designated for interest on the PhaRMA Notes (defined in Note <em style="font: inherit;">3</em>) and $1,425 and $1,417, respectively, the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Investments</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that <em style="font: inherit;"> may </em>consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#8217;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of <span style="-sec-ix-hidden:c69828560">three</span> years and requires an average portfolio maturity of <em style="font: inherit;">no</em> more than 18 months. Some of the securities the Company invests in <em style="font: inherit;"> may </em>have market risk. This means that a change in prevailing interest rates <em style="font: inherit;"> may </em>cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does <em style="font: inherit;">not</em> believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#8217;s investments are <em style="font: inherit;">not</em> collateralized. The Company has <em style="font: inherit;">not</em> realized any significant losses from its investments.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 7pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond <em style="font: inherit;">three</em> months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At <em style="font: inherit;"> December 31, 2020, </em>the Company believes that the cost of its investments is recoverable in all material respects.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 14pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The following tables summarize the fair value of the Company&#8217;s investments by type. The estimated fair values of the Company&#8217;s fixed income investments are classified as Level <em style="font: inherit;">2</em> in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but <em style="font: inherit;">not</em> identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are <em style="font: inherit;">not</em> active. These fair values are obtained from independent pricing services which utilize Level <em style="font: inherit;">2</em> inputs.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 14pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>December 31, 2020</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Amortized Cost</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Accrued Interest</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Gross Unrealized Gains</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Gross Unrealized Losses</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Estimated Fair Value</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Obligations of U.S. Government and its agencies</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">24,986</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">14</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">3</em></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">(3</em></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">25,000</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Certificates of deposit</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">3,225</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">11</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">3</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">3,239</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Total Investments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">28,211</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">25</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">(3</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">28,239</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="margin: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>December 31, 2019</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Amortized Cost</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Accrued Interest</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Gross Unrealized Gains</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Gross Unrealized Losses</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Estimated Fair Value</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Obligations of U.S. Government and its agencies</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">10,488</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">50</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">23</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">10,561</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Corporate debt securities</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">9,742</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">59</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">10</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(1</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">9,810</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Certificates of deposit</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,669</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">7</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">7</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,683</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Total Investments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">21,899</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">116</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">40</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(1</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">22,054</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company&#8217;s investments at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> have maturities of <em style="font: inherit;">one</em> year or less.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Receivables from Collaborations</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 1pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&#8220;Green Cross&#8221;), Mundipharma International Holdings Limited (&#8220;Mundipharma&#8221;) and Seqirus UK Limited (&#8220;SUL&#8221;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date&#160;</span>based on historical collection experience or specific circumstances and no amounts were recorded at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">At <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em>the Company had the following receivables:</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b style="font-size: 10pt;">December 31, 20</b><b style="font-size: 10pt;">20</b><b style="font-size: 10pt;"> </b><b style="font-size: 10pt;"> </b><b style="font-size: 10pt;"> </b></b></span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Billed</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Unbilled</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Total</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">U.S. Department of Health and Human Services</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">5,402</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">5,402</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Shionogi &amp; Co. Ltd.</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2,037</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">4</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2,041</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Green Cross Corporation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">740</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">21</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">761</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Mundipharma International Holdings Limited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">39</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">39</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Total receivables</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2,816</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">5,427</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">8,243</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="11" rowspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b style="font-size: 10pt;">December 31, 2019</b></span></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Billed</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Unbilled</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Total</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">U.S. Department of Health and Human Services</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,353</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">15,023</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">16,376</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Shionogi &amp; Co. Ltd.</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,336</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">4</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,340</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Green Cross Corporation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2,924</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">8</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2,932</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Mundipharma International Holdings Limited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">56</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">-</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">56</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Seqirus UK Limited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,091</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">351</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,442</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Total receivables</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">6,760</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">15,386</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">22,146</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: justify; text-indent: 26.75pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: justify; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Receivables from Product Sales</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 3.05pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Receivables&#160;</span>from product sales are recorded for amounts due to the Company related to sales of RAPIVAB and ORLADEYO.&#160; At <em style="font: inherit;"> December 31, 2020, </em>receivables related to sales of RAPIVAB and ORLADEYO were $254 and $149, respectively.&#160; There were no receivables from product sales as of <em style="font: inherit;"> December 31, 2019. </em>Receivables from product sales are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions and the Company&#8217;s own historical collection experience. &#160;No reserve or allowance amounts were recorded at <em style="font: inherit;"> December 31, 2020</em><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Inventory</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">At <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> the Company&#8217;s inventory related to peramivir which is being manufactured for the Company&#8217;s partners and the U.S. Government.&#160; Inventory as of <em style="font: inherit;"> December 31, 2020, </em>consisted of raw materials of $206, work-in-process of $2,555 and finished goods of $4,548. As of <em style="font: inherit;"> December 31, 2019, </em>the Company inventory consisted of peramivir finished goods of $276.&#160; Inventory is stated at the lower of cost and net realizable value, determined under the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out (&#8220;FIFO&#8221;) method, or market. As of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> the Company had inventory reserves of $270 and $276, respectively, for estimated unrecoverable capitalized inventory costs.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company capitalizes subsequent costs related to the production of inventories.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>&#160;</b></i></span></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Property and Equipment</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of <span style="-sec-ix-hidden:c69828591">three</span> years. Laboratory equipment, office equipment, and software are depreciated over a life of <span style="-sec-ix-hidden:c69828592">five</span> years. Furniture and fixtures are depreciated over a life of <span style="-sec-ix-hidden:c69828593">seven</span> years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are <em style="font: inherit;">not</em> expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Patents and Licenses</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 12pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"/>


   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"/>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Accrued Expenses</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 5pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company generally enters into contractual agreements with <em style="font: inherit;">third</em>-party vendors who provide research and development, manufacturing,&#160;</span>distribution,&#160;<span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has <em style="font: inherit;">not</em> yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#9679;</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</span></p> </td></tr>
</tbody></table>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#9679;</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">fees paid to investigative sites in connection with clinical trials;</span></p> </td></tr>
<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#9679;</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">fees paid to contract manufacturers in connection with the production of the Company&#8217;s raw materials, drug substance, drug products, and product candidates; and</span></p> </td></tr>
</tbody></table>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#9679;</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">professional fees.</span></p> </td></tr>
</tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-17.15pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and <em style="font: inherit;"> may </em>result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em>the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Accrued expenses were comprised of the following:</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><b><b>December 31,</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Compensation and benefits</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,030</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,190</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Development costs</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">15,150</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">11,302</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Inventory</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,453</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">29</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Professional fees</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">333</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">326</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Duties and taxes</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">80</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">67</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Other</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">4,896</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">3,451</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Total accrued expenses</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">33,942</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">21,365</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Income Taxes</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The liability method is used in the Company&#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Accumulated Other Comprehensive Loss</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. For the year ended <em style="font: inherit;"> December 31, 2020, </em>realized gains of $1 were reclassified out of accumulated other comprehensive loss. No reclassifications out of accumulated other comprehensive loss were recorded in <em style="font: inherit;">2019.</em></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Revenue Recognition</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:14pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company recognizes revenue when it satisfies a performance obligation by transferring promised goods or services to a customer. Revenue is measured at the transaction price that is based on the amount of consideration that the Company expects to receive in exchange for transferring the promised goods or services to the customer. The transaction price includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will <em style="font: inherit;">not</em> occur.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
      <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">The Company has collaboration and license agreements with a number of <em style="font: inherit;">third</em> parties as well as research and development agreements with certain government entities. The Company&#8217;s primary sources of revenue are license, service, royalty and product sale revenues from these collaborative and other research and development arrangements.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has <em style="font: inherit;">no</em> further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Arrangements that involve the delivery of more than <em style="font: inherit;">one</em> performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort we expend or costs we incur toward the satisfaction of performance obligation in relation to the total estimated effort of costs. Variable consideration is assessed at each reporting period as to whether it is <em style="font: inherit;">not</em> subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is <em style="font: inherit;">not</em> directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each <em style="font: inherit;"> may </em>be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was <em style="font: inherit;">not</em> probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#8221;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Under certain of the Company&#8217;s license agreements, the Company receives royalty payments based upon its licensees&#8217; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:14pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Product Sales</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">The Company&#8217;s principal sources of product sales are sales of peramivir to our licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services under the Company&#8217;s procurement contract. In <em style="font: inherit;"> December 2020, </em>the Company launched ORLADEYO and began recording product revenue. The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">The Company recorded the following revenues for the years ended <em style="font: inherit;"> December 31:</em></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><span style="color:#000000;">2020</span></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><span style="color:#000000;">2019</span></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><span style="color:#000000;">2018</span></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Product sales, net</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,301</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">17,533</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Royalty revenue</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,381</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,303</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,101</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Collaborative and other research and development revenues:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"><span style="color:#000000;">U.S. Department of Health and Human Services</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">9,231</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,898</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,552</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"><span style="color:#000000;">Torii Pharmaceutical Co., Ltd.</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,899</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">20,101</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"><span style="color:#000000;">Seqirus UK Limited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">12,000</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Total collaborative and other research and development revenues</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">11,130</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">24,999</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">14,552</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Total revenues</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">17,812</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">48,835</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">20,653</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#160;</p>
      <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Advertising</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed in &#8220;Selling, general and administrative&#8221; as the costs are incurred. Advertising expenses related to the launch of ORLADEYO were $6,567 for year ended <em style="font: inherit;"> December 31, 2020. </em>The Company did <span style="-sec-ix-hidden:c69828614"><span style="-sec-ix-hidden:c69828615">not</span></span> incur advertising and product promotion expenses in <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018.</em></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Research and Development Expenses</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company&#8217;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s manufacturing and clinical and preclinical studies are performed by <em style="font: inherit;">third</em>-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#8217;s on-going review of the level of services actually performed.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Additionally, the Company has license agreements with <em style="font: inherit;">third</em> parties, such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;), and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Deferred collaboration expenses represent sub-license payments, paid to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#8217;s academic partners for modification to existing license agreements. These deferred expenses would <em style="font: inherit;">not</em> have been incurred without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Stock-Based Compensation</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which <em style="font: inherit;">no</em> compensation expense is recognized until &#8220;performance&#8221; is deemed to have occurred.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Interest Expense and Royalty </b></i><i><b>Financing Obligation</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The royalty financing obligation is eligible to be repaid based on royalties from net sales of ORLADEYO. Interest expense is accrued using the effective interest rate method over the estimated period the related liability will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of the royalty financing obligation and records interest expense using an imputed effective interest rate. The Company will reassess the expected royalty payments each reporting period and account for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that the Company make estimates that could impact the carrying value of the liability, as well as the period over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact the liability balance, interest expense and the time period for repayment.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Interest Expense and Deferred Financing Costs</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Interest expense for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> was $14,501 $11,892 and $9,176, respectively, and primarily relates to the issuance of the PhaRMA Notes (defined in Note <em style="font: inherit;">3</em>) and the Prior Credit Facility and Amended and Restated Senior Credit Facility (each defined in Note <em style="font: inherit;">4</em>). Costs directly associated with the issuance of the PhaRMA Notes, the Prior Credit Facility and the Amended and Restated Senior Credit Facility have been capitalized and are netted against the non-recourse notes payable and senior credit facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Amended and Restated Senior Credit Facility (as subsequently amended and restated) using the effective interest rate method. In <em style="font: inherit;"> December 2020, </em>the Company incurred costs directly associated with its royalty monetization (defined in Note <em style="font: inherit;">3</em>) and borrowings under the Credit Agreement (defined in Note <em style="font: inherit;">4</em>). These costs have been deferred and are being amortized to interest expense over the terms of the respective arrangements. Amortization of deferred financing costs and original issue discount included in interest expense was $1,217, $1,278 and $885 for each of the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively. In <em style="font: inherit;"> December 2020, </em>the outstanding principal balance of the Senior Credit Facility was repaid and related unamortized deferred financing costs and original issue discount of $1,211 were fully expensed as part of loss on debt extinguishment.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Currency Hedge Agreement</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The final tranche of the options under the Currency Hedge Agreement expired in <em style="font: inherit;"> November </em>of <em style="font: inherit;">2020.</em>&#160; The Currency Hedge Agreement did <em style="font: inherit;">not</em> qualify for hedge accounting treatment; therefore mark-to-market adjustments were recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> resulted in losses of $632, $347 and $1,049, respectively. Mark-to-market adjustments were determined by a <em style="font: inherit;">third</em>-party pricing model which uses quoted prices in markets that are <em style="font: inherit;">not</em> actively traded and for which significant inputs are observable directly or indirectly, representing Level <em style="font: inherit;">2</em> in the fair value hierarchy as defined by U.S. GAAP. In addition, realized currency exchange gains of $662, $863 and $941 were recognized in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under the Company&#8217;s foreign currency hedge.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Net Loss Per Share</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&#8217;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018</em> does <em style="font: inherit;">not</em> include 14,957, 2,805, and 2,274, respectively, of potential common shares as their impact would be anti-dilutive.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Use of Estimates</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#8217;s consolidated financial statements relate to the valuation of stock options,&#160;</span>the royalty financing&#160;<span style="color:#000000;">and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Significant Customers and Other Risks</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:23pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Significant Customers</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Other than royalty revenues, the Company&#8217;s primary sources of revenue that have an underlying cash flow stream are the reimbursement of galidesivir (formerly <em style="font: inherit;">BCX4430</em>) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS and sales of RAPIVAB (peramivir injection) under our procurement contract with the Assistant Secretary for Preparedness and Response within the United States Department of Health and Human Services. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#8217;s collaborative and other research and development revenues. The completion or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&#8217;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&#8217;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#8217;s drug development activities are performed by a limited group of <em style="font: inherit;">third</em>-party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:23pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Risks from Third Party Manufacturing and Distribution Concentration</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on single source distributors for distribution of approved drug products. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#8217;s product candidates in development.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
      <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:23pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Credit Risk</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances <em style="font: inherit;"> may </em>exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which there is <em style="font: inherit;">no</em> assumed credit risk.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"/>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Recent Accounting Pronouncements</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In <em style="font: inherit;"> June 2016, </em>the FASB issued Accounting Standards Update <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of</i> <i>Credit Losses on Financial Instruments </i>(&#8220;ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13&#8221;</em>)<i>.</i><i> </i>ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires a financial asset (or a group of financial assets) measured at amortized<i> </i>cost basis to be presented at the net amount expected to be collected. In addition, ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires credit losses relating to available-for-sale debt securities to be recorded through an allowance for credit losses. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is effective for public companies for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2019. </em>The Company adopted ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em> as of <em style="font: inherit;"> January 1, 2020. </em>Given the nature of the Company&#8217;s receivables from collaborators, investment portfolio and other financial assets, adoption of this standard did <em style="font: inherit;">not</em> have a material effect on the Company's financial position, results of operations or cash flows.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In <em style="font: inherit;"> August 2018, </em>the FASB issued Accounting Standards Update <em style="font: inherit;">No.</em> <em style="font: inherit;">2018</em>-<em style="font: inherit;">15,</em> <i>Intangibles - Goodwill and Other - Internal-Use Software (Subtopic</i> <i><em style="font: inherit;">350</em>-<em style="font: inherit;">40</em>) </i>(&#8220;ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15&#8221;</em>). ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15</em> aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service<i> </i>contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance requires entities to capitalize costs for certain implementation activities in the application development stage and expense the capitalized implementation costs over the expected term of the hosting arrangement. ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2019, </em>with early adoption permitted. The Company elected to adopt this standard early, beginning <em style="font: inherit;"> October 1, 2019 </em>on a prospective basis. Adoption did <em style="font: inherit;">not</em> have a material effect on the Company's financial position, results of operations or cash flows.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;">The Company has reviewed other new accounting pronouncements that were issued as of <em style="font: inherit;"> December 31, 2020 </em>and does <em style="font: inherit;">not</em> believe that these pronouncements are either applicable to the Company, or that they will have a material impact on its financial position or results of operations.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"/>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766374369448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note <em style="font: inherit;">2</em> &#8212; Property and Equipment</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;"><span style="color:#000000;">Property and equipment consisted of the following at <em style="font: inherit;"> December 31:</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Furniture and fixtures</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">722</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">602</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Office equipment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">211</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">184</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Software</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,159</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,159</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Laboratory equipment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,774</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,462</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Leasehold improvements</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="color:#000000;">8,583</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="color:#000000;">8,528</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">14,449</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">13,935</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Less accumulated depreciation and amortization</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(7,336</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(6,588</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Property and equipment, net</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">7,113</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">7,347</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">Depreciation and amortization expense for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018</em> was $748, $724, and $770, respectively.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766374299848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Royalty Monetizations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyMonetizationTextBlock', window );">Royalty Monetization [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note <em style="font: inherit;">3&#8212;Royalty</em> Monetizations</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#160;</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>RAPIACTA Royalty Monetization</b></i><i><b>s</b></i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13.5pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Overview</i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:13pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On&#160;</span><em style="font: inherit;"> March 9, 2011, </em>the Company completed a $30,000 financing transaction to monetize certain future royalty and milestone payments under the Company&#8217;s agreement with Shionogi (the &#8220;Shionogi Agreement&#8221;), pursuant to which Shionogi licensed from the Company the rights to market RAPIACTA in Japan and Taiwan. The Company received net proceeds of $22,691 from the transaction after transaction costs of $4,309 and the establishment of a $3,000 interest reserve account by Royalty Sub, available to help cover interest shortfalls in the future. All of the interest reserve account has been fully utilized with the <em style="font: inherit;"> September 2012 </em>interest payment<span style="color:#000000;">.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">As&#160;</span>part of the transaction, the Company entered into a purchase and sale agreement dated as of <em style="font: inherit;"> March 9, 2011 </em>with JPR Royalty Sub, LLC, a wholly-owned subsidiary of the Company (&#8220;Royalty Sub&#8221;), whereby the Company transferred to Royalty Sub, among other things, (i) its rights to receive certain royalty and milestone payments from Shionogi arising under the Shionogi Agreement, and (ii) the right to receive payments under a Japanese yen/US dollar foreign currency hedge arrangement (as further described below, the &#8220;Currency Hedge Agreement&#8221;) put into place by the Company in connection with the transaction. Royalty payments are paid by Shionogi in Japanese yen, and any milestone payments will be paid in U.S. dollars. The Company&#8217;s collaboration with Shionogi was <em style="font: inherit;">not</em> impacted as a result of this transaction<span style="color:#000000;">.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13.5pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Non-Recourse Notes Payable</i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> March 9, 2011, </em>Royalty Sub completed a private placement to institutional investors of $30,000 in aggregate principal amount of its PhaRMA Senior Secured 14.0% Notes due on <em style="font: inherit;"> December 1, 2020 (</em>the &#8220;PhaRMA Notes&#8221;). The PhaRMA Notes were issued by Royalty Sub under an Indenture, dated as of <em style="font: inherit;"> March 9, 2011 (</em>the &#8220;Indenture&#8221;), by and between Royalty Sub and U.S. Bank National Association, as Trustee. Principal and interest on the PhaRMA Notes issued are payable from, and are secured by, the rights to royalty and milestone payments under the Shionogi Agreement transferred by the Company to Royalty Sub and payments, if any, made to Royalty Sub under the Currency Hedge Agreement. The PhaRMA Notes bear interest at 14% per annum, payable annually in arrears on <em style="font: inherit;"> September </em><em style="font: inherit;">1st</em> of each year. The Company remains entitled to receive any royalties and milestone payments related to sales of peramivir by Shionogi following repayment of the PhaRMA Notes.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Royalty Sub&#8217;s obligations to pay principal and interest on the PhaRMA Notes are obligations solely of Royalty Sub and are without recourse to any other person, including the Company, except to the extent of the Company&#8217;s pledge of its equity interests in Royalty Sub in support of the PhaRMA Notes. The Company <em style="font: inherit;"> may, </em>but is <em style="font: inherit;">not</em> obligated to, make capital contributions to a capital account that <em style="font: inherit;"> may </em>be used to redeem, or on up to <em style="font: inherit;">one</em> occasion pay any interest shortfall on, the PhaRMA Notes.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">In <em style="font: inherit;"> September 2014, </em>Royalty Sub was unable to pay the accrued interest obligation due <em style="font: inherit;"> September 3, 2013. </em>Under the terms of the Indenture, Royalty Sub&#8217;s inability to pay the full amount of interest payable in <em style="font: inherit;"> September 2013 </em>by the next succeeding payment date for the PhaRMA Notes, which was <em style="font: inherit;"> September 1, 2014, </em>constituted an event of default. Accordingly, the PhaRMA Notes and related accrued interest have been classified as current liabilities on the <em style="font: inherit;"> December 31, 2014 </em>balance sheet, and thereafter. As a result of the event of default under the PhaRMA Notes, the holders of the PhaRMA Notes <em style="font: inherit;"> may </em>foreclose on the collateral securing the PhaRMA Notes and the equity interest in Royalty Sub and exercise other remedies available to them under the Indenture in respect of the PhaRMA Notes. In such event, the Company <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> realize the benefit of future royalty payments that might otherwise accrue to it following repayment of the PhaRMA Notes and it might otherwise be adversely affected. Due to the non-recourse nature of the PhaRMA Notes, in the event of any potential foreclosure, the primary impact to the Company would be the loss of future royalty payments from Shionogi and legal costs associated with retiring the PhaRMA Notes. As the PhaRMA Notes are the obligation of Royalty Sub and non-recourse to the Company, the event of default of the PhaRMA Notes is <em style="font: inherit;">not</em> expected to have a significant impact on the Company&#8217;s future results of operations or cash flows. The PhaRMA Notes had a final legal maturity date of <em style="font: inherit;"> December 1, 2020, </em>at which time the outstanding principal amount of the PhaRMA Notes of $30,000, together with accrued and unpaid interest of $20,614, was due in full. As of <em style="font: inherit;"> December 31, 2020, </em>the PhaRMA Notes remain outstanding and in default and the Company will continue to record the liability and accrued interest owed until the Company is determined to <em style="font: inherit;">no</em> longer be the financial obligor.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:38pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Indenture does <em style="font: inherit;">not</em> contain any financial covenants. The Indenture includes customary representations and warranties of Royalty Sub, affirmative and negative covenants of Royalty Sub, Events of Default and related remedies, and provisions regarding the duties of the Trustee, indemnification of the Trustee, and other matters typical for indentures used in structured financings of this type.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">As of <em style="font: inherit;"> December 31, 2020, </em>the aggregate fair value of the PhaRMA Notes was estimated to be approximately 3% of its carrying value of $30,000. The estimated fair value of the PhaRMA Notes is classified as Level <em style="font: inherit;">3</em> in the fair value hierarchy as defined in U.S. GAAP.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Foreign Currency Hedge</i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. Under the Currency Hedge Agreement, the Company had&#160;the right to purchase dollars and sell yen at a rate of 100 yen per dollar. The final tranche of the options under the Currency Hedge Agreement expired in <em style="font: inherit;"> November </em>of <em style="font: inherit;">2020.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Currency Hedge Agreement did <em style="font: inherit;">not</em> qualify for hedge accounting treatment; therefore mark-to-market adjustments were recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> resulted in losses of $632, $347 and $1,049, respectively. In addition, realized currency exchange gains of $662, $863 and $941 were recognized in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under the Company&#8217;s foreign currency hedge.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><i><b>ORLADEYO Royalty Monetization</b></i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">On <em style="font: inherit;"> December 7, 2020, </em>the Company and RPI <em style="font: inherit;">2019</em> Intermediate Finance Trust (&#8220;RPI&#8221;) entered into a Purchase and Sale Agreement (the &#8220;Royalty Purchase Agreement&#8221;), pursuant to which the Company sold to RPI the right to receive certain royalty payments from the Company for a purchase price of $125,000 in cash (the &#8220;Royalty Sale&#8221;).&#160; Under the Royalty Purchase Agreement, RPI is entitled to receive tiered, sales-based royalties on net product sales of ORLADEYO in the United States, certain key European markets, and other markets where the Company sells ORLADEYO directly or through distributors (collectively, the &#8220;Key Territories&#8221;) in an amount equal to:&#160;(i) 8.75% of aggregate annual net sales of ORLADEYO in the Key Territories for annual net sales up to <em style="font: inherit;">$350,000</em> and (ii) 2.75% of annual net sales in the Key Territories for annual net sales between <em style="font: inherit;">$350,000</em> and <em style="font: inherit;">$550,000.</em>&#160; No royalty payments are payable on annual net sales in the Key Territories over <em style="font: inherit;">$550,000.</em>&#160; In addition, RPI will be entitled to receive 1.0% of global net sales, if any, of <em style="font: inherit;">BCX9930.</em></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">Under the Royalty Purchase Agreement, RPI is also entitled to receive a tiered revenue share on ORLADEYO sublicense revenue or net sales by licensees outside of the Key Territories (the &#8220;Other Markets&#8221;) equal to: (i) 20% of the proceeds received by the Company for upfront license fees and development milestones for ORLADEYO in the Other Markets; (ii) 20% of proceeds received on annual net sales of up to <em style="font: inherit;">$150,000</em> in the Other Markets; and (iii) 10% of proceeds received by the Company on annual net sales between <em style="font: inherit;">$150,000</em> and <em style="font: inherit;">$230,000</em> in the Other Markets. No royalty payments are payable on annual net sales above <em style="font: inherit;">$230,000</em> in the Other Markets. <em style="font: inherit;">No</em> payment will be due to RPI for any achievement milestone which <em style="font: inherit;"> may </em>be payable under the existing out-license for ORLADEYO.</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company will be required to make royalty payments of amounts owed to RPI each calendar quarter following the <em style="font: inherit;">first</em> commercial sale of ORLADEYO in any country.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Under the Royalty Purchase Agreement, the Company has agreed to specified affirmative and negative covenants, including covenants regarding periodic reporting of information by the Company to RPI, <em style="font: inherit;">third</em>-party audits of royalties paid under the Royalty Purchase Agreement, and restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness other than certain royalty sales and as is permitted to be incurred under the terms of the Company&#8217;s Credit Agreement with Athyrium Opportunities III Co-Invest <em style="font: inherit;">1</em> LP. Refer to Note <em style="font: inherit;">4</em> for further details on the Credit Agreement. The restrictions on the ability of the Company or any of its subsidiaries to incur indebtedness are eliminated after the achievement of certain specified milestones in the Royalty Purchase Agreement.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The cash consideration of $125,000 obtained pursuant to the Royalty Purchase Agreement is recorded in &#8220;Royalty financing obligation&#8221; on the Company&#8217;s consolidated balance sheet as of <em style="font: inherit;"> December 31, 2020. </em>The fair value for the royalty financing obligation at the time of the transaction was based on the Company&#8217;s estimates of future royalties expected to be paid to RPI over the life of the arrangement. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration and sales price and are determined using forecasts from market data sources, which are considered Level <em style="font: inherit;">3</em> inputs. Deferred issuance costs, which consist primarily of advisory and legal fees, totaled $2,370 as of <em style="font: inherit;"> December 31, 2020. </em>The liability and the deferred issuance costs are amortized using the effective interest method over the term of the arrangement, in accordance with the respective guidance. The effective interest rate as of <em style="font: inherit;"> December 31, 2020 </em>was approximately 24%. For <em style="font: inherit;">2020,</em> accrued interest expense in the amount of $2,108 was added to the initial balance of the liability. The Company will utilize the prospective method to account for subsequent changes in the estimated future payments to be made to RPI.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#160;</b></span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyMonetizationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyMonetizationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766297794296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Credit Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember', window );">Senior Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note </b><b><em style="font: inherit;">5</em></b><b> &#8212; Senior Credit Facility</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> February 5, 2019, </em>the Company entered into a $100,000 Senior Credit Facility with an affiliate of MidCap Financial Services, LLC, as administrative agent (the &#8220;Second Amended and Restated Senior Credit Facility&#8221;). Borrowings under the Second Amended and Restated Senior Credit Facility were available in <em style="font: inherit;">three</em> tranches, with (i) the <em style="font: inherit;">first</em> tranche comprised of $50,000 funded at closing, which included $30,000 of proceeds that were deemed rolled over from the outstanding principal amount under the Company&#8217;s prior credit agreement, (ii) the <em style="font: inherit;">second</em> tranche comprised of $30,000, and (iii) the <em style="font: inherit;">third</em> tranche comprised of $20,000, with the <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> tranches to have been funded upon the completion of certain contingencies related to the Company&#8217;s development activities of its product candidates and the establishment of certain financial covenants. On <em style="font: inherit;"> September 10, 2019 </em>the Company executed the <em style="font: inherit;">first</em> amendment to the Second Amended and Restated Credit Facility which extended the commitment termination date for the <em style="font: inherit;">second</em> tranche to <em style="font: inherit;"> November 30, 2019. </em>On <em style="font: inherit;"> November 30, 2019, </em>the Company&#8217;s access to the <em style="font: inherit;">second</em> tranche expired.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Second Amended and Restated Senior Credit Facility refinanced and replaced the Amended and Restated Senior Credit Facility dated as of <em style="font: inherit;"> July 20, 2018 (</em>the &#8220;Amended and Restated Senior Credit Facility&#8221;). The Second Amended and Restated Senior Credit Facility had a variable interest rate of LIBOR (which was <em style="font: inherit;">not</em> to be less than 0.5%) plus 8%. The Second Amended and Restated Senior Credit Facility included an interest-only payment period through <em style="font: inherit;"> June 2020 </em>and scheduled monthly principal and interest payments for the subsequent 30 months. The Company used a portion of the proceeds of the Second Amended and Restated Senior Credit Facility to pay off outstanding amounts under the Amended and Restated Senior Credit Facility and the remainder was used for general corporate purposes.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In <em style="font: inherit;"> December 2020, </em>the Company repaid the outstanding principal of the Second Amended and Restated Senior Credit Facility of $40,000 along with exit fees and accrued interest through the payoff date that totaled $3,298. The unamortized deferred financing cost and original issue discount of $1,211 was expensed as a loss on debt extinguishment.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
  <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note </b><b><em style="font: inherit;">4</em></b><b> &#8212; </b><b>Credit Agreement</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><b>&#160;</b></span></p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">On <em style="font: inherit;"> December 7, 2020, </em>the Company entered into a $200,000 Credit Agreement with Athyrium Opportunities III Co-Invest <em style="font: inherit;">1</em> LP (&#8220;Athyrium&#8221;), as lender and as administrative agent for the lenders.&#160;BioCryst Ireland Limited, BioCryst US Sales Co., LLC, and BioCryst UK Limited, each of which is a wholly-owned subsidiary of the Company, are guarantors to the Credit Agreement. The Credit Agreement provides for an initial term loan in the principal amount of $125,000 (the &#8220;Term A Loan&#8221;), which was received by the Company on <em style="font: inherit;"> December 7, 2020 </em>and is recorded in &#8220;Secured term loan&#8221; on the Company&#8217;s balance sheet as of <em style="font: inherit;"> December 31, 2020.&#160; </em>The Company used a portion of the proceeds from the Term A Loan to repay $43,298 of outstanding indebtedness, including accrued interest, under its existing credit facility with MidCap Financial Trust.&#160; The Company intends to use the remaining proceeds to support the launch of ORLADEYO in the United States and Europe and to advance the development of <em style="font: inherit;">BCX9930</em> into clinical trials in multiple complement-mediated diseases, and for other general corporate purposes.&#160;</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Credit Agreement also provides for <em style="font: inherit;">two</em> additional term loans, at the Company's option, in the respective principal amounts of $25,000 (the &#8220;Term B Loan&#8221;) and $50,000 (the &#8220;Term C Loan&#8221;).&#160; The Term B Loan and the Term C Loan <em style="font: inherit;"> may </em>be drawn upon if, among other conditions, the Company reaches defined revenue milestones and, with respect to a draw on the Term C Loan, the Term B Loan has been funded prior to or contemporaneously with the Term C Loan.&#160; The maturity date of the Credit Agreement is <em style="font: inherit;"> December 7, 2025.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Credit Agreement provides for quarterly interest-only payments until the maturity date, with the unpaid principal amount of the outstanding Term Loans due and payable on the maturity date.&#160; For each of the <em style="font: inherit;">first</em> <em style="font: inherit;">eight</em> full fiscal quarters following <em style="font: inherit;"> December 7, 2020, </em>the Company has the option to make the applicable interest payment-in-kind (a &#8220;PIK Interest Payment&#8221;) by capitalizing the entire amount of interest accrued during the applicable interest period with the unpaid original principal amount outstanding on the last day of such period. The Term Loans will bear interest at a rate equal to the <em style="font: inherit;">three</em>-month LIBOR rate, which shall be <em style="font: inherit;">no</em> less than 1.75% and <em style="font: inherit;">no</em> more than 3.50% (&#8220;LIBOR&#8221;), plus 8.25%, or for each interest period in which a PIK Interest Payment is made, the LIBOR plus 10.25%.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Subject to certain exceptions, the Company is required to make mandatory prepayments of the Term Loans with the proceeds of certain asset sales, certain ORLADEYO out-licensing or royalty monetization transactions (excluding the Royalty Sale), extraordinary receipts, debt issuances, or upon a change of control of the Company and specified other events, subject to certain exceptions. The Company <em style="font: inherit;"> may </em>make voluntary prepayments in whole or in part. Prepayments are subject to a premium equal to, (i) with respect to any voluntary prepayment and certain mandatory prepayments paid on or prior to the <em style="font: inherit;">second</em> anniversary of the applicable Term Loan borrowing date, the amount, if any, by which (a) the sum of (<em style="font: inherit;">1</em>) 102.00% of the principal amount of the Term Loan being prepaid plus (<em style="font: inherit;">2</em>) the present value of all interest that would have accrued on the principal amount of the Term Loan being prepaid through and including the <em style="font: inherit;">second</em> anniversary of the date of the borrowing of such Term Loan, plus 0.50%, exceeds (b) the principal amount of the Term Loan being prepaid; (ii) with respect to any prepayment made between the <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> anniversaries of the applicable Term Loan borrowing date, 2.00% of the principal amount of the Term Loan being prepaid; (iii) with respect to any prepayment made between the <em style="font: inherit;">third</em> and <em style="font: inherit;">fourth</em> anniversaries of the applicable Term Loan&#160;</span>borrowing date<span style="color:#000000;">, 1.00% of the principal amount of the Term Loan being prepaid; and (iv) with respect to any prepayment made after the <em style="font: inherit;">fourth</em> anniversary of the applicable Term Loan borrowing date, 0.00% of the principal amount of the Term Loan being prepaid. Upon the prepayment or repayment, including at maturity, of all or any of the Term Loans, the Company is obligated to pay an exit fee in an amount equal to 2.00% of the principal amount of the Term Loans prepaid or repaid. In addition, each Term Loan is subject to a 1.00% commitment fee at its respective borrowing date.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Credit Agreement also contains representations and warranties and affirmative and negative covenants customary for financings of this type, as well as customary events of default. &#160;Certain of the customary negative covenants limit the ability of the Company and certain of its subsidiaries to, among other things, grant liens, make investments, incur additional indebtedness, engage in mergers, acquisitions, and similar transactions, dispose of assets, license certain property, distribute dividends, make certain restricted payments, change the nature of the Company's business, engage in transactions with affiliates and insiders, prepay other indebtedness, or engage in sale and leaseback transactions, subject to certain exceptions. &#160;Additionally, as of the last day of each fiscal quarter (a &#8220;Test Date&#8221;), beginning with the <em style="font: inherit;">first</em> Test Date occurring immediately after the Term C Loan is drawn, if applicable, the Company <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> permit consolidated net revenues from ORLADEYO sales in the United States for the <em style="font: inherit;">four</em>-fiscal quarter period ending on such Test Date to be less than the specified amounts set forth in the Credit Agreement (collectively, the &#8220;Revenue Tests&#8221;).&#160; If the Company fails to satisfy the Revenue Tests as of any Test Date, it will have a <em style="font: inherit;">one</em>-time right (the &#8220;Cure Right&#8221;) to repay in full the entire amount of the Term C Loans outstanding at such time together with all accrued and unpaid interest thereon plus the prepayment premium, exit fee, and any other fees or amounts payable under the Credit Agreement at such time.&#160; In addition, the Credit Agreement contains a minimum liquidity covenant requiring the Company to maintain at all times, as applicable, at least $15,000 of unrestricted cash and cash equivalents if only the Term A Loan has been drawn; at least $20,000 of unrestricted cash and cash equivalents if the Term B Loan has been drawn but the Term C Loan has <em style="font: inherit;">not</em> been drawn; and at least $15,000 (or, if the Cure Right has been exercised, $20,000) of unrestricted cash and cash equivalents if the Term C Loan has been drawn, subject to certain exceptions.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">A failure to comply with the covenants in the Credit Agreement could permit the Lenders under the Credit Agreement to declare the outstanding principal as well as accrued interest and fees, to be immediately due and payable.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The Company's obligations under the Credit Agreement are secured by a security interest in, subject to certain exceptions, substantially all of the Company's assets.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">As of <em style="font: inherit;"> December 31, 2020, </em>the Company had borrowings of $125,000 under the Credit Agreement. The carrying amount of the debt approximates its fair value based on prevailing interest rates as of the balance sheet date.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The Credit Agreement provides for quarterly interest-only payments until the maturity date, with the unpaid principal amount of the outstanding Term Loans due and payable on the maturity date of <em style="font: inherit;"> December 7, 2025. </em>The Company has elected the <em style="font: inherit;">first</em> quarterly interest payment to be a PIK Interest Payment and began accruing interest at a rate of 12.17%. As of <em style="font: inherit;"> December 31, 2020, </em>debt fees and issuance costs totaled $7,764 and are being amortized as interest expense on an effective interest rate method over the term of the Term A Loan. Interest expense of $925, net of deferred financing amortization of $131, related to the Credit Agreement was recognized in <em style="font: inherit;">2020</em> related to the Term A Loan.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The Credit Agreement contains <em style="font: inherit;">two</em> provisions that, if deemed probable, would create the recognition of an embedded feature; however, at this time, the Company does <em style="font: inherit;">not</em> believe either provision is probable.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#160;</b></span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766374467480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Senior Credit Facility<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember', window );">Senior Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note </b><b><em style="font: inherit;">5</em></b><b> &#8212; Senior Credit Facility</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> February 5, 2019, </em>the Company entered into a $100,000 Senior Credit Facility with an affiliate of MidCap Financial Services, LLC, as administrative agent (the &#8220;Second Amended and Restated Senior Credit Facility&#8221;). Borrowings under the Second Amended and Restated Senior Credit Facility were available in <em style="font: inherit;">three</em> tranches, with (i) the <em style="font: inherit;">first</em> tranche comprised of $50,000 funded at closing, which included $30,000 of proceeds that were deemed rolled over from the outstanding principal amount under the Company&#8217;s prior credit agreement, (ii) the <em style="font: inherit;">second</em> tranche comprised of $30,000, and (iii) the <em style="font: inherit;">third</em> tranche comprised of $20,000, with the <em style="font: inherit;">second</em> and <em style="font: inherit;">third</em> tranches to have been funded upon the completion of certain contingencies related to the Company&#8217;s development activities of its product candidates and the establishment of certain financial covenants. On <em style="font: inherit;"> September 10, 2019 </em>the Company executed the <em style="font: inherit;">first</em> amendment to the Second Amended and Restated Credit Facility which extended the commitment termination date for the <em style="font: inherit;">second</em> tranche to <em style="font: inherit;"> November 30, 2019. </em>On <em style="font: inherit;"> November 30, 2019, </em>the Company&#8217;s access to the <em style="font: inherit;">second</em> tranche expired.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Second Amended and Restated Senior Credit Facility refinanced and replaced the Amended and Restated Senior Credit Facility dated as of <em style="font: inherit;"> July 20, 2018 (</em>the &#8220;Amended and Restated Senior Credit Facility&#8221;). The Second Amended and Restated Senior Credit Facility had a variable interest rate of LIBOR (which was <em style="font: inherit;">not</em> to be less than 0.5%) plus 8%. The Second Amended and Restated Senior Credit Facility included an interest-only payment period through <em style="font: inherit;"> June 2020 </em>and scheduled monthly principal and interest payments for the subsequent 30 months. The Company used a portion of the proceeds of the Second Amended and Restated Senior Credit Facility to pay off outstanding amounts under the Amended and Restated Senior Credit Facility and the remainder was used for general corporate purposes.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In <em style="font: inherit;"> December 2020, </em>the Company repaid the outstanding principal of the Second Amended and Restated Senior Credit Facility of $40,000 along with exit fees and accrued interest through the payoff date that totaled $3,298. The unamortized deferred financing cost and original issue discount of $1,211 was expensed as a loss on debt extinguishment.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766374739272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Lease Obligations and Other Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLessorDisclosureTextBlock', window );">Leases of Lessor Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note <em style="font: inherit;">6</em></b><b> &#8212; Lease Obligations and Other Contingencies</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In <em style="font: inherit;"> February 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02:</em> <i>Leases (Topic <em style="font: inherit;">842</em>)</i>. This ASU requires a lessee to recognize a right-of-use asset and a lease liability on its balance sheet for most operating leases. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em> is effective for annual and interim periods beginning after <em style="font: inherit;"> December 15, 2018, </em>including interim periods within those fiscal years. In <em style="font: inherit;"> July 2018, </em>the FASB issued ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">11,</em> <i>Leases (Topic <em style="font: inherit;">842</em>): Targeted Improvements</i>, which provides companies with an additional optional transition method to apply the new standard to leases in effect at the adoption date through a cumulative effect adjustment. The Company adopted the new lease standard as of <em style="font: inherit;"> January 1, 2019 </em>using this optional transition method.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company elected the package of practical expedients referenced in ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02,</em> which permits companies to retain original lease identification and classification without reassessing initial direct costs for existing leases. The Company also elected the practical expedient that exempts leases with an initial lease term of <em style="font: inherit;">twelve</em> months or less, as well as the practical expedient that allows companies to select, by class of underlying asset, <em style="font: inherit;">not</em> to separate lease and non-lease components. Adoption of this standard resulted in the recognition of a right-of-use asset and a lease liability on the Company&#8217;s <em style="font: inherit;"> January 1, 2019 </em>Consolidated Balance Sheet of $3,621 and $4,822, respectively. There was <em style="font: inherit;">no</em> material impact on the Company&#8217;s Consolidated Statement of Comprehensive Loss, and the cumulative transition adjustment recorded to retained earnings upon adoption was $238.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company leases certain assets under operating leases, which primarily consisted of real estate leases, laboratory equipment leases and office equipment leases as of <em style="font: inherit;"> December 31, 2020. </em>Certain operating leases provide for renewal options, which can vary by lease. The right-of-use asset and lease liabilities on the Company&#8217;s Consolidated Balance Sheet represent payments over the lease term, which includes renewal options for certain real estate leases that we are likely to exercise. As part of the Company&#8217;s assessment of the lease term, the Company elected the hindsight practical expedient, which allows companies to use current knowledge and expectations when determining the likelihood to extend lease options. Renewal options for our leases range from 1 to 5 years in length and begin from <em style="font: inherit;">2023</em> through <em style="font: inherit;">2026.</em> The weighted average lease term for the Company&#8217;s operating leases was 13.1 years. The discount rate used in the calculation of the Company&#8217;s right-of-use asset and lease liability was determined based on the stated rate within each contract when available, or the Company&#8217;s collateralized borrowing rate from lending institutions. The weighted average discount rate for the Company&#8217;s operating leases was 12.7%.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:19pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company has <em style="font: inherit;">not</em> made any residual value guarantees related to its operating leases; therefore, the Company has <em style="font: inherit;">no</em> corresponding liability recorded on its Consolidated Balance Sheets.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">Aggregate lease expense under operating leases was $1,754 and $1,464 for the <em style="font: inherit;">twelve</em>-month periods ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively. Certain operating leases include rent escalation provisions, which the Company recognizes as expense on a straight-line basis. Lease expense for leases with an initial term of <em style="font: inherit;">twelve</em> months or less was <em style="font: inherit;">not</em> material.</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Future lease payments for assets under operating leases as of <em style="font: inherit;"> December 31, 2020, </em>are as follows:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Remaining Maturities of Lease Liabilities</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Year Ending December 31,</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0.5pt 0pt 0pt; text-align: center;"><span style="color:#000000;"><b><b>Operating Leases</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">2021</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,302</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">2022</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">758</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">2023</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">619</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">2024</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">577</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">2025</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">582</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Thereafter</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">7,327</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 12pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Total lease payments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">11,165</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Less imputed interest</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">6,115</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 12pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Total</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">5,050</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The&#160;</span>Company&#8217;s current lease liability at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> was $1,179 and $1,377, respectively. The Company&#8217;s long-term lease liability as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> was $3,871 and $3,406, respectively. The current and long-term portions of the Company&#8217;s lease liability are presented within &#8220;Lease financing obligations&#8221; on the Consolidated Balance Sheets. Cash paid for amounts included in the measurement of lease liabilities was $1,696 and $1,457 for the years ended <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively. The Company&#8217;s right-of use asset balance associated with operating leases totaled $3,802 and $3,590 at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively. These amounts are presented within &#8220;Other assets&#8221; on the Consolidated Balance Sheets. Operating right-of-use assets are recorded net of accumulated amortization of $2,641 and $1,386 as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> respectively<span style="color:#000000;">.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor entity's leasing arrangements for operating, capital and leveraged leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766374806776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note </b><b><em style="font: inherit;">7</em></b><b> &#8212; Stockholders&#8217; Equity</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Sales of Common Stock</b></i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:22pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> November 8, 2017, </em>the Company filed a $200,000 shelf registration statement on Form S-<em style="font: inherit;">3</em> with the SEC. This shelf registration statement became effective on <em style="font: inherit;"> December 12, 2017 </em>and allowed the Company to sell securities, including common stock, preferred stock, depository shares, stock purchase contracts, warrants and units, from time to time at prices and on terms to be determined at the time of sale.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> August 6, 2018, </em>the Company completed an underwritten public offering of 10,455 shares of its common stock, offered at a price to the public of $5.50 per share, including shares issued pursuant to the underwriters&#8217; <em style="font: inherit;">30</em>-day option to purchase additional shares, which was exercised in full. The net proceeds from this offering were approximately $53,400 after deducting underwriting discounts and commissions and estimated offering expenses.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> November 18, 2019, </em>the Company completed an underwritten public offering of 43,621 shares of its common stock, offered at a price to the public of $1.45 per share, including shares issued pursuant to the underwriters&#8217; <em style="font: inherit;">30</em>-day option to purchase additional shares, which was exercised in full. The net proceeds from this offering were approximately $58,500 after deducting underwriting discounts and commissions and estimated offering expenses.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> November 21, 2019, </em>the Company completed an offering of pre-funded warrants to purchase up to 11,765 shares of its common stock at a price of $1.69 per warrant. Each pre-funded warrant is exercisable subject to conditions in the warrant agreement into <em style="font: inherit;">1</em> share of common stock at an exercise price of $0.01 per share. The net proceeds from this offering were $19,882, excluding any proceeds the Company <em style="font: inherit;"> may </em>receive upon the subsequent exercise of the pre-funded warrants. All warrants issued in this offering remain outstanding at <em style="font: inherit;"> December 31, 2020.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> April 24, 2020, </em>the Company filed a $500,000 shelf registration statement on Form S-<em style="font: inherit;">3</em> with the SEC. This shelf registration statement became effective on <em style="font: inherit;"> May 14, 2020 </em>and allows the Company to sell securities, including common stock, preferred stock, depository shares, purchase contracts, warrants, debt securities, and units, from time to time at prices and on terms to be determined at the time of sale.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> June 1, 2020, </em>the Company issued 22,044 shares of common stock to the public at a purchase price of $4.50 per share and pre-funded warrants to purchase 3,511 shares of common stock at a purchase of $4.49 per pre-funded warrant, for total net proceeds to the Company of $108,096 million after deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant is exercisable subject to conditions in the warrant agreement into <em style="font: inherit;">1</em> share of common stock at an exercise price of $0.01 per share. All warrants issued in this offering remain outstanding at <em style="font: inherit;"> December 31, 2020.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766374532984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payment Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note <em style="font: inherit;">8</em></b><b> &#8212; Stock-Based Compensation</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">As of <em style="font: inherit;"> December 31, 2020, </em>the Company had <em style="font: inherit;">three</em> stock-based employee compensation plans, the Amended and Restated Stock Incentive Plan (&#8220;Incentive Plan&#8221;), the&#160;</span>Amended and Restated&#160;<span style="color:#000000;">Inducement Equity Incentive Plan (&#8220;Inducement Plan&#8221;) and the Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The Incentive Plan was amended and restated on <em style="font: inherit;"> March 19, 2020 </em>and approved by the Company&#8217;s stockholders on <em style="font: inherit;"> May 12, 2020. </em>The Inducement Plan was adopted by the Board of Directors on <em style="font: inherit;"> April 24, 2019 </em>and amended and restated by the Board of Directors in <em style="font: inherit;"> February 2020 </em>and in <em style="font: inherit;"> July 2020. </em>The ESPP was amended and restated in <em style="font: inherit;"> March 2020 </em>and approved by the Company&#8217;s stockholders on <em style="font: inherit;"> May 12, 2020. </em>Stock-based compensation expense of $14,794 ($12,938 of expense related to the Incentive Plan, $1,494 of expense related to the Inducement Plan, $362 of expense related to the ESPP) was recognized during <em style="font: inherit;">2020,</em> while $17,719 ($17,164 of expense related to the Incentive Plan, $323 of expense related to the Inducement Plan, $232 of expense related to the ESPP) was recognized during <em style="font: inherit;">2019</em> and $9,396 ($9,223 of expense related to the Incentive Plan, $173 of expense related to the ESPP) was recognized during <em style="font: inherit;">2018.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:23pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company accounts for stock-based compensation in accordance with FASB authoritative guidance regarding share-based payments. Total stock-based compensation was allocated as follows:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><span style="color:#000000;"><b><b>Year Ended December 31,</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>8</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Research and development</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">10,222</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">13,977</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,867</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Selling, general and administrative</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">4,572</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">3,742</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">2,529</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Total stock-based compensation expense</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">14,794</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">17,719</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">9,396</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Stock Incentive Plan</b></i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company grants stock option awards and restricted stock unit awards to its employees, directors, and consultants under the Incentive Plan. Under the Incentive Plan, stock option awards are granted with an exercise price equal to the market price of the Company&#8217;s stock at the date of grant. Commencing <em style="font: inherit;"> March 1, 2011, </em>stock option awards and restricted stock units granted to employees generally vest 25% each year until fully vested after <span style="-sec-ix-hidden:c69829093">four</span> years. In <em style="font: inherit;"> August 2013, </em><em style="font: inherit;"> December 2014 </em>and <em style="font: inherit;"> December 2019, </em>the Company issued 1,032, 1,250 and 315 performance-based stock options, respectively. These awards vest upon successful completion of specific development milestones. As of <em style="font: inherit;"> December 31, 2020, </em>100%, 85% and 100% of the <em style="font: inherit;"> August 2013, </em><em style="font: inherit;"> December 2014 </em>and <em style="font: inherit;"> December 2019 </em>grants, respectively, have vested. During <em style="font: inherit;">2020,</em> the Company recognized $1,768 and $684 of stock compensation expense related to milestones within the <em style="font: inherit;"> August 2013 </em>and <em style="font: inherit;"> December 2019 </em>grants for which achievement became probable. Stock option awards granted to non-employee directors of the Company generally vest over <em style="font: inherit;">one</em> year. All stock option awards have contractual terms of 10 years. The vesting exercise provisions of all awards granted under the Incentive Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Incentive Plan.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Related activity under the Incentive Plan is as follows:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Weighted</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Average</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Awards</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Options</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Exercise</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Available</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Outstanding</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Price</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2017</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">468</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">14,452</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6.06</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Plan amendment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,400</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Restricted stock awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(13</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(4,272</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,272</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">7.15</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards exercised</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(1,011</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2.92</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards cancelled</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">222</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(222</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">7.44</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2018</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">805</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">17,491</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6.49</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Plan amendment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,000</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Restricted stock awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(27</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(4,511</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,511</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3.91</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards exercised</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(251</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3.75</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards cancelled</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">701</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(701</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6.82</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2019</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">968</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">21,050</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">5.96</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Plan amendment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">8,000</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Restricted stock awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(31</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(7,469</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">7,469</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">8.06</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards exercised</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(510</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.56</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards cancelled</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">3,124</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(3,124</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6.93</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2020</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">4,592</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">24,885</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6.52</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">For stock option awards granted under the Incentive Plan during <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018</em> was $5.48, $2.63, and $4.92, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Inducement Equity Incentive Plan</b></i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The&#160;</span>Company has the ability to grant stock option awards to newly-hired employees as inducements material to each employee entering employment with the Company. Stock option awards granted to newly hired employees generally vest 25% each year until fully vested after <span style="-sec-ix-hidden:c69829118">four</span> years. Each stock option has a term of 10 years and is subject to the terms and conditions of the Inducement Plan. The vesting and exercise provisions of all awards granted under the Inducement Plan are subject to acceleration in the event of certain stockholder-approved transactions, or upon the occurrence of a change in control as defined in the Inducement Plan<span style="color:#000000;">.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Related activity under the Inducement Plan is as follows:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:16pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Weighted</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Average</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Awards</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Options</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Exercise</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Available</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Outstanding</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Price</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2019</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">171</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,329</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3.60</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Plan amendment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,900</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(3,002</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,002</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.02</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards cancelled</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">160</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(160</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.15</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2020</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">229</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">4,171</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3.88</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">For stock option awards granted under the Inducement Plan during <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> the fair value was estimated on the date of grant using a Black-Scholes option pricing model and the assumptions noted in the table below. The weighted average grant date fair value of these awards granted during <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019</em> was $2.73 and $2.41, respectively. The fair value of the stock option awards is amortized to expense over the vesting periods using a straight-line expense attribution method.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b>&#160;</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The following table summarizes the key assumptions used by the Company to value the stock option awards granted under all plans during <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> respectively. The expected life is based on the average of the assumption that all outstanding stock option awards will be exercised at full vesting and the assumption that all outstanding stock option awards will be exercised at the midpoint of the current date (if already vested) or at full vesting (if <em style="font: inherit;">not</em> yet vested) and the full contractual term. The expected volatility represents the historical volatility on the Company&#8217;s publicly traded common stock. The Company has assumed no expected dividend yield, as dividends have never been paid to stock or option holders and will <em style="font: inherit;">not</em> be paid for the foreseeable future. The weighted average risk-free interest rate is the implied yield currently available on <em style="font: inherit;">zero</em>-coupon government issues with a remaining term equal to the expected term.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors under the Plans</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; padding-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>8</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Expected Life</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">5.5</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">5.5</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">5.5</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Expected Volatility</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">84</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">81</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">82</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Expected Dividend Yield</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">0.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">0.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">0.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Risk-Free Interest Rate</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">0.4</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1.8</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2.7</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The total intrinsic value of stock option awards exercised under the Incentive Plan was $1,562 during <em style="font: inherit;">2020,</em> $1,127 during <em style="font: inherit;">2019,</em> and $4,504 during <em style="font: inherit;">2018.</em> The intrinsic value represents the total proceeds (fair market value at the date of exercise, less the exercise price, times the number of stock option awards exercised) received by all individuals who exercised stock option awards during the period. No stock option awards were exercised under the Inducement Plan in <em style="font: inherit;">2020.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:25pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">The following table summarizes, at <em style="font: inherit;"> December 31, 2020, </em>by price range: (<em style="font: inherit;">1</em>) for stock option awards outstanding under the Incentive Plan, the number of stock option awards outstanding, their weighted average remaining life and their weighted average exercise price; and (<em style="font: inherit;">2</em>) for stock option awards exercisable under the Plan, the number of stock option awards exercisable and their weighted average exercise price:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td colspan="9" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"><span style="color:#000000;"><b style="font-size: 10pt;">Outstanding</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Exercisable</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Weighted</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Weighted</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Weighted</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Average</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Average</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Average</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Remaining</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Exercise</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Exercise</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Range</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Number</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;"><b><b>Life</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Price</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Number</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Price</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>$</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>0</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>3</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,514</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6.1</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2.19</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,414</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1.25</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>3</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>6</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">12,689</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">7.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.22</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,854</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2.48</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>6</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>9</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">10,852</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">9.2</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">7.88</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,005</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.89</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>9</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>12</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,347</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.5</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">10.85</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,129</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.51</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>12</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>15</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">559</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.1</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">12.30</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">539</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6.43</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>15</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>18</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">95</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.5</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">15.39</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">95</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">10.57</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>$</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>0</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>18</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">29,056</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">7.5</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6.14</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">13,036</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3.27</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The weighted average remaining contractual life of stock option awards exercisable under the plans at <em style="font: inherit;"> December 31, 2020 </em>was 5.3 years.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">The aggregate intrinsic value of stock option awards outstanding and exercisable under the plans at <em style="font: inherit;"> December 31, 2020 </em>was $29,716. The aggregate intrinsic value represents the value (the period&#8217;s closing market price, less the exercise price, times the number of in-the-money stock option awards) that would have been received by all stock option award holders under the plans had they exercised their stock option awards at the end of the year.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The total fair value of the stock option awards vested under the plans was $18,739&#160;during <em style="font: inherit;">2020,</em> $12,499 during <em style="font: inherit;">2019,</em> and $8,952 during <em style="font: inherit;">2018.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:4pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">As&#160;</span>of <em style="font: inherit;"> December 31, 2020, </em>the number of stock option awards vested and expected to vest under the plans is 26,487. The weighted average exercise price of these stock option awards is $6.13 and their weighted average remaining contractual life is 7.4 years<span style="color:#000000;">.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The following table summarizes the changes in the number and weighted-average grant-date fair value of non-vested stock option awards during <em style="font: inherit;">2020:</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;"><b><b>Non-Vested Stock Option Awards</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><b>Weighted Average Grant-Date Fair Value</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Balance December 31, 2019</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">11,688</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3.77</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Stock option awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">10,471</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.69</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Stock option awards vested</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(4,543</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.12</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Stock option awards forfeited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(1,596</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">3.96</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Balance December 31, 2020</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">16,020</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">4.25</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">As of <em style="font: inherit;"> December 31, 2020, </em>there was approximately $56,094 of total unrecognized compensation cost related to non-vested employee stock option awards granted by the Company. That cost is expected to be recognized as follows: $17,758 in <em style="font: inherit;">2021,</em> $16,281 in <em style="font: inherit;">2022,</em> $12,484 in <em style="font: inherit;">2023,</em> and $9,571 in <em style="font: inherit;">2024.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><b><i>Employee Stock Purchase Plan</i></b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company has reserved a total of 4,475 shares of common stock to be purchased under the ESPP, of which 2,873 shares remain available for purchase at <em style="font: inherit;"> December 31, 2020. </em>Eligible employees <em style="font: inherit;"> may </em>authorize up to 15% of their salary to purchase common stock at the lower of 85% of the beginning or 85% of the ending price during <em style="font: inherit;">six</em>-month purchase intervals. <em style="font: inherit;">No</em> more than 3 shares <em style="font: inherit;"> may </em>be purchased by any <em style="font: inherit;">one</em> employee at the <em style="font: inherit;">six</em>-month purchase dates and <em style="font: inherit;">no</em> employee <em style="font: inherit;"> may </em>purchase stock having a fair market value at the commencement date of $25 or more in any <em style="font: inherit;">one</em> calendar year.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:11pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">There were 246, 115, and 92 shares of common stock purchased under the ESPP in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> respectively, at a weighted average price per share of $2.56, $3.51, and $3.83, respectively. Expense of $362, $232, and $173 related to the ESPP was recognized during <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> respectively. Compensation expense for shares purchased under the ESPP related to the purchase discount and the &#8220;look-back&#8221; option were determined using a Black-Scholes option pricing model. The weighted average grant date fair values of shares granted under the ESPP during <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> were $1.47, $2.01, and $1.89, respectively.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>&#160;</b></span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766295573208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note </b><b><em style="font: inherit;">9</em></b><b> &#8212; Income Taxes</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The Company has incurred net losses since inception and, consequently, has <em style="font: inherit;">not</em> recorded any U.S. Federal and state income tax expense or benefit.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The components of loss before provision for income taxes were as followings:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>2020</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Domestic</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(176,613</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Foreign</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(6,201</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Loss before provision for income taxes</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">(182,814</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;">The differences between the Company&#8217;s effective tax rate and the statutory tax rate in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> are as follows:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>8</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Income tax benefit at federal statutory rate (<span style="-sec-ix-hidden:c69831164"><span style="-sec-ix-hidden:c69831165"><span style="-sec-ix-hidden:c69831166">21%</span></span></span> for 2020, 2019 and 2018)</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(38,391</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(22,868</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(21,263</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">State and local income taxes net of federal tax benefit</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(2,544</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(1,591</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(2,547</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Permanent items</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">774</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">691</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">503</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Rate change</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(82</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">625</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(29</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Expiration of attribute carryforwards</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,774</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,976</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,183</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Research and development tax credits</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830313">(4,080</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830314">(4,938</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830315">(4,905</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Foreign rate differential</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">542</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">-</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">-</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Other</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830319">1,456</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830320">281</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830321">18</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Change in valuation allowance</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">38,551</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">23,824</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">26,040</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Income tax expense</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: #000000; "><span style="-sec-ix-hidden:c69830325">-</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830326">-</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830327">-</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company recognizes the impact of a tax position in its financial statements if it is more likely than <em style="font: inherit;">not</em> that the position will be sustained on audit based on the technical merits of the position. The Company has concluded that it has an uncertain tax position pertaining to its research and development and orphan drug credit carryforwards. The Company has established these credits based on information and calculations it believes are appropriate and the best estimate of the underlying credit. Any changes to the Company&#8217;s unrecognized tax benefits are offset by an adjustment to the valuation allowance and there would be <em style="font: inherit;">no</em> impact on the Company&#8217;s financial statements. The Company does <em style="font: inherit;">not</em> expect its unrecognized tax benefits to change significantly over the next <em style="font: inherit;">12</em> months.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:10pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Balance at January 1,</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">7,210</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">5,976</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Additions to current period tax positions</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,020</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,234</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Additions to prior period tax positions</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Reductions to prior period tax provisions</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Balance at December 31,</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">8,230</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">7,210</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company&#8217;s ability to utilize the net operating loss and tax credit carryforwards in the future <em style="font: inherit;"> may </em>be subject to substantial restrictions in the event of past or future ownership changes as defined in Section <em style="font: inherit;">382</em> of the Internal Revenue Code of <em style="font: inherit;">1986,</em> as amended and similar state tax law.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows:</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Deferred tax assets:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Net federal and state operating losses</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">159,939</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">155,190</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Research and development credits</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">66,331</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">63,275</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Royalty income</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">28,034</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock-based compensation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">10,732</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">9,786</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Leasing obligations</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,135</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,070</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Other</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">5,563</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">3,801</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Total deferred tax assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">271,734</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">233,122</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Deferred tax liabilities:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Fixed assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(124</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(114</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Right of use asset</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(854</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(803</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Total deferred tax liabilities</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(978</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(917</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Valuation allowance</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(270,756</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(232,205</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Net deferred tax assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The majority of the Company&#8217;s deferred tax assets relate to net operating loss and research and development carryforwards that can only be realized if the Company is profitable in future periods. It is uncertain whether the Company will realize any tax benefit related to these carryforwards. Accordingly, the Company has provided a full valuation allowance against the net deferred tax assets due to uncertainties as to their ultimate realization. The valuation allowance will remain at the full amount of the deferred tax assets until it is more likely than <em style="font: inherit;">not</em> that the related tax benefits will be realized. The Company&#8217;s valuation allowance increased by $38,551, $23,824, and $26,040 in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> respectively.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">As of <em style="font: inherit;"> December 31, 2020, </em>the Company had U.S. federal operating loss carryforwards of $677,109, state operating loss carryforwards of $494,608, foreign net operating losses of $6,427, and U.S. research and development and orphan drug credit carryforwards of $74,561, which will expire at various dates from <em style="font: inherit;">2021</em> through <em style="font: inherit;">2040.</em> Federal losses, state losses, research and development credit carryforwards began expiring in <em style="font: inherit;">2020.</em> The foreign net operating losses have an indefinite carryforward period.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:center;"><span style="color:#000000;"><b>&#160;</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Tax years <span style="-sec-ix-hidden:c69829408">2017</span>-<em style="font: inherit;">2020</em> remain open to examination by the major taxing jurisdictions to which the Company is subject. Additionally, years prior to <em style="font: inherit;">2017</em> are also open to examination to the extent of loss and credit carryforwards from those years. The Company recognizes interest and penalties accrued related to unrecognized tax benefits as components of its income tax provision. However, there were no provisions or accruals for interest and penalties in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766298351064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Employee 401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefits [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note </b><b><em style="font: inherit;">10</em></b><b> &#8212; Employee <em style="font: inherit;">401</em>(k) Plan</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In <em style="font: inherit;"> January 1991, </em>the Company adopted an employee retirement plan (<em style="font: inherit;">&#8220;401</em>(k) Plan&#8221;) under Section <em style="font: inherit;">401</em>(k) of the Internal Revenue Code covering all employees. Employee contributions <em style="font: inherit;"> may </em>be made to the <em style="font: inherit;">401</em>(k) Plan up to limits established by the Internal Revenue Service. Company matching contributions <em style="font: inherit;"> may </em>be made at the discretion of the Board of Directors. The Company made matching contributions of $1,569, $926, and $724 in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018,</em> respectively.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766374483736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Collaborative and Other Research and Development Contracts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note <em style="font: inherit;">11</em></b><b> &#8212; Collaborative and Other Research and Development Contracts</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;)</i>. In&#160;</span><em style="font: inherit;"> September 2013, </em>NIAID/HHS contracted with the Company for the development of galidesivir as a treatment for Marburg virus disease and subsequently, Yellow Fever and Ebola virus disease. As of <em style="font: inherit;"> December 31, 2020, </em>all options under this contract have been awarded, and the total value of the contract, as amended, is $45,931, inclusive of the <em style="font: inherit;">$2,897</em> added to the contract in <em style="font: inherit;"> August 2020 </em>to support the development of galidesivir. In <em style="font: inherit;"> August 2020, </em>NIAID/HHS awarded the Company a new contract, with potential aggregate funding up of to $43,908 if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir. NIAID/HHS made an initial award of $6,326 to the Company under this new contract<span style="color:#000000;">.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>Biomedical Advanced Research</i><i> and </i><i>Development Authority</i><i> (&#8220;BARDA/HHS&#8221;)</i>. In <em style="font: inherit;"> March 2015, </em>BARDA/HHS awarded the Company a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses. This BARDA/HHS contract includes a base contract of $16,265 to support galidesivir drug manufacturing, as well as $22,855 in additional development options that can be exercised by the government, bringing the potential value of the contract to $39,120. As of <em style="font: inherit;"> December 31, 2020, </em>a total of $20,574 has been awarded under exercised options within this contract.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The contracts with NIAID/HHS and BARDA/HHS are cost-plus-fixed-fee contracts. That is, the Company is entitled to receive reimbursement for all costs incurred in accordance with the contract provisions that are related to the development of galidesivir plus a fixed fee, or profit. BARDA/HHS and NIAID/HHS will make periodic assessments of progress, and the continuation of the contract is based on the Company&#8217;s performance, the timeliness and quality of deliverables, and other factors. The government has rights under certain contract clauses to terminate these contracts. These contracts are terminable by the government at any time for breach or without cause.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>U.S. Department of Health and Human Services (&#8220;HHS&#8221;)</i>. In&#160;</span><em style="font: inherit;"> September 2018, </em>HHS awarded the Company a $34,660 contract for the procurement of up to <em style="font: inherit;">50,000</em> doses of RAPIVAB (peramivir injection) over a <span style="-sec-ix-hidden:c69829532">five</span>-year period, including an initial base order of <em style="font: inherit;">10,000</em> doses. In <em style="font: inherit;"> September 2019, </em>HHS exercised its option to purchase an additional <em style="font: inherit;">10,000</em> doses of RAPIVAB. The Company delivered a total of <em style="font: inherit;">20,000</em> doses of RAPIVAB and approximately $13,864 of product sales in <em style="font: inherit;">2019.</em> On <em style="font: inherit;"> September 3, 2020, </em>the Company announced that HHS had exercised an option under this contract to purchase an additional <em style="font: inherit;">10,000</em> doses of RAPIVAB for $6,932, which the Company expects to deliver in <em style="font: inherit;">2021.</em>&#160; <em style="font: inherit;">No</em> shipments were delivered in <em style="font: inherit;">2020</em> under this additional <em style="font: inherit;">10,000</em> dose option<span style="color:#000000;">.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>Torii Pharmaceutical Co., Ltd. (&#8220;Torii&#8221;)</i>. On <em style="font: inherit;"> November 5, 2019, </em>the Company entered into a Commercialization and License Agreement with Torii (the &#8220;Torii Agreement&#8221;), granting Torii the exclusive right to commercialize ORLADEYO&#8482; for the prevention of hereditary angioedema (&#8220;HAE&#8221;) attacks in Japan.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>&#160;</i></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Under the Torii Agreement, the Company received an upfront, non-refundable payment of $22,000 and is eligible to receive an additional milestone payment of $15,000 upon receipt from Japan&#8217;s National Health Insurance System of a reimbursement price approval for ORLADEYO in excess of the threshold specified in the Torii Agreement.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In addition, under the Torii Agreement, the Company is entitled to receive tiered royalty payments, ranging from 20% to 40% of annual net sales of ORLADEYO in Japan during each calendar year. Torii&#8217;s royalty payment obligations are subject to customary reductions in certain circumstances, but <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be reduced by more than 50% of the amount that otherwise would have been payable to the Company in the applicable calendar quarter. Torii&#8217;s royalty payment obligations commence upon the <em style="font: inherit;">first</em> commercial sale of ORLADEYO in Japan and expire upon the later of (i) the <span style="-sec-ix-hidden:c69829552">tenth</span> anniversary of the date of <em style="font: inherit;">first</em> commercial sale of ORLADEYO in Japan, (ii) the expiration of the Company&#8217;s patents covering ORLADEYO, and (iii) the expiration of regulatory exclusivity for ORLADEYO in Japan. The Company will be responsible for supplying Torii with its required amounts of ORLADEYO. The activities of the parties pursuant to the Torii Agreement will be overseen by a joint steering committee, to be composed of an equal number of representatives from each party to coordinate the development and commercialization of ORLADEYO in Japan.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Under the Torii Agreement, the Company has granted Torii a right of <em style="font: inherit;">first</em> negotiation (&#8220;ROFN&#8221;) to commercialize ORLADEYO in Japan for the acute treatment of HAE attacks if the Company develops ORLADEYO for such indication and to commercialize any additional kallikrein inhibitor that the Company <em style="font: inherit;"> may </em>develop in the future for use in HAE in Japan. Under both ROFNs, if the parties do <em style="font: inherit;">not</em> agree to terms with respect to a definitive amendment to the Torii Agreement or new agreement, as applicable, the terms of the amendment or agreement would be set by a <em style="font: inherit;">third</em>-party arbitrator.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company identified performance obligations related to (i) the license to develop and commercialize ORLADEYO, (ii) regulatory approval support and (iii) reimbursement pricing approval support. These were each determined to be distinct from the other performance obligations. The Company allocated the <em style="font: inherit;">$22,000</em> upfront consideration to the identified performance obligations using estimation approaches to determine the standalone selling prices under ASC <em style="font: inherit;">606.</em> Specifically, in determining the value related to the license, a valuation approach utilizing risk adjusted discounted cash flow projections was used and an expected cost plus margin approach was utilized for the other performance obligations. The Company recognized $20,101 in revenue in <em style="font: inherit;">2019</em> including $19,344 associated with the license which was transferred to Torii at the execution of the Agreement and $757 related to the <em style="font: inherit;">2020</em> services provided in the performance of the <em style="font: inherit;">two</em> approvals. The remaining $1,899 of the <em style="font: inherit;">$22,000</em> upfront payment was recognized as revenue in <em style="font: inherit;">2020</em> as the services were delivered.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>Seqirus UK Limited (&#8220;SUL&#8221;). </i>On <em style="font: inherit;"> June 16, 2015, </em>the Company and SUL, a limited company organized under the laws of the United Kingdom and a subsidiary of CSL Limited, a company organized under the laws of Australia,<i> </i>entered into a License Agreement (the &#8220;SUL Agreement&#8221;) granting SUL and its affiliates worldwide rights to develop, manufacture and commercialize RAPIVAB (peramivir injection) for the treatment of influenza except for the rights to conduct such activities in Israel, Japan, Korea and Taiwan (the permitted geographies together constituting the &#8220;Territory&#8221;). Under the terms of the SUL Agreement, the Company received an upfront payment of $33,740 and has achieved all development milestones under the contract totaling $12,000.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">On <em style="font: inherit;"> March 4, 2020, </em>the International Court of Arbitration of the International Chamber of Commerce (&#8220;ICC Tribunal&#8221;) delivered a Partial Arbitration Award (the &#8220;Partial Arbitration Award&#8221;) in an arbitration matter between the Company and SUL with respect to the SUL Agreement. In the Partial Arbitration Award, the ICC Tribunal found that, during the term, SUL materially breached and abandoned its core duties to the Company under the Diligent Efforts (as defined in the SUL Agreement) requirements of the SUL Agreement as applicable in the U.S. The ICC Tribunal granted a declaratory judgment in favor of the Company terminating the SUL Agreement and restoring all rights to peramivir to the Company. The parties agreed on a transition process for the product, with a full transition of commercialization of the product in the U.S. and Australia returned to the Company as of <em style="font: inherit;"> August 1, 2020 </em>and <em style="font: inherit;"> November 1, 2020, </em>respectively. The ICC Tribunal also awarded the Company its attorneys&#8217; fees and expenses incurred in securing the declaratory judgment as well as the costs incurred by the Company in the arbitration. Finally, the ICC Tribunal found that SUL breached the SUL Agreement by failing to pay the milestone payment due to the Company within <em style="font: inherit;">30</em> days of the approval of peramivir for adult use in the European Union and awarded the Company $5,000 (plus interest) for this claim. The ICC Tribunal retained jurisdiction for further proceedings relating to the award of attorneys&#8217; fees and for any dispute relating to the return to the Company of all rights to peramivir in the Territory. The Company recorded the settlement gain of $8,893 in other income and legal fees and other expenses of $5,026 in selling, general and administrative expenses for the year ended <em style="font: inherit;"> December 31, 2020.</em></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>Shionogi &amp; Co., Ltd. (&#8220;Shionogi&#8221;). </i>In <em style="font: inherit;"> February 2007, </em>the Company entered into an exclusive license agreement with Shionogi to develop and commercialize peramivir in Japan for the treatment of seasonal and potentially<i> </i>life-threatening human influenza. Under the terms of the agreement, Shionogi obtained rights to injectable formulations of peramivir in Japan. The Company developed peramivir under a license from UAB and will owe sublicense payments to UAB on any future milestone payments and/or royalties received by the Company from Shionogi. In <em style="font: inherit;"> October 2008, </em>the Company and Shionogi amended the license agreement to expand the territory covered by the agreement to include Taiwan. Shionogi has commercially launched peramivir under the commercial name RAPIACTA in Japan and Taiwan.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In <em style="font: inherit;"> December 2017, </em>the Company, on behalf of Royalty Sub, instituted arbitration proceedings against Shionogi in order to resolve a dispute with Shionogi under the Shionogi Agreement regarding the achievement of sales milestones and escalating royalties. The arbitration proceedings have concluded, with the decision that <em style="font: inherit;">no</em> sale milestones had been achieved and that royalties would remain the same. The costs associated with the arbitration proceedings are recoverable from the assets of Royalty Sub in accordance with the terms of the indenture and servicing agreement relating to the PhaRMA Notes.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>Green Cross Corporation (&#8220;Green Cross&#8221;). </i>In <em style="font: inherit;"> June 2006, </em>the Company entered into an agreement with Green Cross to develop and commercialize peramivir in Korea. Under the terms of the agreement, Green Cross will be<i> </i>responsible for all development, regulatory, and commercialization costs in Korea. The Company received a <em style="font: inherit;">one</em>-time license fee of $250. The license also provides that the Company will share in profits resulting from the sale of peramivir in Korea, including the sale of peramivir to the Korean government for stockpiling purposes. Furthermore, Green Cross will pay the Company a premium over its cost to supply peramivir for development and any future marketing of peramivir products in Korea.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>Mundipharma International Holdings Limited (&#8220;Mundipharma&#8221;). </i>In <em style="font: inherit;"> February 2006, </em>the Company entered into an exclusive, royalty bearing right and license agreement with Mundipharma for the development and<i> </i>commercialization of Mundesine, a Purine Nucleoside Phosphorylase (&#8220;PNP&#8221;) inhibitor, for use in oncology. The agreement, as amended and restated, provides for the possibility of future event payments totaling $15,000 for achieving specified regulatory events for certain indications and tiered royalties ranging from mid to high single-digit percentages of net product sales in each country where Mundesine is sold by Mundipharma. The Company licensed forodesine and other PNP inhibitors from AECOM/IRL (as defined below) and will owe sublicense payments to AECOM/IRL on all milestone payments and royalties received from Mundipharma.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>


   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:27pt;"><span style="color:#000000;"><i>Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. (&#8220;AECOM&#8221; and &#8220;IRL&#8221; respectively). </i>In <em style="font: inherit;"> June 2000, </em>the Company licensed a series of potent inhibitors of PNP from AECOM and IRL,<i> </i>(together, the &#8220;Licensors&#8221;). The lead product candidates from this collaboration is forodesine. The Company has obtained worldwide exclusive rights to develop and ultimately distribute these, or any other, product candidates that might arise from research on these inhibitors. The Company has the option to expand the agreement to include other inventions in the field made by the investigators or employees of the Licensors. Under this agreement, as amended and restated, the Company has agreed to use commercially reasonable efforts to develop these drugs and to pay certain milestone payments for each licensed product (which range in the aggregate from $1,400 to almost $4,000 per indication) for future development, single digit royalties on net sales of any resulting product made by the Company, and to share a portion of future payments received from other <em style="font: inherit;">third</em>-party partners, if any. In addition, the Company has agreed to pay annual license fees, which can range from $150 to $500, that are creditable against actual royalties and other payments due to the Licensors. The Licensors have also granted the Company an exclusive worldwide license of galidesivir for any antiviral use.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;"><i>The University of Alabama at Birmingham (&#8220;UAB&#8221;). </i>The Company currently has agreements with UAB for influenza neuraminidase and complement inhibitors. Under the terms of these agreements, UAB performed specific<i> </i>research for the Company in return for research payments and license fees. UAB has granted the Company certain rights to any discoveries in these areas resulting from research developed by UAB or jointly developed by UAB with the Company. The Company has agreed to pay single digit royalties on sales of any resulting product and to share in future payments received from other <em style="font: inherit;">third</em>-party partners. The Company has completed the research under the UAB agreements. These <em style="font: inherit;">two</em> agreements each have an initial 25-year term, are automatically renewable for <span style="-sec-ix-hidden:c69829592">five</span>-year terms throughout the life of the last patent and are terminable by the Company upon <em style="font: inherit;">three</em> months&#8217; notice and by UAB under certain circumstances. Upon termination both parties shall cease using the other parties&#8217; proprietary and confidential information and materials, the parties shall jointly own joint inventions and UAB shall resume full ownership of all UAB licensed products. There is currently <em style="font: inherit;">no</em> activity between the Company and UAB on these agreements, but when the Company licenses this technology, such as in the case of the Shionogi and Green Cross, or commercializes products related to these programs, the Company will owe sublicense fees or royalties on amounts received.</span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766298351064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Quarterly Financial Information (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information [Text Block]</a></td>
<td class="text">
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Note <em style="font: inherit;">12</em></b><b>&#160;&#8212; Quarterly Financial Information (Unaudited)</b></span></p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>First</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Second</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Third</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Fourth</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>20</b><b>20</b><b> Quarters</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Revenues</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,823</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,871</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,102</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,016</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Net Loss</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(37,599</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(38,607</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(46,115</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(60,493</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Basic and diluted net loss per share</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.24</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.24</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.26</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.34</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>2019 Quarters</b></span></p> </td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Revenues</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">5,887</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,448</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,775</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">39,725</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Net Loss</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(31,054</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(37,629</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(37,592</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(2,622</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Basic and diluted net loss per share</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.28</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.34</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.34</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.02</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
   <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b/></span></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766297765000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DescriptionOfCompanyPolicyTextBlock', window );">Description of Company [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>The Company</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left; text-indent: 27pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">BioCryst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) is a commercial-stage biotechnology company that discovers novel, oral, small-molecule medicines. The Company focuses on the treatment of rare diseases in which significant unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. The Company was founded in <em style="font: inherit;">1986</em> and incorporated in Delaware in <em style="font: inherit;">1991,</em> and its headquarters is located in Durham, North Carolina. The Company integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. The Company has incurred losses and negative cash flows from operations since inception.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">Based on the Company&#8217;s expectations for revenue, operating expenses, and its option to access an additional $75 million from its existing credit facility, the Company believes its financial resources available at <em style="font: inherit;"> December 31, 2020 </em>will be sufficient to fund its operations into <em style="font: inherit;">2023.</em> The Company has sustained operating losses for the majority of its corporate history and expects that its <em style="font: inherit;">2021</em> expenses will exceed its <em style="font: inherit;">2021</em> revenues. The Company expects to continue to incur operating losses and negative cash flows until revenues reach a level sufficient to support ongoing operations. The Company&#8217;s liquidity needs will be largely determined by the success of operations in regard to the successful commercialization of its products and the progression of its product candidates in the future. The Company also <em style="font: inherit;"> may </em>consider other plans to fund future operations, including: (<em style="font: inherit;">1</em>) securing or increasing U.S. Government funding of its programs, including obtaining procurement contracts; (<em style="font: inherit;">2</em>) out-licensing rights to certain of its products or product candidates, pursuant to which the Company would receive cash milestones; (<em style="font: inherit;">3</em>) raising additional capital through equity or debt financings or from other sources, including royalty or other monetization transactions; (<em style="font: inherit;">4</em>) obtaining additional product candidate regulatory approvals, which would generate revenue, milestones and cash flow; (<em style="font: inherit;">5</em>) reducing spending on <em style="font: inherit;">one</em> or more research and development programs, including by discontinuing development; and/or (<em style="font: inherit;">6</em>) restructuring operations to change its overhead structure. The Company <em style="font: inherit;"> may </em>issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings in the future. The Company&#8217;s future liquidity needs, and ability to address those needs, will largely be determined by the success of its products and product candidates, timing, scope and magnitude of its commercial expenses and key development and regulatory events and its decisions in the future.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Basis of Presentation</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany transactions and balances among the consolidated entities have been eliminated from the consolidated financial statements.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 9pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company&#8217;s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;). Such consolidated financial statements reflect all adjustments that are, in management&#8217;s opinion, necessary to present fairly, in all material respects, the Company&#8217;s consolidated financial position, results of operations, and cash flows. There were <em style="font: inherit;">no</em> adjustments other than normal recurring adjustments.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Cash and Cash Equivalents</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 1pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company generally considers cash equivalents to be all cash held in commercial checking accounts, certificates of deposit, money market accounts or investments in debt instruments with maturities of <em style="font: inherit;">three</em> months or less at the time of purchase. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Restricted Cash</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Restricted cash as of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> reflects $796 and $134, respectively, in royalty revenue paid by Shionogi &amp; Co., Ltd. (&#8220;Shionogi&#8221;) designated for interest on the PhaRMA Notes (defined in Note <em style="font: inherit;">3</em>) and $1,425 and $1,417, respectively, the Company is required to maintain as collateral for a letter of credit associated with the lease execution and build-out of its new Birmingham research facilities.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Investments</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company invests in high credit quality investments in accordance with its investment policy, which is designed to minimize the possibility of loss. The objective of the Company&#8217;s investment policy is to ensure the safety and preservation of invested funds, as well as maintaining liquidity sufficient to meet cash flow requirements. The Company places its excess cash with high credit quality financial institutions, commercial companies, and government agencies in order to limit the amount of its credit exposure. In accordance with its policy, the Company is able to invest in marketable debt securities that <em style="font: inherit;"> may </em>consist of U.S. Government and government agency securities, money market and mutual fund investments, municipal and corporate notes and bonds, commercial paper and asset or mortgage-backed securities, among others. The Company&#8217;s investment policy requires it to purchase high-quality marketable securities with a maximum individual maturity of <span style="-sec-ix-hidden:c69828560">three</span> years and requires an average portfolio maturity of <em style="font: inherit;">no</em> more than 18 months. Some of the securities the Company invests in <em style="font: inherit;"> may </em>have market risk. This means that a change in prevailing interest rates <em style="font: inherit;"> may </em>cause the principal amount of the investment to fluctuate. To minimize this risk, the Company schedules its investments with maturities that coincide with expected cash flow needs, thus avoiding the need to redeem an investment prior to its maturity date. Accordingly, the Company does <em style="font: inherit;">not</em> believe it has a material exposure to interest rate risk arising from its investments. Generally, the Company&#8217;s investments are <em style="font: inherit;">not</em> collateralized. The Company has <em style="font: inherit;">not</em> realized any significant losses from its investments.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 7pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company classifies all of its investments as available-for-sale. Unrealized gains and losses on investments are recognized in comprehensive loss, unless an unrealized loss is considered to be other than temporary, in which case the unrealized loss is charged to operations. The Company periodically reviews its investments for other than temporary declines in fair value below cost basis and whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. The Company believes the individual unrealized losses represent temporary declines primarily resulting from interest rate changes. Realized gains and losses are reflected in interest and other income in the Consolidated Statements of Comprehensive Loss and are determined using the specific identification method with transactions recorded on a settlement date basis. Investments with original maturities at date of purchase beyond <em style="font: inherit;">three</em> months and which mature at or less than 12 months from the balance sheet date are classified as current. Investments with a maturity beyond 12 months from the balance sheet date are classified as long-term. At <em style="font: inherit;"> December 31, 2020, </em>the Company believes that the cost of its investments is recoverable in all material respects.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 14pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The following tables summarize the fair value of the Company&#8217;s investments by type. The estimated fair values of the Company&#8217;s fixed income investments are classified as Level <em style="font: inherit;">2</em> in the fair value hierarchy as defined in U.S. GAAP. These valuations are based on observable direct and indirect inputs, primarily quoted prices of similar, but <em style="font: inherit;">not</em> identical, instruments in active markets or quoted prices for identical or similar instruments in markets that are <em style="font: inherit;">not</em> active. These fair values are obtained from independent pricing services which utilize Level <em style="font: inherit;">2</em> inputs.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 14pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>December 31, 2020</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Amortized Cost</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Accrued Interest</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Gross Unrealized Gains</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Gross Unrealized Losses</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Estimated Fair Value</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Obligations of U.S. Government and its agencies</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">24,986</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">14</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">3</em></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">(3</em></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">25,000</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Certificates of deposit</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">3,225</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">11</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">3</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">3,239</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Total Investments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">28,211</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">25</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">(3</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">28,239</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="margin: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>December 31, 2019</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Amortized Cost</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Accrued Interest</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Gross Unrealized Gains</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Gross Unrealized Losses</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Estimated Fair Value</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Obligations of U.S. Government and its agencies</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">10,488</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">50</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">23</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">10,561</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Corporate debt securities</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">9,742</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">59</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">10</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(1</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">9,810</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Certificates of deposit</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,669</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">7</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">7</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,683</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Total Investments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">21,899</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">116</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">40</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(1</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">22,054</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 27pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company&#8217;s investments at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em> have maturities of <em style="font: inherit;">one</em> year or less.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivable [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Receivables from Collaborations</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 1pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Receivables from collaborations are recorded for amounts due to the Company related to reimbursable research and development costs from the U.S. Department of Health and Human Services, royalty receivables from Shionogi, Green Cross Corporation (&#8220;Green Cross&#8221;), Mundipharma International Holdings Limited (&#8220;Mundipharma&#8221;) and Seqirus UK Limited (&#8220;SUL&#8221;), and product sales to SUL. These receivables are evaluated to determine if any reserve or allowance should be established at each reporting date&#160;</span>based on historical collection experience or specific circumstances and no amounts were recorded at <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019</em><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 27pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">At <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em>the Company had the following receivables:</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b style="font-size: 10pt;">December 31, 20</b><b style="font-size: 10pt;">20</b><b style="font-size: 10pt;"> </b><b style="font-size: 10pt;"> </b><b style="font-size: 10pt;"> </b></b></span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Billed</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Unbilled</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Total</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">U.S. Department of Health and Human Services</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">5,402</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">5,402</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Shionogi &amp; Co. Ltd.</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2,037</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">4</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2,041</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Green Cross Corporation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">740</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">21</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">761</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Mundipharma International Holdings Limited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">39</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">39</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Total receivables</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2,816</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">5,427</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">8,243</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="11" rowspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b style="font-size: 10pt;">December 31, 2019</b></span></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Billed</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Unbilled</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Total</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">U.S. Department of Health and Human Services</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,353</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">15,023</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">16,376</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Shionogi &amp; Co. Ltd.</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,336</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">4</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,340</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Green Cross Corporation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2,924</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">8</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2,932</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Mundipharma International Holdings Limited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">56</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">-</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">56</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Seqirus UK Limited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,091</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">351</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,442</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Total receivables</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">6,760</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">15,386</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">22,146</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: justify; text-indent: 26.75pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 2pt 0pt 0pt; text-align: justify; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Monthly invoices are submitted to the U.S. Department of Health and Human Services related to reimbursable research and development costs. The Company is also entitled to monthly reimbursement of indirect costs based on rates stipulated in the underlying contract. The Company&#8217;s calculations of its indirect cost rates are subject to audit by the U.S. Government.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Receivables from Product Sales</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 3.05pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Receivables&#160;</span>from product sales are recorded for amounts due to the Company related to sales of RAPIVAB and ORLADEYO.&#160; At <em style="font: inherit;"> December 31, 2020, </em>receivables related to sales of RAPIVAB and ORLADEYO were $254 and $149, respectively.&#160; There were no receivables from product sales as of <em style="font: inherit;"> December 31, 2019. </em>Receivables from product sales are evaluated to determine if any reserve or allowance should be recorded based on consideration of the current economic environment, expectations of future economic conditions and the Company&#8217;s own historical collection experience. &#160;No reserve or allowance amounts were recorded at <em style="font: inherit;"> December 31, 2020</em><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Inventory</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">At <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> the Company&#8217;s inventory related to peramivir which is being manufactured for the Company&#8217;s partners and the U.S. Government.&#160; Inventory as of <em style="font: inherit;"> December 31, 2020, </em>consisted of raw materials of $206, work-in-process of $2,555 and finished goods of $4,548. As of <em style="font: inherit;"> December 31, 2019, </em>the Company inventory consisted of peramivir finished goods of $276.&#160; Inventory is stated at the lower of cost and net realizable value, determined under the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out (&#8220;FIFO&#8221;) method, or market. As of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;">2019,</em> the Company had inventory reserves of $270 and $276, respectively, for estimated unrecoverable capitalized inventory costs.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company expenses costs related to the production of inventories as research and development expenses in the period incurred until such time it is believed that future economic benefit is expected to be recognized, which generally is reliant upon receipt of regulatory approval. Upon regulatory approval, the Company capitalizes subsequent costs related to the production of inventories.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>&#160;</b></i></span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Property and Equipment</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Computer equipment is depreciated over a life of <span style="-sec-ix-hidden:c69828591">three</span> years. Laboratory equipment, office equipment, and software are depreciated over a life of <span style="-sec-ix-hidden:c69828592">five</span> years. Furniture and fixtures are depreciated over a life of <span style="-sec-ix-hidden:c69828593">seven</span> years. Leasehold improvements are amortized over their estimated useful lives or the expected lease term, whichever is less.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 6pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">In accordance with U.S. GAAP, the Company periodically reviews its property and equipment for impairment when events or changes in circumstances indicate that the carrying amount of such assets <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are <em style="font: inherit;">not</em> expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their estimated fair values. Property and equipment to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Patents and Licenses</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 12pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company seeks patent protection on all internally developed processes and products. All patent related costs are expensed to selling, general and administrative expenses when incurred as recoverability of such expenditures is uncertain.</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses [Policy Text Block]</a></td>
<td class="text"><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 0pt 0pt 11pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><i><b>Accrued Expenses</b></i></span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt 5pt 0pt 0pt; text-align: left; text-indent: 26.75pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">The Company generally enters into contractual agreements with <em style="font: inherit;">third</em>-party vendors who provide research and development, manufacturing,&#160;</span>distribution,&#160;<span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">and other services in the ordinary course of business. Some of these contracts are subject to milestone-based invoicing and services are completed over an extended period of time. The Company records liabilities under these contractual commitments when it determines an obligation has been incurred, regardless of the timing of the invoice. This process involves reviewing open contracts and purchase orders, communicating with applicable Company personnel to identify services that have been performed on its behalf and estimating the level of service performed and the associated cost incurred for the service when the Company has <em style="font: inherit;">not</em> yet been invoiced or otherwise notified of actual cost. The majority of service providers invoice the Company monthly in arrears for services performed. The Company makes estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances. The Company periodically confirms the accuracy of its estimates with the service providers and makes adjustments if necessary. Examples of estimated accrued expenses include:</span></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;">&#160;</p>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#9679;</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">fees paid to Clinical Research Organizations (&#8220;CROs&#8221;) in connection with preclinical and toxicology studies and clinical trials;</span></p> </td></tr>
</tbody></table>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#9679;</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">fees paid to investigative sites in connection with clinical trials;</span></p> </td></tr>
<tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#9679;</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">fees paid to contract manufacturers in connection with the production of the Company&#8217;s raw materials, drug substance, drug products, and product candidates; and</span></p> </td></tr>
</tbody></table>
    <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="width: 27pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#9679;</span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; margin-right: 0pt; margin-top: 0pt; text-align: left; margin-bottom: 0pt; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">professional fees.</span></p> </td></tr>
</tbody></table> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-17.15pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company bases its expenses related to clinical trials on its estimates of the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that conduct and manage clinical trials on the Company&#8217;s behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and <em style="font: inherit;"> may </em>result in uneven payment flows. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, the Company estimates the time period over which services will be performed and the level of effort expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. As of <em style="font: inherit;"> December 31, 2020 </em>and <em style="font: inherit;"> December 31, 2019, </em>the carrying value of accrued expenses approximates their fair value due to their short-term settlement.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Accrued expenses were comprised of the following:</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><b><b>December 31,</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Compensation and benefits</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,030</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,190</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Development costs</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">15,150</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">11,302</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Inventory</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,453</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">29</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Professional fees</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">333</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">326</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Duties and taxes</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">80</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">67</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Other</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">4,896</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">3,451</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Total accrued expenses</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">33,942</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">21,365</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Income Taxes</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:15pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The liability method is used in the Company&#8217;s accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Accumulated Other Comprehensive Loss</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:7pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Accumulated other comprehensive loss is comprised of unrealized gains and losses on available-for-sale investments and is disclosed as a separate component of stockholders&#8217; equity. Amounts reclassified from accumulated other comprehensive loss are recorded as interest and other income on the Consolidated Statements of Comprehensive Loss. For the year ended <em style="font: inherit;"> December 31, 2020, </em>realized gains of $1 were reclassified out of accumulated other comprehensive loss. No reclassifications out of accumulated other comprehensive loss were recorded in <em style="font: inherit;">2019.</em></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Revenue Recognition</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:14pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Collaborative and Other Research and Development Arrangements and Royalties</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company recognizes revenue when it satisfies a performance obligation by transferring promised goods or services to a customer. Revenue is measured at the transaction price that is based on the amount of consideration that the Company expects to receive in exchange for transferring the promised goods or services to the customer. The transaction price includes estimates of variable consideration to the extent it is probable that a significant reversal of revenue recognized will <em style="font: inherit;">not</em> occur.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
      <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">The Company has collaboration and license agreements with a number of <em style="font: inherit;">third</em> parties as well as research and development agreements with certain government entities. The Company&#8217;s primary sources of revenue are license, service, royalty and product sale revenues from these collaborative and other research and development arrangements.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">Revenue from license fees, royalty payments, milestone payments, and research and development fees are recognized as revenue when the earnings process is complete and the Company has <em style="font: inherit;">no</em> further continuing performance obligations or the Company has completed the performance obligations under the terms of the agreement.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Arrangements that involve the delivery of more than <em style="font: inherit;">one</em> performance obligation are initially evaluated as to whether the intellectual property licenses granted by the Company represent distinct performance obligations. If they are determined to be distinct, the value of the intellectual property licenses would be recognized up-front while the research and development service fees would be recognized as the performance obligations are satisfied. For performance obligations based on services performed, the Company measures progress using an input method based on the effort we expend or costs we incur toward the satisfaction of performance obligation in relation to the total estimated effort of costs. Variable consideration is assessed at each reporting period as to whether it is <em style="font: inherit;">not</em> subject to significant future reversal and, therefore, should be included in the transaction price at the inception of the contract. If a contract includes a fixed or minimum amount of research and development support, this also would be included in the transaction price. Changes to collaborations, such as the extensions of the research term or increasing the number of targets or technology covered under an existing agreement, are assessed for whether they represent a modification or should be accounted for as a new contract. For contracts with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is <em style="font: inherit;">not</em> directly observable, then the Company estimates the standalone selling price using either an adjusted market assessment approach or an expected cost plus margin approach, representing the amount that the Company believes the market is willing to pay for the product or service. Analyzing the arrangement to identify performance obligations requires the use of judgment, and each <em style="font: inherit;"> may </em>be an obligation to deliver services, a right or license to use an asset, or another performance obligation.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:12pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Milestone payments are recognized as licensing revenue upon the achievement of specified milestones if (i) the milestone is substantive in nature and the achievement of the milestone was <em style="font: inherit;">not</em> probable at the inception of the agreement; and (ii) the Company has a right to payment. Any milestone payments received prior to satisfying these revenue recognition criteria are recorded as deferred revenue.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Reimbursements received for direct out-of-pocket expenses related to research and development costs are recorded as revenue in the Consolidated Statements of Comprehensive Loss rather than as a reduction in expenses. Under the Company&#8217;s contracts with the Biomedical Advanced Research and Development Authority within the United States Department of Health and Human Services (&#8221;BARDA/HHS&#8221;) and the National Institute of Allergy and Infectious Diseases (&#8220;NIAID/HHS&#8221;), revenue is recognized as reimbursable direct and indirect costs are incurred.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Under certain of the Company&#8217;s license agreements, the Company receives royalty payments based upon its licensees&#8217; net sales of covered products. Royalties are recognized at the later of when (i) the subsequent sale or usage occurs, or (ii) the performance obligation to which some or all of the sales-based or usage-based royalty has been satisfied.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:14pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Product Sales</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:justify;text-indent:26.75pt;"><span style="color:#000000;">The Company&#8217;s principal sources of product sales are sales of peramivir to our licensing partners and sales of RAPIVAB to the U.S. Department of Health and Human Services under the Company&#8217;s procurement contract. In <em style="font: inherit;"> December 2020, </em>the Company launched ORLADEYO and began recording product revenue. The Company recognizes revenue for sales when the customer obtains control of the product, which generally occurs upon delivery.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">The Company recorded the following revenues for the years ended <em style="font: inherit;"> December 31:</em></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><span style="color:#000000;">2020</span></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><span style="color:#000000;">2019</span></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><span style="color:#000000;">2018</span></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Product sales, net</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,301</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">17,533</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Royalty revenue</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,381</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,303</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,101</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Collaborative and other research and development revenues:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"><span style="color:#000000;">U.S. Department of Health and Human Services</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">9,231</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,898</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,552</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"><span style="color:#000000;">Torii Pharmaceutical Co., Ltd.</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,899</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">20,101</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"><span style="color:#000000;">Seqirus UK Limited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">12,000</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Total collaborative and other research and development revenues</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">11,130</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">24,999</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">14,552</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Total revenues</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">17,812</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">48,835</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">20,653</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;">&#160;</p>
      <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Advertising</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:8pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company engages in very limited distribution and direct-response advertising when promoting RAPIVAB. Advertising and promotional costs are expensed in &#8220;Selling, general and administrative&#8221; as the costs are incurred. Advertising expenses related to the launch of ORLADEYO were $6,567 for year ended <em style="font: inherit;"> December 31, 2020. </em>The Company did <span style="-sec-ix-hidden:c69828614"><span style="-sec-ix-hidden:c69828615">not</span></span> incur advertising and product promotion expenses in <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018.</em></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Research and Development Expenses</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company&#8217;s research and development costs are charged to expense when incurred. Research and development expenses include all direct and indirect development costs related to the development of the Company&#8217;s portfolio of product candidates. Advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as expense when the related goods are delivered or the related services are performed. Research and development expenses include, among other items, personnel costs, including salaries and benefits, manufacturing costs, clinical, regulatory, and toxicology services performed by CROs, materials and supplies, and overhead allocations consisting of various administrative and facilities related costs. Most of the Company&#8217;s manufacturing and clinical and preclinical studies are performed by <em style="font: inherit;">third</em>-party CROs. Costs for studies performed by CROs are accrued by the Company over the service periods specified in the contracts and estimates are adjusted, if required, based upon the Company&#8217;s on-going review of the level of services actually performed.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:14pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Additionally, the Company has license agreements with <em style="font: inherit;">third</em> parties, such as Albert Einstein College of Medicine of Yeshiva University (&#8220;AECOM&#8221;), Industrial Research, Ltd. (&#8220;IRL&#8221;), and the University of Alabama at Birmingham (&#8220;UAB&#8221;), which require fees related to sublicense agreements or maintenance fees. The Company expenses sublicense payments as incurred unless they are related to revenues that have been deferred, in which case the expenses are deferred and recognized over the related revenue recognition period. The Company expenses maintenance payments as incurred.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Deferred collaboration expenses represent sub-license payments, paid to the Company&#8217;s academic partners upon receipt of consideration from various commercial partners, and other consideration paid to the Company&#8217;s academic partners for modification to existing license agreements. These deferred expenses would <em style="font: inherit;">not</em> have been incurred without receipt of such payments or modifications from the Company&#8217;s commercial partners and are being expensed in proportion to the related revenue being recognized. The Company believes that this accounting treatment appropriately matches expenses with the associated revenue.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Stock-Based Compensation</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">All share-based payments, including grants of stock option awards and restricted stock unit awards, are recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss based on their fair values. The fair value of stock option awards is estimated using the Black-Scholes option pricing model. The fair value of restricted stock unit awards is based on the grant date closing price of the common stock. Stock-based compensation cost is recognized as expense on a straight-line basis over the requisite service period of the award. In addition, we have outstanding performance-based stock options for which <em style="font: inherit;">no</em> compensation expense is recognized until &#8220;performance&#8221; is deemed to have occurred.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock', window );">Interest Expense and Royalty Financing Obligation [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Interest Expense and Royalty </b></i><i><b>Financing Obligation</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:5pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The royalty financing obligation is eligible to be repaid based on royalties from net sales of ORLADEYO. Interest expense is accrued using the effective interest rate method over the estimated period the related liability will be paid. This requires the Company to estimate the total amount of future royalty payments to be generated from product sales over the life of the agreement. The Company imputes interest on the carrying value of the royalty financing obligation and records interest expense using an imputed effective interest rate. The Company will reassess the expected royalty payments each reporting period and account for any changes through an adjustment to the effective interest rate on a prospective basis. The assumptions used in determining the expected repayment term of the debt and amortization period of the issuance costs requires that the Company make estimates that could impact the carrying value of the liability, as well as the period over which associated issuance costs will be amortized. A significant increase or decrease in forecasted net sales could materially impact the liability balance, interest expense and the time period for repayment.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock', window );">Interest Expense and Deferred Financing Costs [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Interest Expense and Deferred Financing Costs</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Interest expense for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> was $14,501 $11,892 and $9,176, respectively, and primarily relates to the issuance of the PhaRMA Notes (defined in Note <em style="font: inherit;">3</em>) and the Prior Credit Facility and Amended and Restated Senior Credit Facility (each defined in Note <em style="font: inherit;">4</em>). Costs directly associated with the issuance of the PhaRMA Notes, the Prior Credit Facility and the Amended and Restated Senior Credit Facility have been capitalized and are netted against the non-recourse notes payable and senior credit facility on the Consolidated Balance Sheets. These costs are being amortized to interest expense over the terms of the PhaRMA Notes and the Amended and Restated Senior Credit Facility (as subsequently amended and restated) using the effective interest rate method. In <em style="font: inherit;"> December 2020, </em>the Company incurred costs directly associated with its royalty monetization (defined in Note <em style="font: inherit;">3</em>) and borrowings under the Credit Agreement (defined in Note <em style="font: inherit;">4</em>). These costs have been deferred and are being amortized to interest expense over the terms of the respective arrangements. Amortization of deferred financing costs and original issue discount included in interest expense was $1,217, $1,278 and $885 for each of the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively. In <em style="font: inherit;"> December 2020, </em>the outstanding principal balance of the Senior Credit Facility was repaid and related unamortized deferred financing costs and original issue discount of $1,211 were fully expensed as part of loss on debt extinguishment.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock', window );">Currency Hedge Agreement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Currency Hedge Agreement</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 4pt 0pt 0pt; text-align: left; text-indent: 26.75pt;">In connection with the issuance by Royalty Sub of the PhaRMA Notes, the Company entered into a Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar. The final tranche of the options under the Currency Hedge Agreement expired in <em style="font: inherit;"> November </em>of <em style="font: inherit;">2020.</em>&#160; The Currency Hedge Agreement did <em style="font: inherit;">not</em> qualify for hedge accounting treatment; therefore mark-to-market adjustments were recognized in the Company&#8217;s Consolidated Statements of Comprehensive Loss. Cumulative mark-to-market adjustments for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019</em> and <em style="font: inherit;">2018</em> resulted in losses of $632, $347 and $1,049, respectively. Mark-to-market adjustments were determined by a <em style="font: inherit;">third</em>-party pricing model which uses quoted prices in markets that are <em style="font: inherit;">not</em> actively traded and for which significant inputs are observable directly or indirectly, representing Level <em style="font: inherit;">2</em> in the fair value hierarchy as defined by U.S. GAAP. In addition, realized currency exchange gains of $662, $863 and $941 were recognized in <em style="font: inherit;">2020,</em> <em style="font: inherit;">2019</em> and <em style="font: inherit;">2018,</em> respectively, related to the exercise of a U.S. dollar/Japanese yen currency option under the Company&#8217;s foreign currency hedge.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Net Loss Per Share</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Net loss per share is based upon the weighted average number of common shares outstanding during the period. Diluted loss per share is equivalent to basic net loss per share for all periods presented herein because common equivalent shares from unexercised stock options, outstanding warrants, and common shares expected to be issued under the Company&#8217;s employee stock purchase plan were anti-dilutive. The calculation of diluted earnings per share for the years ended <em style="font: inherit;"> December 31, 2020, </em><em style="font: inherit;">2019,</em> and <em style="font: inherit;">2018</em> does <em style="font: inherit;">not</em> include 14,957, 2,805, and 2,274, respectively, of potential common shares as their impact would be anti-dilutive.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:11pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Use of Estimates</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. The most significant estimates in the Company&#8217;s consolidated financial statements relate to the valuation of stock options,&#160;</span>the royalty financing&#160;<span style="color:#000000;">and the valuation allowance for deferred tax assets resulting from net operating losses. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock', window );">Concentration of Market Risk [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Significant Customers and Other Risks</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:23pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Significant Customers</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:6pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Other than royalty revenues, the Company&#8217;s primary sources of revenue that have an underlying cash flow stream are the reimbursement of galidesivir (formerly <em style="font: inherit;">BCX4430</em>) development expenses earned under cost-plus-fixed-fee contracts with BARDA/HHS and NIAID/HHS and sales of RAPIVAB (peramivir injection) under our procurement contract with the Assistant Secretary for Preparedness and Response within the United States Department of Health and Human Services. The Company relies on BARDA/HHS and NIAID/HHS to reimburse predominantly all of the development costs for its galidesivir program. Accordingly, reimbursement of these expenses represents a significant portion of the Company&#8217;s collaborative and other research and development revenues. The completion or termination of the NIAID/HHS and BARDA/HHS galidesivir contracts could negatively impact the Company&#8217;s future Consolidated Statements of Comprehensive Loss and Cash Flows. The Company recognizes royalty revenue from the net sales of RAPIACTA by Shionogi; however, the underlying cash flow from these royalty payments, except for Japanese government stockpiling sales, goes directly to pay the interest, and then the principal, on the Company&#8217;s non-recourse notes payable. Payment of the interest and the ultimate repayment of principal of these notes will be entirely funded by future royalty payments derived from net sales of RAPIACTA. Further, the Company&#8217;s drug development activities are performed by a limited group of <em style="font: inherit;">third</em>-party vendors. If any of these vendors were unable to perform their services, this could significantly impact the Company&#8217;s ability to complete its drug development activities.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:23pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Risks from Third Party Manufacturing and Distribution Concentration</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:3.05pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">The Company relies on single source manufacturers for active pharmaceutical ingredient and finished drug product manufacturing of product candidates in development and on single source distributors for distribution of approved drug products. Delays in the manufacture or distribution of any product could adversely impact the commercial revenue and future procurement stockpiling of the Company&#8217;s product candidates in development.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p>
      <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:23pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i>Credit Risk</i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">Cash equivalents and investments are financial instruments which potentially subject the Company to concentration of risk to the extent recorded on the Consolidated Balance Sheets. The Company deposits excess cash with major financial institutions in the United States. Balances <em style="font: inherit;"> may </em>exceed the amount of insurance provided on such deposits. The Company believes it has established guidelines for investment of its excess cash relative to diversification and maturities that maintain safety and liquidity. To minimize the exposure due to adverse shifts in interest rates, the Company maintains a portfolio of investments with an average maturity of approximately 18 months or less. Other than product sale and collaborative partner receivables discussed above, the majority of the Company&#8217;s receivables from collaborations are due from the U.S. Government, for which there is <em style="font: inherit;">no</em> assumed credit risk.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:13pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;"><i><b>Recent Accounting Pronouncements</b></i></span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:9pt;margin-top:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In <em style="font: inherit;"> June 2016, </em>the FASB issued Accounting Standards Update <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of</i> <i>Credit Losses on Financial Instruments </i>(&#8220;ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13&#8221;</em>)<i>.</i><i> </i>ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires a financial asset (or a group of financial assets) measured at amortized<i> </i>cost basis to be presented at the net amount expected to be collected. In addition, ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires credit losses relating to available-for-sale debt securities to be recorded through an allowance for credit losses. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is effective for public companies for interim and annual periods beginning after <em style="font: inherit;"> December 15, 2019. </em>The Company adopted ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em> as of <em style="font: inherit;"> January 1, 2020. </em>Given the nature of the Company&#8217;s receivables from collaborators, investment portfolio and other financial assets, adoption of this standard did <em style="font: inherit;">not</em> have a material effect on the Company's financial position, results of operations or cash flows.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&#160;</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;"><span style="color:#000000;">In <em style="font: inherit;"> August 2018, </em>the FASB issued Accounting Standards Update <em style="font: inherit;">No.</em> <em style="font: inherit;">2018</em>-<em style="font: inherit;">15,</em> <i>Intangibles - Goodwill and Other - Internal-Use Software (Subtopic</i> <i><em style="font: inherit;">350</em>-<em style="font: inherit;">40</em>) </i>(&#8220;ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15&#8221;</em>). ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15</em> aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service<i> </i>contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance requires entities to capitalize costs for certain implementation activities in the application development stage and expense the capitalized implementation costs over the expected term of the hosting arrangement. ASU <em style="font: inherit;">2018</em>-<em style="font: inherit;">15</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2019, </em>with early adoption permitted. The Company elected to adopt this standard early, beginning <em style="font: inherit;"> October 1, 2019 </em>on a prospective basis. Adoption did <em style="font: inherit;">not</em> have a material effect on the Company's financial position, results of operations or cash flows.</span></p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 26.75pt;">The Company has reviewed other new accounting pronouncements that were issued as of <em style="font: inherit;"> December 31, 2020 </em>and does <em style="font: inherit;">not</em> believe that these pronouncements are either applicable to the Company, or that they will have a material impact on its financial position or results of operations.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:26.75pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued expenses policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ConcentrationOfMarketRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents concentration of market risk policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ConcentrationOfMarketRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CurrencyHedgeAgreementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents currency hedge agreement policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CurrencyHedgeAgreementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DescriptionOfCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of company policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DescriptionOfCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest expense and deferred financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for interest expense and royalty financing obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766297826040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Debt Securities, Available-for-sale [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>December 31, 2020</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Amortized Cost</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Accrued Interest</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Gross Unrealized Gains</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Gross Unrealized Losses</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Estimated Fair Value</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Obligations of U.S. Government and its agencies</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">24,986</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">14</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">3</em></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">(3</em></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">25,000</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Certificates of deposit</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">3,225</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">11</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">3</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">3,239</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Total Investments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">28,211</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">25</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">(3</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">28,239</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>December 31, 2019</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Amortized Cost</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Accrued Interest</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Gross Unrealized Gains</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Gross Unrealized Losses</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Estimated Fair Value</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Obligations of U.S. Government and its agencies</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">10,488</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">50</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">23</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">10,561</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Corporate debt securities</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">9,742</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">59</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">10</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(1</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">9,810</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Certificates of deposit</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,669</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">7</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">7</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,683</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Total Investments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">21,899</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">116</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">40</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(1</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">22,054</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock', window );">Schedule of Receivables from Collaborations [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b style="font-size: 10pt;">December 31, 20</b><b style="font-size: 10pt;">20</b><b style="font-size: 10pt;"> </b><b style="font-size: 10pt;"> </b><b style="font-size: 10pt;"> </b></b></span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Billed</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Unbilled</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 0pt; margin: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b><b>Total</b></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">U.S. Department of Health and Human Services</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">5,402</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">5,402</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Shionogi &amp; Co. Ltd.</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2,037</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">4</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2,041</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Green Cross Corporation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">740</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">21</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">761</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Mundipharma International Holdings Limited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">39</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">39</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Total receivables</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2,816</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">5,427</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">8,243</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="11" rowspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b style="font-size: 10pt;">December 31, 2019</b></span></td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Billed</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Unbilled</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-indent: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><b>Total</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">U.S. Department of Health and Human Services</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,353</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">15,023</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">16,376</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Shionogi &amp; Co. Ltd.</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,336</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">4</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,340</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Green Cross Corporation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2,924</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">8</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">2,932</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Mundipharma International Holdings Limited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">56</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">-</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">56</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Seqirus UK Limited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,091</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">351</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">1,442</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0pt; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Total receivables</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">6,760</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">15,386</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;; font-size: 10pt;">22,146</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><b><b>December 31,</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Compensation and benefits</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,030</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,190</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Development costs</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">15,150</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">11,302</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Inventory</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,453</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">29</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Professional fees</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">333</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">326</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Duties and taxes</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">80</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">67</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Other</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">4,896</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">3,451</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Total accrued expenses</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">33,942</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">21,365</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><span style="color:#000000;">2020</span></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><span style="color:#000000;">2019</span></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b><span style="color:#000000;">2018</span></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Product sales, net</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,301</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">17,533</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Royalty revenue</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,381</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,303</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,101</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Collaborative and other research and development revenues:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"><span style="color:#000000;">U.S. Department of Health and Human Services</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">9,231</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,898</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,552</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"><span style="color:#000000;">Torii Pharmaceutical Co., Ltd.</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,899</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">20,101</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;"><span style="color:#000000;">Seqirus UK Limited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">12,000</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Total collaborative and other research and development revenues</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">11,130</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">24,999</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">14,552</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Total revenues</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">17,812</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">48,835</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">20,653</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure representing receivables from collaborations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766297815160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Furniture and fixtures</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">722</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">602</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Office equipment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">211</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">184</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Software</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,159</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,159</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Laboratory equipment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,774</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,462</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Leasehold improvements</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="color:#000000;">8,583</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid black;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;"><span style="color:#000000;">8,528</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid black;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">14,449</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">13,935</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Less accumulated depreciation and amortization</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(7,336</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(6,588</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Property and equipment, net</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">7,113</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">7,347</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766382326616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Lease Obligations and Other Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LesseeLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 85%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Remaining Maturities of Lease Liabilities</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom;"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>Year Ending December 31,</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0.5pt 0pt 0pt; text-align: center;"><span style="color:#000000;"><b><b>Operating Leases</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">2021</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,302</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">2022</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">758</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">2023</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">619</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">2024</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">577</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">2025</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">582</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Thereafter</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">7,327</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 12pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Total lease payments</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">11,165</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Less imputed interest</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">6,115</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 12pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:12pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Total</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">5,050</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LesseeLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of both operating and finance lease liabilities. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating and finance lease liabilities recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LesseeLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766293525352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="10" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0); text-align: center;"><span style="color:#000000;"><b><b>Year Ended December 31,</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>8</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Research and development</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">10,222</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">13,977</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,867</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Selling, general and administrative</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">4,572</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">3,742</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">2,529</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Total stock-based compensation expense</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">14,794</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">17,719</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">9,396</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Share-based Payment Arrangement, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Weighted</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Average</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Awards</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Options</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Exercise</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Available</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Outstanding</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Price</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2017</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">468</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">14,452</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6.06</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Plan amendment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,400</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Restricted stock awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(13</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(4,272</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,272</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">7.15</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards exercised</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(1,011</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2.92</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards cancelled</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">222</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(222</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">7.44</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2018</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">805</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">17,491</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6.49</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Plan amendment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,000</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Restricted stock awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(27</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(4,511</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,511</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3.91</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards exercised</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(251</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3.75</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards cancelled</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">701</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(701</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6.82</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2019</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">968</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">21,050</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">5.96</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Plan amendment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">8,000</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Restricted stock awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(31</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(7,469</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">7,469</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">8.06</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards exercised</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(510</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">3.56</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards cancelled</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">3,124</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(3,124</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6.93</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2020</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">4,592</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">24,885</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6.52</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Weighted</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Average</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Awards</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Options</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Exercise</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Available</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Outstanding</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b><em style="font: inherit;">Price</em></b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2019</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">171</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,329</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3.60</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Plan amendment</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,900</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(3,002</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,002</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.02</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock option awards cancelled</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">160</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(160</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.15</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Balance at December 31, 2020</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">229</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">4,171</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3.88</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; padding-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>8</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 55%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Expected Life</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">5.5</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">5.5</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">5.5</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Expected Volatility</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">84</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">81</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">82</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Expected Dividend Yield</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">0.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">0.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">0.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Risk-Free Interest Rate</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">0.4</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1.8</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2.7</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">%</span></td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td colspan="9" rowspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: center; border-bottom: thin solid rgb(0, 0, 0);"><span style="color:#000000;"><b style="font-size: 10pt;">Outstanding</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Exercisable</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Weighted</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Weighted</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Weighted</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Average</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Average</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Average</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Remaining</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Exercise</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Exercise</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Range</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Number</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;"><b><b>Life</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Price</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Number</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Price</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>$</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>0</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>3</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,514</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6.1</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2.19</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,414</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1.25</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>3</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>6</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">12,689</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">7.0</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.22</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,854</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2.48</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>6</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>9</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">10,852</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">9.2</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">7.88</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,005</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.89</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>9</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>12</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,347</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.5</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">10.85</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,129</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.51</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>12</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>15</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">559</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.1</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">12.30</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">539</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6.43</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>15</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>18</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">95</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.5</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">15.39</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">95</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">10.57</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><b>$</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>0</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 5pt; text-align: center;"><span style="color:#000000;"><b><em style="font: inherit;">to</em></b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"><span style="color:#000000;"><b>18</b></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">29,056</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">7.5</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6.14</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">13,036</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3.27</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt; background-color: rgba(0, 0, 0, 0); color: rgb(0, 0, 0);"><span style="color:#000000;"><b><b>Non-Vested Stock Option Awards</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><span style="color:#000000;"><b><b>Weighted Average Grant-Date Fair Value</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Balance December 31, 2019</span></p> </td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">11,688</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3.77</span></td><td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Stock option awards granted</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">10,471</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.69</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Stock option awards vested</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(4,543</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4.12</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Stock option awards forfeited</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(1,596</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">3.96</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Balance December 31, 2020</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">16,020</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">4.25</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766386083768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>2020</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Domestic</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(176,613</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Foreign</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(6,201</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Loss before provision for income taxes</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">(182,814</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>8</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 55%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Income tax benefit at federal statutory rate (<span style="-sec-ix-hidden:c69831164"><span style="-sec-ix-hidden:c69831165"><span style="-sec-ix-hidden:c69831166">21%</span></span></span> for 2020, 2019 and 2018)</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(38,391</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(22,868</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(21,263</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">State and local income taxes net of federal tax benefit</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(2,544</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(1,591</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(2,547</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Permanent items</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">774</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">691</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">503</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Rate change</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(82</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">625</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(29</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Expiration of attribute carryforwards</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,774</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">3,976</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,183</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Research and development tax credits</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830313">(4,080</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830314">(4,938</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830315">(4,905</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Foreign rate differential</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">542</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">-</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">-</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Other</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830319">1,456</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830320">281</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830321">18</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Change in valuation allowance</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">38,551</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">23,824</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">26,040</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Income tax expense</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color: #000000; "><span style="-sec-ix-hidden:c69830325">-</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830326">-</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><span style="-sec-ix-hidden:c69830327">-</span></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Balance at January 1,</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">7,210</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">5,976</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Additions to current period tax positions</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,020</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,234</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Additions to prior period tax positions</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Reductions to prior period tax provisions</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><span style="color:#000000;">Balance at December 31,</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">8,230</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">7,210</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>20</b><b>20</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>201</b><b>9</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Deferred tax assets:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Net federal and state operating losses</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">159,939</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">155,190</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Research and development credits</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">66,331</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">63,275</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Royalty income</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">28,034</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">-</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Stock-based compensation</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">10,732</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">9,786</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Leasing obligations</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,135</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,070</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Other</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">5,563</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">3,801</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Total deferred tax assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">271,734</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">233,122</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Deferred tax liabilities:</span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 9pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:9pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Fixed assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(124</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(114</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Right of use asset</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(854</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(803</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Total deferred tax liabilities</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(978</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(917</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Valuation allowance</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(270,756</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">(232,205</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><span style="color:#000000;">)</span></td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;">Net deferred tax assets</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;">$</span></td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><span style="color:#000000;"><em style="font: inherit;">&#8722;</em></span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766374748392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Quarterly Financial Information (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly Financial Information [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>First</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Second</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Third</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center; text-indent: 0pt;"><span style="color:#000000;"><b><b>Fourth</b></b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; width: 52%;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>20</b><b>20</b><b> Quarters</b></span></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Revenues</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,823</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">2,871</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">6,102</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">4,016</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Net Loss</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(37,599</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(38,607</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(46,115</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(60,493</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Basic and diluted net loss per share</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.24</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.24</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.26</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.34</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><span style="color:#000000;"><b>2019 Quarters</b></span></p> </td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td><td style="border-bottom: 1px rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><span style="color:#000000;"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Revenues</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">5,887</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,448</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">1,775</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">$</span></td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">39,725</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Net Loss</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(31,054</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(37,629</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(37,592</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(2,622</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10pt;"> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:10pt;margin-right:0pt;margin-top:0pt;text-align:left;"><span style="color:#000000;">Basic and diluted net loss per share</span></p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.28</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.34</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.34</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">(0.02</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><span style="color:#000000;">)</span></td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766303749992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current, Total</a></td>
<td class="nump">$ 2,221,000<span></span>
</td>
<td class="nump">$ 2,221,000<span></span>
</td>
<td class="nump">$ 1,551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Inventory, Raw Materials, Gross, Total</a></td>
<td class="nump">206,000<span></span>
</td>
<td class="nump">206,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Inventory, Work in Process, Gross</a></td>
<td class="nump">2,555,000<span></span>
</td>
<td class="nump">2,555,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Inventory, Finished Goods, Gross, Total</a></td>
<td class="nump">4,548,000<span></span>
</td>
<td class="nump">4,548,000<span></span>
</td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Inventory Valuation Reserves, Ending Balance</a></td>
<td class="nump">270,000<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="nump">276,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax', window );">Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,567<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,501,000<span></span>
</td>
<td class="nump">11,892,000<span></span>
</td>
<td class="nump">9,176,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts', window );">Amortization of Debt Financing Costs and Original Issue Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,217,000<span></span>
</td>
<td class="nump">$ 1,278,000<span></span>
</td>
<td class="nump">$ 885,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,957<span></span>
</td>
<td class="nump">2,805<span></span>
</td>
<td class="nump">2,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 632,000<span></span>
</td>
<td class="nump">$ 347,000<span></span>
</td>
<td class="nump">$ 1,049,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 662,000<span></span>
</td>
<td class="nump">863,000<span></span>
</td>
<td class="nump">$ 941,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember', window );">Laboratory Equipment, Office Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember', window );">Collaboration Receivables [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts Receivable, Allowance for Credit Loss, Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember', window );">Trade Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Accounts Receivable, Allowance for Credit Loss, Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember', window );">Trade Accounts Receivable [Member] | RAPIVAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss, Total</a></td>
<td class="nump">254,000<span></span>
</td>
<td class="nump">254,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember', window );">Trade Accounts Receivable [Member] | ORLADEYO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts Receivable, after Allowance for Credit Loss, Total</a></td>
<td class="nump">149,000<span></span>
</td>
<td class="nump">$ 149,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities', window );">Maturity Period of High Quality Marketable Securities (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities', window );">Average Maturity Period of High Quality Marketable Securities (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaturityperiodOfShortTermInvestment', window );">Maturity Period of Short Term Investment (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AverageMaturityForPortfolioInvestments', window );">Average Maturity for Portfolio Investments (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_LongtermInvestmentMaturityMinimum', window );">Long-term Investment Maturity, Minimum (Month)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember', window );">Royalty Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current, Total</a></td>
<td class="nump">796,000<span></span>
</td>
<td class="nump">$ 796,000<span></span>
</td>
<td class="nump">134,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember', window );">Collateral for Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted Cash and Cash Equivalents, Current, Total</a></td>
<td class="nump">1,425,000<span></span>
</td>
<td class="nump">1,425,000<span></span>
</td>
<td class="nump">$ 1,417,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember', window );">Senior Credit Facility [Member] | MidCap Financial Services, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of Credit Facility, Remaining Borrowing Capacity</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write off of Deferred Debt Issuance Cost</a></td>
<td class="nump">$ 1,211,000<span></span>
</td>
<td class="nump">$ 1,211,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization of debt financing costs and original issue discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AverageMaturityForPortfolioInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity for portfolio investments during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AverageMaturityForPortfolioInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_LongtermInvestmentMaturityMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents long term investment maturity minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_LongtermInvestmentMaturityMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityPeriodOfHighQualityMarketablesecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maturity period of high quality marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityPeriodOfHighQualityMarketablesecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaturityperiodOfShortTermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maturity period of short term investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaturityperiodOfShortTermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724394-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bcrx_CollaborationReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_RAPIVABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_RAPIVABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_ORLADEYOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_ORLADEYOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_RoyaltyReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=bcrx_CollateralForCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766303380312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk - Fair Value of the Company's Investments by Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 28,211<span></span>
</td>
<td class="nump">$ 21,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">28,239<span></span>
</td>
<td class="nump">22,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">24,986<span></span>
</td>
<td class="nump">10,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">10,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">3,225<span></span>
</td>
<td class="nump">1,669<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">3,239<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest', window );">Accrued Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AvailableForSaleDebtSecuritiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued interest in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AvailableForSaleDebtSecuritiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766302438376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk - Summary of Receivables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 8,243<span></span>
</td>
<td class="nump">$ 22,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember', window );">Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">2,816<span></span>
</td>
<td class="nump">6,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember', window );">Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">5,427<span></span>
</td>
<td class="nump">15,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">5,402<span></span>
</td>
<td class="nump">16,376<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">5,402<span></span>
</td>
<td class="nump">15,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">2,041<span></span>
</td>
<td class="nump">1,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">2,037<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember', window );">Shionogi and Co. Ltd [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">2,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">740<span></span>
</td>
<td class="nump">2,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_MundipharmaInternationalHoldingsLimitedMember', window );">Mundipharma International Holdings Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_MundipharmaInternationalHoldingsLimitedMember', window );">Mundipharma International Holdings Limited [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member] | Billed Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember', window );">Seqirus UK Limited [Member] | Unbilled Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_BilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis=us-gaap_UnbilledRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_ShionogiAndCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_MundipharmaInternationalHoldingsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_MundipharmaInternationalHoldingsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis=bcrx_SeqirusUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766295504280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and benefits</a></td>
<td class="nump">$ 11,030<span></span>
</td>
<td class="nump">$ 6,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccruedDevelopmentCosts', window );">Development costs</a></td>
<td class="nump">15,150<span></span>
</td>
<td class="nump">11,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AccruedInventoryExpense', window );">Inventory</a></td>
<td class="nump">2,453<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">333<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Duties and taxes</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">4,896<span></span>
</td>
<td class="nump">3,451<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 33,942<span></span>
</td>
<td class="nump">$ 21,365<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents accrued development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AccruedInventoryExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued inventory expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AccruedInventoryExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766302860264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Significant Accounting Policies and Concentrations of Risk - Summary of Revenues (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 4,016,000<span></span>
</td>
<td class="nump">$ 6,102,000<span></span>
</td>
<td class="nump">$ 2,871,000<span></span>
</td>
<td class="nump">$ 4,823,000<span></span>
</td>
<td class="nump">$ 39,725,000<span></span>
</td>
<td class="nump">$ 1,775,000<span></span>
</td>
<td class="nump">$ 1,448,000<span></span>
</td>
<td class="nump">$ 5,887,000<span></span>
</td>
<td class="nump">$ 17,812,000<span></span>
</td>
<td class="nump">$ 48,835,000<span></span>
</td>
<td class="nump">$ 20,653,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301,000<span></span>
</td>
<td class="nump">17,533,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,381,000<span></span>
</td>
<td class="nump">6,303,000<span></span>
</td>
<td class="nump">6,101,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember', window );">Collaborative and Other Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,130,000<span></span>
</td>
<td class="nump">24,999,000<span></span>
</td>
<td class="nump">14,552,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember', window );">Collaborative and Other Research and Development [Member] | US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,231,000<span></span>
</td>
<td class="nump">4,898,000<span></span>
</td>
<td class="nump">2,552,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember', window );">Collaborative and Other Research and Development [Member] | Torii Pharmaceutical Co. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,899,000<span></span>
</td>
<td class="nump">$ 20,101,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember', window );">Collaborative and Other Research and Development [Member] | Seqirus UK Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_CollaborativeAndOtherResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_SeqirusUKLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_SeqirusUKLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766303770968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Property and Equipment (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation, Depletion and Amortization, Total</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="nump">$ 724<span></span>
</td>
<td class="nump">$ 770<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766298345000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Property and Equipment - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 14,449<span></span>
</td>
<td class="nump">$ 13,935<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(7,336)<span></span>
</td>
<td class="num">(6,588)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">7,113<span></span>
</td>
<td class="nump">7,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">722<span></span>
</td>
<td class="nump">602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">211<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">1,159<span></span>
</td>
<td class="nump">1,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">3,774<span></span>
</td>
<td class="nump">3,462<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 8,583<span></span>
</td>
<td class="nump">$ 8,528<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bcrx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766302913720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Royalty Monetizations (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 07, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 09, 2011 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>&#165; / $</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from Issuance of Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 119,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Future Royalties Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,717<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_Rpi2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_FutureRoyaltiesPayable', window );">Future Royalties Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_Rpi2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | ORLADEYO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Sublicense Revenue in Other Markets</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_Rpi2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | ORLADEYO [Member] | Annual Net Sales Under $350,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Key Territories</a></td>
<td class="nump">8.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_Rpi2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | ORLADEYO [Member] | Annual Net Sales Between $350,000 and $550,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Key Territories</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_Rpi2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | ORLADEYO [Member] | Annual Net Sales Over $550,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Key Territories</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_Rpi2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | ORLADEYO [Member] | Annual Net Sales Under $150,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Other Markets</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_Rpi2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | ORLADEYO [Member] | Annual Net Sales Between $150,000 and $230,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Other Markets</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_Rpi2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | ORLADEYO [Member] | Annual Net Sales Over $230,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets', window );">Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Other Markets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_Rpi2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | BCX9930 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales', window );">Royalty Purchase Agreement, Royalties, Percentage of Global Annual Net Sales</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_Rpi2019IntermediateFinanceTrustMember', window );">RPI 2019 Intermediate Finance Trust [Member] | Future Royalties Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from Issuance of Debt</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt Issuance Costs, Net, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLossOnDerivative', window );">Derivative, Loss on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 632<span></span>
</td>
<td class="nump">347<span></span>
</td>
<td class="nump">$ 1,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Derivative, Gain on Derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 662<span></span>
</td>
<td class="nump">$ 863<span></span>
</td>
<td class="nump">$ 941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember', window );">PhaRMA Notes Member] | Currency Hedge Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeForwardExchangeRate1', window );">Derivative, Forward Exchange Rate (in JPY per USD) | &#165; / $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PrivatePlacementOfSeniorSecuredNotes', window );">Private Placement of Senior Secured Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredDebt', window );">Secured Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCarryingAmountInExcessOfFairValue1', window );">Percentage of Carrying Amount in Excess of Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | PhaRMA Notes Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes Payable, Fair Value Disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember', window );">JPR Royalty Sub LLC [Member] | Royalty Monetization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from Issuance of Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_TransactionCosts', window );">Transaction Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_InterestReserve', window );">Interest Reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_FutureRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations for future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_FutureRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_InterestReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents interest reserve established as part of the royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_InterestReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCarryingAmountInExcessOfFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of carrying amount in excess of fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCarryingAmountInExcessOfFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PrivatePlacementOfSeniorSecuredNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents private placement of senior secured notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PrivatePlacementOfSeniorSecuredNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of net sales in key territories for royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of annual net sales in other markets of royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of global annual net sales of royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of sublicense revenue in other markets of royalties to be paid under the royalty purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_TransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents transaction costs associated with royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_TransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeForwardExchangeRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual rate at which a foreign currency can be purchased or sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeForwardExchangeRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLossOnDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLossOnDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_Rpi2019IntermediateFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_Rpi2019IntermediateFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_ORLADEYOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_ORLADEYOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AnnualNetSalesUnder350000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AnnualNetSalesUnder350000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AnnualNetSalesBetween350000And550000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AnnualNetSalesBetween350000And550000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AnnualNetSalesOver550000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AnnualNetSalesOver550000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AnnualNetSalesUnder150000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AnnualNetSalesUnder150000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AnnualNetSalesBetween150000And230000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AnnualNetSalesBetween150000And230000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AnnualNetSalesOver230000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AnnualNetSalesOver230000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bcrx_BCX9930Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bcrx_BCX9930Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_FutureRoyaltiesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_FutureRoyaltiesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_PhaRMANotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bcrx_CurrencyHedgeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bcrx_JPRRoyaltySubLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bcrx_RoyaltyMonetizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766303671784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Credit Agreement (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 07, 2020</div></th>
<th class="th"><div>Feb. 05, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of Lines of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,501<span></span>
</td>
<td class="nump">$ 11,892<span></span>
</td>
<td class="nump">9,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428<span></span>
</td>
<td class="nump">$ 1,278<span></span>
</td>
<td class="nump">$ 885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayments of Lines of Credit</a></td>
<td class="nump">$ 43,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">MidCap Financial Services, LLC [Member] | Senior Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentLiborFloor', window );">Debt Instrument, LIBOR Floor</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentLiborCap', window );">Debt Instrument, LIBOR Cap</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentExitFeePercentageOfPrincipal', window );">Debt Instrument, Exit Fee, Percentage of Principal</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentCommitmentFeePercentage', window );">Debt Instrument, Commitment Fee Percentage</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Prior to the Second Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments', window );">Debt Instrument, Prepayment Fee, Percentage of Principal Voluntary Payments</a></td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest', window );">Debt Instrument, Prepayment Fee, Percentage of Accrued Interest</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Between the Second and Third Anniversaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments', window );">Debt Instrument, Prepayment Fee, Percentage of Principal Voluntary Payments</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Between the Third and Fourth Anniversaries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments', window );">Debt Instrument, Prepayment Fee, Percentage of Principal Voluntary Payments</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | After Fourth Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments', window );">Debt Instrument, Prepayment Fee, Percentage of Principal Voluntary Payments</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Term Loan A Drawn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents', window );">Debt Instrument, Covenant, Minimum Unrestricted Cash and Cash Equivalents</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Term Loan A and B Drawn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents', window );">Debt Instrument, Covenant, Minimum Unrestricted Cash and Cash Equivalents</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Term Loans A, B and C Drawn [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents', window );">Debt Instrument, Covenant, Minimum Unrestricted Cash and Cash Equivalents</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Term Loans A, B and C Drawn and Cure Right Exercised [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents', window );">Debt Instrument, Covenant, Minimum Unrestricted Cash and Cash Equivalents</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | London Interbank Offered Rate (LIBOR) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | London Interbank Offered Rate (LIBOR) [Member] | PIK Interest Payment is Made [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">10.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Term A Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from Issuance of Long-term Debt, Total</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Term B Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember', window );">Credit Agreement [Member] | Athyrium [Member] | Term C Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The commitment fee percentage of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of unrestricted cash and cash equivalents required under the covenant of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentExitFeePercentageOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of principal for exit fee of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentExitFeePercentageOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentLiborCap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum LIBOR interest rate for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentLiborCap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentLiborFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum LIBOR interest rate for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentLiborFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of interest that would have accrued on principal voluntary paid for prepayment fee of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of principal paid voluntarily for prepayment fee of the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_AthyriumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_AthyriumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_PriorToTheSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_PriorToTheSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_BetweenTheSecondAndThirdAnniversariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_BetweenTheSecondAndThirdAnniversariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_BetweenTheThirdAndFourthAnniversariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_BetweenTheThirdAndFourthAnniversariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_AfterFourthAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_AfterFourthAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_TermLoanADrawnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_TermLoanADrawnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_TermLoanAAndBDrawnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_TermLoanAAndBDrawnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_TermLoansABAndCDrawnMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_TermLoansABAndCDrawnMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bcrx_PikInterestPaymentIsMadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=bcrx_PikInterestPaymentIsMadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_TermALoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_TermALoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_TermBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_TermBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bcrx_TermCLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bcrx_TermCLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766303326696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Senior Credit Facility (Details Textual) - MidCap Financial Services, LLC [Member] - Senior Credit Facility [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 05, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DebtInstrumentMinimumLibor', window );">Debt Instrument, Minimum LIBOR</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term (Month)</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Payment for Debt Extinguishment or Debt Prepayment Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write off of Deferred Debt Issuance Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,211<span></span>
</td>
<td class="nump">$ 1,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">London Interbank Offered Rate (LIBOR) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">Secured Credit Facility, First Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of Long-term Debt, Total</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">Secured Credit Facility, Second Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember', window );">Secured Credit Facility, Third Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DebtInstrumentMinimumLibor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum LIBOR interest that will be added to the basis spread.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DebtInstrumentMinimumLibor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bcrx_MidCapFinancialServicesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=bcrx_SeniorCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_SecuredCreditFacilityFirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_SecuredCreditFacilityFirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_SecuredCreditFacilitySecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_SecuredCreditFacilitySecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bcrx_SecuredCreditFacilityThirdTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bcrx_SecuredCreditFacilityThirdTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766302430440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Lease Obligations and Other Contingencies (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit), Ending Balance</a></td>
<td class="num">$ (1,023,442)<span></span>
</td>
<td class="num">$ (840,628)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term (Year)</a></td>
<td class="text">13 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">12.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">$ 1,754<span></span>
</td>
<td class="nump">1,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">1,696<span></span>
</td>
<td class="nump">1,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization', window );">Operating Lease, Right-of-Use Asset, Accumulated Amortization</a></td>
<td class="nump">2,641<span></span>
</td>
<td class="nump">1,386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=bcrx_AccruedLiabilitiesCurrentMember', window );">Accrued Liabilities, Current [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">1,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="nump">3,871<span></span>
</td>
<td class="nump">3,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 3,802<span></span>
</td>
<td class="nump">$ 3,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member] | Cumulative Effect, Period of Adoption, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit), Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization on lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bcrx_AccruedLiabilitiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bcrx_AccruedLiabilitiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766303283720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 1,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">7,327<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">11,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="nump">6,115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember', window );">Accrued Liabilities, Current and Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 5,050<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766302437784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 01, 2020</div></th>
<th class="th"><div>Nov. 21, 2019</div></th>
<th class="th"><div>Nov. 18, 2019</div></th>
<th class="th"><div>Aug. 06, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
<th class="th"><div>Nov. 08, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumAggregateOfferingPrice', window );">Maximum Aggregate Offering Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">22,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,621,000<span></span>
</td>
<td class="nump">10,455,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="nump">$ 1.69<span></span>
</td>
<td class="nump">$ 1.45<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58,500<span></span>
</td>
<td class="nump">$ 53,400<span></span>
</td>
<td class="nump">$ 93,279<span></span>
</td>
<td class="nump">$ 58,500<span></span>
</td>
<td class="nump">$ 53,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,765,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,817<span></span>
</td>
<td class="nump">$ 19,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total</a></td>
<td class="nump">$ 108,096,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bcrx_WarrantsIssuedInPublicOfferingMember', window );">Warrants Issued in Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">3,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant', window );">Class of Warrant or Right, Warrants Issued, Price Per Warrant (in dollars per share)</a></td>
<td class="nump">$ 4.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of warrants issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bcrx_WarrantsIssuedInPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bcrx_WarrantsIssuedInPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766302045960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-based Compensation (Details Textual) - USD ($)<br> $ / shares in Units, shares in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Aug. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,794,000<span></span>
</td>
<td class="nump">$ 17,719,000<span></span>
</td>
<td class="nump">$ 9,396,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,094,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Next Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,758,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,281,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,484,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,571,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,938,000<span></span>
</td>
<td class="nump">$ 17,164,000<span></span>
</td>
<td class="nump">$ 9,223,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.48<span></span>
</td>
<td class="nump">$ 2.63<span></span>
</td>
<td class="nump">$ 4.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,562,000<span></span>
</td>
<td class="nump">$ 1,127,000<span></span>
</td>
<td class="nump">$ 4,504,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="nump">968<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,592<span></span>
</td>
<td class="nump">968<span></span>
</td>
<td class="nump">805<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Share-based Payment Arrangement, Option [Member] | Vest 25% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | August 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,768,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | December 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 684,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | August 2013 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | December 2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member] | Performance Shares [Member] | Vest Upon Successful Completion of Specific Development Milestones [Member] | December 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,494,000<span></span>
</td>
<td class="nump">$ 323,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.73<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,716,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan [Member] | Vest 25% Each Year Until Fully Vested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 362,000<span></span>
</td>
<td class="nump">$ 232,000<span></span>
</td>
<td class="nump">$ 173,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum', window );">Percentage of Salary to Purchase Common Stock, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesBeginning', window );">Percentage of Common Stock Shares, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PercentageOfCommonStockSharesEnding', window );">Percentage of Common Stock Shares, Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount', window );">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased', window );">Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.56<span></span>
</td>
<td class="nump">$ 3.51<span></span>
</td>
<td class="nump">$ 3.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.47<span></span>
</td>
<td class="nump">$ 2.01<span></span>
</td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanAndInducementPlanMember', window );">Incentive Plan and Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,739<span></span>
</td>
<td class="nump">$ 12,499,000<span></span>
</td>
<td class="nump">$ 8,952,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee service share-based compensation nonvested awards compensation cost expected to be recognized next year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesBeginning">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares beginning.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesBeginning</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfCommonStockSharesEnding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of common stock shares ending.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfCommonStockSharesEnding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of salary to purchase common stock maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average purchase price of capital shares purchased through an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_Vest25PercentEachYearUntilFullyVestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_August2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_August2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_December2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_December2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=bcrx_December2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=bcrx_December2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanAndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanAndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766295621848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-Based Compensation - Stock-based Compensation Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">$ 14,794<span></span>
</td>
<td class="nump">$ 17,719<span></span>
</td>
<td class="nump">$ 9,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">10,222<span></span>
</td>
<td class="nump">13,977<span></span>
</td>
<td class="nump">6,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="nump">$ 4,572<span></span>
</td>
<td class="nump">$ 3,742<span></span>
</td>
<td class="nump">$ 2,529<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766302856184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-based Compensation - Stock Plan Activities (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember', window );">Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, beginning balance (in shares)</a></td>
<td class="nump">968<span></span>
</td>
<td class="nump">805<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">21,050<span></span>
</td>
<td class="nump">17,491<span></span>
</td>
<td class="nump">14,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Awards available, plan amendment (in shares)</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards available, Restricted stock awards granted (in shares)</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable', window );">Awards available, stock option awards granted (in shares)</a></td>
<td class="num">(7,469)<span></span>
</td>
<td class="num">(4,511)<span></span>
</td>
<td class="num">(4,272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options outstanding, stock option awards granted (in shares)</a></td>
<td class="nump">7,469<span></span>
</td>
<td class="nump">4,511<span></span>
</td>
<td class="nump">4,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards granted (in dollars per share)</a></td>
<td class="nump">$ 8.06<span></span>
</td>
<td class="nump">$ 3.91<span></span>
</td>
<td class="nump">$ 7.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options outstanding, stock option awards exercised (in shares)</a></td>
<td class="num">(510)<span></span>
</td>
<td class="num">(251)<span></span>
</td>
<td class="num">(1,011)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards exercised (in dollars per share)</a></td>
<td class="nump">$ 3.56<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="nump">$ 2.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable', window );">Awards available, stock option awards cancelled (in shares)</a></td>
<td class="nump">3,124<span></span>
</td>
<td class="nump">701<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options outstanding, stock option awards cancelled (in shares)</a></td>
<td class="num">(3,124)<span></span>
</td>
<td class="num">(701)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards cancelled (in dollars per share)</a></td>
<td class="nump">$ 6.93<span></span>
</td>
<td class="nump">$ 6.82<span></span>
</td>
<td class="nump">$ 7.44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, ending balance (in shares)</a></td>
<td class="nump">4,592<span></span>
</td>
<td class="nump">968<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">24,885<span></span>
</td>
<td class="nump">21,050<span></span>
</td>
<td class="nump">17,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in dollars per share)</a></td>
<td class="nump">$ 6.52<span></span>
</td>
<td class="nump">$ 5.96<span></span>
</td>
<td class="nump">$ 6.49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember', window );">Inducement Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, beginning balance (in shares)</a></td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">1,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Awards available, plan amendment (in shares)</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable', window );">Awards available, stock option awards granted (in shares)</a></td>
<td class="num">(3,002)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options outstanding, stock option awards granted (in shares)</a></td>
<td class="nump">3,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards granted (in dollars per share)</a></td>
<td class="nump">$ 4.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable', window );">Awards available, stock option awards cancelled (in shares)</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options outstanding, stock option awards cancelled (in shares)</a></td>
<td class="num">(160)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, stock option awards cancelled (in dollars per share)</a></td>
<td class="nump">$ 4.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Awards available, ending balance (in shares)</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">4,171<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance (in dollars per share)</a></td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="nump">$ 3.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents share based compensation arrangement by share based payment award options grants in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options forfeitures in period awards available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766293544696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details) - Incentive Plan and Inducement Plan [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life (Year)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected Volatility</a></td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-Free Interest Rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bcrx_IncentivePlanAndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bcrx_IncentivePlanAndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766302736888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-based Compensation - Number of Stock Option Awards Exercisable and their Weighted Average Exercise Price (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share)</a></td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">29,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life (Year)</a></td>
<td class="text">7 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 6.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">13,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 3.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange01Member', window );">Exercise Price Range 01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">2,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life (Year)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 2.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">1,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 1.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange02Member', window );">Exercise Price Range 02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share)</a></td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">12,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life (Year)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 4.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">6,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 2.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange03Member', window );">Exercise Price Range 03 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share)</a></td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">10,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life (Year)</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 7.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">2,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 4.89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange04Member', window );">Exercise Price Range 04 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share)</a></td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">2,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life (Year)</a></td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 10.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">2,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 4.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange05Member', window );">Exercise Price Range 05 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share)</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life (Year)</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 12.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 6.43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange06Member', window );">Exercise Price Range 06 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Exercise Price Range (in dollars per share)</a></td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding Number (in shares) | shares</a></td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding Weighted Average Remaining Life (Year)</a></td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 15.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable Number (in shares) | shares</a></td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 10.57<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange01Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange01Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange02Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange02Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange03Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange03Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange04Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange04Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange05Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange05Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange06Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=bcrx_ExercisePriceRange06Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766301510072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Stock-based Compensation - Changes in the Number and Weighted-Average Grant-Date Fair Value (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested stock option awards (in shares) | shares</a></td>
<td class="nump">11,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock option awards granted (in shares) | shares</a></td>
<td class="nump">10,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Stock option awards granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Stock option awards vested (in shares) | shares</a></td>
<td class="num">(4,543)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Stock option awards vested (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Stock option awards forfeited (in shares) | shares</a></td>
<td class="num">(1,596)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Stock option awards forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Non-vested stock option awards (in shares) | shares</a></td>
<td class="nump">16,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766302030648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</a></td>
<td class="nump">$ 38,551,000<span></span>
</td>
<td class="nump">$ 23,824,000<span></span>
</td>
<td class="nump">$ 26,040,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2017 2018 2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">74,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Total</a></td>
<td class="nump">677,109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Total</a></td>
<td class="nump">494,608,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Total</a></td>
<td class="nump">$ 6,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766295794520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Loss Before Provision for Income Taxes (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (176,613)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(6,201)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before provision for income taxes</a></td>
<td class="num">$ (182,814)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766298315400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at federal statutory rate (21% for 2020, 2019 and 2018)</a></td>
<td class="num">$ (38,391)<span></span>
</td>
<td class="num">$ (22,868)<span></span>
</td>
<td class="num">$ (21,263)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local income taxes net of federal tax benefit</a></td>
<td class="num">(2,544)<span></span>
</td>
<td class="num">(1,591)<span></span>
</td>
<td class="num">(2,547)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent items</a></td>
<td class="nump">774<span></span>
</td>
<td class="nump">691<span></span>
</td>
<td class="nump">503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Rate change</a></td>
<td class="num">(82)<span></span>
</td>
<td class="nump">625<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards', window );">Expiration of attribute carryforwards</a></td>
<td class="nump">3,774<span></span>
</td>
<td class="nump">3,976<span></span>
</td>
<td class="nump">2,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credits</a></td>
<td class="num">(4,080)<span></span>
</td>
<td class="num">(4,938)<span></span>
</td>
<td class="num">(4,905)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1,456<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">38,551<span></span>
</td>
<td class="nump">23,824<span></span>
</td>
<td class="nump">26,040<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation income tax expense benefit expiration of carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32059-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766295501272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) (Parentheticals)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax benefit at federal statutory rate, percentage</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766302696568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance</a></td>
<td class="nump">$ 7,210<span></span>
</td>
<td class="nump">$ 5,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions to current period tax positions</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">1,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance</a></td>
<td class="nump">$ 8,230<span></span>
</td>
<td class="nump">$ 7,210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766297875368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Net federal and state operating losses</a></td>
<td class="nump">$ 159,939<span></span>
</td>
<td class="nump">$ 155,190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">66,331<span></span>
</td>
<td class="nump">63,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredTaxAssetsRoyaltyIncome', window );">Royalty income</a></td>
<td class="nump">28,034<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">10,732<span></span>
</td>
<td class="nump">9,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredTaxAssetsLeasingObligations', window );">Leasing obligations</a></td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">1,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">5,563<span></span>
</td>
<td class="nump">3,801<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">271,734<span></span>
</td>
<td class="nump">233,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(124)<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_DeferredTaxLiabilitiesRightOfUseAssets', window );">Right of use asset</a></td>
<td class="num">(854)<span></span>
</td>
<td class="num">(803)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(978)<span></span>
</td>
<td class="num">(917)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (270,756)<span></span>
</td>
<td class="num">$ (232,205)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredTaxAssetsLeasingObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from leasing obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DeferredTaxAssetsLeasingObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredTaxAssetsRoyaltyIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from royalty income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DeferredTaxAssetsRoyaltyIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_DeferredTaxLiabilitiesRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from right of use assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_DeferredTaxLiabilitiesRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766298290248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Employee 401(k) Plan (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="nump">$ 1,569<span></span>
</td>
<td class="nump">$ 926<span></span>
</td>
<td class="nump">$ 724<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766288215448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Collaborative and Other Research and Development Contracts (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">67 Months Ended</th>
<th class="th" colspan="1">69 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 03, 2020</div></th>
<th class="th"><div>Mar. 04, 2020</div></th>
<th class="th"><div>Nov. 05, 2019</div></th>
<th class="th"><div>Sep. 06, 2018</div></th>
<th class="th"><div>Jun. 16, 2015</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2006</div></th>
<th class="th"><div>Jun. 30, 2000</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Nov. 11, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,016<span></span>
</td>
<td class="nump">$ 6,102<span></span>
</td>
<td class="nump">$ 2,871<span></span>
</td>
<td class="nump">$ 4,823<span></span>
</td>
<td class="nump">$ 39,725<span></span>
</td>
<td class="nump">$ 1,775<span></span>
</td>
<td class="nump">$ 1,448<span></span>
</td>
<td class="nump">$ 5,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,812<span></span>
</td>
<td class="nump">$ 48,835<span></span>
</td>
<td class="nump">$ 20,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bcrx_ArbitrationProceedingsOfSulAgreementMember', window );">Arbitration Proceedings of SUL Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Litigation Settlement, Amount Awarded from Other Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bcrx_ArbitrationProceedingsOfSulAgreementMember', window );">Arbitration Proceedings of SUL Agreement [Member] | Other Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain (Loss) Related to Litigation Settlement, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=bcrx_ArbitrationProceedingsOfSulAgreementMember', window );">Arbitration Proceedings of SUL Agreement [Member] | Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember', window );">US Department of Health and Human Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementContractValue', window );">Collaborative Agreement Contract Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ContractTerm', window );">Contract Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from Collaborators</a></td>
<td class="nump">$ 6,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_UpfrontPaymentsReceivableAmount', window );">Upfront Payments Receivable Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021', window );">Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MaximumCustomaryReductionOnRoyaltyRate', window );">Maximum Customary Reduction on Royalty Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial', window );">Royalty Payments Receivable, Expiration Term From First Commercial (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Contract with Customer, Liability, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member] | License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member] | Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation', window );">Royalty Rate if Maintains Sakigake Designation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember', window );">Torii Pharmaceutical Co. [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation', window );">Royalty Rate if Maintains Sakigake Designation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bcrx_CSLLimitedMember', window );">CSL Limited [Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentReceived', window );">Milestone Payment Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember', window );">Base Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember', window );">Additional Development Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember', window );">ASPRBARDA Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GovernmentContractReceivable', window );">Government Contract Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts', window );">Proceeds from awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember', window );">Green Cross Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Proceeds from License Fees Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember', window );">Mundipharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PotentialMilestonePaymentsReceivable', window );">Potential Milestone Payments Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember', window );">AECOM and IRL [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMinimum', window );">Milestone Payment Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_MilestonePaymentMaximum', window );">Milestone Payment Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMinimum', window );">Annual License Fee Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_AnnualLicenseFeeMaximum', window );">Annual License Fee Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">National Institute of Allergy and Infectious Diseases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts', window );">Expected Receivable From Awards for Research and Development Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding', window );">Collaborative Agreement Contract, Covenant, Maximum Amount of Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_CollaborativeAgreementContractValue', window );">Collaborative Agreement Contract Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember', window );">UAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_PeriodOfAgreement', window );">Period of Agreement (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bcrx_RenewablePeriodOfAgreement', window );">Renewable Period of Agreement (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents annual maximum license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_AnnualLicenseFeeMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent minimum annual license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_AnnualLicenseFeeMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative agreement contract maximum amount if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_CollaborativeAgreementContractValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents collaborative agreement contract value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_CollaborativeAgreementContractValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between the contract date and its expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents expected receivable from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MaximumCustomaryReductionOnRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum percentage of customary reductions allowed on royalty rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MaximumCustomaryReductionOnRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment maximum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment minimum.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PotentialMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents potential milestone payments receivable based on possibility of future event payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PotentialMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of potential milestone payments receivable if regulatory approval is granted before December 31, 2021.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents proceeds from awards for research and development contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RenewablePeriodOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents renewable period of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RenewablePeriodOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expiration term of the royalty payments from first commercial date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_RoyaltyRateIfMaintainsSakigakeDesignation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_RoyaltyRateIfMaintainsSakigakeDesignation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bcrx_UpfrontPaymentsReceivableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents upfront payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bcrx_UpfrontPaymentsReceivableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bcrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentContractReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables that are derived from government contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118261985&amp;loc=d3e55295-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentContractReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=bcrx_ArbitrationProceedingsOfSulAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=bcrx_ArbitrationProceedingsOfSulAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_USDepartmentOfHealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_ToriiPharmaceuticalCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bcrx_CSLLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bcrx_CSLLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_BaseContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AdditionalDevelopmentOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_ASPRBARDAContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_MundipharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bcrx_AECOMAndIRLMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=bcrx_UABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139766303016376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 4,016<span></span>
</td>
<td class="nump">$ 6,102<span></span>
</td>
<td class="nump">$ 2,871<span></span>
</td>
<td class="nump">$ 4,823<span></span>
</td>
<td class="nump">$ 39,725<span></span>
</td>
<td class="nump">$ 1,775<span></span>
</td>
<td class="nump">$ 1,448<span></span>
</td>
<td class="nump">$ 5,887<span></span>
</td>
<td class="nump">$ 17,812<span></span>
</td>
<td class="nump">$ 48,835<span></span>
</td>
<td class="nump">$ 20,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (60,493)<span></span>
</td>
<td class="num">$ (46,115)<span></span>
</td>
<td class="num">$ (38,607)<span></span>
</td>
<td class="num">$ (37,599)<span></span>
</td>
<td class="num">$ (2,622)<span></span>
</td>
<td class="num">$ (37,592)<span></span>
</td>
<td class="num">$ (37,629)<span></span>
</td>
<td class="num">$ (31,054)<span></span>
</td>
<td class="num">$ (182,814)<span></span>
</td>
<td class="num">$ (108,897)<span></span>
</td>
<td class="num">$ (101,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="num">$ (0.28)<span></span>
</td>
<td class="num">$ (1.09)<span></span>
</td>
<td class="num">$ (0.94)<span></span>
</td>
<td class="num">$ (0.98)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M_V2?W=OMMH@;:R/#/!@(0C_*_O*7/!%' ;9U(H#E >Q- #TU@IT'V$T#NGE
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M;:ZQ-R]&KIJ;X =IC*R:QR5G0-X"X/>%A-*P?;&7R]M_)IS]!U!+ P04
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MZ(TB+#O5-L%V8635])%':; K-=,"OQM 60,\7TEI=@O;FOHOD?0O4$L#!!0
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M4"L;RH?0'D_<Q1,[XVE$<JJZTK2I$5D@M&EVV8.Z9C;9C TBL1=KQ^_J!&A
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M=4-D0+*.1KP'[= ICF8(1*D65S-S@N/RS6XF+UPB:HR%1-=8WJPN<,;KQ"N
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MROMP2L[E\MJ2=(9&2(5@MRMP@>!"I+VV*DM=<)8M)T2PVG>,966+R@^ZIOX
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M78J1)56+\T,YP<>Z*\<77!+)-F$*[ZVB!-$Q@G%\QKV/^ROD.O!6XM<G#U!
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MT='@[7ZO*O'-)-@B7O07-N#9$(<9WFGD> .^+RT:7CUA ^W+[^Q?4$L#!!0
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M6\B(AUAYI^BBB%/3*,2.C"UO,CK\" <)O!=07(\/48$RFBEC.!6[NI@J-A<
M'EDXPU#J*2Y.Q50JS4YD'>% ])V.[@ZJ*G6&M8S,;:T1&]2 !LEO>+1RW+**
M)J'7:""HH!S@H;7>=*_(W.6;S'-74]$UQ^CQ*7$5!:L,D2A+B( 3H/N#EK92
M @$,FVDU:^K%%A59-U3&FKM1ACQ,"\[03@EEOA+>>,R6!<7Q1?%Z6-FA3\H2
M("'&?FT,Z?_?IX<5J[J1*.%Q@[5Q&-MH<E?U>=!BX&X:4(?W7I-C[>*/ 9Y!
M:D)Z8^YVN^\-I^DU^^YZ^ECQ5KH9B],T!>EH\!PO6BY] $B+8*OXTIW9@ H?
M'^>$5N;X LZG%K-ILV !W5>8D[\ 4$L#!!0    ( &Q*85+AB!Y0J@(  #H&
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;)55WV_:,!#^5TZ9-.V!
M$0AE8QT@E3*T3FI7E6Y[J/I@DH-8=>S,OI3VO]_9"1G5"M)>R/W\[CO[?(RW
MQCZX')'@J5#:3:*<J#R-8Y?F6 C7-25J]JR-+02Q:C>Q*RV*+"05*DYZO0]Q
M(:2.IN-@N[;3L:E(28W7%EQ5%,(^SU"9[23J1SO#C=SDY WQ=%R*#2Z1?I37
MEK6X1<ED@=I)H\'B>A*=]4]G0Q\? GY*W+H]&7PG*V,>O'*13:*>)X0*4_((
M@C^/>(Y*>2"F\;O!C-J2/G%?WJ$O0N_<RTHX/#?JE\PHGT2C"#)<BTK1C=E^
MQ::?0# URH5?V-:Q@R2"M')DBB:9&112UU_QU)S#7L*H=R A:1*2P+LN%%C.
M!8GIV)HM6!_-:%X(K89L)B>UOY0E6?9*SJ/IE2&$(;R')6II+)Q;S"3!0J12
M27H>Q\1%?&B<-H"S&C Y -A/X-)HRAU\T1EF+P%B9M=23'849\E1Q#FF71CT
M.Y#TDMX1O$';\B#@G1S >[U3N+O$8H7V_DB%D[;"2:@P.'*H#LC 0FJA4RD4
M+$D0\C"3.X(_;/&'1SN8XXI@+EVJC*LLPMTM/A',E$D?[E^[L:-H_MF?NE*D
M.(GX73NTCQCMYN+MFU'23SX?F [XKF&!*UOQ<X:AOZ#^IPY0;A%A+:TC<)@:
MG;%)VNRELL22PH%#OU=GODRY,H^U>]"XN_^:.KO@VQP9,(AG?,@\=R!8OD'G
MCST[1)\70+B@)MQBJ817B.'^!R<+3N' K.%;I9Z97" X@G>@#;%-8YA>N-#
MXUQWX0T=>&T<XKWW7*#=A*WE(#65IOIIM]9V,9[5^^!O>+U5+X7=2.U X9I3
M>]V// NVWE2U0J8,VV%EB'=-$'->[FA] /O7AB>A47R!]N]B^@=02P,$%
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MI8+50"U0,T=3+Q7"MN)Y1=YPZF2<8LV)56Z<P^0D-4?RS[@"&A0$6RO"4.0
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MM%:67CD_K>BW K43H/.-HC;6+YR!X4=E]2]02P,$%     @ ;$IA4@9V?%&
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M?:W$55ZFG__=1][!OE%>?[ [F:J?7H! 6F6^J!=O/FU4&.5*E]=F;RMQNY'
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M0-<TJ#C0@_":Z3%/B.Y2AV745P)*U(J(UD?G1LNBA.JJ=BHUU@G4M?9H;(T
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M' 8E%Y4WG[J]I9I/96,*4>%2@6[*DJO7!19R._,B;[]Q+]8;8S>"^;3F:WQ
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M9D^2+>.JFI+,XJ*H@IQ.2Y+Y+)ZR\I!M%J=E@";>$S8;M7+&O,;(Q?Z';'5
M[D#2H$Z?NAK)P3OLT&S"MK%0ZUZYX4GNO?N%=CZ\XS_APS;\R,U&* L2UY2:
MGDW+",RP80;#Z6UXU7?:T8X(:DM+&8T/H.]K3?=X-'R!_9I?_@902P,$%
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M#^@%!WT' B[#?KW$3!R&@\'I(AI@FS_VYP^Z+66\,/H;36E22*:-?IN\);P
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MQ_L8I G \4Q@C6X[IN1W-_ST'U!+ P04    " !L2F%258\B5%L$  ")$@
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M,6:E@/@^I^+\6;^4'32W3X/_ %!+ P04    " !L2F%2#?O(+$D"  !J!0
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MIC%Q/IXU+OK8\RYVNB/V*(4KHZER<*E++-\2Q"QD4).^JIFG'S+F6!S">'0
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MNI5B.%,-)7 =H/9CIGJ,:J);EKI%'?P#4$L#!!0    ( &Q*85+L_AZ7I08
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MKGVNA-XE&J=&W[D"U$.W:*YX^G([T19F:,I+_5I);&]FN[4XW!I3RM-Z>)6
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MAJJ=:Z[H H/*3J#QA:0:57;L!ZHKT>074$L#!!0    ( &Q*85+ [&IB@04
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M<R]S:&5E=#0U+GAM;,66VV[:0!"&7V5D]2*1"CX -D2 %)*>+A)%H4VN%WO
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ME25/DI/L[T=)CI<,;EYL4>+A.11)I7NIWG4)8,BAXD+/@M*8^CX,=5Y"1?5
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MHY-30M)=D^HF5K7^GC\H2UW##VOJZZA= .V7BNYZ/W$O&/XILC]02P,$%
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MEMA2@K("N+Z3V&5T ]NT]$WJZC=02P,$%     @ ;$IA4@NLF411 @  @ 4
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M&?5&-B/5S'MS,;+R$["4QLZ3/Y9V1:)R#O9])>T4M!<7H%NZZ3]02P,$%
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M/4XNT*=?/J-?4)RAAR4O<L#GQQT)2BO1G6FEX-E:0=*BX(2MCI#G'R+B$<\
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MQXGG>.IV3NSI!L2SRMWM.[03-I3_E28%,];>7I,_@VZWY3+AK98([]&HDOS
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ ;$IA4I&V?\IR!   IB0
M  \   !X;"]W;W)K8F]O:RYX;6S%FEV/FS@40/^*Q<NF#]T$,)D/-95V,IW=
MD;J=[&34UY$#3F*-L;.VTVGFU^\%%-6T\=6^Q#PE@('#!=]S;?CPJLW+2NL7
M\KV6RLZ2K7.[Z_'8EEM>,_N[WG$%6];:U,S!HMF,[<YP5MDMYZZ6XVPRF8YK
M)E3R\</Q6 LS]A>TXZ436L'*9L57P5_MC^W-(ODFK%@)*=QAEK3_)4](+92H
MQ1NO9LDD(7:K7__21KQIY9A<ED9+.4O2;L-7;IPH?UF];""?V,JV:QQ;/3(
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M_R?5Y7QONC[^LOP^.7I[+S@'^)/@\0M02P,$%     @ ;$IA4B%=IR;- 0
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M<',O87!P+GAM;%!+ 0(4 Q0    ( &Q*85*[=I.O[0   "L"   1
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M965T,BYX;6Q02P$"% ,4    " !L2F%2 %MI>IP"  "5"   &
M    @(%<%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @
M;$IA4IJU+$ZY!0  0!8  !@              ("!+A<  'AL+W=O<FMS:&5E
M=',O<VAE970T+GAM;%!+ 0(4 Q0    ( &Q*85+AH?J^3P<  *X=   8
M          " @1T=  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M    " !L2F%2&TO1Z.L%  !$&P  &               @(&B)   >&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ ;$IA4ABAN*?5 @  )P@
M !@              ("!PRH  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+
M 0(4 Q0    ( &Q*85)&-F[V&!L  )5/   8              " @<XM  !X
M;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " !L2F%254@NZ/D"
M  !%!@  &               @($<20  >&PO=V]R:W-H965T<R]S:&5E=#DN
M>&UL4$L! A0#%     @ ;$IA4JNSJK[I!0  !0X  !D              ("!
M2TP  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " !L2F%2
MC**;_Y(&  "1$0  &0              @(%K4@  >&PO=V]R:W-H965T<R]S
M:&5E=#$Q+GAM;%!+ 0(4 Q0    ( &Q*85+AB!Y0J@(  #H&   9
M      " @319  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%
M  @ ;$IA4N0;UQ/( P  M @  !D              ("!%5P  'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " !L2F%2!G9\48 "  "1!0
M&0              @($48   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+
M 0(4 Q0    ( &Q*85)K6XV#F@@  $$8   9              " @<MB  !X
M;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ ;$IA4@A>#5N9
M!@  -@\  !D              ("!G&L  'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"% ,4    " !L2F%2NJ$'-#\"  #-!   &0
M@(%L<@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( &Q*
M85)J1>/5(P<  %@0   9              " @>)T  !X;"]W;W)K<VAE971S
M+W-H965T,3@N>&UL4$L! A0#%     @ ;$IA4AWW[F[. @  1@8  !D
M         ("!/'P  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M    " !L2F%2CV3DO@(=   ,7P  &0              @(%!?P  >&PO=V]R
M:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( &Q*85)/X?1$I 4  &$.
M   9              " @7J<  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL
M4$L! A0#%     @ ;$IA4F_K;0RQ @  EP4  !D              ("!5:(
M 'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " !L2F%2"6W'
M+:$"  !O!0  &0              @($]I0  >&PO=V]R:W-H965T<R]S:&5E
M=#(S+GAM;%!+ 0(4 Q0    ( &Q*85)SP?7X[ 4  !\1   9
M  " @16H  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @
M;$IA4EG7(FD3!0  -PP  !D              ("!.*X  'AL+W=O<FMS:&5E
M=',O<VAE970R-2YX;6Q02P$"% ,4    " !L2F%22NJ@,K8"  #R!0  &0
M            @(&"LP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4
M Q0    ( &Q*85*1SZZWY0<  &,B   9              " @6^V  !X;"]W
M;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ ;$IA4L3J-7SJ P
M1@\  !D              ("!B[X  'AL+W=O<FMS:&5E=',O<VAE970R."YX
M;6Q02P$"% ,4    " !L2F%2.":_AU$$  #+%   &0              @(&L
MP@  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( &Q*85*)
M-4(YS@(  .T'   9              " @33'  !X;"]W;W)K<VAE971S+W-H
M965T,S N>&UL4$L! A0#%     @ ;$IA4E6/(E1;!   B1(  !D
M     ("!.<H  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &Q*85*!7$;VHP,  &4,   9              "
M@3[B  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ ;$IA
M4NSLL:VM!   ,Q$  !D              ("!&.8  'AL+W=O<FMS:&5E=',O
M<VAE970S-RYX;6Q02P$"% ,4    " !L2F%2ME )C+\"  "[!P  &0
M        @('\Z@  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0
M   ( &Q*85*&L!7F0P0  !P0   9              " @?+M  !X;"]W;W)K
M<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ ;$IA4M)#KW>."0  $3P
M !D              ("!;/(  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q0
M2P$"% ,4    " !L2F%28':BP-D"   B"   &0              @($Q_
M>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( &Q*85*0NK*4
M?@4  "T=   9              " @4'_  !X;"]W;W)K<VAE971S+W-H965T
M-#(N>&UL4$L! A0#%     @ ;$IA4@%:\V/Q @  '@D  !D
M ("!]@0! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !L
M2F%2P.QJ8H$%  #M(   &0              @($>" $ >&PO=V]R:W-H965T
M<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( &Q*85*ES8R^$0,  $0*   9
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M970T.2YX;6Q02P$"% ,4    " !L2F%2HQJ>_XL"   U!@  &0
M    @($&'@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (
M &Q*85+Y"\K]: ,  + *   9              " @<@@ 0!X;"]W;W)K<VAE
M971S+W-H965T-3$N>&UL4$L! A0#%     @ ;$IA4@NLF411 @  @ 4  !D
M             ("!9R0! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"
M% ,4    " !L2F%2V+OL!<((   T*P  &0              @('O)@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( &Q*85)K("C)VP,
M +\.   9              " @>@O 0!X;"]W;W)K<VAE971S+W-H965T-30N
M>&UL4$L! A0#%     @ ;$IA4O^^WX<H @  V0@   T              ( !
M^C,! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !L2F%2EXJ[',     3 @
M"P              @ %--@$ 7W)E;',O+G)E;'-02P$"% ,4    " !L2F%2
MD;9_RG($  "F)   #P              @ $V-P$ >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ ;$IA4@^45$C: 0  62   !H              ( !U3L!
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ;$IA4B%=
MIR;- 0  )"   !,              ( !YST! %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&     #X /@#I$   Y3\!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>275</ContextCount>
  <ElementCount>439</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>115</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 2 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment</Role>
      <ShortName>Note 2 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 3 - Royalty Monetizations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations</Role>
      <ShortName>Note 3 - Royalty Monetizations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 4 - Credit Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement</Role>
      <ShortName>Note 4 - Credit Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 5 - Senior Credit Facility</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility</Role>
      <ShortName>Note 5 - Senior Credit Facility</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 6 - Lease Obligations and Other Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies</Role>
      <ShortName>Note 6 - Lease Obligations and Other Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 7 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity</Role>
      <ShortName>Note 7 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 8 - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation</Role>
      <ShortName>Note 8 - Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 9 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-9-income-taxes</Role>
      <ShortName>Note 9 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 10 - Employee 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-</Role>
      <ShortName>Note 10 - Employee 401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 11 - Collaborative and Other Research and Development Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts</Role>
      <ShortName>Note 11 - Collaborative and Other Research and Development Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 12 - Quarterly Financial Information (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited</Role>
      <ShortName>Note 12 - Quarterly Financial Information (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 2 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-tables</Role>
      <ShortName>Note 2 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 6 - Lease Obligations and Other Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-tables</Role>
      <ShortName>Note 6 - Lease Obligations and Other Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 8 - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables</Role>
      <ShortName>Note 8 - Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 9 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables</Role>
      <ShortName>Note 9 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-9-income-taxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 12 - Quarterly Financial Information (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-tables</Role>
      <ShortName>Note 12 - Quarterly Financial Information (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk - Fair Value of the Company's Investments by Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk - Fair Value of the Company's Investments by Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk - Summary of Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk - Summary of Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk - Summary of Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details</Role>
      <ShortName>Note 1 - Significant Accounting Policies and Concentrations of Risk - Summary of Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 2 - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-details-textual</Role>
      <ShortName>Note 2 - Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-tables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 2 - Property and Equipment - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details</Role>
      <ShortName>Note 2 - Property and Equipment - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 3 - Royalty Monetizations (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual</Role>
      <ShortName>Note 3 - Royalty Monetizations (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 4 - Credit Agreement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual</Role>
      <ShortName>Note 4 - Credit Agreement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 5 - Senior Credit Facility (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual</Role>
      <ShortName>Note 5 - Senior Credit Facility (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 6 - Lease Obligations and Other Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual</Role>
      <ShortName>Note 6 - Lease Obligations and Other Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-tables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 6 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details</Role>
      <ShortName>Note 6 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 7 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual</Role>
      <ShortName>Note 7 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 8 - Stock-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual</Role>
      <ShortName>Note 8 - Stock-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 8 - Stock-Based Compensation - Stock-based Compensation Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details</Role>
      <ShortName>Note 8 - Stock-Based Compensation - Stock-based Compensation Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 8 - Stock-based Compensation - Stock Plan Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details</Role>
      <ShortName>Note 8 - Stock-based Compensation - Stock Plan Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 8 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details</Role>
      <ShortName>Note 8 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 8 - Stock-based Compensation - Number of Stock Option Awards Exercisable and their Weighted Average Exercise Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details</Role>
      <ShortName>Note 8 - Stock-based Compensation - Number of Stock Option Awards Exercisable and their Weighted Average Exercise Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 8 - Stock-based Compensation - Changes in the Number and Weighted-Average Grant-Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details</Role>
      <ShortName>Note 8 - Stock-based Compensation - Changes in the Number and Weighted-Average Grant-Date Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note 9 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual</Role>
      <ShortName>Note 9 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Note 9 - Income Taxes - Loss Before Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details</Role>
      <ShortName>Note 9 - Income Taxes - Loss Before Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Note 9 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details</Role>
      <ShortName>Note 9 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Note 9 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals</Role>
      <ShortName>Note 9 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note 9 - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details</Role>
      <ShortName>Note 9 - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note 9 - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 9 - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Note 10 - Employee 401(k) Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-details-textual</Role>
      <ShortName>Note 10 - Employee 401(k) Plan (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Note 11 - Collaborative and Other Research and Development Contracts (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual</Role>
      <ShortName>Note 11 - Collaborative and Other Research and Development Contracts (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="bcrx20201231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Note 12 - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details</Role>
      <ShortName>Note 12 - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-tables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="bcrx20201231_10k.htm">bcrx20201231_10k.htm</File>
    <File>bcrx-20201231.xsd</File>
    <File>bcrx-20201231_cal.xml</File>
    <File>bcrx-20201231_def.xml</File>
    <File>bcrx-20201231_lab.xml</File>
    <File>bcrx-20201231_pre.xml</File>
    <File>ex_227978.htm</File>
    <File>ex_227979.htm</File>
    <File>ex_227980.htm</File>
    <File>ex_227981.htm</File>
    <File>ex_227982.htm</File>
    <File>ex_230463.htm</File>
    <File>ex_230468.htm</File>
    <File>ex_230469.htm</File>
    <File>ex_230470.htm</File>
    <File>ex_230471.htm</File>
    <File>ex_230489.htm</File>
    <File>ex_230490.htm</File>
    <File>ex_230492.htm</File>
    <File>ex_230493.htm</File>
    <File>ex_230494.htm</File>
    <File>ex_230497.htm</File>
    <File>ex_230510.htm</File>
    <File>ex_230714.htm</File>
    <File>ex_230719.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>98
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bcrx20201231_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 36,
   "contextCount": 275,
   "dts": {
    "calculationLink": {
     "local": [
      "bcrx-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bcrx-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "bcrx20201231_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bcrx-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bcrx-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "bcrx-20201231.xsd"
     ],
     "remote": [
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 604,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 48,
    "http://www.biocryst.com/20201231": 6,
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 60
   },
   "keyCustom": 76,
   "keyStandard": 363,
   "memberCustom": 73,
   "memberStandard": 39,
   "nsprefix": "bcrx",
   "nsuri": "http://www.biocryst.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.biocryst.com/20201231/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:RoyaltyMonetizationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Note 3 - Royalty Monetizations",
     "role": "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
     "shortName": "Note 3 - Royalty Monetizations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:RoyaltyMonetizationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Note 4 - Credit Agreement",
     "role": "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
     "shortName": "Note 4 - Credit Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31_DebtInstrumentAxis-CreditAgreementMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31_CreditFacilityAxis-SeniorCreditFacilityMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Note 5 - Senior Credit Facility",
     "role": "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
     "shortName": "Note 5 - Senior Credit Facility",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Note 6 - Lease Obligations and Other Contingencies",
     "role": "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
     "shortName": "Note 6 - Lease Obligations and Other Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLessorDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Note 7 - Stockholders' Equity",
     "role": "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity",
     "shortName": "Note 7 - Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Note 8 - Stock-based Compensation",
     "role": "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
     "shortName": "Note 8 - Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Note 9 - Income Taxes",
     "role": "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes",
     "shortName": "Note 9 - Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Note 10 - Employee 401(k) Plan",
     "role": "http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-",
     "shortName": "Note 10 - Employee 401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Note 11 - Collaborative and Other Research and Development Contracts",
     "role": "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
     "shortName": "Note 11 - Collaborative and Other Research and Development Contracts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Note 12 - Quarterly Financial Information (Unaudited)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited",
     "shortName": "Note 12 - Quarterly Financial Information (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "role": "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:DescriptionOfCompanyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:DescriptionOfCompanyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables",
     "shortName": "Note 1 - Significant Accounting Policies and Concentrations of Risk (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Note 2 - Property and Equipment (Tables)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-tables",
     "shortName": "Note 2 - Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:LesseeLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Note 6 - Lease Obligations and Other Contingencies (Tables)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-tables",
     "shortName": "Note 6 - Lease Obligations and Other Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bcrx:LesseeLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note 8 - Stock-based Compensation (Tables)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables",
     "shortName": "Note 8 - Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Note 9 - Income Taxes (Tables)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables",
     "shortName": "Note 9 - Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Note 12 - Quarterly Financial Information (Unaudited) (Tables)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-tables",
     "shortName": "Note 12 - Quarterly Financial Information (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
     "shortName": "Note 1 - Significant Accounting Policies and Concentrations of Risk (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InventoryPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2019-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk - Fair Value of the Company's Investments by Type (Details)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details",
     "shortName": "Note 1 - Significant Accounting Policies and Concentrations of Risk - Fair Value of the Company's Investments by Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock",
       "us-gaap:ReceivablesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk - Summary of Receivables (Details)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details",
     "shortName": "Note 1 - Significant Accounting Policies and Concentrations of Risk - Summary of Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "bcrx:ScheduleOfReceivablesFromCollaborationsTableTextBlock",
       "us-gaap:ReceivablesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "role": "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "bcrx:AccruedExpensesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk - Accrued Expenses (Details)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details",
     "shortName": "Note 1 - Significant Accounting Policies and Concentrations of Risk - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "bcrx:AccruedExpensesPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-10-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk - Summary of Revenues (Details)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details",
     "shortName": "Note 1 - Significant Accounting Policies and Concentrations of Risk - Summary of Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31_CounterpartyNameAxis-USDepartmentOfHealthAndHumanServicesMember_ProductOrServiceAxis-CollaborativeAndOtherResearchAndDevelopmentMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note 2 - Property and Equipment (Details Textual)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-details-textual",
     "shortName": "Note 2 - Property and Equipment (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Note 2 - Property and Equipment - Property and Equipment (Details)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details",
     "shortName": "Note 2 - Property and Equipment - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfSecuredDebt",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Note 3 - Royalty Monetizations (Details Textual)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual",
     "shortName": "Note 3 - Royalty Monetizations (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "bcrx:RoyaltyMonetizationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31_CounterpartyNameAxis-Rpi2019IntermediateFinanceTrustMember",
      "decimals": "-6",
      "lang": null,
      "name": "bcrx:FutureRoyaltiesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2018-01-01_2018-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfLinesOfCredit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Note 4 - Credit Agreement (Details Textual)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
     "shortName": "Note 4 - Credit Agreement (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-12-07_2020-12-07_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RepaymentsOfLinesOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Note 5 - Senior Credit Facility (Details Textual)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual",
     "shortName": "Note 5 - Senior Credit Facility (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2019-02-05_2019-02-05_CreditFacilityAxis-SeniorCreditFacilityMember_LineOfCreditFacilityAxis-MidCapFinancialServicesLLCMember",
      "decimals": "3",
      "lang": null,
      "name": "bcrx:DebtInstrumentMinimumLibor",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Note 6 - Lease Obligations and Other Contingencies (Details Textual)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual",
     "shortName": "Note 6 - Lease Obligations and Other Contingencies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "bcrx:LesseeLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Note 6 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details",
     "shortName": "Note 6 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "bcrx:LesseeLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLessorDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-04-24",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "bcrx:MaximumAggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Note 7 - Stockholders' Equity (Details Textual)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual",
     "shortName": "Note 7 - Stockholders' Equity (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-04-24",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "bcrx:MaximumAggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "-4",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Note 8 - Stock-based Compensation (Details Textual)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual",
     "shortName": "Note 8 - Stock-based Compensation (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Note 8 - Stock-Based Compensation - Stock-based Compensation Allocation (Details)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details",
     "shortName": "Note 8 - Stock-Based Compensation - Stock-based Compensation Allocation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2019-12-31_PlanNameAxis-IncentivePlanMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Note 8 - Stock-based Compensation - Stock Plan Activities (Details)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details",
     "shortName": "Note 8 - Stock-based Compensation - Stock Plan Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2017-12-31_PlanNameAxis-IncentivePlanMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Note 8 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
     "shortName": "Note 8 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31_PlanNameAxis-IncentivePlanAndInducementPlanMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Note 8 - Stock-based Compensation - Number of Stock Option Awards Exercisable and their Weighted Average Exercise Price (Details)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details",
     "shortName": "Note 8 - Stock-based Compensation - Number of Stock Option Awards Exercisable and their Weighted Average Exercise Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2019-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Note 8 - Stock-based Compensation - Changes in the Number and Weighted-Average Grant-Date Fair Value (Details)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details",
     "shortName": "Note 8 - Stock-based Compensation - Changes in the Number and Weighted-Average Grant-Date Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2019-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Note 9 - Income Taxes (Details Textual)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual",
     "shortName": "Note 9 - Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Note 9 - Income Taxes - Loss Before Provision for Income Taxes (Details)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details",
     "shortName": "Note 9 - Income Taxes - Loss Before Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Note 9 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details",
     "shortName": "Note 9 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Note 9 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) (Parentheticals)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals",
     "shortName": "Note 9 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2018-01-01_2018-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GainLossOnDispositionOfAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2019-12-31",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Note 9 - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details",
     "shortName": "Note 9 - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2018-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Note 9 - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details",
     "shortName": "Note 9 - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Note 10 - Employee 401(k) Plan (Details Textual)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-details-textual",
     "shortName": "Note 10 - Employee 401(k) Plan (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-10-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Note 11 - Collaborative and Other Research and Development Contracts (Details Textual)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
     "shortName": "Note 11 - Collaborative and Other Research and Development Contracts (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-03-04_2020-03-04_LitigationCaseAxis-ArbitrationProceedingsOfSulAgreementMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:LitigationSettlementAmountAwardedFromOtherParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-10-01_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Note 12 - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Information (Details)",
     "role": "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details",
     "shortName": "Note 12 - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "us-gaap:QuarterlyFinancialInformationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-07-01_2020-09-30",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2017-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201409Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-RetainedEarningsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "i_2017-12-31_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201409Member_CumulativeEffectPeriodOfAdoptionAxis-CumulativeEffectPeriodOfAdoptionAdjustmentMember_StatementEquityComponentsAxis-RetainedEarningsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Consolidated Statements of Stockholders' Equity (Parentheticals)",
     "role": "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Note 1 - Significant Accounting Policies and Concentrations of Risk",
     "role": "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
     "shortName": "Note 1 - Significant Accounting Policies and Concentrations of Risk",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Note 2 - Property and Equipment",
     "role": "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment",
     "shortName": "Note 2 - Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "bcrx20201231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 115,
   "tag": {
    "bcrx_AECOMAndIRLMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AECOM and IRL",
        "label": "AECOM and IRL [Member]"
       }
      }
     },
     "localname": "AECOMAndIRLMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ASPRBARDAContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The potential value of the ASPR/BARDA Contract.",
        "label": "ASPRBARDA Contract [Member]"
       }
      }
     },
     "localname": "ASPRBARDAContractMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AccruedDevelopmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents accrued development costs.",
        "label": "bcrx_AccruedDevelopmentCosts",
        "terseLabel": "Development costs"
       }
      }
     },
     "localname": "AccruedDevelopmentCosts",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AccruedExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents accrued expenses policy.",
        "label": "Accrued Expenses [Policy Text Block]"
       }
      }
     },
     "localname": "AccruedExpensesPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_AccruedInventoryExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of accrued inventory expense.",
        "label": "bcrx_AccruedInventoryExpense",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "AccruedInventoryExpense",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to accrued liabilities, current and other noncurrent liabilities.",
        "label": "Accrued Liabilities, Current and Other Noncurrent Liabilities [Member]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndOtherNoncurrentLiabilitiesMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AccruedLiabilitiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing current accrued liabilities.",
        "label": "Accrued Liabilities, Current [Member]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AdditionalDevelopmentOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The additional development options that can be exercised by the Government.",
        "label": "Additional Development Options [Member]"
       }
      }
     },
     "localname": "AdditionalDevelopmentOptionsMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AfterFourthAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents after the fourth anniversary.",
        "label": "After Fourth Anniversary [Member]"
       }
      }
     },
     "localname": "AfterFourthAnniversaryMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of amortization of debt financing costs and original issue discounts.",
        "label": "bcrx_AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts",
        "terseLabel": "Amortization of Debt Financing Costs and Original Issue Discounts"
       }
      }
     },
     "localname": "AmortizationOfDebtFinancingCostsAndOriginalIssueDiscounts",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AmortizationOfDiscountAndPremiumOnInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to the discount and premium on investments.",
        "label": "Amortization of premium/discount on investments"
       }
      }
     },
     "localname": "AmortizationOfDiscountAndPremiumOnInvestments",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AnnualLicenseFeeMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual maximum license fee.",
        "label": "bcrx_AnnualLicenseFeeMaximum",
        "terseLabel": "Annual License Fee Maximum"
       }
      }
     },
     "localname": "AnnualLicenseFeeMaximum",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AnnualLicenseFeeMinimum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent minimum annual license fee.",
        "label": "bcrx_AnnualLicenseFeeMinimum",
        "terseLabel": "Annual License Fee Minimum"
       }
      }
     },
     "localname": "AnnualLicenseFeeMinimum",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AnnualNetSalesBetween150000And230000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales between $150,000 and $230,000.",
        "label": "Annual Net Sales Between $150,000 and $230,000 [Member]"
       }
      }
     },
     "localname": "AnnualNetSalesBetween150000And230000Member",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesBetween350000And550000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales between $350,000 and $550,000.",
        "label": "Annual Net Sales Between $350,000 and $550,000 [Member]"
       }
      }
     },
     "localname": "AnnualNetSalesBetween350000And550000Member",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesOver230000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales over $230,000.",
        "label": "Annual Net Sales Over $230,000 [Member]"
       }
      }
     },
     "localname": "AnnualNetSalesOver230000Member",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesOver550000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales over $550,000.",
        "label": "Annual Net Sales Over $550,000 [Member]"
       }
      }
     },
     "localname": "AnnualNetSalesOver550000Member",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesUnder150000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales under $150,000.",
        "label": "Annual Net Sales Under $150,000 [Member]"
       }
      }
     },
     "localname": "AnnualNetSalesUnder150000Member",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AnnualNetSalesUnder350000Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents annual net sales under $350,000.",
        "label": "Annual Net Sales Under $350,000 [Member]"
       }
      }
     },
     "localname": "AnnualNetSalesUnder350000Member",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ArbitrationProceedingsOfSulAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the arbitration proceedings of several terms under SUL Agreement.",
        "label": "Arbitration Proceedings of SUL Agreement [Member]"
       }
      }
     },
     "localname": "ArbitrationProceedingsOfSulAgreementMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AthyriumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Athyrium Opportunities III Co-Invest 1 LP (\u201cAthyrium\u201d).",
        "label": "Athyrium [Member]"
       }
      }
     },
     "localname": "AthyriumMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_August2013Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents award date of August 2013.",
        "label": "August 2013 [Member]"
       }
      }
     },
     "localname": "August2013Member",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_AvailableForSaleDebtSecuritiesAccruedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of accrued interest in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Accrued Interest"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccruedInterest",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_AverageMaturityForPortfolioInvestments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average maturity for portfolio investments during the period.",
        "label": "bcrx_AverageMaturityForPortfolioInvestments",
        "terseLabel": "Average Maturity for Portfolio Investments (Month)"
       }
      }
     },
     "localname": "AverageMaturityForPortfolioInvestments",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average maturity period of high quality marketable securities.",
        "label": "bcrx_AverageMaturityPeriodOfHighQualityMarketableSecurities",
        "terseLabel": "Average Maturity Period of High Quality Marketable Securities (Month)"
       }
      }
     },
     "localname": "AverageMaturityPeriodOfHighQualityMarketableSecurities",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_BCX9930Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents BCX9930.",
        "label": "BCX9930 [Member]"
       }
      }
     },
     "localname": "BCX9930Member",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_BaseContractMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The base contract of ASPR/BARDA to support BCX4430 drug manufacturing.",
        "label": "Base Contract [Member]"
       }
      }
     },
     "localname": "BaseContractMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_BetweenTheSecondAndThirdAnniversariesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents between the second and third anniversaries.",
        "label": "Between the Second and Third Anniversaries [Member]"
       }
      }
     },
     "localname": "BetweenTheSecondAndThirdAnniversariesMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_BetweenTheThirdAndFourthAnniversariesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents after the third anniversary and before the fourth anniversary.",
        "label": "Between the Third and Fourth Anniversaries [Member]"
       }
      }
     },
     "localname": "BetweenTheThirdAndFourthAnniversariesMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_CSLLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents CSL Limited which is a company organized under the laws of Australia.",
        "label": "CSL Limited [Member"
       }
      }
     },
     "localname": "CSLLimitedMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ClassOfWarrantOrRightIssuedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights issued during period.",
        "label": "Warrants issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriod",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of warrants issued.",
        "label": "bcrx_ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant",
        "terseLabel": "Class of Warrant or Right, Warrants Issued, Price Per Warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWarrantsIssuedPricePerWarrant",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "bcrx_CollaborationReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents receivables from collaborations for reimbursable research and development costs.",
        "label": "Collaboration Receivables [Member]"
       }
      }
     },
     "localname": "CollaborationReceivablesMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents collaborative agreement contract maximum amount if all contract options are exercised, to manufacture and evaluate the safety, efficacy and tolerability of galidesivir.",
        "label": "bcrx_CollaborativeAgreementContractCovenantMaximumAmountOfFunding",
        "terseLabel": "Collaborative Agreement Contract, Covenant, Maximum Amount of Funding"
       }
      }
     },
     "localname": "CollaborativeAgreementContractCovenantMaximumAmountOfFunding",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_CollaborativeAgreementContractValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents collaborative agreement contract value.",
        "label": "bcrx_CollaborativeAgreementContractValue",
        "terseLabel": "Collaborative Agreement Contract Value"
       }
      }
     },
     "localname": "CollaborativeAgreementContractValue",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_CollaborativeAndOtherResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Collaborative and other research and development.",
        "label": "Collaborative and Other Research and Development [Member]"
       }
      }
     },
     "localname": "CollaborativeAndOtherResearchAndDevelopmentMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_CollateralForCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted cash and cash equivalents required to maintain as collateral for a letter of credit.",
        "label": "Collateral for Credit [Member]"
       }
      }
     },
     "localname": "CollateralForCreditMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ConcentrationOfMarketRiskPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents concentration of market risk policy.",
        "label": "Concentration of Market Risk [Policy Text Block]"
       }
      }
     },
     "localname": "ConcentrationOfMarketRiskPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_ContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between the contract date and its expiration.",
        "label": "bcrx_ContractTerm",
        "terseLabel": "Contract Term (Year)"
       }
      }
     },
     "localname": "ContractTerm",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the credit agreement.",
        "label": "Credit Agreement [Member]"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_CurrencyHedgeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Currency Hedge Agreement to hedge certain risks associated with changes in the value of the Japanese yen relative to the U.S. dollar.",
        "label": "Currency Hedge Agreement [Member]"
       }
      }
     },
     "localname": "CurrencyHedgeAgreementMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_CurrencyHedgeAgreementPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents currency hedge agreement policy.",
        "label": "Currency Hedge Agreement [Policy Text Block]"
       }
      }
     },
     "localname": "CurrencyHedgeAgreementPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_DebtInstrumentCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The commitment fee percentage of the debt instrument.",
        "label": "bcrx_DebtInstrumentCommitmentFeePercentage",
        "terseLabel": "Debt Instrument, Commitment Fee Percentage"
       }
      }
     },
     "localname": "DebtInstrumentCommitmentFeePercentage",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount of unrestricted cash and cash equivalents required under the covenant of the debt instrument.",
        "label": "bcrx_DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents",
        "terseLabel": "Debt Instrument, Covenant, Minimum Unrestricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMinimumUnrestrictedCashAndCashEquivalents",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_DebtInstrumentExitFeePercentageOfPrincipal": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of principal for exit fee of the debt instrument.",
        "label": "bcrx_DebtInstrumentExitFeePercentageOfPrincipal",
        "terseLabel": "Debt Instrument, Exit Fee, Percentage of Principal"
       }
      }
     },
     "localname": "DebtInstrumentExitFeePercentageOfPrincipal",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtInstrumentLiborCap": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum LIBOR interest rate for debt instrument.",
        "label": "bcrx_DebtInstrumentLiborCap",
        "terseLabel": "Debt Instrument, LIBOR Cap"
       }
      }
     },
     "localname": "DebtInstrumentLiborCap",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtInstrumentLiborFloor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum LIBOR interest rate for debt instrument.",
        "label": "bcrx_DebtInstrumentLiborFloor",
        "terseLabel": "Debt Instrument, LIBOR Floor"
       }
      }
     },
     "localname": "DebtInstrumentLiborFloor",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtInstrumentMinimumLibor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum LIBOR interest that will be added to the basis spread.",
        "label": "bcrx_DebtInstrumentMinimumLibor",
        "terseLabel": "Debt Instrument, Minimum LIBOR"
       }
      }
     },
     "localname": "DebtInstrumentMinimumLibor",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of interest that would have accrued on principal voluntary paid for prepayment fee of the debt instrument.",
        "label": "bcrx_DebtInstrumentPrepaymentFeePercentageOfAccruedInterest",
        "terseLabel": "Debt Instrument, Prepayment Fee, Percentage of Accrued Interest"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentageOfAccruedInterest",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of principal paid voluntarily for prepayment fee of the debt instrument.",
        "label": "bcrx_DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments",
        "terseLabel": "Debt Instrument, Prepayment Fee, Percentage of Principal Voluntary Payments"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentageOfPrincipalVoluntaryPayments",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_December2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents award date of December 2014.",
        "label": "December 2014 [Member]"
       }
      }
     },
     "localname": "December2014Member",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_December2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents award date of December 2019.",
        "label": "December 2019 [Member]"
       }
      }
     },
     "localname": "December2019Member",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_DeferredTaxAssetsLeasingObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from leasing obligations.",
        "label": "Leasing obligations"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeasingObligations",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_DeferredTaxAssetsRoyaltyIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from royalty income.",
        "label": "Royalty income"
       }
      }
     },
     "localname": "DeferredTaxAssetsRoyaltyIncome",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_DeferredTaxLiabilitiesRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from right of use assets.",
        "label": "bcrx_DeferredTaxLiabilitiesRightOfUseAssets",
        "negatedLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAssets",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_DescriptionOfCompanyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of company policy.",
        "label": "Description of Company [Policy Text Block]"
       }
      }
     },
     "localname": "DescriptionOfCompanyPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards compensation cost expected to be recognized year four.",
        "label": "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Four"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearFour",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards compensation cost expected to be recognized year three.",
        "label": "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Three"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearThree",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share based compensation nonvested awards compensation cost expected to be recognized year two.",
        "label": "bcrx_EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Year Two"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedYearTwo",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee service share-based compensation nonvested awards compensation cost expected to be recognized next year.",
        "label": "bcrx_EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear",
        "terseLabel": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Expected to be Recognized Next Year"
       }
      }
     },
     "localname": "EmployeeServiceSharebasedCompensationNonvestedAwardsCompensationCostExpectedToBeRecognizedNextYear",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan, (ESPP).",
        "label": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ExercisePriceRange01Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the first exercise range.",
        "label": "Exercise Price Range 01 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRange01Member",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ExercisePriceRange02Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the second exercise range.",
        "label": "Exercise Price Range 02 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRange02Member",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ExercisePriceRange03Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the third exercise range.",
        "label": "Exercise Price Range 03 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRange03Member",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ExercisePriceRange04Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the fourth exercise range.",
        "label": "Exercise Price Range 04 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRange04Member",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ExercisePriceRange05Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the fifth exercise range.",
        "label": "Exercise Price Range 05 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRange05Member",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ExercisePriceRange06Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the sixth exercise range.",
        "label": "Exercise Price Range 06 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRange06Member",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents expected receivable from awards for research and development contracts.",
        "label": "bcrx_ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts",
        "terseLabel": "Expected Receivable From Awards for Research and Development Contracts"
       }
      }
     },
     "localname": "ExpectedReceivableFromAwardsForResearchAndDevelopmentContracts",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_FutureRoyaltiesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations for future royalties.",
        "label": "Royalty financing obligation",
        "terseLabel": "Future Royalties Payable"
       }
      }
     },
     "localname": "FutureRoyaltiesPayable",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_FutureRoyaltiesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents future royalties payable.",
        "label": "Future Royalties Payable [Member]"
       }
      }
     },
     "localname": "FutureRoyaltiesPayableMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_GreenCrossCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Green Cross Corporation.",
        "label": "Green Cross Corporation [Member]"
       }
      }
     },
     "localname": "GreenCrossCorporationMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_IncentivePlanAndInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the incentive and inducement plans.",
        "label": "Incentive Plan and Inducement Plan [Member]"
       }
      }
     },
     "localname": "IncentivePlanAndInducementPlanMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_IncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Incentive Plan.",
        "label": "Incentive Plan [Member]"
       }
      }
     },
     "localname": "IncentivePlanMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation income tax expense benefit expiration of carryforwards.",
        "label": "Expiration of attribute carryforwards"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitExpirationOfCarryForwards",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_IncreaseDecreaseInFinancingLeaseObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period for financing lease obligations.",
        "label": "(Decrease) increase in lease financing obligation"
       }
      }
     },
     "localname": "IncreaseDecreaseInFinancingLeaseObligations",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_InducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the Inducement Plan.",
        "label": "Inducement Plan [Member]"
       }
      }
     },
     "localname": "InducementPlanMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_InterestAndOtherIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income (loss) recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income (loss) from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and other income"
       }
      }
     },
     "localname": "InterestAndOtherIncomeLoss",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_InterestExpenseAndDeferredFinancingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents interest expense and deferred financing costs.",
        "label": "Interest Expense and Deferred Financing Costs [Policy Text Block]"
       }
      }
     },
     "localname": "InterestExpenseAndDeferredFinancingCostsPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for interest expense and royalty financing obligation.",
        "label": "Interest Expense and Royalty Financing Obligation [Policy Text Block]"
       }
      }
     },
     "localname": "InterestExpenseAndRoyaltyFinancingObligationPolicyTextBlock",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_InterestReserve": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents interest reserve established as part of the royalty monetization.",
        "label": "bcrx_InterestReserve",
        "terseLabel": "Interest Reserve"
       }
      }
     },
     "localname": "InterestReserve",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_JPRRoyaltySubLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents JPR Royalty Sub LLC.",
        "label": "JPR Royalty Sub LLC [Member]"
       }
      }
     },
     "localname": "JPRRoyaltySubLLCMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to laboratory equipment.",
        "label": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_LaboratoryEquipmentOfficeEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to laboratory equipment, office equipment and software.",
        "label": "Laboratory Equipment, Office Equipment and Software [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentOfficeEquipmentAndSoftwareMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_LesseeLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of both operating and finance lease liabilities. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating and finance lease liabilities recognized in statement of financial position.",
        "label": "Lessee, Lease, Liability, Maturity [Table Text Block]"
       }
      }
     },
     "localname": "LesseeLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_LongtermInvestmentMaturityMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents long term investment maturity minimum.",
        "label": "bcrx_LongtermInvestmentMaturityMinimum",
        "terseLabel": "Long-term Investment Maturity, Minimum (Month)"
       }
      }
     },
     "localname": "LongtermInvestmentMaturityMinimum",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_MaturityPeriodOfHighQualityMarketablesecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents maturity period of high quality marketable securities.",
        "label": "bcrx_MaturityPeriodOfHighQualityMarketablesecurities",
        "terseLabel": "Maturity Period of High Quality Marketable Securities (Year)"
       }
      }
     },
     "localname": "MaturityPeriodOfHighQualityMarketablesecurities",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_MaturityperiodOfShortTermInvestment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturity period of short term investment.",
        "label": "bcrx_MaturityperiodOfShortTermInvestment",
        "terseLabel": "Maturity Period of Short Term Investment (Month)"
       }
      }
     },
     "localname": "MaturityperiodOfShortTermInvestment",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_MaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum aggregate offering price of common stock, preferred stock, depository shares, stock purchase contracts, warrants and units.",
        "label": "bcrx_MaximumAggregateOfferingPrice",
        "terseLabel": "Maximum Aggregate Offering Price"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPrice",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_MaximumCustomaryReductionOnRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum percentage of customary reductions allowed on royalty rate.",
        "label": "bcrx_MaximumCustomaryReductionOnRoyaltyRate",
        "terseLabel": "Maximum Customary Reduction on Royalty Rate"
       }
      }
     },
     "localname": "MaximumCustomaryReductionOnRoyaltyRate",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_MidCapFinancialServicesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents MidCap Financial Services, LLC entity.",
        "label": "MidCap Financial Services, LLC [Member]"
       }
      }
     },
     "localname": "MidCapFinancialServicesLLCMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_MilestonePaymentMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents milestone payment maximum.",
        "label": "bcrx_MilestonePaymentMaximum",
        "terseLabel": "Milestone Payment Maximum"
       }
      }
     },
     "localname": "MilestonePaymentMaximum",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_MilestonePaymentMinimum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents milestone payment minimum.",
        "label": "bcrx_MilestonePaymentMinimum",
        "terseLabel": "Milestone Payment Minimum"
       }
      }
     },
     "localname": "MilestonePaymentMinimum",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_MilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of milestone payment received.",
        "label": "bcrx_MilestonePaymentReceived",
        "terseLabel": "Milestone Payment Received"
       }
      }
     },
     "localname": "MilestonePaymentReceived",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_MundipharmaInternationalHoldingsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Mundipharma International Holdings Limited.",
        "label": "Mundipharma International Holdings Limited [Member]"
       }
      }
     },
     "localname": "MundipharmaInternationalHoldingsLimitedMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_MundipharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Mundipharma.",
        "label": "Mundipharma [Member]"
       }
      }
     },
     "localname": "MundipharmaMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents National Institute of Allergy and Infectious Diseases.",
        "label": "National Institute of Allergy and Infectious Diseases [Member]"
       }
      }
     },
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_NoteToFinancialStatementDetailsTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "localname": "NoteToFinancialStatementDetailsTextual",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_NotesToFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "localname": "NotesToFinancialStatementsAbstract",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_ORLADEYOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents ORLADEYO.",
        "label": "ORLADEYO [Member]"
       }
      }
     },
     "localname": "ORLADEYOMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization on lessee's right to use underlying asset under operating lease.",
        "label": "bcrx_OperatingLeaseRightofuseAssetAccumulatedAmortization",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Accumulated Amortization"
       }
      }
     },
     "localname": "OperatingLeaseRightofuseAssetAccumulatedAmortization",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_PercentageOfCarryingAmountInExcessOfFairValue1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of carrying amount in excess of fair value.",
        "label": "bcrx_PercentageOfCarryingAmountInExcessOfFairValue1",
        "terseLabel": "Percentage of Carrying Amount in Excess of Fair Value"
       }
      }
     },
     "localname": "PercentageOfCarryingAmountInExcessOfFairValue1",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_PercentageOfCommonStockSharesBeginning": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of common stock shares beginning.",
        "label": "bcrx_PercentageOfCommonStockSharesBeginning",
        "terseLabel": "Percentage of Common Stock Shares, Beginning"
       }
      }
     },
     "localname": "PercentageOfCommonStockSharesBeginning",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_PercentageOfCommonStockSharesEnding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of common stock shares ending.",
        "label": "bcrx_PercentageOfCommonStockSharesEnding",
        "terseLabel": "Percentage of Common Stock Shares, Ending"
       }
      }
     },
     "localname": "PercentageOfCommonStockSharesEnding",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of salary to purchase common stock maximum.",
        "label": "bcrx_PercentageOfSalaryToPurchaseCommonStockMaximum",
        "terseLabel": "Percentage of Salary to Purchase Common Stock, Maximum"
       }
      }
     },
     "localname": "PercentageOfSalaryToPurchaseCommonStockMaximum",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_PeriodOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents period of agreement.",
        "label": "bcrx_PeriodOfAgreement",
        "terseLabel": "Period of Agreement (Year)"
       }
      }
     },
     "localname": "PeriodOfAgreement",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_PhaRMANotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents PhaRMA notes.",
        "label": "PhaRMA Notes Member]"
       }
      }
     },
     "localname": "PhaRMANotesMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_PikInterestPaymentIsMadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents PIK interest payment is made.",
        "label": "PIK Interest Payment is Made [Member]"
       }
      }
     },
     "localname": "PikInterestPaymentIsMadeMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_PotentialMilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents potential milestone payments receivable based on possibility of future event payments.",
        "label": "bcrx_PotentialMilestonePaymentsReceivable",
        "terseLabel": "Potential Milestone Payments Receivable"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsReceivable",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of potential milestone payments receivable if regulatory approval is granted before December 31, 2021.",
        "label": "bcrx_PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021",
        "terseLabel": "Potential Milestone Payments Receivable if Regulatory Approval Before December 31, 2021"
       }
      }
     },
     "localname": "PotentialMilestonePaymentsReceivableIfRegulatoryApprovalBeforeDecember312021",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_PriorToTheSecondAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents prior to the second anniversary.",
        "label": "Prior to the Second Anniversary [Member]"
       }
      }
     },
     "localname": "PriorToTheSecondAnniversaryMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_PrivatePlacementOfSeniorSecuredNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents private placement of senior secured notes.",
        "label": "bcrx_PrivatePlacementOfSeniorSecuredNotes",
        "terseLabel": "Private Placement of Senior Secured Notes"
       }
      }
     },
     "localname": "PrivatePlacementOfSeniorSecuredNotes",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents proceeds from awards for research and development contracts.",
        "label": "bcrx_ProceedsFromAwardsForResearchAndDevelopmentContracts",
        "terseLabel": "Proceeds from awards for Research and Development Contracts"
       }
      }
     },
     "localname": "ProceedsFromAwardsForResearchAndDevelopmentContracts",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_ProceedsFromRealizedGainOnInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from realized gain on investments.",
        "label": "Realized gain on investments"
       }
      }
     },
     "localname": "ProceedsFromRealizedGainOnInvestments",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_ProceedsFromRoyaltyFinancingObligation": {
     "auth_ref": [],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from royalty financing obligation.",
        "label": "Net proceeds from royalty financing obligation"
       }
      }
     },
     "localname": "ProceedsFromRoyaltyFinancingObligation",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_RAPIVABMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents RAPIVAB product.",
        "label": "RAPIVAB [Member]"
       }
      }
     },
     "localname": "RAPIVABMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_RenewablePeriodOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents renewable period of agreement.",
        "label": "bcrx_RenewablePeriodOfAgreement",
        "terseLabel": "Renewable Period of Agreement (Year)"
       }
      }
     },
     "localname": "RenewablePeriodOfAgreement",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_RoyaltyMonetizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty monetization transaction.",
        "label": "Royalty Monetization [Member]"
       }
      }
     },
     "localname": "RoyaltyMonetizationMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_RoyaltyMonetizationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty monetization.",
        "label": "Royalty Monetization [Text Block]"
       }
      }
     },
     "localname": "RoyaltyMonetizationTextBlock",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expiration term of the royalty payments from first commercial date.",
        "label": "bcrx_RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial",
        "terseLabel": "Royalty Payments Receivable, Expiration Term From First Commercial (Year)"
       }
      }
     },
     "localname": "RoyaltyPaymentsReceivableExpirationTermFromFirstCommercial",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of net sales in key territories for royalties to be paid under the royalty purchase agreement.",
        "label": "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories",
        "terseLabel": "Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Key Territories"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInKeyTerritories",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of annual net sales in other markets of royalties to be paid under the royalty purchase agreement.",
        "label": "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets",
        "terseLabel": "Royalty Purchase Agreement, Royalties, Percentage of Annual Net Sales in Other Markets"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfAnnualNetSalesInOtherMarkets",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of global annual net sales of royalties to be paid under the royalty purchase agreement.",
        "label": "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales",
        "terseLabel": "Royalty Purchase Agreement, Royalties, Percentage of Global Annual Net Sales"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfGlobalAnnualNetSales",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of sublicense revenue in other markets of royalties to be paid under the royalty purchase agreement.",
        "label": "bcrx_RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets",
        "terseLabel": "Royalty Purchase Agreement, Royalties, Percentage of Sublicense Revenue in Other Markets"
       }
      }
     },
     "localname": "RoyaltyPurchaseAgreementRoyaltiesPercentageOfSublicenseRevenueInOtherMarkets",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyRateIfMaintainsSakigakeDesignation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent of net sales that the company will receive if berotralstat maintains its Sakigake designation during the PMDA review.",
        "label": "bcrx_RoyaltyRateIfMaintainsSakigakeDesignation",
        "terseLabel": "Royalty Rate if Maintains Sakigake Designation"
       }
      }
     },
     "localname": "RoyaltyRateIfMaintainsSakigakeDesignation",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "bcrx_RoyaltyReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents royalty receivable.",
        "label": "Royalty Receivable [Member]"
       }
      }
     },
     "localname": "RoyaltyReceivableMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_Rpi2019IntermediateFinanceTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents RPI 2019 Intermediate Finance Trust (RPI)..",
        "label": "RPI 2019 Intermediate Finance Trust [Member]"
       }
      }
     },
     "localname": "Rpi2019IntermediateFinanceTrustMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ScheduleOfReceivablesFromCollaborationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure representing receivables from collaborations.",
        "label": "Schedule of Receivables from Collaborations [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfReceivablesFromCollaborationsTableTextBlock",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bcrx_SecuredCreditFacilityFirstTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the first tranche of a secured credit facility.",
        "label": "Secured Credit Facility, First Tranche [Member]"
       }
      }
     },
     "localname": "SecuredCreditFacilityFirstTrancheMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_SecuredCreditFacilitySecondTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the second tranche of a secured credit facility.",
        "label": "Secured Credit Facility, Second Tranche [Member]"
       }
      }
     },
     "localname": "SecuredCreditFacilitySecondTrancheMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_SecuredCreditFacilityThirdTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represent the third tranche of a secured credit facility.",
        "label": "Secured Credit Facility, Third Tranche [Member]"
       }
      }
     },
     "localname": "SecuredCreditFacilityThirdTrancheMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_SeniorCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents senior credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Senior Credit Facility [Member]"
       }
      }
     },
     "localname": "SeniorCreditFacilityMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_SeqirusUKLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Seqirus UK Limited.",
        "label": "Seqirus UK Limited [Member]"
       }
      }
     },
     "localname": "SeqirusUKLimitedMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents share based compensation arrangement by share based payment award options grants in period awards available.",
        "label": "bcrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable",
        "negatedLabel": "Awards available, stock option awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodAwardsAvailable",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents share-based compensation arrangement by share-based payment award maximum value per employee amount.",
        "label": "bcrx_ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee, Amount"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardMaximumNumberOfSharesPerEmployeeAmount",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options forfeitures in period awards available.",
        "label": "Awards available, stock option awards cancelled (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeituresInPeriodAwardsAvailable",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "bcrx_ShionogiAndCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shionogi &amp; Co. Ltd.",
        "label": "Shionogi and Co. Ltd [Member]"
       }
      }
     },
     "localname": "ShionogiAndCoLtdMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermALoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term A loan.",
        "label": "Term A Loan [Member]"
       }
      }
     },
     "localname": "TermALoanMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermBLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term B loan.",
        "label": "Term B Loan [Member]"
       }
      }
     },
     "localname": "TermBLoanMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermCLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term C loan.",
        "label": "Term C Loan [Member]"
       }
      }
     },
     "localname": "TermCLoanMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermLoanAAndBDrawnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term loan A and B drawn.",
        "label": "Term Loan A and B Drawn [Member]"
       }
      }
     },
     "localname": "TermLoanAAndBDrawnMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermLoanADrawnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term loan A drawn.",
        "label": "Term Loan A Drawn [Member]"
       }
      }
     },
     "localname": "TermLoanADrawnMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermLoansABAndCDrawnAndCureRightExercisedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term loans A, B and C drawn and the Cure Right has been exercised.",
        "label": "Term Loans A, B and C Drawn and Cure Right Exercised [Member]"
       }
      }
     },
     "localname": "TermLoansABAndCDrawnAndCureRightExercisedMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TermLoansABAndCDrawnMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents term loans A, B and C drawn.",
        "label": "Term Loans A, B and C Drawn [Member]"
       }
      }
     },
     "localname": "TermLoansABAndCDrawnMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_ToriiPharmaceuticalCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to Torii Pharmaceutical Co., Ltd.",
        "label": "Torii Pharmaceutical Co. [Member]"
       }
      }
     },
     "localname": "ToriiPharmaceuticalCoMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_TransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents transaction costs associated with royalty monetization.",
        "label": "bcrx_TransactionCosts",
        "terseLabel": "Transaction Costs"
       }
      }
     },
     "localname": "TransactionCosts",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_UABMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UAB",
        "label": "UAB [Member]"
       }
      }
     },
     "localname": "UABMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_USDepartmentOfHealthAndHumanServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States department of health and human services.",
        "label": "US Department of Health and Human Services [Member]"
       }
      }
     },
     "localname": "USDepartmentOfHealthAndHumanServicesMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_UpfrontPaymentsReceivableAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents upfront payments receivable.",
        "label": "bcrx_UpfrontPaymentsReceivableAmount",
        "terseLabel": "Upfront Payments Receivable Amount"
       }
      }
     },
     "localname": "UpfrontPaymentsReceivableAmount",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bcrx_Vest25PercentEachYearUntilFullyVestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents vest 25% each year until fully vested.",
        "label": "Vest 25% Each Year Until Fully Vested [Member]"
       }
      }
     },
     "localname": "Vest25PercentEachYearUntilFullyVestedMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents vesting upon successful completion of specific development milestones.",
        "label": "Vest Upon Successful Completion of Specific Development Milestones [Member]"
       }
      }
     },
     "localname": "VestUponSuccessfulCompletionOfSpecificDevelopmentMilestonesMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_WarrantsIssuedInPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents warrants issued in public offering.",
        "label": "Warrants Issued in Public Offering [Member]"
       }
      }
     },
     "localname": "WarrantsIssuedInPublicOfferingMember",
     "nsuri": "http://www.biocryst.com/20201231",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Significant Accounting Policies and Concentrations of Risk - Accrued Expenses (Details)"
       }
      }
     },
     "localname": "statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Significant Accounting Policies and Concentrations of Risk - Fair Value of the Company's Investments by Type (Details)"
       }
      }
     },
     "localname": "statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Significant Accounting Policies and Concentrations of Risk - Summary of Receivables (Details)"
       }
      }
     },
     "localname": "statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Significant Accounting Policies and Concentrations of Risk - Summary of Revenues (Details)"
       }
      }
     },
     "localname": "statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Significant Accounting Policies and Concentrations of Risk"
       }
      }
     },
     "localname": "statement-statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Quarterly Financial Information (Unaudited) - Schedule of Quarterly Information (Details)"
       }
      }
     },
     "localname": "statement-statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-12-quarterly-financial-information-unaudited-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 12 - Quarterly Financial Information (Unaudited)"
       }
      }
     },
     "localname": "statement-statement-note-12-quarterly-financial-information-unaudited-tables",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-2-property-and-equipment-property-and-equipment-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Property and Equipment - Property and Equipment (Details)"
       }
      }
     },
     "localname": "statement-statement-note-2-property-and-equipment-property-and-equipment-details",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-2-property-and-equipment-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Property and Equipment"
       }
      }
     },
     "localname": "statement-statement-note-2-property-and-equipment-tables",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Lease Obligations and Other Contingencies - Remaining Maturities of Lease Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-6-lease-obligations-and-other-contingencies-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Lease Obligations and Other Contingencies"
       }
      }
     },
     "localname": "statement-statement-note-6-lease-obligations-and-other-contingencies-tables",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Stock-based Compensation - Changes in the Number and Weighted-Average Grant-Date Fair Value (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Stock-based Compensation - Number of Stock Option Awards Exercisable and their Weighted Average Exercise Price (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-8-stockbased-compensation-stock-plan-activities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Stock-based Compensation - Stock Plan Activities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-stockbased-compensation-stock-plan-activities-details",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Stock-Based Compensation - Stock-based Compensation Allocation (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-8-stockbased-compensation-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Stock-based Compensation"
       }
      }
     },
     "localname": "statement-statement-note-8-stockbased-compensation-tables",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Stock-based Compensation - Weighted Average Assumptions for Stock Option Awards Granted to Employees and Directors Under the Plans (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details)"
       }
      }
     },
     "localname": "statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes - Differences Between the Company's Effective Tax Rate and the Statutory Tax Rate (Details) (Parentheticals)"
       }
      }
     },
     "localname": "statement-statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes - Loss Before Provision for Income Taxes (Details)"
       }
      }
     },
     "localname": "statement-statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes - Reconciliation of Beginning and Ending Amount of Unrecognized Tax Benefits (Details)"
       }
      }
     },
     "localname": "statement-statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-note-9-income-taxes-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes"
       }
      }
     },
     "localname": "statement-statement-note-9-income-taxes-tables",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "bcrx_statement-statement-significant-accounting-policies-policies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-significant-accounting-policies-policies",
     "nsuri": "http://www.biocryst.com/20201231",
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets",
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables",
      "http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-",
      "http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-tables",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-tables",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-tables",
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables",
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets",
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables",
      "http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-",
      "http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-tables",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-tables",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-tables",
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables",
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r53",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r110",
      "r117",
      "r180",
      "r294",
      "r295",
      "r296",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r110",
      "r117",
      "r180",
      "r294",
      "r295",
      "r296",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r110",
      "r117",
      "r180",
      "r294",
      "r295",
      "r296",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r248",
      "r250",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r424",
      "r465",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r248",
      "r250",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r424",
      "r465",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r154",
      "r225",
      "r227",
      "r429",
      "r464",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r154",
      "r225",
      "r227",
      "r429",
      "r464",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r229",
      "r248",
      "r250",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r424",
      "r465",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r229",
      "r248",
      "r250",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r424",
      "r465",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r209",
      "r249",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by billing status of receivables.",
        "label": "Billing Status, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.",
        "label": "Legal Entity of Counterparty, Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r20",
      "r450"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "us-gaap_AccountsReceivableNet",
        "terseLabel": "Accounts Receivable, after Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r20",
      "r157",
      "r158"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Receivables"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r40"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "us-gaap_AccruedProfessionalFeesCurrent",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r34",
      "r203"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r56",
      "r57",
      "r58",
      "r453",
      "r475",
      "r479"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r55",
      "r58",
      "r59",
      "r107",
      "r108",
      "r109",
      "r352",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r297"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r294",
      "r295",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r333",
      "r334",
      "r335",
      "r336",
      "r431",
      "r432",
      "r433",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r252",
      "r254",
      "r300",
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r211",
      "r219",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Issuance of pre-funded warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "us-gaap_AdvertisingExpense",
        "terseLabel": "Advertising Expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r254",
      "r286",
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "terseLabel": "Share-based Payment Arrangement, Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r160",
      "r183",
      "r185",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable",
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r72",
      "r90",
      "r379"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of debt issuance costs",
        "terseLabel": "Amortization of Debt Issuance Costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r99",
      "r144",
      "r147",
      "r152",
      "r176",
      "r350",
      "r353",
      "r368",
      "r435",
      "r451"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r52",
      "r99",
      "r176",
      "r350",
      "r353",
      "r368"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r168",
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r165",
      "r169",
      "r191",
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r167",
      "r191"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r255",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r255",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r356",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BilledRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Billed amounts due for services rendered or products shipped. This element is distinct from Billed contracts receivables because this is based on noncontract transactions.",
        "label": "Billed Revenues [Member]"
       }
      }
     },
     "localname": "BilledRevenuesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r31",
      "r92"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r93",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r10",
      "r93",
      "r95",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r86",
      "r92",
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r86",
      "r369"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r222",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r346",
      "r347",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.01 par value; shares authorized \u2014 450,000; shares issued and outstanding \u2014 176,883 at December 31, 2020 and 154,082 at December 31, 2019"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r62",
      "r64",
      "r65",
      "r71",
      "r444",
      "r461"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "us-gaap_ComprehensiveIncomeNetOfTax",
        "totalLabel": "Net comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized",
        "terseLabel": "Contract with Customer, Liability, Revenue Recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r230",
      "r244",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r74",
      "r429"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 0.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "us-gaap_CostsAndExpenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r436",
      "r438",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1",
        "terseLabel": "Debt Instrument, Basis Spread on Variable Rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r378",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "us-gaap_DebtInstrumentFaceAmount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r42",
      "r214",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "us-gaap_DebtInstrumentInterestRateEffectivePercentage",
        "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_DebtInstrumentTerm",
        "terseLabel": "Debt Instrument, Term (Month)"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r212",
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
        "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r35",
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "us-gaap_DeferredFinanceCostsNet",
        "terseLabel": "Debt Issuance Costs, Net, Total"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r16",
      "r17",
      "r321",
      "r437",
      "r448"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "us-gaap_DeferredIncomeTaxLiabilities",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred collaboration revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "us-gaap_DeferredTaxAssetsGross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Net federal and state operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "us-gaap_DeferredTaxAssetsOther",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r327",
      "r329",
      "r330"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "negatedTerseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount",
        "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r90",
      "r142"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization",
        "terseLabel": "Depreciation, Depletion and Amortization, Total"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeForwardExchangeRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual rate at which a foreign currency can be purchased or sold.",
        "label": "us-gaap_DerivativeForwardExchangeRate1",
        "terseLabel": "Derivative, Forward Exchange Rate (in JPY per USD)"
       }
      }
     },
     "localname": "DerivativeForwardExchangeRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DerivativeGainOnDerivative": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.",
        "label": "us-gaap_DerivativeGainOnDerivative",
        "terseLabel": "Derivative, Gain on Derivative"
       }
      }
     },
     "localname": "DerivativeGainOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r357",
      "r359",
      "r362",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLossOnDerivative": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.",
        "label": "us-gaap_DerivativeLossOnDerivative",
        "terseLabel": "Derivative, Loss on Derivative"
       }
      }
     },
     "localname": "DerivativeLossOnDerivative",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted net loss per common share (in dollars per share)",
        "terseLabel": "Basic and diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r312",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Income tax benefit at federal statutory rate, percentage"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "us-gaap_EmployeeRelatedLiabilitiesCurrent",
        "terseLabel": "Compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r287"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average purchase price of capital shares purchased through an employee stock ownership plan.",
        "label": "us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased",
        "terseLabel": "Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased (in dollars per share)"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r112",
      "r119",
      "r121",
      "r131",
      "r180",
      "r219",
      "r221",
      "r294",
      "r295",
      "r296",
      "r335",
      "r336",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "us-gaap_ExtinguishmentOfDebtAmount",
        "terseLabel": "Extinguishment of Debt, Amount"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r244",
      "r367",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r230",
      "r232",
      "r237",
      "r244",
      "r367",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r230",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r244",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Lease financing obligation"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "us-gaap_FinanceLeaseLiabilityNoncurrent",
        "terseLabel": "Lease financing obligation"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r172",
      "r173",
      "r184",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r230",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r90",
      "r201",
      "r205"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "us-gaap_GainLossOnDispositionOfAssets",
        "negatedLabel": "Loss (gain) on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r357",
      "r361"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (loss) on foreign currency"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "us-gaap_GainLossRelatedToLitigationSettlement",
        "terseLabel": "Gain (Loss) Related to Litigation Settlement, Total"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r90",
      "r216",
      "r217"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Loss on extinguishment of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentContractReceivable": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of receivables that are derived from government contracts.",
        "label": "us-gaap_GovernmentContractReceivable",
        "terseLabel": "Government Contract Receivable"
       }
      }
     },
     "localname": "GovernmentContractReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r355",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r104",
      "r339"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r104",
      "r339"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r104",
      "r144",
      "r146",
      "r148",
      "r151",
      "r153"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r313",
      "r319",
      "r326",
      "r337",
      "r341",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r100",
      "r120",
      "r121",
      "r143",
      "r311",
      "r338",
      "r342",
      "r463"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "totalLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r66",
      "r95",
      "r309",
      "r310",
      "r319",
      "r320",
      "r325",
      "r331",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r308",
      "r312"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Rate change"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Income tax benefit at federal statutory rate (21% for 2020, 2019 and 2018)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Permanent items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "us-gaap_IncomeTaxReconciliationOtherAdjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "State and local income taxes net of federal tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r312"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "us-gaap_IncomeTaxReconciliationTaxCreditsResearch",
        "negatedLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as assets that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "us-gaap_IncreaseDecreaseInDerivativeAssets",
        "negatedLabel": "Change in fair value of foreign currency derivative"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "us-gaap_IncreaseDecreaseInInterestPayableNet",
        "verboseLabel": "Interest payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "us-gaap_IncreaseDecreaseInInventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "us-gaap_IncreaseDecreaseInReceivables",
        "negatedTerseLabel": "Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r95",
      "r200",
      "r426",
      "r427",
      "r428",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r68",
      "r141",
      "r377",
      "r379",
      "r445"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "us-gaap_InterestExpense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r77",
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "us-gaap_InterestExpenseDebt",
        "terseLabel": "Interest Expense, Debt, Total"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r40"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest payable"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r441",
      "r458"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "us-gaap_InterestPayableCurrentAndNoncurrent",
        "terseLabel": "Interest Payable"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "us-gaap_InventoryFinishedGoods",
        "terseLabel": "Inventory, Finished Goods, Gross, Total"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r50"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r51",
      "r95",
      "r128",
      "r196",
      "r197",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r49"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "us-gaap_InventoryRawMaterials",
        "terseLabel": "Inventory, Raw Materials, Gross, Total"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r50",
      "r105",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "us-gaap_InventoryValuationReserves",
        "terseLabel": "Inventory Valuation Reserves, Ending Balance"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "us-gaap_InventoryWorkInProcess",
        "terseLabel": "Inventory, Work in Process, Gross"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r175",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesOfLessorDisclosureTextBlock": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessor entity's leasing arrangements for operating, capital and leveraged leases.",
        "label": "Leases of Lessor Disclosure [Text Block]"
       }
      }
     },
     "localname": "LeasesOfLessorDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LegalEntityTypeOfCounterpartyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of the other party participating in a financial transaction.",
        "label": "Legal Entity Type of Counterparty [Domain]"
       }
      }
     },
     "localname": "LegalEntityTypeOfCounterpartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "us-gaap_LegalFees",
        "terseLabel": "Legal Fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r391"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_LesseeOperatingLeaseTermOfContract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r99",
      "r176",
      "r368",
      "r439",
      "r455"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r41",
      "r99",
      "r176",
      "r351",
      "r353",
      "r354",
      "r368"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r15",
      "r438",
      "r449"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Senior credit facility"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r37",
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity",
        "terseLabel": "Line of Credit Facility, Remaining Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LinesOfCreditCurrent": {
     "auth_ref": [
      "r13",
      "r436"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "us-gaap_LinesOfCreditCurrent",
        "terseLabel": "Senior credit facility"
       }
      }
     },
     "localname": "LinesOfCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded from other party in judgment or settlement of litigation.",
        "label": "us-gaap_LitigationSettlementAmountAwardedFromOtherParty",
        "terseLabel": "Litigation Settlement, Amount Awarded from Other Party"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r15",
      "r213",
      "r438",
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "us-gaap_LongTermDebt",
        "terseLabel": "Long-term Debt, Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Secured term loan"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r43",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash provided by (used in) investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r86",
      "r88",
      "r91"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r60",
      "r63",
      "r69",
      "r91",
      "r99",
      "r111",
      "r115",
      "r116",
      "r117",
      "r118",
      "r120",
      "r121",
      "r123",
      "r144",
      "r146",
      "r148",
      "r151",
      "r153",
      "r176",
      "r368",
      "r442",
      "r459"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "terseLabel": "Net Loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Non-recourse notes payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "us-gaap_NotesPayableFairValueDisclosure",
        "terseLabel": "Notes Payable, Fair Value Disclosure"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office Equipment [Member]"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in CCYY format.",
        "label": "us-gaap_OpenTaxYear",
        "terseLabel": "Open Tax Year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r144",
      "r146",
      "r148",
      "r151",
      "r153"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 4.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "us-gaap_OperatingLeaseExpense",
        "terseLabel": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Total",
        "terseLabel": "Operating Lease, Liability, Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "us-gaap_OperatingLeaseLiabilityCurrent",
        "terseLabel": "Operating Lease, Liability, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "us-gaap_OperatingLeaseLiabilityNoncurrent",
        "terseLabel": "Operating Lease, Liability, Noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r386",
      "r388"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "us-gaap_OperatingLeasePayments",
        "terseLabel": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "us-gaap_OperatingLeaseRightOfUseAsset",
        "terseLabel": "Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r390",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent",
        "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r389",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1",
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term (Year)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "us-gaap_OperatingLossCarryforwards",
        "terseLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r40"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "us-gaap_OtherAccruedLiabilitiesCurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of other commitment.",
        "label": "Other Commitments [Axis]"
       }
      }
     },
     "localname": "OtherCommitmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation.",
        "label": "Other Commitments [Domain]"
       }
      }
     },
     "localname": "OtherCommitmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r61",
      "r64",
      "r67",
      "r70",
      "r219",
      "r370",
      "r375",
      "r376",
      "r443",
      "r460"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r54",
      "r56"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Unrealized gain (loss) on available for sale investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeMember": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other revenue.",
        "label": "Other Income [Member]"
       }
      }
     },
     "localname": "OtherIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfDebtExtinguishmentCosts": {
     "auth_ref": [
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.",
        "label": "us-gaap_PaymentsOfDebtExtinguishmentCosts",
        "terseLabel": "Payment for Debt Extinguishment or Debt Prepayment Cost"
       }
      }
     },
     "localname": "PaymentsOfDebtExtinguishmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r78",
      "r80",
      "r166"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "us-gaap_PaymentsToAcquireProductiveAssets",
        "negatedLabel": "Acquisition of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r229",
      "r231",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r255",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $0.01 par value; shares authorized \u2014 5,000; no shares outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "us-gaap_ProceedsFromCollaborators",
        "terseLabel": "Proceeds from Collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Sale of common stock, net",
        "terseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "us-gaap_ProceedsFromIssuanceOfDebt",
        "terseLabel": "Proceeds from Issuance of Debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "us-gaap_ProceedsFromIssuanceOfLongTermDebt",
        "terseLabel": "Proceeds from Issuance of Long-term Debt, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Net proceeds from secured term loan",
        "terseLabel": "Proceeds from Issuance of Secured Debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Sale of pre-funded warrants",
        "terseLabel": "Proceeds from Issuance of Warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity",
        "terseLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "us-gaap_ProceedsFromLicenseFeesReceived",
        "terseLabel": "Proceeds from License Fees Received"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r83",
      "r103"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from senior credit facility"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r78",
      "r79",
      "r166"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r82",
      "r289"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Net proceeds from common stock issued under stock-based compensation plans"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r34",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r207",
      "r483",
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r33",
      "r202"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r204",
      "r457"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r32",
      "r95",
      "r204",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life (Year)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesBillingStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due from customers (or dealers) within the next year (or operating cycle, if longer) for goods or services that have been delivered or used, but not yet paid.",
        "label": "Receivables Billing Status [Domain]"
       }
      }
     },
     "localname": "ReceivablesBillingStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r20",
      "r27",
      "r456",
      "r481"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "us-gaap_ReceivablesNetCurrent",
        "verboseLabel": "Receivables"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r159",
      "r162",
      "r163",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": {
     "auth_ref": [
      "r58",
      "r59",
      "r370",
      "r374",
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
        "terseLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "auth_ref": [
      "r84",
      "r103"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "us-gaap_RepaymentsOfLinesOfCredit",
        "negatedLabel": "Payment of senior credit facility",
        "terseLabel": "Repayments of Lines of Credit"
       }
      }
     },
     "localname": "RepaymentsOfLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "us-gaap_RepaymentsOfLongTermDebt",
        "terseLabel": "Repayments of Long-term Debt, Total"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r304",
      "r486"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r95",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r10",
      "r92",
      "r94"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted cash",
        "terseLabel": "Restricted Cash and Cash Equivalents, Current, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage.",
        "label": "Restricted Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r221",
      "r297",
      "r454",
      "r474",
      "r479"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit",
        "terseLabel": "Retained Earnings (Accumulated Deficit), Ending Balance"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r112",
      "r119",
      "r121",
      "r180",
      "r294",
      "r295",
      "r296",
      "r335",
      "r336",
      "r470",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r139",
      "r140",
      "r145",
      "r149",
      "r150",
      "r154",
      "r155",
      "r156",
      "r224",
      "r225",
      "r429"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenues",
        "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r254",
      "r285",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r270",
      "r273",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r262",
      "r273",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r318",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebt": {
     "auth_ref": [
      "r15",
      "r438",
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.",
        "label": "us-gaap_SecuredDebt",
        "terseLabel": "Secured Debt, Total"
       }
      }
     },
     "localname": "SecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
        "negatedLabel": "Awards available, Restricted stock awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected Dividend Yield",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Awards available, plan amendment (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "periodEndLabel": "Awards available, ending balance (in shares)",
        "periodStartLabel": "Awards available, beginning balance (in shares)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted average exercise price, ending balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
        "negatedLabel": "Options outstanding, stock option awards cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Weighted average exercise price, stock option awards cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "negatedLabel": "Stock option awards forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Options outstanding, stock option awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Stock option awards granted (in shares)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Stock option awards granted (in dollars per share)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r264",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted average exercise price, ending balance (in dollars per share)",
        "periodStartLabel": "Weighted average exercise price, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r253",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted average exercise price, stock option awards exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, stock option awards granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r95",
      "r255",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Lower Exercise Price Range (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Exercisable Number (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Outstanding Number (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Upper Exercise Price Range (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r280",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected Life (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
        "periodEndLabel": "Non-vested stock option awards (in shares)",
        "periodStartLabel": "Non-vested stock option awards (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Stock option awards forfeited (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
        "periodEndLabel": "Weighted average grant-date fair value (in dollars per share)",
        "periodStartLabel": "Weighted average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r261"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
        "negatedLabel": "Stock option awards vested (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Stock option awards vested (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Exercisable Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Outstanding Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Outstanding Weighted Average Remaining Life (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r44",
      "r107",
      "r108",
      "r109",
      "r112",
      "r119",
      "r121",
      "r131",
      "r180",
      "r219",
      "r221",
      "r294",
      "r295",
      "r296",
      "r335",
      "r336",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r376",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets",
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables",
      "http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-",
      "http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-tables",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-tables",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-tables",
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables",
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r131",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets",
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-revenues-details",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables",
      "http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-",
      "http://www.biocryst.com/20201231/role/statement-note-10-employee-401k-plan-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-schedule-of-quarterly-information-details",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-tables",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-property-and-equipment-details",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-tables",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations",
      "http://www.biocryst.com/20201231/role/statement-note-3-royalty-monetizations-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-remaining-maturities-of-lease-liabilities-details",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-tables",
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-changes-in-the-number-and-weightedaverage-grantdate-fair-value-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-number-of-stock-option-awards-exercisable-and-their-weighted-average-exercise-price-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stockbased-compensation-allocation-details",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-weighted-average-assumptions-for-stock-option-awards-granted-to-employees-and-directors-under-the-plans-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-components-of-deferred-tax-assets-and-liabilities-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-differences-between-the-companys-effective-tax-rate-and-the-statutory-tax-rate-details-parentheticals",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-loss-before-provision-for-income-taxes-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables",
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r18",
      "r19",
      "r219",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Employee stock purchase plan sales, shares (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r219",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of common stock, shares (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals",
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r219",
      "r221",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercise of stock options, shares (in shares)",
        "negatedLabel": "Options outstanding, stock option awards exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity-parentheticals",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-stock-plan-activities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r18",
      "r19",
      "r219",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Employee stock purchase plan sales, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r219",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of common stock, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r44",
      "r219",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Exercise of stock options, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r24",
      "r25",
      "r99",
      "r161",
      "r176",
      "r368"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "us-gaap_StockholdersEquity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 (deficit) equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets",
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r221",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-7-stockholders-equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "localname": "TableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-tables",
      "http://www.biocryst.com/20201231/role/statement-note-12-quarterly-financial-information-unaudited-tables",
      "http://www.biocryst.com/20201231/role/statement-note-2-property-and-equipment-tables",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-tables",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-tables",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "us-gaap_TaxCreditCarryforwardAmount",
        "terseLabel": "Tax Credit Carryforward, Amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes",
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "us-gaap_TaxesPayableCurrent",
        "terseLabel": "Duties and taxes"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services  that have been delivered or sold in the normal course of business.",
        "label": "Trade Accounts Receivable [Member]"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk",
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r172",
      "r173",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r333",
      "r334",
      "r335",
      "r336",
      "r431",
      "r432",
      "r433",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-stockholders-equity",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies",
      "http://www.biocryst.com/20201231/role/statement-note-6-lease-obligations-and-other-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts",
      "http://www.biocryst.com/20201231/role/statement-note-11-collaborative-and-other-research-and-development-contracts-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r230",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-fair-value-of-the-companys-investments-by-type-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnbilledRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled amounts due for services rendered or products shipped. This element is distinct from unbilled contracts receivables because this is based on noncontract transactions.",
        "label": "Unbilled Revenues [Member]"
       }
      }
     },
     "localname": "UnbilledRevenuesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-summary-of-receivables-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r307",
      "r316"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "us-gaap_UnrecognizedTaxBenefits",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Additions to current period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-9-income-taxes-reconciliation-of-beginning-and-ending-amount-of-unrecognized-tax-benefits-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement",
      "http://www.biocryst.com/20201231/role/statement-note-4-credit-agreement-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation",
      "http://www.biocryst.com/20201231/role/statement-note-8-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r122",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.",
        "label": "us-gaap_WriteOffOfDeferredDebtIssuanceCost",
        "terseLabel": "Write off of Deferred Debt Issuance Cost"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.biocryst.com/20201231/role/statement-note-1-significant-accounting-policies-and-concentrations-of-risk-details-textual",
      "http://www.biocryst.com/20201231/role/statement-note-5-senior-credit-facility-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32059-109318"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624186-113959"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=118261985&loc=d3e55295-109406"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(1),(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r487": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r488": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r489": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r491": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r492": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0001171843-21-001411-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001171843-21-001411-xbrl.zip
M4$L#!!0    ( &Q*85*WA#?->QH  +$U 0 1    8F-R>"TR,#(P,3(S,2YX
M<V3M75MSVSBR?C]5YS_P^&5G'QA;=IP9IY+9DF\9[]JQ5[9G9Y^V(!*24*8(
M#4C:UO[ZTPV0%$6!%"5!%A1KJJ8B$[?^T!^ QJWQY6^OP\!YIB)B//RZU_IP
ML.?0T.,^"_M?]Q[OW?;]V=75GA/%)/1)P$/Z=2_D>W_[]7__Y\O_N>XW&E)!
M8NH[W;'S,$A"GXIS/J3.'Z>=:\=U#HX^MSZV;YS'AS/G\."PY1X<N0<MU_WU
MRVOD?XZ\ 1T2!R0(H\_PX>O>((Y'G_?W7UY>/KP<?>"BOW]X<-#:_^/F^E[&
MW4LC=SWQ.A6[R[@GQE'\P>-#2'-XT#H\:F6Q/9Z$L1CG"5Z[(O@04>]#GS_O
MIX$R$<I62)8( 751E2X-U23T*=.G@0"(WCJ9CDY?O8$^/H9H\@]8^#2%7B9*
M:^MH'X.[)*)9]) P+](7((-0I-9T"2$/PV2H+\./Q7X\'M%]B.1"+"J8EZ>;
MGV@Z0<0\O600H$$>B3B/WB-15^8-'_5172PQTB900;ID\4A42 0A6%6_3"=(
M(K=/R&BVE#1 4P:$5$B6A6@2H2Q^/"U:JO+C?158C,IJ",)";,Y>3I#7&4*E
MC:]U<G*R+T/W'!+'@G63F%YR,3RG/9($($T2_IF0@/48]:'C".B0AO%4A$)P
M3$2?QM_)D$8CXM$&[1=Z&<>1704;CKB(G7 F<2UI5 =SS3T2R^X-TT15B?"'
M.TG] 8K=VU]4@ID6VTB$/)7\M;(0LZU:)T5U*O73G6306(PZKE7(,)L$_W*S
M="Y^<EN'BTA1VP3KJD*;<)\&<91]65DWNN&F$4>*";,_EI&FOJ]9OG9D7LL(
MU&!P:4*=8LKO*B%RYP2YT_JTG+)FNOQF'4J62OYR)^D7$V*F<V_8@+($B/YX
M52TLIP%#U:\UL9HUEF+*_*^5FHO>:&C47C(#1;65/*.5&PO6[[[@ =0X[:,5
MWDQ/@1!3J9;14Z7QM62%5%<%"4,>R\SDM^SK:,3"'D\_P4<T4CYGEF^']AQI
MMGPFPD.H]<;-_DCP$14Q ^46C&>9P4#0WM<]G&^XF5GRGX!T/X#EE$69*6!Z
M.)-5#4EH<#T1+TN+1/BZ%T$]!S1%_>9P/!(L"@>2>$D@M6(I*)_V%@4%25C(
M+,8T$G113) D I-\*4UA!@\0P6$P,P=K+);6O>MS+Y$_2.B[\"^+QRZV13&4
MI>PYF.ZQ<S7?OE<B-L\YER^3<*(Q-9-I,BG^]>#@P'&=\[2LXL]VZ#L7LECG
M:E+LE_U263-B)!'U;\-?Y>]2RT@3IS'J$DZSKWFZLH;U*=.OF4J;:=KC8<0#
MYLM!HDL":8]' TKC: 4MU^5J2L,M4.M]5B+\/BN4Z9RJ,IU[6>9.O1I%N","
M%E,\H#$#Q&O2=KD04\H_;*Y\YZ>[*1G^NF.#5%3^.7)Y#X*&4/" AA%[IF[
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M4((I,NAW#G17F'8\:'CYR#0;&I=CBA/Z#8/J2T\[9JQP%, P658IVA1_]#L
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MJHNQ%8 .YP(ZW"Y 1W,!67!D;A% '^<"LGEVJQ'W>"Z@X^T"]&DNH$^;!U0
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M,]@T\N:MF.QESMM>P;TLCM13KF<C_3FZ91-;Z=(BG:DK1XJ7Q).G J6]\B!
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MWAV[?!K*_EY0G!/A$#!4CG[P(_1$*H=@\N!-8[:MN_0?4P\-:;I4EMM38[_
M!^X]R7U8.<?)]FI=;X![M3C?D?.?4.YO2^@O%'<"J$^>J2!]ZO9Q%<&';(O3
MIJ;D?0,!?@1MI.BAI<H8+I?[Y"Z1F^(N5;LRB%)6$-07U$-636Y63VDT"CTO
M\TRH:+U2_0AZ4_4R"@C4BA>SY\5Z]N7S_6'J3O.=! 'W%IL?&"KD1ZC5AN->
M@PQ^A-J8Z8U(%"5#=0C)A5F.MF.3XPW.>+A+TU->RBCPF:!>S$4$TR(?.D8<
MM["-FFCQ;R_I]NCW!(P$] ,.W'P%@%AO/)0KM# T^:FK; S$2J.QJH)E3&V#
M!6UM[?H,=XC Y(7?71J_4!I.KY#3GG1W]BP3N +MLG3XESDGZ.Q@$K1DU:]-
MBIU>IFK$'1'($^+(,R66J&E6J*W56L CK!ET^8$+(L\LPNX;^_/I>ERNE2R<
M^];6HYAZTP2[XV[F2DNM+TDG5"Z19SPP. E%_ABB)%A7O7NR=%VO18*MU4=#
M,[,JU5;@GK>UD_VHJX4%\GBS.OFRCU6"VR1# G_^/U!+ P04    " !L2F%2
MQ59?GZP.  #/S@  %0   &)C<G@M,C R,#$R,S%?8V%L+GAM;.U=ZV_C-A+_
M?L#]#[[<9VU>?>UBT\*;9+<!LIL@R5Y[GPI9HF->9=$E:2?N7W]#2GY+Y.AA
MD48+%,U:&E+S&Y+SXHAZ_]/K..G-"!>4I1='IV].CGHDC5A,T^>+HZ^/0?_Q
M\N;FJ"=DF,9APE)R<92RHY]^_.<_WO\K"#Z1E/!0DK@WF/>>1M,T)OR*C4GO
MUP\/M[V@=W+^[O2;_N?>UZ?+WMG)V6EP<AZ<G ;!C^\3FO[^3OUO$ K2 R92
MH7]>'(VDG+P[/GYY>7GS.N#)&\:?C\].3LZ/%]1'.;FZ&\ME@W7B;X^SFTO2
MG:Y?SC7MZ=NW;X_UW26IH$6$T.GI\:^?;Q^C$1F' 4V51"+%BZ#OA+YXRZ)0
M:C%:(?1**=2O8$$6J$O!Z5EP?OKF5<1'(/5>+Q,=9PEY(,.>^OOUX6;CF0/*
M(CX7\DW$QM#KV<GIV?GIL:(\!JXE&9-4!BF3T'\PX6Q"N)P',+X!^6-*)_IN
MR>68R) F E!K)D:<#"^.!A%_#1:/47S^N]VGR/D$9IV@XTE"CH[79!"%231-
MM,QOX7=.KG"Z$4?&*'F5!-9!/EH+7A,6;0AM?=(.0S'0,V J@N<PG&@FCTDB
MQ>**%J]:.;F \\N_]:-H.E8B(/$5F7 242T-^'="U#_Z:=P?,R[IG_KZ?0[C
M/@E3"?>N%T@6"))P0)*+HWUUGPDH4>N$\7PH]RN@4I8^<29$"6Q<(X_ ?"%E
M(XAI8@*RML3Z/.HQ#@K^X@B,Q NASR-0OH$V&5E'(8]V%M^F=LLICL5T/-:=
M!A36WZ+]D+-Q1=;9OB<K<(P2R>E*)-Y(I,H\7N%\?URD7%LW/6_!A@(1"63X
M2D20 $?!@ P9)TK;SJAR2 +XN4E6SP"U\JSNS%"+['9IC&XT-[? [4>8MI<L
ME32=@A]Y-U$^(O L/F@0&=V38EKYBD+2J$1[M=!C]UJZ!M,?X2=]3MN3PE:'
M!R&$SS1EG,KY32H)AS$$A;79BU)?<OZ9R!&#.S,@44NFS(@[X*"1(=V;U7 A
M"-;^[/7)$!^>2(O5HFNC']/A$*0!<;0R</*%D#20(Q( R21,YR(@<#^2=*8;
M!"K3H",P1:-ZGL(ZFZ]NM>(<[)<G9TY$%[!PSL;N@*@KORTGZP.)6!K1)'/?
MEY>O7R<D%>0#2<F02OA%L[E^-[P,.9^#SG@)>;QM#?;1M2MKNL.IT?*54CMD
M?U/^EZ,P?08E=45@9G(2 T%?""+%?\)DFJGU)&$O>9K-B+1QQ]X)Y3H-(ZE9
M?X#U5@]_<1_>0,W-_.HN,'F5JRE)PZ0::&QOWL O6:9]^9& (Q,FCPNMNP&I
MFE":/<,;47UARJQ,P3P-$I)#J28(4P_>P+P#8\O[\?^FF,@&W=H;>&JR$?![
MU3Y)LN:;5H-IZ\4;N'#A$HP/E>*!" *N]J@:T/+VGB9L;7['3@13&;)_,6 3
MM&TH9ZQ$S@Y"(KBUC<5\?A"8J_DM6.S?' 1VL\G"8OWV(+#:/1 LWN\. B\F
M",$B_OZ@$%<..[%B^,$/,>POI])E/A*X%BRAL=HO#@9AHH8E$"-"9(4$(J*3
M3C)^:#X:I>@^3N64DP<V#Q-)B;@/YR'HLJ*,FYFR>Q>]'T5L"@8F9^1RRKFQ
MZL5 [(YY6&F$SA1+7XC$03 U<0*$3TE\2\,!Z LU,:PHS/1.("R*3+3S<LG&
M$TY&H.KHC*SV94#:=T/0@O:ZJBJ].( ;0S &"BI,[D,:WZ27X83*TLR<A=H!
M^]K\EG&[<=,5<Y854$3C@-592!.E1<!L/X8)>231E.L%>44&<O7+ J9>+]W#
MO0S%"*)0]4?MRLZ 5]"E?:D]%YH^*W^N+/]8J:T#:&P\5G$VBWXWHB@AZY[A
MA3/]0&8DG5HLMYFX>^8_TE1Y8K<D%&1AQ>9F")@FG@"!B#:JCF6WE8N,;5:$
M@7('S<0NF(?)K=*"Y56_123=,[KFMX%&U,IDQ!*(9$56ZU+"/+:94T#F*>.3
MQPJQ)8&@6Z?52]G=)7'#J%BP89-O.:D#QEGZ_$3X6'DQ5IUH)NZ>^2],$EQ8
M;*#LGNTL<ZR]8ZO(C;0NWN+(O12K%V:@=,+V!**Z/*\'FGE-K.:)4Z'E7^*=
MFOT >0 7A5.5:F\2OM3LQ05<&8(5B*]#G@(W8N/MGR&-2HT=OF'WH- ^4CVO
MR%T->O%B9QB/U:<]?RN,RJK.I_U[*[H:*L&GO7HKOD;*SZ>=>2O21JDXG_;E
M[4C1.R%86-WIRT(\S75)=YJR6$5BO2?_=&,1'D1TX=/,,J0F-LRQ/>?ETW3#
MH<*DAWV:=#A4^(RQ3\88A\V>Z/')[.(P6?,H/ME7'"1,Q81/U6UH5)CR Y^T
MNR$NW(Q2S'DEGU0[#A*J], GW8Z$U:10Q"=UCX-;-3?CD_+'(31OK/ND2M#;
M<%OFNG@CR2>-4@L98MO&)_52;_3:,70=NX]6?.B*5)_429T!K%1OX:F7B09K
M2X$[JR5?7A8!&^KS%9866Q_EM&"S8G4YMMONZ\VK<=;PD(CEZ2G:'UJY0%L;
M)4AJ)P5XVQZ<I5@8T<(%# $L?&(LUBN6\!F-B'B$Y5B*PM; #0C%3;Y=4U8H
M7$;6/<.?P#M6T_=N\=9@9J>C^17A=!9*/4&$Y%.]&K\P>44$4*E5VA<_D_@9
MG.HU@A*\>WJ*&W$)A80 ENM7"7Q-J1@IKNZ&RI,S" #5SEWEHNT0A$(J!]5%
M1):J:".-@XJB[/ L-74M#!LH'15"%9B(KRDG84+_)/'/H&.!V=6J7FWO]3D5
M<.L*?J;/]["Z66PQ1OM^G).Z&7W2 "CX*S(C"=.;4>;UA6KC HK>UU@<"L?#
M2/Y"Y>AR*B0,D7)_DJD:&[5;!?_%Y</<H"<'L'50-[<,62&1@Q(?DB1J>>B#
M\Q-U)G$\IBD%:ZD-JQE$M<9^E@*5>E.LNK/H4U8)@ZN"WO IF82!5F=J^I10
M0@V?08?XE+HU.2BL125?8_GM[_0A)&AS,.?3*!;[Q:QB;L.K,2J%A I<?%*)
M5B058TB?5"$*V]X2!#XEX:V2L(:"/BD43")QN[!M[Z&>7RY<)0$9$A==;C[H
MTYY/ [7"Z)!&(5P*LWH<$'TP80F-8$#T8<[JI!Z2ROR0<)6MAV'Z79&K0I>
MY#:QYD':>^6ANX.S.X#1: \D+TM:"R"T3U.T 6(AK1+]FIE9OKY1'+]B2/\^
MCJ8^A'O.AN"BZ_JGCP2)P]*H>S#7L+;9G( VU!4_Z'%!MW/UFFK%>89KU#T8
M?10GZE5A Z6?22F[M'<J_MLM#NWDG8PJ("LN*I]B,Q1.O'WT*32K#,UL;7V*
MM2K-SBHFS*="ITH@K5JT\RCCNR!1M64!&R3T.?=\E3/,E$94+K'RDTFJG61.
MQA 7*K\9I))'A<I-SGI(5A*H&6UTPDMW44>'<+K\)N"MRAR399IDLS01YK9.
M %V5'D=0M;F#PU^0'/:'DO#_DI!_I+.F: O[\A?Z%YAP3R\DF9'/,(U'9645
M3;OS5P M#?OAC+CFE$UY&X#7NO$;\!,\N(TAWNC'<\@OK W JU[\C XK6R'6
MME;S*8SL0AHEZ\"G*+,S,6RO#I_BT:Z$L&OV? I=.Y/"CBWT*;;M0@H&S[?S
M8'CK ZOJO1>6+MZ"B?,WK/474T-].H@.YYK'O6T_MKL0=S^<-]I+V_E4BYIY
MZDO*JRB\:"NK0K,6]MAVGI;7H66;SRC^"ENTR]I:3NM!:9J[X5=!"@_@K]'2
MW;GCRP_:K'%9XO-BFK@#LIP+GWCYJPUF8@^87YD(X$N?QC;,OR2T_85S&S)\
M3S[ 5EE -+)U8@^87W[5<4/*EH]BUNS%#[B+:_FFBZHK@K^94Y;&^3>QQ.,H
MY.0#>#KQ.H':@:H@D[8>Y51P:XJR]'@XNTRJ].)GHL&B?EE=]\.G]($=8VLJ
MVZ=T01/8N_K<IQQ  V15=+I/ 7_==6IPPWV*Y)N-:+L6R:<":I2#7RR=ZK;)
M1YUM UX[LNLR>6,ZNR04HV"8L)>6#FG9Z<[YX2PE'#4K2!XS+NF?FOF[X145
MNF(:9O8])V,Z'=^EJ@IIZQ//&Y7!=3IH(7L!TYFK3.,5R?[>I-D)2HL,I"4+
M5*-Y"TR#^H@(B85Z;>\A?Q%#O8%AE7*EAFTSFAF^I7Q6HK%R:FWIH.IZ8[XN
M62LJPZ_2Q,$!.* .MLZXWSD#?_/"&F7V5L_N(LC?&KU^C?3WL-57OZ^'0Q*5
M17!NF' 1[TXXB;+/9,._$Y)[1.M3HS3(Q3=U>2H1J.X)$S2;Y,:/KZ+:N#A>
M9WLB;1UM7 ('W<X'2$4O>R\WV]  4;WX '?U4JIQ1N(;^@!JZX!^TZ<@\4W]
M )85K)=OLZ#:^  E_QC05CR\^5$@-,8JG?D ?O6]%3S&@C9.CBQ3/@;XH#,*
M$=&'.82L\9IKWX] (YBV :MWX W(+!!H -+0@3<@EUGDNB -'?Q]PIZ!U44=
MSQ/K1^#!<V+^"E4)F)J]>  7YE$\C:R."+J= TAK@?F-$%-UVO3=<.U,^S)(
MV':^0-)S2+T86#X-L>U\@?1+R'E8?N@KKI%;,+?K7P-"X"BD=PM!*2APVCYG
M[VW-(>(MU5X(@#5Z<PQ?+?:[B<Z)7K\2'E&PJ!B@IG8N#MJ<Y$KZ;HB9E%9Z
M!^=0%NZ_E?!O)FY42['7P\:J>F^L?CK MW/66H5>&IC5J+ X'-2E:06?JB^:
M@<9O2_A4?E$/<].M1I\J-)J->O7M!"SV+C[>U_XR-^=#L=B_/T#L%9+X6#'\
MX+T8,-X,%NW;0S1LU7/):.^FHX-Q&X@#=6JC!647-5=M#[IQ0Q*-_  <N0I;
MRSX5%];(J+.6LP(^E1S6$T?=0J=#B&.P,Z%:^KA&+',PR*OL#!R *C#M():I
M GO>[  6?0W@ABS;(:QU)&)D7O$ \A4UAABQZW( 28M&P$MWT X@5]$(>/&^
MU %D*2RH:Y<_'T"2 @.]=DF]3^;;44$S:S0"WOD"WDK16OY3P\'XZTG16BF&
M>"4LOZ'^-P#&X,K_ 5!+ P04    " !L2F%2!1#0N]!H   [>P@ %0   &)C
M<G@M,C R,#$R,S%?9&5F+GAM;.V]6W?CMI8N^G[&./\A)^=9*ZFJ)"O5H]?>
M0Y;MBKM=EK?M2GJ=EQXT"4GL4(0"DK:U?OT!2-UL$< $"8*3,GIT=UPV ,X/
MEXF)>?WW__VR3+Y[(BR+:?J/[S_\[<?OOR-I2*,XG?_C^V_WH_']Y.KJ^^^R
M/$BC(*$I^<?W*?W^?_^O__O_^O?_9S3Z0E+"@IQ$WSVNOWM8%&E$V#E=DN_^
MZ^SN^KO1=S]^^K<//XV_?O?M8?+=QQ\_?AC]^&GTXX?1Z'_]>Q*G?_Z;^'^/
M04:^XT2D6?G/?WR_R//5O_WPP_/S\]]>'EGR-\KF/WS\\<=//VQ;?[]I+OX:
MY;L.AXU__J'ZXZ[IT=#/G\JV'SY__OQ#^===TRRN:\@'_?##?WV]O@\79!F,
MXE3,2"AHR>)_R\I?7M,PR,MIU$+X3MI"_&NT;382OQI]^#CZ].%O+UGT/9_U
M[[ZKIBY@(:,)N2.S[S8_?KN[.IZ+.,U_B.+E#YLV/P1)PDDN1U@P,I.2NIU
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M96[C9"UP#X7_-QI&(%-;46T<"*J##%7+(3]>NM60A[ZXC:RV>+7:<XI'<Z9
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M_I\4RR+A^_Z)7' Q)\QO"8MI-)V-([HJV6GT/T662XM(M1D""<#Z4@<FW7
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MEVL;V/AP59]ISTX5)*B;6B#FGJ3QEHE>!F$5XRRE1]\:DTH1(TWO2,V9L?Q
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MCB0.A5'YCCR1M""6%Q4XO@W8JUCHE\N+>4DB_HXGE3F9/+ B4XA=1ATM$/K
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M".\_;_ )U/D["[(XNU\Q$D33]'?.2H0]1UU]R:Q[WP!](4-3>T]_4'V-/RQ
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M_#4@POL/GO>)OWSBK\X!^&Q86( (!0P(PF%#]T1?O.3\W5G$V4+04A6H4YX
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MD/FX16LQKAKR-G6\E'KEJG8'4B.-!]1-P?I6545<MS^/ XG!-EE,(UD>:A1
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M4,PZ]PT.>%Q@G7" T>\Z8"^?$:K/C% ^K9)WFO).4^_*::K-%3HP_Z@F%^O
MG* :W;8#]8$R?AT-S!7*^-DT,*<GHS?50%V@X&\MAXJ^E.9D]&$D?%;B61P&
M_%=!& I3(J=JM*))',8D&W$JA:8L).DF<"X;T=F(Q=F?HZQ8"L^0\M^5N3SC
MMWX>Q":Z02=DN% G.@0"TT!**HJ^=HY-H]):7.]6*:^%VG@0DT>2!, ]^2MF
M1?;M/VMC;@^I5+>T0 K.LKJ(J]QZK?A):\5/JY"LKX&)G&1?.G%(D/JO0;'9
M2,H*!;5MW)/Z3LME;)RQE2M4V\9;#+S% +G%X%V7,3B9=/\^4YLVX9?B"D5E
MT?*9VMXLG.)F=0O*9_GU67Y[SO+K)N<@Z'C:T+BB8DIX<AMCSRP)T6"[A>K]
M7KS?R^GYO5@,@G9CN/TX6C'*3V*^+BV*Y*\B+GF_[-?-[+(MO^+,[&J%SE96
MU>MM6I/UQ?8K<AN;MC$F\Q5&FMZ12<U8Q3<.PV)9E)'2_%' 2!A7^4<)/X0E
M%TZC\9*R//[7-@]R>4)NDR#-^=]V.U*B'+0]O/L)NBP8YST%$U+T9?PB?E+7
M7]9W< _B6M1G6] DNEJ*E#M5'DXE"D /]S"FLQE_\ZA9)JAM+\:D^IU]7%#N
MV,0$[8D(UA>1E=<4T:M.B,#<$!E_@W1!!.0XMRP43TU6VM."U;^]^9[.\N=
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MP[1BIJ)E+V2O^!M[XY[#.?3!M*HWCD'//F#1%6'Y6A3'%!D(Q%VS$KIJN?@
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M)&",-7UZB?45,@9_MCW%$8G.UM\RD3!B)QN/0\X15-EKS0=  [)Z.[< J1@
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MZJU2=#I3;_OYY\K:?W^2B)T_5](77.33.X-5N]X)R8LQ_YX;\^H$Z@%@3\B
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M8V.AKK6M\QA]_S^7-S51C<*4+O\=<6ET#L QCWXM"0"ZYMQ&H#MJ-8.4)?&
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M:CY'*6POY^59E.>O?.\J[M,4-@0Y"])HC(3FVDKLT"$+C@A&W9U3A-#O%EF
M3=4@C__0PFM&9(I0T#<%L,+'+/'?K\*:J*D/Y9R$2C8""PHI:C@J/(((*%HL
M)R^,=^PU2N%0LJ>8O',,UO*WYW)NUR6PL$7AW=QC6BSQG*PDNX#2N+N-8?^;
M9N,^QB8J:0'Q5I:MA0VJZ-H1G2X>+PKY3MI(H6-F'/9=[?(4I9=4F1MX]'=T
M]4HUCR^U:0!B-,, 6X3P"VAD&%=GI3.'2\P&.1$D?.AW#=V#S ((3Z:^@A8R
M<.@Q8GV\&",'12T(!5U\_<2>OXEIPM%]_SW\< (_M):>_^J_YMSTQV#^+]/H
MZ6#5E7\?N>!'\[AO!%8!(P#-ZY*K><8&&>%Y\\J=9$Y77-Y$.0?<X'ZBY<WR
M(7I1;5F'O\!N5-4S^_)E/2A@O)M5BI =0Q=M'#3ZA[K:<FN(#4-PSJE=/$O*
MUWE.HS,6'SI#U9\15K$]C?-S& Z+ # "T+P;Q4Z.L2$V^#6)GPMX9J,J75%%
MZ]V#D(9O?S+7(L"A02%! V]&;EF:+%[)3]5_0U>8*WC+]!CFNSWVERH+(\F>
M;G.6\1\7\FD(R4WYOT,M#;#3H)MLCP/GO@_W%[)#B.QC-#GY1"\6L[4"AIV%
MSUC*IV-Y]>C7@B;/D#_4W7IZQ!>8WL'],SMWAVWHI 4>_[*C;8*,'W3,6U2!
M(/.(L(5A(=+#<YJL'[=Y(9( X4,N6_*^)J;/-&6B817_L C2%%A3^AAB!4+G
MH];ES7])RM79MBAYG)M?)]&C>)Q2X2R0LUC+5>V%YKZT?4ES>(@TYX*9!:HG
MQJY ;S;G"+9Z/R-8LTST-9;-[F^V95%RX\!=E_J08/ 3_"F!<FKW[@)@DP*
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M1@LZ\'1._W K>1*[:<.D1.S@FV<_F-!B(]$!X(=]>69 8)2Y"RK.>3G0>.!
M>LXQVG\V.+Z :;R=6@"P8$<5>PQC0USP:P)_X)NG MZ<I<5-=O$"NZQM4JP
M-;#9CRI;J/T=TB@.SN]:=,1KQRPC= \V>.:80P]B3O1YSM",]+!CNE]':7JZ
M+9*,%EUW7CVCT#NDO=D\[8P$3%(##;0AZF8CT^2-W98HERR_97FY9&G".E[4
M;M^^C/O20LL3!800+4X4J)AV\+!&H8T6)M 6L,&F5;QLK5^)-6HM]2<!@C<-
MP4F+X)@/@#N\%:VJG<.W)QE2-T4[$BV>^P]OP/G=T132)Q_8=5(F3V(M[VE9
MIK2C80+J6X,P9Q"&KXV@%C*87:$C*A&&"# A[P"7KTB%#=R>[_ A.X1"/G(X
M3O:8$:M]A'PKFJ9#9^-=@_ !7VLR7_$>@ Q\_MW)0Z;'&"]G"ZT,EFL><%Z5
M=-V7]]8WW.#LH6M:;V<1[22>GP \$?#]MAO79C(;RSG?8O0 -?=Z(K0WU([X
MB"G#B(X /0FIV>>K6F(ZF.4W'+RG^7.RH+T/F':.089W>W.YEI(*6-@'3+NY
MQ[18XB$0N=T^ILGB,F718=3?.P8=AK3F\A2%2(A$@ P4A'0QD&EQQ5.N3G[&
M8^,GEJMCT<Y11AD[S6P>DW9R4@,-F+=SS,:CU!T%;T)>!L]?$E6]K7J@E0M@
MF-#].P=[-Z7D)P :QF'T<%-Y.WK,(@^&H^K%=D?A&"_)GJ!]3&?-CLYPM"GI
MGM:33:E[Z#70B00?R+H,L)B-Y5M(>_,I6M-S!JFL6E;G>+@5V[.;UK,%FA$
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MM$FAL<EIVY<FAIP>G98-S)XUJ;8)CS5V@<V*AHIUF1-=;OL.DV6GQH3"R97
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MUWO*PI(9W^#A^U?9T8-/K*3%;?0*+NXR2G)14;B[;%<(N^972(D>F-W79<@
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MT&5AL<CYQNRJ:OS;9:90$V",U"A SI]7D.#(E59+9/_4&.M>N??>;5216W>
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M]=UUG=N#I^0QI?+._S+).&+7R3.->TNIM;]#]V$?F-]]0_8: 2(QF!&)PXE
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MR=:*QQ5W"TCBWT@'$!TL2I"FP#Z,&/,O&T'*"NYD8Q; 5793'.IXI?V=6<F
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M(3J8<QPG; S/7[];O2;30M8O0[Z%8D_7,Q*Y>>N8T=<NK0,T9CMFA0+$O@L
MR0?(F&:>@*,=5I]0L!%\\GS\7#TJ_)>D7)UMBY*CE%\GT6.2)N7K?O?7ORD?
M\<--@CW^'07,V_'M**Q0QZ^.Z39Y%?P+QXG42,U(@]:,U%V0=6EW=62*DU!F
MA_V3.+)L# _VR+)G KM'EAV  A]9=F!D\<C2"KTF1Y;;0M9%[A)I)WI<V2>"
MP\>5@WPVW;T!76 E9#;ZQRC_F99W2?&SS@9NY+>H/9PF#.?;N#8>D$\G,2&
MBIVMG#-"S7=SA[2O)>TYT!YN1S=6^I@1IWT7@U)H);P[UQ$=JV0V4'\'E1%?
MHHM!!R&X[T8A4-@=NL/Y'@,TJJ.'DD0"GT UH?I+P SX.HD033:M,0C1>B:P
M&Z)U  H<HG5@9#%$LT*OK5OE=U6\!KDJ%5I3#=CZ!'(X8!ODNN^SDJ*\6?[
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MD$XV<J'\YW^#WM=MGA2;1]4P@USO]G3^*MKWX>)JUDUQ1]1,B.O45BTKU2+
M899ZIS P72X9]PN+MW)O"^>C:M_1-P[7Z>MX/O?WF#5,\;(RWE'801[K(E(X
MW0<[#C;]@*8@#;9Z)(-I<\QWT2=;<&]87'(Z(#[CD1N]$<^HWRSA@J!\51W
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M)M<48R+#!B41#59($8D5O(,B\8(_ F9$H#8YPJV< V_V6+&H61$UK* -*Y;
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M7B5DD)-,ESVFR?9BXD^TA">'BL_P:-MWO_N6_[^>W'N]3U"I^/U3.\_,E_(
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M_MF>'S2'SJ,9T9TUZO$P3TQ\3N=Z8I2^SK5<\L7_:5^'%G5PT6OBD*M#P/Z
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ML,1+!N(M+_&?\88G$6Z#*G=)#ENITUFL[I/H7L7"+NQ%U#6]0X5NLC5=T^%
MZ_>PAD_+5+3E6U%0(LQ'1V>FABSXM(/0GL6Z^07FZ885LODF''6;^<0_2M_S
MQ8 BXBB8J<_,^RKBW!!P_ ]U/_2@OF);X[AKLMU)$/>!(:0Y6!6:T$-.#;]7
M]X"I-/FR)ZQ$Y!4;$;]LJ52QOVZR328ZCPM!<@[FP@$TWQ,!(W>H\8S\[/3>
M]^#[LA6D(SHKM]V&E#5T#,(D:>^%41:FS?AQQAV1\ZTS'446"#U'?YMX!-1=
M:Q-L?<4+3FN\'V_@0^Y:Q=3GL R)48;T<KWE7:MD_'WO6J<&-:QN?\1E]IA
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M7Z$8SW%\@9Y12E95D!).V122"=)IS#XTV/+=*US@< 9Y2--NE<O\$M'D0EZ
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M1>7@D/7?(=OF2B<=CF9?\%);PK2%I+'[8SHN):B2XHLYN25, "7"%VMS2X2
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M<<,$H;0@J5,DR71):('_51$_FU]L&D*QH_:6HB4NE[/L.GM&>:4S-OJZ6SW
M@*__.HLI[]%T@>K_O<Y>+X>J=Y.BYF:+Z0:(OJ4D1BC)>6SB'=._\;]0\BG"
MF1)EK8FF":UK$+SBLX-&2:ER9HA6<#Q:X<WN?OV0O'J"T-D.F#(\(^?L\.3_
MCR=?/T<IWRYW;-]0'+.#EO_ 3JRW?]@;^1HRS(ZW%<FC]!,EY:H*!V7''??J
ME"C95( Y/F]LD##Y*4 ]%-0_CQ3J6T0Q28XOP@WWE]_B190]H3LF@US.YR@6
MA0,,2X3=.J],UHMQW=D$,3EP4VIF_\@3@*0S=7C&N"C!(_]G6;WF<7UX-];;
M!LVQ6N3Q>#5MC0FWT5H2;*&<9S/&Y9BXIN26HXZE2A9!3W&!W0MV4CQ7_4ZD
MRU(]T;&U61GXV/&X66-,TP9S=CS5K17*=9.,O5Y<DEPZQ[$/Q13:5823@ZIC
M[ RO*D-I+DK(PQSC?\\<!&9S;X[52L?<?L4$#Z:</N,$)6?KKSFOH?.JG4QC
M=C[(:N?#'V!30!%06=L(.K#9\  'V7RMP=F6S88'6&93KX2%/5+9#529H![(
M-&;"/473YPBG?-]?$7K/1/U[%)>T0O0"/8IN.,VG6#T?CVAEBRDI8Z5\HIQG
MEZL]Z]UUGI>\3!;WJ2V7)+OG#4-%7$'GN<)2M9)0(EN,T'FNL/1'1&ET;#_6
MFV27&>Z.RMFZJ4H# _AH'&^7!7Y,,3'N<U3PDVK-%&+A&09@L,73++//-_ML
M55G&+K\A&N-<6#T*/,]&.LQJ<T[/YI!%*1QOM]M%8^EC 0O-@VU6Q1IW6@];
M 4S$O.+^VNEC7ME85.1+IGB3GS3RV';9)PK9.*>3C1/J4CD=5>5B72J)JN[=
MDI "H>\+ZR$6T]W"Z.T<;/W%:CI;I LFL?H2< [L=PZ.OO$E4!S09:!#C"(8
M)7B##_=/GA8^5#!.;?M].-MH0,_I!<;)AQ8?[;R\8(C:-O<8!T2M/,1P0=*G
M1 7MP!TX3-H"]ZA@4@>0P)$:2QJ4)D0:\5%PK/1E<%?[$;7WI,/1@@OF[I_S
M^NY?.$YP07V$.&F& L!1T^[,Y^*Y9<1G",<,+L0[B%G;A"HX/'#9?:3'.R >
M#(X67(QW<#&U#("!&S2],'WKQ)[ H?'"&*X9! %'QPMY'!CL T<%+GF[+R/!
M@T[@^'AA!-<,W8.C,WY3>)OT;#@^HY:EN]4%@(.D+3R/33H$)$7 T?)'EK:;
M)PM'7%L>7U6T,1!HX1WN'?/NX5YY;3F_1OTR<U(TL9F O\/<;D6BG$OS"Y*R
M[YM/$&-O9R_N5)I(\ESK-8J4M,&*%35&L.:TV(M>9?]U&+G*_O3?Y^6R3"M'
M=7T,UN?F;#Y-2*5739/_*6OK3F,)^RZ/Z!RB:X;!XXHRNM/<8*2Q9H_^1&L-
M;>I"KED2T23_NN*;A>VFGW[\*&V=H#77+=9^^?%]:]:.YEIAK5Y7J':P\Y R
MBA8HR]E"J^,V5>SIS;? 8I+@NH[H;829+'D>K3"3E>5L0>;88&5[!N=7A'Y!
M+[O5Q;21C/TSKB\E65>H-L^PRNH#$7R.*A+R\3 2\HY?P#DNT*:X>WU0WJ&8
M/&754WZ/TIV0*$:GU]>Z">C&-,V-1\+TM=;/L5 G:N>'D.YVX;CA2;ZLA$>^
MKDC&()8VU9*.#7G[$E)%5Q6GBI$XF^\UQS[@0&>JC03.@JT!E&P;.4N7O7RP
MQ=2[@X4MN\U <T(.IVX.Y_V>0ELC"T_F5,_U)JNS+V(9@/7=>5%2+I=5HD0E
M/UPN5RE9(U2-N2UIO&!RR&T:"=.;NSS++=:9J%K](MY*&G/=8DVG?$#KYUAB
M^<U)(./IS4";E5R[D&VQ*FK==FUK#I+>_+*A7F>Q ^ZF$TEG5_!(VMI/QXZ+
M-M=0I*3F<WC8H)NHJ5>3 ?/3V)=6-PB.^_7IF,M]66"]8B>PQ\-C"-S&3J-R
MA5J;]F4SPE@F8&.A+QM-&Q<-EXEW&PJ,43MO&3R<QC.\(!9*7Q93YYM-K=2!
MH1I+.#1T'0$\)6,_M_O26SIA-9;SR,%27HY'EZHM=F/?4-HQX9VKG#E^0<&
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M6HXC,+W*W!LFG'.OS88B9.Y6(&[FWK8*B;8=#2(7&X^068(_2]Y'L)D:T^U
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M_#S"/(%'/!"S)H,3;T7P4X5"?<E%SSM]LOLX++H-SY/,UH#X\SMW>L+KG?
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M.Y6&G@[U=T[TL<'VCYL_;KC\<7<2TY<C'H NOJ4NO +44K!TW+ 3@;_;;!S
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M40[ZJE:C9IE,_JOIAJ57WEBGH"H&=D6#K0"YK9J5TDFOA^%E5]_8?0\8[JP
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MG6B_DWJH&7(5/QM0[#\"X&91E"6"L29=Z+ B[*EA%>&L,HXP"O:DVFA)*C=
MV/AC#FTEQA<&?%-?&PM#/4S3; \$5]BO6;^"D>+IM4REFI$?J?Y<JC4=@ :;
MX\ *ABZS.>(A0C)V!77RTGSS3!^M.7KQ3" <US!@#KX"") %IJH#,Z_4PLOO
M MO!WSXMD.@C9#^YVCD6@H@NVMMPLT-=2NB7=!T8;BH:TO,TIRC0I,4"-40<
M1G"/C:OP/!_!10M)80!OE_Q!J'Y0^K#RC#UC"(-W,<4U*592!PRI<Y7-AR%N
M'QFSPTWTGEB.3E%VN8,=R+"7DFF7Y++'(&-B;I%QMIH>C4C]7>+NN$=C^JM,
MC\8<4;#%+1CG;("ZTZC-H8);'G#U V@+)1*5B-5=2?$7W\7F@22*:MI6^@/$
M3]#W(]<!"01HB)"!05TX2CA@U3:I424C@--!D07"Z(:,+*.?E9P;4RNY<GZB
MM5F.$IEH=J9T"?(F<\###SA*B6Z7JM R9ZB28(IMFJQ55%@R5XXSUP>1$9>?
M*JTA/#(X]-H2L4FZ@:YX01,U[.L(C\5HJ"T<K6T4UL8P9E#4TGK3B,RDH9VE
M&$@WZJ->;VP6":"4Q@0(=0-46G%$FC,NL%6ZME"\5C9A*Z-'J]H,VD; Z#ZR
MG>>#X@?I(,$_>! R2C4^:%__\_RDVCA*VA' ,QT^$#9<3Z*2FKQ:P-RNRX&_
MJ1R641-&U=1R[.QGRO"NQ&4XU !19_\=,#U'U%'3'PY9#V&$7@%VBTUL57@&
M&O(@A$R]@1(\I@Y7FZTF^F6.:<=5^BE3IY+.A0ZECV=RS&N":(BU^+ Y@:+1
M] ^%K\#]8%K2IK)#3)WHH;)]7?, PL56E?X#:OE&)I@2R7S"M(:+R7'$!W M
MR[M@<B)9<"KM'R3VHE$PNBFIHR26ZFF[0DTS1\2P#+F70O-="$T3V 'Q@^$:
MQW)]%!86B#;-S?AAJ 29BL"H(SU@%7H15_:-C0EG/Q$R:,)Y((\D.EFJ_P3J
M^9+O2K[;^)*+W[DF;^IN/+5ZPF@L%9(PUOYYU]351YZIK%=/,+<]XI0+?#CU
MJ,^^BSG_CH)P3,76BD5-)4^5/+4P\J[IN)JR-!T^Q.[\5C34X="T,:H:I*7/
MDJ2[IX1]Z4<]Y:N;X#@U_R63/6,@DU&MPO'IN^)^R:$4JE[>)@.?8HPV1]<Z
M<_PEIQM3W-PL:9I*;9?&NBY-GGSQ#0A4F";=<U7%5-4;>-RL0H>#TTW4]()5
ML 8#WMS)]07TT AL:?.4C5M73&P479^PK]J]*8\$=E_13Z:P*?PQP,"*&1N!
MP9**BE'0^!V*"F/L8HYN&RJ#@!,WZ'WD*,#[:CA(!%[/<*45A( +3T;!F:GV
MY)Z-01GEOF&<*R#)J@%6T<D53(F -P6HM>-"MD=&YXLQ9U69BAZ]7VR2I4P?
MNB(E\^.&UUC7[0]#^@)#Y0$PJIFTH/) <2M [*F "8$T^M(C%X(H0$:@J#F7
M W"O](F/+(TJ%PMC]1H/3&^.7JH@DLH]:2=/T6< C*!J;(UOF&G?,'N%M:+(
MVE+CO!>-4[S-_$[9NQ&F41]@A4II@224CIH'E.W/FY'4.GY3B7N"^ND_4%"I
M%J"^[#%/'R0QJ@)?4,4GC%0\1]"# "(1QHS!WI3Z2D>@N.M$ZN'4"X6R!0,,
M@S#B9Z,><X5?9LDJ2C6FVU(-P;4&F;-QL3&)4?=WF7 Q<4<ES%JUZLQJ^I!X
M15G4^F*=*J0^Q G(R4[0U003Q]I5WCO58((B;)&6H=EGJP%#F070^CB?'.>D
MY2PYTBP6MR:+$4?6O'G2&$K!YN0Q2N^YE+L;;^DK!QC9C +:'6+UO+-P9$O9
M&'DB<\^(2^1")B6FW7127_O(G;1+K2S;D$\T&58YSAS9-8^)ZLLD[)5ARV)0
M8LF/[X4?B[>9^ZR_^R!2O6CR7%>M,#O*"0672% Y@<F JVM$8-%<U]@;5*,)
ME>+%\)C-(O1E57<W2<R/U0OZ!NT"/7(]DFR(145^%* 7%,\6),V/XDA5&ME]
MJC=4>2TC?S#BT 'GN3\*!&R/.N$![ROQD[;%AFQ$=E9?=U_7S=J3JG4Z:U_J
M\5)NE'(CEAM4'>FA*/!\*MB43!4%ZL#16%OR.-\]J<:![<&K04>( ^,Y)N$=
M1RSB9LRQHJ?82G*VQ,)YH2H*@I+!I-IU5:$^_*^GE*I,<Y $SDJV+MFZ9.LX
M+)*3*H:OF.<DW1RS9GDJH&NSH;(?3*5=W'N=2G]QAD%%Z^@X=AE'.I OTP\P
ME>#DRZ-;';L,W ,K!$M=,]4XZA"U6:6J]C:EB<IJ@5?):#B1AROYO^3_37?/
M?T??W%9=H[!'8WP@TT2F1$X"6UW$$SO='56TYSV@@Q/C:C>NOH<_N1/GQI-
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M]S\OCWFL$T-SV]TG(&4_X[^LMG'>QVV9*7&??, IN#3_Y[FHT5)@;]9KS6T
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MY"U-WCE%!%R*G9; 1-P"L7#<_M?N[DZ]-'%?E@NX:ED.Q];;>.P!_[KQW=$
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M 6 'Z$F1VHF'5-+C\4\>J@;OI.=QU&DPQUCS5Q6\N9=.$UZS[/J%C-*,5BL
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M=4H6JO0R^GF8=X?;'P%-Y&3HJ!DEXUT6 ,A^QH.1*RF=C'H4H8\A.HR!@=(
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MK-V*HQ<)..[L/A^D)-=IZ_)NPLOY$8MP_+F2B>TFH:'?:M.D"(70>U3-,A%
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M(3'O"&S[@*R?+%*JHDJXT -S)3"A_SBE/%D(.N!@L#J!:3Y E?Z$/4J%@AN
MRI@4G_9S\@!/5YMST !"ROK&)]'B:J$4^/+$]2U SCI31PJT/:Q^VOTZ>V@
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MS=6]!C&<Y;,3, -\:;XCU0^<Y5U!;>?O])Y1/E/2;#))RV24J/5$T]#R?0#
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M:6A^Q>C1D!MB9.3KA<F@39A,C8U-$)>V7^5XH1Q/JRM>\/"S8RU\1ELY+8D
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M$S#CMF'Y)S#)-'53Q+3K3 U8*X1;U)P]Z5!7\WG D0F8]>FS;@Z>Y&YI2&(
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MUKL=M\72+PWYY8:M#3'/D.>[;K-F#5F]*&3UV1JR>F<@J\L@S=-5S-GZJ!;
ML>T6"+R$+.P.[A]\X ?6,5_F.IS?2KB3X%5/XK/UM /,EK6KC\,3<K8"9&N"
MDU)CYIB51;L!2BY\RWGJBI99.%Q]T=(8XH9=[EE:D;K>X+28*X\Q1K)5TGR[
MLZZW;(;6RFDLD6/Z\SAQAHWCRI0206%,;%0:\S#;R('E3ZKJYT]GT02E@IEK
M@5!J2V_.3M0%6 /) 'LKZ+D96WOA0O. D>'@AE!DN,V2>B8-Q85$IJR"-N)-
M>HPVAV!0I.-KO!HCUT+A<$]>@;G-<K5QO+3A(35+MN*S5&I9>AQ7LG5J]97
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MU4E SA6^(?'X+!EM(--*J[]A)1[3E\S!(9A5\43"2%I9$_"4 "W,U..(C=%
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M"D328?)M@QDE]?LV[L-9#XZH*RWS/!E)Z:FKY1PD)LOXB0:==88@,R_B$LA
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M -FO\A"'+6$!%H^.:%+T>I[(D&Y&#"RK_\H=.HB7=:)^HZ^/3"GJ$L!U54E
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M9[GHVQ(! 0[\((J1D,9@U,"XO>8VVLEY8RL6.6TAD8U@E0-&L<X%]NL7BMC
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MR"WOX[PN'%EG/VWR/$4\B^D9F.+6AMG %8D:6I8>R5PI#6.Y"6O0Q7T_-_$
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MG+](?S)U,-U.(%0LZS%S.3/YLS!$<!25L6.T#T*]*??$X@!443:7,>C0P:4
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M[F>^?I?S]OT&=!92A6>"2^[^$'J[6D8M^R=\, (<XU)(7C8A[*?ELXB14KJ
M+3V$+%"N"K2,_7:-RSCU!#EOZ*/(LVAW"YM&/V5I7;-UN\:"Y\G=?H(DMI%
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M3<U4R\>W^CRW11"^R39?.VU!2B)OOF'I\O5D"66H$"V/H4U97[()_I*?[>K
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MS>XI;&+ )4DT-XQT':$AYCTX[\&'M0?]9B @KPI\U*5T-B@E.,3FJWSM?3_
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MNZ8FS*1_3<!2TMOL*W80UN+M^%_Y-]DZ[8O0F C?$HQ XNHF/E8;34>^"K_
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MZ?OR:*^H)(<Z'*=*<P )B]*U75W)A@0!U#MX016Q'A95L>VWL4IIXZW%DJ\
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M>.'EO,D@\-]3E[+*LVK^(>])74M,07,?2Z!_Z/94H6MA/M(J!\69-M"VF7O
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M WQ\ OR=4'=20LXG+PKV]98[@R>-4%4E,$X2B*-E$AV+R! '8H)]WD3%+W6
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M2Q*%0V$WWG$&/!2MCQ<<A.K?"YNXJ(951N5H4Z"C34+B-1$A^MZ2&!+<\4&
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MD\:(P]&QP+N1F6+B-;XF"F"7)F1=UTV,O"S(Y(L4G09 CS2N%KC+AW.&.2Z
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MW7\,U7 "NB\0D;&V4%1]4(.4;]LV;5]OV?8=_O'I"UD'P2B945@%C9*0TQE
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M0MC8"B!=K8_IRQYE>7 FUA^GG5(.57\%:R0'.W R&+%G>0P)1+9V^]M=SN]
M\XX4>>R8X:\O8]FCBD^@OHV^M2"U&@>Z:C%%E5(VU+<9IZ>*JY<QS(QF! _
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MI5U+S;>CYNZNW]UYA#2"EII;:K[SY>UM^7M[3YR8'84/?C1PC_ SXD[RSX\
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M#<TB/\$:=8PZVS!47?=GG39 ^UYZW=9&=1[FNT(C[)N 11_",%BZ2%0LR0E
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M9)?PO@$V\L/2L/KV>?R@)M]ZGRH2BKH2*)TRKM0[S2B)GS!B1#D,(7",RDR
M0?;Q-0,U":(QWU&W\& 1762QKLV)AVMP&@OPQEA/=&"BHP0C>%M(IE=(B%<S
MTR>8B"W [JL._--C U<\@OYXZ[;"*Y6P"V[_G8/,9J N8(5Q()U+!75,=*X;
M>M6S<!X&V(N=A11PF"+6VH9TC33DGM )(PX/]<$4Y57.VQ7$982L >A)2,PH
M9V!XW2LZ0CZ6<L_J_7<9AJ2GH6!PI>:;U+^>;B#POV00:5904CF60[Z1NI2Y
M>\2M",OY3^5>Y7!S0.?PO<N4$$-%+N?SF9)>M2HVS0?!PE+(;Z;!5RO"G8Z$
M[S34&GT5T4CUEU")=>4'X]I5$*E0*QE.E/2@!*UW^4K?Z20N;*2J=1@%TAN+
M.8(A7-HL=)AH!ML PKT"C34*LYDH>'IE#!NFW QU<KK0EX$&!P7P.3 -,?EQ
M5-T)3::(Z"&@R.\TWA0)KT"+6V)>0FCN4DJ@3ERU-497C5$H0J8R>(B<.7/3
M)Q3W2XWX?:AIF5=FNM<S=5DB3<P=!2P4;\ 0=PF!D(HVD)5O&@.>89HH]T5F
M?"4^J'& 'Z^BRE7]M:G;,;7#!2N/:@1L(8V=P8JW/Q].NV2\E>SQE_"W7P:_
MV2[WIT4>)<E7$DRPQ[_\-("=">5K/?/K\]ZS6XB9$Q8ATMT;[GR8C"K!"J(^
MJH:D=K=HU'*+=0&X(P57(^.1H#"(DY<%:%E VAV/@$*]6X"#^K=!!V5;O]3$
MB*^/=(">+X"$:L1> O)+B_@:>$P.3"Y#D6DQ0)\Y :UUZ4['XXWW040LZWR"
M38D/'*O[^5VU98H@!:F^-\)XPPZODAA8@XF7KQ0X@3L)-Q?N$5CD(TKOP^J$
M7%<GC\>L>FV^&\B)971BKI^D)6H@ZD-QXV'$Z=0JH"^'FA?,FOL!C!9Y(T%H
M,&NOB;9!"T5!D'-]LK2'I^^P"G=)W7P'H8"I.A:"TR+3C;>3T'"^YO2K#[AK
M@'AMM8$3$$;H5W2#N3#*[#B*!.*3G$>!]NG#;W-Z;H@WBSV\0?T%[GCGX@JQ
MN/CH!!/30(JKL9D\OR5%YZ%(3#C9@*^J-:/073(UVC$9'3/9CX&87JC@VPVH
M^ =#,-T+MMD%7CX!LT1,);+_8W6-+D+00D-LIHQ[IQ7TJM_!36,0+$L0^(HM
M3I[)BODB5U,HSX,4?0E2C (F+T_,/40=1.%["E]&2P!V3@,\D_;"=BEU9I#N
MS^RR&V- V1K-M-&/SOJ^.QE#PGWC,+[ 1^N#N;<.B%:#>3^:YL&\IC;3X[93
M6NS,LC)+Y+Z' ?Z&%/3KJ][>S3'J.YG''62ZK!^CU=-?R'6Y2:@.\/]?=(ND
M(W0PS;TO=$%9I@Y^6Y'.\@"G]\MZC4A;"KYK"A9N9YIW]6;?/-)>JSE13XC0
MWY!:DQ092+?L[2,0^-J;VMZ#!QOF)KK1TW (I79&]RM.[FJ6SWE&-S#.?BOY
MJPSQ(QI,%Y,@;H:P?]+#M'SDN<RH)9A&'T_S9M0*GN\5/)1UU1S!TQSM6N>6
M;Z&#J&(M8"[$0]M@3G_GLF-ZS;->Z;!_.+M+?'6NX=64>_L<#>V+) ^B)V5?
MMU37:*J[KYH])M>>]R\5I"V]MO3ZH%RR]__8^]+FQ)&LW>_S*Q2>Z7NK(H2+
M?>GJ=@2%7=6\[;+]VJ[IVY\FA)0830F)UN(R_>OO.;EH ;$8!"0X8WJZ 8.4
MRGS.OI5J%'B!0IY"WEZ15RLU%/(4\@Z O&/$W>NLPWQ5Y5VU7->U:JT-_VHT
MWN?:D#D+S"SM*%P%6QF,M\D0=$P'3V>5K($4D5PQ;SGO<BO7ZGZQSR7--PE8
ML>O_6NXGX\_06><9THR"YJ<=\+$J%;W2;*SU; <_'^E ).&2%*XYKO4:5DXH
M6"M8GQBL6VT%:P7K4X-UI:%@K6!]8K!NZ;5JZTAA78P]WVA04WZ)/7_RYOI=
MY)NC&3O]7>7]ZTSU_3.+_=ZQ\]/>*;?3T5OUROXV8AMAHHY?';\Z_KW)[=+:
M,ENA0Z%#H4.A0WIT["L\=_+J/.9JVNX3]E<1C:8V#L IVMRWFZG<*,M)GU*<
MET)(1>%#JCO*AH]:6>%#ICLJ?"A\*'Q(8Q\H=__%C>>6?&)ZV/\=6]S!*B;&
M%/L;O:LJI[_4Q-FHZ;5:14[ZE.+ %$041*2[HVP0D=0!*,59*70H=,AT1X4.
M%3S8IW'P@ /-"!O,HSD>=O9X&P9!,?6,AZ+:M5>_]/"KY0XHCYW]D_AZJW^;
M<D(!\R!21T%207)I'*ZIE]L'<)4J7"I<+L5EIZ97&TJ&*V!*!LSCEN$J^E20
M@<E[RKT1HW(E+=4 DY87X5R2UQ#3^N5H!^44BY^NUJKKS6KS<,Q@T=+>J(!2
M0%WP=)5&76]4ZPJH"JAR W6Y5=#26Z^H7U=85EB6]NDJG;K>JJQ?M:[ K, L
M[=.U0 L^<BBG3&-X&8\JA->84\A>QZ9HIA]E\6C?=-!C9JOI6,?TVEXYDG+!
MV,:%1UMIKTNQ])LS/@<PQA=;^ZM6_MJ!RO-3;>>>?2G<UVLK<<Q/F-=,(YX[
MFYZ9FYJ1:SJVB\^K6>29.-X$OZ#C)-H(![Q&/G;2Q$FN/@F( 9<7@]O%1%XV
M#'8B[IRZR_F"W7X5S6Y!"CN=SGJJ1/L:5KBPO^]_HR"TA],<WK^WKOSKI9/O
MC-AK]:74+C9H,X+7Q&-J9Q>/(R)@0)_V;F3<?^UJ-S2U?F18FJ$-;1?(FT[6
MAB-#D@ZG&DZ0S\ROCN?/XY#LD0V$'L+3L<',41B$!AO(/0&&@%.B'1V8QQ.A
MQ/_##D>:89I^A*.C@2=$[L2P<?YR2(!M #OY802:%1$VP=EQSK5N_O!L-@@Z
M\PP^&1OPL_0:\!;PD46&1N2$]"W^K.>-80>F;'!T/-8;6!P6'/CL.XYM\-'7
M=#HU7[-8J.;](+CZT'8R5[1A]02SDFR7,4W7TQS/?8*5#]@6X1[#OL .4];K
M^4O!>4R<T;*?Q2CJNR^??L\?0SVOH6:H 3\2/"YSO<^/]TO;H*=N(@(6Z0N,
MAB7?^Y&$,K)_0I:MW7VY^?9U=:OU-(]:EQTF,11MZ6G710-AL<P/L,[XQ./7
MZ9<C7_N0MU^_7>;O%SVZ G;K\;9W;;O?SR[X<VD,#.LN//4J7[BLPNDBVR='
MQN CSX&U..)(\^0TNE/O&;:KJ]6ZM-"K-L];C34B5<!3C('W#/\>@VP$E8V\
M,#5N& $')]H$F"/P*6 X$S%Z&T0H,"0O\N$QIX8#/"[6![M//B'X+<:K[^_Z
M.JIL063 1\#/&,/_ 7>#2_ODK\CV&:,;&]]!IP,IB3S8YY>-[PA?@$N!" _@
MVYZKN20$ >%9D1EJ@>$0RN1O[Z^[EU=_WE*.^ZGW_SJ=&DJ9 &X'B(/_P@_%
M'>+O!F /\OX1/NBEP,C/Z6AQN".R6]>@FP!7#T? G W?-X ;,]65LN.%FY32
M?/&+1HCWI3L#%T-]#S5;^(%/GB+XIN>#I)C ,ST;#M-WZ7.5V",#O$!J>"X^
M**@2(&M!-[8]"Z\5P+)]N- 49Q70?;5=$)9P)V<*1\6?6!=R" 04B#9GJJ-L
M$6<^,@   T)<V%50OUU<^-#S<>7!DH?,B)=C(XM3I>B^&\,K!A\2N(YD1P^:
MF4YABO"2H^5G#9M3+5?,CPEYL$^LCQFB!*( ?6=B@'(+VV0$]"6"$I^9_DZH
M42FC#RGWR3?&P;EVEV4I#&Z&X"&!]D1<Q#8 >0"J%6B)J-OAY7@M)Y T@GP"
MCVJ8(QON(2A,$'KJOJA*IJG-M3X Q'$SB$\UJH3*SK5/Q#2B@.E<,Y=FJTR1
M)# &E]C,//6] 5V8"Y?VB1$ C0]@B?!5>XQ_ .1$P &9U@B/9]J$DY_KA8P$
MF1;)&!TRV8'A@,I'M&!$2+A#DEM/3=OY_59.:02S@OH1NL#,(KJ-VIT':(.=
MG!W3<MP;=&!&\@=G%X!=0*X-\+.T9P/$3A100<+W?L+W'N@"++HGE$\N(YO)
M!/Y"/3A(-M_.'\ZU+]WNG1YK <!H(C"!X+&IG84_ OD#/"3^$>(?:(4F-%%Q
MFM@_L*J0L8ESK<>I/6]9MOOL.? 8 >R%/80% 17_-[*>&(>A4C$(HO&$>9H&
M4W1)&4S&LT>BFV"@10M'!3>VP58#O<-C"S9!)YCB#4%P1R3->N"RA-]!6(,V
MLI:OR?7QT6S@? 'C"KF[ZJ'I9PK0YWSE7$,E;O$C1:A!9)\+M818F0+%!A@B
MO3IY0;V"(+=)7&[HGO/\0!P;_2UQD"-:?'4QHR,)(]=,VS>C,=K29IJA,@::
M4:R6+7YL@"J:63QH,FQ$*V@J8)4'L(F1 P+&'@YQL;XWYAPZ>U'&@4,2/P?[
MV6L.EVJ9^:<:^P;$HA"[L?_RA)CVH7G2R$:I#UPA3<YY=(,P'>/D9O0#34$/
M"("&!HS1".T&'3]:I?20NE2.4*%GV_-<M..%0QJ.]]X.OL=*$5>T>FE6]3EF
M50\QJ\*[WZ&.U ?#J \?:NW8N #.Y_DA5=,X?3'^0^T,SW&\'U296O"L^*VQ
M%X0)JX UH7-LZD7"'39EY)GQ;Q&$MD&OA]O*%I%AM +2E#2!R,R0W\Q?QE1C
M>F,/ 0^%U+^8R^<R]M.AFXV4'1OUG;X+9BEJK$RYL=^B@E/9"3.Y!=C9?'>1
MC*@T#JB.CZQ[;#_;%)=,]7GR/(M!^X?G?T<D@[(/HBTC&*F<L#1.M4"RZ"@!
ME0 )$RP"]%N L 2-API+IC)$U$ABSEV@S1(:Z^R5%X7:._N<G.O:Y_[GV_?:
MF(0CSP)]!Z_'XVU!++Q@)0Z8>KY.G00C8EBP^R-[,A&T/H)_.?@&UP,R>78#
M\ G XOLO)7$/M0&;$ZE%.<2Y]@?A)I2/1@UC'62!'N3-7AWM-M][!H5'XTS'
M<VFXSW^&/Z._ 7W@@G& ^C$ 9DI"M)E&P)1*C*W"UR(7P/"=L%A:ZA;G6LKX
MI8QT;$S32DTP\6P'] BQ/-_XD>P>\[I$J+42OCG"&<^62AF9,;]VL 4!I$P1
M8AXM'>$Q:X7_A4XPRBP%WZ-*'[^(+GZ,"AO^A&O&N2R6/BC U863PFM19QO>
MX_-E-W8C42'5O>O_N_LII<WE^9NXS'D"4C&-B1TB0&.8H,;C 6/&O8_OPYUO
M_#D2:DD?QM[YU!K,5+"R W'2-5;8Y:&B*T"M&PB3]I2X?H'V*8VL8%3-HQX5
MGUL&*0\21ZSM6R7T34TUP*<%U@SP;"_F1G'*P8RG:B8]04^1$=*L;5+SDH4N
MT:UJ %'QEF- %0-D[" ?SK4'=%W%GB.QTCE^&[N4N-<7+5?;%,P[OB/^RO3&
M$V2-%O<'N\#E0G@R^"#Q#&-<E;-L&I=,VRMIAUMZZ]+)&S]&Q,5+)TD>($$"
MYJ0"X1/YP.G0^+0#%N!$SS 3B<+H1J7VV294<05SR$T_.TJ#.(T$TR$ -7CW
MR*4<$GY!SP[9-/<D(+>'IPN0[U'UUD:XV,-ILC>)P<Z\V<0'L3+FT6(N682T
M=?"@F0>=_GKFV]2%D; ^*L+IC@@W*CKLIB04^X%GQ<031<@/FS6> ]9-Z&G$
M&QR$S&(?&__U:(B<"Z-X&0R5?B NB@)A#!LW IF+<@7V'5W]*##C!X_73@^<
M.G43#9S?0$2A"6<M-"8RU(@!R,\X&5G0/G804-4D/K2,7:]]=[T?5,)% ;TS
M0Q_:'P[2@@N*S)@[40$PAAD_;;*Z6*C,;P#>CSZ+86$F S>AAJ!'(<J W,Z!
M3QI("NQ)8M5A[E&YLO3SH=GH=OD_/ H^D]SRLBBO9U$!'T\_692$66VMGUS+
M$H2.)&T-S?6&.?RX)&'G6!YE2)#HT;X'VNO=WU)!-*L1@ID=9]U1EN:]V'BA
M)^"8860)I3S^3DCUX$7;LT[2B(*W@G?A\$:C C@[JB#4CQ^27+0K&"L82_8H
M&1@+W3=E5# E+]>2SUK8<\X*7;/\Z FM!Z:)\??\5X$NO"TT1<9$?R_J=,%'
M_%P1AB*, S\*(',(&CQ+@4(J.:9,U=.)IC$CC]ECPE+**]E@$E4DI&0,RY3A
MAK\UB?TLS.TA6*0TH7#"/1.I1,#$$4 YWCAR0GOBI%PQM@MW":.D_H,JN=2^
MA]]2ML:L0XP++UKI@(P,9\C,[23 A#[=(/''I+Q%,PX9ESR! 6\P;_(S>G=H
M>#EFY&FFSA8SY=$RY.J1BPF%(E]*&SK>C_F4IV"!:\@BN&GX'#S\SC,$ K;A
MD8D&\#!R-.+ZGN.(W*0)+#8.P5&W/',4<3&2W:9,PE/?948S>D>$(8Z$27W#
MXL3I)6FZOO RH?>)A3]B$-"T^$&>.R7VN#!H),B W:)>"'956,R0^PRHRP1N
M2!U([$-^6>JM2)PW@<;2%>?N@1DK&%W @TN#ESX772KS+0@G!75CI?(DZ6+@
MJY9''3ZQRXGYQD5LD[N<GB*7*:PFW D69-.?TI..MQ =1,^I]YE%"Q@$*,*9
MSX9N04R=\\D.&8H\>,149?%OG<7?5%G\1Y?%OWF\YYYEG6OWQ/2>7!HP/+V0
MS_IZSFXB_7^@!]F;4+5FQ!W,@4CDZ3[TM&:YR;WA_P/&&4IZ6BA6::>B\V//
M8LY\GX2^%TS08L/@+XW)XZ]IF()86?6&2PB?Q0N2N(W!-1"#>=MII9K!M0<]
MI:S8+I5V5((//9&@0]-_J+#$> SLEDO#1$,,A\T^ 2HU25H_4SOX,]/4!8=I
M"30?YYDLN#4&?N(,928QN6 7!7!!G S(,XAX/J9O45$=!W-2Z8:SN4Q3_H2,
M(OR$(K :$.4[3V?'H^0:#7^0@\N]W=,*-6M?:Z>M9D$]T!XQ:80=/A[H+0UP
MWJ=CHI>I[/UN4@/#U$Q6!$2SK]\DSUI>@;L%R^($\'=<FA3''P,XK0"44".K
M#2=QVL$45'S##4!+]%DUK3>V@SB+*1TYQ#1!S01Z!DO$/]>$/+(#X&Q&0/OD
M\W0F>D7#% 1I\OQ$^&8F5,B*BEC:$TMO3J7/H#'Q,N'V%3<7J?K_8HX05JSL
M*+UTSK"7+)_:.?$#/.:N-$Z6RABO:!Q0C];,2MDU:4@=GH\^8ES9P;. TFDY
M>#Q^P#)N9KC7WS1K!G0E9)X>QD#? *O:<X&"F; P+ 2BF=FLI&\V$<30W(C6
M@;.<VVSMDB@37)0-,G<UD>C/:A[H5] X#./T,8#>&"5Q '+/9(@3\$"AS%>I
M"S#K<>%CVGF+=8#B9T$ZO]V<X]PBPVO1^E.<6Z&P*!0*ADE/1@"/>4YFZUCU
MQ..2^BS3]&3VS&@$@17+QOR$8C0E$"BO,GQ4 8,D R>(E4V6M!IGK6C#R*=
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MK"-GVFR-7"'H0N-%FW@![Z&44RP40W4MM^8BCR8OO6;-O>D2@"BP80'<GP5
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M+)%\XME+4J)F=P][%[%$,K 2_=GL-,J2,:D7%IP4/*8";;%'*:<6@;%B?KD
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M0&^M+G/YD#+<-I9QU .@_+7*P93F/!NGZZ3\23>>:VZA6*,=> (N)45 ;Y*
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MV3(RRRE77D_[*(;,+D!P5AM'2EW*,;%W)2+5D95F?.4J%0=1)?;)S5;RB1I
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MKWM/3._)I5>A+M[-Q'5+;U7R)B8JZE74JV2+0J="IT*G0N<1H'.QYE/9E_=
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M0U/OO;+U).$K2C-30%% 44#9DZ:2,W[[]2J\Y..W$T5(NDZ>2L^7G7H4FU5
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M!<#3&(J6*JMP'\;&/-P3']<!&K2/;"91 RGN\A *C(&JC93!X0>I'WS$*WR
MRRY;=C->MM 6L[R+(G5DN&#-4'$#Y(.Z=*);9IG 6O1O8T\&3J:AG<5)MMGY
MQ"=#0I52_H%%)EX F(3S%#W-XVED,5WJJ29O%*C)K>BFHO81Z#&J)[[]C
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M-J);DQ(5PE4Q-6-7<UYE9<Z-O#7RMCOR]IQZL.TP;%596,.K+YE7M^;65=2
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M'][9[DC41@,T&F G2%&E 2J*,3<EJ>>MSO%V1U.N"W7=A++>&FJ;"?U.1]_
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M9PPRY/:"*%(#>C6$3N*'@J:6.]:#[4K$,/RD("PP^]%V/?1C#T#''T3@VTM
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M_=1F@49>PCKE0LT 1G$K"R(%(R!QTY(8+AV>!@H&Y360KLY4RF8D\OE36LP
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M [UZJS^U+N]NZ*DT@=N3HR.3R<1S4?RH)@[H,1*V@]P6#&PTSS0N,0(_#=<
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M+3D+:EI&>X+*[\N'P!=I7B=3)SMN-G7P,B,_<TX>)A;KP/XS&#\+ABUA]_4
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M@4@K>6@W+T<^PH9FG?\V;%FD'6UYIGCD&?@]2E^GW.%&V7"XZ@AFCXO>YA$
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MM"ZWSP[:H''.*UPG"0ZKD>9H/BRAC;N#)6I8SM%IF3'H+QK]_^R]:7,:2;8
M^OW^B@J_Z7?M"*#9%[NO(V1;\GBFV]:3Y+DQGR8*2$2U2U5T+9*YO_Z=<S*S
M%DB* K$D*",<W0)JR3QY]I6YV$/ZWL$F8+3^,.W0[EE7\ ;KMF@LAN@(2R8D
M#6B\_"B&$14^>\A&L.',C!^_Y/S(1I,?2:JL42]CT?Q8G@Z?'^'"?T:BNT[%
M2D?\C#B!A4A@%;0YQ%P]\<68S?S0H?;9X10L!,1F_ 4'AXZF?&($[YR*G=;L
M 'LZ\L;:>*3P'75"C8 .<!WT?QN[,>.H.]Y_VZ.N::&8 IWIVRK&W] ]P E"
M.&D-E,<CD'YQ,\_]4?Y%? _/MKJYX5!9S,*6V2Y-3()W4&NT)[@U8AY@Q] %
M%<,7U$KF1P%O4$Q>;/2!,53KW<R?&39QB[BHU$Z^T#RI3S$Q">I72->&<#;T
MTY9NKGJEW5E.,A$T@=L3\V\RM.3S4=:(QS;'>"(!G/TBH5/,,17^) 4H@&/"
M/M4 H=5QB!##3"\4,*B7A,&7KU>OWG=JBL P-H7D8,AR%0$7,=P+> 7.I8SD
M_A-4R:I.17RUSKM0CG%>,I]B@=.3)0?*S-Z2/"H=0"];S),G>1*[+O<.HG\C
M&>+,>10-LI((^X3#/^P97 +R!QBU.R\^J^ZF&*R:J"K6<P7+D9,\L<\Y(A7A
M]N:HVX%3P["!RKU%\^'&;!R/R"64' I^D.E9G$<C7L-1)M,8&7"<!YL/71#P
M$LTQM>V4NU\.W=I+,+RL8M;@FME@GQRZIPP[@/;6Z&?^/"*';J\8<[17#KW"
M';@ BL-QZ$:MK1!2AD/#6775;9D+,/AP'+I?Z9P'AS:93WMG]LU&.6:?9>Q@
MU54G,05A$Q,M2Y[Q+#.Y14D\*N.=**;96,?S/Z*_]-OD?_F+OP44_O@:XV:^
M36X3F_0CF*YL_&$NK@O%A5NJZXU*3U&G4B ,LC)@#=?O*IHI*8!Q2*[?561M
M(=<7IUVS+FV:FK6(!C1:F+-?ZK0<QL,_<< F8,,(YR7P=!&1@B'OL>\#QAT7
MCH=H4S"0E_M#".H(U26 >PGS+PEZE4FT$>B5V'@I%D%GD?R8H&!CNV.IU^H*
M?201QAM(N4*0=%;)M69C)73*R34)A^U(<%#I*XKI*Q:/8=#84N!9R=ZSC*R(
M$3Z AD%H%; 10V<933>DT3[Q,&1_Q30)0&*5R'12,,":=>&Z*3L4>A"A>A;^
M 36GMOPXHN&GM.P-\P)JV5C::4JNERIU+X KN5:SG6O9OZGGNZO.#:ZWJ\WV
M03W?G9/W?/\!Q-]H+V8HB %^^_1Y%WF[\89AE'O5*?J_#1?9%Q?Y1^PQJ[&2
MAPC14\1!^NK<U6X2K:<_=^Q]V4C9:38K];9BSE"J<>>4O[R;A>O>DL3*:8+J
MM/9%.!Q."6\7.\>)UM?9807[[2FRV!,44"JUE&4I53B^S2_>-0%<BI*E=,N]
M&G ;@;-5Z30*O7D*XTV"<0WJ]%9D@B]0T^Z@JD!"DO#*%^2?+1%3?+LM:K97
MV(?+"%GAJ=O4-R1GFPB*E4QK'8P5:>K%'*NL51)@:LBW"4^T2>#1+:L&=3&6
MUZ_45;GW(']<&JR^O=_-I]3<99_;N1C@/76.^_X)1D?[W1B06ZI^QTA=3),4
MR6&/=$G6R T?/OK1#Z.0,.X#C@N6-3'JA,:VU@F-JU&K7Y#)6*5]6UG0G%L:
MXZ[4_8NMI_WEI]<6YM9'V!];L&\Z'S[&FCW,7'_.&#G[Y4%9,]?&29?X^(L'
M7FV%TNB&B7'7=,+6%P^3R]',OH;KK=>RGB3_O:PH>4//RU5CJYXM+BB"UQ</
M)"D76%QL%ZPDN3*W%'HC[NY2;I_OZ%JJ?/G'7-Y>7R?W<C_KPALQ[FAG=A-(
M2*UU0, ++8R^++@@, [YB'/ Y^K2RC"3+5S*R]$4O)^_@V\A!QR^A[$_B]+7
M?O#M $-^UB<G #7"7_^NK(>K,<AL2 6<U6]QBM]RQ89!; ?S!:BMN>L?L3M?
M! (>[>K36_- ?GJ'/;G;#/'F:#89.[M&XU)D7FQ<MPJ:"M;>L7$JX;*,_EGS
MA=N5WD!A^+\NW-0*A\;"IOZ#>/X5=D)*9$+"^&V92L%][KI9&;26IY;@8<IS
MS4PUCY884*7XS,L-PEX$CV0/.L"GTE8A11%X<LRM&#Y]12['6OA(T4$$*06'
M!J!J=14UMZL!A0SP#7' 9(KUV!J3.Z^X5 ^4$.&DGSIN<4RQOXLB\WUB5Z_2
M4PP!*>8Y?562\?*F-.8YO4I#-<I]-SRGW]X*/!KQG!;.%]H7QU%'V8NAHRO'
M:;8.PW%DBYIU5=5]57)I/P5N_\CL9E!IJ=R%Q=Q&H>$H]J0OMQE4FIO2TP;,
M1J'@K(6.KN34Z&T$I^W)J;]W1Z"^&?;-_:389QK%8*\+[MC'"$BXRFP#$Q,O
M#,;468,2'JXN;C]8=AQ-?3@JFTC@/G;X!9B[$:0)U^*)LA=[S>(=VE>^C2Q=
MB;K8QV'B4[+#V^,CP?.+R4=3-HXIF",IFP6/#C:+49&HH&#XZ]OD)J$<'L(F
M[ZW:5]M1^FJMWZ@?I&A$0($!K.:?8:*Z=Y]\!AB/DL^\[G_B>'=X:])6(->]
M8.NN#8M=,;.X;-5G/ZFC+V]EN=E<^WUWJMW;\Y-Q\(WZ0>;!:S+]?>GHHQ4M
MGVVY*-X--=,+.OURV]'Q.+S$NB3_6M:5?2X3Y,^,0)HOD#X6NN4LT4PI-&_6
M12Q,_*$S:AN$.@F$:@B,&AB$,@BU2X3J:X]0IS_ @KX1^GRG\XL&<WAN6,@H
M:(D^M#%[9*X_0\OQ)8VI.+7Q$UN/E6C62X9%OW@C_X'=RC**7%]5B3$7WOA3
MBB_"OW5L3UF]TFSJ/&#5$-$9$)'*MZP(U9PL$;4J ZUGFALB.GTB:JBZ92@"
M-*=*1-U*OZLS#9DYEKO1GV^9ZSK>?<6Z9QX+;)?T:'O\X'BB'/61G;$J;:9:
MKN!NY6:!%'(W@5F?.5X!C[O(895@3J4F&NR1S[4KG=Y1%>[=S,8T%'GN%%DN
MX_ ,*+)5Z;4-11J*U)XB5_3DW<0". V*;%8ZS>5DXI.CR/-POQ_?9%B3D26R
M^L[8:C!SHG<U)[K94"35GT#QUND->S;$9XAOB?C*U6SH5L5DB,\0WQD0WXJ!
M"'K7])P>[7&M_U>1&OXK9;5GALHM-%DQPQ9U'+;8,\,6=1^V>.+3]!3M7U[T
M,+W&>L ^LYCLGG<%XYW6Q$0,^\D.QF'2L028<B2;SI(8E!=$/K6GEZU^L,&L
M;+12$5WGO#!V(WH#-:=3%&#6K.\K?JFH5Q4POF@Y WVY-QS[*[9=6<8(X/O!
MHK1KW.K>*;*1+<ZDQBOO>4MZG)K!O-&:LD?9<8?ZTS1$&Z6-H!HFVX*5)S"5
M 6%W;CW"746M-P<K>ADN1@LO<"%W\YFB6O4;+97[.=>6_/[G7SB]P[NGW_'O
M9N<:S@%S)^S1%$MSOL,=[E4,B\>?V7C)@7H=K^AW.ERJJL/V=??DNOTP3R\1
M_<]H2_0?L2;>4$\LQ[Y/=:]JLZ3RU7SUOKD\F>$7BV&#Q#G6'<6X.QH$P\\&
M"Q^I(V..^*HA&U6=G]6I,P8:?2O/"E2[B1\'4ICB \,:$$"907> 82V!8:6:
M>V'WM%)SLG.WJ"9WK&\!/%"U9VC15+%&\N<2$L)!T:%XHJ@RW!8%O\]\[S8>
MC5@8PL%\Y(-&J!3S=@9'.W%&F12?/QP7;@%M8]FSO[H3[W*]YQ)F?EC$3$Y6
MX6?>6]+CM:"? S_<<F1!I:[HC% I/!:5CZ&-#($?2UO)&\RQE#Z6-AY+4]5:
MF6BNX&14!N@@/9F!.9EG$TRKH9XV)D$HXB=9<0T:#$!UQMO]NW-JSH<#PK@0
M)U%, SW"!'9RK!&>+[;!%^#+5D-@YUX!P)JU?7?&(FPJUX6-8],G4'0($;A<
M0>XLL$1S9--8;:AC]< R%_BEF#N7K*?(GYI$#V3?YMR>K^[U5>K>.NY=L@/>
MRI,;F)/;$\5)8T\?A9K?<B^&L63%2\6:VF#U<BNB9GW:I$U>5C_/=.HI:&O4
MJ&]B*>Y;2ARQ]V.OJVB-N:8+6*.N2#@Z(LD?KS2AK^[QQ[4H90O93(>I5!,B
M+XZ8'%"25I])>]0XB<]U!6/> 0:8'?(T"_PA1B=JHG=SWGV3\=' QJM)F^MQ
MVL@XYV-:]-_XC^@@6+UJ@ @G:_0(\-;]*B\2L0LYXXF\732;*1V.O$&_H]TY
MA&Z0\].O8BB81-$="0YA%ERF@RC^EP(#;'P!8 7I<4-##(!W?DQ!<P>0:;S*
M47 GA^;HH7D[C@.$.,J2I8"4<,Z@V_212ZVLQ]%_=/A<#0 ^G/,BHJSR>Y(C
M,S-&PP8A[;(@:=Z%=P!FXF"SB35B0833&3(]GJM)0VC8*(!P)*P60.UDTJ _
M&L5!P#SN^;2MT10AC$\GU/%=[-0U9A,:XR7>N>"=U6&:P]9>\+/UX(MA$!:>
M^B,VJE^)94YXH&YLAS_-'39V6^&H$-"E/FJ+7=OZE_6/5Q>#5K5YV1U4V[UN
MJWK1ZO2JK5:K_7'0:7<N+OH++=UHC8X7 [L"SC-J-=KMRP^M1O7BZJ)?;7_H
MU:L7[7ZO>O&I!8_^T&CU/C9,&[A3Z7*U\^>OZ[HBWS]<E0VR,H% C^6=Y5(,
M4NAR$AHMY:C=IDZJC914YP_90^H%=V;4C^@,>SHZ>])OJP8ICHX41F:ME%G"
M]61$ED'$XR)B@5>9O*=A.E7S*'AJL$-3[!!N=8,>!CU4Z"&G5A\9/\Y9S%G"
MDYOMK7!L]#W'-M5%(O+1=ESTE!\<S37IBFYP\.@X^"V.PLCV\!0,%AHL/!(6
M7F.IU&G@WWGT$M*KE?\'VZ6)<':TF(#>Z)UO-R'M&J=MW]*@N9"@Z& 926_S
M.9Z[+>GX&N/C1:I%F&A;5WY 51[;=0U5Y&_JTQO9D(9^I-'6D32$_R6C_7%B
MV;955KMC9E>8MOM[I:/.;NCH^^VG:Q;LFYH6DH2E/XOTW(3&ZB5I[,O7JU?O
MN[7Z49ORG'U7_F('ZF[;F2QEJ#Z_G0E/\ :4')_W$*QS4@W*-0([O@)],1X[
M>(OM"E6:#_3^/S;>7%_H8.?]MJ)Z3A]>9DCE2*2RVD&$?7.:C>:[;#LP@RD&
M4TX&4T[?;7CB^M'-8@.L?-&<49ATH>W711J3:H"A3AK3Y5^Q$\V_>(!K,7X9
M?HN ,=U-;4_97V;+*8>:Z4Z%Q_GF<&LS1'5& M-@BL$4XWHZ"=6JH&F%4:MT
MH>LBM:JE&C&W0[5J. I^[K@S'T\O3V*Z6TZ ;!YW J31I4Z1DHH(J>1DN&/'
M?7=@A>A(/-J@K*$.)76H&C4_CSJ>$\T--R*2W4=T>S5%CUA]",AX+#54JV43
M,*-8Z\/P3LY@-IBBH0EVJ%P 9"I?:*8";_G*I1N/ZV?Z+\J.A]N$^/F\@$9#
M,^%F3"OM*:2(0!1MYC56'B7Y[%%_;-8&.AM@QBVKH?XXPCH;USUG_?&9587:
M#!Y=N>ZM.:ABY,-^O+S/:+1\Y0<3YD1QP';JZFTVC\HJRQWM2]';7S:%%EH!
MNN>W+%/IA3>^_#ES>!?QY[F4CTRD>SIO8UEH;EFTZUI9%L\EO7TXJMO+<S?.
MQM#0P%&]>SMCQU7X_?,U%\Z)D344)9)'5QGV487?K^L<.3.DH1]I-'4DC=U6
MX?<J[8%N/G=M<-60A9(L5'U;]-)W5T_>VDE1?7N@,<48%_J17>BFJ/[T6)HJ
MR6R06O.#8PO]?135=S$?LVZ*ZC5XE7:D8M*3#*:<*::<ON?OQ/4C4U1_(K1=
M%'1LJS*K=-*8#E%4W^QIICN9F*+V1'5Z M-@BL$4XWHZ"=7*%-6? %T7J54=
M55K)#M4J;8OJ.Z;RPU#2#CVZG8;F]LDNB^KU(QYM4-90AY(Z5+U;GD<=IUQ4
MWZIIG0-A/)8:JM6FJ%X_AG=R!K/!% U-L$/E ARFJ!XT8<U$FS&LM*>/(O+H
MG)3J>("2^E:MIW-BN7'*:J@]FI+Z,R_8+>*@JJX]>_'QZE=2WZL?51LQ)?6&
M0DO9 +IGM^RUI/[(1&I*ZE^H9:%J-7,\RT*_DOINK:]7KXM#N:D5])\7V*;F
M7M3<#TK:$VLA>D!6J,U:FF46<RK,=* HTCRZVK*/LOY!M[\%4SP8TFUE3&A#
M$CJMY9S(LUO7D3QWUUJ@_>I]LU&I=[8I+C2DJ1UI;@ZILR)658L<O:R1O38\
MZ-0&W5.F8Q,!.7($Q'1$.#EG3%>1(=BL)\X8^%,34V+''1'ZIB."%J_2CE1,
M;IG!E#/%%)-??&3]R'1$.!':+HH9=Q6)<5II3(?HB-#2*W)L0L(G0%2G)S -
MIAA,,:ZGDU"M3$>$$Z#K0K5*D16T2[5*TXX(O4J[JUN78:-+:4])182D&!.E
ME7VR.RM$1^+1!F4-=:BHHZ=HO/-,ZCCEC@C]6GV;D.^)J-7&8VDZ(KP,AG=R
M!K/!%/U,L-ZA<@$.T!&A_>I]IZ%;@-\85EK01P$%M$Y*.SQ(TX..2D$\NOPP
M#E<--4/3[>#,:ZF+6*>BG=)^_+?Z=3MH51K-HPY!-OT.#(V6TO!USUW9:[^#
MHY.IZ7APXI;#MK)1T0GHB&:%CAT/!BVM"//<W-"[MS5VV]"@67\Y)D,+F/S8
MCT'9/#%]9/7"MV:,O>6*R^,K(?OH7M"N= 9';>I2\BQ?JHU@B#(ERKZ.1+F[
MG@78++E=Z?>/VLS5D./SM.V_K3FK4[(.%"U\-#,)]MIVH%OKZ-_N[-=HZ(_G
M^ F!\-[Z+\NRY**!$<&C1^++O:O8<G&SG;]P5?Q@*7S07A\^H,^.-P9,>MOL
MUGJ=]30""I:HBU/F<0.F \NTHBFS$D*PJ.7 F*+(5D$6!%)4A5(@BJ]J#,15
M(&+67-D75^)Z)K836(^V&S/KR0XM%D: X+ADV 3^/H8/EC_A.['B$%=K6Q]<
ML!>KMZ.I[\)1B3W/ )/PYP=_S%Q:!C[ #L/X@=.BY?GX9(<_F=#1&C+7?ZI9
M=_#%DZ!/R^8$*MY)*\@L$Q8#MX=L$<;' 26_$$'WM]6,LM'8?7["'GEF8>H>
M_?@)SN0*CN1?>"+;MFQI+W=%JQ1#41'CUK?]YD&@V*QUE]U/%4+<0DBJ)HCT
M4TCV7QXDVS6%E5NQP(R>L1'NVIUS-K7$BI2<WPDM^\$/(FSS846^Q7[BQN&6
M1R$('I'5 K^:T:;"A+6&46#C!JNNX['D-CN* F<8TQL>6#3UQ[6LV^E<Q7>C
MM?OP_V_.^]^&[[]XXWA$R&?QJN,%R?S;KT, K?/^)4!Y24EJ=/>B)0'UR,T1
M4)$;V-[<FH+T)%5AZ+AX$D N7/2K" M^]-B3.Z].G0!(BSW,7'_. !;P$"<Y
MU-!"+29P;)>(SQY-DRLM^)F1JL"_(1QX<J(IK4&LJ685E.4E:[ 6UW#//&!*
M+OR"Y&T5<>#M BMR?RD+_L^_.".A"_#O9@?X)*+R)>SZW\P.O@-6NU<QK I_
M9N,EUGT=K^#9V^0KT'_$FFX0FT*Q'.#5"6>N-DNRYB:.AUIBR[_P$YW#YF 7
ML#MK$DN@H_XX@0.V<JA8#=FHZOP$I!D#QKZ5A]!_]7[BQX' 1WI@6+,0<'G<
M0PRUP2H/'I#G_Y8SGG9SC#N#?QKUDO'F#-8U\R(1H?(6]&;<]ZOW:=)I8A82
M0$B; 'D6QL,_010B]I/^#M#@OP$ >(>K4$K$#'?%+7+!*24>WB(S\<%H\!^=
M4-X+I%-D.N4>:L'NLVNR1R/F,KYU:6.P1[P:'CQB060['C]5L%K0@V7/\.5(
MSO"JD*,6,% PY>*9L'[\T2@. H:1'UR=-9HB^/'I>.B![R+7&;,)B.K$KEE8
M9B%'W*<0/P"W/U]1=<-<LH(1*QY1)JU&0X=$S\1WP9 -WY[7@0([0$1WO-A.
M!5BKT6Y??F@UJA=7%_UJ^T.O7KUH]WO5BT^M^L>K#XU6[V/C%7^ ]9NP\LEG
M3!HYIEG.[#&ZP9// +)1\MFU0V#\0%)W(JLM[S^KUW]1>,*V=:EEP6#59S\I
MQLW]96N#YKEP^+X]UZ?S_&+E>YB\?[C*4YIU?H](6=ME8.#9RSO+I1BDT.4D
M-%K* E+ 8O"%J)0?XE0V2 /:P6M$B%JUH0494>:0X)]T4_&3&KXORA+:SY&5
MS/TR8LQPK'-9BD$*74Y"HZ48,?8,,2:B+$:*&=S4#C<+0O.\-DYTCC@6ZAJ$
M.1V$$:%F@S$&8TIBC,P?/#+*G+-\M(2C.%MEJ"%&EZZ%/ _$3\I*#H[YSRR/
M-FAYSFB9J:\PB&D04Q_$I *#TT#)\R@7MD2LN-/Y1>O2X=*ST/>MKYD>"$55
M3OUN^>&JJL2N$ZKU;?1TFXZC#<(:VE#2AJ(,7@/:V&G);:/2:II>[::2=J]T
MI*A<WXJ.]EB&DZ&F?73K[.K6\]8T[=2H::<9T'UZ/&V[<2Y'4*%W.:&[\^I]
MLS(P$[HU>)5VM&)F'1A,.5-,.7W/X8DK2&:,Y G0=5&'X\%V/4+*JTN:SI%L
M5>IUW;HHF:;%VI-2$25M-POE\/[)78RSUY!ZM,%90QY*\MANWL7>W(['GB39
MKFE-0<;UJ*%F?:QY0>4R?/;X_A<]H*2(J6XWGV0;[5VS*4+M5^\;FL5N=H2E
MAF[/A&X+S>Y=->(ZP<E"ITRZNICHQZ9L[4CV&3*TIY=AHM^TH7:M<=3>_V<?
M!-B]I6*F#9G!)L^W+C88;'+B*<C-X^9:FNDFAB9+TN0&PT].-?6Y73ER18 A
MQ])]=<XI'[I5K^^(N$XW'[J_/!Y#-TU_Y6BA;-/88_7-AV6PGR,W'C/9BW;L
M/,KVLM>?K^YN"LM?,_UF93/;W!.FDVK@/R4_+?Z&T0'K^O/7[W^L+[+=II'M
MN_3-UK:I9-U^-HDLV<BOL)-DQYD/N;^GB9%W??'YLOKAYO+BG]6+J[O+F[>6
M[3[9\U R[[<6H##+ ?2=-26">6LU9S_?6<(&E&M6F(>2Q5F_*L_R[Y_49\DM
MQ5V<Y-VWC[\[WH]7[R7,+8YNFP"-*".'DED<E>B[=,T1&D@/UL?,]CPD*]]B
MN]QHI[(SFP8O>/Q5:1B5FVO5JI^4Q^Y (YEZRR.9UDYD:C6VFFUUYI!L+QL?
M9B03,6&A0&S5:/.(HPEZ>Y$LA ,T@ $/C'-68+OP(E@GGRWT@\USO#@&O+:&
M\^S,'\0)CD2K,"@OJ7!8R0SH+CSN%,=E<D ,'>$Z76?"$.TI'4"*-"E>!*6D
M0(&/=D2[\E/+1@F')P<N&K)DBLL8/=4X@B<WXV6G3\>'/3CCF>_P@2[XF<]F
M$2+RM8/C8P)FC^4<H#<XRF5Q87A9 5Q!1'.HSEF4/$9NAAY$@U^ %\4X6HH%
M#PL@?_1=8*4TQBI@,S@;&D:%=T\=V&R X9#L1>)0! IB<0?@P+O0FL5#UQFY
M<QQ.,V;8M.?AP1?S:_@KL].S",QP59& *1E<(RY_-Y]Q"7,I1EM1#A3G_6+L
MU":":.6 J6TD4")4+E)ROA3@_^0\.L XQC> $:N&3='0(Q \3V"=P.DLNKP\
M?UEX)Z<[%L^WY@YSQQ6:_B.^"N$@'IGE,90F0\9 (;0=DC,"QX-DF!2-'^*C
MDPC7R^ CT ,]#S;"<=%'W&+$ZB8Q!B%7:)&!$_ZH3@*&4XL 7W$L68#TXG"L
M=." '28V)"D*T,Z6SGS$T((%_A\+?%HAF&HT-ND>Q:E'NKL#!\1"/EO-!G)X
ML!V/&#3.T6)_Q7PX6Y0E'Z*H<YJYM]6$PG1Z@"54*BN#[(0#/"F14Z3%<[BL
MS^EXNLMT+!Y@V2<G /#Z@'.IC86$&NY9+2COJ=ELG-H2+QE-V3AVF8A$+;&,
M#/<*D75P5I-"E"8-W<%+/[APH9B8UNAU>OUV_Q48A2-[AIZ% !39ES+7:(5/
M>Y<-YN2S=IZE20W9T-;-_K&ZT[SIW??">_>!RB5P9:!]ASZ#>&>)>'WM$6]_
MN5V*U>2#NR^W=Z2T:ZS?P9(OF?FU%IP'C'MKLY9FF<5H&!M_QHQA,<T<O[WP
MQGN=.5QDDM^!1==XE8OMMPN&$'=JG<4IQ.NCW@=#LZWR3+0A IW6<FX$62)6
MHR]!=@Q!&H(\-X+LIP39/S6"[)XM09Y^-;L>)2*)9?"O))9TOI4AVF67/R.Q
M=;L:MS*LZO#AMA3WB@)NJ[,\FJ_>]]N:9;D6'NPOIO63YN35WRJ-ZGS)2[=Y
M#H:\3IJ\%"V==Z1HGR9YZ=8X:@/R,L7:.];$9?*1]6_,I3':^ GPL\9V^>MZ
M\K,RR6_%Y9[UFE[-8(RZ<.+DM5U1@R$O0UZ&O$J0EZ)C^,EJXR^<O(Q??#?:
M^ VFNU]ANOL7F>Z.&&6T\5/@9]OU;=>+GR$"(OY)]-N.GQ$[,ZYQ0UT[I"Y%
MV_>34\9W1EV-FF[M50QUG31U*?I_GYPNOC/J:M9ZITM=:WH;9?)N3KXZ48.Z
M_<B/;!=K4P/'"YU1VL9!51J>EH1GF\4((N*]8M:U+&D_V^6KZK.QZ_X:LH-8
MTF+C#L'T14(IWU1CLV'FG>YRT&JS#@:%X%7Y)#;2,DX<O(WF,NLK!=Y<ZX="
M$*L4N8U$S4F#N%WIU)<MHW(@[M<XB)'Q++*<A78-G"_- G_$&'">U]1C!EC@
M#VP,03>(KA2R193D317+96$HRMKY5]0;"GZ(B$7C+Q[UY%S+YM[ JD8,3HUZ
ME6#S#&"PZ"B+ 1S6T]3/<$35@P10\(V\J4VMJ$5$>P^C$/3"K#6]'[XJ>C\H
M.Y2 =K1"%N4;ESF%O1,0I+7\'-<SZ'A06J=H=@J5BC_C,'(F\]WW ZH@Y18<
MRW+/]8I%IP0D2(1L$::^M5X7/*1!=[Q!Y%.B4+8)SBI=IE*"562>0Y<#DUIN
M 9)TWJ"&0**=C>K*/,-Z1Y<6[;*Y9I?B>70 ^=839?:6O;OTHM\>GY:>W\_B
MF1SR7]2XB ^EX"4&/GZ5:5A+OR70+>A_,7BA_2]V77.]5:.VO*6\1T_(#E:G
MT5(,H R@=%W*?GMY/&>K28</8/F!_\3_;KS:]1*5[3,6RM.B*2C.VS3^R2TV
M!Y>,[#O .9??T+[Q854;E^YAVKB4AL,)=6W)*$['[-I2#J=*YI6<@LZS:^34
M2BX82!E(:0>IEZ#V&*30!2D.W&+NI'0.V0_VD K'\913@P O$P'T8W9&+!BQ
M8+A"P0$9^_(TB,I RD!*.T@914*7Y9WE4HPB45J1$&-&SMJZ,.?_LL]?/U9G
MA((1"H8I&./RU&G*0,I 2CM(&3U"E^6=Y5*,'E%:C[B1]0=G;5X8#%B;,F?L
M2R,7](24X0HODBML9&!F<Z<5"?(FCWI3M0"KV0Y[]MKP"3V'KI[AB-6O5&&J
M_715@V$Z8IBZVZ8M%\HG9V7:<&XVH9S/=#6(:1!S/ZSO&LOA#8(9!#.RU6#8
M:6+8:;"P3:S(!20Q'X__<7^#D'3H;0E4]+<"@U8LL;?7):HXPOIEU]<O>]^0
M+6Q/NS^8=;:&64&OIL@7K<8."=0=N%PTQM"B?L"*092J7GKJ5D_T;7@11U,?
M6Y:-OV/OK%MLD<4[/&$'K?##7#I024R2.XU:\BU_76^H&O-=PS/Q1>7:3Y5:
MT_*KO\]F+*"_?G<>G"AIS%<OV?+QR]>K5^];BF["6O.&\VS(W3NA?MP+DRH=
M+8AN_^3&;;)ODTR_&]$4;CO*:U8Z#=WF4.A"#H;R-NAQ>'"B4Q#9<$=$MDQ<
MLA!3I,PF&2\? 3!(-+'MWK'@H?DJRZ.:]>7FM.,XF#,[>/6^6VLLMILW5'=T
M:^IOZY54#<E4)2";#1T%Y#JM]& 4G+OE P.H(SE_L.%Q(];84I;6&@,C2H_]
MJE.BT::.-'HX)3;3:>]92FRCTC9*K!&G>R75EHZD>BAQNDRH1>)T2_'9J#4[
M&A/Q_B:X&K_LAG[9EN;>01,Y.',,E=,./E_]X]_MZJ<O7X'4'ZK!^+X:36D.
MQMA_8-61Z\#U56"X?AR,6%C]&(8WXD-U&CVX5>;2N(?J%)BIRQGJLZ(2S9(3
M?@XDL)JG'97HFJB$#J\Z)2VQ=WPM<9GH3B\JT6A6NGWC2SGZJS0E/0W#$LT3
M"DOT"\(2O5K=A"4,U946>!J$X3?7,D\ZRM"N-9<'_!H:-32ZBD9;=1UI]/2B
M#-U*OV.B#$=_U2E1G@8Q^.-)QX,$#9JU=E]CFCRIVH.3=LFN77M7<^>="1J\
M= PMDB1MK1S[K=-V[*L\BUKS!J/)'5N3ZQQ?DULFNA-T[-?!B#+NBZ._2E/2
MT]"QWSH=QWZK6^#8']2:QK%OJ*ZTP-,@DKVYEGG2COU>K:^S*\/0J'8TVM>1
M1D_/L=^LU.LZ9QX;RM..\C0(>Q]/.A[$L=^N:9T MMMJ@(5\XJOO6^83NX['
MOD3LH?K8?*QB#S.$F@D;/,<I.]#<-6C"!B\=0POD5+NI5=B@?=IA@X;*<:DU
M<S"*XI$5Q;8&9:/+5'=Z<8-FI=7N::P.&LHS80,UT>D?-FBW"\(&[5K'A T,
MU966=QK$R3?7,D\Z;-"HU_K&>WGT5YT2D79U)-)3C!LTFCK[* WE:4=Y&D35
MCR<>#Q0WZ#0TIDE3$*"-WQ3=>5I[[XQK_Z6C:($HZ=2U<NUW3MRUK[*@M&8.
M1I<[LB[7T:"X<YGJ3L^UW^D8&^KHK]*4[C1T['=.Q['?:18Z]LW\@6._2E.J
M4TH[#0+9F^N8I^W8;]9:=2,:C_VJ4R+2MHY$>GJ._4[+J*1'?]4IT9T&4>_C
M"<>#N/6[M;9J2*0N-&F& VCC,T57GM:>.^/6?^DH6B1*])HKW#UQM[ZJH%IK
MYK#3E\^P!,R[KW+I ]_.?A[T_4,_@+/.OMX*?=<9D]"K5RS\]T8[/;#TLK=6
M%S6H'ETF[-.+' ST2GO<#;H;8^YEQQ>ZIQ-?Z!;--S:% \=_E:94IY*)70VB
MZ9LKNZ<=7^C47JZ?T^C&>NK&70U&(A]3-]Y5",/HQD9*[T%*:Y %<#PI?9@I
MR/5:1^=*]Y,J8-@<]X<XL_P4?<IUS1V;)NIAHAZKY4JYN<4F#'$6IE;KN*86
MO-X:^S%(\=.RM5:O>VMUKJ <]:0C \U!I=Y1C>_6QP+:$@N-":1G>. D_/7%
M@W^-O_XH^RQ$Q+^M5_,TI!NEK"D(>K\4CWNWUGBQ T2-%JBK%M@KF ]\TC[P
M1JM2;QDMT(@_#<1?KR"^?:ZN[%:MJ;\G^]=HZ(_G^ F!\=[Z+\NR%A5A_N4L
MZRN4"_SOA:7]]\*JTD71FOB2WN*?&<3%%686-SO,"^FS _CB16^;O?78?3=E
MUI/ $LOF:&(%TO(@[!:FA^4Z$V;Y$W@2(*+E$X99]I,=C$.+I:AGT6P#*X('
MSQ!/+3NR"GRRUB<VHMB/U6I4+*0?BYRT3W9H;9'0A:3Q%4B, DU?O'$,#P=8
MX->;Y&!=! %2%-[Z89Y><FW/\:L+W+0@L0S1E;3?&EG[K=$IRK?JU%I+:(N_
MA+6$X@Z$5_M$9"DX,]\0>6<^DQ!XVTV_B/S9XCK_C,/(F<SS)-"M]3KEJ,"^
MOP_8O1TQ0,XH<+P0,.[1=N.5..^GUH8%_]L3#?QMM?QI%'8K*4$)60FU1[KX
M(N'Y+P1G*G=:)>5.M47.OUYC6>VK6<5'%[ 92%)86DB'P;]\3><"L/?'@-3-
M>F/P+K1&KA_B20)^_6"1-4,16;%<%O([Q>$R^4-$>(Z_>*3@(I(@6DY9]<'W
MV%R%,6_@>D"$)S]VQ]84F*TU9,R#-8Z8\PCL=SBW;-=5W&E-?1?P*5Q"JZD]
MQD_S9'GTT0F4^ JOIIT JL)B\4]D)1IP$CA3]G/DQF,AJ:W?QLZCG)YS_?GJ
M[N:57)(B1F5)+:->_^65>$#N"=-)-?"?DI\6?QLQ@/GUYZ_?_RA\RY(B4E:C
M>9>^V2I6-%<SB.Y !"[IJ)*-_ H[27:<^9#[>YI$]:\O/E]6/]Q<7ORS>G%U
M=WGS%M#MR9Z'TH!Y:P%IL1Q WUE3$FIOK298]I8(^LLU*_(!Q$^OK%^59_GW
M3^JS),S8R4G>??OXN^/]>/5>PMSBZ+8)T(C-Y% RBZ,2?9>NT5"UB_P(-+>)
M#2PAD65(^2K^\,A"5 (7><Q:(=0J5]RV((^0KH#KX;<7WOCP\NE?M-LOWC7)
M@2N T()TVC 87.DI\FXYJH ZAY*E@+X13!4B\6)0=Y9!W1@DH(8_3Q/4FR@"
MC6:E/5B&M%4&R(V! #*J:X6 [BD W4\!W7\!@.Y7!HJA[N7@W*]EY=7+,E+:
MA4;*,B<O9Z%<A')K!%)@XQO9$Q5N4.3UU0(AP.V9&1OAA\BGKY<D@Y-8Z$H:
M*BJ(? [A;."S7B:=#X6D R^_%+N^\_&K3$2).[*W,UZZE79_V6O&C9<E[TO>
MU! 2.U3+;*=8-G<+H@#/95Z;96KM\B2*O)I;Q_"6&Y$0$7!S:A,/F;,+OU69
MP]B'[-@ [.7<6U@"5I">T%:[MPI9X3XMUE5<GO3M')NOKV?S)^'\G?BNZS\A
M)I.OW KC!W@#O(U[-T93Q!]@-%[6V8&4(6FB*FGB'E MJH[1#9,W..!XJT*N
MJ'A8.?7XK28:Q?.3B$93-HY=]FVR(LZ:QGG""^!$CTXTO\.CN8,7?7#A1T%@
MC5ZGUT?W,0.6-T.#.HB9-(Y_XZ?)#7OBAF@=BW!]\AF .4H^<SMZXGCTML1,
MSWD#MO:"+,9ULJAJU2EKX#<1M%E;AI K,-AWQ'1OSP=B1%S^GU?-]7ZG0]8F
MKJ"I'03M5N>9+Z)#M*+4Q)8+I;5:F1J4TBD30_SW%3@2%W@6D9O%Z<TB@1CR
M-.YACMGL"RV>64-W-MBY?7'A/F5 ^3*(X7NI'EE"/[(^DSS\A/(037&+;''M
M<6M_I6 [VY9,% &!M$]V17J=E?U" K)$UHC(*5RTQ!N#HH//Y$LHCBYW:(?,
M%-)F+<TRBSF5W"%%3;QTX)9R=CS#U@/QQ_5QF9S'$XZV\\<V*MV^JA1J74;0
MP;!JJPQ9;7#^V)!Z3BK?>1&LHDQ>0; ;)_MM0;8+GAA2-%#/2#S^VZ;V];9)
M[=.&D/?7KW=WQ*ZING*K\,N0/X>-2RHL)YBY7$;=.!7FU-ZTUGHOOGOB1*$,
M0'X._'!+I:)>:?=TGOAI2$ _$E D1^RXW<"VA+ G>=VN=75N]::_)^&DQ#%7
M_8PTUH45O2[B11NW/MF+P?"O71GY[4I'NTD=A8?SYI#]?0R);"&M%1EVSY/6
MSZ:3O4GIQG(:W=E(:6,TYZ4TX,6$.6<MJ'?4]O/@S&HW;6X+Q7ZY.2_[ML*O
M. [&(.VE!;*=%5[I#/2NM-_N",]3.7C99%E$E0.-5(W$AY^GU3WZ](]+PN4.
MU[@2#IV(T*R_' 5EVWXL1V>%NV\+U']N6R =L@[:H)IT*X3"VC"V54?U4@()
M>T/F,BD&YT:D>VHKI$^F0;O6/.HHBQT1[_&:#96N1AQL6XVH027EUFM?4TEI
M;5\]&3"JA[=GL\#_"1@=,7=>7(%7,%RCN!CX\F'F^G/&;EGPZ(R8VBF0$"K/
M7+_#<O_L[Q_],/KJ1_]F\)J1?^]A-[&M? $=$+B#Y3Z75)U(/09B+TC> #M.
MEP ?PL@*F&N+6M),.1 3>U36!8G\$VR+@J5'N"W;FV/1I!WQASIAKDAUB'5Y
MR1KL4-0VA6^+3ZB]Z0D-1\%/Y?$L<=R%XUD\F;34[@-+S^<KK.3?6!^WE<^F
M5^EUEM,QL7ZKN,"J4:+_P&)'_V> :ATFEP,5@NGNR=\.4MU*L[^<8[(>4LTR
MD.KK"*EIP-C631?Z"NI?"ZM6R88+)=N5'A9>5WZ\'1$.*AU%]M)Z:+5?3MN$
M1F.K@MKUXTC>2YP0E5W7<3": DI86#H-9[)4?7.N$%Y2IUI[4:?N4M%L 9PM
M;+<68#<S6R@&J&P5$'[1:,!<47Q"ZWBL\E0/T" B[ZU(F[)NF4C1[BU;/E9(
MST90@>;TX'M"'^(ZS4SL-=N:Z?+V^KJ"US]-G=&T$,!%T]UT!/"C[;AH2%WY
M 9F;VW7<J/1[BHX. LZ\>X-ERU?A<Q,P;]RKL<:M@TL@(P<?)I7:L/ Q#_:<
MWV=+C++B&9YXT5F6R_+=]ECA1Y83K]<LP I(,/SA=&S7#N9WOGS"1T)4>N@?
M-IA"\4-R4-5FR9-JXKS:I5/Z1;0\P3:&]%*$2G(Z.0(1+0U!R><=;8I@5RX]
M="^PR\"*(WDR>F KF/57PPSXA7BR!2A=!(YR&6J' <<E]1?9.2P8[\W*V^BL
M[S(1.C^)(+&!9S1-,<[!&N!'>&&MZ.ZO?+:<]> '#/M\>H70+Q>2U(,_"_+.
MLVDX3[F>K1CT:N9<BFGFQ"+V307MH^!&WV/\=!*'@^ <6Z #-C@)R: IN-GS
M%]Y7:E?).SAWF]J/U%N8MU,1C6EY5Q6Q?&2&S..M@6AAB/I%=E9_#]K HE%6
M%M&6G,_K$.WBP8^WU0<42A<P2")6U 1*H@^^V!O;@2Z=<X]@160-M]V:$>A;
MQ?\4H>]^A;B:;^)M7\(P9N-/)$-X1I607*N>O5V>=;.]G*Q1*02(0HRO[0AZ
M0@!I*/3#"F>^!4#9IGOG"0%EH&C+N<*"7&4[KO=%R7ZTY1NJKFD)*JZ$5:*_
MS7ED[KR"<LQ>[J['-;89K)>VM4ZH#1I[Y0H%<=;<0[X]>2P(I\X,GW)Y^^UZ
M(7B:O 1WEX@W>4!;SL2L*29B5HJAU=PKR] 96JU:9]DM6UGKG!XH.ESOD)_H
M#;'^LJ9>R1%QS4(/NA>N)]/]>B\4(=0+U_5'&'94JZ1BW=O9+]UE)KR&[K9I
MWJWK]ILMU?;7$I)*6]DI(1T0! V5@S$3YDY$[1-YQ9.X]$;=X/<I?6M6%A04
M24<J1E^HT"96:@\+VTQM8R<<H8TF6^=:?+[*Z)WK^S^JF)W+OQB_D[%^TOC'
M+&+!@^/ABT)N\GYPX>+J[6CJNZC6\(M1+Z 9+?Z8N2NZ)U/6@+70A904([$I
MF5:PL*6C'@M!H8!RFO5MABSL1 1M[3:Z_"MVHOD7+XR"&+\,OV'^S-W4]@Y9
M(]^HM9=[VA0RZF9=(:<.HR"=.*R;M?H6ZE6SKA*,!U&O3AS>C5I_N?_#@G)V
M>!_5NA"]]&$M1>%5.9,XX8=/\DFG^*2#>I[?C/F+!^8RN[-_?@+)Y?IA'*QH
ML]Q0MED^/C2_^B#H")C#H@%2<GX472>D<ON=Q;=OP?Y9>&YY$3OKD)[-;G"\
M41P$H#UX++( 7T)8%F@L(_0BCYA(7_3&%<3%D/T5PWO0S8&W%D8+(JF>C3 S
M>4P.Z>^UVYIUQ4!+L5UBHF'$1]S1F47VST1E XUMR#PV<:*#T[L"H"=PI)B?
MZGLT%A 40SQ' . $@P&SP']T0CQ&U(-36,-:24E+LDI!60S?:@CM'?:GY]SA
M P$F993POS!R1A?>^ J^AZ45-*=OFN;TICG]^36G+]4/G-=8FF[?.^KVW>]H
MW.U;,L7SK:DM H"&17K;-_%H-S9NXJ'P.W)Q^3LH%E>!_X 3DAPO!F'V;0;:
M'%F("V*5A1*'MG%&@@YZ#\RZBE[);J6K&&9U,KVZ3#^BK;F0T,?.EPF][!8G
MA4QKFQXG.V!: N6>Q[.ZE:;"<7AN?8;T5[6T96R_ES+0#\SW+&&O9JO(3<<%
MC?=5Q#^;]>/PSS\<SP\HE "6)JA_-.PS^Q0>:?B#15,??L$Z1HHW/%-)[#<K
M_<9R/:=.+'?+0U;QW&,T:#@C9^G8F4P .;T10R8</3'F90OR>3!A\"ZT&%Q'
M<2=R3@?HK)9Y .BZCB,?:WGD3T?+0+2S;MS#^W#WZK*]E$>0\)@;@#66-7LC
MQW6("ZWVU_8'QE]K_+4OUE\KPJ,GX+8U&'4:&-40*#4P&&4P:J<8U=<>H_3W
M=\C04D?GT-*7--U#Y'A@T<Q$I(6D>C7IU*]SCZJ&;%1U?E:GSACP["V:NJT&
M]KMZ7^:R3KG+NJ!;-WY)L##[/_+0\/YIJ*B3BHYZ^)LS]E#O8X+F243.6O7F
M8'>1,S1<<D9+\K5(V?_ :>$B$@E2MY(0<H;/\]PDP'U: [T<TR^SL_V+)BI%
M9$>1C7XR1-5L5OK=;>9%&Z(R1+4CHFK5%>Y^1<G!Z1!5H]+LFJ2/EQ@;O8VD
MGQTK'=U\RC)FJ?N3Q%K(&!'GJX)KE_WQ'#Y5KK/!5GR*$.?"&_^.:),)23Z3
M$U4Z;;T"BR]2NI\5$91K6*$1$>#@-&,W&B+8)1&4ZT&B$1&@)%@NO3X9(M#?
M?:VM2GK- %>PNLYR(O9PZ+P\PV VGCF$_*5<<YZM^,M7WQNS<0SO'+KL.2U7
M>CW=5$MM4,U@M1*KR_5<.BY6=[73%;5!-8/52JPNUT;KN%C=J>OFCS13[W>B
MW:&WVAI-L46.T>QTX1:%IJ.B'>ZN5+N/A =?O$O/IAE*NPAF])=;"YZ,U6CP
M7S]IJ<A*V94.N#OT?]\][D14HP5JB=>%?%V5&;(C-7 ??+VYW*SN9/BZ\09N
MK2^"$>'P\D<,1=M1%#C#&%5(.PCF@$4TE-%HDKIPG *&TWA.D2R-AMDL92;%
MG&^3CX@M5P);MNO873'N0QU>=4H(KTB_**TZ:H#P@][R< B#\ ;A5R.\*M6B
MK$IY=(1O5AJ*:17Z(+QQ.F[O=&0ALX/1E!(=Q^R1N?Z,AMYA2N,H8&,G,CJD
M/AQF7=T8<!J@U]?M2KU?7RP=T]T4-$BE+U*U":D&K;Y!*H-4NT*J#D>J>N?4
MD,HXK9[;2I-75<L&2)%CNT;)T(9T"\R8<L/-M_*,"\S(%6]]RB#(=LD2;=UB
MGMJ@W4O&\-7MS*IBGHM!$8,B)X(BQONQM39"T\6,YJ$-T94P&@98!=;&X<P:
MV S:G*1!FB*D:=9?O6_V&P9E#,J41ID&=G/6#F.,YV%K6<\SK[ [,DXNYGDS
M-G8JMKW1&2=<O^S1'@6^C*8B)+OK[.U/;,)PJB5<<!&&+ K_)5'O0F+>=AD(
M_4JG<]3BIG*G\U($H"&R542FJJ[?<8[XOHBLV:KTFT=-;#-$9HBL#)$I2LQW
MG:^^%R)K Y%U*_5V_?2)S#CA=M&(6<S=-@.GS,"IY7U9<F-6.0N^0Z[ZHQOP
MY?=\.(0S"'\*"+^9PZIKT-V@^\M!]]XIH[MFX_.4D]/8SY$;CYF<5#9V'N7P
ML>O/5W<WA:-F,M/(Y*BSW!.FDVK@/R4_+?Z&0\^LZ\]?O_^Q?J!-]G3*'O.[
M],W6MED O7HV#2#9R*^PDV3'F0^YOZ>)F7!]\?FR^N'F\N*?U8NKN\N;MY;M
M/MGS4.+56PMP@>4 ^LZ:,J3CMU83V)BUJ!LM&QARF+SUJ_(L__Y)?9:$&3LY
MR;MO'W]WO!^OWDN86QS=-@$:T44.);,X*M%WZ9K=$8ZD\,PWQ 4RGXF]OFW5
MZIWT.S2,5"27FQ?9K?4ZZ^VDNW0TI!6 D7[OP1)#F@+IP+<CZDAMDQTU\T.'
M>PG@7Q1:$\<#"]T1<VT833JUG G\9CFA]8#C?UWG!W/G\#2[<'RDYT=\V"-<
M&-&[DW<].7#60V:%,;S$\=C8P@A+/(:7#.V0?\0;(C::>F@;6\CB8"&P[.R#
M:E9VIU,[1.<&'>J8OQ4>B-_"0F-O!'8VO"R_ZQG_$D2^%?D$@&!5F0M^]H,9
M[GH<Q/>BY"5?0[V\(!8BRW;"*2T)GBU+9=*=.A[W@5"8"5X"^QW%+GT.<0=#
MYCJPCI!/S9S- G\6.-G)GD-X";[(><!O!8R K%G@SG%G_(TUZP+6Q+L&A;A;
MY0#1V$L09IQM5L[?[D\F(8,5S1&D]OC/F,_"E4]3A,OD(N'F)S]VQWCLA4C#
M<4:BZ8HQIRHLS<-^[,,FRV G.A)&$1W]ZKW#_CC@J)6",P&<]"*@ ?^1!;1"
M#XBTZ'6-)G_; WP_#6M[''A:FOMD[]F,]^QO8.X!%E_(."^(7:8^34E,0P8O
M(BZ!Z,R\,?WY +*36.EJQ &>>9@YMT<X]AW.S/V> >"=_5.4IH8W #=1CKIZ
M8NZ@;B;F[C5 L[?GFVF49F*NP2CM,.IT)N;JG^,FK>)>7>/YIA]LEZOJD?4/
MVXOM8&XU*F><YW;N8]>*$@ 6.C$ZI5-K5JAH6X7R>Y5FXZB1_)>2!_.2,7V@
MP/12^2T[PW2L*M6\ 91)1ME::EZ (<E]=.@=B@,L/D9_HN./<SY&TQ3G%-A%
MZSF-%==PCB_>*&!VR,(;%L9NY'CW5X'_\)&CS#5A#%Q]+?%E*Y':J-2;1J0>
M_U6GA/+/::UX;)1O(<HW6SIW$]7?.CT-V3H#; F,9-6;S:P.?6'4KMEHOM.L
M%X+!%(,IQD;:>\]0FF.UDI$'_J,3GC<G?^&U2/I1NRF5,^AY]NAI;(]=1,,^
ML1%[&++ :KVL>)@I.MC:I])=CCH\RW>XE3.P7VFV=*J4707G%R-D#87MCL)Z
M)H*].PH[7GG10:HD-,A4/D211YH8;P\=UXGF:&W'$?SY?TRDIT>6#X:WC9YX
MR_7#D.?E)Y,[\F4,6 R"MTWB* X*\_4!O^86J<A4SC'\$W/IX>7P9QC9U(T9
M*RHBP"!1S\"?S!X93YV>V2'\/Y"O\I\\%H139Y84*M@AD-Z$BD3@WEO&&4+!
MDEI]D6LO<K>_8#:<!^NXP9?&"+0Q54D4I>L/^MT*?PJ6CSPPG,A-( L=P!D[
MX'4'!$#7?M(BG]_0B9I.;M.*#1 <#S/?HYHF@1U+%#06[4OH;&UJ8$('[SJ<
MMAQ9B'.0M/[R19B[2L5?:M]RX8U_3_>^.@^_TS%Y^"8/_\5F39L\?(-1)@]_
M%]Y&R?\_7_WCW^WJIZOO</%#-1C?5Z,I5;6._0=6';D. +0*RJ4?!R,65C^&
MF&Q"'ZK3Z,&MNJ T?HG80_6Q^5BU149!CF,O%['OT3(N4PFP2QVA$,<^+6LY
M;P^!7@?G1'L_Z6/MZ-2??RXGLMOL@//C?<7!GIW:E-E+N%&9^6*51;F&47YE
MD35A 'C;Y?8_V?UY7PH[Y_2%EUI"TARTNXIBJ7+!G"4C^IM$F-\!7SYF?6V?
M@*!#X!C;I<!V!I5!:Z!Q$JRA@S.@ U4I5:F0RT'H *L?0((V!CK7/Q@3Z:S5
MA)7#T<U@]-/A<[WZSN0]_/&13C['XR26;"7KN]U*JW7421XO1-2?$T8W=B:Y
M]X'1K4JSU]$8HXUM?]Y"VY_;;C2W'!HK8$3T*3"TYJ8B>C@*?BYS,W'T?*#$
M=C-_^I6ZUN6G!GOUP][6IN+X&=C[?RSPQW8X743<JL8X:ZSDLQ:XMY$_^E'E
MC8\Q%8MY(;59-:+W%)A7>Y?6L?SNDL]Q^IC!A@MO+'.S;Z=VP#X@OF0O^.B'
MT7;N\GJEUVIJS/\,VNN']IU=FM!'0?M!I==_.4W(C-373.K_SNP00^7^$&ZQ
M3>.6D^!\+3!N-ZYE5%LKXOR_I<>_9;NG1DMG9Z'!8/TP>.-:P?UA,._1US,Q
M:B.'CR2'O^$8GO.5O"^\DTD!%]QA&ANBT):-D#O=ED8%TZ;MCR$6);'L,-=M
M:V)I5?KUHV9Z:-&$R-CU>NL3=WYDNZIZZ?/5,;3CA]LSNL[NDMT^!WZXG4W?
M[#4J/1-%U^!5IX2YNTMJ>P;FMEJ51E/G6)*QYLM 3*M"W$R/$5.->U([.O7G
MG\N)&).CF.D-#F9Q#'9O<%PY/[$+E[$QM-+47A>I:ANGZRI4M4SWJ>L *Z^C
M^;5K>]&%-[[\*W:HSFJ[B&)3-\NC$-!O#K<V@^[;H?O&^;T'1??&":.[L6;.
MVI=X@\_!GHQQR+B$-P+^)#C>QDG!BQD6&79'2/!M\CUDW#NS%9?K=TZ8RQD4
MUQ#%-TX WCN*UX\:23^J(#]["_W$!;DB*)CQ:IZO4'_9"16%_'/KD2B2A?(Z
MQSPCW:X0HM?7BG'N!OCGJ4(8@EI)4%M/0-D]035Z9T]0QO-P"G'4?]EN3*GY
MEHU#&7""FU$V7B!OW%VN<X)1%Q*AMDQQJE=Z';W*+XW>86AK"]K:76KTKFBK
MU:PTZWH5!6JH@IR]ST0/%01;A;^H;&@SUG+3L9;:CYLVDUH-2AN4S@A=K4>C
M-M>[Z[6=][CUVM<.17VP__0#'(*ZR8C'@+DTT--?-2LU6-GA.S<Y-9K:^)5G
M^9X[MX: <\S&,:QCR\FMQG)":Q;X$X=/1W0\.0$5WNSXX[!F?8GPFAATXR"R
MX?>G*<."PMQ#GAS7E6^P\ O<T9!W$1);&N.>X)Z0Y5=:LRY&(Z 4V*0[K^2>
M.K5I;8\.#3V%A<%+'I?]*Y9]#^L*HV3"K JNXYB FFR#S\\,Q:*<P(K="#3Z
M2 **WE&S\!Q5KQ0;?D" V)$84@M?V0^@]4;RQ%4+@9\=UW((J \^ -IU?C X
M(CBPPG&RGA_Q0;!TLOCT!*XIK$.^L,QQ\RTLH9YJ3XXW@KNP)]YP;OUM=2NJ
MUF A$KURMF>1+9;X?F\8/&ODN YO+D7C=K]X^S+56OU*I[-<TUHIWG!W><-@
M<<H-ES,^C[3A9JO25^275HA_%&ZZI]AT/]UT7]=-MV'3W4J]O=SB!-E; 8DA
MZHIIRX57-09R)C. L/C*OK@2N/8,1T8#NY[O<TISR3F]1Y"SO;W(V8MPS01M
MZQ,;L8<AR*M6HV+1"?,YX7E!,[:^UVYKR82M!;F;%ZWPP@*Z:=<598&2)?XG
MH8>+.)J2=G#QTPFK<NC,1Y0>P?P/6G$Q9:V>8+-=#_Q>K]*H+T]P@L-73!K;
M$"(%V?>K('*+;\61SS[LY1]QX(1C/KK]"+!I#]J5;GTY9%_!1S! 7X6NQM9#
M19&DO0XJ5_Q]1T232KNY'&KEPH0H:*5ZBI_]8(9:SCB([\5 F@T1J2#+\S_*
MP1 $-3D<H@R\U$\AK2X!6+TDP+Y\O7KUOM>N=+HJA>-IZ@"82%]C/V<.CG*/
M0"\#K3L&=16P/[0F@?^P1F UI%(8^/']M/CB=KW&K[X2;(XCJB1Q^6FUA:$Z
MLB&[AR.E'2#NKY>P8@VHEA:2S]1^1%O"0H$P<>#(\H:#,%#V*4Q+R#:%*!/C
MEM</5Y9".3]0^5CRN;L?.QALDSE@4VCE+JN&;%1U?E:GSAB>]E:2=Y]TIIX
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M&LWFNXQ"A-F)TD3#XA&@&TP<M;U[QV=C]F!G%-F+RS3!TXXB>_2#A,8_;(#
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MTWWV"!PQE6"Q@-:CT.E?-P$C7J)(=QGP6? A*C^Y=5S2;. ;]L1\ [ME:OD
M[;[I_K"&IA?A?P.+K.0Q?FY02F[(UF.EJ(K:P&1X7:PUZA+IL>(5\_(^0]G;
M$KP"VF%Y%<MRT"G#2B6->$?<A8*] PZ!Y<]\8OXWP2EPGVBHIV.3PBYGY@G7
M%ACSGNGM0MH'P4+Z/F&36AG#WE%#8HWWF$VE"&[)3'$4L_P0)DXRM7!D9HZ
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M9R-C$;'Z[JVPT,6OEQR3-\?415&7Q2#,I'$>H52K%\ Q&4B-LTS!N<EH7$B
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M*+O'+LJ+MOX09SAHF^]V_@)02P,$%     @ ;$IA4J0/4BG!!P  4S<   T
M  !E>%\R,C<Y-SDN:'1M[5MK<].Z%OT,OT+3,Y?3SCAM0REPD]"9PBU,SP,Z
MI?<'R+8<ZR);1I*3YO[ZL[;LO!-(BX>T0V884NNU']%:VGO+Z:4N4V>]5/#X
M[.F3GI-.B;/>4?7Y],G3WE'5U0MU/&+6C91XLQ>5QFK38;QTNKN'SF+<D^C<
MM1*>237JL&=?2^VZ-S(3EGT40W:M,YY7C0'SS0&SPLBDR_P\*_\O.JQ]7+@N
MR[CIR[S#Z&'OK!>>/<M#6W1[1R&T*\Z>KI'Y^X*TWQ<$3>5X,;44^M.)6]?B
M2O;SCI']M)9Z<9O*4#IVTCYL_Q392B0D>FSM>FF->9?-2&>1R)TP=9O,8SS.
M? ?O+JYO+M]?OCN_N?ST\?/#\D>3TBX#]H?.V=4A^^QT+E)=6A' -\;)9,1<
MREUG*X8['BK!0FUB8=[L'>]!):4*'L<R[T^>;<&C\7.MW%#&+H6PXW]U?T#/
M/>*#)^ (@S_H,UY8_W4QJ[&+OS%L0+Z,N*J-=;KPRV/XO3Q:N;#E@=N9^K2%
M=5?ZM>X.M7,Z\R.6;&T?>J>32BM,>?CZ7[*4#P0S8B#%4,38M=(RGN<E5V@L
MM'$,6_R]-ADXH?4GTPE[*_4[,[*.7:7<9#P2I;<16E[FT6%WT1_X--41X?=E
MLW"8M:UN(<L[)R^G#1N[:Y;-6NU7AR^+';3NM37;[6\Z^W^E)8;<9'L^WQJ\
MFK/A+;< %E"4C=B77 ^5B/LX)SS2:HC%&GKEVK$(D[G,@< 1*W-G2@%#N!,9
M]B1AC^-,QLDK@<Z$1V@R3&<(/)RNQBT-R$4DK.5F1$,R_D5 [LR:%FTQE(%(
M16:3#!H021.5&8;EF Y-L-W9,)51RFQ)_TWG#X41]2)D0":M0B2([<^&TJ4P
MT!8B\@K2N@54TS',Q%<'IX2C63?LJ&-''?]NY%0[V1IM-*/_6LH0+)$Y0$GX
MGH(P %]@.+K-3+_,$QS;W$FL(_-(E3'6!-!G$!> )*11(U8 IT0Q1#U*33FD
MAJ]=$ V:BB4M'-"(4F$ B$,#W5Z<]?I$W*8L47IHQZQB1%]:9S@$<6JL](:6
MP0PYV+$R2]KN^&''#Z\:P=>+K?%#,_K?S('IV6^OG[=?=6W- '4"2D>P3A*)
MQWU[X)%VR;@1'M/ J*3M!NPQ86GK29O2#!J6(0*A*(2>8VDCI6V)>12;&*TJ
M<!=&1R)&LV7[P'(L0 X58"]NHY3G?<'.<>Q?EPHCVB>\U3[=%Y46[=.X>JH>
M)942\HI4:'U&L<$,UU38)UTV%I3,"<(3F;E(0!A J4_GIY+*XT_?3UX^!B*X
M0WC.'R@7W,&$6%C, "I\</Y]R :4-T2\M)M/H0 ^%&PBJ4H)=&FP ,[M@;0^
M&L HD?MUJ/PUC2-F8Q$C%/=XKG."*2B#.DZA3HF8 KI8K63,G5<TM#*6W$@R
M0%:9BX^.<EJIM)1-> :T/O7PL8.V @HYQ"HTJ>#T99:*4\@#L[P2TZP$,ZH<
M9S8UPU^AH(&(2C!?Q \C"CE]<8\H9$<T=R^*S_F8O9J6Q;V7ETOC8]BR^>^O
M&KA88=\["[=7X'C=2"@RSST;'^9+%+1Y&+ Q$X&]!C(F@N%6YWZS<PMRHJ(&
ML0XW\9@!P$F2AU))-Z)D9958XD-/%IX'*BJ;&SI3%/%AU6UM4%&: CQD?7(5
M18";5\"71_HB1\ZD0$?H$07Q' TI<U=1#OA0%HAL=J2S(YWF2"?:&NF<G#1"
M.F+ 5>FC D*D2!(1.3D ENR*6L,D/=H@RJD>5Y<?/,=@(B(46Q4Y0EVZ]1IL
M$H?QR6A!%9SD^T52%HYK0YXV:T] GRXMOJ.)QTX36Z@FQ \T ]I8_PIHRX"E
M6Y2Z1N![5K+"'0(/2FET%)6&8#F3/ZQ8-=/6H9U>E,!:%OYC7TND'UAZ?\V4
M!/R"D&!A=*UX!-3["Z!\_G;VH-(JY7:2;%$PX?E(Q#[*\OZH(Z 14_*+4/5M
MT,+XX(==]/,YZ/%SR4.IK+8W(.D-P'BZO82F&0/N75OU+U),N"B8'M04-\SR
MP?3,)D3?(65:*IA,M.-E+)TV=I*E^ 8LF672.2&^$16%&GD0]<<2^OE%]L$:
M"$(L!3GXI-+-F.K$UU)"?4]K91[YVYZ#70WU<88/+QH!C-@:XIO1GRX\J98@
M@6>Z&: KAD@*H*].""95S*'@7RC"KW)Y'^/[*H1_#6-\^7DG3-<%Q^I:9L49
MS6-,M&)R1*_%?UV[P!2 &-L^J-(,2XXK,W@!!GMCZM!HY37Q+H7X]3C@VZ\Y
M;8JA9'NG?C,<@$PA,3@T R!2^*,>F/8O--7@#ZI 6^8#K0:"HNV<]^OWLDP=
M'8BL4'HDT#M,=14/\#EJ 14TDHHL>?L7!2GS*%U\#?VVKGDU\ K\>A0O[&E6
M^:C+:L5.H=>/[/&[1#[_P1;ML+^YP4G2#MCSX^?M.Z"1$1SK;V!2.&P7M\Q?
MO3'3#_>/ T;_#K9BW9$]6G[-?LW^W^2+\N;.V;&>@S=UU=:=]* <M 7[WZ52
M).SB5D0EE6'9IRHY^\6\L']571CAJ%ARQ<%]CXP&?Y_U$W^NM" LE@,6*6[M
MF[V_SC_?M*[./URTWEY?G/])OTN;Z;WZ\/[F>J$M35I&#Y<;Z6AB5Q\^_O?O
MJ32,P+A5']#BB'X==]8[\C^F^P=02P,$%     @ ;$IA4DM)P'Z\!P  3S<
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M2V&@+43D%:1Y"ZBF8YB)KPY."4=--VRI8TL=OZ[E5#O:&&VL1_\;*4.P1.8
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MJD=)982\(A6:GU%LT.":"ONDR\H+)3,+X8G,G"<@"%#JT[E74GG\Z?O1R\=
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M16%5BJO=1G-5A?&[B\M/:VLX L?=](4HZN8_UUZW;O^B_0]02P,$%     @
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M7.,8+?*M[P^#'X[PK)^>\-JB#V3D6M EJ-J$]O,T=#_WF2$A^CJF&^7G'HM
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MWIA?8RH+F-9^7*3$7EI^6*@#RED:!]2'RDZFS)\O^ CQ*W,R"A]D^.,J**Z
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MK5,*630W9\"'R%%1JM@18'BR3U.$2)6> L$=VL(8?#&#"8=$A>9"8>K(5+]
MV>8+5)#QUME07J\<X8]U;^CU&$M^5_LI[NT#R#5^J ,AU_C] ^.[GV_DG=V%
M#;VXQHO;Z/U%;?.B%ORDH_Y5XUNB&\!(!6[J?ES;6[NAW]1'N?N^T!)=O>-/
MC5:M_6>GRR[/JNV+:JW^M=NH5<\[)=9HUBIT,MS32]G>^K")ZN$56.^@C%\)
M=N*#1(M??Y)X?=%@R$<ET'!YCX\XV]G;WMV-/\C=[?X U^^3L/0Y_,8WMTQV
M=O_NG=W;++2>0.]X^KX^9>[KR^[I5OE]B9VH8 CC64/)=LI@SXR2/:T-(U6^
MBDJL%? KSO9VM\J;F[M[\6MR.1>UDXMK_'@<>LEA'Q-'5:@X38<M5&E*ARU6
M8UHXEBQH<PM4E#);NY"EOC)=XP=M_ 3&58SL_#29B<IY.FXEJL+./93  N.U
MCJ+CM\%;=L*OI<TNK%KD..C,0&_6Z]?1GI=S+@MV[15\'1#B5Y=?15>*_0E6
M@<U9AX_ASX^!8Z^9E?Z03/RYEW _W-?NSL0MNN5]3PZ4<URW&  O"!U_G+W8
M6PQ87AF5_:"-?SS3M!A9V.0C<1 [3[HR=,0+J +WM8J+6?*,7FE6_\<EJRG?
MJV I^$J)=4*?AV(P*65*P;]^U> G,-R7"?$+5/+GJKNQ4Q7P7B&ZLU:_+RT,
MV*_3N3->YD59IH#[YML+[O(!?G$YY/Z(6R*BM>4N4#B1UP^)I%ZIT:^H\?TE
M9:ZO%]+>[M'XH:[<YQOYP=[<U[SOKW^C'^;6?<9M7M2"5XV7PKF+,;>+=L 5
MZ-YM6:'"O.^MO1)=;??Z%84?T:?[&I"J4*]NC%8[/PI6O6:>N7!N_7+)YC<F
MK)"!<W= \"(R97[",5<Y:]F<M=U5SMK2Y:P9O%D[[M3.ZB=?S^OQ/<_(AR[/
MJITZ:S0:K';>:&+X(^NV&_#?DWJGUFY<=ANMYN+#]@O*F* DH"$/! $DI)N0
M=8Y)$E#H.5Q?/H")O*8^='QW\EOXSP?6=R+,EPB43FK#^M)82D+?%68NR9FY
M92"NJV'*&6%RBR\L(:\Q0>J"^U>"+GRK8B&B:Y@59=AA@[88X(4QV$?57#LJ
M17#S *$O>*CO4.V;:6)W3A3?0N>/(B<S21ED(!*$D8W5+$PU$7LD7;K_C%)#
M8&W7PE51X"Q#AMYJS-68JS%78Z[&7)Q6D%'VSJN=;CE57><JZZ]&"=]+U$T:
M&AIBI[8D0Q0 R9U K.&-0[S,HU"5O8$;C3ZN"=>^EQ(+_^@I>W)\]'88CISC
M_P)02P,$%     @ ;$IA4JM<'K^*#0  H$8   T   !E>%\R,S T-C@N:'1M
M[5QM;QLW$OX<_PK"O:8.("NRDS2-Y1AP'"<-FJ:&K0#W[<#=Y4J,N>2&Y%K1
M_?J;&7+?)-E1>VF;QB[06EIQR>',,R^<&?9PY@MU=#@3/#O:NG?HI5?B2'SZ
MS_ZCT>,??QK"KX</PT/XM1">LW3&K1/^^7;E\]V?MH_"4\T+\7P[-[;@?C<3
M7J1>&KW-4J.]T##:"R7*F='BN3;;1UN'#\.2AXG)%LSYA:+7M=_->2'5XH#=
M_U@9/Y[(0CCV3LS9N2FX#@\'C!X/F!-6YF-&[SGY7W' ]D:E'[.29YG4TP,V
MDIJ-AGM2CUE:66?L >.5-V.DH%RW[ ]+"_ZPM%:[%*U4<#N5^@ ^LJ?#?7C@
MQ2>_RY6<Z@,KIS,/*QTF1Z>?9C*1GCT>[AT^3(X.'Y9'6W\^ 2DP7EB@X+Y.
M7#G^JU>%?;\\O3@Y?W,V>?/;._;;*W9Q>O+^_,WDS>G%Y[C /D?0JLP#3;O>
ME"#VSH/$>&^*\.PO9L6'RGF9+\(CJ3/@S,&C'XF.0WGT0IH3NW">G8%&%3P5
ME9<I5[#0&YT.V<[][W[:WQ^-ZV'T=6_,C&5^)EC\]<04)=>+^.,#-N..@9*Q
M5'$'GW(@&H OO80M63&5#F0C,E8!,99=!"UE>_LX$F>]:$>??@)-UU/!CE./
M/^\]>_1XP&!ZT'1X.V,['3*Z@VM:AH'7K+N!O:=C!S:A*&!5YTUZR>2-=.TD
M#VK2>O1PG>&;"M_+8,-L B/><9?QC^R"YOV5VTOAV=NW)VPG_O!:F80KF%W!
M_'' @[@DKN 616)4O:47)^?_CEL9'CZ4MQZNR.'<*&7F8%F1^9RYJH#Y%K6$
MP/3#DL!A^%,0^%9%STOI803)O@;(9 :SU7/!1VT\8J14X$9J27^L@,9<@K#!
MHDOO&! GK? +EBP 0#F@1Z>">4.4=+2"EH45;,;.A?,<\7(B+&P4E WF!RI!
MW8PMC>4(NFLA?M-+->0'1.XZ"H[CC/A[0\>+A>)S=^V*X>=V;L'3&2X]GTGX
M $S)I<(IX6W-1'0QD0/'6@/'8"D@T:."O +7#-#;_:6=P2/?.ZXI"+7DUM\R
MP).O.J[\S%AX#_ 144J6Y-:[JO>-@;Q9;QI_!C "+P(*Z=4"PZV:K0!-Z5PE
M6%7BY\=/1H/1B/YE#ER@()/1=0X#!".[X@K>^==H.-IC)5!"8QOW>!+&DZCZ
M:OADS>PEF0KT-!LO<-:\TEMC2"Y'5T4";\#,G7VVRW6) R&#L1)@OU(KN$.W
M95DFZB\[2>7)\B4"3"RQNYT\S@@/K0C&5C-3>3 C&N/<!V@$\0V>YQ(C<'DE
MV)4)4L+G,Z- AD02!SH^ *&^,=L]FUP_C/:+S*Q707@XX_#VJ )9A:X$;[TE
M^+F%40_9J"Y=H&  2O!KM0G&<J4P1/ X@ZN20GH?AO,&JP3!"%92,'@3W]8&
M+$I1J0;9&(+0^0J&O80X(/4&9B4Z,+B#>4$CP)>IRL*N6JSC0AB%@)6**M-=
M<A7M&'4*X!+XV-*:*XDNVJ :SJ5#5=[ +.*(VM''V/VUT +H B8VX]A;/F^"
M<!]G>BG@-;)%G:C@Y>N3MZVA^ZQV]P0%YL_!'I%P$(V#YT"1%?%QX!KL\]."
M#&CD,XHN"@Z%"5($JP6<8&@?XG/@5Q*X"S%\"6^LXR[W.)$0..LMLB._0Y%F
M'."-?"-L(U<!V@(QGTD$G\Y<"/<R".' !X @%+=!;NNBSA>&0]R+2&ITI!=@
MXL_-T3&WIF!YA6LH,04Y PJNN%0\42*XGMS8 :KN!SP_H>+J1?2HJ#@ Z)K*
MJ)N$2!BSY$)7_->PC1WP_*K%%4"JY#)#39UU]FY"[-_EV>T&4J#C/6K<.OEG
M$&\959&! 4U7\F,ELVB7 $ H5%!:56E/QS@+AJ'Y.NC:E1O-?8U1- W<.>'7
M 2C': >.ZU8F@1YXL6L=;@;6[\73C0H&W@0F%T5)WB1.C3I5_QH? 2&IT8!%
MCRM(VY]*ZD@H^8-.GF7)<0&9M%00@9/Z$HTJZEEP*0Y^@>7+4H$'(54S*X9[
MR(Z!MYT=7A=CXIH0SLI,+4*LG0U@*90$J1-N4AN-0G(.%[M%VA,.>0"GW0F_
M% 9-S%G#_UL?VEV80G3Q6$</&X<V""T,3>B8T_@QD><BI \SB&46@-P!6H'4
M0%PVI6^@$Z",5ZCG &LJ+V"2#R(4+!U8HY9/)/!"&./J5! PA4]% 5,,V5EE
M7<5UDP>Y:0--LB;LX>#O!X G Y 8"\;K^?9HFZ5"J5C,:+Z[DJ?U]TCI7&9^
M!O(??3_^/Z"S?;1U;^O>O4-OX0/^S?KS/WK6H]AGZX?17&@U,9L=D0=,H.EA
M^!\">60=&>:#@.L.>T?K8=[G-PY:V?#][Y[]^/198#\2MV93_Y"=$(XIW,,L
MWIJD2XSY$L7U)6B0:%(9RTD1-I?P=N7!<=C@VEHWC7X*C 17*RR#OPB;+?B+
M(+Y#\QV:OQ2:J99%R?\!81/.D)@8:_-A0,L5!46>3Z=41_(S"/!V%X+;4(RX
M@^M7*.1O!ZZ]- <&0%3""AFK.ND4DT64GZ+# ,1$]:G\#IY?H5"_'7A>\93K
M%(OZ,4\03&LL2.12*2JBJT6=1Z+?[T#Y%8KRVP'EBLVTHC"4Z:Q3E81(S!NE
MO'*A$Z +TDV*79XI@<G^IT\PX8VM2?4H;[#FU9;8@I'NIK42T2L4=*=5S:FT
MS<.LR[_U2VN4IEHN,;!I* 9@PN8&#\%V>!W!NPJVTJ3Y<8XZA7NGL5\ASK]A
MC?7\$M0P@A4UDRH\606?8#<(\ECM:;2EE_!%A>X7B"ACZE%5.]7!E%1P;O$)
M986P5K4)U!OFQ9Q8R,)\J2;3I=1-)J_"0>7Y]MGK%[\LZ0TCQ:DS0$KDOI\3
M"K+"1]B9VIOKU>2\F:PC-Q;[+%EG@:5W9_FN-?/5AZCA[.SUN_>_MGN $=B4
MV_VS=3BS]<)GQZ]/=U^<GQ[_LGO\:G)Z?@ V<,X7;APMR0&FE46/F#&;B;"K
M_?+3&.2FL/OVNQ'] ^_Q]')J3:6SW?Y/*PSX^>5Z!B 7__#V)[^=O)7Z\D8&
M-'SXLAG!*/GEK=RE N_L]!>RTZ5(L6@6C:];[JRH _]HHU<#?[3,=Z'$UR?8
M;PBB/3C">\Q!(.]R""&R*XZ=O! 'R)1*4JG(*NI^,[%M"!^6QG'EL!BD32$U
MIEG:6)G.#! G2)@^5GHP,.DOVNU#V3".N%45P6.V>M (W?H?*VEC;(9=R^P8
M(0>6X-V;=Y.?*:JKGTQ.\<E&M<30D@P+>BYU7;T+Q[-!DP%.ZQ9M;#'!XR)?
M+@]V6A\B&D*9$MLLFYH?9CQB5+H^-1+>B3O%PB)\1PA1J+MJ3\&68BBLKX]_
M0^%]72#;MHRO++=JQ\E2-X:[:[-O52$_+/MG_!=0R="!K78T=[I3D.G]4GE]
M865_]*C&(];"ASA=/-\/X@&(^\K3Z]1V3PWW5:) 6Q80+ZNL[?GK%JJI-4OH
M*=7,,4_0) .2RDDM'%VJ2= .MK<10JV$ZWJHQ/."H LS'?36@]%F<M0_:;*P
M!RL$PPH*T)C[V &>H?(2.(D)H8<P$2D8 EQI_1*LT@I(C,4;AYT&@MHJD7V!
M+^NV47=+>LNUBZ=,V'I]=V'SY:6+9<MP>X13&V1J98(*RC6(9UBW9*K%8#/>
M2IVJ*A...AKM%(T4M3Y1CP]E>\ _"6IO"/U!W5W \I7RC2ASF%N3IB= 1=Y>
MXNAL(IB)3849+G($]LQG!GALIJ';*V B!PLH.2:\:%;G3$I?@=XY('K'A(&4
MD&IA4 (V+/9O9#CL =M[\CWNKS"VR;TMW8DA2]QM6XHMI>'Z3[CXTVC2!ITC
M5*?>L&UDN8H=>;^F,?56V4ZZC0K8=9@V?65L59#JGT3'>QQ<W*WOAYHT;4$,
MXDQ3=W\'VQ?L6:\K*7IS*O.AAT=4UEK<3>AR[(,'U=4A;YVC  9QILH2WD]F
M& "WU^I6V\'G$+]0T(&S&Q52XZ*1:EY+]8 %=N[(!]2I"&"75V'A.FMG0X0M
M2#L3:RKL.[ZFFS01,ZY M#LRSA<G0<-G:SU47!9(;&+KZVIHX+(*# QL*:NP
M,WT>^_/U8H/HS8"Q2D.#:"][*(I2F840H:V>3XG[_?M_Y$'6WPCLSD4[^MR6
M^!34P_GEZ>,>T)/_49JY!?.'T6A%XJ>.?+SI$! 46F%K$]D)+@8;!-71@P8@
MT]7A'7G5W^B?MJTIMECJ-DPECZ7!R8'WX1+<2692#\9<7(OS<,4J:F%/ 8DI
MS04&*JG @\J"%PBLM)U;&CS%N#I$X8LF1D!%O::)ME:O3$ P3N><V!A,)U*3
MQY ]/HZ:3P,'X4YE.C-A9%3%1GZ]&Z_+"MMWA$KB29<O>W<"+T\D76K!!N69
M,7@3Q;M.&]>'*I,43S26 )LNRPH=/@4 RSJRJ0:N$_2&>\J,"#=[L=.92,=;
ML!#YND!.8]Q6[2 /IK;=3',.ZUHOUY@OG%O#.! !CQ8'>]]KKM%1L,5EY\I[
M>]/]4?=2;J-'_2OQMM/]'6P$TM:&I[G(Z)8/-KN"> @L+7\^P*(.Q.1;6/S]
M7N^?0\>W$8!0">/KV6ZG3O+V^&*RVU9]UE:EOFBUJ2ZVP ?\7\) ]$G_9YK_
M 5!+ P04    " !L2F%2X6(51;4B   I'0$ #0   &5X7S(S,#0V.2YH=&WM
M/6E3VUBVGZ=_A8JIS$"5(4"V[I!010A)IR9-\H">J?GTZEJZQGJ1)>=*PKA_
M_3O+W;386 EA">KJ ):EJ[N<?7TU+B;)_JNQ%-'^+W][5<1%(O?EY?_N/ME^
M^ORW+?CVU6.^"-].9"&"<"Q4+HO7:V4QVOQU;9^OIF(B7Z^-,C41Q68D"QD6
M<9:N!6&6%C*%NPN9R.DX2^7K-%O;_^758W[EJV$6S8.\F"?T>%ILCL0D3N8O
M@W]\+;-B[RR>R#PXEK/@))N(E"\. KH\"'*IXM%>0,_E\5_R9;"S/2WV@JF(
MHC@]?QELQVFPO;43IWM!6*H\4R\#41;9'LY@:EX[$>H\3N%F?/3:YE#(RV)3
M)/$YC*SB\W$!+WTUW#^Z',?#N(";MG:>OWH\W'_U>+K_RX^>S=K^/])A/MVK
MO\P?_Y^UD?]9&]2-24/J><*?P8NM7;C@+3B$(Y>*%_SFPZ?#D_^>G@6??S\X
M^>/@\.C/LP^'!Q]/!\&'X\.MMAVX@4E].'[[Y^'1'T?'9\'1__SYX>R_.!GX
M].'?1\'GCP?'MS&M6SNAXT]P(D?!IW?!^Y,#V!'XX_3LT^&_@D^?SSY\NG(O
M@JNFU<0-GMEFD4TUG.L+PZPHL@E?N^$-2>1(?X[3"#;GY9/G-(GCK(A#&<1Y
M,)9*#N?!>7PATR ;!<58PLJ2))L!J8'99>&7()LBV0O.E4B+8!WO^,???]W=
MW=[[1%_0AYV]C:#(@FFI@)3F,LB!H,(B](B'V60"(YSR<*/@39P=JGE>!)_A
MMHD(90GS$0DL\4,:;E7> 8].13JW+X$WY"5.!-ZFAS;?[[S8RV& J SE!!8;
M''TMXV*.0\(G6&#P.1%I97"\8$9^>?O@4(AA(H-AIB*I7J]M Z.12:+)OOV<
M3T5H/E>HZR:>]LN=K:>/]F9Q5(Q?_OI\Z\6CRO%O[WT'H %[^=LO?P-VJN /
M_!V9]U](1>>GH8Y7J">QL[.U^XB>A4>N%]X;D%[93GS?XR+J,M<GVUN_W9>Y
M_GI_IOKTUF<*OPEH?R[8!=)R*X#[JMQGRB\E$,UR_^<$8;>[MP"_I?ZC__GC
M?K:!;D\H[@[;Z,E#S]YNB;V])U7GK2AZ!M<SN'O[LV=P=VZB/7GH&=RM0ZW5
MWX+/*@Y[%M>SN'O[LV=Q=VZB/7GH6=RM0RT0W^-R,I0*O4W:6!D%I^24ZOE=
MS^_NZ\^>W]VYB?;DH>=WMPZU3J4[NIS&2M"?O?VR9W;W^6?/[.[<1'ORT#.[
M6X=:(+YG\ZETJEW/Y*YYFL=9NGE:B*(L,C7789M:OE@_/OVTL0"^?X'?&,+X
M0*-J 2Z/+J4*XUP&I^%81F4B@\?!OV5>8##MF523'"'U#D2:WM86F;BQH(3+
M*B]$&N5!,18%Q?)J$(MSCC66@!3E\/]D2,&^<&L0IX$(PTQ%(@UE,(N+,3TG
M+Z=*YC 0[C#=&&9I%.-@-@298G_Q*W&N)*P21AQBK"U,)!C.S4.8ZV$BBZ\:
M;>#&_:RR? KS+'.\"//7 =9P-X<2P!\5+*+%%#FMAN*7$4 J=QS@-#&,>2NP
MFR;"+VDV2V1T+O6NA=DTEJO,"E^(7[2_(Q *1K\0<4(1R+ !]IUP6UN8=9P6
ML#!9T,!C<0%;*64*D!<M&&CKX0(]&B.SX&@R3;(Y[7:F@E.I+A!"#C/<R+!
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MG/@<L#*O #AB#)Q7(CT"Z%$W65%5\4DLU(F_/=3Q<%/#L]4 03N9"(H72;#
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M,=RZOBXU$XT7JM*B\]=MY9ZI',13[MW1"-4RH6=5TXB+*\)Y.?-+6U0"2CL
M>1N>$E<U:@SJ"EHKMK>+=K[4MK"KE#8O>/Z;6DQ$)5/#A"M4PB1ZB+X"HKN
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M*C(RN5:VE%/EW*;$8>::_N;3)"X,>:?:(\!K!MA95TQC3(CX2S, )NO.=4C
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M33NJIER7==C;<&_4F^.4BHKB@,$!OJ2?Q%PU2I$#KS"EEI3@0G8,!VSNP0
MIU#8R$PJ*I-SBKX-I49Q=1/^ )I:(NO&G0# 6P2)E;X!$XGQI+*825T^9PQ4
M"KL6#&-.T0+0PH\B_T(="RD-<AV=CO'(A"RXZ@&Q)W+SZ['F "XN!Q;)( HC
M;"S'AL(4V('U?2VQ@8-+?UBX5HPQ)_F7IXA#6Z.H%IK?V9Z)V/\1M)5Y<"+/
ML>9[!G\><,F$8FX5*'SF6.21^!KD<SBYB7$7ZY:+F#U'U[<T & /"/B79MZK
M]3;6]V_1QA@!>Y4]\8H>+3U&;CG5?I@TER4'E7D95!C5*@E4:2;.,T@;CTBJ
M\SSD)0!ZDX39VH0-F.RYWTUY#Q=0JFNE4AY<7D%]6H'N&XB#U>Z;%-/CGYH,
MM+C;6<DF<4_%$[25,UEI1<<:K:&(S1%WQ@']%P_?D694=3.RQA=BRJ8-%XY(
M7;VX-(J>K4=(B'TX.F(L(_7MJ#R^ J'XI@.Q!<>JK^E"%)@F_/!NLS\WHJ^H
M["S \47(D^KF5"OA/2>76$A(3;V@E801OF.$(*CQZZ(*@BLAJZZ-)[[H_E$9
M2<5E6IC.4%P;87$3(GY=WX;H&S2PZU;@PRZ\ZZSA:JS0+J[)F'I>J%KP$R*!
MMFRZ(J=-^-AJ;P5@K<L+3>@NQY%U2'A=6<0)5>$RC*3=E358:N5?:'2ED#[;
MJY7!/[VYTD&+0*9B3;M&(.HMKDLLKL]ZBVMO<?WQ!#M:300YX*:SR(2G"J7=
M$#U?7E%;CXI7.UPS2:?&@M0=$\O7 (6'JR._+2;IK;I*UW(+K36Q;M2(:#W2
M]2(6@<2T3I6E<4@J=<[%M]D<H%G'G+/C/;<8!;KX7C);C=_8B!>^M!<ZOMWL
M*SMF!]A*S!.*H&VKPVQZ,  <CA0K:9R)HWKQL&-6S<YVA]@,4ZYB,DUB9]S^
MB*TB4-K25CI4F>O5*_I3N9GLFK.&[.J5<<V4J2N&(32@5K&6B,H52,2L_Y.\
MM6&K?E'(5QHV;1KUQ,AAI85*Z$"D%@EA!K8,@J/#JC$8.JJ"\SWAS8F8Z=;
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M96W_1;MS /[ R # D'$Q2?;_'U!+ P04    " !L2F%262 M!]!$  !@N $
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M!?H_'1L-_\PF$YT/C$JB]\.A&>A\-_I-0^])EHZB&U..Z<,,_I%'$SWIZ[S
MK_%AT/W^TY=%=)*I/,8?WYH<A)@,W@Q'2S_[L:HT[FP%MDZ-] 36#=80CS[.
M2"5)=*WA>C"3::X+G!R-[6:L2IK=C8$W^CE(+CCKH-T(Q)AR;(HHSQ*]^U R
M !-3FR;N35\/?2Y6.I4KW)]$ER F16H$]PWM?D@[Q_:II1_><!C\M<8-!UEY
M:/))E%5A"T0B0"Y3H$9+%M#'I"#B@V]B.@U$T#/\5$^F23;#;Q=3RFU<;MYR
M[I395)94'O2SLLPF_*RQIZ7J)SKJ9SE(A:\?[8%"H)-$Q'/W=S%5 _NWC/3&
MQ.48V.O>7U]^ 6<&,?\__O(?H-;D\!_X[[C>_M%C>0E^N]=-( M XN<+/C+!
M(NUUW 7U)<,W6F,&A6%_EU<Q6O2O*XW$,HS.P@T7%0%G]%.).AW^&Z</*A=M
MQH8@%A!$]/2OP8!Y_3K>.OKK2^3D=-=9E@*+L#I2VG^V2[3YY<2TI;:;!!%.
MJ&L6D<SRV?._KN.,+JO^[TOP0KHO'<OMU:Y3D -T?R:<LHAJZDJT)>R:CY76
MCENK8H&\8=^.BC'>\P-\)1WH@!M'<,MWR0H9-5'@'>\4A2P'IG^JX+HWJ6HU
M'NOKK(0_JGY1JK2$<22S:%@ER4X)ZP_]H,D%)219HGY5F!0$#EHE-1PJTY)_
MZ"<#JA+\;!*C2ET$W4[4+-HRVW)50<-6F ,A:V"NS:!'9B'#ASO+T92Q,\VS
MH2GAJ(/$5.!#7!,#8R,*D4V$2=-R@:A7V.%.<P-OJRDT< U++ -EP0R'R7(<
M_)X Y6*'-SDVFX)D"$^,7F)NN)?0M0;!$@8QS+-)1$N'(X!_LV"W96#*+,E%
M4Q 9LQ1&@S\P_4,#U[HH<6MA0E.%!\E,H75L&:2*JBA!ULORD4K-OQ73)7X=
MZ\3 L0-985!6.8ZEC'1<#>@5Z,&D16G*2@@9[O-K[J'((I)G8>AI!@LX&--^
M .W@6VI0PD:4."HX$2 OXRK#*.!A7!&!P$LD1@*!C.!8C&CWG' ,$R3K'=*L
MNU.8^(E*40*! 9D^K&"):XQG",0DH/TY%\Y7Y++S/[V=G]6__?IC71'_/'B\
M^WQ%-T)_/6Z$U<WH2JX!)-R WP9D'!&E-NZ$)JN&4Y6HDEY3:>1L>8_9EE<3
MY<^(<< QCM["%_Z&0'40!@),NR0^B9\4&B\F^"W%8U]@F\*?ZJW &!-DTIH,
M%+EO*"8N.0">&]/Q]&<6&*0I[(5WR39W)M6C7=# Z25B'WXA4(G4I8+[(([@
M"JRQR?GW&["WHKS3;'K!Y=S%3X)]LML =U9:$0_NZVB40?-ND+5MDW6B:^#&
M%+(.L9\0717SV-*:R,$/87A"+X3T>HMM?YB!@-&T[3<>OF$7A;0[2%11O'[T
MX=W)WQLR>T1"NUT2'%=]D9@;X"/TRM3:^OGJXZ,%(XZ"#AK?CH<[>7;3?HC:
M1?3AW<4_?JT[6OY2_]=?7HUSV_&'XW=G.R<?SX[_OG/\\]79QQ>P1#=J5KP4
M+48<-U%MMF/-LSJ8?G8&@__<H__K,C+(3ZT%^-O;[@5@^\4]IW_U_O07DWY:
MN !N'59[1.:88CKH5!R'.F:A$OI72:$?1;$JU0[*?K,R@S6Q#ZHRVYF.TFKR
M^A'(Q+E]+KXU>GX@SW!H[*YL3"+X'4?^^A&.7!Y""[(.2IY,<STTGU\_DC^I
MUUH_134,7\ YTY1?/V+R;:S_NJO&:VLK.5C&5G*B"C.(?D8="0=%=YY."S9'
MX[5]HE/8S[*XLPFE1MBKLES^N8PF9*.XCR1ZRJ*;8:UHCAP"O_1I]P?AGH.R
M8]4GE(A0/ 0!HDM,[#75;Y!.4+\N$_9.Y'J@L3?6(D-Y*BI4P@(2+\[_.=SO
M'3S>0UTKFL :CZ.M_W/X]'$/.#\] Z&JFFS7_0V@&$>7U(SW.DS5C ABCEC8
M-#"@D2!&Y1F^RS.8P#1';7%PJQH<Q14[(P+YNKXVNQ'*WL$@Q8>A856NC;[1
M)"FR_AD*9Z2Q>H, _I!K:!U/(AH;L %ET$,B1A-@Y .06\7M4VN'-&'7U.Y&
M"^T\8OU['K$.VH=7#9(?4 GH*BENI"K&P)[2JO#$":159,A<\7@I-)[T@0B$
M]"SYXD9"]QKI,YJA?W8(!)K=(-5IA?M:^_%6>NSA40>J$=6K>1* O'X"BFDI
M(]"3 3W):HVA+237":E@HPSD#]0TIEG!FD;@XR.[&MFK&DK(/#I'[M,Y0&_4
M&@+%@P)&\PXYPGF*X@,RG/ .L\R!#V3W.V@CXJ.(VZ;C7F3PQ,UZ?F\Q<@NU
M3M8Y2=_+DH6G;]XI=DVZ#5$1B$@C#:LU =&WC/0?,!@D(EB,<H:+/B"/V='>
M7[==-P%GX4'C\CJ:%'H@#C!OO:ZXTV/JM+Y,"R<!;*A'EKRR".;?L_L,DYRW
MS' "B"J0LWX>D*K*LZD-!1>_:7AC(ALK:+&O-7^N0;$-3;$5*.*PK(,JAUNK
M3*P5V[/*P&=, D-X1Y7SB<..&DF3CEZPH!NF^E5->\]WGZ[&LC?X0LO><H(.
M'3<VPO=%:J8C#Y3\1V4*@_9U9Y*![PH#:Z)R(%7XK2)NJC_K044TR-Z/EC_"
M>PB@@4D6&WB+Z33SEC'B:<A]9V*UOQD;&)H;%$H2)ATD52R6[JPJHP1&4RH^
MR^YBTM&UDO:W_,D:HCM]ZV@[NM'Z4P&"%TB1GT!AA?/9BR:@FN+YL+WUH.4A
M7FI%E>-A9A^"=PM@VW DQ2M2H+L$6!?,!AE+SO<(Z*IIT3QL:V*P6F\=9&VU
MT\-EM-,/P1UP0O?E&9PDN!2/;]!YMG'K/[2&NG:</OY"3O_V=DEZL>1O+P--
MA+K#4EY-PP;!?R7BI&7KHA<6=?=_0W2'JP2=&S6IBL5.4$= ]FH*YPWE,3K&
M@"Q\5IN7HF/H%Z)8(@0!>QN2']]T*R.790:WB9?&/@#SOTTA)T7CAASA=J/@
M@Z*H=,S+93VR&Q[QP]P@1\O&@HE(M+DM-K?%>L: K6Q"YXL=RG"/!<[SAI<;
M]=M35144-1,:$UBC(=__M,J+2J7$X!5\F19E7K%-.3AH/6PA9H\U>=H_3XT$
MN,NU5I0T@NX;-NJR1,5:P8T!O[PUA:)8FUD]=(WO(%#6_< Q,HOLS8-!7FF.
MD:K2J3)Q:#_QECDQCJ6P[LXD',- 7U+$TWISCN_3U;RHX=:J+.M#@J4YV#BO
MU\YYO;G;ONE5$*S]O:^W7)M)'UB^=@90&S6*O':2I1COJ.)KU"9(:P!.#VH.
MQ>R2M8C4&Y#]4P[!8E?<HAMJ2'8?9WS"KN!;75 \5;OUVC45YE\U+S8Q*)LL
MCG0:DX$I=2J*-9G%'/E)2I78XIUFXY:"<Y,X[PC-\UN'>]OPY6QNXA0IA%/V
MG^09NC/C;%#A;,7ABLJ,G05=-7)MU93&$G.AW%S'*H;&]+7)JB*9P>4XU+0>
M6VS5([]O*B&ONBBMBP!CC7.,'+%:499N]^9Y2^?'C^O0'>/ZK@V7#':DM^:Y
M2D>BD,&GJ5?C>EX^P(B6"(.&\9;NCHMK;Q1=Y*%$4@NL(V6U<Q@O)8CYFI?9
M=LL;GCG;K1,+V/>-K[I?4".%-V$_1[F:+%Y!ZS<AWPO0HAYEN#^P"9/"Y:])
MC&)T!"(IRS4V-TIDE_=].*0<+.U\-1OGPZK'.I^)?]4$W)^10E%ZK7+THA9S
MPBU4[1 @6[.IHBBV"UD(RYIH-)HX0Q-_4C/RU#A*%R_NZU!;L-Q?.(!W1S.[
M+EZ0N#U4)JERS>;[856P(Q-9 ^4%4 L3C"7&&%J;O$<')E$WPRIQJ0H]%YU1
M<&.C*E&.!PF/9<$<I@F,,'$*AHJ&&I8/,R1RUC2P\7HK(0=K)H/4^;CER, $
MK\W >EHP"1=?3#,.R"M$)1KJ)(,IVOVCGEV+_TB)\UZ6E&DAZTE_O61V-,Q5
M15QZ DH.NE.GL$YV6GQYE,B%,-VA(QD6$QEJV1S0+#*YJ)^3XW+>^LOP'.OD
MRR<=&DP A1=)U\*DCE3LEP40K]74>)2ZQ O:I QT0F_5$S4;XZ1G"HEJHFUF
MILY[,-Z B-!%!HT50X7YQIA9(M;+#O6PHMP+-<0P];&Z9L(D2VSLTF#2K#2<
MQ<&.<>F&Y)D2W5<4RMVXU9%\\:WP$U)P8:B8!F,*O!ZK 2T&R/] 0*D>P?&F
MT/D.\6>9I!*>CJ2I/@Q/"F7WM>:*P@.]7:"#$>*: Q_CWVOY#["]MQ&5,Q\C
M_V1N1^=Q/"O(T8GG%:4YS% :*%1@2A8Z4^ G2$O/A990MM1D3 &:*)RC%[/"
M8!X2LR&'S_U<WN@$_K6U?[ ML7$LQVZRB[Y.7->7F-"L*YWNXU[3CK:L\8RD
M9/<5Q0U:IQ)VTB$1(@NK!09X<7*PW9O35NT6?\%+#5>XI)NX:R>,-$*BSE(D
MQNUF4!K)\2[ M$M87QB:R3=SWA&)V7$;;[N8'/@1QU,2_VE'KU&$I8VNFA/>
M$WB51$\, Z;@5]8';]5'HFR 2%JUF7(D%^8M B=B%0BS=\(98_#'8*SC"F-)
MW.SIA+?2->T <<H+EY_',PS':)4>7#T3\#^-V9:%H"QPGM%8JX2\<Q*P ;_
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MNZ;A'E^MCW]_50'1QRV/\@(7_[K.P15EBR:S^0G[T3FCW@Z5*<<(],N>_-A
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M'=7_91>ZCU9U^.;T_:\?CB_^%9W\X_*<8BVP;/F'C^^OSDZOCD]^.8O.+ZZ
M\B^O+G=9!Z.OZE).0&B<^/&"D%]!@K\V>5E15D6;X6>%J0/CN@@]SS,QSIA"
ME!7%ZR%;G5\K0I).D)GCO=# H4"AHJM.U5CXLE3C8B1Q%,2OE4F($+><6N%#
MJ,.NK:CRDO%@:]DQM41ZCCSLPZ$V"N$ NI26Z!UPJ6FH8 T(KJI,9JZF.<P?
MZ,9@<HXM8J4_#Y*J(!7"92(U$=1L?;!9K>"YJ"#V=K3Y+!@>K&/@+ZEP,2F<
MSJ@$.6I"T!X"HM6G<2*=UA8%5B6 B?/(^"VB"'/XPW5TBT)OV3XHL4M_GA(3
MS:/!6*4C*L(NVXS)7SV.4:>W"IN]S&\6#A8@0,)(PA:WS#!2??@#*Y)M^^AF
M6DTD+V/7JGOV-4[KAA_>!U8&"55'7+)K7#$7RBJQF;*/)ZX$_3R*K!6C:R\D
MKI  .M@T-9*"$%262((02"B'SPRJ1-7W.[K)JB3F8^GIQE>(]L"X# 7.ZHO=
M_)#R:C1F448IDLIVQ6#;24#$" [M+UQ"T6"\<:OB"(H?@R0'2V)1;C&AEL<5
MS$-%J1XQ5GDP)0-K-BAM"EIM"86/;EUO=RPO1:91.4[8(UN1K7"ZOH*;C?O"
M%4[QIP;LRC]20FR_++DHM,R,P%C<7XC=;$  J*T(Y^YS#3EW_"4ZWY:J +[1
MRM@?*+Q-+>X1K)S[F(1<;+(#T9A7@L&7KX7SU8'7FSG-A/DHB!NSH'@&I?43
MA.6"8X^(\J7!%,-@;K8 >J_>N,6HX4)D\$YN"&R>!*<!G Q:+32Z<$IFB$E9
ME+D9<$5%AI.F3D#)D"7@*P(N,/@GPYWP U?*B4+*\<#H8I";/F9GXG=.8"L%
M:G$@]=^9DVB[WIHGX&[!LI$6J/T,6";D 3/RS&1*I1XIU-ZVL$P90+*=HS8#
M_XL-/0:I1B6%?D08C#N$0%-FKQ^5]D%59CO345I-7C^"H>7V.9S=::)F]'Q?
MGJ$$D\+!?OVH(14%OZ.  U^@;X0?0@LB72EY KK3T'Q^_>AD1QY0O[6>:)'A
M%?D3)262I5X_8KMNPQ/PH'+NQG^UK/]J4<.MG5A6%L=0HIW]C4_L._&);53/
M-58]#^ZI>IY=G5^=__,L4#]/X6]X=E;3-\,&&KHG"A>B^75"42_0,>9(-!:M
M&$5@UXP@RU$>FPB$#!B -WG.3W4TTR L,X:8>V/1 "S&&"I1AK006PM+H#-,
M/L!;$,7TPB&-!LADVTUM&>255G3D>D$$K/<1V]\[_$IGS/[_T>,O.&I;:OOV
M@Q9E'1X9++Y-B/:DF[G'?0TZ\- #SS/DD"2]]*32#F(.PAS5"!^!.C/X-,X2
MJAXG&@S\K"=]_#?<--G <"F?&_K%PA?U;'D))154/'Q]+%JCY"B3(=+62T!]
M(M8.621 T:LKFXQ3Y I049F\+"JRS6FXVVEPQ:T/6[+A$98VCF1P3-2'1[O/
M'PMA/]M?PAS_^&B%QVNAE &'Q2QS6'Q!E-"XPG>#<&0&)+*6"J9*-H;16QV>
M'DNN"2)K76?)-4/9\&EK GGQK2.WUZ+K(LM;PVKT[?" YIN&;NWFY9UAX9@R
M;D^&ITWJB(R\8[CF,F&B*R'C&M&V*1LI;!D2*SBTAM&=O.U";-&%,WOUT,]N
MT-[&!3$\@R1WDX_9<7*+-P42TI.E#XN_:KFAT<6+"*X.Z#(CRT2'=8J*6G0:
MI[JH]66$E:B$^J7G!B7F%"J#4M&0?H6W:D?$P6(E!)Z-*X0VEU2/LA(OD+@7
M5-F@(W]M!ERS9*QB?R%0?1U;-*O+5M>XZV#H@^V.<]0]BV7/DX7KXT)+?U06
M&G[1<>ZRS7)=N9BWZD9_X5Z%Y90"Z1CTP9)EU7L)R"^I6"(;S]U*.?![.#35
M@%$[+>&3U-I!E&1=K+ @$A4D'."MG@B,5K_&B-MCV#"G)9C38N[$&'RA.I+U
M"$*]SGSL+N(Q#D,K7/DP[3^072;JQ5-*@*X.KE[J$]*!ZG1,K(Y&!133\J<@
M<[O-.HH[>Z?N? *:BX6;-]6T@X[+,<!A>R8_^%J2F=[JP1$Z#)##UPES_HI1
M"2DT?8_-="Z[RO+U%/Z_;GS,;0IGIW[97T9DIJIW=+\,V/?N1)E [HUUF1LN
M#]QK2C,>YQ/K.,7 1EOUUQIW-X;'H($#! 22E-SUX B "FG1?2YA-Q:QN5@<
M7[51\YHN@,/6%=1!2O7XJJ[K9[ ,*5TU/5BU*+Q+J8IR ,(KAI1P,0@A%&\G
M*#0(0 3?C^XT*F<"4MU(HY(V'>,%C5*O*C@NQ?E2)6#C@GH[!LD*WI1PA;,*
MRR:()WZ#MOF=.',.-LZ<M7/F?$><[Y:LW6]E^'WTIA;_ 4Q(HDSD\=]AI>)L
M\M('7="+*&8Q*SM5.8B=J:(WFJ\<@]JH)O*;8468"I _V=N9&*J#$INJL"#P
M]7B;CD"BAL*,,J$S($LM& (7#41%4>6+94Q>\T2Z+?-YFP8XH.B?"0@;&49D
ME- Y\GHIL#23PO*L,F,9GEE[T*Y?#,Y#\W1MD*2$BQF:BW\.VW8"G';X=0WS
MFXN6MM<*:U>Q7;"^JM 9UL\H2*Y*M)?YNPT&6U^^$AT[6_#6LZ9!I0;0"W#O
M'4-70NRDMGM4GK@EJUO>.EHQ,NBS);/2%S*5%<A2\=>2I0BVG<.O."/442=9
M%,DXSID^8;B4JR8?R/N![9(0V_W;;<JWD:RWF,1OMW=S#%\04T:(;O@RJQ<8
M#3C/='<'6-H_-_'I98CO(BMQKRA(S>K_KM)7K],?"5H?:.W6R9C,1,V7OWI(
M$QA^-\ER@AU.R<4.]\E ^[KSIBBP$@0I?%7I>B<GI8V(S*>99&F0I7T,A%OX
ME D.^AMAG"L>!;C^F#!5Q"YVN@L&P/>(EO5G#AZV14^P\@'LX0[\QXZ4],/+
M_Y.V^+<X@VN38:%K>P0+.H,[H&NO&^+L]R.LK6\HS.$]0F$^GOUZ]K81\W)+
MCD7[1 V5203_6/719T[B0BT E]DEH69&&&^":C/N..94=]I? EG'@B^C(Q3%
M(FJJC]8<.#%_5 HK7%UA AR>>HK"MZ4UK:.>6W"FXEPGF)GGF'J[<R[<XO+D
M;LDHZ9Z_+L*@Y)=S>BFT_A3!+#CR5886U(?TF18)7'-\N5!M3OPS51)9C$57
M5<K9W[]7*8?RV+8ZTQZYGB#5#QUC^+U&<^XR$^G5L[@H]@=I<9*:89<UV!85
ME=*:15#Z4I5EEJ=Z5LBHHJ'F2QL712JWV)J:S6'<79"3@WNK-^9@#;PQ--;Z
M!1JRAUMO3CC%1_?@!E?O?_GE_.)=BQE<^< VD<,;TM $*W#! <RQ.*JK_1-(
M8ET"H;^-@H+&"$D0>]_FS/;;%N606(N%I+J\G/4GHXW']Z"-?YZ__^7XZOS]
M173RKTB2]]J1DOC@G*43?>TJ(?G+!'9WY/.Z"$1?A!1)E>F0Q8<=547:KP$A
MN&[Z88DV9/MA#46J24V.8=^QEYA S,([JJZ,+,RD"D$2FI44D7=#SWCIN!9]
MF0Q[NW#51[[=?/:?RTNR^39^N+R,L5_&.Z@4?S)2?W(/4G^/.=?1\;N/9R =
M770DH(+*,1;=M.PJ/>&\BCW8V.OLDY;*V%1>HL/\$Y*3['JW,TI*:'/1;J$8
MSN0#JN:,H) 8;?(INZJD%!KJ&:A8Y+JT(65=Q1@W%#6'HI[>@Z* BLX_GGF2
MZKAA6S4X_?:Y9%X,\0&>@06[B</:W%N;2LO%<SWKLW L87)^TZY!!-PHG,M9
M_AA1H6/BUC;6E2O)"_\-\\0*++-.L;%,CG1S)PJSH_-<2<7XM76';]Q9=7?6
MX<:=M7%GW=^=56.R<F">4R.!5%:3X7:CBRSR]JU)%J/$,Z?LM9>@KF&YR$U0
M*_04<CLI6DKBWISV#=N)T<PFX92$.S4*XILL(MJJK\3H\ B/PBI-M_L'A\^@
MS0>_)9_=XY;\[?C\GR!XO?\Y0LYR^K=./33 V&/9J<.X<:/@4LRMYB"E"<DF
MZY3#N62%2@!]3]^B:XV":EU]:R$)O@\)4F]#%LN3Q?-[D,7E&5#%\<GY+^=7
M_VJ1Q#E;VBNN^BR( ;!;OU>Y*6+V1T68-&1]1RB8>"+(<8=WJ&@T;JCF@I42
MW=B!K8B\@KA.+S()F15)M*]2L5,AD^Y9# AZD7RC\J[UR :ODYLV(#U%H)1A
M>I$;;&LXN]&Q&#K1#P:]#,-LIEL!$<8ZB>LC)\7YMM4D@)0ZEP4AT>12H9%#
MKFW?/;QGJ6@U:AKC'+$U^@ZSI9]4>B>:(DHAZ,$6NX2"*VVQ8SEN/"9;.ODS
M#:J&XI!KDCM-&07SV9S,Y4_F_MZBH]D\DQ^./V*J;'3R_A\7;SOY-$';]6J&
M8P0!2E4J"JR3!8J%1XZ/AHV_Z[7*.M*%?7OYQ2#4HJL"8]VJ[5[N*!9YMQJ1
MNX&-5,WXA%./S:.\H=3E*74AW-A7\7!Y$6*!7RLTV[1\7-Z=%:N)&H5^+)!%
MAPAW5!(')]P7!%.A!*4>&;B+@<9<%2;V;^H.NYLCS"Y3S:DT;^UZK8YN\X5U
MN,+NX@GC\P[,A*?M+:UV+3>'\ Z'<"'P0O,0OGL/(MS%^<6[Z)?CWY8U?@6A
M7;5DBP&1EM1-],H@H2 !.91B&"=C65[QI:(& ]"<R4#EPL02=>/RUN8$,H;$
M1R!Z\%I5<A '$:'- ,!&$41K9*X)<)FE.#EO6 (] >%I)QON4*=YE8BT9,.(
M,#W=AG7@76?JP8]VJ(J8A<Z;,AE#AUMQC#(!V0;L380U@1AZJD_4>1NF58Y
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MWI;8:3]=([OH8V<!O+W^3U#N1Z?Q4G9%^(]^%L^ -8W+2?+F_P-02P,$%
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MUKNU2#UP'(+M9;:9V*R^)OA0XZ[7,ZI9H9@^$Y_QP6%)BB;.D#'O;KF>B$"
MD[>*EI]4UI5C:-($4K#,Q9!DE>MB+\6[R'0=,Q06/+M^T);>-FIPEG1'(NTI
MPL@[,%F.)\ILN=Z(9@3J1HQZJ8S4Q?LF.#VR>V'&JPB8"RX#Z;ET_65DWNNZ
MIB"NZ5:_D_%6+B_%_\&"+ [UR[:8B6AM^C8!T8(LG.X8%S-A"F&1(Y@A[;)W
MX<RDX+WONI;!U!RQK)U%28HPIE2^27R/JNPP+4Q034@W+[BX4Y53*G[T)$:A
MYD A<ZZ$>M<HME6A015*DVB2I%RI2* W(6V'@1-S$9@#KD7B:ECC<, $3.)]
MA-OLK,SX0]B>(#V#(R)R=9J3_0JTB5UNFIN;]G27F[;+33.H3<K1=Q\.C,;\
M#35@4GT8XP>3L5=KNBX:NZE4:%R&%M3)R:1%J50DJM)9NCU(VP(U"*SECO4'
M]F[<Y46ZU2&#V:SA"B4_T2;X,U#QN4B5?KG->S>?-_?N^OB^VM._HVX67%=*
MZ<HT0LML90!TP[[Z>$<:&/3IP>$V'\/"8L5LAL$DT S$>*XPK9Y-235=L.<C
MR;A'IJY-U"CB/@^"B6/9@WV6'5@M0R9F1Q7YNA%OI)6+9$'B&+<<<_3X7Z2P
M,G+<H!.P4U [O(1!4=U%FS1@N%3%'I4VK\LWI;H?:<&$"-@:3!D4W+RNR'>T
M9O5UDFK?LS@M8)E%S&KS(/3PU4J=A'A?'<(]2)>(^DO5(V[UA^-UI.,T=IES
MX'ARG/N*$*J-G&<LY.!8&U:<Y3$?;%VJ69V:]@)N3P%Q9Q.X[Q+=YZS^4D$(
MH].L0%V)R #8ZZY+=0I!#=S,OT"1QI<#(+((1*=1]R7W8>/$4VS[O?AI[]@!
M!]TS,24ZX%R+FK(,N-H&GM!U/',YX%*;U&\32B6,JC)7M^P1P(_G;B"1BHUL
M]P 36='NJ5ULMA/1H0GIT+P1N\AL-U;#6W,YVA4:'Q(4T"4'!&SK?.X2*CLR
M36,, \S)6>0FVX[E$%^ ?\HG-BZEG0&="*M>]4-GZ+"C(*4776N"_<'$!Q8'
M]2K/))JA>T'X,I5=,^B&4N2C !:.21Z<'.Q?W\X8*F%SW;\LE+@T,Q<K>!<C
M=>$T4L,4.DY[R,> F]36N\^&PX8:J$/C!MKWOF/LCWQW3&;3==GF(UPNG2,$
MI1C=RV]*M>/B?GFUK:\^>WWZ2[\A?L;)S*3 OU916BW"X#2:Y'5!*LLO*IUA
M(H"VT^]+=X97'E#6SO9N?6XK+,_[DLPCFU_C,)V-23:N-4,6:+T2L#:Q/! [
MDO^4LPB-1'3S-+J- YQ2!E-"' 2=MXN$0^=]#UO;-:9R:OI6#:WS7%7!->(D
M[2I:>BK/;.D9.V[[L2":N0H6<-2T)14/BI#DK)96?1W>VA_( 2#=WN@&\;\U
MN9-V^9Q,?(E2\D>A_R<L9Q^E-!I[MPGFKF$=,[<"F\"<JKI2WI"=*1H2(VR^
M'UX_'0@B),\S*<L:7381@=83.YZF$<)+S!E?,^' ZH9!<5'Q0,+Y-!XJV>H=
M0N.(]Z%0P O8\H034UQY[-98T.B:_U!\E]Z"??4(:J)2 VW*.K,HQ6NB=*@P
M Z59?&4R MNZ1N%W/M;_@E'CF',VS"XTW_,5W*==E,^-\CW;1?EV43Y3^UE8
MCK_ K)9Q<*P3!V]0G^_3F?STPJY4;T='*I?LI\>.&XT'==V8SCUT6HUZ_OL\
MZP8V-/BPG(2*/N-4%9+DX.6J,K@/EV0XW[Q-,K#VIJ;KA_X\7F<1PT&P -$H
M@EWVH3;^.[9 JJY4&E,>!0&^SFJ"_Y$>@O";H\/@^.55\.3PZ. (&\+I3!X?
MR)[$EW5 4J;<3MVSY;AEDY0?2LMWP"/VG98S#Z)MG2&+!*++V5#ZVNP7TX 0
M*!H3H>AW%G\J5AA&TM"KY%;J(2(F;DGI(AQQ@J:G1C84M3(WQK0\K?S@UP1#
M/ ^[/T"DN!\28M+)Y9EN3NDT28KSDC%+YG"4F:E?(F *;ADH$19TME&G0H%(
M:8.\?.XK-ME=L0\JV:Y:5^RA=RRE--E.$6#A@<C/YM!P5B\G'(C1EXWO26)<
MN U(7/JVTZK6EX@*&_ %T33)Z[+S4H6-6W4744XUP:.H:517!@V.T&Y+JLV0
M1@3<NJ$@D*%\FD0Z=WDS]>JK1)TH&$,&@=.G13+1/><^Y_68[J['!]78UPV'
M V*V]#D;_!!F$PR(^ESIQ/AVM.'RZVAV]>5JZ6TQ_66A]D?:Y7!#F0H<ZY&K
MT.]NC4SB1DS7-*) P'E^JXCK'#T)@\/OOW_*R;K8^KVZ4PI1)ICD$<)_@5_<
M8.W]\$5P);"8P4LT=,2+Z!5OPZ\:TQD(.*D,2>)QX3;T='O1"!P.H=SHCW:=
M)MUB^3N'+ AN'%U @8Y-]*<0M=BFS?/ /2?@-X,9C@]@U\\*B0$U/\KTF1?1
M"A2^T,$!A9^#?I,CQ\3FH:@%5@1]9RVCW_*ZP"EJV'0EJ'0,YWZ;E)2'G2"V
M;:HXVKE("/5<+4N3IP+:Y 2WHJ 8+4W)9#P@6E>J_]CG//^R7F)A@X5J#ZF-
M;0&6$('?L;";%'D43Z.R:LQ.:OY20KA;)ER0 E,,]F;DI(H0=Q>6,"VBBOQ
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M8LZXY9"TV_IY))!YVP;98V>T4>H4ZFOIF_CE;O"SID;L D+X^C!NHLYP3[D
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MJK1KP82BZ*UB;5P#BKK?HN,Y=(,.#"% &]<2-::C#IP#R+62>Q7/9@FA+F*
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MT^[^[='C1P%.>X6W/YN;O\L5:*7RMT?"= "N+'O\_".D)NSAO_WEW_[MQZJ
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M^OYF:9611<U&]6;'0\F7$(GTP_8*(VR_1W=HXT3^Y'LPV>T!MA7;^CV(90]
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M_LOL&OYTNR4"@=Y>6,2'!I91@_^X>.19WD$D4:&:'3C[X"0^;'"_ VTO4H5
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MX^_[ON5HA6W7SMYFTV' S=S$81[4F!PV:\HHM9)**+:M$1$88")T:,3YA8?
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M\Q+1GYWDQ-44AVF7R4Y&N8R@CC21X&@0+T/PU:"O8<)5:TT).74P/])Y[Z7
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M?7JZ/%@O;>\C]M/U?&]1,A[(OV8BD59\KS"4A1"=]J735!J\D[3KUHKU!W=
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M6AA\$H,[7W,4\(,U>KM3G>)*/NJJ$FS!C*4*B?Y&* +F692;:>SN6K0'+=S
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M!-"$$BT  ,DIYE&NW!@.4QGMCQ'<5"?CZ5!I00(X%1$38 6%CEE\NM )!-*
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MT'\KZ+DT^+?Z46QNC+*W8B1]/X@N?Q0;020V6IM!]%;T\B2-DQ^%S+/X+<[
M#Z[,])0?9+)+4Y!AJEX(7V;RI1R-PG$6P]S-!_#HR]%EE ]_?I%F,C&?^T$Z
M"N68/M_4G^&<>%,FEN!\CU.&)V#*^D,806^%U)^,$M4/OOW\0O]);RV])\W[
M[@\R]2V387 9_?RBAPM+7KS[>]1-1V]_^@'6^^ZO?_UI9'9[*)/+(((]PAU[
MM*W'";RD&?PHDN!RD,%>_]1]U_XV"+I!!C]J;6_]]$/WW4\_C+[_;(K%EU]6
M&O^_)H;^KUO7R'-]F<4C/5_]03?.LGC(G\WRZMO>7+QX<PN&U%L$HXM7+?S
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MM/($2A%(,K!&2&&$#SH'NQLD\T#W04,%OHP$==GV4##YJ!H. ZVEH P<JFP
MHM)7:2\)NN0>$.\EUO5ZXJ?@G0+I& +G"][!G_F[SG"81_&([; XC"_'R#O
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MV!SN3Q>&OT3Z3/'6]B;X!/[+5U<JC$=X_3PP3Z*\+WM9CLYSTL;@21FJDI\
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M!].BS-T"EKC45RAZ^6A]A=S;65[,9#.PYJK-[ZHM:-](B,Y[TTXBIPF4C*(
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M'F3Y<(+^+FS@%:$&SW4=)7HHMT:P^;)!1#VVJ>67RK1-A(T.T)SIQO%7JC9
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MX+!.1[/[6;*<EXAW-FA(BP^0OFD"I$L7(%V-L.5J:3D[B]5R+/ONJEZ,YQ<
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M;GI5TM!CR.2W-M[6S)V^V0054LF(71=4<,XS ST;/7&9AJX*#?X7YM6;E/F
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MJ*O2J+Q+33#L5-EL,F=6@YLN^#@;'71E>)8+D-B409?*H'>:,NBE*X.F.<,
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M#/>?([3-XD?31=&0P:#),<)V[VE8"I3PH+!K6N["YI2Q)]I.AC9'^[2)^W(
M Q'VB-$^F1*N5/QNS/C"YBM@,;>I2ZW^-4NQ7\/"Z-3* D(H3E0H$-\2!(RQ
MK1_I""'8D>C#&"Y8S(*)(7RYU&1"JI,:19-A[J('Q'!!+9Y_JB6Q!P5=*6.@
MO69>1,NP&5IH&(6QA CB5F;)XPCN.T.B<] 3Z)AP+/(%I*W.%:J"Q]TN1[]$
MC5,+8#0XZ78'-4P.PKW558!"CMP."H0%/?B8RQ?2&9\'B G))I" !B5\QXLP
MVJ,FL32-Q\-E-TT9JDQ(6.T[?(5E7)-Z('0/U^P^92.,K,PZ#I0<,D^C]OI(
M@(8F\Y"4$*\Z4ND>L+:D&$!TQM;E(4HKM(*_(QZB&3)P!>*GHOE).U,4AF '
M8Y1WX4))-W)T4AP/CD1BZ$/3E(4)MV%L V<VM3TT,S2K9,05ALKBC*7L/M)2
M%&?N&G.("".\D4:'/>9YL:.>!A$D!S5.^H3;0Y*K\> C35T" 9I<(;2E0C,Y
MS.0SX'#/2W*.H^]AP)ST>T+I0+BZA_++_[+_#-%GCC;>;;Q[=Z 57M"G.]W_
M[NX4Q=I=7*U LX:K9;,.2F8.A6"ZQ^I/4I)$=";OMQ?KQ81X\PO49%K85&..
M6Q:##Q&U@)FWP(%UXW"*71#C ^X(7#93#@35/0M1D 0X'>&1\B-VC"QDDT#;
MAU*'[B&X;Q'R<(:H;-<JMR$]-3)UQC!_2]6M[*PQHKU-F5KL,+))A#6R1EI4
M^!*%Q#NX(C:V$,??&AR5IM+1H3#*ZX#)5)@X+^D W(A/#Q-$*HPPO(PC=<HO
MC4)TN'QI =WM"F^7A?1Q-1(WFZ.W&;6#D8^@ 8SOC"E^8^+#@CN$IWO,N#DD
M-DO1BT!^.LS!8,45&*)K%!$+0^D(LZBDZ,<P,*&+FR+'<]AUE_MH< X--J^(
M<I!&2G<S>I?<YU #/PUB?C_@O+WE ZHO'7GQ!,03TN9&[=($V"+1+]"64'JT
MA%]L<;FE9?RUYV7)O%5[)?RM\'&E&D/2O9AXT6,8Y]LV. @LQ#R8S'28@!EU
MQ]P^W@KU.'VR"#TI Q=@#8)QL@J3G% "61H2N 4R-!EBA% >A@37HP$YI3R8
M,]P?^8J$J#F:'M1OR#J<UI_H5>)\N+P2/L>)#;=,!\:)KDYL\2+*<+O<GA]R
M9!_@^V8805*--XRI^[&"KLE1N]O\R8PSP?%N$73*8YJ:UB;#2"F^(=C^-2X=
M19=IJ;+ K[E/21023-(4$2$* JF2UN.9QFD>/9<:]X$=IF.U)I]4Y> ,0Q2$
MPFS:_UVM@/LDS/ NQ3(IM;@5\I2R/L<[MIO,"LWW$RCI<.Z&,QV& M&8J=MD
M:M*D?I(KC>>)$C]"Q6*:F:!T"AW9CZ?1/-YB0V+RC49=&_A)Y"_>DO)B&U)F
M\@AF!Y*'J'R8N3@]_C*3)P"3*$C3$>3[IA,4L<\$T^U,7R>MQJBSR0TYR0,T
MF!A@IFVOLZWD8+Z0,AIP<5J[/+^SX[GLRD,%1RGI9(O2],?&04^E(UZ43JWM
MXX95^K)=.FE9C3U@WH -P_TD%[-'B,:GV-N''H_E5 QN]NDY,NT!^T?>_,-V
MS+GJ*HDXM#U]:TZD9Y7%(C4QR5,%VJJ7J\*_FMFC=8L<7C;AE>C2+"NKE>E:
MKXC6*Z('K"><]8KHEB#X,5'P>O7P1,%-HH6]@LN'MQE2+@]Y:[>UFF[+_>G=
MUN0>R,(?^^$<YJ8WMJ!C=K"EVX@0W;H2)> 3P- >TP 7SM=XL7E2*=$JFU:_
M^-UL5$KOT3Y3L"(E \YHOU3D:V5R:)]9P/RM>-^9NN+Z/@=H_T0.\&U-P>L]
M_",F4K+7WG.94'KM/9=S7I;,]\RG,M^:]VR9Q_Z$N1K'BA]3=1$7NI03'N\[
ME)TYE0UO4=88?VF'('<BLW=;#[B''WT<&_$->9&TZ8WP/'%03_%C\0Z#-3P^
MR0P_/HR\PALQP\Y*F^&<O6T6BENK:'3/U>JU[WN,RLYOGEIIHTOLS=C>*AG=
MDGNZG\SH>C^%T2&)3N2-<LAC4YO4S,E54PB;G2VC]9O=K?CH2V)!_,:<,=J#
M3;'UM'@UWBVU*>YO?]\:;:'I+-PUL#KG.79R0#-.KTE!01%04;K#',I/#D??
M>0!PO*2F G-6IDV/(-*#V.:,X6UG-PFD.Q&VIPF.6S):GFB.2N69[4#44'&S
M[0TO9=3MF1;#B8-6.CX^GH.O(OY&.L>#R1.0L4*RE'Z4G]F@'*/P#+N+Z(RY
M5+R/$#XB&D=/3H7'IV"7X'C5>B_*Y%Z4XGHORM+M1?E1,&?7X*O=JEG-)GRE
M$]/UD^E3Q80A]"8*ACAA5"\%KOC=$11$$KK=#8;)HV37G.$T<6L,/ ,EM.;^
M$@#$"VP%FA1N_OML#)H)DV)^]I. ,5?XY3%1Z53C?*[X],:['W(??]#0/Z[Q
MLSC>>7KCG6)N=YGDM6@A@P"/IN(?9G8R=P3XB1SSOSPKU+\5 N? S[RXK%0]
MMAHML.Q:LX7_0;E>K5JGUN@=8 ];GSQ+IF/>OY/V/D;\.Y]RGUYU H[M>KGQ
MK=E:(HF_,16NG\"Y5;'+=LT"O/YF-<_LOTI+),^?7(,OZ.V"I;)UV;++I6HS
M"W:MG%LB\;\Q=;ZLV7]9C:;=^K9$,OS^P[YB_#!A*Z\:/#Q!3^_K* ER7T<Y
MCX=[KZ^.:3#]2O87';T/W\-GV?.AFH,SIMHQS?#@CY3':,5L]PWHX'-AXE5U
ML.0QG\,Q4SX/'ZN#=WTLD68^ _%>6\5?%X9JK,_WIE!H26;L)X\#7G-V)^U[
M269W;8^WS%B+?A,!IRP,!;W?3T.%,_^@'4NI22^GU*(C'*@'R5LLEV5&U_;Z
M<K-_2N\P8AZ49>2'W%N2&7Z#-KL4JZV?W#*60L;W95Z4',37A?NS,(G.'K2/
M[%KELMDR/WW1L)I6J5$^@VHK_=V*M5*MH%(M.>#AHA72S +O=* Z=+C6CURQ
MK15[K=C+IMC).G6LTVLU7:OI\JEI',#''1Q+IESZI0K%-5/#M<*NBL*NTO;=
MAXSYZAM-JZ5F:WN\D7+AUM&EV1*Z<^>.2+R@7[+$J,S\H.;_ 5!+ P04
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M22E91.LY8G=@H)4(J1 1ZFM?)@/?4&#!P^S#I$6Q='JP6X#/(GUG4&\X>V#
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M.&EW=R+4G\WWJ1*<?R;_!E!+ P04    " !L2F%2>:L(9-\"  "]&0  #0
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M:CZ.T"IY@=^913S@"(T]KQ;X7BWQ2ZO7#^VZ,ST/8#@)#*><:&Z=JQ%@Q&#
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MI[";4U?,V"!LJQ+MX?=]A34>Q*+##%8J"UY&,5J9CF%1*9\1_D:';HZL2%K
M\((8F!F>&'E@@#P"MO.$P?_YQS_^\7^'R::I$JE2IRR^Y<@)N=JWR] C+\<X
M*H- ^?]N0!4FM3%'BV0#U#Z+YG2.>'$;Z)3/\))>3WD8O?1%F24W*$M&5W!>
M7*&-4X_P3-64RH]*IT3_0$<2UT/1(K!]<,OI )+(/<F@.VEH.TC8L"-FZO;H
MITU6I[,L%7=<KJR;:_]OVU9>\D?^\>-8TM%]ITL=\W4<S7NT&U CDF@>.(0
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MEA42\Z#Q$@TENE2,4\95S$^M:=0&)Z\2:F@*[Y [3CM[',,RE]!)\;.:&1!
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M30F_E_JYEG3<[)N7:E0V>!(^I@2<IZ&?UN@F)-+?S:B"K125#I4*L77R_\*
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MHM)+"NO<56A=@9DE;0<85B''N^#+2L"KH'8JPC9= 6F8*W$[';DE6I:A%'?
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MF\0C*HP6DOQ752SE%@NJ,I*H=9V**#%7-97/*[0BBS$2(T7%Z&#XJI*2)!Y
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M/TH,FF5QU<U1EHS+%_]]]/3IP[U.O7#"6+<=8S[WL K.9/0O (:LVHA5"CJ
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M8AQA8>?;.I\,B\5:;$Q<?YM>PL$24G>@GPP<S'9^T>X((!WCU0=MER,GI#H
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MA$C.P:UT-) > !5*XMG";Z-4;Y1,=:HW5>61&FKM?/'/.<C=H(WE6[NUJ\(
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MH]FAZBL72X4V'VF>;4'X,KVH!S^FHX7]:73J<NPT)E)4<D@B$+><PHQXKH]
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M:$H=?YQO!Y0OCCN[ P@FD&M^-<2NI.\Z$WKBGBWKI(336UALJ+/=+<[>4C#
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MY#PN6-83K4T]"W[!_.4+T4EY!2\=]V!%">,&8)F9)P)V\27,.J=<\\RI:"\
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M)1*( Q<8YX2P.5*I.[K U!BN$@G3"OK ;4 65<-G(TRN(>ZG8=_]J)M6C)6
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M5[K<K*C_% FR(%?"7K-4%*L+PM9+F)6H8LD>%W:\,26Q#48.1Y",.'U/]19
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MDA0*#,:(*>V#4P,)^ARQO2L",':(QE[UVPI=N,Z5L@Y7"%LI=37,,8S:Y+9
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M4N? .!G!/[#H@>OV+FT0^1D<MUDU"ZX2\ XRZ;I5"PS!]H9>3)AO0'6H41N
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M]NHF@&>]'1X/KP:GZA?\#K?G)S?#8_[H-8UP-KPZ.1H$UR<W-R?G/P<GYV9
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MGZ\LRH1_C/)X"2KV?C&;_O3_ 5!+ P04    " !L2F%2,@ERLP\\ @!B;@\
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M/7K=+KM79@O9:>4+6!ME-N?O?O^7/J$C%19]-O5.5*CF$Q#KE[X'Y^C!'V(
M@GF6WOXAWO1X?#&\^M?UC7?YP^#J;# <?;@9#P>GU[XW/A_N^]]/\K=_ D'
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M3L T&U_?7#$3R^#]Z/RFZR;:%FX,AQTVT0:+11:GQ)Y!>-M!5<ZRO#]Y-DW
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M^K(//3B$ =DYVK6/9JHT6&'&PC9UT@OC\20+65&%>NI.X X,KSWGQ8YVE'V
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M3[V7=/MX/L$A-&'7G<&NP!0].+H%C<CL'#"P59Y_WC.PQ6.!94C,:@&#'G,
M<QY$30Y[@W[@8M7K3IUFZ2<;J%V9#\E$WWF^6X-^.BPZMDI44?<@6;YB$<6/
M,:$26A\?$C  +PP%+K].<':H'H!F(%98/,38&$_K8L@$K/9A1LG_LMO)  N2
M7 71DO/#:5GBQ.;JLP3Y,P3#"'S15O.L[@B;HH[8> ]>):1%)DNR\.XL$;,N
M-,H["[6H@]LXW"X/.!V,.A'^"57B;*:#T7)H[/5XN]TTH\V\"GJN:,W^D@EC
MYOK?<LWK90L6]%XVW5MD(>:#T$ZP4EM:]@6X"U=TJP-WI2<U#3'G8\-@CQRR
M'</X9+$F#08>"CA+U.21.=#CMP(!\MJ/,7$'"^J$GRZ)O!C-(=R0F<$F3;(%
M[HIW\4#^)1@OHW@]78$& 36N+*PGD%^W_UR::F(U0G7<^OY3;UL7(G;Y'B3V
M;[:_E1"YNYVMKWC4I_:^?1>$:QBS'%M(7^3;+X_-ESK&1%\/G6MU$7B$"WXJ
MB6E1MLE^V,W@W3APF9/69'UR^@ENVV0Z.$PUQF<CRY].1\FKB-B/XUR-D+I8
MEB9=:9"0#C5CO1817V?/60WCP96-*K*[UAQ>-=%MIAI/ZQYBUH&;9ESHDO(*
MZ!GHJD:JEWYQ:BF)6XK%^(T(CZDN>Z>X4!,Y.>0@FIIV5@CN@@E&]#*,>^+T
M@TYE:@F3XH/5901YQS5@* %(ZED^4K*ZG\!W@YMA"_&.27P^?/[R$&8HSZK;
M&7YX_G#.M(W4M;(2$VR>I\EBW\5D-&JOX32X0P79J>>KRPEK#SM:/%E.Y;AR
M9,RC.@AS!/[B(;YK NB<P$5ZR[1">)Y+">I H9'P$#&K5/L!'@&65>E>A'H%
MO86!+=9473=>8Q#_,'RHG1P^P@BBNTI,!$N?M7/;2Z9,A!MK;*(.T6BM(SN\
M<<F:(H.@Y.QT5N!J)EC"R&3[K%UG1/KU\>YD#2U5/8_D'58CQDD\R:O;&K*"
M)Z^>[2%,'F)0]8/\[J1M#\)1?B<)/SB^/@TN>Q^&63%791QBHC'I<;*S^-[1
M83/KYMG!H:>PB."_]PV'GKL!8'WK*KFU-FXO^CPK>NR)1.2J3?7S38 U"D3W
M)O3-@JS4M)I;;PS^1A@@TN-@%PMNC6<NY](5J<?UJC$#1F=ZD:?1K10O]<8;
ME:YU7Z\4C (2SQ+]L&8\)5V@WN(DSS[2_9)90/W'.O5-]H9FR\=!2OQ]. '_
MRO*/.FW%I#"?@!61HCE!ZYU(7<PCWJ =JRUE4Y$2#S[)19R:2XTGL]:R7U\5
M9F9L6!IO-;D!] TG#LE[UD92NDZ]7:#/@#I;>Q-D^\F<47%O<5[0O6<#5DX?
M9JJ%F9[U8:8^S-38W!/46)AM>GW"MR>E1!*;8EW+E3[+\A++D1C=G6NC!7 +
MNN^@-VX*IMZV1G-09*G4XUF0!D)(/>!O@D*7LJ'2@+A?4T_1%UI%10(;IW#5
M;T(X^VM/XM5QN]ITG.&TPBGUGD[4[-&#,NN+X;:-+^Q>#Y:"J:&XO13K,\/8
M\H^[9E'L4,2$3N1=MW[///A(/,7BFZ:_L9*Z<"K;1%^NT8A?QQ2WI7H3&?>%
M2NQJ5+,I]<.N:%WP<5T(!H,(J O<D>>EG^_W@\'EZGQS.0'*&24V 17IB#JS
MBYB47AGHNF58HY^B>5C$J2FB =MJ"BV%]1C<P#9_:9OG16W0^[")QB'(W=BD
MC2)F$;UB%$:XY#H<TE1@ZME:?.GZY]O"8$Y/KI&#&_==[HC/$5W$*I4. P\9
M6#U[V<-B9IPX>GR]$S4ILQ8"KE5YLAX@(4;,$LV!6$U GXD+!WCK&]\#E\^A
MARWY,$UCD*M QT<BA<FA'.H+^"@FGU-1YER\.#$>"\[."23;1.K-">&^!B60
M<\F\G4Y'77K.JU_5XJ:@@MSFP=QT&/N 7;&>E"SWV0=&P7.N%QZ"@1<KBW3I
M"U$\+F3Z8\O!!E<0@:6Y0[:L-)BK%4H/$@&)F3,$$NF8Y\Q6)= =6OQK>\);
MD.3%RR^1_"([D7D>(=;9K]GLI&/MUI*FFXB'>K:O5$QSH\:]T+QWW<L/%,"D
MC#UG(VK1'NM4&+I" R>J$WSIX7U+,WW3QH6W2>4O[2CG/<JW-3/]YF9E_.>8
M/CG)(JJI5.6PJ:!-C7K:A%PY.D(O3EGU"?D\"B:04V&%80@,+PG3)W[XN8HH
M2N C&HZT-N=)^-KUQ+H%@C8*CCZDVO,RE;1*S'T3NF]G0!LQL*):Y,$>CR'V
M.XLP\L4LS$)*6JOWJ@/>YMNAO#$ZK_JHY=O'3J'V3.(S.'?@P%',Q\6?XH@3
M>.OF+1>L*+P?P'(&Q>]8<A&E=3D.#3O47_[[\,7+-_Q?[]7K@R/MK>:,X)NK
M\7!P->)<W^$/@[/+'X5U>+I+=2(M1XE#?ZPQ#9E4#Q]8GI;UQVM#<#7 Z[&3
MMZ\$U2ID.BVV+3)>- L_:2H[BT%86P+.-TEO8H76<Z=S[4 A@!>T 6=RJ+5Q
MN+-V->47NYD+9CNT'3$814D$S_(Y?:3X.E^LS>'2$HN 730G6<%V,DU*OZNQ
M7\S49??Y]N)POM!6N9NAT['Z./C2B-N$3^!0#LZ:>DSP/AR1CNXX-R>GC'1X
M.,<&VFHX6<56@(:/C9K/H,3&H[G6FV7V<PI:82]4?A>'JM8#+!)!9V916*X^
M>HQ2#8K1)_5+KU3S0G92)4_IZ:_'[T=YV 'Q .;HT- )VKX&P>F$[9I&T)+R
MZ)#9XU#%<+=F$4S4G2*$4,R5?V@'*F;H'+PW;U27.(Q;\#I37 >Y[1J<GF#Y
MU%<FI.G=;CW:_M!<B;!S2T).]]O.GT9\RKMQ$5&I*"8/#6X#5)4(F^KV0-^Z
M0Q20&2_X."76H%U+0LG\F,(;5J=[D&V A?JINXOH@^Y&XK<6$'NT):=NX619
M+WPFHD>1G8<W5KP,G7"<3;[Z8 1 $V.!Q<CCB)B2,10,7=F'UE?VA->30IM@
M3DEW"40<-P\$WA9@A\J#^Q161%E* %3\?"WI'FZC&B9-4#NW4:)82!TNCYQ]
M!4Q[S*<]@EII+1;WP<(E?:O=A"N=+T_0&^E<9J:K5J'2+4CIA L<P368>"VT
MTZ1"9+4P)M<?7SB=UJ4 =6S9?0>" !?[W@T.UMQ-C3%GMC4J(^RNII=JR3(@
MM'1)_28WBJ 5":\TM_-@B^W6MB"[L2 A2LT"6DL?;3L9%PP0)P5MRBNEM2L<
M-IZ#M3*OYC6*$!!%= /A/4X!T-5-@?C9FMPH-55")@KNO<6 S30 993'&&_3
M:H'IO%.E)D (V(3PE8@2S-FI1 >^<#AO@#;9AY1K(>7G?4BY#RFW&CQ9OJ:B
M 66X.&GNS;2\&)OEX(5;XLHTJUO4/+%T7"":<X$UKSW)3M(0<7I:S3JAP_!G
M,$X+;M\T[#6)O%O(QKG:V[HN\6F!K_I04H$OG:+WGI-N<!='5,%@U\EBJCDQ
MVTB:#,4OY_S<YYBFDFI>*E_3H^CO55*O(V_+>=?2CIH6O%#S2ODT'E4D>75)
M14HJ^&V C1)3,HDSL'Q@DOK HEX::SRI^M=:MI==336.3_Q)\Y&*7[PIN@,D
MK*,J4QO"9OF5![^EI'H[A8/ZM$#0^AT9/GD0Q5G Z0J"2 ]9D;P/BE((M3F;
M13=/-M>G.'2N]_751@%>@&Y<E5P V2G'K+!:I0+EC.PY_2%"^@GB7B6GT00T
MW8P]Z_+WGE YDZYD2\[#0Y;A#(Y(R9N9Q(N92I?X$[P7NHP">CR3^G'7Y^30
M3)JOQ[UN'0%1FF47%A\X:KB./#*WG2E;#^V?!O>]3+)G&+W)Q$37+H]U5NYZ
M;5!V9F2X$0C[-B-$?%#3[U22+?C;, '9P%GEW(ETSWRA[H*D<I(+"&&B[1%H
M.:K0_!+621^=%]44DUKQ&).?8_:Y%4SMI#\1(0!V!*OAY:6T"&O+?JC0U@;S
M+$KH0LI]Y("-XXR'00_0<DF"B>+KB.FQC+EU1&UGCO54E',NL=8,^Y%!CJA\
M_5+B"X!6T&[6":T9]#9E!D1C@!FW8^'.!?GZ3X8#3RC$"7ECXE1X?H(8$ >/
MK\O0)BIREY#Y#9T5N>E8$4Q5N91?;;3!1AI,*."'\>5@X'O#T_& 3;M+&%D)
M8)1RVF/O!M,I)H$3?SG*&M;)WKG</]WW#@\/]PZ?OWB%V?P@:AH<;2 BWC0/
M*H%S3##7EWMEQH1+P2 =F*7WYZ[HI@:@S.W](PX_HMI.04'$J.P\/ZK'/0Z?
M'1T$>R\G0CD:@DJ4>.]@%\,4HB">%]SI9X?UVYZ]/'JMXR2[9K/B3F)H,:2
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MSJBN3EQSV$]/AS"LH +!=H8'\=IT@ T8VSYR6HN<ONHCIWWDM+[\_Z&6Z%7
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MZV]?BG]DJE*),A:JW,NF4RXQ6%'&$+;6S]MO1RJJ%[R)ZTI^NR1+(4[]$WK
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M@U^U.]7IQNV7QIYYJ3/R+\T'37QXGJ'%B+,5_&>L^>4\_/']V7GRVLWJ.3]
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MV+2KVR1\;/^B0QER+:O1W0%'ELP[N0'91%3-9\S\B=YIQT1Z^('XS>Y@5GE
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MF1P(I \^_^#3*)G (L *U@8U3"N;FHXGF(HC1W.4@9]&!?;9)\JAK=SI@6N
MP2XI9X,!8N,J^<(S2J8AZCUFP3SE.=6(U55#64$&P<-.RX5#/T"(H@4'!PT%
M"0;*-AUN^1U!+GP++T)H#@?1-VL!:]'SD\/O]K"!=X5:8!W7=([2,E&M="KB
MP5ZBG,NM4" OX5NST&TC/3S71AP\?RTP4)+6R[M5'%O(64SXMPK-3-?2T"UE
M<U\9YB?Q,]'"E!I K2M#A]-$X9VA@>,7(<4=>-NUQ4!"RQWKL738##J#7?3@
MYZ6'4GUE.GQ-\'V79Z8=*EWF$0-IU$H8]ZN@'6\DZ7/I.;%I84(IM*_K.?)Z
MH$7V:KGCN:(>P6Y-(V9Q41FMEY@UYEFT?=*4G=DLX#\P:UZIB/LS#<1YJRKU
M,9'U4L029.DJJS'%6FOD1!;+A#7Z[H=&)P\9H1MA$Z44OI$-*G*Y;>M8NC54
MJ%,\,2YYWH2CT.D:RJ0P5]W$+?^OVJ1N[XS78/LL&@E/>=6&P<="J,!F':TW
MSS[:\]3G61M---B*!3@#\->!=G(#"$ZA&\Y]MV\@C\-IYJ-J>LT@<Y'?4D8+
M,4:5N$Q>W^%\1*[!9"4?UC3S--_V$BMEE>.@S\+*C!VJ55<#UC"_R4K293,5
MIX;TUA46H_,7:TKMT444HVR<!X092M((=V9?($XH>&?,51B K3+Z.^+W-UB>
MD,T8ZZ]/IX=B[;ZQC#1U-<GS*7E5;^LRF^:;B@+CJOK>9Z+9;=0\^)+*Z%&?
MH0FRCX:7<I4]HV0]=L$.DR^\?ZWQ-FU=R!(R?;R"L?.PY4UAG?<\QCHIA'^M
MX>747]\1B?,R*A:%-32-)6=G"TMD2.,AC,8G?!FJJ* ,H"[L<RX3X#75QU[@
MA0=?+BDU2N889 <%+N4]EY?8+;3J&]<7'4HDU^$6!BWS8+I>22V%D\_W<#R1
MFOWZ4]89V]>;-K!/<V,VP4T?R)>-;TG[[O#I8VY*TRWUCJNY^-CZ#=XA6W%J
M2,TC-Y5?]*DND]>9MBE"TN1^AHX/I6NODY^D$7J0QB\Q3%M1LF.!ONQ VJND
MD_'%G]R[5'P"Y;M6Z[Z(M9VPKR#5Q77WJ(83K.>H#LY;##7(I38;3K4X=(KW
MGWLQO"TY._%(E//P__SG?_[G_\4G[BX)<!CK3O/2V;OE3>#=;_?JJ1D@191\
M8$>")-AOVR2.\8?:?9WA?YVWO?EXU0%M:1I3_/9!8_@N<R06]-BKQLB\JV('
M9M:)T7>Q7E4=!(XP6&3\E9'CS<-(%#B'C.N=<ER.AK9/.0;30&MO9'I7$X7"
M4(S"U>$9F&3,KK7QT+$T9%=9P/BQN<>[Q<HP1TF]?7FH5Y<J&S+:)9L=49/M
MB9:5 [^715DI8393KO'X)8C)PW9A0WC].WI_#2W4$BH-)F.WW/5.25]D!6D6
M$'HDDS(/SX9!3EXV!NDP>)A4I-,=(C4)+!W-SEW/\9#NNF_IKN,AW36DNW:E
MNTS>/EX+4-)W1AMM*QT9*D?^F)4CO1TR*U-F'/[VVRTM_NV6Y_W_SN;+9^^Z
MR^)(E.@'R;NJ\D%8WT?]7E$^7K\^Q\W7!$6I/TW^6F<W#WY$U%YW#1,>I:Z*
MQUM,XN(,B_(^FR%GU!O"HFJV@8L%YKM!%WMR>/+P8$ 6T^DL.47_&D&2J2CA
M@V](VA,&L-M>8U-KE!WS,#_:[U-N;/=:N9%;&R"4&Y1YR5>&CVBCL+"G@5S&
MY"1*_BE1/FP&EQ?B:_CO;%TJ[JKV*J6.,H4:O8@H.FCWDNZRJ0/IUR]JJ?M@
M1&]V#_29+L7F4U_47+LB9P1+V6$&T=G@\ IE=5=,K,T9C7FN;<2)[2@627=W
M9>":!B&NS?O7 RH;"OB"1/F@&<51\QKY@4.8S 726[#''0S0SXL"#2)0_MBT
M[>OQ3;E%G-C\[<O3\U%J[_%&LJVN;.$<;/I)4?*/7JQQ74'>?U[0]3^" /V4
M_9(WAHSH _>];Y(#_ZH__O3!O.+(]$CF97Y-;>'RKHTV8-_?[N7?4$(F5_ET
M7<*R_+P0;@G$VMI02?W6 P9T()O#+8#9(\2O')!E97I?G,<-6Q'^0@!B7TCV
M'?;"?%XH,%L;$2X %2/S**<Z)SF)7*4!;,EBB2P[:Y'X82%:W%.1LWU2E:6R
M,:0[JHD$WE&KT:?Y'%4;%0=077CU@#!\^;0>\]_9DD#G=B"B=WW+.$!&<GQ\
M>/286LT<5KDXFJ"X\\L*Y8)-B39MEW)V#4)A-N'II,<##7^#<WS\_<.'P]SI
MO$CEVNWM9H7/-G6_J,I:@ !Y+;"/T9\$U9Y,&D.54097,VPB-V%LL;,C>* A
M-#;RG:!Q347 1&!M@T)J;I*VYB+#+%I*F"H"0),&1<FNGC0U: ZS-19#B57M
MFEFIOAI&N49H2M,&ZJ_32FR<8CZAD?M ;.@F@#S-++B >=]!LIU=NJ,)SJUR
M/'Z)/[&@E%+YR@;33OZ=U %'C/-%/BM<=67K($OQ-+':W_F*]*6/;%*"\3,C
MF*M[$Q0;TC!!&N9D2,,,:9BV]N+ :U=G.>!E1SS0@Q7L<6<T7XN!FL4#]_E4
M+<LTV8:V+!$&.MO KZQJ;J;(%EFY:8K& %9;2""#>XSDO7F-AYB:&6&'YU6>
ME:NK25;G#VJA\-"7O >ZZFL+PAS#@F>*H]UOX'9^EQP</TX(#/"\FL(A=I4M
M,=9W_.B4\C''</EI087RX;6C8=+;DVE.]HAAS%$Q0EW<=MTPK>^KLLW\ ;JJ
M_?VDBV.]S?40.RV3"KLU(:H0\B+%J94_;,K5SZ/ *<""%ZE !)N;P3#S\<IV
MO8&F' ML/2DX5&D4$S -)_[7J.J*E2=QO<J).6#-?+<H)UNPQKB8VXYO6N6-
ME)]AJ#U!/DXJ[]+/$;X_O\Y=2!X)-%.N1Y,WJ8)7@ LVE2)*MAB"-&0HDZ%9
M63\A]C[!2Q5U^[6XP+HUU534N$!6-^D/L>P F74(^2T5RV:,YQ%1=!(CW*Y+
M/?=+["U=ON&&.('QR"* \QR.1LN#/.>ZKV5!!-J4);DLB.1DNLZYKVFJ4#I2
MG(45?%E1,BD0CF;B5AUV!&R0VM#7M^9&YZ6B*BSWLEQQ3>&@K!#@1-/](1F:
M6?MNE\1"6OLRRA61I&1SQ:X+I'I'Z-\(?7!9A'L*"XYE)AH*@^&@P72@318,
MGEK-.OQ5LN(E+JP;NXR:1-P3Q J7B BKS,>826X+%>76[:N%W>*R/;70;DRP
M]IQ(9.F>'B:OF*1Z[7@)_13&IR6DQRD(A)8W+P[6<6;;*_2=^$'H>*[LHTA<
MJ'RUI'X%*=!EF9C(UIP4]60]YX9*$*9/TG-G&1M23\/3=.9UDBTL"R)RIU![
M%,^P3A$ZEZLUMW7+%/G)'HZW]RZ7(F7U$>L=3R!O-,RK,I\@.-8T;R9U,6;%
M6"RNT:+FTR5#6.&;9%JO+[6A5$)FK]X\'W%U>!K\AP2"_P)#/Y_Z,,#+YZ<"
MAC;+J5RYZSO KE!PQ_-_/GJ$)?F7R&2<-Z#\ZI%E2L/#RF )22=!\";XQ1MX
MZ)OJ,#DY>O+HY,GG#>GB]-VKOY^>P=,??7?R[  QS.8X'GC&+QQ('T7@7/ #
MW E4F!V/YCS#6+PZ4H+XEIFH379=%5.MY)Y6Z_$*&W23SDI+]MY5B0LVGGP[
M;(WWJVKR<0E+WX-=2/M"?HX8YN?.9>0+3*E8JSIL"X95$,?[*8/?)=]C$>+Q
M<7\1XG^_NW %9^_7XQ0+GW:B*C#+MP$A"B&'G+#CS5_1#!$U$+;5.[C![3)G
M7' -5:,WCH'E)G6<1P'X]+)BQ&6'6V@$TNU?=U]JDKC-:.29,HCHDQGAUCV3
M^T!AL\V*U1[6,!X\T9QIP1W;5.$)HU?)8M*_=2,&XG(-!OI$8@L)R$.-&"##
M*?6#3Y$$?MB,:=LH52(L;@IB3U:@@;%/DU^(=^M:!9FL16L+, 3PPA0/N55%
M\!6VS-@.QB[Q7X20B/6SQ[[^.Y&5):0\R%<SJ)8<3Y]PH1'5.J6*'>Q1JOUC
MX&J?[4'3K<8\\=07<J5A)1>VA%;KRROJGZ.8>RW=%U28S/U=V#A180/.>!/D
M7I*?%V3"^B>Z,@O&)W6G74,JI%APJD<6*6Q^%R\9?M#^NO!ZD8\?NBW?*B3&
M"T$;VNQ!;ZH5JBB'5!YDGU/PBU9%2;S>L#"7SH(/E%F0G2/?K9N(,"GO8PU)
MXMUIJL#<1#YO8B^0L";/3+IU\)$.K98&'S;\^YMLB7C?*_1)^QD,*":+0H0'
M6X/7V PMR'C6(*$&?(&!$*;;! ^XN.9T5_AC$)\;+"ZFFX5?88BDFE+IB]S+
M?2# ^/YR_]5$QH^U&0R0+M0 E)Z=YI_X;J1P]"[CBAD*Z+_+NN#V//I7_!(!
M>J='Z\7!O]U-@D_Y9N%;NI0QS4#GQ7![P0(ZN([V''5F?U966A5I9K+$8%?K
M0^Y$W,26<%)73?/ _:)OI=T/W+#A2%_9)5!(&%+MFK\.$OKR"UC ,1SP"EIA
M&'Y]>8O)_=/WLA84 \$@!EE4L2M'ON"UJCE4I% EMOZ@T$)'04"N+9814WLV
M0?]*&IA'NB_"U^-W^5@L?#%MHLD+0AFKYYE,GIQS==[&4.*L+!.1@N;5.Z<>
M*IE&++450G[0'BP;.LV5=YRH?6:ASN-[DG%\R'.W69ODM&FJ22%'N];K;UJ7
MOA0A=55M/_&S#7Y5( B=H1VX]>A.\:JZY*5S%=,N]R.UC)CW-L'A]L-MF:A-
M8+EGMH#I;,B%>S'QE^V[WH/C8DB.!\GQAT-R?$B.1RR:#P3OST?+WS&T',D:
MA0!ZI*F,.1\81JAM*,J_8I0P/G6$[075JKK_?!\B>@-K50KL*>Z\R%<<=74*
MD%2:E/9ROT?KD6A\*>02112DE(U'HF&&R*6&AVQ25M06LA8L&S,O%'(_:$:6
M#2&TS%<>#MGUX'6NUN,P&"G80NR6N&&:&!X7DVL7>F8(WSCJW!J3%J5G]4=0
ME0^X=L _WP%W=%8LX'D8$Y8? ?/999X74[VCZ2;(I@5BD7&M/"P>ZAL%MS2%
M%7PP3:K+!1&]3?.L)),DNB8'?-1CJ:''BQ#>^4Y1!GG<_.60<?_AO4-GI":N
MGC87]R,*.C'R:YTC^089F(Z54;ZN9K,'XZPD00<+"00 L?]LS67W%[Y U92?
M!FU<]O.B<:E E!?V2J<@=XN<_1*'5$CQ-!BNZW_">!M>CJJ?8\D9\36WWH*1
MSB7=ZP,*V7*9X_@I%QJ\ -LVR&DR2-6'[-/G]5<^/#PZ%K4US*+P=)S:OJ)W
M1/$3+X5A^A\N^Q*TZX4$A=1([U35<@C=POV">)<%>M (6PS'Y'^O0:<?$XC
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MN"'-F4G!A30H,AMH'E2MMBN@M4=0^_C@M[.<C?E&X+CS3TLF*>\A1W>TGO=
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M::;.D:A-(G8!RX5Q4P*FK!9@2!V/NKP79B%H.3M%<MS<U;G.E_C P44P^K(
MQ/U($7#PF]8EV&MYM6Y BB1*&BQ4$\LIP*^*6L\D/$P[JX@=9ZT!-<0<6DQY
M%?E/;'IS,*/,5SKD-'=JE+.[UBAG7T6CG-V)1CF+:I2S.]8H9[]WC7+VF1KE
M;*=&.=M3HYS=7J.<133*V>]3HPS9BR![<3QD+X;LQ;[9"]KWYW=]Z)U_E4/O
M_$X.O?/HH7=^QX?>^>_]T#O_S$/O?.>A=[[GH7=^^T/O/'+HG?\^#[VO%<38
M#4_CI_.;#+/N&\-X@=JRO1>TA'B]K$*X2Z>-BKK.KRL&9<+\[H2(^+3:=\[-
M*5IQ216%;^A7*9?1@7+*J"Y>2^19!6 KC0"\(804AWI+6]7S=C:#N]3M_.2H
MIWQ-Z@RYEW\.TX2O=ED@T##N)NZG)*WR_9^/CI+L<'ZHM)F4[P-5A$4XH)!N
MX$:;Y.#D:!3H4L8[9KZYJPJ+/J6?4X%)HC%IW,VD[A24H:E**OI%DFAL2R)=
M,KW.#%NF+Y:;&DCXM@L>.#1^6447MS5-ZLA&&;03P3 /$Q()LV9:TDEII@T5
M+?8/R#_S0! 45**R8.)&85%BK/B ]2\7-3F51V4-?>=*;$;\ *BE(/:@_S@^
M>9R"E4C_BT_@'C?Q]W!5DSU'S=;;/#[2VWRS.FM7E.0EX0\Q\=HD+Y;<$!&(
M[(SPI%]F$TD4]6Y%5P0[7R+*)^HRD'&R(4^]IE)#4H3<+Q=NWE./3P?&'CI/
M""0MY:RH&708[G*#7HDR+ELN\CP>'9FJW>?2^W9HX*-OB6IF/L^GHG7]13,8
M9J.XI[%+G<9GS=M6F\>H-I=&;0:F<< 8$GES6:W#Y&<\:-C4S!RF?.N"J-$/
M]S45\X_!," 3&/L94U>1X?>?<,=3>@ZVG5&$X5V./<]/JPH\'GW>&D=J:8/.
MI>TVT.VBRGX+-H71TE&A/6R":SQ"V[)@>W^H^U*6N_'7B"D;?> 84Z54[,HM
MK*[0FF\3L7<9@VKBV%G)6<#14(,I)W%E@*.MS[6C_^;TH#=S=_=_OD,'8>,
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M/;X*<=)>N*POIV>(DTJR8%(T))R"KF*_:3,'%BN*N>=4X08F(FPC#HE)&VH
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M!Q I83E?^R(N0>Q'"TG39 [DR/Z)PQB5%O!#+@UX(GUM#'A#A(6>!W@&6C5
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MWVT1R3/W B"'FT%V2@K8R59C\\^JD>R .1&$T<)&#O"%F) -'08G-]4=>BM
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MA*Z-'PUT07?(.2>G4@C> <*3F/<&I[+GO.%390"07[+\XW4*30V)PW):IR[
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MD74\81\E7/ARC;'JZK#.1;>QIC;KLI4]R.O*JC/2-_A?0  U:;_$-MZ$I-S
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MO7=C#!&A!%<"6>H?N7QVFI=N*6Z4,U6*'6()8Z>.'%2[GK/8.]+ 12!&R_7
MF.QY=<781KA$*@^89S#_8"*^<F7?"8H9KCDI<C=W.=Y JF$.UKWK=?=P?2YF
M%AQ-?IO9N%H'VL+_CGS:N1SCK)#->YGBUV)G"TK4"G]WDY6J:Y*?1'Y*HJ$,
M?M\ VJEW&>I4[>"8P3+#&A[.GQLZ;S6,#Y9R43$1N!P3^ 3QR5*Z$[UEZAW<
M[OE(+IL^]Y\\9=N!BW99 4DM0DVQZ1]?A(Y/,SOT+WX9ZA8CL$2)N\GJ(:T_
M[N&Q#.;P84K%0(D3W%<EV-T-U,ROJT.4>YT*'7P7GD*>3WE'U!'8,"CRI.(B
MR4*F/^L%@[8\=@A$,,KESH;:A%7>(R8JM"4(U-$R\K%EA\45\F[AV%N1(C2>
M@*!1)VI12Y%_P?1>A6$*_#<T]26VJ5W[MKUS6X\8>^KD$^,&*WL_\ [4G:;X
MS%98DV, H@0AO7.(&I,)"V*^!.V:4O@-> T5/-#E+_4?<6:;QJPB/IEQ'A,^
MSZD*3$]!.VMEG>^8RU3UWA6_JGW="6_KX)V8"9:%92)>;G 'E  >C6:6S(.M
MTDUZW3NN3Z%GB=')6A-AE1.'<Q^G+%DF0BLGT=:"H30V6M**ARR#9JD&=4-
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MR*W<$DO D^J@FP!#":P5-&F!#9],K>X"D65O*0JW J_=JA:"ZD2<%+B[YZ/
M'\A%X<('470T' /%2F945C"_SEI.MW*E306\.)K62_(-_SY;/F+*9SY+I-KI
M?^ V=RYQJX2-L,53,XK?:VT>K.FXN:\T8>38N\T(->"E E3/B)ER%"NCHFMF
M(FS;^@;\^LSEE=<>2LD2I7*?,&7)RS4!:E(ITK4A[\.%^L[L,N@(\_ EV@[@
MT5MU-;(=KB@O_T9MLK><]G@ Z^28GO;2TU\>T]/']#2:LOR3>D%K](+^^N?O
M]T\WF'(7]1<T$#B GGU0WX!'G=Y-8#R+_9,PX':P?]=T&]>?.[7-5<>7+A;:
MVEJ[^1;,,7?0?G5Z]K6MB%+QG2@LI\C&2M,W.WJ4^T#@TB9;[=2ZXD2NUS3;
M$/\$!+^*H3]5"6LM"A&B8$1&)NLA56KJJ &&2O@9YA*1#'G)T+*FJ98Y#AJF
M'F)%DEKB?944LQJY!%LP]M(,]G$_W&\_/!_;#Y00P'[:D?1)6(2R%*;2D),<
MM]$?N(WBNR?<- _ 8?RSVLJ^'F^)JHK;K%SN#KFMU NP3 1+8\(!LJ+NH #7
M147[*9"@0JNO%*%#.M0!-ROSF]&5:7;O.K.\WF^E4'NIVVC\2ONAK^$8YH#!
MB(RH[)6[79C/2$G6R%&70J:RNK5,%,N*J$I:.K<200#V+^TNRZQ?B54AQ]/6
M X%S&Q4011(;BLC%I:[MFCE&8X=H;S%HDM<M+:4L.@#N*4]:#POJJIU[?[5,
M 2&B[K'@$L+O]D)S)+^C5G-7\1J%NA[HSOCR],GC46/S7)+7/U34X'C0/ M[
M:+>?//;$'Z0GFCIM=(I<P$D$+#6+%:A''4.BA\H9B$A/2.7APQR+JH"7VGH4
MW?$;1GSRDQU?PKRWPB)1LR#3+NA+]1Z;$][_FH/@0M!\)YU"@)ZJWC>JB:69
MB0'Q+C\_G>T?8,=KCI8R_0"4N.":^.H*2@ZB\MF-XU^48=,$&M&!1^)H8P6!
MT:G(KLT%RW1#Z=]]<AOP;^"Q: -W:G^VQ[TO#O&"FQ^_[U) :1$LC;$YDZYB
M(X'@^_;+9U**^$>58\G547%I1)_"M;MG661+' DN&!.V0,/Z]C^B /KZ$)Q5
M5TLM; VQVBY+:^2+6F:V2.;O#?.*2V/E44C,G$=NGA@WH#_<+Y)"(V9^@H5!
M5PJ?;;+Z&B +Z28MKE/AN')NK! P=[99%7CWH'!G'H7N?Z@6U$SWV7CLE0JG
MS 6TC]1 ('QN-NZC"[-[.K)U0%#S[>S-^;NKRY_>';F$)W!\] 851VP6<*GV
M,='TMY[D4#E5*U?"PKP.2MV(!F'&[L21>)-*60: $D(:*^KNVI'54>ZF)4&^
MA*5S5$R*?7-M[@[ A+E>[0FV9*[83"-[AW]/IL4J0"-TFCLKP>4DK4A.&]G!
M9J.32U>C6;D_O3J_L(#9']A/>+O-N#CY@D]C\^77?&Z9J_S]QW?V-Q<Z7I8+
MO+*TEFZBW^$SV0G0U+3/S6#!3RTKKD"7T7'A_),E0PC:91M[A]3R3UAC651+
M:O)B8RH=N0T>OE1Y5^_X#V6"'\#V/58PO0KF5\<*YK&".8GXP9PPL2.:SIAW
M-WWY]/ \F,5D@X@"P#*NT:\LH&J S\YGUWE5U6:U 3,X/IB)?B"M "1SEI;[
MJZ\HN?/S?\R>0^])393=3QZ?/5;9"-O< :^Y=*\)&/"&D_IY*:D+UR:AG<Q&
M<4A8'5>"S4JX9/ZY-=9]*4.";=K&#<X:#M18#*2N-I5EXKH!2M3>8* #BCI"
M?[YA?9@=V9!.#5S(L/%9]0+K)M6/6LXA!R."WSQ9<JZA"1/O"8N< S@(0AR[
MQE^6V097*77B$B@[<1VS"D -BY\E#-CC 8X!D>:0;_J;YAU I+H:O!&(>PC#
M_O1L=O'J*H$WH;[:Y\GLXB;=0F7PG_HY")SM'(<,L%;P^'JK@'_U(5MVZ,;A
M40$.!K9#>-!U*_2N)NJS7L]X>L5#IR>CJ]E6R%$( :A?#C(N$EY4UQP(*TAK
M7:E*P)Z81:RYDPC;E\AX0NF:01B)TQR#=)!28U;7QRJ"9#:<TM-XKVB".2)N
MUH<]M3"C9<X3A!"ZZUM(;I$NJCIZ9[BN!&$3FE03:,C4%UHC!PH\.:Q$K5&E
MV>,:@A\KE8$1B+;JS*Q0?=UJ$TB#9@( <?TDH"%0VSS1OE> ;! ;28WAMLIL
M2OFC):IV]]R*3"K0@YOTR-F<TJ 9*V9C7C5QQ7US::^>S].7I=16V6O(^)@1
MM7H,*63,@">"4KQF1(B+*14>._Z$;IIYQ%X.CF <'AAT;"IML=66%73-N["4
M"K=WS)J;K%B+BLJ6(-=0R#E90[#=&',BY!9;H-7]C6\YPOZ6J<RBV=NVZ2CE
M_*3YF\U5PG^OU']G+ED+_US#O^;(4U%8305;0,L8$I+HIJB6>Z557[#?1I;T
M9_T3M;5\%-8=0O[KN3KG?3.CU48^9J[$!,M(F3B2B<V(:JL6>C6_B]KV9 @G
MLVVOQN$HL[MQ39$1.N:XW7=,N7T9!5>6T;O<;Z*ZKQ$<ZGB#OZ2K5:U:3B1/
M90LY,K; _89>)[*)GD >[H[.*>7V.C&2H-B$1U36WE0K^!>XM9VX;_Z5YQ0"
MW@_^I0MB$8 5-.?.L/\2<_*U%<Q0.PCZ+=/;RK(?>>UL/5>)>?EZ?\?3^G?K
MWNSA8WK=F_$T:ZAN];$MGE)=RJE?TR4X ]HX:ST<F$UL%\_4GF4[E"ONO82C
M!="CX'/>Q3H>>Z/H.A[-E\ 4,)\%:*_\AA[(_N+0[8_37O+A]4@^C!;)0;'C
M,D9X: ,<]JE1H1FRRK#;:$7F-7./:"_%F"LX-XT9!!9+S[,'\N06CFNS$6($
M),[!)R$!_Z9S]I-2EKV")R[2NX2:XK);.?DMRP;J//6)-MB_/-28S0SST]$P
MER4F0=76:8$\$);_8PG!*R%\?2PA'$L(D62,: ,Z:4,_H4(/#-;@LVMV^I25
M_7>C_B0&,]6":PL>76C8$:!HE_ETE8X"U[&-EZP*]'0'+X1ZW0LZ817K:,U=
M\UX8[K3Q9&G8;GKV][C>0R'GNJI[A0ZDN5;$5%J\R&=X[#VH<ZFLQ[V' OS@
M#N6IY;^)RY#859@1%E:&97 PCF%76G462!S!QP-B%S:O9[,$+K6Z1I\0%HFG
MFF@)/8O\/6=D= 3)Q ,ZSA'/E@!;PN8WM)(LD$))0<FE4#4*5:&LE@<N4?X%
M^*B$D? DKO;?#8D0H$$INV5D+F4=5G5Z!TG7IFN OAW_#MLU\;(EB7O-(M\P
M,W;B9Y]J)7>)_#Y.5WO?HV%:Z((>3E&-MS>(MP<3Q&$Q!044AC591M3V)C3*
MS#+5041B?O!KE9>:_X+8*(#-;M%9L-Y-6I"'C2MLVR94.VT:8=CB]"*_A"0;
M$YP<XV&PP-G,C*!]=4 @9HPGSP V:%P1:/67+!0I?'W_XYM&TDZ>FEK8F+5O
MX [6MHP5:77LSRBQ)K'(L<8AQN"1;LP>Y_0[ \AH4BV(; KMIDI7C# Q];(%
M>7D+O4VV3T$QN" .V/$ZR)JO72QCN_S,^IH/\K58KAJS$,U?D*Z,]N2RAEY-
M1*Y=I]=:XX<.5#@[*<VXRA9I362FC=:E,8'SD[/9SZ=O3R\ C4V;Y>G3+U+>
M<?_=F?FTI@"CW661@^$NN$:27\.[L(B-N=;%Z:O3J]/9__O_G'UIAN[IV9/3
MKQZ'H+/@[&8FGXF4K4$6R*T05<.B^=R?>KJ6Q+7X/D"63?3?T<%4J:,I.1,W
MXO<;R8,U"Z.4O@_<+'#9,Z49AY>#XQ 6@%M@=FU%NC\2348\ Y&N3DE&P^/:
M\UGDI]=UVD'L!!A-^T5^XE<OSI/9Q8]O??;5 0?+RYE*A*;3?GA'*R%##7 ]
MD?K[W!)/86[+ DFU)1)>P;MKG7;ON5!'V_O8BRLFY321.POOXDB:^-%1L-18
M<W,3U"T%4-;.TOD8P\V5S%<PZ,GL9YJ@MT[36XO!O$K1TV!X&1FXRX*:$[ZO
MTY85>*00ZK69?_'E[!7HOEQEUZ>S9U^>?7,V.WEK0ND,NU?.'B>SLV^^.9M+
M<!0;:36U[JU2:W_YW<R/C?D]6(,S1L1[[J),QO(!->S:_;/I%B ,3__P],\I
M?P_B+EM+-P7KUKBP^5*W/*[2-ITQGQ0*&T!9S%@M#)@PSH'8*)D9K[?  SNE
M9BBW>K%6ON"=1$SE)9_CU@6U\;C9P-BUB>MFV*6WA?Q[&1$'YQJC.!, G:/*
MLP",1%P@&B5V@IJ$I(3<FWZ4R4'=$MBVB2]M"NA.UJR*HO-4E66%?0EK-?>)
M1;^YS(:+[E:S;KLB1CT*+#'^P-L)WD1'6XW5 /%7WM!2PWOC(G(R4%9,"F-E
MZB_^30-'U=SAG HI9LJ9=J\U(_8W.ND8OU/#-FZ@;LL-V.9.W"P-O2%I3< *
M*,Q 3-L(JW):[)J<A:KIK.H>!&W:PZ15!G,'<!AQ2DE+B/_14G",9ZQ;:0ZI
M;;[\EXKDQZSH-G^T(%[(09F?6/;(Y\4$7X0?X [_05YV$UO\WD(?3BF%Q)MP
M_LN#< T6DI_FAE5=K.Z,RY"HEY.L:3 (/CY]T)B$0NPK]% @E,-G!![":EE!
M%Y#"@O,9 7!>=7ZP[DX_01H&6.YME]__\(:N]OW%&T*/G)?YQMSXEZQ8PSL2
MRMA/L8KG@'DLBWJ/0-VMF'QX&C"](B=C;CJSQ 5R $IE]]#KB"84A;5=R%O1
M"HV?"!;N1]A\:ANNL]O<;,-%E=8KN2,4L@ES;79$FTO+D\YSH:=%GWF0@XJ3
M<]@8)2DW^HJ_OV;-%EJ]:F=+]1&Z;X^DE+ZN& P";:=R94H&$DE"7QK"@N#D
MZV)09Y02M']OVFZU"UAE'X I/19?O>+K-\?BZ['X.HF'>ZK!'<BV48W,)MPF
MF>5IIS&<7U77JCJ%L^<(ZF=1US6WN.*A:A[R>\8LF@_^_O>WDIWWVUQ4=XOY
MVC]@^)8(PR*^X!):8)6MGV;?HTB_*E1[%&D^10]\GR067I REC#R+HTEIKV'
M0NNGE^@!!,K=> 3CM?(P4GX45:3AB@S&A>SOP"<V?N/9-1=C!COIN>X:U56,
M#[71.7&<6?H1RC&KE(;UFY;Y;5Y :0G:JA)/MQ9J1UP=@E1XCKKT#Z6U^&&2
M:)^C2RKSCLZL:WX(?38;E?TV;UXYR^@B1H*$_3ZL9;S',!S*;S,T..P^>T4,
M*3Q\<0;J+4_F5#A=^:0DYG:N5/$&'?TGW/SYY.R,ON]N?]WEA*5=.2HMU_W&
MV1*HQ,"PY:!3?1_K.CW#K,6&U"ZTG35[I53[[J-GM'7*QYBN7](:.XE^R "U
MDT!7[08^>O3LZZ>8^X2&P)7]F)QL5]ROP<Q5L#()N1\<!V8B\,EI,KC46IB5
MA>% SESMU0+>3/7E<$G6<FKB:L!@0Q,8V-."AQO655KC%8,'L[ #PNA#FT6%
MD:]-3S"N'] '$D_:*C5G*>!GSH39;@1/O,'F)'2!>FO\II2DHJC9)>$F7U*U
M3A=9@1_VM!V,#=Q (@0EV_%_21>B7R!GV,X>+8CI8R2MI2HZEF5VS]$>N-*^
MB3A8<SY&)#[5T #:!?:[#5ZEN@D:" 7D&M9Y1G)(.L/]8UJ_-T;S%PLT@40L
MF0;S7UP0>0%ZTR\J\!JDGE&@7< 05=6(:??#X*3K#/74LKIUUX$AJ[K&0<P!
M0BU7E$RZ;8AC4P(+A[T!%0Y#=95+L;RRKO+F_>PEZ#>XO.F/.3X9_/,MD -G
MUY17K)K DNAS,2VM(;(N"K\/YD$I]VM+_#HAA!\/GK%N6X89U7V)="^+H$<[
MD9R<8.'=V7'" XXL0?CDKVEF 'G) SXGR!&LF5X9'=\)Z N::$_=&PNTL>_C
MV4CIV\K7-A<_O1'!C"6S)$/Q[\-2=3V],ZYZ S9O=KX!T\*]+A<#;T' ,575
M]U5D'&[,W1X;+MRT>X.W=RCTY!+1&/1FA/@KA^&"9V0D"77HKN0,D:?G=X[=
MX&"-Y:\3?-_^XDSTTD2S,%SH*'G[4E JW5;9!Q 1A"T^U(U3:Z%!W61R=OKX
MS/:1>GL=V?"(,-55;2Q;>4GXMMSYC]X-EV;=$,1A+_[7,T;4HS2V=]DR@5WI
M6@!;BL&-\2<>ZD)\/R;_D;JAED:\U*P'X+=M:70W>;.H4XPO^*0."PEH<!AU
MMLG2DHT#'5H7YP<[^,7'#+X98A-Y+2G61"UEB8ERJ+D(C-3\HZ+.+?)4V3?/
M9B+:O0MBU0<T&\=4N4Z5?_7XF"H_ILK18&P^1F]8#(C"*R1$\Y(*76[D*P[+
MBX"&FQ3IX-&W@WHBNWSPGRI_L()43;DJX#\H:0#_U;05?H2Y@QP+DQN"1R24
M?L5(+;NI( 4+UX-(#OY+YQ/PDL0L!I?"4B%F'N"?Z\X$>LT-/IBD%O2E9DQ7
M!H"Z5=!UOK_X'127Q1M!+GDL5T.#>O![#/\2%T/:R$9!8T*$H@<&&$"@L.7V
M"N8J81GB9SBH6,X94$7\UL%]%;?;R.7]?&B1WD$==Z<O,#22#^!$^7.V:SEA
MN]H"DA09F-&"E1J5>! T' J3NW"Y" _WHH(^_S"NBZ?2> :E?![L9MG@ [O:
M;KE]V]OMT^AN[&]L9P\H3^BV./7&T+[].'C.A*]8SA&W]KVNPH2V@62@$\9X
M*<.I1M>92DW#NTY&XAN'R(L@(PF"X_!C2GK7)FR]-"[.%_[996=U%M=,60JY
M^D@ZU\_-TIS=+[LK<R;I@:&1@CH'X@>52.U'H+(JYC/W<TVK$2WR3U':2/K5
M9,[UV0RR6E(QS+,9,J!7ACPF&-,>THLEPHG3/H:9SAM=7T&>:4FL<:J&(4+0
MX7,^']\-\M8\3-$ML;.$SUY]+O' L6L_5<'UA$RI#4>6!+4 X6YSF'TOI%QE
M:V @+9?,\Q0IL7!=8R27X%(50?>>>U+UO8$'I@S9\[F##>QMZG5.%31'OJ?X
M67HC2Z(SAZ_8"PUX IS:P.P:\E/B/#,:(!4LET5.83<'EL6#OJ_$Y>KJL-8Z
MO&_#7&]L&1WLF5\]S#/?G;UTKOHG\+V.61]F\SL<MG2"/H C5QU^=+)%Q.NG
MGW6.OXI..']*J+W/FY2/\W<>]M'G8ZD^YO +#.'TXV_<.N/!\3_&CG_"U2DO
M/FCQ,_=V#G]!#[ MTN7AYL^W4U*XDEW5M8G9JBN0+@**+34+5Q'@34+QP$J2
M;T.7\N2!B!=1W0'W!:M=4$=,4#=".RE5$VOX90'H+YL+<SLP9)D%M;W,MY;&
M$*ZE7-.K+-\LNKJA#D^SEJ[K5,C\>EI6/B=XR%.>-Z1S4DAM55_9#='HS<GC
ME->ML3 5?UUS%_>V"W,H@Z])_HR0KX\R'5*WO0PKF"7S7^L,TSX <L_2 H@9
M8&3M,W%WG&?J \VR$T>#:_XFV,OA_MTYSAVV[6_KG,CC[/J"2N MB EXZR@O
M'=,G,04C"K+)BEOPM3N4RQI\&5Y&]>&Z?O\]Q1;L7?X*<MNCC%1GK9-D@$2F
M6<L"/S9_N*XJ;.#D:F>YLC!E$ZRG.?7Y \S53VR>\W7@1YJ,O+%]Y<P0K*&,
MD"!4$%EDYS:?WJ8%?5.H_.<2DA'G(2_NGRA81.A>2J+9+;."LQ\KYBR0@@J1
MWA-'S7HH[&E%2'V&1H'= L^^@@""(B*M4,%)9U?7>8&Z<T5:$@FMM%)&?79_
M(INNOLUV(O0V1Y8&:,DDZD:J6V,>VON5$,)HIA^/WB?R, ]@MQ[+?5ZY[^Q8
M[CN6^_! J<=00A$KZLIVR-C#/0W 3&VCW6@P@C[.SY$2D%7MCOL*>(!%_,Z$
MD];:(:NY(SUT;)UE=^"$H>@QZN)9<,3:"3K3[?$W-;;4.(\Q&#-RD>F[RAT&
MIVSP-[Y='2#Y6U7X5(#]R]CI[LSYM[4JSU2#,\=RO/IVN*Y4,\JP$Y6&W.\0
M>-_;T^,TJ!\9Y02/7$IU1D6YF[B>%+ W<1G$2G'0DKY/IW:P;_Z.WCDZY[B8
MHB%,+"8;&D-BPW"$AD*BYY@.7;FXK'1#FI>6(9*(;965P"I.35/J"Y#[S\RB
M6L'P+>T/F!(3L_.H@]%(M]9 <B7J986-&>C&NK>O:J\5CJ8\&,<$-_2V#1QC
M/W/T^[PPP8^)JC(&0;9B*4XMM-A1C$A&]_H:6D10B\%J2?P.A.G<H?<[/.R0
M\,6A&LKV=XTY&5*R1EXKL&%IU]ACR_O0LTK+JFEM&X0.&/W=.G"6RV2C&;&W
M1L:M&'!=*R+U>TGWA(Z1C!/$=!0U"B>Q>REX[&U*JEA>+UK _55GZZX,BI8I
MHOQM?#9E%,PF<$:*#5&/*T/"0QWI#IHGXWV $KIU$*'FOVTQ"<ED-3YT.PE[
MX:"BPHEM?80D_KOJ<<)T-@Z'>O5W6$6@Z7B3[@Z81["[CY>S5U-DFF.CFK>A
ME&![XN_G\-R5T$<)>6#\#Y;"MB W9AOEA /W[]"=.5O)_PW7:6[RK=67D :J
MDY2;7;8W-;C:D"S/U@(Q>_8D(.Y\]N3QZ9/'9W/QH_SC/"1*[+\4K&?8^+@I
M[.XPFPAUL1.BQV2$$Y*CD$'";SF:DE5&+3)B'DG3&Z:;LLDIMIAE9DWD6/*L
M5";=4CC?.$]#>8R<0T:SP,__,>0$"<<89@"]!F0>QK.G3QZGC[Z"&_-_IM^2
M=:$,5!-45V?$1A,OMWGR=GFD:F =)7ZQA#6ZQQAD_?XV_QJSA7E?\#=V63L^
M?WKJED5:X^J2^6'3>CL?<-)M;]B,4]\,Q*?F4O,G/"F)$5Z1 DC;+:5:K![A
MBAKPP-F#-=0T&$1\8):]Q"=H5:U76W-J=&EIO5O:_4"'J8+Z0S6NM[^;9Q1J
MY8Y$97^_?'-^'IS&[B0_V/FY&YF?_[S*H#Z6K?[K8(?HP\?Z!WW75N<^T!UP
MWD!XEC,6#*&BJM#8JTA..ER5*B 525!;5&(!%_FA$W"-<;L2E5Q6M7%-Z8#<
M^[':C.IS$"L#RP\&ND%!YZK4GUN?!4DJ"W)/^+^= *)-K0SD&8 /-2,.BI 8
M),@<2!G,(^(?$2UX (O_6)_QZC-/CO69 Z_/.#VX9_L-]-^Z[WY ,>L?25+J
MD!7/W^G,,?:A$^XX'GG&.,%L-AG@<.]1B;I:OH?F;F?)23M\E3?;#FH^I'DQ
M+K/-\#?SQ7@*\C?K\OZ],KXZ4+2^ETP8 "DI2X*I+>C6&U0VCU)5T5"V?J9H
MJ /;0M!R8$:%,7H+&)$46L+.*3)W%*0JSX0RD37T_SNR$(0:F)--PDP*PE@U
M[5"7MS$&7XP:@W.I3[[*2^,EP 1=.C[70[8.OBN[-TF+/-FS_4-YJ,-H5N&7
MHZOP*BW?<XL'C/FAGTIFW:RRA5E*R ]99UOHM"L#G6^'FR43^=.BD.+> %K7
M%P>/5%HQC=!2/@J!6KQ\ 1=:Y@A974+WI?=\3%V-[<MT6N7\-VF"2)#BTOQG
MBR-W=Y,7V:37, $)( HU60K'*\+E0H<<;$SUG0L41Z&WM(+/R>QO^7<F[,O-
M(=<TW>QO?\F_PS?"%P-R&A%%ET/0 BF\V3C),3J:6_"Z&[]#7;%FBW\UNL4O
M(GKV5]4.>$G%8);7A[[OV]IL""ZX8[(='+!4;?S>B*D-[4J4E*EWW3VV?>@=
MJ">>LQ='SA*U*2UE=O8TS7O)W?8F9!8=>;P$^<JX#,_R(8YI2759XAMXY$WG
MJTU>0@\P(1/.J;R#'NC0H\8H47N0J$-=:6:_?CU^)#O/^N^'O"U?0_V<E"4
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M>-T\P\.AK"A(3*T>==R9+H%]EU\GS+*)>F*MX2XLN>GTB- 3UVH(NJJ>-8F
ML/<6V&N0^V/A&M%#^)>X-.@#)W7D*-SJC+KQ*4Q@"X7F-^0GA'S+.I!^FJX
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M#'ZK.ZLG^2_;+R1KQ;_[L^<][ED'07^P#H7S_CGM:AM!P$9%!Q4 CY9YYHY
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M5W(NW*64Z:^EI[?O]/2,?8OTP142,[SC_R(Q>H=]F4YVS77UL&./EEX[KO,
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M\6^7CFQ;]'**X AK,LZW"4#/Q-EUO^.:QSZQQ=4TNK\X#K6#L&:>"(#=#O#
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M0#01-FW2/R5!SAQDM@56P@,-J+/RI.@B-2[<<S11J@@[R;O4ZV>!$M7IPF!
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M4ML$%*?,9J3CM$8D*UJI)C<EP5:F[BST_7?L2#$A&8]V:&D7R;6F\A?0YEK
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M;;#@EW88&Z"D_>=8H8UT%R8D('O8S9-,(*L&&7*"?E^R48O4WYYI,[!FR5#
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M/CU[?G9Q@E^UHJ;AN1?L+>_/F5VFM7B?[I3NWPZN:!K/64<A5Z56(="&DKC
M2@J!I.B\6GKMG!97&$M#^LI$*K[2]2V6]M;EZAHU!@-2N>;855JN:,-BP:JC
MG^ 7P:'66*[GP'_NV<S%1H^+[@>G'ZUN9[E1G0"B$&$_,7B7^!F8I&_3=511
MAD34">'+F.H%!BGG"BXZVJC4F(JD$^K\97I591;660Z\7!'/7>15D.!K975#
MZP%$0DQ;[>BTZ^I*>$WW/Q>)W,N%.LIN)CO/AEM5,*S+U4HP>KC>A?N_\R1;
M<E')@OA.\$14C!^:$#K0==[ Y($/D]4U/?3HIB/,N]@EDN&9MWMH[SY%PP>C
MVX @9+Y&)K:* *8D6RHK?<M@(^O%&FA8HB(FC'P="B>;'K?4#3FU!FAN;4_T
M&M3Z))M1C4]QT]C.="ZZ/E&L+U/JKL.B,6J$30=D;$D)V77LJ/?2_S-?[J_&
M0U;]<;OF+E:4B-*W2E,H_YV&(I;4<BB8'N_APZ0UZST_)@ "TYN<H0IS<V%_
MK,$;?W<7S[T'T8E#08LM:('1'"I:]KRBQ>>^OQS-?9]8&/Y%] R6L-[GC/>)
M :C45,;"IR8"&YU)'$WHD!EBB3W(W484)N$#](6.MP3E4&O7*3%3@#4OYRSC
M#97=N.5C#5JZHM]:^1U\'V9J  X'@L]<9-L4?;$J;Y(Q&89+D/7>2D9LNJ%(
MNWQ.DJ5/,9_0&4/2%!PQY@H<ZNX2":O\+*OJM1B:I<6.)DL&@<6,Y6>7RT4?
MB7XH32G8.$^7!=6\Q@1V4=2]J0\3:><?,FQQK3;'%'T?@;=>J(\XEK!S=U<)
M=QDF(52N(R%4IJOA\W^15+OKM]T_8QK46;)*9A0V93B;SRKY]^?(&VB5LIA_
M?('K$S/30.@2??%=,GAA14)'5*C$6_BE< CMCL4^49I\F/0+)#'>[KV>CA'+
MK/;]&MV$]NY[B:[\%R\E/(0;DI<EAT26N&>0/T,6M#M^?4875DHPI0)I:<W]
M\K#U[KSU"._@@W?>E@QE)'F(W?95X,&V\;9-7*<C6LYY_!@2YB8%O)!<;8Z#
M=+V'(8%8A==_A'CY(@V-,/T9@N'?)Y2,SZU$Z\^1CN>)LS)A*:9)CLG&6)BI
M%;O?U-I:^0@ 8X@#-,-E%]4C"3U9Y*#>W78(VA#9\^1V7WU0<.:^&H>+QDSC
M!:XY-Q*\:&4\8,FP2?1*)QV+M"ML*?"$OX8EW6966_EI;&PAUEJ#0XD7H>&R
M;);1RRI/YNFF##N/WSR\A#&!\ZKMZI<)6B2RP@Q#8EU;X\M^]_#X6^UJEA#P
M:SRX3EUAF!,@ U:48)O- \K?T$Z(CO!*#_$0SI<B.@A4XXKQ(ZF4@Z:B6&>5
M[6K%#Y%L-'HJ#KTM"P+-22D8>OBZO.(<,G?N8U9\RV',Y1*@"?.F;L>>W[=D
M8CCRW*GG"\HF< @^:4T5<675L3)]*:]];0[)VY )CL#/N0\<F,:F,#C@2*P1
M+B69#"ZT=,Y[J.I^9[!"_!'NX56@5E\);._MLJ:X*!S\=N_1>HFV 42O[V23
M$(ARCY3P_0^/'D7)P^5#C<Q3([WK"EO@8(^^GD1/- E[BE!%V#@VOZ$.YV &
MELE;362:$5D3#A:21]3SO9M^3&AVFJV+THY[ #TI?-F'T;, MV'+TJL\>F'6
MK196Z#!6K8EH?<6'$8SNU%.$[UBD*D+M< ] B>&(F$2<N-19*<+=$N$4=2SH
M?;JH7:NB>%E4?Z. 4#"-:.4DB$^+"6*P;_"+90*':9T)_7E8_%.E#/@!NC4+
MV]H],H0;Y1:-^8UFC;(;FS:Z!T?H(3\3YF>.#_F9/<K/B,R ?8V7!S-+91RH
M'GYH5J"4L,KM"XW=Z.CP1S__ZZ=I!1.$_W/^XBG(Q>79:?3TY>7K2RJH.G]Q
M\N3\^?GK?V.%V>G9:RPL>W$679R\/KO\]-O_DUC0QX_@#-B!DH QCA )J5X;
MEO)]F[5=6P:[<Q;]HJS#3.\N#:-/72\Z,FC3V7E(^]S-'Q\E,\R6JQ+K8@4:
MCV!HTJ7%KN%:?4*LC+FF#,O#4_@90NVAS='D-?(IY&5";J"2A'*PVQ(U6[_-
MT:+68(_4U*4K-Q7FQ+)R=I=/)3)D/_%K,GGIG&MQJ0X=(T>""33=Q"95>8CQ
MW55JQL1&_2]"*0*16&7B])"?G;QK)2D0\OB<,SA4/<U7D+OQ9(*@.7DSUX^1
M!#?BPBZ*_>%_;%+'- ?'OC^S;#$-,>LXRU.L\HM?K2U_7<;>Z2Q990ALEZR9
M.X*S#]RS^KGA5_PYXK.;VE'J"NU_<&$#Y\7C<M?"_$Y)YD"L1%X2HD=@']+6
M[/]HG$9;"NB:_*OTJJ1*6==3CF6> EG(GEWM770M>UBH%TV0 PS3HO#$Y)8=
ME7*5_X[J)WU?HVUD="C$$_+LX)6IMU+##=R1[(#)>!"M !9U,5'=81E>)1TE
MU#^(< =35.%4YSOG^36UED&_(MT1=3O,.<8;1N_J*XC]G6<E4U12GXFT3!#3
M$O7Y4ZWM_!ZXEO>S=Q^#C:*6+ORQ&0(%BT3.4RYK5?[&KNWD=T@@R;Y#%+]Z
M2?#V+4ES$'JMUBV$Y^9XVW)%<7V-[R.=2<5?R?#+2KJ@L)S"F  U5<$CT"65
M#%,@A() 0FNS8''1V% E )*@E)NJB!0KHC4N\U")E[E/%G=[$:HA)A"1WQMM
M;P[U"^_"IP:LHCMWOGA+8V;V NJ9RY&P!S917M[R^C&@P-T709AH.)"-Y 54
ML]6L_>8,I>)HS7J,<('")H&^IZU*, FU_H*BS/K!;E/;"7RZ8W<.4YS,-J(
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ML1V6&X7TD?S=[\5I8UF#+,^4-/"/IH,BE8H<^F.KG.BN4&%Q54>M=:>,!Z)
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M]U).9L2V7_7M%TX+"I)X&(*M7&BO;S1O"F$YX^ WAT[X &]YZW-9?TYSJJ&
M9R1G% -(AR$^*5W?+0>=4M>Z@RZ.#-E2>UP]QAT<X6452[4_9I-P/^A<B#MN
MA0KKFXH''18R"E_$08R! <Q%(G@H,B?X&JB0*>&\J!",G%4NAZ](,8H<BFH+
M JY(D9.)"NX+OM(5=IH%8Y(S75E%T0A"X*Y25Q^LVE+U(@VHK1FY10T1.-&B
M:6>^$@M=[G)VVZP4MVI[JV'3N]@6O=N/M:DC'NL Q&@5-<AI""73R;V,;?3[
M%PB+YDW58R[TJZE]%;'%;BT1J(5.<;JQ,1:64H[IDQJKASR,W1;5NQ>9NH_8
MM^IAO@8#0H+X)<DRW!%ULX2MX,&FDASV'5413-U-Z#"3!-Z2:JZYDI2PP"Y?
M/KN0])QCA:GIB![9NIVX@H30L;LC[.8BYEVVQVIW^--AQSIG;AP<ZP+K(8Q/
M6:8SL%:R>DGFI&H7M]D3OMCEGO(4JXO"(H\GY9P0!DBA$"?'39G?2((($Q\/
MNKPZ\"(W4D7<?F[B6@(]2W'=>@-X\_Z,%R'+S<L\3ZH'( .E4$E']08.<J8U
M$IB!13+35G'%QZ)9[S7N3IRY\J-'>0_JFOM_AQU%I=79CD8E1X.22K^/'W[[
M]5^P\AC&433+>,OMU$KQ,%/P1^OWKM(&# *,8/EJ]?OD9QWR&F%>XZM#7N,S
MSFM\^D/.:+#.>1?WA($WN\9,"[0"Z=Z#[CHJ)')?3 RT51; 2J^&<R*9&]^0
M"A67*7A,7+'KJ*SX;.F<5CTW,,<S$E-$!!U"L6OP,-,K/GAODKRA3_Z35N4]
M.K3_B G1XV&W]6V%KD?7^L\U%/[WS<_[VR@63_73G]__2W3C]P]WTX[]&80=
MM.1 !!&_6H-E72"=#_P9J@R,>*U$'R">BH0+#:V$?J0-@(%[+B_35J$ZVC6S
M'E))5\4@%X2-8X5?:"TI?D6Q, %?K4.SVQ-RA"^P3-9P23WQ13\#98XST'NU
M4[XK3*I6&64+RZ#0+)F7*Q<BZ\9JMZ0I2/$2;NLRTWOYH6@[(MQCA(L(N>Z*
M@KI\IAA77&?$PT2ZNUZ[7*EH)2FR0MBBRKD 6^> $5ST-27B:R#UZ17;=\]J
M*=2S-X91"8)Z:NKXQ^I,Z?E%V7F$J\L/9ZW<YM50N193D].PA<B8YP]?+;S7
MMGRX3H]EMMX88(>>KI*AT0:TS@<5^;%5)"94^D,E2,&9<8<9)[X=$)=B0%/4
MONXHT,Z9NA>1K:^_^O!5>_R8RI._^/GH> R13=&2A(M8\$R.)V2(/1Z( (LP
M#&?U_&D#OV5X<,P.2K!L+@$<#D-,P3J"687/--_#G[F]F]'ARW^Z</6<-7=6
M!.$9OG,A6$HM5<"9I*ZEAH=#4J1$ $S)<GE95*4S;#7G[C>.ZW1_OR\U[Q]7
M,!^_GV!^^5$D\J,*X.$L^1AG27N]^L^2,.%;%F3B$$S&X5"Y/X=*<M=--=T(
M<M\TO4[RA2[F#KH;C,JR*00M4)W@\'<8J9DQ8D@I,'(SAOK<HM3C;:="W [R
MBY=#-5IJK ^]>\QZ@XUWO!1MV;)J#9H1 1F@#FNQFNW#_:SZ9N[' ?0^0LR!
MH2L,*2$T=MV $"'A;M7G1PV(-,<Z*0CT+,6P("*!$HYQ=+D!5W.)X0/$VR[S
M&_'=%QFA<Y.J^ZVILGJ>2=SP)NU[+ ZFY[F80X.[-NR5N=;L#[LM5?,@1&6E
MI5X8KM/;*D2X?9VJ?QAW>Q<!TUQ3(,.%(790*.^E+?Z7*8M[8; >4GQABN_K
M0XIO#U-\'_=,^_*>GFD=,ZU[!6LX:?BL4JQ?Y!#OS2&?\;$=+%\"W?6R,$;3
M\KVWE6_'08A/*L '&UIZJ[09&:D3Q>\4BF.O^UWEET8/!Z$CADW]H+]_!,(W
M3S9A(P[B&%$Z5V,$-"QNBTX\YO4=QW'D(_']#^B,$5]WD=XZ/L!''3J]K39#
M>/>A2R<N>-9>\L&*?'=O#X4\4C[>U^'5J>R?;EP'5]C2OJ7)YJ@U:-L\/H"&
M,&DW+1QTRX?7D0S60[<2I-E()\@=NCNHM4J"0?/Q& _=6FJ>W3YGPL[^TTC[
M,*G"0U+]\ZUM@"RG A!Z]&X"/X79+83BU1G\/DBQ]>UJ_W*(LF>S^\1IV?]C
M_)T;;'\!9,+,F5SYY]'_>N"HQLJ,675L)E'JB&S#MQSJEWS_4=ZE >6PL=]W
M8_<J_AW"L8= ZHXS?OS=;F%4J@-K=4Z-G+5<.B78S[/@)UU@H"U=U4>BZF;E
M:M,^D4U9QU#CMJMGIBO?JZ!IFE(0_UTZ:_""4 -JS$,KZO.DN&J2J]3%DVC(
M28N:=URC56G[N:B,EH0%W85,(&SH$K24[UHK5ZCW"A UWP;@ZF4J5]DR@))
M#8Z'772W7306QU6'Q!53[K*%^G[0MX$053*I], ;0D<(SG-'HZ-X\7VV\/
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M_4QOE.WJMXI[H5G;K]W2ND.*J[O/CIIM@$$-J<D7N5M$3;J-,9%E_L8'2=C
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MEUDE(8@CAXF$,D4Z0^&LQ.>+*+9_YHTBPKR1^JBC&#89N1\AGS6%F+(LT2;
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MQFR1/>8V#V1,^:V$1YYMJB'A& %"KVM6(RUPE;2H++R+%"A<X!*"[6[NAWH
MI'QXVQ"3:T'8)T7@W9*D#WS6=;=<KA;9&@6&_IPA5\A>*YE8C&$?:9\C7[R&
M\"+-EY5/]Z!L,+R* 84@K2T0#"L9YLJ[@]2%&0D%AH(!$%S1$; 5LE:"9 E:
M+@%*[C/U B'%B]ZDB)4B \;?X-ZX%RS*&@EHID[OJCTC#38$R)4 U0D-4,8O
M[ 15,"NS92WZ=,FY#SR9NVT)LR&.!R- V/0;+C!&1329[QM22G,=.^\:A.L
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M>%;9'4)\P4_!HY\7&TH?@IC<0(I:9@R9 VXH ;>2W7>;SCP'(AX*62_>?_)
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M] .]=U6A5LPQ!H:J+3=KJIGP=5.;:GH+"(V2T*V9>\UDNYJ2UZ_##Q,/M(/
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MAUZ[%\%3'T;\)'SFYO_JN\DE32%(&6DK(H#@*VC1]>/LDN;HTK<$0LBU1L_
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M%\0&QPOKIE\NZ[F(;Y\FU2(SGS=''E0=,Z,=[X#AH,CRM5#L156$(F0(N&6
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M,C,Q+GAS9%!+ 0(4 Q0    ( &Q*85+%5E^?K X  ,_.   5
M  "  :H:  !B8W)X+3(P,C Q,C,Q7V-A;"YX;6Q02P$"% ,4    " !L2F%2
M!1#0N]!H   [>P@ %0              @ &)*0  8F-R>"TR,#(P,3(S,5]D
M968N>&UL4$L! A0#%     @ ;$IA4IL^!9W,BP  +, ' !4
M ( !C)(  &)C<G@M,C R,#$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( &Q*85+P
M'=>I+6H  ./="  5              "  8L> 0!B8W)X+3(P,C Q,C,Q7W!R
M92YX;6Q02P$"% ,4    " !L2F%2+NOW?JE/ P"7/R, %
M@ 'KB $ 8F-R>#(P,C Q,C,Q7S$P:RYH=&U02P$"% ,4    " !L2F%2#C1#
M-XD$  "^(P  #0              @ '&V 0 97A?,C(W.3<X+FAT;5!+ 0(4
M Q0    ( &Q*85*D#U(IP0<  %,W   -              "  7K=! !E>%\R
M,C<Y-SDN:'1M4$L! A0#%     @ ;$IA4DM)P'Z\!P  3S<   T
M     ( !9N4$ &5X7S(R-SDX,"YH=&U02P$"% ,4    " !L2F%2O]5VJED%
M  "I'0  #0              @ %-[00 97A?,C(W.3@Q+FAT;5!+ 0(4 Q0
M   ( &Q*85*_CV@L404  -\;   -              "  ='R! !E>%\R,C<Y
M.#(N:'1M4$L! A0#%     @ ;$IA4I#&MGO.&   ==    T
M ( !3?@$ &5X7S(S,#0V,RYH=&U02P$"% ,4    " !L2F%2JUP>OXH-  "@
M1@  #0              @ %&$04 97A?,C,P-#8X+FAT;5!+ 0(4 Q0    (
M &Q*85+A8A5%M2(  "D= 0 -              "  ?L>!0!E>%\R,S T-CDN
M:'1M4$L! A0#%     @ ;$IA4ED@+0?01   8+@!  T              ( !
MVT$% &5X7S(S,#0W,"YH=&U02P$"% ,4    " !L2F%2E@D5XDF+  "E2 ,
M#0              @ '6A@4 97A?,C,P-#<Q+FAT;5!+ 0(4 Q0    ( &Q*
M85+LD#5CQTT  (X5 P -              "  4H2!@!E>%\R,S T.#DN:'1M
M4$L! A0#%     @ ;$IA4LA_OK*5#0  5W,   T              ( !/& &
M &5X7S(S,#0Y,"YH=&U02P$"% ,4    " !L2F%2)[24MDT+  !K1@  #0
M            @ '\;08 97A?,C,P-#DR+FAT;5!+ 0(4 Q0    ( &Q*85+S
M52N?+0P  (!+   -              "  71Y!@!E>%\R,S T.3,N:'1M4$L!
M A0#%     @ ;$IA4K:LVF4! @  ;0@   T              ( !S(4& &5X
M7S(S,#0Y-"YH=&U02P$"% ,4    " !L2F%2GCWKASX"   M#P  #0
M        @ 'XAP8 97A?,C,P-#DW+FAT;5!+ 0(4 Q0    ( &Q*85)YJPAD
MWP(  +T9   -              "  6&*!@!E>%\R,S U,3 N:'1M4$L! A0#
M%     @ ;$IA4O]%)@,UP@  [J\%  T              ( !:XT& &5X7S(S
M,#<Q-"YH=&U02P$"% ,4    " !L2F%2,@ERLP\\ @!B;@\ #0
L    @ '+3P< 97A?,C,P-S$Y+FAT;5!+!08     &0 9 .X%   %C D    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
